Cop Defin 8 Maggio 2006.Eps

XIV International Symposium on Atherosclerosis Rome, Italy, June 18-22, 2006

CONTENTS

• Address from the Presidents III • Scientific Committees IV • International Advisory Board V • Sponsorship VII • Contact Information VIII • General Information XI • Registration XIII • How to reach the Symposium Venue XV • Practical Information XVI • Scientific Program Information XVII • Social Program XXI • Satellite Symposia XXIII • In Grateful Appreciation XXVI • Exhibition Floor Map XXVIII • Exhibitors XXIX • Time Table XXXI • Scientific Program XXXIII • Topic Index 199 • Author Index 217

Address from the Presidents

On behalf of the XIV International Symposium on ATHEROSCLEROSIS (ISA2006) organizing committee, the International Atherosclerosis Society (IAS), and the Italian Society for the Study of Atherosclerosis (S.I.S.A.), we wish to welcome all our participants, speakers, and presenters to Rome. We are pleased to host our participants, both established investigators and young promising researchers, from more than 70 countries, and hope that your stay in Rome is exciting and re- warding.

The first International Symposium on ATHEROSCLEROSIS was held in 1965, some 40 years ago. Well in the twenty-first century, it is exciting to note the dramatic changes in the perception of the field within the last decade alone and to ex- plore the explosion in the field of atherosclerosis prevention and treatment. The ISA2006 will cover the traditional in- terests of atherosclerosis specialists, such as lipid/lipoprotein, lipid lowering drugs, diets, and clotting mechanisms as related to lipids, but will also expand the focus to new and exciting areas, which may potentially affect the development of atherosclerosis and ultimately improve patient care. Themes will include obesity, metabolic syndrome, diabetes, AIDS, rheumatoid arthritis, as well as novel diagnostic technologies for arterial disease determination and biochemical traits affecting atherosclerosis development and outcomes. This very rich scientific program was developed from suggestions originating from the members of the International Advisory Board, the IAS Program Committee, and the Local Scientific Program Committee. Our heartfelt thanks go out to the 184 members from 47 countries and their collaborative efforts in making this such a successful program. We hope that you will find the format of the meeting one that will allow you to participate in as many topics and aspects as you wish through Plenary Sessions, Workshops, Master Lectures, Oral Communications, Posters, and Symposia. The selection of subjects of the scientific sessions has attempted to minimize overlaps and we hope that the program Time Table in the Final Program and the Programme at-a-Glance will help you easily and successfully navigate our meeting and to promote a lively interdisciplinary exchange of ideas. The scientific sessions in Rome will be enriched and complemented by the pre- and post-meeting satellites throughout Italy (Bologna, Milan, Naples, Parma, and Rome), in Madrid, Spain and Belgrade, Serbia and Montenegro. Each satellite will focus on a single topic which will be covered in great depth by internationally recognized experts in the field. Last but not the least, a heartfelt thanks is extended to all our sponsors which have supported us throughout all these months not only financially but also with timely suggestions. We hope that you will enjoy the scientific sessions and the social program and that your visit to Rome will be most re- warding. Do take advantage of all that the city has to offer during your leisure time. You will find information in your registration bag and hostesses are available during the entire meeting in the registration area to help you and your guests. We would like to remind you that places for the Gala Dinner at the beautiful and ancient Complesso Monumentale S. Spirito in Saxia on Tuesday evening are limited: this is yet another opportunity to foster old friendships and forge new collaborations.

Welcome to Rome!

Rodolfo Paoletti, M.D., Ph.D Cesare R. Sirtori, M.D., Ph.D. Elmo Mannarino, M.D. Honorary President President Vice-President

XIV INTERNATIONAL SYMPOSIUM ON ATHEROSCLEROSIS III Scientific Committees

Congress President: Cesare R. Sirtori (Milan, Italy) Congress Vice-President: Elmo Mannarino (Perugia, Italy) Honorary President: Rodolfo Paoletti (Milan, Italy)

ISA 2006 Local Scientific Program Committee Alberico L. Catapano (Milan, Italy) Guido Franceschini (Milan, Italy) Cesare R. Sirtori (Milan, Italy) Elena Tremoli (Milan, Italy) Laura Calabresi (Milan, Italy) - Secretary

IAS Program Committee Jean-Charles Fruchart (Lille, France) Heiner Greten (Hamburg, Germany) Scott M. Grundy (Dallas, TX, USA) Steve Humphries (London, UK) Eran Leitersdorf (Jerusalem, Israel) Ernst J. Schaefer (Boston, MA, USA)

International Atherosclerosis Society (IAS) President and Website Editor-in-Chief: Scott M. Grundy (Dallas, TX, USA) Past-President: Heiner Greten (Hamburg, Germany) President-Elect: Jean-Charles Fruchart (Lille, France) Treasurer: Walter F. Riesen (St. Gallen, Switzerland) Secretary: Marja-Riitta Taskinen (Helsinki, Finland) Members-at-Large: Philip Barter (Sydney, Australia), M. John Chapman (Paris, France), Emilio Moriguchi (Porto Alegre, Brazil) Senior Advisers to the Board: Antonio M. Gotto, Jr. (New York, NY, USA), Rodolfo Paoletti (Milan, Italy) President XIV ISA Congress: Cesare R. Sirtori (Milan, Italy) Regional Federation Chairs: Jean Davignon (Montreal, QC, Canada), Yuji Matsuzawa (Osaka, Japan), S. Lale Tokgözoglu (Ankara, Turkey)

Italian Society for the Study of Atherosclerosis (S.I.S.A.) President: Elmo Mannarino (Perugia, Italy) Secretary: Arturo Pujia (Catanzaro, Italy) Past President: Alberto Notarbartolo (Palermo, Italy) Executive Committee: Maurizio Averna (Palermo, Italy), Stefano Bertolini (Genoa, Italy) Alberico L. Catapano (Milan, Italy), Luigi Cattin (Trieste, Italy), Davide Lauro (Rome, Italy) Andrea Mezzetti (Chieti, Italy), Paolo Rubba (Naples, Italy), Giovanni B. Vigna (Ferrara, Italy)

IV International Advisory Board

Abdel-Aziz O. (Egypt) Fellin R. (Italy) Adlouni A. (Morocco) Fernández-Britto J.E. (Cuba) Agabiti Rosei E. (Italy) Ferrannini E. (Italy) Angelin B. (Sweden) FitzGerald G.A. (USA) Assmann G. (Germany) Fonseca F.A.H. (Brazil) Auwerx J. (France) Forte T. (USA) Averna M. (Italy) Fruchart J.-C. (France) Aviram M. (Israel) Fuster V. (USA) Avogaro A. (Italy) Gaddi A.V. (Italy) Badimon L. (Spain) Galli C. (Italy) Ballantyne C.M. (USA) Gensini G.F. (Italy) Barter P. (Australia) Gimbrone M.A., Jr. (USA) Beisiegel U. (Germany) Ginsberg H.N. (USA) Benlian P. (France) González Santos P. (Spain) Bermúdez F. (Venezuela) Gotlieb A.I. (Canada) Bertolini S. (Italy) Gotto A.M., Jr. (USA) Betteridge D.J. (UK) Greten H. (Germany) Breslow J.L. (USA) Grundy S.M. (USA) Brewer H.B., Jr. (USA) Guyton J.R. (USA) Brown W.V. (USA) Hajjar D.P. (USA) Calandra S. (Italy) Hamsten A. (Sweden) Calvo Monfil C.E. (Chile) Hancu N. (Romania) Campbell G.R. (Australia) Hanefeld M. (Germany) Carmeliet P. (Belgium) Hansson G.K. (Sweden) Carmena R. (Spain) Havekes L.M. (The Netherlands) Carrageta M. (Portugal) Humphries S. (UK) Cattaneo M. (Italy) Iliceto S. (Italy) Cattin L. (Italy) Juhan-Vague I. (France) Ceska R. (Czech Republic) Kanjuh V. (Serbia and Montenegro) Chait A. (USA) Kastelein J.J.P. (The Netherlands) Chandrakasan G. (India) Katan M.B. (The Netherlands) Chapman M.J. (France) Kipshidze N.N. (Republic of Georgia) Chen M.-F. (Taiwan, R.O.C.) Kisyanto Y. (Indonesia) Chiariello M. (Italy) Kita T. (Japan) Corsini A. (Italy) Kovanen P. (Finland) Crea F. (Italy) Lauro D. (Italy) Crepaldi G. (Italy) Lauro R. (Italy) Cuevas A.M. (Chile) Leiter L.A. (Canada) Curtiss L.K. (USA) Leitersdorf E. (Israel) Davignon J. (Canada) Libby P. (USA) De Backer G. (Belgium) Licata G. (Italy) De Caterina R. (Italy) Lim-Abrahan M.A. (Philippines) de Gaetano G. (Italy) Lin S.-J. (Taiwan, R.O.C.) Dejana E. (Italy) Lissmann S. (Uruguay) Després J.-P. (Canada) Lüscher T.F. (Switzerland) Ding P.Y.-A. (Taiwan, R.O.C.) Mahley R.W. (USA) Djuric D.M. (Serbia and Montenegro) Mancia G. (Italy) Drexler H. (Germany) Mancini M. (Italy) Durrington P.N. (UK) Mangelsdorf D. (USA) Ersanli M. (Turkey) Manzato E. (Italy) Farese R. (USA) Marais D. (South Africa)

V Marchioli R. (Italy) Staels B. (France) Marcovina S.M. (USA) Stalenhoef A.F. (The Netherlands) Maseri A. (Italy) Stein O. (Israel) Matsuzawa Y. (Japan) Stein Y. (Israel) McPherson R. (Canada) Steiner G. (Canada) Mezzetti A. (Italy) Sy R.G. (Philippines) Montagnani M. (Italy) Szollár L.G. (Hungary) Morales D.D. (Philippines) Tall A. (USA) Moriguchi E. (Brazil) Taskinen M.-R. (Finland) Naruszewicz M. (Poland) Tavassoli A. (Iran) Nestel P. (Australia) Tesone P.A. (Argentina) Newby A.C. (UK) Tikkanen M.J. (Finland) Nielsen L.B. (Denmark) Tokgözoglu L. (Turkey) Nissen S.E. (USA) Tonkin A. (Australia) Noseda G. (Switzerland) Turay J. (Slovak Republic) Notarbartolo A. (Italy) Tybjærg-Hansen A. (Denmark) Novo S. (Italy) Uauy R. (UK and Chile) O'Brien R. (Australia) Utermann G. (Austria) O'Leary D. (USA) Vella S. (Italy) Olsson A.G. (Sweden) Vigna G.B. (Italy) Packard C.J. (UK) Violi F. (Italy) Pagnan A. (Italy) Volpe M. (Italy) Park J.E. (Korea) von Eckardstein A. (Switzerland) Patrono C. (Italy) Wenger N.K. (USA) Patsch J. (Austria) Yamashita S. (Japan) Pedersen T.R. (Norway) Yang Y. (China) Pitt B. (USA) Ylä-Herttuala S. (Finland) Poledne R. (Czech Republic) Zàk A. (Czech Republic) Poli A. (Italy) Zambon A. (Italy) Pujia A. (Italy) Zannis V.I. (USA) Rader D.J. (USA) Zhu J.-R. (China) Reddy K.S. (India) Reiner Z. (Croatia) Ricci G. (Italy) Riesen W.F. (Switzerland) Rubba P. (Italy) Rubinstein A. (Israel) Rye K.-A. (Australia) Sacks F.M. (USA) Sansoy V. (Turkey) Santamarina-Fojo S. (USA) Sarrafzadegan N. (Iran) Schaefer E.J. (USA) Schneider W.J. (Austria) Scott J. (UK) Shepherd J. (UK) Sierra Ariza I.D. (Colombia) Smirnov V. (Russia) Smith S.C., Jr. (USA) Sniderman A. (Canada) Soltero I.F. (Venezuela)

VI Sponsorship

• American Heart Association: Council for High Blood Pressure Research Council on Arteriosclerosis, Thrombosis, and Vascular Biology Council on Basic Cardiovascular Sciences Council on Clinical Cardiology Council on Epidemiology and Prevention Council on the Kidney in Cardiovascular Disease Council on Nutrition, Physical Activity, and Metabolism • European Association for the Study of Diabetes (EASD) • European Federation for Internal Medicine (EFIM) • European Renal Association, European Dialysis and Transplant Association (ERA-EDTA) • European Society for Clinical Investigation (ESCI) • European Society of Hypertension (ESH) • European Union Geriatric Medicine Society (EUGMS) • International Association of Gerontology (IAG) • International Conference on the Bioscience of Lipids (ICBL) • International Diabetes Federation (IDF) • International Society for the Study of Fatty Acids and Lipids (ISSFAL) • International Society of Hypertension (ISH) • International Society on Thrombosis and Haemostasis (ISTH) • International Task Force for Prevention of Coronary Heart Disease • International Therapeutics Society (ITS) • International Union of Angiology (I.U.A.) • Italian Association for the Study of the Liver (A.I.S.F.) • Italian Association of Hospital Cardiologists (ANMCO) • Italian Diabetologists Association (AMD) • Italian Federation of Cardiology (FIC) • Italian Heart Foundation (FIpC) • Italian Out-Patient Cardiologists Association (ANCE) • Italian Society for Cardiovascular Prevention (SIPREC) • Italian Society for the Study of Haemostasis and Thrombosis (SISET) • Italian Society of Allergy and Clinical Immunology (SIAIC) • Italian Society of Biochemistry and Molecular Biology (SIB) • Italian Society of Cardiology (SIC) • Italian Society of Clinical Biochemistry and Clinical Biology (SIBioC) • Italian Society of Experimental and Clinical Therapy (S.I.Te.C.S.) • Italian Society of Gerontology and Geriatrics (SIGG) • Italian Society of Hypertension (SIIA) • Italian Society of Immunology, Clinical Immunology, and Allergology (SIICA) • Italian Society of Internal Medicine (SIMI) • Italian Society of Nephrology (SIN) • Italian Society of Neurology (SIN) • Italian Society of Pharmacology (SIF) • The American Society of Hypertension (ASH) • The Federation of European Pharmacological Societies (EPHAR) • Vascular - Independent Research and Education - European Organisation (VAS) • World Federation of Neurology (WFN) • World Heart Federation (WHF)

VII Contact Information

Scientific-Organizing Secretariat FONDAZIONE GIOVANNI LORENZINI MEDICAL SCIENCE FOUNDATION ISA 2006 Via A. Appiani 7 20121 MILAN (ITALY) Phone: (+39) 02 29006267 Fax: (+39) 02 29007018 E-mail: [email protected]

GIOVANNI LORENZINI MEDICAL FOUNDATION ISA 2006 6535 Fannin, M.S. A-601 HOUSTON, TEXAS 77030 (USA) Phone: (+1) 713 797 0401 Fax: (+1) 713 796 8853 E-mail: [email protected]

Local-Organizing Secretariat For registrations, housing bureau, travel agency, exhibition management:

AISC & MGR-AIM GROUP Milan office Via G. Ripamonti 129 20141 MILAN (ITALY) Phone: (+39) 02 566011 Fax: (+39) 02 70048584 E-mail: [email protected]

Rome office Via A. Ristori 38 00197 ROME (ITALY) Phone: (+39) 06 809681 Fax: (+39) 06 8088491 E-mail: [email protected]

VIII © 2006 AstraZeneca CV06/004 00 03 2006 AstraZeneca has an established heritage in cardiovascular medicine and currently offers a comprehensive portfolio of products. In particular, these medicines aim to reduce the risk, prevalence and impact of: • Hypertension • Heart failure • Dyslipidaemia • Diabetic complications

AstraZeneca has an extensive research pipeline of new cardiovascular products with emphasis on the treatment of: • Thromboembolic disorders • Type 2 diabetes/the metabolic syndrome

For latest news and more information, please visit InCirculation.net and AstraZeneca.com AstraZeneca, Mölndal, Sweden © 2006 AstraZeneca CV06/004-00 03.2006 © 2006 AstraZeneca CV06/004-00 GROWTH ISN’T JUST ABOUT GETTING BIGGER, IT’S ABOUT WORKING TOGETHER. General Information

Venue The Symposium is held at: FIERA DI ROMA VIA C. COLOMBO, 293 00147 ROME, ITALY

Secretariat and Registration Desk The pre-registration and on-site registration desks are open as follows:

Sunday, June 18 7.30 am – 8.30 pm Monday, June 19 7.30 am – 7.00 pm Tuesday, June 20 7.30 am – 7.00 pm Wednesday, June 21 7.30 am – 7.00 pm Thursday, June 22 7.30 am – 5.00 pm

In the Registration/Secretariat Area the following services are available: • Pre-Registration • On-site Registration • Invited Speakers Desk • ISA 2006 Secretariat • ECM/CME Credits • Information • Local Agency: - Hotel Booking - Travel - Transfers - Shuttle Bus - Social Program and Rome Tours - Car Rental

Mobile Phones, Beepers, and Electronic Devices Delegates are kindly requested to turn off their mobile phones, beepers, and other electronic devices during all scientific sessions.

Slide Library A Slide Library of key selected presentations will be available after the Symposium on www.isa2006.org, www.athero.org, and www.lorenzinifoundation.org

Internet Point An Internet Point is offered to participants during the Symposium. The Internet Point will be equipped with computers, printers and Internet connections and is located in the Exhibition Area. Supported in part by an unrestricted educational grant from Sankyo Pharma Inc. and Sankyo Co. Ltd.

Symposium Website Home page for the ISA 2006 Symposium is: www.isa2006.org

Message Center A computerized and staffed Message Center is located at Booth F1. Attendees will be able to deliver and collect personal messages from fellows attendees at the Message Center. Hours of operation are from Monday, June 19 to Thursday, June 22 from 9.00 am to 5.00 pm. Supported in part by an unrestricted educational grant from Takeda Italia Farmaceutici S.p.A.

XI Insurance Registration for the Symposium implies that the delegate agrees that neither the IAS (International Atherosclerosis Society), ISA 2006 Committee, nor the Fondazione Giovanni Lorenzini (Milan and Houston) assume any liability or responsibility whatsoever. Symposium delegates are requested to make their own arrangements for medical, travel, and personal insurance.

Official Language The official language of the Symposium is English. Simultaneous translation is not provided.

Press Office A press office is available in the Symposium Venue (in the building where Room 2 and Room 5 are located). Journalists and interested participants may refer to the Press Office for more information about press material and press conferences.

Scientific Exhibition During the Symposium an exhibition of pharmaceuticals, instruments, publishing, and suppliers of medical technology is held in the Exhibition Area. Exhibition hours will be the following:

I Sunday, June 18: 1.30 pm – 8.30 pm

I Monday, June 19: 8.30 am – 6.30 pm

I Tuesday, June 20: 8.30 am – 6.30 pm

I Wednesday, June 21: 8.30 am – 6.30 pm

I Thursday, June 22: 8.30 am – 4.30 pm

Cloakroom A cloakroom will be at the disposal of all participants in the Symposium Venue in the Registration Area, free of charge. Delegates will be kindly requested not to leave their personal belongings after closing-time.

XII Registration

Only registered participants may attend the scientific sessions and the social events offered by the Symposium.

REGISTRATION FEES (all amounts given in Euros, VAT 20% included)

Participant € 690,00 Student/Nurse* € 380,00 Accompanying Person € 150,00

* Student/Nurse registration rates will be granted only to those who document their position by presenting an official statement from the head of their Department or Institution or a copy of their license.

Participants and Students/Nurses are entitled to: • receive Final Program and Abstract Book • attend all Scientific Sessions • attend the Opening Ceremony of the Symposium and the Welcome Reception • Box Lunches and Coffee Breaks from June 19 to June 22 included • Shuttle Bus from the ISA 2006 Symposium Hotels (booked through the Congress) to the Symposium Venue • Shuttle Bus from Basilica S. Paolo underground station to the Symposium Venue.

Accompanying Persons are entitled to: • attend the Welcome Reception • ticket for the Tour • Shuttle Bus from the ISA 2006 Symposium Hotels (booked through the Congress) to the Symposium Venue • Shuttle Bus from Basilica S. Paolo underground station to the Symposium Venue.

SOCIAL PROGRAM (all amounts given in Euros, VAT 20% included)

Date Place Fees

Welcome Reception June 18, 2006 Fiera di Roma Complimentary h. 7.30 pm

Concert June 19, 2006 Basilica Santa Maria degli € 30,00 h. 8.00 pm Angeli e dei Martiri

Gala Dinner June 20, 2006 Complesso Monumentale h. 8.00 pm di Santo Spirito in Saxia € 95,00 (Borgo S.Spirito)

Tour (for accompanying June 19, 2006 Tour of San Pietro in Vincoli Complimentary persons only) h. 9.00 am and San Clemente Church

XIII For Italian Participants Only All the Italian participants with the VAT/IVA number must indicate this number (and the corresponding address) in the registration form (DPR 633/72). The regular invoice for the registration will be sent only to those who have indicated the fiscal code and/or the IVA number (compulsory if available) of the actual payer.

Privacy Law The personal data will be handled exclusively by ISA 2006 Committee according to the law 675/96 and law decree 196/2003.

Name Changes Name changes on site are charged a handling fee of € 30,00 (VAT 20% included).

Badges The official badge must be worn for admission to all scientific sessions and other activities of the Symposium. Accompanying persons can attend the Opening Ceremony and Welcome Reception but they are not entitled to attend the scientific sessions. Lost badges are replaced for a handling fee of € 30,00 (VAT 20% included) with proof of the original registration.

Badges will show different colours: • Invited Speakers and Chairs RED • Participants TRANSPARENT • Students GREEN • Exhibitors BLUE • Accompanying Persons YELLOW

Box Lunches On June 19, 20, 21 and 22, from 12.30 to 2.30 pm box lunches will be offered in the Catering Areas No.: 1-2-4-7 to participants. Daily box lunch tickets wil be found in the Symposium badge.

Coffee Breaks Coffee breaks will be offered to all registered participants in the Catering Areas No.: 4-6-7 from Monday, June 19 morning until Thursday, June 22 morning.

Bar and Self Service Cash bars and a self service are located in the Catering Areas No.: 3 (self service) - 5 and 8 (cash bars).

Certificate of Attendance Attendance certificates will be issued on request to all regularly registered participants at the Secretariat Desk at the end of the Symposium. The request form is enclosed in the Symposium registration envelope.

XIV How to reach the Symposium Venue

From the Leonardo da Vinci Airport by train: Fiera di Roma is located 20 minutes from the Leonardo da Vinci/Fiumicino Intercontinental Airport. When arriving at Leonardo da Vinci/Fiumicino Airport, after the Passport Check, follow the sign railway station. From here the “Treno regionale” leaves every 15 minutes to reach the main railway stations in Rome (including 8 subway stations). Get off the train at the Ostiense railway station and you can reach the Symposium Venue (Fiera di Roma) either by underground (Metropolitana linea B stop: Basilica S. Paolo) or by bus (no. 30-715-716).

Train Service Time Table: Every day from 6.27 a.m. to 11.27 p.m. Price € 5,00

From the Rome Termini Railway Station: • By underground When arriving at the Termini railway station, follow the signs for the “Metropolitana Linea B” and take the train towards the “Laurentina” station. Get off the train at the Basilica S. Paolo station (approximately 20 min). From there you can reach the Symposium Venue (Fiera di Roma) either by public buses (no. 670 - 715 – 716), or by the Congress shuttle bus, or by walking (approximately 15 minutes).

• By bus From Termini railway station bus no. 714 will take you directly to the Fiera di Roma (bus stop in front of the main entrance of the Fiera di Roma).

From the City Center: The underground and several bus lines connect the City Center to the Fiera di Roma, as follows: • From Cicerone / Cavour: bus no. 30 • From Piazza Venezia: bus no. 160 • From Flaminio / Piazza Barberini: Underground (Metropolitana linea A – stop: Termini) and bus no. 714 or at Termini station change Metropolitana and take the Linea B towards the “Laurentina” station. Get off the train at the Basilica S. Paolo station (approximately 20 min.). From there you can reach the Symposium venue (Fiera di Roma) either by public buses (no. 670 - 715 - 716), or by the Congress shuttle bus, or by walking (approximately 15 minutes). Tickets valid for the entire urban system (underground and buses) can be purchased at tobacco shops, news-stands and automatic dispenser located near the major bus or underground stops. Costs for tickets are: • BIT ticket (valid for 75 minutes) = € 1,00 • BIG ticket (valid for one day) = € 4,00 • 5BIT or MULTIBIT ticket (valid for 5 trips of 75 minutes each) = € 5,00

From any direction by car: In less than 10 minutes, Via Cristoforo Colombo connects Fiera di Roma with Grande Raccordo Anulare (G.R.A., the Rome ringroad) which is linked to all the main motorway junctions: A1 for Florence and Naples, A2 for the Leonardo da Vinci/Fiumicino Airport for Civitavecchia, A24 for L’Aquila and Pescara, Via Pontina for Latina.

Shuttle Buses: A shuttle bus service from the ISA 2006 Symposium hotels (booked through the Congress) and from the Basilica S. Paolo underground station to the Symposium Venue and vice versa is provided. Further details about the shuttle bus schedule are available in the Symposium registration envelope.

XV Official Carrier of the Symposium

Alitalia is the Official Carrier for ISA 2006 Symposium.

Practical Information

Currency The official currency in Italy is the Euro (€).

Tipping Service is usually included in the bill in bars and restaurants, but tips are welcome.

Bank Banks are open from Monday to Friday from 8.30 am to 1.30 pm and from 3.00 pm to 4.00 pm. Banks are closed on Saturday and Sunday. Many banks have automatic currency exchange machines that also take credit cards.

Post Office The nearest post office is located at Via Tarigo 5/11 (Piazza dei Navigatori) Opening Hours: from Monday to Friday 8.30 am - 2.00 pm and Saturday 8.30 am - 1.30 pm.

Electricity The electrical power voltage is 220 volts – 50 Hz. Foreign voltage could require an adapter.

Useful Numbers Ambulance dial 118 Police dial 113 Fire Brigade dial 115

Weather June weather in Rome is generally sunny and warm. The temperature often rises during the day at an average of 28° C (82° F).

XVI Scientific Program Information

The Scientific Program includes: Plenary Lectures, Master Lectures, Symposia, Workshops, Selected Oral Communications and Poster Sessions for submitted papers.

Audiovisual Equipment • The Slide Center is linked with all the Symposium Rooms. • The Symposium rooms will be equipped for PowerPoint presentations (LCD-panel projection system for video projection and one computer).

Guidelines for Speakers and Chairmen For Chairmen: • Locate your Symposium Room in due time. • Find yourself in the Room at least 10 minutes before the beginning of the Session. • Respect the timing assigned to the Session and to each presentation. • All presentations, discussions, and questions will be in English.

For Speakers: • The CD-ROM or the Pen Drive must be delivered to the Slide Center, if it is possible the day before, otherwise at least two hours before the beginning of the Sessions. • Locate your Symposium Room in due time. • Be in the Room assigned for your presentation at least 10 minutes before the beginning of the Session. • Respect the timing allowed for your presentation. • All presentations, discussions, and questions will be in English. • Please bring two copies (one as back up) of the electronic media containing your slides.

CME/ECM Credits Italian CME Credits/Crediti ECM (for Italian participants only) CME credits (Crediti ECM) have been applied for from the Italian Ministry of Health. Interested Italian participants must request the ECM envelope at the ECM/CME Desk in the Registration Area. The following credits have been awarded on a daily basis. • Sunday, June 18: I educational pathway: 2 credits • Monday, June 19: II educational pathway: 5 credits • Tuesday, June 20: III educational pathway: 5 credits • Wednesday, June 21: IV educational pathway: 7 credits • Thursday, June 22: V educational pathway: 4 credits

Participants will find all the necessary forms and questionnaires in the ECM envelope (please request it at the CME Desk in the Registration Area).

The electronic portal is placed at the entrance of the Symposium Venue. Please wear the electronic tags all the time and use the electronic portal for complete recording data. Please do not forget that in order to be eligible for ECM credits participants must attend the scientific sessions for 100% of their duration. Incomplete attendance data will automatically invalidate the accreditation procedure.

Please check the ECM/CME Desk in the Registration Area for more information.

After having collected their badge, Italian participants are asked to go to the ECM/CME Desk in order to receive the electronic tag which will be instantly associated to the registrant’s name. It is sufficient to pass through the electronic portal to have the credits recorded.

XVII To obtain credits, Italian participants must: • Record both the entrance and the exit of each Meeting day; • Return the evaluation form, duly filled in, to the ECM/CME Desk; • Return the multiple choice questionnaires. The anagraphical data must be compulsorily indicated since required by the Italian Ministry of Health; • Return the electronic tag to the ECM/CME Desk at the end of the Symposium.

Please note that should you loose or fail to return the tag, you will be charged € 10,00 by the Organizing Secretariat.

European CME Credits (EACCME) (for European and USA citizens) • The Fondazione Giovanni Lorenzini Medical Science Foundation is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide ISA 2006 Symposium the following CME activity for medical specialists. The EACCME is an Institution of the European Union of Medical Specialists (UEMS), www.uems.be The Fondazione Giovanni Lorenzini Medical Science Foundation is designated for a maximum of 27 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. EACCME credits are recognized by the American Medical Association towards the Physician’s Recognitions Award (PRA). To convert EACCME credit to AMA PRA category 1 credit, contact the AMA.

Federation of the Royal Colleges of Physicians of the UK • CME Credits for the ISA 2006 Symposium have been requested from the Federation of the Royal Colleges of Physicians of the UK.

Poster Sessions Posters have been selected among the abstracts submitted by the participants. All participants are invited to come and view the posters which are displayed in Poster Area “A” and in Poster Area “B” from Monday, June 19 to Thursday, June 22, 2006.

Mounting and Removal of the Posters: the mounting and the removal of the posters must be done by the authors according to the following schedule:

I Monday, June 19 Mounting: from 7.30 am to 8.30 am Removal: from 6.30 pm to 7.00 pm

I Tuesday, June 20 Mounting: from 7.30 am to 8.30 am Removal: from 6.30 pm to 7.00 pm

I Wednesday, June 21 Mounting: from 7.30 am to 8.30 am Removal: from 6.30 pm to 7.00 pm

I Thursday, June 22 Mounting: from 7.30 am to 8.30 am Removal: from 4.00 pm to 4.30 pm

The organizers are not responsible for any item, including posters, left in the room.

Poster Display: Each poster session will have a duration of ONE DAY: I Monday, June 19 from 8.30 am to 6.30 pm I Tuesday, June 20 from 8.30 am to 6.30 pm I Wednesday, June 21 from 8.30 am to 6.30 pm I Thursday, June 22 from 8.30 am to 4.00 pm

XVIII Poster Discussion: one of the authors will be available at the poster site as follows: I Monday, June 19 from 10.30 am to 11.00 am from 1.00 pm to 2.30 pm from 4.10 pm to 4.30 pm I Tuesday, June 20 from 10.30 am to 11.00 am from 1.00 pm to 2.30 pm from 4.00 pm to 4.30 pm I Wednesday, June 21 from 10.30 am to 11.00 am from 1.00 pm to 2.30 pm from 4.00 pm to 4.30 pm I Thursday, June 22 from 10.30 am to 11.00 am from 12.30 pm to 2.00 pm

Guidelines for Poster Display • Poster size must be: cm 90 width x 150 height. • The poster number assigned to your abstract may be found at the top of the board. The authors must use the board with this number. • It is requested to use paper sheet as posters must be mounted with scotch tape, not with drawing pins.

Please note • For each accepted abstract, the registration fee of at least one of the Authors is required. • “Poster assistants” will be present for any information or help you may need. • Facilities for slide projection are not available at the site of poster presentation. • Photocopies made from the reduced photograph of your poster and any additional material may be distributed by the author(s) at the poster site.

Young Investigator Poster Awards Thursday, June 22 - h. 1.30 pm – Room 10

• 20 awards will be made to recognize scientific merit and outstanding research achievements in a poster presentation by an investigator 35 years old or less, who has submitted an abstract in the competition. Selection is based on originality, importance of work, work accomplished, quality of experimental design and methodology, strength and reliability of data and means of expression.

These posters will be reviewed each day of the Symposium by the Awards Committee for the selection of up to 20 winners and the names of the semi-finalists will be posted each day in the Registration area. Each winner will receive a certificate and an award.

The Poster Awards for Young Investigators will be announced and presented on Thursday, June 22 at 1.30 pm in Room 10. The poster presenter must be present at the ceremony to win the award as no awards may be accepted in absentia.

Support for the Young Investigator Poster Awards is made possible through the generosity of the INTERNATIONAL ATHEROSCLEROSIS SOCIETY WYETH

XIX Registration Fees and Hotel/Travel Grants for Young Investigators • 200 Registration Fees and Hotel/Travel Grants have been made available by ISA2006 Symposium to young investigator 35 years old or less, with limited financial resources whose abstract has been selected for an oral or poster presentation.

ISA 2006 gratefully acknowledges the 6 awards made available by the EUROPEAN ATHEROSCLEROSIS SOCIETY and the 10 Awards by the IAS ASIAN-PACIFIC FEDERATION.

Other Meetings • European Atherosclerosis Society (EAS) Members Assembly Wednesday, June 21 at 12.30 pm – Room 15 • International Atherosclerosis Society (IAS) General Assembly Thursday, June 22 at 12.30 pm – Room 10 • Young Investigator Poster Award Ceremony Thursday, June 22 at 1.30 pm – Room 10

XX Social Program

Tickets will be required for all the Social Events, whether or not a charge is made. No admittance to the events will be possible without presentation of the corresponding ticket. Tickets will be found in the Symposium badge. Please note that tickets for the reserved events are valid for one person only.

SOCIAL EVENTS (for registered participants and accompanying persons)

• SUNDAY, JUNE 18, 2006 - h. 7.30 pm WELCOME RECEPTION AT THE “FIERA DI ROMA” (complimentary) - no ticket is required

• MONDAY, JUNE 19, 2006 CONCERT IN THE “BASILICA SANTA MARIA DEGLI ANGELI E DEI MARTIRI” (Piazza della Repubblica) h. 8.00 pm : Visit of the Basilica h. 8.30 pm : Concert (duration: approximately one hour) Ticket price per person is € 30,00

The Concert, for organ, trumpet and 4 soloist voices will be performed by musicians and singers of the worldwide well-known Santa Cecilia Academy and of the Conservatoire of Rome.

Santa Maria degli Angeli e dei Martiri Santa Maria degli Angeli e dei Martiri was built by Michelangelo in 1563 on a site occupied by the ruins of the Baths of Diocletian; after the great artist died, in 1564, his design was completed by his pupil Jacopo Lo Duca. The Church is dedicated to the Blessed Virgin Mary, the Angels and the Christian sla- ves who died building the Baths of Diocletian. Although the interior has changed consider-ably, this is one of the few places one can appreciate the size and splendor of the imperial baths. In 1749 major alterations were carried out by Luigi Vanvitelli in preparation for the Holy Year of 1750. Santa Maria degli Angeli was the official State Church during the Kingdom of Italy and since 1896 it has been the official Roman site of religious ceremonies promoted by the Italian State. In 1920, the church was given the status of basilica by Pope Benedict XV.

• TUESDAY, JUNE 20, 2006 GALA DINNER AT THE “COMPLESSO MONUMENTALE S. SPIRITO IN SAXIA” (Borgo S. Spirito 2/3) h. 8.00 pm : Cocktail h. 8.30 pm : Gala Dinner Ticket price per person is € 95,00

The ancient Corsia Sistina (Sistina Ward) is adorned with a cycle of frescoes commemorating the history of the former hospital. The origins of Santo Spirito in Saxia complex date back to A.D. 727 when the Saxon king Ina founded the "Schola Saxonum" (from where the word "Saxia" derives), a refuge center for pilgrims arriving in Rome to visit St. Peter the Apostle's tomb. The complex, destroyed by fire and pillage, was rebuilt by Marchionne d'Arezzo in 1198 under the Pontificate of Innocent III. He en- trusted the construction and organization to the knight Guido of the Counts of Guillaume of Montpellier whose devotion and diligence gave life to a wonderful institution destined to assist the poor, the sick and the orphans.

XXI SOCIAL EVENT (for registered accompanying persons)

• MONDAY, JUNE 19, 2006 (morning - half day) TOUR OF “SAN PIETRO IN VINCOLI” AND “SAN CLEMENTE CHURCH” - (complimentary) - Lunch not included. The tour will start with a visit to San Pietro in Vincoli. This church was built in the 5th century to house a reliquary believed to contain the prison chains of Saint Peter. The “vincoli” or chains may have given the church its name, but today it is best known for Michelangelo’s Moses.

From the church, there will be a 20-minute walk through the park of Colle Oppio, one of the Seven Hills of Rome, which offers one of the best views of the Coliseum.

The tour will end with a visit to the Basilica of San Clemente. One of the most interesting churches of Rome, San Clemente is a 12th century church built on top of another church from the 4th century, which in turn was built over a 2nd century pagan temple dedicated to the god Mithras.

Meeting point: At the entrance of San Pietro in Vincoli Church (Piazza San Pietro in Vincoli, 4/A) at 8.45 am.

XXII Satellite Symposia

BELGRADE, SERBIA & MONTENEGRO FROM VASCULAR BIOLOGY TO ATHEROSCLEROSIS PREVENTION: AN EASTERN EUROPEAN PERSPECTIVE June 15-16, 2006 MILITARY MEDICAL ACADEMY (Str. Crnotravska 17) Chairperson: Dragan M. Djuric´ Contact person: Dragan M. Djuric´ Institute of Medical Physiology School of Medicine, University of Belgrade Visegradska 26/II, P.O.Box 783 11000 BELGRADE - SERBIA & MONTENEGRO Phone: (+381) 64 23 06 714 Fax: (+381) 11 684 558 E-mail: [email protected] Website: http://www.physiology.org.yu/eng/htm/konf2006/announcement.pdf

MADRID, SPAIN BIOLOGICAL MARKERS IN METABOLIC SYNDROME June 15-17, 2006 CONGRESS PALACE Chairperson: Jesus Millan Nuñez-Cortes Contact person: Prof. Jesus Millan Nuñez-Cortes Department of Internal Medicine, Hospital General Universitario Gregorio Marañón, School of Medicine Universidad Complutense MADRID - SPAIN Phone: (+34) 91 5868270 / 3941261 Fax: (+34) 91 5866728 E-mail: [email protected]

XXIII MILAN, ITALY NOVEL INSIGHTS IN ATHEROTHROMBOSIS: FROM PATHOPHYSIOLOGY TO THERAPY June 16-17, 2006 CENTRO CARDIOLOGICO MONZINO, IRCCS (Via Parea 4) Chairperson: Elena Tremoli Scientific Director: Paolo Biglioli Organizing Secretariat: Viviana Biagioli, Ivan Celi, Luisa Triglia Scientific Direction Centro Cardiologico Monzino Via Parea 4 20138 MILAN - ITALY Phone: (+39) 02 58002456 E-mail: [email protected] Website: www.cardiologicomonzino.it

NAPLES, ITALY ATHEROSCLEROSIS: FROM PLAQUE DEVELOPMENT TO CLINICAL DISEASE June 16-17, 2006 JOLLY HOTEL (Via Medina, 70) Chairpersons: Alberico L. Catapano, Andrea Mezzetti Organizing Secretariat: Aristea Roma Via Tolmino 5 00198 ROME - ITALY Phone: (+39) 06 845431 Fax: (+39) 06 84543700 E-mail: [email protected] Website: www.aristea.com/isa2006

ROME, ITALY THE BURDEN OF ATHEROTHROMBOSIS June 23, 2006 ROME CAVALIERI HILTON (Via A. Cadlolo 101) Chairperson: Juan Badimon Contact person: Katy Brooks Photosound Communications Ltd Sion Park Stansted Road Birchanger Herts, CM23 5PU - UK Tel: (+44) (0) 1279 818400 Fax: +44 (0) 1279 647746 E-mail: [email protected]

XXIV PARMA, ITALY

HIGH DENSITY LIPOPROTEINS: FROM BASIC SCIENCE TO THERAPEUTIC APPLICATIONS June 23-24, 2006 STARHOTEL DU PARC (Viale Piacenza, 12/C) Chairpersons: Laura Calabresi, Franco Bernini Contact person: Laura Calabresi E. Grossi Paoletti Center Department of Pharmacological Sciences University of Milan Via Balzaretti 9 20133 MILAN - ITALY Phone: (+39) 02 50319906 Fax: (+39) 02 50319900 E-mail: [email protected]; [email protected] Website: http://linux.farma.unimi.it/HDL2006

BOLOGNA AND FORLÍ, ITALY PHYSICAL ACTIVITY, EXERCISE AND CARDIOVASCULAR HEALTH June 23-25, 2006 AULA ABSIDALE DI SANTA LUCIA (Via De’ Chiari, 23, Bologna) and COMPLESSO MONUMENTALE S. DOMENICO (Piazza Guido da Montefeltro, Forlì) Chairpersons: Antonio V. Gaddi, Franco Rusticali Organizing Secretariat: Istituto per lo Sviluppo della Cardiologia Soc. Coop. a.r.l. P.tta F.lli Ruffini 6 47100 FORLÌ - ITALY Phone: (+39) 0543 33283 Fax: (+39) 0543 31720 E-mail: [email protected] Website: www.isa2006.unibo.it

XXV In Grateful Appreciation

The Organizing Committee gratefully acknowledges the generous support of the following:

PLATINUM LEVEL PFIZER Inc.

GOLD LEVEL SANOFI AVENTIS ASTRAZENECA ROCHE UNILEVER MERCK SHARP & DOHME/SCHERING PLOUGH FOURNIER PHARMA BRISTOL-MYERS SQUIBB TAKEDA PHARMACEUTICALS NORTH AMERICA, Inc. ABBOTT SANKYO PHARMA Inc. and SANKYO Co. Ltd KOWA COMPANY Ltd. ALPRO FOUNDATION MERCK KgaA Germany

SILVER LEVEL SCHERING PLOUGH S.p.A. MERCK SHARP & DOHME ITALIA S.p.A. RECORDATI GLAXOSMITHKLINE NOVARTIS PHARMA AG CHIESI FARMACEUTICI TAKEDA ITALIA FARMACEUTICI S.p.A. MERCK PHARMA S.p.A. SIGMA-TAU ESPERION THERAPEUTICS

XXVI BRONZE LEVEL

INDENA S.p.A.

PRONOVA BIOCARE

SCHERING S.p.A.

NUTRITION FOUNDATION OF ITALY - NFI

MONSANTO COMPANY

WYETH and

PFIZER ITALIA S.r.l. CV THERAPEUTICS EUROPE Ltd. DOMPE' FARMACEUTICI S.p.A. INSTITUT DE RECHERCHES INTERNATIONALES SERVIER WYETH S.p.A. SPA – SOCIETÀ PRODOTTI ANTIBIOTICI BIOCENTRIC Inc. NICOX RESEARCH INSTITUTE S.r.l. B. BRAUN MEDIZINTECHNOLOGIE GMBH ETHICON ENDO-SURGERY

EXHIBITORS Alpro Soya AstraZeneca Bayer S.p.A. B. Braun Medizintechnologie GmbH Cayman Chemical Company/Cabru s.a.s. Chiesi Farmaceutici Comocuore Danone S.p.A. EAS - European Atherosclerosis Society Fondazione Giovanni Lorenzini Medical Science Foundation Fournier Pharma Fresenius Medical Care Deutschland GmbH Fukuda Denshi GlaxoSmithKline IAS - International Atherosclerosis Society Indena S.p.A. Jurilab Ltd. Kenes International Kowa Company Limited Medpace Inc. Merck Merck KGaA Mercodia AB Miltenyi Biotec Noberasco S.p.A. Pfizer Inc. Quantrimetrix Corporation Raisio Benecol Ltd. Roche SAIP - Society of Atherosclerosis Imaging & Prevention Schering-Plough Sigma-Tau S.I.S.A. - Italian Society for the Study of Atherosclerosis Skylight Biotech, Inc. SPA Società Prodotti Antibiotici S.p.A. Unilever Wisepress On-Line Bookshop

The Organizing Committee gratefully acknowledges Noberasco S.p.A. for offering its products during the exhibition XXVII Exhibition Floor Map

Exhibition Hours Sunday June 18, 2006 1.30 pm - 8.30 pm Monday June 19, 2006 8.30 am - 6.30 pm Tuesday June 20, 2006 8.30 am - 6.30 pm Wednesday June 21, 2006 8.30 am - 6.30 pm Thursday June 22, 2006 8.30 am - 4.30 pm

XXVIII Exhibitors

No. A1 Roche No. A2-A4-A6-A8 Astra Zeneca No. A3 Comocuore - Noberasco No. A9 Indena S.p.A. No. A10 Chiesi Farmaceutici No. A11 Mercodia AB No. A12-A14 Pfizer Inc. No. A13 Alpro Soya

No. B1-B2-B3 Merck KGaA No. B4 Skylight Biotech, Inc. No. B5-B7 Medpace Inc. No. B6 Sigma-Tau No. B8 Quantrimetrix Corporation No. B9 Danone S.p.A. No. B10 Miltenyi Biotec No. B11 B. Braun Medizintechnologie GmbH No. B12-B13-B14 Unilever

No. C1-C2-C4 Schering-Plough No. C3 Cayman Chemical Company/Cabru s.a.s. No. C5-C6-C7- Fournier Pharma C8-C9-C10

No. D1-D2-D3 Merck No. D4 SPA - Società Prodotti Antibiotici S.p.A. No. D5 Jurilab Ltd. No. D6 Bayer S.p.A. No. D7-D9 GlaxoSmithKline No. D8-D10 Fresenius Medical Care Deutschland GmbH

No. E1 Kowa Company Limited No. E2-E3 Raisio Benecol Ltd. No. E4-E5 Wisepress On-Line Bookshop No. E6 Fukuda Denshi

No. F1 International Atherosclerosis Society (IAS)/Italian Society of Atherosclerosis (S.I.S.A.)/Fondazione Giovanni Lorenzini Medical Science Foundation (Milan-Houston) No. F2 ISA 2006 Exhibition Management - Fiera di Roma No. F3 European Atherosclerosis Society (EAS) No. F4 Society of Atherosclerosis Imaging and Prevention (SAIP) No. F5 Kenes International

XXIX PLEASE NOTE:

ECM Credits (Italy):2 ALL THE SESSIONS

EACCME Credits (Europe and USA): 1 ALL THE SESSIONS

Federation of the Royal Colleges of Physicians (UK):3 ALL THE SESSIONS

Credits received - Credits received - Credits pending

XXX Time Table 7.30 8.30 9.30 8.00 9.00 10.30 11.30 12.30 13.30 14.30 15.30 16.30 17.30 18.30 19.30 20.30 21.30 10.00 11.00 12.00 13.00 14.00 15.00 16.00 17.00 18.00 19.00 20.00 21.00 TIME Investigator Ceremony Poster Lectures General Assembly • Plenary • Workshops • IAS • Young • Young T E S P S R O I I I E T X B H O N THURSDAY, June 22 THURSDAY, I I I T E T E T T E A S C S A A R O N R R G R Lectures Symposia Lectures • Plenary • Sponsored • Workshops • Master T E S P S R O I I I T E B X H O N WEDNESDAY, June 21 WEDNESDAY, I I I T E T E T T E A S C S A A R O N R R G R Lectures Symposia Lectures • Plenary • Sponsored • Workshops • Master T E S P S R O • 20.00 Gala Dinner I I I E T X B H O N I I I T E T T E T E A S C S A A R O N R R G R Lectures Symposia Lectures • Plenary • Sponsored • Workshops • Master • 20.00 Concert T E S P S R O I I I T E X B H O N I I I T E T E T T E A S C S A A R O N R R G R • 17.00 Opening Ceremony • 18.30 Concert by the Band of the Carabinieri Corps • 19.30 Welcome Reception Pre-ISA 2006 Sessions I I I E T X B H O N SUNDAY, June 18 SUNDAY, I I I E T E T T T E S C A A A S O N R R R R G 7.30 8.30 9.30 8.00 9.00 10.30 11.30 12.30 13.30 14.30 15.30 16.30 17.30 18.30 19.30 20.30 21.30 TIME June 19 MONDAY, June 20 TUESDAY, 10.00 11.00 12.00 13.00 14.00 15.00 16.00 17.00 18.00 19.00 20.00 21.00 XXXI

XIV International Symposium on Atherosclerosis Rome, Italy, June 18-22, 2006

Scientific Program (THE AUTHOR IN BOLD FACE IS THE PRESENTING AUTHOR) PARTICIPANTS ARE REQUESTED TO REFRAIN FROM SMOKING IN THE MEETING AREA

ADMISSION TO THE SCIENTIFIC SESSIONS RESERVED ONLY FOR PARTICIPANTS WEARING THE MEETING BADGE S U N D A Y

PRE-ISA 2006 SESSIONS

13.30 - 16.45 SUNDAY, June 18 ROOM 2

Su-S1 Joint ISA2006-National Lipid Association (NLA) S Symposium 1 U REPORT OF THE NLA TASK FORCE ON STATIN SAFETY N Chair: P.H. Jones (Houston, TX, USA) D hour: abstract bk. A page ref.: 13.30 - 13.35 INTRODUCTION Y SAFETY OF LIPID LOWERING AGENTS: A COMPLEX – PUBLIC HEALTH ANALYSIS P.H. Jones (Houston, TX, USA) 13.35 - 13.50 THE LIVER 1 P.H. Jones (Houston, TX, USA) replacing J.M. McKenney 13.50 - 14.05 THE NEUROLOGICAL SYSTEM 1 J.R. Guyton (Durham, NC, USA) 14.05 - 14.20 THE KIDNEY 1 M.H. Davidson (Chicago, IL, USA) 14.20 - 14.35 THE MUSCLE 2 T.A. Jacobson (Atlanta, GA, USA) 14.35 - 14.45 SUMMARY OF TASK FORCE RECOMMENDATIONS – P.H. Jones (Houston, TX, USA) 14.45 - 15.00 AUDIENCE DISCUSSION – M.H. Davidson (Chicago, IL, USA) - J.R. Guyton (Durham, NC, USA) - T.A. Jacobson (Atlanta, GA, USA) - P.H. Jones (Houston, TX, USA) 15.00 End of the Session

15.00 - 15.15 BREAK

Su-S2 Joint ISA2006-National Lipid Association (NLA) Symposium 2 ETIOLOGY OF THE METABOLIC SYNDROME? Chair: S.M. Grundy (Dallas, TX, USA)

15.15 - 15.20 INTRODUCTION – S.M. Grundy (Dallas, TX, USA) 15.20 - 15.30 THE METABOLIC SYNDROME: A DISEASE OR A METHOD TO IDENTIFY 2 HIGH RISK PATIENTS? W.V. Brown (Decatur, GA, USA) 15.30 - 15.40 CARNEADES: WHO IS HE? OR THE METABOLIC SYNDROME 3 S. Del Prato (Pisa, Italy) 15.40 - 15.50 IS INSULIN RESISTANCE THE CENTRAL CAUSE OF THE METABOLIC SYNDROME? 3 A.C. Goldberg (St. Louis, MO, USA) 15.50 - 16.00 THE METABOLIC SYNDROME-IMPORTANCE OF VISCERAL ADIPOSITY AND 4 ADIPOCYTOKINES Y. Matsuzawa (Osaka, Japan) 16.00 - 16.10 LIFESTYLE IS A CRUCIAL FEATURE OF THE METABOLIC SYNDROME 4 N.J. Stone (Chicago, IL, USA) 16.10 - 16.20 DYSLIPIDEMIA IS A CENTRAL MANIFESTATION OF THE METABOLIC SYNDROME 4 R. Carmena (Valencia, Spain) 16.20 - 16.45 PROGRAM SUMMARY/ PANEL Q&A SESSION – W.V. Brown (Decatur, GA, USA) - R. Carmena (Valencia, Spain) - S. Del Prato (Pisa, Italy) - A.C. Goldberg (St. Louis, MO, USA) - S.M. Grundy (Dallas, TX, USA) - Y. Matsuzawa (Osaka, Japan) - N.J. Stone (Chicago, IL, USA) 16.45 End of the Session Symposia organized in collaboration with the National Lipid Association (NLA) 3 14.30 - 16.30 SUNDAY, June 18 ROOM 3

S Su-S3 Symposium 3 U GENOMIC RESEARCH IN CARDIOVASCULAR N MEDICINE AND THE SUPPORT OF TECHNOLOGY D hour: A Chairs: I. Zavaroni (Parma, Italy); L. Gnudi (London, UK) abstract bk. page ref.: Y 14.30 - 14.40 WELCOME AND INTRODUCTION – I. Zavaroni (Parma, Italy) 14.40 - 15.00 GENE-EXPRESSION PROFILING IN ATHEROSCLEROSIS 5 P.S. Tsao, T. Quertermous (Stanford, CA, USA) 15.00 - 15.20 DATA INTEGRATION AND DATA ANALYSIS FOR COLLABORATIVE STUDIES 5 IN CARDIOVASCULAR DISEASES Z. Yakhini (Tel Aviv and Haifa, Israel) 15.20 - 15.40 CAN HIGH-THROUGHPUT TECHNOLOGIES CONTRIBUTE TO CARDIOVASCULAR 5 RISK ESTIMATION? D. Ardigò, T. Quertermous, I. Zavaroni (Parma, Italy and Stanford, CA, USA) 15.40 - 16.00 THE CONTEXT OF EUROPEAN UNION IST FUNDING MECHANISM IN THE 6TH – FRAMEWORK PROGRAM S. Copelli (Parma, Italy) 16.00 - 16.15 THE INTEGRATION OF CLINICAL DATA AND HIGH-THROUGHPUT TECHNOLOGIES 6 IN CARDIOVASCULAR RESEARCH: PRESENTATION OF THE MULTIKNOWLEDGE PROJECT F. Mercalli, D. Ardigò, on behalf of the Multi-Knowledge Consortium (Como and Parma Italy) 16.15 - 16.30 GENERAL DISCUSSION – 16.30 End of the Session

The meeting will be hosted and funded by the Multi-Knowledge Consortium, which is a research project granted by the European Union, 6th Framework Program (reference: IST-2004-027106)

4 XIV International Symposium on Atherosclerosis

17.00 - 19.30 SUNDAY, June 18 ROOM 1

17.00 - 18.30 OPENING CEREMONY S U E. Mannarino (Perugia, Italy) - President of the Italian Society for the N Study of Atherosclerosis and Vice-President of the ISA 2006 Symposium D A C.R. Sirtori (Milan, Italy) - President of the ISA 2006 Symposium Y S.M. Grundy (Dallas, TX, USA) - President of the International Atherosclerosis Society R. Paoletti (Milan, Italy) - Honorary President of the ISA 2006 Symposium and President of the Giovanni Lorenzini Foundation

18.30 - 19.30 CONCERT BY THE BAND OF THE CARABINIERI CORPS Chairs: Brewer H.B., Jr. (Bethesda, MD, USA) Grundy S.M. (Dallas, TX, USA)

19.30 WELCOME RECEPTION

7 8.30 - 12.30 MONDAY, June 19 ROOM 1

Mo-PL1 Plenary Session 1 VASCULAR BIOLOGY Chairs: G. Hansson (Stockholm, Sweden); P. Libby (Boston, MA, USA); hour: A.L. Catapano (Milan, Italy) abstract bk. page ref.: 8.30 - 9.00 LIPOPROTEINS AND THE ARTERIAL WALL 7 A.M. Gotto, Jr. (New York, NY, USA) 9.00 - 9.30 THE PPAR ALPHA SYSTEM: A PROTOTYPE OF NUCLEAR RECEPTOR 7 J.-C. Fruchart (Lille, France) 9.30 - 10.00 WOUNDING AND HEALING OF VULNERABLE PLAQUES - A TWO-EDGED 8 M SWORD OF PLAQUE INFLAMMATION O P.T. Kovanen (Helsinki, Finland) 10.00 - 10.30 THE INTERPLAY OF DYSLIPIDEMIA AND INFLAMMATION IN THE EVOLUTION 8 N OF ATHEROSCLEROTIC PLAQUE D A. Mezzetti, A. Iezzi, M.L. Fazia, F. Cipollone (Chieti, Italy) A 10.30 End of the Session Y

10.30 - 11.00 BREAK - POSTERS - EXHIBITS

Mo-S4 Sponsored Symposium 4

CB1 BLOCKADE: NEW APPROACH FOR THE MANAGEMENT OF ATHEROGENIC DYSLIPIDAEMIA AND MULTIPLE CARDIOMETABOLIC RISK FACTORS IN ABDOMINALLY OBESE PATIENTS Chairs: J.-C. Fruchart (Lille, France); C.R. Sirtori (Milan, Italy)

11.00 - 11.05 WELCOME AND INTRODUCTION – J.-C. Fruchart (Lille, France) 11.05 - 11.20 PHYSIOPATHOLOGY OF ADIPOSE TISSUE: ROLE OF ADIPOKINES AND 40 FREE FATTY ACIDS M. Lafontan (Toulouse, France) 11.20 - 11.35 ROLE OF HDL-C AND TG METABOLISM IN ABDOMINAL OBESITY 40 P.J. Barter (Sydney, NSW, Australia) 11.35 - 11.55 CB1 BLOCKADE, A NEW THERAPEUTIC TARGET FOR THE TREATMENT OF 41 CARDIOMETABOLIC DISORDERS: MECHANISM(S) OF ACTION V. Di Marzo (Pozzuoli, Naples, Italy) 11.55 - 12.20 RESULTS FROM THE RIO PROGRAM 41 J.P. Després (Sainte-Foy, QC, Canada) 12.20 - 12.30 CONCLUSIONS/QUESTIONS AND ANSWERS – C.R. Sirtori (Milan, Italy) 12.30 End of the Session

Supported in part by an unrestricted educational grant provided by: Sanofi Aventis

12.30 - 14.30 LUNCH - SCIENTIFIC SESSIONS - POSTERS - EXHIBITS

8 11.00 - 14.30 MONDAY, June 19 ROOM 2

Mo-W1 Workshop 1 PHARMACOLOGY OF ARTERIAL DISEASE: HDL-TARGETED THERAPIES (1st part) hour: Chairs: R.S. Newton (Ann Arbor, MI, USA); R. Lauro (Rome, Italy) abstract bk. page ref.:

11.00 - 11.20 EFFECTS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITION ON 11 LIPOPROTEIN METABOLISM IN HUMANS M.E. Brousseau, M.R. Diffenderfer, J.S. Millar, C. Nartsupha, B.F. Asztalos, F.K. Welty, M.L. Wolfe, J.P. Mancuso, A.G. Digenio, D.J. Rader, E.J. Schaefer (Boston, MA, Philadelphia, PA, Groton and New London, CT, USA) 11.20 - 11.40 HDL THERAPY FOR THE SUB-ACUTE TREATMENT OF PATIENTS WITH 11 M ACUTE CORONARY SYNDROMES O R.S. Newton (Ann Arbor, MI, USA) N 11.40 - 12.00 MODULATION OF CHOLESTEROL ESTER TRANSFER PROTEIN ACTIVITY 12 IN THE TREATMENT OF CARDIOVASCULAR DISEASE D J.-C. Tardif (Montreal, QC, Canada) A 12.00 - 12.15 CHOLESTERYL ESTER TRANSFER PROTEIN CONCENTRATIONS PREDICT 12 Y CARDIOVASCULAR EVENTS IN PATIENTS WITH CORONARY ARTERY DISEASE TREATED WITH PRAVASTATIN P. Marschang, A. Sandhofer, A. Ritsch, I. Fiser, E. Kvas, J.R. Patsch (Innsbruck, Vienna and Graz, Austria) 12.15 - 12.30 EFFECT OF ROSUVASTATIN ON REMODELLING OF HIGH-DENSITY 12 LIPOPROTEINS IN ATHEROGENIC DYSLIPIDAEMIAS: ROLE OF CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) M.J. Chapman, M.J. Caslake, M. Guerin, P.N. Durrington, M.K. Palmer, F. McTaggart, C.J. Packard (Paris, France, Glasgow, Manchester and Cheshire, UK) 12.30 - 12.45 EFFECT OF THE LXR AGONIST T0901317 ON REVERSE CHOLESTEROL 12 TRANSPORT IN VIVO I. Zanotti, F. Potì, E. Favari, S. Bellosta, F. Bernini (Parma and Milan, Italy) 12.45 - 13.00 IN VITRO INCUBATION OF ETC-642 DISCS: POTENTIAL REMODELING OF HDL 13 SUBFRACTIONS AS CHARACTERIZED BY CAPILLARY ISOTACHOPHORESIS B. Zhang, Y. Uehara, S. Miura, K. Saku (Fukuoka, Japan) 13.00 End of the Session

13.00 - 14.30 LUNCH - SCIENTIFIC SESSIONS - POSTERS - EXHIBITS

Mo-S5 Sponsored Symposium 5 (Session in Italian) UN APPROCCIO INNOVATIVO AL TRATTAMENTO DELL’IPERCOLESTEROLEMIA: EFFICACIA E SICUREZZA CON LA DOPPIA INIBIZIONE Chairs: E. Mannarino (Perugia, Italy); R. Paoletti (Milano, Italy); C.R. Sirtori (Milano, Italy) 13.00 - 13.05 BENVENUTO – 13.05 - 13.20 FISIOPATOLOGIA DELL’ASSORBIMENTO INTESTINALE DEL COLESTEROLO – A. Mezzetti (Chieti, Italy) 13.20 - 13.35 UN INNOVATIVO MECCANISMO D’AZIONE DALLA RICERCA MOLECOLARE E – RELATIVE RICADUTE CLINICHE S. Bertolini (Genova, Italy) 13.35 - 13.50 L’ESPERIENZA CLINICA CON LA DOPPIA INIBIZIONE – A. Notarbartolo (Palermo, Italy) 13.50 - 14.05 GLI STUDI IN CORSO E LE PROSPETTIVE FUTURE – E. Manzato (Padova, Italy) 14.05 - 14.25 DISCUSSIONE GENERALE – 14.25 - 14.30 CHIUSURA – 14.30 Fine della Sessione

Supported in part by an unrestricted educational grant provided by: 9 Merck Sharp & Dohme Italia S.p.A. - Schering-Plough S.p.A. 11.00 - 13.45 MONDAY, June 19 ROOM 3

Mo-W2 Workshop 2 DIABETES AND ATHEROSCLEROSIS hour: Chairs: J. Betteridge (London, UK); E. Bartoli (Novara, Italy) abstract bk. page ref.: 11.00 - 11.20 DIABETES AND THE VASCULAR WALL: ROLE OF INFLAMMATORY 13 MOLECULES A. Chait, S. Subramanian, C.Y. Han, T Chiba., J.F. Oram, J.W. Heinecke, T.N. Wight (Seattle, WA, USA) 11.20 - 11.40 GENETICS OF OBESITY AND DIABETES: LESSONS FROM THE EXTREMES 13 S. O'Rahilly (Cambridge, UK) 11.40 - 12.00 LIPOPROTEIN ABNORMALITIES AND GLUCOSE CONTROL IN YOUTH 13 M WITH TYPE 1 AND TYPE 2 DIABETES O S.M. Marcovina, J.J. Albers, B.M. Snively (Seattle, WA and Winston-Salem, NC, USA) N 12.00 - 12.15 PROATHEROGENIC METABOLIC CHANGES IN INFANTS OF MOTHERS 14 D WITH DIABETES A M.L.S. Lindegaard, E.M.M. Svarrer, P. Damm, E.R. Mathiesen, Y L.B. Nielsen (Copenhagen, Denmark) 12.15 - 12.30 INCREASED VASCULAR WALL ENDOTHELIAL NITRIC OXIDE SYNTHASE (eNOS) 14 LEVELS IN UMBILICAL CORDS FROM GESTATIONAL DIABETIC WOMEN P. Di Fulvio, G. Formoso, S. Di Silvestre, P. Di Tomo, A. Giardinelli, R. La Sorda, N. Di Pietro, M. Piantelli, A. Consoli, A. Pandolfi (Chieti, Italy) 12.30 - 12.45 THE RELATIONSHIP BETWEEN CALCIFIED ATHEROSCLEROTIC PLAQUE AND 14 BONE MINERAL DENSITY: THE DIABETES HEART STUDY B.I. Freedman, F.C. Hsu, K. Lohman, D.W. Bowden, L. Leonchik, C.D. Langefeld, J. Xu, T.C. Register, S.S. Rich, L.E. Wagenknecht (Winston-Salem, NC, USA) 12.45 - 13.00 ANTI-INFLAMMATORY AND PRO-PROLIFERATIVE PROPERTIES OF 14 ROSIGLITAZONE IN FIBROBLASTS FROM TYPE 2 DIABETIC PATIENTS S. Madec, E. Santini, M. Nannipieri, E. Ferrannini, A. Solini (Pisa, Italy) 13.00 End of the Session

13.00 - 14.30 LUNCH - SCIENTIFIC SESSIONS - POSTERS - EXHIBITS

Mo-ML1 Master Lecture 1 DYSLIPIDEMIA IN RENAL IMPAIRMENT – FROM PATHOPHYSIOLOGY TO EVIDENCE Chair: P. Rubba (Naples, Italy)

13.00 - 13.30 DYSLIPIDEMIA IN RENAL IMPAIRMENT - FROM PATHOPHYSIOLOGY 9 TO EVIDENCE B. Fellström (Uppsala, Sweden) 13.30 - 13.45 GENERAL DISCUSSION – 13.45 End of the Session

Supported in part by an unrestricted educational grant provided by: Novartis Pharma AG

10 11.00 - 13.45 MONDAY, June 19 ROOM 4

Mo-W3 Workshop 3 LIPASES hour: Chairs: C. Ehnholm (Helsinki, Finland); G. Sesti (Catanzaro, Italy) abstract bk. page ref.: 11.00 - 11.20 ADIPOSE TRIGLYCERIDE LIPASE: FUNCTIONAL ROLE IN FAT CELL 15 LIPOLYSIS AND INVOLVEMENT IN LIPID AND ENERGY METABOLISM G. Haemmerle, R. Zimmermann, A. Lass, G. Höfler, E. Wagner, R. Zechner (Graz and Vienna, Austria) 11.20 - 11.40 COMPARISON OF THE POTENTIAL ATHEROGENICITY OF SECRETORY 15 PHOSPHOLIPASE A2 GROUP IIA AND V: ACTIVATION BY PROTEOGLYCANS AND DIFFERENTIAL INDUCTION BY INFLAMMATION AND WESTERN DIET B. Rosengren, H. Peilot, M. Umaerus, A.-C. Jönsson-Rylander, L. Mattsson-Hultén, M C. Hallberg, M. Rodriguez-Lee, E. Hurt-Camejo (Mölndal and Göteborg, Sweden) O 11.40 - 12.00 VLDL SECRETION AND CATABOLISM IN INSULIN RESISTANCE AND 15 TYPE 2 DIABETES MELLITUS N A. Hernandez-Ono, B. Moon, Y.-L. Zhang, H.N. Ginsberg (New York, NY, USA) D 12.00 - 12.15 HEPATIC LIPASE IS UPREGULATED BY GLUCOSE AND FATTY ACIDS VIA 16 A INDUCTION OF UPSTREAM STIMULATORY FACTORS Y D. van Deursen, M. van Leeuwen, H. Jansen, A. Verhoeven (Rotterdam, The Netherlands) 12.15 - 12.30 A CARBOXYTERMINAL REGION OF ENDOTHELIAL LIPASE IS A BINDING 16 SITE FOR HDL K.O. Badellino, C. Long, K. Kitajima, K. Trindade, D.J. Rader (Philadelphia, PA, USA) 12.30 - 12.45 LPLS447X DECREASES MICROALBUMINURIA RELATED CARDIOVASCULAR 16 RISK IN MALES M.C. Nierman, M. Zuurman, B.A. Hutten, P.E. de Jong, J.J.P. Kastelein, E.S.G. Stroes, W.H. van Gilst (Amsterdam and Groningen, The Netherlands) 12.45 - 13.00 FREQUENCY OF HETEROZYGOUS LIPOPROTEIN LIPASE (LPL) DEFICIENCY 16 IN THE GENERAL POPULATION OF JAPANESE: THE SUITA STUDY A. Takagi, Y. Ikeda, N. Iwai, Y. Kokubo, H. Tomoike (Suita and Osaka, Japan) 13.00 End of the Session

13.00 - 14.30 LUNCH - SCIENTIFIC SESSIONS - POSTERS - EXHIBITS

Mo-ML2 Master Lecture 2 NOVEL IMAGING IN ATHEROSCLEROTIC VASCULAR DISEASE: GLIMPSE INTO PLAQUE CHARACTERIZATION Chair: M.F. Oliver (Edinburgh and London, UK)

13.00 - 13.30 NOVEL IMAGING IN ATHEROSCLEROTIC VASCULAR DISEASE: GLIMPSE INTO 9 PLAQUE CHARACTERIZATION A. Zalewski (Philadelphia, PA, USA) 13.30 - 13.45 GENERAL DISCUSSION – 13.45 End of the Session

Supported in part by an unrestricted educational grant provided by: GlaxoSmithKline

11 11.00 - 13.45 MONDAY, June 19 ROOM 5

Mo-W4 Workshop 4 STROKE hour: Chairs: J.M. Gaziano (Boston, MA, USA); C. Fieschi (Rome, Italy) abstract bk. page ref.: 11.00 - 11.20 DIFFERENCES IN RISK FACTORS FOR STROKE AND HEART DISEASE 17 J.M. Gaziano (Boston, MA, USA) 11.20 - 11.40 LIPID AND STROKE 17 P. Amarenco (Paris, France) 11.40 - 11.55 INSULIN RECEPTOR SUBSTRATE-1 GENE VARIANT IN EXTRACORONARY 17 ATHEROSCLEROSIS: EVIDENCE FOR AN ASSOCIATION WITH INCREASED RISK OF ISCHEMIC STROKE M F. Campagna, D. Siepi, G. Lupattelli, E. Mannarino, F. Cipollone, A. Mezzetti, O A. Montali, R. Verna, M. G. Baroni, M. Arca (Rome, Perugia and Chieti, Italy) 11.55 - 12.10 APOE GENE PROMOTER POLYMORPHISMS AS DETERMINANT OF MIDDLE 18 N AGE ISCHEMIC STROKE D S. Abboud, L. Viiri, D. Luetjohann, S. Blecic, S. Friedrichs, P. Karhunen, T. Lehtimäki, A M. Pandolfo, R. Laaksonen (Brussels, Belgium, Tampere, Finland and Bonn, Germany) 12.10 - 12.25 INCREASED EXPRESSION OF NEURODEGENERATIVE DISEASE RELATED GENES 18 Y IN THE CAROTID PLAQUES FROM SYMPTOMATIC STROKE PATIENTS R.J. Dempsey, R. Vemuganti, B. Hermann (Madison, WI, USA) 12.25 - 12.40 ELEVATED MATRIX METALLOPROTEINASE-9 ASSOCIATED WITH TRANSIENT 18 ISCHEMIC ATTACK, STROKE OR DEATH IN PATIENTS WITH CAROTID STENOSIS N. Eldrup, M.L. Gronholdt, H. Sillesen, B.G. Nordestgaard (Copenhagen, Denmark) 12.40 - 12.55 ACUTE EFFECTS OF LIPOPROTEIN(a) IN AN EXPERIMENTAL MODEL OF 18 CEREBRAL STROKE R. Paternò, A. Ruocco, F. Ferrara, A. Baiano, C. Edelstein, A. Postiglione, M. Mancini, A.M. Scanu (Naples, Italy and Chicago, IL, USA) 12.55 End of the Session

12.55 - 14.30 LUNCH - SCIENTIFIC SESSIONS - POSTERS - EXHIBITS

Mo-ML3 Master Lecture 3 EDIBLE PLANTS AND OPTIMIZED NUTRITION Chair: V. Silano (Rome, Italy)

13.00 -13.20 ROLE OF PLANT DERIVED ESSENTIAL FATTY ACIDS IN HEART DISEASE 10 PREVENTION? E.J. Schaefer (Boston, MA, USA) 13.20 - 13.40 A STANDARDIZED APPROACH TO DIETARY ANTIOXIDANT TREATMENT 10 P. Morazzoni, A. Riva, E. Bombardelli (Milan, Italy) 13.40 - 13.45 GENERAL DISCUSSION – 13.45 End of the Session

Supported in part by an unrestricted educational grant provided by: Indena S.p.A

12 11.00 - 12.20 MONDAY, June 19 ROOM 6

Mo-W5 Workshop 5 THE EUROPEAN NETWORK FOR INHERITED DYSLIPIDEMIA Chairs: O. Descamps (Haine Saint-Paul, Belgium); hour: S. Calandra (Modena, Italy) abstract bk. page ref.: 11.00 - 11.20 IS MOLECULAR GENETIC TESTING FOR FAMILIAL HYPERCHOLESTEROLEMIA 19 COST EFFECTIVE AND CLINICALLY USEFUL? J.C. Defesche (Amsterdam, The Netherlands) 11.20 - 11.40 A GENE THERAPY APPROACH TO TREAT HUMAN LIPOPROTEIN LIPASE 19 DEFICIENCY M M.C. Nierman, E.S. Stroes, J. Twisk, J. Rip, P. Dijkhuizen, C.J.D. Ross, A.C. Bakker, W.T. Hermens, J.M. Meulenberg, M.R. Hayden, J.J.P. Kastelein, O J.A. Kuivenhoven (Amsterdam, The Netherlands and Vancouver, BC, Canada) N 11.40 - 12.00 MOLECULAR DIAGNOSIS AND TREATMENT OF HYPOBETALIPOPROTEINAEMIA 19 D P. Tarugi, E. Di Leo, S. Lancellotti, T. Fasano (Modena, Italy) A 12.00 - 12.20 APOA5 DEFICIENCY: METABOLIC AND CLINICAL CONSEQUENCES 20 P.J. Talmud (London, UK) Y 12.20 End of the Session

Workshop organized in collaboration with the European Network for Inherited Dyslipidemia (ENID)

12.20 - 14.30 LUNCH - SCIENTIFIC SESSIONS - POSTERS - EXHIBITS

13 11.00 - 13.00 MONDAY, June 19 ROOM 7

Mo-W6 Workshop 6 ATHEROSCLEROSIS: BASIC SCIENCE (1st part) hour: Chairs: C.C. Shoulders (London, UK); M. Chiariello (Naples, Italy) abstract bk. page ref.: 11.00 - 11.20 METABOLIC AND VASCULAR CONTROL BY LIPID-SENSING NUCLEAR 20 RECEPTORS: ROLE OF THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-ALPHA AS A MEDIATOR OF THE PLEIOTROPIC EFFECTS OF STATINS B. Staels (Lille, France) 11.20 - 11.40 APOPTOSIS IN ATHEROSCLEROSIS - CONSEQUENCES OF CELL DEATH IN 21 VASCULAR DISEASE V.E.A.S. Stoneman, M.C. Clarke, D.M.B. Braganza, N. Figg, T.D. Littlewood, M M.R. Bennett (Cambridge, UK) O 11.40 - 12.00 GENETICS OF INTRACELLULAR LIPID TRANSPORT AND FAMILIAL COMBINED 21 HYPERLIPIDEMIA N C.C. Shoulders, B. Jones, E.L. Jones, S.A. Bonney, P.A. Williams, D A.R. Mensenkamp, A.K. Towney, S.D. Horswell, D.J. Stephens, R.P. Naoumova A (London, Bristol, UK and Nijmegen, The Netherlands) 12.00 - 12.15 INTERLEUKIN-6 IMPAIRS THE INSULIN SIGNALING PATHWAY PROMOTING 21 Y PRODUCTION OF NITRIC OXIDE IN HUMAN UMBILICAL VEIN ENDOTHELIAL (HUVEC) CELLS F. Andreozzi, E. Laratta, M.L. Hribal, A. Sciacqua, M. Perticone, C. Miele, F. Perticone, G. Sesti (Catanzaro and Naples, Italy) 12.15 - 12.30 ENDOTHELIAL PROTEIN C PATHWAY MODULATES NEUTROPHIL 22 INFLAMMATORY EVENTS Q. Zheng, S. Kurosawa, D.J. Stearns-Kurosawa (Oklahoma City, OK, USA) 12.30 - 12.45 AUGMENTED LEVELS OF CD44 IN MACROPHAGES FROM ATHEROSCLEROTIC 22 SUBJECTS: A POSSIBLE IL-6 - CD44 FEEDBACK LOOP? S. Sjoberg, D. Hagg, L. Mattson Hultén, B. Fagerberg, O. Wiklund, A. Rosengren, L.M.S. Carlsson, J. Borén, P.-A. Svensson, A. Krettek (Goteborg, Sweden) 12.45 - 13.00 CHOLESTEROL CRYSTALS RUPTURE PLAQUES DURING MYOCARDIAL 22 INFARCTION G. Abela, K. Aziz (East Lansing, MI, USA) 13.00 End of the Session

13.00 - 14.30 LUNCH - SCIENTIFIC SESSIONS - POSTERS - EXHIBITS

14 11.00 - 12.55 MONDAY, June 19 ROOM 8

Mo-W7 Workshop 7 BIOMARKERS FOR RISK DETERMINATION: NOVEL RISK FACTORS hour: Chairs: R.H. Böger (Hamburg, Germany); A.P. Peracino (Milan, Italy) abstract bk. page ref.: 11.00 - 11.20 ASYMMETRIC DIMETHYLARGININE (ADMA), AN ENDOGENOUS INHIBITOR OF 22 NITRIC OXIDE SYNTHASE, ACTS AS A NOVEL CARDIOVASCULAR RISK FACTOR R.H. Böger (Hamburg, Germany) 11.20 - 11.40 PARTICULATE AIR POLLUTION AND ATHEROSCLEROTIC CARDIOVASCULAR 23 DISEASE R.D. Brook (Ann Arbor, MI, USA) M 11.40 - 11.55 HOXA9 AND FLK1 EXPRESSION IN CD34+ PERIPHERAL CELLS OF 23 HYPERTENSIVE PATIENTS CORRELATES WITH THE NUMBER OF CIRCULATING O ENDOTHELIAL PROGENITOR CELLS N M. Pirro, C. Menecali, F. Bagaglia, M.R. Mannarino, G. Schillaci, E. Mannarino D (Perugia, Italy) 11.55 - 12.10 ASYMMETRIC DIMETHYLARGININE (ADMA) IS ASSOCIATED WITH INCIDENT 23 A CARDIOVASCULAR DISEASE IN THE GENERAL POPULATION. THE HOORN STUDY Y T. Teerlink, R.J. Heine, G. Nijpels, L.M. Bouter, C.D.A. Stehouwer, J.M. Dekker (Amsterdam, The Netherlands) 12.10 - 12.25 MYELOPEROXIDASE LEVELS ARE ASSOCIATED WITH THE FUTURE RISK OF 24 CORONARY ARTERY DISEASE IN APPARENTLY HEALTHY INDIVIDUALS M.C. Meuwese, S.M. Boekholdt, J.J.P. Kastelein, S.L. Hazen, J.A. Kuivenhoven, S.A. Bingham, N.J. Wareham, R. Schaub, E.S.G. Stroes, K.T. Thaw (Amsterdam, The Netherlands, Cambridge, UK, Cleveland, OH and Cambridge, MA, USA) 12.25 - 12.40 TAGGING SNP HAPLOTYPE ANALYSIS OF THE SECRETORY PLA2-IIA GENE 24 PLA2G2A SHOWS STRONG ASSOCIATION WITH SERUM LEVELS OF SPLA2IIA P. Wootton, F. Drenos, J. Cooper, S. Thompson, J. Stephens, E. Hurt-Camejo, O. Wiklund, S. Humphries, P. Talmud (London, Swansea, UK, Molndal and Goteborg, Sweden) 12.40 - 12.55 SERUM LEVELS OF OSTEOPROTEGERIN AND RANKL IN PATIENTS WITH ST 24 ELEVATION ACUTE MYOCARDIAL INFARCTION F. Luca', S. Raffa, A. Crisafulli, F. Saporito, A. Micari, D. Altavilla, A. Sardella, M. Passaniti, F. Arrigo, F. Squadrito (Messina, Italy) 12.55 End of the Session

12.55 - 14.30 LUNCH - SCIENTIFIC SESSIONS - POSTERS - EXHIBITS

15 14.30 - 18.00 MONDAY, June 19 ROOM 1

Mo-S6 Sponsored Symposium 6 NEW TECHNOLOGIES: PREDICTION OF CORONARY EVENT RISK Chairs: J.J.P. Kastelein (Amsterdam, The Netherlands); hour: C.R. Sirtori (Milan, Italy) abstract bk. page ref.: 14.30 - 14.35 INTRODUCTION – 14.35 - 14.50 OVERVIEW OF VASCULAR IMAGING TECHNOLOGIES IN ATHEROSCLEROSIS 41 J.J.P. Kastelein (Amsterdam, The Netherlands) 14.50 - 15.05 CAROTID INTIMA MEDIA THICKNESS (IMT) AND IMT-PROGRESSION AS 42 PREDICTORS OF VASCULAR EVENTS IN A HIGH RISK EUROPEAN POPULATION: “THE IMPROVE STUDY” M E. Tremoli, D. Baldassarre, on behalf of the IMPROVE Study Group (Milan, Italy) O 15.05 - 15.20 RELATION BETWEEN IVUS PLAQUE PROGRESSION AND CARDIOVASCULAR RISK 42 N C. von Birgelen, M. Hartmann (Enschede, The Netherlands) 15.20 - 15.35 THE PLACE FOR VASCULAR IMAGING DATA IN THE EVIDENCE PACKAGE FOR 42 D NEW DRUGS FOR ATHEROSCLEROSIS: REGULATORY PRINCIPLES A D.G. Orloff (Cincinnati, OH, USA) Y 15.35 - 15.50 ARTERIAL INTIMA-MEDIA THICKNESS AS A SURROGATE MARKER FOR 43 ATHEROSCLEROSIS - REGULATORY PERSPECTIVE IN EU J.T. Salonen (Kuopio, Finland) 15.50 - 16.05 PANEL DISCUSSION: WHERE IS THE FIELD GOING – PHYSIOLOGY – AND THERAPEUTICS 16.05 - 16.10 CLOSING REMARKS – 16.10 End of the Session Supported in part by an unrestricted educational grant provided by: Pfizer Inc.

16.10 - 16.30 BREAK - POSTERS - EXHIBITS

Mo-S7 Sponsored Symposium 7 HELPING TO SET A NEW STANDARD IN CHOLESTEROL MANAGEMENT: TREATING 2 SOURCES OF CHOLESTEROL Chairs: A.L. Catapano (Milan, Italy); T. Pedersen (Oslo, Norway)

16.30 - 16.35 WELCOME – A.L. Catapano (Milan, Italy) 16.35 - 16.45 THE CARDIOVASCULAR BENEFITS OF INTENSIVE LIPID LOWERING EFFICACY 43 C. Cortese (Rome, Italy) 16.45 - 17.00 CLINICAL REALITY AND THE TREATMENT GAP 44 D.A. Wood (London, UK) 17.00 - 17.15 CRITICAL ROLE OF THE INTESTINAL ABSORPTION IN CHOLESTEROL 44 MANAGEMENT A.L. Catapano (Milan, Italy) 17.15 - 17.30 CHOLESTEROL MANAGEMENT THROUGH TARGETED PATHWAYS 44 D. Harats (Tel Aviv, Israel) 17.30 - 17.40 CARDIOVASCULAR OUTCOMES STUDIES TO SEAS: THE FUTURE 44 T.R. Pedersen (Oslo, Norway) 17.40 - 17.55 GENERAL DISCUSSION – 17.55 - 18.00 CLOSING REMARKS – T.Pedersen (Oslo, Norway) 18.00 End of the Session Supported in part by an unrestricted educational grant provided by: Merck Sharp & Dohme/Schering-Plough

20.00 VISIT OF THE BASILICA - 20.30 CONCERT

16 16.30 - 18.35 MONDAY, June 19 ROOM 2

Mo-W8 Workshop 8 METABOLIC SYNDROME (1st part) hour: Chairs: J.-C. Fruchart (Lille, France); H. Greten (Hamburg, Germany) abstract bk. page ref.: 16.30 - 16.50 IS LIVER FAT THE COMMON NOMINATOR OF DYSLIPIDEMIA AND – THE METABOLIC SYNDROME? M.-R. Taskinen (Helsinki, Finland) 16.50 - 17.10 TARGETING ABDOMINAL OBESITY FOR THE OPTIMAL MANAGEMENT OF 24 HIGH-RISK PATIENT WITH THE METABOLIC SYNDROME J.P. Després (Sainte-Foy, QC, Canada) 17.10 - 17.30 METABOLIC SYNDROME IN ASIAN INDIANS 25 C. Snehalatha, A. Ramachandran (Royapuram and Chennai, India) M 17.30 - 17.50 STATINS IN TREATMENT OF METABOLIC SYNDROME 25 O K. Yokote, Y. Saito (Chiba, Japan) 17.50 - 18.05 CRITICAL ROLE OF ATP-BINDING CASSETTE TRANSPORTER A1 (ABCA1) IN 25 N BETA-CELL FUNCTION AND GLUCOSE HOMEOSTASIS D L.R. Brunham, T. D. Pape, G. Soukhatcheva, B. Verchere, M. Hayden A (Vancouver, BC, Canada) Y 18.05 - 18.20 PITAVASTATIN EFFECTIVELY ADDRESSES LIPID DERANGEMENTS ASSOCIATED 25 WITH METABOLIC SYNDROME R.E. Morgan (Morrisville, NC, USA) 18.20 - 18.35 EFFECT OF ROSUVASTATIN ON HEPATIC AND WHOLE BODY INSULIN SENSITIVITY 25 IN AN ANIMAL MODEL OF INSULIN RESISTANCE AND METABOLIC SYNDROME L. Federico, M. Naples, D. Taylor, K. Adeli (Toronto, ON, Canada) 18.35 End of the Session

20.00 VISIT OF THE BASILICA - 20.30 CONCERT

17 16.30 - 18.30 MONDAY, June 19 ROOM 3

Mo-W9 Workshop 9 CELLULAR LIPID TRAFFICKING hour: Chairs: Y. Stein (Jerusalem, Israel); A. Saitta (Messina, Italy) abstract bk. page ref.: 16.30 - 16.50 CELLULAR LIPIDOMICS; LIPID DOMAINS AND TRANSLOCATORS 26 G. van Meer, J. Wolthoorn, S. Groux-Degroote, D. van den Heuvel, H. Gerritsen, D. Halter, S. van der Poel, H. Sprong (Utrecht, The Netherlands) 16.50 - 17.10 THE ABCA1 PATHWAY DETERMINES INTRACELLULAR PHOSPHOLIPID 26 AND CHOLESTEROL TRAFFICKING G. Schmitz, M. Grandl, G. Liebisch, A. Böttcher, M. Binder, E. Orso, T. Langmann (Regensburg, Germany) M 17.10 - 17.30 StAR - RELATED LIPID TRANSFER PROTEINS IN INTRACELLULAR 27 O CHOLESTEROL METABOLISM M. Pan, R.S. Soccio, J.L. Breslow (New York, NY, USA) N 17.30 - 17.45 LXR/RXR AGONISTS ENHANCE HDL-INDEPENDENT CHOLESTEROL EFFLUX 27 D FROM HUMAN MONOCYTE-DERIVED MACROPHAGES A A. Cignarella, T. Engel, A. von Eckardstein, P. Cullen, G. Assmann (Milan, Padua, Italy, Münster, Germany and Zurich, Switzerland) Y 17.45 - 18.00 APOLIPOPROTEIN E SECRETION FROM HUMAN MACROPHAGES OCCURS 27 VIA A PROTEIN KINASE A-DEPENDENT PATHWAY M. Kockx, L. Guo, W. Jessup, L. Kritharides (Sydney, Australia) 18.00 - 18.15 FAMILIAL INTRAHEPATIC CHOLESTASIS 1 GENE PRODUCT, A NOVEL 28 CONTRIBUTOR FOR CHOLESTEROL EFFLUX K. Hirano, Y. Nakagawa-Toyama, A. Ota, Z. Zhang, C. Ikegami, K. Tsukamoto, M. Koseki, D. Masuda, M. Nishida, S. Yamashita (Osaka, Japan) 18.15 - 18.30 REGULATION OF SCAVENGER RECEPTOR CLASS B TYPE I SUBCELLULAR 28 LOCALIZATION AND FUNCTION BY HDL AND INSULIN S. Shetty, E.R. Eckhardt, S.R. Post, D.R. van der Westhuyzen (Lexington, KY, USA) 18.30 End of the Session

20.00 VISIT OF THE BASILICA - 20.30 CONCERT

18 16.30 - 18.25 MONDAY, June 19 ROOM 4

Mo-W10 Workshop 10 THROMBOSIS (1st part) Chairs: B. Furie (Boston and Cambridge, MA, USA); hour: C. Barbagallo (Palermo, Italy) abstract bk. page ref.: 16.30 - 16.50 THROMBUS FORMATION IN VIVO 28 B. Furie, B.C. Furie (Boston and Cambridge, MA, USA) 16.50 - 17.10 PURINERGIC REGULATION OF PLATELET FUNCTION 28 C. Gachet (Strasbourg, France) 17.10 - 17.25 DECREASED ANNEXIN A5 BINDING TO ENDOTHELIUM IS ASSOCIATED WITH 29 CARDIOVASCULAR DISEASE IN SYSTEMIC LUPUS ERYTHEMATOSUS AND INHIBITED BY IVIG M A. Cederholm, P. Von Landenberg, J. Frostegard (Stockholm, Sweden and O Mainz, Germany) N 17.25 - 17.40 REDUCED THROMBOXANE BIOSYNTHESIS IN CARRIERS OF TOLL-LIKE 29 RECEPTOR 4 POLYMORPHISMS IN VIVO D P. Patrignani, C. Di Febbo, S. Tacconelli, M. Guglielmi, L. Stuppia, A E. Porreca (Chieti, Italy) Y 17.40 - 17.55 MECHANISMS OF SPATIAL CLOT GROWTH ON OXIDIZED LOW DENSITY 29 LIPOPROTEIN (OxLDL)-TREATED VASCULAR CELLS AS A MODEL OF ATHEROTHROMBOSIS N.M. Ananyeva, M.V. Ovanesov, F.I. Ataullakhanov, E.L. Saenko (Baltimore, MD, USA and Moscow, Russia) 17.55 - 18.10 THE ATHEROSCLEROTIC PLAQUE COMPONENTS LYSOPHOSPHATIDIC ACID 30 AND COLLAGEN SYNERGISTICALLY ACTIVATE PLATELETS O. Bikou, S. Penz, D. Pandey, R. Brandl, W. Siess (München, Germany) 18.10 - 18.25 SIROLIMUS INHIBITS KEY EVENTS OF RESTENOSIS IN VITRO AND EX VIVO: 30 IMPACT OF SI/MPL AND SI/DES-RATIO FOR THE INTERPRETATION OF THE DATA R. Voisard, S. Zellmann, F. Müller, F. Fahlisch, L. von Müller, R. Baur, J. Braun, J. Gschwend, M. Kountidis, V. Hombach (Ulm, Biberach and Heidenheim, Germany) 18.25 End of the Session

20.00 VISIT OF THE BASILICA - 20.30 CONCERT

19 16.30 - 18.25 MONDAY, June 19 ROOM 5

Mo-W11 Workshop 11 POST-PRANDIAL LIPEMIA hour: Chairs: J. Heeren (Hamburg, Germany); R. Miccoli (Pisa, Italy) abstract bk. page ref.: 16.30 - 16.50 NEW MOLECULAR MECHANISM IN THE REGULATION OF POSTPRANDIAL 30 LIPEMIA J. Heeren, A. Laatsch, P.J. Talmud, U. Beisiegel (Hamburg, Germany and London, UK) 16.50 - 17.10 POST-PRANDIAL LIPOPROTEINS AND ENDOTHELIAL DYSFUNCTION. IN VITRO 30 AND IN VIVO STUDIES G.D. Norata, A.L. Catapano (Milan and Cinisello Balsamo, Italy) M 17.10 - 17.25 POSTPRANDIAL LEUKOCYTE ACTIVATION: A POSSIBLE MECHANISM FOR 31 O ATHEROSCLEROSIS AND INFLAMMATION BY TRIGLYCERIDE RICH LIPOPROTEINS A. Alipour, A. van Oostrom, A. Izraeljan, J. Collins, K. Frayn, J.W. Elte, N M. Castro Cabezas (Rotterdam, Nieuwegein, The Netherlands and Oxford, UK) D 17.25 - 17.40 DIETARY TRANS, POLYUNSATURATED AND SATURATED FATTY ACIDS MODIFY 31 A LIPOPROTEIN COMPOSITION DIFFERENTIALLY IN THE FASTING AND IN THE POSTPRANDIAL PERIODS Y V. Buonacorso, E.C.R. Quintão, V.S. Nunes, E.R. Nakandakare, A.M.P. Lottenberg (São Paulo, Brazil) 17.40 - 17.55 NUTRIENT DETERMINANTS OF POSTPRANDIAL TRIGLYCERIDE RESPONSE IN 31 TYPE 2 DIABETES E. Lapice, C. Iovine, G. Donnarumma, G. Romano, O. Ciano, L. Costaiola, R. Galasso, A.A. Rivellese, G. Riccardi, O. Vaccaro (Naples, Italy) 17.55 - 18.10 ACCELERATED LIPID ABSORPTION IN MICE OVEREXPRESSING INTESTINAL SR-BI 31 F. Bietrix, Y. Daogang, M. Nauze, C. Rolland, C. Coméra, R. Barbaras, A.K. Groen, B. Perret, F. Tercé, X. Collet (Toulouse, France and Amsterdam, The Netherlands) 18.10 - 18.25 DIETARY SPHINGOLIPIDS LOWER PLASMA CHOLESTEROL AND 32 TRIGLYCERIDES AND PREVENT STEATOSIS P.C.N. Rensen, I. Duivenvoorden, P.J. Voshol, W. van Duyvenvoorde, J.A. Romijn, J.J. Emeis, L.M. Havekes, W.F. Nieuwenhuizen (Leiden and Zeist, The Netherlands) 18.25 End of the Session

20.00 VISIT OF THE BASILICA - 20.30 CONCERT

20 16.30 - 18.25 MONDAY, June 19 ROOM 6

Mo-W12 Workshop 12 PROGENITOR CELLS AND ANGIOGENESIS Chairs: M.D. Schneider (Houston, TX, USA); hour: G. de Gaetano (Campobasso, Italy) abstract bk. page ref.: 16.30 - 16.50 THE ROLE OF STEM CELLS IN ATHEROSCLEROSIS 32 Q. Xu (London, UK) 16.50 - 17.10 CARDIOPOIESIS: CARDIAC MUSCLE CELL CREATION BY ADULT AND 32 EMBRYONIC PROGENITOR CELLS M.D. Schneider (Houston, TX, USA) 17.10 - 17.25 ABSENCE OF GRANULOCYTE MACROPHAGE-COLONY STIMULATING FACTOR 33 ACCELERATES DEVELOPMENT OF ATHEROSCLEROSIS IN APOLIPOPROTEIN M E-DEFICIENT MICE O M. Ditiatkovski, B.H. Toh, A. Bobik (Melbourne, NSW, Australia) N 17.25 - 17.40 VACCINATION AGAINST VEGFR2 ATTENUATES BOTH THE INITIATION AND 33 PROGRESSION OF ATHEROSCLEROSIS D A.D. Hauer, T. van Es, P. de Vos, P.H.A. Quax, Th.J.C. van Berkel, R.A. Reisfeld, A J. Kuiper (Leiden, The Netherlands and La Jolla, CA, USA) Y 17.40 - 17.55 ANANDAMIDE INHIBITS ENDOTHELIAL CELL PROLIFERATION IN VITRO 33 AND ANGIOGENESIS IN VIVO S. Pisanti, P. Gazzerro, C. Grimaldi, A.M. Malfitano, A. Santoro, D. Sarnataro, C. Borselli, C. Laezza, M. Bifulco (Salerno and Naples, Italy) 17.55 - 18.10 THE EFFECT OF GRANULOCYTE-COLONY STIMULATING FACTOR ON AORTIC 33 ATHEROSCLEROSIS FORMATION IN CHOLESTEROL-FED RABBITS T. Matsumoto, H. Watanabe, T. Ueno, A. Tsunemi, K. Tahira, B. Hatano, K. Wakabayashi, N. Fuikuda, M. Mitsumata, H. Mugishima (Tokyo, Japan) 18.10 - 18.25 THE OPPOSING ROLES OF MONOCYTES IN ATHEROSCLEROSIS 34 H.J. Medbury, A.K. Guiffre, M.W.Y. Williams, M. Vicaretti, J.P. Fletcher (Westmead, NSW, Australia) 18.25 End of the Session

20.00 VISIT OF THE BASILICA - 20.30 CONCERT

21 16.30 - 18.30 MONDAY, June 19 ROOM 7

Mo-W13 Workshop 13 GENETICS (1st part) hour: Chairs: A.J. Lusis (Los Angeles, CA, USA); S. Bertolini (Genoa, Italy) abstract bk. page ref.: 16.30 - 16.50 INTEGRATING GENETIC AND GENE EXPRESSION DATA FOR 34 CARDIOVASCULAR DISEASE A.J. Lusis (Los Angeles, CA, USA) 16.50 - 17.10 GENES FOR DIABETES SUSCEPTIBILITY FROM GENETIC AND GENOMIC 34 STUDIES IN MICE A.D. Attie (Madison, WI, USA) 17.10 - 17.30 CAN GENETIC EPIDEMIOLOGY CONTRIBUTE TO UNDERSTANDING THE 34 M ENVIRONMENTAL DETERMINANTS OF DISEASE? O D.A. Lawlor (Bristol, UK) 17.30 - 17.45 FREQUENCY OF CARRIERS OF AUTOSOMAL RECESSIVE 35 N HYPERCHOLESTEROLEMIA (ARH) IN THE SARDINIAN POPULATION: D PRELIMINARY RESULTS A I. Sirinian, F. Quagliarini, N. Glorioso, S. Bertolini, S. Calandra, A. Montali, Y F. Campagna, M. Arca (Rome, Sassari, Genoa and Reggio Emilia, Italy) 17.45 - 18.00 THE CETP I405V POLYMORPHISM IS ASSOCIATED WITH HIGH DENSITY 35 LIPOPROTEIN CHOLESTEROL LEVELS AND DECREASED RISK OF MYOCARDIAL INFARCTION A. Isaacs, F.A. Sayed-Tabatabaei, J.C.M. Witteman, A. Hofman, C.M. van Duijn (Rotterdam, The Netherlands) 18.00 - 18.15 GENETIC VARIATION IN ATP BINDING CASSETTE TRANSPORTER A1 PREDICTS 35 ISCHEMIC HEART DISEASE IN THE GENERAL POPULATION R. Frikke-Schmidt, B.G. Nordestgaard, P. Schnohr, R. Steffensen, A. Tybjærg-Hansen (Copenhagen and Hillerød, Denmark) 18.15 - 18.30 GENETIC VARIATION LINKED TO LIPID METABOLISM AND POSTPRANDIAL 35 LIPEMIA. THE STUDY IN POLISH OBESE FAMILIES I.I. Wybranska, M.M. Malczewska-Malec, I. Leszczynska-Golabek, L. Partyka, A. Dembinska-Kiec (Cracow, Poland) 18.30 End of the Session

20.00 VISIT OF THE BASILICA - 20.30 CONCERT

22 16.30 - 18.30 MONDAY, June 19 ROOM 8

Mo-W14 Workshop 14 BIOMARKERS FOR RISK DETERMINATION: NEW LABORATORY APPROACHES hour: Chairs: C.J. Packard (Glasgow, UK); F. Perticone (Catanzaro, Italy) abstract bk. page ref.: 16.30 - 16.50 NOVEL APPROACHES AND NEW BIOMARKERS FOR CHD RISK ASSESSMENT 36 C.J. Packard (Glasgow, UK) 16.50 - 17.10 IF APOB IS SO GOOD, WHY IS EVERYBODY NOT DOING IT? 36 A.D. Sniderman (Montreal, QC, Canada) 17.10 - 17.30 APPLICATION OF GENETIC TESTING IN CASCADE GENETIC SCREENING FOR 36 FAMILIAL HYPERCHOLESTEROLEMIA M T.P. Leren, T.E. Manshaus, L. Ose, K.E. Berge (Oslo, Norway) 17.30 - 17.45 APOLIPOPROTEINS AS PREDICTORS OF CARDIOVASCULAR RISK IN THE 37 O COLLABORATIVE ATORVASTATIN DIABETES STUDY (CARDS) N P.N. Durrington, S. Livingstone, V. Charlton-Menys, H. Colhoun, D.J. Betteridge, D J. Fuller, G. Hitman, H.A.W. Neil, C. Newman, M. Szarek (Manchester, London, Oxford, UK, Dublin, Ireland and New York, NY, USA) A 17.45 - 18.00 PLASMA APOLIPOPROTEIN E LEVELS AND RISK OF CARDIOVASCULAR 37 Y DISEASE MORTALITY IN OLD AGE S.P. Mooijaart, J.F.P. Berbée, D. van Heemst, L.M. Havekes, A.J.M. de Craen, P.C.N. Rensen, R.G.J. Westendorp (Leiden, The Netherlands) 18.00 - 18.15 COMMON SNPS IN APOB CONTRIBUTE TO CHOLESTEROL AND APOB LEVELS 37 IN BOTH GENDERS AND PREDICT RISK OF ISCHEMIC HEART DISEASE IN THE GENERAL POPULATION M. Benn, B.G. Nordestgaard, A. Tybjærg-Hansen (Copenhagen, Denmark) 18.15 - 18.30 VALUE OF APOLIPOPROTEIN B/A1 RATIO IN CARDIOVASCULAR RISK 37 ASSESSMENT; CASE CONTROL ANALYSIS IN EPIC-NORFOLK STUDY S.M. Boekholdt, W.A. van der Steeg, E.A. Stein, E.S.G. Stroes, N.J. Wareham, J.W. Jukema, S.A. Bingham, A.H. Zwinderman, J.J.P. Kastelein, K.T. Khaw (Amsterdam, Leiden, The Netherlands, Cincinnati, OH, USA and Cambridge, UK) 18.30 End of the Session

20.00 VISIT OF THE BASILICA - 20.30 CONCERT

23 16.30 - 18.30 MONDAY, June 19 ROOM 9

Mo-W15 Workshop 15 LIPID AND LIPOPROTEIN METABOLISM hour: Chairs: M. Wassef (Bethesda, MD, USA); G. Lupattelli (Perugia, Italy) abstract bk. page ref.: 16.30 - 16.45 APOA5 AFFECTS LIPOLYSIS OF TRIGLYCERIDE-RICH LIPOPROTEINS AND 38 LIVER UPTAKE OF THEIR REMNANTS I. Grosskopf, H. Cohen, A. Shaish, D. Harats (Tel Hashomer, Israel) 16.45 -17.00 APOLIPOPROTEIN(APO)A5 MEDIATED ACCELERATION OF PLASMA 38 TRIGLYCERIDE HYDROLYSIS IS INDEPENDENT OF APOC3 M. Merkel, L. Ewerlin, U. Beil, J. Heeren (Hamburg, Germany) 17.00 - 17.15 PLASMA APOLIPOPROTEIN AV IN TYPE 2 DIABETES MELLITUS EMPHASIZES 38 M THAT MICE ARE NOT MEN O G.M. Dallinga-Thie, A. van Tol, H. Hattori, E.J.G. Sijbrands (Rotterdam, The Netherlands and Saitama, Japan) N 17.15 - 17.30 APO AV DOES NOT CONTRIBUTE TO HYPERTRIGLYCERIDEMIA OR 38 D TRIGLYCERIDE LOWERING BY FISH OIL DIET AND ROSIGLITAZONE IN A OBESE ZUCKER RATS W. Strobl, B. Dorfmeister, S. Brandlhofer, F.G. Schaap, B. Hagerty, C. Fürnsinn, Y H. Stangl, W. Patsch (Vienna, Salzburg, Austria and Amsterdam, The Netherlands) 17.30 - 17.45 HEPATIC OVEREXPRESSION OF OXYSTEROL BINDING PROTEIN(OSBP) RESULTS 39 IN HYPERTRIGLYCERIDEMIA D. Yan, M. Lehto, R. Käkelä, S. Ylä-Herttuala, C. Ehnholm, M. Jauhiainen, V.M. Olkkonen (Helsinki and Kuopio, Finland) 17.45 - 18.00 DOES FASTING ALTER GENES REGULATING CHOLESTEROL METABOLISM? 39 A STUDY OF INTESTINAL AND HEPATIC NIEMANN PICK-C1-LIKE 1, ABCG5/G8, AND MTP AND HMGCOA REDUCTASE G. Tomkin, S. Lally, D. Owens (Dublin, Ireland) 18.00 - 18.15 LOSS OF RESISTANCE TO CHOLESTEROL FEEDING IN THE HYPOPHYSECTOMIZED 39 RAT: INCREASED CHOLESTEROL ABSORPTION, WHICH IS ABOLISHED BY EZETIMIBE TREATMENT M. Matasconi, C. Gälman, Y. Bonde, P. Parini, B. Angelin, M. Rudling (Stockholm, Sweden) 18.15 - 18.30 NOVEL PATHWAY OF BIOGENESIS OF APOE-CONTAINING HDL WITH THE 39 PARTICIPATION OF ABCA1 AND LCAT: IMPLICATIONS FOR DYSLIPIDEMIAS AND ATHEROGENESIS V.I. Zannis, K. E. Kypreos (Boston, MA, USA and Crete, Greece) 18.30 End of the Session

20.00 VISIT OF THE BASILICA - 20.30 CONCERT

24 POSTER AREA “A” MONDAY, June 19 1-167,461,462

POSTER DISPLAY: for the duration of one day (Monday, June 19 from 8.30 am to 6.30 pm). Participants may view the posters displayed during this day.

POSTER DISCUSSION: one of the authors will be available at the poster site as follows: Monday, June 19: from 10.30 am to 11.00 am Monday, June 19: from 1.00 pm to 2.30 pm Monday, June 19: from 4.10 pm to 4.30 pm

Mo-P1 Poster Session 1 poster EPIDEMIOLOGY OF CARDIOVASCULAR DISEASE abstract bk. board no.: page ref.: 1 ASSESSMENT OF CORONARY HEART DISEASE RISK IN THE MIDDLE EAST AREA: 46 M DO WE NEED TO MODIFY THE EXISTED RISK CHARTS O N. Sarrafzadegan, A. Tavassoli (Isfahan, Iran) 2 CORONARY RISK ASSESSMENT IN SPANISH POPULATION ACCORDING WITH 46 N POBLATIONAL DATA: DORICA'S RISK CHARTERS D J. Millan, J. Aranceta, M. Foz, B. Gil, E. Jover, T. Mantilla, S. Monereo, B. Moreno (Spain) A 3 YOUNG ASYMPTOMATIC SUBJECT IN PREVENTIVE CARDIOLOGY 46 Y C.A. Sarau, S. Mancas, D.M. Duda-Seiman, G. Mihalas, St.I. Dragulescu, L. Noveanu, L. Barbu, G. Ciorica, A. Avram, L. David (Timisoara, Romania) 4 RISK FOR CARDIOVASCULAR EVENTS IN A LOCAL POPULATION OF DIABETIC 46 PATIENTS E. Pellegrini, M. Maurantonio, R. D'Amico, B. Madeo, I.M. Giannico, D. Ganazzi, L. Carulli, P. Loria, M. Bertolotti, N. Carulli (Modena, Italy) 5 RISK FACTORS ANALYSIS BY INDUCTIVE MACHINE LEARNING IN CORONARY HEART 47 DISEASE PATIENTS G. Krstacic, A. Krstacic, D. Gamberger, M. Jembrek-Gostovic (Zagreb, Croatia) 6 LIFE-STYLE, PHARMACOLOGICAL AND MAXIMIZING COMPLIANCE INTERVENTIONS 47 TO REDUCE HYPERTENSION AND DYSLIPIDEMIA IN THE LONG-TERM R. Volpe, J. Pille (Rome, Italy) 7 POSTER WITHDRAWN – 8 EVALUATION OF CHOLESTEROL LEVELS AND PREDICTORS OF GOAL ACHIEVEMENT 47 IN A HYPERCHOLESTEROLEMIC POPULATION P. Deambrosis, C. Saramin, G. Terrazzani, L. Scaldaferri, M. Orrasch, G. Bader, A. Chinellato, P. Giusti (Treviso, Rome and Padua, Italy) 9 IMPACT OF APOE, APOA5 AND CETP POLYMORPHISM ON PLASMA LIPID 47 CONCENTRATIONS AND RESPONSE TO A MEDITERRANEAN DIET IN THE PREDIMED STUDY F. Frances, P. Carrasco, J.V. Sorli, C. Ortega, O. Portoles, M.M. Rubio, E.M. Sanchis, E. Godoy, V. Pascual, D. Corella (Valencia and Castellon, Spain) 10 POSTER WITHDRAWN – 11 POSTER WITHDRAWN – 12 SERUM C-REACTIVE PROTEIN AND ITS RELATION TO CARDIOVASCULAR RISK 48 FACTORS AND ADIPOCYTOKINES IN JAPANESE CHILDREN T. Ohta, T. Yoshida, T. Shimabukuro, T. Kaneshi, K. Takada (Nishihara and Hiroshima-City, Japan) 13 CHANGES OF DEVELOPMENT OF THE RISK FACTORS OF CVD IN CZECH REPUBLIC 48 (CZECH-POST-MONICA STUDY) V. Adamkova, Z. Skodova, R. Cifkova, R. Poledne, P. Stavek, V. Lanska (Prague, Czech Republic) 14 INFLUENCE OF SMOKING HABIT ON RESIDUAL LIFETIME RISK OF CARDIOVASCULAR 48 DISEASES IN JAPANESE REPRESENTATIVE POPULATION Y. Murakami, H. Ueshima, T. Okamura, Y. Kita, T. Kadowaki, T. Hayakawa, A. Okayama (Otsu, Izumo and Suita, Japan) 15 HEMOGLOBIN LEVEL AS AN INDEPENDENT PREDICTOR FOR CARDIOVASCULAR 48 DISEASES IN CHIN-SHAN COMMUNITY COHORT IN TAIWAN K.L. Chien, P.C. Chen, H.C. Hsu, T.C. Su, M.F. Chen, F.C. Sung, Y.T. Lee (Taipei, Taichung and Taoyuang, Taiwan)

25 16 THE APOB/APOA1 RATIO AS A DETERMINANT OF CARDIOVASCULAR RISK AT 49 LDL CHOLESTEROL (LDL-C) THERAPEUTIC TARGET LEVELS L. Bergamasco, S. Onolfo, R. Pedrazzoli, E. Salviti, P.P. Sainaghi, L. Castello, G.P. Carnevale Schianca, E. Bartoli (Novara, Italy) 17 PLASMA HEPARIN COFACTOR II ACTIVITY IS A NOBLE PREDICTOR OF 49 CARDIOVASCULAR RISK IN PATIENTS WITH CORONARY HEART DISEASE N. Takamori, M. Akaike, K. Aihara, A. Hirono, H. Yamaguchi, H. Azuma, K. Tamura, T. Matsumoto (Tokushima Japan) 18 CHANGES IN MALE-FEMALE DIFFERENCE IN BLOOD LIPIDS WITH PROGRESSIVE 49 GLUCOSE INTOLERANCE L. Bergamasco, R. Pedrazzoli, S. Onolfo, E. Salviti, F. Corlianò, L. Castello, P.P. Sainaghi, G.P. Carnevale Schianca, E. Bartoli (Novara, Italy) 19 PATIENTS WITH LOW HDL-C DESPITE TREATMENT FOR DYSLIPIDAEMIA ARE AT 49 HIGH CARDIOVASCULAR RISK: AN ANALYSIS FROM THE PAN-EUROPEAN SURVEY OF HDL-C E. Bruckert, M. Baccara-Dinet, E. Windler (Paris, France, Darmstadt and Hamburg, Germany) M 20 SURVEY OF GENE POLYMORPHISMS ON FOUR GENES RELATED TO TRIGLYCERIDE 49 O AND HDL-CHOLESTEROL IN JAPANESE IN 2000 H. Arai, T. Kita (Kyoto, Japan) N 21 IDENTIFICATION OF FACTORS RELATED TO A CHANGE IN HBA1 THAT MAY 50 D CONTRIBUTE TO CAD RISK A T. J. Orchard, T. Costacou, C. Prince (Pittsburgh, PA, USA) 22 ESTIMATION OF FAMILIAL COMBINED HYPERLIPOPROTEINEMIA PREVALENCE IN A 50 Y SOUTH-EUROPEAN POPULATION: THE BRISIGHELLA HEART STUDY (BHS) A.V. Gaddi, A.F.G. Cicero, A. Dormi, M. Bove, Brisighella Study Group (Bologna, Italy) 23 BLOOD PRESSURE AND BODY SIZE: A CROSS-SECTIONAL STUDY IN BRAZILIAN 50 ADOLESCENTS. CUBA-BRASIL ATHEROSCLEROSIS PROJECT J.E. Fernandez-Britto, J. Bacallao, A. Pereira, H. Xavier, T. Martinez (Havana, Cuba and Sao Paulo, Brazil) 24 BRISIGHELLA HEART STUDY: METABOLIC SYNDROME IN A BORDERLINE AREA 50 A. Dormi, L. Laghi, R. Bernardi, M. Veronesi, S. D'Addato, C. Borghi (Bologna, Italy) 25 CHANGING THE DEFINITION FOR NORMOGLYCEMIA: IMPACT ON DISEASE 51 PREVALENCE AND ASSOCIATED CARDIOVASCULAR RISK M. Masulli, P. Di Bonito, R. Galasso, G. Donnarumma, E. Lapice, G. Riccardi, O. Vaccaro (Naples, Italy) 26 THE ASSOCIATION OF CARDIOVASCULAR DISEASE RISK FACTORS WITH PULSE 51 PRESSURE AMONG WHITE AND BLACK MEN AND WOMEN D. Lackland, G. Gilbert, W. Mountford, J. Abell, P. Gazes (Charleston, SC, USA) 27 TROPONIN T IN HOSPITALIZED PATIENTS - IS IT REALLY A SPECIFIC MARKER FOR 51 THE DIAGNOSIS OF ACS? D. Planer, R. Alcalai, C. Afsin, A. Osman, A. Pollak, C. Lotan (Jerusalem, Israel) 28 EVALUATION OF MANDATORY STUDIES IN DYSLIPIDEMIC PATIENTS AT A LIPID 51 CLINIC IN HAVANA A. Nasiff-Hadad, E. Merino-Ibarra, A. Herrera-Gonzalez (Ciudad de La Habana, Cuba) 29 PREVALENCE OF DYSLIPIDEMIA ESTIMATED FROM A SELF-REPORTED SURVEY 51 VERSUS CLINICAL AND LABORATORY EVALUATION: COMPARISON OF SHIELD AND NHANES DATA H.E. Bays, R.H. Chapman, S. Grandy (Louisville, KY, Falls Church, VA and Wilmington, DE, USA) 30 TOTAL CHOLESTEROL LEVELS OF 16106 INDIVIDUALS IN GREECE. DATA FROM A 52 HELLENIC HEART FOUNDATION SURVEY D.J. Richter, G.K. Andrikopoulos, P.A. Cribas, S. Tzeis, D.A. Athanasias, G.S. Goumas, P.K. Toutouzas (Attica and Athens, Greece) 31 INFLUENCE OF CIGARETTE SMOKING ON CORONARY AND AORTIC CALCIFICATION 52 AMONG COMMUNITY-BASED JAPANESE YOUNG MEN T. Kadowaki, A. Sekikawa, T. Okamura, T. Takamiya, K. Murata, Y. Nakamura, K. Mitsunami, Y. Kita, L.H. Kuller, H. Ueshima (Shiga, Kyoto, Japan and Pittsburgh, PA, USA) 32 SUBCLINICAL ATHEROSCLEROSIS IN A POPULATION-BASED SAMPLE OF 52 64-YEAR-OLD WOMEN WITH VARYING GLUCOSE TOLERANCE B. Fagerberg, G. Brohall, C.J. Behre, J. Wikstrand, J. Hulthe (Göteborg, Sweden)

26 33 DIABETES AND HYPERTENSION, BUT NOT METABOLIC SYNDROME, PREDICT THE 52 SEVERITY AND EXTENT OF CORONARY ARTERY DISEASE IN WOMEN T. Zornitzki, O. Ayzenberg, G. Gandelman, S. Vered, A. Schattner, H. Knobler (Rehovot and Haifa, Israel) 34 RESULTS OF CORONARY PREVENTION STUDY IN BANJA LUKA REGION, REPUBLIKA 53 SRPSKA, B&H-WE CHANGE THERAPEUTIC APROACH CHD PATIENTS D. Vulic, M. Krneta, S. Loncar, D. Roganovic, M. Ostojic (Banja Luka, Bosnia Herzegovina and Belgrade, Serbia-Montenegro) 35 PREVALENCE OF OBESITY AND ITS IMPORTANCE TO CARDIOVASCULAR DISEASES 53 IN GERMANY: FINDINGS FROM THE DETECT STUDY T. Stojakovic, H. Scharnagl, F. Freisinger, D. Pittrow, H. Glaesmer, S. Boehler, G. Ruf, W. Maerz, H.U. Wittchen (Graz, Austria, Dresden and Karlsruhe, Germany) 36 POPULATION PREVALENCE OF ELEVATED TOTAL/HIGH-DENSITY LIPOPROTEIN 53 CHOLESTEROL RATIO AND MODELED TREATMENT EFFECTS E.J. Stanek, S.L. Charland (Cranbury, NJ, USA) 37 RISK FACTORS OF ATHEROSCLEROSIS IN CHILDREN - YUSAD STUDY 53 S. Simeunovic, Z. Milincic, S. Nedeljkovic, M. Bajcetic, M. Vukotic, D. Djuric, M D. Simeunovic, D. Nikolic (Belgrade, Serbia-Montenegro) O 38 HYPERTRIGLYCERIDEMIC WAIST IN AN IRANIAN WOMEN SAMPLE: ISFAHAN 53 HEALTHY HEART PROGRAM (IHHP) N A. Tavassoli, N. Sarrafzadegan, M. Saeidi, A. Akhavan, A. Khosravi (Isfahan, Iran) D 39 ANTHROPOMETRIC MARKERS OF HYPERTENSION FOR POPULATION ASSESSMENT 54 A M.J. Albert, J.L. Penas, M.F. Blanco, J. Bacallao, J.E. Fernandez-Britto (Havana, Y Cuba and Mexico) 40 MENSTRUAL CYCLE LENGTH, SERUM LIPIDS AND LIPOPROTEINS IN A COHORT OF 54 ITALIAN MEDITERRANEAN WOMEN: FINDINGS FROM PROGETTO ATENA F. Rubba, A. Mattiello, P. Chiodini, E. Celentano, R. Galasso, A.V. Ciardullo, M. Gentile, M. Triassi, P. Rubba, S. Panico (Naples, Italy) 41 DETERMINATION OF PLASMA ANTIBODIES ANTI-MODIFIED LDL IN CHILDREN AND 54 THEIR CORRELATION WITH LIPIDS, NUTRITIONAL STATUS, BLOOD PRESSURE AGE AND GENDER A. Pereira, T. Leme da Rocha Martinez, L. Proença Vieira (São Paulo, Brazil) 42 BIOLOGICAL RHYTHMS IN SERUM LIPIDS AND LIPOPROTEINS OF A BRAZILIAN 55 POPULATION CORRELATE WITH THE PREVALENCE OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE F. Dalpino, L. Menna-Barreto, H. Oliveira, E. de Faria (Campinas and São Paulo, Brazil) 43 SERUM TOTAL AND HDL-PHOSPHOLIPID LEVELS IN A POPULATION BASED STUDY 55 AND RELATION TO RISK OF METABOLIC SYNDROME AND CORONARY DISEASE G. Hergenc, A. Onat, S. Turkmen, M. Yazici, I. Sari, G. Can (Istanbul, Gaziantep and Duzce, Turkey) 44 EXPOSURE TO TOBACCO SMOKE AND SERUM LIPID PROFILES IN 11-YEAR-OLD 55 CHILDREN K. Kallio, E. Jokinen, O. Simell (Turku and Helsinki, Finland) 45 PREDICTION OF CARDIOVASCULAR DEATH BY SELF-REPORTED PAST HISTORY OF 55 HYPERTENSION IN A 19-YEAR COHORT STUDY IN JAPAN A. Higashiyama, Y. Murakami, T. Kadowaki, Y. Kita, T. Okamura, T. Hayakawa, A. Okayama, H. Ueshima (Otsu, Izumo and Suita, Japan) 46 BODY MASS INDEX AND HS-CRP IN A COHORT OF MEDITERRANEAN WOMEN: 56 FINDINGS FROM PROGETTO ATENA M. Gentile, F. Rubba, A. Mattiello, E. Celentano, R. Galasso, M. Santucci de Magistris, M. Del Pezzo, P. Rubba, S. Panico (Naples, Italy) 47 ALCOHOL INTAKE AND BLOOD PRESSURE: THE INTERMAP STUDY 56 Q. Chan, P. Elliott, J. Stamler, M. Daviglus, A.R. Dyer, H. Ueshima, B. Zhou (London, UK, Chicago, IL, USA, Shiga, Japan and Beijing, China) 48 LONG-TERM OUTCOME AFTER STROKE AMONG THE PARTICIPANTS OF THE NATIONAL 56 SURVEY ON CIRCULATORY DISORDEERS IN JAPAN (NIPPON DATA80, 1980-1994) T. Yamamoto, Y. Nakamura, T. Okamura, T. Kadowaki, T. Hayakawa, Y. Kita, A. Okayama, H. Ueshima (Otsu, Kyoto, Matsue and Suita, Japan) 49 CARDIOVASCULAR RISK FACTORS IN OBESITY 56 M. Bonas, A. Bonas, E. Perdikari, G. Markou, D. Tassopoulos (Nafpaktos, Agrinio, Gastouni and Rio Patra, Greece)

27 50 TREND OF INCREASE IN ACUTE MYOCARDIAL INFARCTION INCIDENCE AMONG OLD 56 AGED IN A RURAL JAPANESE POPULATION T.C. Turin, Y. Kita, Y. Murakami, N. Rumana, A. Wakayama, Y. Nakamura, H. Ueshima (Otsu, Suita and Kyoto, Japan) 51 RISK FACTORS OF DIABETIC ARTERIOPATHY: CORRELATIONS WITH SEVERITY AND 57 EXTENT OF THE PERIPHERAL ARTERIAL DISEASE O. Suciu, C. Le Hello, D. Maiza, C. Duncea, C. Hotoleanu (Cluj-Napoca, Romania and Caen, France) 52 THE EFFECT OF FOOD AND LIFESTYLE ON THE ANTIOXIDANT VITAMIN LEVELS IN 57 HUMAN SERUM H. Stritecka, P. Hlubik (Hradec Kralove, Czech Republic) 53 ATHEROSCLEROSIS-CONNECTED DISEASES IN SIBERIA 57 Y.P. Nikitin, G.I. Simonova, S.K. Malyutina, V.L. Feigin, T.V. Vinogradova (Novosibirsk, Russia) 54 UNIVERSAL SCREENING OF RISK FACTORS FOR PREMATURE ATHEROSCLEROSIS IN 57 CHILDREN AND ADOLESCENTS M S. Rosipal, P. Simurka, M. Debreova, M. Datelova, F. Hruba (Poprad and Banska Bystrica, O Slovak Republic) 55 EPIDEMIOLOGY OF RISK FACTORS AS LIPIDS, HYPERTENSION, CHD, DIABETES 58 N MELLITUS, AND SMOKE ON ISLAND LEMNOS GREECE POPULATION D S. Paximadas, S. Pagoni, D. Syrigos, K. Rousodimos, A. Tzovaras, G. Kalokerinos, A S. Kastellanos (Athens, Greece) 56 THREE YEARS SURVIVAL AFTER AN ACUTE CORONARY SYNDROME. THE IMPACT 58 Y OF SMOKING V.N. Nicolaou, I.E. Papadakis, D.B. Panagiotakos, C. Couremenou, X. Krinos, P.G. Marnelos, N.M. Bourboulis, A.K. Tsakiris, P.D. Skoufas (Athens, Greece) 57 THE PREVALENCE AND THE RISK FACTORS OF ASYMPTOMATIC ARTERIOSCLEROSIS 58 OBLITERANS IN SOUTHWESTERN JAPAN H. Ohnishi, Y. Sawayama, S. Maeda, J. Hayashi (Kyushu, Japan) 58 THE RELATIONSHIP BETWEEN ALCOHOL INTAKE AND TRADITIONAL OR 58 NON-TRADITIONAL RISK FACTORS FOR CARDIOVASCULAR DISEASE IN THE MIDDLE-AGED JAPANESE MEN N. Miyamatsu, T. Kadowaki, T. Okamura, A. Sekikawa, K. Murata, A. Kashiiwagi, Y. Nakamura, T. Takamiya, Y. Kita, H. Ueshima (Otsu, Kyoto, Japan and Pittsburgh, PA, USA) 59 CONTROL OF CARDIOVASCULAR RISK FACTORS IN TYPE 2 DIABETES MELLITUS IN 58 PRIMARY CARE T. Mantilla, C. Perez De Oteyza, A. Gomez De La Camara, L. Alvarez-Sala, M.D. Alonso De Caso (Madrid, Spain) 60 AN ASSOCIATION BETWEEN THE RISK FACTORS OF CAROTID ATHEROSCLEROSIS 59 AND THE FATAL EVENTS OF PATIENTS UNDERGOING MAINTENANCE HEMODIALYSIS S. Maeda, Y. Sawayama, N. Maeda, H. Oonishi, K. Okada, M. Shigematsu, N. Furusyo, J. Hayashi (Fukuoka, Japan) 61 THE INCIDENCE AND RISK FACTORS OF ATHEROSCLEROSIS PLAQUE IN CHINESE 59 HEALTHY POPULATION WITHOUT CLASSIC RISK FACTORS FOR ATHEROSCLEROSIS PLAQUE D.Y. Li, S.P. Lin, X.J. Liu, Q. Fan, P. Ye (Beijing, China) 62 CORRELATION OF HIGH DENSITY LIPOPROTEIN CHOLESTEROL WITH CARDIOVASCULAR 59 RISK FACTORS IN PATIENTS HAVING CORONARY ARTERY DISEASE A. Kalvelis, G. Bahs (Riga, Latvia) 63 ASSOCIATION BETWEEN FAMILY HISTORY OF STROKE AND MORTALITY FROM 59 ISCHEMIC STROKE AMONG JAPANESE A. Kadota, T. Okamura, K. Nakamura, Y. Murakami, T. Kadowaki, T. Hayakawa, Y. Kita, A. Okayama, Y. Nakamura, H. Ueshima (Otsu, Izumo, Suita and Kyoto, Japan) 64 ASSOCIATION OF PLASMA URIC ACID CONCENTRATIONS WITH THE OCCURRENCE 60 AND THE SEVERITY OF CORONARY ARTERY DISEASE L. Memon, V. Spasojevic-Kalimanovska, Z. Jelic-Ivanovic, N. Bogavac-Stanojevic, D. Kalimanovska-Ostric, S. Spasic (Belgrade, Serbia-Montenegro) 65 PLASMA ENDOTHELIN-1(ET-1) IS A USEFUL MARKER FOR RENAL DYSFUNCTION 60 Y. Hirai, H. Adachi, M. Enomoto, A. Satoh, K. Furuki, A. Hino, T. Imaizumi (Kurume, Japan) 66 PLASMA LEVELS OF ASYMMETRIC DIMETHYLARGININE (ADMA) ARE RELATED TO 60 INTIMA-MEDIA THICKNESS OF THE CAROTID ARTERY IN A GENERAL POPULATION K. Furuki, H. Adachi, M. Enomoto, A. Satoh, A. Hino, Y. Hirai, H. Matsuoka, T. Imaizumi (Kurume, Japan)

28 67 THE RELATIONSHIP BETWEEN PLASMA ALDOSTERONE AND ORGAN DAMAGE 60 M. Enomoto, H. Adachi, K. Furuki, Y. Hirai, A. Hino, T. Imaizumi (Kurume, Japan) 68 PREVALENCE OF CARDIOVASCULAR RISK FACTORS IN A POPULATION OF 309,064 60 SPANISH WORKERS. RELATIONSHIP WITH PROFESSIONAL ACTIVITY SECTORS M.A. Sánchez Chaparro, J. Román García, E. Calvo Bonacho, A. Fernández Meseguer, M. Cabrera Sierra, J.C. Sainz Gutiérrez, A. García García, P. Gómez Martínez, A. Galvez Moraleda, A. González Quintela (Madrid, Spain) 69 PREVALENCE OF HYPO- AND HYPERALPHALIPOPROTEINEMIA ACCORDING TO 61 DIFFERENT DIAGNOSTIC CRITERIA IN THE MASSA LOMBARDA PROJECT COHORT M. Bove, G. Noera, S. Linarello, A.F.G. Cicero, A. Lucicesare, M. Manca, M. Gaddoni, A.V. Gaddi (Bologna, Italy) 70 BODY MASS INDEX AND ITS RELATION WITH PULSE PRESSURE FOR POPULATION 61 SCREENING AND ASSESSMENT M.F. Blanco, J.L. Peña, M. Albert, J.E. Fernandez-Britto (Distrito Federal, Mexico and Havana, Cuba) 71 PREVALENT OF OBESITY RELATIONSHIPS BETWEEN ANTHROPOMETRIC OBESITY 61 AND CARDIOVASCULAR DISEASE M R. Ansari, A. Khosravi, R. Kelishadi (Isfahan, Iran) O 72 CARDIOVASCULAR RISK FACTORS IN ELDER PEOPLE IN OUR HEALTH AREA 61 M. Villaescusa Pedemonte, P. Alarcon Sabater, J.L. Valdes Belmar, J.J. López-Picazo Ferrer, N J.A. Alarcón González, J.M. Bernal Romero (Murcia, Spain) D 73 THE METABOLIC SYNDROME PREDICTS CARDIOVASCULAR EVENTS IN SUBJECTS 62 A WITH NORMAL GLUCOSE TOLERANCE. A 15 YEARS FOLLOW-UP IN A Y MEDITERRANEAN POPULATION D. Noto, C.M. Barbagallo, A.B. Cefalù, A. Falletta, M. Sapienza, G. Cavera, S. Amato, G. Pagano, A. Notarbartolo, M.R. Averna (Palermo, Italy) 74 LIFE EXPECTANCY OF ADULT-OLD MEN WITH PERIPHERAL ARTERIAL DISEASE: A 62 POPULATION-BASED STUDY A. Planas, A. Clara, A. Gasol, N. De La Fuente, R. Martinez-Cercos, E. Mateos, E. Ortiz, F. Vidal-Barraquer (Hospitalet and Barcelona, Spain) 75 PRIMARY CARE ROLE IN LACK OF AWARENESS AND CONTROL IN AN URBAN 62 POPULATION OF BUENOS AIRES C.A. Feldstein, D. Garrido, R. Cossalter, P. Luna, M. Mendez, X. Manglano, A.R. de los Santos (Buenos Aires, Argentina) 76 SCREENING OF ATHEROSCLEROTIC RISK FACTORS BASED ON ETHNIC CRITERIA 62 IN CHILDREN E. Boeriu, M. Cucuruz, S. Arghirescu, M. Marc, C. Damacus, M. Serban (Timisoara, Romania) 77 RISK FACTORS AND CORONARY HEART DISEASE PREVENTION IN SELECTED LODZ 62 (POLAND) POPULATION J. Blaszczyk, J. Kowalski, M. Barylski, L. Pawlicki, M. Godala (Lodz, Poland) 78 THE EFFECT OF DRINKING PATTERN AND TYPE OF ALCOHOLIC BEVERAGE ON THE 63 PREVALENCE OF METABOLIC SYNDROME, DIABETES, CORONARY HEART DISEASE AND STROKE IN A MEDITERRANEAN COHORT V.G. Athyros, E.N. Liberopoulos, D.P. Mikhailidis, E.S. Ganotakis, K. Tziomalos, A. Kakafika, A. Kargiannis, S. Lambropoulos, M. Elisaf (Thessaloniki, Ioannina, Heraklion, Kozani, Greece and London, UK) 79 HDL-CHOLESTEROL (HDL-C) IN CHILDREN FROM A SAMPLE OF THE SOUTH OF BRAZIL - 63 FLORIPA SAUDAVEL 2040 STUDY I. Giuliano, M. Coutinho, S. Freitas, M. Pires, J. Zunino, R. Ribeiro, C. Vieira, B. Caramelli (Santa Catarina, Minas Gerais and São Paulo, Brazil) 80 STUDY OF MYOCARDIAL INFARCTION EPIDEMIOLOGY IN KOHGILOYEH & BOIRAHMAD 63 STATE IN I.R IRAN IN THE YEAR 2005 S. Najafi Doulatabad, Z. Mohebbi Nobandegani, A. Mohammadi, M. Askari (Kohgiloye and Boyer, Iran) 81 INCREASED INCIDENCE AND CASE-FATALITY RATE OF ACUTE MYOCARDIAL INFARCTION 63 IN A RURAL AREA IN JAPAN M. Nakamura, F. Tanaka, K. Sato, T. Onoda, K. Itai, K. Sakata, A. Okayama (Morioka and Osaka, Japan) 82 ANALYSIS AND STUDY OF SUDDEN CARDIAC DEATHS IN A REGION OF CENTRAL GREECE 64 Th. Galeas, Th. Potsis, K. Koutrakis, S. Betsimeas, A. Xifoli, V. Galea, S. Mylonas, E. Zaggelidou, R. Leontari (Trikala and Larisa, Greece)

29 83 OBESITY, ADIPONECTIN AND THE PREVALENCE OF THE METABOLIC SYNDROME AMONG 64 JAPANESE MEN AND WOMEN IN JAPAN AND HAWAII: THE INTERLIPID STUDY Y. Nakamura, N. Okuda, A. Higashiyama, Y. Kita, T. Okamura, A. Okayama, S. Choudhury, B. Rodriguez, D. Curb, H. Ueshima (Kyoto, Otsu, Suita, Japan, Dhaka, Bangladesh and Honolulu, HI, USA) 84 PREMATURE MYOCARDIAL INFARCTION AS A SERIOUS PUBLIC HEALTH IN IRAN. AN 64 EPIDEMIOLOGIC SURVEY OF PREMATURE MYOCARDIAL INFARCTION IN SOUTH OF IRAN M. Shojaie (Jahrom, Iran) 85 RISK STRATIFICATION FOR CARDIAC EVENTS IN AN ALBANIAN POPULATION WITH 64 UNSTABLE CORONARY DISEASE M. Çafka, A. Doko, D. Teferici, N. Kasemi, N. Çene, A. Goda (Tirane, Albania) 86 HOW TO DO PREVENTION IN IMMIGRANT WOMEN 65 M. Hochleitner, A. Bader, F. Sahin, H. Bezirkan (Innsbruck, Austria) 87 SOCIAL-ECONOMICAL AND BEHAVIORAL FACTORS IN GEORGIAN GERONTOLOGIC 65 POPULATION N. Kakauridze, N. Kipshidze, Z. Chkhaidze, R. Shengelia (Tbilisi, Georgia) M 88 IMPACT EVALUATION ON THE INTERVENTION OF MULTIPLE CARDIOVASCULAR DISEASE 65 O RISK FACTORS IN CLINICAL SETTINGS Z.W. Wang, Y.F. Wu, L.C. Zhao, Y. Li, B.F. Zhou, R.L. Gao (Beijing, China) N 89 HIGH BLOOD PRESSURE AND DIABETES PLAY AN IMPORTANT ROLE IN THE 65 D DEVELOPMENT AND PROGNOSIS OF MYOCARDIAL INFARCTION IN WOMEN A S. Kunstmann, M.T. Lira, R. Corbalan, J.C. Molina, D. Gainza (Santiago, Chile) 90 NON-INVASIVE SUBCLINICAL ATHEROSCLEROSIS ASSESSMENT AND CARDIOVASCULAR 65 Y RISK STRATIFICATION G. Elikir, A. Christen, S. Graf, L. Brandani, A. Miranda, G. Giunta, A. Ramirez, H. Baglivo, R. Sanchez (Buenos Aires, Argentina) 91 PREDICTORS OF HOSPITALIZATION FOR CARDIOVASCULAR DISEASE IN A 66 HYPERCHOLESTEROLEMIC POPULATION C. Saramin, P. Deambrosis, L. Scaldaferri, E. Kiwanuka, G. Terrazzani, G. Bader, P. Giusti, A. Chinellato (Treviso, Rome and Padua, Italy) 92 DIABETES AND TRIGLYCERIDES ARE STRONG PREDICTORS OF CORONARY ARTERY 66 REEVENTS: A T2-YEAR FOLLOW- UP STUDY V. Dzenkeviciute, Z. Petrulioniene, S. Kurkutyte (Vilnius, Lithuania) 93 A PROSPECTIVE STUDY OF CHANGE IN BMI AND RISK OF CARDIOVASCULAR 66 DISEASE IN MEN T.S. Bowman, T. Kurth, H.D. Sesso, J.M. Gaziano (Boston, MA, USA) 94 WEIGHT AT BIRTH AND CORRELATIONS WITH CARDIOVASCULAR RISK FACTORS 66 IN BRAZILIAN PUBLIC SCHOOLS T.L.R. Martinez, A. Pereira, L.P. Vieira (Sao Paulo, Brazil) 95 DYSLIPIDEMIA IN PATIENTS WITH CEREBROVASCULAR INSULT 66 A. Arsovska, A. Popovski (Skopje, Macedonia) 96 FATTY ACIDS COMPOSITION IN PATIENTS WITH CAROTID ATHEROSCLEROSIS 67 A.S. Galyavich, L.R. Salakhova (Kazan, Russia) 97 ROLE OF LIPOPROTEIN (a) AND APOLIPOPROTEIN A1 IN CORONARY OBSTRUCTION 67 B. Martinez, E. Molinero, R. Caso, I. Narvaez, M. Vacas, Y. Saez, J.A. Iriarte, J.M. Gandarias (Bilbao, Spain) 98 DYSLIPIDAEMIA ON PATIENTS WITH ACUTE MYOCARDIAL INFARCTION ON UZBEK 67 MEN POPULATION N.U. Zokirov, G.U. Tukhtamuradova, M.B. Mavlyanova, R.D. Kurbanov, Y.U.G. Kevorkova, A.V. Ziyaeva (Tashkent, Uzbekistan) 99 SERUM LEVELS OF OXIDIZED LOW DENSITY LIPOPROTEIN RELATE TO THE EXTENT AND 67 SEVERITY OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY SYNDROMES S. Koulouris, K.A. Triantafyllou, C. Dasopoulou, P. Symeonides, I. Michaelides, I. Karabinos, A. Papapanagiotou, C. Nounopoulos, A. Kalofoutis, A.S. Manolis (Athens, Greece) 100 HIGH LDL AND LOW HDL LEVELS ARE IMPORTANT FACTORS INCREASING PULSE WAVE 68 VELOCITY IN THE GENERAL POPULATION F. Tanaka, K. Sato, M. Nagano, T. Segawa, M. Nakamura (Morioka, Japan) 101 21-YEAR FOLLOW-UP OF SERUM LIPIDS AND LIPOPROTEINS IN APOLIPOPROTEIN E 68 PHENOTYPES. THE CARDIOVASCULAR RISK IN YOUNG FINNS STUDY P. Grönroos, O.T. Raitakari, M. Kähönen, N. Hutri-Kähönen, J. Marniemi, J. Viikari, T. Lehtimäki (Tampere and Turku, Finland)

30 102 HIGH-DENSITY LIPOPROTEIN AND RISK OF CARDIOVASCULAR EVENTS: A CLINICAL 68 INVESTIGATION IN A SAMPLE OF ADULTS FROM THE BRISIGHELLA HEART STUDY COHORT M. Bove, A.F.G. Cicero, A. Dormi, A. Lucicesare, L. Laghi, A. Fiorito, C. Borghi, A.V. Gaddi (Bologna, Italy) 103 ATHEROGENIC LIPID DISORDERS AMONG ADOLESCENTS IN NOVOSIBIRSK: 68 PREVALENCE AND 15-YEAR TRENDS (1989-2003) D.V. Denisova, L.G. Zavjalova, S.V. Burakova (Novosibirsk, Russia) 104 CONVERSION OF TYPE B TO TYPE A LDL-CHOLESTEROL WITH PIOGLITAZONE IN 69 NON-DIABETIC PATIENTS: INITIAL CLINICAL OBSERVATIONS S. Feinstein, M. Arnsdorf (Chicago, IL, USA) 105 PHOSPHOLIPID TRANSFER ACTIVITY AND LIPID STATUS IN TUNISIAN PATIENTS WITH 69 CORONARY ARTERY DISEASE N. Attia, A. Nakbi, K. Ben Hamda, S. Hammami, R. Jemaa, F. Chanussot, M. Hammami (Monastir, Tunis, Tunisia and Marseille, France) 106 APOLIPOPROTEIN E GENOTYPES - A RISK FACTOR FOR OBESITY 69 C. Catana-Negreanu, R. Albu, C. Glavce, M. Vladica, A. Sima (Bucharest, Romania) M 107 SERUM LP(a) CONCENTRATIONS IN A GROUP OF DYSLIPAEMIC PATIENTS ATTENDED 69 O IN CORPORACIÓ PARC TAULI A. Gavarró, R. Ustrell, E. Berlanga, F. Campos, M. Torra (Sabadell, Spain) N 108 THE ROLE OF LP(a) LEVELS AND APOPROTEIN(a) PHENOTYPE IN THE DEVELOPMENT 70 D OF ATHEROSCLEROSIS IN PATIENTS WITH CORONARY ARTERY DISEASE A D.D. Labudovic, K.N. Toseska Trajkovska, S.B. Alabakovska, B.B. Todorova, S. Jovanova Y (Skopje, Macedonia) 109 LDL PARTICLE NUMBER AND RISK FOR FUTURE CARDIOVASCULAR RISK 70 K. Elharchaoui, W.A. van der Steeg, S.M. Boekholdt, E.S.G. Stroes, J.D. Otvos, J.A. Kuivenhoven, S.A. Bingham, N.E. Day, K.T. Khaw, J.J.P. Kastelein (Amsterdam, The Netherlands, Raleigh, NC, USA and Cambridge, UK) 110 LIPID PENTAD INDEX: A BETTER INDEX OF DYSLIPIDEMIAS IN CHILDREN OF 70 PREMATURE CORONARY ARTERY DISEASE PATIENTS IN INDIA B. Das, M.K. Daga, S.K. Gupta (New Delhi, India) 111 LOW HDL IS PREDICTOR OF DEATH IN PATIENTS WITH LEFT VENTRICULAR 70 DYSFUNCTION INDEPENDENTLY ON CORONARY ATHEROSCLEROSIS F. Bigazzi, M. Puntoni, F. Minichilli, P. Landi, S. Lusso, A. Bionda, C. Carpeggiani, T. Sampietro (Pisa, Italy) 112 PROPOSAL FOR A LIPID DISORDER CLASSIFICATION 70 W.E. Feeman (Bowling Green, KY, USA) 113 INHIBITION OF APOLIPOPROTEIN A-I GLYCATION RESTORES ITS ABILITY TO 71 ACTIVATE LECITHIN:CHOLESTEROL ACYL TRANSFERASE E. Nobecourt, M. Davies, J. Zeng, K.A. Rye (Camperdown, VIC, Australia) 114 EVIDENCE THAT GLYCATION OF APOLIPOPROTEIN A-I INHIBITS THE 71 ANTI-INFLAMMATORY PROPERTIES OF HDL IN VIVO E. Nobecourt, R. Puranik, S. Bao, M. Davies, P. Barter, K.A. Rye (Camperdown, VIC, Australia) 115 EVALUATION OF PLANT STEROL SERUM LEVELS IN 4222 VOLUNTEERS OF THE 71 MONICA SURVEY U. Ceglarek, G.M. Fiedler, J. Lembcke, S. Baumann, A. Leichtle, A. Döring, H. Löwel, E. Wichmann, J. Thiery (Leipzig and Neuherberg, Germany) 116 GAMMA-GLUTAMYL TRANSFERASE LEVELS ARE ASSOCIATED TO CAROTID 71 INTIMA-MEDIA THICKNESS M. Ferraro, S. La Carrubba, G. Barone, V. Spagnuolo, G. Mauro (San G. Fiore, Palermo and Cosenza, Italy) 117 CARRIER-STATE OF TWO OR THREE VARIANTS WITHIN MTHFR, ICAM1, PAI-1, IL-6 72 AND FGB GENES IS RISK FACTOR OF CORONARY ARTERY DISEASE B. Sarecka, I. Zak, J. Krauze (Katowice, Poland) 118 FREE FATTY ACIDS ARE INDEPENDENTLY ASSOCIATED WITH ALL-CAUSE AND 72 CARDIOVASCULAR MORTALITY IN SUBJECTS WITH CORONARY ARTERY DISEASE S. Pilz, H. Scharnagl, B. Tiran, B.O. Boehm, W. März (Graz, Austria and Ulm, Germany) 119 HIGH ADIPONECTIN IS INDEPENDENTLY ASSOCIATED WITH TOTAL MORTALITY AND 72 CARDIOVASCULAR MORTALITY IN CORONARY ARTERY DISEASE S. Pilz, H. Mangge, B. Tiran, B.O. Boehm, B.R. Winkelmann, W. März (Graz, Austria, Ulm and Frankfurt, Germany)

31 120 C-REACTIVE PROTEIN IS AN INDEPENDENT PREDICTOR OF ALL-CAUSE MORTALITY IN 72 A JAPANESE GENERAL POPULATION M. Nakamura, K. Sato, F. Tanaka, T. Segawa, M. Nagano, T. Onoda, A. Okayama (Morioka and Osaka, Japan) 121 PLASMA BRAIN-DERIVED NEUROTROPHIC FACTOR PREDICTS LONG-TERM MORTALITY 73 IN PATIENTS WITH CHRONIC STABLE CORONARY ARTERY DISEASE P. Minoretti, V. Olivieri, A. Aldeghi, S. Pesenti, R. Arra, R. Sangiorgio, C. Barranco, E. Emanuele (Pavia, Italy) 122 RENAL DYSFUNCTION MAY PREDICT THE PRESENCE OF ATHEROSCLEROSIS 73 M. Chou, M. Morihira, K. Haraguchi, A. Satoh, H. Yoshie, R. Kataoka, I. Makino, H. Kondoh (Eniwa, Japan) 123 INFLUENCE OF AGE, GENDER, SMOKING, ALCOHOL CONSUMMATION AND BLOOD 73 PRESSURE ON PLASMA HOMOCYSTEINE LEVELS G. Bosilkova, M. Krstevska, S. Dzhekova-Stojkova, N. Bogoeska (Skopje and Vevchani, Macedonia) 124 ANALYSIS OF POLYMORPHIC VARIANTS OF GENES INVOLVED IN LIPID METABOLISM 73 M IN PATIENTS WITH CORONARY ARTERY DISEASE O A. Balcerzyk, I. Zak, M. Trusz-Gluza (Katowice, Poland) 125 ASSOCIATION BETWEEN OSTEOPROTEGERIN GENE POLYMORPHISM AND CORONARY 73 N ARTERY DISEASE IN JAPANESE MEN D R. Ohmori, Y. Momiyama, M. Nagano, H. Taniguchi, N. Tanaka, R. Kato, T. Egashira, A K. Arakawa, H. Nakamura, F. Ohsuzu (Saitama, Japan) 126 POSTER WITHDRAWN – Y 127 VENOUS THROMBOEMBOLISM AND THE RISK OF SUBSEQUENT SYMPTOMATIC 74 ATHEROSCLEROSIS P. Prandoni, R. Pesavento, A.W.A. Lensing, A. Ghilarduzzi, M.H. Prins, V. Pengo, B.L. Davidson, D. Tormene, M. Iotti, A. Pagnan (Padua, Reggio Emilia, Italy, Amsterdam, Maastricht, The Netherlands and Seattle, WA, USA) 128 IMPROVING PREDICTION OF ISCHEMIC CARDIOVASCULAR DISEASE IN THE GENERAL 74 M. Benn, B.G. Nordestgaard, A. Tybjærg-Hansen (Copenhagen, Denmark) 129 PLASMA BRAIN NATRIURETIC PEPTIDE LEVELS ARE RELATED WITH LESION 74 COMPLEXITY IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE A. Yildirir, S. Acikel, C. Ertan, A. Aydinalp, O. Gulmez, M. Yucel, B. Ozin, H. Muderrisoglu (Ankara, Turkey) 130 THE ASSOCIATION BETWEEN CORONARY ARTERY BYPASS GRAFT STENOSIS AND 74 SERUM GAMMA GLUTAMYL TRANSFERASE ACTIVITY T. Ulus, A. Yildirir, S. Balta, O. Demir, M.A. Kucuk, Y.C. Gursoy, S. Mermer, A. Aydinalp, H. Muderrisoglu (Ankara, Turkey) 131 COPPER CONCENTRATION IN SERUM AND ATHEROSCLEROTIC PLAQUE IN PATIENTS 75 WITH CAROTID ATHEROSCLEROSIS N. Tasic, D.J. Radak, G. Djordjevic-Denic, D. Tasic, D. Djarmati, P. Gajin (Belgrade, Serbia-Montenegro) 132 SERUM AND PLAQUE ZINC CONCENTRATION IN PATIENTS WITH DIFFERENT 75 MORPHOLOGY CAROTID ATHEROSCLEROTIC PLAQUES D. Tasic, N. Tasic, D.J. Radak, T. Radosavljevic, G. Djordjevic-Denic, D. Djarmati (Belgrade, Serbia-Montenegro) 133 SERUM 25-HYDROXYVITAMIN D3 CONCENTRATIONS AND PREVALENCE OF 75 CARDIOVASCULAR DISEASE AMONG TYPE 2 DIABETIC PATIENTS G. Targher, M.P. Iagulli, V. Miconi, M. Galiotto, S. Lombardi, M. Cigolini (Negrar and Arzignano, Italy) 134 DETERMINANTS OF ENDOTHELIAL DYSFUNCTION AND CAROTID INTIMA MEDIA 75 THICKNESS IN COMBINED HYPERLIPIDEMIA M. Sebestjen, B. Zegura, V. Videcnik, I. Keber (Ljubljana, Slovenia) 135 ROLE OF ENDOTHELIAL FUNCTION AND INFLAMMATION IN PATIENTS WITH 76 CARDIOVASCULAR RISK FACTORS, WITH AND WITHOUT A HISTORY OF MYOCARDIAL INFARCTION M. Sebestjen, B. Erzen, B. Zegura, M. Sabovic, P. Poredos, I. Keber (Ljubljana, Slovenia) 136 CHLAMYDIA PNEUMONIAE IgG AND IgA SEROPOSITIVITY IN PATIENTS WITH 76 CORONARY HEART DISEASE WITHOUT TRADITIONAL RISK FACTORS D. Drobniak-Heldak, W. Kolasinska-Kloch, R. Rajtar, M. Kloch, B. Kiec-Wilk, A. Zdzienicka, A. Dembinska-Kiec (Cracow, Poland)

32 137 ELECTROCARDIOGRAM SCREENING FOR LEFT HIGH R-WAVE PREDICTS 76 CARDIOVASCULAR DEATH IN A JAPANESE COMMUNITY-BASED POPULATION; NIPPON DATA90 K. Nakamura, T. Okamura, T. Hayakawa, T. Kadowaki, Y. Kita, A. Okayama, H. Ueshima (Otus, Izumo and Suita, Japan) 138 HEMOGLOBIN A1C IS ASSOCIATED WITH RESTING AND EXERCISE BLOOD PRESSURES 76 IN HEALTHY SUBJECTS E. Matteucci, J. Rosada, M. Pinelli, C. Giusti, O. Giampietro (Pisa, Italy) 139 DO PLASMA GHRELIN HAVE A BENEFICIAL EFFECT ON THE METABOLIC SYNDROME? 76 A. Hino, H. Adachi, Y. Hirai, M. Enomoto, K. Furuki, T. Imaizumi (Kurume, Japan) 140 SERUM VITAMIN B12 IS INVERSELY RELATED TO BLOOD PRESSURE AND ANXIETY 77 IN ELDERLY WOMEN BUT NOT IN ELDERLY MEN P.D. Roach, N. Naumovski, B. Blades, M. Lucock, C. Travers, P. Lewis, J. Sturm, M. Veysey (Ourimbah and Gosford, NSW, Australia) 141 LOW BIRTH WEIGHT AND EARLY PUBERTAL DEVELOPMENT AS RISK FACTORS FOR 77 HIGH BLOOD PRESSURE IN ADOLESCENCE R.M. Izquierdo, J. Bacallao (Ciudad Habana, Cuba) M 142 ANTIOXIDANT ENZYMES AND CARDIOVASCULAR RISK FACTORS IN END-STAGE 77 O RENAL DISEASE C.A. Fytili-Kavakiotou, E. Gounari, F. Zisi, M. Daskalaki, E. Hatzikallinikidou, E. Progia N (Thessaloniki, Greece) D 143 UNRESTS OF THE HAEMOSTASIS TO RISK CORONARY HEART DISEASE AT 77 A HAEMODIALYSIS PATIENTS Y F. Sadiq, A. Tissent, N. Habti, T. Moutiqui, D. Radallah, N. Benchemsi (Casablanca, Morocco) 144 TURNER SYNDROME IS A GREATER RISK OF CORONARY ARTERY DISEASE IN 78 POLISH YOUNG WOMEN POPULATION M. Kozlowska-Wojciechowska, W. Jez (Warsaw and Bytom, Poland) 145 THE STRUCTURE OF CARDIOVASCULAR MORTALITY IN DIFFERENT AGE GROUPS OF 78 HEMODIALYSIS PATIENTS B. Bikbov, N. Tomilina (Moscow, Russia) 146 DETERMINATION IN RISK FACTORS IN FIVE ETHNIC GROUPS WITH KNOWN CORONARY 78 ARTERY DISEASE PRESENTING FOR INTERVENTION AT A SUBURBAN HOSPITAL C. Ryan, M. Pliam, F. Millhouse, N. Baladi, A. Yap, L. Manila, A. Pagador, L. Lee, M. Cavanaugh (Daly City, CA, USA) 147 APOLIPOPROTEIN E POLYMORPHISM IN WEST SIBERIA CAUCASIAN POPULATION AND 78 ITS ASSOCIATION WITH PLASMA LIPID LEVELS M.I. Voevoda, E.V. Shakhtshneider, I.V. Kulikov, V.N. Maksimov, S.N. Ustinov, M.V. Ivanova, V.F. Kobzev, S.K. Malyutina, A.G. Romashchenko (Novosibirsk, Russia) 148 RISK FACTORS FOR ALL-CAUSE MORTALITY IN FRAIL VERY OLD PEOPLE 78 O.D. Vasovic, L.J. Zikic, G. Sevo, M. Zamaklar, D. Milosevic (Belgrade, Serbia-Montenegro) 149 HDL-CHOLESTEROL IS DECREASED IN ASIAN INDIAN WOMEN LIVING IN INDIA AS 79 WELL AS UNITED STATES WHEN COMPARED TO CAUCASIAN WOMEN M. Chandalia, R. Deepa, V. Mohan, S.M. Grundy, N. Abate (Dallas, TX, USA and Chennai, India) 150 RISK FACTORS IN A RURAL SCHOOLCHILDREN POPULATION FROM SOUTHEASTERN 79 BRAZIL A. Pereira, T. Leme da Rocha Martinez, L. Proença Vieira (São Paulo, Brazil) 151 MALE SPINAL CORD INJURY PATIENTS OF THORACIC LEVEL 6 AND ABOVE ASSOCIATED 79 WITH IMPAIRED GLUCOSE TOLERANCE AND CAROTID ATHEROSCLEROSIS T.C. Su, Y.H. Wang, T.S. Huang, P.H. Hwang (Taipei, Taiwan) 152 AGE AT ONSET OF SMOKING AND CARDIOVASCULAR MORTALITY 79 A. Clara, A. Planas, A. Gasol, A. De Moner, C. Contreras, J.M. Pou, J. Marrugat, F. Vidal-Barraquer (Barcelona and Hospitalet, Spain) 153 C-REACTIVE PROTEIN AND AORTIC STIFFNESS AND WAVE REFLECTIONS IN 79 MIDDLE-AGED MEN H.R. Nakhai Pour, D.E. Grobbee, M. Muller, Y.T. van der Schouw (Utrecht, The Netherlands) 154 GENDER, CAROTID STENOSIS, AND RISK FACTOR TREATMENT IN AFRICAN-AMERICAN 80 PATIENTS WITH ISCHEMIC HEART DISEASE S. Modi, M. Kronenberg, L. Afonso, S. Chaturvedi (Detroit, MI and Nashville, TN, USA) 155 SOUTH ASIANS HAVE NARROWER CORONARY ARTERIES AND DIFFERENT 80 REMODELLING RESPONSES TO DISEASE COMPARED TO WHITE EUROPEANS T. Tillin, H. Dhutia, J. Chambers, I. Malik, E. Coady, J. Mayet, A. Wright, J. Kooner, N. Chaturvedi, A. Hughes (London, UK)

33 156 BRITISH SOUTH ASIAN MEN HAVE MORE ADVERSE PLAQUE MORPHOLOGY DESPITE 80 EQUIVALENT ATHEROSCLEROTIC BURDEN TO WHITE EUROPEANS T. Tillin, H. Dhutia, J. Chambers, I. Malik, E. Coady, J. Mayet, A. Wright, J. Kooner, N. Chaturvedi, A. Hughes (London, UK) 157 CARDIOVASCULAR RISK PROFILE IN ELDERLY HEALTHY PEOPLE IN CHILE 80 S. Kunstmann, M.T. Lira, J.C. Molina, D. Gainza (Santiago, Chile) 158 APOLIPOPROTEIN E POLYMORPHISM IN NATIVE POPULATION OF MOUNTAIN SHORIYA 81 (WEST SIBERIA) AND ITS ASSOCIATION WITH PLASMA LIPID LEVELS E.V. Shakhtshneider, O.L. Barbarash, M.Y. Ogarkov, I.V. Kulikov, V.A. Baum, S.N. Ustinov, N.S. Yudin, V.F. Kobzev, A.G. Romashchenko, M.I. Voevoda (Novosibirsk, Russia) 159 DISTRIBUTION OF OCHRONOTIC PIGMENT IN THE CARDIOVASCULAR SYSTEM – 81 A REAPPRAISAL L.R. Ranganath, T. Helliwell (Liverpool, UK) 160 A SURVEY ON KNOWLEDGE OF CHINESE PHYSICIAN IN PREVENTION AND CONTROL 81 OF DYSLIPIDEMIA J.Y. Li, D.Y. Hu, X.B. Shi, Q.G. Tong (Shanghai and Beijing, China) M 161 DIFFERENCES IN RISK FACTORS AND ANGIOGRAPHIC FINDINGS BETWEEN THREE 81 O ETHNIC GROUPS OF CARIBBEAN PATIENTS WITH LOWER LIMB ARTERIAL DISEASE M. Deneuville, F. Losy (Pointe-à-Pitre, Guadaloupe) N 162 FAMILIAL HYPERCHOLESTEROLEMIA-SCREENING OF RELATIVES 81 D K. Gkogkos, G. Pavlidis, A. Karakozoglou, S. Fragidis, A. Maliouri, J. Kountouras A (Thessaloniki, Greece) 163 PREVALENCE OF DYSLIPIDEMIA IN MEXICAN URBAN ADOLESCENTS 82 Y R. Posadas-Sanchez, J. Zamora-Gonzalez, L. Yamamoto-Kimura, G. Cardoso-Saldaña, C. Posadas-Romero (Mexico City, Mexico) 164 LEVELS OF SERUM LIPOPROTEIN (a) IN PATIENTS WITH PRIMARY HYPOTHYROIDISM 82 AND EUTHYROID GOITER M. Djeric, S. Kojic-Damjanov, M. Ninkovic (Novi Sad, Serbia-Montenegro) 165 ATHEROSCLEROSIS, HEMORHEOLOGICAL PARAMETERS AND AGING 82 G. Feher, K. Koltai, P. Kenyeres, H. Rapp, G. Kesmarky, L. Szapary, I. Juricskay, K. Toth (Pecs, Hungary) 166 POSTER WITHDRAWN – 167 YOUNGER MENOPAUSE AGE PREDICTS ADVERSE OUTCOME AFTER MYOCARDIAL 82 INFARCTION S. Mallik, J.A. Spertus, K.J. Reid, J. Lichtman, N. Dawood, N. Wenger, V. Vaccarino (Atlanta, GA, Kansas City, KS and New Haven, CT, USA) 461 HOUSEHOLD FOOD SECURITY AND C.V.D. AND ITS RISK FACTORS IN IRAN 82 M. Rafiei, M. Boshtam (Isfahan, Iran) 462 INFLUENCE OF A DIABETES DECOMPENSATION ON SOME PARAMETERS OF LIPID 83 METABOLISM AND CAROTID “INTIMA-MEDIA” THICKNESS IN UNSTABLE ANGINA PECTORIS PATIENTS R.D. Kurbanov, F.H. Kamilova. A.B. Shek (Tashkent, Uzbekistan)

34 POSTER AREA “A” MONDAY, June 19 168-216

POSTER DISPLAY: for the duration of one day (Monday, June 19 from 8.30 am to 6.30 pm). Participants may view the posters displayed during this day.

Mo-P2 Poster Session 2 poster PATHOPHYSIOLOGY OF THROMBOSIS abstract bk. board no.: page ref.: M 168 ENDOGENOUS HEPARIN - A PROTECTIVE MARKER IN MEN WITH 83 MYOCARDIAL INFARCTION O W. Sinkiewicz, E. Zekanowska, J. Dudziak (Torun, Poland) N 169 HIGH IMMUNOGLOBULIN E SERUM CONCENTRATION – THE IMPORTANT 83 D MARKER OF DEVELOPMENT OF CORONARY ARTERY DISEASE W. Sinkiewicz, E. Zekanowska, J. Dudziak (Torun, Poland) A 170 DYSLIPIDAEMIA AND METABOLIC SYNDROME IN PATIENTS WITH ACUTE 83 Y CORONARY SYNDROME I. Premuzic, S. Kranjcevic, I. Prkacin, T. Mestrovic (Zagreb, Croatia) 171 A 3 YEARS FOLLOW-UP: PREVALENCE AND CHARACTERISTICS OF THE PATIENTS 84 WITH ACUTE CORONARY SYNDROME V.N. Nicolaou, I.E. Papadakis, D.B. Panagiotakos, C. Couremenou, X. Krinos, E.N. Karatzis, K.E. Loutsidis, K. Dimopoulos, P.D. Skoufas (Athens, Greece) 172 INFLAMMATION AND REDOX BALANCE MARKERS LEVELS IN PATIENTS WITH ACUTE 84 MYOCARDIUM INFARCTION P. Napoleão, A. Melão, M.C. Santos, L. Veiga, M. Selas, R. Ferreira, A.M. Viegas-Crespo, T. Pinheiro (Lisbon and Sacavém, Portugal) 173 IS THERE AN ASSOCIATION BETWEEN CHLAMYDIA PNEUMONIAE INFECTION AND 84 PLATELET ACTIVATION IN PATIENTS WITH CORONARY ARTERY DISEASE H. Kälvegren, J. Fridfeldt, P. Leanderson, E. Kihlström, A. Richter, T. Bengtsson (Linköping, Sweden) 174 STUDY OF BIOLOGIC PROFILE IN ACUTE VS CHRONIC MYOCARDIAL ISCHAEMIA 84 R. Caso, E. Molinero, B. Martinez, I. Narvaez, M. Vacas, Y. Saez, J.A. Iriarte, J.M. Gandarias (Bilbao, Spain) 175 DO FIBRINOGEN AND VON WILLEBRAND FACTOR HAVE PROGNOSTIC VALUE IN 84 PATIENTS WITH ACUTE CORONARY SYNDROME J. Zielonka, M. Jastrzebska, M. Lewandowski, Z. Kornacewicz-Jach, J. Goracy (Szczecin, Poland) 176 CORRELATION BETWEEN CIRCULATING CHLAMYDIAL LIPOPOLYSACCHARIDE AND 85 CRP LEVELS DURING ACUTE CORONARY SYNDROME? T. Tiirola, J. Sinisalo, M.S. Nieminen, S. Silvennoinen-Kassinen, M. Paldanius, P. Saikku, M. Jauhiainen, M. Leinonen (Helsinki and Oulu, Finland) 177 PROTEIN Z LEVELS AND PROGNOSIS IN PATIENTS WITH ACUTE CORONARY 85 SYNDROMES F. Sofi, F. Cesari, R. Marcucci, C. Fatini, A.M. Gori, A. Rogolino, E. Sticchi, S. Fedi, R. Abbate, G.F. Gensini (Florence and Impruneta, Italy) 178 LOW GLOMERULAR FILTRATION RATE PREDICTS POOR LONG-TERM OUTCOME AFTER 85 NON-ST-SEGMENT ELEVATION ACUTE CORONARY SYNDROMES J. Rueda, O. Cano, E. Zorio, A. Osa, M.A. Arnau, R. Sánchez, L. Martínez-Dolz, L. Almenar, M. Palencia, A. Salvador (Valencia, Spain) 179 SERUM SOLUBLE SR-PSOX/CXCL16 IS AN INDEPENDENT BIOMARKER FOR ACUTE 85 CORONARY SYNDROME H. Mitsuoka, N. Kume, K. Hayashida, M. Tanaka, T. Kita (Kyoto and Osaka, Japan) 180 CYTOKINES IMBALANCE IN ACUTE CORONARY SYNDROMES 86 S. Maffei, M. Di Renzo, L. Puccetti, G. Bova, M. Pastorelli, A.L. Pasqui, A. Auteri (Siena, Italy)

35 181 NEUROTROPHINS AND ACUTE CORONARY SYNDROMES 86 G.N. Chaldakov, L. Manni, V. Nikolova, D. Vyagova, L. Aloe (Varna, Bulgaria and Rome, Italy) 182 ENRICHMENT OF Z-DIM CD4+ T-CELLS CORRELATES WITH C-REACTIVE PROTEIN 86 (CRP) IN PATIENTS WITH ACUTE CORONARY SYNDROME (ACS) E. Ammirati, M. Banfi, D. Cianflone, A.P. Cope, A. Maseri, C. Monaco (Milan, Italy and London, UK) 183 THE ULTRASTRUCTURE OF CORONAROPATHY STUDIED ON HUMAN BIOPSIES 86 DURING BPAC G. Martines, G.P. Esposito, M. Scorsin, L. Stellin, C. Zuch, P. Boldrini, M.R. Bovolenta, A. Aleotti (Chieti-Pescara, Lecce and Ferrara, Italy) 184 CHOLESTEROL CONTENT OF ERYTHROCYTE MEMBRANES - A NEW MARKER OF 87 CAD INSTABILITY - MAY INDUCE SYSTEMIC INFLAMMATORY RESPONSES D.N. Tziakas, J.C. Kaski, G.K. Chalikias, C. Romero, S. Fredericks, I.K. Tentes, A.X. Kortsaris, D.I. Hatseras, D.W. Holt (Alexandroupolis, Greece and London, UK) 185 eNOS- AND iNOS-DERIVED NITRIC OXIDE REGULATES IN VIVO OXYGEN 87 CONSUMPTION IN THE POSTISCHEMIC MYOCARDIUM M G. He, X. Zhao, Y. Chen, J.L. Zweier (Columbus, OH, USA) O 186 ROLES OF BILIRUBIN/BILIRUBIN OXIDATIVE METABOLITES PATHWAY IN ACUTE 87 MYOCARDIAL INFARCTION N K. Ishikawa, H. Kunii, T. Yamaguchi, Y. Maruyama (Fukushima and Tokyo, Japan) D 187 LAMINAR SHEAR STRESS SUPPRESSES THE FIBRINOLYTIC CAPACITY IN CULTURED 87 A VASCULAR ENDOTHELIAL CELLS E. Ulfhammer, N. Bergh, L. Karlsson, M. Andersson, S. Jern (Göteborg, Sweden) Y 188 INVOLVEMENT OF RAF/ERK PATHWAY IN PRODUCTION OF PLASMINOGEN 87 ACTIVATOR INHIBITOR-1 IN VASCULAR ENDOTHELIAL CELLS INDUCED BY OXIDIZED OR GLYCATED LDL G. Sangle, F. Zhu, S. Ren, G. Shen (Winnipeg, MB, Canada) 189 OXIDIZED LDL INCREASED THE EXPRESSION OF HEAT SHOCK FACTOR-1 IN 88 VASCULAR ENDOTHELIAL CELLS AND ITS RELATIONSHIP WITH PLASMINOGEN ACTIVATOR INHIBITOR-1 G. Shen, R. Zhao (Winnipeg, MB, Canada) 190 THE HUMAN AORTA ENDOTHELIOPATHY: ULTRASTRUCTURAL STUDY IN PATIENTS 88 TREATED WITH BPAC G. Martines, L. Stellin, C. Zuch, G.P. Esposito, M. Scorsin, P. Boldrini, M.R. Bovolenta, A. Aleotti (Chieti-Pescara, Lecce and Ferrara, Italy) 191 PROTEOME OF ENDOTHELIAL CELL-DERIVED PROCOAGULANT MICROPARTICLES 88 M. Brioschi, R. Wait, L. Mussoni, E. Tremoli, C. Banfi (Milan, Italy and London, UK) 192 POLYCYTHEMIA VERA AND ENDOTHELIAL DYSFUNCTION: ROLE OF CD40 LIGAND 88 G. Lessiani, A. Falco, A. Dragani, G. Fioritoni, G. La Barba, F. Fioritoni, N. Michetti, A. Recchiuti, G. Davi' (Chieti and Pescara, Italy) 193 VALIDITY OF PLASMA FIBRINOGEN, D-DIMER AND VON WILLEBRAND FACTOR AS 89 MARKERS OF CARDIOVASCULAR MORBIDITY IN PATIENTS ON CHRONIC HAEMODIALYSIS D. Kirmizis, A. Tsiandoulas, M. Pangalou, E. Koutoupa, P. Rozi, M. Protopappa, K. Barboutis (Serres, Greece) 194 LEVELS AND 1040C/T POLYMORPHISM OF THE THROMBIN ACTIVATABLE 89 FIBRINOLYSIS INHIBITOR (TAFI) IN YOUNG SURVIVORS OF MYOCARDIAL INFARCTION (MI) E. Zorio, R. Castelló, L. Ramón, J. Rueda, C.I. Chamorro, L. Almenar, M. Palencia, A. Salvador, A. Estellés, F. España (Valencia, Spain) 195 ROLE OF HEMOSTATIC GENE POLYMORPHISMS IN THE EARLY DEVELOPMENT OF 89 CORONARY ARTERY DISEASE E.Y. Andreenko, A.N. Meshkov, A.V. Balatsky, P.I. Makarevich, M.R. Lalayanc, P.P. Malyshev, V.N. Bochkov, L.M. Samohodskaya, V.A. Tkachuk (Moscow, Russia) 196 A GENOME SCAN FOR SUBCLINICAL CARDIOVASCULAR DISEASE IN THE DIABETES 89 HEART STUDY D.W. Bowden, A.B. Lehtinen, J.T. Ziegler, D. Herrington, L.E. Wagenknecht, S.S. Rich, B.I. Freedman, J.J. Carr, C.D. Langefeld (Winston-Salem, NC, USA) 197 POSTER WITHDRAWN – 198 EFFECT OF SR-BI DEFICIENCY ON PLATELET AGGREGATION AND SUSCEPTIBILITY 90 TO THROMBOSIS I. Meurs, S.J. Korporaal, A. Hauer, J.W. Akkerman, J. Kuiper, T.J. van Berkel, M. Van Eck (Leiden and Utrecht, The Netherlands)

36 199 INDIUM-111 OXINE PLATELETS SURVIVAL IN PATIENTS SUFFERING OF CARDIAC 90 AND CEREBRAL ARTERIOSCLEROSIS A. Indovina, G. Avellone, V. Di Garbo, D. Campisi (Palermo, Italy) 200 C-REACTIVE PROTEIN ENHANCES SHEAR STRESS-DEPENDENT PLATELET ADHESION 90 A.J. Flammer, N. Amacker, L.E. Spieker, J.J. Badimon, B. Sasse, F. Ruschitzka, I. Sudano, T. F. Lüscher, G. Noll, R. Corti (Zurich, Switzerland and New York, NY, USA) 201 THE EXTRACELLULAR ION ENVIRONMENT MODULATES PLATELET ADHESION 90 AFTER LYSOPHOSPHATIDIC ACID TREATMENT IN VITRO A.C. Eriksson, U.K. Nilsson, P.A. Whiss (Linköping, Sweden) 202 THE MAJORITY OF PLASMINOGEN ACTIVATOR INHIBITOR 1 IN PLATELETS IS 90 FUNCTIONALLY ACTIVE H. Brogren, L. Karlsson, K. Wallmark, S. Jern (Gothenburg, Sweden) 203 ASPIRIN AND SALICYLATE PREVENT POLYMORPHONUCLEAR LEUKOCYTE 91 SURVIVAL MEDIATED BY PLATELETS AND ACIDOSIS E. Malaver, S. Negrotto, N. Pacienza, P. D'Atri, R. Pozner, P. Urdinez, R. Gomez, M. Schattner (Buenos Aires, Argentina) 204 THE ROLE OF PLATELET ACTIVITY IN PATIENTS WITH PATENT VERSUS OCCLUDED 91 M CORONARY ARTERY BYPASS GRAFTS. PRAGUE-4 TRIAL SUBANALYSIS O P. Osmancik, F. Bednar, H. Mocikova, P. Stros, P. Widimsky (Prague, Czech Republic) 205 PLATELET - VASCULAR WALL INTERACTION REGULATE BY POLIPHENOLS AND ZINC 91 N IN EXPERIMENTAL DIABETES MELLITUS D M. Badescu, M. Ciocoiu, D. Jitaru, D. Ungureanu, M. Chicu, C. Badescu (Iasi, Romania) A 206 MECHANISMS UNDERLYING PLATELET DESENSITISATION TOWARDS NITRIC OXIDE 91 Y M. Grenegård, E. Lindström, A. Asplund-Persson, P. Gunnarsson (Linköping, Sweden) 207 EFFECT OF ASPIRIN IN CANCER PATIENTS WITH ACUTE MYOCARDIAL INFARCTION: 91 INFLUENCE OF THROMBOCYTOPENIA D.J. Lenihan, M.G. Sarkiss, C. Warneke, G.H. Botz, J.B. Durand (Houston, TX, USA) 208 DOES THE MEASUREMENT OF MEAN PLATELET VOLUME PROVIDE ADDITIONAL 92 INFORMATION IN ACUTE CORONARY SYNDROMES? S. Acikel, A. Yildirir, A. Aydinalp, O. Eldem, U. Bal, G. Kaynar, K. Demirtas, B. Ozin, H. Muderrisoglu (Ankara, Turkey) 209 TISSUE FACTOR INDUCTION BY PROTEASE-ACTIVATED RECEPTOR-1 REQUIRES INTACT 92 CAVEOLIN-ENRICHED MEMBRANE MICRODOMAINS IN HUMAN ENDOTHELIAL CELLS C. Banfi, M. Brioschi, S. Barcella, M. Bailo, E. Tremoli, A. Parolari, P. Biglioli, L. Mussoni (Milan, Italy) 210 PAR-1 AND PAR-2 ACTIVATION MEDIATES TISSUE FACTOR INDUCTION IN 92 ENDOTHELIAL CELLS THROUGH A REDOX-SENSITIVE SIGNALING PATHWAY C. Banfi, M. Brioschi, S.S. Barbieri, S. Eligini, S. Barcella, E. Tremoli, S. Colli, L. Mussoni (Milan, Italy) 211 INHIBITION OF TISSUE FACTOR SIGNALLING REDUCES PRODUCTION OF 92 PRO-INFLAMMATORY CYTOKINES IN ATHEROMA SMOOTH MUSCLE CELLS L. Persson, T. Navin, S. Gregan, A.H. Davies, M. Feldmann, C. Monaco (London, UK) 212 INTRAVASCULAR TISSUE FACTOR IN CORD VS. ADULT WHOLE BLOOD 93 G. Cvirn, M. Koestenberger, J. Kutschera, U. Ferstl, W. Muntean, P. Sedlmayr, G. Juergens, S. Gallistl (Graz, Austria) 213 ATHEROSCLEROSIS IN MIDDLE CEREBRAL ARTERY: HISTOLOGICAL COMPARISON 93 BETWEEN SYMPTOMATIC AND ASYMPTOMATIC PLAQUES IN POST-MORTEM STUDY X.Y. Chen, H.L. Zhao, W.M.W. Lam, H.K. Ng, K.S. Wong (Shatin, China) 214 IS INTERLEUKIN 18 A DETERMINANT OF ENDOTHELIAL DYSFUNCTION AND 93 PROTHROMBOTIC STATUS IN PATIENTS WITH UNSTABLE ANGINA? R. Jurcut, I. Arsenescu, T. Puscariu, V. Uscatescu, C. Jurcut, E. Apetrei, C. Ginghina (Bucharest, Romania) 215 INCREASED EXPRESSION OF INTERLEUKIN-10 IN UNSTABLE PLAQUE OBTAINED BY 93 DIRECTIONAL CORONARY ATHERECTOMY K. Nishihira, T. Imamura, A. Yamashita, K. Hatakeyama, H. Date, T. Eto, Y. Asada (Miyazaki, Japan) 216 ADIPOPHILIN EXPRESSION IN CAROTID ATHEROSCLEROSIS 93 P.M. Isoviita, K. Nuotio, J. Saksi, P. Ijäs, J. Pitkäniemi, P.T. Kovanen, M. Kaste, P.J. Lindsberg (Helsinki, Finland)

37 POSTER AREA “B” MONDAY, June 19 217-233

POSTER DISPLAY: for the duration of one day (Monday, June 19 from 8.30 am to 6.30 pm). Participants may view the posters displayed during this day.

Mo-P3 Poster Session 3 poster GENE THERAPY AND STEM CELLS abstract bk. board no.: page ref.: M 217 HYBRID CELL-GENE THERAPY FOR PULMONARY HYPERTENSION BASED ON 94 O PHAGOCYTOSING ACTION OF ENDOTHELIAL PROGENITOR CELLS N N. Nagaya, K. Kangawa, M. Kanda, Y. Tabata, H. Mori (Suita and Kyoto, Japan) D 218 ATP-BINDING CASSETTE TRANSPORTER A1 GENE TRANSFER INCREASES HDL 94 CHOLESTEROL BUT ACCELERATES PROGRESSION OF ATHEROSCLEROSIS IN APO A E-/- MICE Y J. Lievens, Y. Feng, J. Snoeys, D. Collen, B. De Geest (Leuven, Belgium) 219 EXPRESSION OF HUMAN APOLIPOPROTEIN AI IN APOE-/- MICE REDUCES BOTH 94 ATHEROSCLEROTIC LESIONS AND MARKERS OF INFLAMMATION A.K. Zaiss, M. Li, D.A. Muruve, L.B. Chan, N.C. Wong (Calgary, AB, Canada and Houston, TX, USA) 220 TARGETED CORRECTION OF LDL RECEPTOR GENE POINT MUTATION BY MODIFIED 94 SINGLE-STRANDED OLIGONUCLEOTIDES IN HEPG2 CELL LINE L.M. Fan, Y.L. Xu, D.P. Guo, X.Y. Li, Q. Chen (Nanjing, China) 221 HEME OXYGENASE-1 GENE TRANSFER VIA A HYPOXIA-RESPONSIVE 95 ADENO-ASSOCIATED VIRAL VECTOR SUPPRESSES PROGRESSIVE HEART FAILURE AFTER MYOCARDIAL INFARCTION L.Y. Chau, Y.H. Chen, H.H. Lin, N.C. Yang, M.T. Chiang, P.F. Chang (Taipei, Taiwan) 222 MECHANISM OF INHIBITING NEOINTIMAL HYPERPLASIA AFTER ARTERY BALLOON 95 INJURY BY DNA ENZYME TARGETING EARLY GROWTH RESPONSE FACTOR 1 MRNA IN RATS G. Liu, Y. Teng, X. Yuan (Shengyang, China and Linköping, Sweden) 223 OPTIMIZATION OF ADENO-ASSOCIATED VIRUS MEDIATED APOLIPOPROTEIN A-I 95 GENE DELIVERY TO THE MURINE LIVER TO ASSESS EFFECTS ON ATHEROSCLEROSIS S.F.C. Vaessen, R.J. Veldman, E.M. Comijn, J. Snapper, S. Derks, J.J.P. Kastelein, J. Twisk, J.A. Kuivenhoven (Amsterdam, The Netherlands) 224 INTRAMUSCULAR ELECTROTRANSFER OF A PLASMID EXPRESSING APOLIPOPROTEIN 95 E (APO-E) TO REVERSE HYPERLIPIDAEMIA IN APO-E-DEFICIENT MICE V. Evans, I. Graham, H. Foster, K. Foster, J.P. Simons, G. Dickson, J.S. Owen (London and Egham, UK) 225 PYRROLE-IMIDAZOLE POLYAMIDE TARGETING HUMAN LECTIN-LIKE OXIDIZED LDL 96 RECEPTOR 1 GENE REDUCED ENDOTHELIAL CELL APOPTOSIS INDUCED BY ANGIOTENSIN II AND OXIDIZED LDL T. Ueno, N. Fukuda, K. Tahira, R. Suzuki, T. Matsumoto, H. Matsuda, A. Tsunemi, K. Matsumoto, H. Sugiyama, T. Sawamura (Itabashi, Sakyo-Ku and Suita, Japan) 226 STABLE TRANSDUCTION OF MURINE BONE MARROW LIN-C-KIT+ SUBPOPULATION 96 WITH HIV-BASED PSEUDOVIRAL PARTICLES N.V. Radukhina, O.P. Ilyinskaya, P.N. Rutkevich, T.N. Vlasik, T.I. Aref'eva, I.N. Rybalkin, M.M. Peklo, E.V. Janushevskaya, E.M. Tararak (Moscow, Russia) 227 EASY-TO-USE SYSTEM FOR TESTING EFFICIENCY OF TARGETS FOR RNA INTERFERENCE 96 N.M. Kashirina, P.N. Rutkevich, E.V. Yanushevskaya, M.M. Peklo, M.A. Slinkin, T.N. Vlasik, A.Y. Shevelev (Moscow, Russia) 228 POSTER WITHDRAWN – 229 THE FIBROCYTE IN INTIMAL HYPERPLASIA 96 R.L. Varcoe, H. Medbury, M. Vicaretti, A. Guiffre, J.P. Fletcher (Sydney and Westmead, NSW, Australia)

38 230 A NEW METHOD OF PURIFYING VEGFR-2/CD133/CD34 ENDOTHELIAL PROGENITOR 96 CELLS FROM RAT BONE MARROW Z. Wang, Z.Y. Tong, B.L. Hu, Z.S. Jiang, G.H. Li, F. Yao, Y.Z. Yang, G.X. Wang (Heng Yang and Chongqing, China) 231 IN VIVO TRANSFER OF HUMAN CHEMOKINE-LIKE FACTOR 1 GENE INCREASES 97 PERIPHERAL BLOOD CD34+ STEM CELLS AFTER MYOCARDIAL INFARCTION IN RATS X.R. Feng, Z.W. Xiong, Y.J. Gong, D.F. Bu, Y. Huo, T. Hong (Beijing, China) 232 MONOLAYERED MESENCHYMAL STEM CELLS REPAIR SCARRED MYOCARDIUM 97 WHILE GROWING IN SITU Y. Miyahara, N. Nagaya, H. Mori (Suita, Japan) 233 THE AMOUNT OF CD34, CD133+, CD34- AND GP-A CELLS IN PERIPHERAL BLOOD 97 IN PATIENTS WITH CHRONIC HEART FAILURE Z. Gurtskaia (Tbilisi, Georgia)

M O N D A Y

39 POSTER AREA “B” MONDAY, June 19 234-295

POSTER DISPLAY: for the duration of one day (Monday, June 19 from 8.30 am to 6.30 pm). Participants may view the posters displayed during this day.

Mo-P4 Poster Session 4 poster CLINICAL ASPECTS OF CARDIOVASCULAR abstract bk. board no.: page ref.: M DISEASE O 234 CORRELATION BETWEEN TC99M SESTAMIBI SPECT AND CAROTID ARTERIES 97 N ULTRASOUND IN PREDICTING OUTCOMES AFTER LONG-TERM AGGRESSIVE D LIPID LOWERING THERAPY A T. Vakhtangadze, F. Todua, M. Balavadze, M. Akhvlediani, D. Gachechiladze, Y M. Razmadze (Tbilisi, Georgia) 235 A POSSIBLE ROLE OF LIPOPOLYSACCHARIDE-BINDING PROTEIN IN INFECTION 98 RELATED ANGINA PECTORIS T. Rechcinski, A. Grebowska, M. Kurpesa, M. Krzeminska - Pakula, W. Rudnicka, M. Chmiela (Lodz, Poland) 236 RANTES IS TRANSIENTLY RAISED IN PATIENTS WITH UNSTABLE ANGINA PECTORIS 98 A.O. Kraaijeveld, W.J. de Jager, B.J. Prakken, E.E. van der Wall, T.J.C. van Berkel, J.W. Jukema, E.A.L. Biessen (Leiden and Utrecht, The Netherlands) 237 CLINICAL COURSE AND PROGNOSIS OF ISCHEMIC HEART DISEASE WITH STABLE 98 ANGINA PECTORIS (DATA OF A 5-YEAR STUDY) S. Evstifeeva, V. Lupanov, A. Samco, V. Naumov (Moscow, Russia) 238 DIAGNOSTIC VALUE OF SIMULTANEOUS ANKLE-BRACHIAL PRESSURE INDEX AND 98 PULSE WAVE VELOCITY AS MARKERS FOR PRESENCE OF CORONARY ARTERY DISEASE J.Y. Kim, H.J. Park, H.Y. Ryu, H.M. Choi, B.S. Yoo, S.H. Lee, J. Yoon, K.H. Choe (Wonju, South Korea) 239 THE DIAGNOSTIC VALUE OF ISCHEMIA MODIFIED ALBUMIN ACCORDING TO THE 98 TIME INTERVAL FROM ONSET OF CHEST PAIN J.Y. Kim, J. Yoon, H.Y. Ryu, H.M. Choe, B.S. Yoo, S.H. Lee, K.H. Choe (Wonju, South Korea) 240 THE LOADS OF PREMATURE ATRIAL CONTRACTION IS ASSOCIATED WITH INCREASED 99 AORTIC STIFFNESS J.Y. Chen, W.C. Tsai, C.H. Lee, T.H. Chao, C.H. Hsu, P.Y. Liu, L.M. Tsai, J.H. Chen, L.J. Lin (Tainan, Taiwan) 241 LDL-ASSOCIATED PLATELET-ACTIVATING FACTOR ACETYLHYDROLASE MAY BE 99 THERAPEUTIC TARGET FOR PREVENTING ATRIAL FIBRILLATION K. Okamura, S. Miura, B. Zhang, K. Kumagai, K. Saku (Fukuoka, Japan) 242 ASSOCIATION OF PLASMA COENZYME Q10 WITH MORTALITY IN A HEART FAILURE 99 POPULATION S.L. Molyneux, C.M. Florkowski, A.M. Richards, P.M. George (Christchurch, New Zealand) 243 SHORT TERM SIMVASTATIN IN PATIENTS WITH HEART FAILURE OF ISCHEMIC ORIGIN. 99 CHANGES OF LIPIDS, SOME INFLAMMATION MARKERS, AND LEFT VENTRICULAR FUNCTION I.N. Smetanina, N.A. Vaulin, N.A. Gratsiansky (Moscow, Russia) 244 EFFECT OF SEPERATE AND COMBINED TREATMENT BY LOSARTAN AND ENDURANCE 100 TRAINING IN HEART FAILURE M. Hoydal, O. Kemi, P.M. Haram, U. Wisloff, O. Ellingsen (Trondheim, Norway) 245 OSTEOPROTEGERIN IS INCREASED IN HEART FAILURE DUE TO LEFT VENTRICULAR 100 PRESSURE OVERLOAD IN AORTIC STENOSIS S. Helske, P.T. Kovanen, K.A. Lindstedt, J. Lommi, H. Turto, K. Werkkala, M. Kupari (Helsinki, Finland)

40 246 IS IT POSSIBLE TO INCREASE THE DIAGNOSTIC VALUE OF TREADMILL TESTING 100 USING POSTEXERCISE BRAIN NATRIURETIC PEPTIDE LEVELS? A. Yildirir, S. Balta, G. Kaynar, A. Aydinalp, O. Gulmez, M. Yucel, B. Ozin, H. Muderrisoglu (Ankara, Turkey) 247 THE EFFECT OF RELAXATION TECHNIQUES ON ANXIETY IN PATIENTS WITH 100 MYOCARDIAL INFARCTION S.S. Bassampour (Tehran, Iran) 248 OBSERVED VS. PREDICTED MORTALITY IN THE PATIENTS AFTER MYOCARDIAL 100 REVASCULARISATION WITH SKELETONIZED INTERNAL MAMMARY ARTERY S. Susak, S. Nicin, N. Radovanovic (Novi Sad, Serbia-Montenegro) 249 PLASMA OXIDIZED PROTEINS IN HUMAN HEART FAILURE: ROLE IN ENDOTHELIAL 101 DYSFUNCTION C. Banfi, M. Brioschi, S. Barcella, P. Biglioli, E. Tremoli (Milan, Italy) 250 FLUCTUATING HIGH-SENSITIVITY C REACTIVE PROTEIN IN STABLE CHRONIC 101 HEART FAILURE J.P. Araújo, A. Azevedo, F. Friões, P. Lourenço, A. Ferreira, F. Rocha Gonçalves, P. Bettencourt (Porto, Portugal) M 251 CORRELATION BETWEEN CHOLESTEROL LEVELS AND NUTRITIONAL STATUS IN 101 O HEART FAILURE J.P. Araújo, A. Azevedo, P. Lourenço, A. Ferreira, F. Rocha Gonçalves, P. Bettencourt N (Porto, Portugal) D 252 IMPROVEMENT OF CARDIAC FUNCTION IN RESPONSE TO CARVEDILOL IS 101 A ACCOMPANIED BY INCREASED ADIPONECTIN LEVELS IN PATIENTS WITH CHRONIC Y HEART FAILURE M. Fujimura, M. Akaike, T. Iwase, S. Yagi, Y. Ikeda, S. Hashizume, K. Aihara, H. Azuma, T. Matsumoto (Tokushima, Japan) 253 RELATIONSHIP BETWEEN EXTENT OF MYOCARDIAL VIABILITY AND 101 POST-REVASCULARIZATION IMPROVEMENT OF LEFT VENTRICULAR EJECTION FRACTION I. Peovska, J. Maksimovic, M. Vavlukis, D. Pop Gorceva, V. Majstorov, M. Bosevski, B. Taneva (Skopje, Macedonia) 254 CLINICAL UTILITY OF THE ANKLE BRACHIAL INDEX IN ASSESSING THE EXTENT AND 102 DISTRIBUTION OF ATHEROSCLEROSIS R. Bedair, S. El-Tobgy, H. Rizk, H. Yehya (Cairo, Egypt) 255 UNDER DIAGNOSIS OF PERIPHERAL ARTERY DISEASE IN CVD PATIENTS REFLECTS 102 ON UNDERTREATMENT OF RISK FACTORS: THE AGATHA LIKE STUDY D. Gavish, Y. Beigel, R. Zimlichman, E. Leibovitz (Holon and Tel Aviv, Israel) 256 PERIPHERAL ARTERIAL OCCLUSIVE DISEASE: WHAT’S ABOUT THE QUALITY OF 102 DETECTION AND OF FOLLOWING UP IN ALGERIAN POPULATION A. Berrah, N. Ouadahi, D. Hakem, M. Boucelma, D. Zemmour, M. Ibri (Bab-el-Qued, Algeria) 257 SERUM CREATININE PREDICTS ALL-CAUSE AND CARDIOVASCULAR MORTALITY IN 102 PATIENTS WITH PERIPHERAL ARTERIAL DISEASE: THE ROLE OF ANTIPLATELET TREATMENT L. Pasqualini, F. Gemelli, G. Vaudo, M.R. Mannarino, S. Innocente, G. Schillaci, E. Mannarino (Perugia, Italy) 258 PROTHROMBOTIC ACTIVITY IS ASSOCIATED WITH ANATOMICAL AS WELL AS 103 FUNCTIONAL SEVERITY OF PERIPHERAL ARTERIAL OCCLUSIVE DISEASE M. Nylænde, A. Kroese, E. Stranden, B. Morken, G. Sandbæk, A.K. Lindahl, H. Arnesen, I. Seljeflot (Oslo, Norway) 259 ANKLE-BRACHIAL INDEX IN SUBJECTS WITH TYPE 2 DIABETES: ASSOCIATION WITH 103 RISK FACTORS AND CHRONIC DIABETIC COMPLICATIONS J. Mostaza, R. Cañizares, M. Mauri, P. Burillo, J.M. Barragan, J. Montes, P. Roman, A. Costo (Madrid, Alicante, Barcelona, Teruel, Avila, Vigo, Valencia and Caceres, Spain) 260 ABDOMINAL AORTIC ANEURYSM IN ELDERLY PATIENTS WITH CORONARY ARTERY 103 DISEASE I. Riecansky, J. Madaric, I. Vulev, A. Mistrik, J. Bartunek (Bratislava, Slovak Republic and Aalst, Belgium) 261 INTRA ABDOMINAL FAT IS ASSOCIATED WITH AN INCREASED RISK OF CORONARY 103 HEART DISEASE IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE B.G. Brouwer, F.L.J. Visseren, Y. van der Graaf (Utrecht, The Netherlands) 262 FEMORAL ATHEROSCLEROSIS IS REDUCED IN SOUTH ASIAN COMPARED WITH 104 EUROPEAN MEN N. Chaturvedi, E. Coady, J. Mayet, A.R. Wright, A.C. Shore, S.A.M.C.G. Thom, J. Kooner, A.D. Hughes (London and Exeter, UK)

41 263 POSTOPERATIVE ANALGESIA IN MEDIAL VASCULAR OPERATIONS-A PROSPECTIVE 104 RANDOMISED STUDY ON SOLPADEINE AND ANALGIN L. Beshev, A. Marinov, A. Nedyalkov (Pleven, Bulgaria) 264 DELIVERY MAY PREVENT THE PROGRESS OF ATHEROSCLEROSIS IN WOMEN 104 M. Hashimoto, C. Iwai, Y. Miyamoto, M. Shimizu, Y. Matsuda, K. Kanazawa, K. Nishimura, D. Sugiyama, K. Ito, H. Akita (Kobe, Japan) 265 LYMPHATIC SYSTEM OF THE ARTERIAL WALL IN NORMAL AND ATHEROSCLEROTIC 104 ARTERIES A. Szuba, P. Dziegiel, M. Podhorska, M. Zabel, D. Janczak, P. Chudoba, W. Polak, D. Patrzalek, R. Andrzejak (Wroclaw, Poland) 266 A SIMPLE PERIPHERAL ATHEROSCLEROSIS SCORING SYSTEM CAN READILY PREDICT 104 THE SEVERITY OF CORONARY ARTERY DISEASE S. Koulouris, K.A. Triantafyllou, C. Dasopoulou, P. Symeonides, I. Michaelides, V. Tsagou, D. Agelidou, A. Kranidis, A.S. Manolis (Athens, Greece) 267 RELATIONSHIP BETWEEN PERIPHERAL ARTERIAL DISEASE (PAD) AND PLASMA 105 FREE SH-GROUP CONCENTRATION M I. Jassó, A. Blázovics, K. Hagymási, E. Dinya, A. Landi (Budapest, Hungary) O 268 CLINICAL SIGNIFICANCE OF THE DETECTION OF UNKNOWN PERIPHERAL ARTERIAL 105 DISEASE IN PATIENTS WITH VASCULAR RISK N J.D. García-Díaz, L.F. Viejo, L. Manzano (Alcalá de Henares, Toledo and Madrid, Spain) D 269 DIFFERENT CONTEXT OF THE FINDING OF LOW AND HIGH EXTREME VALUES IN THE 105 A ANKLE-BRACHIAL INDEX MEASUREMENT J.D. García-Díaz, L.F. Viejo, L. Manzano (Alcalá de Henares, Toledo and Madrid, Spain) Y 270 POTENTIAL ROLE OF A DIGITAL PALPATION METHOD FOR THE MEASUREMENT OF 105 ANKLE/BRACHIAL INDEX IN PERIPHERAL ARTERIAL DISEASE SCREENING A. Clara, J. Merino, A. Planas, A. Braojos, L. Roig, A. Garcia, R. Portas, F. Vidal-Barraquer (Barcelona and Hospitalet, Spain) 271 PLASMA HEPARIN COFACTOR II ACTIVITY IS A PREDICTOR FOR INCIDENCE OF 106 PERIPHERAL ARTERIAL DISEASE IN PATIENTS WITH CARDIOVASCULAR RISK FACTORS K. Aihara, H. Azuma, M. Akaike, H. Kurobe, M. Fujimura, S. Hashizume, Y. Ikeda, S. Yagi, T. Kitagawa, T. Matsumoto (Tokushima, Japan) 272 INTIMAL NEOVASCULARISATION IS A PROMINENT FEATURE OF ATHEROSCLEROTIC 106 PLAQUES OF DIABETIC PATIENTS WITH CRITICAL LIMB ISCHAEMIA A. Carter, F. Serracino-Inglott, M. Murphy, N. Turner, A. Halka, F. Syed, R. McMahon, M G. Walker (Manchester, UK) 273 ACUTE IMPAIRMENT OF ENDOTHELIAL FUNCTION (EF) BY MAXIMAL TREADMILL 106 EXERCISE IN CLAUDICANTS (IC), AND ITS IMPROVEMENT AFTER SUPERVISED PHYSICAL TRAINING G.M. Andreozzi, A. Leone, R. Laudani, G. Deinite, R. Martini (Padua and Catania, Italy) 274 THE EFFECT OF HEMODIALYSIS ON AORTIC STIFFNESS IN PATIENTS WITH CHRONIC 106 RENAL FAILURE: A PILOT STUDY A. Celik, M. Melek, S. Yuksel, A. Avsar, C. Kilit, E. Onrat, H. Saglam, S. Demir (Afyonkarahisar, Turkey) 275 SOME EXPERIENCES RELATED TO DILATED AORTIC SEGMENTS AND INFLUENCE OF 106 AGE AND SIZE OF AORTIC ANEURYSM TO ITS RUPTURE B. Pojskic, M. Dilic, M. Buksa, N. Krdzalic (Zenica and Sarajevo, Bosnia Herzegovina) 276 THE MANAGEMENT OF ACUTE STROKE BY IN-HOSPITAL CARE PATHWAYS: A 107 NON-RANDOMIZED STUDY IN THE ELDERLY L. Denti, U. Scoditti, C. Tonelli, R. Valcavi, S. Riboldi, V. Campana, G.P. Ceda (Parma, Italy) 277 CD4+CD28NULL T CELLS IN PATHOGENESIS OF ACUTE ISCHEMIC STROKE 107 M. Nowik, P. Nowacki (Szczecin, Poland) 278 UNDERUTILIZATION OF VASCULAR MEDICATIONS FOLLOWING CAROTID 107 ENDARTERECTOMY R. Madhavan, N. Raje, A. Murugappan, S. Chaturvedi (Detroit, MI, USA) 279 PREVALENCE AND PREDICTORS OF SUBCLINICAL ATHEROSCLEROSIS AMONG 107 ASYMPTOMATIC LOW RISK INDIVIDUALS IN A MULTIETHNIC POPULATION J. Grewal, S. Anand, E. Lonn (Hamilton, ON, Canada) 280 CEREBRAL CIRCULATION & ITS CORRELATION WITH SYSTEMIC HEMODYNAMICS 107 IN ISCHEMIC STROKE PATIENTS DURING REHABILITATION S.M. Kuznetsova, D.V. Shulzhenko (Kiev, Ukraine) 281 CAROTID ARTERY STENOSIS, CHOLESTEROL AND SILENT STROKE IN PATIENTS 108 WITH TYPE 2 DIABETES MELLITUS AND HYPERTENSION L.A. Chugunova, E.V. Tarasov, N.A. Galitsina, M.V. Shestakova (Moscow, Russia)

42 282 APOLIPOPROTEIN A-1, APOLIPOPROTEIN B AND LIPOPROTEIN (A) LEVELS AT 108 PATIENTS WITH ISCHEMIC STROKE D. Agapakis, G. Ntaios, E. Massa, C. Savopoulos, G. Kaiafa, A. Hatzitolios (Thessalonica, Greece) 283 KIDNEY DISEASE IS A NEGATIVE PREDICTOR OF 30-DAY SURVIVAL AFTER ACUTE 108 ISCHEMIC STROKE S. Brzosko, T. Szkolka, M. Mysliwiec (Bialystok, Poland) 284 FACTORS ASSOCIATED WITH SHORT-TERM MORTALITY IN OLDER PATIENTS WITH 108 ACUTE ISCHEMIC STROKE G. Guerra, G. Zuliani, A. Cherubini, C. Ruggiero, F. Di Todaro, A.R. Atti, R. Fellin (Ferrara and Perugia, Italy) 285 RISK FOR TRANSIENT ISCHEMIC ATTACKS IS MAINLY DETERMINED BY INTIMA-MEDIA 109 THICKNESS AND CAROTID PLAQUE ECHOGENICITY A. Kalogeropoulos, G. Hahalis, G. Terzis, A. Chrysanthopoulou, D. Siablis, D. Alexopoulos (Patras, Greece) 286 SEASONAL VARIATION IN THE OCCURRENCE OF STROKE IN NORTHERN GREECE 109 A. Karagiannis, P. Semertzidis, K. Tziomalos, A. Kakafika, M. Sileli, E. Kountana, M V. Athyros, C. Zamboulis (Thessaloniki, Greece) O 287 CORRELATION BETWEEN METABOLISM AND CEREBRAL HEMODYNAMICS IN 109 ELDERLY PATIENTS AFTER ISCHEMIC STROKE CAUSED BY ATHROSCLEROTIC VESSEL N LESIONS D S. Kuznetsova, Z. Rozhkova, V. Kuznetsov (Kiev, Ukraine) A 288 THE DIABETES MELITUS AS MAIN RISK FACTOR FOR STROKE IN ISLAND LEMNOS 109 Y GREECE POPULATION S. Paximadas, S. Pagoni, P. Nikitopoulou, G. Kalokerinos, G. Katsigianni, B. Kalompokis (Athens, Greece) 289 INTRACRANIAL ATHEROSCLEROSIS IN FIRST EVER ISCHEMIC STROKE: A PROSPECTIVE 109 STUDY IN THAILAND K. Phanthumchinda, Y. Likitjaroen, N.C. Suwanwela (Bangkok, Thailand) 290 THE UNUSUAL PRESENTATION OF ACUTE INTERNAL CAROTID ARTERY OCCLUSION 110 IN EMERGENCY DEPARTMENT S.P. Tung, L.M. Wang, C.I. Huang (Taipei, Taiwan) 291 CARDIOVASCULAR RISK FACTORS INCIDENCE IN PATIENTS WITH AORTIC VALVULAR 110 PROSTHESES FOR DEGENERATIVE AORTIC STENOSIS WITH AND WITHOUT CAD D. Velimirovici, M. Rada, D. Berceanu, D.M. Duda-Seiman, S. Dragan, F. Cobzariu, A. Cocoana, S. Mancas (Timisoara, Romania) 292 VEGF-SECRETING MAST CELLS COLOCALIZE WITH NEOVESSELS IN STENOTIC AORTIC 110 VALVES - A NOVEL MECHANISM OF ANGIOGENESIS IN AORTIC STENOSIS S. Syväranta, S. Helske, M. Kupari, M. Mäyränpää, J. Lommi, H. Turto, K. Werkkala, P.T. Kovanen, K.A. Lindstedt (Helsinki, Finland) 293 RISK FACTORS ASSOCIATED WITH ACCELERATED AORTIC STENOSIS: SPECIAL 110 EMPHASIS ON DIABETES MELLITUS A. Ozgul, L.E. Sade, S. Balta, O. Eldem, A. Yildirir, B. Ozin, H. Muderrisoglu (Ankara, Turkey) 294 CARDIOVASCULAR RISK FACTORS INCIDENCE IN PATIENTS WITH AORTIC PROSTHESES 111 FOR DEGENERATIVE VS. OTHER LESIONS M. Rada, D. Velimirovici, D. Berceanu, D.M. Duda-Seiman, F. Cobzariu, S. Dragan, A. Cocoana, S. Mancas (Timisoara, Romania) 295 AGE AND MALE GENDER ARE INDEPENDENT PREDICTORS OF SIGNIFICANT CORONARY 111 ARTERY DISEASE IN PATIENTS WITH SEVERE AORTIC STENOSIS K. Linhartova, G. Sterbakova, I. Hanisova, I. Bernat, V. Beranek, T. Hajek (Plzen, Czech Republic)

43 POSTER AREA “B” MONDAY, June 19 296-377d

POSTER DISPLAY: for the duration of one day (Monday, June 19 from 8.30 am to 6.30 pm). Participants may view the posters displayed during this day.

Mo-P5 Poster Session 5 poster abstract bk. board no.: CLINICAL PRACTICE IN CARDIOVASCULAR page ref.: M DISEASE O 296 THE EFFECT OF INTERVAL AND CONTINUE ECCENTRIC ACTIVITIES ON CPK, 111 N LDH ENZYMES D J. Karimian (Isfahan, Iran) A 297 THE EFFECTS OF WARM UP ON RELATIONSHIP BETWEEN CK AND LDH IN 111 Y RECOVERY PERIOD P. Shekarchizadeh, J. Karimian (Isfahan, Iran) 298 ARE DIFFERENCES IN CARDIOMYOCYTE CONTRACTILITY RELATED TO AEROBIC 111 CAPACITY MEDIATED BY nNOS ? M. Hoydal, U. Wisloff, O. Kemi, S. Britton, O. Ellingsen (Trondheim, Norway and Ann Arbor, MI, USA) 299 THE EFFECT OF DIET AND EXERCISE ON SERUM LIPIDS LEVELS ON CLIENTS WITH 112 HYPERCHOLESTEROLEMIA REFERRING TO SHAHID MOFATEH CLINIC IN YASOUJ DURING 2003-2 Z. Mohebi Nobandegani, A. Marbaghi, S. Najafi Doulatabad (Yasouj and Tehran, Iran) 300 AEROBIC EXERCISE TRAINING REDUCES AORTIC STIFFNESS IN UNTREATED 112 PATIENTS WITH MILD ESSENTIAL HYPERTENSION F. Gemelli, L. Pasqualini, G. Savarese, M. Pirro, G. Pucci, F. Coscia, S. Simonetti, G. Schillaci, E. Mannarino (Perugia, Italy) 301 EFFECTS OF EXERCISE ON BIOCHEMICAL ASPIRIN RESISTANCE 112 O. Gulmez, A. Yildirir, U. Bal, D. Konas, O. Demir, A. Aydinalp, C. Ertan, I. Atar, B. Ozin, H. Muderrisoglu (Ankara, Turkey) 302 THE EFFECT OF REGULAR WALKING EXERCISE ON SERUM LIPID LEVELS OF 112 PATIENTS WITH HYPERCHOLESTEROLEMIA REFERRING TO SHAHID MOFATEH CLINIC IN YASOOJ (IRAN) Z. Mohebi Nobandegani, G. Malekzadeh, S. Najafi Doulatabad (Yasouj, Iran) 303 APOE GENOTYPE MODULATES EXERCISE-INDUCED CHANGE IN INTERMEDIATE 113 DENSITY LIPOPROTEIN CHOLESTEROL R.L. Seip, J.D. Otvos, P.D. Thompson (Hartford, CT and Raleigh, NC, USA) 304 EFFECTS OF EXERCISE TRAINING ON LDL PLASMA REMOVAL AND ON OXIDIZED 113 LDL PLASMA LEVELS IN HYPERCHOLESTEROLEMIA E.S. Ficker, A.P.M. Chacra, V.C. Neves, C.E. Negrão, C.G. Puk, R.C. Maranhão, C.G. Vinagre (São Paulo, Brazil) 305 THE EFFECTS OF AEROBIC AND ANAEROBIC EXERCISE ON THE LIPID TRANSFER 113 PROCESS FROM PLASMA LIPOPROTEINS TO HDL V.M. Silva, T.S. Vitório, J.L. Silva, R.C. Maranhão, C.G. Vinagre (São Paulo, Brazil) 306 STRESS TESTING IN CLINICAL EVALUATION OF FAMILIAL HYPERCHOLESTEROLAEMIA 113 HETEROZYGOTES D.S. Damaskos, G.D. Kolovou, K.K. Anagnostopoulou, K.D. Salpea, A. Dritsas, A.N. Pavlidis, I.S. Hoursalas, I.K. Vasiliadis, D.V. Cokkinos (Athens, Greece) 307 EFFECT OF VITAMIN E SUPPLEMENTATION ON IMMUNE RESPONSES TO PROLONGED 113 EXERCISE S. Kinoshita, E. Tsuji (Kakogawa, Japan)

44 308 SPECIFIC UNITS FOR ASSESSING CARDIOVASCULAR RISK FACTORS IN PRIMARY 114 CARE. CAN THE MEDICAL RESOURCES USED IN THESE PATIENTS BE OPTIMIZED? C. Sanchez Fernandez De La Vega (Lugo, Spain) 309 INFLUENCE OF BMI AND HBA1C ON CARDIOVASCULAR RISK FACTORS: LDL 114 CHOLESTEROL AND NON HDL CHOLESTEROL IN TYPE 2 DIABETIC PATIENTS O. Disoteo, G.L. Pizzi, D. Zanni, C. Fossati (Milan, Italy) 310 THE BEST LIPID PREDICTORS 114 W.E. Feeman (Bowling Green, OH, USA) 311 NON INVASIVE EVALUATION OF LEFT VENTRICULAR END DIASTOLIC PRESSURE 114 BY ECHOCARDIOGRAPHY IN ISCHEMIC HEART DISEASE M. Shojaie, M. Pourmoghadas (Jahrom and Esfahan, Iran) 312 SERUM CREATININE LEVEL AND CORONARY COLLATERAL DEVELOPMENT 114 A. Sahinarslan, S. Ozturk, C. Ozer (Ankara, Turkey) 313 EFFECTS OF ORLISTAT ON WEIGHT LOSS, RISK FACTORS AND GLOBAL 115 CARDIOVASCULAR RISK IN OBESE PATIENTS E. Stokic, A. Nikolic, D.J. Radak (Novi Sad and Belgrade, Serbia-Montenegro) 314 PHYSICIAN SUB-SPECIALTY AND VARIANCE IN CLINICAL OUTCOMES IN THE 115 M TREATMENT OF DYSLIPIDEMIC PATIENTS O E. Leibovitz, D. Waitman, N. Kahan, D. Gavish (Holon, Tel Aviv and Jerusalem, Israel) 315 USE OF THE LIPID OPTIMIZATION TOOL (LOT) TO ACHIEVE VARIOUS LDL TARGETS 115 N IN COMMUNITY PRACTICE D J. Niznick, C. Boutin, S. Dugas (Ottawa, ON, Canada) A 316 LIPID PROFILE IN TYPE 2 DIABETES: COMPARING PRACTICE AND GUIDELINES 115 Y S. Giannini, G. Bardini, C.M. Rotella (Florence, Italy) 317 THE POTENTIAL BENEFITS OF TREATING TO LDL-C GOAL OF 70 MG/DL VS 100 116 MG/DL IN CHD/DIABETIC PATIENTS IN EUROPE O. Shavit, E.A. Alemao, G. Davies, D. Yin, J R. Cook (Philadelphia, PA, and Whitehouse Station, NJ, USA) 318 SPECIALIZED CARE VS CONVENTIONAL CARE FOR GLOBAL RISK CONTROL. 116 STRENGTHS AND YET UNSOLVED ISSSUES J.P. Werba, P.G. Massironi, A. Parolari, F. Veglia, E. Tremoli (Milan, Italy) 319 POSTER WITHDRAWN – 320 HDLC RECOMMENDATIONS FOR CARDIOVASCULAR PREVENTION 116 J. Millan (Madrid, Spain) 321 TREATMENT WITH STATINS AND ATTAINMENT OF LDL-C GOALS IN CHD PATIENTS 116 WITH HYPERLIPIDEMIA: MAIN RESULTS OF THE MOSCOW STATINS SURVEY (MSS) A. Sussekov, M. Zubareva, E. Solovieva, T. Rozkova, A. Deev, V. Kukharchuk (Moscow, Russia) 322 PATIENTS COMPLIANCE WITH THERAPEUTIC OBJECTIVES AFTER CORONARY 116 ARTERY REVASCULARIZATION S. Hijano, J.M. de la Vega Jr., P. Fernandez-Riejos, R. de la Iglesia, M.A. Rico, T. Holgado, A. Oribe, M. Cruz, E. Martinez, F. Fabiani (Sevilla, Spain) 323 GATED-SPECT IN THE DETECTION OF SILENT MYOCARDIAL ISCHEMIA. ALGORITHM 117 FOR THE REALIZATION IN TYPE 2 DIABETIC PATIENTS Y. Peña Quián, J. Fernández Britto, J. Bacallao Gallestey, M.A. Coca Pérez, J.F. Batista Cuellar, R. Castellano Laje (City Havana, Cuba) 324 HOW A NON-ACADEMIC HOSPITAL (WITHOUT RESIDENTS OR FELLOWS) REACHED 117 A DOOR TO DILATION TIME OF LESS THAN 80 MINUTES C. Ryan, R. Dunlap, D. Goldschmid, M. Girolami, F. Millhouse, M. Pliam, M. Cavanaugh, L. Manila (Daly City, CA, USA) 325 PROJECTED ABILITY OF LIPID LOWERING THERAPY TO OBTAIN NEW NCEP GOAL OF 70 117 MG/DL IN TREATED CHD/DIABETIC PATIENTS NOT AT GOAL AND ITS CLINICAL IMPACT O. Shavit, E.A. Alemao, G.M. Davies, D. Yin, J.R. Cook (Philadelphia, PA, and Whitehouse Station, NJ, USA) 326 APOLIPOPROTEIN B AND NON-HDL-CHOLESTEROL ASSESSMENTS IN DIFFERENT 117 AT RISK CATEGORIES: A COMMUNITY BASED ANALYSIS G. Hoag, V. Dias (Vancouver, BC, Canada) 327 SECONDARY PREVENTION OF CORONARY HEART DISEASE IN COUNTY HOSPITAL 118 M. Ivanusa (Bjelovar, Croatia) 328 COMPARISON OF EFFECTIVE FACTORS ON SLEEPING FROM ASPECT OF NURSE 118 AND HOSPITALIZED PATIENT IN CORONARY CARE UNIT OF HOSPITALS OF TEHRAN UNIVERSITY OF MEDICAL SCIENCES M. Shaban, M. Zakerimoghadam, L. Gadyani (Tehran, Iran)

45 329 ROSUVASTATIN, THE ALTERNATIVE OF INSUFFICIENTLY EFFECTIVE STATINS 118 M. Gajdos, Z. Krivosikova (Bratislava, Slovak Republic) 330 STATIN THERAPY AND ACHIEVEMENT OF CHOLESTEROL GOALS IN SLOVAK HIGH 118 AND VERY HIGH RISK PATIENTS Z. Krivosikova, M. Gajdos (Bratislava, Slovak Republic) 331 THE STUDY OF THE EFFECTS OF 8 WEEK CARDIOVASCULAR REHABILITATION 118 PROGRAM ON DECREASED BLOOD PRESSURE IN MEN WITH HYPERTENSION J. Karimian (Isfahan, Iran) 332 COMMUNICATION BETWEEN PHYSICIANS AND PATIENTS WITH HIGH CHOLESTEROL: 118 FROM THE HEART STUDY F.D.R. Hobbs, L.R. Erhardt (Birmingham, UK and Malmö, Sweden) 333 PHYSICIANS' PERCEPTIONS OF CHOLESTEROL MANAGEMENT: FROM THE HEART STUDY 119 F.D.R. Hobbs, L.R. Erhardt (Birmingham, UK and Malmö, Sweden) 334 PATIENT AND THEIR FAMILY PRACTICE ABOUT THERAPEUTIC REGIMEN IN 119 CORONARY ARTERY DISEASE IN TEHRAN UNIVERSITY OF MEDICAL SCIENCES S.F. Jalalinia, Z. Monjamed (Tehran, Iran) M 335 INFLUENCE OF LIFE STYLE KNOWLEDGE ON THE OCCURRENCE OF CARDIOVASCULAR 119 O RISK FACTORS IN ADULTS LIVING IN CRACOW - SOUTH POLAND T. Brzostek, B. Piorecka, M. Cisek, A. Piskorz, P. Jagielski, M. Schlegel-Zawadzka N (Cracow, Poland) D 336 SLEEP RESTRICTION INCREASES WHITE BLOOD CELLS-MAINLY NEUTROPHILS 119 A COUNTS IN YOUNG HEALTHY MEN K. Zouaoui Boudjeltia, P. Stenuit, M.J. Esposito, M. Guillaume, D. Brohee, P. Cauchie, Y M. Vanhaeverbeek, M. Kerkhofs (Charleroi, Belgium) 337 MANAGEMENT OF HYPERTENSION AND OBESITY TO PREVENT ATHEROSCLEROSIS 120 R.M. Santos, J. Freitas, M.E. Macedo, I. Rebelo (Porto, Portugal) 338 NON PHARMACOLOGICAL DYSLIPIDEMIA INTERVENTION: A BRAZILIAN LIFESTYLE 120 STUDY C.M.A. Almeida, H. Nascimento Maria Do, T.M. Leme da Rocha (São Paulo, Brazil) 339 POSTER WITHDRAWN – 340 RELATION BETWEEN STRESS AND OTHER LIFE STYLE FACTORS 120 H. Roohafza, M. Sadeghi, N.L. Sarraf-Zadegan, L. Baghaei, N. Toghianifar, M. Talaei (Isfahan, Iran) 341 EFFECTS OF HEALTH BEHAVIOR TRAINING ON LIFE STYLE CHANGES OF THE 120 CORONARY ARTERIES PATIENTS M.H. Yarmohamadian, M. Abdar Esfahani, A.R. Yousefi, S.H. Shooshtarizadeh (Isfahan, Iran) 342 LIFESTYLE 120 S. Martinovic, L. Sokolova Djokic, M. Bosnjak, M. Stic (Sombor, Serbia-Montenegro) 343 THE COMPARISON OF ACTIVE AND INACTIVE EMPLOYEES ON RISK FACTORS OF 121 CORONARY P. Shekarchizadeh (Isfahan, Iran) 344 COST-EFFECTIVENESS OF INTENSIVE LIPID-LOWERING TREATMENT WITH ATORVASTATIN 121 80MG VERSUS 10MG IN SECONDARY CARDIOVASCULAR PREVENTION IN THE UK D.C.A. Taylor, A. Pandya, D. Thompson, P. Chu, J. Graff, M. Drummond, J.C. Larosa, S.M. Grundy, J. Shepherd, N.K. Wenger (Medford, NJ, New York, Brooklyn, NY, Dallas, TX, Atlanta, GA, USA and Glasgow, UK) 345 COST OF PHARMACOLOGICAL TREATMENT WITH STATINS 121 P. Deambrosis, C. Saramin, G. Terrazzani, E. Kiwanuka, L. Scaldaferri, G. Bader, P. Giusti, A. Chinellato (Treviso, Rome and Padua, Italy) 346 HEALTH ECONOMIC STUDY OF RAISING HDL-C WITH PROLONGED-RELEASE NICOTINIC 121 ACID (NIASPAN® LP) WHEN ADDED TO STATIN THERAPY IN DYSLIPIDEMIC PATIENTS C. Renaudin, S. Roze, W. Valentine, A.J. Palmer, W. Berger, D. Liens (Lyon, France, Binningen-Basel, Switzerland and Darmstadt, Germany) 347 AN EVALUATION OF USING EZETIMIBE AND NIASPAN IN A CARDIOVASCULAR 122 DISEASE PREVENTION CLINIC C. Van Heyningen (Liverpool, UK) 348 EFFICACY AND SAFETY OF COMBINED HYPOLIPIDEMIC TREATMENT WITH ATORVASTATIN 122 K. Gkogkos, G. Pavlidis, A. Karakozoglou, S. Fragidis, A. Maliouri, J. Kountouras (Thessaloniki, Greece) 349 THE MELATONIN ADJUNCT IN THE ACUTE MYOCARDIAL INFARCTION TREATED 122 WITH PRIMARY ANGIOPLASTY: STUDY DESIGN AND RATIONALE (MARIA TRIAL) A. Dominguez-Rodriguez, P. Abreu-Gonzalez, M.J. Garcia-Gonzalez, J.C. Kaski, R.J. Reiter (Tenerife, Spain, London, UK and San Antonio, TX, USA)

46 350 REGRESSION OF MINIMAL LUMEN DIAMETER BY HMG-COA REDUCTASE INHIBITOR IN 122 JAPANESE PATIENTS WITH PRE-EXISTING CORONARY ATHEROSCLEROSIS: ATHEROMA STUDY A. Kawaguchi, K. Mitsudo, H. Yokoi, M. Nobuyoshi, A. Yamamoto, Atheroma Study Group (Sapporo, Kurashiki, Kitakyushu and Osaka, Japan) 351 JPPP: THE LARGE-SCALE RANDOMIZED CONTROLLED TRIAL OF PRIMARY PREVENTION 123 OF ATHEROSCLEROTIC DISEASES BY ENTERIC-COATED LOW-DOSE ASPIRIN IN JAPAN T. Teramoto (Tokyo, Japan) 352 RISK REDUCTION AND SAFETY OF FLUVASTATIN IN PATIENTS WITH THE METABOLIC 123 SYNDROME K. Winkler, C. Abletshauser, C. Gimpelewicz, M. Bortolini, J. Isaacsohn (Freiburg, Nürnberg, Germany, Basel, Switzerland and Cincinnati, OH, USA) 353 FOLIC ACID TREATMENT EFFECT ON CAROTID INTIMA-MEDIA THICKNESS OF 123 PATIENTS WITH CORONARY DISEASE C. Fernández-Miranda, M. Yebra, J.L. Aranda, P. Gómez, J. Martínez, V. Núñez (Madrid, Spain) 354 EPIDEMIOLOGICAL STUDY OF MYOCARDIAL INFARCTION OR ACUTE EVENTS IN LOWER 123 M LIMB ARTERIAL DISEASE IN THE FRENCH OVERSEAS COMMUNITIES: THE IDEALE STUDY O M. Deneuville, Ideale Study Group (Pointe-à-Pitre, Guadeloupe, Martinique, Reunion Island, France) N 355 WHICH MANAGEMENT OF FAMILIAL HYPERCHOLESTEROLEMIA IN MOROCCO? 123 D M. El Messal, K. Aït Chihab, R. Chater, M. Loutfi, A. Kettani, A. Hafidi, C. Boileau, A L. Masana, A. Adlouni (Casablanca, Rabat, Morocco, Paris, France and Reus, Spain) Y 356 CARDIOVASCULAR RISK FACTORS IN TWO CZECH FEMALE POPULATION SAMPLES 124 R. Cifkova, J. Pitha, M. Lejskova, R. Poledne, P. Stavek, V. Lanska, S. Zecova (Prague, Czech Republic) 357 ENHANCED ATHEROGENESIS AND ALTERED HIGH DENSITY LIPOPROTEIN IN PATIENTS 124 WITH CROHN'S DISEASE S.I. van Leuven, R. Hezemans, J.H. Levels, J.J.P. Kastelein, E.S. Stroes, D.W. Hommes, E. de Groot (Amsterdam, The Netherlands) 358 CAROTID INTIMA-MEDIA LAYER THICKNESS IN CHILDREN WITH RENAL OR LIVER 124 TRANSPLANTS A. Siirtola, M. Antikainen, T. Kallio, M. Ala-Houhala, T. Lehtimäki, H. Korvenranta, C. Holmberg, M.K. Salo (Tampere, Helsinki and Turku, Finland) 359 DIFFERENCES IN LIPID PROFILE AND MORTALITY AMONG PATIENTS WITH ATRIAL 124 FIBRILLATION AND HAEMODIALYSIS J.A. Díaz-Peromingo, A. Albán-Salgado, D. Güimil-Carbajal, J. Sánchez-Leira, F. García-Suárez, E. Padín-Paz, J. Saborido-Froján, M. Iglesias-Gallego (La Coruña, Spain) 360 PULSE WAVE VELOCITY (PWV) AND CAROTID INTIMA-MEDIA THICKNESS (IMT): DO THEY 125 CORRELATE WITH THE DEGREE OF RENAL DYSFUNCTION AND ITS METABOLIC ABNORMALITIES E. Ferramosca, E. Mancini, A. Di Felice, E. Aloisi, A. Lopez, M. Mandreoli, A. Santoro (Bologna, Italy) 361 NON DIABETIC END STAGE RENAL DISEASE PATIENTS IN CHRONIC HEMODIALYSIS 125 HAVE HIGH PREVALENCE OF CARDIOVASCULAR DAMAGE L. Michea, S. Kunstmann, A. Vukusic, I. Alliende, C. Varela, D. Gainza, S. Bravo, D. Sepulveda, E. Marusic (Santiago, Chile) 362 ATHEROSCLEROSIS IN PREGNANCY 125 M. Nadafi, S. Mohammd Hossini, E. Momeni (Yasuj-Kohgilouyeh and Boyerahmad, Iran) 363 VASCULAR PHENOTYPE AND SUBCLINICAL INFLAMMATION IN DIABETIC ASIAN 125 INDIANS WITHOUT CARDIOVASCULAR DISEASE IN THE NETHERLANDS A. Ray, E.D. Beishuizen, A. Misra, M.V. Huisman, J.T. Tamsma (Leiden, The Netherlands and New Delhi, India) 364 EFFECTS OF A CHOLESTEROL-LOWERING DIET DURING PREGNANCY ON CARDIOVASCULAR 126 RISK FACTORS AND PREGNANCY OUTCOME: A RANDOMIZED CLINICAL TRIAL J. Khoury, T. Henriksen, I. Seljeflot, B. Christophersen, L. Morderid, K. Fey Froslie, S. Tonstad (Oslo, Norway) 365 CARDIOVASCULAR RISK IN OBESE WOMEN WITH POLYCYSTIC OVARY SYNDROME: 126 A FRAMINGHAM SCORING I. Bozic, D. Macut, B. Popovic, T. Isailovic, M. Petakov, S. Ognjanovic, S. Damjanovic (Belgrade, Serbia-Montenegro)

47 366 THE SYNERGISTIC EFFECTS OF SIMVASTATIN AND BETA EPOETIN ON 126 CARDIOVASCULAR OUTCOMES IN PATIENTS WITH END-STAGE RENAL DISEASE W.J. Haykal, O.V. Kuryata (Dnepropetrovsk, Ukraine) 367 EVALUATION OF LIPID AND BLOOD PREASSURE LEVELS IN YOUNG PATIENTS WITH 126 POLYCYSTIC OVARY SYNDROME (PCOS) D. Stamenkovic-Pejkovic, D. Micic, M. Sumarac-Dumanovic, G. Cvijovic, M. Georgiev, A. Kendereski, S. Zoric, K. Cubrilo (Belgrade, Serbia-Montenegro) 368 METFORMIN TREATMENT AND ATHEROGENIC FACTORS IN WOMEN OF REPRODUCTIVE 126 AGE WITH POLYCYSTIC OVARIES SYNDROME WITH DIABETES MELLITUS IN ANAMNESIS AND WITHOUT IT A. Strelkova, K. Balandina, O. Batrakova, T. Zykova (Arkhangelsk, Russia) 369 POSTER WITHDRAWN – 370 OXIDIZED LOW-DENSITY LIPOPROTEIN IN BETA-THALASSEMIA MAJOR 127 A. Tavridou, D. Stakos, A. Vryonidou, C. Tsigalou, G. Kambouromiti, C. Phenekos, V.G. Manolopoulos (Alexandroupolis and Athens, Greece) 371 CONNECTION BETWEEN AUGMENTATION INDEX, PULSUS WAVE VELOCITY 127 M CHANGE IN METABOLIC AND LIPID ALTERATIONS IN RENAL FAILURE O L. Locsey, B. Borbas, B. Szlanka, I. Menes, L. Asztalos, L. Szabo, A. Dan, I. Lorincz (Debrecen, Hungary) N 372 ATHEROSCLEROSIS IN PATIENT WITH DIALYSIS 127 D S. Mohammad Hossini, M. Nadafi, N. Hossini, L. Gholizade, A. Afrasiabiyfar, A A. Khodavandi (Kohgilouyeh and Boyerahmad, Iran) 373 ATHEROSCLEROTIC CHANGES ON CORONARY ARTERIES IN DIABETICS PREPARING 127 Y FOR MYOCARDIAL REVASCULARIZATION M. Zdravkovic, M. Ristic, N. Milic, S.U. Pavlovic, M. Krotin, D. Trifunovic-Zamaklar, D. Zdravkovic, D. Gostiljac, R. Zivkovic, N. Milinic (Belgrade, Serbia-Montenegro) 374 HEMODIALYSIS RELATED TO ATHEROSCLEROSIS 128 B. Dejanova, S. Petrovska, S. Subeska Stratova, P. Dejanov (Skopje, Macedonia) 375 SCREENING FOR LATENT DIABETES MELLITUS IN ELDERLY OVER 65 128 K. Visev (Sofia, Bulgaria) 376 PRESENCE OF GILBERT´S SYNDROME IN PATIENTS WITH HYPERLIPOPROTEINEMIAS 128 L. Taborsky, J. Dvorakova, J. Hyanek, V. Matoska, S. Pekova (Prague, Czech Republic) 377 TUBULOINTERSTITIAL NEPHRITIS AND UVEITIS SYNDROME IN ADULT: A CASE REPORT 128 E. Vlachogiannis, S. Goutkidou, D. Toptsi, J. Samouilidis, K. Mahera, S. Stefanidou, E. Theodosiou, E. Vlachogiannis (Thessaloniki, Greece) 377a* EFFECT OF TORCETRAPIB COMBINED WITH ATORVASTATIN ON HDL-C AND LDL-C 550 LEVELS, PARTICLE SIZE, AND COMPOSITION: A PHASE 2 DOSE-RANGING CLINICAL TRIAL T. Thuren, A. Longcore, C. Powell, J. Strand, K. Durham, C.L. Shear (New London, CT and Ann Arbor, MI, USA) 377b* INHIBITION OF CEPT BY TORCETRAPIB RAISES HDL-C AND LOWERS LDL-C 550 INDEPENDENT OF GENDER OR BASELINE HDL-C LEVELS J.H. Revkin, K. Durham, C.L. Shear, T.T. Nguyen (New London, CT, USA) 377c* ENHANCED LDL-C LOWERING EFFECT OF TORCETRAPIB WHEN ADMINISTERED 550 WITH ATORVASTATIN TO SUBJECTS WITH HIGH BASELINE TRIGLYCERIDE LEVELS J.H. Revkin, C.L. Shear (New London, CT, USA) 377d* THE CAPACITY OF HDL TO SIMULATE CHOLESTEROL EFFLUX IS MAINTAINED IN 550 SUBJECTS WITH AND WITHOUT LOW HDL-C TREATED WITH TORCETRAPIB M.J. Bamberger, M.D. Moya, K. Durham, C.L. Shear, T.T. Nguyen, J.H. Revkin, G.H. Rothblat (Groton, CT and Philadelphia, PA, USA)

* These posters are displayed after poster board no.: 462

48 POSTER AREA “B” MONDAY, June 19 378-460

POSTER DISPLAY: for the duration of one day (Monday, June 19 from 8.30 am to 6.30 pm). Participants may view the posters displayed during this day.

Mo-P6 Poster Session 6 poster GENETICS OF CARDIOVASCULAR DISEASE abstract bk. board no.: page ref.: M 378 GENETIC DIAGNOSIS OF FAMILIAL HYPERCHOLESTEROLEMIA: NOVEL GENES 128 AND TECHNIQUES O I. Tosi, P. Toledo-Leiva, C. Neuwirth, R.P. Naoumova, A.K. Soutar (London, UK) N 379 THE CONTRIBUTIONS OF THE CANDIDATE GENES TO ATHEROSCLEROSIS ARE NOT 129 D UNIFORM AMONG THE ARTERIAL SYSTEMS M. Sawabe, T. Arai, T. Hosoi, M. Muramatsu, K. Oda, N. Tanaka, T. Shirasawa A (Tokyo and Aichi, Japan) Y 380 THE EVALUATION OF CARDIOVASCULAR RISK ASSOCIATED WITH MULTIPLE GENE 129 POLYMORPHISM DURING 7 YEAR FOLLOW-UP OF THE 691 COHORT OF HEALTHY SUBJECTS K. Chlebus, J. Bellwon, K. Ochman, I. Stopczynska, M. Gruchala, B. Curyllo, B. Wasag, W. Sobiczewski, J. Limon, A. Rynkiewicz (Gdansk, Poland) 381 AN ARMS-BASED DIAGNOSTIC KIT FOR GENETIC TESTING FOR FAMILIAL 129 HYPERCHOLESTEROLEMIA IN THE UK M. Sozen, R. Whittall, M.B.T. Webb, G. Norbury, S. Tabrah, A. Taylor, S. Humphries (Ankara, Turkey, London and Abingdon UK) 382 GENETIC BACKGROUND OF FAMILIAL HYPERCHOLESTEROLEMIA IN SPAIN. AN UPDATE 129 S. Castillo, R. Alonso, M. Pocoví, J.L. Díaz, J.M. Cepeda, E. Martorell, J. Galiana, C. Vázquez, M. Franco, P. Mata (Barcelona, Madrid, Zaragoza, La Coruña, Alicante, Palma de Mallorca and Ciudad Real, Spain) 383 FINE MAPPING A REGION ON CHROMOSOME 11P FOR FAMILIAL COMBINED 130 HYPERLIPIDEMIA C.L. Plaisier, A.J. Lusis, R.P. Naoumova, C.C. Shoulders, M.R. Taskinen, T.W. de Bruin, P. Pajukanta (Los Angeles, CA, USA, London, UK, Helsinki, Finland and Maastricht, The Netherlands) 384 VARIABILITY OF LDLR GENE MUTATIONS IN AN OPENED MEDITERRANEAN 130 POPULATION FROM SPAIN S. Blesa, A.B. Garcia, S. Martinez, M.L. Mansego, V. Gonzalez, J. Ascaso, R. Carmena, J. Real, F.J. Chaves (Valencia, Spain) 385 FAMILIAL HYPERCHOLESTEROLEMIA SCREENING PROGRAM USING A NOVEL 130 DNA-ARRAY IN SPAIN R. Alonso, L. Forga, N. Mata, P. Gomez-Enterria, M. Laclaustra, S. Zabala, P. Saenz, S. Castillo, D. Tejedor, P. Mata (Madrid, Pamplona, Oviedo, Zaragoza, Teruel, Merida, Barcelona and Bilbao, Spain) 386 CORONARY HEART DISEASE IN A COHORT OF 811 PATIENTS WITH GENETIC 130 DIAGNOSIS OF FAMILIAL HYPERCHOLESTEROLEMIA IN SPAIN N. Mata, R. Alonso, S. Castillo, F. Fuentes, J. Villar, E. Ros, R. Figueras, P. Saenz, F. Almagro, P. Mata (Madrid, Barcelona, Córdoba, Sevilla, Badajoz and San Sebastian, Spain) 387 GENETIC PREDISPOSITION TO EARLY ONSET OF CORONARY ARTERY DISEASE IN 131 RUSSIAN PATIENTS D.A. Zateyshchikov, E.N. Dankovtseva, A.G. Nikitin, O.S. Koroleva, A.N. Brovkin, N.Yu. Yakunina, D.A. Chudakova, V.V. Nosikov, B.A. Sidorenko (Moscow, Russia) 388 IS C667T MUTATION OF MIETHYLENE TETRAHYDROFOLATE REDUCTASE RELATED 131 TO HYPERHOMOCYSTEINEMIA IN TUNISIAN TYPE 2 DIABETIC PATIENTS N. Koubaa, S. Hammami, M. Smaoui, A. Nakbi, M. Abid, M. Hammami (Monastir, Tunisia)

49 389 ACE INSERTION/DELETION POLYMORPHISM INTERACTION ASSOCIATED WITH 131 REGIONAL INCIDENCE OF MYOCARDIAL INFARCTION (MI) IN EUROPE A. Muthumala, J. Cooper, S.E. Humphries (London, UK) 390 MOLECULAR STUDY OF FAMILIAL HYPERCHOLESTEROLEMIA IN PORTUGAL 131 M. Bourbon, A.C. Alves, A.M. Medeiros, S. Silva, A.K. Soutar (Lisbon, Portugal and London, UK) 391 IDENTIFICATION OF A CHROMOSOME 8P LOCUS FOR CORONARY HEART DISEASE 131 IN THE FRENCH CANADIAN FOUNDER POPULATION J.C. Engert, G. Pare, M. Lemire, J. Faith, D. Brisson, M.C. Vohl, G. Tremblay, TJ. Hudson, D. Gaudet (Quebec, QC, Canada) 392 MOLECULAR GENETIC VERSUS CLINICAL DIAGNOSIS OF FAMILIAL 132 HYPERCHOLESTEROLEMIA IN A CZECH POPULATION T. Freiberger, H. Grombirikova, L. Kopalkova, P. Zapletalova, O. Letocha, L. Kozak (Brno, Czech Republic) 393 GENETIC FACTORS OF ATHEROSCLEROSIS 132 N.N. Kipshidze, M.B. Khelaia, A.T. Jabauri (Tbilisi, Georgia) 394 GENETIC PREDISPOSITION IN THE CORONARY ARTERY DISEASE PATIENTS WITH 132 M POSITIVE FHX OF CORONARY ARTERY DIS. IN KOREA MAY BE RELATED TO LIPID O METABOLISM H.J. Kim, M.G. Kang, S.E. Yoo, K.M. Kim, S.W. Kim, S.H. Jee, J.E. Park (Seoul, South Korea) N 395 ASSOCIATION OF THE -250G/A PROMOTER POLYMORPHISM OF THE HEPATIC LIPASE 132 D GENE WITH THE RISK OF PERIPHERAL ARTERIAL DISEASE IN TYPE 2 DIABETICS A M.J. Ariza, M.T. González-Alegre, E. Ulzurrun, J. Rioja, F. Escalona-Pérez, P. Valdivielso, P. González-Santos (Málaga, Spain) Y 396 NOVEL DNA SEQUENCE VARIATIONS IN ENDOTHELIAL LIPASE GENE IN SUBJECTS 133 WITH HIGH HDL-CHOLESTEROL LEVELS A. Cenarro, F. Ghisoni, P. Martín-Fuentes, D. Recalde, A.L. García-Otín, F. Civeira (Zaragoza, Spain) 397 SMOKING ELIMINATES THE PROTECTIVE EFFECT OF ENDOTHELIAL LIPASE GENE 133 POLYMORPHISM AGAINST ACUTE MYOCARDIAL INFARCTION M. Shimizu, K. Kanazawa, K. Hirata, E. Hiraoka, Y. Matsuda, C. Iwai, Y. Miyamoto, M. Hashimoto, H. Akita, M. Yokoyama (Kobe, Japan) 398 THE EFFECT OF THE APOE POLYMORPHISM ON HDL-C CONCENTRATIONS DEPENDS 133 ON THE CETP GENE VARIATION IN A SPANISH POPULATION J.V. Sorli, F. Frances, M. Guillen, J.I. Gonzalez, P. Carrasco, C. Ortega, F. Gimenez, C. Saiz, J. Valderrama, D. Corella (Valencia, Spain) 399 CETP GENETIC POLYMORPHISMS PREDICT EARLY-ONSET MYOCARDIAL INFARCTION 133 IN WOMEN H. Milo, S.M. Schwartz, L. Ben Avi, S. Shpitzen, M. Shaham, D.S. Siscovick, E. Leitersdorf, Y. Friedlander, V. Meiner (Jerusalem, Israel and Seattle, WA, USA) 400 A NOVEL NONSENSE MUTATION IN THE CETP GENE IN ITALIAN 133 HYPERALPHALIPOPROTEINEMIC SUBJECTS A.B. Cefalú, S. Martini, D. Noto, I. Cortella, V. Valenti, F. Fayer, M.C. Gueli, C.M. Barbagallo, A. Notarbartolo, M. Averna (Palermo and Padua, Italy) 401 APOE GENOTYPE AND ALLELE DISTRIBUTION IN A SAMPLE OF DYSLIPIDAEMIC PATIENTS 134 L.R. Ranganath, W. Taylor, J.L. Usher (Liverpool, UK) 402 CHOLESTEROL ESTER TRANSFER PROTEIN (CETP) POLYMORPHISM AND MILD 134 DYSLIPIDEMIA IN A CLOSED POPULATION S. Tisheva, A. Neykova, R. Komsa, N. Ignatov (Pleven and Teteven, Bulgaria) 403 ENHANCED APOB48 METABOLISM IN LIPOPROTEIN LIPASE S447X CARRIERS 134 M.C. Nierman, J. Rip, J.A. Kuivenhoven, N. Sakai, J.J.P. Kastelein, M.G.M. de Sain-van der Velden, E.S.G. Stroes, B.H. Prinsen (Amsterdam, Utrecht, The Netherlands and Osaka, Japan) 404 FAMILIAL DEFECTIVE APOLIPOPROTEIN B100 IN GREECE 134 E. Koniari, E. Laios, E. Drogari (Athens, Greece) 405 FAMILIAL DEFECTIVE APOLIPOPROTEIN B-100 IN POLAND - HIGH PREVALENCE OF 135 APOB ARG3500GLN MUTATION M. Bednarska-Makaruk, G. Broda, S. Rywik, H. Wehr (Warsaw, Poland) 406 PCSK9 ANALYSIS IN FAMILIAL HYPERCHOLESTEROLAEMIA PATIENTS NEGATIVE FOR 135 LDLR AND APOB MUTATIONS P.M. George, V.M. Homer, A.D. Laurie, N. Hurndell, R.S. Scott (Christchurch, New Zealand)

50 407 VARIATIONS IN SREBP2 AND PCSK9 GENES IN AUTOSOMAL DOMINANT 135 HYPERCHOLESTEROLEMIC PATIENTS LACKING PATHOGENIC MUTATIONS IN LDLR AND APOB GENES S. Blesa, A.B. Garcia, S. Martinez, V. Gonzalez, J. Ascaso, R. Carmena, J.T. Real, F.J. Chaves (Valencia, Spain) 408 POSTPRANDIAL LIPEMIA IS MODIFIED BY THE PRESENCE OF THE APOB -516C/T 135 POLYMORPHISM P. Perez-Martinez, F. Perez-Jimenez, J.A. Moreno, F. Fuentes, R.A. Fernandez de la Puebla, J.A. Paniagua, J.M. Ordovas, J. Lopez-Miranda (Cordoba, Spain and Boston, MA, USA) 409 PRELIMINARY CHARACTERIZATION OF A FRENCH CANADIAN FAMILY WITH THE 136 R237W MUTATION OF PCSK9/NARC1 L. Bernier, G. Dubuc, C. Gagné, N.G. Siedah, J. Davignon (Montreal and Quebec, QC, Canada) 410 MUTATION DETECTION IN LDLR GENE BY DHPLC AND SEQUENCING 136 A.C. Alves, A.K. Soutar, M. Bourbon (Lisbon, Portugal and London, UK) 411 NOVEL APPROACHES TO THE DETECTION OF HETEROZYGOTE LDLR MUTATIONS 136 CAUSING SEVERE FAMILIAL HYPERCHOLESTEROLEMIA A. Cantafora, I. Blotta, L. Pisciotta, R. Careri, S. Calandra, S. Bertolini (Rome, Genoa M and Modena, Italy) O 412 LARGE REARRANGEMENTS OF LOW DENSITY LIPOPROTEIN GENE: A NEW 136 SEMIQUANTITATIVE PCR PROCEDURE N A.B. Garcia, S. Blesa, S. Martinez, M.L. Mansego, V. Gonzalez, J.F. Ascaso, R. Carmena, D J.T. Real, F.J. Chaves (Valencia, Spain) A 413 GENOTYPE-PHENOTYPE RELATIONSHIP IN LCAT DEFICIENCIES 136 Y E. Moleri, S. Calandra, T. Fasano, S. Bertolini, G. Franceschini, L. Calabresi (Milan, Modena and Genova, Italy) 414 A RAPID RT-PCR TAQMAN ASSAY TO DETECT MUTTIONS IN THE GENE OF AUTOSOMAL 137 RECESSIVE HYPERCHOLESTEROLEMIA A. Errigo, P. Marongiu, N.A. Canu, G. Secchi, S. Bertolini, M. Maioli, G.M. Pes (Sassari and Genoa, Italy) 415 PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR OR LIPOPROTEIN LIPASE 137 POLYMORPHISM IN CHILDREN BORN WITH LOW BIRTH WEIGHT RELATED TO ATHEROSCLEROTIC MEN A. Skoczynska, E. Barg, A. Derkacz, T. Dobosz, R. Poreba, A. Lebioda, B. Turczyn (Wroclaw, Poland) 416 PPAR GAMMA POLYMORPHISM 12PRO>ALA AS THE POSSIBLE DETERMINANT OF 137 IMPAIRED GLUCOSE TOLERANCE A. Zdzienicka, M. Malczewska-Malec, L. Partyka, I. Wybranska, A. Dembinska-Kiec (Cracow, Poland) 417 PRO12ALA POLYMORPHISM OF THE PPAR GAMMA GENE IS ASSOCIATED WITH 137 POSTPRANDIAL HYPERTRIGLYCERIDAEMIA IN NON E3/E3 PATIENTS WITH THE METABOLIC SYNDROME F. Cardona, S. Morcillo, M. Gonzalo-Marin, F.J. Tinahones (Málaga, Spain) 418 ASSOCIATION OF PPARGAMMA2 PRO12ALA VARIANT WITH LARGER BODY MASS IN 138 MESTIZO AND AMERINDIAN POPULATIONS OF MEXICO S. Canizales-Quinteros, C.A. Aguilar, G. Ortiz, M. Rodriguez, T. Villarreal, R. Coral, A. Huertas, A. Hernandez, M. Menjivar, T. Tusie (Mexico City, Mexico) 419 A COMMON NOVEL SNP IN THE PEROXISOME PROLIFERATIVE ACTIVATED RECEPTOR 138 GAMMA GENE IS ASSOCIATED WITH EARLY-ONSET CORONARY ARTERY DISEASE C. Iribarren, A.S. Go, M.A. Hlatky, A. Southwick, S.P. Fortmann, M. Fornage, T. Quertermous, R. Myers, N. Risch (Oakland, Stanford, San Francisco, CA and Houston, TX, USA) 420 TWO NOVEL APOA5 MISSENSE MUTATIONS IN PATIENTS WITH SEVERE 138 HYPERTRIGLYCERIDEMIA B. Dorfmeister, W.-W. Zeng, F. Schaap, M. Nierman, J.A. Kuivenhoven, J. Kastelein, J.A. Hubacek, M. Vrablik, S.E. Humphries, P.J. Talmud (London, UK, Amsterdam, The Netherlands and Prague, Czech Republic) 421 GENETIC VARIANTS IN THE ANGIOPOIETIN-LIKE 4 GENE OF HYPERTRIGLYCERIDEMIC 138 PATIENTS S.W. Fouchier, C.J.A. Moen, K. Willems van Dijk, J.C. Defesche, R.R. Frants (Leiden and Amsterdam, The Netherlands)

51 422 APOA5 GENE POLYMORPHISMS DO NOT AFFECT FASTING AND POSTPRANDIAL 139 TRIGLYCERIDE LEVELS IN SARDINIANS G.M. Pes, V.V. Buttolu, A. Errigo, G. Tonolo, G. Secchi, M. Maioli (Sassari, Italy) 423 APOA5 VARIANT T-1131C AND PLASMA TRIGLYCERIDES AND CHOLESTEROL IN DIABETICS 139 J. Hubacek, Z. Skodova, V. Adamkova, V. Lanska, Z. Vlasakova (Prague, Czech Republic) 424 THE APOA-V GENE VARIANTS AND ABNORMALITIES OF GLUCOREGULATION 139 J. Kovar, J.A. Hubacek, V. Adamkova (Prague, Czech Republic) 425 THE APO5 -1131 T>C POLYMORPHISM IS ASSOCIATED WITH INCREASED 139 CONCENTRATIONS OF VITAMIN E AND TRIGLYCERIDES IN TYPE 2 DIABETIC PATIENTS J. Girona, M. Guardiola, A. Cabré, J.M. Manzanares, M. Heras, J. Ribalta, L. Masana (Reus, Spain) 426 ASSOCIATION OF APOLIPOPROTEIN(a) POLYMORPHISM WITH LIPOPROTEIN(a) 139 CONCENTRATION IN CORONARY ARTERY DISEASE N. Bogavac-Stanojevic, Z. Jelic-Ivanovic, V. Spasojevic-Kalimanovska, A. Topic, S. Spasic, D. Kalimanovska-Ostric, A. Zeljkovic (Belgrade, Serbia-Montenegro) 427 THE ASSOCIATION OF SERUM LIPOPROTEIN(a) LEVELS, APOLIPOPROTEIN(a) SIZE AND 140 M G/A-21 POLYMORPHISM WITH CORONARY HEART DISEASE O A. Kalina, I. Karadi, Z. Prohaszka, Gy. Fust, I. Palasti, P. Volf, F. Alwazir, C.S. Balak, A. Barbara, A. Csaszar (Budapest, Hungary) N 428 APOLIPOPROTEIN (a) POLYMORPHISMS IN A HEALTHY MACEDONIAN POPULATION 140 D K. Tosheskatrajkovska, D. Labudovic, S. Alabakovska, B. Todorova (Skopje, Macedonia) A 429 COMPLEX HAPLOTYPES FROM APOLIPOPROTEIN(a) GENE LOCUS CONTROL REGIONS 140 AND CORRELATION TO LIPOPROTEIN(a) PLASMA LEVELS Y K. Zidkova, V. Kebrdlova, L. Zlatohlavek, R. Ceska (Prague, Czech Republic) 430 LIPOPROTEIN (a), ITS RELATION TO GENE CONTROL REGIONS 140 L. Zlatohlavek, K. Zidkova, M. Vrablik, R. Ceska (Prague, Czech Republic) 431 CORRELATION OF SNP -420C/G AND PLASMA LEVELS OF RESISTIN WITH 141 DETERMINANTS OF METABOLIC SYNDROME AND ATHEROSCLEROSIS PROGRESSION M. Ongari, G. Norata, K. Garlaschelli, S. Raselli, L. Redaelli, L. Grigore, A. Catapano (Cinisello Balsamo and Milan, Italy) 432 GENETIC VARIANTS OF ADIPOR 2 ARE ASSOCIATED WITH INCREASED ADIPONECTIN 141 LEVELS AND DECREASED TRIGLYCERIDE/VLDL LEVELS U.C. Broedl, M. Lehrke, E. Fleischer-Brielmaier, A.B. Tietz, J.M. Nagel, B. Goke, P. Lohse, K.G. Parhofer (Munich, Germany) 433 APO E POLYMORPHISM, ADIPONECTIN AND INSULIN SENSITIVITY IN OBESE FAMILIES 141 M. Kwasniak, M. Malczewska-Malec, I. Wybranska, A. Zdzienicka, A. Dembinska-Kiec (Cracow, Poland) 434 ASSOCIATION BETWEEN APOLIPOPROTEIN APOE3/4 GENOTYPE AND METABOLIC 141 SYNDROME(MS) A. Pujia, K. Altomare, T. Montalcini, N. Gelonesi, G. Gorgone, C. Gazzaruso, G. Sesti, F. Perticone (Catanzaro and Pavia, Italy) 435 LEU72MET POLYMORPHISMS IN GHRELIN AND WEIGHT LOSS IN INTERVENTIONAL STUDY 141 P. Suchanek, J. Hubacek, D. Bobkova, A. Lorenzova, R. Poledne (Prague, Czech Republic) 436 ACE GENE POLYMORPHISM IN PATIENT WITH THE METABOLIC SYNDROME 142 G. Nowicka, A. Walczak (Warsaw, Poland) 437 ASSOCIATION OF CYTOKINE POLYMORPHISMS WITH BLOOD CELLS COUNT 142 ABNORMALITIES IN PATIENTS WITH TYPE 2 DIABETES I. Parra-Rojas, B. Ruìz-Madrigal, E. Martìnez-Lòpez, A. Panduro (Jalisco, Mexico) 438 HAPLOTYPES OF INTERLEUKIN-6 PROMOTER CORRELATE WITH CHOLESTEROL 142 LEVELS IN PATIENTS TREATED WITH STATINS G. Latkovskis, N. Licis, M. Zabunova, M. Berzina, A. Erglis (Riga, Latvia) 439 INFLUENCE OF NOS3 GENE POLYMORPHISMS ON CYTOKINES AND GROWTH FACTORS 142 IN THE SERUM OF HEALTHY INDIVIDUALS I. Zineh, T.R. Wessel, C.B. Arant, T.Y. Langaee, R.S. Schofield (Gainesville, FL, USA) 440 ASSOCIATION OF COMMON CRP GENE POLYMORPHISMS WITH CAROTID 142 ATHEROSCLEROSIS E. Ben Assayag, S. Shenhar-Tsarfaty, I. Bova, S. Berliner, H. Peretz, S. Usher, I. Shapira, N.M. Bornstein (Tel-Aviv, Israel) 441 PROTECTIVE EFFECT OF THE G-765C COX-2 POLYMORPHISM ON SUBCLINICAL 143 ATHEROSCLEROSIS AND INFLAMMATORY MARKERS IN HYPERCHOLESTEROLEMIC SUBJECTS J. Orbe, O. Beloqui, J.A. Rodriguez, M. Belzunce, C. Roncal, J.A. Páramo (Pamplona, Spain)

52 442 GENETIC VARIANTS OF THE PROMOTER OF THE HEME OXYGENASE-1 GENE AND THEIR 143 INFLUENCE ON CARDIOVASCULAR DISEASE N. Lüblinghoff, K. Winkler, B. Winkelmann, B. Boehm, W. März, M. Hoffmann (Freiburg, Frankfurt Sachsenhausen, Ulm, Germany and Graz, Austria) 443 LACK OF ASSOCIATION BETWEEN 159T/C POLYMORPHISM AND CLINICAL PROFILE 143 OF FIRST MYOCARDIAL INFARCTION SURVIVORS T. Rechcinski, A. Grebowska, M. Kurpesa, W. Rudnicka, M. Krzeminska-Pakula, M. Chmiela (Lodz, Poland) 444 POLYMORPHIC VARIANTS OF CYBA GENE AND GENES ENCODING RENIN-ANGIOTENSIN 143 SYSTEM (RAS) COMPONENTS ARE ASSOCIATED WITH CORONARY ARTERY DISEASE (CAD) P. Niemiec, I. Zak, M. Trusz-Gluza (Katowice, Poland) 445 POLYMORPHISM OF -191C/G OF ABCA1 GENE IN PATIENTS WITH CORONARY ARTERY 144 DISEASE IN HANS POPULATION W.Y. Shi, Y.Z. Yang, Z.H. Quan, C.K. Tang, C.H. Liu, G. Ouyang, H.B. Li, Y.Q. Li, X. Yang (Hengyang, China) 446 ADENOSINE MONOPHOSPHATE KINASE ALPHA-2 SUBUNIT GENE: SINGLE NUCLEOTIDE 144 POLYMORPHISMS ASSOCIATED WITH TOTAL- AND LOW DENSITY LIPOPROTEIN M CHOLESTEROL O S.D. O'Dell, N.J. Spencer-Jones, H. Snieder, D. Ge, N.D. Carter, T.D. Spector (London, UK and Augusta, GA, USA) N 447 MECHANISMS OF ARTERIAL CALCIFICATION: GENOTYPE AND PHENOTYPE OF NPP1 144 D DEFICIENCY IN MICE AND MAN A F. Rutsch, Y. Nitschke, U. Hansen, W. Völker, P. Bruckner, N. Ruf, D. Schnabel, R. Terkeltaub, Y P. Nürnberg, G. Weissen-Plenz (Münster, Berlin, Cologne, Germany and San Diego, CA, USA) 448 FATTY ACID BINDING PROTEIN 2 GENE POLYMORPHISMS: CONNECTION WITH PLASMA 144 AND VLDL TRIGLYCERIDE LEVELS M. Jáchymová, M. Vecka, E. Tvrzická, L. Janíková, B. Stanková, A. Zák (Prague, Czech Republic) 449 A NEW OX40L PROMOTER HAPLOTYPE SHOWING ASSOCIATION WITH CORONARY 145 ARTERY DISEASE IN THE PROCARDIS TRIO FAMILY AND SCARF COHORTS M. Ria, The Procardis Consortium, P.G. Olsson, O. Bengtsson, P. Eriksson, A. Hamsten, J. Lagercrantz (Stockholm, Mölndal, Sweden and Oxford, UK) 450 BETA2-ADRENERGIC RECEPTOR GENE POLYMORPHISMS DO NOT PREDICT 145 CARDIOVASCULAR DISEASE IN THE GENERAL A.A. Sethi, B.G. Nordestgaard, A. Tybjaerg-Hansen (Copenhagen, Denmark) 451 SINGLE-STRAND CONFORMATION POLYMORPHISM FOR THE MUTATION SCANNING OF 145 PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 IN FAMILIAL HYPERCHOLESTEROLAEMIA S. Mapplebeck, R. Whittall, C.S. Hubbart, M. Thomas, S.E. Humphries (London, UK) 452 GENOTYPES AT THE MATRIX METALLOPROTEINASE (MMP) LOCI FOR MMP9 AND 145 MMP12 ARE ASSOCIATED WITH CAROTID IMT MEASURES OF PLAQUE STABILITY A. Panayiotou, M. Griffin, N. Georgiou, D. Bond, T. Tyllis, S.E. Humphries, A.N. Nicolaides (Nicosia, Cyprus and London, UK) 453 STROMELYSIN GENE PROMOTER POLYMORPHISM AND COMMON CAROTID GEOMETRY 146 IN DIABETIC SUBJECTS C. Irace, C. Cortese, M. Migale, L. Liberatoscioli, L. Mannucci, G. Federici, A. Gnasso (Catanzaro and Rome, Italy) 454 MATRIX METALLOPROTEINASE-3 GENOTYPE IS ASSOCIATED WITH HIGHER CORONARY 146 PLAQUE BURDEN, POSITIVE REMODELING AND INCREASED RISK OF UNSTABLE DISEASE A.J. White, S.J. Duffy, A.S. Walton, G.E. Rice, S. Mukherjee, J.A. Shaw, G.L. Jennings, A.M. Dart, B.A. Kingwell (Melbourne, VIC, Australia) 455 GENETIC PREDISPOSITION TO UNFAVOURABLE OUTCOMES IN PATIENTS WITH 146 UNSTABLE ANGINA V.V. Nosikov, D.A. Zateyshchikov, D.A. Chudakova, A.A. Zateyshchikova, O.E. Voron'ko, L.O. Minushkina, O.S. Chumakova, B.A. Sidorenko (Moscow, Russia) 456 INTERACTIONS BETWEEN GENETIC VARIATION OF INTESTINAL STEROL ABSORPTION, 146 SERUM STEROLS, AND RESPONSE TO PLANT STEROL IN HYPERCHOLESTEROLEMIC PATIENTS M. Cofan, B. Cortes, E. Ros, I. de Castro, B. Martin, P. Mozas, M. Pocovi, X. Pinto, J. Salas-Salvado, M. Bullo (Barcelona, Zaragoza, Hospitalet Llobregat and Reus, Spain) 457 IDENTIFICATION OF A NEW NONSENSE MUTATION IN THE ABCG5 GENE CAUSING 147 BETA-SITOSTEROLEMIA L. Mannucci, P. Bertucci, O. Guardamagna, P. Indigeno, L. Liberatoscioli, L. Pisciotta, S. Bertolini, A. Gnasso, G. Federici, G. Cortese (Rome, Turin, Genoa and Catanzaro, Italy)

53 458 A 1-YEAR STUDY ON HYDROXY-METHYLGLUTARYL COENZYME - A REDUCTASE GENE 147 EXPRESSION AND POLYMORPHISMS IN HYPERCHOLESTEROLEMIC TREATED WITH STATINS A. Bonaiuto, A. Bitto, M.A. Sardo, F. Polito, C. Saitta, F. Squadrito, A. Saitta (Messina, Italy) 459 CYTOCHROME P-450 2D6 GENOTYPE HAS A MAJOR EFFECT ON LOVASTATIN 147 PHARMACOKINETICS IN CHINESE SUBJECTS O.Q.P. Yin, B. Tomlinson, Q. Chang, E. Poon, M.S.S. Chow (Shatin, Hong Kong, China) 460 3UTR/T POLYMORPHISM OF LECTIN-LIKE OXIDIZED-LDL RECEPTOR-1 (LOX-1) 147 INFLUENCES ANTIPLATELET ACTIVITY OF ATORVASTATIN IN HYPERCHOLESTEROLEMIC SUBJECTS M. Martino, A.L. Pasqui, F. Bruni, M. Pastorelli, F. Ciani, A. Palazzuoli, A. Auteri, L. Puccetti (Siena and Florence, Italy)

M O N D A Y

54 8.30 - 12.30 TUESDAY, June 20 ROOM 1

Tu-PL2 Plenary Session 2 LIPOPROTEINS AND THROMBOSIS Chairs: E. Leitersdorf (Jerusalem, Israel); hour: M.-R. Taskinen (Helsinki, Finland); E. Tremoli (Milan, Italy) abstract bk. page ref.: 8.30 - 9.00 HDL STRUCTURE AND METABOLISM AS RELATED TO CARDIOVASCULAR 149 DISEASE H.B. Brewer, Jr. (Washington, DC, USA) 9.00 - 9.30 MOLECULAR AND PHARMACOLOGIC REGULATION OF REVERSE 149 CHOLESTEROL TRANSPORT D.J. Rader, X. Wang, J. Tohyama, H. Tanigawa, H. Collins, M. Cuchel, I. Fuki, J. Billheimer, G. Rothblat (Philadelphia, PA, USA) 9.30 - 10.00 QUEST FOR GENES PREDISPOSING TO ATHEROTHROMBOSIS 149 A. Hamsten (Stockholm, Sweden)

XXXII LORENZINI ANNUAL LECTURE 10.00 - 10.30 GENETIC PROTECTION FROM CORONARY ATHEROSCLEROSIS: FROM 150 GENES TO PUBLIC HEALTH J.C. Cohen, I. Kotowski, A. Pertsemlidis, E. Boerwinkle, T.H. Mosley, H.H. Hobbs (Dallas, Houston, TX and Jackson, MS, USA)

10.30 End of the Session T 10.30 - 11.00 BREAK - POSTERS - EXHIBITS U E S Tu-S8 Sponsored Symposium 8 D CETP INHIBITORS AND THEIR EFFECTS ON A CARDIOVASCULAR RISK FACTORS Y Chairs: G. Steiner (Toronto, ON, Canada); J.J.P. Kastelein (Amsterdam, The Netherlands)

11.00 - 11.05 OPENING REMARKS – G. Steiner (Toronto, ON, Canada) 11.05 - 11.25 PRE-CLINICAL EVALUATION OF NOVEL CETP INHIBITORS 180 M.J. Chapman (Paris, France) 11.25 - 11.45 EPIDEMIOLOGICAL EVIDENCE FOR HDL-C AND OTHER CARDIOVASCULAR 180 RISK FACTORS J. Tuomilehto (Helsinki, Finland) 11.45 - 12.05 MODIFICATION OF CARDIOVASCULAR RISK FACTORS: CLINICAL BENEFITS 180 D.J. Rader (Philadelphia, PA, USA) 12.05 - 12.25 GENERAL DISCUSSION – 12.25 - 12.30 CLOSING REMARKS – J.J.P. Kastelein (Amsterdam, The Netherlands) 12.30 End of the Session

Supported in part by an unrestricted educational grant provided by: Roche

12.30 - 14.30 LUNCH - SCIENTIFIC SESSIONS - POSTERS - EXHIBITS

55 11.00 - 13.05 TUESDAY, June 20 ROOM 2

Tu-W16 Workshop 16 HDL FUNCTIONS hour: Chairs: K.-A. Rye (Sydney, NSW, Australia); L. Calabresi (Milan, Italy) abstract bk. page ref.: 11.00 - 11.20 HDL AND THE INHIBITION OF INFLAMMATION IN VIVO 152 K.-A. Rye, R. Puranik, E. Nobecourt, S. Bao, S.J. Nicholls, P.J. Barter (Sydney, NSW, Australia) 11.20 - 11.35 CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) PRODUCTION BY 152 MACROPHAGES PROMOTES ATHEROSCLEROTIC LESION DEVELOPMENT M. van Eck, D. Ye, R.B. Hildebrand, J.K. Kruijt, M. Jauhianen, Th.J.C. van Berkel (Leiden, The Netherlands and Helsinki, Finland) 11.35 - 11.50 NORMAL ENDOTHELIAL FUNCTION IN CARRIERS OF THE APOLIPOPROTEIN 152 A-IMILANO MUTANT DESPITE LOW HDL-CHOLESTEROL LEVELS M. Gomaraschi, D. Baldassarre, M. Amato, S. Eligini, C.R. Sirtori, G. Franceschini, L. Calabresi (Milan, Italy) 11.50 - 12.05 SINGLE INFUSION OF LIPID FREE APO A1 CAN RESCUE VASCULAR 153 INFLAMMATION R. Puranik, S. Bao, E. Nobecourt, S.J. Nicholls, P.J. Barter, D.S. Celermajer, K.-A. Rye (Sydney, NSW, Australia) 12.05 - 12.20 HIGH DENSITY LIPOPROTEIN ABOLISHES ATHEROTHROMBOTIC EFFECTS OF 153 C-REACTIVE PROTEIN IN HUMANS S.I. van Leuven, R.S. Birjmohun, J.H.M. Levels, R. Bisoendial, J.C.M. Meijers, J.J.P. Kastelein, E.S. Stroes (Amsterdam, The Netherlands) T 12.20 - 12.35 HIGH DENSITY LIPOPROTEIN CHOLESTEROL IMPROVES LEFT VENTRICULAR 153 U FUNCTION IN OBESE RATS VIA ACTIVATION OF AMP-ACTIVATED PROTEIN KINASE E S. van Linthout, F. Spillmann, C. Bürkner-Gartner, J. Lievens, A. Subasigüller, B. De Geest, C. Tschöpe (Berlin, Germany and Leuven, Belgium) S 12.35 - 12.50 A NEW CELL PATHWAY TO REGULATE HEPATIC HDL ENDOCYTOSIS: INVOLVEMENT 153 D OF ECTO-F1-ATPASE, PURINERGIC RECEPTOR P2Y13 AND RHO KINASE A C. Malaval, J. Jacquet, L.O. Martinez, C. Rolland, F. Tercé, X. Collet, R. Barbaras Y (Toulouse, France) 12.50 - 13.05 A STRUCTURAL MODEL FOR APOLIPOPROTEIN A-I MILANO (A-IM) IN ITS 154 HETERODIMERIC FORM WITH APOLIPOPROTEIN A-II (A-II) A. Guerini Rocco, L. Mollica, E. Gianazza, L. Calabresi, C.R. Sirtori, I. Eberini (Milan, Italy) 13.05 End of the Session

13.05 - 14.30 LUNCH - SCIENTIFIC SESSIONS - POSTERS - EXHIBITS

56 11.00 - 14.35 TUESDAY, June 20 ROOM 3

Tu-W17 Workshop 17 METABOLIC SYNDROME (2nd part) hour: abstract bk. Chairs: K. Pyörälä (Kuopio, Finland); A. Pagnan (Padua, Italy) page ref.: 11.00 - 11.20 METABOLIC SYNDROME IN NON-DIABETIC EUROPEANS: RELATION TO 154 CARDIOVASCULAR MORTALITY K. Pyörälä, Q. Qiao, W.G. Gao, B. Balkau, K. Borch-Johnsen, K.G.M.M. Alberti, J. Tuomilehto, for the DECODE Study Group (Kuopio, Helsinki, Finland, Paris, France, Gentofte, Denmark and Newcastle, UK) 11.20 - 11.40 METABOLIC SYNDROME AS A CORONARY RISK FACTOR IN A POPULATION 154 WITH LOW CHOLESTEROL LEVELS V. Sansoy (Istanbul, Turkey) 11.40 - 11.55 CAROTID ATHEROSCLEROSIS AND THE METABOLIC SYNDROME: A 155 COMPARISON OF NCEP-ATPIII, IDF AND AHA/NHLBI DEFINITIONS M. Skilton, P. Moulin, A. Serusclat, P. Nony, F. Bonnet (Lyon, France) 11.55 - 12.10 THE METABOLIC SYNDROME AS NEWLY DEFINED BY THE IDF: CONCORDANCE 155 WITH ESTABLISHED DEFINITIONS AND USEFULNESS TO ESTIMATE CVD RISK A. Sandhofer, B. Iglseder, B. Paulweber, C. Ebenbichler, J.R. Patsch (Innsbruck and Salzburg, Austria) 12.10 - 12.25 A PROSPECTIVE STUDY ON THE PREVALENCE OF METABOLIC SYNDROME AMONG 155 HEALTHY FRENCH FAMILIES.THE IMPORTANCE OF PLASMA CONCENTRATION OF TNF-ALPHA IN ADDITION TO ITS GENETIC POLYMORPHISM S. Visvikis-Siest, S. Maumus (Nancy, France) 12.25 - 12.40 THE HYPERTENSIVE WAIST - FIRST STEP OF THE SCREENING OF THE 155 T METABOLIC SYNDROME U N. Hancu, C. Nita, G. Roman, L. Szentagotai (Cluj Napoca, Romania) 12.40 - 12.55 PREVALENCE OF METABOLIC SYNDROME ESTIMATED BY IDF CRITERIA IN A 156 E HUNGARIAN POPULATION S A. Császár, S. Balogh, E. Kékes (Budapest, Hungary) D 12.55 End of the Session A Y 12.55 - 14.30 LUNCH - SCIENTIFIC SESSIONS - POSTERS - EXHIBITS

Tu-S9 Sponsored Symposium 9 OMEGA-3 FATTY ACIDS IN CARDIOVASCULAR DISEASE Chairs: W. Harris (Kansas City, MO, USA); R. Marchioli (Chieti, Italy); R. De Caterina (Chieti, Italy)

13.00 - 13.03 WELCOME – W. Harris (Kansas City, MO, USA) and R. Marchioli (Chieti, Italy) 13.03 - 13.23 FISH CONSUMPTION, OMEGA-3 FATTY ACIDS AND CARDIOVASCULAR 180 DISEASES: AN EPIDEMIOLOGICAL AND INTERVENTIONAL PERSPECTIVE M. de Lorgeril, P. Salen (Grenoble, France) 13.23 - 13.43 OMEGA-3 FATTY ACIDS AND ATHEROSCLEROSIS: EVIDENCE AND MECHANISMS 181 R. De Caterina (Chieti, Italy) 13.43 - 14.03 OMEGA-3 FATTY ACIDS AND FATAL ARRHYTHMIAS 181 E. Berg Schmidt, J. Hagstrup Christensen (Aalborg, Denmark) 14.03 - 14.23 RECENT INSIGHT FROM LARGE-SCALE CLINICAL TRIAL: THE JELIS TRIAL 181 M. Yokoyama (Kobe, Japan) 14.23 - 14.28 GENERAL DISCUSSION 14.28 - 14.31 CLOSING REMARKS – R. De Caterina (Chieti, Italy) 14.35 End of the Session

Supported in part by an unrestricted educational grant provided by: Pfizer Italia, Pronova Biocare, Sigma-Tau, SPA - Societa’ Prodotti Antibiotici

57 11.00 - 13.45 TUESDAY, June 20 ROOM 4

Tu-W18 Workshop 18 UNSTABLE PLAQUE hour: Chairs: P.K. Shah (Los Angeles, CA, USA); M. Cortellaro (Milan, Italy) abstract bk. page ref.: 11.00 - 11.20 NEW INSIGHTS INTO MOLECULAR MECHANISMS OF PLAQUE INSTABILITY 156 P.K. Shah, L. Wang, B. Sharifi (Los Angeles, CA, USA) 11.20 - 11.40 ARACHIDONIC ACID METABOLISM AND PLAQUE INSTABILITY 156 F. Cipollone (Chieti, Italy) 11.40 - 12.00 IMAGING OF ATHEROSCLEROSIS: CAN WE PREDICT PLAQUE RUPTURE? 156 P.L. Weissberg (Cambridge and London, UK) 12.00 - 12.15 VULNERABLE PLAQUES ARE CHARACTERISED BY DISTINCT POPULATIONS 157 OF HLADR+/ CD163- AND HLADR-/CD163+ MACROPHAGE SUBTYPES J.J. Boyle, P. Philippidis, D. Horncastle, R.C. Landis, D.O. Haskard (London, UK) 12.15 - 12.30 RECEPTORS FOR THE ANAPHYLATOXINS C3A AND C5A ARE EXPRESSED IN 157 HUMAN ATHEROSCLEROTIC CORONARY PLAQUES P. Laine, R. Oksjoki, S. Helske, P. Vehmaan-Kreula, M. Mäyränpää, P. Gasque, P.T. Kovanen, M.O. Pentikäinen (Helsinki, Finland and Cardiff, UK) 12.30 - 12.45 SIMVASTATIN REDUCES MMP1 EXPRESSION IN HUMAN SMOOTH MUSCLE CELLS 157 CULTURED ON POLYMERIZED COLLAGEN BY INHIBITING RAC1 ACTIVATION N. Ferri, G. Colombo, C. Ferrandi, B. Levkau, A. Corsini (Milan, Italy and Essen, Germany) 12.45 - 13.00 ISOLATION AND CYTOCIDAL EFFECTS OF CEROID AND LIPIDACEOUS GRUEL FROM 158 ATHEROMATOUS PLAQUE W. Li, M. Ostblom, L.H. Xu, A. Hellsten, P. Leandersson, B. Liedberg, U.T. Brunk, T J.W. Eaton, X.M. Yuan (Linköping, Sweden and Louisville, KY, USA) U 13.00 End of the Session E S D 13.00 - 14.30 LUNCH - SCIENTIFIC SESSIONS - POSTERS - EXHIBITS A Y Tu-ML4 Master Lecture 4 ENDOTHELIAL DYSFUNCTION AND ATHEROSCLEROSIS: MECHANISMS AND THERAPEUTICAL INTERVENTION Chair: L. Jonasson (Eksjo, Sweden)

13.00 - 13.30 ENDOTHELIAL DYSFUNCTION AND ATHEROSCLEROSIS: MECHANISMS 151 AND THERAPEUTICAL INTERVENTION S. Taddei (Pisa, Italy) 13.30 - 13.45 GENERAL DISCUSSION – 13.45 End of the Session

Supported in part by an unrestricted educational grant provided by: Recordati

58 11.00 - 13.45 TUESDAY, June 20 ROOM 5

Tu-W19 Workshop 19 THROMBOSIS (2nd part) hour: Chairs: P. Eriksson (Stockholm, Sweden); R. Abbate (Florence, Italy) abstract bk. page ref.: 11.00 - 11.20 FUNCTIONAL POLYMORPHISMS IN FIBRINOLYSIS AND PROTEOLYSIS 158 GENES: INFLUENCES OF GENE-ENVIRONMENT INTERACTIONS P. Eriksson (Stockholm, Sweden) 11.20 - 11.40 ROLE OF THE FIBRINOLYTIC SYSTEM IN THE DEVELOPMENT OF OBESITY 158 AND THE METABOLIC SYNDROME M.C. Alessi, I. Juhan-Vague (Marseille, France) 11.40 - 11.55 PROINFLAMMATORY CYTOKINE MEDIATED T-PA SUPPRESSION IN VASCULAR 159 ENDOTHELIAL CELLS IS NF-KAPPAB AND P38 DEPENDENT P. Larsson, E. Ulfhammer, L. Karlsson, W. Ridderstråle, T. Hrafnkelsdottir, S. Jern (Göteborg, Sweden) 11.55 - 12.10 IMPACT OF METFORMIN VERSUS REPAGLINIDE ON GLYCEMIC REGULATION AND 159 NON-GLYCEMIC CARDIOVASCULAR RISK-MARKERS IN NON-OBESE PATIENTS WITH TYPE-2 DIABETES S. Lund, L. Tarnow, G. Poulsen, C. Stehouwer, C. Schalkwijk, J. Gram, U. Smidt, O. Pedersen, H.-H. Parving, A. Vaag (Maastrict, Amsterdam, The Netherlands, Gentofte and Esbjerg, Denmark) 12.10 - 12.25 NOR-1 (NEURON- DERIVED ORPHAN RECEPTOR-1) IS INVOLVED IN 159 THROMBIN-INDUCED VASCULAR CELL ACTIVATION: IMPLICATIONS IN ATHEROSCLEROSIS J. Martínez-González, L.L. Martorell, J. Crespo, L. Badimon (Barcelona, Spain) T 12.25 - 12.40 ENDOTHELIAL CELLS SEEDED ON PROTEIN-COATED VASCULAR PROSTHESES 159 U UNDER EXPERIMENTAL SHEAR STRESS CONDITIONS E J. Chlupac, E. Filova, T. Riedel, E. Brynda, M. Remy-Zolghadri, R. Bareille, P. Fernandez, R. Daculsi, L. Bordenave, L. Bacakova (Prague, Czech Republic and Bordeaux, France) S 12.40 - 12.55 ANGIOGENIC EFFECTS OF OXIDIZED PHOSPHOLIPIDS ARE MEDIATED VIA 160 D AUTOCRINE STIMULATION BY VEGF, IL-8 AND COX-2-DERIVED PROSTAGLANDINS A M. Philippova, A. Kadl, O. Oskolkova, A. Furkranz, E. Karabeg, J. Breuss, T.J. Resink, Y B.R. Binder, N. Leitinger, V. Bochkov (Vienna, Austria, Basel, Switzerland and Charlottesville, VA, USA) 12.55 End of the Session

12.55 - 14.30 LUNCH - SCIENTIFIC SESSIONS - POSTERS - EXHIBITS

Tu-ML5 Master Lecture 5 CARDIOVASCULAR CONSEQUENCES OF CYCLOOXYGENASE INHIBITION; PHARMACOLOGICAL TARGETS BEYOND COX-2 Chair: C. Patrono (Chieti, Italy)

13.00 - 13.30 CARDIOVASCULAR CONSEQUENCES OF CYCLOOXYGENASE INHIBITION; 151 PHARMACOLOGICAL TARGETS BEYOND COX-2 G.A. FitzGerald (Philadelphia, PA, USA) 13.30 - 13.45 GENERAL DISCUSSION – 13.45 End of the Session

59 11.00 - 13.15 TUESDAY, June 20 ROOM 6

Tu-W20 Workshop 20 CLINICAL TRIALS (1st part) hour: Chairs: H.C. Bucher (Basel, Switzerland); S. Giampaoli (Rome, Italy) abstract bk. page ref.: 11.00 - 11.20 LIPID GUIDELINES - ONE FOR ALL? 160 T.R. Pedersen (Oslo, Norway) 11.20 - 11.40 META-ANALYSIS VERSUS CONTROLLED CLINICAL TRIALS IN CARDIOVASCULAR 160 DISEASE: WHAT ARE THE DIFFERENCES? H.C. Bucher (Basel, Switzerland) 11.40 - 12.00 LONG CHAIN OMEGA-3 FATTY ACIDS ENTER ADVANCED ATHEROSCLEROTIC 160 PLAQUES AND ARE ASSOCIATED WITH DECREASED INFLAMMATION AND DECREASED INFLAMMATORY GENE EXPRESSION A.L. Cawood, R. Ding, F.L. Napper, J. Williams, O. Gudmundsen, S. Payne, H. Vik, C.P. Shearman, S. Ye, P.J. Gallagher, R.F. Grimble, P.C. Calder (Southampton, Portsmouth, UK, Kjeller and Lysaker, Norway) 12.00 - 12.15 APOLIPOPROTEIN B/A1 RATIO IS A BETTER DISCRIMINATOR OF RISK OF 161 CORONARY HEART DISEASE THAN IS LDL/HDL CHOLESTEROL RATIO IN THE IDEAL STUDY A. Olsson, I. Holme, T. Pedersen (Linkoping, Sweden and Oslo, Norway) 12.15 - 12.30 AGGRESSIVE RISK FACTOR MODIFICATION IN PATIENTS WITH SUBCLINICAL 161 ATHEROSCLEROSIS REDUCES PLAQUE BURDEN AND REGRESSES CAROTID ARTERY WALL THICKNESS B.F. Bale, A.L. Doneen, R. Drueding, S.L. Charland (Spokane, WA, Salt Lake City, UT, T and Cranbury, NJ, USA) U 12.30 - 12.45 FIRST LARGE RANDOMIZED TRIAL OF STATIN THERAPY IN SOUTH ASIAN 161 E PATIENTS AT RISK FOR CORONARY HEART DISEASE: THE IRIS TRIAL P. Deedwania, M. Gupta, M. Stein, J. Ycas, A. Gold (Fresno, CA, Wilmington, NC S USA and Brampton, ON, Canada ) D 12.45 - 13.00 THE RELATIONSHIP BETWEEN BASELINE RISK FACTORS AND THE INCIDENCE 161 A OF CHD AMONG JAPANESE -NEW FINDINGS FROM THE MEGA STUDY Y T. Ishikawa, H. Nakamura (Tokyo, Japan) 13.00 - 13.15 EFFECTS OF LIPOPHILICITY OF STATINS ON CARDIOVASCULAR EVENTS AFTER 162 ACUTE MYOCARDIAL INFARCTION (AMI) T. Sakamoto, S. Kojima, H. Ogawa (Kumamoto, Japan) 13.15 End of the Session

13.15 - 14.30 LUNCH - SCIENTIFIC SESSIONS - POSTERS - EXHIBITS

60 11.00 - 12.55 TUESDAY, June 20 ROOM 7

Tu-W21 Workshop 21 NOVEL ASPECTS OF CLINICAL PRACTICE: HIV INFECTION AND PHYSICAL ACTIVITY Chairs: D. Sviridov (Melbourne, NSW, Australia); hour: G. Valenti (Parma, Italy) abstract bk. page ref.: 11.00 - 11.20 AEROBIC CAPACITY AND HEALTH: RUN FOR YOUR LIFE 162 U. Wisløff (Trondheim, Norway) 11.20 - 11.40 HIV INFECTION AND EXERCISE: THE BLACK AND WHITE KNIGHTS OF 162 HIGH DENSITY LIPOPROTEIN METABOLISM D. Sviridov, B.A. Kingwell, H. Rose, M. Bukrinsky, J. Hoy, A.M. Dart (Melbourne, NSW, Australia and Washington, DC, USA) 11.40 - 11.55 CARDIAC RISK IN HIV POSITIVE PATIENTS: A NEW GROUP FOR AGRESSIVE 163 PREVENTION OF ATHEROSCLEROSIS? C.Y. Pai, D. Calderaro, C.L. Zilli Vieira, E. de Oliveira Lima, I. Giuliano, B. Caramelli (São Paulo, Brazil) 11.55 - 12.10 INFLUENCE OF PRAVASTATIN ON CAROTID ARTERY STRUCTURE AND 163 FUNCTION IN DYSLIPIDEMIC HIV-INFECTED PATIENTS RECEIVING ANTIRETROVIRAL THERAPY F. Boccara, T. Simon, K. Lacombe, A. Cohen, B. Laloux, E. Bozec, S. Durant, P.M. Girard, S. Laurent, P. Boutouyrie (Paris, France) 12.10 - 12.25 HIV-INFECTED PATIENTS PRESENTED IMPAIRED ENDOTHELIAL FUNCTION 163 ASSESSED BY PERIPHERAL ARTERIAL TONOMETRY T B. Coll, S. Parra, F. Marimon, G. Aragones, A. Castro, C. Alonso-Villaverde, U L. Masana (Tarragona, Spain) 12.25 - 12.40 PHYSICAL EXERCISE CAPACITY IS ASSOCIATED WITH CORONARY AND 163 E PERIPHERAL VASCULAR FUNCTION IN HEALTHY YOUNG ADULTS S U. Hägg, B. Wandt, G. Bergström, R. Volkmann, L.-M. Gan (Göteborg, Sweden) D 12.40 - 12.55 RELATIONSHIP BETWEEN ASPIRIN RESISTANCE AND C-REACTIVE PROTEIN 164 A LEVELS DURING EXERCISE O. Gulmez, C. Ertan, A. Yildirir, D. Konas, U. Bal, O. Demir, A. Aydinalp, I. Atar, Y B. Ozin, H. Muderrisoglu (Ankara, Turkey) 12.55 End of the Session

12.55 - 14.30 LUNCH - POSTERS - EXHIBITS

61 11.00 - 12.55 TUESDAY, June 20 ROOM 8

Tu-W22 Workshop 22 ADIPOSE TISSUE hour: Chairs: H. Hauner (Munich, Germany); A. Tiengo (Padua, Italy) abstract bk. page ref.: 11.00 - 11.20 ROLE OF ADIPOKINES IN OBESITY-LINKED INSULIN RESISTANCE, METABOLIC 164 SYNDROME AND ATHEROSCLEROSIS T. Kadowaki, T. Yamauchi, N. Kubota, N. Kamei, K. Tobe (Tokyo, Japan) 11.20 - 11.40 SECRETORY FACTORS FROM ADIPOSE TISSUE AND ENDOTHELIAL 164 FUNCTION H. Hauner (Munich, Germany) 11.40 - 11.55 ADIPONECTIN MODULATES TRANSCRIPTION FACTOR ACTIVATION BY 164 ANGIOTENSIN II IN SMOOTH MUSCLE CELLS N. Yamada, I. Manabe, Y. Oishi, K. Fujiu, K. Tobe, T. Yamauchi, T. Kadowaki, R. Nagai (Tokyo, Japan) 11.55 - 12.10 TYPE 2 DIABETES IS CHARACTERIZED BY LOW POSTPRANDIAL ADIPONECTIN 165 PLASMA LEVELS AND ADIPOSE TISSUE GENE EXPRESSION L. Bozzetto, G. Annuzzi, C. Santangelo, L. Patti, R. Giacco, L. Di Marino, R. Masella, G. Riccardi, A.A. Rivellese (Naples and Rome, Italy) 12.10 - 12.25 THE HYPOADIPONECTINEMIA OF NEWLY DIAGNOSED UNTREATED TYPE 2 165 DIABETIC PATIENTS CANNOT BE ENTIRELY EXPLAINED BY THEIR EXCESS VISCERAL ADIPOSITY M. Côté, P. Poirier, P. Mauriège, J. Bergeron, N. Alméras, I. Lemieux, A. Tremblay, J.-P. Després (Ste-Foy, QC, Canada) T 12.25 -12.40 ROLE OF MACROPHAGE INFILTRATION IN INFLAMMATORY CHANGES OF OBESE 165 U SUBJECT ADIPOSE TISSUE E M. D'Adamo, C. Consoli, V. Guglielmi, P. Gentileschi, M. Federici, D. Lauro, G. Donadel, R. Lauro, P. Sbraccia (Rome, Italy) S 12.40 - 12.55 LIPOPROTEIN LIPASE, AN ADIPOCYTE-DERIVED PARACRINE MEDIATOR OF 165 D MACROPHAGE ACTIVATION AND RECRUITMENT IN THE OBESE ADIPOSE TISSUE? A L. Ling, G. Renier (Montreal, QC, Canada) Y 12.55 End of the Session

12.55 - 14.30 LUNCH - POSTERS - EXHIBITS

62 16.30 - 18.00 TUESDAY, June 20 ROOM 1

Tu-S10 Sponsored Symposium 10 NEW TREATMENT PARADIGMS: INTENSIVE CHOLESTEROL LOWERING THERAPY hour: Chairs: S.M. Grundy (Dallas, TX, USA); R. Paoletti (Milan, Italy) abstract bk. page ref.: 16.30 - 16.35 OPENING REMARKS – R. Paoletti (Milan, Italy) 16.35 - 17.00 SUMMARY OF RECENT TRIALS IN SECONDARY PREVENTION AND THE HIGH 182 RISK PATIENT D.J. Betteridge (London, UK) 17.00 - 17.25 INTENSIVE VERSUS USUAL TREATMENT: SAFETY AND EFFICACY 182 D.D. Waters (San Francisco, CA, USA) 17.25 - 17.50 IMPACT OF CHOLESTEROL LOWERING ON STROKE 182 K.M.A. Welch, on behalf of the SPARCL Investigators (Chicago, IL, USA) 17.50 - 17.55 CLOSING REMARKS – S.M. Grundy (Dallas, TX, USA) 17.55 - 18.00 QUESTION AND ANSWER SESSION – 18.00 End of the Session

Supported in part by an unrestricted educational grant provided by: Pfizer Inc.

T 20.00 COCKTAIL - 20.30 GALA DINNER U E S D A Y

63 14.30 - 18.25 TUESDAY, June 20 ROOM 2

Tu-S11 Sponsored Symposium 11 ATHEROSCLEROSIS: FROM LIPIDS TO CORONARY HEART DISEASE Chairs: C.M. Ballantyne (Houston, TX, USA); hour: J.J.P. Kastelein (Amsterdam, The Netherlands) abstract bk. page ref.: 14.30 - 14.35 OPENING REMARKS – C.M. Ballantyne (Houston, TX, USA) 14.35 - 14.55 ADVANCES IN DYSLIPIDAEMIA THERAPY 183 H. Schuster (Berlin, Germany) 14.55 - 15.15 STATIN SAFETY IN PERSPECTIVE 183 J. Shepherd (Glasgow, UK) 15.15 - 15.35 HOW FAR SHOULD WE REDUCE PLASMA LDL-CHOLESTEROL LEVEL IN HIGH 183 RISK PATIENTS? INSIGHTS FROM INTRAVASCULAR ULTRASOUND STUDIES S.E. Nissen, C.M. Ballantyne (Cleveland, OH and Houston, TX, USA) 15.35 - 15.55 GENERAL DISCUSSION – 15.55 - 16.00 CLOSING REMARKS – J.J.P. Kastelein (Amsterdam, The Netherlands) 16.00 End of the Session Supported in part by an unrestricted educational grant provided by: AstraZeneca

T 16.00 - 16.30 BREAK - POSTERS - EXHIBITS U E Tu-W23 Workshop 23 S HDL CHOLESTEROL AND REVERSE TRANSPORT D Chairs: A.R. Tall (New York, NY, USA); A. Corsini (Milan, Italy) A Y 16.30 - 16.50 ABC TRANSPORTERS, LIPID EFFLUX AND ATHEROSCLEROSIS 166 A.R. Tall, N. Wang, F. Matsuura, M. Ranalletta (New York, NY, USA) 16.50 - 17.10 CAN LXR, A TRANSCRIPTIONAL REGULATOR OF LIPID METABOLISM, 166 SUCCEED AS AN HDL DRUG TARGET? R.M. Lawn (Palo Alto, CA, USA) 17.10 - 17.25 INCREASED ABCA1-MEDIATED CHOLESTEROL EFFLUX POTENTIAL OF SERA 166 FROM APOA-IMILANO CARRIERS E. Favari, I. Zanotti, F. Zimetti, F. Bernini, M. Lee, P.T. Kovanen, C.R. Sirtori, G. Franceschini, L. Calabresi (Parma, Milan, Italy and Helsinki, Finland) 17.25 - 17.40 HEPATIC ABCA1 IS A KEY MOLECULE IN HDL CHOLESTERYL ESTER 166 METABOLISM IN MICE M. Brundert, R.R. Singaraja, B. Stahmer, J.S. Parks, M.R. Hayden, F. Rinninger (Hamburg, Germany, Vancouver, BC, Canada and Winston-Salem, NC, USA) 17.40 - 17.55 INTRAVENOUS ADMINISTRATION OF LARGE UNILAMELLAR VESICLES AND APO 167 AI/PHOSPHOLIPID COMPLEXES INCREASES FREE CHOLESTEROL IN PLASMA BY DIFFERENT MECHANISM M. Cuchel, S. Lund-Katz, M. de la Llera-Moya, G.H. Rothblat, M.C. Phillips, D.J. Rader (Philadelphia, PA, USA) 17.55 - 18.10 EXOGENOUS APOLIPOPROTEIN A-I PROMOTES FAECAL STEROL EXCRETION IN 167 HYPERCHOLESTEROLEMIC RABBITS J. Taylor, K.-A. Rye, T. Sloane, K. Gaus, K. Ruberu, W. Jessup, L. Kritharides (Sydney, NSW, Australia) 18.10 - 18.25 EFFECT OF HIGH CHOLESTEROL DIET ON CHOLESTEROL AND BILE ACID 167 METABOLISM IN A-IM AND A-I TRANSGENIC MICE C. Parolini, S. Caligari, D. Gilio, M. Montagnani, E.M. Rubin, C.R. Sirtori, G. Chiesa (Milan, Bologna, Italy and Berkeley, CA, USA) 18.25 End of the Session

64 20.00 COCKTAIL - 20.30 GALA DINNER 16.30 - 18.25 TUESDAY, June 20 ROOM 3

Tu-W24 Workshop 24 INFLAMMATION (1st part) hour: Chairs: C.A. Dujovne (Mission, KS, USA); A. Rappelli (Ancona, Italy) abstract bk. page ref.: 16.30 - 16.50 IMMUNE REGULATION IN ATHEROSCLEROSIS 167 G.K. Hansson, G. Berne, X. Zhou, Z.-Q. Yan (Stockholm, Sweden) 16.50 - 17.10 INFLAMMATORY COMPONENTS OF THE ATHEROSCLEROTIC PLAQUE 168 P. Libby (Boston, MA, USA) 17.10 - 17.25 INTEGRATION OF LIPID SIGNALING AND INFLAMMATORY PATHWAYS 168 IN MACROPHAGES AND GLIAL CELLS: A PROPOSED ROLE FOR STEROL 27-HYDROXYLASE F. Gilardi, B. Viviani, A. Torri, O. Maschi, D. Caruso, M. Crestani, M. Marinovich, E. De Fabiani (Milan, Italy) 17.25 - 17.40 METFORMIN INHIBITS PROINFLAMMATORY RESPONSES IN HUMAN VASCULAR 168 WALL CELLS: INHIBITION OF NUCLEAR FACTOR-KAPPA B SIGNALING IN SMOOTH MUSCLE CELLS J.L. Young, K. Isoda, A. Zirlik, L.A. MacFarlane, N. Tsuboi, N. Gerdes, U. Schönbeck, P. Libby (Boston, MA, USA) 17.40 - 17.55 ALTERATION OF VASCULAR SMOOTH MUSCLE CELLS NOTCH SIGNALLING 168 PATHWAY BY INTERLEUKIN-1BETA N. Clement, M. Glorian, M. Andreani, R. Blaise, C. Brou, I. Limon, P. Bausero (Paris, France) 17.55 - 18.10 C-REACTIVE PROTEIN IMPAIRS GLUCOSE TRANSPORT BY INDUCING 169 PHOSPHORYLATION OF INSULIN RECEPTOR SUBSTRATE-1 ON SER307 AND T SER612 IN L6 MUSCLE CELLS U C. D'Alessandris, R. Lauro, G. Sesti (Rome and Catanzaro, Italy) E 18.10 - 18.25 INTERLEUKIN-1 ALPHA DEFICIENCY INHIBITS ATHEROGENESIS IN 169 HYPERCHOLESTEROLEMIC MICE: THE ROLE OF MACROPHAGE IL-1 ALPHA S Y. Kamari, R. Werman-Venkert, A. Shaish, A. Harari, A. Gonen, E. Grossman, D Y. Iwakura, C.A. Dinarrelo, R.N. Apte, D. Harats (Tel Hashomer, Beer-Sheva, Israel, A Tokyo, Japan and Denver, CO, USA) Y 18.25 End of the Session

20.00 COCKTAIL - 20.30 GALA DINNER

65 16.30 - 18.25 TUESDAY, June 20 ROOM 4

Tu-W25 Workshop 25 LIFESTYLE AND CLINICAL PRACTICE Chairs: J.K. Cruickshank (Manchester, UK); hour: D. Sommariva (Garbagnate Milanese, Italy) abstract bk. page ref.: 16.30 - 16.50 PSYCHOSOCIAL FACTORS IN ATHEROSCLEROSIS 169 P. Hjalmarsson, L. Jonasson, M. Kristenson, J. Nijm, L.C. Nilsson, A.G. Olsson (Linköping, Sweden) 16.50 - 17.10 GEOGRAPHIC AND HISTORICAL, INTERGENERATIONAL RATHER THAN GENETIC 170 BACKGROUND TO ETHNIC VARIATION IN CHRONIC VASCULAR DISEASE J.K. Cruickshank (Manchester, UK) 17.10 - 17.25 LEVELS OF CIRCULATING MATRIX METALLOPROTEINASE-9 IS ASSOCIATED TO 170 PSYCHOSOCIAL FACTORS AND LIFE STYLE P. Hjalmarsson, L. Jonasson, J. Carstensen, L.C. Nilsson, J. Ernerudh, M. Kristenson (Linköping, Sweden) 17.25 - 17.40 HEPATIC STEATOSIS IS INDEPENDENTLY ASSOCIATED WITH PRESENCE OF 170 CORONARY ARTERY CALCIFICATION R.D. Santos, K. Nasir, I. Pimentel, R. Conceicao, R. Meneghelo, J.A.M. Carvalho, R. Blumenthal (Sao Paulo, Brazil, Pittsburgh, PA and Baltimore, MD, USA) 17.40 - 17.55 A LIPOGENIC DIET LACKING METHIONINE AND CHOLINE CAUSES HEPATIC 171 ACCUMULATION OF TOXIC SATURATED FATTY ACIDS G. Rizki, L. Arnaboldi, B. Gabrielli, D. Ginzinger, J. Yan, G. Lee, S. Kakar, D. Maltby, R.E. Pitas, J.J. Maher (San Francisco, CA, USA and Milan, Italy) T 17.55 - 18.10 SERUM MMP-9 CONCENTRATIONS CORRELATE WITH DENTAL STATUS IN 171 U PATIENTS WITH ACUTE CORONARY SYNDROME: A ONE-YEAR FOLLOW-UP E STUDY S S. Paju, P.J. Pussinen, J. Sinisalo, S. Asikainen, V.-J. Uitto, M.S. Nieminen (Helsinki, Finland and Umea, Sweden) D 18.10 - 18.25 PORPHYROMONAS GINGIVALIS INCREASES THE EXPRESSION OF APO M AND 171 A CLEAVES APO B-100 IN LDL IN WHOLE BLOOD - EFFECTS ON FIBROBLAST Y PROLIFERATION T. Bengtsson, H. Karlsson, A.-C. Svensson, P. Gunnarsson, M. Lindahl (Linköping, Sweden) 18.25 End of the Session

20.00 COCKTAIL - 20.30 GALA DINNER

66 16.30 - 18.30 TUESDAY, June 20 ROOM 5

Tu-W26 Workshop 26 PLATELETS hour: Chairs: D.J. Fitzgerald (Dublin, Ireland); G.F. Gensini (Florence, Italy) abstract bk. page ref.: 16.30 - 16.50 PLATELET CONTRIBUTION TO THE DEVELOPMENT OF ATHEROSCLEROSIS 171 D.J. Fitzgerald (Dublin, Ireland) 16.50 - 17.10 ENDOTHELIAL CELLS AND THE REGULATION OF THROMBOSIS 172 Z.M. Ruggeri (La Jolla, CA, USA) 17.10 - 17.30 DETERMINANTS OF PLATELET ACTIVATION ASSOCIATED WITH INSULIN 172 RESISTANCE G. Davì, F. Santilli, A. Falco (Chieti, Italy) 17.30 - 17.45 CIRCULATING MICROPARTICLES OF PLATELET ORIGIN ARE CARRIERS OF 173 PAF-ACETYLHYDROLASE J.V. Mitsios, M.P. Vini, D. Stengel, E. Ninio, A.D. Tselepis (Ioannina, Greece and Paris, France) 17.45 - 18.00 RELATIONSHIP BETWEEN PLATELET CD40 LIGAND EXPRESSION AND PLATELET 173 SUPEROXIDE ANION IN HYPERCHOLESTEROLEMIA. EFFECT OF ATORVASTATIN V. Sanguigni, P. Pignatelli, L. Lenti, S. Di Santo, R. Carnevale, R. Sorge, R. Lauro, F. Violi (Rome, Italy) 18.00 - 18.15 THE ROLE OF REACTIVE OXYGEN SPECIES AND 5-LIPOXYGENASE IN 173 PLATELET-INDUCED AIRWAY SMOOTH MUSCLE CELL PROLIFERATION A.-C. Svensson, T. Bengtsson, M. Grenegård, M. Söderström, E. Lindström (Linköping, Sweden) 18.15 - 18.30 OXIDATIVE STRESS AND PLATELET ACTIVATION IN SUBJECTS WITH MODERATE 173 T HYPERHOMOCYSTEINEMIA DUE TO MTHFR C677T POLYMORPHISM U A. Falco, S. Basili, A. Dragani, G. Rolandi, G. La Barba, C. Passeri, G. Ciabattoni, E C. Patrono, G. Davì (Chieti, Rome and Pescara, Italy) 18.30 End of the Session S D A 20.00 COCKTAIL - 20.30 GALA DINNER Y

67 16.30 - 18.25 TUESDAY, June 20 ROOM 6

Tu-W27 Workshop 27 CLINICAL TRIALS (2nd part) hour: Chairs: A.C. Keech (Sydney, NSW, Australia); M. Trovati (Turin, Italy) abstract bk. page ref.: 16.30 - 16.50 CLINICAL TRIAL DESIGN & MANAGEMENT: THE ROLE OF PPAR-ALPHA 174 AGONISTS IN PREVENTION OF CVD A.C. Keech, R.J. Simes, for the FIELD Study Investigators (Sydney, NSW, Australia) 16.50 - 17.10 LARGE-SCALE CLINICAL TRIALS: RELIABLE ANSWERS IN CARDIOVASCULAR 174 MEDICINE L.J. Bowman (Oxford, UK) 17.10 - 17.25 EFFICACY AND SAFETY OF CO-ADMINISTERED EZETIMIBE/SIMVASTATIN 174 (EZE/SIMVA) AND FENOFIBRATE (FENO) IN PATIENTS WITH MIXED HYPERLIPIDEMIA M. Farnier, E. Roth, B. Gil-Extremera, G.F. Mendez, I. Perevozskaya, C. Hamlin, G. Macdonell, M. Davies, D. Kush, Y. Mitchel (Dijon, France, Granada, Spain Veracruz, Mexico, Cincinnati, OH, and Rahway, NJ, USA) 17.25 - 17.40 COMPARATIVE LIPID EFFECTS OF COMBINATION THERAPY WITH A STATIN 174 AND EXTENDED-RELEASE NIACIN VERSUS STATIN PLUS EZETIMIBE VERSUS A STATIN ALONE J.M. McKenney, P.H. Jones, H.E. Bays, R.H. Knopp, M.L. Kashyap, G.E. Ruoff, E.J. Stanek, M.E. McGovern (Richmond, VA, Houston, TX, Louisville, KY, Seattle, WA, Long Beach, CA, Kalamazoo, MI, and Cranbury, NJ, USA) 17.40 - 17.55 ADIPONECTIN AND THE ANTI-INFLAMMATORY EFFECTS OF FENOFIBRATE IN 175 T PATIENTS WITH HYPERTRIGLYCERIDEMIA AND THE METABOLIC SYNDROME U R.S. Rosenson, A.L. Huskin, D.A. Wolff (Chicago, IL, USA) E 17.55 - 18.10 RELATIONSHIP BETWEEN TRIGLYCERIDE-ENRICHED HDL PARTICLES AND 175 INTOLERANCE TO STATIN THERAPY S M. Santure, D. Brisson, G. Tremblay, B. Lamarche, D. Gaudet (Québec, QC, Canada) D 18.10 - 18.25 COMBINATION THERAPY OF STATIN WITH FLAVONOIDS-RICH EXTRACT FROM 175 A CHOKEBERRY FRUITS ENHANCED REDUCTION IN CAD RISK MARKERS IN Y PATIENTS AFTER MI M. Naruszewicz, I. Laniewska, B. Milo, M. Dluzniewski (Szczecin and Warsaw, Poland) 18.25 End of the Session

20.00 COCKTAIL - 20.30 GALA DINNER

68 16.30 - 18.25 TUESDAY, June 20 ROOM 7

Tu-W28 Workshop 28 NUTRITIONAL APPROACHES: THE GLOBAL PICTURE hour: Chairs: J.M. Ordovas (Boston, MA, USA); E. Manzato (Padua, Italy) abstract bk. page ref.: 16.30 - 16.50 NUTRIGENOMICS AND CARDIOVASCULAR DISEASES 175 J.M. Ordovas, D. Corella (Boston, MA, USA and Valencia, Spain) 16.50 -17.10 LOW-CARBOHYDRATE OR LOW-FAT, HIGH-CARBOHYDRATE DIETS FOR 176 TREATMENT OF OBESITY: WHICH OPTION TO SELECT? A. Astrup (Frederiksberg, Denmark) 17.10 - 17.25 THE EFFECTS OF AN 8-YEAR LOW-FAT DIETARY PATTERN ON 176 CARDIOVASCULAR DISEASE (CVD) B.V. Howard, L. Van Horn, J. Hsia, J.E. Manson, M.L. Stefanick, S. Wassertheil-Smoller, S.A.A. Beresford, R.L. Prentice (Hyattsville, MD, Chicago, IL, Washington, DC, Chestnut Hill, MA, San Jose, CA, Bronx, NY and Seattle, WA, USA) 17.25 - 17.40 FACTOR ANALYSIS IDENTIFIES A MEDITERRANEAN-STYLE PATTERN OF DIETARY 177 INTAKE THAT IS PROTECTIVE AGAINST DIABETIC RETINOPATHY L. Brazionis, C. Itsiopoulos, K. Rowley, K. O'Dea (Clayton and Melbourne, NSW, Australia) 17.40 - 17.55 LACK OF ASSOCIATION OF PLASMA PHYTOSTEROLS WITH RISK OF CORONARY 177 HEART DISEASE IN THE CORA-STUDY E. Windler, B.C. Zyriax, F. Kuipers, J. Linseisen, H. Boeing (Groningen, The Netherlands, Hamburg, Heidelberg and Potsdam-Rehbrücke, Germany) T 17.55 - 18.10 REDUCTION IN POSTPRANDIAL GLYCEMIC AND INSULINEMIC RESPONSES AND 177 U OXIDATIVE DAMAGE BY ALMONDS A.R. Josse, C.W.C. Kendall, S. Salvatore, L.S.A. Augustin, F. Brighenti, P.R. Ellis, E D.J.A. Jenkins (Toronto, ON, Canada, Parma, Italy and London, UK) S 18.10 - 18.25 AN ISOFLAVONE METABOLITE TRANS-TETRAHYDRODAIDZEIN REDUCES 177 D ARTERIAL STIFFNESS AND ARTERIAL PRESSURES IN SUBJECTS WITH METABOLIC A SYNDROME P. Nestel, L. Zhang, A. Fujii (Melbourne, NSW, Australia and Tokyo, Japan) Y 18.25 End of the Session

20.00 COCKTAIL - 20.30 GALA DINNER

69 16.30 - 18.25 TUESDAY, June 20 ROOM 8

Tu-W29 Workshop 29 PHARMACOECONOMY hour: Chairs: A. McGuire (London, UK); G.B. Vigna (Ferrara, Italy) abstract bk. page ref.: 16.30 - 16.50 ECONOMIC BURDEN OF ATHEROSCLEROSIS AND ITS MANAGEMENT 178 L.G. Mantovani (Naples, Italy) 16.50 - 17.10 STATINS: A POTTED ECONOMIC HISTORY 178 A. McGuire (London, UK) 17.10 - 17.25 COST-UTILITY ANALYSIS: EZETIMIBE+STATIN VERSUS STATIN THERAPY UNDER 178 THE THIRD JOINT EUROPEAN SOCIETIES TASKFORCE GUIDELINES IN CORONARY HEART DISEASE N.M. Draeger, M.V. Holm, M.M. Schwenkglenks, T.D. Szucs (Basel, Switzerland) 17.25 - 17.40 COST-EFFECTIVENESS OF PROLONGED-RELEASE NICOTINIC ACID (NIASPAN® ER) 178 FOR STATIN-TREATED PATIENTS AT LDL-C GOAL BUT REMAINING AT RISK DUE TO LOW HDL-C C. Renaudin, D. Liens, W. Valentine, A.J. Palmer, W. Berger, S. Roze (Lyon, France, Binningen-Basel, Switzerland and Darmstadt, Germany) 17.40 - 17.55 TRIAL BASED ECONOMIC EVALUATION OF INTENSIVE ATORVASTATIN COMPARED 178 TO STANDARD SIMVASTATIN IN THE IDEAL TRIAL P. Lindgren, B. Jonsson, Ideal Steering Committee (Stockholm, Sweden ) 17.55 - 18.10 PATIENT KNOWLEDGE OF HIGH CHOLESTEROL AND CARDIOVASCULAR RISK: 179 FROM THE HEART STUDY L.R. Erhardt, F.D.R. Hobbs (Malmö, Sweden and Birmingham, UK) T 18.10 - 18.25 EFFECT OF DIFFERENTIAL TREATMENT ADHERENCE ON OUTCOME IN THE 179 U IDEAL TRIAL E I. Holme, M. Szarek, T. Pedersen (Oslo, Norway and New York, NY, USA) 18.25 End of the Session S D A 20.00 COCKTAIL - 20.30 GALA DINNER Y

70 POSTER AREA “B” TUESDAY, June 20 1-290

POSTER DISPLAY: for the duration of one day (Tuesday, June 20 from 8.30 am to 6.30 pm). Participants may view the posters displayed during this day.

POSTER DISCUSSION: one of the authors will be available at the poster site as follows: Tuesday, June 20: from 10.30 am to 11.00 am Tuesday, June 20: from 1.00 pm to 2.30 pm Tuesday, June 20: from 4.00 pm to 4.30 pm

Tu-P7 Poster Session 7 poster BASIC SCIENCE (1st part) abstract bk. board no.: page ref.:

1 CHRONIC CENTRAL OVEREXPRESSION OF LEPTIN ELEVATES BLOOD PRESSURE 185 DESPITE EXTREME HYPOLEPTINEMIA N. Tumer, M.K. Matheny, P.J. Scarpace (Gainesville, FL, USA) 2 ALTERED GENE EXPRESSION IN ABDOMINAL ADIPOSE TISSUE OF A NOVEL ANIMAL 185 MODEL FOR THE METABOLIC SYNDROME K. Tahira, T. Ueno, N. Fukuda, H. Takagi, M. Mitsumata, A. Tsunemi, K. Ikeda, J. Yamamoto, K. Matsumoto, Y. Yamori (Itabashi, Tokyo, Nishinomiya, Sakyo-ku and Kyoto, Japan) 3 SEX- AND SITE-SPECIFIC GENE EXPRESSION IN THE ADIPOSE TISSUE OF OB/OB MICE 185 S. Shiozaki, T. Chiba, K. Kokame, T. Miyata, M. Ai, E. Kaneko, M. Yoshida, K. Shimokado (Tokyo and Osaka, Japan) 4 A NEW HUMAN ADIPOCYTE CELL SYSTEM TO STUDY ENERGY METABOLISM 185 J. Prawitt, A. Niemeier, M. Kassem, U. Beisiegel, J. Heeren (Hamburg, Germany and T Odense, Denmark) U 5 RELATIONSHIP BETWEEN THROMBOSPONDINS AND DIFFERENTIATION OF ADIPOCYTES 186 S. Nomura, T. Shingu, A. Nakata, R. Kuwashima, Y. Umeda, K. Chayama (Hiroshima, Japan) E 6 ENDOPLASMIC RETICULUM STRESS DOWN-REGULATES THE ADIPOCYTE PRODUCTION 186 S OF THE ANTI-DIABETIC AND ANTI-ATHEROGENIC HORMONE ADIPONECTIN D R.L.C. Hoo, A. Xu, M.C.W. Lam, Y. Wang, B. Chen, R.L.C. Wong, J. Zhang, K.W. Chan, A K.S.L. Lam (Hong Kong, China) 7 INCREASED EXPRESSION OF CD36 IN 3T3-L1 CELLS, INDUCED BY OXIDIZED LDL, 186 Y INVOLVES NRF2 ACTIVATION M. D'Archivio, R. Varì, B. Scazzocchio, M. Sanchez, C. Giovannini, R. Masella (Rome, Italy) 8 APOLIPOPROTEIN E PROMOTES CELL PROLIFERATION AND INHIBITS MATURATION 186 OF HUMAN ADIPOCYTES J.F. Carmel, L. Bernier, J. Davignon, J.S. Cohn (Montreal, QC. Canada and Sydney, NSW, Australia) 9 INHIBITION OF CHOLESTEROL BIOSYNTHESIS PREVENTS ADIPOCYTE DIFFERENTIATION 186 R. Busto, J. Sánchez-Wandelmer, M.A. Lasunción (Madrid, Spain) 10 INVESTIGATION OF THE RECEPTOR AND POSTRECEPTOR SIGNALLING PATHWAYS THAT 187 UNDERLIE THE END0THELIAL ACTION OF THE FAT-DERIVED HORMONE ADIPONECTIN K.Y. Cheng, K.S.L. Lam, A. Xu (Hong Kong, China) 11 HEXYL-3,4-DEPHOSTATIN-SENSITIVE PERIOD IN THE EARLY PHASE OF INSULIN-INDUCED 187 ADIPOCYTE DIFFERENTIATION OF 3T3-L1 CELLS H. Uto, T. Chiba, K. Umezawa, T. Hosokawa, S. Shinozaki, M. Ai, K. Konodo, K. Shimokado (Bunkyo-ku, Tokyo, Kouhoku-ku and Yokohama, Japan) 12 HEAT SHOCK PROTEIN 70-2 PROTECTS ADIPOCYTES FROM APOPTOSIS 187 T. Ueno, N. Fukuda, K. Tahira, T. Matsumoto, R. Suzuki, A. Tsunemi, K. Matsumoto (Itabashi and Japan) 13 EFFECT OF ENDOGENOUS AND EXOGENOUS INSULIN ON PLASMA ADIPONECTIN LEVELS 187 R. Chin, M. Kawamura, E. Yano, Y. Yamazaki, S. Miyazaki, T. Teramoto, Y. Hirata (Tokyo, Japan) 14 APELIN AND HEART FUNCTION IN HEMODIALYZED PATIENS: ARE THEY RELATED? 188 J. Malyszko, J. Malyszko, P. Kozminski, M. Mysliwiec (Bialystok and Dzialdowo, Poland) 15 EFFECT OF ALDEHYDES, ARACHIDONIC ACID AND ROSIGLITAZONE ON ADIPOCYTE 188 DIFFERENTIATION A. Cabre, I. Lazaro, J. Girona, L. Masana (Reus, Spain)

71 16 ADIPOBIOLOGY OF ATHEROSCLEROSIS 188 G.N. Chaldakov, I.S. Stankulov, P. Atanassova, M. Fiore, P.I. Ghenev, A.B. Tonchev, L. Aloe (Varna, Plovdiv, Bulgaria and Rome, Italy) 17 GENETIC VARIABILITY IN BIOTRANSFORMATION AND ANTIOXIDANT ENZYMES 188 AND THEIR ROLE IN THE PROCESS OF AGING A. Horská, C. Mislanová, M. Baceková, Z. Hudecová, L. Wsólová, M. Dusinská (Bratislava, Slovak Republic) 18 INTESTINAL CHOLESTEROL ABSORPTION IS NOT A MAJOR DETERMINANT FOR THE 188 AGE-INDUCED INCREASE IN PLASMA CHOLESTEROL IN RATS C. Gälman, M. Matasconi, P. Parini, B. Angelin, M. Rudling (Stockholm, Sweden) 19 POLYMORPHISMS IN DNA REPAIR GENES AND THEIR IMPORTANCE IN PROCESSES 189 OF AGING Z. Dzupinkova, M. Dusinska, L. Wsolova (Bratislava, Slovak Republic) 20 PARAOXONASE (PON1) 192 AND 55 POLYMORPHISMS AND ITS EFFECTS ON 189 HIGH-DENSITY LIPOPROTEINS (HDL) ANTIOXIDANT ACTIVITY WITH AGEING M. Cherki, H. Berrougui, M. Isabelle, M. Cloutier, A. Khalil (Sherbrooke, QC, Canada) 21 THE INTERRELATION BETWEEN THE FUNCTIONAL STATE OF THE ENDOTHELIUM 189 AND THE INDICES OF INFLAMMATION IN IHD PATIENTS AGED OVER 60 V. Lishnevskaya, O. Korkushko, M. Kalmykov (Kiev, Ukraine) 22 LIPIDS IN ELDERLY PATIENTS WITH ISCHAEMIC HEART DISEASE 189 H.V. Tereshina, O.P. Pleteneva, N.Y.E. Osokina (Moscow, Russia) 23 LOW LEVEL LAZER IN THE THERAPY OF ATHEROSCLEROSIS IN ELDERLY 189 O.M. Karpenko, L.V. Rusak, S.I. Svinolupova, Y.E.A. Gavrilova (Moscow, Russia) 24 IMPACT OF AUTOIMMUNITY ON ATHEROSCLEROSIS PROGRESSION: 190 AUTOIMMUNE-SPECIFIC MECHANISMS OVERRIDE OXIDATIVE AND INFLAMMATORY PROCESSES E. Gautier, T. Huby, B. Ouzilleau, G. Gremy, J. Chapman, P. Lesnik (Paris, France) 25 COMPOUND 48/80 PROMOTES ATHEROSCLEROTIC PLAQUE AND INTRAPLAQUE 190 T ANGIOGENESIS IN APOLIPOPROTEIN E DEFICIENT MICE WITH CAROTID COLLAR U PLACEMENT E Y.L. Tang, Y.Z. Yang, S. Wang, B.H. Dong, W.Q. Sun, H.Y. Jin, Z.X. Xu, X. Ye, Y.H. Sun (Hengyang, China) S 26 BONE MARROW-DERIVED MONONUCLEAR CELLS ADMINISTRATION ABROGATES 190 D IRRADIATION-INDUCED IMPAIRMENT IN WOUND HEALING A R. Tamarat, T.G. Ebrahimian, C. Squiban, P. Voisin, J. Aigueperse, J.S. Silvestre, Y M. Benderitter (Paris, France) 27 CHARACTERIZATION AND ANTI-ANGIOGENIC ANALYSIS OF THREE DIFFERENT 190 RECOMBINANT HUMAN APOLIPOPROTEIN(A) KRINGLES EXPRESSED BY PICHIA PASTORIS L. Shen, W.W. Zeng, G. Wu, H. Xue, B.S. Chen (Beijing, China) 28 THERAPEUTIC ANGIOGENESIS USING NOVEL VASCULAR ENDOTHELIAL GROWTH 191 FACTOR-E / HUMAN PLACENTAL GROWTH FACTOR CHIMERA GENES N. Inoue, T. Kondo, Y. Numaguchi, T. Murohara, M. Shibuya (Nagoya and Tokyo, Japan) 29 NITROPRAVASTATIN, NCX 6550, STIMULATES THERAPEUTIC NEOVASCULARIZATION AND 191 IMPROVES CLINICAL RECOVERY IN LIMB ISCHEMIA IN STZ-INDUCED DIABETIC MICE C. Emanueli, A. Monopoli, M. Melloni, S. Gadau, I. Campesi, E. Ongini, P. Madeddu (Bristol, UK, Milan, Osilo and Alghero, Italy) 30 IDENTIFICATION OF MEMBRANE ADAPTOR MOLECULES FOR ATYPICAL GPI-ANCHORED 191 T-CADHERIN D. Ivanov, M. Philippova, P. Erne, T. Resink (Basel and Lucerne, Switzerland) 31 DIRECT EFFECT OF HMG-COA REDUCTASE INHIBITORS TO HUMAN ENDOTHELIAL 191 CELLS AND ON ANGIOGENESIS DEPENDS ON KINDS OF STATIN T. Shingu, M. Katsumoto, S. Nomura, A. Nakata, R. Kuwashima, K. Chayama (Hiroshima, Japan) 32 APPLICATION OF VASOHIBIN FOR PREVENTION OF ADVENTITIAL ANGIOGENESIS AND 191 ARTERIAL NEOINTIMAL FORMATION H. Yamashita, M. Abe, T. Shibuya, K. Watanabe, K. Shimizu, Y. Sato (Sendai, Miyagi, Japan) 33 REGULATION OF ANGIOGENESIS AND ANGIOGENIC FACTORS BY CARDIOVASCULAR 192 MEDICATIONS S. Miura, H. Nishikawa, A. Iwata, S. Imaizumi, Y. Matsuo, K. Saku (Fukuoka, Japan)

72 34 MICROPARTICLES DERIVED FROM BONE MARROW ISOLATED CELLS REGULATE 192 ANGIOGENESIS IN VITRO J. Grzybowska, L. Partyka, T. Petriczek, Z. Walter, A. Polus, R. Nizankowski, A. Dembinska-Kiec (Cracow and Warsaw, Poland) 35 THE EFFECT OF ASPIRIN ON SERUM VASCULAR ENDOTHELIAL GROWTH FACTOR AND 192 NITRIC OXIDE CONCENTRATIONS IN HIGH-CHOLESTEROL FED RABBITS M. Khazaei, J.I. Mobarake, M. Nematbakhsh, H. Ahmadi (Birjand, Teheran and Isfahan, Iran) 36 FATTY ACIDS AND BETA-CAROTENE IN PROGENITOR CELL DIFFERENTIATION 192 A.M. Dembinska-Kiec, A. Polus, B. Kiec-Wilk, T. Langmann, G. Schmitz (Cracow, Poland and Regensburg, Germany) 37 THE ANTI-ANGIOGENIC EFFECTS OF PLASMA LOW DENSITY LIPOPROTEINS 193 SUBFRACTIONS FROM PATIENTS WITH FAMILIAL HYPERCHOLESTROLEMIA M.H. Tai, H. Liang, S. Kuo, K. Chio, H. Lam, C. Hsu, H.J. Pownall, H. Chen, M. Huang, C.Y. Yang (Kaohsiung, Taiwan and Houston, TX, USA) 38 POSTER WITHDRAWN – 39 VASCULAR INFLAMMATION AND ATHEROSCLEROSIS DEVELOPMENT IN A MOUSE 193 MODEL OF ALZHEIMER’S DISEASE ON A APOE KO BACKGROUND G. Tibolla, G.D. Norata, P. Uboldi, E. Vegeto, A. Maggi, A.L. Catapano (Milan and Cinisello Balsamo, Italy) 40 THE HYPERLIPEMIC HAMSTER, A MODEL TO STUDY STATINS ANTI-ATHEROSCLEROTIC 193 EFFECTS C. Stancu, E. Constantinescu, G. Botez, A. Sima (Bucharest, Romania) 41 DEFICIENCY OF HERP, AN ER STRESS PROTEIN, SUPPRESSES ATHEROSCLEROSIS IN 193 APOE KNOCKOUT MICE S. Shinozaki, K. Hatori, K. Kokame, T. Miyata, K. Shimokado (Tokyo and Osaka, Japan) 42 NEUROPROTECTIVE EFFECT OF CALCIUM CHANNEL BLOCKER NIMODIPIN 193 N. Naumovic, D. Filipovic, K. Boskovic, V. Ivetic, O. Barak (Novi Sad, Serbia-Montenegro) 43 CHRONIC CIGARETTE MAINSTREAM SMOKE EXPOSURE INCREASES PLAQUE SIZE IN 194 THE BRANCHIOCEPHALIC ARTERY IN APOLIPOPROTEIN E-DEFICIENT MICE ON CHOW T AND MILK-F U S. Lebrun, W. Stinn, H. Weiler, P. Kuhl, K. von Holt, T. Wallerath, R. Schleef (Cologne, Germany) E 44 MOUSE MODEL OF DIABETIC ATHEROSCLEROSIS - CHARACTERIZATION AND 194 APPLICATIONS IN VASCULAR RESEARCH S S. Koota, P. Leppänen, I. Kholová, M. Laakso, S. Ylä-Herttuala (Kuopio, Finland) D 45 PSAMMOMYS OBESUS, ANIMAL MODEL OF ATHEROSCLEROSIS 194 A N. Hamlat, S. Neggazi, Y. Benazzoug, G. Kacimi, M. Ardjoun, M.C. Bourdillon, Y S. Aouichat-Bouguerra (Algiers, Algeria and Lyon, France) 46 IDENTIFICATION OF ATHEROSCLEROSIS SUSCEPTIBILITY GENES AT A QUANTITATIVE 194 TRAIT LOCUS (QTL) ON MOUSE CHROMOSOME 19 J. Ernst, R. Burkhardt, J.L. Breslow, J. Thiery, D. Teupser (Leipzig, Germany and New York, NY, USA) 47 ROLES OF THROMBOXANE A2 AND PROSTACYCLIN IN THE DEVELOPMENT OF 195 ATHEROSCLEROSIS IN APOE-DEFICIENT MICE T. Kobayashi, H. Oida, T. Yurugi-Kobayashi, H. Katagiri, M. Majima, M. Yokode, T. Kita, S. Narumiya (Kyoto, Fukui, Kawasaki and Kanagawa, Japan) 48 ANTIOXIDANT ENZYMES AND NITRIC OXIDE BIOAVAILABILITY IN A RABBIT MODEL OF 195 HYPERTENSION G. Yannarelli, C. Pesiney, F. Brites, N. Canel, L. Masnatta, L. Schreier, J.P. Werba, L. Cuniberti (Buenos Aires, Argentina and Milan, Italy) 49 EFFECTS OF NO-1886 ON INFLAMMATION-ASSOCIATED CYTOKINES IN 195 ATHEROSCLEROSIS ASSOCIATED DIABETES MELLITUS MINIATURE PIGS M.B. Cai, J.J. Li, W.D. Yin, D.F. Liao, Q.K. Li, Y. Liu, Z.B. Wang, C. Zhang, J.X. Xiao, H.J. Hou (Hunan, China) 50 OVEREXPRESSION OF SOLUBLE PECAM-1 (CD31) REGULATES THE T CELL COMPARTMENT 195 AND REDUCES ATHEROGENESIS IN APOLIPOPROTEIN E KNOCKOUT MICE E. Groyer, A. Nicoletti, J. Khallou-Laschet, A-T. Gaston, O. Thaunat, S.K. Kaveri, H. Stockinger, G. Caligiuri (Paris, France and Vienna, Austria) 51 TISSUE FACTOR AND PLATELET DERIVED GROWTH FACTOR EXPRESSION IN 196 CAROTID SMOOTH MUSCLE CELLS OF DIABETIC RAT WITH ENDOTHELIAL INJURY X. Zhang, J. Wang, L. Zhang, J. Shao, W. Hu (Jinan, China) 52 INVESTIGATION OF LATERAL PLATE MESODERM CONTRIBUTION TO THE SMC 196 POPULATION IN THE DESCENDING MOUSE AORTA P. Wasteson, B.R. Johansson, P. Lindahl (Gothenburg, Sweden)

73 53 KLF5 IS INVOLVED IN BOTH METABOLIC REGULATION AND ATHEROSCLEROTIC 196 LESION FORMATION Y. Oishi, I. Manabe, K. Tobe, T. Kadowaki, R. Nagai (Tokyo, Japan) 54 MODULATION OF LDL RECEPTOR AND APOLIPOPROTEIN B EXPRESSION BY 196 SELENIUM STATUS DURING HYPERCHOLESTEROLEMIA S. Dhingra, M.P. Bansal (Chandigarh, India) 55 THE STUDY OF THE EFFECT OF COPPER (CU) ON THE PLASMA CHANGES OF 196 CHOLESTEROL AND TRIGLYCERIDE P. Yaghmai, S.H. Orian, E. Azimi, E. Amini (Tehran, Iran) 56 ATHEROGENESIS IN FEMALE LDLR-/- MICE: S-NITROSO-N-ACETYLCYSTEINE 197 (SNAC) EFFECTS A.C.B.A. Wanschel, J.A.D. Garcia, L. Dos Santos, S.M. Shishido, V.M. Caceres, M.H. Krieger (Campinas, Brazil) 57 THE EFFECT OF MODERATE ALCOHOL CONSUMPTION IN A RAT MODEL OF 197 METABOLIC SYNDROME E. Jindrichova, M. Buresova, L. Kazdova, J. Kovar (Prague, Czech Republic) 58 PASSIVE IMMUNIZATION WITH ANTI-LDL(-) ANTIBODIES INHIBIT 197 ATHEROSCLEROSIS IN LDLR-/- MICE D.M. Grosso, A. Bonito, M.H. Krieger, D.S.P. Abdalla (São Paulo and Campinas, Brazil) 59 RECOMBINEERING OF A BACTERIAL ARTIFICIAL CHROMOSOME FOR GENERATION 197 OF TRANSGENIC MICE EXPRESSING MYC-TAGGED WILD TYPE OR MUTANT (D374Y) HUMAN PCSK9 X.M. Sun, E.R. Eden, S.N. Waddington, A.K. Soutar (London, UK) 60 PHYSIOLOGICAL INTAKES OF MYRISTIC AND ALPHA-LINOLENIC ACIDS IN SN-2 198 INCREASE LECITHIN CHOLESTEROL ACYLTRANSFERASE ACTIVITY AND MEMBRANE FLUIDITY H. Dabadie, N. Combe, C. Motta, E. Peuchant, F. Mendy (Pessac, Bordeaux, Rennes and Paris, France) T 61 HEME OXYGENASE-1 ALLEVIATES ALDOSTERONE-INDUCED VASCULAR INJURY 198 U THROUGH INHIBITION OF NAD(P)H OXIDASE/NFKB PATHWAY E T. Morita, E. Terada, B. Saji, G. Yoshino (Tokyo, Japan) 62 HEME OXYGENASE-1 DERIVED CARBON MONOXIDE INHIBITS ATHEROSCLEROSIS 198 S I. Pombo Gregoire, A.M. Correia, M.P. Soares (Oeiras, Portugal) D 63 VOLTAGE-SENSITIVE K+ CHANNELS MEDIATED THE ENDOTHELIUM-INDEPENDENT 198 A RELAXATION OF RAT RENAL ARTERY INDUCED BY RESVERATROL Y L.J. Gojkovic Bukarica, Z. Sajic, V. Kanjuh, H. Heinle (Belgrade, Serbia-Montenegro and Tübingen, Germany) 64 MECHANISM OF PATHOLOGICAL ANGIOGENESIS IN MOUSE NZO AND NZO/SJL 199 MODELS RESEMBLE THE HUMAN METABOLIC SYNDROME X A. Polus, U. Razny, L. Wator, J. Stachura, G. Dyduch, H.G. Joost, A. Dembinska-Kiec (Cracow, Poland and Potsdam-Rehbrucke, Germany) 65 EFFECT OF HYPERLEPTINEMIA ON ALCOHOL - INDUCED OXIDATIVE STRESS IN 199 SWISS MICE V. Balasubramaniyan, N. Nalini (Tamilnadu, India) 66 ANGIOGENESIS IN ENOS-/- MICE USED AS MODEL OF HUMAN METABOLIC 199 SYNDROME L. Wator, U. Razny, A. Polus, J. Stachura, G. Dyduch, A. Dembinska-Kiec (Cracow, Poland) 67 THE ROLE OF THROMBOMODULIN IN THE NEOINTIMA FORMATION IN MOUSE 199 CAROTID LIGATION MODEL Y.H. Li, S.L. Liu, G.Y. Shi, G.H. Tseng, P.Y. Liu, H.L. Wu (Tainan, Taiwan) 68 MECHANISMS OF PATHOLOGICAL ANGIOGENESIS IN THE RXRfÑ-/- MICE 200 METABOLIC SYNDROME X MODEL U. Razny, L. Wator, A. Polus, J. Stachura, G. Dyduch, Y.U. Wan (Cracow, Poland and Los Angeles, CA, USA) 69 HAEMODYNAMIC STRESSES AND WALL STRUCTURE CAN ACCOUNT FOR THE 200 PATTERN OF LIPID DEPOSITION AROUND AORTIC BRANCHES IN MICE A.R. Bond, P.D. Weinberg (London, UK) 70 ARSENIC EXPOSURE EXACERBATE ATHEROSCLEROSIS IN APOE-NULL MICE 200 S. Srivastava, S.E. D'Souza, J.C. States (Louisville, KY, USA)

74 71 IDENTIFICATION OF MACROPHAGE ARGINASE I AS A NEW CANDIDATE GENE OF 200 ATHEROSCLEROSIS RESISTANCE R. Burkhardt, D. Teupser, I. Haffner, J. Wilde, W. Wilfert, J. Thiery (Leipzig, Germany) 72 ATHEROSCLEROSIS BEFORE AND AFTER TRANSFORMATION OF FATTY STREAKS 200 INTO PLAQUES - IMPLICATIONS FOR DISEASE EXPANSION AND GENE EXPRESSION A. Kovacs, J. Skogsberg, R. Nilsson, M. Köhler, J. Lundström, I. Kurtsdotter, B. Brinne, A. Hamsten, J. Tegnér, J. Björkegren (Stockholm and Linköping, Sweden) 73 FUNCTIONAL AND STRUCTURAL CARDIAC RESPONSES TO SPIRONOLACTONE IN 201 UREMIC RATS L. Michea, S. Kunstmann, A. Urzua, A. Villagran, P. Venegas, E. Marusic (Santiago, Chile) 74 HYPERCHOLESTEROLEMIA AND ATORVASTATIN TREATMENT AFFECT ENDOTHELIAL 201 EXPRESSION OF ENDOGLIN IN MICE P. Nachtigal, N. Pospisilova, G. Jamborova, K. Pospechova, D. Solichova, C. Andrys, P. Zdansky, V. Semecky (Hradec Kralove, Czech Republic) 75 CHRONIC GUANYLYL CYCLASE ACTIVATION REDUCES PLATELET ACTIVATION IN 201 DIABETIC RATS U. Flierl, J. Bauersachs, A. Schäfer (Würzburg, Germany) 76 EFFECT OF GENOTYPE AND DIET ON CAROTID LESIONS INDUCED BY PERIVASCULAR 201 COLLAR PLACEMENT IN APOE-/- AND WILD-TYPE MICE F. Silva, M. Uzzo, I. Eberini, A. Corsini, R. Baetta (Milan, Italy) 77 ENDURANCE TRAINING REDUCES DISEASE RISK FACTORS IN RATS ARTIFICIALLY 202 SELECTED FOR LOW AEROBIC CAPACITY P.M. Haram, S.J. Lee, Q.Y. Al-Share, M.O. Bendheim, S. Pierre, O.J. Kemi, H. Waldum, I. Bakke, M.F. Mcinerey, L.G. Koch (Trondheim, Norway, Glasgow, UK, Toledo, OH and Ann Arbor, MI, USA) 78 EXPERIMENTAL ATHEROSCLEROSIS AND THE EFFECTS OF HYPERBARIC OXYGEN 202 TREATMENT T. Jovanovic, P. Brkic, A. Mitrovic, D. Popovic (Belgrade, Serbia-Montenegro) 79 ADVENTITIAL ACCUMULATION OF INFLAMMATORY CELLS INDUCES THE FORMATION 202 T AND EXTENDING OF ATHEROSCLEROTIC LESIONS IN APOLIPOPROTEIN E GENE U KNOCKOUT MICE E J. Wang, R. Ma, F. Xu, L. Li, R. Chen, W. Hu (Jinan, Shandong, China) 80 POSTER WITHDRAWN – S 81 DIETARY CHOLESTEROL AND DIFFERENTIAL MONOCYTE CHEMOATTRACTANT 202 D PROTEIN-1 GENE EXPRESSION IN AORTA AND LIVER OF APO E-DEFICIENT MICE A M. Tous, N. Ferre, A. Rull, J. Marsillach, B. Coll, C. Alonso-Villaverde, J. Camps, Y J. Joven (Reus, Spain) 82 STUDY OF BIOCHEMICAL PARAMETERS OF CD36 PROTEIN AND EFFECT OF RNA 203 INTERFERENCE ON ITS FUNCTION J. Zidkova, K. Kontrova, J. Sajdok, J. Kas, K. Mikulik, J. Peknicova, V. Zidek, M. Pravenec (Prague, Czech Republic) 83 THE INFLUENCE OF A PROSTAGLANDIN ANALOGUE ON EXPERIMENTAL INDUCED 203 HEPATOPATHY IN RATS C. Filip, E. Albu, N. Gheorghita, M. Nechifor (Iasi, Romania) 84 JE mRNA EXPRESSION AND MONOCYTE CHEMOATTRACTANT PROTEIN-1 EXPRESSION 203 IN THE ADVENTITIAL FIBROBLASTS OF AORTIC ROOT IN APOLIPOPROTEIN GENE KNOCKOUT MICE BEFORE THE INTIMAL LESION FORMATION F. Xu, J. Ji, L. Li, R. Chen, W. Hu (Jinan, Shandong, China) 85 5-LIPOXYGENASE ACTIVITY IS INVOLVED IN PLATELET-INDUCED FIBROBLAST 203 PROLIFERATION A.-C. Svensson, C. Berg, H. Herbertsson, M. Söderström, S. Hammarström, E. Lindström, T. Bengtsson (Linköping, Sweden) 86 ELEVATION OF SERUM TROPONIN I AND CK.MB AFTER PERCUTANEOUS TRANSLUMINAL 203 CORONARY ANGIOPLASTY M. Rohbaninoubar, N. Rashtchizadeh, A. Ghorbanihaghjo (Tabriz, Iran) 87 PARENTAL EARLINESS OF CHD AND PARENTAL HISTORY OF SMOKING AS 204 DETERMINANTS OF CAROTID IMT IN THE PROGENY J.P. Werba, M. Amato, E.C. Oldani, A.L. Ravani, P.G. Massironi, F. Veglia, E. Tremoli, D. Baldassarre (Milan, Italy) 88 FERRITIN/FOLATE INDEX AS AN EARLY PREDICTOR OF ATHEROSCLEROSIS IN 204 PATIENTS WITH PRE-DIABETES D. Jurisic-Erzen, R. Jerkovic (Rijeka, Croatia)

75 89 PLASMA CONCENTRATION OF BRAIN NATRIURETIC PEPTIDE AS INDICATOR OF 204 ATHEROGENESIS AND CARDIAC EVENTS IN PATIENTS ON HEMODIALYSIS B.J. Jeren, L.M. Majer, J.C. Crnjakovic, J.G. Gudel, K.J. Juric, Z.R. Romic (Dubrava, Croatia) 90 EFFECT OF DOBUTAMINE STRESS ECHOCARDIOGRAM ON MYOCARDIAL 204 PERFORMANCE INDEX IN CORONARY ARTERY DISEASE AND IN SYNDROME X I. Moyssakis, M. Daskalaki, D. Papadopoulos, E. Gialafos, A. Zilidis, V. Votteas (Athens, Greece) 91 THE ASSESSMENT OF MINOR MYOCARDIAL DAMAGE IN THE CRITICALLY ILL PATIENTS 205 M. Cubrilo-Turek, Z. Reiner, Z. Durakovic, S. Turek (Zagreb, Croatia) 92 CYSTATIN C PREDICTS THE RADIOCONTRAST NEPHROPATHY AFTER THE 205 CORONOGRAPHY M. Conte, S. Brugaletta, G. Di Giannuario, L.M. Biasucci, G. Liuzzi, F. Crea (Rome, Italy) 93 INVOLVEMENT OF PRO- OR ANTI-ATHEROSCLEROTIC PROTEINS IN EARLY STAGES 205 OF ATHEROGENESIS F. Bonomini, R. Coleman, T. Hayek, M. Aviram, S. Keidar, R. Bianchi, R. Rezzani (Brescia, Italy and Haifa, Israel) 94 THE EFFECT OF MATERNAL HYPERCHOLESTEROLEMIA ON FETAL PLASMA LIPID 205 LEVELS AND VASCULAR DIFFERENTIATION F.E. Alkemade, M.C. DeRuiter, K. Willems van Dijk, J.C. VanMunsteren, L.M. Havekes, A.C. Gittenberger-de Groot (Leiden, The Netherlands) 95 GLYCOSPHINGOLIPIDS AS A EARLY MARKERS OF CARDIOVASCULAR DISEASES 206 IN DIABETES MELLITUS G.S. Akramova (Tashkent, Uzbekistan) 96 SOLUBLE P-SELECTIN LEVELS IN SUBJECTS WITH PREDIABETES 206 T. Dogru, I. Tasci, A. Sonmez, H. Genc, A. Olgun, M. Gok, E. Bozoglu, S. Kilic, A.U. Ural, F. Avcu (Ankara, Turkey) 97 ADIPONECTIN DECREASES THE EXPRESSION OF THE PROINFLAMMATORY 206 MEDIATOR CD40L IN VASCULAR CELLS T C. Natal, I. Colina, J. Díez, N. Varo (Navarra, Spain) U 98 THE MECHANISM OF RELAXATION IN HUMAN INTERNAL MAMMARY ARTERY 206 E INDUCED BY RESVERATROL A. Novakovic, L.J. Gojkovic Bukarica, M. Peric, D. Nezic, V. Kanjuh S (Belgrade, Serbia-Montenegro) D 99 POSTER WITHDRAWN – A 100 EFFECTS OF GROWTH HORMONE AND INSULIN-LIKE GROWTH FACTOR-1 ON 206 Y CARDIAC HYPERTROPHY OF HYPERTENSIVE PATIENTS M. Vatrano, F. Andreozzi, A. Scozzafava, F. Borrello, R.D. Grembiale, A. Sciacqua, G. Sesti, F. Perticone (Catanzaro, Italy) 101 GENE EXPRESSION PROFILE AND AORTIC DISTENSIBILITY IN VOLUNTARILY 207 EXERCISED SPONTANEOUSLY HYPERTENSIVE RATS, POTENTIAL ROLE OF HEAT SHOCK PROTEINS U. Hagg, M.E. Johansson, J. Gronros, A.S. Naylor, I.H. Jonsdottir, G. Bergstrom, P.A. Svensson, L.M. Gan (Göteborg, Sweden) 102 mRNA EXPRESSION OF GENES INVOLVED IN ATHEROSCLEROTIC DISEASE 207 B. Giusti, L. Rossi, I. Lapini, M.L. Lavitrano, I. Sestini, M. Lenti, G. Biasi, C. Pratesi, R. Abbate, G.F. Gensini (Florence and Milan, Italy) 103 CIRCULATING STROMAL STEM/PROGENITOR CELLS AND CORONARY STENOSIS 207 E. Soboleva, Z. Gabbasov, O. Saburova, A. Agapov, R. Akchurin, Y.U. Romanov, V. Smirnov, E. Chazov (Moscow, Russia) 104 PRECLINICAL CARDIOVASCULAR ABNORMALITIES AND THROMBOTIC RISK IN 207 PATIENTS WITH PRIMARY GLOMERULONEPHRITIS WITH MILD OR NO IMPAIRMENT OF RENAL FUNCTION V. Palmieri, P. Esposito, S. Martino, C. Russo, P. Migliaresi, S. Pezzullo, P. Marotta, G. Di Minno, M.M. Balletta, A. Celentano (Naples, Italy) 105 SELECTED MARKERS OF INFLAMMATION, PAST CHLAMYDIA PNEUMONIAE INFECTION 208 IN PATIENTS WITH STABLE ANGINA PECTORIS, WITHOUT TRADITIONAL RISK FACTORS D. Drobniak-Heldak, W. Kolasinska-Kloch, R. Rajtar, M. Kloch, B. Kiec-Wilk, A. Zdzienicka, A. Dembinska-Kiec (Cracow, Poland) 106 CELLULAR ADHESION MOLECULES IN HEALTHY SUBJECTS: SHORT TIME VARIATIONS 208 AND RELATION TO FLOW MEDIATED DILATION O. Eschen, J.H. Christensen, O. Frøbert, E.B. Schmidt (Aalborg, Denmark)

76 107 IDENTIFYING UNIQUE PROTEIN KINASE B PATHWAYS USING PROTEOME ACTIVITY 208 ANALYSIS AND TRANSCRIPTOME MINING OF SMC WITH DISTINCT PHENOTYPES N. Emmett, A. Davis, S. Harris-Hooker (Atlanta, GA, USA) 108 THE SYSTOLIC AND DIASTOLIC FUNCTION OF THE LEFT VENTRICLE IN THE 208 PATIENTS WTH DIABETES MELLITUS OR METABOLIC SYNDROME M. Dluzniewski, A. Mamcarz, M. Janiszewski, A. Cudnoch-Jedrzejewska, W. Braksator (Warsaw, Poland) 109 COMPUTER IMAGE SIMULATION AND MATHEMATIC MODELING OF THE VERY 208 EARLY STAGE OF ATHEROSCLEROSIS IN HUMAN K.A. Lusta, A.N. Orekhov (Moscow, Russia) 110 SERUM ATHEROGENICITY PREDICTS THE PROGRESSION OF ATHEROSCLEROSIS 209 A.N. Orekhov, I.A. Sobenin (Moscow, Russia) 111 ENDOTHELIAL DYSFUNCTION AND HS-CRP LEVEL ARE EARLIER MARKERS OF 209 ATHEROSCLEROSIS IN PATIENTS WITH IMPAIRED GLUCOSE TOLERANCE AND DIABETES MELLITUS TYPE N.A. Galitsina, L.A. Chugunova, M.V. Shestakova, O.Y. Sukhareva (Moscow, Russia) 112 ADVANCED OXIDATION PROTEIN PRODUCTS (AOPP) AND HIGH-SENSITIVE C-REACTIVE 209 PROTEIN (HS-CRP) IN AN “ATHEROMA-FREE MODEL”: DOWN'S SYNDROME G. Goi, C. Baquero-Herrera, F. Licastro, A.E. Malavazos, G. Dogliotti, M.M. Corsi (Milan and Bologna, Italy) 113 THE UTILITY OF ALIZARIN RED S STAINING IN DETECTION OF PERIPHERAL 209 VASCULAR CALCIFICATION IN COMPARISON WITH H&E STAINING M. Afshar, N. Taibi, M.J. Golalipoor (Birjand, Mashhad and Gorgan, Iran) 114 THE ROLE OF ERYTHROCYTES STRUCTURAL AND FUNCTIONAL PARAMETERS IN 210 ISCHEMIC HEART DISEASE I. Khakhutaishvili, M. Jangavadze (Tbilisi, Georgia) 115 D-GLUCOSE ENHANCES FETUIN-A EXPRESSION IN HEPATOCYTES 210 Y. Ikeda, T. Suehiro, H. Takata, S. Inada, F. Osaki, M. Inoue, K. Arii, Y. Kumon, K. Hashimoto (Nankoku, Japan) T 116 GENOMIC SCREENING OF UNSTABLE PLAQUES: VITAMIN D RECEPTOR AS A NEW 210 U TARGET FOR ATHEROSCLEROSIS E R.A. McDonald, N. El-Shanti, D. Mallinson, H.J. Mckinnon, C.J. Long, C.L. Jackson (Bristol and Newhouse, UK) S 117 AN ENDOTHELIAL CELL RETENTION STUDY ON TISSUE ENGINEERED VASCULAR 210 D GRAFTS A G.X. Wang, D.H. Wei, L.S. Liu, C.J. Tang, Y.Z. Yang, Q.S. Yu (Chongqing, Hengyang, Y China and Columbia, MO, USA) 118 PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIAC AUTONOMIC 210 NEUROPATHY HAVE IMPAIRED ELASTIC PROPERTIES OF ASCENDING AORTA I. Moyssakis, N. Tentolouris, M. Daskalaki, E. Gialafos, I. Paizis, S. Vichos, V. Votteas (Athens, Greece) 119 POTASSIUM CHANNEL OPENER PINACIDIL RELAXES THE ISOLATED HUMAN RADIAL 211 ARTERY IN ENDOTHELIUM-DEPENDENT AND ENDOTHELIUM-INDEPENDENT MANNER N. Stojnic, L.J. Gojkovic-Bukarica, M. Peric, J. Markovic-Lipkovski, B. Djukanovic, H. Heinle, V. Kanjuh (Belgrade, Serbia-Montenegro and Tubingen, Germany) 120 DIHYDROTESTOSTERONE DECREASES TUMOR NECROSIS FACTOR A AND 211 LIPOPOLYSACCHARIDE INDUCED INFLAMMATORY RESPONSE IN HUMAN ENDOTHELIAL CELLS G.D. Norata, G. Tibolla, P.M. Seccomandi, A. Poletti, A.L. Catapano (Milan and Cinisello Balsamo, Italy) 121 SOLUBLE THROMBOMODULIN (STM) - A MOLECULAR MARKER OF ENDOTHELIAL 211 CELL INJURY IN CHILDREN AND ADOLESCENTS WITH TYPE 1 DIABETES K. Wojtkielewicz, M. Urban, M. Kowalewski, J. Peczynska, B. Glowinska (Bialystok, Poland) 122 RELATIONSHIP BETWEEN BRACHIAL ARTERY FLOW-MEDIATED DILATION AND 211 CARDIOVASCULAR RISK FACTORS O. Nemchyna, M. Lutay, O. Tsizh, V. Slobodskiy, I. Golikova (Kiev, Ukraine) 123 DISTINCT ROLES FOR PAR1 AND 2-MEDIATED VASOMOTOR MODULATION IN HUMAN 212 ARTERIAL AND VENOUS CONDUITS USED IN CORONARY ARTERY BYPASS SURGERY R. Ballerio, M. Brambilla, D. Colnago, A. Parolari, M. Agrifoglio, F. Alamanni, M. Camera, E. Tremoli, L. Mussoni (Milan, Italy)

77 124 HIGH GLUCOSE INDUCES TRANSDIFFERENTIATION OF ENDOTHELIAL CELLS INTO 212 SMOOTH MUSCLE CELLS Y. Liu, X.H. Zu, H.G. Li, Q.K. Li, M.B. Cai, Y.C. Lv, Z.Q. Wang, Z. Wang, W.D. Yin, Z.B. Wang (Hengyang, China) 125 ENDOTHELIAL DYSFUNCTION IN DIABETIC RETINOPATHY 212 A. Lipinska, M. Puchta, K. Jankowski, D. Korczak, Z. Lewandowski, D. Liszewska-Pfejfer (Warsaw, Poland) 126 IL-6 CORRELATES WITH ENDOTHELIAL DYSFUNCTION IN YOUNG 212 POST-MYOCARDIAL INFARCTION PATIENTS B. Erzen, M. Sabovic, M. Sebestjen, P. Poredos, I. Keber (Ljubljana, Slovenia) 127 REACTIVE OXYGEN SPECIES SIGNAL FOR CYCLOOXYGENASE-2 INDUCTION IN 212 HUMAN ENDOTHELIAL CELLS: ROLE IN THE REPAIR OF WOUND S. Eligini, I. Arenaz, S.S. Barbieri, M.L. Faleri, E. Tremoli, S. Colli (Milan, Italy) 128 PLASMA TRIGLYCERIDES AND APOLIPOPROTEIN B LEVELS ARE NEGATIVELY 213 CORRELATED TO FLOW MEDIATED VASODILATION R. Bülow, I.V. Aardestrup, J.G. Rasmussen, C. Dethlefsen, O. Frøbert, L.J. Bjerregaard, E.B. Schmidt (Aalborg, Denmark) 129 PROFILE OF COX-2 AND PGI2 IN HUMAN DIABETIC VERSUS HIGH GLUCOSE 213 TREATED ENDOTHELIAL CELLS C. Bolego, C. Buccellati, T. Radaelli, I. Cetin, G.C. Folco, A. Sala (Milan, Italy) 130 PULSE PRESSURE IS A PREDICTOR OF ENDOTHELIAL FUNCTION ASSESSED BY 213 BRACHIAL ARTERY VASOREACTIVITY TESTING IN HEALTHY VOLUNTEERS M. Shechter, R. Beigel, D. Dvir, Y. Arbel, D. Freimark, V. Usmanov, S. Gilman, Y. Beigel, M.S. Feinberg (Tel-Hashomer and Holon, Israel) 131 TOBACCO SMOKE ENHANCES INTERLEUKIN-1BETA-INDUCED CYCLOOXYGENASE-2 213 EXPRESSION BY AKT/GSK-3BETA/BETA-CATENIN PATHWAYS IN VITRO AND IN VIVO S.S. Barbieri, B.B. Weksler (New York, NY, USA) 132 THE IMPAIRMENT OF FLOW-MEDIATED DILATATION REFLECTS THE PROGRESSION OF 214 T ATHEROSCLEROSIS IN PATIENTS WITH SINGLE VESSEL CORONARY ARTERY DISEASE U J. Badariene, L. Ryliskyte, Z. Petrulioniene, V. Dzenkeviciute, A. Laucevicius E (Vilnius, Lithuania) 133 ENDOTHELIAL FUNCTION AND INSULIN SENSITIVITY IN YOUNG NON-OBESE MALE 214 S SMOKERS AFTER ACUTE NICOTINE TEST D G.E. Roytberg, A. Miroslawa, T.I. Ushakova (Moscow, Russia) A 134 THE THROMBIN RECEPTOR THROMBOMODULIN INDUCES ENDOTHELIAL NITRIC 214 Y OXIDE SYNTHESIS THROUGH PHOSPHOLIPASE C GAMMA E. Millanvoye-Van Brussel, M. David-Dufilho, F. Rendu (Paris, France) 135 THE BIO-COMPLEX RIV REDUCES CELLULAR ADHESION MOLECULE mRNA 214 EXPRESSION BY ATTENUATION OF P50 AND P65 NUCLEAR TRANSLOCATION IN CYTOKINE-TREATED HUVEC M. Landsberger, C. Rönnau, B. Wolff, H. Liebermann, F. Helbig, S.B. Felix, R. Ewert (Greifswald, Germany) 136 EPICARDIAL FAT THICKNESS CORRELATES WITH ENDOTHELIAL FUNCTION IN 215 METABOLIC SYNDROME PATIENTS H. Aydin, A. Toprak, O. Deyneli, D. Yazici, O. Tarcin, S. Sancak, D. Yavuz, S. Akalin (Istanbul, Turkey) 137 PROTECTIVE EFFECTS OF THE EFFECTIVE PARTS OF ZINGIBER OFFICINAL ON ECV-304 215 CELLS OXIDATIVE STRESS INJURY INDUCED BY HYDROGEN PEROXIDE IN VITRO Y. Song, H. Ding (Jinan, Shandong, China) 138 ANGIOTENSIN II DECREASES THE EXPRESSION OF SCAVENGER RECEPTOR CLASS 215 BI IN VASCULAR ENDOTHELIAL CELLS H. Imachi, K. Murao, X. Yu, W.M. Cao, J. Li, A.R. Abdel-Muneem, T. Ishida (Kagawa, Japan) 139 THE EFFECTS OF LONG TERM CARBON MONOXIDE EXPOSURE ON CARDIOVASCULAR 215 FUNCTION IN RATS A. Bye, S. Sørhaug, T. Stølen, A. Tjønna, M. Høydal, Ø. Ellingsen, S. Steinshamn, O. Nilsen, H. Waldum, U. Wisløff (Trondheim, Norway) 140 PAULLINIA PINNATA EXTRACTS RICH IN POLYPHENOL PROMOTE VASCULAR 215 RELAXATION VIA ENDOTHELIUM-DEPENDENT MECHANISMS A. Zamble, M. Carpentier, A. Kandoussi, S. Sahpaz, O. Petrault, J.C. Fruchart, R. Bordet, P. Duriez, F. Bailleul, F. Martin-Nizard (Lille, France)

78 141 INDUCTION OF ENDOTHELIAL DYSFUNCTION BY HOMOCYSTEINE IS MEDIATED BY A 216 REDOX-SENSITIVE MAP KINASE SIGNALING R. Foncea, F. Reyes, L. Rubio, R. Lagunas, V. Serrano, A. Maiz, R. Ebensperger (Santiago, Chile) 142 EXPRESSION KINETICS OF NOX1 AND NOX4 REGULATED BY PROTEIN KINASE C IN 216 HUMAN ENDOTHELIAL CELLS H. Xu, I. Brausch, M. Hortmann, U. Forstermann, H. Li (Mainz, Germany) 143 MACRO- AND MICROVASCULAR ENDOTHELIAL DYSFUNCTION DURING ACUTE 216 HYPERHOMOCYSTEINEMIA CAN BE COMPENSATED BY THIOL-ANTIOXIDANTS IN AGED GARLIC EXTRACT N. Weiss, T. Abahji, N. Ide, C. Keller, U. Hoffmanm (Munich, Germany) 144 PRO-INFLAMMATORY EFFECTS OF ERYTHROCYTES FROM UREMIC PATIENTS ON 216 CULTURED HUMAN ENDOTHELIAL CELLS: INSIGHTS INTO THE SIGNALING PATHWAYS N. Di Pietro, V. Sirolli, A. Giardinelli, S. Di Silvestre, L. Amoroso, P. Di Tomo, F. Capani, A. Consoli, M. Bonomini, A. Pandolfi (Chieti, Italy) 145 CORONARY ARTERY ECTASIA AND CORONARY ENDOTHELIAL DYSFUNCTION 217 S.W. Rha, S.Y. Suh, J.W. Kim, C.G. Park, H.S. Seo, D.J. Oh (Seoul, South Korea) 146 EVIDENCE FOR A FUNCTIONAL ROLE FOR ANGIOTENSIN (1-7), ANGIOTENSIN IV 217 AND THE ANGIOTENSIN II TYPE 2 RECEPTOR IN HUMAN BLOOD VESSELS A. Zulli, R. Widdop, B. Buxton, L. Burrell, D. Hare (Heidelberg and Clayton, VIC, Australia) 147 RALOXIFEN ANALOG LY117018 INHIBITS ENDOTHELIAL APOPTOSIS BY 217 ACTIVATING ERK SIGNALING J. Yu, K. Kozaki, M. Eto, M. Akishita, Y. Ouchi (Tokyo, Japan) 148 ROSUVASTATIN STIMULATES ENDOTHELIAL NITRIC OXIDE SYNTHASE AND INHIBITS 217 APOPTOSIS IN HUMAN ENDOTHELIAL CELLS T. Bachetti, L. Agnoletti, G. Francolini, D. Bastianon, R. Ferrari (Gussago and Ferrara, Italy) 149 ROSUVASTATIN: ITS EFFECTS ON HUMAN ENDOTHELIAL CELLS EXPOSED TO SERA 218 FROM PATIENTS WITH CARDIOVASCULAR DISEASES L. Agnoletti, T. Bachetti, D. Bastianon, G. Francolini, R. Ferrari (Gussago and Ferrara, Italy) T 150 IMPACT OF VITAMIN D THERAPY ON ARTERIAL AND CARDIAC DISEASE IN YOUNG 218 U ADULTS WITH RENAL DISEASE E S. Briese, S. Wiesner, J. Will, A. Lembcke, B. Opgen-Rhein, R. Nissel, K. Wernecke, J. Andreae, D. Haffner, U. Querfeld (Berlin, Germany) S 151 THE ACUTE EFFECT OF HEMODIALYSIS ON ENDOTHELIAL FUNCTIONS IN PATIENTS 218 D WITH CHRONIC RENAL FAILURE A A. Celik, M. Melek, S. Yuksel, A. Avsar, C. Kilit, E. Onrat (Afyonkarahiar, Turkey) Y 152 PHARMACOLOGICAL MODULATION OF SHEAR STRESS-DEPENDENT CONNECTIVE 218 TISSUE GROWTH FACTOR EXPRESSION IN ENDOTHELIAL CELLS: POSSIBLE ROLE IN ATHEROGENESIS I. Cicha, S. Muehlich, A. Yilmaz, W.G. Daniel, M. Goppelt-Struebe, C.D. Garlichs (Erlangen, Germany) 153 IMPROVEMENT OF VASCULAR DYSFUNCTION IN DIABETES BY CHRONIC 218 GUANYLYL CYCLASE ACTIVATION C. Vogt, D. Fraccarollo, M. Leutke, J. Bauersachs, A. Schäfer (Würzburg, Germany) 154 LAMINAR FLOW ATTENUATES CYTOKINE-INDUCED STAT ACTIVATION IN 219 ENDOTHELIAL CELLS L. Wang, Y.-C. Tsai (Taipei, Taiwan) 155 EFFECTS OF THE ANTIPHOSPHOLIPID ANTIBODIES ON THE ENDOTHELIAL 219 VASCULAR REACTIVITY C. Belizna, V. Richard, A. Lartigue, D. Gilbert, F. Tron, H. Levesque, C. Thuillez (Rouen, France) 156 REGULATION OF CONNEXIN 37 BY OXIDIZED PHOSPHOLIPIDS IN ATHEROSCLEROSIS 219 C.E. Culler, P.S. Gargalovic, T.G. Kirchgessner, A.J. Lusis (Los Angeles, CA and Princeton, NJ, USA) 157 THE NITROPRAVASTATIN DERIVATIVE, NCX 6550, IMPROVES ENDOTHELIAL 219 DYSFUNCTION IN SPONTANEOUSLY HYPERTENSIVE RATS C. Presotto, D. Miglietta, R. Olivieri, A. Monopoli (Bresso, Italy) 158 IN VITRO ARTERIAL RESPONSE TO PLAQUE-PRONE HEMODYNAMICS 220 V. Gambillara, C. Chambaz, G. Montorzi, S. Roy, N. Stergiopulos, P. Silacci (Lausanne, Switzerland) 159 ENDOTHELIAL CELL – A KEY PLAYER IN ALL STAGES OF ATHEROSCLEROSIS 220 M. Simionescu (Bucharest, Romania)

79 160 FLOW MEDIATED DILATATION CORRELATES WITH LEFT VENTRICLE DIASTOLIC 220 DYSFUNCTION IN HYPERTENSIVE AND HEALTHY SUBJECTS. PRELIMINARY STUDY A. Szuba, R. Poreba, A. Pyszel, P. Gac, A. Derkacz, M. Protasiewicz, R. Andrzejak (Wroclaw, Poland) 161 INFLUENCE OF ENDOTHELIAL CELLS ON VASCULAR SMOOTH MUSCLE CELLS 220 PHENOTYPE AFTER IRRADIATION. IMPLICATION IN RADIATION-INDUCED VASCULAR DAMAGES F. Milliat, A. Francois, M. Isoir, E. Deutsch, R. Tamarat, G. Tarlet, A. Atfi, J. Bourhis, J.C. Sabourin, M. Benderitter (Fontenay Aux Roses, Villejuif and Paris, France) 162 DEXAMETHASONE ALLEVIATES THROMBIN-INDUCED ENDOTHELIAL INFLAMMATION 220 THROUGH AKT/NO PATHWAY M. Ohno, N. Yamamoto, E. Terada, T. Morita, G. Yoshino (Tokyo, Japan) 163 SERUM TESTOSTERONE AND BRACHIAL ENDOTHELIAL FUNCTION IN AGING MEN 221 J.I. Mäkinen, A. Perheentupa, K. Irjala, P. Pöllänen, J. Mäkinen, I. Huhtaniemi, O.T. Raitakari (Turku, Finland and London, UK) 164 DIABETIC NEPHROPATHY UPREGULATES ENDOTHELIAL VCAM-1 EXPRESSION: 221 POTENTIAL IMPLICATIONS FOR THE HIGH INCIDENCE OF ATHEROSCLEROSIS K.C-Y. McGrath, T. Wu, A.K. Heather (Sydney, NSW, Australia) 165 FAT DISTRIBUTION AND ENDOTHELIAL FUNCTION IN NORMAL WEIGHT PATIENTS 221 S. Marchesi, G. Lupattelli, G. Vaudo, R. Lombardini, A.R. Roscini, M. Brozzetti, D. Siepi, E. Mannarino (Perugia, Italy) 166 ROLE OF SGK-1 IN THE PREVENTION OF ENDOTHELIAL DYSFUNCTION 221 F. Ferrelli, M. Lombardo, M. Blot-Chabaud, C. Mammi, R. Lauro, M. Federici, G. Donadel, P. Sbraccia, M. Tesauro, D. Lauro (Rome, Italy and Marseille, France) 167 TRANSFECTION OF SDF-1A INTO ENDOTHELIAL CELLS ENHANCES ITS ADHESION 222 WITH MONOCYTES F. Yao, Z. Wang, Y.L. Tu, Z.S. Jiang, Y.C. Lv, L.Y. Xie, B.L. Hu, D.H. Wei, G.X. Wang (Hunan, China) T 168 ENDOTHELIAL FUNCTION IN PATIENTS WITH SIGNIFICANT CORONARY ARTERY STENOSIS: 222 U INTERRELATION WITH CORONARY STENOSIS INDEX, LIPID AND INSULIN LEVEL E Y.V. Yegorova (Dnepropetrovsk, Ukraine) 169 SWISS DARK CHOCOLATE IMPROVES ENDOTHELIAL AND PLATELET FUNCTION 222 S F. Hermann, L. Spieker, F. Ruschitzka, M. Hermann, T. Luescher, W. Riesen, G. Noll, D R. Corti (Zurich and St. Gallen, Switzerland) A 170 LIM-KINASES REGULATE THROMBIN-STIMULATED STRESS FIBER FORMATION IN 222 Y ENDOTHELIAL CELLS P. Goyal, D. Pandey, W. Siess (Munich, Germany) 171 PLATELET-ACTIVATING FACTOR MEDIATES CYTOKINE-INDUCED MONOCYTE 222 ADHESION TO ENDOTHELIUM: SUPPRESSION BY CONJUGATED LINOLEIC ACID A.A. Sneddon, E. McLeod, K.W.J. Wahle, J.R. Arthur (Aberdeen, UK) 172 POTENTIAL MECHANISM FOR MAST CELL PROGENITOR TRANSENDOTHELIAL 223 MIGRATION M.C. Meyer, J. McHowat (St. Louis, MO, USA) 173 THE EFFECTS OF ACRYLAMIDE ON ENDOTHELIAL CELL AND MONOCYTE-DERIVED 223 MACROPHAGES APOPTOSIS D. Zapolska-Downar, A. Kosmider, M. Tornqvist, M. Naruszewicz (Warsaw, Poland and Stockholm, Sweden) 174 FLAVONOIDS-RICH EXTRACT FROM CHOKEBERRY FRUITS INHIBITS 223 OXLDL-INDUCED APOPTOSIS OF ENDOTHELIAL CELLS D. Zapolska-Downar, A. Kosmider, M. Naruszewicz (Warsaw, Poland) 175 EFFECTS OF HIGH LEVEL EXPRESSION OF NADPH OXIDASE 4 ON APOPTOSIS OF 223 ENDOTHELIAL CELLS S.L. Qu, W.Q. Sun, S. Wang, F. Guo, X.D. Yang, J. Li (Beijing and Hunan, China) 176 LOW TO MODERATE TOCOTRIENOL CONCENTRATION EXHIBITS OPTIMAL 224 ANTIOXIDANT ACTIVITY AND REDUCES PRODUCTION OF INFLAMMATORY MARKERS BY ENDOTHELIAL CELLS H. Nawawi, S. Muid, A. Manaf, K. Yusoff (Shah Alam and Serdang, Malaysia) 177 MECHANISM INVOLVED IN THE APOPTOSIS OF HUMAN UMBILICAL VEIN 224 ENDOTHELIAL CELLS INDUCED BY PROTEASOME INHIBITOR MG132 F. Guo, S.L. Qu, W.Q. Sun, D.M. Feng, H. He, X.D. Yang (Hengyang, China)

80 178 INFLAMMATION IS THE PRIMARY SIGNATURE OF GENE EXPRESSION PROFILE IN 224 LEUKOCYTES OF INSULIN-RESISTANT SUBJECTS D. Ardigó, B. Byers, S. Valtueña, L. Franzini, T. Quertermous, I. Zavaroni (Parma, Italy and Stanford, CA, USA) 179 POSTER WITHDRAWN – 180 SIGNIFICANT IMPLICATIONS FOR CHEMOKINES IL-8, GRO-ALPHA, MCP-1 & THEIR 224 RECEPTORS CXCR2 & CCR2 IN THE ADHESION OF U937 CELLS TO HUMAN ENDOTHELIUM C. Papadopoulou, P.R. Taylor, R.N. Poston (London, UK) 181 HEMATOPOIETIC DEFICIENCY OF P55 TNF RECEPTOR NEGATIVELY REGULATES 225 PLASMA LIPID LEVELS AND RESULTS IN SMALLER ATHEROSCLEROTIC LESIONS S. Xanthoulea, T. Ambagts, M.J.J. Gijbels, I. van der Made, M.H. Hofker, M.P.J. De Winther (Maastricht and Leiden, The Netherlands) 182 CORRELATION BETWEEN SERUM LIPIDS AND SOLUBLE ADHESION MOLECULES 225 CONCENTRATON IN CHILDREN WITH ATHEROSCLEROSIS RISK FACTORS A. Sierakowska-Fijalek (Lodz, Poland) 183 MYELOPEROXIDASE EXPRESSION IS REDUCED UPON CHOLESTEROL LOWERING 225 IN FAMILIAL HYPERCHOLESTEROLEMIA M. Puntoni, F. Bigazzi, F. Minichilli, F. Sbrana, A. Bionda, T. Sampietro (Pisa, Italy) 184 EFFECTS OF INTERACTIONS WITH LIPOPROTEINS ON MACROPHAGES CYTOKINES 225 SECRETION M. Napolitano, E. Berardi, E. Bravo (Rome, Italy) 185 INHIBITORY EFFECT OF T CELLS ON APOA1-MEDIATED CHOLESTEROL EFFLUX 225 THROUGH ATP-BINDING CASSETTE TRANSPORTER A1 Y. Nakajima, H. Kotake, K. Tanimura, F. Okajima, H. Sugihara, S. Oikawa (Tokyo and Sendai, Japan) 186 INTERMEDIATE DENSITY LIPOPROTEIN STIMULATES ALTERED EXPRESSION AND 226 DISTRIBUTION OF VASCULAR CELL ADESION MOLECULE-1 C. McFarlane, I.S. Young, N. Frizzell, B. McKibben, J. McEneny (Belfast, UK) T 187 NF-KB IN A GENETIC MODEL OF INSULIN RESISTANCE AND POSTPRANDIAL LIPEMIA 226 U S. Martinez-Hervas, T. Pedro, J.T. Real, A. Bartual, F.J. Chaves, M. Castro Cabezas, E J.F. Ascaso, J. Viña, R. Carmena (Valencia, Spain and Utrecht, The Netherlands) 188 PALMITATE INDUCES PROINFLAMMATORY CYTOKINE SECRETION IN 226 S MACROPHAGES D L. Håversen, K. Ekström, C. Améen, O. Wiklund (Goteborg, Sweden) A 189 EXPRESSION OF ARGINASE I IN MACROPHAGES IS REGULATED BY PROTEIN 226 Y KINASE A TYPE I AND REQUIRES HISTONE DEACETYLASE ACTIVITY I. Haffner, D. Teupser, J. Thiery (Goteborg, Germany) 190 STEARATE INDUCES PROINFLAMMATORY CYTOKINE SECRETION IN 227 MACROPHAGES K. Ekström, L. Håversen, L. Svensson, O. Wiklund (Göteborg, Sweden) 191 INFLAMMATION IMPAIRS THE ABILITY OF MOUSE SERUM TO REMOVE CELLULAR 227 LIPIDS BY THE ABCA1 PATHWAY T. Chiba, C.Y. Han, A. Vaughan, J. Heinecke, A. Chait, J.F. Oram (Seattle, WA, USA) 192 LIPID DEPOSITION IN GROSSLY NORMAL HUMAN AORTA CORRELATES WITH 227 INFLAMMATORY MANIFESTATIONS E. Andreeva, I. Mikhailova, A. Orekohov (Moscow, Russia) 193 INTERRELATION OF LIPIDS, INTERLEUKINS AND CHLAMIDIA INFECTION 227 CAUSED BY CHLAMIDIA PNEUMONIAE IN PATIENTS WITH ATHEROSCLEROTIC LESIONS OF VARIOUS VESSELS M. Akhvlediani, M. Emukhvari, T. Vakhtangadze, M. Balavadze (Tbilisi, Georgia) 194 APOLIPOPROTEIN CI STIMULATES THE INFLAMMATORY RESPONSE TO 227 LIPOPOLYSACCHARIDE IN MICE AND HUMANS J.F.P. Berbée, E.F. Schippers, C.C. van der Hoogt, R.L. Kitchens, J.T. van Dissel, I.A.J.M. Bakker-Woudenberg, L.M. Havekes, P.C.N. Rensen (Leiden, Rotterdam, The Netherlands and Dallas, TX, USA) 195 CONCERTED ACTION OF AP1 AND NFKB IN APOE GENE REGULATION BY LPS IN 228 MACROPHAGES A. Gafencu, M. Robciuc, A. Dobrin, D. Kardassis, V. Zannis, M. Simionescu (Bucharest, Romania and Heraklion, Greece) 196 CO-EXISTENT OBESITY, HYPERLIPIDEMIA AND SYSTEMIC INFLAMMATION IN A 228 RODENT MODEL OF ATHEROSCLEROSIS S. Filippov, B. Goetz, C. Whitinger, N. Brooks, P. Amor, R. Homan (Ann Arbor, MI, USA)

81 197 SUPPRESSORS OF CYTOKINE SIGNALING (SOCS) ARE EXPRESSED IN 228 ATHEROSCLEROTIC LESIONS AND REGULATE JAK-STAT PATHWAY IN VASCULAR CELLS G. Ortiz-Muñoz, J.L. Martin-Ventura, P. Hernandez-Vargas, B. Muñoz-Garcia, O. Lopez-Franco, V. Lopez-Parra, L. Ortega, J. Egido, C. Gomez-Guerrero (Madrid, Spain) 198 POSTER WITHDRAWN – 199 NO-1886 (IBROLIPIM) REDUCED PLASMA TRIGLYCERIDES AND FREE FATTY ACIDS 228 IN FAT-LOADED BAMA MINIPIGS H.J. Hou, W.D. Yin, Q.K. Li, M.B. Cai, C. Zhang, Y. Liu, J.X. Xiao (Hunan, China) 200 GROUP IVC PHOSPHOLIPASE A2 SUPPLIES FATTY ACIDS UTILIZED FOR THE 229 FORMATION OF CHOLESTERYL ESTER AND TRIACYLGLYCEROL IN MACROPHAGES H. Ii, M. Oka, S. Akiba, T. Sato (Kyoto, Japan) 201 OXIDIZED LDL (OXLDL) AND THEIR PHOSPHOLIPID FRACTION IN NEUTROPHIL 229 AND MONOCYTES CULTURE CELLS M.C. Jurado, S. Jancar, S.L. Gómez, M. Gidlund (São Paulo, Brazil) 202 A COMPREHENSIVE PLATFORM OF CELL-BASED ASSAYS FOR TARGETS RELEVANT 229 IN ATHEROSCLEROSIS C. Caserini, A. Della Bella, M.G. Giribaldi, G. Piazza, M. Bruno, M. De Silvestris, L. Redaelli, A. Rossignoli, L. Scarabottolo (Milan, Italy) 203 DISTURBED Ca2+ TRANSPORT IN NEUTROPHILS OF OBESE PATIENTS 229 I. Seres, G. Paragh, B. Kosztáczky, T. Kalmár, H.Z. Mirdamadi, A. Kassai, G. Fóris (Debrecen, Hungary) 204 NUTRITION, INFLAMMATION AND ATHEROSCLEROSIS 229 R. Singh, M. Saxena, J. Sharma (Moradabad, India) 205 CHARACTERIZATION OF INTRACELLULAR LOOPS OF PROSTACYCLIN RECEPTOR 230 COUPLED TO GS PROTEIN USING MINIGENE TECHNIQUE K.-H. Ruan, L. Zhang (Houston, TX, USA) 206 MOLECULAR SIGNATURES DETERMINING CORONARY ARTERY AND SAPHENOUS 230 T VEIN SMOOTH MUSCLE CELL PHENOTYPES: DISTINCT RESPONSES TO STIMULI U D.X. Deng, J.M. Spin, A. Tsalenko, A. Vailaya, A. Ben-Dor, Z. Yakhini, P. Tsao, L. Bruhn, E T. Quertermous (Palo Alto and Stanford, CA, USA) 207 RESISTANCE TO DIABETIC VASCULAR DISEASE AND THE HAPTOTGLOBIN 1-1 230 S GENOTYPE: THE ROLE OF OXIDATIVE STRESS AND THE INDUCTION OF D INTERLEUKIN-10 A J. Guetta, N. Levy, A.P. Levy (Haifa, Israel) Y 208 ATHEROSCLEROTIC LESION PROGRESSION CHANGES LYSOPHOSPHATIDIC ACID 230 HOMEOSTASIS TO FAVOR ITS ACCUMULATION M. Bot, I. Bot, T.J.C. van Berkel, E.A.L. Biessen (Leiden, The Netherlands) 209 THE REDUCTION OF SERUM ATHEROGENICITY BY NATURAL ANTI-INFLAMMATORY 230 DRUG T.V. Gorchakova, V.A. Myasoedova, I.A. Sobenin, A.N. Orekhov (Moscow, Russia) 210 HYPOXIA INDUCES VASCULAR INFLAMMATION BY UPREGULATE OXLDL RECEPTOR 231 S. Ogura, T. Shimosawa, H. Matsui, T. Sawamura, T. Fujita (Tokyo, Japan) 211 MORE INFLAMMATION IN FAMILIAL HYPERCHOLESTEROLEMIA THAN IN FAMILIAL 231 COMBINED HYPERLIPIDEMIA P. Pauciullo, M. Gentile, G. Marotta, S. Ubaldi, F. Jossa, G. Iannuzzo, F. Faccenda, A. Baiano, C. Mormile, P. Rubba (Naples, Italy) 212 ASPIRIN AND SALICYLATE SUPPRESS POLYMORPHONUCLEAR APOPTOSIS DELAY 231 MEDIATED BY PROINFLAMMATORY STIMULI S. Negrotto, E. Malaver, N. Pacienza, L.P. D'Atri, P. Urdinez, R.G. Pozner, R.M. Gomez, M. Schattner (Buenos Aires and La Plata, Argentina) 213 RELATIONSHIPS BETWEEN AUTOANTIBODIES AGAINST MODIFIED LDL AND 231 ADVANCED GLYCATION END-PRODUCTS IN CLINICALLY HEALTHY MEN P. Sjögren, G.N. Fredrikson, G. Basta, A. Hamsten, J. Nilsson, M.L. Hellenius, R. De Caterina, R.M. Fisher (Stockholm, Malmö, Sweden and Pisa, Italy) 214 MODIFIED LIPOPROTEINS DISINTEGRATE INTIMAL NETWORK FORMING BY 232 PERICYTES AND DENDRITIC CELLS A.N. Orekhov (Moscow, Russia) 215 ATORVASTATIN AND CANDESARTAN EFFECTS ON INTERFERON-G, TUMOR NECROSIS 232 FACTOR-A, INTERLEUKIN-6, AND C-REACTIVE PROTEIN IN DIABETICS WITH ATHEROSCLEROSIS L.G. Tan, L.S. Berk, D.S. Chang, S.T. Lukman, S.A. Tan (Yucaipa, CA, USA)

82 216 SECRETION OF IL-8 BY HYDROLASE-MODIFIED LDL (H-LDL)- TREATED MACROPHAGES 232 DEPENDS ON DEGRADATION OF H-LDL LIPIDS BY LYSOSOMAL ACID LIPASE J.K. Hakala, K.A. Lindstedt, M.O. Pentikäinen, P.T. Kovanen (Helsinki, Finland) 217 EFFECT OF STROMAL CELL DERIVED-FACTOR 1A ON RAT VASCULAR SMOOTH 232 MUSCLE CELLS/MONOCYTES ADHESION Y.C. Lv, Z. Wang, D.H. Wei, Z.S. Jiang, G.H. Li, F. Yao, L.S. Liu, G.X. Wang (Hunan and Chongqing, China) 218 HDL EXERTS NOVEL ANTI-INFLAMMATORY EFFECTS ON ENDOTHELIAL CELLS VIA 232 THE SUPPRESSION OF NFKB A.K. Heather, K.C.-Y. McGrath, R. Puranik, T. Tsatralis, D. Celermajer, P. Barter, K. Rye (Sydney, NSW, Australia) 219 OXIDIZED LOW DENSITY LIPOPROTEIN UP-REGULATE PCSK9 EXPRESSION IN RAT 233 VASCULAR SMOOTH MUSCLE CELLS IN VITRO L.S. Liu, Y.L. Cheng, M. Xie, C.K. Tang, Z. Wang, Y.C. Lv, G.H. Yi, Z. Ren, Y.Z. Yang, G.X. Wang (Hunan and Chongqing, China) 220 INTER-INDIVIDUAL VARIABILITY IN THE INFLAMMATORY RESPONSE TO OXIDIZED 233 LDL: IDENTIFICATION OF HIGH- AND LOW-RESPONDERS P. Martin-Fuentes, M. Artieda, D. Recalde, A.L. Garcia-Otin, A. Cenarro, F. Civeira (Zaragoza, Spain) 221 OXIDIZED PHOSPHOLIPIDS RECRUIT MONOCYTES AND INDUCE EXPRESSION OF 233 PRO-INFLAMMATORY CYTOKINES IN MOUSE MACROPHAGES K.E. Olofsson, J. Nilsson, H. Björkbacka (Malmö, Sweden) 222 "DANGER" EFFECT OF LDL AND OXIDIZED LDL ON HUMAN IMMATURE 233 DENDRITIC CELLS R. Zaguri, I. Verbovetski, M. Atallah, U. Trahtemberg, A. Krispin, E. Nahari, E. Leitersdorf, D. Mevorach (Jerusalem, Israel) 223 PRODUCTION OF C-REACTIVE PROTEIN IN U937 MONOCYTE-LIKE CELLS IS 233 UPREGULATED BY STIMULATION WITH INTERFERON-GAMMA AND OXIDIZED LDL K. Tashiro, E. Ishii, Y. Hamasaki (Saga, Japan) T 224 LDTI INHIBITS THE SPECIFIC ACTIVITY OF TRYPTASE IN MAST CELL GRANULES 234 U AND BLOCKS ITS FUNCTION IN INHIBITING CHOLESTEROL EFFLUX E Z.Z. Zhao, Y. Z. Yang, Z. Wang, B.H. Dong, S. Wang, W.Q. Sun, D.H. Wei, L.S. Liu (Hengyang, China) S 225 IRS2 EXPRESSION IS ELEVATED IN MACROPHAGES FROM SUBJECTS WITH 234 D ATHEROSCLEROSIS A D.A. Hägg, H. Samuelsson, M. Jernås, C. Standing, D. Thelle, L.M.S. Carlsson, Y P.-A. Svensson (Göteborg, Sweden) 226 BIPHASIC CONTROL OF MONOCYTE-ENDOTHELIAL CELL INTERACTION BY 234 SPHINGOSINE 1-PHOSPHATE THROUGH RHOA ACTIVITY M. Tani, A. Kawakami, M. Nagai, K. Shimokado, K. Kondo, M. Yoshida (Tokyo, Japan) 227 PG201, AN ETHANOL EXTRACT FROM HERB, INHIBITS INOS GENE EXPRESSION ON 234 LPS STIMULATED RAW264.7 THROUGH BLOCKAGE OF NUCLEAR FACTOR-KB J.Y. Choi, K.M. Kim, M.Y. Park, S.E. Yoo, E.J. Park, H.J. Choi, K.C. Park, S.Y. Kim, J.E. Park (Seoul, South Korea) 228 THIOREDOXIN-1 INHIBITS LIPOPOLYSACCHARIDE-INDUCED INTERLEUKIN-1BETA 234 EXPRESSION IN MACROPHAGES L. Billiet, C. Furman, G. Larigauderie, C. Copin, J.C. Fruchart, M. Rouis (Lille, France) 229 MANNOSE BINDING LECTIN SERUM LEVELS AND GENOTYPE ARE NOT 235 ASSOCIATED WITH SIGNIFICANT CORONARY SCLEROSIS IN DUTCH PATIENTS N. Goudriaan, A. Alipour, T. Njo, R. van Mechelen, M. Castro Cabezas, J.W. Janssen (Rotterdam, The Netherlands) 230 HUR, BUT NOT AUF1 AND TTP IN MEDIATING THE STABILIZATION OF TOLL-LIKE 235 RECEPTOR 4 mRNA INDUCED BY LIPOPOLYSACCHARIDE F.Y. Lin, Y.H. Chen, Y.L. Chen, J.W. Chen, S.J. Lin (Taipei, Taiwan) 231 HIF1ALPHA-ARNT TRANSCRIPTIONAL SYSTEM OF T LYMPHOCYTES MAY REGULATE 235 THE VASCULAR INFLAMMATION AND REMODELING IN THE ARTERIOSCLEROSIS DISEASE H. Kurobe, Y. Isawa, Y. Fukuhara, K. Aihara, M. Akaike, T. Kitagawa, T. Matsumoto, T. Tamaki, S. Tomita, M. Yoshizumi (Tokushima and Nara, Japan) 232 DO ABDOMINAL AORTAS CONTAIN BACTERIAL DNA? 235 J. Lehtiniemi, N. Oksala, S. Nikkari, S.T. Nikkari (Tampere and Helsinki, Finland)

83 233 IS INFLAMMATION THE COMMON PATHWAY TOWARDS AORTIC SCLEROSIS AND 236 ATHEROSCLEROSIS? M. Rugina, R. Jurcut, A. Salageanu, C. Jurcut, I. Caras, F. Serbanescu, E. Apetrei (Bucharest, Romania) 234 TRANSCRIPTION PROFILING SHOW INDUCTION OF A WIDE RANGE OF 236 PROINFLAMMATORY GENES IN RESPONSE TO LYSOPHOSPHATIDYLCHOLINE STIMULATION IN MONOCYTES J. Oestvang, H.-R. Brattbakk, S. Huseby, M. Langaas, A. Lægreid, B. Johansen (Trondheim, Norway) 235 CHLAMYDIA PNEUMONIAE INFECTION AND LIPID METABOLISM 236 J. Alvesalo, R. Laaksonen, P. Vuorela, T. Seppänen-Laakso, M. Oresic (Helsinki and Espoo, Finland) 236 5-LIPOXYGENASE INHIBITION SLOWS PROGRESSION OF ATHEROSCLEROTIC 236 LESIONS IN THE AORTA OF LDLR-/- MICE AS ASSESSED BY IN VIVO ULTRASOUND BIOMICROSCOPY R. Fritsche-Danielson, M. Wågberg, L.-M. Gan, W.L. McPheat (Mölndal, Sweden) 237 DEFECTIVE CHOLESTEROL EFFLUX INCREASED LIPID RAFTS AND ENHANCED 237 LIPOPOLYSACCHARIDE-INDUCED CYTOKINE RELEASE M. Koseki, K. Hirano, D. Masuda, Z. Zhang, C. Ikegami, Y. Nakagawa-Toyama, Y. Ohno-Iwashita, I. Shimomura, M. Hori, S. Yamashita (Osaka and Tokyo, Japan) 238 SIGNALLING PATHWAYS UNDERLYING TRANSFORMING GROWTH FACTOR-BETA 237 REGULATED EXPRESSION OF KEY GENES IMPLICATED IN THE CONTROL OF FOAM CELL FORMATION P. Foka, N.N. Singh, S.A. Irvine, E.J. Harvey, E. Huwait, S.A. Rogers, S. Ali, K. Arnaoutakis, N. Li, D.P. Ramji (Cardiff, UK) 239 CELLULAR AND TISSUE DISTRIBUTION OF GLOBOTRIAOSYLCERAMIDE (GB3) IN 237 FABRY DISEASE (FD) H. Askari, D. Kleiner, C. Kaneski, L. Spollen, R. Schiffmann (Bethesda, MD and T Columbia, MO, USA) U 240 T CELLS SPECIFIC FOR AN OXIDATION-INDUCED EPITOPE IN HUMAN LDL 237 E A. Hermansson, D.F.J. Ketelhuth, I. Törnberg, E. Hansson, G. Paulsson-Berne, A. Nicoletti, G.K. Hansson (Stockholm, Sweden and Paris, France) S 241 UPREGULATION OF MMP-1, -3, -12 AND -13 IS ASSOCIATED WITH 238 D ATHEROSCLEROTIC LESIONS A Y. Yu, T. Koike, S. Kitajima, M. Morimoto, M. Shiomi, J. Fan (Yamanashi, Saga and Y Hyogo, Japan) 242 CARVEDILOL ATTENUATES TNF-ALPHA-INDUCED EXPRESSION OF MATRIX 238 METALLOPROTEINASES IN HUMAN AORTIC SMOOTH MUSCLE CELLS T.C. Wu, Y.H. Chen, H.B. Leu, S.J. Lin, J.W. Chen (Taipei, Taiwan) 243 THE STRUCTURAL PHENOTYPE OF THE VESSEL WALL: IMPACT OF THE 238 GM-CSF/IL3/IL5-RECEPTOR SYSTEM G. Weissen-Plenz, H. Eschert, J.R. Sindermann, A. Rokusujew, A. Loeher, A. Hoffmeier, G. Breithardt, H.H. Scheld (Muenster, Germany) 244 LIPOPOLYSACCHARIDE ENHANCES MATRIX METALLOPROTEINASE-9 ACTIVITY IN 238 HUMAN CORONARY ARTERY SMOOTH MUSCLE CELL(CAS) K. Tanimura, M. Kawahara, Y. Nakajima, F. Okajima, A. Asai, S. Oikawa (Tokyo, Japan) 245 SERUM MATRIX METALLOPROTEINASE-2 AND INCREASED OXIDATIVE STRESS ARE 238 ASSOCIATED WITH CAROTID ATHEROSCLEROSIS IN HEMODIALYZED PATIENTS D. Pawlak, K. Pawlak, M. Mysliwiec (Bialystok, Poland) 246 PROTECTIVE ROLE OF HSP27 IN ATHEROSCLEROSIS 239 J.L. Martin-Ventura, V. Nicolas, X. Houard, L.M. Blanco-Colio, A. Leclercq, J. Egido, R. Vranckx, J.B. Michel, O. Meilhac (Paris, France and Madrid, Spain) 247 ANGIOTENSIN-CONVERTING ENZYME INHIBITION REDUCES THE ACTIVITY OF MMP 239 WHILE ANGIOTENSIN II RECEPTOR BLOCKADE INHIBITS THE MMP EXPRESSION AND ACTIVITY H. Kurata, N. Machida, C. Yanagisawa, Y. Kishimoto, M. Hasegawa, T. Kido, H. Uto, K. Utsunomiya, N. Tajima, K. Kond (Tokyo, Japan) 248 EFFECTS OF ENDOTHELIN-1 ON MATRIX METALLOPROTEINASE SECRETION IN 239 HUMAN VASCULAR SMOOTH MUSCLE CELLS O. Korzh, S. Krasnokutskiy, G. Kotchuev (Kharkov, Ukraine)

84 249 HYPOXIA DECREASES SYNDECAN CORE PROTEIN AND HEPARAN SULFATE 239 BIOSYNTHESIS IN HUMAN MACROPHAGES - POSSIBLE CONSEQUENCES FOR MACROPHAGE MOTILITY? A. Ingemansson, G. Östergren-Lundén, G. Camejo, P. Stillemark-Billton, G. Bondjers (Gothenburg and Mölndal, Sweden) 250 POSTER WITHDRAWN – 251 PLASMA MARKERS OF FIBROSIS LEVELS IN HYPERTENSION IN COMBINATION WITH 240 ISCHEMIC HEART DISEASE A. Belovol, O. Kovalyova, E. Kolosov (Kharkov, Ukraine) 252 GROUP IVA PHOSPHOLIPASE A2-MEDIATED PRODUCTION OF FIBRONECTIN BY 240 OXIDIZED LDL IN MESANGIAL CELLS S. Akiba, Y. Mukaida, K. Hane, M. Oka, T. Sato (Kyoto, Japan) 253 SUBSTRATE-DEPENDENT REGULATION OF INFLAMMATORY 240 S. Filippov, M. Chambers, R. Homan (Ann Arbor, MI, USA) 254 MATRIX METALLOPROTEINASES AND TISSUE INHIBITOR METALLOPROTEINASES IN 240 HYPERTENSIVE PATIENTS BEFORE AND AFTER ANTIHYPERTENSIVE THERAPY G. Derosa, S. Salvadeo, A. D'Angelo, C. Tinelli, A.F.G. Cicero, L. Ciccarelli, M.N. Piccinni, F. Pricolo, A. Gravina, R. Fogari (Pavia and Bologna, Italy) 255 MATRIX METALLOPROTEINASES AND TISSUE INHIBITOR METALLOPROTEINASES 240 IN HYPERTENSIVE PATIENTS G. Derosa, A. D'Angelo, C. Tinelli, L. Ciccarelli, M. Piccinni, F. Pricolo, S. Salvadeo, M. Ghelfi, I. Ferrari, A. Cicero (Pavia and Bologna, Italy) 256 MATRIX METALLOPROTEINASE 9 EXPRESSION IN HUMAN MONOMAC 6 CELLS. 241 EFFECTS OF ARACHIDONIC ACID AND N-3 FATTY ACIDS T. Solakivi, O. Jaakkola, S. Kärkkäinen, T. Kunnas, S.T. Nikkari (Tampere, Finland) 257 THE EFFECT OF LEMON FLAVONOIDS ON MATRIX METALLOPROTEINASE 241 N. Machida, H. Kurata, C. Yanagisawa, Y. Kishimoto, M. Hasegawa, E. Yoshioka, M. Tani, T. Kido, H. Uto, K. Kondo (Bunkyo-Ku, Tokyo and Minato-Ku, Japan) 258 INHIBITION OF FOCAL ADHESION KINASE SIGNALING REDUCES THE DEPTH OF 241 T MATRIX INVASION BY VASCULAR SMOOTH MUSCLE CELLS IN A NOVEL 3-D U CO-CULTURE ASSAY E L.P. Brewster, E.M. Brey, M. Liwanag, E.S. Szotek, A.M. Samarel, H.P. Greisler (Maywood, Hines, Chicago and Decatur, IL, USA) S 259 NEUROHORMONAL ACTIVATION IS ASSOCIATED WITH INCREASED LEVELS OF 241 D PLASMA MMP-2 IN HUMAN HEART FAILURE A C. Banfi, V. Cavalca, F. Veglia, M. Brioschi, S. Barcella, L. Mussoni, P. Biglioli, P. Agostoni, Y E. Tremoli (Milan, IL, Italy) 260 GINKGO BILOBA EXTRACT INHIBITS IN VITRO AND IN VIVO EXPRESSIONS AND 242 ACTIVITIES OF MATRIX METALLOPROTEINASE-2 AND -9 C.R. Tsao, J.W. Chen, S.J. Lin, W.L. Lee, Y.H. Chen, C.T. Ting, F.Y. Lin (Taichung, and Taipei, Taiwan) 261 INFLAMMATION DEPENDANT UPREGULATION OF MATRIX METALLOPROTEINASES 242 IN MONOCYTE-MACROPHAGES P.R. Sudhakaran, A. Radhika, K. Saja (Kerala, India) 262 INHIBITED COLLAGEN MATURATION, BUT ONLY MODEST PROTEOLYTIC ACTIVITY 242 IN HYPERINFLAMED ATHEROSCLEROTIC LESIONS O.A. Ovchinnikova, A.K.L. Robertson, N.A. Gavrisheva, E.V. Shlyakhto, Z. Chaoyong, P. Ericsson, G.K. Hansson (Stockholm, Sweden and St. Petersburg, Russia) 263 VASOACTIVE PEPTIDES STIMULATE ATHEROGENIC CHANGES IN VASCULAR 242 PROTEOGLYCANS M.E. Ivey, P.J. Little (Melbourne, VIC, Australia) 264 INCREASED EXPRESSION OF ELASTOLYTIC CATHEPSINS S, K, AND V, AND THEIR 242 INHIBITOR CYSTATIN C IN STENOTIC AORTIC VALVES S. Helske, S. Syväranta, K.A. Lindstedt, J. Lappalainen, K. Öörni, J. Lommi, H. Turto, K. Werkkala, M. Kupari, P. Kovanen (Helsinki, Finland) 265 COLLAGEN I MODIFIED BY MATRIX METALLOPROTEASE 13 OR MAST CELLS 243 DECREASES ADHESION AND STIMULATES GROWTH OF VASCULAR SMOOTH MUSCLE CELLS L. Bacakova, R. Vytasek, H. Maxova, J. Novotna, A. Eckhart, J. Herget (Prague, Czech Republic) 266 SAA INCREASES THE LDL BINDING AFFINITY OF VASCULAR PROTEOGLYCANS 243 P.G. Wilson, J.C. Thompson, K.D. Drennon, L.R. Tannock (Lexington, KY, USA)

85 267 SIGNIFICANCE OF CHYMASE IN THE PROGRESSION OF ABDOMINAL AORTIC 243 ANEURYSMS S. Takai, K. Furubayashi, D. Jin, M. Miyazaki (Osaka, Japan) 268 MACROPHAGE-ELASTIN CONTACT INDUCES TUMOR NECROSIS FACTOR ALPHA 243 EXPRESSION: A ROLE OF MACROPHAGE IN VERY EARLY ATHEROGENESIS I. Mori, T. Higuchi, M. Nakamura, Y. Nakamura, T. Ozaki, T. Sanke, K. Kakudo (Wakayama, Japan) 269 ACTIVATED MAST CELLS INDUCE ENDOTHELIAL CELL APOPTOSIS BY A COMBINED 244 ACTION OF CHYMASE AND TNF-ALPHA H.M. Heikkilä, S. Lätti, M.J. Leskinen, J.K. Hakala, N. Shiota, P.T. Kovanen, K.A. Lindstedt (Helsinki, Finland) 270 HIGH SERUM MMP-9 LEVEL FOUND IN DIABETIC PATIENTS AFTER MYOCARDIAL 244 INFARCTION IS ASSOCIATED WITH AN INCREASED RISK OF IN-HOSPITAL CARDIAC EVENTS A. Dominguez-Rodriguez, P. Abreu-Gonzalez, M.J. Garcia-Gonzalez, J.C. Kaski (Tenerife, Spain and London, UK) 271 SELECTIVE INHIBITION ON GELATINASE A AND B VERSUS COLLAGENASE-1 BY AN 244 AMINO-SULPHONE-HYDROXAMATE DERIVATIVE R. Parente, M. Canavesi, N. Ferri, M. Sani, M. Zanda, S. Bellosta (Milan, Italy) 272 MATRIX METALLOPROTEINASES AND THEIR INHIBITOR IN THE PATHOGENESIS OF 244 ABDOMINAL AORTIC ANEURYSMS C. Gasparetto, D. Culacciati, A. Malinverno, R. Moia, G. Ricevuti (Pavia, Italy) 273 SUPPRESSION OF ATHEROSCLEROTIC PLAQUE PROGRESSION AND INSTABILITY BY 244 TISSUE INHIBITOR OF METALLOPROTEINASE-2: EFFECTS ON MACROPHAGE BEHAVIOUR J. Johnson, A. Baker, K. Oka, L. Chan, A. Newby, C. Jackson, S. George (Bristol, Glasgow, UK and Houston, TX, USA) 274 PHAGOCYTIC NADPH OXIDASE OVERACTIVITY ASSOCIATES WITH PLASMA LEVELS 245 T OF MATRIX METALLOPROTEINASE-9 IN SUBJECTS FREE OF CLINICAL U ATHEROSCLEROTIC DISEASE E G. Zalba, J. Orbe, O. Beloqui, G. San José, M.U. Moreno, M. Belzunce, J.A. Páramo, A. Fortuño, J. Díez (Pamplona, Spain) S 275 PROTEIN-LIPID INTERACTIONS IN LOW DENSITY LIPOPROTEINS (LDL): 245 D COMPUTATIONAL STUDIES OF BETA-SHEET ON HYDROPHOBIC EXTERIOR A A. Koivuniemi, P.T. Kovanen, M.T. Hyvönen (Helsinki, Finland) Y 276 CHRONIC ROSUVASTATIN-TREATMENT OF APOE-DEFICIENT MICE INCREASES 245 ACCUMULATION OF COLLAGEN AND COLLAGEN-BINDING PROTEOGLYCANS IN ATHEROSCLEROTIC LESIONS A. Marzoll, J.W. Fischer (Düsseldorf, Germany) 277 SECRETED SOLUBLE FORM OF LR11, AN LDL RECEPTOR GENE FAMILY MEMBER, 245 IS A POTENT REGULATOR OF MACROPHAGE ADHESION AND SMOOTH MUSCLE CELL MIGRATION K. Ohwaki, H. Bujo, M. Jiang, H. Yamazaki, Y. Saito (Chiba and Tokyo, Japan) 278 GENE EXPRESSION IN UNSTABLE ATHEROSCLEROTIC CAROTID ARTERY PLAQUES 246 J. Saksi, P. Ijäs, K. Nuotio, M. Mäyränpää, P.T. Kovanen, M. Kaste, P.J. Lindsberg (Helsinki, Finland) 279 LACK OF ASSOCIATION BETWEEN CHLAMYDIA PNEUMONIAE INFECTION AND PLAQUE 246 INSTABILITY OR RESTENOSIS IN CORONARY ATHEROSCLEROTIC LESIONS K. Hatakeyama, Y. Azuma, H. Hao, T. Imamura, K. Nishihira, M. Shirai, H. Ogawa, Y. Asada (Kiyotake, Ube, Nishinomiya and Kumamoto, Japan) 280 HUR PROTEIN AS POTENTIAL MODULATOR OF ANGIOTENSIN II TYPE 1 RECEPTOR 246 EXPRESSION IN HUMAN ATHEROSCLEROTIC PLAQUE C. Cuccurullo, M.L. Fazia, A. Iezzi, D. De Cesare, S. Ucchino, F. Spigonardo, M. Bucci, F. Cuccurullo, A. Mezzetti, F. Cipollone (Chieti, Italy) 281 STUDY OF CHANGES IN GENE AND PROTEIN EXPRESSION INVOLVED DURING THE 246 DEVELOPMENT OF ATHEROSCLEROTIC PLAQUES P. Ethirajan, M. Slevin, J. Gaffney, P. Kumar, J. Verran (Manchester, UK) 282 OVEREXPRESSION OF PROTEIN AUF1 AS A PROTECTIVE MECHANISM AGAINST 247 PGE2- DEPENDENT ATHEROSCLEROTIC PLAQUE INSTABILITY IN HUMANS M.L. Fazia, C. Cuccurullo, A. Iezzi, D. De Cesare, S. Ucchino, F. Spigonardo, F. Cuccurullo, A. Mezzetti, F. Cipollone (Chieti, Italy)

86 283 PROSTACYCLIN INHIBITS CALCIFICATION OF HUMAN VASCULAR SMOOTH MUSCLE 247 CELLS IN CULTURE C. Glandorff, A. Marzoll, J. Meyer-Kirchrath, K. Schrör, J.W. Fischer (Düsseldorf, Germany) 284 SYSTEMIC MAST CELL ACTIVATION INDUCES ATHEROSCLEROTIC PLAQUE 247 PROGRESSION IN APOE-/- MICE I. Bot, S.C.A. de Jager, Th.J.C. van Berkel, E.A.L. Biessen (Leiden, The Netherlands) 285 DECREASED PHOSPHORYLATION OF HEAT SHOCK PROTEIN 27 IN HUMAN 247 ATHEROSCLEROTIC PLAQUES MAY BE ASSOCIATED WITH THE PROGRESSION OF THE PLAQUE M.Y. Park, H.K. Park, E. Park, S.W. Bae, K.M. Kim, Y.H. Ko, Y. Choi, Y.W. Kim, J. Yoon, J.E. Park (Seoul, South Korea) 286 MODIFIED ALIZARIN RED S STAINING TO DETECT VASCULAR CALCIFICATION 247 M. Afshar, N. Taibi, M.J. Golalipoor (Birjand, Mashhad and Gorgan, Iran) 287 OVEREXPRESSION OF TOLL LIKE RECEPTOR 4 AS A BASIS OF CYCLOOXYGENASE 248 2-DEPENDENT ATHEROSCLEROTIC PLAQUE INSTABILITY IN HUMANS A. Iezzi, M.L. Fazia, C. Cuccurullo, D. De Cesare, S. Ucchino, F. Spigonardo, F. Cuccurullo, A. Mezzetti, F. Cipollone (Chieti, Italy) 288 INHIBITION OF SMOOTH MUSCLE CELL APOPTOSIS BY SOLUBLE N-CADHERIN 248 C.A. Beeching, G.B. Sala-Newby, S.J. George (Bristol, UK) 289 INFLAMMATORY RESPONSE IN HUMAN ATHEROSCLEROSIS: BIKE – BIOBANK OF 248 KAROLINSKA ENDARTHERECTOMY G. Paulsson-Berne, A. Gabrielsen, H.E. Agardh, J. Ekstrand, D. Marcus, I. Bodin, J. Swedenborg, G.K. Hansson, U. Hedin (Stockholm, Sweden) 290 GLYCOSYLATION IN NON-DIABETIC PATIENTS WITH ATHEROSCLEROSIS 248 M. Castagnini, M.C. Epistolato, R. De Caterina, S. Del Turco, G. Basta, G.M. Sangiorgi, P. Righini, P. Tanganelli (Siena, Pisa and Milan, Italy)

T U E S D A Y

87 POSTER AREA “A” TUESDAY, June 20 291-331

POSTER DISPLAY: for the duration of one day (Tuesday, June 20 from 8.30 am to 6.30 pm). Participants may view the posters displayed during this day.

Tu-P8 Poster Session 8 poster nd abstract bk. board no.: BASIC SCIENCE (2 part) page ref.:

291 HUMAN MATURING MAST CELLS ENHANCE T CELL PROLIFERATION IN VITRO 249 J.A. Trosien, K.A. Lindstedt, P.T. Kovanen (Helsinki, Finland) 292 HOW ASPIRIN MODULATES THE TGF-B PATHWAY IN HUMAN VASCULAR SMOOTH 249 MUSCLE CELLS S. Redondo, E. Ruiz, A. Gordillo-Moscoso, T. Tejerina (Madrid, Spain) 293 TRANILAST INHIBITS TRANSDIFFERENTIATION OF MACROPHAGES INTO SMOOTH 249 MUSCLE-LIKE CELLS K. Ninomiya, Y. Fujioka, A. Takahashi, A. Fukuda, Y. Ishikawa, M. Yokoyama (Kobe, Japan) 294 ESSENTIAL ROLE OF INCREASED RELEASE OF MCP-1 IN THE MECHANISM OF 249 PLATELET-DERIVED GROWTH FACTOR (PDGF)-INDUCED PROLIFERATION AND MIGRATION OF VASCULAR SMOOTH MUSCLE CELLS T K. Nakano, K. Egashira, K. Sunagawa (Fukuoka, Japan) 295 NUCLEAR PHOSPHATIDYL INOSITOL (3,4,5)TRISPHOSPHATE REGULATION IN 249 U VASCULAR SMOOTH MUSCLE CELLS PROLIFERATION/DIFFERENTIATION E M. Laffargue, S. Gayral, A. Fougerat, P. Deleris, N. Malet, M. Douillon (Toulouse, France) S 296 EFFECT OF SEX HORMONES ON ATHEROSCLEROTIC INDICES IN PRIMARY CULTURE 250 D OF FEMALE CELLS A R.A. Kireev, E. Kuvshinova, I.V. Andrianova, I.A. Sobenin, A.N. Orekhov (Moscow, Russia) 297 GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR CONTRIBUTES TO 250 Y RESTENOSIS FOLLOWING EXPERIMENTAL ENDOTHELIAL DENUDATION A.K. Harris, J. Shen, B.D. Hambly, S. Bao (Sydney, NSW, Australia) 298 PROTEIN STRUCTURES FOR REGENERATION OF VASCULAR WALL 250 E. Filova, E. Brynda, L. Bacakova, M. Houska, T. Riedel (Prague, Czech Republic) 299 IN VITRO ENHANCED ANTIPROLIFERATIVE ACTIVITY OF EVEROLIMUS BY 250 FLUVASTATIN ON ARTERIAL SMOOTH MUSCLE CELLS N. Ferri, A. Granata, C. Pirola, P.J. Pfister, R. Dorent, A. Corsini (Milan, Italy and Basel, Switzerland) 300 SERA FROM PATIENTS TREATED WITH FLUVASTATIN XL INHIBIT HUMAN ARTERIAL 251 MYOCYTE PROLIFERATION L. Arnaboldi, F. Pazzucconi, C.R. Gimpelewicz, G. Bermann, R. Paoletti, C.R. Sirtori, A. Corsini (Milan, Italy and Basel, Switzerland) 301 AGGRAVATION OF ATHEROSCLEROSIS BY MAST CELLS IN THE NEW ZEALAND 251 WHITE RABBIT WITH STENOTIC CAROTID ARTERY W.Q. Sun, Y.Z. Yang, X. Ye, Y.L. Tang, K. Peng, B.H. Dong, Y.H. Sun, H.Y. Jin (Hengyang, China) 302 CORONARY INTIMA THICKNESS IN RELATION TO ESTROGEN RECEPTOR GENOTYPE 251 IN WOMEN YOUNGER THAN 50 YEARS OF AGE A.T. Henttonen, M.-L. Kortelainen, S.T. Nikkari, T.A. Kunnas (Tampere and Oulu, Finland) 303 INCREASED ARTERIAL INTIMA-MEDIA THICKNESS IS RELATED TO LP(A) LEVELS IN 251 CHILDREN HETEROZYGOUS FOR FAMILIAL HYPERCHOLESTEROLEMIA A. Skouma, K. Stamatelopoulos, P. Voidonikola, P. Katsichti, C. Papamichael, E. Drogari (Athens, Greece) 304 EFFECT OF ANTIOXIDANTS ON HIGH GLUCOSE-CAUSED INHIBITION OF ENDOTHELIAL 251 PROGENITOR CELL PROLIFERATION Y.H. Chen, F.Y. Lin, S.J. Lin, T.C. Wu, J.W. Chen (Taipei, Taiwan)

88 305 MODULATION OF CLUSTERIN ISOFORMS IS ASSOCIATED TO ALL-TRANS-RETINOIC 252 ACID-INDUCED PROLIFERATIVE ARREST AND APOPTOSIS OF ARTERIAL INTIMAL SMOOTH MUSCLE CELLS A. Orlandi, S. Pucci, A. Ciucci, F. Pichiorri, A. Ferlosio, L.G. Spagnoli (Rome, Italy) 306 RESVERATROL INHIBITS NICOTINE INDUCED SMOOTH MUSCLE CELLS 252 PROLIFERATION IN VITRO B. Poussier, A. Cordova, J.P. Becquemin, B. Sumpio (New Haven, CT, USA and Paris, France) 307 SELECTIVE ACTIVATION OF NUCLEAR PLD1 BY GPCR-AGONISTS IN VASCULAR 252 SMOOTH MUSCLE CELLS S. Gayral, P. Deleris, K. Laulagnier, M. Laffargue, M. Record, M. Breton-Douillon (Toulouse, France, Montreal, QC, Canada and Geneva, Switzerland) 308 ANTIPROLIFERATIVE AGENT CVT-313 HAS A DIFFERENT IMPACT ON VASCULAR 252 SMOOTH MUSCLE CELLS FROM ADULT AND NEWBORN RATS E. Filova, V. Bryja, L. Noskova, L. Cajanek, L. Bacakova, M. Lapcikova, F. Rypacek (Prague, Czech Republic) 309 MECHANISM FOR BLOCKADE OF ANGIOTENSIN SUBTYPE 1 RECEPTORS TO 253 LOWER PLASMA GLUCOSE IN STREPTOZOTOCIN-INDUCED DIABETIC RATS P. Chan, J.T. Cheng (Taipei and Tainan, Taiwan) 310 UROKINASE PLASMINOGEN ACTIVATOR (UPA) STIMULATES MACROPHAGE 253 CHOLESTEROL BIOSYNTHESIS VIA INCREMENT OF CELLULAR OXIDATIVE STATE B. Fuhrman, O. Nitzan, N. Volkova, M. Aviram (Haifa and Afula, Israel) 311 INSULIN SIGNALING IN ARTERIES PREVENTS SMOOTH MUSCLE APOPTOSIS 253 K. Shimokado, T. Nakazawa, T. Chiba, E. Kaneko (Tokyo, Japan) 312 SUPEROXIDE DISMUTASE AND CATALASE INHIBIT OXIDIZED LOW DENSITY 253 LIPOPROTEIN-INDUCED HUMAN AORTIC SMOOTH MUSCLE CELL PROLIFERATION S.J. Lin, Y.H. Chen, J.W. Chen, Y.L. Chen (Taipei, Taiwan) 313 THE RECRUITMENT OF HISTONE DEACETYLASES INDUCED BY BILE ACIDS 253 INHIBITS TRANSCRIPTION OF CHOLESTEROL 7ALPHA-HYDROXYLASE GENE (CYP7A1) E. Scotti, C. Godio, N. Mitro, E. Gers, E. De Fabiani, A.B. Vigil Chacon, D. Caruso, T M. Crestani (Milan, Italy) U 314 TRANSCRIPTIONAL REGULATION OF RETINOIC ACID RECEPTOR-RELATED ORPHAN 254 E RECEPTOR ALPHA 4 F. Osaki, H. Takata, T. Suehiro, M. Inoue, K. Arii, Y. Ikeda, Y. Kumon, K. Hashimoto S (Nankoku, Japan) D 315 PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA COACTIVATOR-1BETA 254 A HEPATIC OVEREXPRESSION IN MICE RESULTS IN COMBINED HYPERLIPIDEMIA Y A. Ljungberg, C. Lelliott, A. Ahnmark, L. William-Olsson, A. Elmgren, J. Oscarsson, D. Lindén (Göteborg and Mölndal, Sweden) 316 PROFILING OF LXR RESPONSES GENES IN RESPONSE TO A NOVEL LXR AGONIST 254 COMPARED TO REFERENCE COMPOUNDS H. Davidson-Smith, N. Barnett, E. Kennedy-Walton, A. Parker, H.J. Mckinnon, A. Cooke, D.J. Bennett, D. Mallinson (Newhouse, UK) 317 THE PREVENTIVE AND THERAPEUTIC EFFECT OF A LIVER X RECEPTOR AGONIST 254 ON ATHEROSCLEROTIC LESIONS IN APOLIPOPROTEIN E KNOCKOUT MICE X.Y. Dai, C.K. Tang, X. Ou, J.H. Yang, Z.S. Jiang, D.L. Cao, X.R. Hao, G.H. Yi, Z. Wang, L.S. Liu (Hengyang, China) 318 MODULATION OF PLASMA HDL BY INTESTINE SPECIFIC ACTIVATION OF THE LIVER 255 X RECEPTOR J.K. Kruit, R. Havinga, R. Boverhof, F. Kuipers (Groningen, The Netherlands) 319 A NOVEL LXR RESPONSIVE ELEMENT EXISTS IN ATP-BINDING CASSETTE 255 TRANSPORTER G1 (ABCG1) GENE PROMOTER S. Abe, Y. Uehara, S. Miura, S. Furuyama, C. Kitaguchi, H. Urata, T. Yamada, K. Saku (Fukuoka, Japan) 320 LYSOPHOSPHATIDIC ACID INDUCES NEOINTIMA AND VSMC DEDIFFERENTIATION 255 VIA PPARG G. Tigyi, N. Makarova, L. Balazs, C. Zhang, D. Baker (Memphis, TN, USA ) 321 RXR-GAMMA AND FXR VARIANTS AFFECT SERUM CHOLESTEROL LEVELS MAINLY 255 THROUGH LIPOPROTEIN LIPASE LEVELS A. Nohara, M. Tsuchida, M. Takata, S. Katsuda, K. Miwa, M. Kawashiri, A. Inazu, J. Kobayashi, J. Koizumi, H. Mabuchi (Kanazawa, Japan)

89 322 THE DIETARY ANTIOXIDANT RESVERATROL AFFECTS REDOX CHANGES OF 255 PPAR-ALFA ACTIVITY F.P. Mancini, P. Iannelli, A. Meoli, V. Zarrilli, D. Tramontano (Benevento and Naples Italy) 323 HEPATIC NUCLEAR RECEPTORS IN HUMAN CHOLELITHIASIS: A LINK WITH INSULIN 256 RESISTANCE? M. Bertolotti, C. Gabbi, C. Anzivino, M. Crestani, N. Mitro, M. Del Puppo, A. Rossi, L. Carulli, P. Loria, N. Carulli (Modena, Milan and Monza, Italy) 324 A MIXED LXR / PPAR GAMMA/DELTA AGONIST FAILS TO RESCUE LXR-MEDIATED 256 DYSLIPIDEMIA IN A NONHUMAN PRIMATE MODEL E.M. Quinet, A.R. Halpern, M.D. Basso, D.W. Yates, M.D. Collini, J. Wrobel, P. Nambi (Collegeville, PA, USA) 325 WAY-254011, A NOVEL LIVER X RECEPTOR MODULATOR, INHIBITS ATHEROSCLEROTIC 256 LESION PROGRESSION IN APOLIPOPROTEIN E KNOCKOUT MICE P. Nambi, M. Basso, L. Chen, Q. Liu, V. Clerin, J. Feldman, D. Pittman, J. Keith, E. Quinet, J. Wrobel (Collegeville, PA and Cambridge, MA, USA) 326 ESTROGEN RECEPTOR SIGNALING ANTAGONIZES FARNESOID X RECEPTOR 256 TRANSCRIPTIONAL ACTIVITY AND TRIGLYCERIDE REGULATION L. Borges-Marcucci, M. Heayn, D.C. Harnish (Collegeville, PA, USA) 327 MOUSE, BUT NOT HUMAN, MACROPHAGES ACTIVATE NFKAPPAB P50 HOMODIMERS 256 IN RESPONSE TO LOW EXTRACELLULAR PH TO LIMIT TNF-ALPHA INDUCED CYTOKINE SECRETION A.B. Gerry, D.S. Leake (Reading, UK) 328 MOLECULAR REGULATION OF STEROL METABOLISM BY BILE ACIDS IN CULTURED 257 HUMAN HEPATOCYTES C. Anzivino, M. Bertolotti, C. Gabbi, M. Ricchi, E. Tagliafico, E. Tenedini, L. Carulli, F. Carubbi, P. Loria, N. Carulli (Modena, Italy) 329 BILE ACIDS INDUCE HYPERCHOLESTEROLEMIA THROUGH A FXR-INDEPENDENT 257 MECHANISM IN LDLR KNOCKOUT MICE T P. Qin, K. Lai, D.C. Harnish (Collegeville, PA, USA) U 330 NUCLEAR FACTOR OF ACTIVATED T-CELLS (NFAT) COUPLES INNATE IMMUNITY 257 E PROGRAMMING TO CHOLESTEROL METABOLISM IN MONOCYTE-MACROPHAGES F. Gilardi, A. Torri, N. Mitro, D. Caruso, M. Crestani, E. De Fabiani (Milan, Italy) S 331 ANGIOPOIETIN-LIKE PROTEINS 3 AND 4: IMPORTANT REGULATORS OF PLASMA 257 D LIPOPROTEIN METABOLISMS A S. Kersten (Wageningen, The Netherlands) Y

90 POSTER AREA “A” TUESDAY, June 20 332-388

POSTER DISPLAY: for the duration of one day (Tuesday, June 20 from 8.30 am to 6.30 pm). Participants may view the posters displayed during this day.

Tu-P9 Poster Session 9 poster abstract bk. board no.: DIAGNOSTIC TECHNOLOGIES FOR page ref.: CARDIOVASCULAR DISEASES

332 APOLIPOPROTEINS: CORRELATION WITH CAROTID INTIMA-MEDIA THICKNESS AND 258 CORONARY ARTERY DISEASE L. Vladimirova-Kitova (Plovdiv, Bulgaria) 333 FAMILIAL AGGREGATION OF CAROTID ARTERY INTIMA MEDIA THICKNESS: A 258 THREE-GENERATION STUDY E.C. Oldani, A. Ravani, M. Amato, E. Tremoli, J.P. Werba, D. Baldassarre (Milan, Italy) 334 CAROTID ARTERY INTIMA-MEDIA THICKNESS IN 65-100 YEARS OLD 258 H. Nakano, K. Watanabe, K. Oba (Tokyo, Japan) 335 THE EFFECT OF AGE AND OTHER ATHEROSCLEROTIC RISK FACTORS ON CAROTID 258 ARTERY BLOOD VELOCITY IN SUBJECTS RANGING FROM YOUNG ADULTS TO CENTENARIANS T S. Homma, G. Sloop, A. Zieske, J.P. Strong (Higashi-murayama, Japan and U New Orleans, LA, USA) E 336 SMOKING HABITS AS DETERMINANT OF CAROTID IMT IN PATIENTS IN PRIMARY 258 S AND SECONDARY PREVENTION A. De Jong, S. Castelnuovo, B. Frigerio, M. Amato, A. Ravani, E. Oldani, G. De Giosa, D E. Tremoli, C.R. Sirtori, D. Baldassarre (Milan, Italy) A 337 RELATIONSHIP BETWEEN CARDIOVASCULAR GLOBAL RISK IN PRIMARY AND 259 Y SECONDARY PREVENTION AND CAROTID ATHEROSCLEROSIS S. Castelnuovo, B. Frigerio, G. De Giosa, M. Amato, E. Tremoli, C.R. Sirtori, D. Baldassarre (Milan, Italy) 338 FLOW-MEDIATED VASODILATATION OF THE BRACHIAL ARTERY AND INTIMA-MEDIA 259 THICKNESS OF CAROTID ARTERY IN NEVER-TREATED SUBJECTS C. Irace, M. Migale, C. Cortese, R. Fiorentino, A. Gnasso (Catanzaro and Rome, Italy) 339 EFFECT OF PITAVASTATIN ON THORACIC AORTA IN HYPERLIPIDEMIA EVALUATED 259 WITH INTEGRATED BACKSCATTER AND THICKNESS BY TRANSESOPHAGEAL ECHOCARDIOGRAPHY K. Ono, R. Tanaka, N. Sato, T. Katou, S. Warita, T. Kojima, M. Iwama, T. Segawa,H. Matuo, S. Watanabe (Gifu City, Japan) 340 CHRONIC USE OF LIGHT OR HEAVY CIGARETTES AND CAROTID IMT 259 D. Baldassarre, S. Castelnuovo, B. Frigerio, M. Amato, G. De Giosa, E. Tremoli, C.R. Sirtori (Milan, Italy) 341 THE ATHEROSCLEROTIC BURDEN, ASSESSED BY CAROTID ULTRASONOGRAPHY, 259 IN LOW-RISK PATIENTS WITH DYSLIPIDEMIA L. Denti, R. Valcavi, S. Riboldi, V. Campana, G. Valenti, G.P. Ceda (Parma, Italy) 342 ENDOTHELIAL DYSFUNCTION PRECEDES ARTERIAL WALL STIFFENING IN CHRONIC 260 RENAL INSUFFICIENCY IN CHILDREN V. Slooff, B. Elsen, J. Butselaar, E. de Groot, J.W. Groothoff (Amsterdam, The Netherlands) 343 SMOKING HABITS AS DETERMINANT OF CAROTID IMT IN GENDER SPECIFIC 260 MODELS B. Frigerio, S. Castelnuovo, G. De Giosa, M. Amato, E. Tremoli, C.R. Sirtori, D. Baldassarre (Milan, Italy)

91 344 THE METABOLIC SYNDROME AND PRECLINICAL ATHEROSCLEROSIS IN 260 MIDDLE-AGED JAPANESE MEN Y. Ueno, Y. Nakamura, T. Kadowaki, T. Okamura, T.Y. Kita, N. Miyamatsu, A. Sekikawa, T. Takamiya, K. Sutton-Tyrell, H. Ueshima (Nagahama, Kyoto, Otsu, Japan and Pittsburgh, PA, USA) 345 DETERMINANTS OF AN INCREASED INTIMA MEDIA THICKNESS IN PATIENTS WITH 260 FAMILIAL COMBINED HYPERLIPIDEMIA (FCH) E. ter Avest, S. Holewijn, S.J.H. Bredie, A.F.H. Stalenhoef, J. de Graaf (Nijmegen, The Netherlands) 346 POSTER WITHDRAWN – 347 INTERPRETATION OF DOPPLER SIGNAL IN VASCULAR DISEASES 261 B. Djokic, M. Kocic (Nis and Serbia, Serbia-Montenegro) 348 CAROTID REMODELING IN CHILDREN WITH METABOLIC SYNDROME 261 A. Iannuzzi, M.R. Licenziati, C. Acampora, G. Chiariello, G. Covetti, A. Bresciani, S. Panico, P. Rubba (Naples, Italy) 349 INFLUENCE OF THE HDL CHOLESTEROL LEVEL ON PRECLINICAL CAROTID 261 ATHEROSCLEROSIS IN FAMILIAL HYPERCHOLESTEROLEMIA M. Junyent, M. Cofán, I. Núñez, R. Gilabert, D. Zambón, E. Ros (Barcelona, Spain) 350 EFFECT OF CAROTID INTIMA-MEDIA THICKNESS MEASUREMENTS ON 261 FRAMINGHAM RISK STRATIFICATION IN PATIENTS WITH PRIMARY DYSLIPIDEMIA M. Junyent, R. Gilabert, I. Núñez, E. Corbella, D. Zambón, E. Ros (Barcelona, Spain) 351 ARTERIAL WALL THICKNESS AND RIGIDITY IN ANTIPHOSPHOLIPID SYNDROME 261 PATIENTS C. Belizna, J.M. Kerleau, N. Cailleux, E. Primard, J.P. Louvel, V. Richard, C. Thuillez, H. Levesque (Rouen, France) 352 ATHEROSCLEROSIS OF CAROTID ARTERIES IN PATIENTS WITH LOW HDL CHOLESTEROL 262 P. Meszaros, N. Cemerlic-Adjic, K. Pavlovic, M. Maletin, D. Sakac, M. Kovac (Sremska Kamenica, Serbia-Montenegro) T 353 THE CAROTID INTIMAL MEDIAL THICKNESS IS NOT CORRELATED WITH THE PRESENCE 262 U OF CORONARY ARTERY CALCIFICATION IN FAMILIAL HYPERCHOLESTEROLEMIA E L. Martinez, M. Miname, A.P. Marte, L.A. Bortolotto, W. Salgado, C.E. Rochite, R.D. Santos (São Paulo, Brazil) S 354 CORRELATION BETWEEN CAROTID INTIMA-MEDIA THICKNESS AND ACHILLES TENDON 262 D THICKNESS IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA A E. Jarauta, A. Cenarro, P. Martín-Fuentes, A.L. García-Otín, D. Recalde, F. Civeira Y (Zaragoza, Spain) 355 ASYMMETRIC DIMETHYLARGININE AND INTIMA-MEDIA THICKNESS IN 262 HYPERCHOLESTEROLEMIC SUBJECTS L. Vladimirova-Kitova, D. Terzieva, T. Tzvetkova (Plovdiv, Bulgaria) 356 CAROTID ARTERY INTIMA-MEDIA THICKNESS AND 10-YEAR CORONARY RISK IN 262 YOUNG MALE SMOKERS WITH METABOLIC SYNDROME G.E. Roytberg, A. Miroslava, T.I. Ushakova (Moscow, Russia) 357 EVALUATION OF ATHEROSCLEROTIC PLAQUES OF YOUNG PATIENTS WITH 263 HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA BY 64 DETECTOR ROW COMPUTED TOMOGRAPHY M. Miname, L. Martinez, A.P. Marte, W. Salgado, E. Nakandakare, C.E. Rochitte, R.D. Santos (São Paulo, Brazil) 358 CUTANEOUS VASOMOTOR RESPONSES IN PATIENTS WITH METABOLIC 263 SYNDROME AND INSULIN RESISTANCE P. Tretjakovs, A. Jurka, K. Geldnere, A. Stifts, J.I. Aivars, V. Pirags (Riga, Latvia) 359 CUSHING'S SYNDROME, CARDIOVASCULAR RISK AND FLOW MEDIATED DISEASE 263 F. Bilora, C. Scaroni, D. Trevisan, F. Petrobelli, F. Mantero, A. Pagnan (Padua, Italy) 360 CORONARY RISK ASSESSMENT BY CAROTID-RADIAL PULSE WAVE VELOCITY 263 M.C.O. Izar, M.L.G. Dabela, W.G.M. Relvas, A.O. Santos, T. Helfenstein, C.M.R. Monteiro, S.A.B. Brandao, W.J. Gomes, A.C.C. Carvalho, F.A.H. Fonseca (São Paulo, Brazil) 361 MENTAL STRESS, HEART RATE, ENDOTHELIAL FUNCTION IN PATIENTS WITH 263 SYNDROME X K. Mizia-Stec, Z. Gasior, M. Mizia, S. Gomulka, P. Kumor, A. Niedojadlo, L. Goliszek (Katowice, Poland)

92 362 DOES AORTIC STIFFNESS ALTERNATE IN PATIENTS WITH MIGRAINE? 264 C. Kilit, A. Avsar, M. Yaman, M. Melek, A. Taner, S. Oruc, A. Celik, E. Onrat (Afyonkarahisar, Turkey) 363 ATORVASTATIN NORMALIZES ENDOTHELIAL FUNCTION IN HEALTHY SMOKERS 264 S. Agewall, Å. Hernberg (Stockholm, Sweden) 364 ELASTIC PROPERTIES OF LARGE ARTERIES IN PATIENTS WITH MIGRAINE 264 C. Kilit, M. Melek, M. Yaman, A. Taner, S. Oruc, A. Avsar, A. Celik, E. Onrat (Afyonkarahisar, Turkey) 365 AGING PROGRESSIVELY IMPAIRS ENDOTHELIAL FUNCTION 264 B. Yavuz, D.S. Dede, B.B. Yavuz, M. Cankurtaran, M. Halil, N. Nazli, G. Kabakci, K. Aytemir, S. Ariogul, L. Tokgozoglu (Ankara, Turkey) 366 SERUM HEAT SHOCK PROTEIN 60 AND CORONARY ARTERY FUNCTION IN HEALTHY 264 YOUNG VOLUNTEERS L.-M. Gan, J. Dalén, R. Fritsche-Danielson, B. Wandt, U. Hägg (Göteborg and Mölndal, Sweden) 367 OPTIMIZATION OF ULTRASOUND BRACHIAL ENDOTHELIAL FUNCTION 265 H.J. Scholten, B.M. Elsen, R. Duivenvoorden, J.C. Schilder, R. Draijer, W. Hanselaar, E.S. Stroes, A. Donald, J.J.P. Kastelein, E. de Groot (Amsterdam, Vlaardingen, The Netherlands and London, UK) 368 ALCOHOL CONSUMPTION AND CORONARY ARTERY CALCIFICATION DETECTED BY 265 ELECTRON-BEAM COMPUTED TOMOGRAPHY IN MIDDLE-AGED JAPANESE MEN T. Okamura, T. Kadowaki, A. Sekikawa, K. Murata, N. Miyamatsu, T. Takamiya, A. El-Saed, Y. Nakamura, A. Kashiwagi, H. Ueshima (Otsu, Kyoto, Japan and Pittsburgh, PA, USA) 369 CLINICAL IMPLICATION AND METABOLIC FACTORS OF NON-CALCIFIED CORONARY 265 PLAQUES DETECTED WITH CARDIAC COMPUTED TOMOGRAPHY T.Y. Chiu, C.W. Chen, C.S. Kang, H.Y. Chou, C.P. Lin, C.I. Chern (TauYuan and Taipei, Taiwan) 370 ASSOCIATION OF ENDOTHELIAL SHEAR STRESS WITH THE TYPE OF 265 ATHEROSCLEROTIC LESIONS IN ANGIOGRAPHICALLY NORMAL CORONARY ARTERIES T M. Papafaklis, C. Bourantas, P. Theodorakis, C. Katsouras, D. Fotiadis, L. Michalis U (Ioannina, Greece) E 371 RELATION BETWEEN VESSEL REMODELLING AND INTRAVASCULAR ULTRASOUND 266 MEASUREMENTS OF ATHEROSCLEROTIC CORONARY ARTERY PLAQUES S I. Diab, S. ElTobgi, M. Ibrahim, K. Sorour, M. Abdel Ghany (Cairo, Egypt) D 372 ATHEROSCLEROTIC LESION AND ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH 266 A MYOCARDIAL BRIDGING ASSESED BY INTRACORONARY ULTRASOUND Y S.W. Rha, S.Y. Suh, J.W. Kim, C.G. Park, H.S. Seo, D.J. Oh (Seoul, South Korea) 373 SPATIAL DISTRIBUTION OF CORONARY ARTERIAL DISTENSIBILITY ASSESSED BY 266 INTRAVASCULAR ULTRASOUND - IN RELATION TO BIFURCATION SITE J.W. Kim, H.S. Seo, B.W. Cheon, H.W. Kim, H.H. Kim, S.K. Moon, S.Y. Suh, S.W. Rha, C.G. Park, D.J. Oh (Seoul, South Korea) 374 DETECTION OF CORONARY ARTERY STENOSES USING BREATH-HOLD MAGNETIC 266 RESONANCE CORONARY ANGIOGRAPHY. COMPARISON WITH CONVENTIONAL X-RAY ANGIOGRAPHY S. Leonetti, R. Licitra, A. Arrivi, F. Mirabelli, M. Scappaticci, G. Tanzilli, C. Gaudio (Rome, Italy) 375 REPRODUCIBILITY OF THE CAROTID VESSEL WALL AREA AND DIMENSIONS 267 AT 3.0T MRI R. Alizadeh Dehnavi, J. Doornbos, J.T. Tamsma, M. Stuber, H. Putter, H.J. Lamb, A. de Roos (Leiden, The Netherlands and Baltimore, MD, USA) 376 CHANGES OF CAROTID ATHEROMA SEEN BY CONTRAST-ENHANCED HIGH RESOLUTION 267 MRI AFTER PROLONGED TREATMENT WITH USUAL DOSE OF STATINS I.L. Rhee, Y.H. Choe, D.K. Kim, S.H. Lee, J.E. Park (Seoul, South Korea ) 377 CIRCULAR BLOOD FLOW IN AORTIC ARCH AND INITIAL FACTORS OF ATHEROSCLEROSIS 267 I. Todua, V. Beraia (Tbilisi, Georgia) 378 THE FORGOTTEN SIDE: ASSESSMENT OF INFLAMMATORY BURDEN CONTRALATERAL 267 TO SYMPTOMATIC CAROTID STENOSIS USING HIGH RESOLUTION USPIO ENHANCED MR IMAGING T. Tang, S.P.S. Howarth, S.R. Miller, R. Trivedi, M.J. Graves, J.U. King Im, A. Brown, P. Kirkpatrick, M.E. Gaunt, J.H. Gillard (Cambridge, Harlow and Greenford, UK)

93 379 FEASIBILITY CHARACTERIZATION OF ATHEROSCLEROTIC PLAQUE BY MAGNETIC 267 RESONANCE MICROSCOPY ON THE MURINE MODEL OF ATHEROSCLEROSIS A. Naumova, V. Yarnykh, M. Ferguson, M. Rosenfeld, C. Yuan (Seattle, WA, USA) 380 PERFUSIONAL SCINTIGRAPHIC STUDY IN PATIENTS WITH ACUTE CORONARY 268 SYNDROME AND SLOW CORONARY FLOW A. Arrivi, S. Leonetti, R. Licitra, M. Scappaticci, F. Mirabelli, G. Tanzilli, C. Gaudio, E. Mangeri (Rome, Italy) 381 SCREENING OF PERIPHERAL ARTERIAL DISEASE BY MEANS OF AN 268 OSCILLOTONOMETRIC BLOOD PRESSURE MONITOR A. Planas, A. Clara, P. Armario, R. Hernandez, F. Castro, M.P. Martorell, R. Faro, F. Vidal-Barraquer (Hospitalet and Barcelona, Spain) 382 ARE SURROGATE MARKERS OF ATHEROSCLEROTIC DISEASE USEFUL IN CLINICAL 268 EVALUATION OF PATIENTS WITH TYPE 2 DIABETES MELLITUS? C. Irace, F. Caruso, F. Dell'Aquila, C. Cortese, A. Gnasso (Catanzaro and Rome, Italy) 383 CLINICAL SIGNIFICANCE OF THE CORONARY CALCIFICATION SCORE BY 268 MULTI-DETECTOR ROW COMPUTED TOMOGRAPHY FOR THE EVALUATION OF CORONARY STENOSIS R. Mitsutake, H. Niimura, S. Miura, B. Zhang, A. Iwata, H. Nishikawa, K. Kumagai, K. Shirai, A. Matsunaga, K. Saku (Fukuoka, Japan) 384 CAROTID STENOSIS VERSUS TOTAL PLAQUE AREA AS PHENOTYPES OF 269 ATHEROSCLEROSIS J.D. Spence (London, ON, Canada) 385 CORONARY CALCIUM SCORE IS ASSOCIATED WITH BLOOD MYELOPEROXIDASE LEVEL 269 A. Deniz, T. Hazirolan, B. Yavuz, L. Tokgozoglu, O. Duzguncinar, E. Demirpence, T. Bayrak, A. Bayrak, K. Aytemir (Ankara, Turkey) 386 AGE-SPECIFIC RELATIONSHIP BETWEEN AORTIC PULSE WAVE VELOCITY AND LEFT 269 VENTRICULAR GEOMETRY AND FUNCTION IN HYPERTENSION M. Mannarino, G. Schillaci, M. Pirro, G. Pucci, G. Savarese, G. Vaudo, L. Pasqualini, T E. Mannarino (Perugia, Italy) U 387 INTIMA-MEDIA THICKNESS HAS A POSITIVE PREDICTIVE VALUE FOR RENAL 269 E ARTERY STENOSIS J.-L. Megnien, N. Denarie, V. Joguet, J. Levenson, A. Simon (Paris, France) S 388 A NEW HEART RATE VARIABILITY ANALYSIS APPROACH. MAY INFORMATION PLAY 269 D A GREATER ROLE IN OUR CLINICS? A M. Manca, J.H. Christensen, M. Kowalska, M. Degli Esposti (Bologna, Italy and Aalborg, Y Denmark)

94 POSTER AREA “A” TUESDAY, June 20 389-518

POSTER DISPLAY: for the duration of one day (Tuesday, June 20 from 8.30 am to 6.30 pm). Participants may view the posters displayed during this day.

Tu-P10 Poster Session 10 poster BIOMARKERS FOR CARDIOVASCULAR DISEASE abstract bk. board no.: page ref.:

389 EFFECTS OF SHORT-TERM AND LONG-TERM HYPOXIA ON CARDIAC APOPTOSIS IN 270 RAT HEART S.D. Lee, W.W. Kuo, C.Y. Huang (Taichung, Taiwan) 390 MORE ACTIVATED CARDIAC MITOCHONDRIAL-DEPENDENT APOPTOTIC PATHWAY 270 IN OBESITY S.D. Lee, C.Y. Huang, W.W. Kuo, F.L. Wu (Taichung, Taiwan) 391 DETECTION OF APOPTOTIC (FAS, FASL) AND ANTIAPOPTOTIC (BCL-2) MARKERS IN 270 PATIENTS WITH ACUTE CORONARY SYNDROMES A. Bossowska, A. Bossowski, B. Kiersnowska-Rogowska, B. Galar (Bialystok, Poland) 392 EXERCISE-INDUCED APOPTOSIS IN ENDOTHELIAL CELLS AND RENAL TUBULES IN 270 RAT M. Podhorska-Okolow, P. Dziegiel, A. Szuba, B. Krajewska, K. Rossini, U. Carraro, M. Zabel T (Wroclaw, Poznan, Poland and Padua, Italy) U 393 RELATIONSHIP BETWEEN SODIUM IODIDE SYMPORTER & THYROID PEROXIDASE 271 EXPRESSION AND APOPTOTIC MARKERS ON THYROCYTES FROM GRAVES' PATIENTS E A. Bossowski, B. Czarnocka, A. Stasiak-Barmtua, K. Bardadin, M. Urban, J. Dadan S (Bialystok and Warsaw, Poland) D 394 THE EFFECT OF IL-10 ON CARDIOMYOCYTES APOPTOSIS DURING 271 A ISCHEMIA-REPERFUSION S. Chu, W. Ding, D. Cai, C. Tang (Beijing, China) Y 395 NEUTROPHIL ACTIVATION AND RELEASE OF GRANULAR CONTENTS MAY LEAD TO 271 MONOCYTE/MACROPHAGE RECRUITMENT AND APOPTOSIS E. Laurent, S. Parthasarathy (Atlanta, GA and New Orleans, LA, USA) 396 APOPTOSIS INDUCED BY OXIDIZED LOW-DENSITY LIPOPROTEIN AND 271 7BETA-HYDROXYCHOLESTEROL IN T CELLS AND NK CELLS W. Li, X.-M. Yuan, L. Jonasson (Linköping, Sweden) 397 RELATION BETWEEN HOMOCYSTEINE SERUM LEVELS AND LIPID PARAMETERS IN 271 CHILDREN AT RISK OF CHD A. Sierakowska Fijalek, P. Kaczmarek, L. Pokoca, M. Wosik Erenbek, Z. Baj (Lodz, Poland) 398 REDUCED ANTIOXIDANT CAPACITY IN HYPERHOMOCYSTEINEMIC PATIENTS WITH 272 PERIPHERAL ARTERIAL OCCLUSIVE DISEASE V.M. Shmeleva, L.P. Rybakova (St. Petersburg, Russia) 399 HOMOCYSTEINE AND ITS RELATION WITH CORONARY STENOSIS 272 N. Heta Alliu, L. Simoni, E. Refatllari, A. Bulo, I. Korita, A. Goda, A. Doko, I. Temali (Tirana, Albania) 400 THE SIGNIFICANCE OF HOMOCYSTEINE ON DIABETUS MELITUS 272 S. Pagoni, S. Paximadas, M. Vagena, K. Rousodimos, P. Nikitopoulou, G. Kalokerinos, G. Katsigianni (Athens, Greece) 401 HYPERHOMOCYSTEINEMIA AS A RISK FACTOR FOR STROKE 272 D. Agapakis, G. Ntaios, E. Massa, C. Savopoulos, G. Kaiafa, A. Hatzitolios (Thessaloniki, Greece) 402 DETERMINATION OF HOMOCYSTEINE IN PATIENTS WITH ARTERIAL THROMBOSIS 272 M. Krstevska, T. Darkovska, S. Dzhekova-Stojkova, G. Bosilkova, S. Kostovska (Skopje, Macedonia)

95 403 ASSOCIATION OF HOMOCYSTEINE, VITAMIN B12 AND FOLATE SERUM LEVELS WITH 273 PROSTATIC SPECIF ANTIGEN(PSA) SERUM LEVELS P. Fernández-Riejos, C. Sánchez Mora, S. Hijano, M.C. Cruz, A.I. Orive, A. Barco, F. Fabiani (Seville, Spain) 404 HOMOCYSTEINE-N-PROTEINS IN CAROTID ARTERY PLAQUE 273 I. Ciari, E. Marinello, L. Terzuoli, C. Felici, G. Ramponi, B. Porcelli (Siena and Florence, Italy) 405 INCREASED LEVELS OF CYSTEINE AND HOMOCYSTEINE IN SARDINIAN 273 CENTENARIANS (AKEA-PROJECT) C. Carru, A. Zinellu, S. Sotgia, E. Ricciardi, A. Mura, G. Pes, C. Franceschi, G. Baggio, L. Deiana (Sassari, Bologna and Padua, Italy) 406 PLASMA HOMOCYSTEINE LEVELS IN POLYCYSTIC OVARY SYNDROME 273 A. Atanasova, S. Popovska, G.L. Dimitrov (Skopje, Macedonia) 407 CLINICAL SIGNIFICANCE OF SERUM HOMOCYSTEINE AND ITS RELATION WITH 274 CORONARY STENOSIS N. Heta Alliu, L. Simoni, A. Bulo, E. Refatllari, I. Korita, A. Goda, A. Doko, I. Temali (Tirana, Albania) 408 ELEVATED LEVEL OF SERUM HS-CRP AND HOMOCYSTEINE IN PATIENTS WITH 274 CORONARY HEART DISEASE (CHD) AND ITS RELATION WITH LIPID PROFILE N. Heta Alliu, A. Bulo, E. Refatllari, I. Korita, A. Goda, A. Doko, L. Simoni, I. Temali (Tirana, Albania) 409 BETAINES AFFECT PLASMA TOTAL HOMOCYSTEINE CONCENTRATIONS AND 274 INDICES OF INSULIN RESISTANCE P.M. George, M. Lever, S. Slow, S.T. Chambers (Christchurch, New Zealand) 410 REGULATION OF HOMOCYSTEINE-INDUCED SUPEROXIDE ANION GENERATION 274 AND NUCLEAR FACTOR KAPPA B ACTIVATION BY FOLIC ACID K. O, K.W. Au-Yeung, C.W. Woo, E.R.V. Edirimanne, Y.L. Siow (Winnipeg, MB, Canada) 411 PLASMA HOMOCYSTEINE DISTRIBUTION AND VITAMIN STATUS IN A POPULATION 275 OF CHILDREN WITH FAMILIA HYPERCHOLESTEROLEMIA T S. Rossi, C. Pederiva, R. Restelli, F. Ferrante, M. Sala, E. Riva, M. Giovannini (Milan, Italy) U 412 HOMOCYSTEINE STIMULATES SCAVENGER RECEPTOR (CD36) EXPRESSION IN 275 E MACROPHAGES THROUGH PPAR GAMMA ACTIVATION, AND AGED GARLIC EXTRACT REVERSES IT S N. Ide, C. Keller, N. Weiss (Munich, Germany) D 413 POSTER WITHDRAWN – A 414 RELATIONSHIP OF HOMOCYSTEINE LEVELS WITH PARAOXONASE ACTIVITY AND 275 Y LIPOPROTEIN PROFILE IN ADULT POPULATION OF WEST POMERANIA H. Bukowska, A. Mierzecki, T. Wesolowska, K. Chelstowski, I. Goracy, M. Naruszewicz (Szczecin, Poland) 415 STUDY OF THE EFFECT OF LIPOFACTOR ON SERUM HOMOCYSTEINE, HIGH SENSITIVE 275 C-REACTIVE PROTEIN AND LIPIDS IN PATIENTS WITH DYSLIPIDEMIA AND OVERWEIGHT N.I. Doncheva, B. Popov, M. Boev, R. Shekerdjiski (Sofia, Bulgaria) 416 CIRCADIAN PATTERN OF HOMOCYSTEINE, INTERLEUKIN-6 AND C-REACTIVE PROTEIN 276 IN PATIENTS WITH HYPERTENSION AND IN PATIENTS WITH OBSTRUCTIVE SLEEP APNEA H. Berent, K. Kuczynska, M. Dutkiewicz, B. Symonides, P. Gryglas, J. Lewandowski, B. Wocial, M. Lapinski (Warsaw, Poland) 417 RELATION BETWEEN HOMOCYSTEINE AND HEAT SHOCK PROTEINS IN GENERAL 276 POPULATION E. Dulin-Iñiguez, M.C. Guisasola-Zulueta, M.M. Desco-Menéndez, M.J. Sánchez-Fernández, P. García-Barreno (Madrid, Spain) 418 ACTIVATION OF cAMP RESPONSE ELEMENT BINDING PROTEIN (CREB) DURING 276 HYPERHOMOCYSTEINEMIA C.W. Woo, Y.L. Siow, K. O (Winnipeg, MB, Canada) 419 HOMOCYSTEINE AS THE KEY CAUSATIVE FACTOR IN CVD AS WELL AS ALZHEIMER'S 276 DISEASE A.J.C. Strydom (Bloemfontein, South Africa) 420 TIME-COURSE OF REDOX-STATUS AND INFLAMMATORY MARKERS IN ACUTE 276 CORONARY SYNDROMES V. Sedda, B. De Chiara, R. Caruso, R. De Maria, C. Dellanoce, M. Caracciolo, A. Mafrici, A. De Biase, O. Parodi (Milan, Italy) 421 ANTIBODIES TO CHLAMYDIA PNEUMONIAE IN ACUTE AND CHRONIC PHASE OF 277 MYOCARDIAL INFARCTION TREATED WITH PTCA P.J. Kraml, T. Altannavch, J. Potockova, L. Fialova, K. Roubalova, M. Andel (Prague, Czech Republic)

96 422 DISREGULATED T-CELL FUNCTION AND ACUTE PHASE RESPONSE IN TYPE 1 AND 277 TYPE 2 DIABETES MELLITUS S. Giubilato, S. Brugaletta, D. Pitocco, V. Colafrancesco, M. Narducci, M. Conte, L. Biasucci, G. Ghirlanda, G. Liuzzo, F. Crea (Rome, Italy) 423 ROLE OF ENDOTHELIUM IN SUBCLINICAL ATHEROSCLEROSIS OF PRIMARY 277 SJÖGREN’S SYNDROME PATIENTS G. Vaudo, S. Marchesi, G. Lupattelli, G. Schillaci, A.R. Roscini, R. Gerli, M. Brozzetti, M. Pirro, M. Mannarino, E. Mannarino (Perugia, Italy) 424 HELICOBACTER PYLORI INFECTION IN RELATION TO HS-CRP AND LIPOPROTEIN 277 LEVELS IN PATIENTS WITH DYSLIPIDEMIA C. Liavas, C. Papadopoulos, Z. Koukoulidou, I. Kosmidou, J. Samouilidis, E. Vlachogiannis (Thessaloniki, Greece) 425 ANTI-BETA2-GLYCOPROTEIN I ANTIBODIES DO NOT INCREASE IN ACUTE 278 CORONARY SYNDROMES A.M.B. Medeiros, C.A. von Mulhen, L.C. Bodanese, G. Norman (Porto Alegre, Brazil and San Diego, CA, USA) 426 T CELL VACCINATION MODULATES EXPERIMENTAL ATHEROGENESIS 278 A. Varthaman, J. Khallou-Laschet, E. Groyer, A.T. Gaston, S. Kaveri, G. Caligiuri, A. Nicoletti (Paris, France) 427 COMPLEMENT C6 DEFICIENCY PROTECTS AGAINST DIABETES-INDUCED VASCULAR 278 DAMAGE IN RATS R. Candido, F. Fischetti, F. Tedesco, B. Toffoli, P. Durigutto, E. Manca, M. Fonda, L. Cattin, R. Carretta, B. Fabris (Trieste, Italy) 428 IMPAIRED CORTISOL RESPONSE IN PATIENTS WITH CORONARY ARTERY DISEASE - 278 RELATION TO INFLAMMATORY ACTIVITY J. Nijm, A.G. Olsson, L. Jonasson (Eksjö and Linköping, Sweden) 429 BCT-1, AN ETHANOL EXTRACT FROM HERB, INHIBITS INFLAMMATION IN 279 LIPOPOLYSACCHARIDE-STIMULATED MACROPHAGES BY SUPPRESSING REDOX-BASED NF-KB ACTIVATION T S.E. Yoo, K.M. Kim, M.Y. Park, J.Y. Choi, H.M. Shin, J.E. Park (Seoul and Kyongju, U South Korea) E 430 CONCENTRATIONS OF SERUM LEPTIN AND PLASMA C-REACTIVE PROTEIN IN 279 ADULT POPULATION: EFFECT OF COMORBIDITIES S L. Viikari, O. Raitakari, J. Viikari, R. Huupponen (Turku, Finland) D 431 EFFECT OF VERY-LOW-CALORIE-DIET (VLCD) ON CYTOKINE AND ADHESION 279 A MOLECULES IN PATIENTS WITH OBESITY Y S. Usui, K. Kuboki, K. Iso, E. Murakami, G. Yoshino (Tokyo, Japan) 432 ASSOCIATION OF C-REACTIVE PROTEIN AND FIBRINOGEN WITH THE SEVERITY OF 279 ANGIOGRAPHICALLY VERIFIED CORONARY ARTERY DISEASE V. Spasojevic-Kalimanovska, L. Memon, N. Bogavac-Stanojevic, D. Ostric-Kalimanovska, Z. Jelic-Ivanovic, S. Spasic (Belgrade, Serbia-Montenegro) 433 C-REACTIVE PROTEIN DURING CHRONIC HEMODIALYSIS TREATMENT 279 V. Soska, D. Sobotova (Brno, Czech Republic) 434 INFLUENCE OF EOTAXIN 67G>A POLYMORPHISM ON PLASMA EOTAXIN CONCENTRATIONS 280 IN MYOCARDIAL INFARCTION SURVIVORS AND HEALTHY CONTROLS Y. Sheikine, B. Olsen, B. Gharizadeh, K. Jatta, P. Tornvall, M. Ghaderi (Stockholm and Orebro, Sweden) 435 THE ASSOCIATION OF LEUKOCYTE COUNT, C-REACTIVE PROTEIN AND METABOLIC 280 SYNDROME IN JAPANESE J. Sasaki, M. Fujii, R. Nonaka, K. Naito, R. Togashi, K. Yamamoto, S. Kono, M. Yamaguchi (Fukuoka, Japan) 436 EVIDENCE FOR THE PRESENCE OF INTACT SERUM AMYLOID A APOLIPOPROTEIN 280 (APO SAA) IN AMYLOID DEPOSITS H. Lebrazi, H. Lahrach, H. Souhaili, H. Taki, A. Derouiche, R. Saile (Casablanca, Morocco) 437 CO-INFECTION RATES VERSUS INFLAMMATION, GROWTH FACTORS AND 280 PROGRESSION OF EARLY ATHEROMAS M.M. Reis, J.M. Gois, M.L. Higuchi, M.H. Higuchi-dos-Santos, J. Diament, J.M. Souza, A.S. Oliveira, J.A.F. Ramires (São Paulo, Brazil) 438 CIRCULATING LEVELS OF INFLAMMATORY MEDIATORS IN PATIENTS WITH AND 281 WITHOUT RESTENOSIS AFTER CORONARY STENT IMPLANTATION M. Protasiewicz, A. Derkacz, R. Poreba, W. Kuliczkowski, A. Szuba, M. Kawecka, W. Mazurek (Wroclaw, Poland)

97 439 PROGNOSTIC VALUE OF PLASMA HIGH-SENSITIVITY C-REACTIVE PROTEIN LEVELS 281 IN JAPANESE PATIENTS WITH STABLE CORONARY ARTERY DISEASE Y. Momiyama, A. Kawaguchi, I. Kajiwara, R. Ohmori, F. Ohsuzu, M. Tsushima (Saitama, Hokkaido, Kumamoto and Shizuoka, Japan) 440 LEVELS OF THE CHEMOKINE RECEPTOR ANTAGONIST EOTAXIN-3 PREDICTS FUTURE 281 ADVERSE CARDIAC EVENTS IN PATIENTS WITH CORONARY ARTERY DISEASE P. Minoretti, A. Aldeghi, V. Olivieri, E. Coen, M. Arra, C. Barranco, R. Sangiorgio, E. Emanuele (Pavia, Italy) 441 ROLE OF LOW-GRADE INFLAMMATION MARKERS AND SOLUBLE CELL ADHESION 281 MOLECULES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS O. Korzh, O. Pavlova (Kharkov, Ukraine) 442 CORRELATION OF C-REACTIVE PROTEIN WITH OTHER BIOCHEMICAL INDICATORS 281 IN PATIENTS HAVING ACUTE CORONARY SYNDROME G. Bahs, A. Kalvelis, V. Kalme, M. Zilica, J. Verbovenko, A.V. Putnina (Riga, Latvia) 443 PLASMA LIPIDS AND MARKERS OF INFLAMMATION IN PATIENTS WITH A 6-MONTHS 282 HISTORY OF MYOCARDIAL INFARCTION OR STROKE G. Gromadzka, I. Sarzynska-Dlugosz, I. Kurkowska-Jastrzebska, K. Filipiak, A. Czlonkowska (Warsaw, Poland) 444 CIRCULATING MARKERS OF INFLAMMATION IN PATIENTS WITH STABLE ANGINA 282 PECTORIS I. Golikova, O. Lomakovsky, O. Nemchyna, M. Lutay (Kiev, Ukraine) 445 INFLAMMATORY MARKERS IN FAMILIAL COMBINED HYPERLIPIDEMIA 282 M. Gentile, P. Pauciullo, S. Ubaldi, G. Marotta, F. Jossa, G. Iannuzzo, F. Faccenda, P. Rubba (Naples, Italy) 446 RELATIONSHIP BETWEEN C-REACTIVE PROTEIN AND CEREBROVASCULAR STENOSIS 282 Z. Flegar-Mestric, D. Vrhovski-Hebrang, S. Perkov, V. Preden-Kerekovic, A. Hebrang, V. Vidjak, D. Odak, A. Grga (Zagreb, Croatia) 447 PLATELET ACTIVATION AND BIOCHEMICAL MARKERS OF INFLAMMATION IN 283 T PATIENTS WITH DEPRESSION AND CORONARY HEART DISEASE U L.I. Bouriachkovskaia, E.O. Poliakova, A.V. Zorin, I.A. Uchitel, N.L. Dovlatova, E A.B. Sumarokov, V.P. Masenko, T.V. Kuznetsova (Moscow, Russia) 448 HS-CRP LEVEL IN RELATION WITH SEVERITY OF CORONARY LESIONS IN PATIENTS 283 S UNDERGOING DIAGNOSTIC CORONARY ANGIOGRAPHY D A. Bulo, N. Heta, E. Refatllari, I. Korita, A. Goda, A. Doko, L. Simaku, I. Temali A (Tirana, Albania) Y 449 ERYTHROCYTE SEDIMENTATION RATE AND CORONARY ATHEROSCLEROSIS 283 J. Auer, T. Weber, R. Berent, G. Lamm, W. Stainer, G. Krennmair, B. Eber (Wels, Austria) 450 SIMILARITY AND DIFFERENCE BETWEEN OSTEOPROTEGERIN (OPG) AND 283 OSTEOPONTIN (OPN) LEVELS IN PATIENTS RECEIVING CORONARY ROTATIONAL ATHERECTOMY (RA) H. Akao, M. Kitayama, H. Uenishi, T. Kasuga, M. Asano, R. Sato, A. Motoyama, M. Wakasa, C. Kitaoka, K. Kajinami (Ishikawa, Japan) 451 CAROTID ATHEROSCLEROSIS IS ASSOCIATED WITH ENHANCED B-CHEMOKINE 284 LEVELS IN PATIENTS ON CONTINUOUS AMBULATORY PERITONEAL DIALYSIS K. Pawlak, D. Pawlak, S. Brzosko, M. Mysliwiec (Bialystok, Poland) 452 C-REACTIVE PROTEIN INHIBIT COMPLEMENT-MEDIATED PLATELET ACTIVATION 284 SUGGESTING A PROTECTIVE ROLE IN ATHEROGENESIS C. Skoglund, C. Sjöwall, T. Skogh, J. Wetterö, P. Tengvall, T. Bengtsson (Linköping, Sweden) 453 EQUAL EFFECTS OF CLOPIDOGREL AS COMPARED TO ASPIRIN ON CIRCULATING 284 MARKERS OF INFLAMMATION IN PATIENTS WITH CORONARY HEART DISEASE S. Solheim, A. Pettersen, H. Arnesen, I. Seljeflot (Oslo, Norway) 454 COMPARATIVE EFFECTS OF DOXAZOSIN AND GUANABENZ ON VASCULAR 284 INFLAMMATION AND COLLAGEN METABOLISM IN PATIENTS WITH MORNING HYPERTENSION E. Terada, B. Saji, G. Yoshino, T. Morita (Tokyo, Japan) 455 THE ASSOCIATION BETWEEN STENT RESTENOSIS AND SERUM GAMMA GLUTAMYL 284 TRANSFERASE ACTIVITY T. Ulus, A. Yildirir, S. Demirtas, Y.C. Gursoy, E. Sade, A. Temiz, M. Bilgi, A. Aydinalp, H. Muderrisoglu (Ankara, Turkey) 456 EFFECT OF VALSARTAN ON CRP, ADHESION MOLECULES AND URINE OXIDATIVE 285 STRESS MARKERS IN TYPE2 DIABETIC SUBJECTS G. Yoshino, E. Murakami, S. Abe, E. Araki (Tokyo, Japan)

98 457 INFLAMMATORY MARKERS AND CAROTID INTIMA MEDIA THICKNESS (C-IMT) IN 285 STABLE IHD PATIENTS B. Porta, M. Camera, D. Baldassarre, M. Amato, M. Arquati, E. Tremoli, M. Cortellaro (Milan, Italy) 458 GENETIC EFFECT OF CRP CONCENTRATION 285 R. Poledne, M. Setina, A. Lorenzova, H. Pospisilova, P. Stavek (Prague and Ceske Budejovice, Czech Republic) 459 INFLAMMATORY BIOMARKERS AND CAROTID ARTERY STENOSIS 285 E. Ben Assayag, S. Berliner, I. Bova, I. Shapira, N.M. Bornstein (Tel-Aviv, Israel) 460 N-TERMINAL PRO-B-TYPE NATRIURETIC PEPTIDE IN RISK STRATIFICATION AFTER 286 ACUTE MYOCARDIAL INFARCTION IN PATIENTS ON LONG-TERM BETA-BLOCKER THERAPY G. Jonsson, M. Abdelnoor, S. Landaas, C. Müller, S.E. Kjeldsen, I. Os, A. Westheim (Oslo, Norway) 461 LONG-TERM OUTCOME OF PATIENTS WITH UNSTABLE ANGINA AND EARLY 286 CORONARY REVASCULARIZATION: PROGNOSTIC VALUE OF FIBRINOGEN LEVELS J. Rueda, E. Zorio, O. Cano, M.T. Izquierdo, M.A. Arnau, A. Osa, L. Martínez-Dolz, L. Almenar, M. Palencia, A. Salvador (Valencia, Spain) 462 RELATIONSHIP BETWEEN PREVIOUS INFLAMMATORY BIOMARKERS LEVEL, 286 CPR-HS, AND CORONARY AETIOLOGY IN ACUTE CHEST PAIN C. Holgado, M. Maestre, J. De La Vega, T. Holgado, M.A. Rico, A. Aznar, F. Fabiani (Seville, Spain) 463 MONOCYTE CHEMOATTRACTANT PROTEIN-1 IS BETTER MARKER OF 286 ANTI-INFLAMMATORY EFFECT OF ATORVASTATIN THAN C-REACTIVE PROTEIN IN ACUTE CORONARY SYNDROME M. Lewandowski, B. Millo, J. Zielonka, Z. Kornacewicz-Jach, M. Naruszewicz, R. Kaliszczak, E. Plonska (Szczecin, Poland) 464 LACK OF EFFECT OF LOW-DOSED ATORVASTATIN ON TUMOR NECROSIS FACTOR 287 ALPHA (TNF ALPHA) LEVEL IN ACUTE CORONARY SYNDROME T M. Lewandowski, B. Millo, J. Zielonka, Z. Kornacewicz-Jach, M. Naruszewicz, U R. Kaliszczak, E. Plonska (Szczecin, Poland) E 465 THE PREDICTIVE VALUE OF THE CRP, FIBRINOGEN AND ESR IN ISCHEMIC HEART 287 DISEASE (IHD) S M. Jangavadze, I. Khakhutaishvili (Tbilisi, Georgia) D 466 SEROLOGIC INFECTION AND INFLAMMATORY MARKERS IN CORONARY ARTERY 287 A DISEASE Y D. Gusev, E. Paltseva (Moscow, Russia) 467 THE ACUTE-PHASE PROTEIN ALPHA1-ACID GLYCOPROTEIN ACTIVATES NEUTROPHIL 287 GRANULOCYTES VIA SIGLEC-5 (CD170) P. Gunnarsson, L. Levander, P. Påhlsson, M. Grenegård (Linköping, Sweden) 468 RELATIONSHIP OF SERUM GAMMA-GLUTAMYLTRANSFERASE AND ADIPOSITY 287 MEASURES WITH C-REACTIVE PROTEIN IN SEVERE OBESE WOMEN M. Georgiev, D. Micic, M. Sumarac-Dumanovic, D. Stamenkovic-Pejkovic, A. Kendereski, S. Zoric, G. Cvijovic, K. Cubrilo (Belgrade, Serbia-Montenegro) 469 INFLAMMATION, CHLAMYDIA PNEUMONIAE SEROPOSITIVITY IN PATIENTS UNDERGOING 288 CORONARY ANGIOPLASTY WITH AND WITHOUT STENT IMPLANTATION D. Drobniak-Heldak, W. Kolasinska-Kloch, R. Rajtar, M. Kloch, B. Kiec-Wilk, A. Zdzienicka, A. Dembinska-Kiec (Cracow, Poland) 470 MARKERS OF INFLAMMATION IN ACUTE CORONARY SYNDROMES. CRP AS 288 PROGNOSTIC FACTOR IN SHORT AND LONG TERM PROGNOSIS I. Burazor, M. Burazor, S. Ciric-Zdravkovc, S. Nagorni, E. Dimitrijevic, J. Dordjevic, Z. Burazor, N. Burazor, M. Zivkovic (Nis, Serbia-Montenegro) 471 NFKB-INDUCED GENE EXPRESSION IN VEIN GRAFT INTIMAL HYPERPLASIA 288 J. Finch, S. Gregan, B. Foxwell, D. Haskard, C. Monaco, P. Hornick (London, UK) 472 THE INFLAMMATION BIOMARKERS CORRELATE WITH INTIMA-MEDIA THICKNESS 288 IN DYSLIPEMIC CHILDREN P. Giachino, P. Saracco, S. Martino, V.G. Naretto, N. Crescenzio, E. Rolfo, O. Guardamagna (Turin, Italy) 473 THE ASSOCIATION BETWEEN SERUM GAMMA GLUTAMYL TRANSFERASE, 289 C-REACTIVE PROTEIN AND LOW DENSITY LIPOPROTEIN IN SIGNIFICANT CORONARY ARTERY DISEASE S. Demirtas, T. Ulus, A. Yildirir, O. Demir, A. Temiz, S. Balta, G. Kaynar, M.A. Kucuk, M. Bilgi, H. Muderrisoglu (Ankara, Turkey)

99 474 IMMUNOLOGICAL AND STRUCTURAL MARKERS OF ATHEROSCLEROSIS IN 289 PATIENTS WITH DISTURBANCES OF CARBOHYDRATE METABOLISM L.A. Chugunova, M.V. Shestakova, N.A. Galitsina, O.Y. Sukhareva (Moscow, Russia) 475 INTERLEUKIN-6 PROMOTER POLYMORPHISMS INFLUENCE THE INTER-INDIVIDUAL 289 MACROPHAGE INFLAMMATORY RESPONSE L. Beeton, H. Khwaja, K. Bodman-Smith, G. Ferns, F. Green (Guildford and Oxford, UK) 476 SERUM HIGH SENSITIVE C REACTIVE PROTEIN IN HYPERALPHALIPOPROTEINEMIC 289 S. de Barros-Mazon, M.L.Y. Cruz, L.N. Castilho, E.C. de Faria (São Paulo, Brazil) 477 VASCULAR CHIMERISM OF HUMAN CARDIAC ALLOGRAFT IS THE RESULT OF 289 INFLAMMATORY RESPONSE P. Religa, M. Grudzinska, N. Wolmer, K. Bojakowski, J. Nozynski, M. Zakliczynski, M. Zembala, Z. Gaciong, C. Soderberg-Naucler (Stockholm, Sweden, Warsaw and Zabrze, Poland) 478 ACUTE ELEVATION OF INTERLEUKIN6 WITH REDUCTION OF LIPOPROTEIN(A) 290 PREDICTS RESTENOSIS OF ANGIOPLASTY A. Fujino, T. Watanabe, K. Taira, K. Ashikawa, Y. Maruyama (Yonezawa and Fukushima, Japan) 479 INFLAMMATORY MARKERS, HEAT SHOCK PROTEIN 60 AND CHLAMYDIA 290 PNEUMONIAE INFECTION IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE TREATED WITH PTCA R. Rajtar, W. Kolasinska-Kloch, M. Kloch, B. Kiec-Wilk, L. Partyka, A. Zdziennicka, A. Dembinksa-Kiec (Cracow, Poland) 480 ENDOGENOUS SEX HORMONES LEVELS AND C-REACTIVE PROTEIN IN 290 MIDDLE-AGED MEN H.R. Nakhai Pour, D.E. Grobbe, M. Muller, Y.T. van der Schouw (Utrecht, The Netherlands) 481 RELATIONSHIP OF DIETARY INTAKE OF FATTY ACIDS TO PLASMA C-REACTIVE 290 PROTEIN IN JAPANESE S. Yoneyama, K. Miura, S. Sasaki, K. Yoshita, Y. Morikawa, Y. Soyama, M. Ishizaki, T. Kido, Y. Naruse, H. Nakagawa (Ishikawa, Tokyo and Toyama, Japan) T 482 POSSIBLE MECHANISM UNDERLYING THE ASSOCIATION BETWEEN C-REACTIVE 291 U PROTEIN AND CARDIOVASCULAR RISK E M.D. van der Krabben, D. Posthouwer, H.A.M. Voorbij, D.E. Grobbee, J.C.M. Meijers, J.G. van der Bom (Leiden, Utrecht and Amsterdam, The Netherlands) S 483 ANALYSIS OF SERUM LEVEL OF CYTOKINES AND ADHESION MOLECULES AS A 291 D NEW RISK FACTORS IN ACUTE CORONARY SYNDROMES A A. Bossowska, A. Bossowski, B. Kiersnowska-Rogowska, B. Galar (Bialystok, Poland) Y 484 PRE-EXISTENCE INFECTION, IMMUNOSUPPRESSIVE THERAPY AND ACCELERATED 291 GRAFT CORONARY ATHEROSCLEROSIS N.V. Sambiase, M.L. Higuchi, M.M. Reis, N. Stolf, S. Oliviera, J.L. Ramires (São Paulo, Brazil) 485 MICROPARTICLES FROM PLATELETS (PMP), ENDOTHELIA (EMP), LEUKOCYTES (LMP), 291 AND RBC (RMP) EXHIBIT DISTINCT HEMOSTATIC ACTIVITIES: NEW FINDINGS ON RMP W. Jy, Y.S. Ahn, L.L. Horstman, J.J. Jimenez, E.R. Ahn, V. Fontana (Miami, FL, USA) 486 MICROPARTICLES FROM RBC (RMP) EXHIBIT HEMOSTATIC ACTIVITIES IN VITRO AND 292 IN VIVO, AND APPEAR TO PROTECT ITP PATIENTS FROM THROMBOCYTOPENIC BLEEDING Y.S. Ahn, W. Jy, L.L. Horstman, V. Fontana, J.J. Jimenez, E.R. Ahn (Miami, FL, USA) 487 FREE RADICALS DURING HYPERTRIGLYCERIDEMIA TREATMENT BY N-3 FATTY 292 ACIDS M. Zeman, P. Stopka, M. Vecka, A. Zak (Prague and Rez, Czech Republic) 488 EFFECT OF AGING ON ANTIOXIDANT PROTECTION MARKERS AND OXIDATIVE 292 DAMAGE OF BIOMOLECULES K. Volkovova, M. Staruchova, Z. Hudecova, M. Bacekova, C.S. Mislanova, L. Wsolova, M. Dusinska (Bratislava, Slovak Republic) 489 DISCORDANCE BETWEEN PHENOTYPIC AND GENOTYPIC DETERMINATIONS OF 292 HUMAN PARAOXONASE-1 IN UREMIC AND KIDNEY TRANSPLANTED PATIENTS G. Paragh, I. Seres, M. Harangi, Z. Pocsai, H.Z. Mirdamadi, L. Asztalos, L. Locsey, L. Kardos, E. Varga, R. Adany (Debrecen, Hungary) 490 EFFECTS OF HIGH CONCENTRATION OF GLUCOSE, LOW DENSITY LIPOPROTEIN 293 AND ANGIOTENSIN MEDIUM ON NADPH OXIDASE 4 AND APOPTOSIS OF ENDOTHELIAL CELLS S.L. Qu, S. Wang, F. Guo, X.D. Yang, J. Li (Beijing and Hunan, China) 491 THR40ALA AND ARG213GLY POLYMORPHISMS OF EXTRACELLULAR SUPEROXIDE 293 DISMUTASE EC-SOD GENE IN THE CAUCASIAN POPULATION FROM WESTERN ROMANIA C. Samoila, G. Otiman, A. Carter, S. Feuters, A. Anghel (Timisoara, Romania and Leeds, UK)

100 492 ANTI-OXIDATIVE EFFECT OF AZELNIDIPINE AS EVALUATED BY ANALYTICAL 293 CAPILLARY ISOTACHOPHORESIS K. Okamura, S. Miura, H. Tanigawa, Y. Uehara, B. Zhang, K. Saku (Fukuoka, Japan) 493 CIRCULATING MONONUCLEAR SUPEROXIDE PRODUCTION AND INFLAMMATORY 293 MARKERS FOR LONG-TERM PROGNOSIS IN PATIENTS WITH CARDIAC SYNDROME X H.B. Leu, C.P. Lin, T.C. Wu, S.J. Lin, J.W. Chen (Taipei, Taiwan) 494 VITAMIN C ADMINISTRATION INCREASES OXIDATIVE STRESS IN IRON 293 SUPPLEMENTED HEMODIALYSIS PATIENTS D. Borrey, A. Devriese, E. Mahieu, M. Langlois (Bruges, Belgium) 495 SERUM LEVEL OF SOLUBLE RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS 294 IS ASSOCIATED WITH CIRCULATING ADVANCED GLYCATION END PRODUCTS IN TYPE 2 DIABETES K.C.B. Tan, W.S. Chow, S.W.M. Shiu, R. Bucala, D.J. Betteridge (Hong Kong, China, New Haven, CT, USA and London, UK) 496 POSTER WITHDRAWN – 497 OXIDATIVE MODIFIED FIBRINOGEN AS MARKER OF OXIDATIVE STRESS IN 294 MYOCARDIAL INFARCTION Y.I. Ragino, V.A. Baum, A.A. Gromov (Novosibirsk, Russia) 498 A PROPOSED NEW COMPREHENSIVE INDEX OF OXIDATIVE STRESS: OXISCORE 294 F. Veglia, G. Cighetti, L. Zingaro, E. Tremoli, V. Cavalca (Milan, Italy) 499 CLINICAL IMPLICATION OF CIRCULATING LYSOPHOSPHATIDYLCHOLINE IN TYPE 2 294 DIABETICS: ROLE OF SERUM HYDROLYTIC ESTERASES Y. Kumon, S. Yamanaka, Y. Ikeda, H. Takeuchi, M. Inoue, K. Arii, T. Suehiro, K. Hashimoto, T. Sugiura (Nankoku Kochi, Japan) 500 DECREASED SERUM ANTIOXIDANT CAPACITY IN PATIENTS WITH DIABETES AND 295 ATHEROSCLEROSIS CAN BE AMELIORATED AFTER VITAMIN C AND E ADMINISTRATION D. Hamidi Alamdari, K. Paletas, T. Pegiou, M. Sarigianni, A. Tsapas, H. Kostidou, G. Koliakos (Thessaloniki, Greece) T 501 HSCRP, ISCHEMIA MODIFIED ALBUMIN LEVELS AND THE MODALITY OF 295 U SUPPLEMENTATION WITH VITAMIN E AND C AS PREDICTORS OF PLASMA E OXIDATIVE STRESS REDUCTION J. Hartwich, J. Goralska, D. Siedlecka, M. Dolecki, W. Drozdz, A. Dembinska-Kiec S (Cracow, Poland) D 502 PROTECTION OF VASCULAR CELLS FROM ENHANCED OXIDATIVE STRESS BY 295 A PARAOXONASE-2 Y S. Horke, P. Wilgenbus, M. Krüger, D. Strand, U. Förstermann (Mainz, Germany) 503 METALLOTHIONEIN SUPPRESSION OF NADPH OXIDASE ACTIVATION IS INVOLVED 295 IN THE PREVENTION OF ANGIOTENSIN-INDUCED CELL DEATH L. Cai, G. Zhou, Y.J. Kang (Louisville, KY, USA) 504 HUMAN PARAOXONASE-1 ACTIVITY AND INTIMA-MEDIA THICKNESS IN SUBJECTS 296 UNDER 55 YEARS OF AGE WITH CAROTID ARTERY DISEASE M. Harangi, I. Seres, M.T. Magyar, I. Csípö, E. Varga, S. Sipka, L. Csiba, D. Bereczki, G. Paragh (Debrecen, Hungary) 505 EFFECT OF HOMOCYSTEINE AND OTHER THIOL COMPOUNDS ON LOX-1 296 ACTIVATION BY OXIDISED LDL S. Miret, E. Dorignac, D. Maussang, G. Duchateau, W. Klaffke (Vlaardingen, The Netherlands) 506 CONJUGATED DIENES AND MALONDIALDEHYDE LEVELS IN PREMATURE 296 CORONARY ARTERY DISEASE A. Ghorbanihaghjo, N. Rashtchizadeh, M. Rohbaninoubar, A. Vatankhah (Tabriz, Iran) 507 HYDROXYRADICAL SCAVENGER EDARAVONE IMPROVES VASCULAR ENDOTHELIAL 296 FUNCTION AND RESTORES HDL CHOLESTEROL LEVEL IN LDL-RECEPTOR KNOCKOUT MICE S. Kimura, K. Ishikawa, A. Kobayashi, Y. Kamiyama, Y. Maruyama (Fukushima, Japan) 508 LEPTIN INDUCES ENDOTHELIN-1 GENE EXPRESSION VIA 296 RAS/RAF/EXTRACELLULAR SIGNAL-REGULATED KINASE PATHWAY IN RAT AORTIC SMOOTH MUSCLE CELLS J.C. Liu, H.H. Chao, C.H. Chen, T.H. Cheng (Taipei, Taiwan) 509 ATTENUATION OF ANGIOTENSIN II-MEDIATED REACTIVE OXYGEN SPECIES GENERATION 297 VIA CARBON MONOXIDE FROM HEME OXYGENASE-1 IN MACROPHAGES Y. Kamiyama, K. Ishikawa, A. Kobayashi, S. Kimura, Y. Maruyama (Fukushima, Japan)

101 510 PLASMA METHYLARGININES IN ACUTE AND CHRONIC CORONARY SYNDROMES 297 V. Cavalca, F. Veglia, I. Squellerio, G. Marenzi, P. Ravagnani, M. De Metrio, E. Tremoli (Milan, Italy) 511 DIMINISHED ACTIVITY OF NITRIC OXIDE SYSTEM IN PATIENTS WITH RESTENOSIS 297 AFTER CORONARY STENT IMPLANTATION A. Derkacz, M. Protasiewicz, R. Poreba, A. Skoczynska, P. Nowicki, R. Skalik, W. Mazurek (Wroclaw, Poland) 512 NITRIC OXIDE IN PREGNANCY 297 V. Maleska Ivanovska, B. Dejanova, B. Gerasimova, S. Petrovska, V. Antevska, K. Zafirovska (Skopje, Macedonia) 513 SHORT AND LONG-TERM EFFECT OF ELECTIVE PERCUTANEOUS TRANSLUMINAL 298 CORONARY ANGIOPLASTY ON L-ARGININE-NO PATHWAY IN CORONARY PATIENTS L. Zingaro, V. Cavalca, F. Veglia, G. Marenzi, P. Ravagnani, P. Montorsi, E. Tremoli (Milan, Italy) 514 GP91-PHOX IS DETERMINANT FOR ISCHEMIA-INDUCED OXIDATIVE STRESS AND 298 ARTERIAL VASODILATATION: A CLINICAL STUDY V. Sanguigni, P. Pignatelli, L. Loffredo, L. Lenti, R. Carnevale, M. Tesauro, A. Finocchi, P. Rossi, R. Lauro, F. Violi (Rome, Italy) 515 ASYMMETRIC DIMETHYLARGININE AS A NOVEL INDEPENDENT RISK FACTOR FOR 298 CARDIOVASCULAR DISEASE IN HEMODIALYSIS PATIENTS R. Cibulka, R. Siroka, D. Rajdl, J. Racek (Plzen, Czech Republic) 516 IMPAIRMENT OF THE NITRIC OXIDE/cGMP/PKG PATHWAY IN VASCULAR SMOOTH 298 MUSCLE CELLS FROM AN ANIMAL MODEL OF INSULIN RESISTANCE, THE ZUCKER FA/FA RAT I. Russo, P. Del Mese, G. Doronzo, L. Mattiello, G. Anfossi, M. Trovati (Orbassano, Italy) 517 AORTIC PULSE WAVE VELOCITY AS A PREDICTOR OF THE PRESENCE OF CAD IN 298 SUBJECTS WITH SUSPECTED CAD AND RELATIONSHIP WITH THE METABOLIC SYNDROME T A. Kotsia, K. Naka, M. Papafaklis, C. Bourantas, T. Tzimas, K. Vakalis, D. Fotiadis, U L. Michalis (Ioannina, Greece) E 518 DYSLIPIDEMIA IN SLE-RELATED CARDIOVASCULAR DISEASE: PARADOXICAL 299 LIPID PATTERN AND ANTIBODIES AGAINST APO A1 AND LIPOPROTEIN LIPASE S X. Hua, J. Su, E. Svenungsson, A. Cederholm, J. Frostegård (Stockholm, Sweden) D A Y

102 8.30 - 13.00 WEDNESDAY, June 21 ROOM 1

We-PL3 Plenary Session 3 NOVEL APPROACHES TO TREATMENT Chairs: O. Faergeman (Åarhus, Denmark); hour: A.M. Gotto, Jr. (New York, NY, USA); M. Averna (Palermo, Italy) abstract bk. page ref.: 8.30 - 9.00 ADIPOCYTOKINES: EMERGING THERAPEUTIC TARGET FOR METABOLIC 301 SYNDROME Y. Matsuzawa (Osaka, Japan) 9.00 - 9.30 HDL THERAPY FOR CARDIOVASCULAR DISEASES 301 G. Franceschini (Milan, Italy) 9.30 - 10.00 CAN CANDIDATE GENE GENOTYPES IMPROVE ESTIMATION OF CHD RISK 301 OVER-AND ABOVE CONVENTIONAL RISK FACTORS IN HEALTHY UK MEN? S.E. Humphries, J.A. Cooper, P.J. Talmud, G.J. Miller (London, UK) 10.00 - 10.30 STEM CELLS: ROLE IN CARDIOVASCULAR DISEASE PROGRESSION AND 302 THERAPY S. Dimmeler (Frankfurt, Germany) 10.30 End of the Session

10.30 - 11.00 BREAK - POSTERS - EXHIBITS

We-S12 Sponsored Symposium 12 PHYTOSTEROL-BASED FUNCTIONAL FOODS: NEW TOOLS IN CARDIOVASCULAR PREVENTION Chairs: E. Bruckert (Paris, France); R. Paoletti (Milan, Italy)

11.00 - 11.05 OPENING REMARKS – R. Paoletti (Milan, Italy) 11.05 - 11.30 PHYTOSTEROLS: PHYSIOLOGY AND MECHANISM OF ACTION 337 P.J. Jones (Winnipeg, MB, Canada) 11.30 - 11.55 PHYTOSTEROLS AND CHOLESTEROL-LOWERING EFFICACY IN 337 DIFFERENT FOOD FORMATS W E.A. Trautwein (Vlaardingen, The Netherlands) E 11.55 - 12.20 PHYTOSTEROL INTAKE AND DIETARY RECOMMENDATIONS 337 D L. Ose (Oslo, Norway) 12.20 - 12.45 PLANT STEROL INTAKE TO REDUCE RISK FOR CORONARY HEART DISEASE 338 N E. Windler (Hamburg, Germany) E 12.45 - 12.55 GENERAL DISCUSSION – S 12.55 - 13.00 CLOSING REMARKS – D E. Bruckert (Paris, France) A 13.00 End of the Session Y

Supported in part by an unrestricted educational grant provided by: Unilever

13.00 - 14.30 LUNCH - SCIENTIFIC SESSIONS - POSTERS - EXHIBITS

103 11.00 - 14.30 WEDNESDAY, June 21 ROOM 2

We-W30 Workshop 30 FAMILIAL HYPER- AND HYPOLIPIDEMIAS hour: Chairs: P. Pajukanta (Los Angeles, CA, USA); S. Calandra (Modena, Italy) abstract bk. page ref.: 11.00 - 11.20 GENETIC DETERMINANTS OF PLASMA LIPOPROTEINS 305 J.C. Cohen, A. Pertsemlidis, H.H. Hobbs (Dallas, TX, USA) 11.20 - 11.40 LECITHIN: CHOLESTEROL ACYLTRANSFERASE DEFICIENCY SYNDROMES 305 L. Calabresi, G. Franceschini (Milan, Italy) 11.40 - 12.00 FROM MAPPING TOWARDS FUNCTION: SUSCEPTIBILITY GENES OF 305 FAMILIAL COMBINED HYPERLIPIDEMIA P. Pajukanta (Los Angeles, CA, USA) 12.00 - 12.15 GENOME-WIDE EXPRESSION ANALYSIS OF CELLS EXPRESSING WILD-TYPE 306 OR GAIN OF FUNCTION MUTANT (D374Y) PCSK9 A. Chester, X.M. Sun, A.K. Soutar (London, UK) 12.15 - 12.30 EPISTATIC EFFECT OF FREQUENT APOLIPOPROTEIN E AND LIPOPROTEIN LIPASE 306 GENE VARIANTS ON HYPERTRIGLYCERIDEMIA-HYPERAPOBETALIPOPROTEINEMIA EXPRESSION P. Perron, D. Brisson, M. Santure, P. Blackburn, J.P. Despres, D. Gaudet (Quebec, QC, Canada) 12.30 - 12.45 THE APOAV GENE IS ASSOCIATED WITH FAMILIAL COMBINED HYPERLIPIDEMIA 306 AND DYSLIPIDEMIA G.M. van der Vleuten, A. Isaacs, W. Zeng, P.H. Talmud, C.M. van Duijn, A.F.H. Stalenhoef, J. de Graaf (Nijmegen, Rotterdam, The Netherlands and London, UK) 12.45 - 13.00 FASTING INDUCES HYPERLIPIDEMIA IN MICE OVEREXPRESSING PCSK9 306 G. Lambert, T. Pineau, M. Krempf, P. Costet (Nantes and Toulouse, France) 13.00 End of the Session

13.00 - 14.30 LUNCH - SCIENTIFIC SESSIONS - POSTERS - EXHIBITS

We-S13 Sponsored Symposium 13 INHIBITION OF SQUALENE SYNTHASE W Chairs: R. Laaksonen (Helsinki, Finland); A. Corsini (Milan, Italy) E D 13.00 - 13.20 INHIBITION OF CHOLESTEROL BIOSYNTHESIS BEYOND HMG-CoA 338 N REDUCTASE: PERSPECTIVES AND ADVANTAGES E A. Corsini (Milan, Italy) S 13.20 - 13.40 SQUALENE SYNTHASE INHIBITOR IN THE SCENARIO OF LIPID – D LOWERING THERAPY D. Harats (Tel Aviv, Israel) A 13.40 - 14.00 A NOVEL SQUALENE SYNTHASE INHIBITOR: LIPID LOWERING PROPERTIES 339 Y IN ANIMAL MODELS T. Nishimoto, Y. Amano, R. Tozawa (Osaka, Japan) 14.00 - 14.20 STABILIZATION OF CORONARY ATHEROSCLEROSIS BY A SQUALENE 339 SYNTHASE INHIBITOR M. Shiomi, S. Yamada, Y. Amano, T. Nishimoto, T. Ito (Kobe and Osaka, Japan) 14.20 - 14.30 QUESTION AND ANSWER SESSION – 14.30 End of the session

Supported in part by an unrestricted educational grant provided by: Takeda Pharmaceuticals North America, Inc.

104 11.00 - 13.45 WEDNESDAY, June 21 ROOM 3

We-W31 Workshop 31 DIAGNOSTIC TECHNOLOGIES FOR ARTERIAL DISEASES (1st part) hour: Chairs: D.H. O'Leary (Boston, MA, USA); G. Vaudo (Perugia, Italy) abstract bk. page ref.:

11.00 - 11.05 XX ANNIVERSARY OF THE CAROTID INTIMA MEDIA THICKNESS DETERMINATION – AWARD PRESENTED BY: Sirtori C.R. (Milan, Italy)

11.05 - 11.35 ASSESSMENT OF STRUCTURAL MARKERS AS SURROGATE ENDPOINTS 307 FOR ARTERIAL DISEASE D.H. O'Leary (Boston, MA, USA) 11.35 - 11.55 INTIMA-MEDIA THICKNESS AS AN ADDITIVE MARKER OF CARDIOVASCULAR 307 RISK D. Baldassarre (Milan, Italy) 11.55 - 12.10 VASA VASORUM NEOVASCULARIZATION VISUALIZED WITHIN THE HUMAN 308 CAROTID ATHEROSCLEROTIC PLAQUE: CONTRAST-ENHANCED ULTRASOUND IMAGING AND HISTO-PATHOLOGIC CORRELATES S. Feinstein, M. Davidson, M. Feinstein, R. Neems, M. Goldin, P. Balan, F. Shah, P. Espinosa (Chicago, IL, and Princeton, NJ, USA) 12.10 - 12.25 ULTRASOUND PHENOTYPES OF CAROTID ATHEROSCLEROSIS ARE BIOLOGICALLY 308 AND GENETICALLY DISTINCT J.D. Spence, A.A. House, A. Fenster, R.A. Hegele (London, ON, Canada) 12.25 - 12.40 HOMOCYSTEINE AND FOLIC ACID LEVELS AND RELATION TO CAROTID 308 ATHEROSCLEROSIS IN HIGH-RISK INDIVIDUALS C. Held, G. Sumner, P. Sheridan, M. McQueen, S. Smith, S. Yusuf, E. Lonn (Stockholm, Sweden and Hamilton, ON, Canada) 12.40 - 12.55 CAROTID INTIMA-MEDIA THICKNESS BY B-MODE ULTRASOUND AS A NEW 308 TOOL TO RECOGNIZE CAD IN PATIENTS WITH NO EVICENCES OF ANGIOGRAPHIC NARROWINGS M. Amato, P. Montorsi, A. Ravani, E. Oldani, S. Galli, E. Tremoli, D. Baldassarre (Milan, Italy) 12.55 End of the Session W 12.55 - 14.30 LUNCH - SCIENTIFIC SESSIONS - POSTERS - EXHIBITS E D N We-ML6 Master Lecture 6 E S LIFESTYLE MODULATION OF INFLAMMATORY D PROCESSES A Y Chair: F. Crea (Rome, Italy)

13.00 - 13.30 LIFESTYLE MODULATION OF INFLAMMATORY PROCESSES 303 E.B. Rimm (Boston, MA, USA) 13.30 - 13.45 GENERAL DISCUSSION – 13.45 End of the Session

Supported in part by an unrestricted educational grant provided by: Nutrition Foundation of Italy

105 11.00 - 13.45 WEDNESDAY, June 21 ROOM 4

We-W32 Workshop 32 INFLAMMATION (2nd part) hour: Chairs: H.N. Ginsberg (New York, NY, USA); P. Pintus (Cagliari, Italy) abstract bk. page ref.: 11.00 - 11.20 ROLE OF INFLAMMATION IN ATHEROGENESIS AND IN PLAQUE INSTABILITY 309 F. Crea (Rome, Italy) 11.20 - 11.35 A STANDARIZED STIMULUS AUGMENTS CRP SIMILARLY IN PATIENTS WITH 309 A HISTORY OF STABLE OR UNSTABLE CHD J.P. Werba, P.G. Massironi, M. Frigerio, C. Biancardi, M. Amato, D. Baldassarre, F. Veglia, E. Tremoli, M. Camera (Milan, Italy) 11.35 - 11.50 INFUSION OF C-REACTIVE PROTEIN MEDIATES ACTIVATION OF CIRCULATING 309 LEUKOCYTES IN HUMANS R. Bisoendial, R. Birjmohun, F. Akdim, C. van 't Veer, C. Spek, D. Hartman, E. de Groot, D. Bankaitis-Davis, J. Kastelein, E. Stroes (Amsterdam, The Netherlands, Reykjavik, Iceland and Boulder, CO, USA) 11.50 - 12.05 INFLUENZA VIRUS DIRECTLY INFECTS ATHEROSCLEROTIC PLAQUES OF NORMAL 309 AND ATHEROSCLEROTIC MICE AND EXACERBATES INFLAMMATION IN THE ATHEROSCLEROTIC PLAQUE M. Madjid, M. Haidari, D. Vela, S. Litovsky, P. Wyde, W. Casscells (Houston, TX, USA) 12.05 - 12.20 RESISTIN CORRELATES WITH LOW GRADE INFLAMMATION, BUT NOT WITH 310 PREATHEROSCLEROSIS AND INSULIN RESISTANCE IN OBESE JUVENILES H. Mangge, S. Pilz, K. Sargsyan, R. Horejsi, R. Moeller, R. Dimitrova, G. Weihrauch, W. März (Graz, Austria) 12.20 - 12.35 HIGHER SYSTEMIC INFLAMMATORY RESPONSE IN UNSTABLE ANGINA AND 310 CORONARY ACCELERATED ATHEROSCLEROSIS. OSTEOPONTIN, A MARKER OF PERSISTENT INFLAMMATION A. Mazzone, M.S. Parri, D. Giannessi, M. Ravani, P. Altieri, L. Casalino, M.S. Maltinti, A. Biagini, S. Berti, A. Barsotti (Massa, Pisa and Genoa, Italy) 12.35 - 12.50 APOLIPOPROTEIN A-I MIMETIC PEPTIDE L-4F, PREVENTS 310 LIPOPOLYSACCHARIDE-INDUCED CHANGES IN VASCULAR FUNCTION H. Gupta, Z. Zhang, L. Dai, J. Honavar, G.M. Anantharamaiah, C.R. White (Birmingham, AL, USA) 12.50 - 13.05 TARGETING OF SCAVENGER RECEPTOR CLASS B TYPE I BY SYNTHETIC 310 AMPHIPATHIC HELICAL CONTAINING PEPTIDES BLOCKS LPS UPTAKE AND LPS-INDUCED PROINFLAMMATOR W A. Bocharov, T. Eggerman (Bethesda, MD, USA) E 13.05 End of the Session D N E 13.05 - 14.30 LUNCH - SCIENTIFIC SESSIONS - POSTERS - EXHIBITS S D A We-ML7 Master Lecture 7 Y THE METABOLIC SYNDROME IN AN ELDERLY ITALIAN COHORT: THE ILSA STUDY Chair: J. Davignon (Montreal, QC, Canada)

13.00 - 13.30 THE METABOLIC SYNDROME IN AN ELDERLY ITALIAN COHORT: THE 303 ILSA STUDY G. Crepaldi (Padua, Italy) 13.30 - 13.45 GENERAL DISCUSSION – 13.45 End of the Session

106 11.00 - 13.45 WEDNESDAY, June 21 ROOM 5

We-W33 Workshop 33 OBESITY AND WEIGHT REDUCTION (1st part) hour: Chairs: J.W. Anderson (Lexington, KY, USA); G. Paolisso (Naples, Italy) abstract bk. page ref.: 11.00 - 11.20 THE GENETICS OF HUMAN OBESITY 310 P. Froguel (London, UK and Lille, France) 11.20 - 11.40 EFFECTS OF OBESITY TREATMENT ON PLASMA LIPOPROTEINS 311 J.W. Anderson (Lexington, KY, USA) 11.40 - 11.55 ADIPOSITY IS AN IMPORTANT DETERMINANT OF CHRONIC LOW-GRADE 311 INFLAMMATION AND IS ASSOCIATED WITH CAROTID ARTERY INTIMA-MEDIA THICKNESS A. Passaro, E. Dalla Nora, E. Mari, C. Marcello, R. Fellin (Ferrara, Italy) 11.55 - 12.10 INABILITY OF HDL FROM OBESE SUBJECTS IN COUNTERACTING THE INHIBITORY 311 EFFECT OF OXIDIZED LDL ON ENDOTHELIUM-DEPENDENT VASORELAXATION L. Perségol, B. Vergès, P. Gambert, L. Duvillard (Dijon, France) 12.10 - 12.25 AN INTERLEUKIN-18 (IL-18) HAPLOTYPE IS ASSOCIATED WITH HIGHER BMI AND 312 INFLAMMATORY MARKERS IN SUBJECTS WITH DIABETES AND CORONARY HEART DISEASE S.R. Thompson, J. Sanders, J.W. Stephens, G.D. Lowe, S.E. Humphries (London, Swansea and Glasgow, UK) 12.25 - 12.40 VARIATION IN THE UCP2-UCP3 GENE CLUSTER PREDICTS THE DEVELOPMENT 312 OF TYPE 2 DIABETES IN HEALTHY MIDDLE-AGED MEN D. Gable, J. Stephens, J. Cooper, G. Miller, S. Humphries (London and Swansea, UK) 12.40 - 12.55 TACE+/- MICE ARE PROTECTED FROM OBESITY AND INSULIN RESISTANCE 312 M. Serino, M. Hribal, R. Menghini, D. Lauro, P. Sbraccia, R. Lauro, M. Federici (Rome, Italy) 12.55 End of the Session

12.55 - 14.30 LUNCH - SCIENTIFIC SESSIONS - POSTERS - EXHIBITS

We-ML8 Master Lecture 8 POSCH TRIAL AND THE INITIAL PROOF OF THE W CHOLESTEROL HYPOTHESIS: IMPLICATIONS FOR TODAY E Chairs: C.J. Packard (Glasgow, UK); C.R. Sirtori (Milan, Italy) D N 13.00 - 13.30 POSCH TRIAL AND THE INITIAL PROOF OF THE CHOLESTEROL HYPOTHESIS: 304 E IMPLICATIONS FOR TODAY S H. Buchwald (Minneapolis, MN, USA) D 13.30 - 13.45 GENERAL DISCUSSION – A 13.45 End of the Session Y

107 11.00 - 14.30 WEDNESDAY, June 21 ROOM 6

We-W34 Workshop 34 DIAGNOSTIC TECHNOLOGIES FOR ARTERIAL DISEASES: ARTERIAL PHYSIOLOGY hour: Chairs: J.A. Vita (Boston, MA, USA); M. Montagnani (Siena, Italy) abstract bk. page ref.: 11.00 - 11.20 REGULATION OF ARTERIAL INTIMAL HYPERPLASIA BY ANGIOGENESIS 312 RELATED AND UNRELATED MECHANISMS J.F. Martin (London, UK) 11.20 - 11.40 WHAT IS THE CLINICAL SIGNIFICANCE OF ENDOTHELIAL DYSFUNCTION? 313 J.A. Vita (Boston, MA, USA) 11.40 - 11.55 THE FAMILIALITY OF THE COMMON DYSLIPIDEMIAS IN CHILDHOOD AFFECTS 313 THE SUBSEQUENT ARTERY FLOW MEDIATED DILATATION. THE STRIP-STUDY J. Lapinleimu, I.O. Nuotio, O. Raitakari, J.S.A. Viikari (Turku, Finland) 11.55 - 12.10 ENDOTHELIAL DYSFUNCTION PREDICTS TYPE 2 DIABETES IN ESSENTIAL 313 HYPERTENSION R. Maio, M. Vatrano, G. Iemma, A. Sciacqua, F. Borrello, R.D. Grembiale, G. Sesti, F. Perticone (Catanzaro, Italy) 12.10 - 12.25 FRACTALKINE INDUCES VASCULAR DYSFUNCTION AND REDUCES NITRIC OXIDE 313 BIOAVAILABILITY BY INCREASED GENERATION OF SUPEROXIDE ANIONS A. Schäfer, C. Schulz, D. Fraccarollo, M. Leutke, G. Ertl, J. Bauersachs (Würzburg and Munich, Germany) 12.25 - 12.40 LIPOPOLYSACCHARIDE-INDUCED CORONARY AND PERIPHERAL VASCULAR 314 DYSFUNCTION IS REDUCED IN MICE LACKING THE 5-LIPOOXYGENASE GENE J. Wikström, J. Grönros, U. Brandt-Eliasson, D. Carlsson, R. Fritsche-Danielson, L.-M. Gan (Göteborg and Mölndal, Sweden) 12.40 - 12.55 HETEROGENEITY OF CONCORDANCE BETWEEN CORONARY PLAQUE BURDEN AND 314 ENDOTHELIAL DYSFUNCTION IN THE SAME CORONARY ARTERY J.W. Kim, H.S. Seo, B.W. Cheon, H.W. Kim, H.H. Kim, S.K. Moon, S.Y. Suh, S.W. Rha, C.G. Park, D.J. Oh (Seoul, South Korea) 12.55 End of the Session

12.55 - 14.30 LUNCH - SCIENTIFIC SESSIONS - POSTERS - EXHIBITS

W E We-S14 Joint ISA2006 - International Chair on Cardiometabolic Risk D Symposium 14 N E INTERNATIONAL CHAIR ON CARDIOMETABOLIC RISK S Chairs: H.B. Brewer, Jr. (Washington, DC, USA); P.J. Barter (Sydney, NSW, Australia) D A 13.00 - 13.05 OPENING REMARKS – Y H.B. Brewer, Jr. (Washington, DC, USA) 13.05 - 13.30 IDENTIFYING INDIVIDUALS AT HIGH RISK OF CARDIOVASCULAR DISEASE: 340 IS THERE A ROLE FOR THE METABOLIC SYNDROME? M. Stern (San Antonio, TX, USA) 13.30 - 13.55 SCIENTIFIC RATIONALE FOR THE 2005 AHA/NHLBI UPDATE OF THE 340 NCEP-ATPIII METABOLIC SYNDROME S.M. Grundy (Dallas, TX, USA) 13.55 - 14.20 FROM CVD RISK TO CARDIOMETABOLIC RISK 340 J.P. Després (Sainte-Foy, QC, Canada) 14.20 - 14.30 CLOSING REMARKS: FROM METABOLIC SYNDROME TO CARDIOMETABOLIC 341 RISK: THE COMMON GROUND P.J. Barter (Sydney, NSW, Australia) 14.30 End of the Session Symposium organized in collaboration with the International Chair on Cardiometabolic Risk

108 11.00 - 12.40 WEDNESDAY, June 21 ROOM 7

We-W35 Workshop 35 GENETICS (2nd part) hour: Chairs: B. Dahlbäck (Malmö, Sweden); P. Alessandrini (Venice, Italy) abstract bk. page ref.: 11.00 - 11.20 GENETIC MECHANISMS OF THROMBOPHILIA 314 B. Dahlbäck (Malmö, Sweden) 11.20 - 11.40 INHERITED AND ACQUIRED RISK FACTORS FOR JUVENILE MYOCARDIAL 315 INFARCTION IN AN EUROPEAN COHORT G. Di Minno, M. Margaglione, S. Pezzullo, V. Palmieri, P. Migliaresi, A. Celentano, S.E. Humphries, P. Morange, I. Juhan-Vague, A. Hamsten, E. Tremoli, HIFMECH Study Group (Naples, Italy) 11.40 - 11.55 A VARIANT IN THE THROMBOMODULIN PROMOTER LEADS TO IMPAIRED 315 EXPRESSION IN RESPONSE TO INFLAMMATORY CYTOKINES; PREVIOUS CHD-RISK ASSOCIATION EXPLAINED C.J. Konstantoulas, J. Cooper, J. Grizenkova, G.J. Miller, S.E. Humphries, H. Ireland (London, UK) 11.55 - 12.10 COMPLEMENT FACTOR H Y402H POLYMORPHISM DECREASES CARDIOVASCULAR 315 DISEASE RISK IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA K.C.M.C. Koeijvoets, G.M. Dallinga-Thie, E.J.G. Sijbrands (Rotterdam, The Netherlands) 12.10 - 12.25 ADAM17: A NEW CANDIDATE GENE OF ATHEROSCLEROSIS SUSCEPTIBILITY 316 IDENTIFIED BY QUANTITATIVE TRAIT LOCUS MAPPING IN LDL-RECEPTOR DEFICIENT MICE L.M. Holdt, D. Teupser, J.L. Breslow, J. Thiery (Leipzig, Germany and New York, NY, USA) 12.25 - 12.40 MATRIX METALLOPROTEINASE-1 GENE HAPLOTYPE INFLUENCES RISK OF 316 MYOCARDIAL INFARCTION E. Pearce, D. Tregouet, A. Samnergard, A. Morgan, C. Cox, A. Hamsten, P. Eriksson, S. Ye (Southampton, UK, Paris, France and Stockholm, Sweden) 12.40 End of the Session

12.40 - 14.30 LUNCH - SCIENTIFIC SESSIONS - POSTERS - EXHIBITS

W E D N E S D A Y

109 11.00 - 12.55 WEDNESDAY, June 21 ROOM 8

We-W36 Workshop 36 INTERVENTION AT THE POPULATION LEVEL hour: Chairs: A.P. Simopoulos (Washington, DC, USA); S. Muntoni (Cagliari, Italy) abstract bk. page ref.: 11.00 - 11.20 RECENT DATA ON OMEGA-3 FATTY ACIDS IN PREVENTION OF 316 CARDIAC DEATH M. de Lorgeril, P. Salen (Grenoble, France) 11.20 - 11.40 HEALTH EFFECTS OF A MEDITERRANEAN DIET: WHAT IS SO SPECIAL 316 ABOUT THE DIET OF GREECE? THE SCIENTIFIC EVIDENCE A.P. Simopoulos (Washington, DC, USA) 11.40 - 11.55 VITAMIN B12 IS A BETTER INVERSE CORRELATE FOR HOMOCYSTEINE THAN 317 FOLATE IN AN ELDERLY POPULATION SAMPLE B. Blades, N. Naumovski, P.D. Roach, M. Lucock, C. Travers, P. Lewis, J. Sturm, M. Veysey (Ourimbah and Gosford, Australia) 11.55 - 12.10 LOW ATHEROSCLEROSIS RISKS OF FISH AND SOY EATERS IN THE WORLD 317 Y. Yamori, M. Sagara, M. Mori, H. Mori (Nishinomiya and Kyoto, Japan) 12.10 - 12.25 ALCOHOL CONSUMPTION, MORTALITY AND CARDIAC EVENTS: EFFECT OF 317 INFLAMMATION. THE HEALTH, AGING, AND BODY COMPOSITION STUDY C. Maraldi, S. Volpato, S. Kritchevsky, E. Andresen, T. Harris, A. Newman, A. Kanaya, K. Johnson, R. Fellin, M. Pahor (Ferrara, Italy, Gainesville, FL, Winston-Salem, NC, Bethesda, MD, Pittsburgh, PA, San Francisco, CA, and Memphis, TN, USA) 12.25 - 12.40 PLASMA LEVELS OF PLANT STEROLS AND THE RISK OF FUTURE CORONARY 318 ARTERY DISEASE IN HEALTHY MEN AND WOMEN; THE PROSPECTIVE EPIC-NORFOLK POPULATION STUDY M.N. Vissers, S. Pinedo, S.M. Boekholdt, K. von Bergmann, K. Elharchaoui, S.A. Bingham, N.J. Wareham, D. Lütjohann, J.J.P. Kastelein, K.T. Khaw (Amsterdam, The Netherlands, Bonn, Germany and Cambridge, UK) 12.40 - 12.55 DECREASE OF INTIMA-MEDIA THICKNESS IN PATIENTS AT RISK TO CEREBRAL 318 ISCHEMIA AFTER SUPPLEMENTATION WITH FOLIC ACID, VITAMINS B6 AND B12 U. Till, A. Jentsch, K. Bellstedt, A. Müller, R. Vollandt, H.S. Fink (Jena, Germany) 12.55 End of the Session

12.55 - 14.30 LUNCH - SCIENTIFIC SESSIONS - POSTERS - EXHIBITS W E D N E S D A Y

110 11.00 - 12.55 WEDNESDAY, June 21 ROOM 9

We-W37 Workshop 37 ANIMAL MODELS (1st part) hour: Chairs: L. Havekes (Leiden, The Netherlands); P. Pauletto (Treviso, Italy) abstract bk. page ref.: 11.00 - 11.20 THE METABOLIC SYNDROME: IT'S IN THE MOVEMENT OF FATTY ACIDS, 318 AS LEARNT FROM STUDIES IN TRANSGENIC MICE L. Havekes, P. Voshol, P. Rensen, K. Willems van Dijk, F. Kuipers, J.A. Romijn (Leiden and Groningen, The Netherlands) 11.20 - 11.40 UNSTABLE PLAQUE IN LABORATORY ANIMALS: THE APOLIPOPROTEIN E 319 KNOCKOUT MOUSE FED A HIGH-FAT DIET J.L. Johnson (Bristol, UK) 11.40 - 11.55 AUTOSOMAL RECESSIVE HYPERCHOLESTEROLEMIA (ARH) KNOCKOUT 319 MOUSE HAS DELAYED CATABOLISM OF LDL IN VIVO BUT NORMAL INTERNALIZATION OF LDL IN VITRO M. Harada-Shiba, A. Takagi, K. Marutsuka, S. Moriguchi, H. Yagyu, S. Ishibashi, Y. Asada, S. Yokoyama (Suita, Osaka, Miyazaki, Miyazaki, Kawachi-gun, Tochigi, and Nagoya, Aichi, Japan) 11.55 - 12.10 INCREASED ACTIVITY OF ABCA1 PROTECTS AGAINST ATHEROSCLEROSIS 319 R.R. Singaraja, C. Fievet, M.R. Hayden (Vancouver, BC, Canada and Lille, France) 12.10 - 12.25 MACROPHAGE ABCB4 DEFICENCY PROMOTES ATHEROSCLEROTIC LESION 319 DEVELOPMENT IN LDLR DEFICIENT MICE M. Pennings, R.B. Hildebrand, Th.J.C. van Berkel, A.K. Groen, M. van Eck (Leiden and Amsterdam, The Netherlands) 12.25 - 12.40 DEFICIENCY OF MACROPHAGE PHOSPHOLIPID TRANSFER PROTEIN PROTECTS 320 AGAINST ATHEROSCLEROTIC LESION DEVELOPMENT R. Vikstedt, J. Metso, D. Ye, R.B. Hildebrand, Th.J.C. van Berkel, C. Ehnholm, M. Jauhiainen, M. van Eck (Helsinki, Finland and Leiden, The Netherlands) 12.40 - 12.55 METABOLIC CHARACTERIZATION OF A DOMINANT NEGATIVE PPAR-GAMMA 320 MOUSE LINE E. Dalla Nora, S.L. Gray, J. Grosse, S. O'Rahilly, P.J. Voshol, S. Cinti, A. Vidal Puig (Cambridge, UK, Martinsried, Germany, Leiden, The Netherlands, Ferrara and Ancona, Italy) 12.55 End of the Session

12.55 - 14.30 LUNCH - SCIENTIFIC SESSIONS - POSTERS - EXHIBITS W E D N E S D A Y

111 14.30 - 18.30 WEDNESDAY, June 21 ROOM 1

We-S15 Sponsored Symposium 15 KEY QUESTIONS IN THE MANAGEMENT OF PATIENTS WITH TYPE 2 DIABETES: NEW FINDINGS FROM THE FIELD TRIAL hour: Chairs: S.M. Grundy (Dallas, TX, USA); C.R. Sirtori (Milan, Italy) abstract bk. page ref.: 14.30 - 14.50 PATIENT WITH TYPE 2 DIABETES: MAIN CHALLENGES TO FACE THE 342 GLOBAL BURDEN OF THE DISEASE G. Steiner (Toronto, ON, Canada) 14.50 - 15.20 EFFECTS OF LONG-TERM FENOFIBRATE THERAPY ON CARDIOVASCULAR 342 EVENTS AMONG 9795 PEOPLE WITH TYPE 2 DIABETES MELLITUS: THE FIELD STUDY, A RANDOMISED CONTROLLED TRIAL A.C. Keech, on behalf of the FIELD Study Investigators (Sydney, NSW, Australia) 15.20 - 15.40 THE FIELD TRIAL: CLINICAL IMPLICATIONS 342 A. Zambon (Padua, Italy) 15.40 - 16.00 COMBINATION THERAPY WITH FIBRATE PLUS STATINS: WHERE DO WE 343 STAND IN 2006? P.H. Jones (Houston, TX, USA) 16.00 End of the Session

Supported in part by an unrestricted educational grant provided by: Fournier Pharma, member of the Solvay Group & Abbott

16.00 - 16.30 BREAK - POSTERS - EXHIBITS

We-S16 Sponsored Symposium 16 DIETARY APPROACHES FOR ATHEROSCLEROSIS PREVENTION: VEGETABLE PROTEIN Chairs: K. Widhalm (Vienna, Austria); C.R. Sirtori (Milan, Italy) W 16.30 - 16.35 OPENING REMARKS – E C.R. Sirtori (Milan, Italy) D 16.35 - 16.55 HEALTHY FOOD CHOICES RECOMMENDED IN THE EUROPEAN GUIDELINES 343 N ON CVD PREVENTION: HOW ABOUT THE IMPLEMENTATION IN CLINICAL E PRACTICE? S G.G. De Backer (Ghent, Belgium) D 16.55 - 17.15 VEGETABLE PROTEINS: MECHANISM FOR CHOLESTEROL REDUCTION 343 A M.R. Lovati, C. Manzoni, S. Castiglioni (Milan, Italy) Y 17.15 - 17.35 SOY AND IMPACT ON PEROXISOME PROLIFERATOR ACTIVATED 344 RECEPTORS (PPARs) S. Kersten (Wageningen, The Netherlands) 17.35 - 17.55 SOY AND PHYTOESTROGENS: BEYOND LIPID LOWERING, ANTI-OXIDANT, 344 ANTI-INFLAMMATORY EFFECTS T.A.B. Sanders (London, UK) 17.55 - 18.15 SAFETY AND EFFICACY OF SOY IN PREVENTION OF ATHEROSCLEROSIS IN 344 CHILDREN K. Widhalm, D. Weghuber (Vienna, Austria) 18.15 - 18.30 GENERAL DISCUSSION – 18.30 End of the Session

Supported in part by an unrestricted educational grant provided by: Alpro Foundation

112 16.30 - 18.35 WEDNESDAY, June 21 ROOM 2

We-W38 Workshop 38 PHARMACOLOGY OF ARTERIAL DISEASE: HDL-TARGETED THERAPIES (2nd part) hour: Chairs: M.J. Chapman (Paris, France); R. Fellin (Ferrara, Italy) abstract bk. page ref.: 16.30 - 16.50 THE ROLE OF VARIOUS STRUCTURAL MOTIFS OF HDL-MIMETIC 320 PEPTIDES IN CHOLESTEROL EFFLUX BY THE ABCA1 TRANSPORTER A.T. Remaley, J. Stonik, T. Fairwell, S. Demosky, E.B. Neufeld, H.B. Brewer (Bethesda, MD and Washington, DC, USA) 16.50 - 17.10 PHARMACOLOGICAL MODULATION OF CELLULAR CHOLESTEROL EFFLUX 320 F. Bernini (Parma, Italy) 17.10 - 17.30 HOW DOES NICOTINIC ACID MODIFY THE ATHEROGENIC LIPID PROFILE? 321 M.J. Chapman, W. Le Goff, M. Guerin, A. Kontush (Paris, France) 17.30 - 17.50 PHARMACOLOGIC COMBINATION THERAPY FOR REGRESSION OF 321 ATHEROSCLEROSIS B.G. Brown (Seattle, WA, USA) 17.50 - 18.05 EFFECT OF INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ON THE 322 KINETICS OF HDL CHOLESTERYL ESTER TRANSPORT IN PLASMA: IN VIVO STUDIES IN RABBITS P.H.R. Barrett, P. Kee, D. Caiazza, K.A. Rye, L.A. Morehouse, P.J. Barter (Perth, WA, Sydney, NSW, Australia and Groton, CT, USA) 18.05 - 18.20 ANTIOXIDANT EFFECTS OF α-HELIX APOLIPOPROTEIN A-I PEPTIDE MODELS 322 IN RELATION TO THEIR STRUCTURE M. Petraki, K. Harilogis, C. Sakarellos, M. Sakarellos-Daitsiotis, A.D. Tselepis (Ioannina, Greece) 18.20 - 18.35 NO-1886 SUPPRESSING ATHEROSCLEROSIS IN HIGH-FAT/ HIGH-SUCROSE/ 322 HIGH-CHOLESTEROL FED BAMA MINIPIGS IS RELATED TO UPREGULATING ABCA1 C. Zhang, W.D. Yin, D.F. Liao, L. Huang, Z.B. Wang, K. Tsutsumi, C.K. Tang, Y. Liu, Q.K. Li, M.B. Cai (Hengyang, China and Tokushima, Japan) 18.35 End of the Session

W E D N E S D A Y

113 16.30 - 18.30 WEDNESDAY, June 21 ROOM 3

We-W39 Workshop 39 DIAGNOSTIC TECHNOLOGIES FOR ARTERIAL DISEASES (2nd part) hour: Chairs: A.M. Zeiher (Frankfurt, Germany); A. Capurso (Bari, Italy) abstract bk. page ref.: 16.30 - 16.50 ENDOTHELIAL FUNCTION AS A SURROGATE ENDPOINT TO ASSESS 322 ARTERIAL DISEASE A.M. Zeiher (Frankfurt, Germany) 16.50 - 17.10 EARLY DIAGNOSIS OF ATHEROSCLEROSIS BY NON-INVASIVE 323 ULTRASOUND TO IMPROVE CARDIOVASCULAR EVENT PREDICTION P. Rubba (Naples, Italy) 17.10 - 17.30 INFLAMMATORY ACTIVITY AS A MARKER AND TARGET OF THERAPY OF 323 CORONARY DISEASE L. Jonasson (Linköping, Sweden) 17.30 - 17.45 CLINICAL SIGNIFICANCE AND UNDERLYING MECHANISMS REGULATING 323 VASCULAR CALCIFICATION C.M. Giachelli (Seattle, WA, USA) 17.45 - 18.00 FLOW-MEDIATED VASODILATION PREDICTS OCCULT CORONARY ARTERY 324 DISEASE DETECTED BY POSITRON EMISSION TOMOGRAPHY V. Vaccarino, J. Goldberg, F.A. Cheema, U. Reddy, C. Maisano, L. Jones, N.V. Murrah, A.Q. Quyyumi, J.D. Bremner (Atlanta, GA and Seattle, WA, USA) 18.00 - 18.15 EFFECT OF SMOKING HABITS ON THE RELATIONSHIPS BETWEEN 324 ATHEROSCLEROSIS RISK FACTORS AND CAROTID IMT S. Castelnuovo, B. Frigerio, G. De Giosa, M. Amato, E. Tremoli, C.R. Sirtori, D. Baldassarre (Milan, Italy) 18.15 - 18.30 CAROTID INTIMA-MEDIA THICKNESS TESTING IDENTIFIES AT RISK PATIENTS 324 MISSED BY FRAMINGHAM 10-YEAR RISK SCORING A.L. Doneen, B.F. Bale, S.L. Charland, T.F. Smith (Spokane, WA, Cranbury, NJ and Austin, TX, USA) 18.30 End of the Session

W E D N E S D A Y

114 16.30 - 18.25 WEDNESDAY, June 21 ROOM 4

We-W40 Workshop 40 ANTITHROMBOTIC THERAPY hour: Chairs: J.I. Weitz (Hamilton, ON, Canada); P.M. Mannucci (Milan, Italy) abstract bk. page ref.: 16.30 - 16.50 NEW ANTICOAGULANTS FOR ATHEROTHROMBOSIS 324 J.I. Weitz (Hamilton, ON, Canada) 16.50 - 17.10 DETERMINANTS OF THE INTERINDIVIDUAL VARIABILITY IN THE 325 ANTIPLATELET EFFECTS OF LOW-DOSE ASPIRIN B. Rocca (Chieti, Italy) 17.10 - 17.25 PLATELET FUNCTION IS AN INDEPENDENT PREDICTOR OF MYOCARDIAL 325 DAMAGE IN PATIENTS WITH ACUTE MI TREATED BY PCI R. Marcucci, R. Paniccia, E. Antonucci, S. Poli, G. Ciuti, A.M. Gori, D. Poli, D. Prisco, R. Abbate, G.F. Gensini (Florence, Italy) 17.25 - 17.40 PLATELET ADP RECEPTORS AND PHOSPHOINOSITIDE 3-KINASES ARE ESSENTIAL 325 IN PREVENTING THROMBOEMBOLISM ON COLLAGEN AND FIBROUS ATHEROSCLEROTIC LESIONS J. Cosemans, I. Munnix, R. Wetzker, R. Heller, S.P. Jackson, J.W.M. Heemskerk (Maastricht, The Netherlands, Jena, Germany and Melbourne, VIC, Australia) 17.40 - 17.55 S18886, A SELECTIVE ANTAGONIST OF TP-RECEPTORS, ENHANCES 325 ATHEROSCLEROTIC PLAQUE STABILITY K. Tailford, S. Jhanke, P. Stickler, S.-J. Le, Z. Cong, G.R. Campbell, J.H. Campbell (Brisbane, QLD, Australia) 17.55 - 18.10 PLATELET ASSOCIATED TISSUE FACTOR EXPRESSION: MODULATION BY 326 NITRIC OXIDE M. Camera, M. Frigerio, E. Tremoli (Milan, Italy) 18.10 - 18.25 GLYCOPROTEIN VI INHIBITION IS MORE POTENT THAN ADP-RECEPTOR 326 ANTAGONISM OR ASPIRIN IN REDUCING PLAQUE-INDUCED PLATELET THROMBUS FORMATION S. Penz, A.J. Reininger, R. Brandl, R. Farndale, W. Siess (Munich, Germany and Cambridge, UK) 18.25 End of the Session

W E D N E S D A Y

115 16.30 - 18.25 WEDNESDAY, June 21 ROOM 5

We-W41 Workshop 41 IMMUNE SYSTEM hour: Chairs: S.C. Whitman (Ottawa, ON, Canada); M. Federici (Rome, Italy) abstract bk. page ref.: 16.30 - 16.50 THE IMMUNE SYSTEM AND ATHEROSCLEROSIS: DEFINING THE ROLE 326 OF INNATE IMMUNITY USING MOUSE MODELS OF THE DISEASE S.C. Whitman (Ottawa, ON, Canada) 16.50 - 17.10 PATHOGENIC AND REGULATORY IMMUNE PATHWAYS IN 326 ATHEROSCLEROSIS. IMPLICATIONS FOR RISK DETERMINATION Z. Mallat (Paris, France) 17.10 - 17.25 INCREASED LEVELS OF IGG1 AGAINST AN ALDEHYDE-MODIFIED PEPTIDE 327 SEQUENCE IN APOB-100 IS ASSOCIATED WITH DECREASED SEVERITY OF CAROTID STENOSIS G.N. Fredrikson, A. Schiopu, G. Berglund, R. Alm, J.Å. Nilsson, P.K. Shah, J. Nilsson (Malmö, Sweden and Los Angeles, CA, USA) 17.25 - 17.40 CD4+ NATURAL KILLER T CELLS AUGMENT ATHEROSCLEROSIS IN 327 APOLIPOPROTEIN-E DEFICIENT MICE K.Y.Y. To, B.H. Toh, D. Godfrey, A. Bobik (Melbourne, VIC, Australia) 17.40 - 17.55 PRO-ATHEROGENIC EFFECT OF CD1D-RESTRICTED NKT CELLS IN FORMATION 327 OF EARLY PLAQUE E. Tupin, H.E. Agardh, N. Gerdes, I. Bodin, A. Nicoletti, G.K. Hansson, G. Paulsson-Berne (Stockholm, Sweden, Paris, France and San Diego, CA, USA) 17.55 - 18.10 IMPACT OF DENDRITIC CELL LIFESPAN AND IMMUNOGENICITY ON 328 ATHEROSCLEROSIS PROGRESSION E. Gautier, T. Huby, B. Ouzilleau, J. Chapman, P. Lesnik (Paris, France) 18.10 - 18.25 THE EFFECTS OF 7BETA-HYDROXYCHOLESTEROL ON NK CELLS IN PATIENTS 328 WITH CORONARY ARTERY DISEASE W. Li, X.-M. Yuan, L. Jonasson (Linköping, Sweden) 18.25 End of the Session

W E D N E S D A Y

116 16.30 - 18.25 WEDNESDAY, June 21 ROOM 6

We-W42 Workshop 42 OBESITY AND WEIGHT REDUCTION (2nd part) hour: abstract bk. Chairs: F.F. Samaha (Philadelphia, PA, USA); A. Angeli (Turin, Italy) page ref.:

16.30 - 16.50 DIET AND INFLAMMATION 328 D. Giugliano, K. Esposito (Naples, Italy) 16.50 - 17.10 POPULAR DIETS AND PREVENTION OF CARDIOVASCULAR DISEASE 328 F.F. Samaha (Philadelphia, PA, USA) 17.10 - 17.25 RIMONABANT IMPROVES CARDIOMETABOLIC RISK FACTORS IN 329 OVERWEIGHT/OBESE PATIENTS IRRESPECTIVE OF TREATMENT WITH STATINS: POOLED DATA FROM THE RIO PROGRAM J.-P. Després, L. Van Gaal, A. Scheen, F.X. Pi-Sunyer (Sainte-Foy, QC, Canada, Edegem-Antwerp, Liège, Belgium and New York, NY, USA) 17.25 - 17.40 WEIGHT LOSS RESTORES PLATELET SENSITIVITY TO ANTI-AGGREGATING 329 EFFECTS OF NITRIC OXIDE, PROSTACYCLIN, cGMP AND cAMP IN SUBJECTS WITH CENTRAL OBESITY I. Russo, M. Traversa, L. Mattiello, K. Bonomo, A. De Salve, G. Doronzo, P. Del Mese, M. Trovati, G. Anfossi (Orbassano, Italy) 17.40 - 17.55 COMPARISON OF EFFECTS OF ATORVASTATIN AND FISH OILS ON APOC3 329 METABOLISM IN OBESITY M.N. Nguyen, D.C. Chan, G.F. Watts, P.H.R. Barrett (Perth, WA, Australia) 17.55 - 18.10 PIOGLITAZONE, BUT NOT GLICLAZIDE OR METFORMIN, IMPROVES THE ADIPOKINE 330 PROFILE OF OVERWEIGHT TYPE 2 DIABETES PATIENTS INDEPENDENT OF GLYCAEMIC CONTROL J. Reid, J.M. Lawrence, G.J. Taylor, C.A. Stirling, J.P.D. Reckless (Bath and Salisbury, UK) 18.10 - 18.25 OBESITY AND ADIPOKINES AS RISK FACTORS FOR MAJOR CORONARY HEART 330 DISEASE EVENTS IN PATIENTS WITH CHD: RESULTS FROM THE LIPID TRIAL D. Colquhoun, S. Soderberg, A. Kirby, A. Keech, J. Simes, W. Hague, I. Hamilton-Craig, A. Tonkin (Brisbane, QLD, Sydney, NSW, Adelaide, SA, Melbourne, VIC, Australia and Umea, Sweden) 18.25 End of the Session

W E D N E S D A Y

117 16.30 - 18.25 WEDNESDAY, June 21 ROOM 7

We-W43 Workshop 43 LIPOPROTEIN RECEPTORS hour: Chairs: M. Krieger (Cambridge, MA, USA); A. Pontiroli (Milan, Italy) abstract bk. page ref.: 16.30 - 16.50 THE HDL RECEPTOR SR-BI AND MURINE MODELS OF FATAL CORONARY 330 HEART DISEASE M. Krieger (Cambridge, MA, USA) 16.50 - 17.10 ADAPTOR PROTEINS A NOVEL MECHANISM FOR THE REGULATION OF 330 LIPOPROTEIN RECEPTORS: THE CASE OF AUTOSOMAL RECESSIVE HYPERCHOLESTEROLEMIA (ARH) PROTEIN AND LDLR M. Arca, I. Sirinian, F. Campagna, F. Belleudi, T. Garofano, M. Sorice, M.R. Torrisi (Rome, Italy) 17.10 - 17.25 ACTIVATION OF PPAR INDUCES HEPATIC LDL RECEPTOR EXPRESSION 331 J. Han, Z. Huang, W. He, X. Zhou, A.C. Nicholson, A.M. Gotto, Jr., D.P. Hajjar (New York, NY, USA) 17.25 - 17.40 PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 IS REGULATED BY 331 INSULIN, SREBP-1C AND PPARALPHA P.H. Costet, B. Cariou, T. Pineau, B. Staels, M. Krempf (Nantes, Lille, and Toulouse, France) 17.40 - 17.55 STEROL REGULATORY ELEMENT-BINDING PROTEIN-2 NEGATIVELY 331 REGULATES LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN (LRP1)TRANSCRIPTION V. Llorente Cortes, P. Costales, J. Bernues, S. Camino Lopez, L. Badimon (Barcelona, Spain) 17.55 - 18.10 MACROPHAGE LOW-DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN 331 DEFICIENCY ENHANCES ATHEROSCLEROSIS L. Hu, L.S.M. Boesten, P. May, J. Herz, N. Bovenschen, M.V. Huisman, J.F.P. Berbee, L.M. Havekes, B.J.M. van Vlijmen, J.T. Tamsma (Freiburg, Germany, Dallas, TX, USA, Leiden and Utrecht, The Netherlands) 18.10 - 18.25 EXTRA-HEPATIC EXPRESSION OF HUMAN-SR-BI (CLA-1) ENHANCED THE 332 ATHEROSCLEROTIC LESION FORMATION IN CLA-1 TRANSGENIC MOUSE Y. Ueda, H. Komori, T. Kita (Kyoto, Japan) 18.25 End of the Session

W E D N E S D A Y

118 16.30 - 18.25 WEDNESDAY, June 21 ROOM 8

We-W44 Workshop 44 GENETICS (3rd part) hour: Chairs: R.W. James (Geneva, Switzerland); A.V. Gaddi (Bologna, Italy) abstract bk. page ref.: 16.30 - 16.50 GENETIC ASSOCIATION ANALYSIS OF CANDIDATE GENES FOR 332 CARDIOVASCULAR DISEASE H.A. Erlich, S. Cheng, B.K. Rhees, V.H. Brophy (Alameda, CA, USA) 16.50 - 17.10 PHARMACOGENETICS OF ANTI-ATHEROSCLEROTIC DRUGS FROM THE 332 PERSPECTIVE OF LIPOPROTEIN OXIDATION AND ASSOCIATED INFLAMMATION R.W. James, S. Deakin (Geneva, Switzerland) 17.10 - 17.25 LECTIN-LIKE OXIDIZED-LDL RECEPTOR-1 (LOX-1) POLYMORPHISM IS 333 ASSOCIATED WITH INCREASED RATE OF CARDIOVASCULAR EVENTS DURING STATIN TREATMENT G. Todiere, F. Bruni, A.L. Pasqui, M. Pastorelli, F. Ciani, A. Palazzuoli, A. Auteri, L. Puccetti (Siena and Florence, Italy) 17.25 - 17.40 ARYLESTERASE ACTIVITY AND HDL-CHOLESTEROL LEVELS ARE DEPENDENT 333 ON THE PON 55M AND PON 192R POLYMORPHISMS M. Nus, F. Frances, J.M. Sánchez-Montero, D. Corella, F.J. Sánchez-Muniz (Madrid and Valencia, Spain) 17.40 - 17.55 A TWO STEP STRATEGY TO LOCALIZE GENE(S) INFLUENCING LOW HIGH-DENSITY 333 LIPOPROTEIN CHOLESTEROL LEVEL ON CHROMOSOME 16Q23-24 J.L. Lee, B. Aouizerat, J. Genest, M.-R. Taskinen, P. Pajukanta (Los Angeles, San Francisco, CA, USA, Montreal, QC, Canada and Helsinki, Finland) 17.55 - 18.10 DEVELOPMENT OF A MULTIPLEX ASSAY FOR DIAGNOSIS OF FAMILIAL 333 HYPERCHOLESTEROLEMIA IN GREECE BY USE OF NANOCHIP® MICROELECTRONIC ARRAY TECHNOLOGY E. Laios, E. Drogari (Athens, Greece) 18.10 - 18.25 CXCL5 GENE POLYMORPHISM AND MAJOR CARDIOVASCULAR EVENTS IN THE 334 INTERNATIONAL VERAPAMIL SR-TRANDOLAPRIL STUDY (INVEST) I. Zineh, A.L. Beitelshees, T.Y. Langaee, R.M. Cooper-DeHoff, C.J. Pepine, J.A. Johnson (Gainesville, FL and St. Louis, MO, USA) 18.25 End of the Session

W E D N E S D A Y

119 16.30 - 18.25 WEDNESDAY, June 21 ROOM 9

We-W45 Workshop 45 EPIDEMIOLOGY OF CARDIOVASCULAR DISEASE: PREVENTION hour: Chairs: H. Arnesen (Oslo, Norway); E. Agabiti Rosei (Brescia, Italy) abstract bk. page ref.: 16.30 - 16.50 THE VENTIMIGLIA DI SICILIA HEART PROJECT: A PROSPECTIVE STUDY 334 IN A MEDITERRANEAN POPULATION A. Notarbartolo (Palermo, Italy) 16.50 - 17.10 DIETARY COUNSELING FOR CORONARY PREVENTION IN MEN WITH 334 LONG STANDING HYPERLIPIDEMIA H. Arnesen (Oslo, Norway) 17.10 - 17.25 MORTALITY AND RISK FACTORS IN THE AUSTRALIAN ELDERLY: THE DUBBO 335 STUDY L.A. Simons, J. Simons, J. McCallum, Y. Friedlander (Sydney, NSW, Melbourne, VIC, Australia and Jerusalem, Israel) 17.25 - 17.40 INFLUENCE OF THE LOCATION AND THE EXTENT OF ATHEROSCLEROTIC 335 VASCULAR DISEASE ON NEW CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES P.M. Gorter, F.L.J. Visseren, A. Algra, Y. Van der Graaf (Utrecht, The Netherlands) 17.40 - 17.55 HUMAN LIPOXYGENASE GENE VARIATION IN SUBCLINICAL ATHEROSCLEROSIS: 335 THE DIABETES HEART STUDY S.S. Rich, K.P. Burdon, C.D. Langefeld, Y. Liu, B.I. Freedman, J.J. Carr, C.C. Hedrick, D.W. Bowden (Winston-Salem, NC and Charlottesville, VA, USA) 17.55 - 18.10 APOLIPOPROTEIN AV, TRIGLYCERIDES AND RISK OF FUTURE CORONARY ARTERY 335 DISEASE IN APPARENTLY HEALTHY MEN AND WOMEN; THE EPIC-NORFOLK POPULATION STUDY S.F.C. Vaessen, F.G. Schaap, J.A. Kuivenhoven, A.K. Groen, B.A. Hutten, S.M. Boekholdt, M.S. Sandhu, S.E. Humphries, P.J. Talmud, K.T. Khaw (Amsterdam, The Netherlands, Cambridge and London, UK) 18.10 - 18.25 GENE POLYMORPHISMS IN PLATELET RECEPTORS, FIBRINOLYTIC SYSTEM AND 336 COAGULATION FACTORS OF THE MYOCARDIAL RISK INFARCTION IN YOUNG SARDINIAN R. Rossi, L. Musino, A. Partenza, G. Mureddu, I. Maoddi, C. Carru, G. Baggio, L. Deiana (Sassari, Nuoro and Padua, Italy) W 18.25 End of the Session E D N E S D A Y

120 POSTER AREA “B” WEDNESDAY, June 21 1-277

POSTER DISPLAY: for the duration of one day (Wednesday, June 21 from 8.30 am to 6.30 pm). Participants may view the posters displayed during this day.

POSTER DISCUSSION: one of the authors will be available at the poster site as follows: Wednesday, June 21: from 10.30 am to 11.00 am Wednesday, June 21: from 1.00 pm to 2.30 pm Wednesday, June 21: from 4.00 pm to 4.30 pm

We-P11 Poster Session 11 poster OPTIMAL ATHEROSCLEROSIS abstract bk. board no.: page ref.: MANAGEMENT (1st part)

1 REDUCING THE CARDIOVASCULAR RISK AT PATIENTS WITH TYPE 2 DIABETES BY 346 CONTROLLING THE RISK FACTORS C. Tudor, R.A. Jeberean, R. Buzas, A. Popescu, M. Ionita (Timisoara, Romania) 2 PERIPHERAL ARTERIAL DISEASE AND PREDICTOR RELATED FACTORS IN DIABETIC 346 ELDERLY PATIENTS T. Kuswardhani, I. Aryana, P.K. Wirajaya, N. Astika, K. Suastika (Denpasar, Bali, Indonesia) 3 PULSE PRESSURE, AN IMPORTANT RISK FACTOR FOR ATHEROSCLEROSIS, IS 346 SIGNIFICANTLY INCREASED IN DIABETES TYPE II L. Salvanos (Pireaus and Vyronas, Greece) 4 NORMAL GLUCOSE DISPOSAL AND DECREASED INSULIN SENSITIVITY IN YOUNG 346 NORMAL WEIGHT MEN WITH NON-TREATED HYPERTENSION L. Salvanos (Pireaus and Vyronas, Greece) 5 POSTPRANDIAL LIPEMIA AND INSULIN RESISTANCE IN INDIVIDUALS WITH AND 347 WITHOUT TYPE 2 DIABETES J. Rioja, F. Escalona, M.J. Ariza, M.T. Gonzalez-Alegre, E. Ulzurrun, P. Valdivielso, P. Gonzalez-Santos (Malaga, Spain) 6 ANTI-ELASTIN IGG SUBCLASSES AND MICROVASCULAR COMPLICATIONS 347 A. Nikolov, G. Nicoloff (Pleven, Bulgaria) 7 SERUM FIBRILLIN-ANTIFIBRILLIN IMMUNE COMPLEXES AMONG DIABETIC CHILDREN 347 A. Nikolov, G. Nicoloff (Peven, Bulgaria) 8 ABILITY OF HDL TO RECEIVE LIPIDS FROM AN ARTIFICIAL LIPOPROTEIN MODEL IN 347 DIABETIC PATIENTS WITH OR WITHOUT CORONARY ARTERY DISEASE C.H. Dina, R.F. Amâncio, W. Hueb, N.H. Lopes, M.R. Rodrigues, M.C.M. Latrilha, W R.C. Maranhão (São Paulo, Brazil) E 9 BLOOD PRESSURE VARIATION AND ANTIHYPERTENSIVE TREATMENT 347 D MODIFICATION IN TYPE 2 DIABETES MELLITUS N I. Lentzas, A. Alevizos, P. Daskalakis, M. Papathanasiou, L. Salvanos, E. Konstantinou, E A. Kamaratos, A. Katsanaki, G. Belos, A. Melidonis (Pireaus and Vyronas, Greece) S 10 MANAGEMENT OF HYPERTENSIVE PATIENTS WITH AND WITHOUT DIABETES IN 348 D PIRAEUS A I. Lentzas, P. Daskalakis, A. Alevizos, M. Papathanasiou, L. Salvanos, B. Gizlis, Y A. Kamaratos, A. Katsanaki, G. Belos, A. Mariolis (Pireaus and Vyronas, Greece) 11 RELATIONSHIP BETWEEN CIRCULATING THROMBOMODULIN LEVELS AND LATENT 348 PROGRESSION OF ATHEROSCLEROSIS IN TYPE 2 DIABETIC PATIENTS I. Korzh, I. Fedotova, V. Nemtsova (Kharkov, Ukraine) 12 RELATIONSHIP OF CORONARY HEART DISEASE MORTALITY TO CASUAL BLOOD 348 GLUCOSE LEVEL AND SELF-REPORTED PAST HISTORY OF DIABETES MELLITUS S. Kadowaki, T. Hayakawa, T. Okamura, K. Nakamura, Y. Murakami, Y. Nakamura, T. Kadowaki, S. Saito, A. Okayama, H. Ueshima (Otsu, Izumo, Kyoto, Sapporo and Suita, Japan) 13 GENETICS AND OUTCOMES ON LIPIDS IN TYPE 2 DIABETES-BASELINE 348 CHARACTERISTICS OF A PROSPECTIVE STUDY OF MYOCARDIAL INFARCTION IN DIABETICS M.C.O. Izar, W.G.M. Relvas, R.M.S. Povoa, N. Kasinski, L. Pinto, S.S.M. Ihara, T. Helfenstein, A.O. Santos, A.C.C. Carvalho, F.A.H. Fonseca (São Paulo, Brazil)

121 14 THE ASSESMENT OF PULSE WAVE VELOCITY AND ANKLE-BRACHIAL INDEX IN 348 PATIENTS WITH TYPE2 DIABETES M. Iiyama, Y. Go, H. Kitaoka (Sakai, Japan) 15 THE D9N POLYMORPHISM IS A MARKER OF MYOCARDIAL INFARCTION AMONG 349 DIABETICS M. Izar, T. Helfenstein, W. Relvas, S. Ihara, M. Fonseca, L. Pinto, S. Fischer, A. Santos, A. Carvalho, F. Fonseca (Sao Paulo, Brazil) 16 DIABETES MELLITUS HAVE IMMUNE SYSTEM ALTERATIONS SIMILAR TO THAT OF 349 UNSTABLE ANGINA: A CLUE TO EXPLAIN HIGH CARDIOVASCULAR RISK OF DIABETES S. Brugaletta, S. Giubilato, D. Pitocco, M. Narducci, V. Colafrancesco, G. Ghirlanda, L. Biasucci, G. Liuzzo, M. Conte, F. Crea (Rome, Italy) 17 DURATION OF TYPE 2 DIABETES AND THE OCCURRENCE OF SUBCLINICAL 349 ATHEROSCLEROSIS IN 64-YEAR-OLD WOMEN G. Brohall, C.J. Behre, J. Wikstrand, J. Hulthe, B. Fagerberg (Gothenburg, Sweden) 18 THE EFFECTS OF APOE POLYMORPHISM ON THE RELATIONSHIPS BETWEEN CETP 349 ACTIVITY AND LIPID PROFILE IN TUNISIAN PATIENTS WITH TYPE 2 DIABETES MELLITUS M. Smaoui, N. Attia, S. Hammami, R. Chaaba, N. Koubaa, A. Nakbi, A.S. Masmoudi, M. Hammami (Monastir, Tunisia) 19 ASSESSMENT OF VON WILLEBRAND FACTOR (VWF) AND ITS CORRELATION WITH 350 CARDIOVASCULAR RISK FACTORS IN TYPE 2 DIABETES AND NON DIABETIC POPULATION R. Kapoor, A. Kapoor, K.S. Gill (Amritsar, India) 20 IMPACT OF AORTIC VALVE CALCIFICATION IN CARDIAC DEATH FOR JAPANESE 350 TYPE 2 DIABETIC PATIENTS DURING END-STAGE RENAL DISEASE THERAPY A. Sato, T. Nakagami, T. Babazono, Y. Iwamoto (Tokyo, Japan) 21 INSULIN THERAPY REDUCE PROGRESSION OF CAROTID STENOSIS IN TYPE 2 350 DIABETIC PATIENTS: A RETROSPECTIVE LONGITUDINAL STUDY F. Piarulli, S. Viaggi, G. Bax, B. Laverda, G. Sartore, D. Fedele (Padua, Italy) 22 CAROTID ATHEROSCLEROTIC PLAQUES IN TYPE 2 DIABETIC PATIENTS: ROLE OF 350 GLYCOXIDATION F. Piarulli, A. Lapolla, G. Sartore, B. Laverda, R. Reitano, R. Marin, E. Manzato, D. Fedele (Padua, Italy) 23 ACE AND PAI-1 INSERTION/DELETION POLYMORPHISMS AND AGE-RELATED 350 CHANGES IN PULSE PRESSURE IN SUBJECTS WITH TYPE 2 DIABETES G. Penno, D. Lucchesi, L. Pucci, C. Fotino, S. Triscornia, F. Caricato, S. Del Prato, R. Miccoli (Pisa, Italy) 24 ATHEROGENIC EFFECTS OF UPPER RESPIRATORY INFECTIONS AND PASSIVE 351 SMOKING IN CHILDREN WITH TYPE 1 DIABETES MELLITUS M. Odermarsky, S. Willers, P. Liuba (Lund, Sweden) 25 CORONARY ARTERY DISEASE IN TYPE 2 DIABETES: EFFECTS OF WEIGHT LOSS ON 351 LIPID PEROXIDE LEVELS, ANTIOXIDANT ENZYME ACTIVITY AND INSULIN SENSITIVITY W N.M. Lalic, M. Ostojic, K. Lalic, A. Jotic, M. Zamaklar, L.J. Lukic, T. Milicic, N. Rajkovic E (Belgrade, Serbia-Montenegro) D 26 CORONARY ARTERY DISEASE IN TYPE 2 DIABETES: RELATIONSHIP BETWEEN CHANGES 351 N IN LDL PARTICLE SIZE, LIPOPROTEIN SUBFRACTION LEVELS AND INSULIN RESISTANCE E K. Lalic, M. Zamaklar, N.M. Lalic, M. Ostojic, V. Kalimanovska, A. Topic, N. Rajkovic, A. Jotic, S J. Vekic (Belgrade, Serbia-Montenegro) D 27 INSULIN RESISTANCE AND HYPOFIBRINOLYSIS FACILITATE GRAFT STENOSIS 351 A AFTER CORONARY ARTERY BYPASS GRAFTING IN TYPE 2 DIABETIC PATIENTS Y V. Kanjuh, N.M. Lalic, M. Ostojic, K. Lalic, S. Kanjuh, A. Jotic, L.J. Lukic, T. Milicic (Belgrade, Serbia-Montenegro) 28 LOWER ANTIOXIDANT ENZYME ACTIVITY IS ASSOCIATED WITH INSULIN 352 RESISTANCE IN TYPE 2 DIABETICS WITH DIFFERENT SUBTYPES OF ISCHEMIC STROKE A. Jotic, N.M. Lalic, VS. Kostic, N. Sternic, T. Milicic, L.J. Lukic, M. Mijailovic, M. Macesic (Belgrade, Serbia-Montenegro) 29 RAS ASSOCIATED WITH DIABETES (RAD) MODULATES INDUCIBLE NITRIC OXIDE 352 SYNTHASE (INOS) ACTIVITY IN VASCULAR SMOOTH MUSCLE CELLS (VSMC) FROM DIABETIC RATS P. Di Tomo, A. Giardinelli, S. Di Silvestre, N. Di Pietro, G. Formoso, P. Di Fulvio, F. Capani, A. Consoli, A. Pandolfi (Chieti-Pescara, Italy) 30 MARBURG HYPOTHESIS OF CORONARY ARTERY DISEASE: A NEW CONCEPT OF 352 ATHEROSCLEROSIS IN PATIENTS WITH DIABETES MELLITUS J.R. Schaefer, S. Klumpp, B. Hufnagel, B. Maisch, J. Krieglstein (Marburg and Muenster, Germany)

122 31 DIABETES MELLITUS AND ARTHEROSCLEROSIS 352 L. Vasilje, M. Galjak (Novi Pazar, Serbia-Montenegro) 32 UNCOUPLED ENDOTHELIAL NITRIC OXIDE SYNTHASE IN DIABETIC BONE 353 MARROW-IMPACT ON ENDOTHELIAL PROGENITOR CELLS T. Thum, D. Fraccarollo, P. Galuppo, M. Schultheiss, G. Ertl, J. Bauersachs (Würzburg, Germany) 33 PARAOXONASE GENE POLYMORPHISM (PON1 192) IS ASSOCIATED WITH 353 ENDOTHELIAL FUNCTION IN PATIENTS WITH TYPE 2 DIABETES C. Irace, C. Cortese, F. Dell'Aquila, L. Liberatoscioli, L. Mannucci, G. Federici, A. Gnasso (Catanzaro and Rome, Italy) 34 DYSLIPIDAEMIAS IN NON-OBESE TYPE II DIABETIC PATIENTS WITH 353 ATHEROSCLEROSIS (HORMONAL PATTERNS) V. Anestiadi, V. Anestiadi, Z. Anestiadi, I. Tsiple, I. Cosciug (Chisinau, Moldova) 35 METFORMIN IMPROVES OXIDATIVE STRESS AND DECREASES PLATELET 353 ACTIVATION IN NEWLY DIAGNOSED TYPE 2 DIABETIC SUBJECTS G. Formoso, E.A. De Filippis, N. Michetti, G. Ciabattoni, P. Di Fulvio, A. Pandolfi, F. Capani, G. Davì, A. Consoli (Chieti-Pescara, Italy) 36 IMPAIRED GLUCOSE METABOLISM IN PATIENTS WITH NEWLY DIAGNOSED 353 CORONARY ARTERY DISEASE A. Gotsis, P. Bozia, S. Dourtsiou, A. Labrou, L. Papadopoulou, A. Savvopoulou, L. Borghi, D. Theodoridis, S. Karras, A. Panagiotidou (Komotini, Greece) 37 HUMAN SERUM PARAOXONASE (PON1) CONCENTRATION PREDICTS 354 CARDIOVASCULAR DISEASE IN DIABETIC PATIENTS M. Inoue, Y. Ikeda, T. Suehiro, H. Takata, S. Inada, N. Ogami, F. Osaki, K. Arii, K. Hashimoto (Nankoku, Japan) 38 NEWLY DIAGNOSED ABNORMAL GLUCOSE TOLERANCE IN PATIENTS WITH ACUTE 354 CORONARY SYNDROME S. Denchev, R. Ivanova, S. Dimitrov, L. Terzieva (Sofia, Bulgaria) 39 OXIDATIVE STRESS DURING DIABETES AND HEART FAILURE 354 Z. Lankin, E. Arzamastseva, K. Tikhaze, T. Ageev, Yu. Mareev, N. Belenkov (Moscow, Russia) 40 IS ELEVATED BLOOD GLUCOSE ESSENTIAL FOR ENHANCED VASCULAR DISEASE 354 IN DIABETES? R.G. Gerrity, J.L. Nadler (Augusta, GA, and Charlottesville, VA, USA) 41 HIGH GLUCOSE STIMULATES FRACTALKINE AND MCP-1 EXPRESSION IN HUMAN 355 AORTIC SMOOTH MUSCLE CELLS E. Dragomir, M. Voinea, I. Manduteanu, M. Tircol, M. Simionescu (Bucharest, Romania) 42 DIABETES INDUCES A SPECIFIC FORM OF ATHEROSCLEROSIS AT THE 355 MOLECULAR, CELLULAR AND FUNCTIONAL LEVEL A.C. Calkin, T.J. Allen, E.E. Jones, J.P. Chin-Dusting, K.A. Jandeleit-Dahm, P. Kantharidis, M.E. Cooper (Prahran, VIC, Australia) 43 DECREASED LEVELS OF SOLUBLE RECEPTOR FOR ADVANCED GLYCATION END 355 W PRODUCTS IN TYPE 2 DIABETES: ASSOCIATION WITH OXIDATIVE STRESS AND E METABOLIC CONTROL D F. Santilli, E. Devangelio, G. Formoso, P. Ferroni, L. Bucciarelli, N. Mchetti, C. Clissa, N G. Ciabattoni, A. Consoli, G. Davì (Chieti, Rome and Milan, Italy) E 44 REGULATION OF IRAP AND GLUT4 MRNA EXPRESSION BY ANGIOTENSIN II, 355 S ANGIOTENSIN IV AND INSULIN IN VASCULAR SMOOTH MUSCLE CELLS: ALTERED D RESPONSE IN PATIENTS WITH TYPE 2 DIABETES A W. Hodroj, J. Randon, N. Foudi, L. Legedz, M.-C. Bourdillon, P. Feugier, C. Cerutti, Y G. Bricca (Lyon, France) 45 ROLE OF COAGULATION PARAMETERS IN THE DEVELOPMENT OF DIABETIC 356 VASCULAR COMPLICATIONS IN PATIENTS WITH DIABETES MELLITUS TYPE 2 A. Severina, L. Chirkova, M. Shestakova (Moscow, Russia) 46 DIABETES MELLITUS AS A RISK FACTOR IN OCCURRENCE OF ATHEROSCLEROTICAL 356 CHANGES OF THE BRAIN S. Makrevska, E. Manasievska, Z. Krstevska (Kumanovo, Macedonia) 47 THE EFFECT OF BLOOD GLUCOSE LEVELS ON HEMORHEOLOGICAL PARAMETERS, 356 PLATELET ACTIVATION AND AGGREGATION IN ORAL GLUCOSE TOLERANCE TESTS K. Koltai, G. Feher, G. Kesmarky, Z. Keszthelyi, L. Czopf, K. Toth (Pécs, Hungary) 48 PREVALENCE OF RENAL ARTERY STENOSIS IN TYPE 2 DIABETES 356 I. Klefortova, M. Shamkhalova, N. Smirnova, M. Shestakova, V. Alpenidze, E. Tugeeva, U. Buziashvili (Moscow, Russia)

123 49 SAFETY AND EFFICACY OF LONG-TERM (UP TO 24 MONTHS) EZETIMIBE (EZE) 356 THERAPY IN HYPERCHOLESTEROLEMIC PATIENTS E. Veltri, R. Suresh, J. Strony (Kenilworth, NJ, USA) 50 THE STOCKHOLM ATHEROSCLEROSIS GENE EXPRESSION (STAGE) STUDY - 357 MULTIORGAN EXPRESSION PROFILING IN WELL-CHARACTERIZED CORONARY ARTERY DISEASE PATIENTS S. Hägg, J. Lundström, J. Skogsberg, R. Nilsson, K. Hallén, P. Noori, T. Ivert, A. Hamsten, J. Tegnér, J. Björkegren (Stockholm and Linköping, Sweden) 51 A RANDOMIZED CONTROLLED TRIAL FOR RISK FACTOR REDUCTION IN PATIENTS WITH 357 SYMPTOMATIC VASCULAR DISEASE: THE VASCULAR PREVENTION BY NURSES STUDY B.M.B. Goessens, F.L.J. Visseren, B.G.M. Sol, J.M. de Man- van Ginkel, Y. van der Graaf (Utrecht, The Netherlands) 52 DECREASED LEVELS OF ASYMMETRIC DIMETHYLARGININE (ADMA) DURING ACUTE 357 HYPERINSULINEMIA H.M.A. Eid, H. Reims, H. Arnesen, S.E. Kjeldsen, T. Lyberg, I. Seljeflot (Oslo, Norway) 53 SCREENING FOR SILENT MYOCARDIAL ISCHEMIA IN TYPE 2 DIABETIC PATIENTS? 357 D. Dvorscak, D. Trsinski, K. Koscak, D. Slunjski, K. Kukolja, J. Dumicic, M. Jeric (Varazdin, Croatia) 54 EFFECT OF LOSARTAN, COMPARED TO ATENOLOL, ON ENDOTHELIAL FUNCTION 358 AND OXIDATIVE STRESS IN PATIENTS WITH DIABETES TYPE 2 AND HYPERTENSION A.J. Flammer, F. Hermann, P. Wiesli, B. Schwegler, F. Ruschitzka, T.F. Luescher, I. Sudano, W. Riesen, G. Noll, R. Lehmann (Zurich and St. Gallen, Switzerland) 55 PIOGLITAZONE AND METFORMIN HAVE FAVOURABLE EFFECTS ON PAI-1 IN 358 OVERWEIGHT PATIENTS WITH TYPE 2 DIABETES J.M. Lawrence, J. Reid, G.J. Taylor, C.A. Stirling, J.P.D. Reckless (Salisbury and Bath, UK) 56 NEWLY DIAGNOSED ABNORMAL GLUCOSE TOLERANCE - IMPORTANT FACTOR 358 AFFECTING OUTCOME OF PRIMARY PERCUTANEOUS INTERVENTION M. Roik, G. Horszczaruk, J. Kochman, Z. Huczek, G. Opolski (Warsaw, Poland) 57 DIABETES MELLITUS AND ITS INFLUENCE ON QUALITY OF LIFE FIVE YEARS AFTER 358 MYOCARDIAL REVASCULARIZATION M. Zdravkovic, M. Ristic, N. Milic, S.U. Pavlovic, M. Krotin, D. Trifunovic-Zamaklar, D. Zdravkovic, D. Gostiljac, R. Zivkovic, N. Milinic (Belgrade, Serbia-Montenegro) 58 INCREASE OF HDL LEVEL BY FIBRATE THERAPY WAS ASSOCIATED WITH DECREASED 358 ARTERIAL STIFFNESS IN DIABETIC PATIENTS WITH HYPERTRIGLYCERIDEMIA S.H. Kim, J.H. Zo, M.A. Kim (Seoul, South Korea) 59 THE CONTRIBUTION OF NIACIN FOR THE TREATMENT OF DYSLIPIDEMIA IN PATIENTS 359 WITH TYPE 2 DIABETES RECEIVING COMBINATION THERAPY WITH STATINS A. Bozinovska, L. Balalovska, D. Bozinovski (Bitola, Macedonia) 60 THE IMPACT OF ATORVASTATIN ON ENDOTHELIAL DYSFUNCTION AND CHOLESTEROL 359 TURNOVER IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR W DISEASE E V. Blaha, C. Andrys, A. Smahelova, R. Hyspler, D. Solichova, A. Ticha, D. Cernohorsky, D F. Musil, Z. Zadak (Hradec Kralove, Czech Republic) N 61 CONCOMITANT REDUCTION OF LDL-CHOLESTEROL AND BIOMARKERS OF INFLAMMATION 359 E WITH LOW DOSE SIMVASTATIN THERAPY IN PATIENTS WITH TYPE 1 DIABETES S I. Jialal, E. Miguelino, S. Griffen, N. Glaser, S. Devaraj (Sacramento, CA, USA) D 62 REDUCTION OF LARGE VLDL PARTICLES BY FENOFIBRATE IS ASSOCIATED WITH 359 A REDUCTION OF SMALL DENSE LDL IN TYPE 2 DIABETES: FIELD HELSINKI SUBSTUDY Y A. Hiukka, E. Leinonen, H. Hilden, H. Perttunen-Nio, A. Keech, M.R. Taskinen (Helsinki, Finland and Sydney, NSW, Australia) 63 POSTER WITHDRAWN – 64 REDUCTION IN PRO-INFLAMMATORY MARKERS BY STATINS AND RAS-INHIBITORS 360 AFFECTS THE DEVELOPMENT OF VASCULAR DISEASE S. Ljubic, M. Vucic Lovrencic, J. Bozikov, Z. Metelko (Zagreb, Croatia) 65 ROSIGLITAZONE THERAPY IMPROVES INSULIN RESISTANCE PARAMETERS IN 360 OVERWEIGHT AND OBESE DIABETIC PATIENTS INTOLERANT TO METFORMIN G. Derosa, S.A.T. Salvadeo, A. D'Angelo, I. Ferrari, L. Ciccarelli, M.N. Piccinni, F. Pricolo, M. Ghelfi, A. Gravina, P.D. Ragonesi (Pavia and Milan, Italy) 66 FEATURES OF INSULIN MEDIATE GLUCOSE UTILIZATION IN WOMEN WITH 360 POLYCYSTIC OVARIES SYNDROME (PCO) AND CORONARY HEART DISEASE (CHD) IN ANAMNESIS T. Zykova, A. Strelkova, K. Balandina, O. Batrakova (Arkhangelsk, Russia)

124 67 UNDIAGNOSED DIABETES AND IMPAIRED FASTING GLYCAEMIA AMONGST PATIENTS 360 PRESENTING FOR SURGERY, AND THEIR IMPACT ON POST-OPERATIVE OUTCOMES D. Mullhi, A. Barnett, A. Jones, F. Gao (Birmingham, UK) 68 INSULIN SENSITIVITY IN PATIENTS WITH PRIMARY HYPERPARATHYROIDISM 361 BEFORE AND AFTER SURGICAL TREATMENT D. Micic, G. Cvijovic, A. Kendereski, M. Sumarac-Dumanovic, S. Zoric, D. Pejkovic, K. Cubrilo, M. Georgiev (Belgrade, Serbia-Montenegro) 69 GLUCOSE INTOLERANCE AND INSULIN SENSITIVITY IN PATIENTS WITH 361 OBSTRUCTIVE SLEEP APNEA SYNDROME E. Vlachogiannis, Z. Koukoulidou, C.H. Liavas, E. Gouridou, E. Daskalopoulou, A. Dougalis (Thessaloniki, Greece) 70 INSULIN SENSITIVITY AND LIPID LEVELS IN OBESE PATIENTS WITH POLYCYSTIC 361 OVARY SYNDROME A. Kendereski, D. Micic, G. Cvijovic, M. Sumarac-Dumanovic, S. Zoric, D. Pejkovic, K. Cubrilo, M. Georgiev (Belgrade, Serbia-Montenegro) 71 INSULIN RESISTANCE BEFORE AND AFTER TRANSSFENOIDAL SURGERY IN 361 PATIENTS WITH ACROMEGALY T. Isailovic, M. Petakov, S. Ognjanovic, D.J. Macut, B. Popovic, I. Bozic, S. Damjanovic (Belgrade, Serbia-Montenegro) 72 HIGH-SENSITIVITY C-REACTIVE PROTEIN AND SERUM AMYLOID A REFLECT 361 INSULIN RESISTANCE IN SMOKERS O. Hanyu, T. Miida, A. Takahashi, K. Obayashi, K. Kosuge, Y. Aizawa (Niigata and Oita, Japan) 73 CARDIOVASCULAR RISK: ENDOTHELIAL DYSFUNCTION, INSULIN RESISTANCE AND 362 ASSOCIATED FACTORS D.M. Duda-Seiman, C.A. Sarau, S. Iurciuc, M. Iurciuc, L. Barbu, G. Ciorica, B. Petcov, S. Mancas (Timisoara, Romania) 74 FIRST PHASE INSULIN RESPONSE AND INSULIN SENSITIVITY IN OBESE AND LEAN 362 WOMEN WITH POLYCYSTIC OVARY DISEASE G. Cvijovic, D. Micic, A. Kendereski, M. Sumarac-Dumanovic, S. Zoric, D. Pejkovic, K. Cubrilo, M. Georgiev (Belgrade, Serbia-Montenegro) 75 INSULIN SENSITIVITY AND LIPID LEVELS IN LEAN PATIENTS WITH POLYCYSTIC 362 OVARY SYNDROME K. Cubrilo, D. Micic, A. Kendereski, G. Cvijovic, M. Sumarac-Dumanovic, S. Zoric, D. Stamenkovic-Pejkovic, M. Georgiev (Belgrade, Serbia-Montenegro) 76 RAPID INTRAVENOUS INSULIN INFUSION REDUCES PLASMA ADIPONECTIN LEVELS 362 K. Ashidate, M. Kawamura, R. Chin, E. Yano, Y. Yamazaki, S. Miyazaki, T. Teramoto, Y. Hirata (Tokyo, Japan) 77 ARGATROBAN, A SYNTHETIC THROMBIN ANTAGONIST, CAN REDUCE INSULIN 362 RESISTANCE THROUGH THROMBIN INACTIVATION IN THE DB/DB MOUSE MODEL OF TYPE 2 DIABETES K. Aihara, M. Mihara, H. Azuma, M. Akaike, Y. Ikeda, S. Yagi, T. Iwase, S. Hashizume, W M. Fujimura, T. Matsumoto (Tokushima, Japan) E 78 INSULIN RESISTANCE AS A DETERMINANT OF PLATELET ACTIVATION IN OBESE WOMEN 363 D S. Basili, F. Santilli, G. Pacini, M.T. Guagnano, M.R. Manigrasso, L. Pescara, G. Ciabattoni, N C. Patrono, G. Davì (Rome, Chieti and Padua, Italy) E 79 ASSOCIATION BETWEEN MILD CHANGES IN THYROID STATUS AND INSULIN 363 S RESISTANCE IN EUTHYROID SUBJECTS D O. Mayer, Jr., Z. Hess, H. Rosolová, J. Vrzalová, O. Topolcan (Plzen, Czech Republic) A 80 HYPERINSULINISM AND INSULIN RESISTANCE: TWO ENEMIES TO DEFEAT 363 Y L.M. Pérez-Pérez, R.M. González, G. Pereira, A. Seuc, C. Valenti, O. Mateo de Acosta (Havana, Cuba) 81 ASSOCIATION OF INSULIN RESISTANCE WITH INCREASED PLASMA 363 TRANSAMINASES LEVELS IN A SWISS POPULATION / THE COLAUS STUDY M. Firmann, V. Mayor, K. Song, F. Paccaud, D. Waterworth, V. Mooser, G. Waeber, P. Vollenweider (Lausanne, Switzerland and Collegeville, PA, USA) 82 PREVALENCE OF DIABETES AND IMPAIRED GLUCOSE REGULATION IN A SWISS 364 POPULATION / THE COLAUS STUDY M. Firmann, V. Mayor, V. Mooser, F. Paccaud, G. Waeber, P. Vollenweider (Lausanne, Switzerland and Collegeville, PA, USA) 83 DIFFERENTIAL CORRELATION OF ORAL AND INTRAVENOUS GLUCOSE INTAKE. INSULIN 364 SENSITIVITY TAKEN AS A RISK FACTOR FOR CAROTID INTIMA MEDIA THICKNESS IN ATHEROSCLEROSIS PATIENTS S. Deo, S.R. Mahadik, A.R. Chogle, S.L. Sonoji, C.P. Lulla (Mumbai, India)

125 84 THE INFUSION OF C-REACTIVE PROTEIN ADVERSELY AFFECTS GLUCOSE 364 METABOLISM IN HUMANS R. Birjmohun, R. Bisoendial, M. Ackermans, A. Zwinderman, D. Hartman, J. Kastelein, E. Stroes, H. Sauerwein (Amsterdam, The Netherlands and Reykjavik, Iceland) 85 INSULIN RESISTANCE AND CARDIOVASCULAR RISK IN OBESE CHILDREN 364 S. Hijano, J.A. Bermúdez, P. Fernandez-Riejos, R. de la Iglesia, P. Lopez-Campos, A. Barco, J. Gentil, E. Martínez, F. Fabiani (Seville, Spain) 86 FACTOR ANALYSIS OF PULSE WAVE VELOCITY INCREASE IN ASYMPTOMATIC 365 SUBJECTS S. Mancas, D.M. Duda-Seiman, S. Iurciuc, L. Barbu, M. Rada, L. David, G. Ciorica, E. Nistor (Timisoara, Romania) 87 INSULIN RESISTANCE, PULSE WAVE VELOCITY AND CARDIOVASCULAR RISK 365 S. Mancas, C.A. Sarau, D. Velimirovici, M. Dumitrasciuc, L. Barbu, D.M. Duda-Seiman, S. Urseanu, B. Petcov (Timisoara, Romania) 88 TERM NEONATES WHOSE MOTHERS SHOW AN O´SULLIVAN POSITIVE TEST 365 PRESENT HIGH INSULIN LEVELS AND LOWER INSULIN SENSITIVITY AT BIRTH E. Gesteiro, A. Fernández de los Ríos, S. Bastida, F.J. Sánchez-Muniz (Badajoz and Madrid, Spain) 89 POSTER WITHDRAWN – 90 METABOLIC SYNDROME: CONNECTION WITH SOME GENE POLYMORPHISMS, 365 FATTY ACID COMPOSITION AND OXIDATIVE STRESS L. Janíková, B. Stanková, M. Vecka, M. Jáchymová, E. Tvrzická, A. Zak (Prague, Czech Republic) 91 REDUCED SENSITIVITY OF ISLET INSULIN SECRETION AND GLUCOSE 365 INTOLERANCE IN HYPERCHOLESTEROLEMIC LDL RECEPTOR KNOCKOUT MICE M.L. Bonfleur, P.R. Patricio, G.G. Dorighello, E.M. Carneiro, A.C. Boschero, H.C.F. Oliveira (Campinas, Brazil) 92 ACTIVITY OF INDUCIBLE NO-SYNTHASE AND SERUM LEVEL OF FIBRONECTIN IN 366 METABOLIC SYNDROME PATIENTS WITH AND WITHOUT DIABETES L. Mogylnytska, B.N. Mankovsky (Khmelnitsky and Kiev, Ukraine) 93 COMBINING NATURAL TREATMENTS TO REACH LIPID TARGET IN METABOLIC 366 SYNDROME PATIENTS: A RANDOMIZED CLINICAL TRIAL A. Lucicesare, A.F.G. Cicero, G. Derosa, A.V. Gaddi (Bologna and Pavia, Italy) 94 METABOLIC SYNDROME AND HDL LEVEL ARE HIGHLY ASSOCIATED WITH 366 ARTERIAL STIFFNESS IN DIABETIC PATIENTS S. Kim, J.-H. Zo, M.-A. Kim (Seoul, South Korea) 95 METABOLIC SYNDROME IN A POPULATION OF 259,014 SPANISH WORKERS. 366 IBERMUTUAMUR CARDIOVASCULAR RISK PREVENTION STUDY GROUP M.A. Sánchez Chaparro, J. Román García, E. Calvo Bonacho, A. Fernández Meseguer, M. Cabrera Sierra, J.C. Sainz Gutiérrez, A. García García, J. Rueda Vicente, W A. Gálvez Moraleda, A. González Quintela (Madrid, Spain) E 96 SERUM ADIPONECTIN CONCENTRATION AND METABOLIC SYNDROME 366 D F. Okajima, Y. Nakajima, T. Kyoko, H. Sugihara, S. Ohtani, H. Kotake, S. Oikawa N (Tokyo and Sendai, Japan) E 97 CLUSTERING OF BORDERLINE RISK FACTORS INCORPORATED IN METABOLIC 367 S SYNDROME DEFINITION IS SIMILAR TO AN ESTABLISHED ONE REGARDING D INFLAMMATORY CONDITION A K. Matsushita, H. Yatsuya, K. Tamakoshi, T. Kondo, T. Murohara, H. Toyoshima Y (Nagoya, Japan) 98 PLASMA INTERLEUKIN-6 LEVELS ARE INCREASED IN SUBJECTS WITH IMPAIRED 367 GLUCOSE TOLERANCE BUT NOT IN THOSE WITH IMPAIRED FASTING GLUCOSE IN A COHORT OF ITALIAN CAUCASIAN M. Cardellini, F. Andreozzi, M.A. Marini, E. Laratta, M. Perticone, M.R. Mancuso, E. Succurro, A. Sciacqua, M.L. Hribal, G. Sesti (Rome and Catanzaro, Italy) 99 HISPANICS WITH THE METABOLIC SYNDROME SHOWED HIGHER INCIDENCE OF 367 ATRIAL FIBRILLATION P.I. Altieri, H.L. Banchs, M. Crespo, N. Escobales, Y. Figueroa, J.C. Lopez, J. Hernandez, H. Mundo, P. Casillas (San Juan, Puerto Rico) 100 FATTY LIVER CONTRIBUTES SIGNIFICANTLY TO THE PROGRESSION OF 367 CORONARY ARTERY DISEASE IN PATIENTS WITH METABOLIC SYNDROME K. Takata, Y. Toyota, A. Hiraoka, N. Mitauba, I. Takahashi, T. Ohta (Hiroshima and Okinawa, Japan)

126 101 THE PREVALENCE OF METABOLIC SYNDROME AMONGST PATIENTS PRESENTING 368 FOR ELECTIVE SURGERY, AND ITS ASSOCIATION WITH POST-OPERATIVE COMPLICATIONS D. Mullhi, J. Wu, T. Melody, A. Barnett, A. Jones, F. Gao (Birmingham, UK) 102 ASSOCIATION OF THE TNF-ALFA -308 G/A PROMOTER POLYMORPHISM WITH 368 DYSLIPIDEMIA, INSULIN RESISTANCE AND METABOLIC SYNDROME N. Kondratova, G. Roytberg, T. Ushakova (Moscow, Russia) 103 IDENTIFIED VARIANTS IN THE ADIPONECTIN GENE ACT AS MARKERS FOR THE 368 METABOLIC SYNDROME IN SOUTHERN EUROPE BUT NOT THE NORTH D. Gable, R. Whitall, L.I. Ka Wah, H. Cakmak, J. Cooper, S. Humphries (London, UK) 104 LDL SUBFRACTIONS IN PATIENTS WITH METABOLIC SYNDROME 368 I. Gazi, T. Filippatos, E. Bairaktari, C. Kostara, A. Tselepis, M. Elisaf (Ioannina, Greece) 105 THE HYPERTRIGLYCERIDAEMIC WAIST PHENOTYPE AS A MARKER OF THE 369 ATHEROGENIC LIPOPROTEIN PROFILE IN METABOLIC SYNDROME I. Gazi, V. Tsimihodimos, G. Liamis, M. Kostapanos, A. Tselepis, M. Elisaf (Ioannina, Greece) 106 CONSISTENCY AND CLASSIFICATION OF VARIOUS METABOLIC SYNDROME 369 CRITERIA AMONG ETHNIC CHINESE: PATTERNS VARIED BY GENDER AND AGE K.L. Chien, T.C. Su, H.C. Hsu, M.F. Chen, F.C. Sung, Y.T. Lee (Taipei, Taichung and Taoyuang, Taiwan) 107 METABOLIC SYNDROME: EVALUATION OF RESPONSE TO METFORMIN, DIET AND 369 PHYSICAL ACTIVITY G. Altamore, D. De Meo, R.E. Castracane, M. Fioravanti, M.A. Germani (Rome, Italy) 108 THE ASSOCIATION OF METABOLIC SYNDROME WITH NOVEL MARKERS OF 369 ATHEROSCLEROSIS POTENTIATES CORONARY HEART DISEASE RISK IN PATIENTS WITH TYPE 2 DIABETES C. Bianchi, G. Penno, F. Caricato, M.G. Giovannitti, L. Malloggi, S. Del Prato, R. Miccoli (Pisa and Cisanello, Italy) 109 USEFULNESS OF CAVI (CARDIO-ANKLE VASCULAR INDEX) IN THE METABOLIC 369 SYNDROME (MS) AND DIABETES MELLITUS (DM): A NEW INDEX OF ARTERIOSCLEROSIS A. Fukuda, Y. Fujioka, K. Ninomiya, Y. Ishikawa, M. Yokoyama (Kobe, Japan) 110 EFFECT OF FENOFIBRATE ON THE HEMOSTATIC SYSTEM IN PATIENTS WITH THE 370 METABOLIC SYNDROME IN RELATION TO SOME GENE POLYMORPHISMS AND SMOKING STATUS M. Jastrzebska, I. Goracy, H. Bukowska, A. Mierzecki, K. Klimek, K. Chelstowski, M. Naruszewicz (Szczecin, Poland) 111 LIPID TRANSFER PROTEINS AND APOLIPOPROTEIN B-100 METABOLISM IN THE 370 METABOLIC SYNDROME TREATED WITH FENOFIBRATE J. Ji, P.H.R. Barrett, A.G. Johnson, D.C. Chan, A.P. Serone, K.A. Rye, G.F. Watts (Perth, WA, Sydney, NSW, Australia and King of Prussia, PA, USA) W 112 EFFECT OF OMEGA-3 FATTY ACIDS ON RISK FACTORS FOR THE METABOLIC SYNDROME 370 E D. Dimitrov (Varna, Bulgaria) D 113 INFLUENCE OF METABOLIC SYNDROME WITH AND WITHOUT DIABETES ON 370 N HOSPITAL OUTCOMES AFTER ACUTE MYOCARDIAL INFARCTION E M. Farnier, M. Zeller, P.G. Steg, G. Dentan, Y. Laurent, M. Vincent-Martin, I. L’Huillier, S J.C. Beer, L. Rochette, Y. Cottin (Dijon, Paris, Fontaine les Dijon, Semur en Auxois and D Beaune, France) A 114 DISCORDANCE BETWEEN INSULIN RESISTANCE AND METABOLIC SYNDROME 371 Y A. Onat, G. Hergenc, S. Turkmen, M. Yazici, I. Sari, G. Can (Istanbul, Gaziantep and Duzce, Turkey) 115 EFFECT OF ACUTE HYPERINSULINAEMIA AND AT-1 RECEPTOR BLOCKADE ON 371 PLASMA CONCENTRATIONS OF TNF ALPHA AND RESISTIN IN DIABETES MELLITUS E. Krusinova, J. Kopecky, Jr., M. Klementova, P. Wohl, L. Kazdova, T. Pelikanova (Prague, Czech Republic) 116 VARIANTS OF THE INTERLEUKIN-10 PROMOTER GENE ARE ASSOCIATED WITH OBESITY 371 AND INSULIN RESISTANCE BUT NOT TYPE 2 DIABETES MELLITUS IN CAUCASIAN ITALIAN D. Scarpelli, M. Cardellini, F. Andreozzi, E. Laratta, M. Perticone, M.L. Hribal, M.A. Marini, F. Perticone, D. Lauro, G. Sesti (Catanzaro and Rome, Italy) 117 ROSIGLITAZONE IMPROVES QUALITY OF LIPOPROTEINS IN PATIENTS WITH TYPE 2 371 DIABETES M. Vrablik, M. Dobiasova, T. Stulc, Z. Kasalova, R. Ceska (Prague, Czech Republic)

127 118 PIOGLITAZONE INDUCES APOPTOSIS IN HUMAN VASCULAR SMOOTH MUSCLE 371 CELLS FROM HYPERCHOLESTEROLEMIC PATIENTS BY INVOLVING THE TGF-B PATHWAY E. Ruiz, A. Gordillo-Moscoso, S. Redondo, T. Tejerina (Madrid, Spain) 119 3D STRUCTURE AND BIOLOGICAL ACTIVITY OF NOVEL DUAL PEROXISOME 372 PROLIFERATOR-ACTIVATED RECEPTORS ALPHA/GAMMA LIGANDS C. Godio, V. Cafiero, N. Mitro, F. Loiodice, A. Lavecchia, E. Novellino, V. Tortorella, G. Pochetti, F. Mazza, M. Crestani (Milan, Bari, Naples and Rome, Italy) 120 ROLE OF PEROXISOME PROLIFERATORS ACTIVATED RECEPTOR-GAMMA IN MEDIATING 372 PROLIFERATION OF RAT VASCULAR SMOOTH MUSCLE CELLS INDUCED BY ADVANCED GLYCATION END PRODUCTS X. Yuan, N. Liu (Nanjing, China) 121 PROTECTIVE EFFECT OF PIOGLITAZONE ON MYOCARDIAL ISCHEMIA-REPERFUSION 372 INJURY IN RATS P. Ye, Z.L. Cao, C.L. Long, K. Chen (Beijing, China) 122 INCREASED TNF-ÁLPHA IN PATIENTS AFFECTED BY CORONARY ARTERY DISEASE 372 IS ASSOCIATED TO UNDIAGNOSED IMPAIRED GLUCOSE METABOLISM. ROLE OF PIOGLITAZONE S. Rizza, F. Clementi, M. Cardellini, A. Savo, O. Porzio, M. Serino, D. Lauro, R. Lauro, M. Federici (Rome, Italy) 123 LONG-TERM EFFECTS OF PIOGLITAZONE ON CARDIOVASCULAR RISK FACTORS IN 373 SUCROSE FED RATS V. Zidek, M. Pravenec, P. Mlejnek, L. Kazdova, T.W. Kurtz (Prague, Czech Republic and San Francisco, CA, USA) 124 EFFECTS OF PIOGLITAZONE AND METFORMIN ON BODY WEIGHT AND THE INSULIN 373 RESISTANCE PARAMETERS IN OBESE PATIENTS WITH PUBERTAL HYPOTHALAMIC SYNDROME O. Oleksyk, A. Serhiyenko, V. Serhiyenko (Lviv, Ukraine) 125 EFFECT OF TROGLITAZONE ON SERUM GAMMA-GLUTAMYLTRANSFERASE ACTIVITY 373 AND PLASMA T-PA/PAI-1 COMPLEX IN TYPE 2 DIABETIC PATIENTS H. Koh, Y. Akiyama, K. Yui (Tokyo, Japan) 126 LEPTIN, HYPERTENSION AND OBESITY 373 S. Trajkovska, B. Sidovska-Ivanovska, S. Shubevska, M. Krstevska, G. Bosilkova (Skopje, Macedonia) 127 OBESITY AND ITS ASSOCIATION WITH OTHER CARDIOVASCULAR RISK FACTORS IN 374 WOMEN IN CENTRAL IRAN - WOMEN'S HEALTHY HEART PROJECT M. Sadeghi, H. Roohafza (Isfahan, Iran) 128 POLYCYSTIC OVARY SYNDROME ACCOMPANIED BY HYPERTENSION AND OBESITY: 374 A PREMATURE ASSOCIATION? S. Popova (Kharkov, Ukraine) 129 HYPERTENSION AND OBESITY AT PATIENTS WITH POLYCYSTIC OVARY SYNDROME: 374 W CLINICAL AND HORMONAL CORRELATION E S. Popova (Kharkov, Ukraine) D 130 EVOLUTION AND IMPROVEMENT OF RISK FACTORS ASSOCIATED WITH MORBID 374 N OBESITY IN BARIATRIC SURGERY E R. Llamas, M. Cubells, R. Catalán, J.M. Fort, R. Galard, A. Lecube, J.A. Baena, S J. Peinado-Onsurbe (Barcelona, Spain) D 131 THE WEIGHT OF BODY WEIGHT IN CAROTID ATHEROSCLEROSIS 374 A C. Irace, C. Cortese, C. Carallo, A. Gnasso (Catanzaro and Rome, Italy) Y 132 ADIPONECTIN IN OBESE TYPE 2 DIABETICS AND GLUCOSE-INTOLERANT PATIENTS 375 M.T. Gonzalez-Alegre, A. Pozo, E. Ulzurrun, M.J. Ariza, A. Hornos, J. Rioja, P. Gonzalez-Santos (Malaga, Spain) 133 PREVALENCE OF LEFT VENTRICULAR HYPERTROPHY IN ELDERLY MEN WITH 375 HYPERTENSION AND OBESITY IN TALLINN, ESTONIA (2002-2003) J. Abina, M. Saava, P. Laane, M. Kalev (Tallinn, Estonia) 134 EFFECTS OF OBESITY AND DIET-INDUCED WEIGHT LOSS ON VASCULAR AND CARDIAC 375 FUNCTION: INSIGHTS FROM IMAGING C. Piantadosi, M. Worthley, A. McAinch, E. Nalivaiko, S.G. Worthley, G.A. Wittert (Adelaide, SA, Australia) 135 5-LIPOXYGENASE: PLEIOTROPIC EFFECTS ON ATHEROSCLEROSIS, OBESITY AND 375 INSULIN RESISTANCE M. Mehrabian, J. Stockton, M. Suh, H. Allayee, L.W. Castellani, Z. Zhou, A.J. Lusis (Los Angeles, CA, USA)

128 136 METABOLIC SYNDROME (MS) IN EARLY PHASE OF ESSENTIAL HYPERTENSION (EH) 376 B. Jelakovic, M. Laganovic, I. Pecin, G. Borso, D. Kuzmanic, T. Zeljkovic Vrkic, Z. Dika (Zagreb, Croatia) 137 RELATIONSHIPS BETWEEN INSULIN RESISTANCE, OBESITY AND DYSLIPIDEMIA 376 WITH AMBULATORY BLOOD PRESSURE MONITORING IN AN URBAN ARGENTINE POPULATION C.A. Feldstein, M. Akopian, A. Renauld, D. Garrido (Buenos Aires, Argentina) 138 THE IDF DEFINITION OF METABOLIC SYNDROME IS A BETTER PREDICTOR OF CHD RISK 376 THAN THE NCEP CRITERIA IN BRAZILIAN PATIENTS WITH DIFFERENT COMPONENTS OF THE SYNDROME M.C. Batista, A. Hirota, R.L. Borges, O. Kohlmann, M.T. Zanella, A.B. Ribeiro (São Paulo, Brazil) 139 USEFULNESS OF REPEATED OFFICE BLOOD PRESSURE TO DEFINE BP LEVELS OF 376 THE METABOLIC SYNDROME G. Crippa, A. Cassi, C. Venturi, P. Cavallotti (Piacenza, Italy) 140 EFFECTS OF ANTIOXIDANTS, ZINC AND VITAMIN C, ON BLOOD PRESSURE IN RATS 377 H. Hashimoto, E. Amano, M. Atake, Y. Nakai, N. Takechi, M. Takenaka, N. Kurihara (Kobe, Japan) 141 CORRELATION BETWEEN BIOCHEMICAL AND BIOPHYSICAL MARKERS OF 377 ENDOTHELIAL DYSFUNCTION IN CHILDREN WITH OBESITY M. Urban, B. Glowinska, J. Tolwinska, M. Kowalewski (Bialystok, Poland) 142 EFFECTS OF VERY LOW CALORIE DIET (VLCD) ON SERUM LEPTIN, INSULIN 377 RESISTANCE AND CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH METABOLIC SYNDROME E. Stokic, D. Tomic, B. Srdic, T. Ivkovic-Lazar (Novi Sad, Serbia-Montenegro) 143 CARDIOVASCULAR RISK FACTORS AND OBESITY 377 L. Sokolova Djokic, S. Martinovic, D. Zivic, M. Bosnjak (Sombor and Novi Sad, Serbia-Montenegro) 144 BENIGN OBESITY AND MALIGNANT OBESITY 377 M. Morihira, M. Chou, K. Haraguchi, A. Satoh, H. Yoshie, R. Kataoka, H. Kondoh, K. Kikuchi (Eniwa and Asahikawa, Japan) 145 ASSOCIATION OF T54 ALLELE OF THE FABP2 GENE TO CARDIOVASCULAR RISK 378 FACTOR IN OBESE MEXICAN PATIENTS E. Martinez-Lopez, A. Hernandez-Nazara, B. Ruiz-Madrigal, M. Gonzalez-Hita, A. Panduro (Guadalajara, Mexico) 146 FAVORABLE IMPACT OF GROWTH HORMONE (GH) ON ATHEROGENIC RISKS IN 378 PATIENTS WITH GH DEFICIENCY H. Kohno, S. Kinjo (Fukuoka, Japan) 147 RELATION BETWEEN CAROTID INTIMA-MEDIA THICKNESS AND ABDOMINAL OBESITY 378 C. Hotoleanu, O. Suciu (Cluj-Napoca, Romania) 148 LIPID PEROXIDES AND IMMUNOGLOBULIN PLASMA LEVELS ASSOCIATED WITH 378 BODY MASS INDEX W M. González-Hita, T. García-Iglesias, L. Aranda-Acosta, B.E. Bastidas-Ramírez, E B. Ruíz-Madrigal, S. Sánchez-Enriquez (Guadalajara, Mexico) D 149 ASSOCIATION OF C-REACTIVE PROTEIN WITH MEASURES OF OBESITY AND 378 N INSULIN SENSITIVITY IN SEVERE OBESE WOMEN WITH NORMAL AND IMPAIRED E GLUCOSE TOLERANCE S M. Sumarac-Dumanovic, D. Micic, D. Stamenkovic-Pejkovic, M. Georgiev, A. Kendereski, D S. Zoric, G. Cvijovic, K. Cubrilo (Belgrade, Serbia-Montenegro) A 150 TEN YEARS RISK FOR FATAL CORONARY DISEASE IN OBESE PERSONS WITH 379 Y IMPAIRED GLUCOSE TOLERANCE OR METABOLIC SYNDROME P.B. Djordjevic, V. Kanjuh, V. Dimitrijevic-Sreckovic, M. Ostojic, F. Canovic, D. Gostiljac, T. Novakovic, E. Colak, R. Obrenovic (Belgrade, Serbia-Montenegro) 151 LEPTIN DOES NOT MODULATE THE RELATIONSHIP BETWEEN BLOOD PRESSURE 379 AND OBESITY IN CHINESE SIBLINGS WITH A FAMILY HISTORY OF HYPERTENSION T.T.W. Chu, Y.J. Fang, G.N. Thomas, B. Tomlinson (Shatin and Pokfulam, Hong Kong, China) 152 REDUCING CARDIOVSCULAR RISK FACTORS IN OBESE ADOLESCENTS 379 T. Stølen, A.E. Tjønna, R. Ødegård, U. Wisløff (Trondheim, Norway) 153 CAROTID ARTERY INTIMA-MEDIA THICKNESS IN OBESE, PREOBESE AND NORMAL 379 WEIGHT POSTMENOPAUSAL WOMEN A. Starodubova, O. Kisliak, G. Storozhakov (Moscow, Russia) 154 CONTRIBUTING FACTORS FOR DYSLIPIDEMIA IN A POPULATION WITH TYPE 2 DIABETES 380 J. Silva-Nunes, L. Gardete-Correia (Lisbon, Portugal)

129 155 CARDIOVASCULAR RISK FACTORS INCIDENCE IN BOTH, INDIGENOUS AND URBAN 380 POPULATION GROUPS FROM WEST OF MEXICO P. Nuño-González, B. Ruiz-Madrigal, E. Zepeda-Carrillo, M.F. Bueno Cortés, A. Rodríguez Martínez, A. Panduro (Guadalajara and Tepic, Mexico) 156 VISCERAL BUT NOT SUBCUTANEOUS FAT REDUCTION IS RESPONSIBLE FOR 380 METABOLIC IMPROVEMENTS (MI) AFTER WEIGHT LOSS (WL) G. Formoso, M. Taraborrelli, E. Ciccarone, A. Pandolfi, S. Martinotti, M.T. Guagnano, A. Tartaro, A. Consoli (Chieti-Pescara, Italy) 157 BODY COMPOSITION, PLASMA ADIPOCYTOKINES, AND CARDIOVASCULAR RISK 380 FACTORS BEFORE AND AFTER WEIGHT LOSS IN OVERWEIGHT AND OBESE WOMEN I. Demonty, S. Santosa, A.H. Lichtenstein, K. Cianflone, P.J.H. Jones (Montreal, Ste-Foy, QC, Canada and Boston, MA, USA) 158 FITNESS CAPACITY IS THE MAJOR PREDICTOR OF THE NUMBER OF 381 CARDIOVASCULAR RISK FACTORS IN OBESE ADOLESCENTS P.A. Velasquez-Mieyer, P.A. Cowan, B.S. Alpert, C. Villegas-Barreto, S. Perez-Faustinelli, G. Burghen, A.J. Mendez, F. Tylavsky (Memphis, TN and Miami, FL, USA) 159 HYPOCALORIC DIET RAPIDLY AND SIGNIFICANTLY REDUCES IN SHORT TERM 381 CARDIOVASCULAR INFLAMMATORY MARKERS IN OVERWEIGHT AND OBESE PATIENTS P. Giordano Sciacca, F. Graziani, A. Sica, M. Conte, A. Rebuzzi, L.M. Biasucci, F. Crea (Rome, Italy) 160 CARDIOVASCULAR RISK FACTORS IN CHINESE-AMERICAN CHILDREN 381 J. Chen, Y. Wu (San Francisco, CA, USA) 161 PLASMA LEPTIN CONCENTRATION IN SERBIAN PATIENTS WITH TYPE 2 DIABETES 381 MELLITUS: RELATIONSHIP TO OBESITY AND CHD RISK FACTORS A. Stefanovic, J. Kotur-Stevuljevic, S. Spasic, N. Bujisic (Belgrade and Zemun, Serbia-Montenegro) 162 BARIATRIC SURGERY, ALBUMINURIA AND CARDIOVASCULAR RISK – INITIAL CHANGES 381 M. Phillips, S. Wahlroos, L. Kow, J. Slavotinek, J. Toouli, C. Thompson (Adelaide, SA, Australia) 163 ADIPONECTIN LEVELS IN PATIENTS REFERRED TO ELECTIVE CORONARY ANGIOGRAPHY 382 J.G. Rasmussen, E.B. Schmidt, E. Toft, J.H. Christensen (Aalborg, Denmark) 164 GUIDELINES FOR EARLY PREVENTION OF ATHEROSCLEROSIS IN PATIENTS WITH 382 FAMILY HISTORY OF ATHEROSCLEROSIS J. Tyaneva, I.V. Sterev, D. Kostov, K. Nenova (Varna, Bulgaria) 165 ADIPONECTIN AND SUBCLINICAL ATHEROSCLEROSIS IN 64-YEAR OLD WOMEN WITH 382 VARYING DEGREES OF GLUCOSE TOLERANCE C.J. Behre, G. Brohall, J. Hulthe, J. Wikstrand, B. Fagerberg (Goteborg, Sweden) 166 INVESTIGATION OF DIETARY HABITS IN PATIENTS WITH PRIMARY HYPERTENSION IN 382 INTERNAL AND HEART CLINIC IN TEHRAN UNIVERSITY OF MEDICAL SCIENCES HOSPITALS M. Zakerimoghadam, M. Salsali, Z. Monjamed (Tehran, Iran) 167 LIPID SOLUBLE SMOKING PARTICLES ENHANCE ENDOTHELIN RECEPTOR EXPRESSION 382 W IN VASCULATURE E C.-B. Xu, P. Vikman, T. Krag, L. Edvinsson (Lund, Sweden and Copenhagen, Denmark) D 168 PATIENTS WITH ESSENTIAL HYPERTENSION HAVE HIGH PREVALENCE OF METABOLIC 383 N SYNDROME E J.A. Papadakis, G.E. Vrentzos, A. Repa, G. Roditakis, E. Mavrogeni, E.S. Ganotakis S (Heraklion, Greece) D 169 ESSENTIAL HYPERTENSION PECULIARITIES AT METABOLIC SYNDROM PATIENTS 383 A N. Velykykh, I. Snegurskaya, D. Myloslavsky, S. Koval, Y. Karachentsev, N. Kravchun Y (Kharkov, Ukraine) 170 C-REACTIVE PROTEIN IS CORRELATED WITH MICROVASCULAR DYSFUNCTION BUT NOT 383 LARGE ARTERY STIFFNESS IN ESSENTIAL HYPERTENSIVE PATIENTS W.C. Tsai, C.C. Lin, C.H. Lee, W.T. Li, J.H. Chen (Dou-Liou and Tainan, Taiwan) 171 HAPLOTYPES IN THE KCNMA1 POTASSIUM CHANNEL ALPHA-SUBUNIT GENE AS 383 RISK FACTORS FOR HUMAN ESSENTIAL HYPERTENSION M. Tomas, E. Vazquez, M. Fernandez-Fernandez, R. Elosua, I. Subirana, G. Latorre, C. Plata, M.A. Valverde, J. Marrugat, M. Senti (Barcelona, Spain) 172 HAPLOTYPES OF THE KCNMB1 POTASSIUM CHANNEL SUBUNIT AS GENETIC 384 MARKERS FOR HYPERTENSION AND RESPONSE TO ANTIHYPERTENSIVE THERAPY M. Sentí, M. Tomás, J.M. Fernández-Fernández, M.A. Valverde, J. Marrugat (Barcelona, Spain) 173 LIPID PROFILE IN UNCOMPLICATED NON DIABETIC HYPERTENSIVE 384 M. Sadeghi, H. Roohafza (Isfahan, Iran)

130 174 COMPARISON OF CARDIAC GEOMETRY AND FUNCTION IN NORMOALBUMINURIC 384 PATIENTS WITH SYSTO-DIASTOLIC AND ISOLATED SYSTOLIC ARTERIAL HYPERTENSION M. Picca, F. Agozzino, G.C. Pelosi (Milan, Italy) 175 APO E AND ACE GENES IN MILD ESSENTIAL HYPERTENSION (EH) 384 I. Pecin, M. Laganovic, J. Sertic, Z. Reiner, D. Kuzmanic, B. Jelakovic (Zagreb, Croatia) 176 ADMINISTRATION OF DOXAZOSIN COULD IMPROVE ATHEROSCLEROSIS AND 384 INFLAMMATION IN THE PATIENTS WITH HYPERTENSION IN THE MORNING Y. Miyashita, I. Saito (Shizuoka and Tokyo, Japan) 177 STUDY 0F INCIDENCE OF NUTRIENT CANALS IN HYPERTENSIVE AND NON 385 HYPERTENSIVE PATIENTS M. Mehdizadeh, A. Azimipour (Isfahan, Iran) 178 INTRAVENOUS INFUSION OF SODIUM SELENITE DECREASES BLOOD PRESSURE IN 385 NORMOTENSIVE RATS E. Amano, H. Hashimoto, Y. Nakai, M. Atake, N. Takechi, M. Takenaka, N. Kurihara (Kobe, Japan) 179 GENETIC POLYMORPHISMS OF CHOSEN CANDIDATE GENES IN ESSENTIAL 385 HYPERTENSION CONTROLLED AND RESISTANT TO THE ANTIHYPERTENSIVE THERAPY M. Jáchymová, K. Hork´y, Z. Hlubocká, V. Lánská (Prague, Czech Republic) 180 PREVENTION OF CARDIOVASCULAR AND RENAL EVENTS WITH AN 385 ANTIHYPERTENSIVE REGIMEN OF PRETERAX (NOLIPREL) ADDING SIMVASTATIN IN PATIENTS WITH DIABETES K. Gogoladze, N. Chachanidze (Tbilisi, Georgia) 181 EFFECTS OF LONG-TERM ANTIHYPERTENSIVE THERAPY WITH LACIDIPINE ON 385 AMBULATORY BLOOD PRESSURE AND ON CARDIOVASCULAR REMODELING PROCESSES Sh.D. Chumburidze, G.V. Lomtatidze, G.D. Shelia, T.I. Kurtanidze (Tbilisi, Georgia) 182 CIRCULATING LEVELS OF OXLDL AND CRP IN PREHYPERTENSION 386 Z. Caparevic, N. Kostic, M. Dekleva, B. Pencic, S. Ilic (Belgrade, Serbia-Montenegro) 183 HYPERTENSION 386 M. Bosnjak, L. Sokolova Djokic, S. Martinovic, M. Stic (Sombor, Serbia-Montenegro) 184 ENDOTHELIAL NITRIC OXIDE SYNTHASE (ENOS) GLU298ASP AND T-786C GENE 386 POLYMORPHISM AND METABOLIC SYNDROME IN ESSENTIAL HYPERTENSION L. Pucci, D. Lucchesi, C. Fotino, S. Triscornia, G. Dell'Omo, R. Pedrinelli, R. Miccoli, S. Del Prato, G. Penno (Pisa, Italy) 185 A LIFESTYLE PROGRAM FOR TREATED HYPERTENSIVES IMPROVES 386 CARDIOVASCULAR RISK FACTORS: A RANDOMIZED CONTROLLED TRIAL V. Burke, L. Beilin, H. Cutt, J. Mansour, A. Williams, T. Mori (Perth, WA, Australia) 186 ENDOTHELIAL NITRIC OXIDE SYNTHASE E298D AND T-786C POLYMORPHISMS DO 387 NOT AFFECT POST-CHALLENGE GLUCOSE AND INSULIN IN NONDIABETIC HYPERTENSIVE MEN D. Lucchesi, L. Pucci, C. Fotino, S. Triscornia, G. Dell'Omo, R. Pedrinelli, R. Miccoli, G. Penno, S. Del Prato (Pisa, Italy) W 187 MONOCYTE/MACROPHAGE STATUS AND THE LEVELS OF SOLUBLE CELL ADHESION 387 E MOLECULES AND INTERLEUKIN-6 IN YOUNG PATIENTS WITH ESSENTIAL HYPERTENSION D D. Zapolska-Downar, A. Siennicka, K. Chelstowski, K. Widecka, I. Goracy, B. Millo, N M. Naruszewicz (Szczecin and Warsaw, Poland) E 188 REDUCED AORTIC ROOT COMPLIANCE STATUS AND LIKELIHOOD OF ASSOCIATED 387 S CORONARY ARTERY DISEASE IN HYPERTENSIVE PATIENTS D A.M. Hegazy, B.A. Abdulkader (Farwania, Kuwait) A 189 ARTERIAL HYPERTENSION IN PATIENTS SUFFERING OF PERIPHERAL ARTERITIS 387 Y A. Berrah, N. Ouadahi, D. Hakem, M. Boucelma, D. Zemmour, C. Farad, M. Ibrir (Algiers, Algeria) 190 ASSOCIATION OF INTERLEUKIN-6 GENE POLYMORPHISM WITH ESSENTIAL 387 HYPERTENSION IN TATARS FROM RUSSIA Y.R. Timasheva, T.R. Nasibullin, A.N. Zakirova, O.E. Mustafina (Ufa, Russia) 191 THE RESULTS OF PROLONGED TREATMENT OF PATIENTS WITH DIABETES MELLITUS 388 AND ARTERIAL HYPERTENSION WITH PERINDOPRIL L.S. Pachulia, Sh.D. Chumburidze (Tbilisi, Georgia) 192 ANTIHYPERTENSIVE AND ANTIOXIDANT EFFECTS OF CARBON MONOXIDE 388 SUPPRESSES ANGIOTENSIN II MEDIATED CARDIAC HYPERTROPHY IN LDL-RECEPTOR KNOCKOUT MICE A. Kobayashi, K. Ishikawa, S. Kimura, Y. Kamiyama, H. Matsumoto, Y. Maruyama (Fukushima, Japan)

131 193 ACE2 ACTIVITY IS INCREASED IN MONOCYTES DERIVED MACROPHAGES FROM 388 PREHYPERTENSIVE SUBJECTS A. Raz, A. Strizevsky, A. Gamliel-Lazarovich, S. Keidar (Haifa, Israel) 194 TIME STRUCTURE OF BLOOD PRESSURE VARIATION AND RISK FACTORS IN 388 NON-DIPPER KAZAKHS H. Kawamura, Y. Izumi, H. Mitsubayashi, Y. Ozawa, R. Masum (Tokyo, Japan and Urumqi, China) 195 COMPARISON OF CAROTID INTIMA-MEDIA THICKNESS IN PATIENTS WITH PRIMARY 389 AND SECONDARY HYPERTENSION R. Holaj, B. Strauch, O. Petrak, T. Zelinka, J. Widimsky (Prague, Czech Republic) 196 ANTIAGGREGATION AND HIGH BLOOD PRESSURE 389 M. Ferraro, V. Spagnuolo, G.F. Mauro (San Giovanni in Fiore and Cosenza, Italy) 197 THIOREDOXIN AND GLUTATHIONE SYSTEMS MRNA LEVELS IN HUMAN HYPERTENSION 389 M.L. Mansego, S. Blesa, V. Gonzalez, M.C. Tormos, O. Espinosa, G. Saez, J. Redon, F.J. Chaves (Valencia, Spain) 198 DYSLIPIDEMIA AND STATE OF THE CARDIOVASCULAR SYSTEM AND CIRCADIAN 389 BLOOD PRESSURE RHYTHM IN MEN WITH MILD TO MODERATE HYPERTENSION K. Chagunava, T. Kurtanidze, D. Tsiskarishvili, G. Lomtatidze (Tbilisi, Georgia) 199 ACHIEVEMENT OF THE THERAPEUTIC GOAL IN A SELECTED HYPERTENSIVE 389 POPULATION OF OVER 50 YEAR OLD M. Ferraro, V. Spagnuolo, G.F. Mauro (San Giovanni in Fiore and Cosenza, Italy) 200 MORE PRONOUNCED ANTIOXIDATIVE EFFECT OF LONG-TERM TREATMENT WITH 390 CARVEDILOL COMPARED TO ATENOLOL IN POST-MYOCARDIAL INFARCTION PATIENTS G. Jonsson, M. Abdelnoor, I. Seljeflot, H. Arnesen, A.T. Hostmark, S.E. Kjeldsen, I. Os, A. Westheim (Oslo, Norway) 201 METABONOMIC CHARACTERIZATION OF NUTRITIONAL AND ENVIRONMENTAL 390 SIGNATURES IN HUMAN POPULATION STUDIES L.M. Smith, E. Maibaum, A. Maher, Q. Chan, P. Elliott, J. Mancilha-Carvalho, J. Stamler, H. Kesteloot, J.K. Nicholson, E. Holmes (London, UK, Rio de Janeiro, Brazil, Chicago, IL, USA and Leuven, Belgium) 202 COMPLEMENTARY ROLES OF COLLAGEN AND TISSUE FACTOR OF ATHEROSCLEROTIC 390 LESIONS IN SHEAR-INDUCED THROMBUS FORMATION VIA PLATELET GLYCOPROTEIN VI J. Cosemans, I. Munnix, P. van der Meijden, M. Kuijpers, J. Auger, S. Watson, S. Heeneman, M. oude Egbrink, M. Jandrot-Perrus, J. Heemskerk (Maastricht, The Netherlands, Birmingham, UK and Paris, France) 203 PLATELET-DEPENDENT THROMBIN GENERATION IS REQUIRED FOR TISSUE 390 FACTOR- AND COLLAGEN TRIGGERED THROMBOSIS IN VIVO M.J.E. Kuijpers, I.C.A. Munnix, C.P.M. Reutelingsperger, M.G.A. Oude Egbrink, J.W.M. Heemskerk (Maastricht, The Netherlands) 204 PLASMA CD40L LEVELS AND THROMBIN GENERATION AFTER LIPID-LOWERING 391 W THERAPY AND FOLIC ACID SUPPLEMENTATION E T.B. Domagala, M. Celinska-Lowehoff, J. Dropinski, M. Gnass, T. Iwaniec, D A. Borkowska-Mosur, A. Szczeklik (Cracow, Poland) N 205 ANTI-INFLAMMATORY ACTION OF A NEW LOW MOLECULAR WEIGHT HEPARIN-LIKE 391 E DERIVATIVE IN AN ACUTE EXPERIMENTAL INFLAMMATORY MODEL S E. Masini, A.M. Gori, C. Mazzocca, D. Bani, L. Giannini, M. Falciani, M. Manoni, I. Lapini, D R. Abbate, G.F. Gensini (Florence and Pistoia, Italy) A 206 INDOBUFEN INHIBITS TISSUE FACTOR IN HUMAN MONOCYTES THROUGH A 391 Y THROMBOXANE-MEDIATED MECHANISM S. Eligini, F. Violi, C. Banfi, S.S. Barbieri, M. Brambilla, E. Tremoli, S. Colli (Milan and Rome, Italy) 207 ANTI-THROMBIC ACTIVITY OF KOREAN HERBAL MEDICINE, DAE-JO-WHAN AND 391 ITS HERBS J. Kim, G. Chang, C. Kim (Seoul and Gyeoingju, South Korea) 208 PHARMACOLOGICAL CHARACTERIZATION OF 2NTX-99, A POTENTIAL 392 ANTIATHEROTHROMBOTIC AGENT WITH ANTITHROMBOXANE AND NO-DONOR ACTIVITY C. Buccellati, A. Sala, G. Rossoni, V. Capra, G. Rovati, A. Di Gennaro, G. Folco, S. Colli, C. Casagrande (Milan, Italy) 209 PURIFICATION AND CHARACTERIZATION OF A NEW ANTICOAGULANT PROTEIN, 392 PP27, FROM PLACENTA G. Chang, J. Kim, C. Kim (Gyeongju and Seoul, South Korea)

132 210 EVALUATION OF NOVEL PHOSPHATIDIC ACID DERIVATIVES AS ANTAGONISTS OF 392 PLATELET ACTIVATION INDUCED BY THE PLAQUE LIPID LYSOPHOSPHATIDIC ACID P. Goyal, G.G. Durgam, N. Wilke, D.D. Miller, G. Tigyi, W. Siess (München, Germany and Memphis, TN, USA) 211 AGI-1067, AN ANTIOXIDANT, ANTI-INFLAMMATORY VASCULAR PROTECTANT, 392 REDUCES ACTIVITY OF HUMAN PLATELETS V. Serebruany, A. Malinin, R. Scott (Baltimore, MD and Alpharetta, GA, USA) 212 PLATELET INHIBITION WITH PRASUGREL (CS-747) VERSUS CLOPIDOGREL IN 393 PATIENTS UNDERGOING CORONARY STENTING (JUMBO PLATELET SUBSTUDY) V. Serebruany, M. Midei, H. Meilman, A. Malinin, D. Lowry (Baltimore, MD, USA) 213 POSTER WITHDRAWN – 214 CLOPIDOGREL IN THERAPY OF PATIENTS WITH ACS WITHOUT ST SEGMENT 393 ELEVATION. OUR FIRST EXPERIENCE M. Burazor, I. Burazor, S. Ciric-Zdravkovic, L. Todorovic, S. Nagorni, M. Zivkovic, M. Lazovic, L. Pesic, V. Stojanovic, V. Erakovic (Nis, Serbia-Montenegro) 215 THE THROMBOXANE RECEPTOR ANTAGONIST S 18886 (TERUTROBAN) FAVORED 393 ATHEROSCLEROSIS REGRESSION IN APOE*3 LEIDEN TRANSGENIC MICE J.W.A. van der Hoorn, J.W. Jukema, H.M.G. Princen, L. Chancharme, J.J. Emeis (Leiden, The Netherlands and Courbevoie, France) 216 CD137 AND CD137 LIGAND IN VASCULAR SMOOTH MUSCLE CELLS 393 D. Wågsäter, P.S. Olofsson, A. Sirsjö (Stockholm and Örebro, Sweden) 217 EFFECT ON RAT VASCULAR SMOOTH MUSCLE CELLS /MONOCYTES ADHESION BY 393 STROMAL CELL DERIVED-FACTOR 1 ALPHA G.H. Li, Y.L. Tu, Z. W, Y.C. Lv, D.H. W, Z.Y. T, F. Y, Z.S. J, G.H. Y, Y.Z. Y (Heng Yang, China) 218 THROMBIN INHIBITION PREVENTS RUPTURE OF ESTABLISHED PLAQUES IN 394 APOLIPOPROTEIN E KNOCKOUT MICE S. Karanam, R. Fritsche-Danielson, C.L. Jackson (Bristol, UK and Mölndal, Sweden) 219 BENEFICIAL EFFECT OF CILOSTAZOL ON ATHEROSCLEROSIS DEVELOPMENT IN 394 APOLIPOPROTEIN-E KNOCKOUT MICE. H. Takase, A. Hashimoto, R. Okutsu, Y. Hirose, H. Ito, T. Imaizumi, G. Miyakoda, T. Mori (Tokushima, Japan) 220 EFFECTS OF CLOPIDOGREL ON KEY EVENTS OF RESTENOSIS IN VITRO: 394 EVALUATION OF THE CLINICAL RELEVANCE OF THE DATA WITH THE SI/MPL-RATIO R. Voisard, B. Eisler, R. Baur, V. Hombach (Ulm, Germany) 221 PLATELET ACTIVATION AND RED BLOOD CELLS ABNORMALITIES IN CORONARY 394 HEART DISEASE PATIENTS T.E. Pogorelova, A.B. Sumarokov, L.I. Buriachkovskaia, I.A. Uchitel (Moscow, Russia) 222 THE EFFECT OF OPIUM ADDICTION ON THE PLASMA LEVELS OF FIBRINOGEN, 394 FACTOR VII AND CRP G.H. Naderi, S. Asgary, H. Oroojy, N. Bashardoost (Isfahan, Iran) 223 IS MORPHINE USE EFFECTIVE IN PREVENTING ATHEROSCLEROSIS IN ANIMALS ON 395 W NORMAL AND HIGH-CHOLESTEROL DIET? E S. Asgary, H.R. Barkhordari, H. Hojjat, G.H. Naderi, G. Dashti (Isfahan, Iran) D 224 LEVELS OF ACTIVATED PROTEIN C INVERSELY CORRELATED WITH THREE CORONARY 395 N ARTERIOSCLEROSIS SCORES IN YOUNG SURVIVORS OF MYOCARDIAL INFARCTION (MI) E P. Cubillo, E. Zorio, S. Navarro, P. Medina, M.A. Arnau, J. Rueda, M. Palencia, A. Salvador, S A. Estellés, F. España (Valencia, Spain) D 225 CHANGES OF COAGULATION FACTORS AND NORMAL INHIBITORS OF COAGULATION 395 A DURING ACUTE PHASE OF MYOCARDIAL INFARCTION Y I. Moyssakis, M. Daskalaki, D. Papadopoulos, E. Gialafos, K.R. Georgakopoulos, E.A. Sanidas, V. Votteas (Athens, Greece) 226 THE EFFECT OF FIBRINOGEN AND PLATELET AGGREGATION ON CARDIOVASCULAR 395 RISK IN PREDIABETIC SUBJECTS T. Dogru, A. Sonmez, H. Genc, I. Tasci, A.U. Ural, F. Avcu, M.I. Yilmaz, M. Gok, S. Savasci, S. Kilic (Ankara, Turkey) 227 HYPERVISCOSITY AS A POSSIBLE RISK FACTOR FOR CEREBRAL ISCHEMIC 396 COMPLICATIONS IN NONVALVULAR ATRIAL FIBRILLATION PATIENTS E. Cecchi, R. Marcucci, S. Poli, G. Ciuti, D. Poli, S. Ferrini, E. Antonucci, R. Abbate, G.F. Gensini, L. Mannini (Florence and Impruneta, Italy) 228 ASSOCIATION OF THE -308 G/A POLYMORPHISM OF TUMOR NECROSIS FACTOR 396 ALPHA GENE WITH MYOCARDIAL INFARCTION AND SUDDEN CARDIAC DEATH G.H. Tulyakova, T.R. Nasibullin, A.N. Zakirova, E.K. Khusnutdinova, O.E. Mustafina (Ufa, Russia)

133 229 APOLIPOPROTEIN A5 GENE POLYMORPHISMS, -1131T>C AND C.553G>T WERE IN 396 STRONG LINKAGE DISEQUILIBRIA AND ASSOCIATED WITH HYPERTRIGLYCERIDEMIA IN JAPANESE A. Matsunaga, H. Arishima, Y. Uehara, B. Zhang, H. Niimura, K. Saku (Fukuoka, Japan) 230 MUTATION SCREENING ANALYSIS OF PEROXISOME PROLIFERATOR-ACTIVATED 396 RECEPTORS-GAMMA (PPARG) PROMOTERS IN CAD PATIENTS AND CONTROL L. Evangelisti, M. Attanasio, L. Lucarini, L. Rossi, E. Romano, M. Lenti, P. Bolli, G. Pepe, R. Abbate, G.F. Gensini (Florence, Italy) 231 C161T POLYMORPHISM OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR 397 GAMMA GENE IS ASSOCIATED WITH PROGNOSIS OF MYOCARDIAL INFARCTION T.H. Chao, Y.H. Li, H.L. Wu, G.Y. Shi, J.H. Chen, W.C. Tsai, L.M. Tsai, L.J. Lin (Tainan, Taiwan) 232 GENETIC VARIANT C677T IN THE METHYLENTETRAHYDROFOLATE REDUCTASE 397 GENE IN PATIENT WITH RECURRENT INCIDENCE OF ARTERIAL AND VENOUS THROMBOSIS P. Ivanov, S. Gecheva, R. Komsa-Penkova, O. Matkov, K. Kovacheva, A. Kamenova (Pleven, Bulgaria) 233 INFLUENCE OF AMPD1 GENE POLYMORPHISM ON COAGULATION FACTORS IN 397 PATIENTS WITH CORONARY HEART DISEASE S. Agewall, B. Norman (Stockholm, Sweden) 234 HEPATIC NUCLEAR FACTOR 4 ALPHA GENE IMPLICATED IN FINNISH AND MEXICAN 397 FAMILIAL COMBINED HYPERLIPIDEMIA FAMILIES A. Huertas-Vazquez, D. Weissglas, T. Tusie, C. Aguilar-Salinas, M.R. Taskinen, P. Pajukanta (Los Angeles, CA, USA, Mexico City, Mexico and Helsinki, Finland) 235 TREATMENT OF PATIENTS WITH VASCULAR DISEASE WITH LOW-DOSE ASPIRIN. IS 397 BLOCKADE OF PLATELET THROMBOXANE A2 SYNTHESIS ALWAYS ACHIEVED? M.T. Santos, J. Valles, A. Lago, J. Tembl, J. Cosin, A. Moscardo, M.P. Fuset, S. Breña (Valencia, Spain) 236 ACETYLSALICYLIC ACID AND CLOPIDOGREL RESISTANCE: POSSIBLE ROLE OF 398 RISK FACTORS, MEDICATION AND HEMORHEOLOGICAL VARIABLES G. Feher, K. Koltai, E. Papp, Z. Keszthelyi, B. Alkonyi, P. Kenyeres, H. Rapp, G. Kesmarky, K. Toth (Pecs, Hungary) 237 ASPIRIN RESISTANCE IS ASSOCIATED WITH ASPIRIN DOSAGE, MEAN PLATELET 398 VOLUME AND PLATELET COUNT IN PATIENTS WITH ACUTE CORONARY SYNDROMES S. Acikel, A. Yildirir, A. Aydinalp, U. Bal, G. Kaynar, K. Demirtas, B. Ozin, H. Muderrisoglu (Ankara, Turkey) 238 EFFECT OF TWO DIFFERENT DOSES OF ASPIRIN ON PLATELET AGGREGATION AND 398 THROMBOXANE FORMATION IN PATIENTS UNDERGOING CABG M. Brambilla, A. Anselmo, C. Centenaro, E. Tremoli, A. Parolari, M. Camera (Milan, Italy) 239 ERYTHROCYTE DEFORMABILITY AND WHITE BLOOD CELL COUNT ARE 398 ASSOCIATED WITH ASPIRIN RESISTANCE IN HIGH-RISK VASCULAR PATIENTS W L. Mannini, R. Marcucci, R. Paniccia, E. Antonucci, L. Evangelisti, L. Lucarini, A.M. Gori, E D. Prisco, G.F. Gensini, R. Abbate (Florence and Impruneta, Italy) D 240 EFFECTS OF POMACE OLIVE OIL ON THE POSTPRANDIAL METABOLISM IN HIV PATIENTS 399 N F. Rivas-Garcia, J.S. Perona, M.J. Aguilar, M. Garcia, J.L. Prada, A. del Arco, V. Ruiz-Gutierrez E (Seville and Marbella, Spain) S 241 CARDIOVASCULAR RISK REDUCTION IN HIV+ PATIENTS: RESULTS FROM 399 D SHORT-TERM PHARMACOLOGICAL AND LIFESTYLE INTERVENTION A C.Y. Pai, D. Calderaro, C.L. Zilli Vieira, E. de Oliveira Lima, I. Giuliano, B. Caramelli Y (São Paulo, Brazil) 242 CARDIOVASCULAR RISK DUE TO LIPOPROTEIN (A) IN HIV-INFECTED SUBJECTS 399 W.O. Richter, E. Schnaitmann, A. Trein (Windach and Stuttgart, Germany) 243 PON1 ACTIVITY IS NOT IMPAIRED IN HIV POSITIVE PATIENTS 399 L.P. Pucillo, E. Foschi, E. Valente, M. Brescia, F. Soldani, A. Antinori (Rome, Italy) 244 OXIDIZED LDL IN HIV INFECTED PERSONS 399 L.P. Pucillo, M. Brescia, E. Valente, E. Foschi, F. Soldani, A. Antinori (Rome, Italy) 245 ATHEROSCLEROTIC RISK IN CHILDREN WITH ACQUIRED IMMUNODEFICIENCY 400 SYNDROME (AIDS) – PERI STUDY I. Giuliano, M. Grimaldi, D. Blanco, E. Lima, P. Yu, D. Calderaro, M. Silva, B. Caramelli (Santa Catarina and São Paulo, Brazil) 246 A NEW BIOMARKER TO ASSESS CARDIOCYTOTOXICITY AND LIPODYSTROPHY IN 400 HIV PATIENTS UNDERGOING ART M. Gidlund, K. Ronchini, H. Goto (São Paulo, Brazil)

134 247 PROTEASE INHIBITOR-ASSOCIATED DYSLIPIDEMIA IN HIV PATIENTS IS STRONGLY 400 INFLUENCED BY THE APOLIPOPROTEIN A5 GENE M. Guardiola, R. Ferré, C. Alonso-Villaverde, B. Coll, J. Salazar, J. Ribalta, L. Masana (Reus, Spain) 248 HIGHLY ACTIVE ANTIRETROVIRAL THERAPY FOR HIV-INFECTION INCREASES 400 PLASMA HOMOCYSTEINE CONCENTRATIONS N. Weiss, P. Koelle, J. Bogner, F.D. Goebel (Munich, Germany) 249 INCREASED ENDOTHELIAL ACTIVATION IN A HUMAN MODEL OF ISOLATED 400 ENDOTHELIAL VASOMOTOR DYSFUNCTION S.S. Shankar, H.O. Steinberg (Indianapolis, IN, USA) 250 EFFECTS OF NEVIRAPINE AS COMPARED TO LAMIVUDINE ON LIPIDS AND 401 LIPOPROTEINS IN HIV-1 UNINFECTED NEWBORNS: THE SIMBA LIPID SUBSTUDY R.R. Sankatsing, F.W. Wit, N. Pakker, J. Vyankandondera, F. Mmiro, P. Okong, J.J.P. Kastelein, J.M. Lange, E.S.G. Stroes, P. Reiss (Amsterdam, The Netherlands, Kigali, Rwanda and Kampala, Uganda) 251 SMALL DENSE LDL IN HIV-INFECTED PATIENTS TREATED WITH LOPINAVIR/RITONAVIR 401 OR ATAZANAVIR W.O. Richter, F. Berger, S. Mauss (Munich and Duesseldorf, Germany) 252 PLASMA CHOLESTEROL CONCENTRATIONS IN DEPRESSION AND POSTTRAUMATIC 401 STRESS DISORDER J. Bremner, V. Vaccarino (Atlanta, GA, USA) 253 INTERLEUKIN-6 PLASMA LEVELS ARE INCREASED IN SUBJECTS WITH VASCULAR 401 DEMENTIA BUT NOT WITH LATE ONSET ALZHEIMER'S DISEASE G. Guerra, M. Ranzini, L. Rossi, M.R. Munari, A. Zurlo, A.R. Atti, A. Ble', G. Zuliani (Ferrara and Treviso, Italy) 254 ATHEROSCLEROSIS AND DEMENTIA: IMPLICATION OF OXIDATIVE STRESS IN THE 402 IMPAIREMENT OF COGNITIVE FUNCTION I. Squellerio, F. Veglia, M. Alimento, L. Boccotti, J. Campodonico, E. Tremoli, V. Cavalca (Milan, Italy) 255 VASCULAR RISK FACTORS, MILD COGNITIVE IMPAIRMENT, AND CONVERSION TO 402 DEMENTIA. THE ITALIAN LONGITUDINAL STUDY ON AGING F. Panza, C. Capurso, A. D'Introno, A.M. Colacicco, A. Capurso, V. Solfrizzi (Bari, Italy) 256 DYSLIPIDEMIA-RELATED MEMORY IMPAIRMENT IN TYPE 2 DIABETES 402 S. Miclea, N. Hancu (Cluj-Napoca, Romania) 257 PERCEPTION OF STRESSORS BY SELECTED PATIENTS OF CORONARY CARE 402 UNITS IN YAZD, IRAN Z. Kalani, H. Abdi, M.R. Aminipour (Yazd, Iran) 258 PHYSICAL CHARACTERIZATION OF A POLYMERIC CARRIER FOR AN ANTIBODY 402 ELUTING STENT L.L. Luo, G.X. Wang, T.Y. Yin, C.G. Ruan, R. Guidoin (Chongqing, Suzhou, China and Quebec, QC, Canada) W 259 SURFACE TREATMENT EFFECTS ON BIOCOMPATIBILITY OF NITINOL ALLOY STENTS 403 E G.X. Wang, Y. Shen, S.S. Luo, Q.S. Yu (Chongqing, China and Columbia, MO, USA) D 260 ELUTING CHARACTERISTICS OF A PLATELET GLYCOPROTEIN RECEPTOR ANTIBODY 403 N POLYMER-COATED STENT E T.Y. Yin, G.X. Wang, L.L. Luo, C.G. Ruan, R. Guidoin (Chongqing, Suzhou, China and S Quebec, QC, Canada) D 261 FLUORESCENCE STAINING AND SEMI-QUANTITATIVE IMAGE ANALYSIS OF DRUG 403 A ELUTING STENTS Y T.Y. Yin, G.X. Wang, L.L. Luo, C.G. Ruan, R. Guidoin (Chongqing, Suzhou, China and Quebec, QC, Canada) 262 PLASMA SURFACE TREATMENT EFFECTS ON ADHESION PROPERTY OF STAINLESS 403 STEEL STENTS TO ENDOTHELIAL CELLS S.S. Luo, G.X. Wang, C.J. Tang, L.S. Liu, Q.S. Yu (Chongqing, China and Columbia, MO, USA) 263 INTERLEUKIN 6 IS ASSOCIATED WITH RESTENOSIS AFTER IMPLANTATION OF 404 DRUG-ELUTING CORONARY STENTS V.G. Naumov, M.V. Ezhov, I.R. Raimbekova, A.B. Sumarokov, A.N. Samko, V.P. Masenko (Moscow, Russia) 264 USE OF STENTS WITH SIROLIMUS IS SIGNIFICANTLY ASSOCIATED WITH A REDUCTION 404 IN MORTALITY AND CARDIOVASCULAR MORBIDITY AT 6- AND 12-MONTHS POST-PTCA M. Rizzo, L. Campolo, A. Frasheri, V. Pernice, G. Barone, F. Contorno, S. Amato, C.M. Barbagallo, A. Notarbartolo, M.R. Averna (Palermo and Milan, Italy)

135 265 BIOARTIFICIAL VASCULAR GRAFTS: A NOVEL APPROACH TO TREATMENT OF BLOOD 404 VESSELS DAMAGED BY VASCULAR DISEASES L. Bacakova, E. Filova, D. Kubies, L. Machova, V. Proks, V. Malinova, F. Rypacek (Prague, Czech Republic) 266 ERECTILE DYSFUNCTION AS PREDICTOR OF MAJOR ADVERSE CARDIAC EVENTS 404 IN DIABETIC PATIENTS WITH SILENT CORONARY ARTERY DISEASE C. Gazzaruso, A. Pujia, C. Falcone, F. Salvucci, D. Geroldi, E. Emanuele, B. Solerte, A. Garzaniti (Pavia, Catanzaro and Vigevano, Italy) 267 CARDIOVASCULAR SAFETY OF VARDENAFIL IN PATIENTS ON ANTIHYPERTENSIVES 404 AND / OR ALPHA BLOCKERS: ANALYSIS OF 17 PLACEBO-CONTROLLED TRIALS P. Montorsi, H. van Ahlen, P. Kell, F. Montorsi (Milan, Italy, Osnabrück, Germany and London, UK) 268 CARDIOVASCULAR RISK FACTORS DETERMINE ERECTILE AND ARTERIAL RESPONSE 405 TO SILDENAFIL A. Wierzbicki, H. Solomon, P. Lumb, G. Jackson (London, UK) 269 RELATIVE HYPOGONADISM AS AN INDEPENDENT DETERMINANT OF ENDOTHELIAL 405 DYSFUNCTION IN MEN M. Akishita, M. Hashimoto, Y. Ohike, K. Iijima, M. Eto, Y. Ouchi (Tokyo and Kobe, Japan) 270 CLINICAL AND IMMUNOLOGICAL EFFECTS OF ONE-WEEK TREATMENT WITH 405 INTRAVENOUS ILOPROST IN CRITICAL LIMB ISCHEMIA PATIENTS S. Meini, D. Pieragalli, M. Di Renzo, V. De Franco, A.L. Pasqui, A. Auteri (Siena, Italy) 271 HUMORAL RESPONSE AGAINST HIGH DENSITY LIPOPROTEINS (HDL) IN NORMAL 405 POPULATION J. Batuca, J. Delgado Alves (Lisbon, Portugal) 272 INVARIANT NKT CELLS PRESENT IN HUMAN ATHEROSCLEROTIC LESIONS 406 H.E. Agardh, P. Eriksson, E. Tupin, M. Kazi, U. Hedin, A. Olsson, G.K. Hansson, J. Swedenborg, G. Paulsson-Berne (Stockholm, Sweden and San Diego, CA, USA) 273 IMMUNOMODULATORY PROPERTIES OF APOB-100 DERIVED PEPTIDES ON DENDRITIC 406 CELLS AND T-LYMPHOCYTES A. Bermudez-Fajardo, N. Milioti, G. Nordin Fredrikson, J. Nilsson, E. Oviedo-Orta (Guildford, UK and Malmo, Sweden) 274 CHLAMYDOPHILA PNEUMONIAE, GROWTH FACTORS AND MEMBRANE ATTACK 406 COMPLEX IN ACCELERATED GRAFT CORONARY ATHEROSCLEROSIS (AGCA) M.L. Higuchi, M.M. Reis, N.V. Sambiase, S.A.P. Palomino, N. Stolf, J.A.F. Ramires (São Paulo, Brazil) 275 ANALYSIS OF TLR-4 AND CD14 POLYMORPHISMS IN FAMILIAL 406 HYPERCHOLESTEROLAEMIA PATIENTS D. Recalde, P. Martin-Fuentes, B. Puisac, A.L. Garcia-Otin, A. Cenarro, E. Jarauta, J.A. Lopez-Cabañas, F. Civeira (Zaragoza, Spain) 276 THE IMMUNOMODULATOR FTY720 INHIBITS EARLY ATHEROSCLEROSIS IN 407 W APOE-/- MICE E R. Klingenberg, F. Bea, E. Blessing, M. Preusch, H.-J. Groene, V. Brinkmann, F. Picard, D H.A. Katus, G.K. Hansson, T.J. Dengler (Heidelberg, Germany, Basel, Switzerland and N Stockholm, Sweden) E 277 ANTIMICROBIAL PEPTIDE LL-37 IN HUMAN ATHEROSCLEROSIS 407 S K. Edfeldt, B. Agerberth, M.E. Rottenberg, G.H. Gudmundsson, K. Mandal, Q.B. Xu, D G.K. Hansson, Z.Q. Yan (Stockholm, Sweden, Reykjavik, Iceland and London, UK) A Y

136 POSTER AREA “A” WEDNESDAY, June 21 278-311

POSTER DISPLAY: for the duration of one day (Wednesday, June 21 from 8.30 am to 6.30 pm). Participants may view the posters displayed during this day.

We-P12 Poster Session 12 poster abstract bk. board no.: OPTIMAL ATHEROSCLEROSIS page ref.: MANAGEMENT (2nd part)

278 ESTROGEN REPLACEMENT THERAPY DECREASES RLP CONCENTRATION IN 407 PLASMA: ORAL AND TRANSDERMAL ERT COMPARISON M. Vrablik, T. Fait, J. Kovar, L. Zlatohlavek, R. Poledne, R. Ceska (Prague, Czech Republic) 279 SOME OF ARTERIOSCLEROTIC RISK FACTORS RELATED TO SERUM ESTRADIOL 407 LEVEL IN WOMEN DURING MENOPAUSE S. Petrovska, B. Dejanova, P. Kandikjan (Skopje, Macedonia) 280 METABOLIC ABERRATIONS AT THE WOMEN WITH POLYCYSTIC OVARY SYNDROME 407 IN ANAMNESIS T. Arkhypkina, L. Liubimova (Kharkov, Ukraine) 281 ANTIOXIDANTS IN MENOPAUSAL WOMEN WITH CORONARY ARTERY DISEASE 408 M. Andonovska (Kumanovo, Macedonia) 282 HORMONE REPLACEMENT THERAPY AND RISK OF CORONARY HEART DISEASE IN 408 THE CORA-STUDY E. Windler, B. Zyriax, B. Eidenmüller, H. Boeing (Hamburg and Potsdam-Rehbrücke, Germany) 283 EFFECTS OF SEXUAL STEROIDS ON MICROVESSELS 408 G.L. Nádasy, B. Székács, M. Mericli, S. Várbíró, N. Ács, M. Szekeres, R. Kakucs, M. Mátrai, E. Monos (Budapest, Hungary) 284 OESTROGEN AND FEMALES ISCHEMICAL HEART DISEASE 408 V. Stevitsh Gajitsh, M. Borzanovitsh, R. Obrenovitsh (Krusevac and Belgrade, Serbia-Montenegro) 285 THE EFFECTS ON LIPIDS OF A 2-YEAR ADJUVANT TREATMENT WITH EXEMESTANE 409 AFTER TAMOXIFEN IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER S. Gonnelli, A. Montagnani, A. Cadirni, C. Caffarelli, M. Montomoli, M.S. Campagna, W R. Petrioli, K. Del Santo, C. Cuda, R. Nuti (Siena, Italy) E 286 THE EFFECT OF MOXONIDINE IN COMPARISON WITH PRESTARIUM ON 409 D PARAMETERS OF LIPID METABOLISM IN POSTMENOPAUSAL WOMEN N G.M. Dadashova, A.B. Bakhshaliyev (Baku, Azerbaijan) E 287 HIGH ORAL DOSE OF ESTROGEN INHIBITS ATHEROSCLEROSIS BY INHIBITING NADPH 409 S OXIDASE AND INCREASING OXIDATIVE STRESS SCAVENGERS IN APO E-DEFICIENT MICE D Y.C. Chen, L.Y.C. Wing, Y.Y. Shih, J.C. Cheng, M.J. Jiang (Tainan, Taiwan) A 288 INDUCTION OF MACROPHAGE RECEPTOR WITH COLLAGENOUS STRUCTURE 409 Y (MARCO) SUGGESTS POSSIBLE INVOLVEMENT OF ENDOTOXIN IN NONALCOHOLIC STEATOHEPATITIS (NASH) M. Takeya, M. Terasaki, Y. Terasaki, N. Sakashita, H. Sato (Kumamoto, Japan) 289 STRUCTURE AND CONCENTRATION OF DIFFERENT FATTY ACIDS (FFAS) AFFECT 410 STEATOSIS EXTENT AND APOPTOSIS IN HEPATOCYTE CULTURES M. Ricchi, L. Carulli, M.R. Odoardi, M.L. Bormioli, C. Anzivino, A. Lonardo, M. Bertolotti, N. Carulli, P. Loria (Modena, Italy) 290 ENDOTHELIAL FUNCTION IS IMPAIRED IN NON-ALCOHOLIC STEATOHEPATITIS 410 S.S. Shankar, N.P. Chalasani, H.O. Steinberg (Indianapolis, IN, USA) 291 THE TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE WITH METFORMIN 410 AND LACTULOSE M. Meparidze, N.N. Kipshidze, T. Kodua, M. Jebashvili, N. Kakauridze, M. Khelashvili, M. Mosistrapishvili (Tbilisi, Georgia)

137 292 HEPATIC APOLIPOPROTEIN-A5 MRNA EXPRESSION DECREASES WITH WEIGHT LOSS 410 IN MORBIDLY OBESE SUBJECTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE S. Kaser, A. Sandhofer, A. Moschen, H. Tilg, C. Ebenbichler, J. Patsch (Innsbruck, Austria) 293 ASSOCIATIONS BETWEEN CAROTID ARTERY WALL THICKNESS AND LIVER 411 HISTOLOGY IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE G. Targher, L. Bertolini, R. Padovani, S. Rodella, L. Zenari, M. Cigolini, G. Falezza, G. Arcaro (Negrar and Arzignano, Italy) 294 DOES FATTY LIVER ASSOCIATE WITH CAROTID ATHEROSCLEROSIS? 411 F. Scaglioni, S. Lombardini, M. Ricchi, A.M. Verrone, S. Ballestri, L. Carulli, A. Lonardo, N. Carulli, P. Loria (Modena, Italy) 295 ASSOCIATION BETWEEN BONE MINERAL DENSITY AND ATHEROSCLEROSIS IN 411 POSTMENOPAUSAL WOMEN R. Sato, M. Okabayashi, H. Akao, K. Kajinami (Ishikawa, Japan) 296 EXPRESSION OF OSTEOPROTEGERIN IN THP-1 CELLS. INFLUENCE OF MACROPHAGE 411 TRANSFORMATION AND CO-CULTURE WITH SMOOTH MUSCLE CELLS Y. Nagano, K. Nakai, M. Daito, N. Domae (Hirakata, Japan) 297 HIGH PREVALENCE OF PERIPHERAL ARTERIAL DISEASE AMONG OSTEOPOROTIC 411 POSTMENOPAUSAL WOMEN R. Mangiafico, E. Russo, S. Riccobene, P. Pennisi, M. Mangiafico, F. D'Amico, N. Parisi, C. Fiore (Catania, Italy) 298 EFFECT OF SHORT-TERM RHG-CSF STIMULATION ON LIPOPROTEIN PROFILE AND 412 OSTEOPROTEGERIN S. Bergmann, G. Siegert, F. Kroschinsky (Dresden, Germany) 299 ASSESSMENT OF PERIODONTAL STATE IN PATIENTS WITH CORONARY HEART 412 DISEASE L. Pawlicki, M. Kowalski, J. Kowalski, J. Blaszczyk, M. Barylski, A. Lewinski (Lodz, Poland) 300 THE FIMBRIAE OF PORPHYROMONAS GINGIVALIS INCREASED ATHEROSCLEROSIS 412 RISK L.P. Nucci da Silva, J.L. Sinone, C. Gun (Sao Paolo, Brazil) 301 PERIODONTAL DISEASE AND ATHEROSCLEROSIS: CAN BRUSHING AND FLOSSING 412 PREVENT CARDIOVASCULAR DISEASE? M. Trevisan, R.J. Genco, O.M. Andriankaja, J. Dorn, K.L. Falkner, S.G. Grossi (Buffalo, NY, USA) 302 PERIODONTAL DISEASE AND CORONARY ARTERY DISEASE: A TALE OF TWO 412 DISEASES? S. Abou-Raya, A. Abou-Raya, A. Naim, H. Abuelkheir (Alexandria, Egypt) 303 PERIODONTAL MICROBIOTA AND CORONARY ARTERY DISEASE 413 B. Shivalkar, W. Hoisington, P. Camp, I. Micholt, J. Bosmans, C. Vrints, M. Toelken (Antwerp and Ninove, Belgium) 304 SEROLOGICAL ANALYSIS OF THE IMPLICATIONS OF PERIODONTITIS IN VASCULAR 413 DISEASES W Y.W. Chen, M. Umeda, Y. Huang, Y. Takeuchi, Y. Inoue, T. Iwai, I. Ishikawa (Tokyo, Japan) E 305 PORPHYROMONAS GINGIVALIS INDUCES PLATELET AGGREGATION AND BLOOD 413 D COAGULATION - ROLE OF GINGIPAINS AND LIPOPOLYSACCHARIDES N T. Bengtsson, M. Nylander, C. Skoglund, N. Tynngård, H. Kälvegren, L. Wallin, M. Grenegård, E T. Lindahl (Linköping, Sweden) S 306 PERIODONTAL DISEASE AND PRESENCE OF CORONARY ARTERY DISEASE IN 413 D PATIENTS UNDERGOING CORONARY ANGIOGRAPHY A J. Auer, G. Szuesz, G. Lamm, G. Krennmair, R. Berent, T. Weber, B. Eber Y (Wels and Vienna, Austria) 307 EFFECT OF ANTI-TNFA ADMINISTRATION ON THE LIPID PROFILE IN PATIENTS WITH 414 INFLAMMATORY DISEASES J.A. Papadakis, E.K. Spanakis, G.E. Vrentzos, G. Katsikas, S.T. Karvounaris, H.D. Kritikos, P.I. Sidiropoulos, E.S. Ganotakis, D.T. Boumpas (Heraklion, Greece) 308 INFLAMMATION AND PLATELET ACTIVATION IN PATIENTS WITH RHEUMATOID 414 ARTHRITIS: POSSIBLE DETERMINANTS OF INCREASED CARDIOVASCULAR RISK C. Jurcut, R. Jurcut, S. Blaj, C. Tanasescu (Bucharest, Romania) 309 RHEUMATHOID ARTHRITIS (RA) AND ATHEROSCLEROSIS: OSTEOPONTIN (OPN) A 414 COMMON INFLAMMATORY MARKER ASSOCIATED WITH CARDIOVASCULAR RISK L. Bazzichi, A. Mazzone, A. Consensi, T. Giuliano, F. De Feo, M. Lanza, C. Giacomelli, S. Bombardieri (Pisa, Italy)

138 310 TNF ALPHA -1031 T>C POLYMORPHISM IS ASSOCIATED WITH ELEVATED MARKERS 414 OF OXIDATION AND WITH SMALLER LDL SIZE IN SUBJECTS WITH RHEUMATOID ARTHRITIS J.C. Vallvé, J. Girona, S. Paredes, E. Hurt-Camejo, L. Masana (Reus, Spain and Mölndal, Sweden) 311 ATHEROSCLEROSIS, INFLAMMATION, CRP AND STATINS IN RHEUMATOID 415 ARTHRITIS A. Abou-Raya, S. Abou-Raya, A. Naim (Alexandria, Egypt)

W E D N E S D A Y

139 POSTER AREA “A” WEDNESDAY, June 21 312-376

POSTER DISPLAY: for the duration of one day (Wednesday, June 21 from 8.30 am to 6.30 pm). Participants may view the posters displayed during this day.

We-P13 Poster Session 13 poster METABOLIC SYNDROME abstract bk. board no.: page ref.:

312 FUNCTIONAL FEATURES OF A CYCLE GLUCOSE - FAT ACIDS IN WOMEN WITH RISK 415 FACTORS OF A METABOLIC SYNDROME Z.A.E. Bakhtina, A.V. Strelkova, T.A. Zykova (Arkhangelsk, Russia) 313 THE METABOLIC SYNDROME IS A POWERFUL DETERMINANT FACTOR OF 415 INFLAMMATION IN THE CALCIFIED AORTIC VALVE C. Côté, A. Cartier, Z. Castonguay-Lebel, R. Shetty, A. Pépin, M. Briand, J.P. Després, P. Pibarot, P. Mathieu (Québec, QC, Canada) 314 LDL FROM OBESE PATIENTS INDUCE AN INCREASE IN SCAVENGER RECEPTORS 415 CD36 AND LOX-1 GENE EXPRESSION IN HUMAN ENDOTHELIAL CELLS C. Stancu, G. Botez, D. Alexandru, M. Vladica, A. Sima (Bucharest, Romania) 315 ELEVATED LEVELS OF THE PROINFLAMMATORY MEDIATOR SCD40L IN THE 415 METABOLIC SYNDROME N. Varo, C. Natal, I. Colina, J. Díez (Navarra, Spain) 316 GLYCEMIA AND TRIGLYCERIDES, BUT NOT TOTAL OR HDL CHOLESTEROL LEVELS, 416 ARE ASSOCIATED WITH HIGHER PLATELET ACTIVITY P. Osmancik, F. Bednar, P. Stros, M. Jares, P. Widimsky (Prague, Czech Republic) 317 PLASMA LIPOLYTIC ACTIVITY AND HEMOSTATIC PARAMETERS IN PATIENTS WITH 416 METABOLIC SYNDROME L.V. Javashvili, D.K. Virsaladze, N. Esakia (Tbilisi, Georgia) 318 CD4+T CELLS ARE RELATED TO THE METABOLIC SYNDROME OF HIV-INFECTED 416 PATIENTS G. Aragones, B. Coll, S. Parra, C. Alonso-Villaverde, J. Joven, L. Masana (Reus, Spain) 319 LEPTIN TO ADIPONECTIN RATIO AS THE NOVEL ATHEROGENESIS RISK INDICATOR 416 W M. Malczewska-Malec, L. Partyka, I. Lesczynska-Golabek, A. Zdzienicka, M. Szopa, E A. Dembinska-Kiec (Cracow, Poland) D 320 THE CLINICAL SIGNIFICANCE OF SERUM 7-KETOCHOLESTEROL LEVELS IN 417 N PATIENTS WITH METABOLIC SYNDROME OR ACUTE MYOCARDIAL INFARCTION E Y. Miyashita, M. Ebisuno, M. Ohira, K. Endoh, A. Saiki, N. Koide, T. Oyama, T. Murano, S H. Watanabe, K. Shirai (Chiba, Japan) 321 CLINICAL SIGNIFICANCE OF ELEVATED LEVELS OF VERY LONG-CHAIN SATURATED FATTY 417 D ACID (HEXACOSANOIC ACID; C26:0) IN WHOLE BLOOD CELL IN METABOLIC SYNDROME A A. Kume, T. Miyazaki, T. Kiyanagi, H. Ohmura, Y. Kitamura, K. Oshida, N. Yanagisawa, Y K. Shimada, H. Mokuno, H. Daida (Hongo and Zama, Japan) 322 INFLAMMATORY CYTOKINES IN METABOLIC SYNDROME (MS) A COMPARISON 417 BETWEEN MS AND SIMPLE OBESITY M. Ohni, S. Mizukawa, H. Ohnuki, K. Nakajima, Y. Suemitsu, M. Kaneko, K. Toba, Y. Hata (Mitaka-city, Japan) 323 LEPTIN LEVELS IN YOUNG, NON-OBESE, MALE SMOKERS AND NON-SMOKERS 417 B. Koc, A. Sonmez, T. Dogru, I. Tasci, H. Genc, M. Gok, E. Bozoglu, M.I. Yilmaz, G. Erdem, S. Erikci (Ankara, Turkey) 324 HYPERTENSION DIFFERENTIATES THE GROUP OF PATIENTS WITH METABOLIC 417 SYNDROME L. Partyka, M. Malczewska-Malec, I. Leszczynska-Golabek, M. Trzos, D. Siedlecka, A. Dembinska-Kiec (Cracow, Poland)

140 325 METABOLIC SYNDROME IN HD PATIENTS: INSULIN RESISTANCE, VISCERAL 418 ADIPOSITY, INFLAMMATION AND IRON Z. Rasic-Milutinovic, G. Perunicic-Pekovic, S. Pljesa, M. Ilic, S. Stankovic (Belgrade, Serbia-Montenegro) 326 DYSLIPIDEMIC PROFILE IN RELATION TO ANTHROPOMETRIC INDEXES OF 418 VISCERAL OBESITY IN METABOLIC SYNDROME S. Subeska Stratrova, B. Dejanova, V. Arsova, P. Kandikijan (Skopje, Macedonia) 327 LEPTINE LEVELS AND INSULIN RESISTANCE INDEX ARE MARKERS OF EARLY 418 METABOLIC DISTURBANCES AT PATIENTS WITH ESSENTIAL HYPERTENSION N. Velykykh, S. Koval, I. Snegurskaya, D. Myloslavsky, Y. Karachentsev, N. Kravchun (Kharkov, Ukraine) 328 METABOLIC SYNDROME IS ASSOCIATED WITH INFLAMMATION BUT NOT 418 PROTHROMBOGENESIS AND ENDOTHELIAL DYSFUNCTION K. Yusoff, H. Nawawi, R. Ibrahim (Shah Alam, Malaysia) 329 SYMPATHETIC ACTIVATION AND RISK OF ATHEROSCLEROSIS IN PATIENTS 419 WITH DIABETES MELLITUS TYPE 1 T. Zykova, A. Strelkova, K. Balandina, O. Batrakova (Arkhangelsk, Russia) 330 ASSOCIATION BETWEEN PLASMA MYELOPEROXIDASE LEVELS AND METABOLIC 419 SYNDROME H. Ghanbari, B. Hassunizadeh, H. Manyam, R. Dandamudi, D. Cunningham, S. David, C. Machado (Southfield, MI, USA) 331 COMPLEX ADAPTIVE RESPONSE IN THE METABOLIC SYNDROME (MS): CLINICAL, 419 FUNCTIONAL AND GENETIC STUDY V. Palmieri, P. Portincasa, I. Grattagliano, A. Genovese, G. Cardinale, G. Palasciano (Bari, Italy) 332 URIC ACID IS ASSOCIATED WITH CORONARY ARTERY CALCIFICATION AMONG 419 ASYMPTOMATIC MEN WITH METABOLIC SYNDROME R.D. Santos, K. Nasir, R. Orakzai, S. Orakzai, R. Meneghelo, J.A.M. Carvalho, R. Blumenthal (São Paulo, Brazil, Pittsburgh, PA and Baltimore, MD, USA) 333 ADJUSTMENT BY HEIGHT IMPROVES THE CORRELATION OF WAIST 420 CIRCUMFERENCE WITH SUBCLINICAL ORGAN DAMAGE IN HYPERTENSIVE MEN G. Lupattelli, G. Schillaci, M.R. Mannarino, G. Pucci, J. Helou, G. Savarese, M. Pirro, E. Mannarino (Perugia, Italy) 334 METABOLIC SYNDROME DIAGNOSTIC CRITERIA. DIVERGING TO THE POINT? A 420 MASSA LOMBARDA PROGRAM COHORT PRELIMINARY ANALYSIS E. Pedro, M. Manca, S. Nascetti, M. Gaddoni, G. Noera, A.M. Bargossi, A. Gaddi (Lisbon, Portugal and Bologna, Italy) 335 ASSOCIATION BETWEEN HIGH-SENSITIVE C-REACTIVE PROTEIN AND 420 HIGH-MOLECULAR WEIGHT ADIPONECTIN IN JAPANESE GENERAL POPULATION S. Nakano, M. Tsusima, Y. Nakano, S. Kyotani, T. Nakamori, C. Maruyama, T. Maruyama (Utsunomiya, Atami, Shinagawa, Osaka, Nagoya, Bunkyou and Saitama, Japan) 336 HAEMOSTATIC AND FIBRINOLYTIC ABNORMALITIES IN OBESE PATIENTS AND IN 420 W PATIENTS WITH TYPE 2 DIABETES WITH METABOLIC SYNDROME E G. Avellone, V. Di Garbo, R. Scaglione, P. Fernandez, R. De Simone, G. Raneli, G. Licata D (Palermo, Italy) N 337 METABOLIC SYNDROME IN ACUTE CORONARY SYNDROMES 421 E I. Burazor, M. Burazor, S. Nagorni, S. Ciric-Zdravkovic, Z. Burazor, N. Burazor S (Nis, Serbia-Montenegro) D 338 SERUM URIC ACID LEVELS AND RISK FOR CARDIOVASCULAR DISEASES IN 421 A PATIENTS WITH AND WITHOUT THE METABOLIC SYNDROME Y J. Hjortnaes, A. Algra, J. Olijhoek, M. Huisman, H. Jacobs, Y. Van der Graaf, F.L.J. Visseren (Utrecht, The Netherlands) 339 THE CORTISOL AWAKENING RESPONSE AND THE METABOLIC SYNDROME - A 421 GENDER SPECIFIC ASSOCIATION? I. Bengtsson, L. Lissner, T. Ljung, A. Rosengren, D. Thelle, P. Währborg (Göteborg, Sweden) 340 INCREASED GLOBAL INFLAMMATION SCORE AMONG MEN WITH THE METABOLIC 421 SYNDROME IDENTIFIED WITH NCEP-ATP III CRITERIA OR HYPERTRIGLYCERIDEMIC WAIST A. Cartier, M. Côté, J. Bergeron, N. Alméras, A. Tremblay, P. Mauriège, I. Lemieux, J.P. Després (Québec, QC, Canada) 341 REDUCED ANTIOXIDATIVE DEFENSE IN CHILDREN AND ADOLESCENTS WITH 421 METABOLIC SYNDROME V. Dimitrijevic-Sreckovic, E. Colak, P. Djordjevic, D. Gostiljac, T. Novakovic, B. Sreckovic, S. Popovic, R. Obrenovic, F. Canovic, T. Nisic (Beograd, Serbia-Montenegro)

141 342 PSYCHOSOCIAL FACTORS AND HEALTH RELATED QUALITY OF LIFE AMONG 422 MIDDLE-AGED INDIVIDUALS WITH AND WITHOUT THE METABOLIC SYNDROME G. Hollman, M. Kristenson (Linköping, Sweden) 343 OBSTRUCTIVE SLEEP APNEA: RELATIONSHIP WITH METABOLIC SYNDROME AND 422 LOW GRADE INFLAMMATION A.M. Maresca, E. Laurita, C. Marchesi, E. Nicolini, F. Solbiati, M. Gianni, D. Tomassetti, M. Marogna, F. Colombo, A.M. Grandi (Varese, Italy) 344 C-REACTIVE PROTEIN, THEIR RELATIONSHIPS WITH METABOLIC SYNDROME AND 422 INSULIN RESISTANCE IN MEXICAN ADOLESCENTS G. Cardoso-Saldaña, J. Juarez-Rojas, J. Zamora-Gonzalez, M. Raygoza-Perez, R. Martinez-Alvarado, R. Posadas-Romero, C. Posadas-Romero (Mexico City, Mexico) 345 OBESE WOMEN AND WAIST CIRCUMFERENCE 422 D. Stojsic, M. Novkovic, J. Stojsic, M. Vejnovic (Sombor and Vrbas, Serbia-Montenegro) 346 METABOLIC SYNDROME, HYPERTENSION AND CAROTID ATHEROSCLEROSIS 423 C. Irace, C. Cortese, C. Carallo, A. Gnasso (Catanzaro and Rome, Italy) 347 LOWER WAIST CIRCUMFERENCE THRESHOLD FOR METABOLIC SYNDROME IN A 423 MALAY ASIAN POPULATION H. Nawawi, T. Ismail, N.M. Mansor, M.M. Mahyuddin, R. Razali, S. Muid, A.R. Azlina, K. Yusoff (Shah Alam, Malaysia) 348 OBESITY AND METABOLIC SYNDROME IN CHILDREN AND ADOLESCENTS 423 I. Schusterova, J. Saligova, L. Potocnakova, M. Andrejkova, I. Marinova, I. Riecansky (Kosice and Bratislava, Slovak Republic) 349 THE PREVALENCE OF METABOLIC SYNDROME IN THE KOREAN PATIENTS WITH 423 CORONARY ARTERY DISEASE J.H. Choi, J. Sung, M.K. Kang, W.J. Lee, Y.H. Choi, M.K. Lee, J.E. Park (Seoul, South Korea) 350 PREVALANCE OF METABOLIC SYNDROME IN A MEDITERRANEAN COHORT OF 423 ANKYLOSING SPONDYLITIS PATIENTS J.A. Papadakis, E.K. Spanakis, G.E. Vrentzos, G. Katsikas, P.I. Sidiropoulos, E.S. Ganotakis, D.T. Boumpas (Heraklion, Greece) 351 METABOLIC SYNDROME RISK FACTORS CORRELATION NETWORKS IN MASSA 424 LOMBARDA POPULATION. RELEVANT STRUCTURAL DIFFERENCES BETWEEN HEALTHY AND AFFECTED GROUPS E. Pedro, M. Manca, A.F.G. Cicero, C. Altini, G. Noera, R. Fellin, A. Gaddi (Lisbon, Portugal, Bologna and Ferrara, Italy) 352 PREDICTIVE VALUE OF NEW METABOLIC SYNDROME DEFINITION 424 J. Bellwon, K. Chlebus, R. Dworakowski, W. Sobiczewski, D. Ciecwierz, J. Siebert, A. Rynkiewicz (Gdansk, Poland) 353 RELATIONSHIP OF DEFINITIONS OF THE METABOLIC SYNDROME TO CORONARY 424 ARTERY DISEASE BURDEN IN PAKISTANIS A. Wierzbicki, S. Nishtar, P. Lumb, M. Crook, J. Gill (London, UK and Islamabad, Pakistan) W 354 METABOLIC SYNDROME, DIABETES AND CARDIOVASCULAR DISEASE IN AN 424 E ELDERLY CAUCASIAN COHORT. THE ITALIAN LONGITUDINAL STUDY ON AGING D S. Maggi, M. Noale, G. Crepaldi (Padua, Italy) N 355 HERITABILITIES OF THE METABOLIC SYNDROME AND ITS COMPONENT TRAITS IN A 425 E CAUCASIAN GENETIC ISOLATE S A. Bellia, D. Lauro, P. Sbraccia, M. Federici, M. Tesauro, G.B. Rini, G. Novelli, M. D'Adamo, D E. Giardina, R. Lauro (Rome and Palermo, Italy) A 356 ESTIMATION OF METABOLIC SYNDROME (MS) OCCURRENCE ACCORDING TO NCEP ATP 425 Y III AND IDF CRITERIA IN THE POPULATION OF RESIDENTS OF LODZ (POLAND) J. Kowalski, J. Blaszczyk, M. Barylski, L. Pawlicki, M. Godala, A. Lewinski (Lodz, Poland) 357 PREVALENCE OF METABOLIC SYNDROME AMONG SCHOOL CHILDREN IN TAIWAN 425 N.F. Chu, H.C. Chin, S.C. Wang, D.M. Wu (Taipei, Taiwan) 358 HYPERTENSION AND METABOLIC SYNDROME IN THE BRISIGHELLA STUDY (BS) 425 S. D'Addato, A. Dormi, L. Laghi, A.V. Gaddi, C. Borghi (Bologna, Italy) 359 PREVALENCE OF METABOLIC SYNDROME IN THE JAPANESE 425 K. Homma, Y. Homma, H. Yamaguchi, G. Uehara, T. Sakai, Y. Morita, M. Igarashi, M. Matsuda, K. Ishiwata (Tokyo and Isehara, Japan) 360 A PRELIMINARY SURVEY ON THE PREVALENCE OF METABOLIC SYNDROME - A 426 HOSPITAL DATA BASED STUDY K. Priya, V.K. Nampoothiri (Kerala, India) 361 TO DETERMINE THE PREVALENCE OF PHENOTYPES OF METABOLIC SYNDROME 426 AMONG HYPERTENSIVE PATIENTS IN CENTRAL AREAS OF IRAN R. Ansari, M. Abdar, R. Kelishadi, A. Khosravi (Isfahan, Iran)

142 362 PREVALENCE OF A METABOLIC SYNDROME AMONG A PEDIATRIC CASISTIC FROM 426 THE MOUNTAIN COMMUNITY (SERRE CALABRE) F. Martino, E. Martino, F. Morrone, R. Papa, T. Niglio, E. Tocci, F. Vecchio, D. Noto, M.R. Averna (Rome, Serra San Bruno, Catanzaro and Palermo, Italy) 363 PREVALENCE OF METABOLIC SYNDROME IN WOMEN WITH POLYCYSTIC OVARY 426 SYNDROME B. Popovic, D. Macut, I. Bozic, M. Petakov, S. Ognjanovic, T. Isailovic, S. Damjanovic (Belgrade, Serbia-Montenegro) 364 THE PREVALENCE OF METABOLIC SYNDROME AND CARDIOVASCULAR EVENTS 427 INCIDENCE RELATED TO ITS COMPONENTS C. Tudor, R.A. Jeberean, R. Buzas, A. Popescu, V. Lungu (Timisoara, Romania) 365 PREVALENCE AND CHARACTERISTIC FEATURES OF METABOLIC SYNDROME WITH 427 AND WITHOUT DIABETES IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION M. Zeller, M. Farnier, P.G. Steg, L. Mock, Y. Laurent, L. Janin-Manificat, P. Sicard, H. Makki, B. Verges, Y. Cottin (Dijon, Paris, Fontaine les Dijon, Semur en Auxois, Beaune and Chatillon sur Seine, France) 366 THE PREVALENCE OF METABOLIC SYNDROME AMONG THE PEOPLE UNDERGOING 427 ANNUAL HEALTH CHECKS IN OUR INSTITUTE J. Suwa, S. Hiramatsu (Tokyo, Japan) 367 IS THE PREVALENCE OF THE METABOLIC SYNDROME INCREASING AMONG 427 MIDDLE-AGED SWEDES? G. Hollman, M. Kristenson (Linköping, Sweden) 368 GENDER - SPECIFIC ISSUES IN METABOLIC SYNDROME IN IRANIAN WOMEN 427 N. Sarrafzadegan, R. Kellishadi, N. Mohammadifard, K. Rabiei (Isfahan, Iran) 369 REVERSING METABOLIC SYNDROME WITH HIGH INTENSITY TRAINING 428 A.E. Tjonna, O. Rognmo, P.M. Haram, T. Stolen, J.P. Loennechen, S. Slordahl, U. Wisloff (Trondheim, Norway) 370 CLINICAL RELEVANCE OF VLDL CHOLESTEROL REDUCTION TO INCREASED SERUM 428 ADIPONECTIN WHEN ASSESSING SERUM LIPID AMELIORATION ACHIEVED BY EXERCISE TRAINING H. Yoshida, H. Yanai, Y. Hirowatari, T. Ishikawa, N. Sato, N. Tada (Kashiwa, Ayase and Shinagawa, Japan) 371 REGULAR AEROBIC EXERCISE CAN REDUCE ARTERIAL STIFFNESS AND VASCULAR 428 INFLAMMATION IN SUBJECTS WITH METABOLIC SYNDROME S. Sha, S. Tanaka, T. Miki (Hidaka, Japan) 372 REDUCTION OF VISCERAL ADIPOSITY UNDERLIES THE IMPROVEMENT OF ARTERIAL 428 STIFFNESS THROUGH EXERCISE TRAINING IN MIDDLE-AGED MEN WITH ABDOMINAL OBESITY Y. Takanami, F. Kinoshita, Y. Kawai, O. Mohira, T. Shimomitsu, T. Yoshikawa (Tokyo, Wakayama and Kyoto, Japan) 373 THE INFLUENCE OF DIET AND PHYSICAL EXERCICE ON PATIENTS WITH DISMETABOLIC 429 W SYNDROME X WHO WERE MONITORED BY THE HEALTH CENTER OF SKIATHOS E A. Sianni, A. Ganotopoulou (Skiathos and Volos, Greece) D 374 CLINICAL UTILITY OF HOMEOSTASIS MODEL ASSESSMENT IN THE PREVENTION OF 429 N TYPE 2 DIABETES AND CARDIOVASCULAR DISEASES E L.L. Faleiro, M.C. Martins, A.E. Fonseca (Lisbon, Portugal) S 375 METABOLIC SYNDROME IN PREMATURE CORONARY HEART DISEASE IN A 429 D HUNGARIAN PATIENT GROUP A L. Szollár (Budapest, Hungary) Y 376 INTRAPERITONEAL LEPTIN REGULATES LIPID AND LIPOPROTEIN 429 METABOLISM IN MICE FED A HIGH-FAT DIET N. Nalini, J. Kalaivani Sailaja (Chidambaram, India)

143 POSTER AREA “A” WEDNESDAY, June 21 377-489

POSTER DISPLAY: for the duration of one day (Wednesday, June 21 from 8.30 am to 6.30 pm). Participants may view the posters displayed during this day.

We-P14 Poster Session 14 poster abstract bk. board no.: NUTRITIONAL APPROACHES page ref.:

377 PALM TOCOTRIENOL SUPPRESSES INSULIN-INDUCED ADIPOGENESIS 430 H. Uto, E. Yoshioka, C. Yanagisawa, Y. Kishimoto, M. Machida, M. Hasagawa, H. Saito, C. Kiyose, K. Shimokado, K. Kondo (Hirosaki City, Sakato City and Bunkyo-Ku, Japan) 378 ERYTHROCYTE FATTY ACID COMPOSITION IN OBESE PATIENTS WITH 430 HYPERLIPIDEMIA M. Postic, D. Ristic-Medic, A. Arsic, M. Glibetic (Belgrade, Serbia-Montenegro) 379 ASSESSING DIETARY BEHAVIOUR BY MICRODIET SOFTWARE AS EDUCATIONAL TOOL 430 M. Mariotti, O. Giampietro, E. Matteucci (Pisa, Italy) 380 DIETARY MEDIUM- AND LONG-CHAIN TRIACYLGLYCEROLS (MLCT) SUPPRESS 430 ACCUMULATION OF BODY FAT M. Kasai, S. Negishi, H. Uto, M. Okazaki, O. Igarashi, K. Kondo (Kanagawa, Tokyo, Sitama and Ibaraki, Japan) 381 METABONOMICS TO ASSESS SELF-REPORTED DATA: THE INTERNATIONAL STUDY 430 ON MACRONUTRIENTS AND BLOOD PRESSURE (INTERMAP) R.L. Loo, E. Holmes, E. Maibaum, M. Coen, T. Ebbels, Q. Chan, P. Elliott, H. Ueshima, B. Zhou, J. Stamler (London, UK, Shiga, Japan, Beijing, China and Chicago, IL, USA) 382 THE EFFECTS OF WEIGHT LOSS ON LP-PLA2 ACTIVITY AND LOW DENSITY 431 LIPOPROTEIN (LDL) PHENOTYPE IN OBESE WOMEN T.D. Filippatos, T. Tzotzas, D.N. Kiortsis, A. Triantos, M. Karamouzis, A. Tselepis (Ioannina and Thessaloniki, Greece) 383 HIGH CALCIUM DIET WITH WHEY PROTEIN INHIBITS WEIGHT GAIN IN A MODEL OF 431 DIET INDUCED OBESITY T.K. Pilvi, R. Korpela, H. Vapaatalo, E. Mervaala (Helsinki, Finland) W 384 DEVELOPMENT OF ANTIOBESITY VEGETABLE & FRUIT EXTRACT 431 E S.H. Bok (Nonsan, South Korea) D 385 RESIDENTIAL MULTIDISCIPLINARY REHABILITATION FOR THE TREATMENT OF 431 N OBESITY E M. Mancini, V. Rendina, R. Caporaso, A. Caporaso, M. Lionetti, F.P. Mancini (Naples and S Benevento, Italy) 386 DEVELOPMENT OF ANTIOBESITY HAMBURGER INGREDIENT SLIM&SLIM PWH 432 D S.H. Bok (Nonsan, South Korea) A 387 THE DIETARY BREAD, BETTER NUTRITION FOR THE PEOPLE WITH DIABETES 432 Y Z. Savoski, Z. Trpkovski, Z. Servini (Prilep and Negotino, Macedonia) 388 EFFECTS OF FOODS AND DIETS VARYING IN GLYCEMIC INDEX AND GLYCEMIC LOAD 432 ON POSTPRANDIAL GLUCOSE AND INSULIN RESPONSE AND MEASURES OF OXIDATIVE STRESS L. Augustin, C.W. Kendall, A. Josse, S. Salvatore, F. Brighenti, D.J. Jenkins (Toronto, ON, Canada and Parma, Italy) 389 THE EFFECT OF PALATINOSE ON ATHEROGENIC INDEX AND VISCERAL FAT IN 432 MALE JAPANESE BRAZILIANS E. Moriguchi, M. Mori, H. Mori, P. Ishikawa, T. Sakuma, Y. Moriguchi, Y. Yamori (Porto Alegre, Brazil, Kyoto and Hyogo, Japan) 390 ACTIVATION OF POLYMORPHONUCLEAR LEUKOCYTES BY POTATO CRIPS 432 CONSUMPTION IN HEALTY SMOKERS D. Zapolska-Downar, A. Kosmider, G. Nowicka, M. Naruszewicz (Warsaw, Poland)

144 391 CLAS INHIBIT TRANSFORMATION OF ARACHIDONIC AND LINOLEIC ACIDS IN 433 MACROPHAGES THROUGH DOWN REGULATION OF CPLA 2/15 LO 1 AND SPLA2/ COX 2 PATHWAYS E. Stachowska, D. Chlubek (Szczecin, Poland) 392 CONJUGATED LINOLEIC ACIDS INCREASE NON-OXIDATIVE OXYGENATION OF 433 ARACHIDONIC ACID IN MONOCYTES VIA PPAR ALPHA RECEPTOR ACTIVATION D. Chlubek, E. Stachowska (Szczecin, Poland) 393 THE NATURAL CONCENTRATION OF THE CONJUGATED LINOLEIC ACID, CIS-9, TRANS-11 433 IN MILK-FAT CAN MODULATE THE ATHEROGENIC RISK IN HYPERLIPIDEMIC HAMSTERS A. Quignard-Boulange, K. Valeille, J. Ferezou, G. Amsler, D. Gripois, J.C. Martin, M. Parquet (Paris, Castres, Orsay and Marseille, France) 394 INHIBITION OF LDL OXIDATION IN RED YEAST RICE 433 E. Yoshioka, H. Uto, C. Yanagisawa, N. Machida, Y. Kishimoto, M. Hasegawa, M. Tani, T. Kido, H. Yoshida, K. Kondo (Bunkyo-ku and Minato-ku, Japan) 395 THE ANTIOXIDANT ACTIVITIES OF ALMONDS AGAINST LDL OXIDATION 434 C. Yanagisawa, H. Uto, M. Tani, Y. Kishimoto, N. Machida, M. Hasegawa, E. Yoshioka, T. Kido, K. Kondo (Tokyo, Japan) 396 THE EFFECT OF ALMONDS ON THE SERUM LIPID, LIPOPROTEIN AND 434 APOLIPOPROTEIN LEVELS IN JAPANESE MALE SUBJECTS C. Yanagisawa, H. Uto, M. Tani, Y. Kishimoto, N. Machida, M. Hasegawa, E. Yoshioka, T. Kido, K.G. Lapsley, K. Kondo (Tokyo, Japan and Modesto, CA, USA) 397 TESTING VARIOUS VEGETABLES FOR ANTI-THROMBOTIC EFFECT: II. CARROTS 434 J. Yamamoto, A. Naemura, Y. Ijiri, K. Ogawa, T. Suzuki, Y. Shimada (Kobe, Kakogawa, Osaka and Shizouka, Japan) 398 ADDITIVE EFFECTS OF STEROLS TO RICE BRAN OIL ON SERUM CHOLESTEROL 434 LEVELS IN RATS E. Tsuji, M. Takahashi, S. Kinoshita, M. Tanaka, K. Tsuji (Kakogawa, Funabashi, Tokyo and Himeji, Japan) 399 CAROTID AND BRACHIAL ARTERIAL FUNCTION IN HEALTHY POSTMENOPAUSAL 434 WOMEN: A COMPARISON BETWEEN VEGETARIANS AND OMNIVORES P.L. Torng, T.C. Su, J.S. Jeng, M.F. Chen, C.S. Liau (Taipei, Taiwan) 400 OLIVE OIL AND RED WINE POLYPHENOLS INHIBIT REACTIVE OXYGEN SPECIES 435 AND EICOSANOID RELEASE INDUCED BY OXIDISED LOW DENSITY LIPOPROTEINS M. Vivancos, J.J. Moreno (Barcelona, Spain) 401 DOES DIETARY INTAKE OF VITAMIN B6 AND FOLATE AFFECT HOMOCYSTEINE 435 AND CRP LEVELS IN PATIENTS WITH HEART FAILURE? M. Makarewicz-Wujec, M. Kozlowska-Wojciechowska (Warsaw, Poland) 402 EFFECT OF SEVERAL FATTY ACIDS ON POSTPRANDIAL HYPERLIPEMIA 435 Y. Kishimoto, M. Tani, A. Takeuchi, C. Yanagisawa, M. Hasegawa, N. Machida, E. Yoshioka, H. Uto, Y. Masuda, K. Kondo (Tokyo, Japan) 403 DRIP PAPER-FILTERED AND BOILED AND COTTON-FILTERED COFFEE REDUCE 435 W LIPID PEROXIDATION AND ANTHROPOMETRIC PARAMETERS IN PRIMARY E HYPERCHOLESTEROLEMIA D R.P. Costa, M.C. Elias, M.C.O. Izar, A.O. Santos, L. Pinto, S.S.M. Ihara, A.A. LasCasas, N W.G.M. Relvas, F.A.H. Fonseca (Sao Paulo, Brazil) E 404 A MUSHROOM, WHITE BUNASHIMEJI (HYPSIZIGUS MARMOREUS) PREVENTS THE 436 S DEVELOPMENT OF ATHEROSCLEROSIS IN APOLIPOPROTEIN E-DEFICIENT MICE D M. Ikeda, K. Mori, C. Kobayashi, Y. Ohmori, T. Tomita (Shizuoka and Nagano, Japan) A 405 MECHANISM OF THE ANTI-THROMBOTIC EFFECT OF DIETARY DIACYLGLYCEROL IN 436 Y ATHEROGENIC MICE Y. Ijiri, A. Naemura, T. Yamashita, H. Ikarugi, J. Yamamoto (Kobe and Kakogawa, Japan) 406 PALM VITAMIN E INHIBITS THE PROGRESSION OF ATHEROSCLEROSIS IN RABBITS 436 FED AN ATHEROGENIC DIET A. Idris, K. Sundram (Kuala Lumpur, Malaysia) 407 EFFECT OF COFFEE ON THE OXIDATIVE SUSCEPTIBILITY OF LOW-DENSITY 436 LIPOPROTEIN M. Hasegawa, C. Yanagisawa, Y. Kishimoto, N. Machida, E. Yoshioka, M. Tani, T. Kido, H. Uto, K. Kondo (Bunkyo-ku, Japan) 408 THE ANTIOXIDATIVE AND ANTI-ATHEROGENIC EFFECTS OF THE FERMENTATION 436 BROTH OF LINGZHI (G. LUCIDUM) CULTIVATED IN THE MEDIUM CONTAINING LEGUMINOUS PLANTS Y.L. Chien, Y.L. Yang, L. Sun Hwang (Taipei, Taiwan)

145 409 SUPPLEMENTATION OF L-ARGININE IMPROVE ENDOTHELIUM-DEPENDENT 437 VASODILATION IN HYPERCHOLESTEROLEMIA WITH IMPAIRED VASODILATION P.R. Chen, C.M. Lee, T.C. Su, T.L. Liu, B.W. Chuo, C.E. Tsai (Taipei and Taoyan, Taiwan) 410 INTAKES OF PHOSPHORUS, MAGNESIUM AND CALCIUM IN RELATION TO BLOOD 437 PRESSURE: THE INTERMAP STUDY P. Elliott, H. Kesteloot, J. Stamler, A.R. Dyer, H. Ueshima, Q. Chan, L. Appel, B. Zhou (London, UK, Leuven, Belgium, Chicago, IL, Baltimore, MD, USA, Otsu, Japan and Beijing, China) 411 MONOSACCHARIDE, DISACCHARIDE INTAKE AND BLOOD PRESSURE IN UK AND 437 USA, MEN AND WOMEN AGES 40-59: THE INTERMAP STUDY I.J. Brown, P. Elliott, C.E. Robertson, Q. Chan, A.R. Dyer, J. Stamler (London, UK and Chicago, IL, USA) 412 EFFECTS OF MODERATE CONSUMPTION OF SICILIAN RED WINES ON SOME 437 CARDIOVASCULAR RISK FACTORS G. Avellone, V. Di Garbo, D. Campisi, G. Raneli, R. De Simone, A. Indovina, G. Abruzzese, G. Licata (Palermo, Italy) 413 EFFECTS OF SOY PROTEIN ISOFLAVONES ON SERUM LIPID PROFILE AND HORMONES 438 OF HYPERCHOLESTEROLEMIC MEN R. Amani (Ahvaz, Iran) 414 THE EFFECT OF ZN ON THE PLASMA LEVEL OF CHOLESTEROL AND TRIGLYCERIDE 438 A H. Masoudi, B. Mohamadi (Tehran, Iran) 415 PROTECTIVE EFFECT OF TUNISIAN OLIVE OIL PHENOLIC COMPOUNDS AGAINST 438 LOW DENSITY LIPOPROTEIN OXIDATION A. Nakbi, M. Issaoui, N. Koubaa, N. Attia, A. Echbili, S. Debbou, A. Trigui, M. Hammami (Monastir and Sfax, Tunisia) 416 HYPOLIPIDEMIC EFFECTS OF PURSLANE LEAF EXTRACT ON DIET INDUCED 438 HYPERCHOLESTEROLEMIC ANIMALS A. Movahedian, A. Ghannadi, M. Vashirnia (Isfahan, Iran) 417 EFFECT OF TRIBESTAN ON LIPID METABOLISM AND HORMONAL STATUS IN MEN 438 IN ANDROPAUSE N.I. Doncheva, G. Sheinkova, K. Kalinov, D. Dobreva, M. Protich (Sofia, Bulgaria) 418 EFFECT OF DIETS WITH DIFFERENT FAT CONTENT ON THE AFFINITY OF LOW-DENSITY 439 LIPOPROTEIN TO THE LOW-DENSITY LIPOPROTEIN RECEPTOR IN HEPG2 CELLS P. Gómez Luna, J. López-Miranda, C. Marín Hinojosa, B. Cortés, J.A. Moreno Gutierrez, M.J. Gómez Luna, J. Delgado Lista, F. Pérez-Jiménez (Córdoba, Spain) 419 MEDITERRANEAN DIET NEEDS CORRECTIONS TO TREAT HYPERTENSION 439 R. Volpe, J. Pille, G. Nantel (Rome, Italy) 420 POLYPHENOLS ENHANCE PLATELET NITRIC OXIDE BY INHIBITING PROTEIN KINASE 439 C-DEPENDENT NADPH OXIDASE ACTIVATION. EFFECT ON PLATELET RECRUITMENT P. Pignatelli, S. Di Santo, B. Buchetti, V. Sanguigni, A. Brunelli, F. Violi (Rome, Italy) W 421 APOLIPOPROTEIN E4 ALLELE IS A GENETIC FACTOR WHICH CONTRIBUTES TO 439 E PLASMA CHOLESTEROL RESPONSIVENESS TO DIET THERAPY IN TYPE 2 DIABETIC D PATIENTS N M. Saito, M. Eto (Koriyama, Japan) E 422 OLIVE OIL PHENOLS MODULATE TNF-ALPHA-INDUCED MATRIX 439 S METALLOPROTEINASE-9 IN THP-1 CELLS D R. Fagnani, M. Dell'Agli, S. Bellosta, G.V. Galli, R. Parente, M. Crestani, E. De Fabiani, A E. Bosisio, D. Caruso (Milan, Italy) Y 423 DIET AND SUPPLEMENT EFFECTS ON LIPID SUBFRACTIONS AND INFLAMMATORY 440 MARKERS IN THE METABOLIC SYNDROME: CHANGE IS POSSIBLE! S.R. Gundry, W.L. Ehrman (Palm Springs, CA, USA) 424 THE EFFECT OF ANTHOCYANINS ON OXIDATIVE-ANTIOXIDATIVE BALANCE 440 HYPERCHOLESTEROLAEMIC PATIENTS A. Kopff, E. Kowalczyk, M. Kopff, J. Blaszczyk (Lodz, Poland) 425 THE INFLUENCE OF ANTHOCYANINS ON THE SELECTED PRO- AND 440 ANTIANGIOGENIC FACTORS IN HYPERCHOLESTEROLEMIA E. Kowalczyk, A. Kopff, M. Kopff, J. Blaszczyk (Lodz, Poland) 426 SUPPLEMENTATION WITH QUERCETIN AND NON-ALCOHOLIC RED WINE EXTRACT 440 INCREASE FIBRINOLYTIC FACTOR t-PA ACTIVITY AND ANTI-INFLAMMATORY CYTOKINE TGF-ß1 G. Mielcarz, A.N. Howard, A. Barinow-Wojewódzki (Poznan, Ludwikowo, Poland and Cambridge, UK)

146 427 LUNCH BOX RICH IN SOY AND FISH REDUCES RISK OF ATHEROSCLEROSIS IN ONE 441 MONTH - A DOUBLE BLIND PLACEBO CONTROLLED STUDY M. Mori, H. Mori, Y. Yamori (Kyoto, Hyogo and Hyoto, Japan) 428 FRUIT AND VEGETABLE INTAKE AND THE RISK OF DEVELOPING CORONARY HEART 441 DISEASE M. Nikolic, Z. Kostic (Nis, Serbia-Montenegro) 429 DESPITE ITS INSTABILITY, EPIGALLOCATECHIN GALLATE EFFECTIVELY LOWERS 441 SERUM CHOLESTEROL IN THE HYPERCHOLESTEROLAEMIC RABBIT P.D. Roach, V.H. Le, N. Naumovski, B. Blades (Ourimbah, NSW, Australia) 430 DIETARY INTERVENTION AND BLOOD LIPID PROFILE IN HYPERCHOLESTEROLEMIC 441 CHILDREN S. Rossi, C. Pederiva, R. Restelli, G. Banderali, E. Riva, M. Giovannini (Milan, Italy) 431 IS ADHERENCE TO MEDITERRANEAN DIET ENOUGH FOR LOWERING LIPID 441 PARAMETERS AMONG A HEALTHY ITALIAN POPULATION? F. Sofi, A.M. Gori, F. Cesari, A.P. Cellai, A. Alessandrello Liotta, A. Abdullahi Said, C. Surrenti, A. Casini, R. Abbate, G.F. Gensini (Florence and Impruneta, Italy) 432 TWO WEEKS SUPPLEMENTATION WITH OLIVE OIL AND EVENING PRIMROSE OIL 442 SIMILARLY AFFECT PLASMA LIPIDS LEVEL IN MEN WITH CORONARY ARTERY DISEASE M. Stolyhwo Gofron, J. Bellwon, W. Sobiczewski, D. Ciecwierz, A. Rynkiewicz, A. Stolyhwo (Gdansk, Poland) 433 POSSIBLE IMPORTANCE OF COLONIC FERMENTATION TO POTENTIATE THE 442 CHOLESTEROL LOWERING PROPERTIES OF SOY BUT NOT OF OAT B-GLUCAN J.M.W. Wong, R. de Souza, C.W.C. Kendall, D.J.A. Jenkins (Toronto, ON, Canada) 434 LOW CHOLESTEROL DIET INFLUENCE ON BLOOD LIPID PROFILE AND 442 ATHEROSCLEROTIC CHANGES IN COMMON CAROTID ARTERIES N.N. Kipshidze, M.G. Beridze, N.G. Kakauridze (Tbilisi, Georgia) 435 NUT CONSUMPTION, CORONARY HEART DISEASE AND RISK FACTORS 442 D. Colquhoun, S. Natoli, N. Lapsys, A. Ferreira-Jardim, K. Kostner (Brisbane, QLD and Sydney, NSW, Australia) 436 COMPARISON OF THE EFFECTS OF CHEESE OR BUTTER ON THE SEVERITY OF 443 ATHEROGENIC MARKERS IN HAMSTERS FED AN HYPERLIPIDEMIC DIET B. Delplanque, A. Thaminy, G. Agnani, J.C. Martin, K. Bensharif, D. Gripois (Orsay and Marseille, France) 437 EFFECT OF TWO NATURALS PRODUCTS OILS, ARGAN AND OLIVE, IN THE 443 NUTRITIONAL PREVENTION ON ATHEROSCLEROSIS IN MAN A.F. Derouiche, R. Saile, A. Drissi, M. Cherki, Y. Bamou, A.I. Oudghiri, J.M. Lecef, A. Adlouni (Casablanca, Meknès, Morocco and Lile, France) 438 AD LIBITUM CONSUMPTION OF A HIGH MONOUNSATURATED FATTY ACID DIET AND 443 OF A LOW FAT DIET REDUCES PLASMA ADIPONECTIN LEVELS S. Desroches, A. Tchernof, W.R. Archer, P. Couture, N. Bergeron, B. Lamarche (Ste-Foy, QC, W Canada and Vallejo, CA, USA) E 439 MEDITERRANEAN DIET AND ITS PROTECTIVE EFFECTS ON CARDIOVASCULAR RISK 443 D FACTORS N G. Godàs, R. Solà, J. Girona, J.C. Vallvé, B. Winklhofer-Roob, E. Rock, J. Ribalta, E L. Masana (Reus, Spain, Graz, Austria and St. Genes Champanelle, France) S 440 MEDITERRANEAN FOOD AND CARDIOVASCULAR HEALTH: IN VIVO STUDIES 443 D F. Visioli, P. Bogani, C. Galli (Milan, Italy) A 441 COFFEE MAY PREVENT THE PROGRESS OF ATHEROSCLEROSIS IN JAPANESE 444 Y C. Iwai, M. Hashimoto, Y. Miyamoto, M. Shimizu, Y. Matsuda, K. Kanazawa, H. Akita, K. Nishimura, D. Sugiyama, K. Ito (Kobe, Japan) 442 BIOFLAVONOID-RICH BOTANICALS REDUCE BLOOD SERUM ATHEROGENICITY IN 444 PERIMENOPAUSAL WOMEN V. V. Korennaya, V.A. Mysoedova, N.A. Nikitina, I.A. Sobenin, A.N. Orekhov (Moscow, Russia) 443 ENDOTHELIAL CELL DYSFUNCTION: ENVIRONMENTAL CONTAMINANTS AND 444 NUTRITIONAL IMPLICATIONS B. Hennig, X. Arzuaga, Z. Majkova, E. Smart, M. Toborek (Lexington, KY, USA) 444 CONSUMPTION OF A POLYPHENOL-RICH GRAPE EXTRACT IMPROVES THE 444 CARDIOVASCULAR RISK PROFILE OF HEALTHY MALES R. Draijer, R. Duivenvoorden, Y. De Graaf, E. Haddeman, E. De Groot, C. Kroner (Vlaardingen and Amsterdam, The Netherlands)

147 445 DESIGN OF THE MET-ANTIOX STUDY: SYNERGIC BIOACTIVITY OF ANTIOXIDANT 445 FUNCTIONAL FOODS IN THE METABOLIC SYNDROME S. Dragan, S. Mancas, D. Cheta, D. Velimirovici, M. Rada, L. Barbu, G. Otiman (Timisoara and Bucharest, Romania) 446 EFFECT OF CRANBERRY JUICE CONSUMPTION ON PLASMA OXIDIZED LDL LEVELS 445 IN MEN: RESULTS FROM A 4-WEEK PLACEBO CONTROLLED CROSS-OVER TRIAL C. Couillard, G. Ruel, S. Pomerleau, P. Couture, S. Lemieux, B. Lamarche (Québec, QC, Canada) 447 A PROTECTIVE ROLE TOWARDS ATHEROSCLEROSIS BY HYDROGEN SULFIDE AND 445 NATURAL ORGANOSULFUR COMPOUNDS DERIVED FROM GARLIC AND ONION M.A. Eghbal, M.Y. Moridani, P.S. Pennefather, P.J. Obrien (Tabriz, Iran and Toronto, ON, Canada) 448 RESVERATROL SUSTAINS THE INFLAMMATORY RESPONSE IN RAT VASCULAR 445 SMOOTH MUSCLE CELLS A. Cignarella, C. Minici, C. Bolego, V. Pelosi, L. Puglisi, R.M. Gaion (Milan and Padua, Italy) 449 THE IMPROVEMENT OF METABOLIC MARKERS WITH NATURAL POLYPHENOLS AND 446 ZINC ON DIABETIC RATS M. Ciocoiu, M. Badescu, M. Chicu, C. Bohotin, D. Tutunaru (Iasi and Galati, Romania) 450 AJUGA IVA TREATMENT ATTENUATES HYPERCHOLESTEROLEMIA INDUCED BY A 446 CHOLESTEROL SUPPLEMENTED DIET AND IMPROVES LIPID PEROXIDATION AND ANTIOXIDANT ENZYMES A. Chenni, D. Ait-Yahia, F.O. Boukortt, J. Prost, M. Bouchenak (Es Senia Oran, Algeria and Dijon, France) 451 DIETARY IRON OVERLOAD IN RATS STRONGLY AFFECTS LIPID PARAMETERS 446 F. Schemeit, D. von Bremen, J. Heeren, P. Nielsen (Hamburg, Germany) 452 EFFECT OF ANTIOXIDANT SUPPLEMENTATION ON GENETIC STABILITY AND LIPID 446 PEROXIDATION IN MIDDLE-AGED MEN J. Gasparovic, K. Raslova, M. Barancokova, A. Kazimirova, A. Coll Ins, B. Smolkova, A. Horska, L. Wsolova, M. Dusinska, K. Volkovova (Bratislava, Slovak Republic and Oslo, Norway) 453 ERYTHROCYTE MEMBRANE ELECTRON TRANSFER, DIET AND LIFESTYLE IN 446 HEALTHY AND IN TYPE 1 DIABETIC FAMILIES E. Matteucci, S. Manzini, I. Chiti, M. Mariotti, O. Giampietro (Pisa, Italy) 454 THE CHRONIC INTAKE OF A MEDITERRANEAN DIET ENRICHED IN VIRGIN OLIVE OIL, 447 DECREASES NUCLEAR TRANSCRIPTION FACTOR KAPPAB ACTIVATION IN HEALTHY MEN P. Perez-Martinez, J. Lopez-Miranda, L.M. Blanco-Colio, Y. Jimenez-Gomez, R. Gallego, F. Lopez-Segura, J. Egido, F. Perez-Jimenez (Cordoba and Madrid, Spain) 455 POSTER WITHDRAWN – 456 EVALUATION OF POLICOSANOLS AS FUNCTIONAL FOOD INGREDIENTS FOR 447 CHOLESTEROL- LOWERING A.N. Kassis, P.J.H. Jones (Ste-Anne-de-Bellevue, QC, Canada) 457 OLIVE OIL RICH MEDITERRANEAN AND A LOW FAT ENRICHED IN A-LINOLENIC ACID 447 W DIETS PREVENT POSTPRANDIAL INCREASE OF FACTOR VII DURING POSTPRANDIAL E LIPEMIA D B. Cortes, J. Lopez-Miranda, C. Marin, A. Lozano, Y. Jimenez, P. Gomez, I. Perez, N F. Perez-Jimenez (Cordoba, Spain) E 458 POSSIBLE ROLE OF UNSATURATED FATTY ACIDS INTAKE IN INCREASED HUMAN 447 S SURVIVAL: A 8.5-YEAR FOLLOW-UP OF THE ITALIAN LONGITUDINAL STUDY ON AGING D V. Solfrizzi, C. Capurso, A.M. Colacicco, A. D'Introno, A. Capurso, F. Panza (Bari, Italy) A 459 OLIVE OIL AND WALNUT MEALS ELICIT THE INFLAMMATORY RESPONSE IN 448 Y MONONUCLEAR CELLS COMPARED WITH BUTTER MEAL DURING POSTPRANDIAL STATE IN HEALTHY MEN Y. Jiménez-Gómez, J. López-Miranda, P. Gómez Luna, C. Marín Hinojosa, R. Moreno Luna, I. Romero García, E. Galán, E. Sánchez, F. Pérez-Jiménez (Córdoba, Spain) 460 ORAL ADMINISTRATION OF EICOSAPENTAENOIC ACID REDUCES AND STABILIZES 448 ATHEROSCLEROTIC LESIONS IN APOE-DEFICIENT MICE M. Matsumoto, M. Sata, M. Soma, K. Tanaka, D. Fukuda, R. Nagai (Tokyo, Japan) 461 DIETARY FISH OIL ALTERS THE PLASMA LIPID PROFILE AND THE EXPRESSION OF 448 HNF4ALPHA IN HYPERCHOLESTEROLEMIC RATS E. Bravo, M. Napolitano, I. Lopez, K.M. Botham, C. Stefanutti (Rome, Italy and London, UK) 462 FISH CONSUMPTION AND SERUM LEVELS OF EICOSAPENTAENOIC AND 448 DOCOSAHEXAENOIC ACID ARE NOT RELATED TO FLOW-MEDIATED VASODILATION L.J. Bjerregaard, I.V. Aardestrup, R. Bülow, O. Frøbert, C. Dethlefsen, J.G. Rasmussen, E.B. Schmidt (Aalborg, Denmark)

148 463 NO PROTECTION OF A HIGH OMEGA-3 INDEX FOLLOWING AN ACUTE MYOCARDIAL 449 INFARCTION H. Aarsetoey, V. Pônitz, H. Grundt, D. Pritchard, H. Staines, W.S. Harris, D.W.T. Nilsen (Stavanger, Norway, Dundee, UK and Kansas City, MO, USA) 464 PLASMA FATTY ACID COMPOSITION IN OVERWEIGHT PATIENTS WITH 449 HYPERTRIGLYCERIDEMIA A. Arsic, D. Ristic-Medic, M. Postic, J. Tepsic, M. Glibetic (Belgrade, Serbia-Montenegro) 465 THE ASSOCIATION OF POLYUNSATURATED FATTY ACIDS AND BLOOD PRESSURE 449 IN MEN WITH CORONARY ARTERY DISEASE M. Stolyhwo Gofron, J. Bellwon, W. Sobiczewski, D. Ciecwierz, A. Rynkiewicz, A. Stolyhwo (Gdansk, Poland) 466 PURE OR BLENDED RAPESEED OIL INTAKE TO REACH HUMAN ALPHALINOLENIC 449 RECOMMENDATION INCREASE PLASMA AVAILABILITY AND CONVERSION TO EICOSAPENTAENOIC (EPA) B. Delplanque, N. Combe, C. Boue-Vaysse, A. Thaminy, G. Agnani, B. Le Roy, A. Ruelland (Orsay, Talence and Rennes, France) 467 EFFECTS OF THE OMEGA-3 POLYUNSATURATED FATTY ACIDS IN THE TREATMENT OF 450 CARDIOVASCULAR AUTONOMIC NEUROPATHY IN TYPE 2 DIABETES MELLITUS PATIENTS V. Serhiyenko, O. Oleksyk, A. Serhiyenko (Lviv, Ukraine) 468 OMEGA-3 SUPPLEMENTATION IS ASSOCIATED WITH AN IMPROVED INFLAMMATION AND 450 ENDOTHELIAL FUNCTION IN NORMOGLYCEMIC FIRST-DEGREE RELATIVES OF DIABETES S. Rizza, M. Iantorno, M. Tesauro, M. Federici, G. Donadel, M. Turriziani, G.C. Cocciolillo, P. Sbraccia, R. Lauro, D. Lauro (Rome, Italy) 469 THE EFFECT OF N-3 FATTY ACIDS ON NUTRITIONAL STATUS AND INFLAMMATORY 450 MARKERS IN HEMODIALYSIS PATIENTS G. Perunicic-Pekovic, Z. Rasic, S. Pljesa, S. Sobajic, I. Djuricic (Belgrade, Serbia-Montenegro) 470 EFFECT OF SHORT-TERM EXPOSURE TO PHYTOSTANOL - AND STEROL ESTERS 450 ON BLOOD LIPIDS IN CHOLESTEROL CHALLENGED WHHL RABBITS M. Schrøder, A. Mortensen, K. Pilegaard, C. Fricke, D. Lütjohann (Copenhagen, Denmark and Bonn, Germany) 471 REDUCTION OF CHOLESTEROL ABSORPTION BY DIETARY PLANT STEROLS AND 450 STANOLS IN MICE IS INDEPENDENT FROM THE ABCG5/ABCG8 TRANSPORTER J.K. Kruit, T. Plösch, V.W. Bloks, N.C.A. Huijkman, R. Havinga, G.S.M.J. Duchateau, Y. Lin, F. Kuipers (Groningen and Vlaardingen, The Netherlands) 472 THE NEW MECHANISM OF THE ACTIVITY OF PLANT STEROLS 451 M. Kozlowska-Wojciechowska (Warsaw, Poland) 473 EFFECT OF THE CONSUMPTION OF PECTIN AND PHYTOSTEROLS ON STEROL LEVELS 451 SUPPLEMENTED TO A SATURATED DIET IN GUINEA PIGS G. Brufau, M.A. Canela, J. Quílez, M. Rafecas (Barcelona and Sarral, Spain) 474 FATTY ACID PROFILE AFTER PLANT STEROLS AND PECTIN CONSUMPTION 451 ENRICHED INTO A SATURATED DIET IN GUINEA PIGS W M. Rafecas, G. Brufau, M.A. Canela, R. Codony (Barcelona, Spain) E 475 DETECTION OF UNSAPONIFIABLE COMPONENTS OF OLIVE OIL IN HIV PATIENTS 452 D I. Kasem, M.C. Pérez-Camino, J.L. Prada, J. Aguilar, J. De la Torre, V. Ruiz-Gutiérrez N (Damascus, Syria, Seville and Malaga, Spain) E 476 TOCOPHEROLS, POLYPHENOLS AND STEROLS DERIVED FROM ARGAN OIL EXERT 452 S AN ANTIOXIDANT EFFECT ON HUMAN LDL D A. Drissi, J. Girona, M. Cherki, R. Sola, A. Adlouni (Casablanca, Morocco and Reus, Spain) A 477 A STANOL YOGURT DRINK ALONE OR COMBINED WITH A LOW-DOSE OTC STATIN 452 Y LOWERS NON-HDLC, BUT ALSO LOWERS TGS & ELEVATES HDLC IN METABOLIC SYNDROME PATIENTS J. Plat, G. Brufau, M. Dasselaar, R.P. Mensink (Maastricht, The Netherlands) 478 REDUCED CALORIE ORANGE JUICE BEVERAGE WITH PLANT STEROLS IN HUMANS 452 RESULTS IN CONCOMITANT REDUCTION IN LDL-C AND HSCRP LEVELS S. Devaraj, B. Autret, I. Jialal (Sacramento, CA, USA) 479 ARE WE GOING TOWARDS PLEIOTROPIC EFFECTS WITH PLANT STEROLS? 453 C. Nicolle, E. Bruckert, L. Massana, J.M. Cobo Sanz, L. Cohen, L. Lalanne (Palaiseau, Paris, France, Reus, Barcelona, Spain and Leiden, The Netherlands) 480 CHOLESTEROL ESTERASE ACTIVITY AND PLANT STEROLS 453 G. Duchateau, J. Ramcharan, J. van Duynhoven (Vlaardingen, The Netherlands)

149 481 DEPENDENCE OF THE CHEMICAL NATURE OF THE SOLUBLE FIBERS ON VERY LOW 453 DENSITY LIPOPROTEIN PRODUCTION BY HEPATOCYTES P.T. Boban, P.R. Sudhakaran (Kerala, India) 482 EFFICACY OF SOLUBLE FIBER SUPPLEMENTATION IN CV DISEASE RISK MANAGEMENT OF 453 PATIENTS WITH METABOLIC SYNDROME: A 6-MONTHS, RANDOMIZED CLINICAL TRIAL A.F.G. Cicero, G. Derosa, M. Bove, L. Laghi, A.V. Gaddi (Bologna and Pavia, Italy) 483 EVALUATION OF NUTRITIONAL AND BIOLOGICAL PROPERTIES OF A LUPIN 453 PROTEIN ISOLATE IN SPRAGUE-DAWLEY RATS M. Marchesi, S. Caligari, D. Gilio, L.A. Rubio, S.K. Johnson, G. Chiesa, C.R. Sirtori (Milan, Italy and Granada, Spain) 484 REDUCED MAMMARY TUMOR PROGRESSION IN A TRANSGENIC MOUSE MODEL 454 FED AN ISOFLAVONE-POOR SOY PROTEIN CONCENTRATE E. Rigamonti, E. Disconzi, S. Soldati, M.G. Sacco, C. Parolini, A. Arnoldi, C.R. Sirtori, M.R. Lovati, G. Chiesa (Milan, Italy) 485 SESAMIN REDUCED BLOOD GLUCOSE CONCENTRATIONS IN ZUCKER FATTY RAT 454 Y. Fujiwara, Y. Okamura, M. Iwamura, S. Ikemoto, Y. Ono, Y. Kiso, Y. Seyama (Tokyo and Osaka, Japan) 486 EPIGALLOCATECHIN GALLATE REDUCES BLOOD PRESSURE, IMPROVES INSULIN 454 SENSITIVITY, AND PROTECTS AGAINST MYOCARDIAL ISCHEMIA/REPERFUSION INJURY IN SHR M.A. Potenza, F.L. Marasciulo, M. Tarquinio, E. Tiravanti, G. Colantuono, A. Federici, M.J. Quon, M. Montagnani (Bari, Italy and Bethesda, MD, USA) 487 THE ROLE OF SOYBEAN PRODUCT PREPARATS IN TREATMENT OF ATHEROSCLEROSIS 454 R. Tabukashvili, V. Kapetivadze, K.H. Chaava, G. Grigorashvili (Tbilisi, Georgia) 488 EFFECT OF A WEIGHT REDUCING HIGH PROTEIN VEGAN DIET ON SERUM LIPIDS 455 J.M.W. Wong, A. Esfahani, C.W.C. Kendall, D.J.A. Jenkins (Toronto, ON, Canada) 489 INHIBITORY EFFECTS OF TILIANIN ON THE EXPRESSION OF INDUCIBLE NITRIC 455 OXIDE SYNTHASE IN LOW DENSITY LIPOPROTEIN RECEPTOR DEFICIENCY MICE K.H. Nam, J.H. Choi, Y.J. Seo, Y.M. Lee, M.R. Lee, M.N. Lee, J.G. Park, G.T. Oh (Seoul and Chung-Nam, South Korea)

W E D N E S D A Y

150 8.30 - 10.30 THURSDAY, June 22 ROOM 1

Th-PL4 Plenary Session 4 FROM CLINICAL TRIALS TO PRACTICE Chairs: S.M. Grundy (Dallas, TX, USA); E. Nabel (Bethesda, MD, USA); hour: F. Violi (Rome, Italy) abstract bk. page ref.: 8.30 - 9.00 INCREASING HIGH-DENSITY LIPOPROTEIN CHOLESTEROL: FROM 457 PROMISE TO PRACTICE J.J.P. Kastelein (Amsterdam, The Netherlands) 9.00 - 9.30 INSIGHTS FROM INTRAVASCULAR ULTRASOUND 457 E.M. Tuzcu (Cleveland, OH, USA) 9.30 - 10.00 HYPERTENSION, INFLAMMATION AND ARTERIAL STIFFNESS: NEW 457 PARADIGMS FOR CARDIOVASCULAR RISK MANAGEMENT G. Schillaci (Perugia, Italy) 10.00 - 10.30 NUTRITION AND HEART DISEASE: WHERE ARE WE? 458 E.J. Schaefer (Boston, MA, USA) 10.30 End of the Session

10.30 - 11.00 BREAK - POSTERS - EXHIBITS

T H U R S D A Y

151 11.00 - 14.00 THURSDAY, June 22 ROOM 2

Th-W46 Workshop 46 OXIDATION hour: abstract bk. Chairs: M. Aviram (Haifa, Israel); A. Pujia (Catanzaro, Italy) page ref.: 11.00 - 11.20 OXIDATION OF LDL LEADS ITS RECOGNITION BY MULTIPLE ARCS OF 459 INNATE IMMUNITY C.J. Binder, M.K. Chang, A. Boullier, M.Y. Chou, P.X. Shaw, K. Hartvigsen, L. Hansen, D.A. Woelkers, Y.I. Miller, S. Hörkkö, J.L. Witztum (San Diego, CA, USA) 11.20 - 11.40 HDL - ASSOCIATED PARAOXONASE 1 (PON1) ATTENUATES LIPOPROTEIN 459 OXIDATION, MACROPHAGE FOAM CELL FORMATION AND ATHEROSCLEROSIS DEVELOPMENT M. Aviram, M. Rosenblat (Haifa, Israel) 11.40 - 11.55 IGG IMMUNE COMPLEXES AGAINST OXIDIZED LDL INDUCE EXPRESSION AND 460 SECRETION OF PROATHEROGENIC CYTOKINES BY CULTURED HUMAN MAST CELLS J. Lappalainen, R. Oksjoki, P.T. Kovanen, K.A. Lindstedt (Helsinki, Finland) 11.55 - 12.10 DENDRITIC CELLS PULSED WITH OXIDISED LOW DENSITY LIPOPROTEIN 460 AGGRAVATE ATHEROSCLEROSIS C. Hjerpe, D. Johansson, X. Zhou, G. K. Hansson (Stockholm, Sweden) 12.10 - 12.25 OXIDIZED LDL INDUCES MONOCYTE-TO-MACROPHAGE DIFFERENTIATION 460 THROUGH ACTIVATION OF THE M-CSF RECEPTOR B. Fuhrman, A. Partoush, N. Volkova, M. Aviram (Haifa, Israel) 12.25 - 12.40 EFFECTS OF SIX MONTHS OF TREATMENT WITH LOW DOSE PRAVASTATIN ON 460 PLASMA LEVELS OF OXIDIZED LDL IN THREE ULTRACENTRIFUGALLY SEPARATED LDL SUBFRACTIONS Y. Homma, K. Homma, H. Yamaguchi, Y. Husegawa, H. Ozawa, Y. Shiina, K. Ishikawa (Isehara and Toyko, Japan) 12.40 - 12.55 SOLUBLE LECTIN-LIKE OXIDIZED LDL RECEPTOR-1 (SLOX-1) IS A SUPERIOR 460 SERUM MARKER FOR ACUTE CORONARY SYNDROME THAN TROPONIN T AND H-FABP N. Kume, H. Mitsuoka, K. Hayashida, M. Tanaka, T. Kita (Kyoto and Osaka, Japan) 12.55 End of the Session

12.55 - 14.00 LUNCH - POSTERS - EXHIBITS

Th-S17 Celebrating Session 50TH ANNIVERSARY OF THE ULTRACENTRIFUGAL SEPARATION OF LIPOPROTEINS IN CLINICAL SCIENCE Symposium 17 Chairs: S.M. Grundy (Dallas, TX, USA); A.G. Olsson (Linköping, Sweden)

13.00 - 13.05 INTRODUCTION – S.M. Grundy (Dallas, TX, USA) 13.05 - 13.15 THE INVENTIONS OF THE ULTRACENTRIFUGE AND THE 491 ELECTROPHORESIS - PREREQUISITES FOR BASIC AND CLINICAL T LIPOPROTEIN RESEARCH H A.G. Olsson (Linköping, Sweden) U 13.15 - 13.30 DEFINITION OF VLDL, LDL AND HDL (AND AN AMERICAN PERSPECTIVE) 491 R R.J. Havel (San Francisco, CA, USA) S 13.30 - 13.45 EARLY EMERGING STUDIES OF THE ATHEROGENICITY OF LIPOPROTEINS 491 (A EUROPEAN PERSPECTIVE) D M.F. Oliver (Edinburgh and London, UK) A 13.45 - 13.55 DISCUSSION – Y 13.55 - 14.00 CONCLUDING REMARKS – S.M. Grundy (Dallas, TX, USA) 14.00 End of the Session

152 11.00 - 12.20 THURSDAY, June 22 ROOM 3

Th-W47 Workshop 47 CHOLESTEROL RISK FACTORS AND MANAGEMENT: A SUCCESS OR A FAILURE? hour: abstract bk. Chairs: R. Ceska (Prague, Czech Republic); M.-R. Taskinen (Helsinki, Finland) page ref.: 11.00 - 11.20 PREVENTING CVD EVENTS WITH RISK FACTOR CONTROL IN THE USA 461 P.W.F. Wilson (Charleston, SC, USA) 11.20 - 11.40 ATHEROSCLEROSIS - A PARADOX OF EASTERN EUROPEAN COUNTRIES 461 Z. Reiner, E. Tedeschi-Reiner (Zagreb, Croatia) 11.40 - 12.00 EUROACTION: A NEW APPROACH TO MANAGING RISK FACTORS IN EUROPE 462 D.A. Wood (London, UK) 12.00 - 12.20 PHYSICIANS' AND PATIENTS' PERCEPTIONS: BARRIERS TO CHOLESTEROL 462 MANAGEMENT IN CLINICAL PRACTICE L.R. Erhardt (Malmö, Sweden) 12.20 End of the Session

Workshop organized in collaboration with the European Atherosclerosis Society (EAS)

12.20 - 14.00 LUNCH - POSTERS - EXHIBITS

T H U R S D A Y

153 11.00 - 13.00 THURSDAY, June 22 ROOM 4

Th-W48 Workshop 48 ANIMAL MODELS (2nd part) hour: abstract bk. Chairs: J.L. Johnson (Bristol, UK); M. Pirro (Perugia, Italy) page ref.: 11.00 - 11.15 MOUSE MODEL OF VEIN GRAFT ARTERIOSCLEROSIS: ROLE OF NITRIC OXIDE 462 AND VEGF IN ENDOTHELIAL PROGENITOR CELL HOMING Y. Hu, U. Mayr, Q. Xu (London, UK) 11.15 - 11.30 HEPARANASE AND ATHEROSCLEROSIS: LESSONS FROM TRANSGENIC MICE 463 OVER-EXPRESSING THE HUMAN HEPARANASE GENE D. Planer, S. Metzger, E. Zcharia, I. Vlodavsky, J. George, T. Chajek – Shaul (Jerusalem and Tel Aviv, Israel) 11.30 - 11.45 EPIDERMAL LANGERHANS CELLS ARE REQUIRED FOR NICOTINIC ACID-INDUCED 463 CUTANEOUS FLUSHING IN THE MOUSE E. Carballo-Jane, T. Ciecko, S. Luell, J.W. Woods, E.I. Zycband, M.G. Waters, M.J. Forrest (Rahway, NJ, USA) 11.45 - 12.00 ATHEROSCLEROSIS INDUCED BY MAJOR PERIODONTAL PATHOGEN IN A MOUSE 463 MODEL: A PILOT STUDY A.M. Tuomainen, M. Jauhiainen, P.T. Kovanen, S. Paju, P.J. Pussinen (Helsinki, Finland) 12.00 - 12.15 PRODIABETOGENIC EFFECTS OF TRANSGENIC RESISTIN IN OLD SPONTANEOUSLY 463 HYPERTENSIVE RATS M. Pravenec, V. Zidek, V. Landa, L. Kazdova, T.W. Kurtz (Prague, Czech Republic and San Francisco, CA, USA) 12.15 - 12.30 ROSUVASTATIN EXERTS RENOPROTECTIVE EFFECTS IN STROKE-PRONE RATS 463 INDEPENDENTLY OF CHANGES IN CHOLESTEROL LEVELS A. Gianella, E. Nobili, P. Gelosa, L. Mussoni, M. Canavesi, S. Bellosta, M. Abbate, C. Zoja, E. Tremoli, L. Sironi (Milan and Bergamo, Italy) 12.30 - 12.45 PORCINE PLASMA PAF-ACETYLHYDROLASE : PHYSIOLOGY UPON DIET 464 HYPERLIPIDEMIA. A SURROGATE MODEL OF HUMAN ATHEROSCLEROSIS W. Wei, P. Holvoet, D. De Keyzer, D. Stengel, H. Durand, F. Cambien, E. Ninio (Paris, France and Leuven, Belgium) 12.45 - 13.00 THE IMMUNOSUPPRESANT EVEROLIMUS SIGNIFICANTLY PREVENTS 464 ATHEROSCLEROSIS IN HYPERCHOLESTEROLEMIC LDLR-/- MICE M.A. Mueller, F. Beutner, D. Teupser, U. Ceglarek, F. Jeromin, C. Weise, J. Thiery (Leipzig, Germany) 13.00 End of the Session

13.00 - 14.00 LUNCH - POSTERS - EXHIBITS

T H U R S D A Y

154 11.00 - 13.00 THURSDAY, June 22 ROOM 5

Th-W49 Workshop 49 PHARMACOLOGY OF ARTERIAL DISEASE: NOVEL THERAPEUTIC APPROACHES (1st part) hour: abstract bk. Chairs: A.S. Wierzbicki (London, UK); S. Iliceto (Padua, Italy) page ref.: 11.00 - 11.20 BERBERINE IS A PROMISING NOVEL CHOLESTEROL-LOWERING DRUG 464 WORKING THROUGH A UNIQUE MECHANISM DISTINCT FROM STATINS W. Kong, J. Wei, P. Abidi, M. Lin, S. Inaba, C. Li, Y. Wang, Z. Wang, S. Si, H. Pan, S. Wang, J. Wu, Y. Wang, Z. Li, J. Liu, J.-D. Jiang (Beijing, Nanjing, China, Palo Alto, CA and New York, NY, USA) 11.20 - 11.40 CHYMASE AS A NOVEL TARGET FOR THE PREVENTION OF VASCULAR 465 STENOSIS M. Miyazaki, S. Takai, D. Jin (Osaka, Japan) 11.40 - 12.00 LIPID-LOWERING THERAPIES IN DEVELOPMENT 465 A.S. Wierzbicki (London, UK) 12.00 - 12.15 IDENTIFICATION OF HISTONE DEACETYLASE 7 AS A NEW TARGET FOR 465 TREATMENT OF HYPERCHOLESTEROLEMIA N. Mitro, C. Godio, E. Scotti, E. Gers, E. De Fabiani, A.B. Vigil Chacon, D. Caruso, M. Crestani (Milan, Italy) 12.15 - 12.30 A HUMAN APOLIPOPROTEIN B ANTISENSE INHIBITOR REDUCES AORTIC SINUS 466 PLAQUE VOLUME IN LDL RECEPTOR DEFICIENT MICE EXPRESSING A HUMAN APOB-100 TRANSGENE E. Chuang, K.M. Lemonidis, C. Whipple, M.J. Graham, C. York-Defalco, G. Hung, R.M. Crooke (Carlsbad, CA, USA) 12.30 - 12.45 SIGNIFICANT REDUCTION OF SMALL DENSE LDL-CHOLESTEROL 466 CONCENTRATIONS IN HEALTHY VOLUNTEERS BY ANTISENSE INHIBITION OF APOLIPOPROTEIN B J.J.P. Kastelein, M.K. Wedel, B. Baker, J. Su, J. Bradley, E. Chuang (Amsterdam, The Netherlands and Carlsbad, CA, USA) 12.45 - 13.00 PACLITAXEL ASSOCIATED WITH A LIPIDIC NANOEMULSION (LDE) PROMOTES 466 ATHEROSCLEROSIS REGRESSION IN THE RABBIT R.C. Maranhão, E.R. Tavares, A.F. Padoveze, C.J. Valduga, T.V. Oliveira, D.G. Rodrigues (São Paulo, Brazil) 13.00 End of the Session

13.00 - 14.00 LUNCH - POSTERS - EXHIBITS

T H U R S D A Y

155 11.00 - 13.00 THURSDAY, June 22 ROOM 6

Th-W50 Workshop 50 GUIDELINES AND GLOBAL RISK (1st part) hour: abstract bk. Chairs: G. Assmann (Münster, Germany); D. Vanuzzo (Udine, Italy) page ref.: 11.00 - 11.20 IMAGING AND APOLIPOPROTEINS IN ASSESSING CARDIOVASCULAR RISK 466 AND DEFINING AIMS OF THERAPY O. Faergeman (London, UK) 11.20 - 11.40 THE EVOLVING PARADIGM OF GLOBAL RISK ASSESSMENT 466 S.M. Grundy (Dallas, TX, USA) 11.40 - 12.00 EMERGING MARKERS IN CARDIOVASCULAR RISK ASSESSMENT IN THE 467 PROCAM STUDY G. Assmann, P. Cullen, M. Stoll, H. Schulte (Münster, Germany) 12.00 - 12.15 THE ABILITY OF THE SCORE RISK MODEL TO PREDICT 10-YEAR CVD 467 MORTALITY IN NORWAY A.S. Lindman, M.B. Veierod, J.I. Pedersen, A. Tverdal, I. Njølstad, R. Selmer (Oslo and Tromsø, Norway) 12.15 - 12.30 ONE THIRD OF THE VARIABILITY IN HDL-CHOLESTEROL LEVEL IN A LARGE 467 DYSLIPIDEMIC POPULATION IS PREDICTED BY AGE, SEX AND TRIGLYCERIDEMIA B. Hansel, A. Kontush, P. Giral, D. Bonnefont, M.J. Chapman, E. Bruckert (Paris, France) 12.30 - 12.45 THE APOB/APOA-I RATIO – A NEW PREDICTOR OF FATAL STROKE, MYOCARDIAL 468 INFARCTION AND OTHER ISCHAEMIC DISEASES - STRONGER THAN LDL AND LIPID RATIOS G. Walldius, I. Jungner (Stockholm and Mölndal, Sweden) 12.45 - 13.00 RISK ASSESSMENT FOR CARDIOVASCULAR DEATH AMONG OLD PEOPLE IN 468 COMPARISON TO YOUNG PEOPLE-THE REYKJAVIK STUDY B. Thorsson, T. Aspelund, G. Sigurdsson, V. Gudnason (Kopavogur and Reykjavik, Iceland) 13.00 End of the Session

13.00 - 14.00 LUNCH - POSTERS - EXHIBITS

T H U R S D A Y

156 11.00 - 12.55 THURSDAY, June 22 ROOM 7

Th-W51 Workshop 51 HYPERTENSION hour: abstract bk. Chairs: E.M. Tuzcu (Cleveland, OH, USA); G. Mancia (Monza, Italy) page ref.: 11.00 - 11.20 ATHEROSCLEROSIS PROGRESSION IN THE CORONARIES DURING 468 ANTIHYPERTENSIVE TREATMENT E.M. Tuzcu (Cleveland, OH, USA) 11.20 - 11.40 THE ROLE OF STATINS IN BLOOD PRESSURE CONTROL 468 C. Borghi (Bologna, Italy) 11.40 - 11.55 HIGH SALT DIET ACCELERATES ATHEROSCLEROSIS IN APOE-/- MICE WITH 469 FIXED HIGH ANGIOTENSIN II LEVELS M.E. Johansson, E. Bernberg, I.J. Andersson, L. Gan, G. Bergström (Göteborg, Sweden) 11.55 - 12.10 LIPID PEROXIDATION AS A DETERMINANT OF PLATELET ACTIVATION IN 469 HYPERTENSIVES WITH MICROALBUMINURIA P. Ferroni, A. Falco, M.T. Guagnano, V. Paoletti, M.R. Manigrasso, N. Michetti, G. Ciabattoni, C. Patrono, G. Davì (Rome and Chieti, Italy) 12.10 - 12.25 LIPOPROTEIN (A) IS ELEVATED IN PATIENTS WITH RENOVASCULAR 469 HYPERTENSION, BUT NOT IN PATIENTS WITH PRIMARY ALDOSTERONISM K. Kostner, Y. Liu, D. Cowley, M. Stowasser (Brisbane, QLD, Australia) 12.25 - 12.40 SEX-SPECIFIC EFFECTS OF THE METABOLIC SYNDROME ON LEFT VENTRICULAR 469 STRUCTURE AND FUNCTION IN HYPERTENSION G. Schillaci, M. Pirro, F. Gemelli, G. Pucci, M.R. Mannarino, G. Vaudo, E. Mannarino (Perugia, Italy) 12.40 - 12.55 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS UP-REGULATE NADPH 470 OXIDASE EXPRESSION IN SPONTANEOUSLY HYPERTENSIVE RATS H. Li, M. Hortmann, A. Daiber, M. Oelze, I. Brausch, C. Mang, P.M. Schwarz, T. Munzel, U. Forstermann (Mainz, Germany) 12.55 End of the Session

12.55 - 14.00 LUNCH - POSTERS - EXHIBITS

T H U R S D A Y

157 11.00 - 13.00 THURSDAY, June 22 ROOM 8

Th-W52 Workshop 52 AGEING hour: abstract bk. Chairs: J. Tuomilehto (Helsinki, Finland); M. Trabucchi (Rome, Italy) page ref.: 11.00 - 11.20 VESSEL-AGING AND MECHANISMS OF ATHEROTHROMBOSIS 470 P. Holvoet (Leuven, Belgium) 11.20 - 11.40 SERUM CHOLESTEROL AND IN-HOSPITAL MORTALITY IN THE ELDERLY 470 R. Bernabei (Rome, Italy) 11.40 - 12.00 IMPACT OF AGE AND GLUCOSE INTOLERANCE ON CARDIOVASCULAR RISK 471 J. Tuomilehto (Helsinki, Finland) 12.00 - 12.15 FACTORS ASSOCIATED WITH ELEVATED C REACTIVE PROTEIN LEVELS IN 471 OLDER INDIVIDUALS WITH AND WITHOUT METABOLIC SYNDROME G. Zuliani, M. Galvani, S. Bandinelli, A.M. Corsi, F. Lauretani, R. Fellin, L. Ferrucci (Ferrara, Florence, Italy and Baltimore, MD, USA) 12.15 - 12.30 AGE-DEPENDENT IMPAIRMENT OF ENDOTHELIAL PROGENITOR CELLS IS 471 CORRECTED BY GROWTH HORMONE MEDIATED INCREASE OF INSULIN-LIKE GROWTH FACTOR-1 T. Thum, S. Hoeber, S. Froese, I. Klinik, D.O. Stichtenoth, D. Tsikas, S.D. Anker, P.A. Poole-Wilson, G. Ertl, J. Bauersachs (London, UK, Würzburg and Hannover, Germany) 12.30 - 12.45 AGE-RELATED ENDOTHELIAL DYSFUNCTION: A NOVEL MECHANISM 472 A. Smith, F. Visioli, B. Frei, T. Hagen (Corvallis, OR, USA and Milan, Italy) 12.45 - 13.00 INFLUENCE OF AGE ON BILE ACID SYNTHESIS: ROLE OF HEPATIC EXPRESSION 472 OF NUCLEAR RECEPTORS C. Gabbi, M. Bertolotti, C. Anzivino, D. Macchioni, M. Crestani, N. Mitro, M. Del Puppo, L. Carulli, P. Loria, N. Carulli (Modena, Milan and Monza, Italy) 13.00 End of the Session

13.00 - 14.00 LUNCH - POSTERS - EXHIBITS

T H U R S D A Y

158 11.00 - 12.55 THURSDAY, June 22 ROOM 9

Th-W53 Workshop 53 UNSATURATED FATTY ACIDS hour: abstract bk. Chairs: W.S. Harris (Kansas City, MO, USA); G. Baggio (Padua, Italy) page ref.: 11.00 - 11.20 INTERPLAY BETWEEN n-6 AND n-3 FATTY ACIDS AND CARDIOVASCULAR 472 RISK C. Galli, P. Risé, F. Marangoni, F. Visioli (Milan, Italy) 11.20 - 11.40 CARDIOPROTECTIVE EFFECTS OF OMEGA-3 FATTY ACIDS 472 W.S. Harris (Kansas City, MO, USA) 11.40 - 11.55 HOW TO IMPROVE ATHEROSCLEROSIS PREVENTION BY ARGAN OIL? 473 A. Adlouni, A. Drissi, M. Cherki, M. El Messal, J.M. Lecerf, A. Khalil, A.F. Derouiche (Casablanca, Morocco, Lille, France and Sherbrooke, QC, Canada) 11.55 - 12.10 DIETARY PREVENTION OF ATHEROSCLEROSIS IN LDL KNOCKOUT MICE: 473 COMBINED EFFECTS OF COMPONENTS OF SESAME OIL THAT GO BEYOND PLASMA LIPID LOWERING S. Bhaskaran, N. Santanam, S. Parthasarathy (New Orleans, LA, USA) 12.10 - 12.25 THE FATTY ACID COMPOSITION OF CHYLOMICRON REMNANT-LIKE PARTICLES 473 INFLUENCES THEIR EFFECTS ON MACROPHAGE FOAM CELL FORMATION C. De Pascale, M. Avella, C.D.P. Wheeler-Jones, K.M. Botham (London, UK) 12.25 - 12.40 THE EFFECT OF N-3 FATTY ACIDS ON HEART RATE VARIABILITY IN PATIENTS 474 TREATED WITH CHRONIC HEMODIALYSIS M. Svensson, E.B. Schmidt, K.A. Jørgensen, J.H. Christensen (Aalborg and Aarhus, Denmark) 12.40 - 12.55 EFFECT OF OMEGA-3 PUFA ON CAROTID IMT AND HAEMOSTASIS IN 474 HYPERTRIGLYCERIDEMIC PATIENTS: A LONGITUDINAL PILOT STUDY IN PRIMARY PREVENTION M. Amato, D. Baldassarre, S. Eligini, S.S. Barbieri, L. Mussoni, B. Frigerio, M. Kozàkovà, E. Tremoli, C.R. Sirtori, S. Colli (Milan and Pisa, Italy) 12.55 End of the Session

12.55 - 14.00 LUNCH - POSTERS - EXHIBITS

T H U R S D A Y

159 12.30 - 14.00 THURSDAY, June 22 ROOM 10

12.30 - 13.30 GENERAL ASSEMBLY of the INTERNATIONAL ATHEROSCLEROSIS SOCIETY (IAS)

13.30 - 14.00 YOUNG INVESTIGATOR AWARDS Best Poster Awards Chairs: Y. Matsuzawa (Osaka, Japan); E. Mannarino (Perugia, Italy)

YOUNG INVESTIGATOR AWARDS CEREMONY The awards will be presented to the winners

T H U R S D A Y

160 14.00 - 15.55 THURSDAY, June 22 ROOM 2

Th-W54 Workshop 54 LIPOPROTEIN PARTICLE hour: abstract bk. Chairs: B. Lamarche (Québec, QC, Canada); P. Pauciullo (Naples, Italy) page ref.: 14.00 - 14.20 RECENT ADVANCES IN THE STUDY OF THE SMALL DENSE LOW-DENSITY 474 LIPOPROTEIN PARTICLE PHENOTYPE B. Lamarche, J.F. Mauger (Québec, QC, Canada) 14.20 - 14.40 WHY METUSELAH LIVED TO BE 969: LONGEVITY GENES AND A NOVEL 474 LIPOPROTEIN CONNECTION N. Barzilai, G. Atzmon (Bronx, NY, USA) 14.40 - 14.55 LDL DENSITY PREDICTS INTIMA-MEDIA THICKNESS IN A FREE-LIVING 475 POPULATION. THE PRESENCE AND PROGRESSION OF LESIONS IN CAROTID ARTERIES (PLIC) STUDY A. Zambon, S. Raselli, G.D. Norata, L. Grigore, F. Maggi, D. Vianello, M. Marchiori, A.L. Catapano (Padua and Milan, Italy) 14.55 - 15.10 RISK OF ANGIOGRAPHICALLY-ASSESSED CORONARY ARTERY DISEASE 475 ASSOCIATED WITH LDL AND HDL PARTICLE SIZES IN WOMEN P. Blackburn, I. Lemieux, B. Lamarche, J. Bergeron, P. Perron, G. Tremblay, D. Gaudet, J.-P. Després (Québec and Chicoutimi, QC, Canada) 15.10 - 15.25 LDL PARTICLE SIZE AND THE RISK OF FUTURE CHD IN APPARENTLY HEALTHY 475 MEN AND WOMEN: THE EPIC-NORFOLK PROSPECTIVE POPULATION STUDY B.J. Arsenault, I. Lemieux, J.P. Després, S.M. Boekholdt, N.J. Wareham, S.A. Bingham, K.-T. Khaw (Québec, QC, Canada, Amsterdam, The Netherlands and Cambridge, UK) 15.25 - 15.40 DIFFERENTIAL EFFECTS OF LDL SUBSPECIES ON SR-BI/CLA-1-MEDIATED 476 CHOLESTEROL EFFLUX M. Tréguier, M. Moreau, A. Sposito, M.J. Chapman, T. Huby (Paris, France) 15.40 - 15.55 NICOTINIC ACID AND GEMFIBROZIL COMBINATION FOR THE TREATMENT OF 476 FAMILIAL COMBINED HYPERLIPIDEMIA AND THE EFFECT ON LDL AND HDL SUBCLASS DISTRIBUTION R. Superko, B. Garrett, S. King III, S. Superko (Atlanta, GA and Portola Valley, CA, USA) 15.55 End of the Session

T H U R S D A Y

161 14.00 - 15.55 THURSDAY, June 22 ROOM 3

Th-W55 Workshop 55 VEGETABLE PROTEINS hour: abstract bk. Chairs: D.J.A. Jenkins (Toronto, ON, Canada); G. Riccardi (Naples, Italy) page ref.: 14.00 - 14.20 THE PORTFOLIO DIET: THE ROLE OF VEGETABLE PROTEIN AND OTHER 476 DIETARY COMPONENTS IN HYPERCHOLESTEROLEMIA D.J.A. Jenkins, C.W.C. Kendall, D.A. Faulkner, J.M.W. Wong, A. Emam, T. Nguyen, A. Marchie, R. de Souza, E. Vidgen, K.G. Lapsley, E.A. Trautwein, T. Kemp, R.G. Josse, L.A. Leiter, P.W. Connelly, W. Singer (Toronto, ON, Canada, Modesto, CA, USA and Vlaardingen, The Netherlands) 14.20 - 14.40 OPTIMAL PROPORTIONS OF DIETARY FAT, PROTEIN, AND 476 CARBOHYDRATE FOR CARDIOVASCULAR HEALTH F.M. Sacks, L.J. Appel (Boston, MA and Baltimore, MD, USA) 14.40 - 14.55 LUPIN PROTEIN: A NEW SOURCE OF CARDIOVASCULAR PROTECTIVE AGENTS? 477 G. Chiesa, S.K. Johnson, M. Marchesi, C. Parolini, S. Caligari, D. Gilio, L. Cornelli, E. Diani, E. Rigamonti, C.R. Sirtori (Milan, Italy and Melbourne, NSW, Australia) 14.55 - 15.10 LUPIN PROTEINS IN THE TREATMENT OF HYPERCHOLESTEROLEMIA 477 G. Nowicka, L. Klosiewicz-Latoszek, C.R. Sirtori, A. Arnoldi, M. Naruszewicz (Warsaw, Poland and Milan, Italy) 15.10 - 15.25 THE EFFECT OF AN INCREASED INTAKE OF VEGETABLES AND FRUIT ON 478 WEIGHT, BLOOD PRESSURE AND ANTIOXIDANT DEFENSE IN SUBJECTS WITH SLEEP APNEA DISORDERS M. Svendsen, R. Blomhoff, I. Holme, S. Tonstad (Oslo, Norway) 15.25 - 15.40 LUPIN PROTEINS REDUCE PROGRESSION OF A FOCAL ATHEROMATOUS LESION 478 IN RABBITS C. Parolini, S.K. Johnson, M. Marchesi, E. Diani, E. Rigamonti, L. Cornelli, C.R. Sirtori, G. Chiesa (Milan, Italy) 15.40 - 15.55 EFFECT OF A DIETARY PORTFOLIO OF CHOLESTEROL LOWERING FOODS ON 478 BLOOD PRESSURE C.W. Kendall, D.J. Jenkins, D. Faulkner, T. Kemp, A. Marchie, J. Wong, R. de Souza, A. Emam, E. Vidgen (Toronto, ON, Canada and Dewsbury, UK) 15.55 End of the Session

T H U R S D A Y

162 14.00 - 16.10 THURSDAY, June 22 ROOM 4

Th-W56 Workshop 56 BIOMARKERS FOR RISK DETERMINATION hour: abstract bk. Chairs: W. Koenig (Ulm, Germany); S. Novo (Palermo, Italy) page ref.: 14.00 - 14.20 RISK STRATIFICATION IN ASYMPTOMATIC SUBJECTS 478 W. Koenig (Ulm, Germany) 14.20 - 14.40 CLINICAL STUDIES ON BIOMARKERS 479 C.M. Ballantyne (Houston, TX, USA) 14.40 - 14.55 PLASMA HOMOCYSTEINE LEVELS ARE INCREASED IN NCEP-DEFINED 479 METABOLIC SYNDROME PATIENTS BUT ARE NOT ASSOCIATED WITH INCREASED VASCULAR RISK G.R. Hajer, Y. van der Graaf, J.K. Olijhoek, M.C. Verhaar, F.L.J. Visseren (Utrecht, The Netherlands) 14.55 - 15.10 HIGH GLUCOSE AND HOMOCYSTEINE SYNERGISTICALLY AFFECT MMP-TIMP, 479 BUT NOT TGFBETA PATTERN IN HUMAN FIBROBLASTS A. Solini, E. Santini, M. Nannipieri, A. Bonotti, E. Ferrannini (Pisa, Italy) 15.10 - 15.25 MMP-10 (STROMELYSIN-2): NEW BIOMARKER FOR CLINICAL AND SUBCLINICAL 480 ATHEROSCLEROSIS J. Orbe, J.A. Rodriguez, I. Montero, N. Varo, O. Beloqui, P. Libby, J.A. Páramo (Pamplona, Spain and Boston, MA, USA) 15.25 - 15.40 DETERMINANTS FOR VITAMIN B6 AND FOLATE CONCENTRATIONS IN ELDERLY: 480 THE INCHIANTI STUDY A.M. Gori, A.M. Corsi, S. Bandinelli, B. Giusti, F. Lauretani, C. Saracini, I. Sestini, L. Ferrucci, R. Abbate, G.F. Gensini (Florence, Italy and Baltimore, MD, USA) 15.40 - 15.55 A COST-BENEFIT APPROACH TO THE REGULATION, QUALIFICATION AND 480 ACCEPTANCE OF BIOMARKERS AND SURROGATE ENDPOINTS S.A. Williams, D.E. Slavin, J.A. Wagner, C.J. Webster (New London, CT, USA, Sandwick, UK, Rahway, NJ and Cambridge, MA, USA) 15.55 - 16.10 INTEGRATED BIOCHEMICAL AND BIOIMAGING MARKERS AS SURROGATE 480 END-POINTS IN CARDIOCEREBROVASCULAR DISEASE DRUG EVALUATION: VALIDATION PROPOSALS S.M. Marcovina, F. Crea, P.L. Pieri, A.P. Peracino (Seattle, WA, USA, Rome, Cesena and Milan, Italy) 16.10 End of the Session

T H U R S D A Y

163 14.00 - 15.55 THURSDAY, June 22 ROOM 5

Th-W57 Workshop 57 PHARMACOLOGY OF ARTERIAL DISEASE: NOVEL THERAPEUTIC APPROACHES (2nd part) hour: abstract bk. Chairs: J. Nilsson (Malmö, Sweden); G. Bittolo Bon (Venice, Italy) page ref.: 14.00 - 14.20 IMMUNOMODULATION OF ATHEROSCLEROSIS 481 J. Nilsson (Malmö, Sweden) 14.20 - 14.40 LOCAL AND SYSTEMIC USES OF METALLOPROTEINASE INHIBITORS IN 481 THE PREVENTION / TREATMENT OF ARTERIAL DISEASE A.C. Newby (Bristol, UK) 14.40 - 14.55 A STRUCTURE-ACTIVITY STUDY FOR THE INHIBITION OF METALLOPROTEINASE-9 481 ACTIVITY AND GENE EXPRESSION BY ANALOGUES OF GALLOCATECHIN-3-GALLATE S. Bellosta, M. Dell'Agli, L. Rizzi, G.V. Galli, M. Canavesi, F. Rota, R. Parente, E. Bosisio, S. Romeo (Milan, Italy) 14.55 - 15.10 STENT-BASED DELIVERY OF NUCLEAR FACTOR-KB DECOY ATTENUATES IN-STENT 482 RESTENOSIS IN HYPERCHOLESTEROLEMIC RABBITS K. Egashira, K. Otani, K. Nakano, K. Sunagawa (Fukuoka, Japan) 15.10 - 15.25 DECREASED PLASMA APOB-CONTAINING LIPOPROTEIN AND ATHEROSCLEROSIS 482 IN ABCG5/G8 X LDLR-KO MICE ON EZETIMIBE F. Basso, L. Freeman, C. Ko, T. Tansey, M.J. Amar, F. Thomas, S. Santamarina-Fojo, H.B. Brewer (Bethesda, MD, USA) 15.25 - 15.40 EZETIMIBE PLUS SIMVASTATIN DECREASES LDL APOLIPOPROTEIN B VIA 482 ENHANCED CLEARANCE MEDIATED BY INCREASED HEPATIC EXPRESSION OF LDL RECEPTORS D.E. Telford, B.G. Sutherland, J.Y. Edwards, J.D. Andrews, P.H.R. Barrett, M.W. Huff (London, ON, Canada and Perth, WA, Australia) 15.40 - 15.55 PITAVASTATIN INHIBITS INTIMAL THICKNESS THROUGH THE ATTENUATION 482 OF LR11/UPA RECEPTOR-MEDIATED MIGRATION OF VASCULAR SMOOTH MUSCLE CELLS M. Jiang, H. Bujo, H. Yamazaki, T. Kanaki, W. Schneider, Y. Saito (Chiba, Tokyo, Japan and Vienna, Austria) 15.55 End of the Session

T H U R S D A Y

164 14.00 - 15.55 THURSDAY, June 22 ROOM 6

Th-W58 Workshop 58 GUIDELINES AND GLOBAL RISK (2nd part) hour: abstract bk. Chairs: D. Lloyd-Jones (Chicago, IL, USA); M. Mancini (Naples, Italy) page ref.: 14.00 - 14.20 LIFE TIME AND VARIABLE CARDIOVASCULAR RISK - LINKS TO 483 ENDOTHELIAL FUNCTION A. Hingorani (London, UK) 14.20 - 14.40 PREDICTING LIFETIME RISK FOR CARDIOVASCULAR DISEASE BASED ON 483 RISK FACTOR BURDEN D. Lloyd-Jones (Chicago, IL, USA) 14.40 - 14.55 CARDIOVASCULAR RISK FACTORS IN CHILDHOOD AND CAROTID ARTERY 483 INTIMA-MEDIA THICKNESS IN ADULTHOOD: THE CHILDHOOD DETERMINANTS OF ADULT HEALTH STUDY C.G. Magnussen, A. Venn, T. Dwyer, O.T. Raitakari (Hobart, TAS, Melbourne, NSW, Australia and Turku, Finland) 14.55 - 15.10 INCIDENCE OF SUB-CLINICAL ATHEROSCLEROSIS IN WOMEN WITH ELEVATED 484 PLASMA HDL CONCENTRATION S. Keidar, A. Ovental, V. Volfson (Haifa, Israel) 15.10 - 15.25 LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 AS A RISK FACTOR FOR 484 CORONARY VASCULAR DISEASE IN THE ELDERLY? M.J. Caslake, J. Cooney, E. Murray, D. Bedford, M. Robertson, J.J. Nelson, C.J. Packard (Glasgow, UK and California, USA) 15.25 - 15.40 COMBINED EFFECT OF ADIPONECTIN AND HDL-CHOLESTEROL ON PREMATURE 484 CORONARY ARTERY DISEASE RISK IN FAMILIAL HYPERCHOLESTEROLEMIA AND OTHER DYSLIPIDEMIAS T. Bouhali, D. Brisson, G. Tremblay, P. Perron, M.C. Vohl, J.P. Despres, M.N. Vissers, B.A. Hutten, J.J.P. Kastelein, D. Gaudet (Québec, QC, Canada and Amsterdam, The Netherlands) 15.40 - 15.55 SYSTEMIC ATHEROSCLEROTIC LESION IN CEREBROVASCULAR DISEASE 484 J.E. Fernandez-Britto, J. Bacallao, R. Campos, D. Contreras (Havana, Cuba) 15.55 End of the Session

T H U R S D A Y

165 14.00 - 15.45 THURSDAY, June 22 ROOM 7

Th-W59 Workshop 59 MENOPAUSE: NEW APPROACHES TO INTERVENTION hour: abstract bk. Chairs: B.V. Howard (Hyattsville, MD, USA); G. Licata (Palermo, Italy) page ref.: 14.00 - 14.20 POSTMENOPAUSAL HORMONE THERAPY - LESSONS FROM THE WOMEN'S 485 HEALTH INITIATIVE B.V. Howard, J. Rossouw, G. Anderson, J.E. Manson, J. Hsia, S. Wassertheil-Smoller, S. Hendrix, R. Chlebowski, M.L. Stefanick, J. Cauley, R. Jackson (Hyattsville, Bethesda, MD, Seattle, WA, Chestnut Hill, MA, Washington, DC, Bronx, NY, Detroit, MI, Torrance, San Jose, CA, Pittsburgh, PA and Columbus, OH, USA) 14.20 - 14.40 INTERNATIONAL GUIDELINES: CARDIOVASCULAR PREVENTION AND 485 ESTROGENS - A CONTRADICTION? M.H. Birkhäuser (Berne, Switzerland) 14.40 - 15.00 MOLECULAR AND CELLULAR BASIS FOR CARDIOVASCULAR GENDER 485 DIFFERENCES R.D. Patten (Boston, MA, USA) 15.00 - 15.15 CD4 T CELL DYSFUNCTION OF PERIMENOPAUSAL WOMEN; THE ROLE OF 486 ESTROGEN IN ATHEROSCLEROSIS K. Sato, K. Murasaki, N. Hagiwara, H. Kasanuki (Tokyo, Japan) 15.15 - 15.30 ESSENTIAL ROLE OF BONE MARROW FGF2 IN THE EFFECT OF ESTRADIOL ON 486 REENDOTHELIALIZATION AND EPC MOBILISATION C. Filipe, V. Fontaine, N. Werner, P. Gourdy, A. Billon, B. Garmy-Susini, L. Brouchet, T. Doetschman, G. Nickenig, J.-F. Arnal (Toulouse, France, Homburg/Saar, Germany and Cincinnati, OH, USA) 15.30 - 15.45 SEX-SPECIFIC INTERACTION BETWEEN APOE AND APOA5 VARIANTS AND 486 PLASMA LIPID LEVELS J. Hubacek, V. Adamkova, V. Lanska, Z. Skodova (Prague, Czech Republic) 15.45 End of the Session

T H U R S D A Y

166 14.00 - 16.00 THURSDAY, June 22 ROOM 8

Th-W60 Workshop 60 ATHEROSCLEROSIS: BASIC SCIENCE (2nd part) hour: abstract bk. Chairs: J.L. Witztum (La Jolla, CA, USA); M. Cattaneo (Milan, Italy) page ref.: 14.00- 14.15 THE ROLE OF LIMK1 IN ENDOTHELIAL BARRIER FUNCTION 487 M. Gorovoy, T. Voyno-Yasenetskaya (Chicago, IL, USA) 14.15 - 14.30 ALKYL-LYSOPHOSPHATIDIC ACID IS A NOVEL ENDOGENOUS PARTIAL 487 AGONIST OF PPAR-GAMMA G. Tigyi, T. Tsukahara, R. Tsukahara, S. Yasuda, N. Makarova, W. Valentine, P. Allison, H. Yuan, A. Parrill, D. Baker (Memphis, TN, USA) 14.30 - 14.45 ACUTE ANTI-INFLAMMATORY PROPERTIES OF STATINS INVOLVE PEROXISOME 487 PROLIFERATOR-ACTIVATED RECEPTOR-ALPHA VIA INHIBITION OF THE PKC SIGNALLING PATHWAY R. Paumelle, C. Blanquart, O. Briand, O. Barbier, C. Duhem, G. Woerly, J.C. Fruchart, D. Dombrowicz, C. Glineur, B. Staels (Lille, France) 14.45 - 15.00 INCREASED ATHEROSCLEROTIC BURDEN IN YOUNG VERSUS AGED LDL-RECEPTOR 487 KNOCKOUT MICE A.O. Kraaijeveld, R. de Nooijer, E.E. van der Wall, J.W. Jukema, T.J.C. van Berkel, E.A.L. Biessen (Leiden, The Netherlands) 15.00 - 15.15 INHIBITION OF FIBROBLAST GROWTH FACTOR RECEPTOR SIGNALING 488 ATTENUATES ATHEROSCLEROSIS IN APOLIPOPROTEIN E-DEFICIENT MICE T. Raj, P. Kanellakis, G. Pomilio, G. Jennings, A. Bobik, A. Agrotis (Melbourne, VIC, Australia) 15.15 - 15.30 TISSUE-SPECIFIC SIALIDASE DEFICIENCY PROTECTS AGAINST 488 ATHEROSCLEROSIS IN EXPERIMENTAL ANIMALS A.E. Yang, V. Tedesco, H.F. Kufaishi, B.L. Trigatti, S.A. Igdoura (Hamilton, ON, Canada) 15.30 - 15.45 SIMVASTATIN ABROGATES LYSYL OXIDASE DOWNREGULATION INDUCED BY 488 TUMOUR NECROSIS FACTOR-ALPHA: LYSYL OXIDASE AS A NEW MARKER IN ENDOTHELIAL DYSFUNCTION C. Rodriguez, J.F. Alcudia, B. Raposo, J. Martínez-González, L. Badimon (Barcelona, Spain) 15.45 - 16.00 THE INTERFERON INDUCIBLE GENE 12, A NOVEL FACTOR MODULATING THE 488 VASCULAR RESPONSE TO INJURY N. Papac-Milicevic, L. Ryban, J. Zaujec, C.J. Binder, J.M. Breuss, E.B. Binder, P. Uhrin, B.R. Binder (Vienna, Austria and Atlanta, GA, USA) 16.00 End of the Session

T H U R S D A Y

167 14.00 - 16.00 THURSDAY, June 22 ROOM 9

Th-W61 Workshop 61 ANIMAL MODELS (3rd part) hour: abstract bk. Chairs: M.J. Quon (Bethesda, MD, USA); S. Bellosta (Milan, Italy) page ref.: 14.00 - 14.15 UROTENSIN-II RECEPTOR KNOCKOUT INCREASES PLASMA TOTAL 489 CHOLESTEROL AND ATHEROSCLEROSIS IN APOE KNOCKOUT MICE N. Bousette, W. Al-Ramli, F. Hu, E.H. Ohlstein, S. Douglas, A. Giaid (Montreal, QC Canada and King of Prussia, PA, USA) 14.15 - 14.30 LEPTIN DEFICIENCY IN APOE*3LEIDEN TRANSGENIC MICE. A NEW MOUSE 489 MODEL WITH COMBINED INSULIN RESISTANCE AND ATHEROSCLEROSIS J.W.A. van der Hoorn, J.W. Jukema, P. Koolwijk, H.M.G. Princen (Leiden, The Netherlands) 14.30 - 14.45 12/15-LIPOXYGENASE DEFICIENCY AUGMENTS ANGIOTENSIN-II-INDUCED 489 ATHEROSCLEROSIS IN APOLIPOPROTEIN E DEFICIENT MICE F. Babamusta, N. Hatch, V.L. King (Lexington, KY, USA) 14.45 - 15.00 REDUCED ATHEROSCLEROSIS IN APO E -/- MICE WITH HEPARAN 489 SULFATE-DEFICIENT PERLECAN K. Tran Lundmark, P.K. Tran, G. Paulsson Berne, R. Soininen, K. Tryggvason, T.N. Wight, M.G. Kinsella, U. Hedin (Stockholm, Sweden, Oulu, Finland and Seattle, WA, USA) 15.00 - 15.15 CHOLESTERYL ESTER TRANSFER PROTEIN EXPRESSION INCREASES THE 489 (V)LDL/HDL RATIO AND SEVERELY AGGRAVATES ATHEROSCLEROSIS IN APOE*3-LEIDEN MICE M. Westerterp, C.C. van der Hoogt, W. De Haan, G.M. Dallinga-Thie, J.W. Jukema, L.M. Havekes, P.C.N. Rensen (Leiden and Rotterdam, The Netherlands) 15.15 - 15.30 NUMBER OF AORTIC ADVENTITIAL MAST CELLS AND SEVERITY OF AORTIC 490 VALVE THICKENING ARE INCREASED IN UREMIC APOE KNOCKOUT MICE M. Simolin, S. Bro, M. Mäyränpää, E. Falk, L.B. Nielsen, P.T. Kovanen (Helsinki, Finland, Copenhagen and Aarhus, Denmark) 15.30 - 15.45 ABSCENCE OF CD36 IS PROTECTIVE AT LATE TIME POINTS IN THE APOE KO MODEL 490 M. Febbraio, E. Guy, S. Kuchibhotla, R. Silverstein (Cleveland, OH, New York, NY, USA) 15.45 - 16.00 HUMAN APO A-1 TRANSFER ENHANCES EXPANSIVE REMODELING AND INTIMAL 490 ANGIOGENESIS IN A MURINE MODEL OF TRANSPLANT VASCULOPATHY Y.M. Feng, J. Lievens, J. Snoeys, F. Jacobs, Z. Zhang, D. Collen, B. De Geest (Leuven, Belgium) 16.00 End of the Session

T H U R S D A Y

168 POSTER AREA “B” THURSDAY, June 22 1-248

POSTER DISPLAY: for the duration of one day (Thursday, June 22 from 8.30 am to 4.00 pm). Participants may view the posters displayed during this day.

POSTER DISCUSSION: one of the authors will be available at the poster site as follows: Thursday, June 22: from 10.30 am to 11.00 am Thursday, June 22: from 12.30 pm to 2.00 pm

Th-P15 Poster Session 15 poster PATHOPHYSIOLOGY OF LIPIDS abstract bk. board no.: page ref.: AND LIPOPROTEINS

1 PERILIPIN, A POTENTIAL SUBSTITUTE FOR ADIPOPHILIN IN TRIGLYCERIDE 492 STORAGE IN HUMAN MACROPHAGES G. Larigauderie, M.A. Bouhlel, C. Furman, M. Jaye, J.C. Fruchart, M. Rouis (Lille, France and King of Prussia, PA, USA) 2 INFLUENCE OF INSIG-1 AND INSIG-2 SILENCING ON THE EXPRESSION OF GENES 492 INVOLVED IN FATTY ACID AND CHOLESTEROL METABOLISM IN HUH7 HUMAN HEPATOMA CELLS E. Chernogubova, S. Krapivner, A. Hamsten, F. van't Hooft (Stockholm, Sweden) 3 EFFECT OF LIVER X RECEPTOR AGONIST ON NIEMANN-PICK C-1 EXPRESSION AND 492 INTRACELLULAR CHOLESTEROL TRANSPORTATION IN LIPID-LOADED THP-1 MACROPHAGES X. Ou, C.K. Tang, X.Y. Dai, J.H. Yang, X.R. Hao, D.L. Cao, Z.S. Jiang, Z.Q. Wang, G.H. Yi, Z. Wang (Hengyang, China) 4 THE LIPID DROPLET SURFACE PROTEIN ADIPOPHILIN INHIBITS CHOLESTEROL 492 CLEARANCE FROM HUMAN MACROPHAGE FOAM CELLS C.M. Quinn, L. Kritharides, W. Jessup (Sydney, NSW, Australia) 5 APOLIPOPROTEIN E DISTRIBUTION IN HEPG2 CELLS UNDER OXIDATIVE STRESS 493 T. Sabaretnam, L. Kritharides, D.G. Le Couteur (Sydney, NSW, Australia) 6 LIPOPROTEINS LABELLED WITH FLUORESCENT AND SUPERPARAMAGNETIC 493 NANOCRYSTALS: NEW TOOLS FOR IN VITRO AND IN VIVO EXPERIMENTS O.T. Bruns, A. Laatsch, M.G. Kaul, N. Bigall, M.S. Nikolic, H. Weller, A. Eychmueller, U. Beisiegel, J. Heeren (Hamburg and Dresden, Germany) 7 ATP-BINDING CASSETTE TRANSPORTER A7 IS NEGATIVELY REGULATED BY STEROL, 493 AND NEEDED TO PROMOTE PHAGOCYTOSIS THROUGH THE STEROL RESPONSIVE ELEMENT PATHWAY N. Iwamoto, S. Abe-Dohmae, R. Sato, S. Yokoyama (Nagoya and Tokyo, Japan) 8 DIFFERENCES IN THE FATTY ACID COMPOSITION OF PRIMARY HUMAN MONOCYTE 493 DERIVED MACROPHAGES AND THP-1 CELLS A.E. Lane, B.J. Meyer, A. Cogny, M. Kockx, W. Jessup, L. Kritharides (Wollongong and Sydney, NSW, Australia) 9 MOLECULAR CONTROL OF LIPID DROPLET BIOGENESIS AND SECRETION 494 H. Robenek, O. Hofnagel, I. Buers, M.J. Robenek, D. Troyer, N.J. Severs (Münster, Düsseldorf, Germany and London, UK) 10 MAST CELLS IMPROVE OX-LDL INDUCED VASCULAR SMOOTH MUSCLE CELLS 494 FOAMING T L. Gan, Y.Z. Yang, S. Wang, Y.L. Tang, B.H. Dong, Z. Wang, H.Y. Jin, C.K. Tang (Hengyang, China) H 11 THE ROLE OF PPARS IN CELLULAR CHOLESTEROL EFFLUX MEDIATED BY HIGH DENSITY 494 U LIPOPROTEIN. A POSSIBLE INVOLVEMENT OF ABCA1, LXRALPHA, AND ERK1/2 R G.-H. Yi, X.-B. Yin, Y.-L. Tan, Y. Zeng, J.-T. Feng, L. Sun, D.-X. Zeng, J. Wang, J.-H. Xia, S Z. Ren (Hengyang, China) D 12 INTRACELLULAR TRAFFICKING OF HUMAN LIPOPROTEINS WITH CELLS IN 494 ATHEROSCLEROSIS A C.H. Ao, Y.J. Mao, L. Xue, D.F. Bu, L.B. Shi, K. Li, C.Y. Zhao, C.S. Tang, Y. Huo, Y Z.W. Xiong (Beijing, China)

169 13 A C-TERMINAL PEPTIDE DERIVED FROM HUMAN SAA DOES NOT INCREASE 495 MACROPHAGE NEUTRAL CHOLESTEROL ESTERASE ACTIVITY BY ENHANCING ITS TRANSCRIPTION S.P. Tam, M. Vincent, R. Kisilevsky (Kingston and Ottawa, ON, Canada) 14 REGULATION OF THE ACTIVITY AND FATTY ACID SPECIFICITY OF LCAT BY 495 SPHINGOMYELIN, AND ITS METABOLITES CERAMIDE, AND CERAMIDE PHOSPHATE P.V. Subbaiah, P. Horvath, S.B. Achar (Chicago, IL, USA) 15 CHARACTERIZATION OF THE DIRECT TRANS-INTESTINAL CHOLESTEROL 495 EXCRETION PATHWAY A. van der Velde, K. van der Oever, C. Vrins, C. Kunne, F. Kuipers, A. Groen (Amsterdam and Groningen, The Netherlands) 16 HIGH INTESTINAL CHOLESTEROL ABSORPTION ASSOCIATED WITH PRIMARY 495 HYPERCHOLESTEROLEMIA NON-RELATED TO DEFECTIVE LDL RECEPTOR A.L. García-Otín, M. Cofán, M. Junyent, D. Recalde, P. Martín-Fuentes, E. Jarauta, A. Cenarro, E. Ros, M. Pocoví, F. Civeira (Barcelona and Zaragoza, Spain) 17 ABNORMAL IN VIVO METABOLISM OF APOB AND VLDL TG ASSOCIATED WITH 496 TWO SIBLING CASES OF SITOSTEROLEMIA K. Matsuo, K. Kosaka, T. Sugimoto, K. Ikewaki (Kyoto and Tokyo, Japan) 18 FACTORS INFLUENCING METABOLISM OF NON-CHOLESTEROL STEROLS IN 496 PRIMARY HYPERLIPIDEMIAS M. Vecka, E. Tvrzická, M. Jáchymová, L. Janíková, B. Stanková, A. Zák (Prague, Czech Republic) 19 PLA2-GENERATED HYDROLYSIS PRODUCTS, FREE FATTY ACID AND 496 LYSOPHOSPHOLIPID MOLECULES, ACCUMULATE IN LDL PARTICLES AT ACIDIC PH K. Lähdesmäki, P. Soininen, M. Ala-Korpela, P.T. Kovanen, K. Öörni (Helsinki and Kuopio, Finland) 20 THIAZOLIDINEDIONES INHIBIT ENDOTHELIAL LIPASE EXPRESSION IN CULTURED 496 ENDOTHELIAL CELLS AND HUMAN PLASMA K. Badellino, K. Trindade, P. Szapary, D.J. Rader (Philadelphia and Collegeville, PA, USA) 21 HIGH LEVEL ENDOTHELIAL CELL LIPASE GENE EXPRESSION IN MACROPHAGES IN 497 ADVANCED HUMAN ATHEROSCLEROTIC LESIONS E.D. Bartels, J.E. Nielsen, M.L.S. Lindegaard, T.V. Schroeder, L.B. Nielsen (Copenhagen, Denmark) 22 DIAGNOSIS OF LIPOPROTEIN LIPASE (LPL) ABNORMALITY LEADING TO 497 HYPERTRIGLYCERIDEMIA BY MEASURING LPL MASS IN PREHEPARIN PLASMA WITH A MARKIT-M LPL ELISA Y. Ikeda, A. Takagi, M. Nishimura, T. Iwanaga, Y. Ohkaru (Suita, Japan) 23 PROTEOLYSIS ENHANCES LIPOLYSIS OF LDL BY SPHINGOMYELINASE AND 497 PHOSPHOLIPASE A2 GROUP V R. Kaakinen, E. Hurt-Camejo, P. Kovanen, K. Öörni (Helsinki, Finland, Gothenburg and Mölndal, Sweden) 24 DECREASE IN PH STRONGLY ENHANCES AGGREGATION OF 497 SPHINGOMYELINASE-TREATED LDL PARTICLES AND THEIR BINDING TO HUMAN AORTIC PROTEOGLYCANS K. Öörni, M. Sneck, P.T. Kovanen (Helsinki, Finland) 25 INTERRELATIONS BETWEEN LIPOPROTEIN LIPASE ACTIVITY, APOLIPOPROTEIN C- I 497 AND POSTPRANDIAL TRIGLYCERIDE RICH LIPOPROTEINS IN A HEALTHY POPULATION A.T.W. Notø, E.B. Mathiesen, J. Bjørkegren, J.B. Hansen (Tromsø, Norway and Stockholm, Sweden) 26 LIPOPROTEIN LIPASE (LPL) FROM TREE SHREW EXHIBITED A SIGNIFICANT HIGHER 498 ACTIVITY THAN THAT FROM HUMAN T W.-W. Zeng, B. Zhou, G.-T. Sun, H.-R. Liu, G.-Q. Liu, B.-S. Chen (Beijing, China) 27 SIMVASTATIN INHIBITS LPS-INDUCED LDL UPTAKE THROUGH SUPPRESSION OF 498 H EL EXPRESSION IN MACROPHAGES U T. Yasuda, K. Hirata, T. Ishida, Y. Kojima, H. Tanaka, T. Okada, K. Taira, M. Yokoyama R (Kobe, Japan) S 28 WHITE ADIPOSE TISSUE LPL ACTIVITY FALLS RAPIDLY IN RESPONSE TO SHORT 498 ACUTE STRESS D A. Casanovas, N. Parramon, O. Andrés, J. Terencio, F. De la Cruz, J. Peinado-Onsurbe, A D. López-Tejero, M. Llobera (Barcelona, Spain) Y

170 29 METFORMIN INCREASES LIPOPROTEIN LIPASE PRODUCTION IN SKELETAL 498 MUSCLE THROUGH ACTIVATED AMP-ACTIVATED PROTEIN KINASE M. Ohira, Y. Miyashita, M. Ebisuno, A. Saiki, K. Endo, N. Koide, T. Oyama, T. Murano, F. Watanabe, K. Shirai (Chiba, Japan) 30 DECREASED HYDROLYSIS OF APOE2-VLDL- TRIGLYCERIDE BY LIPOPROTEIN LIPASE 499 T. Murano, N. Ishihara, Y. Miyashita, K. Shirai (Sakura City, Japan) 31 RECOMBINANT EXPRESSION, PURIFICATION AND HTS ASSAY CONFIGURATION 499 FOR HUMAN HEPATIC LIPASE AND ENDOTHELIAL LIPASE P. Arioli, B. Bellanti, L. Redaelli, D. Carettoni (Milan, Italy) 32 THE APOLIPOPROTEIN B/APOLIPOPROTEIN A1 RATIO IN METABOLIC SYNDROME 499 I. Gazi, V. Tzovaras, E. Liberopoulos, S. Tsouli, A. Spyrou, A. Tselepis, M. Elisaf (Ioannina, Greece) 33 EFFECT OF ROSUVASTATIN ON LOW DENSITY LIPOPROTEIN (LDL) 499 CONCENTRATION AND RELATIVE DISTRIBUTION IN PATIENTS WITH PRIMARY DYSLIPIDAEMIA M. Kostapanos, T. Filippatos, I. Gazi, H. Milionis, A. Tselepis, M. Elisaf (Ioannina, Greece) 34 ANTIBODIES ASSOCIATED WITH LDL ARE PREDOMINATELY BOUND TO LOW 499 DENSITY LIPOPROTEIN AGGREGATES A.A. Melnichenko, D.V. Aksenov, I.A. Sobenin, O.M. Panasenko, A.N. Orekhov (Moscow, Russia) 35 EFFECTS OF PRAVASTATIN ON THE DISTRIBUTION OF LIPOPROTEIN SUBCLASSES 500 PROFILE IN DYSLIPIDEMIC PATIENTS WITH NORMAL AND HIGH TRIGLYCERIDE LEVELS J.L. Vieira, A.M. Gomes, V.L. Portal, E.H. Moriguchi (Porto Alegre, Brazil) 36 LOW RESOLUTION MODEL OF SOLUBILIZED APOLIPOPROTEIN- B100 500 A. Johs, M. Hammel, I. Waldner, R.P. May, P. Laggner, R. Prassl (Graz, Austria, Kansas, KS USA and Grenoble, France) 37 DECREASED HDL PARTICLE SIZE, PREß- AND LARGE HDL SUBSPECIES 500 CONCENTRATION IN FINNISH LOW HDL FAMILIES. RELATIONSHIP WITH INTIMA-MEDIA-THICKNESS (IMT) H. Watanabe, S. Söderlund, A. Soro-Paavonen, A. Hiukka, E. Leinonen, R. Salonen, T.-P. Tuomainen, C. Ehnholm, M. Jauhiainen, M.-R. Taskinen (Helsinki and Kuopio, Finland) 38 PLURONICS INHIBIT AGGREGATION OF LOW DENSITY LIPOPROTEIN 500 A.A. Melnichenko, D.V. Aksenov, A.A. Bukharkov, I.A. Sobenin, O.M. Panasenko, A.A. Yaroslavov, A.N. Orekhov (Moscow, Russia) 39 FOAM CELL DEATH INDUCED BY HYPERLIPIDEMIC SERUM IS RELATED TO 501 PHOSPHATIDYLCHOLINE CHOLESTEROL COMPLEX FORMATION M. Mori, H. Itabe, M. Shiomi, S. Yamaguchi, K. Homma, M. Yoshizumi, T. Takano (Kanagawa, Tokyo, Kobe and Hiroshima, Japan) 40 COMPARABLE EFFECTS OF APOE GENOTYPE ON LIPOPROTEIN PARTICLES 501 MEASURED BY NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY AND LIPIDS MEASURED BY STANDARD CHEMICAL METHODS R.L. Seip, J. Otvos, N. Moyna, M. Miles, R.F. Zoeller, P.S. Vissich, T.J. Angelopoulos, L. Pescatello, P. Gordon (Harford, CT, Raleigh, NC, Bozeman, MO, Davie, FL, Mt. Pleasant, Orlando, FL, Storrs, CT, USA, Morgantown, WV, and Dublin, Ireland) 41 EFFECTS OF GENDER AND MENOPAUSE STATUS ON THE ABILITY OF HDL TO 501 RECEIVE LIPIDS FROM AN NANOEMULSION MODEL OF LDL A.H. Giribela, R.F. Amâncio, N.R. Mello, M.C. Latrilha, C.M. Strunz, R.C. Maranhão (Sao Paulo, Brazil) 42 QUANTITATIVE AND QUALITATIVE CHANGES OF SERUM LIPOPROTEINS IN 501 PATIENTS WITH ACUTE BRUCELLOSIS F. Apostolou, E. Liberopoulos, I. Gazi, S. Tsouli, E. Tsianos, A. Tselepis, M. Elisaf (Ioannina, Greece) T 43 HIGH DENSITY LIPOPROTEIN SUBCLASS DISTRIBUTION IN MACEDONIAN CHILDREN 502 S. Alabakovska, D. Labudovic, K. Tosheska, M. Alabakovski, B. Todorova (Skopje, Macedonia) H 44 SMALL DENSE LOW-DENSITY LIPOPROTEIN IS PROSPECTIVELY ASSOCIATED 502 U WITH CARDIOVASCULAR MORTALITY-THE HOORN STUDY R L.P. van der Zwan, J.M. Dekker, T. Teerlink, G. Nijpels, R.J. Heine, P.G. Scheffer S (Amsterdam, The Netherlands) 45 INCREASED LEVELS OF SMALL, DENSE, OXIDIZED LDL IN PATIENTS WITH 502 D IDIOPATHIC VENOUS THROMBOEMBOLISM: A COMMON LINK WITH ATHEROSCLEROSIS A A. Zambon, P. Simioni, S. Bertocco, M. Marchiori, D. Vianello, D. Tormene, P. Prandoni, Y A. Pagnan (Padua, Italy)

171 46 SMALL DENSE LDL AND OXIDISED LDL IN TYPE 2 DIABETICS 502 M. Zamaklar, K. Lalic, N. Rajkovic, V. Kalimanovska, A. Topic, A. Zeljkovic, M. Dragasevic, L.J. Popovic, D. Draskovic, J. Stojanovic (Belgrade, Serbia-Montenegro) 47 SMALL DENSE LDL AND OXIDISED LDL IN DYSLIPIDEMIC PATIENTS 503 M. Zamaklar, K. Lalic, N. Rajkovic, V. Kalimanovska, A. Topic, A. Zeljkovic, M. Dragasevic, L.J. Popovic, D. Draskovic, J. Stojanovic (Belgrade, Serbia-Montenegro) 48 LOW-DENSITY LIPOPROTEIN PARTICLE SIZE AND METABOLIC SYNDROME IN 503 CHILDREN AND ADOLESCENTS D.J. Kim, S.H. Choi, H. Cho, H.J. Kim, Y.-S. Chung, K.W. Lee (Suwon, Seongnam and Seoul, South-Korea) 49 LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 ACTIVITY (LP-PLA2) IS A MARKER 503 OF SMALL-DENSE LDL PARTICLES I. Gazi, E. Lourida, T. Filippatos, V. Tsimihodimos, V. Saougos, M. Elisaf, A. Tselepis (Ioannina, Greece) 50 CHARACTERIZATION OF LDL-ASSOCIATED PROTEINS IN THE DYSLIPIDEMIA OF 503 TYPE 2 DIABETES AND THE METABOLIC SYNDROME C. Pettersson, J. Borén, L. Fogelstrand, O. Wiklund (Göteborg, Sweden) 51 SIGNIFICANT CORRELATION BETWEEN LDL PARTICLE SIZE AND THE MOLAR RATIO OF 503 CHOLINE PLASMALOGEN TO ETHANOLAMINE PLASMALOGEN (CP/EP RATIO) IN SERUM R. Maeba, M. Kinoshita, T. Maeda, K. Takao, H. Takenaka, J. Kusano, N. Yoshimura, T. Teramoto (Tokyo, Japan) 52 SMALL DENSE LDL, CRP-HS AND INSULIN RESISTANCE ASSOCIATION IN 504 POSTMENOPAUSE G. Berg, M.L. Muzzio, V. Zago, V. Miksztowicz, F. Basilio, R. Wikinski, L. Schreier (Buenos Aires, Argentina) 53 ATHEROGENIC INDEX OF PLASMA (AIP) IS AN EFFECTIVE PREDICTOR OF 504 CARDIOVASCULAR RISK M. Dobiasova, J. Frohlich (Prague, Czech Republic and Vancouver, BC, Canada) 54 CELL ADHESION MOLECULES IN LEUKOCYTES FROM PRIMARY 504 HYPERTRIGLYCERIDEMIC PATIENTS F. Brites, M. Benítez, M. Fornari, V. Berardi, L. Gómez, L. Schreier, G. Elikir, P. Stutzbach, L. Cuniberti, R. Wikinski (Buenos Aires, Argentina) 55 DEVELOPMENT OF A NOVEL METHOD TO DETERMINE VERY LOW DENSITY 504 LIPOPROTEIN (VLDL) KINETICS I.A. Alshayji, J.M.R. Gill, M.J. Caslake (Glasgow, UK) 56 DGAT1 MEDIATES THE EFFECT OF THE MODY1 GENE HNF4A ON HEPATIC 505 SECRETION OF TRIGLYCERIDE-RICH LIPOPROTEINS S. Krapivner, A. Silveira, A. Hamsten, F.M. van't Hooft (Stockholm, Sweden) 57 HIGHER MITOCHONDRIAL RESTING RESPIRATION AND INCREASED WHOLE BODY 505 CO2 PRODUCTION AND BODY TEMPERATURE IN HYPERTRIGLYCERIDEMIC TRANSGENIC MICE L.C. Alberici, H.C.F. Oliveira, A.E. Vercesi (Campinas, Brazil) 58 PROTEOME ANALYSIS OF HYPERTRIGLYCERIDEMIC RABBITS 505 M. Harada-Shiba, N. Minamino, H. Kuwahara, T. Itoh, R. Maeda, M. Ohira, E. Abe, K. Jinno, H. Tomoike (Suita and Yamagata, Japan) 59 DIAGNOSTIC VALIDITY OF PLASMA CONTENTS OF THE ALCOHOLS CHOLESTEROL 505 AND GLYCEROL V.N. Titov, D.M. Lisitzyn (Moscow, Russia) 60 PLASMA TRIGLYCERIDES AND LIPOPROTEINS IN DYSLIPIDAEMIC PATIENTS 505 K.K. Anagnostopoulou, G.D. Kolovou, K.D. Salpea, D.S. Damaskos, T.E. Chimonas, V.N. Giannakopoulou, G.C. Hatzigeorgiou, D. Manolopoulou, D.V. Cokkinos (Athens, Greece) T 61 COMPARISON OF THE EFFECTS OF GLIMEPIRIDE AND GLIBENCLAMIDE ON LIPID 506 METABOLISM IN PATIENTS WITH TYPE 2 DIABETES H J. Matsui, Y. Ogawa, N. Tamasawa, K. Matsuki, J. Tanabe, H. Murakami, T. Suda U (Hirosaki, Japan) R 62 PLASMA APOAV LEVELS ARE MARKEDLY ELEVATED IN SEVERE 506 S HYPERTRIGLYCERIDEMIA AND ARE POSITIVELY CORRELATED WITH THE APOA5 S19W POLYMORPHISM D P. Henneman, F.G. Schaap, L.M. Havekes, P.C.N. Rensen, R.R. Frants, A. van Tol, A H. Hattori, A.H.M. Smelt, K. Willems van Dijk (Leiden, Amsterdam, Rotterdam, Y The Netherlands and Saitama, Japan)

172 63 HIGH SERUM TESTOSTERONE LEVEL IS ASSOCIATED WITH A FAVORABLE LIPID 506 PROFILE - THE TROMSØ STUDY I. Agledahl, P.A. Skjærpe, J.B. Hansen, J. Svartberg (Tromsø, Norway) 64 OBESITY OR OVERWEIGHT AND HYPERTENSION OF MEN 506 R.-M. Korth (Munich, Germany) 65 DEFICIENT ANTIOXIDATIVE ACTIVITY OF SMALL HIGH-DENSITY LIPOPROTEINS 507 (HDL3) IN HYPERTRIGLYCERIDEMIC LOW HDL-CHOLESTEROL (HDL-C) DYSLIPIDEMIA H. Hussein, L. Tokgözoglu, S. Chantepre, M. Alikasifoglu, E. Ozturk, M.J. Chapman, A. Kontush (Paris, France and Ankara, Turkey) 66 CHANGES IN LIPID AND APOLIPOPROTEIN E DISTRIBUTION INDUCED BY 507 LIPOPROTEIN LIPOLYSIS IN VIVO IN HYPERTRIGLYCERIDEMIA A.D. Dergunov, A. Ponthieux, D. Lambert, S. Visvikis, G. Siest (Moscow, Russia and Nancy, France) 67 HYPERTRIGLYCERIDEMIA OCCURS THROUGH ARTERIO-VENOUS SHUNT 507 FOLLOWED BY MICROCIRCULATION DISTURBANCES IN ARTERIOLES - PERFUSION METABOLISM THEORY M. Tsushima, Y. Kakuta, Y. Ishida, Y. Ikeda, S. Kyotani (Atami, Ise and Suita, Japan) 68 DIFFERENCES IN VLDL PRODUCTION IN IMPAIRED GLUCOSE TOLERANCE, TYPE 2 507 DIABETES AND FAMILIAL COMBINED HYPERLIPIDEMIA U.A. Julius, J. Pietzsch (Dresden and Rossendorf, Germany) 69 A NEW CASE OF APOLIPOPROTEIN C-II DEFICIENCY IN FAMILIAL CHYLOMICRONEMIA 507 M. Hoffmann, J. Wiegand, A. Schneider, H. Wieland, K. Winkler (Freiburg, Leipzig and Hannover, Germany) 70 INSULIN STIMULATES THE RECYCLING OF APOLIPOPROTEIN E VIA THE LOW 508 DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN 1 (LRP1) A. Laatsch, M. Sornsakrin, U. Beisiegel, J. Heeren (Hamburg, Germany) 71 REDUCED GENERATION OF REACTIVE OXYGEN SPECIES BY CIRCULATING 508 LYMPHOMONONUCLEAR CELLS AND ENDOTHELIAL CELLULAR MODEL IN POST-PRANDIAL STATE F.L. Sodré, B.A. Paim, A. Urban, A.E. Vercesi, E.C. Faria (São Paulo, Brazil) 72 DENSITY PROFILING OF TRIGLYCERIDE RICH LIPOPROTEINS AND THEIR REMNANTS 508 R. Chandra, R. Macfarlane (College Station, TX, USA) 73 HIGH FAT MEAL INDUCES A PRO-OXIDANT AND PRO-INFLAMMATORY 508 CIRCULATING ENVIRONMENT AND IS PRO-APOPTOTIC FOR ENDOTHELIAL CELLS C. Barisione, P. Altieri, I. Tracchi, P. Fabbi, P. Spallarossa, C. Brunelli, G. Ghigliotti, S. Garibaldi (Genoa, Italy) 74 POSTPRANDIAL LIPEMIA INDUCES IMPAIRMENT IN ANTIOXIDATIVE ACTIVITY OF 509 SMALL HIGH-DENSITY LIPOPROTEIN (HDL) PARTICLES F.L. Sodré, E.C. Faria, S. Chantepie, M.J. Chapman, A. Kontush (Paris, France and São Paulo, Brazil) 75 EFFECTS OF ANABOLIC ANDROGENIC STEROIDS ON CHYLOMICRON METABOLISM 509 A.T. Morikawa, M.J. Alves, C.E. Negrão, C.G. Puk, J.L. Silva, R.C. Maranhão, C.G. Vinagre (São Paulo, Brazil) 76 CONCENTRATION OF APOLIPOPROTEIN B48 IN FASTING SERUM IS AN IMPORTANT 509 MARKER OF POSTPRANDIAL HYPERLIPIDEMIA H. Takenaka, M. Kinoshita, T. Maeda, M. Taki, K. Takao, J. Kusano, N. Yoshimura, M. Fujita, T. Teramoto (Itabashi, Japan) 77 METABOLIC SYNDROME AND GENDER DIFFERENCES IN POSTPRANDIAL LIPAEMIA 509 K.D. Salpea, G.D. Kolovou, K.K. Anagnostopoulou, A.N. Pavlidis, S. Iraklianou, D.P. Mikhailidis, I.S. Hoursalas, K. Sorondila, D.V. Cokkinos (Athens, Piraeus, Greece and London, UK) 78 EFFECT OF BITTERN ON POSTPRANDIAL HYPERLIPEMIA 509 Y. Kishimoto, C. Yanagisawa, M. Hasegawa, N. Machida, E. Yoshioka, M. Tani, T. Kido, T H. Uto, K. Yokota, K. Kondo (Tokyo, Japan) 79 NEW ASSAY FOR REMNANT LIPOPROTEIN CHOLESTEROL USING SELECTIVE 510 H DETERGENTS AND PHOSPHOLIPASE D - CLINICAL SIGNIFICANCE IN POSTPRANDIAL U HYPERLIPIDEMIA R M. Ishigami, S. Yamashita, N. Sakai, K. Miyauchi, T. Yamamura (Suita, Itami and S Sunto-Gun, Japan) 80 EFFECT OF PLANT STEROL INTAKE ON POSTPRANDIAL HYPERLIPEMIA 510 D M. Hasegawa, Y. Kishimoto, M. Usuda, C. Yanagisawa, N. Machida, E. Yoshioka, T. Kido, A H. Uto, Y. Masuda, K. Kondo (Bunkyo-ku, Japan) Y

173 81 GENDER DIFFERENCES IN POSTPRANDIAL LIPAEMIA IN PATIENTS WITH FAMILIAL 510 HYPERCHOLESTEROLAEMIA G.D. Kolovou, K.K. Anagnostopoulou, K.D. Salpea, D.S. Damaskos, G.C. Hatzigeorgiou, A.N. Pavlidis, T.E. Chimonas, V.N. Giannakopoulou, D.V. Cokkinos (Athens, Greece) 82 PITAVASTATIN IMPROVED POSTPRANDIAL HYPERTRIGLYCERIDEMIA CAUSED BY 510 THE ACCELERATED INTESTINAL LIPID ABSORPTION IN CD36 DEFICIENCY D. Masuda, K. Hirano, Y. Tochino, T. Kuwasako, C. Ikegami, M. Koseki, Y. Nakagawa-Toyama, Z. Zhang, I. Shimomura, S. Yamasita (Osaka, Japan) 83 CHYLOMICRON APOB48 IS INCREASED IN DIABETIC PATIENTS 510 T. Matsushima, R. Fujita, K. Kinoshita, T. Teramoto (Tsukuba and Tokyo, Japan) 84 TRIAL BREAKFAST WITH AN ENTERAL NUTRITION FORMULA FOR DIABETES RICH 511 IN MONOUNSATURATED FATS A. Sanz-Paris, A. Rodriguez, M.A. Navarro, A. Caverni, J. Osada, A. Garcia de Jalon, A. Barragan, R. Albero (Zaragoza, Spain) 85 SUBSTITUTING DIACYLGLYCEROL FOR TRIACYLGLYCEROL REDUCES 511 POSTPRANDIAL LIPEMIA IN SUBJECTS WITH INSULIN RESISTANCE - DATA FROM META-ANALYSIS N. Tada, H. Takase, H. Yoshida, H. Yanai, K. Shoji, T. Hase, I. Tokimitsu (Kashiwa and Tokyo, Japan) 86 FASTING SERUM APOLIPOPROTEIN B-48 LEVEL CAN BE A GOOD MARKER OF 511 POSTPRANDIAL HYPERLIPIDEMIA AND CORONARY HEART DISEASE S. Yamashita, T. Sugimoto, K. Hirano, M. Hori, Y. Masuda, T. Okuno, Y. Uchida, K. Matsumoto, T. Kawamoto, N. Sakai (Suita, Tokyo, Kure and Itami, Japan) 87 INCREASED CONCENTRATIONS OF POSTPRANDIAL TRIGLYCERIDE-RICH 511 LIPOPROTEINS AND DECREASED LIPOPROTEIN LIPASE ACTIVITY IN OFFSPRING OF MI PATIENTS S. Lekhal, T. Boervik, A. Nordoy, J.B. Hansen (Tromsoe, Norway) 88 BETA-AMYLOID, A COMPONENT OF SENILE PLAQUES IN ALZHEIMER’S IS ASSOCIATED 512 WITH PLASMA LIPOPROTEINS, PARTICULARLY THOSE ENRICHED WITH TRIGLYCERIDE J.C. Mamo, A.P. James, L. Jian, L. Flicker, P. Lewczuk, J. Wiltfgang (Perth, WA, Australia and Nuremberg, Germany) 89 POSTPRANDIAL PLASMA TRIGLYCERIDE RESPONSE TO DIETARY FAT DIFFERS IN 512 DIABETIC AND NON-DIABETIC SUBJECTS M. Wilke, E. Ryan, M. French, Y. Goh, M. Clandinin (Edmonton, AL, Canada) 90 DIETARY SODIUM CHLORIDE RESTRICTION RAISES FASTING AND POSTPRANDIAL 512 LIPIDS IN HYPERTENSIVE PATIENTS A.M. Charf, F.C. Santos, K. Ortega, A.M. Lottenberg, D. Mion Jr., T. Nakano, K. Nakajima, V.S. Nunes, E.C.R. Quintao, E.R. Nakandakare (São Paulo, Brazil and Guma, Japan) 91 EFFICIENCE OF TRIGLYCERIDES / HDL-CHOLESTEROL RATIO IN COMPARISON TO 512 HOMA AND QUICKI VALUES AS ATHEROGENIC MARKERS T. Martinez Leme da Rocha, J. Nogueira Filho (São Paulo, Brazil) 92 RELATIONSHIP OF TRIGLYCERIDES CONCENTRATIONS IN THE COMPARISONS TO 513 HOMOGENEOUS LDL-C ASSAY WITH FRIEDEWALD FORMULA H. Nascimento Maria Do, W. Salgado Filho, O. Denardin Victor Porto, T. Martinez Leme da Rocha (São Paulo, Brazil) 93 CILOSTAZOL REDUCES EXPRESSION OF SCAVENGER RECEPTOR A AND UPTAKE 513 OF OXIDIZED LOW-DENSITY LIPOPROTEIN IN MACROPHAGES R. Okutsu, H. Takase, G. Miyakoda, T. Mori (Tokushima, Japan) 94 ACTIVATION OF PRO-SURVIVAL AKT SIGNALLING BY PHOSPHOLIPASE A2-TREATED 513 LDL IN THP1 CELLS D. Namgaladze, B. Brüne (Frankfurt, Germany) T 95 THE CELLULAR RETINOIC ACID BINDING PROTEIN II GENE (CRABP-2) IS 513 ASSOCIATED WITH INCREASED PLASMA CHOLESTEROL IN THREE DIFFERENT H GROUPS OF POPULATION U J. Salazar, M. Guardiola, R. Ferré, B. Coll, C. Alonso-Villaverde, B. Winklhoffer-Roob, R E. Rock, J.D. Fernàndez-Ballart, L. Masana, J. Ribalta (Reus, Spain, Graz, Austria and S St. Genes Champanelle, France) 96 APOLIPOPROTEIN A-V INTERACTION WITH MEMBERS OF THE LOW DENSITY 514 D LIPOPROTEIN RECEPTOR GENE FAMILY A S.K. Nilsson, A. Lookene, J.B. Beckstead, J. Gliemann, R.O. Ryan, G. Olivecrona Y (Umeå, Sweden, Tallinn, Estonia, Oakland, CA, USA and Aarhus, Denmark)

174 97 IDENTIFICATION OF APOLIPOPROTEIN A-I AS A PLASMA LIGAND FOR 514 MACROPHAGE SCAVENGER RECEPTOR A C. Neyen, A. Plüddemann, B. Thomas, A. Akoulitchev, L. Cai, D. Van Der Westhuyzen, R. Sim, S. Gordon (Oxford, UK and Lexington, KY, USA) 98 MACROPHAGE SCAVENGER RECEPTOR 1 IS ASSOCIATED WITH ATHEROSCLEROSIS 514 SUSCEPTIBILITY IN HUMANS R. Durst, Y. Neumark, A. Polack, M. Musseri, R. Beeri, H. Dannenberg, Y. Friedlander, E. Leitersdorf, V. Meiner, H. Lotan (Jerusalem, Israel) 99 ALPHA-TOCOPHEROL INTERFERES WITH THE REGULATION OF CD36 AND ABCA1 IN 514 MACROPHAGES, KEY RECEPTORS OF PLAQUE REGRESSION IN THE VESSEL WALL S. Rode, R. Lorenz (Munich, Germany) 100 MACROPHAGE FOAM CELL FORMATION MEDIATED BY RECEPTOR-INDEPENDENT 515 MACROPINOCYTOSIS OF NATIVE LDL H. Kruth, B. Zhao, C. Buono, Y. Li, S. Waldo, N. Jones (Bethesda, MD, and Winston-Salem, NC, USA) 101 FUNCTIONAL ANALYSIS OF CHIMAERAS OF THE LOW DENSITY- AND VERY LOW 515 DENSITY LIPOPROTEIN RECEPTORS (LDLR AND VLDLR) D.D. Patel, D. Norman, B.L. Knight, A.K. Soutar (London, UK) 102 INACTIVATION OF THE NPXYXXL DOMAIN OF THE LOW-DENSITY LIPOPROTEIN 515 RECEPTOR RELATED PROTEIN 1 SHOWS INCREASED ATHEROSCLEROSIS P. Gordts, A. Lauwers, N. Feyaerts, S. Reekmans, A. Roebroek (Leuven, Belgium) 103 THE DI-LEUCINE MOTIF CONTRIBUTES TO CLASS A SCAVENGER 515 RECEPTOR-MEDIATED UPTAKE OF ACETYLATED LIPOPROTEINS Q. Chen, Y.Y. Chen, X.H. Wang, J.J. Beng (Nanjing, China) 104 TRIGLYCERIDE-RICH LIPOPROTEINS DERIVED FROM POMACE OLIVE OIL HAVE 515 DIFFERENTIAL EFFECTS ON THE EXPRESSION OF mRNA FOR MACROPHAGE RECEPTORS R. Cabello-Moruno, J.S. Perona, E. Montero, M. Avella, K.M. Botham, V. Ruiz-Gutierrez (Seville, Spain and London, UK) 105 HUMAN PDZK1 INCREASE HUMAN SRBI (CLA-1) EXPRESSION IN THE MOUSE LIVER 516 H. Komori, Y. Ueda, T. Kita (Kyoto, Japan) 106 ADVANCED GLYCATION END PRODUCTS (AGE), IN CONTRAST TO OXLDL, DO NOT 516 STIMULATE MACROPHAGE GENE EXPRESSION VIA CD36 J. Martin, S. Collot-Teixeira, C. McDermott-Roe, S. Clogenson, J.L. McGregor (London, UK and Paris, France) 107 HIGH GLUCOSE ENHANCES THE EXPRESSION OF CD36 AND THE LIPID 516 ACCUMULATION IN THP-1 MACROPHAGES Y.L. Tan, G.H. Yi, Y. Zeng, L. Sun, J.T. Feng, D.X. Zeng, X.B. Yin, J. Wang, J.H. Xia, A.P. Chen (Hengyang, China) 108 REGULATION OF THE CD36 EXPRESSION AND CHOLESTEROL INFLUX IN THP-1 516 MACROPHAGE BY PPAR G.H. Yi, Z.C. Mo, X. Chen, Z. Wang, Z. Ren, C.K. Tang, L.S. Liu, Y.Z. Yang (Hunan, China) 109 CLA-1 AND ITS SPLICING VARIANT CLA-2 MEDIATE BACTERIAL ADHESION AND 517 CYTOSOLIC BACTERIAL INVASION IN MAMMALIAN CELLS T.G. Vishnyakova, A.P. Patterson (Bethesda, MD, USA) 110 CD36 AND SRA FINGERPRINTING IN CAROTID ENDARTERECTOMY LESIONS 517 S. Collot-Teixeira, F. Bultelle, G. Pasterkamp, C. Barbatis, A. Tedgui, J.L. McGregor (London, UK, The Utrecht, Netherlands, Athens, Greece and Paris, France) 111 APOLIPOPROTEIN E (APOE) INTERRUPTS INTERLEUKIN-1 BETA (IL-1) SIGNALING IN 517 VASCULAR SMOOTH MUSCLE CELLS (VSMC) J.-R. Nofer, A. Kawamura, D. Baitsch, G. Assmann (Münster, Germany) 112 A 14 KDA PROTEIN IS DOMINANTLY APPEARED IN HDL SUB-FRACTION WITH 517 T DECREASING APOA-I FROM SERUM OF A PATIENT WITH HEMORRHAGIC FEVER WITH RENAL SYNDROME H S.H. Park, J.E. Park, Y.K. Kim, K.J. Song, S.S. Kim, S.E. You, K.H. Cho U (Gyeongsan and Seoul, South Korea) R 113 COMBINED EFFECT OF SERUM APOLIPOPROTEIN E CONCENTRATION AND 517 S POLYMORPHISM ON SERUM LIPID PARAMETERS IN HEMODIALYSIS PATIENTS E. Liberopoulos, G. Miltiadous, M. Cariolou, K.C. Siamopoulos, M. Elisaf D (Ioannina, Greece and Nicosia, Cyprus) A 114 CHANGES OF LOW DENSITY LIPOPROTEIN IN CHRONIC HAEMODIALYSIS PATIENTS 518 Y H. Lahrach, H. Taki, H. Lebrazi, H. Souhaili, L. Er-Rachdi, A. Derouiche, B. Ramdani, N. Ghalim, R. Saile (Casablanca, Morocco)

175 115 CONNECTION BETWEEN SERUM PARAOXONASE ACTIVITY, POLYMORPHISM AND 518 CYSTATIN C ,HOMOCYSTEINE,LIPIDS CONCENTRATIONS IN RENAL FAILURE L. Locsey, I. Seres, A. Dan, B. Borbas, G. Paragh (Debrecen, Hungary) 116 HIGH-SENSITIVITY C- REACTIVE PROTEIN, HOMOCYSTEINE AND CARDIOVASCULAR 518 DISEASES RISK IN CHRONIC HAEMODIALYSIS PATIENTS H. Lahrach, N. Ghalim, H. Taki, H. Lebrazi, R. Aarab, H. Souhaili, A. Derouiche, B. Ramdani, R. Saile (Casablanca, Morocco) 117 HYPLIP2, A NEW LOCUS INVOLVED IN LIPID AND GLUCOSE METABOLISM 518 C.J.A. Moen, A.P. Tholens, P.C.N. Rensen, P.J. Voshol, X. Wang, P. Gargalovic, L.M. Havekes, R.R. Frants, A.J. Lusis, M.H. Hofker (Leiden, Maastricht, The Netherlands and Los Angeles, CA, USA) 118 USE OF INTRALIPID FOR KINETIC ANALYSIS OF HDL APOC3: EVIDENCE FOR A 519 HOMOGENEOUS KINETIC POOL OF APOC3 IN PLASMA M.N. Nguyen, D.C. Chan, G.F. Watts, P.H.R. Barrett (Perth, WA, Australia) 119 THE INCORPORATION OF LYCOPENE IN THE CHYLOMICRON REMNANTS 519 DECREASES THEIR UPTAKE BY THE LIVER F. Bejta, M. Napolitano, C. Pranteda, E. Bravo, K. Botham (London, UK and Rome, Italy) 120 HIGH PLASMA LEVEL OF REMNANT-LIKE PARTICLE CHOLESTEROL IN THE 519 METABOLIC SYNDROME A. Satoh, H. Adachi, Y. Hirai, A. Hiratsuka, M. Enomoto, K. Furuki, A. Hino, T. Takeuchi, T. Imaizumi (Kurume, Japan) 121 DEVELOPMENT AND APPLICATION OF A NEW ASSAY SYSTEM FOR APOLIPOPROTEIN 519 B-48 (APO B-48): APO B-48 LEVEL MAY BE A USEFUL MARKER OF CORONARY HEART DISEASE Y. Sakai, K. Moriyama, T. Okuno, H. Miyakoshi, S. Kitajima, K. Yamamoto, N. Sakai, S. Yamashita (Tokyo, Hyogo and Osaka, Japan) 122 THE RELATION OF CHILDREN AND ADOLESCENT OBESITY AND REMNANT 519 LIPOPROTEIN S.H. Choi, D.J. Kim, H.J. Kim, Y.S. Chung, K.W. Lee (Seongnam and Suwon, South Korea) 123 DYSLIPIDEMIA IN DIABETIC NEPHROPATHY:LIPIDIC PROFILE IN RENAL CHRONIC 520 DISEASE PATIENTS J.R. Generoso, Jr., A.R. Gomes, W.L. Medina, I.M. Miura, L.M. Harada (Mogi das Cruzes and Botucatu, Brazil) 124 THE RESEARCH OF PROGRESS FACTORS ON CHRONIC KIDNEY DISEASE (CKD) – 520 ASSOCIATED WITH ATHEROSCLEROSIS H. Fukae, T. Ishihara, E. Hayashi, Y. Imadu, T. Hiratuka, Y. Fujiura, I. Ikushima, J. Ishizaki, M. Ageta (Nichinan City, Japan) 125 DIET INDUCED OBESITY IN C57BL/6 MICE IS ASSOCIATED WITH SUBSTANTIAL 520 ALTERATIONS IN FATTY ACID COMPOSITION IN DIFFERENT ORGANS AND PLASMA LIPOPROTEINS J. Heeren, K. Tödter, K. Seedorf, G. Niederfellner, L. Scheja, U. Beisiegel (Hamburg, Germany) 126 ALDOSE REDUCTASE REGULATES THE PRO-ATHEROGENIC EFFECTS OF OXIDIZED 520 PHOSPHOLIPIDS A. Bhatnagar, M. Spite, Y. Ahmed, S. Srivastava (Louisville, KY, USA) 127 ROLE OF MALONDIALDEHYDE-MODIFIED LOW-DENSITY LIPOPROTEIN IN 520 RESTENOSIS AFTER PERCUTANEOUS CORONARY INTERVENTION J. Tashiro, K. Kotani, K. Yamazaki, Y. Nakamura, A. Miyazaki, H. Bujo, Y. Saito (Ichihara, Tokyo and Chiba, Japan) 128 IMMUNE RESPONSES AGAINST ALDEHYDE-MODIFIED FIBRONECTIN AND 521 ATHEROSCLEROSIS T P. Dunér, E. Bengtsson, F. To, R. Alm, G. Berglund, J. Nilsson (Malmö, Sweden) 129 TO STUDY THE MECHANISMS AND THE EFFECTS OF LYCOPENE ON LIPID 521 H PEROXIDATION INJURE IN HYPERLIPEMIA RABBITS U X.Y. Tang, X.D. Yang, L. Wang, W.Q. Sun, F. Guo, H. He, L. Ding, S.L. Qu, C. Xiao R (Hengyang, China) S 130 AQUEOUS EXTRACT FROM MARRUBIUM VULGARE, INHIBITS LOW-DENSITY 521 LIPOPROTEIN OXIDATION AND PROMOTES CHOLESTEROL EFFLUX D H. Berrougui, I. Maxim, M. Cherki, A. Khalil (Sherbrooke, QC, Canada) A 131 THE ROLE OF OXIDIZED LOW DENSITY LIPOPROTEIN (OXLDL) DERIVED ANTIGENS 521 Y AND IGG AUTOANTIBODIES IN CORONARY ARTERY DISEASE (CAD) D.F.J. Ketelhuth, G.C. Tonini, M.D.T. Carvalho, P. Boschcov, R.F. Ramos, M. Gidlund (Stockholm, Sweden and São Paulo, Brazil)

176 132 THE STIMULATORY EFFECTS OF LOW DENSITY LIPOPROTEIN ON STEROIDOGENESIS 522 IN ADRENOCORTICAL CELLS DECLINE WITH IN VITRO OXIDATION AND IN VIVO MODIFICATION S. Kopprasch, I. Ansurudeen, A.W. Krug, J. Pietzsch, J. Graessler, S.R. Bornstein (Dresden, Germany) 133 ALDEHYDES DERIVED FROM LIPOPROTEIN OXIDATION INDUCE AP2/FABP4 522 EXPRESSION IN HUMAN MACROPHAGES I. Lazaro, A. Cabre, J. Girona, L. Masana (Reus, Spain) 134 OXIDIZED LDL AS A BIOCHEMICAL MARKER OF POLYCYSTIC OVARY SYNDROME 522 D. Macut, S. Damjanovic, D. Panidis, N. Spanos, I. Bozic, B. Popovic, M. Petakov, S. Ognjanovic, T. Isailovic, J. Bjekic (Belgrade, Serbia-Montenegro and Thessaloniki, Greece) 135 A DUPLICITOUS ROLE FOR HIGH DENSITY LIPOPROTEIN SUBFRACTIONS IN 522 LIPOPROTEIN OXIDATION P.A.C. McPherson, I.S. Young, J. McEneny (Belfast, UK) 136 COMPARATIVE EFFECTS OF LOW FAT MEAT VS. WALNUT ENRICHED MEAT ON 523 LDL-CHOLESTEROL AND OX-LDL IN INCREASED CHD-RISK SUBJECTS M. Nus, J. Librelotto, M. Rodero, C. Cuéllar, A. Canales, J.M. Sánchez-Montero, F.J. Sánchez-Muniz (Madrid, Spain) 137 PARAMETERS OF OXIDATIVE STRESS AND ENDOTHELIAL DYSFUNCTION IN 523 CORONARY ATHEROSCLEROSIS MEN Yu.I. Ragino, V. Polonskaya, E.V. Sadovski (Novosibirsk, Russia) 138 EFFECTS OF AMINO ACIDS ON THE RATE OF OXIDATION OF LOW DENSITY 523 LIPOPROTEIN BY IRON AT PH 4.5 L. Satchell, A. Islam, M. Hamed, J. Sharp, I.S. McCue, A.B. Gerry, D.S. Leake (Berkshire, UK) 139 OXIDIZED LDL RECEPTOR LOX-1 IS INVOLVED IN HIGH FAT DIET-INDUCED 523 LIPID-DEPOSITION UNDER HYPERTENSION T. Sawamura, F. Sugawara, A. Nakano (Suita, Japan) 140 EFFECT OF LIPOPHILIC MODIFICATION OF RUTIN WITH MONO- AND 523 POLY-UNSATURATED FATTY ACIDS ON ITS ANTIOXIDANT POTENCY L.D. Tsironis, A. Polydera, H. Stamatis, A.D. Tselepis (Ioannina, Greece) 141 FLUFENAMIC ACID AND ITS 5-HYDROXY-METABOLITE INHIBIT THE SPECIFIC 524 OXIDATION OF LDL BY THE MYELOPEROXIDASE / H2O2/CL- SYSTEM P. Van Antwerpen, K. Zouaoui Boudjeltia, I. Legssyer, S. Babar, P. Moreau, N. Moguilevsky, M. Vanhaeverbeek, J. Ducobu, J. Neve (Brussels, Montigny-Le-Tilleul, Gosselies and La Louvière, Belgium) 142 CHOLESTEROL EFFLUX FROM OXIDIZED LDL LOADED MACROPHAGES 524 E. Favari, F. Zimetti, A.E. Bortnick, M.P. Adorni, I. Zanotti, M. Canavesi, F. Bernini (Parma and Milan, Italy) 143 INCREASED MYELOPEROXIDASE LEVEL IN CORONARY ARTERY DISEASE AND ITS 524 RELATIONSHIP WITH SEVERITY OF THE DISEASE B. Yavuz, A. Deniz, L. Tokgozoglu, O. Duzguncinar, E. Demirpence, T. Bayrak, A. Bayrak, K. Aytemir (Ankara, Turkey) 144 ENHANCED LIPID PEROXIDATION AND PLATELET ACTIVATION AS POTENTIAL 524 CONTRIBUTORS TO INCREASED CARDIOVASCULAR RISK IN THE LOW-HDL PHENOTYPE G. Davì, F. Santilli, A. Ganci, C.M. Barbagallo, V. Davì, A.B. Cefalu', S. Lattanzio, D. Noto, G. Ciabattoni, M. Averna (Chieti and Palermo, Italy) 145 CIRCULATING OXIDIZED LDL IS INVERSELY ASSOCIATED WITH THE ABILITY OF 525 HDL TO INACTIVATE OXIDIZED PHOSPHOLIPIDS P.G. Scheffer, J.M. Dekker, H.P.A. Vermue, L.P. van der Zwan, G. Nijpels, M. Diamant, T R.J. Heine, T. Teerlink (Amsterdam, The Netherlands) 146 LOW-DENSITY LIPOPROTEIN OXIDATION BY MYELOPEROXIDASE OCCURS IN THE 525 H BLOOD CIRCULATION DURING HEMODIALYSIS U M. Vaes, K. Zouaoui Boudjeltia, P. van Antwerpen, S. Babar, F. Deger, J. Neve, R M. Vanhaeverbeek, J. Ducobu (Montigny-Le-Tilleul, La Louvière and Brussels, Belgium) S 147 PLATELETS MODIFY LDL THROUGH GP91PHOX-DEPENDENT O2- FORMATION 525 R. Carnevale, L. Lenti, B. Buchetti, V. Sanguigni, P. Rossi, A. Finocchi, P. Pignatelli, D F. Violi (Rome, Italy) A 148 LIPID PEROXIDATION IN PATIENTS WITH RETINAL ARTERY ARTERIOSCLEROSIS 525 Y A. Javadzadeh, A. Ghorbanihaghjo, N. Rashtchizadeh (Tabriz, Iran)

177 149 THE MAIN COMPONENTS CONTRIBUTING TO THE ANTIDEPRESSANT ACTION OF 525 ST. JOHN´S WORT ARE INHIBITORS OF LOW-DENSITY LIPOPROTEIN ATHEROGENIC MODIFICATIONS H. Laggner, S. Schreier, M. Hermann, M. Exner, B. Gmeiner, S. Kapiotis (Vienna and Neunkirchen, Austria) 150 REACTIVE OXYGEN SPECIES GENERATION IN PERIPHERAL BLOOD MONOCYTES 526 AND OXIDIZED LDL ARE INCREASED IN HYPERCHOLESTEROLEMIC PATIENTS E.M. Albuquerque, G.R. Degasperi, L.S. Kato, A.E. Vercesi, E.C. de Faria, H.C.F. Oliveira, L.N. Castilho (Campinas, Brazil) 151 OZONIZED LOW DENSITY LIPOPROTEIN INHIBITS NF-KB AND IRAK-1-ASSOCIATED 526 SIGNALING C. Cappello, B. Saugel, K.C. Huth, A. Zwergal, M. Krautkrämer, C. Furman, M. Rouis, D. Neumeier, K. Brand (Munich, Germany and Lille, France) 152 LDL RESISTANCE TO COPPER-INDUCED OXIDATION: EFFECT OF LDL LIPID 526 COMPOSITION S. Baldi, A. Natali, S. Frascerra, E. Ferrannini (Pisa, Italy) 153 EVALUATION OF THE EFFECTS OF CIGARETTE ON THE LIPID PEROXIDATION, 526 VALUES OF HBA1C, QUANTITATIVE CRP AND CONJUGATED DIENES (CDS) S. Asgary, Gh. Naderi (Isfahan, Iran) 154 AEROBIC EXERCISE TRAINING REDUCES THE PRE-BETA 1 HDL GENERATION AND 527 ENHANCES THE HDL3 ANTIOXIDANT ROLE IN TYPE 2 DIABETES MELLITUS SUBJECTS I.C.D. Ribeiro, R.T. Iborra, M.Q.T.S. Neves, S.A. Lottenberg, A.M. Charf, V.S. Nunes, C.E. Negrao, E.C.R. Quintao, E.R. Nakandakare, M. Passarelli (São Paulo, Brazil) 155 AEROBIC EXERCISE TRAINING CORRECTS THE HDL2 AND IMPROVES THE HDL3 527 ANTIOXIDANT EFFECTS IN TYPE 2 DIABETES MELLITUS BUT NOT IN HEALTHY CONTROLS R.T. Iborra, I.C.D. Ribeiro, M.Q.TS.. Neves, A.M. Charf, S.A. Lottenberg, C.E. Negrao, E.R. Nakandakare, E.C.R. Quintao, M. Passarelli (São Paulo, Brazil) 156 SODIUM HYPOCHLORITE GENERATES LYSOPHOSPHOLIPIDS IN HUMAN 527 LIPOPROTEINS. A MALDI-TOF MASS SPECTROMETRIC STUDY O. Zschörnig, J. Schiller (Leipzig, Germany) 157 ASPIRIN IS A SUBSTRATE FOR PARAOXONASE–LIKE ACTIVITY: IMPLICATIONS IN 527 ATHEROSCLEROSIS N. Santanam, S. Parthasarathy (New Orleans, LA, USA) 158 ABILITY OF HUMAN SERUM PARAOXONASE TO HYDROLYZE POTENTIAL ATHEROGENIC 527 SUBSTRATES AND ITS IMPLICATION IN CARDIOVASCULAR DISEASES E. Frank, P. Jaichander, C.J.M. D Souza, S. Parthasarathy (Karnataka, India and New Orleans, LA, USA) 159 LACK OF ASSOCIATION BETWEEN SERUM PARAOXONASE 1 ACTIVITY AND CIRCULATING 528 OXIDIZED LOW-DENSITY LIPOPROTEIN IN TYPE 2 DIABETIC PATIENTS D. Lucchesi, L. Pucci, C. Fotino, S. Triscornia, V. Longo, G. Penno, S. Del Prato, R. Miccoli (Pisa, Italy) 160 THE CORRELATION OF PARAOXONASE ENZYME ACTIVITY WITH ANGIOGRAPHIC 528 SEVERITY AND EXTENT OF CORONARY HEART DISEASE IN DIABETICS Z. Tartan, G. Orhan, H. Kasikcioglu, S. Unal, F. Ciloglu, H. Uyarel, E. Okmen, N. Cam, S. Aykut (Instanbul, Turkey) 161 OXIDATIVELY MODIFIED HDL2 IS SUPERIOR TO NATIVE HDL2 IN PROVIDING 528 CHOLESTEROL TO LYMPHOCYTES N. Sakuma, T. Saeki, K. Kobayashi, S. Mukai, S. Sakata, H. Mizuno, T. Kato, M. Kunimatsu, G. Kimura (Nagoya, Japan) 162 15-LIPOXYGENASE-MEDIATED MODIFICATION OF HIGH DENSITY LIPOPROTEINS 528 T IMPAIRS SR-BI- AND ABCA1-DEPENDENT CHOLESTEROL EFFLUX FROM MACROPHAGES A. Pirillo, P. Uboldi, H. Kuhn, A.L. Catapano (Milan, Italy and Berlin, Germany) H 163 INCREASED MACROPHAGE OXIDATIVE STRESS VIA-NADPH-OXIDASE ACTIVATION 529 U AND IMPAIRED CHOLESTEROL FLUXES IN DIABETIC MICE: ROLE OF CELLULAR R GLUCOSE UPTAKE S T. Hayek, M. Kaplan, R. Karry, M. Aviram (Haifa, Israel) 164 THE PROTECTIVE IMPACTS OF TOCOTRIENOLS ON LDL OXIDIZABILITY AND 529 D ACCELERATED ATHEROSCLEROSIS INDUCED BY OXIDIZED CHOLESTEROL IN A CHOLESTEROL FED RABBITS Y M. Zainuddin, W. Ali, Z.H. Beg (Aligarh, India)

178 165 STUDY OF THE EFFECT OF VITAMIN E ON THE PREVENTION OF LDL OXIDATION BY 529 MYELOPEROXIDASE S.Z. Samsam Shariat, M. Taher, F. Khakpour (Isfahan, Iran) 166 THE 7-OXYSTEROLS, AT ATHEROMA RELEVANT PROPORTION, CONFER 529 SYNERGISTIC AND PRO-APOPTOTIC EFFECT IN VITRO D.A. Larsson, S. Baird, J.D. Nyhalah, W. Li, X.M. Yuan (Linköping, Sweden) 167 EFFECT OF OX-LDL ON STROMAL CELL DERIVED-FACTOR 1A EXPRESSION IN RAT 529 VSMCs Z. Wang, Y.C. Lv, G.H. Li, X.F. Zhou, Y.F. Tian, C.K. Tang, Y.L. Tu, G.X. Wang (Chongqing and Hunan, China) 168 CONTROL OF LP(A) WITH DIET AND SUPPLEMENTS: ACCOMPLISHING THE IMPOSSIBLE! 530 S.R. Gundry, W.E. Ehrman (Palm Springs, CA, USA) 169 EFFICACY OF OMEGA-3 FATTY ACIDS IN LOWERING LIPOPROTEIN(A) LEVELS: A 530 PRELIMINARY STUDY R. Marcucci, F. Sofi, S. Ferrini, A. Capalbo, I. Lapini, A. Abdihakim, E. Sticchi, D. Prisco, R. Abbate, G.F. Gensini (Florence, Italy) 170 PLASMA LIPOPROTEIN (A) LEVELS AND LDL-CHOLESTEROL LOWERING RESPONSE 530 TO STATIN THERAPY IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA G. Miltiadous, M. Cariolou, Z. Mitrogianni, M. Doumas, V. Saougkos, E. Bairaktari, M. Elisaf (Ioannina, Greece and Nicosia, Cyprus) 171 LIPOPROTEIN(A) AND PERIPHERAL ARTERIAL DISEASE BY ANKLE/BRACHIAL 530 INDEX: DATA FROM THE INCHIANTI STUDY G.B. Vigna, S. Volpato, G. Zuliani, S. Bandinelli, A.M. Corsi, F. Lauretani, R. Fellin, J.M. Guralnik, L. Ferrucci (Ferrara, Italy, Bethesda and Baltimore, MD, USA) 172 LP(A) SERUM LEVEL IS INCREASED BY SIMVASTATIN AND REDUCED BY 530 SIMVASTATIN PLUS L-CARNITINE IN TYPE 2 DIABETES A. Capurso, V. Solfrizzi, C. Capurso, A.M. Colacicco, A. D'Introno, F. Panza (Bari, Italy) 173 LP(A) CONCENTRATION IN 38-41 WEEK TERM NEWBORNS AND THEIR 531 RELATIONSHIP TO SERUM AND LIPOPROTEIN CHOLESTEROL LEVELS E. Gesteiro, A. Fernández de los Rios, S. Bastida, F.J. Sánchez-Muniz (Badajoz and Madrid, Spain) 174 POLYMORPIC FORMS OF HUMAN APO-LIPOPROTEIN(A) IN HEALTHY POPULATION 531 OF REPUBLIC OF MACEDONIA B. Todorova, K. Tosheska, D. Labudovic, S. Alabakovska, I. Todorov (Skopje, Macedonia) 175 THE SHORT-TERM EFFECT OF HIGH-DOSE STATIN ON LP(A) IN PATIENTS TREATED 531 WITH CORONARY ARTERY BYPASS GRAFTING I.M. Poulsen, S. Riahi, E. Toft, J.H. Christensen, E.B. Schmidt (Aalborg, Denmark) 176 ASSOCIATION OF LIPOPROTEIN(A) WITH CORONARIOGRAPHY PATTERN IN YOUNG 531 SURVIVORS OF MYOCARDIAL INFARCTION (MI) E. Zorio, P. Cubillo, C. Falcó, L. Ramón, J. Rueda, A. Osa, M. Palencia, A. Salvador, A. Estellés, F. España (Valencia, Spain) 177 DIAGNOSTIC VALUE OF SIMULTANEOUS DETERMINATION OF LIPIDS PROFILE, 532 LIPID PEROXIDATION AND LP(A) IN CORONARY HEART DISEASES N. Rashtchizadeh, A. Ghorbanihaghjo, M. Rohbaninoubar, A. Vatankhah, D. Agaverdizadeh (Tabriz, Iran) 178 CORRELATION BETWEEN BLOOD VALUES OF THE LIPOPROTEIN (A) AND DEGREE OF 532 STENOSIS OF THE CORONARY BLOOD VESSELS M. Noshpal, V. Arsova, J. Lovcanska, M. Otljanska, B. Sidovska, S. Malikovska (Skopje, Macedonia) 179 LIPOPROTEIN (A) PLASMA LEVEL, RHEUMATOLOGIC DISEASE AND ALLERGIC 532 DISEASE T A.F.G. Cicero, M. Bove, A. Lucicesare, S. Linarello, L. Laghi, A.V. Gaddi (Bologna, Italy) 180 SIGNIFICANT REDUCTION OF LIPOPROTEIN(a) LEVEL IN LPA-TRANSGENIC MICE 532 H AFTER TREATMENT WITH AN ANTISENSE INHIBITOR OF THE LPA GENE U K. Eliassen, P.A. Teivainen-Lædre, A. Svindland, L.S. Nissen-Meyer, R.M. Crooke, R M.J. Graham, K. Berg (Oslo, Norway and Carlsbad, CA, USA) S 181 IMPLICATIONS OF LOW HDL-C AND HIGH HOMOCYSTEINE LEVELS FOR LEFT 533 VENTRICULAR AKINESIS IN PATIENTS WITH ACUTE CORONARY SYNDROME D M. Dluzniewski, E. Burbicka, E. Kostarska-Srokosz, W. Braksator, H. Bukowska, A K. Chelstowski, M. Naruszewicz (Warsaw and Szczecin, Poland) Y

179 182 IS SERUM HDL A PROGNOSTIC INDICATOR IN CRITICALLY ILL PATIENTS WITH 533 STRESS HYPERGLYCAEMIA? A. Jones, A. Barnett, D. Mullhi, F. Gao (Birmingham, UK) 183 LOW HIGH-DENSITY LIPOPROTEIN CHOLESTEROL PREDISPOSES TO INCREASED 533 INFLAMMATORY AND COAGULATION RESPONSES UPON ENDOTOXIN INFUSION IN VIVO R. Birjmohun, S. van Leuven, C. van 't Veer, H. Levels, R. Bisoendial, J. Meijers, T. van der Pol, M. Levi, J. Kastelein, E. Stroes (Amsterdam, The Netherlands) 184 HDL CHOLESTEROL MAY PARTICIPATE IN CHOLESTEROL EFFLUX FROM 533 ERYTHROCYTE MEMBRANES - A NOVEL ATHEROPROTECTIVE MECHANISM D.N. Tziakas, J.C. Kaski, G.K. Chalikias, C. Romero, S. Fredericks, I.K. Tentes, A.X. Kortsaris, D.I. Hatseras, D.W. Holt (Alexandroupolis, Greece and London, UK) 185 HIGH-DENSITY LIPOPROTIEN TRANSPORT IN THE METABOLIC SYNDROME: 534 APPLICATION OF A NEW MODEL FOR HDL PARTICLE KINETICS J. Ji, G.F. Watts, A.G. Johnson, D.C. Chan, E.M.M. Ooi, K.A. Rye, A.P. Serone, P.H.R. Barrett (Perth, WA, Sydney, NSW, Australia and King of Prussia, PA, USA) 186 FUNCTIONAL AND METABOLIC CHARACTERISTICS OF HDL IN HEALTHY SUBJECTS 534 AND CARDIOVASCULAR DISEASE (CVD) PATIENTS A.X. Medina-Urrutia, O.A. Perez-Mendez, C. Huesca-Gomez, J. Zamora-Gonzalez, C. Posadas-Romero (Mexico City, Mexico) 187 SMALL HIGH-DENSITY LIPOPROTEIN (HDL) PARTICLES POTENTLY PROTECT 534 HUMAN ENDOTHELIAL CELLS AGAINST APOPTOSIS INDUCED BY OXIDISED LOW DENSITY LIPOPROTEIN J.A. de Souza, C. Vindis, S. Chantepie, A. Negre-Salvayre, R. Salvayre, M.J. Chapman, A. Kontush (Paris and Toulouse, France) 188 HIGH INTERLEUKIN-6 PLASMA LEVELS ARE ASSOCIATED WITH LOW HIGH- DENSITY 534 LIPOPROTEIN CHOLESTEROL IN COMMUNITY-DWELLING OLDER ADULTS: THE INCHIANTI STUDY G. Zuliani, S. Volpato, A. Ble', S. Bandinelli, A.M. Corsi, F. Lauretani, G. Paolisso, R. Fellin, L. Ferrucci (Ferrara, Florence, Naples, Italy and Baltimore, MD, USA) 189 POSTER WITHDRAWN – 190 INCREASED APOLIPOPROTEIN A-I TURNOVER RATE INDUCED BY 535 ESTROGENS-PROGESTINS G. Dautin, L. Duvillard, E. Florentin, P. Gambert, B. Verges (Dijon, France) 191 FUNCTIONAL ASPECTS OF HDL IN PATIENTS WITH POLYCYSTIC OVARY 535 SYNDROME (PCOS) R.F. Amâncio, M.P. Rocha, J.A. Marcondes, C.R. Barcellos, M.C. Latrilha, R.C. Maranhão (São Paulo, Brazil) 192 HDL AND THEIR CONSTITUENT S1P ACUTELY PROTECT AGAINST MYOCARDIAL 535 INFARCTION IN VIVO VIA THE S1P3 SPHINGOLIPID RECEPTOR P. Keul, G. Theilmeier, J. Herrmann, J. Larmann, J. Mersmann, G. Heusch, R. Erbel, J. Chun, B. Levkau (Essen, Münster, Germany, Rochester, MN and La Jolla, CA, USA) 193 ROLE OF PLASMA PHOSPHOLIPID TRANSFER PROTEIN ACTIVITY IN DETERMINING 535 HDL KINETICS IN VIVO E.M.M. Ooi, G.F. Watts, J. Ji, K.A. Rye, A.G. Johnson, D.C. Chan, P.H.R. Barrett (Perth, WA, Sydney, NSW, Australia and King of Prussia, PA, USA) 194 USING HUMAN-MOUSE COMPARATIVE GENOMICS TO FIND NEW GENES 535 REGULATING PLASMA HDL CHOLESTEROL LEVELS J. Rollins, Y. Chen, B. Paigen, X. Wang (Bar Harbor, ME, USA) 195 TWO NOVEL MUTATIONS CAUSING LCAT DEFICIENCY IN A SARDINIAN PATIENT 536 S.A. Muntoni, S. Rust, L. Atzori, S.E. Muntoni, G. Assmann (Cagliari, Italy and T Münster, Germany) 196 EFFECTS OF OXIDIZED AND/OR GLYCOSYLATED MODIFICATIONS ON CHOLESTEROL 536 H EFFLUX MEDIATED BY HIGH DENSITY LIPOPROTEIN IN CHOLESTEROL-LOADED U U937 CELLS R G.H. Yi, X.B. Yin, Y. Zeng, Y.L. Tan, J.T. Feng, L. Sun, D.X. Zeng, J. Wang, J.H. Xia, S Z. Ren (Hengyan, China) 197 NEWLY DEVELOPED RECONSTITUTED HIGH-DENSITY LIPOPROTEIN CONTAINING 536 D SPHINGOSINE-1-PHOSPHATE INDUCES ENDOTHELIAL TUBE FORMATION A Y. Matsuo, S. Miura, Y. Kiya, Y. Uehara, S. Imaizumi, K.A. Rye, K. Saku (Fukuoka, Japan Y and Sydney, NSW, Australia)

180 198 IMPAIRED SECRETION OF TWO APOLIPOPROTEIN A-I MUTANTS ASSOCIATED WITH 536 HEREDITARY AMYLOIDOSIS M. Marchesi, C. Parolini, V. Bellotti, P. Mangione, C. Valetti, L. Obici, G. Chiesa (Milan, Pavia and Genoa, Italy) 199 MODULATION OF PENTRAXIN 3 EXPRESSION IN ENDOTHELIAL CELLS: ROLE OF HDL 537 P. Marchesi, G.D. Norata, A. Mantovani, M. Fazia, F. Cipollone, A. Mezzetti, G. Chiesa, A.L. Catapano (Milan, Cinisello Balsamo and Chieti, Italy) 200 CETP AND GROUP IIA SPLA2 LIBERATE BIOACTIVE SAA FROM HDL 537 A. Jahangiri, J. Witta, M.C. de Beer, D.R. van der Westhuyzen, F.C. de Beer (Lexington, KY, USA) 201 ROLE OF SPHINGOSINE-1 PHOSPHATE AND ITS RECEPTORS IN THE INDUCTION 537 OF CYCLOOXYGENASE-2 (COX-2) MEDIATED BY HDL J. Martínez-González, M. González-Díez, C. Rodríguez, L. Badimon (Barcelona, Spain) 202 TRANSFER OF LIPIDS FROM A CHOLESTEROL-RICH NANOEMULSION TO HIGH 537 DENSITY LIPOPROTEIN IN PATIENTS WITH TYPE 2 DIABETES T. Seydell, G. Feitosa-Filho, C.G. Puk, C.H.M. Azevedo, A.C. Lo Prete, J.A. Ramires, R.C. Maranhao (São Paulo, Brazil) 203 ABNORMAL HDL SUBCLASSES DISTRIBUTION IN CHILDREN WITH TYPE 2 DIABETES 537 MELLITUS AND INSULIN RESISTANCE OBESITY O. Pérez-Méndez, M. Torres-Tamayo, C. Posadas-Romero, J. Zamora-González, V. Vidaure Garcés (Mexico City, Mexico) 204 PATIENTS WITH CORONARY SLOW FLOW HAVE AN ABNORMAL LIPID AND 538 APOLIPOPROTEIN PROFILE K. Kostner, D. Colquhoun, J. Franco, S. Moir, J. Sharman, T. Marwick (Brisbane, QLD, Australia) 205 APOLIPOPROTEIN E SECRETION FROM HUMAN MACROPHAGES OCCURS VIA A 538 MICROTUBULE- AND CALCIUM-DEPENDENT PATHWAY M. Kockx, E. Jary, M. Hill, W. Jessup, L. Kritharides (Sydney, NSW, Australia) 206 APOLIPOPROTEIN A-II INDUCES HDL FORMATION BY MACROPHAGES OF CONTROL 538 AND HUMAN APO A-II-TRANSGENIC MICE X. Rousset, N. Fournier, L. Fourchaud, D. Pastier, J.L. Paul, J. Chambaz, M. Chabert, A.D. Kalopissis (Paris, France) 207 PLASMA PLTP ACTIVITY DECREASES IN TYPE 2 DIABETES DURING TREATMENT 538 WITH ATORVASTATIN; AN IMPORTANT ROLE FOR APOLIPOPROTEIN E A. van Tol, G.M. Dallinga-Thie, H. Hattori, E.J.G. Sijbrands (Rotterdam, The Netherlands and Saitama, Japan) 208 HIGH-DENSITY LIPOPROTEIN PREVENTS AND RESCUES MONOCYTIC PMA-INDUCED 539 ACTIVATION OF MAC-1 K. Woollard, A. Murphy, D. Sviridov, J. Chin-Dusting (Melbourne, VIC, Australia) 209 MAST CELLS CHANGE CELLULAR CHOLESTEROL CONTENTS AND INHIBIT CHOLESTEROL 539 EFFLUX FROM THP-1 MACROPHAGE-DERIVED FOAM CELLS Z.Z. Zhao, Y. Z. Yang, S. Wang, B.H. Dong, Z. Wang, D.H. Wei, L.S. Liu (Hengyang, China) 210 ENHANCED UPTAKE OF ACETYLATED LDL-CHOLESTEROL BUT NOT CELL 539 CHOLESTEROL EFFLUX RATES BY TOLL-LIKE RECEPTOR 4 KNOCK OUT MICE PERITONEAL MACROPHAGES P.M. Cazita, M.D.T. Carvalho, E.C.R. Quintao, H.P. De Souza (Sao Paulo, Brazil) 211 SERUM AMYLOID A GENERATES HDL IN AN ABCA1- OR ABCA7-DEPENDENT MANNER 539 S. Abe-Dohmae, Y. Kumon, W. Hu, H. Ishigami, N. Iwamoto, M. Okazaki, K. Ueda, S. Yokoyama (Nagoya, Nankoku, Ichikawa and Kyoto, Japan) 212 AGE-RELATED IMPAIRMENT OF HDL-MEDIATED CHOLESTEROL EFFLUX 539 H. Berrougui, M. Isabelle, M. Cloutier, A. Khalil (Sherbrooke, QC, Canada) 213 REDUCED CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY IN WOMEN 540 MODIFIES THE POSTPRANDIAL METABOLISM OF TRIGLYCERIDE-RICH LIPOPROTEINS AND FATTY ACIDS T A. Urban, R. Schreiber, H. Oliveira, E. de Faria (Campinas, Brazil) 214 CHARACTERIZATION OF BONE MARROW-DERIVED MACROPHAGES FOR STUDIES OF 540 H CHOLESTEROL EFFLUX IN VITRO AND REVERSE CHOLESTEROL TRANSPORT IN VIVO U I.V. Fuki, D.S. Chang, A.H. Faruqi, D.A. Cromley, J.T. Billheimer, X. Wang, M. Jaye, R G.H. Rothblat, D.J. Rader (Philadelphia and King of Prussia, PA, USA) S 215 MACROPHAGE CHOLESTEROL EFFLUX AND LDL ANTIOXIDANT EFFECTS ELICITED 540 BY HUMAN HDL SUBFRACTIONS ARE NOT ALTERED BY DIFFERENCES IN DIETARY D FATTY ACIDS A V. Buonacorso, R.T. Iborra, V.S. Nunes, E.R. Nakandakare, M. Passarelli, A.M.P. Lottenberg Y (São Paulo, Brazil)

181 216 PHOSPHOLIPID TRANSFER PROTEIN (PLTP) DEFICIENCY IMPAIRS 540 ABCA1-DEPENDENT EFFLUX OF CHOLESTEROL FROM MACROPHAGE FOAM CELLS M. Lee-Rueckert, R. Vikstedt, J. Metso, C. Ehnholm, P. Kovanen, M. Jauhiainen (Helsinki, Finland) 217 BIDIRECTIONAL FLUX OF CHOLESTEROL BETWEEN CELLS AND SERUM 541 F. Zimetti, G. Kellner-Weibel, G.H. Rothblat (Philadelphia, PA, USA) 218 GLYCATION OF LIPID-FREE APOLIPOPROTEIN A-I IMPAIRS CHOLESTEROL EFFLUX 541 FROM MACROPHAGES B.E. Brown, E. Nobecourt, K.A. Rye, M.J. Davies (Sydney, NSW, Australia) 219 ABCA1 AND ABCG1 ACT SEQUENTIALLY TO MEDIATE CHOLESTEROL EXPORT TO 541 APOA-I I. Gelissen, M. Harris, K.A. Rye, C.M. Quinn, A.J. Brown, M. Kockx, S. Cartland, M. Packianathan, L. Kritharides, W. Jessup (Sydney, NSW, Australia) 220 IDENTIFICATION OF THE cAMP-RESPONSIVE ENHANCER OF THE MURINE ABCA1 541 GENE: REQUIREMENT FOR CREB1 AND STAT3/4 ELEMENTS W. Le Goff, P. Zheng, G. Brubaker, J.D. Smith (Paris, France, Cleveland, OH and New York, NY, USA) 221 ANTHOCYANINS INDUCE CHOLESTEROL EFFLUX FROM MOUSE PERITONEAL 541 MACROPHAGES W. Ling, M. Xia, M. Hou, H. Zhu, J. Ma (Guangz, China) 222 IDENTIFICATION OF DISTINCT SITES OF ABCA1 INVOLVED IN CHOLESTEROL 542 EFFLUX FROM HUMAN MACROPHAGES N. Mukhamedova, Y. Fu, D. Sviridov (Melbourne, NSW, Australia) 223 BOTH HEPATIC AND EXTRAHEPATIC ABCA1 ARE ESSENTIAL FOR THE MAINTENANCE 542 OF PLASMA HDL-C LEVELS IN VIVO R.R. Singaraja, M. Van Eck, C. Fievet, M.R. Hayden (Vancouver, BC, Canada, Leiden, The Netherlands and Lille, France) 224 SIMULTANEOUS TRANSFER TO HDL OF CHOLESTEROL, TRIGLYCERIDES AND 542 PHOSPHOLIPIDS IN AGING AND CORONARY ARTERY DISEASE C.H.M. Azevedo, C.G. Puk, G. Feitosa-Filho, A.C. Lo Prete, T. Seydell, J. Diament, M. Wajngarten, R.C. Maranhao (Sao Paulo, Brazil) 225 REDUCED CHOLESEROL EFFLUX MAY BE THE CAUSE OF REDUCED PLASMA 542 HDL-C LEVELS IN A PATIENT WITH SPHINGOMYELINASE DEFICIENCY K. Matsuki, N. Tamasawa, S. Takayasu, J. Tanabe, H. Murakami, J. Matsui, T. Suda (Hirosaki, Japan) 226 ABCA1-INDEPEDENT APOLIPOPROTEIN E SECRETION BY MACROPHAGES DERIVED 543 FROM A PATIENT WITH TANGIER DISEASE H. Murakami, N. Tamasawa, K. Matsuki, J. Tanabe, J. Matsui, T. Suda (Aomori, Japan) 227 ALTERATION OF ATP BINDING CASSETTE TRANSPORTER A1 ON LIVER IN 543 ATHEROSCLEROTIC MINIPIGS C.K. Tang, X.Y. Dai, X. Ou, J.H. Yang, D.L. Cao, X.R. Hao, G.H. Yi, Z. Wang, L.S. Liu, Y.Z. Yang (Hengyang, China) 228 PARAOXONASE1 MODULATES HDL-MEDIATED CHOLESTEROL EFFLUX CAPACITY 543 H. Berrougui, I. Maxim, A. Khalil (Sherbrooke, QC, Canada) 229 APOLIPOPROTEIN A-I ACTIVATES ABCA1 GENE TRANSCRIPTION AND PROTEIN 543 SYNTHESIS J.H. Yang, C.K. Tang, X.Y. Dai, X. Ou, Z.Q. Wang, Z.S. Jiang, D.L. Cao, X.R. Hao, G.H. Yi, Z. Wang (Hengyang, China) 230 EFFECTS OF A NOVEL SYNTHETIC HDL ON CHOLESTEROL EFFLUX IN VITRO 543 C. Cramer, G. Fici, S. Tummala, B. Krause, R. Homan (Ann Arbor, MI, USA) 231 INFLUENCES OF THE SR-BI EXPRESSION BY OX-LDL, LDL AND HDL IN HEPG2 AND 544 T THP-1 CELLS Z.C. Mo, G.H. Yi, X. Chen, Z. Wang, Z. Ren, C.K. Tang, L.S. Liu, Y.Z. Yang (Hunan, China) H 232 IN VIVO MACROPHAGE CHOLESTEROL EXPORT CORRELATES WITH REGRESSION 544 U OF AORTIC LESIONS AND MAY SERVE AS A BIOMARKER FOR HUMAN R ANTI-ATHEROGENIC AGENTS S R. Kisilevsky, R. Tan, J.B. Ancsin, P.M. Kim, R. Bender, S.P. Tam (Kingston and Ottawa, ON, Canada) 233 HUMAN IMMUNODEFICIENCY VIRUS IMPAIRS REVERSE CHOLESTEROL 544 D TRANSPORT FROM MACROPHAGES A M. Bukrinsky, Z. Mujawar, M.P. Morrow, J.M. Orenstein, Y.V. Bobryshev, D. Sviridov Y (Washington, DC, USA, Sydney, NSW and Melbourne, VIC, Australia) 234 POSTER WITHDRAWN –

182 235 INCREASED TRIGLYCERIDES LEVELS DRIVE FAECAL STEROL EXCRETION IN 544 FAMILIAL COMBINED HYPERLIPIDEMIA K. Elharchaoui, R.J. Bisoendial, G.K. Hovingh, J.A. Kuivenhoven, E.S.G. Stroes, J.J.P. Kastelein, A.K. Groen (Amsterdam, The Netherlands) 236 COMBINING ACAT INHIBITION AND CHOLESTEROL ESTERASE ENHANCEMENT 544 RESULTS IN MARKED EXPORT OF MACROPHAGE CHOLESTEROL IN VIVO S.P. Tam, R. Tan, P.M. Kim, R. Kisilevsky (Kingston and Ottawa, ON, Canada) 237 CLINICAL CHARACTERISTICS OF PORTUGUESE PATIENTS WITH A CLINICAL 545 DIAGNOSIS OF FAMILIAL HYPERCHOLESTEROLAEMIA M. Bourbon, A.C. Alves, J.M. Silva, Q. Rato, P.M. Silva, I. Azevedo, A. Furtado, R.P. Naoumova (Lisbon, Coimbra, Madeira, Matosinhos, Portugal and London, UK) 238 DESCRIPTIVE STUDY OF FAMILIAL HYPERCHOLESTEROLEMIA IN HAVANA CITY 545 A. Nasiff-Hadad, E. Merino-Ibarra, A. Herrera-Gonzalez (Havana City, Cuba) 239 HIGH FREQUENCY OF CORONARY HEART DISEASE IN JAPANESE PATIENTS WITH 545 TYPE III HYPERLIPOPROTEINEMIA M. Eto, M. Saito (Koriyama, Japan) 240 THE EFFECT OF AGEING AND OBESITY ON THE EXPRESSION OF DYSLIPIDEMIA IN 545 CHILDREN FROM FCH FAMILIES E. ter Avest, A.D. Sniderman, S.J.H. Bredie, A.F.H. Stalenhoef, J. de Graaf (Nijmegen, The Netherlands and Montreal, QC, Canada) 241 ASSESSMENT OF TOCOPHEROL METABOLISM AND OXIDATIVE STRESS IN 546 HETEROZYGOUS FAMILIAL HYPOBETALIPOPROTEINAEMIA M.W. Clarke, A.J. Hooper, H.A. Headlam, J.H.Y. Wu, K.D. Croft, J.R. Burnett (Perth, WA, Australia) 242 ASSESSMENT OF CLINICAL AND NUTRITIONAL PARAMETERS IN SUBJECTS WITH 546 FAMILIAL HYPERCHOLESTEROLAEMIA PRESENTING OR NOT CORONARY ARTERY DISEASE A. Macedo, A.P. Marte, M. Miname, KI. Sebastiao, A. Avila, M. Isosaki, R.D. Santos (São Paulo, Brazil) 243 PERIODONTAL DISEASE IN HYPERCHOLESTEROLEMIA FAMILIAL SUBJECTS: 546 PRELIMINARY RESULTS C. Vieira, M. Miname, L. Martinez, A. P. Marte, L. Bortolotto, B. Caramelli, R. D. Santos (São Paulo, Brazil) 244 CAROTID INTIMA-MEDIA THICKNESS DIFFERENCES BETWEEN FAMILIAL 546 HYPERCHOLESTEROLEMIA AND FAMILIAL COMBINED HYPERLIPIDEMIA E. Jarauta, D. Recalde, A. Cenarro, P. Martín-Fuentes, AL. García-Otín, F. Civeira (Zaragoza, Spain) 245 ANTI-ATHEROGENC FACTOR IN HYPERLIPIDEMIC DOWN SYNDROME CHILDREN-A 546 STUDY IN INDIAN POPULATION R. Singh, P. Goyal, J. Bhattacharjee, A.K. Dutta (New Delhi, India) 246 ANTIOXIDANT ENZYME ACTIVITIES IN PATIENTS WITH HYPERLIPIDEMIA: POSSIBLE 547 INDICATORS FOR HYPERLIPIDEMIA J.J. Bogdanska, B.B. Todorova, P. Korneti, D.D. Labudovic (Skopje, Macedonia) 247 TENDON XANTHOMAS IN FAMILIAL HYPERCHOLESTEROLEMIA ARE ASSOCIATED 547 WITH A PRO-INFLAMMATORY CYTOKINES PROFILE IN MACROPHAGES TO OXIDIZED LDL P. Martin-Fuentes, M. Artieda, D. Recalde, A.L. Garcia-Otin, E. Jarauta, A. Cenarro, F. Civeira (Zaragoza, Spain) 248 COMPUTATIONAL APPROACHES TOWARDS PREDICTION 547 K. Hübner, T. Schwager, K. Winkler, J.G. Reich, H.G. Holzhütter (Berlin and Freiburg, Germany)

T H U R S D A Y

183 POSTER AREA “A” THURSDAY, June 22 249-417

POSTER DISPLAY: for the duration of one day (Thursday, June 22 from 8.30 am to 4.00 pm). Participants may view the posters displayed during this day.

POSTER DISCUSSION: one of the authors will be available at the poster site as follows: Thursday, June 22: from 10.30 am to 11.00 am Thursday, June 22: from 12.30 pm to 2.00 pm

Th-P16 Poster Session 16 poster PHARMACOLOGICAL CONTROL OF LIPIDS abstract bk. board no.: page ref.: AND LIPOPROTEINS

249 AN ACAT1 SELECTIVE INHIBITOR, K-604 DIRECTLY REGULATES 547 ATHEROSCLEROTIC LESIONS. A COMPARISON STUDY WITH THE ACAT1/2 NON-SELECTIVE INHIBITOR CS-505 Y. Yoshinaka, H. Kobayashi, M. Ikenoya, K. Shibuya, H. Kuriyama, T. Yokoyama, F. Sato, K. Sawanobori (Higashimurayama, Japan) 250 CO-TREATMENT WITH SMP-797 AND ATORVASTATIN PROVIDED SUPERIOR 548 CHOLESTEROL-LOWERING EFFECT COMPARED TO MONOTHERAPY K. Kino, K. Ioriya, N. Noguchi (Osaka, Japan) 251 SMP-797, A NEW CLASS OF HYPOLIPIDEMIC DRUGS, INCREASED THE LDL 548 RECEPTOR ACTIVITY VIA ITS ADAPTOR PROTEIN K. Kino, K. Ioriya, N. Imanishi, T. Noguchi (Osaka, Japan) 252 SMP-797, A NEW CLASS OF HYPOLIPIDEMIC DRUGS, INDUCED THE REGRESSION 548 OF PREFORMED ATHEROSCLEROTIC LESIONS, INDEPENDENTLY OF THE LIPID-LOWERING EFFECT K. Ioriya, K. Kino, T. Noguchi (Osaka, Japan) 253 SMP-797, A NEW CLASS OF HYPOLIPIDEMIC DRUGS, REDUCED AND STABILIZED 548 ATHEROSCLEROTIC LESIONS IN WATANABE HERITABLE HYPERLIPIDEMIC (WHHL) RABBITS K. Ioriya, K. Kino, T. Noguchi (Osaka, Japan) 254 THE INFLUENCE OF THERAPY WITH SIMVASTATIN IN DIFFERENT DOSES ON 548 TOLERANCE TO PHYSICAL LOADING IN PATIENTS WITH ACUTE CORONARY SYNDROME E.N. Amosova, P.A. Lazarev, I.S. Kovalyova, E.V. Andreyev, E.M. Yaremenko (Kiev, Ukraine) 255 EFFECT OF PRAVASTATIN ON SYMPATHETIC INNERVATION IN HYPERLIPIDEMIC 549 RABBITS N.C. Chang, M.S. Lin, T.M. Lee (Taipei and Tainan, Taiwan) 256 HYPOLIPIDEMIC AND ANTI-ATHEROSCLEROTIC EFFECTS OF A SQUALENE SYNTHASE 549 INHIBITOR, TAK-475, IN WHHLMI RABBITS M. Shiomi, S. Yamada, Y. Amano, T. Nishimoto, T. Ito (Kobe and Osaka, Japan) 257 SIMVASTATIN TREATMENT REDUCES ANGIOTENSIN II TYPE-1 RECEPTOR MRNA 549 EXPRESSION IN HUMAN LEUKOCYTES OF HIGH-RISK SUBJECTS L. Guasti, F. Marino, M. Cosentino, M. Ferrari, M. Cimpanelli, C. Crespi, L. Maroni, R.C. Maio, S. Lecchini, A. Venco (Varese, Italy) 258 LACK OF PHARMACOKINETIC INTERACTIONS OF AN ANTISENSE OLIGONUCLEOTIDE, 549 TARGETING HUMAN APOB, WHEN COADMINISTERED WITH SIMVASTATIN & EZETIMIBE, T IN MAN R. Geary, R. Yu, J. Bradley, E. Chuang, M. Wedel, A. vanVliet (Carlsbad, CA, USA and Assen, H The Netherlands) U 259 EFFECT OF TORCETRAPIB COMBINED WITH ATORVASTATIN ON HDL-C AND LDL-C 550 R LEVELS, PARTICLE SIZE, AND COMPOSITION: A PHASE 2 DOSE-RANGING CLINICAL TRIAL S T. Thuren, A. Longcore, C. Powell, J. Strand, K. Durham, C.L. Shear (New London, CT and Ann Arbor, MI, USA) D 260 INHIBITION OF CETP BY TORCETRAPIB RAISES HDL-C AND LOWERS LDL-C 550 A INDEPENDENT OF GENDER OR BASELINE HDL-C LEVELS Y J.H. Revkin, K. Durham, C.L. Shear, T.T. Nguyen (New London, CT, USA)

184 261 ENHANCED LDL-C-LOWERING EFFECT OF TORCETRAPIB WHEN ADMINISTERED 550 WITH ATORVASTATIN TO SUBJECTS WITH HIGH BASELINE TRIGLYCERIDE LEVELS J.H. Revkin, C.L. Shear (New London, CT, USA) 262 THE CAPACITY OF HDL TO STIMULATE CHOLESTEROL EFFLUX IS MAINTAINED IN 550 SUBJECTS WITH AND WITHOUT LOW HDL-C TREATED WITH TORCETRAPIB M.J. Bamberger, M.D. Moya, K. Durham, C.L. Shear, T.T. Nguyen, J.H. Revkin, G.H. Rothblat (Groton, CT, and Philadelphia, PA, USA) 263 TORCETRAPIB INHIBITS CHOLESTERYL ESTER TRANSFER PROTEIN AND 551 INCREASES HDL IN CETP.APOE*3-LEIDEN TRANSGENIC MICE W. de Haan, C.C. van der Hoogt, C.M. van den Hoogen, G.M. Dallinga-Thie, H.M.G. Princen, J.W. Jukema, L.M. Havekes, P.C.N. Rensen (Leiden and Rotterdam, The Netherlands) 264 IMPACT OF A MAJOR RANDOMIZED CLINICAL TRIAL ON LDL CHOLESTEROL LEVELS 551 IN THE AGGRESSIVE REDUCTION OF INFLAMMATION STOPS EVENTS (ARISE) TRIAL J.C. Tardif, M.A. Pfeffer, J.J.V. McMurray, E. Klug, R. Scott, D.H.G. Smith, J.A. Smith, R.D. Small (Montreal, QC, Canada, Boston, MA, Alpharetta, GA, Tustin, CA, USA, Glasgow, UK and Sunninghill, South Africa) 265 EFFECT OF ETHNIC ORIGIN, GENDER AND AGE ON BASELINE BLOOD CREATINE KINASE 551 K. Ferdinand, R. Neal, J. Ycas, M. Stein (New Orleans, LA, Houston, TX, Wilmington, DE, USA) 266 THE EFFECT OF RED YEAST RICE ON LIPIDS, INFLAMMATORY MARKERS AND 551 GLUCOSE IN SUBJECTS WITH MILD HYPERCHOLESTEROLEMIA AND MILDLY ELEVATED BLOOD GLUCOSE M.P. Bogsrud, L. Ose, G. Langslet, I. Ottestad, K. Retterstøl (Oslo, Norway) 267 RESULTS OF 3 NORTH AMERICAN TRIALS (ARIES, IRIS, STARSHIP) COMPARING 552 ROSUVASTATIN AND ATORVASTATIN IN AFRICAN AMERICANS, SOUTH ASIANS, AND HISPANICS P. Deedwania, K. Ferdinand, R. Lloret, J. Ycas, M. Stein (Fresno, CA, New Orleans, LA, Miami, FL, and Wilmington, DE, USA) 268 EFFECT OF DOSE AND DOSE SCHEDULE ON THE EFFICACY AND SAFETY OF AN 552 ANTISENSE INHIBITOR OF APOB IN VOLUNTEERS WITH MILD HYPERCHOLESTEROLEMIA J.J.P. Kastelein, J. Bradley, E. Chuang, M.W. Wedel, J. Su, R. Geary, R. Yu (Amsterdam, The Netherlands and Carlsbad, CA, USA) 269 INDICES OF OXIDATIVE STRESS AND INFLAMMATION DURING THE STATIN-FIBRATE 552 COMBINATION TREATMENT T. Vareka, M. Vecka, L. Janikova, M. Zeman (Prague, Czech Republic) 270 EFFICACY AND SAFETY OF ROSUVASTATIN PLUS EZETIMIBE IN HIGH-RISK 552 PATIENTS: RESULTS FROM THE EXPLORER STUDY C. Ballantyne, F. Sosef, E. Duffield (Houston, TX, USA and Macclesfield, UK) 271 EFFECTS OF ORLISTAT AND FENOFIBRATE COMBINATION ON LDL PHENOTYPE IN 553 OVERWEIGHT AND OBESE PATIENTS WITH METABOLIC SYNDROME. THE FENORLI STUDY T.D. Filippatos, D.N. Kiortsis, I. Gazi, E.N. Liberopoulos, M. Georgoula, M.S. Elisaf, A.D. Tselepis (Ioannina, Greece) 272 PROGNOSIS AT 6 MONTHS FOR CORONARY AND CEREBROVASCULAR PATIENTS: IMPACT 553 OF ANTIPLATELET AGENTS AND STATINS: RESULTS FROM THE PREVENIR III STUDY J. Ferrières, J.P. Cambou, C. Cantet, L. Guize (Toulouse and Paris, France) 273 FLUVASTATIN - EZETIMIBE COMBINATION THERAPY 553 J. Dvorakova, L. Taborsky, J. Hyanek, L. Dubska (Prague, Czech Republic) 274 CO-ADMINISTRATION OF EZETIMIBE AND SIMVASTATINE IN ACUTE MYOCARDIAL 553 INFARCTION O.S. Descamps, P. Montant, F. Chenot, P. Boyasis, O. Marcovitch, M. Blaimont, A. de Meester (Haine Saint Paul, Belgium) 275 EFFECTIVENESS OF TREATMENT WITH STATINS AND EZETIMIBE IN PATIENTS WITH 553 T HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIA M. Esteban-Salan, A. Guimon-Bardesi, JM. Viuda-Unceta (Vizcaya, Spain) H 276 EFFICACY AND SAFETY OF ROSUVASTATIN-EZETEMIBE COMBINATION FOR THE 554 U TREATMENT OF SEVERE HYPERCHOLESTEROLEMIA R E. Leibovitz, D. Gavish, R. Bitzur, H. Cohen, D. Harats (Holon, Tel Aviv and Ramat-Gan, Israel) S 277 EFFICACY AND SAFETY OF EZETIMIBE ADDED TO CURRENT THERAPY WITH 554 STATINS IN MOLECULARLY CHARACTERIZED FH PATIENTS D L. Pisciotta, P. Masturzo, A. Bellocchio, R. Fresa, L. Orsini, I. Colangeli, S. Bertolini A (Genoa and Rome, Italy) Y

185 278 EFFECTS OF ADDING FENOFIBRATE IN HIGH RISK PATIENTS WITH COMBINED 554 HYPERLIPIDEMIA NOT CONTROLLED BY PRAVASTATIN M. Farnier, J. Ducobu, L. Bryniarski (Dijon, France, La Louvière, Belgium and Cracov, Poland) 279 PARADOXICAL SEVERE REDUCTION OF HDL IN DIABETIC PATIENTS DURING 554 COMBINED ROSIGLITAZONE FIBRATE THERAPY C. Shapira, I. Fishman, S. Keidar (Haifa, Israel) 280 ATTAINMENT OF OPTIMAL NCEP ATP III TREATMENT GOALS IN HIGH-RISK 555 PATIENTS: DOSE COMPARISON OF EZETIMIBE/SIMVASTATIN AND ROSUVASTATIN M.H. Davidson, A.L. Catapano, C.M. Ballantyne, W.E. Brady, R.A. Gazzara, A. Tershakovec (Chicago, IL, Houston, TX, West Point, NY, USA and Milan, Italy) 281 EVALUATION OF THE EZETIMIBE/SIMVASTATIN TABLET COMPARED WITH 555 ATORVASTATIN OR ROSUVASTATIN ON C-REACTIVE PROTEIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA A.L. Catapano, C.M. Ballantyne, N. Abate, M.H. Davidson, W.E. Brady, R.A. Gazzara, A. Tershakovec (Milan, Italy, Houston, Dallas, TX, Chicago, IL and West Point, NY, USA) 282 A 'STEP-UP' DOSE COMPARISON OF THE EZETIMIBE/SIMVASTATIN SINGLE TABLET 555 VERSUS ATORVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA C.M. Ballantyne, N. Abate, Z. Yuan, R.A. Gazzara, A. Tershakovec (Houston, Dallas, TX, and West Point, NY, USA) 283 LIPID-ALTERING EFFICACY AND SAFETY OF EZETIMIBE/SIMVASTATIN VERSUS 555 ROSUVASTATIN IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA M.H. Davidson, A.L. Catapano, C.M. Ballantyne, W.E. Brady, R.A. Gazzara, A. Tershakovec (Chicago, IL, Houston, TX, West Point, NY, USA and Milan, Italy) 284 PERCENTAGE LDL-C REDUCTION AND NCEP-III GOAL ATTAINMENT IN A CHD/DIABETIC 556 PATIENT COHORT INITIATED ON EZETIMIBE/SIMVASTATIN VS ATORVASTATIN J.L. Vieira, G.M. Davies, D. Yin, E. Alemao, J. Cook, E. Moriguchi (Rio Grande do Su, Brazil, Blu Bell, PA, and Whitehouse Station, NJ, USA) 285 EFFECTS OF FISH OILS AND ATORVASTATIN ON THE KINETICS OF HDL APOA-I AND 556 APOA-II IN MEN WITH VISCERAL OBESITY D.C. Chan, G.F. Watts, M.N. Nguyen, P.H. R. Barrett (Perth, WA, Australia) 286 EFFECTS OF ROSUVASTATIN COMBINED WITH CANDESARTAN ON OXIDATIVE STRESS 556 AND INFLAMMATORY PARAMETERS IN DIABETES ACCELERATED ATHEROSCLEROSIS K. Jandeleit-Dahm, Y. Rajaram, S. Giunti, A. Calkin, V. Boolell, T. Allen, M.E. Cooper (Melbourne, VIC, Australia) 287 ROSIGLITAZONE AND GEMFIBROZIL MEDIATE LIPID AND GLUCOSE INDEPENDENT 556 ANTI-ATHEROGENIC AND RENOPROTECTIVE ACTIONS IN A MODEL OF EXPERIMENTAL DIABETES A.C. Calkin, S. Giunti, M. Lassila, J.M. Forbes, K.A. Jandeleit-Dahm, M.C. Thomas, M.E. Cooper, T.J. Allen (Melbourne, VIC, Australia) 288 TREATMENT OF ATHEROSCLEROTIC PATIENTS WITH CHRONIC LIVER DISEASES 556 BY THIOCTACID AND SILYMARIN V. Kapetivadze, V. Malatsidze, R. Tabukashvili, H. Chaava (Tbilisi, Georgia) 289 PERCENT LDL-C REDUCTION & NCEP-III GOAL ATTAINMENT WITH 557 EZETIMIBE/SIMVASTATIN VS ATORVASTATIN TITRATION IN CHD/DIABETIC PATIENTS NOT AT GOAL J.L. Vieira, G.M. Davies, E. Alemao, D. Yin, J. Cook, E. Moriguchi (Rio Grande do Su, Brazil, Blu Bell, PA, and Whitehouse Station, NJ, USA) 290 INDIVIDUAL AND COMBINED EFFECTS OF FENOFIBRATE AND SULPHONYLUREAS 557 ON HDL CHOLESTEROL AND OUTCOMES D. Sullivan, P. Forder, J. Simes, M. Whiting, A. Keech (Camperdown, VIC, Sydney, NSW and Adelaide, SA, Australia) T 291 OLEIC, LINOLEIC AND LINOLENIC VLDL AND FORMATION OF SMALL DENSE 557 LOW-DENSITY LIPOPROTEIN SUBCLASSES H V.N. Titov, V.V. Kucharchuk, S.V. Osipov, A.M. Arapbaeva (Moscow, Russia) U 292 EFFECT OF EZETIMIBE MONOTHERAPY ON CIRCULATING OXIDIZED LOW-DENSITY 557 R LIPOPROTEIN AND CELL ADHESION MOLECULES S A. Tavridou, A. Efthimiadis, I. Efthimiadis, H. Paschalidou, M. Raptopoulou-Gigi, V.G. Manolopoulos (Alexandroupolis and Thessaloniki, Greece) D 293 EFFECT OF EZETIMIBE MONOTHERAPY ON LIPIDEMIC PROFILE, FIBRINOGEN AND 558 A C-REACTIVE PROTEIN LEVELS IN PATIENTS WITH PRIMARY DYSLIPIDEMIA Y H. Paschalidou, A. Efthimiadis, A. Tavridou, I. Efthimiadis, F. Dogramatzi (Thessaloniki and Alexandroupolis, Greece)

186 294 EZETIMIBE PLUS SINVASTATIN TREATMENT REDUCES FASTING AND POSTPRANDIAL 558 REMNANT-LIKE PROTEIN CHOLESTEROL IN PRIMARY HYPERCHOLESTEROLEMIC PATIENTS V.S. Nunes, M.Q.T.S. Neves, K.N. Katona, T. Nakano, K. Nakajima, E.C.R. Quintao, E.R. Nakandakare (Sao Paulo, Brazil and Guma, Japan) 295 THE EFFECTS OF 1-YEAR EZETIMIBE TREATMENT ON VITAMIN D LEVELS AND 558 BONE TURNOVER MARKERS IN POSTMENOPAUSAL WOMEN A. Montagnani, M. Montomoli, K. Del Santo, A. Bonuso, B. Franci, A. Cadirni, C. Caffarelli, S. Gonnelli, R. Nuti (Siena, Italy) 296 EFFECT OF EZETIMIBE ON HYPERCHOLESTEROLEMIC PATIENTS INTOLERANT TO 558 STATIN TREATMENT L. Pisciotta, P. Masturzo, A. Bellocchio, C. Fioravanti, L. Orsini, I. Colangeli, S. Bertolini (Genoa and Rome, Italy) 297 EARLY CLINICAL CHARACTERIZATION OF MD-0727, A NOVEL CHOLESTEROL 558 ABSORPTION INHIBITOR, IN HEALTHY SUBJECTS J. Johnston, A.P. Bryant, R.W. Busby, B.M. Cali, M.G. Currie, A. Fretzen, S. Geis, D.P. Zimmer (Cambridge, MA, USA) 298 FENOFIBRATE SUPPRESSES A ELECTRONEGATIVE LDL IN SMALL DENSE LDL 559 FRACTION ON CAPILLARY ISOTACHOPHORESIS (CITP) Y. Uehara, B. Zhang, S. Miura, S. Furuyama, T. Yamada, K. Saku (Fukuoka, Japan) 299 THE TREATMENT WITH FENOFIBRATE DECREASES MONOCYTE RELEASE OF 559 PROINFLAMMATORY CYTOKINES IN DYSLIPIDEMIC PATIENTS WITH IMPAIRED FASTING GLUCOSE B. Okopien, A. Kulach, A. Madej, D. Belowski, R. Krysiak, M. Zielinski, Z.S. Herman (Katowice, Poland) 300 EFFECT OF BEZAFIBRATE THERAPY ON ATHEROSCLEROTIC AORTIC PLAQUES 559 AND RELATIONSHIPS BETWEEN PLAQUE REGRESSION AND LIPOPROTEIN PARTICLE CHANGES M. Ogura, Y. Momiyama, M. Ayaori, A. Yonemura, R. Ohmori, T. Kihara, S. Sawada, M. Nagata, H. Nakamura, F. Ohsuzu (Saitama, Japan) 301 DECREASE IN CETP ACTIVITY BY FENOFIBRATE MAY INCREASE LDL PARTICLE SIZE 559 MEASURED BY HPLC METHOD IN PATIENTS WITH CORONARY ARTERY DISEASE T. Kiyanagi, T. Miyazaki, A. Kume, H. Ohmura, K. Shimada, K. Tanimoto, K. Miyauchi, H. Mokuno, H. Daida (Hongo, Japan) 302 FENOFIBRATE INCREASES HOMOCYSTEINE AND N-METHYLNICOTINAMIDE LEVELS 560 THROUGH PPARALPHA-MEDIATED MECHANISM T.B. Domagala, M. Celinska-Lowenhoff, J. Dropinski, H. Gozdecka, M. Gnass, A. Borkowska-Mosur, A. Szczeklik (Cracow, Poland) 303 THE EFFECT OF APOLIPOPROTEIN E POLYMORPHISM ON THE RESPONSE TO 560 LIPID-LOWERING TREATMENT WITH FENOFIBRATE OR ATORVASTATIN D. Christidis, E. Liberopoulos, A. Kakafika, M. Cariolou, M. Elisaf (Ioannina, Greece and Nicosia, Cyprus) 304 INFLUENCE OF FENOFIBRATE AND SILYMARIN ON SELECTED PARAMETERS OF 560 LIPID METABOLISM IN THE WISTAR RAT R. Vecera, J. Orolin, N. Skottova, V. Simanek, P. Anzenbacher (Olomouc, Czech Republic) 305 FENOFIBRATE TREATMENT REDUCES CIRCULATING CONJUGATED DIENE LEVEL AND 560 INCREASES GLUTATHIONE PEROXIDASE ACTIVITY I. Tkac, A. Molcanyiova, M. Javorsky, M. Kozarova (Kosice, Slovak Republic) 306 FENOFIBRATE INCREASES HDL-CHOLESTEROL BY REDUCING THE EXPRESSION 560 OF THE CHOLESTERYL ESTER TRANSFER PROTEIN C.C. Van der Hoogt, W. De Haan, M. Westerterp, G.M. Dallinga-Thie, J.W. Jukema, L.M. Havekes, P.C.N. Rensen (Leiden and Rotterdam, The Netherlands) T 307 GEMFIBROZIL INCREASES HUMAN PLASMA ARACHIDONIC ACID LEVELS 561 F. Faas, J. Straub, W. Smith, D. Collins, S. Robins, H. Bloomfield (Little Rock, AR, H West Haven, CT, Boston, MA and Minneapolis, MN, USA) U 308 THE EFFECT OF HYPOLIPIDAEMIC DRUGS ON LIPOPROTEIN- ASSOCIATED 561 R PHOSPHOLIPASE A2 (LP-PLA2) ACTIVITY AND MASS S V. Saougos, M. Kostapanos, M. Kalogirou, A. Tselepis, M. Elisaf (Ioannina, Greece) 309 DIETARY OXIDIZED LIPIDS MODULATE PLASMA LIPIDS, SIMILAR TO PPAR LIGANDS 561 D A. Wheaton, B. Yu, S. Parthasarathy, N. Santanam (Atlanta, GA and New Orleans, LA, USA) A Y

187 310 PEIOTROPIC ACTION OF HDL AND HDL THERAPY 561 S. Miura, Y. Kiya, S. Imaizumi, B. Zhang, Y. Matsuo, Y. Uehara, KA. Rye, K. Saku (Fukuoka, Japan and Sydney, NSW, Australia) 311 A NOVEL THERAPEUTIC STRATEGY FOR TANGIER DISEASE 562 Y. Uehara, B. Zhang, Y. Tsuboi, S. Miura, S. Abe, M. Higuchi, H. Urata, K.A. Rye, T. Yamada, K. Saku (Fukuoka, Japan and Sydney, NSW, Australia) 312 EFFECTS OF HIGH-DOSAGE ITRACONAZOLE TREATMENT ON SYNTHESIS, 562 TRANSPORT AND METABOLISM OF CHOLESTEROL IN MEN B. Schneider, J. Plat, R. Gerdsen, U. Diczfalusy, I. Björkhem, P.J. Neuvonen, T. Bieber, K. von Bergmann, D. Lütjohann (Bonn, Germany, Maastricht, The Netherlands, Huddinge, Sweden and Helsinki, Finland) 313 PHARMACOLOGICAL INTERVENTION USING RECONSTITUTED HIGH-DENSITY 562 LIPOPROTEIN CHANGES THE LIPID PROFILE IN SPONTANEOUSLY HYPERTENSIVE RATS S. Imaizumi, S. Miura, Y. Kiya, B. Zhang, Y. Uehara, KA. Rye, K. Saku (Fukuoka, Japan and Sydney, NSW, Australia) 314 ENDOTHELIAL DYSFUNCTION, INFLAMMATION AND MACROPHAGE ACTIVATION: 562 THE IMPACT OF LDL-APHERESIS ON ATHEROGENESIS V. Blaha, D. Solichova, M. Blaha, M. Cermanova, J. Zajic, R. Hyspler, P. Vyroubal, E. Havel, Z. Zadak (Hradec Kralove, Czech Republic) 315 ENDOGLIN - ITS SIGNIFICANCE DURING LDL-CHOLESTEROL ELIMINATION THERAPY 562 M. Bláha, M. Cermanová, V. Bláha, C. Andrýs, M. Blazek, J. Malý, J. Zajíc, V. Rehácek, L. Smolej (Hradec Kralove, Czech Republic) 316 LONG LASTING LDL-APHERESIS IN FAMILIAL HYPERLIPOPROTEINAEMIA (TEN 563 YEARS EXPERIENCE) M. Bláha, M. Cermanová, V. Bláha, M. Blazek, J. Malý, D. Solichová, J. Zajíc, O. Siroký, V. Rehacek (Hradec Kralove, Czech Republic) 317 PERFORMANCE OF LDL-APHERESIS AND ITS RELATION TO HAEMOSTASIS 563 M. Blazek, M. Blaha, V. Blaha, J. Maly, M. Cermanova, M. Pecka, L. Slovacek (Hradec Kralove, Czech Republic) 318 LDL APHERESIS-INDUCED REDUCTION IN ENDOTHELIAL ACTIVATION MARKERS IN 563 ISCHEMIC OPTIC NEUROPATHY A. Ramunni, G. Ranieri, M.T. Saliani, R. Ria, P. Coratelli (Bari, Italy) 319 REDUCTION OF INFLAMMATORY HDL FOLLOWING LDL-APHERESIS TREATMENT 563 P.M. Moriarty, J.M. Belmont (Kansas City, MO, USA) 320 PREGNANCY OF HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIC PATIENTS 564 WITH CORONARY ARTERY DISEASE TREATED WITH LDL-APHERESIS A. Nagumo, H. Makino, Y. Miyamoto, Y. Yoshimasa, T. Ikeda, Y. Chiba, S. Yokoyama, M. Tsushima, A. Yamamoto, M. Harada-shiba (Osaka, Aichi and Shizuoka, Japan) 321 LP(A) AND LDL APHERESIS IN FH AFTER APHERESIS TREATMENT 564 M. Manca, E. Pedro, A.F.G. Cicero, M. Giovannini, S. Linarello, M. Migliori, A. Gaddi (Bologna, Italy and Lisbon, Portugal) 322 MICROSOMIAL TRANSFER PROTEIN (MTP) INHIBITION SUBSTANTIALLY REDUCES 564 CHOLESTEROL IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA M. Cuchel, L.T. Bloedon, D.M. Kolansky, P.O. Szapary, M.L. Wolfe, J.S. Millar, K. Ikewaki, E.S. Siegelman, R.E. Gregg, D.J. Rader (Philadelphia, PA, Lawrenceville, GA, USA and Tokyo, Japan) 323 LIPID-LOWERING PROPERTIES OF SQUALENE SYNTHASE INHIBITOR; EFFECTS ON 564 HDL CHOLESTEROL FORMATION AND TRIGLYCERIDE BIOSYNTHESIS A. Kanda, K. Terayama, Y. Ishigai, M. Hamaguchi, S. Moriyama, C. Komiyama, K-I. Nishida (Tokyo, Japan) 324 HYPOLIPIDEMIC ACTIVITY OF TANAKAN (GINKGO BILOBA EXTRACT) IN HUMANS 564 T V. Ivetic, M. Popovic, C. Gavrancic, M. Drazetin (Novi Sad, Serbia-Montenegro) 325 A COMPARISON OF THE EFFECTS OF D-003 AND POLICOSANOL (5 AND 10 MG/D) 565 H IN PATIENTS WITH TYPE II HYPERCHOLESTEROLEMIA: A RANDOMIZED, U DOUBLE-BLINDED STUDY R G. Castaño, R. Mas, L. Fernandez, J. Illnait, S. Mendoza, R. Gamez, J. Fernandez, S M. Mesa (Havana, Cuba) 326 SOY PROTEIN AND SOLUBLE PECTIN COMPOSITION FOR SERUM CHOLESTEROL 565 D LOWERING A B. Anestiadis, E. Vataman, F. Vavil Caragie (Chisinau, Moldova) Y

188 327 NO-1886 ALLEVIATES ATHEROSCLEROSIS OF RENAL ARTERY AND 565 GLOMERULOSCLEROSIS IN HIGH-FAT/HIGH-SUCROSE/HIGH-CHOLESTEROL DIET-FED MINIPIGS Y. Liu, W.D. Yin, W.Z. Wang, Q.K. Li, M.B. Cai, K. Tsutsumi, C. Zhang, J.X. Xiao, H.J. Hou, H.G. Li (Hengyang, China and Naruto, Japan) 328 POLICOSANOL DOES NOT LOWER CHOLESTEROL IN CAUCASIAN PATIENTS WITH 565 HYPERCHOLESTEROLEMIA OR COMBINED HYPERLIPIDEMIA - AN RCT WITH USUAL AND HIGH DOSES H.K. Berthold, S. Unverdorben, R. Degenhardt, I. Gouni-Berthold (Rotenburg an der Fulda and Cologne, Germany) 329 THE EFFECT OF LEPTIN VERSUS FOOD RESTRICTION ON LIPID METABOLISM AND 566 ATHEROSCLEROSIS IN APOE–/–APOB100/100OB–/– AND LDLR–/–APOB100/100 OB–/– MICE J. McCormick, S. Kaufman, J. Witkosky, S. Stanislaus, J. lofing, R. Lindberg, M. Veniant (Thousand Oaks, CA, USA) 330 AN ORALLY ACTIVE CONSTRUCT BASED ON SERUM AMYLOID A PROMOTES 566 CHOLESTEROL EXPORT IN VIVO R. Kisilevsky, R. Tan, J.B. Ancsin, P.M. Kim, S.P. Tam (Kingston and Ottawa, ON, Canada) 331 ASSESSMENT OF LIPOPROTEIN PROFILES (ALPS STUDY) AND ANTIOXIDANT 566 ACTIVITY IN HEALTHY SUBJECTS TREATED WITH AGI-1067 M.H. Davidson, J. Smith, R. Scott, R. Small, J. Choi, J.P. Kane (Chicago, IL, Alpharetta, GA and San Francisco, CA, USA) 332 EVEROLIMUS AFFECTS CHOLESTEROL HOMEOSTASIS IN MACROPHAGES 566 S. Bellosta, L. Arnaboldi, M. Canavesi, P. Pfister, A. Granata, R. Dorent, A. Corsini (Milan, Italy and Basel, Switzerland) 333 LIPID-LOWERING EFFECT OF SYNTHETIC BILE SALT IN DIABETIC DISLIPIDEMIA 566 S. Kojic-Damjanov, M. Djeric, M. Mikov (Novi Sad, Serbia-Montenegro) 334 EARLY POSTPRANDIAL EFFECT OF ORLISTAT ON LIPEMIA AND LEPTIN 567 A. Sanz-Paris, A. Rodriguez, M.A. Navarro, A. Caverni, J. Osada, A. Barragan, D. Alvarez, R. Albero, A. Garcia de Jalon (Zaragoza, Spain) 335 NIACIN INHIBITS OXIDATIVE STRESS & VCAM-1 TRANSCRIPTION IN HUMAN 567 AORTIC ENDOTHELIAL CELLS: ANTIATHEROGENIC PROPERTY OF NIACIN BEYOND LIPID REGULATION S. Ganji, S. Qin, L. Zhang, V. Kamanna, M. Kashyap (Long Beach, CA, USA) 336 SAFETY AND TOLERABILITY OF NIASPAN (PROLONGED-RELEASE NICOTINIC ACID) 567 IN A USUAL CARE SETTING (RESULTS OF THE GERMAN NAUTILUS STUDY) A. Vogt, U. Kassner, U. Hostalek, E. Steinhagen-Thiessen (Berlin and Darmstadt, Germany) 337 NICOTINIC ACID: A WOMAN'S DRUG 567 B. Garrett, A. Superko, M. Mcgovern, R. Superko (Atlanta, GA, Portola Valley, CA and Miami, FL, USA) 338 NICOTINAMIDE AND ALPHA-LIPOIC ACID IN THE TREATMENT OF CARDIOVASCULAR 568 AUTONOMIC NEUROPATHY IN TYPE 2 DIABETIC PATIENTS V. Serhiyenko, A. Serhiyenko, L. Serhiyenko (Lviv, Ukraine) 339 A COMPARISON OF EXTEND-RELEASE NIACIN COMPOUNDS AND COMMONLY 568 USED LIPID-ALTERING MEDICATIONS ON HIGH DENSITY/LOW DENSITY CHOLESTEROL IN MEN AND WOMEN S.L. Charland, R. Quimbo, M.J. Cziraky, E.J. Stanek (Cranbury, NJ, and Wilmington, DE, USA) 340 UROKINASE RECEPTOR AND RHOA MEDIATE NON-LIPID LOWERING EFFECTS OF 568 ROSUVASTATIN ON VASCULAR REMODELING J. Kiyan, A. Kusch, S. Tkachuk, R. Dietz, G. Smith, I. Dumler (Hanover, Berlin, Germany and Cheshire, UK) 341 SIMVASTATIN REDUCES THE PROGRESSION OF THE EARLY STAGES (DRUSEN) OF 568 T AGE-RELATED MACULAR DEGENERATION:A PILOT STUDY T. Tzotzas, D. Apostolopoulou, E. Memi, H. Efthymiou, G.E. Krassas (Thessaloniki, Greece) H 342 ENDOTHELIAL PROGENITOR CELLS ARE REDUCED IN THE METABOLIC SYNDROME 569 U AND NORMALIZE AFTER LIPID-LOWERING THERAPY R P.E. Westerweel, J.K. Olijhoek, I.E. Hoefer, G.R. Hajer, O. van Oostrom, F.L. Visseren, S M.C. Verhaar (Utrecht, The Netherlands) 343 INFLUENCE OF ATORVASTATIN ON HAEMOSTATIC PARAMETERS IN PATIENTS 569 D WITH ACUTE CORONARY SYNDROME A J. Zielonka, M. Jastrzebska, M. Lewandowski, Z. Kornacewicz-Jach, M. Naruszewicz, Y J. Goracy (Szczecin, Poland)

189 344 PITAVASTATIN PREVENTS ANGIOTENSIN II-INDUCED CARDIOVASCULAR 569 REMODELING THROUGH REGULATION OF OXIDATIVE STRESS AND NITRIC OXIDE BIOAVAILABILITY S. Yagi, K. Aihara, M. Akaike, Y. Ikeda, T. Iwase, S. Hashizume, M. Fujimura, H. Azuma, T. Matsumoto (Tokushima, Japan) 345 EFFECTS OF CHRONICALLY LOW-DOSE FLUVASTATIN TREATMENT IN STZ-INDUCED 569 DIABETIC RATS ON VASCULAR REACTIVITY OF AORTA S. Ulusoylar, A. Ceylan-Isik, N. Ari, G. Ozansoy (Ankara, Turkey) 346 EFFECT OF ROSUVASTATIN THERAPY ON LIPID PROFILE, ENDOTHELIAL FUNCTION 569 AND INFLAMMATION FACTORS IN PATIENTS WITH CORONARY HEART DISEASE (CHD) I. Sergienko, M. Ezhov, E. Samoilenko, V. Masenko, T. Balahonova, V. Naumov (Moscow, Russia) 347 ROSUVASTATIN LACKS TRANSCRIPTIONAL EFFECTS ON APOA-I IN A TRANSGENIC 570 MOUSE MODEL S. Caligari, D. Gilio, M. Marchesi, C. Parolini, C.R. Sirtori, G. Chiesa (Milan, Italy) 348 ANTIINFLAMMATORY ACTIVITY OF SIMVASTATIN IN A RAT MODEL OF ACUTE LOCAL 570 INFLAMMATION L. Nezic, R. Skrbic, S. Dobric, Z. Milovanovic, V. Jacevic, S.S. Satara, N. Stojakovic (Banja Luka, Bosnia Herzegovina and Belgrade, Serbia-Montenegro) 349 ROSUVASTATIN REDUCES INTERLEUKIN-6 INDUCED C-REACTIVE PROTEIN 570 EXPRESSION VIA STAT3 AND C/EBP INHIBITION C.M. Mayer, H.-J. Gruber, E.-M. Landl, S. Pailer, H. Scharnagl, W. Maerz (Graz, Austria) 350 EFFECTS OF PITAVASTATIN FOR EXPRESSION OF THE APOLIPOPROTEIN A5 IN 570 HEPG2 CELL A. Matsunaga, H. Arishima, Y. Uehara, B. Zhang, H. Niimura, K. Saku (Fukuoka, Japan) 351 ATORVASTATIN MODULATES THROMBOSPONDIN METABOLISM IN HUMAN 571 UMBILICAL VEIN ENDOTHELIAL CELLS V. Martínez-Sales, V. Vila, E. Reganon, M. Ferrando (Valencia, Spain) 352 ROSUVASTATIN UPREGULATES ENOS EXPRESSION AND ACTIVITY BY ISOPRENOID 571 DEPLETION IN HUMAN VENOUS ENDOTHELIAL CELLS M. Landsberger, F. Jantzen, S.B. Felix (Greifswald, Germany) 353 ATORVASTATIN INHIBITS THE EXPRESSION OF ADHESION MOLECULES ON 571 ENDOTHELIAL CELLS BY REDUCING REACTIVE OXYGEN SPECIES I. Korzh, V. Nemtsova (Kharkov, Ukraine) 354 PITAVASTATIN-INDUCED DOWNREGULATION OF CCR2 AND CCR5 IN MONOCYTES 571 IS ASSOCIATED WITH THE ARREST OF CELL CYCLE IN S PHASE M. Fujino, S. Miura, Y. Kiya, Y. Matsuo, H. Tanigawa, A. Kawamura, K. Saku (Fukuoka, Japan) 355 ANGIOTENSIN II CAUSED A STATIN-SENSITIVE DYSREGULATION OF 571 MEVALONATE CYCLE IN HUMAN MONOCYTES G. Fóris, I. Seres, B. Kosztáczky, P. Fülöp, Z. Balogh, G. Paragh (Debrecen, Hungary) 356 ATORVASTATIN DIMINISHED ICAM-1 AND MCP-1 PLASMA LEVELS IN SUBJECTS 572 AT HIGH CARDIOVASCULAR RISK. ATORVASTATIN ON INFLAMMATORY MARKERS (AIM) STUDY L.M. Blanco-Colio, J.L. Martin-Ventura, E. de Teresa, C. Farsang, A. Gaw, G.F. Gensini, L.A. Leiter, A. Langer, P. Martineau, J. Egido (Madrid, Malaga, Spain, Budapest, Hungary, Glasgow, UK, Florence, Italy, Toronto and Kirkland, ON, Canada) 357 THE INFLUENCE OF A 6-MONTH TREATMENT WITH ATORVASTATIN AND 572 ROSUVASTATIN ON INTIMA MEDIA THICKNESS AND PARAMETERS OF INTERLEUKINS, C-REACTIVE PROTEIN M. Balavadze, M. Akhvlediani, D. Gachechiladze (Tbilisi, Georgia) 358 RAPID ANTI-INFLAMMATORY ACTION OF ROSUVASTATIN IN PATIENTS WITH ACUTE 572 T ISCHEMIC STROKE S. Antonopoulos, M. Mylonopoulou, S. Kokkoris, S. Mikros, T. Nitsotolis, C. Poulopoulou, H D. Vikeli, G.R. Giannoulis (Piraeus, Greece) U 359 PITAVASTATIN AMELIORATES GLUCOCORTICOID-INDUCED HYPERTENSION 572 R THROUGH INCREASING EXPRESSION OF ENDOTHELIAL NITRIC OXIDE SYNTHASE S M. Akaike, K. Aihara, S. Yagi, Y. Ikeda, K. Ishikawa, T. Iwase, S. Hashizume, M. Fujimura, H. Azuma, T. Matsumoto (Tokushima, Japan) D 360 ATORVASTATIN UPREGULATES PEROXISOME PROLIFERATORS-ACTIVATED 572 A RECEPTORS IN PREVENTING CARDIAC HYPERTROPHY OF RATS Y P. Ye, L. Sheng, C. Zhang, Y.X. Liu (Beijing, China)

190 361 SIMVASTATIN AUGMENTS IL-8 SECRETION AND FACILITATES ENDOTHELIAL 573 DIFFERENTIATION OF PERIPHERAL BLOOD MONONUCLEAR CELLS K.W. Park, J. Hur, J.Y. Hahn, H.Y. Lee, S.H. Kim, Y.S. Kim, H.J. Kang, H.S. Kim, B.H. Oh, Y.B. Park (Seoul, South Korea) 362 ROSUVASTATIN REDUCES OXIDATIVE STRESS AND DNA DAMAGE IN HUMAN 573 PROMYELOCYTIC HL-60 CELLS N. Schupp, U. Schmid, E. Arnold, A. Heidland, H. Stopper (Würzburg, Germany) 363 EFFECT OF ATORVASTATIN ON INTERLEUKIN 1 BETA GENE EXPRESSION AND 573 MONOCYTE RELEASE Z.S. Herman, M. Huzarska, K. Labuzek, M. Basiak, A. Stachura-Kulach, B. Okopien (Katowice, Poland) 364 EFFECT OF STATIN TREATMENT ON THE AORTIC GENE EXPRESSION PROFILING 573 IN APOE-DEFICIENT MICE Y.H. Li, S.L. Liu, G.Y. Shi, M.J. Jiang, H.L. Wu (Tainan, Taiwan) 365 ROSUVASTATIN REGULATES EXPRESSION OF THE IMMUNOCOMPETENT 574 ANAPHYLATOXIN C5A RECEPTOR ON HUMAN MESANGIAL CELLS VIA THE TYK2-STAT3 SIGNALING PATHWAY N. Tkachuk, N. Shushakova, I. Dumler (Hannover, Germany) 366 ONLY SINGLE ADMINISRATION OF ATORVASTATIN CAN INCREASE NITRIC OXIDE 574 EXHALATION IN HEART FAILURE PATIENTS WITH NORMOLIPIDEMIA H. Adachi, S. Oshima, K. Taniguchi (Maebashi, Japan) 367 EFFECTS OF ATORVASTATIN ON CD36 EXPRESSION AND LIPID ACCUMULATION IN 574 THP-1 MACROPHAGES Y. Zeng, G.H. Yi, Y.L. Tan, J.T. Feng, L. Sun, D.X. Zeng, X.B. Yin, J.H. Xia, J. Wang, X.H. Zu (Hengyang, China) 368 SIMVASTATIN DECREASES MONOCYTE CHEMOATTRACTANT PROTEIN-1 IN 574 HYPERCHOLESTEROLAEMIC PATIENTS L. Rallidis, E. Hamodraka, G. Moustogiannis, C. Salichou, H. Gika, A. Velissaridou, D. Kremastinos (Athens and Piraeus, Greece) 369 EFFECT ON CAROTID ATHEROSCLEROSIS OF LEVOFLOXACIN PLUS PROBUCOL 574 FOR CHLAMYDIA PNEUMONIAE INFECTION Y. Sawayama, M. Tatsukawa, K. Kikuchi, K. Okada, N. Maeda, J. Hayashi (Fukuoka, Japan) 370 EFFECTS OF PROBUCOL ON LOW DENSITY LIPOPROTEIN SUBTYPE DISTRIBUTION 575 AND RENAL FUNCTION IN HYPERLIPIDEMIC PATIENTS WITH NON-DIABETIC NEPHROPATHY G. Yasuda, D. Ando, N. Hirawa, S. Saka, T. Endo, Y. Yamamoto, S. Umemura (Yokohama, Japan) 371 METALLOTHIONEIN INDUCTION BY PROBUCOL IN ENDOTHELIAL CELL 575 T. Nagamine, T. Kusakabe, H. Takada, K. Nakazato, K. Suzuki, K. Nakajima (Maebashi and Tokyo, Japan) 372 PROBUCOL STABILIZES HEPATIC SCAVENGER RECEPTOR CLASS B TYPE I 575 POSSIBLY THROUGH SPECIES-SPECIFIC FASHION K. Hirano, C. Ikegami, K. Tsujii, Z. Zhang, F. Matsuura, Y. Nakagawa-Toyama, M. Koseki, D. Masuda, Y. Ueda, S. Yamashita (Osaka and Kyoto, Japan) 373 PROBUCOL DECREASES SERUM AMYLOID A (SAA) CONCENTRATION DESPITE 575 HDL-CHOLESTEROL REDUCTION T. Miida, A. Takahashi, K. Kosuge, O. Hanyu, D. Masuda, O. Miyazaki, M. Takeda, A. Hashimoto, M. Okazaki, M. Okada (Niigata, Suita, Ryugasaki and Ichikawa, Japan) 374 EFFICACY AND SAFETY OF MORNING ADMINISTRATION OF FLUVASTATIN 576 EXTENDED RELEASE FORMULATION IS EQUIVALENT TO EVENING ADMINISTRATION H. Scharnagl, M. Vogel, C. Abletshauser, F. Freisinger, T. Stojakovic, W. Maerz (Graz, Austria, Munich and Nürnberg, Germany) T 375 ROSUVASTATIN 5-20 MG IN JAPANESE HYPERTRIGLYCERIDEMIC PATIENTS: 576 DOSE-RESPONSE STUDY H Y. Saito, N. Yamada, K. Shirai, J. Sasaki (Chiba, Tsukuba, Sakura and Fukuoka, Japan) U 376 ABCG5/8 AND NPC1L1 POLYMORPHISMS AND RESPONSE TO PRAVASTATIN IN PROSPER 576 R E. Polisecki, A. Gaw, J. Shepherd, EJ. Schaefer (Boston, MA, USA and Glasgow, UK) S 377 THE EFFECT OF GRAPEFRUIT JUICE CONSUMPTION ON METABOLISM OF STATINS 576 IN PATIENTS WITH PRIMARY DYSLIPIDEMIA D H. Paschalidou, A. Efthimiadis, I. Efthimiadis, M. Raptopoulou-Gigi (Thessaloniki, Greece) A Y

191 378 LOW HDL CHOLESTEROL PREDICTS THE ONSET OF TRANSPLANT VASCULOPATHY 576 IN PEDIATRIC CARDIAC RECIPIENTS ON PRAVASTATIN THERAPY M. Hedman, R. Pahlman, J. Sundvall, C. Ehnholm, M. Syvänne, E. Jokinen, M. Jauhiainen, C. Holmberg, M. Antikainen (Helsinki, Finland) 379 BALANCING FEEDBACK AND LIPOPROTEIN TRANSPORT IN THE METABOLIC SYNDROME 577 E.M.M. Ooi, G.F. Watts, J. Ji, A.G. Johnson, K.A. Rye, D.C. Chan, P.H.R. Barrett (Perth, WA, Sydney, NSW, Australia and King of Prussia, PA, USA) 380 ATORVASTATIN IMPROVES ATHEROGENIC STATE BY DECREASING RLP -C AND NEFA 577 A. Nakata, T. Shingu, S. Nomura, R. Kuwashima, M. Katsumoto, K. Chayama (Hiroshima, Japan) 381 TREATING TO TARGET PATIENTS WITH PRIMARY HYPERLIPIDEMIA: COMPARISON 577 OF THE EFFECTS OF ATORVASTATIN AND ROSUVASTATIN (THE ATOROS STUDY) H. Milionis, E. Rizos, M. Kostapanos, T. Filippatos, J. Goudevenos, D. Mikhailidis, M. Elisaf (Ioannina, Greece and London, UK) 382 MEVALONATE CYCLE OF HUMAN MONOCYTES IS DISTURBED BY LEPTIN IN VITRO 577 B. Kosztáczky, G. Fóris, I. Seres, A. Kassai, T. Kalmár, G. Paragh (Debrecen, Hungary) 383 STATIN EFFECTS ON HIGH-DENSITY LIPOPROTEIN LEVELS HAVE BOTH 577 TRIGLYCERIDE-DEPENDENT AND INDEPENDENT COMPONENTS P.H. Jones, F. McTaggart, H. Southworth (Houston, TX, USA and Macclesfield, UK) 384 EFFECTS OF ROSUVASTATIN AND ATORVASTATIN ON THE APOB/APOA-1 RATIO IN 578 PATIENTS WITH ACUTE CORONARY SYNDROME: THE CENTAURUS STUDY J.-M. Lablanche, J.-C. Tardif, A. Benkritly (Lille, Rueil Malmaison, France and Montreal, QC Canada) 385 EFFICACY AND SAFETY OF LONG-TERM ATORVASTATIN TREATMENT IN PATIENTS 578 WITH STABLE CORONARY ARTERY DISEASE COMPLICATED WITH CONGESTIVE HEART FAILURE S.H.D. Chumburidze, N.N. Kipshidze, G.D. Shelia (Tbilisi, Georgia) 386 INTENSIVE LOWERING OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL PREVENTS 578 THE PROGRESSION OF CORONARY RESTENOSIS A. Iwata, S. Miura, S. Imaizumi, K. Shirai, K. Mori, B. Zhang, H. Nishikawa, K. Mastuo, K. Saku (Fukuoka, Japan) 387 EFFECT OF ROSUVASTATIN ON OUTCOMES IN CHRONIC HAEMODIALYSIS 578 PATIENTS - BASELINE DATA FROM THE AURORA STUDY B. Fellström, F. Zannad, R. Schmieder, H. Holdaas, A. Jardine, H. Rose, W. Wilpshaar (Uppsala, Sweden, Toul, France, Erlangen-Nürnberg, Germany, Oslo, Norway, Glasgow and Macclesfield, UK) 388 EFFECTS OF DIETARY COQ10 SUPPLEMENTATION ON SERUM LIPID, COQ10 AND LIVER 579 ENZYME LEVELS IN HYPERCHOLESTEROLEMIC PATIENTS TREATED WITH ATORVASTATIN H. Mabuchi, A. Nohara, J. Kobayashi, M. Kawashiri, A. Inazu (Kanazawa, Japan) 389 TREATMENT OF ATHEROSCLEROSIS WITH STATINS AT PRESENT AND IN FUTURE 579 N.N. Kipshidze (Tbilisi, Georgia) 390 EVALUATION OF THE SAFETY OF ATORVASTATIN TREATMENT IN ELDERLY 579 PATIENT POPULATION N. N. Kipshidze, I. Petriashvili, K. Kapanadze (Tbilisi, Georgia) 391 THE EFFICACY OF ROSUVASTATIN TREATMENT IN PATIENTS WITH STABLE ANGINA 579 K. Kapanadze (Tbilisi, Georgia) 392 EFFECTS OF PITAVASTATIN ON LIPOPROTEIN METABOLISM IN HYPERCHOLESTEROLEMIC 579 PATIENTS: A STABLE ISOTOPE STUDY K. Ikewaki, Y. Nakada, T. Wakikawa, Y. Inoue, S. Mochizuki (Tokyo, Japan) 393 EFFECTS ON LIPID PROFILE, CHRONIC INFLAMMATION AND RENAL FUNCTION OF 580 FLUVASTATIN TREATMENT IN DYSLIPIDAEMIC PATIENTS WITH CHRONIC RENAL FAILURE T L. Di Lullo, R. Addesse, C. Comegna, C. Galderisi, G.R. Iannacci, P. Polito (Tivoli, Italy) 394 EFFICACY AND TOLERABILITY OF ROSUVASTATIN AND ATORVASTATIN WHEN 580 H FORCE-TITRATED IN HIGH-RISK PATIENTS: RESULTS FROM THE ECLIPSE STUDY U O. Faergeman, F. Sosef, E. Duffield (Aarhus, Denmark and Macclesfield, UK) R 395 EFFECTS OF MAXIMAL STATIN THERAPY ON THE HIGH DENSITY LIPOPROTEIN 580 S (HDL) SUBPOPULATION PROFILES OF HYPERCHOLESTEROLEMIC SUBJECTS B.F. Asztalos, F. McTaggart, K.V. Horvath, F. LeMaulf, G.E. Dallal, E.J. Schaefer D (Boston, MA, USA and Cheshire, UK) A 396 EFFECTS OF LOW-DOSE ATORVASTATIN THERAPY ON THE INSULIN AND LIPID 580 Y LEVELS IN PATIENTS WITH CORONARY ARTERY DISEASE O.V. Kuryata, Y. Yegorova (Dnepropetrovsk, Ukraine)

192 397 ATORVASTATIN AND LDL PROFILE IN NIDDM (ALPIN STUDY) 581 T. Wunderlich, M. Hoffmann, I. Friedrich, H. Wieland, M. Hanefeld, W. März, K. Winkler (Freiburg, Dresden, Germany and Graz, Austria) 398 EFFECT OF ATORVASTATIN ON PLASMA OSTEOPONTIN LEVELS IN PATIENTS WITH 581 HYPERCHOLESTEROLEMIA N. Tanaka, Y. Momiyama, R. Ohmori, A. Yonemura, M. Ayaori, M. Ogura, S. Sawada, M. Kusuhara, H. Nakamura, F. Ohsuzu (Saitama, Japan) 399 EVALUATION OF STATIN IN DECREASING THE EARLY MORTALITY AND MORBIDITY OF 581 ACUTE CORONARY SYNDROME A. Shahmohammadi Mousavi, N. Zafaranloo, M.M. Peighambari, M. Madani, L. Zahedi (Tehran, Iran) 400 THE EFFECT OF ATORVASTATIN ON SERUM PHOSPHOLIPASE A2 IIA TYPE AND 581 LIPIDS COMPOSITION OF LDL PARTICLES IN PATIENTS WITH CORONARY HEART DISEASE A.A. Pirkova, M.V. Ezhov, E.V. Samoilova, E.Y. Samoilenco, A.A. Korotaeva, V.G. Naumov (Moscow, Russia) 401 ATORVASTATIN 80 MG IN ACUTE CORONARY SYNDROME PATIENTS ≥ 65 YEARS: 581 MYOCARDIAL ISCHEMIA REDUCTION WITH AGGRESSIVE CHOLESTEROL LOWERING (MIRACL) STUDY A. Olsson, G. Schwarz, M. Szarek, D. Luo (Linköping, Sweden, Denver, CO and New York, NY, USA) 402 SIMVASTATIN EFFECTS IN PATIENTS WITH HEART FAILURE AND DEPRESSED 582 EJECTION FRACTION V. Mareev, A. Skvortsov, D. Filatov, Yu. Belenkov (Moscow, Russia) 403 BRAIN CHOLESTEROL SYNTHESIS IN MICE IS AFFECTED BY HIGH DOSE OF 582 SIMVASTATIN BUT NOT OF PRAVASTATIN K.M. Thelen, K.M. Rentsch, U. Gutteck, M. Heverin, M. Olin, U. Andersson, A. von Eckardstein, I. Björkhem, D. Lütjohann (Bonn, Germany, Zürich, Switzerland and Huddinge, Sweden) 404 EFFECT OF ROSUVASTATIN ON APOLIPOPROTEIN CII AND CIII SERUM LEVELS IN 582 PATIENTS WITH PRIMARY DYSLIPIDEMIA M. Kostapanos, T. Filippatos, H. Milionis, C. Kostara, E. Bairaktari, M. Elisaf (Ioannina, Greece) 405 PITAVASTATIN DECREASES PLASMA PREBETA1-HDL CONCENTRATION AND PROMOTES 582 ITS CONVERSION RATE TO ALPHA-HDL IN HYPERCHOLESTEROLEMIC PATIENT M. Kawano, S. Nagasaka, H. Yagyu, S. Ihibashi (Saitama and Tochigi, Japan) 406 EFFECTIVE TREATMENT OF ATHEROSCLEROSIS BY DOSAGE OPTIMIZATION OF 583 ATORVASTATIN N.N. Kipshidze, A.T. Jabauri, K.A. Nadaraia (Tbilisi, Georgia) 407 CHANGES IN PLASMA ULTRACENTRIFUGALLY SEPARATED LIPOPROTEIN 583 SUBFRACTIONS AFTER SIX MONTHS OF TREATMENT WITH PITAVASTATIN Y. Homma, K. Homma, H. Yamaguchi, Y. Fusegawa, H. Ozawa, Y. Shiina, K. Ishiwata (Tokyo and Isehara, Japan) 408 NITROPRAVASTATIN (NCX 6550) IS MORE EFFECTIVE THAN PRAVASTATIN IN 583 PREVENTING THROMBUS FORMATION AND INTIMAL THICKENING IN SEVERE HYPERLIPIDEMIC MICE S. Momi, G. Gugliemini, A. Monopoli, E. Ongini, P. Gresele (Perugia and Milan, Italy) 409 ATORVASTATIN IN PATIENTS WITH PRIMARY BILIARY CIRRHOSIS AND AN 583 INCOMPLETE RESPONSE TO URSODEOXYCHOLIC ACID G. Fauler, T. Stojakovic, C. Putz-Bankuti, G.C. Gurakuqi, H. Scharnagl, W. März, M. Trauner (Graz, Austria) 410 BENEFICIAL EFFECTS OF SIMVASTATIN (VASILIP) ON THROMBOGENIC RESPONSE 583 AN LIPID PROFILE IN SUBJECTS WITH CHD E. Chaduneli, K. Chagunava, D. Tsiskarishvili (Tbilisi, Georgia) T 411 INFLUENCE OF SIMVASTATIN ON SERUM LEVELS OF LIPOPROTEIN (A) AND 584 HOMOCYSTEINE IN HYPERCHOLESTEROLEMIC PATIENTS WITH CORONARY HEART H DISEASE U V. Arsova, M. Nospal, S. Subeska Stratrova (Skopje, Macedonia) R 412 EFFICACY AND SAFETY OF ATORVASATIN VS.FENOFIBRATE IN FAMILIAL COMBINED 584 S HYPERLIPIDEMIA (FCHL). A RANDOMIZED, PILOT, COMPARATIVE STUDY A. Montali, T.M. Antonini, M. Bifolco, F. Campagna, G. Pigna, R. Cantini, R. Antonini, D M. Arca (Rome, Italy) A Y

193 413 ATORVASTATIN DECREASED CIRCULATING CD40 LIGAND LEVELS IN SUBJECTS AT HIGH 584 CARDIOVASCULAR RISK. ATORVASTATIN ON INFLAMMATORY MARKERS (AIM) STUDY L.M. Blanco-Colio, J.L. Martin-Ventura, E. de Teresa, C. Farsang, A. Gaw, G.F. Gensini, L.A. Leiter, A. Langer, P. Martineau, J. Egido (Madrid, Malaga, Spain, Budapest, Hungary, Glasgow, UK, Florence, Italy, Toronto and Kirkland, ON, Canada) 414 FORMATION OF LEUCOTRIENES FROM GRANULOCYTES ARE RELATED TO PLASMA 584 LIPIDS BUT ARE NOT MODIFIED BY TREATMENT WITH ATORVASTATIN I.V. Aardestrup, S. Riahi, J.H. Christensen, E. Toft, E.B. Schmidt (Aalborg, Denmark) 415 EFFICACY AND SAFETY OF FLUVASTATIN IN CHILDREN AND ADOLESCENTS WITH 585 HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA A. van der Graaf, M.C. Nierman, J.C. Firth, K.H. Wolmarans, A.D. Marais, E. de Groot (Amsterdam, The Netherlands and Cape Town, South Africa) 416 PRO-OXIDANT ACTION OF STATINS 585 K. Tikhaze, Z. Lankin, I. Kaminniy, E. Arzamastseva, V. Kukharchuk (Moscow, Russia) 417 STATINS INHIBIT VASCULAR CALCIFICATION BY RESTORING GAS6-AXL SURVIVAL 585 PATHWAY IN HUMAN AORTIC SMOOTH MUSCLE CELLS B.K. Son, K. Kozaki, K. Iijima, M. Eto, M. Akishita, Y. Senda, T. Nakano, Y. Ouchi (Tokyo, Japan)

T H U R S D A Y

194 POSTER AREA “A” THURSDAY, June 22 418-445

POSTER DISPLAY: for the duration of one day (Thursday, June 22 from 8.30 am to 4.00 pm). Participants may view the posters displayed during this day.

POSTER DISCUSSION: one of the authors will be available at the poster site as follows: Thursday, June 22: from 10.30 am to 11.00 am Thursday, June 22: from 12.30 pm to 2.00 pm

Th-P17 Poster Session 17 poster NOVEL TECHNOLOGIES FOR RISK DETERMINATION abstract bk. board no.: page ref.:

418 QUANTITATIVE TRAIT LOCI MAPPING OF METABOLIC SYNDROME SUSCEPTIBILITY 585 GENES IN MOUSE S.W. Fouchier, C.J.A. Moen, K. Willems van Dijk, R.R. Frants (Leiden, The Netherlands) 419 THE APOLIPOPROTEIN E GENE PROMOTER (-491A/T) POLYMORPHISM DETERMINES 585 TRIACYLGLYCEROL PLASMA CONCENTRATION IN RESPONSE TO DIETARY FAT J.A. Moreno, F. Pérez-Jiménez, P. Pérez-Martínez, B. Cortés, M. García-Salas, J. Ruano, A. Gallego, J. López-Miranda (Córdoba, Spain) 420 CPT1B GENE VARIANTS INTERACT WITH FAT INTAKE TO MODULATE INDICES OF 586 OBESITY IN FRENCH-CANADIANS J. Robitaille, A. Houde, D. Gaudet, S. Lemieux, L. Perusse, M.-C. Vohl (Quebec, QC, Canada) 421 AN IN VIVO INVERTEBRATE PLATFORM FOR IDENTIFYING NEW 586 PHARMACOLOGICAL AGENTS THAT MODULATE LIPOPROTEIN METABOLISM S. Hekimi, A. Hihi, M.-C. Beauchamp, R. Branicky (Montreal, QC, Canada) 422 DEVELOPMENT AND MULTICENTER EVALUATION OF A NEW HDL-CHOLESTEROL 586 REAGENT ON ROCHE/HITACHI AND COBAS INTEGRA® SYSTEMS H. Klima, I. Domke (Penzberg and Mannheim, Germany) 423 Z-SCAN A NEW METHOD TO DIFFERENTIATE LDL MODIFICATIONS RELATED TO 586 CORONARY ARTERY DISEASE S.L. Gómez, G.C. Tonini, M.C. Jurado, D.F.J. Ketelhuth, A.M. Figueiredo Neto, M. Gidlund (São Paulo, Brazil) 424 DEVELOPMENT OF RAPID MEASUREMENT OF OXIDATION OF LOW-DENSITY 587 LIPOPROTEIN AND ITS APPLICATION IN DIABETIC PATIENTS M. Kawamura, K. Ashidate, H. Tohda, S. Miyazaki, T. Teramoto, Y Hirata (Tokyo, Japan) 425 THE USE OF SYNCHROTRON RADIATION TO MEASURE ION FLUX AND CELLULAR 587 PROTEIN AND LIPID CHANGES WITHIN CARDIAC ISCHEMIA REPERFUSION INJURY B. Rayner, H. Harris, E. Carter, S. Vogt, Z. Cai, B. Lai, C. Chin, Y. Lee, P. Lay, P. Witting (Sydney, NSW, Australia, Argonne, IL, USA and Hsinchu, Taiwan) 426 FLUORESCENCE LIFETIME IMAGING OF UNSTAINED HUMAN ATHEROSCLEROTIC 587 PLAQUES L. Hegyi, C. Talbot, C. Monaco, A. Sandison, A.H. Davies, D. Peston, M.J. Lever, P.M. French, G.W. Stamp (London, UK) 427 ANALYSIS OF HUMAN BLOOD PLASMA BY MALDI-TOF MASS SPECTROMETRY - 587 EVALUATION OF CRITICAL PARAMETERS O. Zschörnig, V. Richter, F. Rassoul, J. Schiller (Leipzig, Germany) 428 QUANTITATION OF LDL CHOLESTEROL AND TRL TRIGLYCERIDES VIA NBD 587 C6-CERAMIDE FLUORESCENCE IMAGING R.R. Henriquez, R. Chandra, B. Hosken, R.D. Macfarlane (College Station, TX, USA) T 429 A RAPID MICROFLUIDIC ASSAY FOR HDL-C AND HDL SUBCLASS DISTRIBUTION 588 H C. Li, D. Deng, D. Jing, W. Love, M. Kratzmeier, F. Bek, X. Tian, R. Romeo, O. Mueller, U R. Superko (Santa Clara, CA, Atlanta, GA, USA and Waldbronn, Germany) 430 CORONARY RISK ASSESSMENT USING A RAPID MICROFLUIDIC LIPOPROTEIN 588 R ASSAY S C. Li, D. Deng, D. Jing, R. Romeo, M. Kratzmeier, F. Bek, X. Tian, O. Mueller, D D. Schreiber, H. Sussman (Santa Clara, Palo Alto, USA and Waldbronn, Germany) A 431 ANALYSIS OF FREE FATTY ACIDS IN ATHEROSCLEROTIC PLAQUES 588 Y C. Pettinella, S.H. Lee, F. Cipollone, C. Patrono, I.A. Blair (Philadelphia, PA, USA, Chieti and Rome, Italy)

195 432 HIGH DENSITY LIPOPROTEIN QUANTITATION AND SUB-FRACTIONATION ANALYSIS 588 BY MICROFLUIDICS TECHNOLOGY O. Mueller, D. Deng, W. Love, D. Jing, M. Kratzmeier, X. Tian, F. Bek, C. Li, R. Romeo, M. McNulty (Santa Clara, CA, USA and Waldbronn, Germany) 433 A METABONOMIC APPROACH DISCRIMINATES THE SEVERITY OF THE 589 ATHEROGENIC OUTCOME AMONG HYPERLIPIDEMIC HAMSTERS G. Gottardi, C. Canlet, B. Delplanque, J.C. Martin, K. Bensharif, A. Thaminy, G. Agnani, D. Gripois, A. Paris (Toulouse, Orsay and Marseille, France) 434 DEVELOPMENT OF A HTS ASSAY FOR ACYL-COA: CHOLESTEROL 589 ACYLTRANSFERASE 2, ACAT2 L. Redaelli, P. Arioli, L. Iuzzolino, D. Carettoni (Milan, Italy) 435 VIRTUAL GEL OF ATHEROMATOUS PLAQUE 589 C. Felici, B. Porcelli, I. Ciari, C. Setacci, R. Guerranti, R. Pagani, L. Terzuoli (Siena, Italy) 436 PROTEOMIC AND METABOLOMIC APPROACHES TO NORMAL AND DISEASED 589 VESSELS: ROLE OF OXIDATIVE STRESS M. Mayr, Y-.L. Chung, Q. Xu (London, UK) 437 SELDI-TOF MS: A HIGH-THROUGHPUT TOOL FOR HIGH-DENSITY LIPOPROTEIN 589 PROTEIN FINGERPRINTING J.H.M. Levels, B. Bleijlevens, J.A. Kuivenhoven, J.M.F.G. Aerts, J.C. Meijers (Amsterdam, The Netherlands) 438 FOLATE RECEPTORS AND PROTEOMIC ANALYSIS OF ENDOTHELIAL CELLS IN 590 ATHEROSCLEROSIS F. Antohe, L. Radulescu, E. Uyy, P.S. Low, M. Simionescu (Bucharest, Romania and West Lafayette, IN, USA) 439 POSTER WITHDRAWN – 440 PLASMA AND URINE SAMPLE PREPARATION USING MULTIDIMENSIONAL 590 SOLID-PHASE EXTRACTION FOR ANALYSIS OF F2 ISOPROSTANES BY LC-MS/MS B. Zhang, K. Saku (Fukuoka, Japan) 441 IDENTIFICATION OF SOLUBLE TNF-LIKE WEAK INDUCER OF APOPTOSIS (STWEAK) 590 BY SELDI TOF-MS PROTEINCHIP SYSTEM AS A POSSIBLE BIOMARKER OF ATHEROSCLEROSIS L.M. Blanco-Colio, J.L. Martin-Ventura, B. Muñoz-Garcia, J. Orbe, J.A. Paramo, J.B. Michel, O. Meilhac, J. Egido (Paris, France, Madrid and Pamplona, Spain) 442 ASYMMETRIC DIMETHYLARGININE - COMPARISON OF CHROMATOGRAPHY AND 590 IMMUNOMETRIC METHODS R. Siroka, R. Cibulka, D. Rajdl, J. Racek, L. Trefil (Pilsen, Czech Republic) 443 THE COMPETITION BETWEEN APOLIPOPROTEIN E AND SERUM AMYLOID PROTEIN 591 FOR COMMON BINDING SITE(S) IN AMYLOID MODEL IN VITRO A.D. Dergunov (Moscow, Russia) 444 A CELL - BASED SYSTEM FOR THE HIGH-THROUGHPUT IDENTIFICATION OF 591 COLLAGEN RECEPTOR ANTAGONISTS C. Caserini, M.G. Giribaldi, S. Bovolenta, L. Scarabollolo (Milan, Italy) 445 PROTEOMIC ANALYSIS OF MEMBRANE MICRODOMAINS DERIVED FROM BOTH 591 FAILING AND NON-FAILING HUMAN HEARTS M. Brioschi, R. Wait, G. Polvani, L. Mussoni, E. Tremoli, C. Banfi (Milan, Italy and London, UK)

T H U R S D A Y

196 Welcome to the ISA congress 2006 please join us at our satellite symposium

CB1 blockade: new approach for the management of atherogenic dyslipidaemia and multiple cardiometabolic risk factors in abdominally obese patients

Monday 19 June 2006 11:00–12:30 Meeting room 1

Supported in part by an educational grant from

CME Accreditation We are pleased to inform you that this is a CME accredited session. Please refer to the CME section of the final programme for further details on credits obtained (U.E.M.S-EACCME/Italian ECM/Federation of the Royal College of Physicians of the UK/AMA).

Topic Index T (Bold number = Abstract page on the right hand side column of the Final Program) O P ACAT Inhibitors AIDS as an Atherogenic Disease 501 (Th-P15:39), 544 (Th-P15:232, Th-P15:236), 547 (Th-P16:249), 548 162 (Tu-W21:2), 163 (Tu-W21:3, Tu-W21:5), 399 (We-P11:240, I (Th-P16:250, Th-P16:251, Th-P16:252, Th-P16:253) We-P11:241, We-P11:242, We-P11:243, We-P11:244), 400 (We-P11:245, We-P11:246, We-P11:248), 416 (We-P13:318), 544 (Th-P15:233) C Acute Coronary Syndromes 11 (Mo-W1:2), 22 (Mo-W6:7), 24 (Mo-W7:7), 29 (Mo-W10:5), 58 (Mo-P1:56), (Mo-P1:92), (Mo-P1:146), (Mo-P2:168, Mo-P2:169, Algorithms for Risk Evaluation 66 78 83 6 (Su-S3:4), 37 (Mo-W14:4), 46 (Mo-P1:1, Mo-P1:2, Mo-P1:3, Mo-P1:4, Mo-P2:170), 84 (Mo-P2:171, Mo-P2:172, Mo-P2:173, Mo-P2:174, Mo-P1:5), (Mo-P1:8), (Mo-P1:34), (Mo-P1:39), (Mo-P1:58), Mo-P2:175), (Mo-P2:176, Mo-P2:177, Mo-P2:178, Mo-P2:179), 47 53 54 58 I 85 86 61 (Mo-P1:70), 65 (Mo-P1:90), 66 (Mo-P1:91), 70 (Mo-P1:112), 74 (Mo-P2:180, Mo-P2:182, Mo-P2:184), 87 (Mo-P2:185, Mo-P2:186), 91 (Mo-P1:129), (Mo-P1:162), (Mo-P4:248), (Mo-P5:312), (Mo-P2:207), (Mo-P2:208), (Mo-P3:221), (Mo-P4:235, 81 100 114 261 92 95 98 (Tu-P9:350), (Tu-P9:368), (We-PL3:3), (We-P11:106), N Mo-P4:236), (Mo-P5:324, Mo-P5:327), (Mo-P5:343), 265 301 369 376 117 121 122 (We-P11:137), (We-P13:352), (Th-W50:1), (Th-W50:3, (Mo-P5:349), (Mo-P6:443), (Tu-W18:4), (Tu-W20:8), 424 466 467 143 157 162 171 Th-W50:4), (Th-W56:8), (Th-W58:1, Th-W58:2), D (Tu-W25:6), (Tu-P7:89), (Tu-P7:123), (Tu-P7:241), 480 483 504 204 211 237 244 (Th-P15:53) (Tu-P7:270), 246 (Tu-P7:279), 268 (Tu-P9:380), 278 (Tu-P10:425, E Tu-P10:428), 285 (Tu-P10:460), 286 (Tu-P10:461), 288 (Tu-P10:470), 297 Ancillary Properties of Lipid Lowering Drugs (Tu-P10:510), 301 (We-PL3:2), 310 (We-W32:6), 314 (We-W35:2), 316 9 (Mo-ML1:1), 32 (Mo-W11:7), 122 (Mo-P5:348), 126 (Mo-P5:366), 250 (We-W35:6), 332 (We-W44:3), 335 (We-W45:4), 390 (We-P11:200), 393 X (Tu-P8:300), 466 (Th-W49:6), 468 (Th-W51:2), 514 (Th-P15:99), 549 (We-P11:214), 396 (We-P11:231), 397 (We-P11:233), 398 (We-P11:237, We-P11:239), (We-P13:349), (We-P14:463), (Th-W46:7), (Th-P16:256, Th-P16:257), 558 (Th-P16:293), 569 (Th-P16:344), 577 423 448 460 486 (Th-P16:381), (Th-P16:406) (Th-W59:4), 533 (Th-P15:184), 535 (Th-P15:192), 551 (Th-P16:264), 553 582 (Th-P16:274), 563 (Th-P16:319), 569 (Th-P16:343), 581 (Th-P16:399), 588 (Th-P17:430) Angina 69 (Mo-P1:108), 74 (Mo-P1:129), 78 (Mo-P1:145), 84 (Mo-P2:174), 85 Adipose Tissue (Mo-P2:178), 89 (Mo-P2:195), 93 (Mo-P2:215), 97 (Mo-P4:234), 98 13 (Mo-W2:1), 40 (Mo-S4:1, Mo-S4:3), 55 (Mo-P1:46), 97 (Mo-P3:232), 114 (Mo-P4:235, Mo-P4:236, Mo-P4:238, Mo-P4:239), 100 (Mo-P4:246), 114 (Mo-P5:311), 164 (Tu-W22:1, Tu-W22:2, Tu-W22:3), 165 (Tu-W22:4, (Mo-P5:312), 117 (Mo-P5:324, Mo-P5:327), 127 (Mo-P5:373), 131 Tu-W22:5, Tu-W22:6, Tu-W22:7), 185 (Tu-P7:1, Tu-P7:2, Tu-P7:3, (Mo-P6:387), 146 (Mo-P6:455), 217 (Tu-P7:145), 266 (Tu-P9:372), 270 Tu-P7:4, Tu-P7:5), 186 (Tu-P7:6, Tu-P7:7, Tu-P7:8, Tu-P7:9), 187 (Tu-P10:391), 276 (Tu-P10:420), 278 (Tu-P10:429), 279 (Tu-P10:432), (Tu-P7:12, Tu-P7:14), 188 (Tu-P7:15), 192 (Tu-P7:36), 195 (Tu-P7:49), 281 (Tu-P10:439), 282 (Tu-P10:444), 286 (Tu-P10:462), 288 196 (Tu-P7:53), 202 (Tu-P7:82), 206 (Tu-P7:97), 214 (Tu-P7:136), 221 (Tu-P10:470), 291 (Tu-P10:483), 357 (We-P11:51, We-P11:53) (Tu-P7:165), 282 (Tu-P10:445), 301 (We-PL3:1), 311 (We-W33:3, We-W33:5), (We-W33:7), (We-W37:7), (We-W42:7), 312 320 330 341 Angiogenesis: Stimulation and Antagonism (We-S14:4), (We-P11:77), (We-P11:79), (We-P11:103), 362 363 368 371 33 (Mo-W12:5), 34 (Mo-W13:2), 94 (Mo-P3:217), 97 (Mo-P3:232), 106 (We-P11:115), (We-P11:130), (We-P11:135), (We-P11:142), 374 375 377 (Mo-P4:272), 110 (Mo-P4:292), 114 (Mo-P5:312), 185 (Tu-P7:5), 190 (We-P11:148), (We-P11:157), (We-P12:285), 378 380 408 415 (Tu-P7:25, Tu-P7:26, Tu-P7:27, Tu-P7:28), 191 (Tu-P7:29, Tu-P7:30, (We-P13:315), (We-P13:319), (We-P13:323), (We-P13:335), 416 417 420 Tu-P7:31, Tu-P7:32), 192 (Tu-P7:33, Tu-P7:34, Tu-P7:35, Tu-P7:36, (We-P14:383), (Th-W48:5), (Th-W58:6), (Th-P15:29), 431 463 484 498 Tu-P7:37), 198 (Tu-P7:64), 199 (Tu-P7:68), 215 (Tu-P7:137), 241 (Th-P15:108), (Th-P15:125) 516 520 (Tu-P7:258), 251 (Tu-P8:304), 295 (Tu-P10:503), 307 (We-W31:3), 312 (We-W34:1), 352 (We-P11:32), 408 (We-P12:283), 462 (Th-W48:1), 490 Ageing (Th-W61:8), 571 (Th-P16:351) 35 (Mo-W14:1), 50 (Mo-P1:23), 65 (Mo-P1:87), 73 (Mo-P1:123), 77 (Mo-P1:140), 82 (Mo-P1:165), 106 (Mo-P4:275), 107 (Mo-P4:280), 108 Animal Models (Mo-P4:284), 109 (Mo-P4:287), 128 (Mo-P5:375), 129 (Mo-P6:379), 188 (Tu-P7:17, Tu-P7:18), (Tu-P7:19, Tu-P7:20, Tu-P7:22, Tu-P7:23), 12 (Mo-W1:6), 13 (Mo-W2:1), 18 (Mo-W4:7), 22 (Mo-W6:7), 25 (Mo-W8:4, 189 193 Mo-W8:6), (Mo-W10:1), (Mo-W12:3), (Mo-W12:6), (Tu-P7:39), 200 (Tu-P7:69), 209 (Tu-P7:112), 250 (Tu-P8:296), 258 28 32 33 38 (Tu-P9:335), (Tu-P9:365), (Tu-P10:405), (Tu-P10:488), (Mo-W15:4), 39 (Mo-W15:5, Mo-W15:6), 40 (Mo-S4:3), 87 (Mo-P2:185), 264 273 292 294 (Mo-P3:222), (Mo-P3:226, Mo-P3:229), (Mo-P5:298), (Tu-P10:498), 303 (We-ML7:1), 317 (We-W36:3), 323 (We-W39:4), 346 95 96 111 144 (We-P11:2), (We-P11:31), (We-P11:253), (We-P11:255), (Mo-P6:447), 151 (Tu-ML5:1), 152 (Tu-W16:2), 153 (Tu-W16:6), 162 352 401 402 411 (Tu-W21:1), (Tu-W25:5), (Tu-P7:1, Tu-P7:3), (Tu-P7:24, (We-P12:294), 415 (We-P13:313), 424 (We-P13:354), 438 (We-P14:414), 170 185 190 (We-P14:458), (Th-W48:5), (Th-W52:1), (Th-W52:4, Tu-P7:25), 191 (Tu-P7:29), 193 (Tu-P7:39, Tu-P7:40, Tu-P7:41, 447 463 470 471 Tu-P7:42), (Tu-P7:43, Tu-P7:45, Tu-P7:46), (Tu-P7:47, Tu-P7:48, Th-W52:5, Th-W52:6), 472 (Th-W52:7), 474 (Th-W54:2), 480 194 195 Tu-P7:50), (Tu-P7:51, Tu-P7:52, Tu-P7:54), (Tu-P7:56, (Th-W56:6), 487 (Th-W60:4), 492 (Th-P15:5), 539 (Th-P15:212), 542 196 197 Tu-P7:58), (Tu-P7:61, Tu-P7:63, Tu-P7:64), (Tu-P7:65, Tu-P7:66, (Th-P15:224), 590 (Th-P17:443) 198 199 Tu-P7:67, Tu-P7:68), 200 (Tu-P7:69, Tu-P7:70, Tu-P7:71, Tu-P7:72), 201 Aggressive versus Non-Aggressive Cholesterol Lowering (Tu-P7:73, Tu-P7:74, Tu-P7:76, Tu-P7:77), 202 (Tu-P7:79, Tu-P7:81), 203 36 (Mo-W14:2), 43 (Mo-S7:1), 122 (Mo-P5:348), 161 (Tu-W20:4, (Tu-P7:83), 205 (Tu-P7:93, Tu-P7:94), 218 (Tu-P7:153), 219 (Tu-P7:155, Tu-W20:5), 178 (Tu-W29:5), 179 (Tu-W29:7), 181 (Tu-S10:1), 182 Tu-P7:157), 220 (Tu-P7:159), 224 (Tu-P7:181), 227 (Tu-P7:194), 228 (Tu-S10:2), 286 (Tu-P10:463, Tu-P10:464), 551 (Th-P16:264), 569 (Tu-P7:196, Tu-P7:197, Tu-P7:199), 236 (Tu-P7:236), 237 (Tu-P7:240), (Th-P16:346), 582 (Th-P16:406) 242 (Tu-P7:262), 243 (Tu-P7:267), 244 (Tu-P7:273), 245 (Tu-P7:277), 250

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

199 T Topic Index O

P ACAT Inhibitors AIDS as an Atherogenic Disease 501 (Th-P15:39), 544 (Th-P15:232, Th-P15:236), 547 (Th-P16:249), 548 162 (Tu-W21:2), 163 (Tu-W21:3, Tu-W21:5), 399 (We-P11:240, I (Th-P16:250, Th-P16:251, Th-P16:252, Th-P16:253) We-P11:241, We-P11:242, We-P11:243, We-P11:244), 400 (We-P11:245, We-P11:246, We-P11:248), 416 (We-P13:318), 544 (Th-P15:233) Acute Coronary Syndromes C 11 (Mo-W1:2), 22 (Mo-W6:7), 24 (Mo-W7:7), 29 (Mo-W10:5), 58 (Mo-P1:56), (Mo-P1:92), (Mo-P1:146), (Mo-P2:168, Mo-P2:169, Algorithms for Risk Evaluation 66 78 83 6 (Su-S3:4), 37 (Mo-W14:4), 46 (Mo-P1:1, Mo-P1:2, Mo-P1:3, Mo-P1:4, Mo-P2:170), 84 (Mo-P2:171, Mo-P2:172, Mo-P2:173, Mo-P2:174, Mo-P1:5), (Mo-P1:8), (Mo-P1:34), (Mo-P1:39), (Mo-P1:58), Mo-P2:175), (Mo-P2:176, Mo-P2:177, Mo-P2:178, Mo-P2:179), 47 53 54 58 85 86 61 (Mo-P1:70), 65 (Mo-P1:90), 66 (Mo-P1:91), 70 (Mo-P1:112), 74 (Mo-P2:180, Mo-P2:182, Mo-P2:184), 87 (Mo-P2:185, Mo-P2:186), 91 (Mo-P1:129), (Mo-P1:162), (Mo-P4:248), (Mo-P5:312), I (Mo-P2:207), (Mo-P2:208), (Mo-P3:221), (Mo-P4:235, 81 100 114 261 92 95 98 (Tu-P9:350), (Tu-P9:368), (We-PL3:3), (We-P11:106), Mo-P4:236), (Mo-P5:324, Mo-P5:327), (Mo-P5:343), 265 301 369 376 117 121 122 (We-P11:137), (We-P13:352), (Th-W50:1), (Th-W50:3, (Mo-P5:349), (Mo-P6:443), (Tu-W18:4), (Tu-W20:8), 424 466 467 N 143 157 162 171 Th-W50:4), (Th-W56:8), (Th-W58:1, Th-W58:2), (Tu-W25:6), (Tu-P7:89), (Tu-P7:123), (Tu-P7:241), 480 483 504 204 211 237 244 (Th-P15:53) D (Tu-P7:270), 246 (Tu-P7:279), 268 (Tu-P9:380), 278 (Tu-P10:425, Tu-P10:428), 285 (Tu-P10:460), 286 (Tu-P10:461), 288 (Tu-P10:470), 297 Ancillary Properties of Lipid Lowering Drugs (Tu-P10:510), 301 (We-PL3:2), 310 (We-W32:6), 314 (We-W35:2), 316 E 9 (Mo-ML1:1), 32 (Mo-W11:7), 122 (Mo-P5:348), 126 (Mo-P5:366), 250 (We-W35:6), 332 (We-W44:3), 335 (We-W45:4), 390 (We-P11:200), 393 (Tu-P8:300), 466 (Th-W49:6), 468 (Th-W51:2), 514 (Th-P15:99), 549 (We-P11:214), 396 (We-P11:231), 397 (We-P11:233), 398 (We-P11:237, X We-P11:239), (We-P13:349), (We-P14:463), (Th-W46:7), (Th-P16:256, Th-P16:257), 558 (Th-P16:293), 569 (Th-P16:344), 577 423 448 460 486 (Th-P16:381), (Th-P16:406) (Th-W59:4), 533 (Th-P15:184), 535 (Th-P15:192), 551 (Th-P16:264), 553 582 (Th-P16:274), 563 (Th-P16:319), 569 (Th-P16:343), 581 (Th-P16:399), 588 (Th-P17:430) Angina 69 (Mo-P1:108), 74 (Mo-P1:129), 78 (Mo-P1:145), 84 (Mo-P2:174), 85 Adipose Tissue (Mo-P2:178), 89 (Mo-P2:195), 93 (Mo-P2:215), 97 (Mo-P4:234), 98 13 (Mo-W2:1), 40 (Mo-S4:1, Mo-S4:3), 55 (Mo-P1:46), 97 (Mo-P3:232), 114 (Mo-P4:235, Mo-P4:236, Mo-P4:238, Mo-P4:239), 100 (Mo-P4:246), 114 (Mo-P5:311), 164 (Tu-W22:1, Tu-W22:2, Tu-W22:3), 165 (Tu-W22:4, (Mo-P5:312), 117 (Mo-P5:324, Mo-P5:327), 127 (Mo-P5:373), 131 Tu-W22:5, Tu-W22:6, Tu-W22:7), 185 (Tu-P7:1, Tu-P7:2, Tu-P7:3, (Mo-P6:387), 146 (Mo-P6:455), 217 (Tu-P7:145), 266 (Tu-P9:372), 270 Tu-P7:4, Tu-P7:5), 186 (Tu-P7:6, Tu-P7:7, Tu-P7:8, Tu-P7:9), 187 (Tu-P10:391), 276 (Tu-P10:420), 278 (Tu-P10:429), 279 (Tu-P10:432), (Tu-P7:12, Tu-P7:14), 188 (Tu-P7:15), 192 (Tu-P7:36), 195 (Tu-P7:49), 281 (Tu-P10:439), 282 (Tu-P10:444), 286 (Tu-P10:462), 288 196 (Tu-P7:53), 202 (Tu-P7:82), 206 (Tu-P7:97), 214 (Tu-P7:136), 221 (Tu-P10:470), 291 (Tu-P10:483), 357 (We-P11:51, We-P11:53) (Tu-P7:165), 282 (Tu-P10:445), 301 (We-PL3:1), 311 (We-W33:3, We-W33:5), (We-W33:7), (We-W37:7), (We-W42:7), 312 320 330 341 Angiogenesis: Stimulation and Antagonism (We-S14:4), (We-P11:77), (We-P11:79), (We-P11:103), 362 363 368 371 33 (Mo-W12:5), 34 (Mo-W13:2), 94 (Mo-P3:217), 97 (Mo-P3:232), 106 (We-P11:115), (We-P11:130), (We-P11:135), (We-P11:142), 374 375 377 (Mo-P4:272), 110 (Mo-P4:292), 114 (Mo-P5:312), 185 (Tu-P7:5), 190 (We-P11:148), (We-P11:157), (We-P12:285), 378 380 408 415 (Tu-P7:25, Tu-P7:26, Tu-P7:27, Tu-P7:28), 191 (Tu-P7:29, Tu-P7:30, (We-P13:315), (We-P13:319), (We-P13:323), (We-P13:335), 416 417 420 Tu-P7:31, Tu-P7:32), 192 (Tu-P7:33, Tu-P7:34, Tu-P7:35, Tu-P7:36, (We-P14:383), (Th-W48:5), (Th-W58:6), (Th-P15:29), 431 463 484 498 Tu-P7:37), 198 (Tu-P7:64), 199 (Tu-P7:68), 215 (Tu-P7:137), 241 (Th-P15:108), (Th-P15:125) 516 520 (Tu-P7:258), 251 (Tu-P8:304), 295 (Tu-P10:503), 307 (We-W31:3), 312 (We-W34:1), 352 (We-P11:32), 408 (We-P12:283), 462 (Th-W48:1), 490 Ageing (Th-W61:8), 571 (Th-P16:351) 35 (Mo-W14:1), 50 (Mo-P1:23), 65 (Mo-P1:87), 73 (Mo-P1:123), 77 (Mo-P1:140), 82 (Mo-P1:165), 106 (Mo-P4:275), 107 (Mo-P4:280), 108 Animal Models (Mo-P4:284), 109 (Mo-P4:287), 128 (Mo-P5:375), 129 (Mo-P6:379), 188 (Tu-P7:17, Tu-P7:18), (Tu-P7:19, Tu-P7:20, Tu-P7:22, Tu-P7:23), 12 (Mo-W1:6), 13 (Mo-W2:1), 18 (Mo-W4:7), 22 (Mo-W6:7), 25 (Mo-W8:4, 189 193 Mo-W8:6), (Mo-W10:1), (Mo-W12:3), (Mo-W12:6), (Tu-P7:39), 200 (Tu-P7:69), 209 (Tu-P7:112), 250 (Tu-P8:296), 258 28 32 33 38 (Tu-P9:335), (Tu-P9:365), (Tu-P10:405), (Tu-P10:488), (Mo-W15:4), 39 (Mo-W15:5, Mo-W15:6), 40 (Mo-S4:3), 87 (Mo-P2:185), 264 273 292 294 (Mo-P3:222), (Mo-P3:226, Mo-P3:229), (Mo-P5:298), (Tu-P10:498), 303 (We-ML7:1), 317 (We-W36:3), 323 (We-W39:4), 346 95 96 111 144 (We-P11:2), (We-P11:31), (We-P11:253), (We-P11:255), (Mo-P6:447), 151 (Tu-ML5:1), 152 (Tu-W16:2), 153 (Tu-W16:6), 162 352 401 402 411 (Tu-W21:1), (Tu-W25:5), (Tu-P7:1, Tu-P7:3), (Tu-P7:24, (We-P12:294), 415 (We-P13:313), 424 (We-P13:354), 438 (We-P14:414), 170 185 190 (We-P14:458), (Th-W48:5), (Th-W52:1), (Th-W52:4, Tu-P7:25), 191 (Tu-P7:29), 193 (Tu-P7:39, Tu-P7:40, Tu-P7:41, 447 463 470 471 Tu-P7:42), (Tu-P7:43, Tu-P7:45, Tu-P7:46), (Tu-P7:47, Tu-P7:48, Th-W52:5, Th-W52:6), 472 (Th-W52:7), 474 (Th-W54:2), 480 194 195 Tu-P7:50), (Tu-P7:51, Tu-P7:52, Tu-P7:54), (Tu-P7:56, (Th-W56:6), 487 (Th-W60:4), 492 (Th-P15:5), 539 (Th-P15:212), 542 196 197 Tu-P7:58), (Tu-P7:61, Tu-P7:63, Tu-P7:64), (Tu-P7:65, Tu-P7:66, (Th-P15:224), 590 (Th-P17:443) 198 199 Tu-P7:67, Tu-P7:68), 200 (Tu-P7:69, Tu-P7:70, Tu-P7:71, Tu-P7:72), 201 Aggressive versus Non-Aggressive Cholesterol Lowering (Tu-P7:73, Tu-P7:74, Tu-P7:76, Tu-P7:77), 202 (Tu-P7:79, Tu-P7:81), 203 36 (Mo-W14:2), 43 (Mo-S7:1), 122 (Mo-P5:348), 161 (Tu-W20:4, (Tu-P7:83), 205 (Tu-P7:93, Tu-P7:94), 218 (Tu-P7:153), 219 (Tu-P7:155, Tu-W20:5), 178 (Tu-W29:5), 179 (Tu-W29:7), 181 (Tu-S10:1), 182 Tu-P7:157), 220 (Tu-P7:159), 224 (Tu-P7:181), 227 (Tu-P7:194), 228 (Tu-S10:2), 286 (Tu-P10:463, Tu-P10:464), 551 (Th-P16:264), 569 (Tu-P7:196, Tu-P7:197, Tu-P7:199), 236 (Tu-P7:236), 237 (Tu-P7:240), (Th-P16:346), 582 (Th-P16:406) 242 (Tu-P7:262), 243 (Tu-P7:267), 244 (Tu-P7:273), 245 (Tu-P7:277), 250

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

200 Topic Index T O ACAT Inhibitors AIDS as an Atherogenic Disease P 501 (Th-P15:39), 544 (Th-P15:232, Th-P15:236), 547 (Th-P16:249), 548 162 (Tu-W21:2), 163 (Tu-W21:3, Tu-W21:5), 399 (We-P11:240, (Th-P16:250, Th-P16:251, Th-P16:252, Th-P16:253) We-P11:241, We-P11:242, We-P11:243, We-P11:244), 400 (We-P11:245, I We-P11:246, We-P11:248), 416 (We-P13:318), 544 (Th-P15:233) Acute Coronary Syndromes 11 (Mo-W1:2), 22 (Mo-W6:7), 24 (Mo-W7:7), 29 (Mo-W10:5), 58 C (Mo-P1:56), (Mo-P1:92), (Mo-P1:146), (Mo-P2:168, Mo-P2:169, Algorithms for Risk Evaluation 66 78 83 6 (Su-S3:4), 37 (Mo-W14:4), 46 (Mo-P1:1, Mo-P1:2, Mo-P1:3, Mo-P1:4, Mo-P2:170), 84 (Mo-P2:171, Mo-P2:172, Mo-P2:173, Mo-P2:174, Mo-P1:5), (Mo-P1:8), (Mo-P1:34), (Mo-P1:39), (Mo-P1:58), Mo-P2:175), (Mo-P2:176, Mo-P2:177, Mo-P2:178, Mo-P2:179), 47 53 54 58 85 86 61 (Mo-P1:70), 65 (Mo-P1:90), 66 (Mo-P1:91), 70 (Mo-P1:112), 74 (Mo-P2:180, Mo-P2:182, Mo-P2:184), 87 (Mo-P2:185, Mo-P2:186), 91 (Mo-P1:129), (Mo-P1:162), (Mo-P4:248), (Mo-P5:312), (Mo-P2:207), (Mo-P2:208), (Mo-P3:221), (Mo-P4:235, 81 100 114 261 I 92 95 98 (Tu-P9:350), (Tu-P9:368), (We-PL3:3), (We-P11:106), Mo-P4:236), (Mo-P5:324, Mo-P5:327), (Mo-P5:343), 265 301 369 376 117 121 122 (We-P11:137), (We-P13:352), (Th-W50:1), (Th-W50:3, (Mo-P5:349), (Mo-P6:443), (Tu-W18:4), (Tu-W20:8), 424 466 467 143 157 162 171 Th-W50:4), (Th-W56:8), (Th-W58:1, Th-W58:2), N (Tu-W25:6), (Tu-P7:89), (Tu-P7:123), (Tu-P7:241), 480 483 504 204 211 237 244 (Th-P15:53) (Tu-P7:270), 246 (Tu-P7:279), 268 (Tu-P9:380), 278 (Tu-P10:425, D Tu-P10:428), 285 (Tu-P10:460), 286 (Tu-P10:461), 288 (Tu-P10:470), 297 Ancillary Properties of Lipid Lowering Drugs (Tu-P10:510), 301 (We-PL3:2), 310 (We-W32:6), 314 (We-W35:2), 316 9 (Mo-ML1:1), 32 (Mo-W11:7), 122 (Mo-P5:348), 126 (Mo-P5:366), 250 E (We-W35:6), 332 (We-W44:3), 335 (We-W45:4), 390 (We-P11:200), 393 (Tu-P8:300), 466 (Th-W49:6), 468 (Th-W51:2), 514 (Th-P15:99), 549 (We-P11:214), 396 (We-P11:231), 397 (We-P11:233), 398 (We-P11:237, We-P11:239), (We-P13:349), (We-P14:463), (Th-W46:7), (Th-P16:256, Th-P16:257), 558 (Th-P16:293), 569 (Th-P16:344), 577 X 423 448 460 486 (Th-P16:381), (Th-P16:406) (Th-W59:4), 533 (Th-P15:184), 535 (Th-P15:192), 551 (Th-P16:264), 553 582 (Th-P16:274), 563 (Th-P16:319), 569 (Th-P16:343), 581 (Th-P16:399), 588 (Th-P17:430) Angina 69 (Mo-P1:108), 74 (Mo-P1:129), 78 (Mo-P1:145), 84 (Mo-P2:174), 85 Adipose Tissue (Mo-P2:178), 89 (Mo-P2:195), 93 (Mo-P2:215), 97 (Mo-P4:234), 98 13 (Mo-W2:1), 40 (Mo-S4:1, Mo-S4:3), 55 (Mo-P1:46), 97 (Mo-P3:232), 114 (Mo-P4:235, Mo-P4:236, Mo-P4:238, Mo-P4:239), 100 (Mo-P4:246), 114 (Mo-P5:311), 164 (Tu-W22:1, Tu-W22:2, Tu-W22:3), 165 (Tu-W22:4, (Mo-P5:312), 117 (Mo-P5:324, Mo-P5:327), 127 (Mo-P5:373), 131 Tu-W22:5, Tu-W22:6, Tu-W22:7), 185 (Tu-P7:1, Tu-P7:2, Tu-P7:3, (Mo-P6:387), 146 (Mo-P6:455), 217 (Tu-P7:145), 266 (Tu-P9:372), 270 Tu-P7:4, Tu-P7:5), 186 (Tu-P7:6, Tu-P7:7, Tu-P7:8, Tu-P7:9), 187 (Tu-P10:391), 276 (Tu-P10:420), 278 (Tu-P10:429), 279 (Tu-P10:432), (Tu-P7:12, Tu-P7:14), 188 (Tu-P7:15), 192 (Tu-P7:36), 195 (Tu-P7:49), 281 (Tu-P10:439), 282 (Tu-P10:444), 286 (Tu-P10:462), 288 196 (Tu-P7:53), 202 (Tu-P7:82), 206 (Tu-P7:97), 214 (Tu-P7:136), 221 (Tu-P10:470), 291 (Tu-P10:483), 357 (We-P11:51, We-P11:53) (Tu-P7:165), 282 (Tu-P10:445), 301 (We-PL3:1), 311 (We-W33:3, We-W33:5), (We-W33:7), (We-W37:7), (We-W42:7), 312 320 330 341 Angiogenesis: Stimulation and Antagonism (We-S14:4), (We-P11:77), (We-P11:79), (We-P11:103), 362 363 368 371 33 (Mo-W12:5), 34 (Mo-W13:2), 94 (Mo-P3:217), 97 (Mo-P3:232), 106 (We-P11:115), (We-P11:130), (We-P11:135), (We-P11:142), 374 375 377 (Mo-P4:272), 110 (Mo-P4:292), 114 (Mo-P5:312), 185 (Tu-P7:5), 190 (We-P11:148), (We-P11:157), (We-P12:285), 378 380 408 415 (Tu-P7:25, Tu-P7:26, Tu-P7:27, Tu-P7:28), 191 (Tu-P7:29, Tu-P7:30, (We-P13:315), (We-P13:319), (We-P13:323), (We-P13:335), 416 417 420 Tu-P7:31, Tu-P7:32), 192 (Tu-P7:33, Tu-P7:34, Tu-P7:35, Tu-P7:36, (We-P14:383), (Th-W48:5), (Th-W58:6), (Th-P15:29), 431 463 484 498 Tu-P7:37), 198 (Tu-P7:64), 199 (Tu-P7:68), 215 (Tu-P7:137), 241 (Th-P15:108), (Th-P15:125) 516 520 (Tu-P7:258), 251 (Tu-P8:304), 295 (Tu-P10:503), 307 (We-W31:3), 312 (We-W34:1), 352 (We-P11:32), 408 (We-P12:283), 462 (Th-W48:1), 490 Ageing (Th-W61:8), 571 (Th-P16:351) 35 (Mo-W14:1), 50 (Mo-P1:23), 65 (Mo-P1:87), 73 (Mo-P1:123), 77 (Mo-P1:140), 82 (Mo-P1:165), 106 (Mo-P4:275), 107 (Mo-P4:280), 108 Animal Models (Mo-P4:284), 109 (Mo-P4:287), 128 (Mo-P5:375), 129 (Mo-P6:379), 188 (Tu-P7:17, Tu-P7:18), (Tu-P7:19, Tu-P7:20, Tu-P7:22, Tu-P7:23), 12 (Mo-W1:6), 13 (Mo-W2:1), 18 (Mo-W4:7), 22 (Mo-W6:7), 25 (Mo-W8:4, 189 193 Mo-W8:6), (Mo-W10:1), (Mo-W12:3), (Mo-W12:6), (Tu-P7:39), 200 (Tu-P7:69), 209 (Tu-P7:112), 250 (Tu-P8:296), 258 28 32 33 38 (Tu-P9:335), (Tu-P9:365), (Tu-P10:405), (Tu-P10:488), (Mo-W15:4), 39 (Mo-W15:5, Mo-W15:6), 40 (Mo-S4:3), 87 (Mo-P2:185), 264 273 292 294 (Mo-P3:222), (Mo-P3:226, Mo-P3:229), (Mo-P5:298), (Tu-P10:498), 303 (We-ML7:1), 317 (We-W36:3), 323 (We-W39:4), 346 95 96 111 144 (We-P11:2), (We-P11:31), (We-P11:253), (We-P11:255), (Mo-P6:447), 151 (Tu-ML5:1), 152 (Tu-W16:2), 153 (Tu-W16:6), 162 352 401 402 411 (Tu-W21:1), (Tu-W25:5), (Tu-P7:1, Tu-P7:3), (Tu-P7:24, (We-P12:294), 415 (We-P13:313), 424 (We-P13:354), 438 (We-P14:414), 170 185 190 (We-P14:458), (Th-W48:5), (Th-W52:1), (Th-W52:4, Tu-P7:25), 191 (Tu-P7:29), 193 (Tu-P7:39, Tu-P7:40, Tu-P7:41, 447 463 470 471 Tu-P7:42), (Tu-P7:43, Tu-P7:45, Tu-P7:46), (Tu-P7:47, Tu-P7:48, Th-W52:5, Th-W52:6), 472 (Th-W52:7), 474 (Th-W54:2), 480 194 195 Tu-P7:50), (Tu-P7:51, Tu-P7:52, Tu-P7:54), (Tu-P7:56, (Th-W56:6), 487 (Th-W60:4), 492 (Th-P15:5), 539 (Th-P15:212), 542 196 197 Tu-P7:58), (Tu-P7:61, Tu-P7:63, Tu-P7:64), (Tu-P7:65, Tu-P7:66, (Th-P15:224), 590 (Th-P17:443) 198 199 Tu-P7:67, Tu-P7:68), 200 (Tu-P7:69, Tu-P7:70, Tu-P7:71, Tu-P7:72), 201 Aggressive versus Non-Aggressive Cholesterol Lowering (Tu-P7:73, Tu-P7:74, Tu-P7:76, Tu-P7:77), 202 (Tu-P7:79, Tu-P7:81), 203 36 (Mo-W14:2), 43 (Mo-S7:1), 122 (Mo-P5:348), 161 (Tu-W20:4, (Tu-P7:83), 205 (Tu-P7:93, Tu-P7:94), 218 (Tu-P7:153), 219 (Tu-P7:155, Tu-W20:5), 178 (Tu-W29:5), 179 (Tu-W29:7), 181 (Tu-S10:1), 182 Tu-P7:157), 220 (Tu-P7:159), 224 (Tu-P7:181), 227 (Tu-P7:194), 228 (Tu-S10:2), 286 (Tu-P10:463, Tu-P10:464), 551 (Th-P16:264), 569 (Tu-P7:196, Tu-P7:197, Tu-P7:199), 236 (Tu-P7:236), 237 (Tu-P7:240), (Th-P16:346), 582 (Th-P16:406) 242 (Tu-P7:262), 243 (Tu-P7:267), 244 (Tu-P7:273), 245 (Tu-P7:277), 250

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

201 T Topic Index O

P ACAT Inhibitors AIDS as an Atherogenic Disease 501 (Th-P15:39), 544 (Th-P15:232, Th-P15:236), 547 (Th-P16:249), 548 162 (Tu-W21:2), 163 (Tu-W21:3, Tu-W21:5), 399 (We-P11:240, I (Th-P16:250, Th-P16:251, Th-P16:252, Th-P16:253) We-P11:241, We-P11:242, We-P11:243, We-P11:244), 400 (We-P11:245, We-P11:246, We-P11:248), 416 (We-P13:318), 544 (Th-P15:233) Acute Coronary Syndromes C 11 (Mo-W1:2), 22 (Mo-W6:7), 24 (Mo-W7:7), 29 (Mo-W10:5), 58 (Mo-P1:56), (Mo-P1:92), (Mo-P1:146), (Mo-P2:168, Mo-P2:169, Algorithms for Risk Evaluation 66 78 83 6 (Su-S3:4), 37 (Mo-W14:4), 46 (Mo-P1:1, Mo-P1:2, Mo-P1:3, Mo-P1:4, Mo-P2:170), 84 (Mo-P2:171, Mo-P2:172, Mo-P2:173, Mo-P2:174, Mo-P1:5), (Mo-P1:8), (Mo-P1:34), (Mo-P1:39), (Mo-P1:58), Mo-P2:175), (Mo-P2:176, Mo-P2:177, Mo-P2:178, Mo-P2:179), 47 53 54 58 85 86 61 (Mo-P1:70), 65 (Mo-P1:90), 66 (Mo-P1:91), 70 (Mo-P1:112), 74 (Mo-P2:180, Mo-P2:182, Mo-P2:184), 87 (Mo-P2:185, Mo-P2:186), 91 (Mo-P1:129), (Mo-P1:162), (Mo-P4:248), (Mo-P5:312), I (Mo-P2:207), (Mo-P2:208), (Mo-P3:221), (Mo-P4:235, 81 100 114 261 92 95 98 (Tu-P9:350), (Tu-P9:368), (We-PL3:3), (We-P11:106), Mo-P4:236), (Mo-P5:324, Mo-P5:327), (Mo-P5:343), 265 301 369 376 117 121 122 (We-P11:137), (We-P13:352), (Th-W50:1), (Th-W50:3, N (Mo-P5:349), (Mo-P6:443), (Tu-W18:4), (Tu-W20:8), 424 466 467 143 157 162 171 Th-W50:4), (Th-W56:8), (Th-W58:1, Th-W58:2), (Tu-W25:6), (Tu-P7:89), (Tu-P7:123), (Tu-P7:241), 480 483 504 204 211 237 244 (Th-P15:53) D (Tu-P7:270), 246 (Tu-P7:279), 268 (Tu-P9:380), 278 (Tu-P10:425, Tu-P10:428), 285 (Tu-P10:460), 286 (Tu-P10:461), 288 (Tu-P10:470), 297 Ancillary Properties of Lipid Lowering Drugs (Tu-P10:510), 301 (We-PL3:2), 310 (We-W32:6), 314 (We-W35:2), 316 E 9 (Mo-ML1:1), 32 (Mo-W11:7), 122 (Mo-P5:348), 126 (Mo-P5:366), 250 (We-W35:6), 332 (We-W44:3), 335 (We-W45:4), 390 (We-P11:200), 393 (Tu-P8:300), 466 (Th-W49:6), 468 (Th-W51:2), 514 (Th-P15:99), 549 (We-P11:214), 396 (We-P11:231), 397 (We-P11:233), 398 (We-P11:237, X We-P11:239), (We-P13:349), (We-P14:463), (Th-W46:7), (Th-P16:256, Th-P16:257), 558 (Th-P16:293), 569 (Th-P16:344), 577 423 448 460 486 (Th-P16:381), (Th-P16:406) (Th-W59:4), 533 (Th-P15:184), 535 (Th-P15:192), 551 (Th-P16:264), 553 582 (Th-P16:274), 563 (Th-P16:319), 569 (Th-P16:343), 581 (Th-P16:399), 588 (Th-P17:430) Angina 69 (Mo-P1:108), 74 (Mo-P1:129), 78 (Mo-P1:145), 84 (Mo-P2:174), 85 Adipose Tissue (Mo-P2:178), 89 (Mo-P2:195), 93 (Mo-P2:215), 97 (Mo-P4:234), 98 13 (Mo-W2:1), 40 (Mo-S4:1, Mo-S4:3), 55 (Mo-P1:46), 97 (Mo-P3:232), 114 (Mo-P4:235, Mo-P4:236, Mo-P4:238, Mo-P4:239), 100 (Mo-P4:246), 114 (Mo-P5:311), 164 (Tu-W22:1, Tu-W22:2, Tu-W22:3), 165 (Tu-W22:4, (Mo-P5:312), 117 (Mo-P5:324, Mo-P5:327), 127 (Mo-P5:373), 131 Tu-W22:5, Tu-W22:6, Tu-W22:7), 185 (Tu-P7:1, Tu-P7:2, Tu-P7:3, (Mo-P6:387), 146 (Mo-P6:455), 217 (Tu-P7:145), 266 (Tu-P9:372), 270 Tu-P7:4, Tu-P7:5), 186 (Tu-P7:6, Tu-P7:7, Tu-P7:8, Tu-P7:9), 187 (Tu-P10:391), 276 (Tu-P10:420), 278 (Tu-P10:429), 279 (Tu-P10:432), (Tu-P7:12, Tu-P7:14), 188 (Tu-P7:15), 192 (Tu-P7:36), 195 (Tu-P7:49), 281 (Tu-P10:439), 282 (Tu-P10:444), 286 (Tu-P10:462), 288 196 (Tu-P7:53), 202 (Tu-P7:82), 206 (Tu-P7:97), 214 (Tu-P7:136), 221 (Tu-P10:470), 291 (Tu-P10:483), 357 (We-P11:51, We-P11:53) (Tu-P7:165), 282 (Tu-P10:445), 301 (We-PL3:1), 311 (We-W33:3, We-W33:5), (We-W33:7), (We-W37:7), (We-W42:7), 312 320 330 341 Angiogenesis: Stimulation and Antagonism (We-S14:4), (We-P11:77), (We-P11:79), (We-P11:103), 362 363 368 371 33 (Mo-W12:5), 34 (Mo-W13:2), 94 (Mo-P3:217), 97 (Mo-P3:232), 106 (We-P11:115), (We-P11:130), (We-P11:135), (We-P11:142), 374 375 377 (Mo-P4:272), 110 (Mo-P4:292), 114 (Mo-P5:312), 185 (Tu-P7:5), 190 (We-P11:148), (We-P11:157), (We-P12:285), 378 380 408 415 (Tu-P7:25, Tu-P7:26, Tu-P7:27, Tu-P7:28), 191 (Tu-P7:29, Tu-P7:30, (We-P13:315), (We-P13:319), (We-P13:323), (We-P13:335), 416 417 420 Tu-P7:31, Tu-P7:32), 192 (Tu-P7:33, Tu-P7:34, Tu-P7:35, Tu-P7:36, (We-P14:383), (Th-W48:5), (Th-W58:6), (Th-P15:29), 431 463 484 498 Tu-P7:37), 198 (Tu-P7:64), 199 (Tu-P7:68), 215 (Tu-P7:137), 241 (Th-P15:108), (Th-P15:125) 516 520 (Tu-P7:258), 251 (Tu-P8:304), 295 (Tu-P10:503), 307 (We-W31:3), 312 (We-W34:1), 352 (We-P11:32), 408 (We-P12:283), 462 (Th-W48:1), 490 Ageing (Th-W61:8), 571 (Th-P16:351) 35 (Mo-W14:1), 50 (Mo-P1:23), 65 (Mo-P1:87), 73 (Mo-P1:123), 77 (Mo-P1:140), 82 (Mo-P1:165), 106 (Mo-P4:275), 107 (Mo-P4:280), 108 Animal Models (Mo-P4:284), 109 (Mo-P4:287), 128 (Mo-P5:375), 129 (Mo-P6:379), 188 (Tu-P7:17, Tu-P7:18), (Tu-P7:19, Tu-P7:20, Tu-P7:22, Tu-P7:23), 12 (Mo-W1:6), 13 (Mo-W2:1), 18 (Mo-W4:7), 22 (Mo-W6:7), 25 (Mo-W8:4, 189 193 Mo-W8:6), (Mo-W10:1), (Mo-W12:3), (Mo-W12:6), (Tu-P7:39), 200 (Tu-P7:69), 209 (Tu-P7:112), 250 (Tu-P8:296), 258 28 32 33 38 (Tu-P9:335), (Tu-P9:365), (Tu-P10:405), (Tu-P10:488), (Mo-W15:4), 39 (Mo-W15:5, Mo-W15:6), 40 (Mo-S4:3), 87 (Mo-P2:185), 264 273 292 294 (Mo-P3:222), (Mo-P3:226, Mo-P3:229), (Mo-P5:298), (Tu-P10:498), 303 (We-ML7:1), 317 (We-W36:3), 323 (We-W39:4), 346 95 96 111 144 (We-P11:2), (We-P11:31), (We-P11:253), (We-P11:255), (Mo-P6:447), 151 (Tu-ML5:1), 152 (Tu-W16:2), 153 (Tu-W16:6), 162 352 401 402 411 (Tu-W21:1), (Tu-W25:5), (Tu-P7:1, Tu-P7:3), (Tu-P7:24, (We-P12:294), 415 (We-P13:313), 424 (We-P13:354), 438 (We-P14:414), 170 185 190 (We-P14:458), (Th-W48:5), (Th-W52:1), (Th-W52:4, Tu-P7:25), 191 (Tu-P7:29), 193 (Tu-P7:39, Tu-P7:40, Tu-P7:41, 447 463 470 471 Tu-P7:42), (Tu-P7:43, Tu-P7:45, Tu-P7:46), (Tu-P7:47, Tu-P7:48, Th-W52:5, Th-W52:6), 472 (Th-W52:7), 474 (Th-W54:2), 480 194 195 Tu-P7:50), (Tu-P7:51, Tu-P7:52, Tu-P7:54), (Tu-P7:56, (Th-W56:6), 487 (Th-W60:4), 492 (Th-P15:5), 539 (Th-P15:212), 542 196 197 Tu-P7:58), (Tu-P7:61, Tu-P7:63, Tu-P7:64), (Tu-P7:65, Tu-P7:66, (Th-P15:224), 590 (Th-P17:443) 198 199 Tu-P7:67, Tu-P7:68), 200 (Tu-P7:69, Tu-P7:70, Tu-P7:71, Tu-P7:72), 201 Aggressive versus Non-Aggressive Cholesterol Lowering (Tu-P7:73, Tu-P7:74, Tu-P7:76, Tu-P7:77), 202 (Tu-P7:79, Tu-P7:81), 203 36 (Mo-W14:2), 43 (Mo-S7:1), 122 (Mo-P5:348), 161 (Tu-W20:4, (Tu-P7:83), 205 (Tu-P7:93, Tu-P7:94), 218 (Tu-P7:153), 219 (Tu-P7:155, Tu-W20:5), 178 (Tu-W29:5), 179 (Tu-W29:7), 181 (Tu-S10:1), 182 Tu-P7:157), 220 (Tu-P7:159), 224 (Tu-P7:181), 227 (Tu-P7:194), 228 (Tu-S10:2), 286 (Tu-P10:463, Tu-P10:464), 551 (Th-P16:264), 569 (Tu-P7:196, Tu-P7:197, Tu-P7:199), 236 (Tu-P7:236), 237 (Tu-P7:240), (Th-P16:346), 582 (Th-P16:406) 242 (Tu-P7:262), 243 (Tu-P7:267), 244 (Tu-P7:273), 245 (Tu-P7:277), 250

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

202 Topic Index T O ACAT Inhibitors AIDS as an Atherogenic Disease P 501 (Th-P15:39), 544 (Th-P15:232, Th-P15:236), 547 (Th-P16:249), 548 162 (Tu-W21:2), 163 (Tu-W21:3, Tu-W21:5), 399 (We-P11:240, (Th-P16:250, Th-P16:251, Th-P16:252, Th-P16:253) We-P11:241, We-P11:242, We-P11:243, We-P11:244), 400 (We-P11:245, I We-P11:246, We-P11:248), 416 (We-P13:318), 544 (Th-P15:233) Acute Coronary Syndromes 11 (Mo-W1:2), 22 (Mo-W6:7), 24 (Mo-W7:7), 29 (Mo-W10:5), 58 C (Mo-P1:56), (Mo-P1:92), (Mo-P1:146), (Mo-P2:168, Mo-P2:169, Algorithms for Risk Evaluation 66 78 83 6 (Su-S3:4), 37 (Mo-W14:4), 46 (Mo-P1:1, Mo-P1:2, Mo-P1:3, Mo-P1:4, Mo-P2:170), 84 (Mo-P2:171, Mo-P2:172, Mo-P2:173, Mo-P2:174, Mo-P1:5), (Mo-P1:8), (Mo-P1:34), (Mo-P1:39), (Mo-P1:58), Mo-P2:175), (Mo-P2:176, Mo-P2:177, Mo-P2:178, Mo-P2:179), 47 53 54 58 85 86 61 (Mo-P1:70), 65 (Mo-P1:90), 66 (Mo-P1:91), 70 (Mo-P1:112), 74 (Mo-P2:180, Mo-P2:182, Mo-P2:184), 87 (Mo-P2:185, Mo-P2:186), 91 (Mo-P1:129), (Mo-P1:162), (Mo-P4:248), (Mo-P5:312), (Mo-P2:207), (Mo-P2:208), (Mo-P3:221), (Mo-P4:235, 81 100 114 261 I 92 95 98 (Tu-P9:350), (Tu-P9:368), (We-PL3:3), (We-P11:106), Mo-P4:236), (Mo-P5:324, Mo-P5:327), (Mo-P5:343), 265 301 369 376 117 121 122 (We-P11:137), (We-P13:352), (Th-W50:1), (Th-W50:3, (Mo-P5:349), (Mo-P6:443), (Tu-W18:4), (Tu-W20:8), 424 466 467 143 157 162 171 Th-W50:4), (Th-W56:8), (Th-W58:1, Th-W58:2), N (Tu-W25:6), (Tu-P7:89), (Tu-P7:123), (Tu-P7:241), 480 483 504 204 211 237 244 (Th-P15:53) (Tu-P7:270), 246 (Tu-P7:279), 268 (Tu-P9:380), 278 (Tu-P10:425, D Tu-P10:428), 285 (Tu-P10:460), 286 (Tu-P10:461), 288 (Tu-P10:470), 297 Ancillary Properties of Lipid Lowering Drugs (Tu-P10:510), 301 (We-PL3:2), 310 (We-W32:6), 314 (We-W35:2), 316 9 (Mo-ML1:1), 32 (Mo-W11:7), 122 (Mo-P5:348), 126 (Mo-P5:366), 250 E (We-W35:6), 332 (We-W44:3), 335 (We-W45:4), 390 (We-P11:200), 393 (Tu-P8:300), 466 (Th-W49:6), 468 (Th-W51:2), 514 (Th-P15:99), 549 (We-P11:214), 396 (We-P11:231), 397 (We-P11:233), 398 (We-P11:237, We-P11:239), (We-P13:349), (We-P14:463), (Th-W46:7), (Th-P16:256, Th-P16:257), 558 (Th-P16:293), 569 (Th-P16:344), 577 X 423 448 460 486 (Th-P16:381), (Th-P16:406) (Th-W59:4), 533 (Th-P15:184), 535 (Th-P15:192), 551 (Th-P16:264), 553 582 (Th-P16:274), 563 (Th-P16:319), 569 (Th-P16:343), 581 (Th-P16:399), 588 (Th-P17:430) Angina 69 (Mo-P1:108), 74 (Mo-P1:129), 78 (Mo-P1:145), 84 (Mo-P2:174), 85 Adipose Tissue (Mo-P2:178), 89 (Mo-P2:195), 93 (Mo-P2:215), 97 (Mo-P4:234), 98 13 (Mo-W2:1), 40 (Mo-S4:1, Mo-S4:3), 55 (Mo-P1:46), 97 (Mo-P3:232), 114 (Mo-P4:235, Mo-P4:236, Mo-P4:238, Mo-P4:239), 100 (Mo-P4:246), 114 (Mo-P5:311), 164 (Tu-W22:1, Tu-W22:2, Tu-W22:3), 165 (Tu-W22:4, (Mo-P5:312), 117 (Mo-P5:324, Mo-P5:327), 127 (Mo-P5:373), 131 Tu-W22:5, Tu-W22:6, Tu-W22:7), 185 (Tu-P7:1, Tu-P7:2, Tu-P7:3, (Mo-P6:387), 146 (Mo-P6:455), 217 (Tu-P7:145), 266 (Tu-P9:372), 270 Tu-P7:4, Tu-P7:5), 186 (Tu-P7:6, Tu-P7:7, Tu-P7:8, Tu-P7:9), 187 (Tu-P10:391), 276 (Tu-P10:420), 278 (Tu-P10:429), 279 (Tu-P10:432), (Tu-P7:12, Tu-P7:14), 188 (Tu-P7:15), 192 (Tu-P7:36), 195 (Tu-P7:49), 281 (Tu-P10:439), 282 (Tu-P10:444), 286 (Tu-P10:462), 288 196 (Tu-P7:53), 202 (Tu-P7:82), 206 (Tu-P7:97), 214 (Tu-P7:136), 221 (Tu-P10:470), 291 (Tu-P10:483), 357 (We-P11:51, We-P11:53) (Tu-P7:165), 282 (Tu-P10:445), 301 (We-PL3:1), 311 (We-W33:3, We-W33:5), (We-W33:7), (We-W37:7), (We-W42:7), 312 320 330 341 Angiogenesis: Stimulation and Antagonism (We-S14:4), (We-P11:77), (We-P11:79), (We-P11:103), 362 363 368 371 33 (Mo-W12:5), 34 (Mo-W13:2), 94 (Mo-P3:217), 97 (Mo-P3:232), 106 (We-P11:115), (We-P11:130), (We-P11:135), (We-P11:142), 374 375 377 (Mo-P4:272), 110 (Mo-P4:292), 114 (Mo-P5:312), 185 (Tu-P7:5), 190 (We-P11:148), (We-P11:157), (We-P12:285), 378 380 408 415 (Tu-P7:25, Tu-P7:26, Tu-P7:27, Tu-P7:28), 191 (Tu-P7:29, Tu-P7:30, (We-P13:315), (We-P13:319), (We-P13:323), (We-P13:335), 416 417 420 Tu-P7:31, Tu-P7:32), 192 (Tu-P7:33, Tu-P7:34, Tu-P7:35, Tu-P7:36, (We-P14:383), (Th-W48:5), (Th-W58:6), (Th-P15:29), 431 463 484 498 Tu-P7:37), 198 (Tu-P7:64), 199 (Tu-P7:68), 215 (Tu-P7:137), 241 (Th-P15:108), (Th-P15:125) 516 520 (Tu-P7:258), 251 (Tu-P8:304), 295 (Tu-P10:503), 307 (We-W31:3), 312 (We-W34:1), 352 (We-P11:32), 408 (We-P12:283), 462 (Th-W48:1), 490 Ageing (Th-W61:8), 571 (Th-P16:351) 35 (Mo-W14:1), 50 (Mo-P1:23), 65 (Mo-P1:87), 73 (Mo-P1:123), 77 (Mo-P1:140), 82 (Mo-P1:165), 106 (Mo-P4:275), 107 (Mo-P4:280), 108 Animal Models (Mo-P4:284), 109 (Mo-P4:287), 128 (Mo-P5:375), 129 (Mo-P6:379), 188 (Tu-P7:17, Tu-P7:18), (Tu-P7:19, Tu-P7:20, Tu-P7:22, Tu-P7:23), 12 (Mo-W1:6), 13 (Mo-W2:1), 18 (Mo-W4:7), 22 (Mo-W6:7), 25 (Mo-W8:4, 189 193 Mo-W8:6), (Mo-W10:1), (Mo-W12:3), (Mo-W12:6), (Tu-P7:39), 200 (Tu-P7:69), 209 (Tu-P7:112), 250 (Tu-P8:296), 258 28 32 33 38 (Tu-P9:335), (Tu-P9:365), (Tu-P10:405), (Tu-P10:488), (Mo-W15:4), 39 (Mo-W15:5, Mo-W15:6), 40 (Mo-S4:3), 87 (Mo-P2:185), 264 273 292 294 (Mo-P3:222), (Mo-P3:226, Mo-P3:229), (Mo-P5:298), (Tu-P10:498), 303 (We-ML7:1), 317 (We-W36:3), 323 (We-W39:4), 346 95 96 111 144 (We-P11:2), (We-P11:31), (We-P11:253), (We-P11:255), (Mo-P6:447), 151 (Tu-ML5:1), 152 (Tu-W16:2), 153 (Tu-W16:6), 162 352 401 402 411 (Tu-W21:1), (Tu-W25:5), (Tu-P7:1, Tu-P7:3), (Tu-P7:24, (We-P12:294), 415 (We-P13:313), 424 (We-P13:354), 438 (We-P14:414), 170 185 190 (We-P14:458), (Th-W48:5), (Th-W52:1), (Th-W52:4, Tu-P7:25), 191 (Tu-P7:29), 193 (Tu-P7:39, Tu-P7:40, Tu-P7:41, 447 463 470 471 Tu-P7:42), (Tu-P7:43, Tu-P7:45, Tu-P7:46), (Tu-P7:47, Tu-P7:48, Th-W52:5, Th-W52:6), 472 (Th-W52:7), 474 (Th-W54:2), 480 194 195 Tu-P7:50), (Tu-P7:51, Tu-P7:52, Tu-P7:54), (Tu-P7:56, (Th-W56:6), 487 (Th-W60:4), 492 (Th-P15:5), 539 (Th-P15:212), 542 196 197 Tu-P7:58), (Tu-P7:61, Tu-P7:63, Tu-P7:64), (Tu-P7:65, Tu-P7:66, (Th-P15:224), 590 (Th-P17:443) 198 199 Tu-P7:67, Tu-P7:68), 200 (Tu-P7:69, Tu-P7:70, Tu-P7:71, Tu-P7:72), 201 Aggressive versus Non-Aggressive Cholesterol Lowering (Tu-P7:73, Tu-P7:74, Tu-P7:76, Tu-P7:77), 202 (Tu-P7:79, Tu-P7:81), 203 36 (Mo-W14:2), 43 (Mo-S7:1), 122 (Mo-P5:348), 161 (Tu-W20:4, (Tu-P7:83), 205 (Tu-P7:93, Tu-P7:94), 218 (Tu-P7:153), 219 (Tu-P7:155, Tu-W20:5), 178 (Tu-W29:5), 179 (Tu-W29:7), 181 (Tu-S10:1), 182 Tu-P7:157), 220 (Tu-P7:159), 224 (Tu-P7:181), 227 (Tu-P7:194), 228 (Tu-S10:2), 286 (Tu-P10:463, Tu-P10:464), 551 (Th-P16:264), 569 (Tu-P7:196, Tu-P7:197, Tu-P7:199), 236 (Tu-P7:236), 237 (Tu-P7:240), (Th-P16:346), 582 (Th-P16:406) 242 (Tu-P7:262), 243 (Tu-P7:267), 244 (Tu-P7:273), 245 (Tu-P7:277), 250

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

203 T Topic Index O

P ACAT Inhibitors AIDS as an Atherogenic Disease 501 (Th-P15:39), 544 (Th-P15:232, Th-P15:236), 547 (Th-P16:249), 548 162 (Tu-W21:2), 163 (Tu-W21:3, Tu-W21:5), 399 (We-P11:240, I (Th-P16:250, Th-P16:251, Th-P16:252, Th-P16:253) We-P11:241, We-P11:242, We-P11:243, We-P11:244), 400 (We-P11:245, We-P11:246, We-P11:248), 416 (We-P13:318), 544 (Th-P15:233) Acute Coronary Syndromes C 11 (Mo-W1:2), 22 (Mo-W6:7), 24 (Mo-W7:7), 29 (Mo-W10:5), 58 (Mo-P1:56), (Mo-P1:92), (Mo-P1:146), (Mo-P2:168, Mo-P2:169, Algorithms for Risk Evaluation 66 78 83 6 (Su-S3:4), 37 (Mo-W14:4), 46 (Mo-P1:1, Mo-P1:2, Mo-P1:3, Mo-P1:4, Mo-P2:170), 84 (Mo-P2:171, Mo-P2:172, Mo-P2:173, Mo-P2:174, Mo-P1:5), (Mo-P1:8), (Mo-P1:34), (Mo-P1:39), (Mo-P1:58), Mo-P2:175), (Mo-P2:176, Mo-P2:177, Mo-P2:178, Mo-P2:179), 47 53 54 58 85 86 61 (Mo-P1:70), 65 (Mo-P1:90), 66 (Mo-P1:91), 70 (Mo-P1:112), 74 (Mo-P2:180, Mo-P2:182, Mo-P2:184), 87 (Mo-P2:185, Mo-P2:186), 91 (Mo-P1:129), (Mo-P1:162), (Mo-P4:248), (Mo-P5:312), I (Mo-P2:207), (Mo-P2:208), (Mo-P3:221), (Mo-P4:235, 81 100 114 261 92 95 98 (Tu-P9:350), (Tu-P9:368), (We-PL3:3), (We-P11:106), Mo-P4:236), (Mo-P5:324, Mo-P5:327), (Mo-P5:343), 265 301 369 376 117 121 122 (We-P11:137), (We-P13:352), (Th-W50:1), (Th-W50:3, N (Mo-P5:349), (Mo-P6:443), (Tu-W18:4), (Tu-W20:8), 424 466 467 143 157 162 171 Th-W50:4), (Th-W56:8), (Th-W58:1, Th-W58:2), (Tu-W25:6), (Tu-P7:89), (Tu-P7:123), (Tu-P7:241), 480 483 504 204 211 237 244 (Th-P15:53) D (Tu-P7:270), 246 (Tu-P7:279), 268 (Tu-P9:380), 278 (Tu-P10:425, Tu-P10:428), 285 (Tu-P10:460), 286 (Tu-P10:461), 288 (Tu-P10:470), 297 Ancillary Properties of Lipid Lowering Drugs (Tu-P10:510), 301 (We-PL3:2), 310 (We-W32:6), 314 (We-W35:2), 316 E 9 (Mo-ML1:1), 32 (Mo-W11:7), 122 (Mo-P5:348), 126 (Mo-P5:366), 250 (We-W35:6), 332 (We-W44:3), 335 (We-W45:4), 390 (We-P11:200), 393 (Tu-P8:300), 466 (Th-W49:6), 468 (Th-W51:2), 514 (Th-P15:99), 549 (We-P11:214), 396 (We-P11:231), 397 (We-P11:233), 398 (We-P11:237, X We-P11:239), (We-P13:349), (We-P14:463), (Th-W46:7), (Th-P16:256, Th-P16:257), 558 (Th-P16:293), 569 (Th-P16:344), 577 423 448 460 486 (Th-P16:381), (Th-P16:406) (Th-W59:4), 533 (Th-P15:184), 535 (Th-P15:192), 551 (Th-P16:264), 553 582 (Th-P16:274), 563 (Th-P16:319), 569 (Th-P16:343), 581 (Th-P16:399), 588 (Th-P17:430) Angina 69 (Mo-P1:108), 74 (Mo-P1:129), 78 (Mo-P1:145), 84 (Mo-P2:174), 85 Adipose Tissue (Mo-P2:178), 89 (Mo-P2:195), 93 (Mo-P2:215), 97 (Mo-P4:234), 98 13 (Mo-W2:1), 40 (Mo-S4:1, Mo-S4:3), 55 (Mo-P1:46), 97 (Mo-P3:232), 114 (Mo-P4:235, Mo-P4:236, Mo-P4:238, Mo-P4:239), 100 (Mo-P4:246), 114 (Mo-P5:311), 164 (Tu-W22:1, Tu-W22:2, Tu-W22:3), 165 (Tu-W22:4, (Mo-P5:312), 117 (Mo-P5:324, Mo-P5:327), 127 (Mo-P5:373), 131 Tu-W22:5, Tu-W22:6, Tu-W22:7), 185 (Tu-P7:1, Tu-P7:2, Tu-P7:3, (Mo-P6:387), 146 (Mo-P6:455), 217 (Tu-P7:145), 266 (Tu-P9:372), 270 Tu-P7:4, Tu-P7:5), 186 (Tu-P7:6, Tu-P7:7, Tu-P7:8, Tu-P7:9), 187 (Tu-P10:391), 276 (Tu-P10:420), 278 (Tu-P10:429), 279 (Tu-P10:432), (Tu-P7:12, Tu-P7:14), 188 (Tu-P7:15), 192 (Tu-P7:36), 195 (Tu-P7:49), 281 (Tu-P10:439), 282 (Tu-P10:444), 286 (Tu-P10:462), 288 196 (Tu-P7:53), 202 (Tu-P7:82), 206 (Tu-P7:97), 214 (Tu-P7:136), 221 (Tu-P10:470), 291 (Tu-P10:483), 357 (We-P11:51, We-P11:53) (Tu-P7:165), 282 (Tu-P10:445), 301 (We-PL3:1), 311 (We-W33:3, We-W33:5), (We-W33:7), (We-W37:7), (We-W42:7), 312 320 330 341 Angiogenesis: Stimulation and Antagonism (We-S14:4), (We-P11:77), (We-P11:79), (We-P11:103), 362 363 368 371 33 (Mo-W12:5), 34 (Mo-W13:2), 94 (Mo-P3:217), 97 (Mo-P3:232), 106 (We-P11:115), (We-P11:130), (We-P11:135), (We-P11:142), 374 375 377 (Mo-P4:272), 110 (Mo-P4:292), 114 (Mo-P5:312), 185 (Tu-P7:5), 190 (We-P11:148), (We-P11:157), (We-P12:285), 378 380 408 415 (Tu-P7:25, Tu-P7:26, Tu-P7:27, Tu-P7:28), 191 (Tu-P7:29, Tu-P7:30, (We-P13:315), (We-P13:319), (We-P13:323), (We-P13:335), 416 417 420 Tu-P7:31, Tu-P7:32), 192 (Tu-P7:33, Tu-P7:34, Tu-P7:35, Tu-P7:36, (We-P14:383), (Th-W48:5), (Th-W58:6), (Th-P15:29), 431 463 484 498 Tu-P7:37), 198 (Tu-P7:64), 199 (Tu-P7:68), 215 (Tu-P7:137), 241 (Th-P15:108), (Th-P15:125) 516 520 (Tu-P7:258), 251 (Tu-P8:304), 295 (Tu-P10:503), 307 (We-W31:3), 312 (We-W34:1), 352 (We-P11:32), 408 (We-P12:283), 462 (Th-W48:1), 490 Ageing (Th-W61:8), 571 (Th-P16:351) 35 (Mo-W14:1), 50 (Mo-P1:23), 65 (Mo-P1:87), 73 (Mo-P1:123), 77 (Mo-P1:140), 82 (Mo-P1:165), 106 (Mo-P4:275), 107 (Mo-P4:280), 108 Animal Models (Mo-P4:284), 109 (Mo-P4:287), 128 (Mo-P5:375), 129 (Mo-P6:379), 188 (Tu-P7:17, Tu-P7:18), (Tu-P7:19, Tu-P7:20, Tu-P7:22, Tu-P7:23), 12 (Mo-W1:6), 13 (Mo-W2:1), 18 (Mo-W4:7), 22 (Mo-W6:7), 25 (Mo-W8:4, 189 193 Mo-W8:6), (Mo-W10:1), (Mo-W12:3), (Mo-W12:6), (Tu-P7:39), 200 (Tu-P7:69), 209 (Tu-P7:112), 250 (Tu-P8:296), 258 28 32 33 38 (Tu-P9:335), (Tu-P9:365), (Tu-P10:405), (Tu-P10:488), (Mo-W15:4), 39 (Mo-W15:5, Mo-W15:6), 40 (Mo-S4:3), 87 (Mo-P2:185), 264 273 292 294 (Mo-P3:222), (Mo-P3:226, Mo-P3:229), (Mo-P5:298), (Tu-P10:498), 303 (We-ML7:1), 317 (We-W36:3), 323 (We-W39:4), 346 95 96 111 144 (We-P11:2), (We-P11:31), (We-P11:253), (We-P11:255), (Mo-P6:447), 151 (Tu-ML5:1), 152 (Tu-W16:2), 153 (Tu-W16:6), 162 352 401 402 411 (Tu-W21:1), (Tu-W25:5), (Tu-P7:1, Tu-P7:3), (Tu-P7:24, (We-P12:294), 415 (We-P13:313), 424 (We-P13:354), 438 (We-P14:414), 170 185 190 (We-P14:458), (Th-W48:5), (Th-W52:1), (Th-W52:4, Tu-P7:25), 191 (Tu-P7:29), 193 (Tu-P7:39, Tu-P7:40, Tu-P7:41, 447 463 470 471 Tu-P7:42), (Tu-P7:43, Tu-P7:45, Tu-P7:46), (Tu-P7:47, Tu-P7:48, Th-W52:5, Th-W52:6), 472 (Th-W52:7), 474 (Th-W54:2), 480 194 195 Tu-P7:50), (Tu-P7:51, Tu-P7:52, Tu-P7:54), (Tu-P7:56, (Th-W56:6), 487 (Th-W60:4), 492 (Th-P15:5), 539 (Th-P15:212), 542 196 197 Tu-P7:58), (Tu-P7:61, Tu-P7:63, Tu-P7:64), (Tu-P7:65, Tu-P7:66, (Th-P15:224), 590 (Th-P17:443) 198 199 Tu-P7:67, Tu-P7:68), 200 (Tu-P7:69, Tu-P7:70, Tu-P7:71, Tu-P7:72), 201 Aggressive versus Non-Aggressive Cholesterol Lowering (Tu-P7:73, Tu-P7:74, Tu-P7:76, Tu-P7:77), 202 (Tu-P7:79, Tu-P7:81), 203 36 (Mo-W14:2), 43 (Mo-S7:1), 122 (Mo-P5:348), 161 (Tu-W20:4, (Tu-P7:83), 205 (Tu-P7:93, Tu-P7:94), 218 (Tu-P7:153), 219 (Tu-P7:155, Tu-W20:5), 178 (Tu-W29:5), 179 (Tu-W29:7), 181 (Tu-S10:1), 182 Tu-P7:157), 220 (Tu-P7:159), 224 (Tu-P7:181), 227 (Tu-P7:194), 228 (Tu-S10:2), 286 (Tu-P10:463, Tu-P10:464), 551 (Th-P16:264), 569 (Tu-P7:196, Tu-P7:197, Tu-P7:199), 236 (Tu-P7:236), 237 (Tu-P7:240), (Th-P16:346), 582 (Th-P16:406) 242 (Tu-P7:262), 243 (Tu-P7:267), 244 (Tu-P7:273), 245 (Tu-P7:277), 250

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

204 Topic Index T O ACAT Inhibitors AIDS as an Atherogenic Disease P 501 (Th-P15:39), 544 (Th-P15:232, Th-P15:236), 547 (Th-P16:249), 548 162 (Tu-W21:2), 163 (Tu-W21:3, Tu-W21:5), 399 (We-P11:240, (Th-P16:250, Th-P16:251, Th-P16:252, Th-P16:253) We-P11:241, We-P11:242, We-P11:243, We-P11:244), 400 (We-P11:245, I We-P11:246, We-P11:248), 416 (We-P13:318), 544 (Th-P15:233) Acute Coronary Syndromes 11 (Mo-W1:2), 22 (Mo-W6:7), 24 (Mo-W7:7), 29 (Mo-W10:5), 58 C (Mo-P1:56), (Mo-P1:92), (Mo-P1:146), (Mo-P2:168, Mo-P2:169, Algorithms for Risk Evaluation 66 78 83 6 (Su-S3:4), 37 (Mo-W14:4), 46 (Mo-P1:1, Mo-P1:2, Mo-P1:3, Mo-P1:4, Mo-P2:170), 84 (Mo-P2:171, Mo-P2:172, Mo-P2:173, Mo-P2:174, Mo-P1:5), (Mo-P1:8), (Mo-P1:34), (Mo-P1:39), (Mo-P1:58), Mo-P2:175), (Mo-P2:176, Mo-P2:177, Mo-P2:178, Mo-P2:179), 47 53 54 58 85 86 61 (Mo-P1:70), 65 (Mo-P1:90), 66 (Mo-P1:91), 70 (Mo-P1:112), 74 (Mo-P2:180, Mo-P2:182, Mo-P2:184), 87 (Mo-P2:185, Mo-P2:186), 91 (Mo-P1:129), (Mo-P1:162), (Mo-P4:248), (Mo-P5:312), (Mo-P2:207), (Mo-P2:208), (Mo-P3:221), (Mo-P4:235, 81 100 114 261 I 92 95 98 (Tu-P9:350), (Tu-P9:368), (We-PL3:3), (We-P11:106), Mo-P4:236), (Mo-P5:324, Mo-P5:327), (Mo-P5:343), 265 301 369 376 117 121 122 (We-P11:137), (We-P13:352), (Th-W50:1), (Th-W50:3, (Mo-P5:349), (Mo-P6:443), (Tu-W18:4), (Tu-W20:8), 424 466 467 143 157 162 171 Th-W50:4), (Th-W56:8), (Th-W58:1, Th-W58:2), N (Tu-W25:6), (Tu-P7:89), (Tu-P7:123), (Tu-P7:241), 480 483 504 204 211 237 244 (Th-P15:53) (Tu-P7:270), 246 (Tu-P7:279), 268 (Tu-P9:380), 278 (Tu-P10:425, D Tu-P10:428), 285 (Tu-P10:460), 286 (Tu-P10:461), 288 (Tu-P10:470), 297 Ancillary Properties of Lipid Lowering Drugs (Tu-P10:510), 301 (We-PL3:2), 310 (We-W32:6), 314 (We-W35:2), 316 9 (Mo-ML1:1), 32 (Mo-W11:7), 122 (Mo-P5:348), 126 (Mo-P5:366), 250 E (We-W35:6), 332 (We-W44:3), 335 (We-W45:4), 390 (We-P11:200), 393 (Tu-P8:300), 466 (Th-W49:6), 468 (Th-W51:2), 514 (Th-P15:99), 549 (We-P11:214), 396 (We-P11:231), 397 (We-P11:233), 398 (We-P11:237, We-P11:239), (We-P13:349), (We-P14:463), (Th-W46:7), (Th-P16:256, Th-P16:257), 558 (Th-P16:293), 569 (Th-P16:344), 577 X 423 448 460 486 (Th-P16:381), (Th-P16:406) (Th-W59:4), 533 (Th-P15:184), 535 (Th-P15:192), 551 (Th-P16:264), 553 582 (Th-P16:274), 563 (Th-P16:319), 569 (Th-P16:343), 581 (Th-P16:399), 588 (Th-P17:430) Angina 69 (Mo-P1:108), 74 (Mo-P1:129), 78 (Mo-P1:145), 84 (Mo-P2:174), 85 Adipose Tissue (Mo-P2:178), 89 (Mo-P2:195), 93 (Mo-P2:215), 97 (Mo-P4:234), 98 13 (Mo-W2:1), 40 (Mo-S4:1, Mo-S4:3), 55 (Mo-P1:46), 97 (Mo-P3:232), 114 (Mo-P4:235, Mo-P4:236, Mo-P4:238, Mo-P4:239), 100 (Mo-P4:246), 114 (Mo-P5:311), 164 (Tu-W22:1, Tu-W22:2, Tu-W22:3), 165 (Tu-W22:4, (Mo-P5:312), 117 (Mo-P5:324, Mo-P5:327), 127 (Mo-P5:373), 131 Tu-W22:5, Tu-W22:6, Tu-W22:7), 185 (Tu-P7:1, Tu-P7:2, Tu-P7:3, (Mo-P6:387), 146 (Mo-P6:455), 217 (Tu-P7:145), 266 (Tu-P9:372), 270 Tu-P7:4, Tu-P7:5), 186 (Tu-P7:6, Tu-P7:7, Tu-P7:8, Tu-P7:9), 187 (Tu-P10:391), 276 (Tu-P10:420), 278 (Tu-P10:429), 279 (Tu-P10:432), (Tu-P7:12, Tu-P7:14), 188 (Tu-P7:15), 192 (Tu-P7:36), 195 (Tu-P7:49), 281 (Tu-P10:439), 282 (Tu-P10:444), 286 (Tu-P10:462), 288 196 (Tu-P7:53), 202 (Tu-P7:82), 206 (Tu-P7:97), 214 (Tu-P7:136), 221 (Tu-P10:470), 291 (Tu-P10:483), 357 (We-P11:51, We-P11:53) (Tu-P7:165), 282 (Tu-P10:445), 301 (We-PL3:1), 311 (We-W33:3, We-W33:5), (We-W33:7), (We-W37:7), (We-W42:7), 312 320 330 341 Angiogenesis: Stimulation and Antagonism (We-S14:4), (We-P11:77), (We-P11:79), (We-P11:103), 362 363 368 371 33 (Mo-W12:5), 34 (Mo-W13:2), 94 (Mo-P3:217), 97 (Mo-P3:232), 106 (We-P11:115), (We-P11:130), (We-P11:135), (We-P11:142), 374 375 377 (Mo-P4:272), 110 (Mo-P4:292), 114 (Mo-P5:312), 185 (Tu-P7:5), 190 (We-P11:148), (We-P11:157), (We-P12:285), 378 380 408 415 (Tu-P7:25, Tu-P7:26, Tu-P7:27, Tu-P7:28), 191 (Tu-P7:29, Tu-P7:30, (We-P13:315), (We-P13:319), (We-P13:323), (We-P13:335), 416 417 420 Tu-P7:31, Tu-P7:32), 192 (Tu-P7:33, Tu-P7:34, Tu-P7:35, Tu-P7:36, (We-P14:383), (Th-W48:5), (Th-W58:6), (Th-P15:29), 431 463 484 498 Tu-P7:37), 198 (Tu-P7:64), 199 (Tu-P7:68), 215 (Tu-P7:137), 241 (Th-P15:108), (Th-P15:125) 516 520 (Tu-P7:258), 251 (Tu-P8:304), 295 (Tu-P10:503), 307 (We-W31:3), 312 (We-W34:1), 352 (We-P11:32), 408 (We-P12:283), 462 (Th-W48:1), 490 Ageing (Th-W61:8), 571 (Th-P16:351) 35 (Mo-W14:1), 50 (Mo-P1:23), 65 (Mo-P1:87), 73 (Mo-P1:123), 77 (Mo-P1:140), 82 (Mo-P1:165), 106 (Mo-P4:275), 107 (Mo-P4:280), 108 Animal Models (Mo-P4:284), 109 (Mo-P4:287), 128 (Mo-P5:375), 129 (Mo-P6:379), 188 (Tu-P7:17, Tu-P7:18), (Tu-P7:19, Tu-P7:20, Tu-P7:22, Tu-P7:23), 12 (Mo-W1:6), 13 (Mo-W2:1), 18 (Mo-W4:7), 22 (Mo-W6:7), 25 (Mo-W8:4, 189 193 Mo-W8:6), (Mo-W10:1), (Mo-W12:3), (Mo-W12:6), (Tu-P7:39), 200 (Tu-P7:69), 209 (Tu-P7:112), 250 (Tu-P8:296), 258 28 32 33 38 (Tu-P9:335), (Tu-P9:365), (Tu-P10:405), (Tu-P10:488), (Mo-W15:4), 39 (Mo-W15:5, Mo-W15:6), 40 (Mo-S4:3), 87 (Mo-P2:185), 264 273 292 294 (Mo-P3:222), (Mo-P3:226, Mo-P3:229), (Mo-P5:298), (Tu-P10:498), 303 (We-ML7:1), 317 (We-W36:3), 323 (We-W39:4), 346 95 96 111 144 (We-P11:2), (We-P11:31), (We-P11:253), (We-P11:255), (Mo-P6:447), 151 (Tu-ML5:1), 152 (Tu-W16:2), 153 (Tu-W16:6), 162 352 401 402 411 (Tu-W21:1), (Tu-W25:5), (Tu-P7:1, Tu-P7:3), (Tu-P7:24, (We-P12:294), 415 (We-P13:313), 424 (We-P13:354), 438 (We-P14:414), 170 185 190 (We-P14:458), (Th-W48:5), (Th-W52:1), (Th-W52:4, Tu-P7:25), 191 (Tu-P7:29), 193 (Tu-P7:39, Tu-P7:40, Tu-P7:41, 447 463 470 471 Tu-P7:42), (Tu-P7:43, Tu-P7:45, Tu-P7:46), (Tu-P7:47, Tu-P7:48, Th-W52:5, Th-W52:6), 472 (Th-W52:7), 474 (Th-W54:2), 480 194 195 Tu-P7:50), (Tu-P7:51, Tu-P7:52, Tu-P7:54), (Tu-P7:56, (Th-W56:6), 487 (Th-W60:4), 492 (Th-P15:5), 539 (Th-P15:212), 542 196 197 Tu-P7:58), (Tu-P7:61, Tu-P7:63, Tu-P7:64), (Tu-P7:65, Tu-P7:66, (Th-P15:224), 590 (Th-P17:443) 198 199 Tu-P7:67, Tu-P7:68), 200 (Tu-P7:69, Tu-P7:70, Tu-P7:71, Tu-P7:72), 201 Aggressive versus Non-Aggressive Cholesterol Lowering (Tu-P7:73, Tu-P7:74, Tu-P7:76, Tu-P7:77), 202 (Tu-P7:79, Tu-P7:81), 203 36 (Mo-W14:2), 43 (Mo-S7:1), 122 (Mo-P5:348), 161 (Tu-W20:4, (Tu-P7:83), 205 (Tu-P7:93, Tu-P7:94), 218 (Tu-P7:153), 219 (Tu-P7:155, Tu-W20:5), 178 (Tu-W29:5), 179 (Tu-W29:7), 181 (Tu-S10:1), 182 Tu-P7:157), 220 (Tu-P7:159), 224 (Tu-P7:181), 227 (Tu-P7:194), 228 (Tu-S10:2), 286 (Tu-P10:463, Tu-P10:464), 551 (Th-P16:264), 569 (Tu-P7:196, Tu-P7:197, Tu-P7:199), 236 (Tu-P7:236), 237 (Tu-P7:240), (Th-P16:346), 582 (Th-P16:406) 242 (Tu-P7:262), 243 (Tu-P7:267), 244 (Tu-P7:273), 245 (Tu-P7:277), 250

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

205 T Topic Index O

P ACAT Inhibitors AIDS as an Atherogenic Disease 501 (Th-P15:39), 544 (Th-P15:232, Th-P15:236), 547 (Th-P16:249), 548 162 (Tu-W21:2), 163 (Tu-W21:3, Tu-W21:5), 399 (We-P11:240, I (Th-P16:250, Th-P16:251, Th-P16:252, Th-P16:253) We-P11:241, We-P11:242, We-P11:243, We-P11:244), 400 (We-P11:245, We-P11:246, We-P11:248), 416 (We-P13:318), 544 (Th-P15:233) Acute Coronary Syndromes C 11 (Mo-W1:2), 22 (Mo-W6:7), 24 (Mo-W7:7), 29 (Mo-W10:5), 58 (Mo-P1:56), (Mo-P1:92), (Mo-P1:146), (Mo-P2:168, Mo-P2:169, Algorithms for Risk Evaluation 66 78 83 6 (Su-S3:4), 37 (Mo-W14:4), 46 (Mo-P1:1, Mo-P1:2, Mo-P1:3, Mo-P1:4, Mo-P2:170), 84 (Mo-P2:171, Mo-P2:172, Mo-P2:173, Mo-P2:174, Mo-P1:5), (Mo-P1:8), (Mo-P1:34), (Mo-P1:39), (Mo-P1:58), Mo-P2:175), (Mo-P2:176, Mo-P2:177, Mo-P2:178, Mo-P2:179), 47 53 54 58 85 86 61 (Mo-P1:70), 65 (Mo-P1:90), 66 (Mo-P1:91), 70 (Mo-P1:112), 74 (Mo-P2:180, Mo-P2:182, Mo-P2:184), 87 (Mo-P2:185, Mo-P2:186), 91 (Mo-P1:129), (Mo-P1:162), (Mo-P4:248), (Mo-P5:312), I (Mo-P2:207), (Mo-P2:208), (Mo-P3:221), (Mo-P4:235, 81 100 114 261 92 95 98 (Tu-P9:350), (Tu-P9:368), (We-PL3:3), (We-P11:106), Mo-P4:236), (Mo-P5:324, Mo-P5:327), (Mo-P5:343), 265 301 369 376 117 121 122 (We-P11:137), (We-P13:352), (Th-W50:1), (Th-W50:3, N (Mo-P5:349), (Mo-P6:443), (Tu-W18:4), (Tu-W20:8), 424 466 467 143 157 162 171 Th-W50:4), (Th-W56:8), (Th-W58:1, Th-W58:2), (Tu-W25:6), (Tu-P7:89), (Tu-P7:123), (Tu-P7:241), 480 483 504 204 211 237 244 (Th-P15:53) D (Tu-P7:270), 246 (Tu-P7:279), 268 (Tu-P9:380), 278 (Tu-P10:425, Tu-P10:428), 285 (Tu-P10:460), 286 (Tu-P10:461), 288 (Tu-P10:470), 297 Ancillary Properties of Lipid Lowering Drugs (Tu-P10:510), 301 (We-PL3:2), 310 (We-W32:6), 314 (We-W35:2), 316 E 9 (Mo-ML1:1), 32 (Mo-W11:7), 122 (Mo-P5:348), 126 (Mo-P5:366), 250 (We-W35:6), 332 (We-W44:3), 335 (We-W45:4), 390 (We-P11:200), 393 (Tu-P8:300), 466 (Th-W49:6), 468 (Th-W51:2), 514 (Th-P15:99), 549 (We-P11:214), 396 (We-P11:231), 397 (We-P11:233), 398 (We-P11:237, X We-P11:239), (We-P13:349), (We-P14:463), (Th-W46:7), (Th-P16:256, Th-P16:257), 558 (Th-P16:293), 569 (Th-P16:344), 577 423 448 460 486 (Th-P16:381), (Th-P16:406) (Th-W59:4), 533 (Th-P15:184), 535 (Th-P15:192), 551 (Th-P16:264), 553 582 (Th-P16:274), 563 (Th-P16:319), 569 (Th-P16:343), 581 (Th-P16:399), 588 (Th-P17:430) Angina 69 (Mo-P1:108), 74 (Mo-P1:129), 78 (Mo-P1:145), 84 (Mo-P2:174), 85 Adipose Tissue (Mo-P2:178), 89 (Mo-P2:195), 93 (Mo-P2:215), 97 (Mo-P4:234), 98 13 (Mo-W2:1), 40 (Mo-S4:1, Mo-S4:3), 55 (Mo-P1:46), 97 (Mo-P3:232), 114 (Mo-P4:235, Mo-P4:236, Mo-P4:238, Mo-P4:239), 100 (Mo-P4:246), 114 (Mo-P5:311), 164 (Tu-W22:1, Tu-W22:2, Tu-W22:3), 165 (Tu-W22:4, (Mo-P5:312), 117 (Mo-P5:324, Mo-P5:327), 127 (Mo-P5:373), 131 Tu-W22:5, Tu-W22:6, Tu-W22:7), 185 (Tu-P7:1, Tu-P7:2, Tu-P7:3, (Mo-P6:387), 146 (Mo-P6:455), 217 (Tu-P7:145), 266 (Tu-P9:372), 270 Tu-P7:4, Tu-P7:5), 186 (Tu-P7:6, Tu-P7:7, Tu-P7:8, Tu-P7:9), 187 (Tu-P10:391), 276 (Tu-P10:420), 278 (Tu-P10:429), 279 (Tu-P10:432), (Tu-P7:12, Tu-P7:14), 188 (Tu-P7:15), 192 (Tu-P7:36), 195 (Tu-P7:49), 281 (Tu-P10:439), 282 (Tu-P10:444), 286 (Tu-P10:462), 288 196 (Tu-P7:53), 202 (Tu-P7:82), 206 (Tu-P7:97), 214 (Tu-P7:136), 221 (Tu-P10:470), 291 (Tu-P10:483), 357 (We-P11:51, We-P11:53) (Tu-P7:165), 282 (Tu-P10:445), 301 (We-PL3:1), 311 (We-W33:3, We-W33:5), (We-W33:7), (We-W37:7), (We-W42:7), 312 320 330 341 Angiogenesis: Stimulation and Antagonism (We-S14:4), (We-P11:77), (We-P11:79), (We-P11:103), 362 363 368 371 33 (Mo-W12:5), 34 (Mo-W13:2), 94 (Mo-P3:217), 97 (Mo-P3:232), 106 (We-P11:115), (We-P11:130), (We-P11:135), (We-P11:142), 374 375 377 (Mo-P4:272), 110 (Mo-P4:292), 114 (Mo-P5:312), 185 (Tu-P7:5), 190 (We-P11:148), (We-P11:157), (We-P12:285), 378 380 408 415 (Tu-P7:25, Tu-P7:26, Tu-P7:27, Tu-P7:28), 191 (Tu-P7:29, Tu-P7:30, (We-P13:315), (We-P13:319), (We-P13:323), (We-P13:335), 416 417 420 Tu-P7:31, Tu-P7:32), 192 (Tu-P7:33, Tu-P7:34, Tu-P7:35, Tu-P7:36, (We-P14:383), (Th-W48:5), (Th-W58:6), (Th-P15:29), 431 463 484 498 Tu-P7:37), 198 (Tu-P7:64), 199 (Tu-P7:68), 215 (Tu-P7:137), 241 (Th-P15:108), (Th-P15:125) 516 520 (Tu-P7:258), 251 (Tu-P8:304), 295 (Tu-P10:503), 307 (We-W31:3), 312 (We-W34:1), 352 (We-P11:32), 408 (We-P12:283), 462 (Th-W48:1), 490 Ageing (Th-W61:8), 571 (Th-P16:351) 35 (Mo-W14:1), 50 (Mo-P1:23), 65 (Mo-P1:87), 73 (Mo-P1:123), 77 (Mo-P1:140), 82 (Mo-P1:165), 106 (Mo-P4:275), 107 (Mo-P4:280), 108 Animal Models (Mo-P4:284), 109 (Mo-P4:287), 128 (Mo-P5:375), 129 (Mo-P6:379), 188 (Tu-P7:17, Tu-P7:18), (Tu-P7:19, Tu-P7:20, Tu-P7:22, Tu-P7:23), 12 (Mo-W1:6), 13 (Mo-W2:1), 18 (Mo-W4:7), 22 (Mo-W6:7), 25 (Mo-W8:4, 189 193 Mo-W8:6), (Mo-W10:1), (Mo-W12:3), (Mo-W12:6), (Tu-P7:39), 200 (Tu-P7:69), 209 (Tu-P7:112), 250 (Tu-P8:296), 258 28 32 33 38 (Tu-P9:335), (Tu-P9:365), (Tu-P10:405), (Tu-P10:488), (Mo-W15:4), 39 (Mo-W15:5, Mo-W15:6), 40 (Mo-S4:3), 87 (Mo-P2:185), 264 273 292 294 (Mo-P3:222), (Mo-P3:226, Mo-P3:229), (Mo-P5:298), (Tu-P10:498), 303 (We-ML7:1), 317 (We-W36:3), 323 (We-W39:4), 346 95 96 111 144 (We-P11:2), (We-P11:31), (We-P11:253), (We-P11:255), (Mo-P6:447), 151 (Tu-ML5:1), 152 (Tu-W16:2), 153 (Tu-W16:6), 162 352 401 402 411 (Tu-W21:1), (Tu-W25:5), (Tu-P7:1, Tu-P7:3), (Tu-P7:24, (We-P12:294), 415 (We-P13:313), 424 (We-P13:354), 438 (We-P14:414), 170 185 190 (We-P14:458), (Th-W48:5), (Th-W52:1), (Th-W52:4, Tu-P7:25), 191 (Tu-P7:29), 193 (Tu-P7:39, Tu-P7:40, Tu-P7:41, 447 463 470 471 Tu-P7:42), (Tu-P7:43, Tu-P7:45, Tu-P7:46), (Tu-P7:47, Tu-P7:48, Th-W52:5, Th-W52:6), 472 (Th-W52:7), 474 (Th-W54:2), 480 194 195 Tu-P7:50), (Tu-P7:51, Tu-P7:52, Tu-P7:54), (Tu-P7:56, (Th-W56:6), 487 (Th-W60:4), 492 (Th-P15:5), 539 (Th-P15:212), 542 196 197 Tu-P7:58), (Tu-P7:61, Tu-P7:63, Tu-P7:64), (Tu-P7:65, Tu-P7:66, (Th-P15:224), 590 (Th-P17:443) 198 199 Tu-P7:67, Tu-P7:68), 200 (Tu-P7:69, Tu-P7:70, Tu-P7:71, Tu-P7:72), 201 Aggressive versus Non-Aggressive Cholesterol Lowering (Tu-P7:73, Tu-P7:74, Tu-P7:76, Tu-P7:77), 202 (Tu-P7:79, Tu-P7:81), 203 36 (Mo-W14:2), 43 (Mo-S7:1), 122 (Mo-P5:348), 161 (Tu-W20:4, (Tu-P7:83), 205 (Tu-P7:93, Tu-P7:94), 218 (Tu-P7:153), 219 (Tu-P7:155, Tu-W20:5), 178 (Tu-W29:5), 179 (Tu-W29:7), 181 (Tu-S10:1), 182 Tu-P7:157), 220 (Tu-P7:159), 224 (Tu-P7:181), 227 (Tu-P7:194), 228 (Tu-S10:2), 286 (Tu-P10:463, Tu-P10:464), 551 (Th-P16:264), 569 (Tu-P7:196, Tu-P7:197, Tu-P7:199), 236 (Tu-P7:236), 237 (Tu-P7:240), (Th-P16:346), 582 (Th-P16:406) 242 (Tu-P7:262), 243 (Tu-P7:267), 244 (Tu-P7:273), 245 (Tu-P7:277), 250

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

206 Topic Index T O ACAT Inhibitors AIDS as an Atherogenic Disease P 501 (Th-P15:39), 544 (Th-P15:232, Th-P15:236), 547 (Th-P16:249), 548 162 (Tu-W21:2), 163 (Tu-W21:3, Tu-W21:5), 399 (We-P11:240, (Th-P16:250, Th-P16:251, Th-P16:252, Th-P16:253) We-P11:241, We-P11:242, We-P11:243, We-P11:244), 400 (We-P11:245, I We-P11:246, We-P11:248), 416 (We-P13:318), 544 (Th-P15:233) Acute Coronary Syndromes 11 (Mo-W1:2), 22 (Mo-W6:7), 24 (Mo-W7:7), 29 (Mo-W10:5), 58 C (Mo-P1:56), (Mo-P1:92), (Mo-P1:146), (Mo-P2:168, Mo-P2:169, Algorithms for Risk Evaluation 66 78 83 6 (Su-S3:4), 37 (Mo-W14:4), 46 (Mo-P1:1, Mo-P1:2, Mo-P1:3, Mo-P1:4, Mo-P2:170), 84 (Mo-P2:171, Mo-P2:172, Mo-P2:173, Mo-P2:174, Mo-P1:5), (Mo-P1:8), (Mo-P1:34), (Mo-P1:39), (Mo-P1:58), Mo-P2:175), (Mo-P2:176, Mo-P2:177, Mo-P2:178, Mo-P2:179), 47 53 54 58 85 86 61 (Mo-P1:70), 65 (Mo-P1:90), 66 (Mo-P1:91), 70 (Mo-P1:112), 74 (Mo-P2:180, Mo-P2:182, Mo-P2:184), 87 (Mo-P2:185, Mo-P2:186), 91 (Mo-P1:129), (Mo-P1:162), (Mo-P4:248), (Mo-P5:312), (Mo-P2:207), (Mo-P2:208), (Mo-P3:221), (Mo-P4:235, 81 100 114 261 I 92 95 98 (Tu-P9:350), (Tu-P9:368), (We-PL3:3), (We-P11:106), Mo-P4:236), (Mo-P5:324, Mo-P5:327), (Mo-P5:343), 265 301 369 376 117 121 122 (We-P11:137), (We-P13:352), (Th-W50:1), (Th-W50:3, (Mo-P5:349), (Mo-P6:443), (Tu-W18:4), (Tu-W20:8), 424 466 467 143 157 162 171 Th-W50:4), (Th-W56:8), (Th-W58:1, Th-W58:2), N (Tu-W25:6), (Tu-P7:89), (Tu-P7:123), (Tu-P7:241), 480 483 504 204 211 237 244 (Th-P15:53) (Tu-P7:270), 246 (Tu-P7:279), 268 (Tu-P9:380), 278 (Tu-P10:425, D Tu-P10:428), 285 (Tu-P10:460), 286 (Tu-P10:461), 288 (Tu-P10:470), 297 Ancillary Properties of Lipid Lowering Drugs (Tu-P10:510), 301 (We-PL3:2), 310 (We-W32:6), 314 (We-W35:2), 316 9 (Mo-ML1:1), 32 (Mo-W11:7), 122 (Mo-P5:348), 126 (Mo-P5:366), 250 E (We-W35:6), 332 (We-W44:3), 335 (We-W45:4), 390 (We-P11:200), 393 (Tu-P8:300), 466 (Th-W49:6), 468 (Th-W51:2), 514 (Th-P15:99), 549 (We-P11:214), 396 (We-P11:231), 397 (We-P11:233), 398 (We-P11:237, We-P11:239), (We-P13:349), (We-P14:463), (Th-W46:7), (Th-P16:256, Th-P16:257), 558 (Th-P16:293), 569 (Th-P16:344), 577 X 423 448 460 486 (Th-P16:381), (Th-P16:406) (Th-W59:4), 533 (Th-P15:184), 535 (Th-P15:192), 551 (Th-P16:264), 553 582 (Th-P16:274), 563 (Th-P16:319), 569 (Th-P16:343), 581 (Th-P16:399), 588 (Th-P17:430) Angina 69 (Mo-P1:108), 74 (Mo-P1:129), 78 (Mo-P1:145), 84 (Mo-P2:174), 85 Adipose Tissue (Mo-P2:178), 89 (Mo-P2:195), 93 (Mo-P2:215), 97 (Mo-P4:234), 98 13 (Mo-W2:1), 40 (Mo-S4:1, Mo-S4:3), 55 (Mo-P1:46), 97 (Mo-P3:232), 114 (Mo-P4:235, Mo-P4:236, Mo-P4:238, Mo-P4:239), 100 (Mo-P4:246), 114 (Mo-P5:311), 164 (Tu-W22:1, Tu-W22:2, Tu-W22:3), 165 (Tu-W22:4, (Mo-P5:312), 117 (Mo-P5:324, Mo-P5:327), 127 (Mo-P5:373), 131 Tu-W22:5, Tu-W22:6, Tu-W22:7), 185 (Tu-P7:1, Tu-P7:2, Tu-P7:3, (Mo-P6:387), 146 (Mo-P6:455), 217 (Tu-P7:145), 266 (Tu-P9:372), 270 Tu-P7:4, Tu-P7:5), 186 (Tu-P7:6, Tu-P7:7, Tu-P7:8, Tu-P7:9), 187 (Tu-P10:391), 276 (Tu-P10:420), 278 (Tu-P10:429), 279 (Tu-P10:432), (Tu-P7:12, Tu-P7:14), 188 (Tu-P7:15), 192 (Tu-P7:36), 195 (Tu-P7:49), 281 (Tu-P10:439), 282 (Tu-P10:444), 286 (Tu-P10:462), 288 196 (Tu-P7:53), 202 (Tu-P7:82), 206 (Tu-P7:97), 214 (Tu-P7:136), 221 (Tu-P10:470), 291 (Tu-P10:483), 357 (We-P11:51, We-P11:53) (Tu-P7:165), 282 (Tu-P10:445), 301 (We-PL3:1), 311 (We-W33:3, We-W33:5), (We-W33:7), (We-W37:7), (We-W42:7), 312 320 330 341 Angiogenesis: Stimulation and Antagonism (We-S14:4), (We-P11:77), (We-P11:79), (We-P11:103), 362 363 368 371 33 (Mo-W12:5), 34 (Mo-W13:2), 94 (Mo-P3:217), 97 (Mo-P3:232), 106 (We-P11:115), (We-P11:130), (We-P11:135), (We-P11:142), 374 375 377 (Mo-P4:272), 110 (Mo-P4:292), 114 (Mo-P5:312), 185 (Tu-P7:5), 190 (We-P11:148), (We-P11:157), (We-P12:285), 378 380 408 415 (Tu-P7:25, Tu-P7:26, Tu-P7:27, Tu-P7:28), 191 (Tu-P7:29, Tu-P7:30, (We-P13:315), (We-P13:319), (We-P13:323), (We-P13:335), 416 417 420 Tu-P7:31, Tu-P7:32), 192 (Tu-P7:33, Tu-P7:34, Tu-P7:35, Tu-P7:36, (We-P14:383), (Th-W48:5), (Th-W58:6), (Th-P15:29), 431 463 484 498 Tu-P7:37), 198 (Tu-P7:64), 199 (Tu-P7:68), 215 (Tu-P7:137), 241 (Th-P15:108), (Th-P15:125) 516 520 (Tu-P7:258), 251 (Tu-P8:304), 295 (Tu-P10:503), 307 (We-W31:3), 312 (We-W34:1), 352 (We-P11:32), 408 (We-P12:283), 462 (Th-W48:1), 490 Ageing (Th-W61:8), 571 (Th-P16:351) 35 (Mo-W14:1), 50 (Mo-P1:23), 65 (Mo-P1:87), 73 (Mo-P1:123), 77 (Mo-P1:140), 82 (Mo-P1:165), 106 (Mo-P4:275), 107 (Mo-P4:280), 108 Animal Models (Mo-P4:284), 109 (Mo-P4:287), 128 (Mo-P5:375), 129 (Mo-P6:379), 188 (Tu-P7:17, Tu-P7:18), (Tu-P7:19, Tu-P7:20, Tu-P7:22, Tu-P7:23), 12 (Mo-W1:6), 13 (Mo-W2:1), 18 (Mo-W4:7), 22 (Mo-W6:7), 25 (Mo-W8:4, 189 193 Mo-W8:6), (Mo-W10:1), (Mo-W12:3), (Mo-W12:6), (Tu-P7:39), 200 (Tu-P7:69), 209 (Tu-P7:112), 250 (Tu-P8:296), 258 28 32 33 38 (Tu-P9:335), (Tu-P9:365), (Tu-P10:405), (Tu-P10:488), (Mo-W15:4), 39 (Mo-W15:5, Mo-W15:6), 40 (Mo-S4:3), 87 (Mo-P2:185), 264 273 292 294 (Mo-P3:222), (Mo-P3:226, Mo-P3:229), (Mo-P5:298), (Tu-P10:498), 303 (We-ML7:1), 317 (We-W36:3), 323 (We-W39:4), 346 95 96 111 144 (We-P11:2), (We-P11:31), (We-P11:253), (We-P11:255), (Mo-P6:447), 151 (Tu-ML5:1), 152 (Tu-W16:2), 153 (Tu-W16:6), 162 352 401 402 411 (Tu-W21:1), (Tu-W25:5), (Tu-P7:1, Tu-P7:3), (Tu-P7:24, (We-P12:294), 415 (We-P13:313), 424 (We-P13:354), 438 (We-P14:414), 170 185 190 (We-P14:458), (Th-W48:5), (Th-W52:1), (Th-W52:4, Tu-P7:25), 191 (Tu-P7:29), 193 (Tu-P7:39, Tu-P7:40, Tu-P7:41, 447 463 470 471 Tu-P7:42), (Tu-P7:43, Tu-P7:45, Tu-P7:46), (Tu-P7:47, Tu-P7:48, Th-W52:5, Th-W52:6), 472 (Th-W52:7), 474 (Th-W54:2), 480 194 195 Tu-P7:50), (Tu-P7:51, Tu-P7:52, Tu-P7:54), (Tu-P7:56, (Th-W56:6), 487 (Th-W60:4), 492 (Th-P15:5), 539 (Th-P15:212), 542 196 197 Tu-P7:58), (Tu-P7:61, Tu-P7:63, Tu-P7:64), (Tu-P7:65, Tu-P7:66, (Th-P15:224), 590 (Th-P17:443) 198 199 Tu-P7:67, Tu-P7:68), 200 (Tu-P7:69, Tu-P7:70, Tu-P7:71, Tu-P7:72), 201 Aggressive versus Non-Aggressive Cholesterol Lowering (Tu-P7:73, Tu-P7:74, Tu-P7:76, Tu-P7:77), 202 (Tu-P7:79, Tu-P7:81), 203 36 (Mo-W14:2), 43 (Mo-S7:1), 122 (Mo-P5:348), 161 (Tu-W20:4, (Tu-P7:83), 205 (Tu-P7:93, Tu-P7:94), 218 (Tu-P7:153), 219 (Tu-P7:155, Tu-W20:5), 178 (Tu-W29:5), 179 (Tu-W29:7), 181 (Tu-S10:1), 182 Tu-P7:157), 220 (Tu-P7:159), 224 (Tu-P7:181), 227 (Tu-P7:194), 228 (Tu-S10:2), 286 (Tu-P10:463, Tu-P10:464), 551 (Th-P16:264), 569 (Tu-P7:196, Tu-P7:197, Tu-P7:199), 236 (Tu-P7:236), 237 (Tu-P7:240), (Th-P16:346), 582 (Th-P16:406) 242 (Tu-P7:262), 243 (Tu-P7:267), 244 (Tu-P7:273), 245 (Tu-P7:277), 250

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

207 T Topic Index O

P ACAT Inhibitors AIDS as an Atherogenic Disease 501 (Th-P15:39), 544 (Th-P15:232, Th-P15:236), 547 (Th-P16:249), 548 162 (Tu-W21:2), 163 (Tu-W21:3, Tu-W21:5), 399 (We-P11:240, I (Th-P16:250, Th-P16:251, Th-P16:252, Th-P16:253) We-P11:241, We-P11:242, We-P11:243, We-P11:244), 400 (We-P11:245, We-P11:246, We-P11:248), 416 (We-P13:318), 544 (Th-P15:233) Acute Coronary Syndromes C 11 (Mo-W1:2), 22 (Mo-W6:7), 24 (Mo-W7:7), 29 (Mo-W10:5), 58 (Mo-P1:56), (Mo-P1:92), (Mo-P1:146), (Mo-P2:168, Mo-P2:169, Algorithms for Risk Evaluation 66 78 83 6 (Su-S3:4), 37 (Mo-W14:4), 46 (Mo-P1:1, Mo-P1:2, Mo-P1:3, Mo-P1:4, Mo-P2:170), 84 (Mo-P2:171, Mo-P2:172, Mo-P2:173, Mo-P2:174, Mo-P1:5), (Mo-P1:8), (Mo-P1:34), (Mo-P1:39), (Mo-P1:58), Mo-P2:175), (Mo-P2:176, Mo-P2:177, Mo-P2:178, Mo-P2:179), 47 53 54 58 85 86 61 (Mo-P1:70), 65 (Mo-P1:90), 66 (Mo-P1:91), 70 (Mo-P1:112), 74 (Mo-P2:180, Mo-P2:182, Mo-P2:184), 87 (Mo-P2:185, Mo-P2:186), 91 (Mo-P1:129), (Mo-P1:162), (Mo-P4:248), (Mo-P5:312), I (Mo-P2:207), (Mo-P2:208), (Mo-P3:221), (Mo-P4:235, 81 100 114 261 92 95 98 (Tu-P9:350), (Tu-P9:368), (We-PL3:3), (We-P11:106), Mo-P4:236), (Mo-P5:324, Mo-P5:327), (Mo-P5:343), 265 301 369 376 117 121 122 (We-P11:137), (We-P13:352), (Th-W50:1), (Th-W50:3, N (Mo-P5:349), (Mo-P6:443), (Tu-W18:4), (Tu-W20:8), 424 466 467 143 157 162 171 Th-W50:4), (Th-W56:8), (Th-W58:1, Th-W58:2), (Tu-W25:6), (Tu-P7:89), (Tu-P7:123), (Tu-P7:241), 480 483 504 204 211 237 244 (Th-P15:53) D (Tu-P7:270), 246 (Tu-P7:279), 268 (Tu-P9:380), 278 (Tu-P10:425, Tu-P10:428), 285 (Tu-P10:460), 286 (Tu-P10:461), 288 (Tu-P10:470), 297 Ancillary Properties of Lipid Lowering Drugs (Tu-P10:510), 301 (We-PL3:2), 310 (We-W32:6), 314 (We-W35:2), 316 E 9 (Mo-ML1:1), 32 (Mo-W11:7), 122 (Mo-P5:348), 126 (Mo-P5:366), 250 (We-W35:6), 332 (We-W44:3), 335 (We-W45:4), 390 (We-P11:200), 393 (Tu-P8:300), 466 (Th-W49:6), 468 (Th-W51:2), 514 (Th-P15:99), 549 (We-P11:214), 396 (We-P11:231), 397 (We-P11:233), 398 (We-P11:237, X We-P11:239), (We-P13:349), (We-P14:463), (Th-W46:7), (Th-P16:256, Th-P16:257), 558 (Th-P16:293), 569 (Th-P16:344), 577 423 448 460 486 (Th-P16:381), (Th-P16:406) (Th-W59:4), 533 (Th-P15:184), 535 (Th-P15:192), 551 (Th-P16:264), 553 582 (Th-P16:274), 563 (Th-P16:319), 569 (Th-P16:343), 581 (Th-P16:399), 588 (Th-P17:430) Angina 69 (Mo-P1:108), 74 (Mo-P1:129), 78 (Mo-P1:145), 84 (Mo-P2:174), 85 Adipose Tissue (Mo-P2:178), 89 (Mo-P2:195), 93 (Mo-P2:215), 97 (Mo-P4:234), 98 13 (Mo-W2:1), 40 (Mo-S4:1, Mo-S4:3), 55 (Mo-P1:46), 97 (Mo-P3:232), 114 (Mo-P4:235, Mo-P4:236, Mo-P4:238, Mo-P4:239), 100 (Mo-P4:246), 114 (Mo-P5:311), 164 (Tu-W22:1, Tu-W22:2, Tu-W22:3), 165 (Tu-W22:4, (Mo-P5:312), 117 (Mo-P5:324, Mo-P5:327), 127 (Mo-P5:373), 131 Tu-W22:5, Tu-W22:6, Tu-W22:7), 185 (Tu-P7:1, Tu-P7:2, Tu-P7:3, (Mo-P6:387), 146 (Mo-P6:455), 217 (Tu-P7:145), 266 (Tu-P9:372), 270 Tu-P7:4, Tu-P7:5), 186 (Tu-P7:6, Tu-P7:7, Tu-P7:8, Tu-P7:9), 187 (Tu-P10:391), 276 (Tu-P10:420), 278 (Tu-P10:429), 279 (Tu-P10:432), (Tu-P7:12, Tu-P7:14), 188 (Tu-P7:15), 192 (Tu-P7:36), 195 (Tu-P7:49), 281 (Tu-P10:439), 282 (Tu-P10:444), 286 (Tu-P10:462), 288 196 (Tu-P7:53), 202 (Tu-P7:82), 206 (Tu-P7:97), 214 (Tu-P7:136), 221 (Tu-P10:470), 291 (Tu-P10:483), 357 (We-P11:51, We-P11:53) (Tu-P7:165), 282 (Tu-P10:445), 301 (We-PL3:1), 311 (We-W33:3, We-W33:5), (We-W33:7), (We-W37:7), (We-W42:7), 312 320 330 341 Angiogenesis: Stimulation and Antagonism (We-S14:4), (We-P11:77), (We-P11:79), (We-P11:103), 362 363 368 371 33 (Mo-W12:5), 34 (Mo-W13:2), 94 (Mo-P3:217), 97 (Mo-P3:232), 106 (We-P11:115), (We-P11:130), (We-P11:135), (We-P11:142), 374 375 377 (Mo-P4:272), 110 (Mo-P4:292), 114 (Mo-P5:312), 185 (Tu-P7:5), 190 (We-P11:148), (We-P11:157), (We-P12:285), 378 380 408 415 (Tu-P7:25, Tu-P7:26, Tu-P7:27, Tu-P7:28), 191 (Tu-P7:29, Tu-P7:30, (We-P13:315), (We-P13:319), (We-P13:323), (We-P13:335), 416 417 420 Tu-P7:31, Tu-P7:32), 192 (Tu-P7:33, Tu-P7:34, Tu-P7:35, Tu-P7:36, (We-P14:383), (Th-W48:5), (Th-W58:6), (Th-P15:29), 431 463 484 498 Tu-P7:37), 198 (Tu-P7:64), 199 (Tu-P7:68), 215 (Tu-P7:137), 241 (Th-P15:108), (Th-P15:125) 516 520 (Tu-P7:258), 251 (Tu-P8:304), 295 (Tu-P10:503), 307 (We-W31:3), 312 (We-W34:1), 352 (We-P11:32), 408 (We-P12:283), 462 (Th-W48:1), 490 Ageing (Th-W61:8), 571 (Th-P16:351) 35 (Mo-W14:1), 50 (Mo-P1:23), 65 (Mo-P1:87), 73 (Mo-P1:123), 77 (Mo-P1:140), 82 (Mo-P1:165), 106 (Mo-P4:275), 107 (Mo-P4:280), 108 Animal Models (Mo-P4:284), 109 (Mo-P4:287), 128 (Mo-P5:375), 129 (Mo-P6:379), 188 (Tu-P7:17, Tu-P7:18), (Tu-P7:19, Tu-P7:20, Tu-P7:22, Tu-P7:23), 12 (Mo-W1:6), 13 (Mo-W2:1), 18 (Mo-W4:7), 22 (Mo-W6:7), 25 (Mo-W8:4, 189 193 Mo-W8:6), (Mo-W10:1), (Mo-W12:3), (Mo-W12:6), (Tu-P7:39), 200 (Tu-P7:69), 209 (Tu-P7:112), 250 (Tu-P8:296), 258 28 32 33 38 (Tu-P9:335), (Tu-P9:365), (Tu-P10:405), (Tu-P10:488), (Mo-W15:4), 39 (Mo-W15:5, Mo-W15:6), 40 (Mo-S4:3), 87 (Mo-P2:185), 264 273 292 294 (Mo-P3:222), (Mo-P3:226, Mo-P3:229), (Mo-P5:298), (Tu-P10:498), 303 (We-ML7:1), 317 (We-W36:3), 323 (We-W39:4), 346 95 96 111 144 (We-P11:2), (We-P11:31), (We-P11:253), (We-P11:255), (Mo-P6:447), 151 (Tu-ML5:1), 152 (Tu-W16:2), 153 (Tu-W16:6), 162 352 401 402 411 (Tu-W21:1), (Tu-W25:5), (Tu-P7:1, Tu-P7:3), (Tu-P7:24, (We-P12:294), 415 (We-P13:313), 424 (We-P13:354), 438 (We-P14:414), 170 185 190 (We-P14:458), (Th-W48:5), (Th-W52:1), (Th-W52:4, Tu-P7:25), 191 (Tu-P7:29), 193 (Tu-P7:39, Tu-P7:40, Tu-P7:41, 447 463 470 471 Tu-P7:42), (Tu-P7:43, Tu-P7:45, Tu-P7:46), (Tu-P7:47, Tu-P7:48, Th-W52:5, Th-W52:6), 472 (Th-W52:7), 474 (Th-W54:2), 480 194 195 Tu-P7:50), (Tu-P7:51, Tu-P7:52, Tu-P7:54), (Tu-P7:56, (Th-W56:6), 487 (Th-W60:4), 492 (Th-P15:5), 539 (Th-P15:212), 542 196 197 Tu-P7:58), (Tu-P7:61, Tu-P7:63, Tu-P7:64), (Tu-P7:65, Tu-P7:66, (Th-P15:224), 590 (Th-P17:443) 198 199 Tu-P7:67, Tu-P7:68), 200 (Tu-P7:69, Tu-P7:70, Tu-P7:71, Tu-P7:72), 201 Aggressive versus Non-Aggressive Cholesterol Lowering (Tu-P7:73, Tu-P7:74, Tu-P7:76, Tu-P7:77), 202 (Tu-P7:79, Tu-P7:81), 203 36 (Mo-W14:2), 43 (Mo-S7:1), 122 (Mo-P5:348), 161 (Tu-W20:4, (Tu-P7:83), 205 (Tu-P7:93, Tu-P7:94), 218 (Tu-P7:153), 219 (Tu-P7:155, Tu-W20:5), 178 (Tu-W29:5), 179 (Tu-W29:7), 181 (Tu-S10:1), 182 Tu-P7:157), 220 (Tu-P7:159), 224 (Tu-P7:181), 227 (Tu-P7:194), 228 (Tu-S10:2), 286 (Tu-P10:463, Tu-P10:464), 551 (Th-P16:264), 569 (Tu-P7:196, Tu-P7:197, Tu-P7:199), 236 (Tu-P7:236), 237 (Tu-P7:240), (Th-P16:346), 582 (Th-P16:406) 242 (Tu-P7:262), 243 (Tu-P7:267), 244 (Tu-P7:273), 245 (Tu-P7:277), 250

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

208 Topic Index T O ACAT Inhibitors AIDS as an Atherogenic Disease P 501 (Th-P15:39), 544 (Th-P15:232, Th-P15:236), 547 (Th-P16:249), 548 162 (Tu-W21:2), 163 (Tu-W21:3, Tu-W21:5), 399 (We-P11:240, (Th-P16:250, Th-P16:251, Th-P16:252, Th-P16:253) We-P11:241, We-P11:242, We-P11:243, We-P11:244), 400 (We-P11:245, I We-P11:246, We-P11:248), 416 (We-P13:318), 544 (Th-P15:233) Acute Coronary Syndromes 11 (Mo-W1:2), 22 (Mo-W6:7), 24 (Mo-W7:7), 29 (Mo-W10:5), 58 C (Mo-P1:56), (Mo-P1:92), (Mo-P1:146), (Mo-P2:168, Mo-P2:169, Algorithms for Risk Evaluation 66 78 83 6 (Su-S3:4), 37 (Mo-W14:4), 46 (Mo-P1:1, Mo-P1:2, Mo-P1:3, Mo-P1:4, Mo-P2:170), 84 (Mo-P2:171, Mo-P2:172, Mo-P2:173, Mo-P2:174, Mo-P1:5), (Mo-P1:8), (Mo-P1:34), (Mo-P1:39), (Mo-P1:58), Mo-P2:175), (Mo-P2:176, Mo-P2:177, Mo-P2:178, Mo-P2:179), 47 53 54 58 85 86 61 (Mo-P1:70), 65 (Mo-P1:90), 66 (Mo-P1:91), 70 (Mo-P1:112), 74 (Mo-P2:180, Mo-P2:182, Mo-P2:184), 87 (Mo-P2:185, Mo-P2:186), 91 (Mo-P1:129), (Mo-P1:162), (Mo-P4:248), (Mo-P5:312), (Mo-P2:207), (Mo-P2:208), (Mo-P3:221), (Mo-P4:235, 81 100 114 261 I 92 95 98 (Tu-P9:350), (Tu-P9:368), (We-PL3:3), (We-P11:106), Mo-P4:236), (Mo-P5:324, Mo-P5:327), (Mo-P5:343), 265 301 369 376 117 121 122 (We-P11:137), (We-P13:352), (Th-W50:1), (Th-W50:3, (Mo-P5:349), (Mo-P6:443), (Tu-W18:4), (Tu-W20:8), 424 466 467 143 157 162 171 Th-W50:4), (Th-W56:8), (Th-W58:1, Th-W58:2), N (Tu-W25:6), (Tu-P7:89), (Tu-P7:123), (Tu-P7:241), 480 483 504 204 211 237 244 (Th-P15:53) (Tu-P7:270), 246 (Tu-P7:279), 268 (Tu-P9:380), 278 (Tu-P10:425, D Tu-P10:428), 285 (Tu-P10:460), 286 (Tu-P10:461), 288 (Tu-P10:470), 297 Ancillary Properties of Lipid Lowering Drugs (Tu-P10:510), 301 (We-PL3:2), 310 (We-W32:6), 314 (We-W35:2), 316 9 (Mo-ML1:1), 32 (Mo-W11:7), 122 (Mo-P5:348), 126 (Mo-P5:366), 250 E (We-W35:6), 332 (We-W44:3), 335 (We-W45:4), 390 (We-P11:200), 393 (Tu-P8:300), 466 (Th-W49:6), 468 (Th-W51:2), 514 (Th-P15:99), 549 (We-P11:214), 396 (We-P11:231), 397 (We-P11:233), 398 (We-P11:237, We-P11:239), (We-P13:349), (We-P14:463), (Th-W46:7), (Th-P16:256, Th-P16:257), 558 (Th-P16:293), 569 (Th-P16:344), 577 X 423 448 460 486 (Th-P16:381), (Th-P16:406) (Th-W59:4), 533 (Th-P15:184), 535 (Th-P15:192), 551 (Th-P16:264), 553 582 (Th-P16:274), 563 (Th-P16:319), 569 (Th-P16:343), 581 (Th-P16:399), 588 (Th-P17:430) Angina 69 (Mo-P1:108), 74 (Mo-P1:129), 78 (Mo-P1:145), 84 (Mo-P2:174), 85 Adipose Tissue (Mo-P2:178), 89 (Mo-P2:195), 93 (Mo-P2:215), 97 (Mo-P4:234), 98 13 (Mo-W2:1), 40 (Mo-S4:1, Mo-S4:3), 55 (Mo-P1:46), 97 (Mo-P3:232), 114 (Mo-P4:235, Mo-P4:236, Mo-P4:238, Mo-P4:239), 100 (Mo-P4:246), 114 (Mo-P5:311), 164 (Tu-W22:1, Tu-W22:2, Tu-W22:3), 165 (Tu-W22:4, (Mo-P5:312), 117 (Mo-P5:324, Mo-P5:327), 127 (Mo-P5:373), 131 Tu-W22:5, Tu-W22:6, Tu-W22:7), 185 (Tu-P7:1, Tu-P7:2, Tu-P7:3, (Mo-P6:387), 146 (Mo-P6:455), 217 (Tu-P7:145), 266 (Tu-P9:372), 270 Tu-P7:4, Tu-P7:5), 186 (Tu-P7:6, Tu-P7:7, Tu-P7:8, Tu-P7:9), 187 (Tu-P10:391), 276 (Tu-P10:420), 278 (Tu-P10:429), 279 (Tu-P10:432), (Tu-P7:12, Tu-P7:14), 188 (Tu-P7:15), 192 (Tu-P7:36), 195 (Tu-P7:49), 281 (Tu-P10:439), 282 (Tu-P10:444), 286 (Tu-P10:462), 288 196 (Tu-P7:53), 202 (Tu-P7:82), 206 (Tu-P7:97), 214 (Tu-P7:136), 221 (Tu-P10:470), 291 (Tu-P10:483), 357 (We-P11:51, We-P11:53) (Tu-P7:165), 282 (Tu-P10:445), 301 (We-PL3:1), 311 (We-W33:3, We-W33:5), (We-W33:7), (We-W37:7), (We-W42:7), 312 320 330 341 Angiogenesis: Stimulation and Antagonism (We-S14:4), (We-P11:77), (We-P11:79), (We-P11:103), 362 363 368 371 33 (Mo-W12:5), 34 (Mo-W13:2), 94 (Mo-P3:217), 97 (Mo-P3:232), 106 (We-P11:115), (We-P11:130), (We-P11:135), (We-P11:142), 374 375 377 (Mo-P4:272), 110 (Mo-P4:292), 114 (Mo-P5:312), 185 (Tu-P7:5), 190 (We-P11:148), (We-P11:157), (We-P12:285), 378 380 408 415 (Tu-P7:25, Tu-P7:26, Tu-P7:27, Tu-P7:28), 191 (Tu-P7:29, Tu-P7:30, (We-P13:315), (We-P13:319), (We-P13:323), (We-P13:335), 416 417 420 Tu-P7:31, Tu-P7:32), 192 (Tu-P7:33, Tu-P7:34, Tu-P7:35, Tu-P7:36, (We-P14:383), (Th-W48:5), (Th-W58:6), (Th-P15:29), 431 463 484 498 Tu-P7:37), 198 (Tu-P7:64), 199 (Tu-P7:68), 215 (Tu-P7:137), 241 (Th-P15:108), (Th-P15:125) 516 520 (Tu-P7:258), 251 (Tu-P8:304), 295 (Tu-P10:503), 307 (We-W31:3), 312 (We-W34:1), 352 (We-P11:32), 408 (We-P12:283), 462 (Th-W48:1), 490 Ageing (Th-W61:8), 571 (Th-P16:351) 35 (Mo-W14:1), 50 (Mo-P1:23), 65 (Mo-P1:87), 73 (Mo-P1:123), 77 (Mo-P1:140), 82 (Mo-P1:165), 106 (Mo-P4:275), 107 (Mo-P4:280), 108 Animal Models (Mo-P4:284), 109 (Mo-P4:287), 128 (Mo-P5:375), 129 (Mo-P6:379), 188 (Tu-P7:17, Tu-P7:18), (Tu-P7:19, Tu-P7:20, Tu-P7:22, Tu-P7:23), 12 (Mo-W1:6), 13 (Mo-W2:1), 18 (Mo-W4:7), 22 (Mo-W6:7), 25 (Mo-W8:4, 189 193 Mo-W8:6), (Mo-W10:1), (Mo-W12:3), (Mo-W12:6), (Tu-P7:39), 200 (Tu-P7:69), 209 (Tu-P7:112), 250 (Tu-P8:296), 258 28 32 33 38 (Tu-P9:335), (Tu-P9:365), (Tu-P10:405), (Tu-P10:488), (Mo-W15:4), 39 (Mo-W15:5, Mo-W15:6), 40 (Mo-S4:3), 87 (Mo-P2:185), 264 273 292 294 (Mo-P3:222), (Mo-P3:226, Mo-P3:229), (Mo-P5:298), (Tu-P10:498), 303 (We-ML7:1), 317 (We-W36:3), 323 (We-W39:4), 346 95 96 111 144 (We-P11:2), (We-P11:31), (We-P11:253), (We-P11:255), (Mo-P6:447), 151 (Tu-ML5:1), 152 (Tu-W16:2), 153 (Tu-W16:6), 162 352 401 402 411 (Tu-W21:1), (Tu-W25:5), (Tu-P7:1, Tu-P7:3), (Tu-P7:24, (We-P12:294), 415 (We-P13:313), 424 (We-P13:354), 438 (We-P14:414), 170 185 190 (We-P14:458), (Th-W48:5), (Th-W52:1), (Th-W52:4, Tu-P7:25), 191 (Tu-P7:29), 193 (Tu-P7:39, Tu-P7:40, Tu-P7:41, 447 463 470 471 Tu-P7:42), (Tu-P7:43, Tu-P7:45, Tu-P7:46), (Tu-P7:47, Tu-P7:48, Th-W52:5, Th-W52:6), 472 (Th-W52:7), 474 (Th-W54:2), 480 194 195 Tu-P7:50), (Tu-P7:51, Tu-P7:52, Tu-P7:54), (Tu-P7:56, (Th-W56:6), 487 (Th-W60:4), 492 (Th-P15:5), 539 (Th-P15:212), 542 196 197 Tu-P7:58), (Tu-P7:61, Tu-P7:63, Tu-P7:64), (Tu-P7:65, Tu-P7:66, (Th-P15:224), 590 (Th-P17:443) 198 199 Tu-P7:67, Tu-P7:68), 200 (Tu-P7:69, Tu-P7:70, Tu-P7:71, Tu-P7:72), 201 Aggressive versus Non-Aggressive Cholesterol Lowering (Tu-P7:73, Tu-P7:74, Tu-P7:76, Tu-P7:77), 202 (Tu-P7:79, Tu-P7:81), 203 36 (Mo-W14:2), 43 (Mo-S7:1), 122 (Mo-P5:348), 161 (Tu-W20:4, (Tu-P7:83), 205 (Tu-P7:93, Tu-P7:94), 218 (Tu-P7:153), 219 (Tu-P7:155, Tu-W20:5), 178 (Tu-W29:5), 179 (Tu-W29:7), 181 (Tu-S10:1), 182 Tu-P7:157), 220 (Tu-P7:159), 224 (Tu-P7:181), 227 (Tu-P7:194), 228 (Tu-S10:2), 286 (Tu-P10:463, Tu-P10:464), 551 (Th-P16:264), 569 (Tu-P7:196, Tu-P7:197, Tu-P7:199), 236 (Tu-P7:236), 237 (Tu-P7:240), (Th-P16:346), 582 (Th-P16:406) 242 (Tu-P7:262), 243 (Tu-P7:267), 244 (Tu-P7:273), 245 (Tu-P7:277), 250

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

209 T Topic Index O

P ACAT Inhibitors AIDS as an Atherogenic Disease 501 (Th-P15:39), 544 (Th-P15:232, Th-P15:236), 547 (Th-P16:249), 548 162 (Tu-W21:2), 163 (Tu-W21:3, Tu-W21:5), 399 (We-P11:240, I (Th-P16:250, Th-P16:251, Th-P16:252, Th-P16:253) We-P11:241, We-P11:242, We-P11:243, We-P11:244), 400 (We-P11:245, We-P11:246, We-P11:248), 416 (We-P13:318), 544 (Th-P15:233) Acute Coronary Syndromes C 11 (Mo-W1:2), 22 (Mo-W6:7), 24 (Mo-W7:7), 29 (Mo-W10:5), 58 (Mo-P1:56), (Mo-P1:92), (Mo-P1:146), (Mo-P2:168, Mo-P2:169, Algorithms for Risk Evaluation 66 78 83 6 (Su-S3:4), 37 (Mo-W14:4), 46 (Mo-P1:1, Mo-P1:2, Mo-P1:3, Mo-P1:4, Mo-P2:170), 84 (Mo-P2:171, Mo-P2:172, Mo-P2:173, Mo-P2:174, Mo-P1:5), (Mo-P1:8), (Mo-P1:34), (Mo-P1:39), (Mo-P1:58), Mo-P2:175), (Mo-P2:176, Mo-P2:177, Mo-P2:178, Mo-P2:179), 47 53 54 58 85 86 61 (Mo-P1:70), 65 (Mo-P1:90), 66 (Mo-P1:91), 70 (Mo-P1:112), 74 (Mo-P2:180, Mo-P2:182, Mo-P2:184), 87 (Mo-P2:185, Mo-P2:186), 91 (Mo-P1:129), (Mo-P1:162), (Mo-P4:248), (Mo-P5:312), I (Mo-P2:207), (Mo-P2:208), (Mo-P3:221), (Mo-P4:235, 81 100 114 261 92 95 98 (Tu-P9:350), (Tu-P9:368), (We-PL3:3), (We-P11:106), Mo-P4:236), (Mo-P5:324, Mo-P5:327), (Mo-P5:343), 265 301 369 376 117 121 122 (We-P11:137), (We-P13:352), (Th-W50:1), (Th-W50:3, N (Mo-P5:349), (Mo-P6:443), (Tu-W18:4), (Tu-W20:8), 424 466 467 143 157 162 171 Th-W50:4), (Th-W56:8), (Th-W58:1, Th-W58:2), (Tu-W25:6), (Tu-P7:89), (Tu-P7:123), (Tu-P7:241), 480 483 504 204 211 237 244 (Th-P15:53) D (Tu-P7:270), 246 (Tu-P7:279), 268 (Tu-P9:380), 278 (Tu-P10:425, Tu-P10:428), 285 (Tu-P10:460), 286 (Tu-P10:461), 288 (Tu-P10:470), 297 Ancillary Properties of Lipid Lowering Drugs (Tu-P10:510), 301 (We-PL3:2), 310 (We-W32:6), 314 (We-W35:2), 316 E 9 (Mo-ML1:1), 32 (Mo-W11:7), 122 (Mo-P5:348), 126 (Mo-P5:366), 250 (We-W35:6), 332 (We-W44:3), 335 (We-W45:4), 390 (We-P11:200), 393 (Tu-P8:300), 466 (Th-W49:6), 468 (Th-W51:2), 514 (Th-P15:99), 549 (We-P11:214), 396 (We-P11:231), 397 (We-P11:233), 398 (We-P11:237, X We-P11:239), (We-P13:349), (We-P14:463), (Th-W46:7), (Th-P16:256, Th-P16:257), 558 (Th-P16:293), 569 (Th-P16:344), 577 423 448 460 486 (Th-P16:381), (Th-P16:406) (Th-W59:4), 533 (Th-P15:184), 535 (Th-P15:192), 551 (Th-P16:264), 553 582 (Th-P16:274), 563 (Th-P16:319), 569 (Th-P16:343), 581 (Th-P16:399), 588 (Th-P17:430) Angina 69 (Mo-P1:108), 74 (Mo-P1:129), 78 (Mo-P1:145), 84 (Mo-P2:174), 85 Adipose Tissue (Mo-P2:178), 89 (Mo-P2:195), 93 (Mo-P2:215), 97 (Mo-P4:234), 98 13 (Mo-W2:1), 40 (Mo-S4:1, Mo-S4:3), 55 (Mo-P1:46), 97 (Mo-P3:232), 114 (Mo-P4:235, Mo-P4:236, Mo-P4:238, Mo-P4:239), 100 (Mo-P4:246), 114 (Mo-P5:311), 164 (Tu-W22:1, Tu-W22:2, Tu-W22:3), 165 (Tu-W22:4, (Mo-P5:312), 117 (Mo-P5:324, Mo-P5:327), 127 (Mo-P5:373), 131 Tu-W22:5, Tu-W22:6, Tu-W22:7), 185 (Tu-P7:1, Tu-P7:2, Tu-P7:3, (Mo-P6:387), 146 (Mo-P6:455), 217 (Tu-P7:145), 266 (Tu-P9:372), 270 Tu-P7:4, Tu-P7:5), 186 (Tu-P7:6, Tu-P7:7, Tu-P7:8, Tu-P7:9), 187 (Tu-P10:391), 276 (Tu-P10:420), 278 (Tu-P10:429), 279 (Tu-P10:432), (Tu-P7:12, Tu-P7:14), 188 (Tu-P7:15), 192 (Tu-P7:36), 195 (Tu-P7:49), 281 (Tu-P10:439), 282 (Tu-P10:444), 286 (Tu-P10:462), 288 196 (Tu-P7:53), 202 (Tu-P7:82), 206 (Tu-P7:97), 214 (Tu-P7:136), 221 (Tu-P10:470), 291 (Tu-P10:483), 357 (We-P11:51, We-P11:53) (Tu-P7:165), 282 (Tu-P10:445), 301 (We-PL3:1), 311 (We-W33:3, We-W33:5), (We-W33:7), (We-W37:7), (We-W42:7), 312 320 330 341 Angiogenesis: Stimulation and Antagonism (We-S14:4), (We-P11:77), (We-P11:79), (We-P11:103), 362 363 368 371 33 (Mo-W12:5), 34 (Mo-W13:2), 94 (Mo-P3:217), 97 (Mo-P3:232), 106 (We-P11:115), (We-P11:130), (We-P11:135), (We-P11:142), 374 375 377 (Mo-P4:272), 110 (Mo-P4:292), 114 (Mo-P5:312), 185 (Tu-P7:5), 190 (We-P11:148), (We-P11:157), (We-P12:285), 378 380 408 415 (Tu-P7:25, Tu-P7:26, Tu-P7:27, Tu-P7:28), 191 (Tu-P7:29, Tu-P7:30, (We-P13:315), (We-P13:319), (We-P13:323), (We-P13:335), 416 417 420 Tu-P7:31, Tu-P7:32), 192 (Tu-P7:33, Tu-P7:34, Tu-P7:35, Tu-P7:36, (We-P14:383), (Th-W48:5), (Th-W58:6), (Th-P15:29), 431 463 484 498 Tu-P7:37), 198 (Tu-P7:64), 199 (Tu-P7:68), 215 (Tu-P7:137), 241 (Th-P15:108), (Th-P15:125) 516 520 (Tu-P7:258), 251 (Tu-P8:304), 295 (Tu-P10:503), 307 (We-W31:3), 312 (We-W34:1), 352 (We-P11:32), 408 (We-P12:283), 462 (Th-W48:1), 490 Ageing (Th-W61:8), 571 (Th-P16:351) 35 (Mo-W14:1), 50 (Mo-P1:23), 65 (Mo-P1:87), 73 (Mo-P1:123), 77 (Mo-P1:140), 82 (Mo-P1:165), 106 (Mo-P4:275), 107 (Mo-P4:280), 108 Animal Models (Mo-P4:284), 109 (Mo-P4:287), 128 (Mo-P5:375), 129 (Mo-P6:379), 188 (Tu-P7:17, Tu-P7:18), (Tu-P7:19, Tu-P7:20, Tu-P7:22, Tu-P7:23), 12 (Mo-W1:6), 13 (Mo-W2:1), 18 (Mo-W4:7), 22 (Mo-W6:7), 25 (Mo-W8:4, 189 193 Mo-W8:6), (Mo-W10:1), (Mo-W12:3), (Mo-W12:6), (Tu-P7:39), 200 (Tu-P7:69), 209 (Tu-P7:112), 250 (Tu-P8:296), 258 28 32 33 38 (Tu-P9:335), (Tu-P9:365), (Tu-P10:405), (Tu-P10:488), (Mo-W15:4), 39 (Mo-W15:5, Mo-W15:6), 40 (Mo-S4:3), 87 (Mo-P2:185), 264 273 292 294 (Mo-P3:222), (Mo-P3:226, Mo-P3:229), (Mo-P5:298), (Tu-P10:498), 303 (We-ML7:1), 317 (We-W36:3), 323 (We-W39:4), 346 95 96 111 144 (We-P11:2), (We-P11:31), (We-P11:253), (We-P11:255), (Mo-P6:447), 151 (Tu-ML5:1), 152 (Tu-W16:2), 153 (Tu-W16:6), 162 352 401 402 411 (Tu-W21:1), (Tu-W25:5), (Tu-P7:1, Tu-P7:3), (Tu-P7:24, (We-P12:294), 415 (We-P13:313), 424 (We-P13:354), 438 (We-P14:414), 170 185 190 (We-P14:458), (Th-W48:5), (Th-W52:1), (Th-W52:4, Tu-P7:25), 191 (Tu-P7:29), 193 (Tu-P7:39, Tu-P7:40, Tu-P7:41, 447 463 470 471 Tu-P7:42), (Tu-P7:43, Tu-P7:45, Tu-P7:46), (Tu-P7:47, Tu-P7:48, Th-W52:5, Th-W52:6), 472 (Th-W52:7), 474 (Th-W54:2), 480 194 195 Tu-P7:50), (Tu-P7:51, Tu-P7:52, Tu-P7:54), (Tu-P7:56, (Th-W56:6), 487 (Th-W60:4), 492 (Th-P15:5), 539 (Th-P15:212), 542 196 197 Tu-P7:58), (Tu-P7:61, Tu-P7:63, Tu-P7:64), (Tu-P7:65, Tu-P7:66, (Th-P15:224), 590 (Th-P17:443) 198 199 Tu-P7:67, Tu-P7:68), 200 (Tu-P7:69, Tu-P7:70, Tu-P7:71, Tu-P7:72), 201 Aggressive versus Non-Aggressive Cholesterol Lowering (Tu-P7:73, Tu-P7:74, Tu-P7:76, Tu-P7:77), 202 (Tu-P7:79, Tu-P7:81), 203 36 (Mo-W14:2), 43 (Mo-S7:1), 122 (Mo-P5:348), 161 (Tu-W20:4, (Tu-P7:83), 205 (Tu-P7:93, Tu-P7:94), 218 (Tu-P7:153), 219 (Tu-P7:155, Tu-W20:5), 178 (Tu-W29:5), 179 (Tu-W29:7), 181 (Tu-S10:1), 182 Tu-P7:157), 220 (Tu-P7:159), 224 (Tu-P7:181), 227 (Tu-P7:194), 228 (Tu-S10:2), 286 (Tu-P10:463, Tu-P10:464), 551 (Th-P16:264), 569 (Tu-P7:196, Tu-P7:197, Tu-P7:199), 236 (Tu-P7:236), 237 (Tu-P7:240), (Th-P16:346), 582 (Th-P16:406) 242 (Tu-P7:262), 243 (Tu-P7:267), 244 (Tu-P7:273), 245 (Tu-P7:277), 250

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

210 Topic Index T O ACAT Inhibitors AIDS as an Atherogenic Disease P 501 (Th-P15:39), 544 (Th-P15:232, Th-P15:236), 547 (Th-P16:249), 548 162 (Tu-W21:2), 163 (Tu-W21:3, Tu-W21:5), 399 (We-P11:240, (Th-P16:250, Th-P16:251, Th-P16:252, Th-P16:253) We-P11:241, We-P11:242, We-P11:243, We-P11:244), 400 (We-P11:245, I We-P11:246, We-P11:248), 416 (We-P13:318), 544 (Th-P15:233) Acute Coronary Syndromes 11 (Mo-W1:2), 22 (Mo-W6:7), 24 (Mo-W7:7), 29 (Mo-W10:5), 58 C (Mo-P1:56), (Mo-P1:92), (Mo-P1:146), (Mo-P2:168, Mo-P2:169, Algorithms for Risk Evaluation 66 78 83 6 (Su-S3:4), 37 (Mo-W14:4), 46 (Mo-P1:1, Mo-P1:2, Mo-P1:3, Mo-P1:4, Mo-P2:170), 84 (Mo-P2:171, Mo-P2:172, Mo-P2:173, Mo-P2:174, Mo-P1:5), (Mo-P1:8), (Mo-P1:34), (Mo-P1:39), (Mo-P1:58), Mo-P2:175), (Mo-P2:176, Mo-P2:177, Mo-P2:178, Mo-P2:179), 47 53 54 58 85 86 61 (Mo-P1:70), 65 (Mo-P1:90), 66 (Mo-P1:91), 70 (Mo-P1:112), 74 (Mo-P2:180, Mo-P2:182, Mo-P2:184), 87 (Mo-P2:185, Mo-P2:186), 91 (Mo-P1:129), (Mo-P1:162), (Mo-P4:248), (Mo-P5:312), (Mo-P2:207), (Mo-P2:208), (Mo-P3:221), (Mo-P4:235, 81 100 114 261 I 92 95 98 (Tu-P9:350), (Tu-P9:368), (We-PL3:3), (We-P11:106), Mo-P4:236), (Mo-P5:324, Mo-P5:327), (Mo-P5:343), 265 301 369 376 117 121 122 (We-P11:137), (We-P13:352), (Th-W50:1), (Th-W50:3, (Mo-P5:349), (Mo-P6:443), (Tu-W18:4), (Tu-W20:8), 424 466 467 143 157 162 171 Th-W50:4), (Th-W56:8), (Th-W58:1, Th-W58:2), N (Tu-W25:6), (Tu-P7:89), (Tu-P7:123), (Tu-P7:241), 480 483 504 204 211 237 244 (Th-P15:53) (Tu-P7:270), 246 (Tu-P7:279), 268 (Tu-P9:380), 278 (Tu-P10:425, D Tu-P10:428), 285 (Tu-P10:460), 286 (Tu-P10:461), 288 (Tu-P10:470), 297 Ancillary Properties of Lipid Lowering Drugs (Tu-P10:510), 301 (We-PL3:2), 310 (We-W32:6), 314 (We-W35:2), 316 9 (Mo-ML1:1), 32 (Mo-W11:7), 122 (Mo-P5:348), 126 (Mo-P5:366), 250 E (We-W35:6), 332 (We-W44:3), 335 (We-W45:4), 390 (We-P11:200), 393 (Tu-P8:300), 466 (Th-W49:6), 468 (Th-W51:2), 514 (Th-P15:99), 549 (We-P11:214), 396 (We-P11:231), 397 (We-P11:233), 398 (We-P11:237, We-P11:239), (We-P13:349), (We-P14:463), (Th-W46:7), (Th-P16:256, Th-P16:257), 558 (Th-P16:293), 569 (Th-P16:344), 577 X 423 448 460 486 (Th-P16:381), (Th-P16:406) (Th-W59:4), 533 (Th-P15:184), 535 (Th-P15:192), 551 (Th-P16:264), 553 582 (Th-P16:274), 563 (Th-P16:319), 569 (Th-P16:343), 581 (Th-P16:399), 588 (Th-P17:430) Angina 69 (Mo-P1:108), 74 (Mo-P1:129), 78 (Mo-P1:145), 84 (Mo-P2:174), 85 Adipose Tissue (Mo-P2:178), 89 (Mo-P2:195), 93 (Mo-P2:215), 97 (Mo-P4:234), 98 13 (Mo-W2:1), 40 (Mo-S4:1, Mo-S4:3), 55 (Mo-P1:46), 97 (Mo-P3:232), 114 (Mo-P4:235, Mo-P4:236, Mo-P4:238, Mo-P4:239), 100 (Mo-P4:246), 114 (Mo-P5:311), 164 (Tu-W22:1, Tu-W22:2, Tu-W22:3), 165 (Tu-W22:4, (Mo-P5:312), 117 (Mo-P5:324, Mo-P5:327), 127 (Mo-P5:373), 131 Tu-W22:5, Tu-W22:6, Tu-W22:7), 185 (Tu-P7:1, Tu-P7:2, Tu-P7:3, (Mo-P6:387), 146 (Mo-P6:455), 217 (Tu-P7:145), 266 (Tu-P9:372), 270 Tu-P7:4, Tu-P7:5), 186 (Tu-P7:6, Tu-P7:7, Tu-P7:8, Tu-P7:9), 187 (Tu-P10:391), 276 (Tu-P10:420), 278 (Tu-P10:429), 279 (Tu-P10:432), (Tu-P7:12, Tu-P7:14), 188 (Tu-P7:15), 192 (Tu-P7:36), 195 (Tu-P7:49), 281 (Tu-P10:439), 282 (Tu-P10:444), 286 (Tu-P10:462), 288 196 (Tu-P7:53), 202 (Tu-P7:82), 206 (Tu-P7:97), 214 (Tu-P7:136), 221 (Tu-P10:470), 291 (Tu-P10:483), 357 (We-P11:51, We-P11:53) (Tu-P7:165), 282 (Tu-P10:445), 301 (We-PL3:1), 311 (We-W33:3, We-W33:5), (We-W33:7), (We-W37:7), (We-W42:7), 312 320 330 341 Angiogenesis: Stimulation and Antagonism (We-S14:4), (We-P11:77), (We-P11:79), (We-P11:103), 362 363 368 371 33 (Mo-W12:5), 34 (Mo-W13:2), 94 (Mo-P3:217), 97 (Mo-P3:232), 106 (We-P11:115), (We-P11:130), (We-P11:135), (We-P11:142), 374 375 377 (Mo-P4:272), 110 (Mo-P4:292), 114 (Mo-P5:312), 185 (Tu-P7:5), 190 (We-P11:148), (We-P11:157), (We-P12:285), 378 380 408 415 (Tu-P7:25, Tu-P7:26, Tu-P7:27, Tu-P7:28), 191 (Tu-P7:29, Tu-P7:30, (We-P13:315), (We-P13:319), (We-P13:323), (We-P13:335), 416 417 420 Tu-P7:31, Tu-P7:32), 192 (Tu-P7:33, Tu-P7:34, Tu-P7:35, Tu-P7:36, (We-P14:383), (Th-W48:5), (Th-W58:6), (Th-P15:29), 431 463 484 498 Tu-P7:37), 198 (Tu-P7:64), 199 (Tu-P7:68), 215 (Tu-P7:137), 241 (Th-P15:108), (Th-P15:125) 516 520 (Tu-P7:258), 251 (Tu-P8:304), 295 (Tu-P10:503), 307 (We-W31:3), 312 (We-W34:1), 352 (We-P11:32), 408 (We-P12:283), 462 (Th-W48:1), 490 Ageing (Th-W61:8), 571 (Th-P16:351) 35 (Mo-W14:1), 50 (Mo-P1:23), 65 (Mo-P1:87), 73 (Mo-P1:123), 77 (Mo-P1:140), 82 (Mo-P1:165), 106 (Mo-P4:275), 107 (Mo-P4:280), 108 Animal Models (Mo-P4:284), 109 (Mo-P4:287), 128 (Mo-P5:375), 129 (Mo-P6:379), 188 (Tu-P7:17, Tu-P7:18), (Tu-P7:19, Tu-P7:20, Tu-P7:22, Tu-P7:23), 12 (Mo-W1:6), 13 (Mo-W2:1), 18 (Mo-W4:7), 22 (Mo-W6:7), 25 (Mo-W8:4, 189 193 Mo-W8:6), (Mo-W10:1), (Mo-W12:3), (Mo-W12:6), (Tu-P7:39), 200 (Tu-P7:69), 209 (Tu-P7:112), 250 (Tu-P8:296), 258 28 32 33 38 (Tu-P9:335), (Tu-P9:365), (Tu-P10:405), (Tu-P10:488), (Mo-W15:4), 39 (Mo-W15:5, Mo-W15:6), 40 (Mo-S4:3), 87 (Mo-P2:185), 264 273 292 294 (Mo-P3:222), (Mo-P3:226, Mo-P3:229), (Mo-P5:298), (Tu-P10:498), 303 (We-ML7:1), 317 (We-W36:3), 323 (We-W39:4), 346 95 96 111 144 (We-P11:2), (We-P11:31), (We-P11:253), (We-P11:255), (Mo-P6:447), 151 (Tu-ML5:1), 152 (Tu-W16:2), 153 (Tu-W16:6), 162 352 401 402 411 (Tu-W21:1), (Tu-W25:5), (Tu-P7:1, Tu-P7:3), (Tu-P7:24, (We-P12:294), 415 (We-P13:313), 424 (We-P13:354), 438 (We-P14:414), 170 185 190 (We-P14:458), (Th-W48:5), (Th-W52:1), (Th-W52:4, Tu-P7:25), 191 (Tu-P7:29), 193 (Tu-P7:39, Tu-P7:40, Tu-P7:41, 447 463 470 471 Tu-P7:42), (Tu-P7:43, Tu-P7:45, Tu-P7:46), (Tu-P7:47, Tu-P7:48, Th-W52:5, Th-W52:6), 472 (Th-W52:7), 474 (Th-W54:2), 480 194 195 Tu-P7:50), (Tu-P7:51, Tu-P7:52, Tu-P7:54), (Tu-P7:56, (Th-W56:6), 487 (Th-W60:4), 492 (Th-P15:5), 539 (Th-P15:212), 542 196 197 Tu-P7:58), (Tu-P7:61, Tu-P7:63, Tu-P7:64), (Tu-P7:65, Tu-P7:66, (Th-P15:224), 590 (Th-P17:443) 198 199 Tu-P7:67, Tu-P7:68), 200 (Tu-P7:69, Tu-P7:70, Tu-P7:71, Tu-P7:72), 201 Aggressive versus Non-Aggressive Cholesterol Lowering (Tu-P7:73, Tu-P7:74, Tu-P7:76, Tu-P7:77), 202 (Tu-P7:79, Tu-P7:81), 203 36 (Mo-W14:2), 43 (Mo-S7:1), 122 (Mo-P5:348), 161 (Tu-W20:4, (Tu-P7:83), 205 (Tu-P7:93, Tu-P7:94), 218 (Tu-P7:153), 219 (Tu-P7:155, Tu-W20:5), 178 (Tu-W29:5), 179 (Tu-W29:7), 181 (Tu-S10:1), 182 Tu-P7:157), 220 (Tu-P7:159), 224 (Tu-P7:181), 227 (Tu-P7:194), 228 (Tu-S10:2), 286 (Tu-P10:463, Tu-P10:464), 551 (Th-P16:264), 569 (Tu-P7:196, Tu-P7:197, Tu-P7:199), 236 (Tu-P7:236), 237 (Tu-P7:240), (Th-P16:346), 582 (Th-P16:406) 242 (Tu-P7:262), 243 (Tu-P7:267), 244 (Tu-P7:273), 245 (Tu-P7:277), 250

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

211 T Topic Index O

P ACAT Inhibitors AIDS as an Atherogenic Disease 501 (Th-P15:39), 544 (Th-P15:232, Th-P15:236), 547 (Th-P16:249), 548 162 (Tu-W21:2), 163 (Tu-W21:3, Tu-W21:5), 399 (We-P11:240, I (Th-P16:250, Th-P16:251, Th-P16:252, Th-P16:253) We-P11:241, We-P11:242, We-P11:243, We-P11:244), 400 (We-P11:245, We-P11:246, We-P11:248), 416 (We-P13:318), 544 (Th-P15:233) Acute Coronary Syndromes C 11 (Mo-W1:2), 22 (Mo-W6:7), 24 (Mo-W7:7), 29 (Mo-W10:5), 58 (Mo-P1:56), (Mo-P1:92), (Mo-P1:146), (Mo-P2:168, Mo-P2:169, Algorithms for Risk Evaluation 66 78 83 6 (Su-S3:4), 37 (Mo-W14:4), 46 (Mo-P1:1, Mo-P1:2, Mo-P1:3, Mo-P1:4, Mo-P2:170), 84 (Mo-P2:171, Mo-P2:172, Mo-P2:173, Mo-P2:174, Mo-P1:5), (Mo-P1:8), (Mo-P1:34), (Mo-P1:39), (Mo-P1:58), Mo-P2:175), (Mo-P2:176, Mo-P2:177, Mo-P2:178, Mo-P2:179), 47 53 54 58 85 86 61 (Mo-P1:70), 65 (Mo-P1:90), 66 (Mo-P1:91), 70 (Mo-P1:112), 74 (Mo-P2:180, Mo-P2:182, Mo-P2:184), 87 (Mo-P2:185, Mo-P2:186), 91 (Mo-P1:129), (Mo-P1:162), (Mo-P4:248), (Mo-P5:312), I (Mo-P2:207), (Mo-P2:208), (Mo-P3:221), (Mo-P4:235, 81 100 114 261 92 95 98 (Tu-P9:350), (Tu-P9:368), (We-PL3:3), (We-P11:106), Mo-P4:236), (Mo-P5:324, Mo-P5:327), (Mo-P5:343), 265 301 369 376 117 121 122 (We-P11:137), (We-P13:352), (Th-W50:1), (Th-W50:3, N (Mo-P5:349), (Mo-P6:443), (Tu-W18:4), (Tu-W20:8), 424 466 467 143 157 162 171 Th-W50:4), (Th-W56:8), (Th-W58:1, Th-W58:2), (Tu-W25:6), (Tu-P7:89), (Tu-P7:123), (Tu-P7:241), 480 483 504 204 211 237 244 (Th-P15:53) D (Tu-P7:270), 246 (Tu-P7:279), 268 (Tu-P9:380), 278 (Tu-P10:425, Tu-P10:428), 285 (Tu-P10:460), 286 (Tu-P10:461), 288 (Tu-P10:470), 297 Ancillary Properties of Lipid Lowering Drugs (Tu-P10:510), 301 (We-PL3:2), 310 (We-W32:6), 314 (We-W35:2), 316 E 9 (Mo-ML1:1), 32 (Mo-W11:7), 122 (Mo-P5:348), 126 (Mo-P5:366), 250 (We-W35:6), 332 (We-W44:3), 335 (We-W45:4), 390 (We-P11:200), 393 (Tu-P8:300), 466 (Th-W49:6), 468 (Th-W51:2), 514 (Th-P15:99), 549 (We-P11:214), 396 (We-P11:231), 397 (We-P11:233), 398 (We-P11:237, X We-P11:239), (We-P13:349), (We-P14:463), (Th-W46:7), (Th-P16:256, Th-P16:257), 558 (Th-P16:293), 569 (Th-P16:344), 577 423 448 460 486 (Th-P16:381), (Th-P16:406) (Th-W59:4), 533 (Th-P15:184), 535 (Th-P15:192), 551 (Th-P16:264), 553 582 (Th-P16:274), 563 (Th-P16:319), 569 (Th-P16:343), 581 (Th-P16:399), 588 (Th-P17:430) Angina 69 (Mo-P1:108), 74 (Mo-P1:129), 78 (Mo-P1:145), 84 (Mo-P2:174), 85 Adipose Tissue (Mo-P2:178), 89 (Mo-P2:195), 93 (Mo-P2:215), 97 (Mo-P4:234), 98 13 (Mo-W2:1), 40 (Mo-S4:1, Mo-S4:3), 55 (Mo-P1:46), 97 (Mo-P3:232), 114 (Mo-P4:235, Mo-P4:236, Mo-P4:238, Mo-P4:239), 100 (Mo-P4:246), 114 (Mo-P5:311), 164 (Tu-W22:1, Tu-W22:2, Tu-W22:3), 165 (Tu-W22:4, (Mo-P5:312), 117 (Mo-P5:324, Mo-P5:327), 127 (Mo-P5:373), 131 Tu-W22:5, Tu-W22:6, Tu-W22:7), 185 (Tu-P7:1, Tu-P7:2, Tu-P7:3, (Mo-P6:387), 146 (Mo-P6:455), 217 (Tu-P7:145), 266 (Tu-P9:372), 270 Tu-P7:4, Tu-P7:5), 186 (Tu-P7:6, Tu-P7:7, Tu-P7:8, Tu-P7:9), 187 (Tu-P10:391), 276 (Tu-P10:420), 278 (Tu-P10:429), 279 (Tu-P10:432), (Tu-P7:12, Tu-P7:14), 188 (Tu-P7:15), 192 (Tu-P7:36), 195 (Tu-P7:49), 281 (Tu-P10:439), 282 (Tu-P10:444), 286 (Tu-P10:462), 288 196 (Tu-P7:53), 202 (Tu-P7:82), 206 (Tu-P7:97), 214 (Tu-P7:136), 221 (Tu-P10:470), 291 (Tu-P10:483), 357 (We-P11:51, We-P11:53) (Tu-P7:165), 282 (Tu-P10:445), 301 (We-PL3:1), 311 (We-W33:3, We-W33:5), (We-W33:7), (We-W37:7), (We-W42:7), 312 320 330 341 Angiogenesis: Stimulation and Antagonism (We-S14:4), (We-P11:77), (We-P11:79), (We-P11:103), 362 363 368 371 33 (Mo-W12:5), 34 (Mo-W13:2), 94 (Mo-P3:217), 97 (Mo-P3:232), 106 (We-P11:115), (We-P11:130), (We-P11:135), (We-P11:142), 374 375 377 (Mo-P4:272), 110 (Mo-P4:292), 114 (Mo-P5:312), 185 (Tu-P7:5), 190 (We-P11:148), (We-P11:157), (We-P12:285), 378 380 408 415 (Tu-P7:25, Tu-P7:26, Tu-P7:27, Tu-P7:28), 191 (Tu-P7:29, Tu-P7:30, (We-P13:315), (We-P13:319), (We-P13:323), (We-P13:335), 416 417 420 Tu-P7:31, Tu-P7:32), 192 (Tu-P7:33, Tu-P7:34, Tu-P7:35, Tu-P7:36, (We-P14:383), (Th-W48:5), (Th-W58:6), (Th-P15:29), 431 463 484 498 Tu-P7:37), 198 (Tu-P7:64), 199 (Tu-P7:68), 215 (Tu-P7:137), 241 (Th-P15:108), (Th-P15:125) 516 520 (Tu-P7:258), 251 (Tu-P8:304), 295 (Tu-P10:503), 307 (We-W31:3), 312 (We-W34:1), 352 (We-P11:32), 408 (We-P12:283), 462 (Th-W48:1), 490 Ageing (Th-W61:8), 571 (Th-P16:351) 35 (Mo-W14:1), 50 (Mo-P1:23), 65 (Mo-P1:87), 73 (Mo-P1:123), 77 (Mo-P1:140), 82 (Mo-P1:165), 106 (Mo-P4:275), 107 (Mo-P4:280), 108 Animal Models (Mo-P4:284), 109 (Mo-P4:287), 128 (Mo-P5:375), 129 (Mo-P6:379), 188 (Tu-P7:17, Tu-P7:18), (Tu-P7:19, Tu-P7:20, Tu-P7:22, Tu-P7:23), 12 (Mo-W1:6), 13 (Mo-W2:1), 18 (Mo-W4:7), 22 (Mo-W6:7), 25 (Mo-W8:4, 189 193 Mo-W8:6), (Mo-W10:1), (Mo-W12:3), (Mo-W12:6), (Tu-P7:39), 200 (Tu-P7:69), 209 (Tu-P7:112), 250 (Tu-P8:296), 258 28 32 33 38 (Tu-P9:335), (Tu-P9:365), (Tu-P10:405), (Tu-P10:488), (Mo-W15:4), 39 (Mo-W15:5, Mo-W15:6), 40 (Mo-S4:3), 87 (Mo-P2:185), 264 273 292 294 (Mo-P3:222), (Mo-P3:226, Mo-P3:229), (Mo-P5:298), (Tu-P10:498), 303 (We-ML7:1), 317 (We-W36:3), 323 (We-W39:4), 346 95 96 111 144 (We-P11:2), (We-P11:31), (We-P11:253), (We-P11:255), (Mo-P6:447), 151 (Tu-ML5:1), 152 (Tu-W16:2), 153 (Tu-W16:6), 162 352 401 402 411 (Tu-W21:1), (Tu-W25:5), (Tu-P7:1, Tu-P7:3), (Tu-P7:24, (We-P12:294), 415 (We-P13:313), 424 (We-P13:354), 438 (We-P14:414), 170 185 190 (We-P14:458), (Th-W48:5), (Th-W52:1), (Th-W52:4, Tu-P7:25), 191 (Tu-P7:29), 193 (Tu-P7:39, Tu-P7:40, Tu-P7:41, 447 463 470 471 Tu-P7:42), (Tu-P7:43, Tu-P7:45, Tu-P7:46), (Tu-P7:47, Tu-P7:48, Th-W52:5, Th-W52:6), 472 (Th-W52:7), 474 (Th-W54:2), 480 194 195 Tu-P7:50), (Tu-P7:51, Tu-P7:52, Tu-P7:54), (Tu-P7:56, (Th-W56:6), 487 (Th-W60:4), 492 (Th-P15:5), 539 (Th-P15:212), 542 196 197 Tu-P7:58), (Tu-P7:61, Tu-P7:63, Tu-P7:64), (Tu-P7:65, Tu-P7:66, (Th-P15:224), 590 (Th-P17:443) 198 199 Tu-P7:67, Tu-P7:68), 200 (Tu-P7:69, Tu-P7:70, Tu-P7:71, Tu-P7:72), 201 Aggressive versus Non-Aggressive Cholesterol Lowering (Tu-P7:73, Tu-P7:74, Tu-P7:76, Tu-P7:77), 202 (Tu-P7:79, Tu-P7:81), 203 36 (Mo-W14:2), 43 (Mo-S7:1), 122 (Mo-P5:348), 161 (Tu-W20:4, (Tu-P7:83), 205 (Tu-P7:93, Tu-P7:94), 218 (Tu-P7:153), 219 (Tu-P7:155, Tu-W20:5), 178 (Tu-W29:5), 179 (Tu-W29:7), 181 (Tu-S10:1), 182 Tu-P7:157), 220 (Tu-P7:159), 224 (Tu-P7:181), 227 (Tu-P7:194), 228 (Tu-S10:2), 286 (Tu-P10:463, Tu-P10:464), 551 (Th-P16:264), 569 (Tu-P7:196, Tu-P7:197, Tu-P7:199), 236 (Tu-P7:236), 237 (Tu-P7:240), (Th-P16:346), 582 (Th-P16:406) 242 (Tu-P7:262), 243 (Tu-P7:267), 244 (Tu-P7:273), 245 (Tu-P7:277), 250

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

212 Topic Index T O ACAT Inhibitors AIDS as an Atherogenic Disease P 501 (Th-P15:39), 544 (Th-P15:232, Th-P15:236), 547 (Th-P16:249), 548 162 (Tu-W21:2), 163 (Tu-W21:3, Tu-W21:5), 399 (We-P11:240, (Th-P16:250, Th-P16:251, Th-P16:252, Th-P16:253) We-P11:241, We-P11:242, We-P11:243, We-P11:244), 400 (We-P11:245, I We-P11:246, We-P11:248), 416 (We-P13:318), 544 (Th-P15:233) Acute Coronary Syndromes 11 (Mo-W1:2), 22 (Mo-W6:7), 24 (Mo-W7:7), 29 (Mo-W10:5), 58 C (Mo-P1:56), (Mo-P1:92), (Mo-P1:146), (Mo-P2:168, Mo-P2:169, Algorithms for Risk Evaluation 66 78 83 6 (Su-S3:4), 37 (Mo-W14:4), 46 (Mo-P1:1, Mo-P1:2, Mo-P1:3, Mo-P1:4, Mo-P2:170), 84 (Mo-P2:171, Mo-P2:172, Mo-P2:173, Mo-P2:174, Mo-P1:5), (Mo-P1:8), (Mo-P1:34), (Mo-P1:39), (Mo-P1:58), Mo-P2:175), (Mo-P2:176, Mo-P2:177, Mo-P2:178, Mo-P2:179), 47 53 54 58 85 86 61 (Mo-P1:70), 65 (Mo-P1:90), 66 (Mo-P1:91), 70 (Mo-P1:112), 74 (Mo-P2:180, Mo-P2:182, Mo-P2:184), 87 (Mo-P2:185, Mo-P2:186), 91 (Mo-P1:129), (Mo-P1:162), (Mo-P4:248), (Mo-P5:312), (Mo-P2:207), (Mo-P2:208), (Mo-P3:221), (Mo-P4:235, 81 100 114 261 I 92 95 98 (Tu-P9:350), (Tu-P9:368), (We-PL3:3), (We-P11:106), Mo-P4:236), (Mo-P5:324, Mo-P5:327), (Mo-P5:343), 265 301 369 376 117 121 122 (We-P11:137), (We-P13:352), (Th-W50:1), (Th-W50:3, (Mo-P5:349), (Mo-P6:443), (Tu-W18:4), (Tu-W20:8), 424 466 467 143 157 162 171 Th-W50:4), (Th-W56:8), (Th-W58:1, Th-W58:2), N (Tu-W25:6), (Tu-P7:89), (Tu-P7:123), (Tu-P7:241), 480 483 504 204 211 237 244 (Th-P15:53) (Tu-P7:270), 246 (Tu-P7:279), 268 (Tu-P9:380), 278 (Tu-P10:425, D Tu-P10:428), 285 (Tu-P10:460), 286 (Tu-P10:461), 288 (Tu-P10:470), 297 Ancillary Properties of Lipid Lowering Drugs (Tu-P10:510), 301 (We-PL3:2), 310 (We-W32:6), 314 (We-W35:2), 316 9 (Mo-ML1:1), 32 (Mo-W11:7), 122 (Mo-P5:348), 126 (Mo-P5:366), 250 E (We-W35:6), 332 (We-W44:3), 335 (We-W45:4), 390 (We-P11:200), 393 (Tu-P8:300), 466 (Th-W49:6), 468 (Th-W51:2), 514 (Th-P15:99), 549 (We-P11:214), 396 (We-P11:231), 397 (We-P11:233), 398 (We-P11:237, We-P11:239), (We-P13:349), (We-P14:463), (Th-W46:7), (Th-P16:256, Th-P16:257), 558 (Th-P16:293), 569 (Th-P16:344), 577 X 423 448 460 486 (Th-P16:381), (Th-P16:406) (Th-W59:4), 533 (Th-P15:184), 535 (Th-P15:192), 551 (Th-P16:264), 553 582 (Th-P16:274), 563 (Th-P16:319), 569 (Th-P16:343), 581 (Th-P16:399), 588 (Th-P17:430) Angina 69 (Mo-P1:108), 74 (Mo-P1:129), 78 (Mo-P1:145), 84 (Mo-P2:174), 85 Adipose Tissue (Mo-P2:178), 89 (Mo-P2:195), 93 (Mo-P2:215), 97 (Mo-P4:234), 98 13 (Mo-W2:1), 40 (Mo-S4:1, Mo-S4:3), 55 (Mo-P1:46), 97 (Mo-P3:232), 114 (Mo-P4:235, Mo-P4:236, Mo-P4:238, Mo-P4:239), 100 (Mo-P4:246), 114 (Mo-P5:311), 164 (Tu-W22:1, Tu-W22:2, Tu-W22:3), 165 (Tu-W22:4, (Mo-P5:312), 117 (Mo-P5:324, Mo-P5:327), 127 (Mo-P5:373), 131 Tu-W22:5, Tu-W22:6, Tu-W22:7), 185 (Tu-P7:1, Tu-P7:2, Tu-P7:3, (Mo-P6:387), 146 (Mo-P6:455), 217 (Tu-P7:145), 266 (Tu-P9:372), 270 Tu-P7:4, Tu-P7:5), 186 (Tu-P7:6, Tu-P7:7, Tu-P7:8, Tu-P7:9), 187 (Tu-P10:391), 276 (Tu-P10:420), 278 (Tu-P10:429), 279 (Tu-P10:432), (Tu-P7:12, Tu-P7:14), 188 (Tu-P7:15), 192 (Tu-P7:36), 195 (Tu-P7:49), 281 (Tu-P10:439), 282 (Tu-P10:444), 286 (Tu-P10:462), 288 196 (Tu-P7:53), 202 (Tu-P7:82), 206 (Tu-P7:97), 214 (Tu-P7:136), 221 (Tu-P10:470), 291 (Tu-P10:483), 357 (We-P11:51, We-P11:53) (Tu-P7:165), 282 (Tu-P10:445), 301 (We-PL3:1), 311 (We-W33:3, We-W33:5), (We-W33:7), (We-W37:7), (We-W42:7), 312 320 330 341 Angiogenesis: Stimulation and Antagonism (We-S14:4), (We-P11:77), (We-P11:79), (We-P11:103), 362 363 368 371 33 (Mo-W12:5), 34 (Mo-W13:2), 94 (Mo-P3:217), 97 (Mo-P3:232), 106 (We-P11:115), (We-P11:130), (We-P11:135), (We-P11:142), 374 375 377 (Mo-P4:272), 110 (Mo-P4:292), 114 (Mo-P5:312), 185 (Tu-P7:5), 190 (We-P11:148), (We-P11:157), (We-P12:285), 378 380 408 415 (Tu-P7:25, Tu-P7:26, Tu-P7:27, Tu-P7:28), 191 (Tu-P7:29, Tu-P7:30, (We-P13:315), (We-P13:319), (We-P13:323), (We-P13:335), 416 417 420 Tu-P7:31, Tu-P7:32), 192 (Tu-P7:33, Tu-P7:34, Tu-P7:35, Tu-P7:36, (We-P14:383), (Th-W48:5), (Th-W58:6), (Th-P15:29), 431 463 484 498 Tu-P7:37), 198 (Tu-P7:64), 199 (Tu-P7:68), 215 (Tu-P7:137), 241 (Th-P15:108), (Th-P15:125) 516 520 (Tu-P7:258), 251 (Tu-P8:304), 295 (Tu-P10:503), 307 (We-W31:3), 312 (We-W34:1), 352 (We-P11:32), 408 (We-P12:283), 462 (Th-W48:1), 490 Ageing (Th-W61:8), 571 (Th-P16:351) 35 (Mo-W14:1), 50 (Mo-P1:23), 65 (Mo-P1:87), 73 (Mo-P1:123), 77 (Mo-P1:140), 82 (Mo-P1:165), 106 (Mo-P4:275), 107 (Mo-P4:280), 108 Animal Models (Mo-P4:284), 109 (Mo-P4:287), 128 (Mo-P5:375), 129 (Mo-P6:379), 188 (Tu-P7:17, Tu-P7:18), (Tu-P7:19, Tu-P7:20, Tu-P7:22, Tu-P7:23), 12 (Mo-W1:6), 13 (Mo-W2:1), 18 (Mo-W4:7), 22 (Mo-W6:7), 25 (Mo-W8:4, 189 193 Mo-W8:6), (Mo-W10:1), (Mo-W12:3), (Mo-W12:6), (Tu-P7:39), 200 (Tu-P7:69), 209 (Tu-P7:112), 250 (Tu-P8:296), 258 28 32 33 38 (Tu-P9:335), (Tu-P9:365), (Tu-P10:405), (Tu-P10:488), (Mo-W15:4), 39 (Mo-W15:5, Mo-W15:6), 40 (Mo-S4:3), 87 (Mo-P2:185), 264 273 292 294 (Mo-P3:222), (Mo-P3:226, Mo-P3:229), (Mo-P5:298), (Tu-P10:498), 303 (We-ML7:1), 317 (We-W36:3), 323 (We-W39:4), 346 95 96 111 144 (We-P11:2), (We-P11:31), (We-P11:253), (We-P11:255), (Mo-P6:447), 151 (Tu-ML5:1), 152 (Tu-W16:2), 153 (Tu-W16:6), 162 352 401 402 411 (Tu-W21:1), (Tu-W25:5), (Tu-P7:1, Tu-P7:3), (Tu-P7:24, (We-P12:294), 415 (We-P13:313), 424 (We-P13:354), 438 (We-P14:414), 170 185 190 (We-P14:458), (Th-W48:5), (Th-W52:1), (Th-W52:4, Tu-P7:25), 191 (Tu-P7:29), 193 (Tu-P7:39, Tu-P7:40, Tu-P7:41, 447 463 470 471 Tu-P7:42), (Tu-P7:43, Tu-P7:45, Tu-P7:46), (Tu-P7:47, Tu-P7:48, Th-W52:5, Th-W52:6), 472 (Th-W52:7), 474 (Th-W54:2), 480 194 195 Tu-P7:50), (Tu-P7:51, Tu-P7:52, Tu-P7:54), (Tu-P7:56, (Th-W56:6), 487 (Th-W60:4), 492 (Th-P15:5), 539 (Th-P15:212), 542 196 197 Tu-P7:58), (Tu-P7:61, Tu-P7:63, Tu-P7:64), (Tu-P7:65, Tu-P7:66, (Th-P15:224), 590 (Th-P17:443) 198 199 Tu-P7:67, Tu-P7:68), 200 (Tu-P7:69, Tu-P7:70, Tu-P7:71, Tu-P7:72), 201 Aggressive versus Non-Aggressive Cholesterol Lowering (Tu-P7:73, Tu-P7:74, Tu-P7:76, Tu-P7:77), 202 (Tu-P7:79, Tu-P7:81), 203 36 (Mo-W14:2), 43 (Mo-S7:1), 122 (Mo-P5:348), 161 (Tu-W20:4, (Tu-P7:83), 205 (Tu-P7:93, Tu-P7:94), 218 (Tu-P7:153), 219 (Tu-P7:155, Tu-W20:5), 178 (Tu-W29:5), 179 (Tu-W29:7), 181 (Tu-S10:1), 182 Tu-P7:157), 220 (Tu-P7:159), 224 (Tu-P7:181), 227 (Tu-P7:194), 228 (Tu-S10:2), 286 (Tu-P10:463, Tu-P10:464), 551 (Th-P16:264), 569 (Tu-P7:196, Tu-P7:197, Tu-P7:199), 236 (Tu-P7:236), 237 (Tu-P7:240), (Th-P16:346), 582 (Th-P16:406) 242 (Tu-P7:262), 243 (Tu-P7:267), 244 (Tu-P7:273), 245 (Tu-P7:277), 250

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

213 T Topic Index O

P ACAT Inhibitors AIDS as an Atherogenic Disease 501 (Th-P15:39), 544 (Th-P15:232, Th-P15:236), 547 (Th-P16:249), 548 162 (Tu-W21:2), 163 (Tu-W21:3, Tu-W21:5), 399 (We-P11:240, I (Th-P16:250, Th-P16:251, Th-P16:252, Th-P16:253) We-P11:241, We-P11:242, We-P11:243, We-P11:244), 400 (We-P11:245, We-P11:246, We-P11:248), 416 (We-P13:318), 544 (Th-P15:233) Acute Coronary Syndromes C 11 (Mo-W1:2), 22 (Mo-W6:7), 24 (Mo-W7:7), 29 (Mo-W10:5), 58 (Mo-P1:56), (Mo-P1:92), (Mo-P1:146), (Mo-P2:168, Mo-P2:169, Algorithms for Risk Evaluation 66 78 83 6 (Su-S3:4), 37 (Mo-W14:4), 46 (Mo-P1:1, Mo-P1:2, Mo-P1:3, Mo-P1:4, Mo-P2:170), 84 (Mo-P2:171, Mo-P2:172, Mo-P2:173, Mo-P2:174, Mo-P1:5), (Mo-P1:8), (Mo-P1:34), (Mo-P1:39), (Mo-P1:58), Mo-P2:175), (Mo-P2:176, Mo-P2:177, Mo-P2:178, Mo-P2:179), 47 53 54 58 85 86 61 (Mo-P1:70), 65 (Mo-P1:90), 66 (Mo-P1:91), 70 (Mo-P1:112), 74 (Mo-P2:180, Mo-P2:182, Mo-P2:184), 87 (Mo-P2:185, Mo-P2:186), 91 (Mo-P1:129), (Mo-P1:162), (Mo-P4:248), (Mo-P5:312), I (Mo-P2:207), (Mo-P2:208), (Mo-P3:221), (Mo-P4:235, 81 100 114 261 92 95 98 (Tu-P9:350), (Tu-P9:368), (We-PL3:3), (We-P11:106), Mo-P4:236), (Mo-P5:324, Mo-P5:327), (Mo-P5:343), 265 301 369 376 117 121 122 (We-P11:137), (We-P13:352), (Th-W50:1), (Th-W50:3, N (Mo-P5:349), (Mo-P6:443), (Tu-W18:4), (Tu-W20:8), 424 466 467 143 157 162 171 Th-W50:4), (Th-W56:8), (Th-W58:1, Th-W58:2), (Tu-W25:6), (Tu-P7:89), (Tu-P7:123), (Tu-P7:241), 480 483 504 204 211 237 244 (Th-P15:53) D (Tu-P7:270), 246 (Tu-P7:279), 268 (Tu-P9:380), 278 (Tu-P10:425, Tu-P10:428), 285 (Tu-P10:460), 286 (Tu-P10:461), 288 (Tu-P10:470), 297 Ancillary Properties of Lipid Lowering Drugs (Tu-P10:510), 301 (We-PL3:2), 310 (We-W32:6), 314 (We-W35:2), 316 E 9 (Mo-ML1:1), 32 (Mo-W11:7), 122 (Mo-P5:348), 126 (Mo-P5:366), 250 (We-W35:6), 332 (We-W44:3), 335 (We-W45:4), 390 (We-P11:200), 393 (Tu-P8:300), 466 (Th-W49:6), 468 (Th-W51:2), 514 (Th-P15:99), 549 (We-P11:214), 396 (We-P11:231), 397 (We-P11:233), 398 (We-P11:237, X We-P11:239), (We-P13:349), (We-P14:463), (Th-W46:7), (Th-P16:256, Th-P16:257), 558 (Th-P16:293), 569 (Th-P16:344), 577 423 448 460 486 (Th-P16:381), (Th-P16:406) (Th-W59:4), 533 (Th-P15:184), 535 (Th-P15:192), 551 (Th-P16:264), 553 582 (Th-P16:274), 563 (Th-P16:319), 569 (Th-P16:343), 581 (Th-P16:399), 588 (Th-P17:430) Angina 69 (Mo-P1:108), 74 (Mo-P1:129), 78 (Mo-P1:145), 84 (Mo-P2:174), 85 Adipose Tissue (Mo-P2:178), 89 (Mo-P2:195), 93 (Mo-P2:215), 97 (Mo-P4:234), 98 13 (Mo-W2:1), 40 (Mo-S4:1, Mo-S4:3), 55 (Mo-P1:46), 97 (Mo-P3:232), 114 (Mo-P4:235, Mo-P4:236, Mo-P4:238, Mo-P4:239), 100 (Mo-P4:246), 114 (Mo-P5:311), 164 (Tu-W22:1, Tu-W22:2, Tu-W22:3), 165 (Tu-W22:4, (Mo-P5:312), 117 (Mo-P5:324, Mo-P5:327), 127 (Mo-P5:373), 131 Tu-W22:5, Tu-W22:6, Tu-W22:7), 185 (Tu-P7:1, Tu-P7:2, Tu-P7:3, (Mo-P6:387), 146 (Mo-P6:455), 217 (Tu-P7:145), 266 (Tu-P9:372), 270 Tu-P7:4, Tu-P7:5), 186 (Tu-P7:6, Tu-P7:7, Tu-P7:8, Tu-P7:9), 187 (Tu-P10:391), 276 (Tu-P10:420), 278 (Tu-P10:429), 279 (Tu-P10:432), (Tu-P7:12, Tu-P7:14), 188 (Tu-P7:15), 192 (Tu-P7:36), 195 (Tu-P7:49), 281 (Tu-P10:439), 282 (Tu-P10:444), 286 (Tu-P10:462), 288 196 (Tu-P7:53), 202 (Tu-P7:82), 206 (Tu-P7:97), 214 (Tu-P7:136), 221 (Tu-P10:470), 291 (Tu-P10:483), 357 (We-P11:51, We-P11:53) (Tu-P7:165), 282 (Tu-P10:445), 301 (We-PL3:1), 311 (We-W33:3, We-W33:5), (We-W33:7), (We-W37:7), (We-W42:7), 312 320 330 341 Angiogenesis: Stimulation and Antagonism (We-S14:4), (We-P11:77), (We-P11:79), (We-P11:103), 362 363 368 371 33 (Mo-W12:5), 34 (Mo-W13:2), 94 (Mo-P3:217), 97 (Mo-P3:232), 106 (We-P11:115), (We-P11:130), (We-P11:135), (We-P11:142), 374 375 377 (Mo-P4:272), 110 (Mo-P4:292), 114 (Mo-P5:312), 185 (Tu-P7:5), 190 (We-P11:148), (We-P11:157), (We-P12:285), 378 380 408 415 (Tu-P7:25, Tu-P7:26, Tu-P7:27, Tu-P7:28), 191 (Tu-P7:29, Tu-P7:30, (We-P13:315), (We-P13:319), (We-P13:323), (We-P13:335), 416 417 420 Tu-P7:31, Tu-P7:32), 192 (Tu-P7:33, Tu-P7:34, Tu-P7:35, Tu-P7:36, (We-P14:383), (Th-W48:5), (Th-W58:6), (Th-P15:29), 431 463 484 498 Tu-P7:37), 198 (Tu-P7:64), 199 (Tu-P7:68), 215 (Tu-P7:137), 241 (Th-P15:108), (Th-P15:125) 516 520 (Tu-P7:258), 251 (Tu-P8:304), 295 (Tu-P10:503), 307 (We-W31:3), 312 (We-W34:1), 352 (We-P11:32), 408 (We-P12:283), 462 (Th-W48:1), 490 Ageing (Th-W61:8), 571 (Th-P16:351) 35 (Mo-W14:1), 50 (Mo-P1:23), 65 (Mo-P1:87), 73 (Mo-P1:123), 77 (Mo-P1:140), 82 (Mo-P1:165), 106 (Mo-P4:275), 107 (Mo-P4:280), 108 Animal Models (Mo-P4:284), 109 (Mo-P4:287), 128 (Mo-P5:375), 129 (Mo-P6:379), 188 (Tu-P7:17, Tu-P7:18), (Tu-P7:19, Tu-P7:20, Tu-P7:22, Tu-P7:23), 12 (Mo-W1:6), 13 (Mo-W2:1), 18 (Mo-W4:7), 22 (Mo-W6:7), 25 (Mo-W8:4, 189 193 Mo-W8:6), (Mo-W10:1), (Mo-W12:3), (Mo-W12:6), (Tu-P7:39), 200 (Tu-P7:69), 209 (Tu-P7:112), 250 (Tu-P8:296), 258 28 32 33 38 (Tu-P9:335), (Tu-P9:365), (Tu-P10:405), (Tu-P10:488), (Mo-W15:4), 39 (Mo-W15:5, Mo-W15:6), 40 (Mo-S4:3), 87 (Mo-P2:185), 264 273 292 294 (Mo-P3:222), (Mo-P3:226, Mo-P3:229), (Mo-P5:298), (Tu-P10:498), 303 (We-ML7:1), 317 (We-W36:3), 323 (We-W39:4), 346 95 96 111 144 (We-P11:2), (We-P11:31), (We-P11:253), (We-P11:255), (Mo-P6:447), 151 (Tu-ML5:1), 152 (Tu-W16:2), 153 (Tu-W16:6), 162 352 401 402 411 (Tu-W21:1), (Tu-W25:5), (Tu-P7:1, Tu-P7:3), (Tu-P7:24, (We-P12:294), 415 (We-P13:313), 424 (We-P13:354), 438 (We-P14:414), 170 185 190 (We-P14:458), (Th-W48:5), (Th-W52:1), (Th-W52:4, Tu-P7:25), 191 (Tu-P7:29), 193 (Tu-P7:39, Tu-P7:40, Tu-P7:41, 447 463 470 471 Tu-P7:42), (Tu-P7:43, Tu-P7:45, Tu-P7:46), (Tu-P7:47, Tu-P7:48, Th-W52:5, Th-W52:6), 472 (Th-W52:7), 474 (Th-W54:2), 480 194 195 Tu-P7:50), (Tu-P7:51, Tu-P7:52, Tu-P7:54), (Tu-P7:56, (Th-W56:6), 487 (Th-W60:4), 492 (Th-P15:5), 539 (Th-P15:212), 542 196 197 Tu-P7:58), (Tu-P7:61, Tu-P7:63, Tu-P7:64), (Tu-P7:65, Tu-P7:66, (Th-P15:224), 590 (Th-P17:443) 198 199 Tu-P7:67, Tu-P7:68), 200 (Tu-P7:69, Tu-P7:70, Tu-P7:71, Tu-P7:72), 201 Aggressive versus Non-Aggressive Cholesterol Lowering (Tu-P7:73, Tu-P7:74, Tu-P7:76, Tu-P7:77), 202 (Tu-P7:79, Tu-P7:81), 203 36 (Mo-W14:2), 43 (Mo-S7:1), 122 (Mo-P5:348), 161 (Tu-W20:4, (Tu-P7:83), 205 (Tu-P7:93, Tu-P7:94), 218 (Tu-P7:153), 219 (Tu-P7:155, Tu-W20:5), 178 (Tu-W29:5), 179 (Tu-W29:7), 181 (Tu-S10:1), 182 Tu-P7:157), 220 (Tu-P7:159), 224 (Tu-P7:181), 227 (Tu-P7:194), 228 (Tu-S10:2), 286 (Tu-P10:463, Tu-P10:464), 551 (Th-P16:264), 569 (Tu-P7:196, Tu-P7:197, Tu-P7:199), 236 (Tu-P7:236), 237 (Tu-P7:240), (Th-P16:346), 582 (Th-P16:406) 242 (Tu-P7:262), 243 (Tu-P7:267), 244 (Tu-P7:273), 245 (Tu-P7:277), 250

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

214 Topic Index T O ACAT Inhibitors AIDS as an Atherogenic Disease P 501 (Th-P15:39), 544 (Th-P15:232, Th-P15:236), 547 (Th-P16:249), 548 162 (Tu-W21:2), 163 (Tu-W21:3, Tu-W21:5), 399 (We-P11:240, (Th-P16:250, Th-P16:251, Th-P16:252, Th-P16:253) We-P11:241, We-P11:242, We-P11:243, We-P11:244), 400 (We-P11:245, I We-P11:246, We-P11:248), 416 (We-P13:318), 544 (Th-P15:233) Acute Coronary Syndromes 11 (Mo-W1:2), 22 (Mo-W6:7), 24 (Mo-W7:7), 29 (Mo-W10:5), 58 C (Mo-P1:56), (Mo-P1:92), (Mo-P1:146), (Mo-P2:168, Mo-P2:169, Algorithms for Risk Evaluation 66 78 83 6 (Su-S3:4), 37 (Mo-W14:4), 46 (Mo-P1:1, Mo-P1:2, Mo-P1:3, Mo-P1:4, Mo-P2:170), 84 (Mo-P2:171, Mo-P2:172, Mo-P2:173, Mo-P2:174, Mo-P1:5), (Mo-P1:8), (Mo-P1:34), (Mo-P1:39), (Mo-P1:58), Mo-P2:175), (Mo-P2:176, Mo-P2:177, Mo-P2:178, Mo-P2:179), 47 53 54 58 85 86 61 (Mo-P1:70), 65 (Mo-P1:90), 66 (Mo-P1:91), 70 (Mo-P1:112), 74 (Mo-P2:180, Mo-P2:182, Mo-P2:184), 87 (Mo-P2:185, Mo-P2:186), 91 (Mo-P1:129), (Mo-P1:162), (Mo-P4:248), (Mo-P5:312), (Mo-P2:207), (Mo-P2:208), (Mo-P3:221), (Mo-P4:235, 81 100 114 261 I 92 95 98 (Tu-P9:350), (Tu-P9:368), (We-PL3:3), (We-P11:106), Mo-P4:236), (Mo-P5:324, Mo-P5:327), (Mo-P5:343), 265 301 369 376 117 121 122 (We-P11:137), (We-P13:352), (Th-W50:1), (Th-W50:3, (Mo-P5:349), (Mo-P6:443), (Tu-W18:4), (Tu-W20:8), 424 466 467 143 157 162 171 Th-W50:4), (Th-W56:8), (Th-W58:1, Th-W58:2), N (Tu-W25:6), (Tu-P7:89), (Tu-P7:123), (Tu-P7:241), 480 483 504 204 211 237 244 (Th-P15:53) (Tu-P7:270), 246 (Tu-P7:279), 268 (Tu-P9:380), 278 (Tu-P10:425, D Tu-P10:428), 285 (Tu-P10:460), 286 (Tu-P10:461), 288 (Tu-P10:470), 297 Ancillary Properties of Lipid Lowering Drugs (Tu-P10:510), 301 (We-PL3:2), 310 (We-W32:6), 314 (We-W35:2), 316 9 (Mo-ML1:1), 32 (Mo-W11:7), 122 (Mo-P5:348), 126 (Mo-P5:366), 250 E (We-W35:6), 332 (We-W44:3), 335 (We-W45:4), 390 (We-P11:200), 393 (Tu-P8:300), 466 (Th-W49:6), 468 (Th-W51:2), 514 (Th-P15:99), 549 (We-P11:214), 396 (We-P11:231), 397 (We-P11:233), 398 (We-P11:237, We-P11:239), (We-P13:349), (We-P14:463), (Th-W46:7), (Th-P16:256, Th-P16:257), 558 (Th-P16:293), 569 (Th-P16:344), 577 X 423 448 460 486 (Th-P16:381), (Th-P16:406) (Th-W59:4), 533 (Th-P15:184), 535 (Th-P15:192), 551 (Th-P16:264), 553 582 (Th-P16:274), 563 (Th-P16:319), 569 (Th-P16:343), 581 (Th-P16:399), 588 (Th-P17:430) Angina 69 (Mo-P1:108), 74 (Mo-P1:129), 78 (Mo-P1:145), 84 (Mo-P2:174), 85 Adipose Tissue (Mo-P2:178), 89 (Mo-P2:195), 93 (Mo-P2:215), 97 (Mo-P4:234), 98 13 (Mo-W2:1), 40 (Mo-S4:1, Mo-S4:3), 55 (Mo-P1:46), 97 (Mo-P3:232), 114 (Mo-P4:235, Mo-P4:236, Mo-P4:238, Mo-P4:239), 100 (Mo-P4:246), 114 (Mo-P5:311), 164 (Tu-W22:1, Tu-W22:2, Tu-W22:3), 165 (Tu-W22:4, (Mo-P5:312), 117 (Mo-P5:324, Mo-P5:327), 127 (Mo-P5:373), 131 Tu-W22:5, Tu-W22:6, Tu-W22:7), 185 (Tu-P7:1, Tu-P7:2, Tu-P7:3, (Mo-P6:387), 146 (Mo-P6:455), 217 (Tu-P7:145), 266 (Tu-P9:372), 270 Tu-P7:4, Tu-P7:5), 186 (Tu-P7:6, Tu-P7:7, Tu-P7:8, Tu-P7:9), 187 (Tu-P10:391), 276 (Tu-P10:420), 278 (Tu-P10:429), 279 (Tu-P10:432), (Tu-P7:12, Tu-P7:14), 188 (Tu-P7:15), 192 (Tu-P7:36), 195 (Tu-P7:49), 281 (Tu-P10:439), 282 (Tu-P10:444), 286 (Tu-P10:462), 288 196 (Tu-P7:53), 202 (Tu-P7:82), 206 (Tu-P7:97), 214 (Tu-P7:136), 221 (Tu-P10:470), 291 (Tu-P10:483), 357 (We-P11:51, We-P11:53) (Tu-P7:165), 282 (Tu-P10:445), 301 (We-PL3:1), 311 (We-W33:3, We-W33:5), (We-W33:7), (We-W37:7), (We-W42:7), 312 320 330 341 Angiogenesis: Stimulation and Antagonism (We-S14:4), (We-P11:77), (We-P11:79), (We-P11:103), 362 363 368 371 33 (Mo-W12:5), 34 (Mo-W13:2), 94 (Mo-P3:217), 97 (Mo-P3:232), 106 (We-P11:115), (We-P11:130), (We-P11:135), (We-P11:142), 374 375 377 (Mo-P4:272), 110 (Mo-P4:292), 114 (Mo-P5:312), 185 (Tu-P7:5), 190 (We-P11:148), (We-P11:157), (We-P12:285), 378 380 408 415 (Tu-P7:25, Tu-P7:26, Tu-P7:27, Tu-P7:28), 191 (Tu-P7:29, Tu-P7:30, (We-P13:315), (We-P13:319), (We-P13:323), (We-P13:335), 416 417 420 Tu-P7:31, Tu-P7:32), 192 (Tu-P7:33, Tu-P7:34, Tu-P7:35, Tu-P7:36, (We-P14:383), (Th-W48:5), (Th-W58:6), (Th-P15:29), 431 463 484 498 Tu-P7:37), 198 (Tu-P7:64), 199 (Tu-P7:68), 215 (Tu-P7:137), 241 (Th-P15:108), (Th-P15:125) 516 520 (Tu-P7:258), 251 (Tu-P8:304), 295 (Tu-P10:503), 307 (We-W31:3), 312 (We-W34:1), 352 (We-P11:32), 408 (We-P12:283), 462 (Th-W48:1), 490 Ageing (Th-W61:8), 571 (Th-P16:351) 35 (Mo-W14:1), 50 (Mo-P1:23), 65 (Mo-P1:87), 73 (Mo-P1:123), 77 (Mo-P1:140), 82 (Mo-P1:165), 106 (Mo-P4:275), 107 (Mo-P4:280), 108 Animal Models (Mo-P4:284), 109 (Mo-P4:287), 128 (Mo-P5:375), 129 (Mo-P6:379), 188 (Tu-P7:17, Tu-P7:18), (Tu-P7:19, Tu-P7:20, Tu-P7:22, Tu-P7:23), 12 (Mo-W1:6), 13 (Mo-W2:1), 18 (Mo-W4:7), 22 (Mo-W6:7), 25 (Mo-W8:4, 189 193 Mo-W8:6), (Mo-W10:1), (Mo-W12:3), (Mo-W12:6), (Tu-P7:39), 200 (Tu-P7:69), 209 (Tu-P7:112), 250 (Tu-P8:296), 258 28 32 33 38 (Tu-P9:335), (Tu-P9:365), (Tu-P10:405), (Tu-P10:488), (Mo-W15:4), 39 (Mo-W15:5, Mo-W15:6), 40 (Mo-S4:3), 87 (Mo-P2:185), 264 273 292 294 (Mo-P3:222), (Mo-P3:226, Mo-P3:229), (Mo-P5:298), (Tu-P10:498), 303 (We-ML7:1), 317 (We-W36:3), 323 (We-W39:4), 346 95 96 111 144 (We-P11:2), (We-P11:31), (We-P11:253), (We-P11:255), (Mo-P6:447), 151 (Tu-ML5:1), 152 (Tu-W16:2), 153 (Tu-W16:6), 162 352 401 402 411 (Tu-W21:1), (Tu-W25:5), (Tu-P7:1, Tu-P7:3), (Tu-P7:24, (We-P12:294), 415 (We-P13:313), 424 (We-P13:354), 438 (We-P14:414), 170 185 190 (We-P14:458), (Th-W48:5), (Th-W52:1), (Th-W52:4, Tu-P7:25), 191 (Tu-P7:29), 193 (Tu-P7:39, Tu-P7:40, Tu-P7:41, 447 463 470 471 Tu-P7:42), (Tu-P7:43, Tu-P7:45, Tu-P7:46), (Tu-P7:47, Tu-P7:48, Th-W52:5, Th-W52:6), 472 (Th-W52:7), 474 (Th-W54:2), 480 194 195 Tu-P7:50), (Tu-P7:51, Tu-P7:52, Tu-P7:54), (Tu-P7:56, (Th-W56:6), 487 (Th-W60:4), 492 (Th-P15:5), 539 (Th-P15:212), 542 196 197 Tu-P7:58), (Tu-P7:61, Tu-P7:63, Tu-P7:64), (Tu-P7:65, Tu-P7:66, (Th-P15:224), 590 (Th-P17:443) 198 199 Tu-P7:67, Tu-P7:68), 200 (Tu-P7:69, Tu-P7:70, Tu-P7:71, Tu-P7:72), 201 Aggressive versus Non-Aggressive Cholesterol Lowering (Tu-P7:73, Tu-P7:74, Tu-P7:76, Tu-P7:77), 202 (Tu-P7:79, Tu-P7:81), 203 36 (Mo-W14:2), 43 (Mo-S7:1), 122 (Mo-P5:348), 161 (Tu-W20:4, (Tu-P7:83), 205 (Tu-P7:93, Tu-P7:94), 218 (Tu-P7:153), 219 (Tu-P7:155, Tu-W20:5), 178 (Tu-W29:5), 179 (Tu-W29:7), 181 (Tu-S10:1), 182 Tu-P7:157), 220 (Tu-P7:159), 224 (Tu-P7:181), 227 (Tu-P7:194), 228 (Tu-S10:2), 286 (Tu-P10:463, Tu-P10:464), 551 (Th-P16:264), 569 (Tu-P7:196, Tu-P7:197, Tu-P7:199), 236 (Tu-P7:236), 237 (Tu-P7:240), (Th-P16:346), 582 (Th-P16:406) 242 (Tu-P7:262), 243 (Tu-P7:267), 244 (Tu-P7:273), 245 (Tu-P7:277), 250

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

215

Author Index A (Bold number = Abstract page on the right hand side column of the Final Program) U T

Aarab, R., 518 (Th-P15:116) Adeli, K., 25 (Mo-W8:6) Akita, H., 104 (Mo-P4:264), 133 (Mo-P6:397), H Aardestrup, I.V., 213 (Tu-P7:128), 448 Adlouni, A., 123 (Mo-P5:355), 443 (We-P14:437), 444 (We-P14:441) (We-P14:462), 584 (Th-P16:414) 452 (We-P14:476), 473 (Th-W53:3) Akiyama, Y., 373 (We-P11:125) O Aarsetoey, H., 449 (We-P14:463) Adorni, M.P., 524 (Th-P15:142) Akkerman, J.W., 90 (Mo-P2:198) Abahji, T., 216 (Tu-P7:143) Aerts, J.M.F.G., 589 (Th-P17:437) Akopian, M., 376 (We-P11:137) Abate, N., 79 (Mo-P1:149), 555 (Th-P16:281, Afonso, L., 80 (Mo-P1:154) Akoulitchev, A., 514 (Th-P15:97) R Th-P16:282) Afrasiabiyfar, A., 127 (Mo-P5:372) Akramova, G.S., 206 (Tu-P7:95) Abbate, M., 463 (Th-W48:6) Afshar, M., 209 (Tu-P7:113), 247 (Tu-P7:286) Aksenov, D.V., 499 (Th-P15:34), 500 (Th-P15:38) Abbate, R., 85 (Mo-P2:177), 207 (Tu-P7:102), Afsin, C., 51 (Mo-P1:27) Al-Ramli, W., 489 (Th-W61:1) 325 (We-W40:3), 391 (We-P11:205), 396 Agapakis, D., 108 (Mo-P4:282), 272 (Tu-P10:401) Al-Share, Q.Y., 202 (Tu-P7:77) I (We-P11:227, We-P11:230), 398 Agapov, A., 207 (Tu-P7:103) Ala-Houhala, M., 124 (Mo-P5:358) (We-P11:239), 441 (We-P14:431), 480 Agardh, H.E., 248 (Tu-P7:289), 327 (We-W41:5), Ala-Korpela, M., 496 (Th-P15:19) N (Th-W56:6), 530 (Th-P15:169) 406 (We-P11:272) Alabakovska, S., 140 (Mo-P6:428), 502 532 Abboud, S., 18 (Mo-W4:4) Agaverdizadeh, D., (Th-P15:177) (Th-P15:43), 531 (Th-P15:174) 354 D Abdalla, D.S.P., 197 (Tu-P7:58) Ageev, T., (We-P11:39) Alabakovska, S.B., 70 (Mo-P1:108) 104 Abdar, M., 426 (We-P13:361) Agelidou, D., (Mo-P4:266) Alabakovski, M., 502 (Th-P15:43) 407 Abdar- Esfahani, M., 120 (Mo-P5:341) Agerberth, B., (We-P11:277) Alamanni, F., 212 (Tu-P7:123) E 520 Abdel-Muneem, A.R., 215 (Tu-P7:138) Ageta, M., (Th-P15:124) Alarcón González, J.A., 61 (Mo-P1:72) 264 397 Abdel Ghany, M., 266 (Tu-P9:371) Agewall, S., (Tu-P9:363), (We-P11:233) Alarcon Sabater, P., 61 (Mo-P1:72) X 506 Abdelnoor, M., 286 (Tu-P10:460), 390 Agledahl, I., (Th-P15:63) Albán-Salgado, A., 124 (Mo-P5:359) 443 449 (We-P11:200) Agnani, G., (We-P14:436), Alberici, L.C., 505 (Th-P15:57) 589 Abdi, H., 402 (We-P11:257) (We-P14:466), (Th-P17:433) Albero, R., 511 (Th-P15:84), 567 (Th-P16:334) 217 218 Abdihakim, A., 530 (Th-P15:169) Agnoletti, L., (Tu-P7:148), (Tu-P7:149) Albers, J.J., 13 (Mo-W2:3) 241 Abdulkader, B.A., 387 (We-P11:188) Agostoni, P., (Tu-P7:259) Albert, M., 61 (Mo-P1:70) Agozzino, F., 384 (We-P11:174) Abdullahi Said, A., 441 (We-P14:431) Albert, M.J., 54 (Mo-P1:39) Agrifoglio, M., 212 (Tu-P7:123) Abe, E., 505 (Th-P15:58) Alberti, K.G.M.M., 154 (Tu-W17:1) Agrotis, A., 488 (Th-W60:5) Abe, M., 191 (Tu-P7:32) Albu, E., 203 (Tu-P7:83) Aguilar, C.A., 138 (Mo-P6:418) Abe, S., 255 (Tu-P8:319), 285 (Tu-P10:456), 562 Albu, R., 69 (Mo-P1:106) Aguilar, J., 452 (We-P14:475) (Th-P16:311) Albuquerque, E.M., 526 (Th-P15:150) Aguilar, M.J., 399 (We-P11:240) Abe-Dohmae, S., 493 (Th-P15:7), 539 Alcalai, R., 51 (Mo-P1:27) Aguilar-Salinas, C., 397 (We-P11:234) (Th-P15:211) Alcudia, J.F., 488 (Th-W60:7) Ahmadi, H., 192 (Tu-P7:35) Abela, G., 22 (Mo-W6:7) Aldeghi, A., 73 (Mo-P1:121), 281 (Tu-P10:440) Ahmed, Y., 520 (Th-P15:126) Abell, J., 51 (Mo-P1:26) Alemao, E., 556 (Th-P16:284), 557 (Th-P16:289) Ahn, E.R., 291 (Tu-P10:485), 292 (Tu-P10:486) Abid, M., 131 (Mo-P6:388) Alemao, E.A., 116 (Mo-P5:317), 117 (Mo-P5:325) Ahn, Y.S., 291 (Tu-P10:485), 292 (Tu-P10:486) Abidi, P., 464 (Th-W49:1) Aleotti, A., 86 (Mo-P2:183), 88 (Mo-P2:190) Ahnmark, A., 254 (Tu-P8:315) 375 441 Abina, J., (We-P11:133) Ai, M., 185 (Tu-P7:3), 187 (Tu-P7:11) Alessandrello Liotta, A., (We-P14:431) 123 576 158 Abletshauser, C., (Mo-P5:352), Aigueperse, J., 190 (Tu-P7:26) Alessi, M.C., (Tu-W19:2) 347 348 (Th-P16:374) Aihara, K., 49 (Mo-P1:17), 101 (Mo-P4:252), 106 Alevizos, A., (We-P11:9), (We-P11:10) 412 415 415 Abou-Raya, A., (We-P12:302), (Mo-P4:271), 235 (Tu-P7:231), 362 Alexandru, D., (We-P13:314) 109 (We-P12:311) (We-P11:77), 569 (Th-P16:344), 572 Alexopoulos, D., (Mo-P4:285) 412 415 335 421 Abou-Raya, S., (We-P12:302), (Th-P16:359) Algra, A., (We-W45:4), (We-P13:338) 237 (We-P12:311) Ait-Yahia, D., 446 (We-P14:450) Ali, S., (Tu-P7:238) 122 244 529 Abreu-Gonzalez, P., (Mo-P5:349), Aït Chihab, K., 123 (Mo-P5:355) Ali, W., (Th-P15:164) 507 (Tu-P7:270) Aivars, J.I., 263 (Tu-P9:358) Alikasifoglu, M., (Th-P15:65) 437 402 Abruzzese, G., (We-P14:412) Aizawa, Y., 361 (We-P11:72) Alimento, M., (We-P11:254) 412 31 235 Abuelkheir, H., (We-P12:302) Akaike, M., 49 (Mo-P1:17), 101 (Mo-P4:252), Alipour, A., (Mo-W11:3), (Tu-P7:229) Acampora, C., 261 (Tu-P9:348) 106 (Mo-P4:271), 235 (Tu-P7:231), 362 Alizadeh Dehnavi, R., 267 (Tu-P9:375) Achar, S.B., 495 (Th-P15:14) (We-P11:77), 569 (Th-P16:344), 572 Alkemade, F.E., 205 (Tu-P7:94) Acikel, S., 74 (Mo-P1:129), 92 (Mo-P2:208), 398 (Th-P16:359) Alkonyi, B., 398 (We-P11:236) (We-P11:237) Akalin, S., 215 (Tu-P7:136) Allayee, H., 375 (We-P11:135) Ackermans, M., 364 (We-P11:84) Akao, H., 283 (Tu-P10:450), 411 (We-P12:295) Allen, T., 556 (Th-P16:286) Ács, N., 408 (We-P12:283) Akchurin, R., 207 (Tu-P7:103) Allen, T.J., 355 (We-P11:42), 556 (Th-P16:287) Adachi, H., 60 (Mo-P1:65, Mo-P1:66, Mo-P1:67), Akdim, F., 309 (We-W32:3) Alliende, I., 125 (Mo-P5:361) 76 (Mo-P1:139), 519 (Th-P15:120), 574 Akhavan, A., 53 (Mo-P1:38) Allison, P., 487 (Th-W60:2) (Th-P16:366) Akhvlediani, M., 97 (Mo-P4:234), 227 Alm, R., 327 (We-W41:3), 521 (Th-P15:128) Adamkova, V., 48 (Mo-P1:13), 139 (Mo-P6:423, (Tu-P7:193), 572 (Th-P16:357) Almagro, F., 130 (Mo-P6:386) Mo-P6:424), 486 (Th-W59:6) Akiba, S., 229 (Tu-P7:200), 240 (Tu-P7:252) Almenar, L., 85 (Mo-P2:178), 89 (Mo-P2:194), Adany, R., 292 (Tu-P10:489) Akishita, M., 217 (Tu-P7:147), 405 (We-P11:269), 286 (Tu-P10:461) Addesse, R., 580 (Th-P16:393) 585 (Th-P16:417) Alméras, N., 165 (Tu-W22:5), 421 (We-P13:340)

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

217 Aloe, L., 86 (Mo-P2:181), 188 (Tu-P7:16) Andreeva, E., 227 (Tu-P7:192) Ardjoun, M., 194 (Tu-P7:45) Aloisi, E., 125 (Mo-P5:360) Andrejkova, M., 423 (We-P13:348) Aref’Eva, T.I., 96 (Mo-P3:226) Alonso, R., 129 (Mo-P6:382), 130 (Mo-P6:385, Andreozzi, F., 21 (Mo-W6:4), 206 (Tu-P7:100), Arenaz, I., 212 (Tu-P7:127) Mo-P6:386) 367 (We-P11:98), 371 (We-P11:116) Arghirescu, S., 62 (Mo-P1:76) A Alonso-Villaverde, C., 163 (Tu-W21:5), 202 Andreozzi, G.M., 106 (Mo-P4:273) Ari, N., 569 (Th-P16:345) (Tu-P7:81), 400 (We-P11:247), 416 Andrés, O., 498 (Th-P15:28) Arii, K., 210 (Tu-P7:115), 254 (Tu-P8:314), 294 (We-P13:318), 513 (Th-P15:95) Andresen, E., 317 (We-W36:5) (Tu-P10:499), 354 (We-P11:37) U Alonso De Caso, M.D., 58 (Mo-P1:59) Andrews, J.D., 482 (Th-W57:6) Ariogul, S., 264 (Tu-P9:365) Alpenidze, V., 356 (We-P11:48) Andreyev, E.V., 548 (Th-P16:254) Arioli, P., 499 (Th-P15:31), 589 (Th-P17:434) T Alpert, B.S., 381 (We-P11:158) Andriankaja, O.M., 412 (We-P12:301) Arishima, H., 396 (We-P11:229), 570 Alshayji, I.A., 504 (Th-P15:55) Andrianova, I.V., 250 (Tu-P8:296) (Th-P16:350) H Altamore, G., 369 (We-P11:107) Andrikopoulos, G.K., 52 (Mo-P1:30) Ariza, M.J., 132 (Mo-P6:395), 347 (We-P11:5), Altannavch, T., 277 (Tu-P10:421) Andrýs, C., 562 (Th-P16:315) 375 (We-P11:132) O Altavilla, D., 24 (Mo-W7:7) Andrys, C., 201 (Tu-P7:74), 359 (We-P11:60) Arkhypkina, T., 407 (We-P12:280) Altieri, P., 310 (We-W32:6), 508 (Th-P15:73) Andrzejak, R., 104 (Mo-P4:265), 220 (Tu-P7:160) Armario, P., 268 (Tu-P9:381) 367 353 Altieri, P.I., (We-P11:99) Anestiadi, V., (We-P11:34) Arnaboldi, L., 171 (Tu-W25:5), 251 (Tu-P8:300), R 424 353 Altini, C., (We-P13:351) Anestiadi, Z., (We-P11:34) 566 (Th-P16:332) 141 565 Altomare, K., (Mo-P6:434) Anestiadis, B., (Th-P16:326) Arnal, J.-F., 486 (Th-W59:5) 567 298 329 Alvarez, D., (Th-P16:334) Anfossi, G., (Tu-P10:516), (We-W42:4) Arnaoutakis, K., 237 (Tu-P7:238) 58 188 Alvarez-Sala, L., (Mo-P1:59) Angelin, B., (Tu-P7:18) Arnau, M.A., 85 (Mo-P2:178), 286 (Tu-P10:461), 131 136 39 I Alves, A.C., (Mo-P6:390), (Mo-P6:410), Angelin, B.O., (Mo-W15:7) 395 (We-P11:224) 545 501 (Th-P15:237) Angelopoulos, T.J., (Th-P15:40) Arnesen, H., 103 (Mo-P4:258), 284 (Tu-P10:453), 509 293 Alves, M.J., (Th-P15:75) Anghel, A., (Tu-P10:491) 334 (We-W45:2), 357 (We-P11:52), 390 N 236 471 Alvesalo, J., (Tu-P7:235) Anker, S.D., (Th-W52:5) (We-P11:200) 140 165 Alwazir, F., (Mo-P6:427) Annuzzi, G., (Tu-W22:4) Arnold, E., 573 (Th-P16:362) D 90 61 426 Amacker, N., (Mo-P2:200) Ansari, R., (Mo-P1:71), (We-P13:361) Arnoldi, A., 454 (We-P14:484), 477 (Th-W55:4) 347 501 398 Amâncio, R.F., (We-P11:8), (Th-P15:41), Anselmo, A., (We-P11:238) Arnsdorf, M., 69 (Mo-P1:104) 535 (Th-P15:191) Ansurudeen, I., 522 (Th-P15:132) E Arquati, M., 285 (Tu-P10:457) Amani, R., 438 (We-P14:413) Antevska, V., 297 (Tu-P10:512) Arra, M., 281 (Tu-P10:440) Amano, E., 377 (We-P11:140), 385 (We-P11:178) Antikainen, M., 124 (Mo-P5:358), 576 X Arra, R., 73 (Mo-P1:121) Amano, Y., 339 (We-S13:2, We-S13:3), 549 (Th-P16:378) Arrigo, F., 24 (Mo-W7:7) (Th-P16:256) Antinori, A., 399 (We-P11:243, We-P11:244) Arrivi, A., 266 (Tu-P9:374), 268 (Tu-P9:380) Amar, M.J., 482 (Th-W57:5) Antohe, F., 590 (Th-P17:438) Arsenault, B.J., 475 (Th-W54:5) Amarenco, P., 17 (Mo-W4:2) Antonini, R., 584 (Th-P16:412) Arsenescu, I., 93 (Mo-P2:214) Amato, M., 152 (Tu-W16:3), 204 (Tu-P7:87), 258 Antonini, T.M., 584 (Th-P16:412) Arsic, A., 430 (We-P14:378), 449 (We-P14:464) (Tu-P9:333, Tu-P9:336), 259 (Tu-P9:337, Antonopoulos, S., 572 (Th-P16:358) Arsova, V., 418 (We-P13:326), 532 (Th-P15:178), Tu-P9:340), 260 (Tu-P9:343), 285 Antonucci, E., 325 (We-W40:3), 396 584 (Th-P16:411) (Tu-P10:457), 308 (We-W31:6), 309 (We-P11:227), 398 (We-P11:239) Arsovska, A., 66 (Mo-P1:95) (We-W32:2), 324 (We-W39:6), 474 Anzenbacher, P., 560 (Th-P16:304) Arthur, J.R., 222 (Tu-P7:171) (Th-W53:7) Anzivino, C., 256 (Tu-P8:323), 257 (Tu-P8:328), Artieda, M., 233 (Tu-P7:220), 547 (Th-P15:247) Amato, S., 62 (Mo-P1:73), 404 (We-P11:264) 410 (We-P12:289), 472 (Th-W52:7) 346 Ambagts, T., 225 (Tu-P7:181) Ao, C.H., 494 (Th-P15:12) Aryana, I.G.P.S., (We-P11:2) 354 585 Améen, C., 226 (Tu-P7:188) Aouichat-Bouguerra, S., 194 (Tu-P7:45) Arzamastseva, E., (We-P11:39), Amini, E., 196 (Tu-P7:55) Aouizerat, B., 333 (We-W44:5) (Th-P16:416) 444 Aminipour, M.R., 402 (We-P11:257) Apetrei, E., 93 (Mo-P2:214), 236 (Tu-P7:233) Arzuaga, X., (We-P14:443) 93 246 319 Ammirati, E., 86 (Mo-P2:182) Apostolopoulou, D., 568 (Th-P16:341) Asada, Y., (Mo-P2:215), (Tu-P7:279), Amor, P., 228 (Tu-P7:196) Apostolou, F., 501 (Th-P15:42) (We-W37:3) 238 Amoroso, L., 216 (Tu-P7:144) Appel, L., 437 (We-P14:410) Asai, A., (Tu-P7:244) 283 Amosova, E.N., 548 (Th-P16:254) Appel, L.J., 476 (Th-W55:2) Asano, M., (Tu-P10:450) 130 135 Amsler, G., 433 (We-P14:393) Apte, R.N., 169 (Tu-W24:7) Ascaso, J., (Mo-P6:384), (Mo-P6:407) 136 226 Anagnostopoulou, K.K., 113 (Mo-P5:306), 505 Aragones, G., 163 (Tu-W21:5), 416 (We-P13:318) Ascaso, J.F., (Mo-P6:412), (Tu-P7:187) 394 395 (Th-P15:60), 509 (Th-P15:77), 510 Arai, H., 49 (Mo-P1:20) Asgary, S., (We-P11:222), (We-P11:223), (Th-P15:81) Arai, T., 129 (Mo-P6:379) 526 (Th-P15:153) Anand, S., 107 (Mo-P4:279) Arakawa, K., 73 (Mo-P1:125) Ashidate, K., 362 (We-P11:76), 587 (Th-P17:424) Anantharamaiah, G.M., 310 (We-W32:7) Araki, E., 285 (Tu-P10:456) Ashikawa, K., 290 (Tu-P10:478) Ananyeva, N.M., 29 (Mo-W10:5) Aranceta, J., 46 (Mo-P1:2) Asikainen, S., 171 (Tu-W25:6) Ancsin, J.B., 544 (Th-P15:232), 566 (Th-P16:330) Aranda, J.L., 123 (Mo-P5:353) Askari, H., 237 (Tu-P7:239) Andel, M., 277 (Tu-P10:421) Aranda-Acosta, L., 378 (We-P11:148) Askari, M., 63 (Mo-P1:80) Anderson, G., 485 (Th-W59:1) Arant, C.B., 142 (Mo-P6:439) Aspelund, T., 468 (Th-W50:7) Anderson, J.W., 311 (We-W33:2) Arapbaeva, A.M., 557 (Th-P16:291) Asplund-Persson, A., 91 (Mo-P2:206) Andersson, I.J., 469 (Th-W51:3) Araújo, J.P., 101 (Mo-P4:250, Mo-P4:251) Assmann, G., 27 (Mo-W9:4), 467 (Th-W50:3), Andersson, M., 87 (Mo-P2:187) Arbel, Y., 213 (Tu-P7:130) 517 (Th-P15:111), 536 (Th-P15:195) Andersson, U., 582 (Th-P16:403) Arca, M., 17 (Mo-W4:3), 35 (Mo-W13:4), 330 Astika, N., 346 (We-P11:2) Ando, D., 575 (Th-P16:370) (We-W43:2), 584 (Th-P16:412) Astrup, A., 176 (Tu-W28:2) Andonovska, M., 408 (We-P12:281) Arcaro, G., 411 (We-P12:293) Asztalos, B.F., 11 (Mo-W1:1), 580 (Th-P16:395) Andreae, J., 218 (Tu-P7:150) Archer, W.R., 443 (We-P14:438) Asztalos, L., 127 (Mo-P5:371), 292 (Tu-P10:489) Andreani, M., 168 (Tu-W24:5) Ardigó, D., 224 (Tu-P7:178) Atake, M., 377 (We-P11:140), 385 (We-P11:178) Andreenko, E.Y., 89 (Mo-P2:195) Ardigò, D., 5 (Su-S3:3), 6 (Su-S3:4) Atallah, M., 233 (Tu-P7:222)

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

218 Atanasova, A., 273 (Tu-P10:406) Bacallao, J., 50 (Mo-P1:23), 54 (Mo-P1:39), 77 Ballantyne, C.M., 183 (Tu-S11:3), 479 Atanassova, P., 188 (Tu-P7:16) (Mo-P1:141), 484 (Th-W58:7) (Th-W56:2), 555 (Th-P16:280, Th-P16:281, Atar, I., 112 (Mo-P5:301), 164 (Tu-W21:7) Bacallao Gallestey, J., 117 (Mo-P5:323) Th-P16:282, Th-P16:283) Ataullakhanov, F.I., 29 (Mo-W10:5) Baccara-Dinet, M., 49 (Mo-P1:19) Ballerio, R., 212 (Tu-P7:123) Atfi, A., 220 (Tu-P7:161) Baceková, M., 188 (Tu-P7:17) Ballestri, S., 411 (We-P12:294) A Athanasias, D.A., 52 (Mo-P1:30) Bacekova, M., 292 (Tu-P10:488) Balletta, M.M., 207 (Tu-P7:104) Atheroma Study Group, , 122 (Mo-P5:350) Bachetti, T., 217 (Tu-P7:148), 218 (Tu-P7:149) Balogh, S., 156 (Tu-W17:7) Athyros, V., 109 (Mo-P4:286) Badariene, J., 214 (Tu-P7:132) Balogh, Z., 571 (Th-P16:355) U 63 496 Athyros, V.G., (Mo-P1:78) Badellino, K., (Th-P15:20) Balta, S., 74 (Mo-P1:130), 100 (Mo-P4:246), 110 396 16 Attanasio, M., (We-P11:230) Badellino, K.O., (Mo-W3:5) (Mo-P4:293), 289 (Tu-P10:473) T 108 401 65 Atti, A.R., (Mo-P4:284), (We-P11:253) Bader, A., (Mo-P1:86) Bamberger, M.J., 550 (Th-P16:262) 69 349 438 47 66 121 Attia, N., (Mo-P1:105), (We-P11:18), Bader, G., (Mo-P1:8), (Mo-P1:91), Bamou, Y., 443 (We-P14:437) H (We-P14:415) (Mo-P5:345) Banchs, H.L., 367 (We-P11:99) 34 91 Attie, A.D., (Mo-W13:2) Badescu, C., (Mo-P2:205) Banderali, G., 441 (We-P14:430) O Atzmon, G., 474 (Th-W54:2) Badescu, M., 91 (Mo-P2:205), 446 (We-P14:449) Bandinelli, S., 471 (Th-W52:4), 480 (Th-W56:6), Atzori, L., 536 (Th-P15:195) Badimon, J.J., 90 (Mo-P2:200) 530 (Th-P15:171), 534 (Th-P15:188) Au-Yeung, K.W., 274 (Tu-P10:410) Badimon, L., 159 (Tu-W19:5), 331 (We-W43:5), R Banfi, C., 88 (Mo-P2:191), 92 (Mo-P2:209, Auer, J., 283 (Tu-P10:449), 413 (We-P12:306) 488 (Th-W60:7), 537 (Th-P15:201) Mo-P2:210), 101 (Mo-P4:249), 241 Auger, J., 390 (We-P11:202) Bae, S.W., 247 (Tu-P7:285) (Tu-P7:259), 391 (We-P11:206), 591 Augustin, L., 432 (We-P14:388) Baena, J.A., 374 (We-P11:130) (Th-P17:445) Augustin, L.S.A., 177 (Tu-W28:6) Baetta, R., 201 (Tu-P7:76) Banfi, M., 86 (Mo-P2:182) I Auteri, A., 86 (Mo-P2:180), 147 (Mo-P6:460), Bagaglia, F., 23 (Mo-W7:3) 391 333 (We-W44:3), 405 (We-P11:270) Baggio, G., 273 (Tu-P10:405), 336 (We-W45:7) Bani, D., (We-P11:205) 309 N Autret, B., 452 (We-P14:478) Baghaei, L., 120 (Mo-P5:340) Bankaitis-Davis, D., (We-W32:3) 196 Avcu, F., 206 (Tu-P7:96), 395 (We-P11:226) Baglivo, H., 65 (Mo-P1:90) Bansal, M.P., (Tu-P7:54) 71 152 153 Avella, M., 473 (Th-W53:5), 515 (Th-P15:104) Bahs, G., 59 (Mo-P1:62), 281 (Tu-P10:442) Bao, S., (Mo-P1:114), (Tu-W16:1), D 250 Avellone, G., 90 (Mo-P2:199), 420 (We-P13:336), Baiano, A., 18 (Mo-W4:7), 231 (Tu-P7:211) (Tu-W16:4), (Tu-P8:297) 209 437 (We-P14:412) Bailleul, F., 215 (Tu-P7:140) Baquero-Herrera, C., (Tu-P7:112) E Averna, M., 133 (Mo-P6:400), 524 (Th-P15:144) Bailo, M., 92 (Mo-P2:209) Barak, O., 193 (Tu-P7:42) Averna, M.R., 62 (Mo-P1:73), 404 (We-P11:264), Bairaktari, E., 368 (We-P11:104), 530 Barancokova, M., 446 (We-P14:452) X 426 (We-P13:362) (Th-P15:170), 582 (Th-P16:404) Barbagallo, C.M., 62 (Mo-P1:73), 133 Avila, A., 546 (Th-P15:242) Baird, S., 529 (Th-P15:166) (Mo-P6:400), 404 (We-P11:264), 524 Aviram, M., 205 (Tu-P7:93), 253 (Tu-P8:310), Baitsch, D., 517 (Th-P15:111) (Th-P15:144) 459 (Th-W46:2), 460 (Th-W46:5), 529 Baj, Z., 271 (Tu-P10:397) Barbara, A., 140 (Mo-P6:427) (Th-P15:163) Bajcetic, M., 53 (Mo-P1:37) Barbaras, R., 31 (Mo-W11:6), 153 (Tu-W16:7) Avram, A., 46 (Mo-P1:3) Baker, A., 244 (Tu-P7:273) Barbarash, O.L., 81 (Mo-P1:158) Avsar, A., 106 (Mo-P4:274), 218 (Tu-P7:151), 264 Baker, B., 466 (Th-W49:6) Barbatis, C., 517 (Th-P15:110) (Tu-P9:362, Tu-P9:364) Baker, D., 255 (Tu-P8:320), 487 (Th-W60:2) Barbier, O., 487 (Th-W60:3) Ayaori, M., 559 (Th-P16:300), 581 (Th-P16:398) Bakhshaliyev, A.B., 409 (We-P12:286) Barbieri, S.S., 92 (Mo-P2:210), 212 (Tu-P7:127), Aydin, H., 215 (Tu-P7:136) Bakhtina, Z.AE., 415 (We-P13:312) 213 (Tu-P7:131), 391 (We-P11:206), 474 Aydinalp, A., 74 (Mo-P1:129, Mo-P1:130), 92 Bakke, I., 202 (Tu-P7:77) (Th-W53:7) 19 (Mo-P2:208), 100 (Mo-P4:246), 112 Bakker, A.C., (Mo-W5:2) Barboutis, K., 89 (Mo-P2:193) 227 (Mo-P5:301), 164 (Tu-W21:7), 284 Bakker-Woudenberg, I.A.J.M., (Tu-P7:194) Barbu, L., 46 (Mo-P1:3), 362 (We-P11:73), 365 92 112 164 (Tu-P10:455), 398 (We-P11:237) Bal, U., (Mo-P2:208), (Mo-P5:301), (We-P11:86, We-P11:87), 445 (We-P14:445) 528 398 Aykut, S., (Th-P15:160) (Tu-W21:7), (We-P11:237) Barcella, S., 92 (Mo-P2:209, Mo-P2:210), 101 264 269 78 Aytemir, K., (Tu-P9:365), (Tu-P9:385), Baladi, N., (Mo-P1:146) (Mo-P4:249), 241 (Tu-P7:259) 524 569 (Th-P15:143) Balahonova, T., (Th-P16:346) Barcellos, C.R., 535 (Th-P15:191) 52 Balak, C.S., 140 (Mo-P6:427) Ayzenberg, O., (Mo-P1:33) Barco, A., 273 (Tu-P10:403), 364 (We-P11:85) 101 Balalovska, L., 359 (We-P11:59) Azevedo, A., (Mo-P4:250, Mo-P4:251) Bardadin, K., 271 (Tu-P10:393) 537 542 Balan, P., 308 (We-W31:3) Azevedo, C.H.M., (Th-P15:202), Bardini, G., 115 (Mo-P5:316) (Th-P15:224) Balandina, K., 126 (Mo-P5:368), 360 Bareille, R., 159 (Tu-W19:6) Azevedo, I., 545 (Th-P15:237) (We-P11:66), 419 (We-P13:329) Barg, E., 137 (Mo-P6:415) Azimi, E., 196 (Tu-P7:55) Balasubramaniyan, V., 199 (Tu-P7:65) Bargossi, A.M., 420 (We-P13:334) Azimipour, A., 385 (We-P11:177) Balatsky, A.V., 89 (Mo-P2:195) Barinow-Wojewódzki, A., 440 (We-P14:426) Aziz, K., 22 (Mo-W6:7) Balavadze, M., 97 (Mo-P4:234), 227 (Tu-P7:193), Barisione, C., 508 (Th-P15:73) Azlina, A.R., 423 (We-P13:347) 572 (Th-P16:357) Barkhordari, H.R., 395 (We-P11:223) Aznar, A., 286 (Tu-P10:462) Balazs, L., 255 (Tu-P8:320) 360 368 Azuma, H., 49 (Mo-P1:17), 101 (Mo-P4:252), 106 Balcerzyk, A., 73 (Mo-P1:124) Barnett, A., (We-P11:67), (We-P11:101), 533 (Mo-P4:271), 362 (We-P11:77), 569 Baldassarre, D., 42 (Mo-S6:2), 152 (Tu-W16:3), (Th-P15:182) 254 (Th-P16:344), 572 (Th-P16:359) 204 (Tu-P7:87), 258 (Tu-P9:333, Tu-P9:336), Barnett, N., (Tu-P8:316) 71 404 Azuma, Y., 246 (Tu-P7:279) 259 (Tu-P9:337, Tu-P9:340), 260 (Tu-P9:343), Barone, G., (Mo-P1:116), (We-P11:264) 285 (Tu-P10:457), 307 (We-W31:2), 308 Baroni, M.G., 17 (Mo-W4:3) Babamusta, F., 489 (Th-W61:3) (We-W31:6), 309 (We-W32:2), 324 Barragan, A., 511 (Th-P15:84), 567 (Th-P16:334) Babar, S., 524 (Th-P15:141), 525 (Th-P15:146) (We-W39:6), 474 (Th-W53:7) Barragan, J.M., 103 (Mo-P4:259) Babazono, T., 350 (We-P11:20) Baldi, S., 526 (Th-P15:152) Barranco, C., 73 (Mo-P1:121), 281 (Tu-P10:440) Bacakova, L., 159 (Tu-W19:6), 243 (Tu-P7:265), Bale, B.F., 161 (Tu-W20:5), 324 (We-W39:7) Barrett, P.H.R., 322 (We-W38:5), 329 250 (Tu-P8:298), 252 (Tu-P8:308), 404 Balkau, B., 154 (Tu-W17:1) (We-W42:5), 370 (We-P11:111), 482 (We-P11:265) Ballantyne, C., 552 (Th-P16:270) (Th-W57:6), 519 (Th-P15:118), 534

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

219 (Th-P15:185), 535 (Th-P15:193), 556 Bek, F., 588 (Th-P17:429, Th-P17:430, Bergeron, N., 443 (We-P14:438) (Th-P16:285), 577 (Th-P16:379) Th-P17:432) Bergh, N., 87 (Mo-P2:187) Barsotti, A., 310 (We-W32:6) Belenkov, N., 354 (We-P11:39) Berglund, G., 327 (We-W41:3), 521 (Th-P15:128) Bartels, E.D., 497 (Th-P15:21) Belenkov, Yu., 582 (Th-P16:402) Bergmann, S., 412 (We-P12:298) A Barter, P., 40 (Mo-S4:2), 71 (Mo-P1:114), 232 Belizna, C., 219 (Tu-P7:155), 261 (Tu-P9:351) Berg Schmidt, E., 181 (Tu-S9:3) (Tu-P7:218), 341 (We-S14:4) Bellanti, B., 499 (Th-P15:31) Bergström, G., 163 (Tu-W21:6), 469 (Th-W51:3) Barter, P.J., 152 (Tu-W16:1), 153 (Tu-W16:4), 322 Belleudi, F., 330 (We-W43:2) Bergstrom, G., 207 (Tu-P7:101) U (We-W38:5) Bellia, A., 425 (We-P13:355) Beridze, M.G., 442 (We-P14:434) Bartoli, E., 49 (Mo-P1:16, Mo-P1:18) Bellocchio, A., 554 (Th-P16:277), 558 Berk, L.S., 232 (Tu-P7:215) T Bartual, A., 226 (Tu-P7:187) (Th-P16:296) Berlanga, E., 69 (Mo-P1:107) Bartunek, J., 103 (Mo-P4:260) Bellosta, S., 12 (Mo-W1:6), 244 (Tu-P7:271), 439 Berliner, S., 142 (Mo-P6:440), 285 (Tu-P10:459) H Barylski, M., 62 (Mo-P1:77), 412 (We-P12:299), (We-P14:422), 463 (Th-W48:6), 481 Bermann, G., 251 (Tu-P8:300) 425 (We-P13:356) (Th-W57:3), 566 (Th-P16:332) Bermúdez, J.A., 364 (We-P11:85) O Barzilai, N., 474 (Th-W54:2) Bellotti, V., 536 (Th-P15:198) Bermudez-Fajardo, A., 406 (We-P11:273) Bashardoost, N., 394 (We-P11:222) Bellstedt, K., 318 (We-W36:7) Bernabei, R., 470 (Th-W52:2) 573 129 424 Basiak, M., (Th-P16:363) Bellwon, J., (Mo-P6:380), (We-P13:352), Bernal Romero, J.M., 61 (Mo-P1:72) R 173 363 442 449 Basili, S., (Tu-W26:7), (We-P11:78) (We-P14:432), (We-P14:465) Bernardi, R., 50 (Mo-P1:24) 504 563 Basilio, F., (Th-P15:52) Belmont, J.M., (Th-P16:319) Bernat, I., 111 (Mo-P4:295) 100 143 245 Bassampour, S.S., (Mo-P4:247) Beloqui, O., (Mo-P6:441), (Tu-P7:274), Bernberg, E., 469 (Th-W51:3) 482 480 Basso, F., (Th-W57:5) (Th-W56:5) Berne, G., 167 (Tu-W24:1) 256 347 348 I Basso, M., (Tu-P8:325) Belos, G., (We-P11:9), (We-P11:10) Bernier, L., 136 (Mo-P6:409), 186 (Tu-P7:8) 256 240 Basso, M.D., (Tu-P8:324) Belovol, A., (Tu-P7:251) Bernini, F., 12 (Mo-W1:6), 166 (Tu-W23:3), 320 231 248 559 Basta, G., (Tu-P7:213), (Tu-P7:290) Belowski, D., (Th-P16:299) (We-W38:2), 524 (Th-P15:142) N 217 218 143 245 Bastianon, D., (Tu-P7:148), (Tu-P7:149) Belzunce, M., (Mo-P6:441), (Tu-P7:274) Bernues, J., 331 (We-W43:5) 365 531 230 Bastida, S., (We-P11:88), (Th-P15:173) Ben-Dor, A., (Tu-P7:206) Berrah, A., 102 (Mo-P4:256), 387 (We-P11:189) D 378 142 285 Bastidas-Ramírez, B.E., (We-P11:148) Ben Assayag, E., (Mo-P6:440), Berrougui, H., 189 (Tu-P7:20), 521 (Th-P15:130), 376 Batista, M.C., (We-P11:138) (Tu-P10:459) 539 (Th-P15:212), 543 (Th-P15:228) Batista Cuellar, J.F., 117 (Mo-P5:323) Ben Avi, L., 133 (Mo-P6:399) E Berthold, H.K., 565 (Th-P16:328) Batrakova, O., 126 (Mo-P5:368), 360 Benazzoug, Y., 194 (Tu-P7:45) Berti, S., 310 (We-W32:6) (We-P11:66), 419 (We-P13:329) Benchemsi, N., 77 (Mo-P1:143) X Bertocco, S., 502 (Th-P15:45) Batuca, J., 405 (We-P11:271) Bender, R., 544 (Th-P15:232) Bertolini, L., 411 (We-P12:293) Bauersachs, J., 201 (Tu-P7:75), 218 (Tu-P7:153), Benderitter, M., 190 (Tu-P7:26), 220 (Tu-P7:161) Bertolini, S., 35 (Mo-W13:4), 136 (Mo-P6:411, 313 (We-W34:5), 353 (We-P11:32), 471 Bendheim, M.O., 202 (Tu-P7:77) Mo-P6:413), 137 (Mo-P6:414), 147 (Th-W52:5) Beng, J.J., 515 (Th-P15:103) (Mo-P6:457), 554 (Th-P16:277), 558 Baum, V.A., 81 (Mo-P1:158), 294 (Tu-P10:497) Bengtsson, E., 521 (Th-P15:128) (Th-P16:296) Baumann, S., 71 (Mo-P1:115) Bengtsson, I., 421 (We-P13:339) Bertolotti, M., 46 (Mo-P1:4), 256 (Tu-P8:323), Baur, R., 30 (Mo-W10:7), 394 (We-P11:220) Bengtsson, O., 145 (Mo-P6:449) 257 (Tu-P8:328), 410 (We-P12:289), 472 Bausero, P., 168 (Tu-W24:5) Bengtsson, T., 84 (Mo-P2:173), 171 (Tu-W25:7), (Th-W52:7) Bax, G., 350 (We-P11:21) 173 (Tu-W26:6), 203 (Tu-P7:85), 284 Bertucci, P., 147 (Mo-P6:457) Bayrak, A., 269 (Tu-P9:385), 524 (Th-P15:143) (Tu-P10:452), 413 (We-P12:305) Berzina, M., 142 (Mo-P6:438) Bayrak, T., 269 (Tu-P9:385), 524 (Th-P15:143) Ben Hamda, K., 69 (Mo-P1:105) 104 Bays, H.E., 51 (Mo-P1:29), 174 (Tu-W27:4) Benítez, M., 504 (Th-P15:54) Beshev, L., (Mo-P4:263) 64 Bazzichi, L., 414 (We-P12:309) Benkritly, A., 578 (Th-P16:384) Betsimeas, S., (Mo-P1:82) 101 Bea, F., 407 (We-P11:276) Benn, M., 37 (Mo-W14:6), 74 (Mo-P1:128) Bettencourt, P., (Mo-P4:250, Mo-P4:251) 37 182 Beauchamp, M.-C., 586 (Th-P17:421) Bennett, D.J., 254 (Tu-P8:316) Betteridge, D.J., (Mo-W14:4), (Tu-S10:1), 294 Beckstead, J.B., 514 (Th-P15:96) Bennett, M.R., 21 (Mo-W6:2) (Tu-P10:495) 464 Becquemin, J.P., 252 (Tu-P8:306) Bensharif, K., 443 (We-P14:436), 589 Beutner, F., (Th-W48:8) 65 Bedair, R., 102 (Mo-P4:254) (Th-P17:433) Bezirkan, H., (Mo-P1:86) 473 Bedford, D., 484 (Th-W58:5) Beraia, V., 267 (Tu-P9:377) Bhaskaran, S., (Th-W53:4) 520 Bednar, F., 91 (Mo-P2:204), 416 (We-P13:316) Beranek, V., 111 (Mo-P4:295) Bhatnagar, A., (Th-P15:126) 546 Bednarska-Makaruk, M., 135 (Mo-P6:405) Berardi, E., 225 (Tu-P7:184) Bhattacharjee, J., (Th-P15:245) 310 Beeching, C.A., 248 (Tu-P7:288) Berardi, V., 504 (Th-P15:54) Biagini, A., (We-W32:6) Beer, J.C., 370 (We-P11:113) Berbée, J.F.P., 37 (Mo-W14:5), 227 (Tu-P7:194) Biancardi, C., 309 (We-W32:2) Beeri, R., 514 (Th-P15:98) Berbee, J.F.P., 331 (We-W43:6) Bianchi, C., 369 (We-P11:108) Beeton, L., 289 (Tu-P10:475) Berceanu, D., 110 (Mo-P4:291), 111 (Mo-P4:294) Bianchi, R., 205 (Tu-P7:93) Beg, Z.H., 529 (Th-P15:164) Bereczki, D., 296 (Tu-P10:504) Biasi, G., 207 (Tu-P7:102) Behre, C.J., 52 (Mo-P1:32), 349 (We-P11:17), 382 Berent, H., 276 (Tu-P10:416) Biasucci, L., 277 (Tu-P10:422), 349 (We-P11:16) (We-P11:165) Berent, R., 283 (Tu-P10:449), 413 (We-P12:306) Biasucci, L.M., 205 (Tu-P7:92), 381 Beigel, R., 213 (Tu-P7:130) Beresford, S.A.A., 176 (Tu-W28:3) (We-P11:159) Beigel, Y., 102 (Mo-P4:255), 213 (Tu-P7:130) Berg, C., 203 (Tu-P7:85) Bieber, T., 562 (Th-P16:312) Beil, U., 38 (Mo-W15:2) Berg, G., 504 (Th-P15:52) Biessen, E.A.L., 98 (Mo-P4:236), 230 Beilin, L., 386 (We-P11:185) Berg, K., 532 (Th-P15:180) (Tu-P7:208), 247 (Tu-P7:284), 487 Beishuizen, E.D., 125 (Mo-P5:363) Bergamasco, L., 49 (Mo-P1:16, Mo-P1:18) (Th-W60:4) Beisiegel, U., 30 (Mo-W11:1), 185 (Tu-P7:4), 493 Berge, K.E., 36 (Mo-W14:3) Bietrix, F., 31 (Mo-W11:6) (Th-P15:6), 508 (Th-P15:70), 520 Berger, F., 401 (We-P11:251) Bifolco, M., 584 (Th-P16:412) (Th-P15:125) Berger, W., 121 (Mo-P5:346), 178 (Tu-W29:4) Bifulco, M., 33 (Mo-W12:5) Beitelshees, A.L., 334 (We-W44:7) Bergeron, J., 165 (Tu-W22:5), 421 (We-P13:340), Bigall, N., 493 (Th-P15:6) Bejta, F., 519 (Th-P15:119) 475 (Th-W54:4) Bigazzi, F., 70 (Mo-P1:111), 225 (Tu-P7:183)

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

220 Biglioli, P., 92 (Mo-P2:209), 101 (Mo-P4:249), Bloomﬁeld, H., 561 (Th-P16:307) Bordet, R., 215 (Tu-P7:140) 241 (Tu-P7:259) Blot-Chabaud, M., 221 (Tu-P7:166) Borén, J., 22 (Mo-W6:6), 503 (Th-P15:50) Bikbov, B., 78 (Mo-P1:145) Blotta, I., 136 (Mo-P6:411) Borges, R.L., 376 (We-P11:138) Bikou, O., 30 (Mo-W10:6) Blumenthal, R., 170 (Tu-W25:4), 419 Borges-Marcucci, L., 256 (Tu-P8:326) Bilgi, M., 284 (Tu-P10:455), 289 (Tu-P10:473) (We-P13:332) Borghi, C., 50 (Mo-P1:24), 68 (Mo-P1:102), 425 A Billheimer, J., 149 (Tu-PL2:2) Boban, P.T., 453 (We-P14:481) (We-P13:358), 468 (Th-W51:2) Billheimer, J.T., 540 (Th-P15:214) Bobik, A., 33 (Mo-W12:3), 327 (We-W41:4), 488 Borghi, L., 353 (We-P11:36) Billiet, L., 234 (Tu-P7:228) (Th-W60:5) Borkowska-Mosur, A., 391 (We-P11:204), 560 U Billon, A., 486 (Th-W59:5) Bobkova, D., 141 (Mo-P6:435) (Th-P16:302) Bilora, F., 263 (Tu-P9:359) Bobryshev, Y.V., 544 (Th-P15:233) Bormioli, M.L., 410 (We-P12:289) T Binder, B.R., 160 (Tu-W19:7), 488 (Th-W60:8) Boccara, F., 163 (Tu-W21:4) Bornstein, N.M., 142 (Mo-P6:440), 285 Binder, C.J., 459 (Th-W46:1), 488 (Th-W60:8) Boccotti, L., 402 (We-P11:254) (Tu-P10:459) H Binder, E.B., 488 (Th-W60:8) Bocharov, A., 310 (We-W32:8) Bornstein, S.R., 522 (Th-P15:132) Binder, M., 26 (Mo-W9:2) Bochkov, V., 160 (Tu-W19:7) Borrello, F., 206 (Tu-P7:100), 313 (We-W34:4) O Bingham, S.A., 24 (Mo-W7:5), 37 (Mo-W14:7), Bochkov, V.N., 89 (Mo-P2:195) Borrey, D., 293 (Tu-P10:494) 70 318 475 278 (Mo-P1:109), (We-W36:6), Bodanese, L.C., (Tu-P10:425) Borselli, C., 33 (Mo-W12:5) 248 327 R (Th-W54:5) Bodin, I., (Tu-P7:289), (We-W41:5) Borso, G., 376 (We-P11:136) 70 225 289 Bionda, A., (Mo-P1:111), (Tu-P7:183) Bodman-Smith, K., (Tu-P10:475) Bortnick, A.E., 524 (Th-P15:142) 309 364 53 Birjmohun, R., (We-W32:3), Boehler, S., (Mo-P1:35) Bortolini, M., 123 (Mo-P5:352) 533 143 (We-P11:84), (Th-P15:183) Boehm, B., (Mo-P6:442) Bortolotto, L., 546 (Th-P15:243) 153 72 Birjmohun, R.S., (Tu-W16:5) Boehm, B.O., (Mo-P1:118, Mo-P1:119) Bortolotto, L.A., 262 (Tu-P9:353) I 485 177 408 Birkhaeuser, M.H., (Th-W59:2) Boeing, H., (Tu-W28:5), (We-P12:282) Borzanovitsh, M., 408 (We-P12:284) 153 309 24 37 Bisoendial, R., (Tu-W16:5), (We-W32:3), Boekholdt, S.M., (Mo-W7:5), (Mo-W14:7), Boschcov, P., 521 (Th-P15:131) 364 533 70 318 335 N (We-P11:84), (Th-P15:183) (Mo-P1:109), (We-W36:6), Boschero, A.C., 365 (We-P11:91) 544 475 Bisoendial, R.J., (Th-P15:235) (We-W45:6), (Th-W54:5) Bosevski, M., 101 (Mo-P4:253) 147 62 D Bitto, A., (Mo-P6:458) Boeriu, E., (Mo-P1:76) Boshtam, M., 82 (Mo-P1:461) 554 511 Bitzur, R., (Th-P16:276) Boervik, T., (Th-P15:87) Bosilkova, G., 73 (Mo-P1:123), 272 (Tu-P10:402), Bjekic, J., 522 (Th-P15:134) Boerwinkle, E., 150 (Tu-PL2:4) 373 (We-P11:126) E Bjerregaard, L.J., 213 (Tu-P7:128), 448 Boesten, L.S.M., 331 (We-W43:6) Bosisio, E., 439 (We-P14:422), 481 (Th-W57:3) (We-P14:462) Boev, M., 275 (Tu-P10:415) Boskovic, K., 193 (Tu-P7:42) X Björkbacka, H., 233 (Tu-P7:221) Bogani, P., 443 (We-P14:440) Bosmans, J., 413 (We-P12:303) Björkegren, J., 200 (Tu-P7:72), 357 (We-P11:50) Bogavac-Stanojevic, N., 60 (Mo-P1:64), 139 Bosnjak, M., 120 (Mo-P5:342), 377 Bjørkegren, J., 497 (Th-P15:25) (Mo-P6:426), 279 (Tu-P10:432) (We-P11:143), 386 (We-P11:183) Björkhem, I., 562 (Th-P16:312), 582 Bogdanska, J.J., 547 (Th-P15:246) Bossowska, A., 270 (Tu-P10:391), 291 (Th-P16:403) Böger, R.H., 22 (Mo-W7:1) (Tu-P10:483) Blackburn, P., 306 (We-W30:5), 475 (Th-W54:4) Bogner, J., 400 (We-P11:248) Bossowski, A., 270 (Tu-P10:391), 271 Blades, B., 77 (Mo-P1:140), 317 (We-W36:3), 441 Bogoeska, N., 73 (Mo-P1:123) (Tu-P10:393), 291 (Tu-P10:483) (We-P14:429) Bogsrud, M.P., 551 (Th-P16:266) Bot, I., 230 (Tu-P7:208), 247 (Tu-P7:284) Bláha, M., 562 (Th-P16:315), 563 (Th-P16:316) Bohotin, C., 446 (We-P14:449) Bot, M., 230 (Tu-P7:208) Blaha, M., 562 (Th-P16:314), 563 (Th-P16:317) Boileau, C., 123 (Mo-P5:355) Botez, G., 193 (Tu-P7:40), 415 (We-P13:314) Bláha, V., 562 (Th-P16:315), 563 (Th-P16:316) Bojakowski, K., 289 (Tu-P10:477) 519 Blaha, V., 359 (We-P11:60), 562 (Th-P16:314), Bok, S.H., 431 (We-P14:384), 432 (We-P14:386) Botham, K., (Th-P15:119) 448 473 563 (Th-P16:317) Boldrini, P., 86 (Mo-P2:183), 88 (Mo-P2:190) Botham, K.M., (We-P14:461), 515 Blaimont, M., 553 (Th-P16:274) Bolego, C., 213 (Tu-P7:129), 445 (We-P14:448) (Th-W53:5), (Th-P15:104) 26 Blair, I.A., 588 (Th-P17:431) Bolli, P., 396 (We-P11:230) Böttcher, A., (Mo-W9:2) 91 Blaise, R., 168 (Tu-W24:5) Bombardelli, E., 10 (Mo-ML3:2) Botz, G.H., (Mo-P2:207) 102 387 Blaj, S., 414 (We-P12:308) Bombardieri, S., 414 (We-P12:309) Boucelma, M., (Mo-P4:256), Blanco, D., 400 (We-P11:245) Bonaiuto, A., 147 (Mo-P6:458) (We-P11:189) 446 Blanco, M.F., 54 (Mo-P1:39), 61 (Mo-P1:70) Bonas, A., 56 (Mo-P1:49) Bouchenak, M., (We-P14:450) 449 Blanco-Colio, L.M., 239 (Tu-P7:246), 447 Bonas, M., 56 (Mo-P1:49) Boue-Vaysse, C., (We-P14:466) 484 (We-P14:454), 572 (Th-P16:356), 584 Bond, A.R., 200 (Tu-P7:69) Bouhali, T., (Th-W58:6) 492 (Th-P16:413), 590 (Th-P17:441) Bond, D., 145 (Mo-P6:452) Bouhlel, M.A., (Th-P15:1) Blanquart, C., 487 (Th-W60:3) Bonde, Y., 39 (Mo-W15:7) Boukortt, F.O., 446 (We-P14:450) Blaszczyk, J., 62 (Mo-P1:77), 412 (We-P12:299), Bondjers, G., 239 (Tu-P7:249) Boullier, A., 459 (Th-W46:1) 425 (We-P13:356), 440 (We-P14:424, Bonﬂeur, M.L., 365 (We-P11:91) Boumpas, D.T., 414 (We-P12:307), 423 We-P14:425) Bonito, A., 197 (Tu-P7:58) (We-P13:350) Blazek, M., 562 (Th-P16:315), 563 (Th-P16:316, Bonnefont, D., 467 (Th-W50:5) Bourantas, C., 265 (Tu-P9:370), 298 (Tu-P10:517) Th-P16:317) Bonnet, F., 155 (Tu-W17:3) Bourbon, M., 131 (Mo-P6:390), 136 (Mo-P6:410), Blázovics, A., 105 (Mo-P4:267) Bonney, S.A., 21 (Mo-W6:3) 545 (Th-P15:237) Ble’, A., 401 (We-P11:253), 534 (Th-P15:188) Bonomini, F., 205 (Tu-P7:93) Bourboulis, N.M., 58 (Mo-P1:56) Blecic, S., 18 (Mo-W4:4) Bonomini, M., 216 (Tu-P7:144) Bourdillon, M.C., 194 (Tu-P7:45), 355 Bleijlevens, B., 589 (Th-P17:437) Bonomo, K., 329 (We-W42:4) (We-P11:44) Blesa, S., 130 (Mo-P6:384), 135 (Mo-P6:407), Bonotti, A., 479 (Th-W56:4) Bourhis, J., 220 (Tu-P7:161) 136 (Mo-P6:412), 389 (We-P11:197) Bonuso, A., 558 (Th-P16:295) Bouriachkovskaia, L.I., 283 (Tu-P10:447) Blessing, E., 407 (We-P11:276) Boolell, V., 556 (Th-P16:286) Bousette, N., 489 (Th-W61:1) Bloedon, L.T., 564 (Th-P16:322) Borbas, B., 127 (Mo-P5:371), 518 (Th-P15:115) Bouter, L.M., 23 (Mo-W7:4) Bloks, V.W., 450 (We-P14:471) Borch-Johnsen, K., 154 (Tu-W17:1) Boutin, C., 115 (Mo-P5:315) Blomhoff, R., 478 (Th-W55:5) Bordenave, L., 159 (Tu-W19:6) Boutouyrie, P., 163 (Tu-W21:4)

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

221 Bova, G., 86 (Mo-P2:180) Brighenti, F., 177 (Tu-W28:6), 432 (We-P14:388) Buers, I., 494 (Th-P15:9) Bova, I., 142 (Mo-P6:440), 285 (Tu-P10:459) Brinkmann, V., 407 (We-P11:276) Bujisic, N., 381 (We-P11:161) Bove, M., 50 (Mo-P1:22), 61 (Mo-P1:69), 68 Brinne, B., 200 (Tu-P7:72) Bujo, H., 245 (Tu-P7:277), 482 (Th-W57:7), 520 (Mo-P1:102), 453 (We-P14:482), 532 Brioschi, M., 88 (Mo-P2:191), 92 (Mo-P2:209, (Th-P15:127) A (Th-P15:179) Mo-P2:210), 101 (Mo-P4:249), 241 Bukharkov, A.A., 500 (Th-P15:38) Bovenschen, N., 331 (We-W43:6) (Tu-P7:259), 591 (Th-P17:445) Bukowska, H., 275 (Tu-P10:414), 370 Boverhof, R., 255 (Tu-P8:318) Brisighella Study Group, , 50 (Mo-P1:22) (We-P11:110), 533 (Th-P15:181) U Bovolenta, M.R., 86 (Mo-P2:183), 88 Brisson, D., 131 (Mo-P6:391), 175 (Tu-W27:6), Bukrinsky, M., 162 (Tu-W21:2), 544 (Mo-P2:190) 306 (We-W30:5), 484 (Th-W58:6) (Th-P15:233) T Bovolenta, S., 591 (Th-P17:444) Brites, F., 195 (Tu-P7:48), 504 (Th-P15:54) Buksa, M., 106 (Mo-P4:275) Bowden, D.W., 14 (Mo-W2:6), 89 (Mo-P2:196), Britton, S., 111 (Mo-P5:298) Bullo, M., 146 (Mo-P6:456) H 335 (We-W45:5) Brkic, P., 202 (Tu-P7:78) Bulo, A., 272 (Tu-P10:399), 274 (Tu-P10:407, Bowman, L.J., 174 (Tu-W27:2) Bro, S., 490 (Th-W61:6) Tu-P10:408), 283 (Tu-P10:448) O Bowman, T.S., 66 (Mo-P1:93) Broda, G., 135 (Mo-P6:405) Bülow, R., 213 (Tu-P7:128), 448 (We-P14:462) Boyasis, P., 553 (Th-P16:274) Broedl, U.C., 141 (Mo-P6:432) Bultelle, F., 517 (Th-P15:110) Boyle, J.J., 157 (Tu-W18:4) Brogren, H., 90 (Mo-P2:202) Buonacorso, V., 31 (Mo-W11:4), 540 R Bozec, E., 163 (Tu-W21:4) Brohall, G., 52 (Mo-P1:32), 349 (We-P11:17), 382 (Th-P15:215) Bozia, P., 353 (We-P11:36) (We-P11:165) Buono, C., 515 (Th-P15:100) Bozic, I., 126 (Mo-P5:365), 361 (We-P11:71), 426 Brohee, D., 119 (Mo-P5:336) Burakova, S.V., 68 (Mo-P1:103) (We-P13:363), 522 (Th-P15:134) Brook, R.D., 23 (Mo-W7:2) Burazor, I., 288 (Tu-P10:470), 393 (We-P11:214), 360 228 I Bozikov, J., (We-P11:64) Brooks, N., (Tu-P7:196) 421 (We-P13:337) 359 332 Bozinovska, A., (We-P11:59) Brophy, V.H., (We-W44:1) Burazor, M., 288 (Tu-P10:470), 393 359 168 Bozinovski, D., (We-P11:59) Brou, C., (Tu-W24:5) (We-P11:214), 421 (We-P13:337) N 206 417 486 Bozoglu, E., (Tu-P7:96), (We-P13:323) Brouchet, L., (Th-W59:5) Burazor, N., 288 (Tu-P10:470), 421 (We-P13:337) 165 11 Bozzetto, L., (Tu-W22:4) Brousseau, M.E., (Mo-W1:1) Burazor, Z., 288 (Tu-P10:470), 421 (We-P13:337) D 466 549 103 Bradley, J., (Th-W49:6), (Th-P16:258), Brouwer, B.G., (Mo-P4:261) Burbicka, E., 533 (Th-P15:181) 552 131 (Th-P16:268) Brovkin, A.N., (Mo-P6:387) Burdon, K.P., 335 (We-W45:5) 555 267 E Brady, W.E., (Th-P16:280, Th-P16:281, Brown, A., (Tu-P9:378) Buresova, M., 197 (Tu-P7:57) 541 Th-P16:283) Brown, A.J., (Th-P15:219) Burghen, G., 381 (We-P11:158) 21 541 X Braganza, D.M.B., (Mo-W6:2) Brown, B.E., (Th-P15:218) Buriachkovskaia, L.I., 394 (We-P11:221) 208 533 321 Braksator, W., (Tu-P7:108), (Th-P15:181) Brown, B.G., (We-W38:4) Burillo, P., 103 (Mo-P4:259) 212 391 437 Brambilla, M., (Tu-P7:123), Brown, I.J., (We-P14:411) Burke, V., 386 (We-P11:185) 398 2 (We-P11:206), (We-P11:238) Brown, W.V., (Su-S2:1) Burkhardt, R., 194 (Tu-P7:46), 200 (Tu-P7:71) 526 221 277 Brand, K., (Th-P15:151) Brozzetti, M., (Tu-P7:165), (Tu-P10:423) Bürkner-Gartner, C., 153 (Tu-W16:6) 65 541 Brandani, L., (Mo-P1:90) Brubaker, G., (Th-P15:220) Burnett, J.R., 546 (Th-P15:241) 263 49 453 Brandao, S.A.B., (Tu-P9:360) Bruckert, E., (Mo-P1:19), (We-P14:479), Burrell, L., 217 (Tu-P7:146) 30 326 467 Brandl, R., (Mo-W10:6), (We-W40:7) (Th-W50:5) Busby, R.W., 558 (Th-P16:297) Brandlhofer, S., 38 (Mo-W15:4) Bruckner, P., 144 (Mo-P6:447) Busto, R., 186 (Tu-P7:9) Brandt-Eliasson, U., 314 (We-W34:6) Brufau, G., 451 (We-P14:473, We-P14:474), 452 Butselaar, J., 260 (Tu-P9:342) Branicky, R., 586 (Th-P17:421) (We-P14:477) Buttolu, V.V., 139 (Mo-P6:422) Braojos, A., 105 (Mo-P4:270) Brugaletta, S., 205 (Tu-P7:92), 277 (Tu-P10:422), Buxton, B., 217 (Tu-P7:146) Brattbakk, H.-R., 236 (Tu-P7:234) 349 (We-P11:16) Buzas, R., 346 (We-P11:1), 427 (We-P13:364) Braun, J., 30 (Mo-W10:7) Bruhn, L., 230 (Tu-P7:206) Buziashvili, U., 356 (We-P11:48) Brausch, I., 216 (Tu-P7:142), 470 (Th-W51:7) Brundert, M., 166 (Tu-W23:4) Bye, A., 215 (Tu-P7:139) Bravo, E., 225 (Tu-P7:184), 448 (We-P14:461), Brüne, B., 513 (Th-P15:94) Byers, B., 224 (Tu-P7:178) 519 (Th-P15:119) Brunelli, A., 439 (We-P14:420) Bravo, S., 125 (Mo-P5:361) Brunelli, C., 508 (Th-P15:73) 515 Brazionis, L., 177 (Tu-W28:4) Brunham, L.R., 25 (Mo-W8:4) Cabello-Moruno, R., (Th-P15:104) Bredie, S.J.H., 260 (Tu-P9:345), 545 (Th-P15:240) Bruni, F., 147 (Mo-P6:460), 333 (We-W44:3) Cabré, A., 139 (Mo-P6:425) Breithardt, G., 238 (Tu-P7:243) Brunk, U.T., 158 (Tu-W18:7) Cabre, A., 188 (Tu-P7:15), 522 (Th-P15:133) Bremner, J., 401 (We-P11:252) Bruno, M., 229 (Tu-P7:202) Cabrera Sierra, M., 60 (Mo-P1:68), 366 Bremner, J.D., 324 (We-W39:5) Bruns, O.T., 493 (Th-P15:6) (We-P11:95) Breña, S., 397 (We-P11:235) Bryant, A.P., 558 (Th-P16:297) Caceres, V.M., 197 (Tu-P7:56) Brescia, M., 399 (We-P11:243, We-P11:244) Bryja, V., 252 (Tu-P8:308) Cadirni, A., 409 (We-P12:285), 558 (Th-P16:295) Bresciani, A., 261 (Tu-P9:348) Brynda, E., 159 (Tu-W19:6), 250 (Tu-P8:298) Caffarelli, C., 409 (We-P12:285), 558 Breslow, J.L., 27 (Mo-W9:3), 194 (Tu-P7:46), 316 Bryniarski, L., 554 (Th-P16:278) (Th-P16:295) (We-W35:5) Brzosko, S., 108 (Mo-P4:283), 284 (Tu-P10:451) Caﬁero, V., 372 (We-P11:119) Breton-Douillon, M., 252 (Tu-P8:307) Brzostek, T., 119 (Mo-P5:335) Çafka, M., 64 (Mo-P1:85) Breuss, J., 160 (Tu-W19:7) Bu, D.F., 97 (Mo-P3:231), 494 (Th-P15:12) Cai, D., 271 (Tu-P10:394) Breuss, J.M., 488 (Th-W60:8) Bucala, R., 294 (Tu-P10:495) Cai, L., 514 (Th-P15:97) Brewer, H.B., 320 (We-W38:1), 482 (Th-W57:5) Buccellati, C., 213 (Tu-P7:129), 392 Cai, L.U., 295 (Tu-P10:503) Brewer Jr, H.B., 149 (Tu-PL2:1) (We-P11:208) Cai, M.B., 195 (Tu-P7:49), 212 (Tu-P7:124), 228 Brewster, L.P., 241 (Tu-P7:258) Bucci, M., 246 (Tu-P7:280) (Tu-P7:199), 322 (We-W38:7), 565 Brey, E.M., 241 (Tu-P7:258) Bucciarelli, L., 355 (We-P11:43) (Th-P16:327) Briand, M., 415 (We-P13:313) Bucher, H.C., 160 (Tu-W20:2) Cai, Z., 587 (Th-P17:425) Briand, O., 487 (Th-W60:3) Buchetti, B., 439 (We-P14:420), 525 (Th-P15:147) Caiazza, D., 322 (We-W38:5) Bricca, G., 355 (We-P11:44) Buchwald, H., 304 (We-ML8:1) Cailleux, N., 261 (Tu-P9:351) Briese, S., 218 (Tu-P7:150) Bueno Cortés, M.F., 380 (We-P11:155) Cajanek, L., 252 (Tu-P8:308)

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

222 Cakmak, H., 368 (We-P11:103) Capra, V., 392 (We-P11:208) Casalino, L., 310 (We-W32:6) Calabresi, L., 136 (Mo-P6:413), 152 (Tu-W16:3), Capurso, A., 402 (We-P11:255), 447 Casanovas, A., 498 (Th-P15:28) 154 (Tu-W16:8), 166 (Tu-W23:3), 305 (We-P14:458), 530 (Th-P15:172) Caserini, C., 229 (Tu-P7:202), 591 (Th-P17:444) (We-W30:2) Capurso, C., 402 (We-P11:255), 447 Casillas, P., 367 (We-P11:99) Calandra, S., 35 (Mo-W13:4), 136 (Mo-P6:411, (We-P14:458), 530 (Th-P15:172) Casini, A., 441 (We-P14:431) A Mo-P6:413) Caracciolo, M., 276 (Tu-P10:420) Caslake, M.J., 12 (Mo-W1:5), 484 (Th-W58:5), Calder, P.C., 160 (Tu-W20:3) Carallo, C., 374 (We-P11:131), 423 (We-P13:346) 504 (Th-P15:55) Calderaro, D., 163 (Tu-W21:3), 399 Caramelli, B., 63 (Mo-P1:79), 163 (Tu-W21:3), Caso, R., 67 (Mo-P1:97), 84 (Mo-P2:174) U (We-P11:241), 400 (We-P11:245) 399 (We-P11:241), 400 (We-P11:245), 546 Casscells, W., 309 (We-W32:4) Cali, B.M., 558 (Th-P16:297) (Th-P15:243) Cassi, A., 376 (We-P11:139) T Caligari, S., 167 (Tu-W23:7), 453 (We-P14:483), Caras, I., 236 (Tu-P7:233) Castagnini, M., 248 (Tu-P7:290) 477 (Th-W55:3), 570 (Th-P16:347) Carballo-Jane, E., 463 (Th-W48:3) Castaño, G., 565 (Th-P16:325) H Caligiuri, G., 195 (Tu-P7:50), 278 (Tu-P10:426) Cardellini, M., 367 (We-P11:98), 371 Castellani, L.W., 375 (We-P11:135) Calkin, A., 556 (Th-P16:286) (We-P11:116), 372 (We-P11:122) Castellano Laje, R., 117 (Mo-P5:323) O Calkin, A.C., 355 (We-P11:42), 556 (Th-P16:287) Cardinale, G., 419 (We-P13:331) Castello, L., 49 (Mo-P1:16, Mo-P1:18) 60 366 137 Calvo Bonacho, E., (Mo-P1:68), Cardona, F., (Mo-P6:417) Castelló, R., 89 (Mo-P2:194) 82 422 R (We-P11:95) Cardoso-Saldaña, G., (Mo-P1:163), Castelnuovo, S., 258 (Tu-P9:336), 259 528 Cam, N., (Th-P15:160) (We-P13:344) (Tu-P9:337, Tu-P9:340), 260 (Tu-P9:343), 324 464 136 Cambien, F., (Th-W48:7) Careri, R., (Mo-P6:411) (We-W39:6) 553 499 589 Cambou, J.P., (Th-P16:272) Carettoni, D., (Th-P15:31), (Th-P17:434) Castiglioni, S., 343 (We-S16:2) 239 350 369 Camejo, G., (Tu-P7:249) Caricato, F., (We-P11:23), (We-P11:108) Castilho, L.N., 289 (Tu-P10:476), 526 I 212 285 517 530 Camera, M., (Tu-P7:123), (Tu-P10:457), Cariolou, M., (Th-P15:113), (Th-P15:150) 309 326 398 560 (We-W32:2), (We-W40:6), (Th-P15:170), (Th-P16:303) Castillo, S., 129 (Mo-P6:382), 130 (Mo-P6:385, 331 N (We-P11:238) Cariou, B., (We-W43:4) Mo-P6:386) 331 314 Camino Lopez, S., (We-W43:5) Carlsson, D., (We-W34:6) Castonguay-Lebel, Z., 415 (We-P13:313) 413 22 234 D Camp, P., (We-P12:303) Carlsson, L.M.S., (Mo-W6:6), (Tu-P7:225) Castracane, R.E., 369 (We-P11:107) 17 35 186 Campagna, F., (Mo-W4:3), (Mo-W13:4), Carmel, J.F., (Tu-P7:8) Castro, A., 163 (Tu-W21:5) 330 (We-W43:2), 584 (Th-P16:412) Carmena, R., 4 (Su-S2:6), 130 (Mo-P6:384), 135 Castro, F., 268 (Tu-P9:381) E Campagna, M.S., 409 (We-P12:285) (Mo-P6:407), 136 (Mo-P6:412), 226 Castro Cabezas, M., 31 (Mo-W11:3), 226 Campana, V., 107 (Mo-P4:276), 259 (Tu-P9:341) (Tu-P7:187) (Tu-P7:187), 235 (Tu-P7:229) X Campbell, G.R., 325 (We-W40:5) Carneiro, E.M., 365 (We-P11:91) Catalán, R., 374 (We-P11:130) Campbell, J.H., 325 (We-W40:5) Carnevale, R., 173 (Tu-W26:5), 298 (Tu-P10:514), Catana-Negreanu, C., 69 (Mo-P1:106) Campesi, I., 191 (Tu-P7:29) 525 (Th-P15:147) Catapano, A., 141 (Mo-P6:431) Campisi, D., 90 (Mo-P2:199), 437 (We-P14:412) Carnevale Schianca, G.P., 49 (Mo-P1:16, Catapano, A.L., 30 (Mo-W11:2), 44 (Mo-S7:3), Campodonico, J., 402 (We-P11:254) Mo-P1:18) 193 (Tu-P7:39), 211 (Tu-P7:120), 475 Campolo, L., 404 (We-P11:264) Carpeggiani, C., 70 (Mo-P1:111) (Th-W54:3), 528 (Th-P15:162), 537 Campos, F., 69 (Mo-P1:107) Carpentier, M., 215 (Tu-P7:140) (Th-P15:199), 555 (Th-P16:280, Th-P16:281, Campos, R., 484 (Th-W58:7) Carr, J.J., 89 (Mo-P2:196), 335 (We-W45:5) Th-P16:283) Camps, J., 202 (Tu-P7:81) Carraro, U., 270 (Tu-P10:392) Cattin, L., 278 (Tu-P10:427) Can, G., 55 (Mo-P1:43), 371 (We-P11:114) Carrasco, P., 47 (Mo-P1:9), 133 (Mo-P6:398) Cauchie, P., 119 (Mo-P5:336) Canales, A., 523 (Th-P15:136) Carretta, R., 278 (Tu-P10:427) 485 Canavesi, M., 244 (Tu-P7:271), 463 (Th-W48:6), Carru, C., 273 (Tu-P10:405), 336 (We-W45:7) Cauley, J., (Th-W59:1) 241 294 481 (Th-W57:3), 524 (Th-P15:142), 566 Carstensen, J., 170 (Tu-W25:3) Cavalca, V., (Tu-P7:259), (Tu-P10:498), 297 298 402 (Th-P16:332) Carter, A., 106 (Mo-P4:272), 293 (Tu-P10:491) (Tu-P10:510), (Tu-P10:513), Candido, R., 278 (Tu-P10:427) Carter, E., 587 (Th-P17:425) (We-P11:254) 376 Canel, N., 195 (Tu-P7:48) Carter, N.D., 144 (Mo-P6:446) Cavallotti, P., (We-P11:139) 78 117 Canela, M.A., 451 (We-P14:473, We-P14:474) Cartier, A., 415 (We-P13:313), 421 (We-P13:340) Cavanaugh, M., (Mo-P1:146), Canizales-Quinteros, S., 138 (Mo-P6:418) Cartland, S., 541 (Th-P15:219) (Mo-P5:324) 62 Cañizares, R., 103 (Mo-P4:259) Carubbi, F., 257 (Tu-P8:328) Cavera, G., (Mo-P1:73) 511 567 Cankurtaran, M., 264 (Tu-P9:365) Carulli, L., 46 (Mo-P1:4), 256 (Tu-P8:323), 257 Caverni, A., (Th-P15:84), (Th-P16:334) 160 Canlet, C., 589 (Th-P17:433) (Tu-P8:328), 410 (We-P12:289), 411 Cawood, A.L., (Tu-W20:3) 539 Cano, O., 85 (Mo-P2:178), 286 (Tu-P10:461) (We-P12:294), 472 (Th-W52:7) Cazita, P.M., (Th-P15:210) Canovic, F., 379 (We-P11:150), 421 (We-P13:341) Carulli, N., 46 (Mo-P1:4), 256 (Tu-P8:323), 257 Cecchi, E., 396 (We-P11:227) Cantafora, A., 136 (Mo-P6:411) (Tu-P8:328), 410 (We-P12:289), 411 Ceda, G.P., 107 (Mo-P4:276), 259 (Tu-P9:341) Cantet, C., 553 (Th-P16:272) (We-P12:294), 472 (Th-W52:7) Cederholm, A., 29 (Mo-W10:3), 299 (Tu-P10:518) Cantini, R., 584 (Th-P16:412) Caruso, D., 168 (Tu-W24:3), 253 (Tu-P8:313), Cefalù, A.B., 62 (Mo-P1:73) Canu, N.A., 137 (Mo-P6:414) 257 (Tu-P8:330), 439 (We-P14:422), 465 Cefalu’, A.B., 133 (Mo-P6:400), 524 Cao, D.L., 254 (Tu-P8:317), 492 (Th-P15:3), 543 (Th-W49:4) (Th-P15:144) (Th-P15:227, Th-P15:229) Caruso, F., 268 (Tu-P9:382) Ceglarek, U., 71 (Mo-P1:115), 464 (Th-W48:8) Cao, W.M., 215 (Tu-P7:138) Caruso, R., 276 (Tu-P10:420) Celentano, A., 207 (Tu-P7:104), 315 (We-W35:2) Cao, Z.L., 372 (We-P11:121) Carvalho, A., 349 (We-P11:15) Celentano, E., 54 (Mo-P1:40), 56 (Mo-P1:46) Capalbo, A., 530 (Th-P15:169) Carvalho, A.C.C., 263 (Tu-P9:360), 348 Celermajer, D., 232 (Tu-P7:218) Capani, F., 216 (Tu-P7:144), 352 (We-P11:29), (We-P11:13) Celermajer, D.S., 153 (Tu-W16:4) 353 (We-P11:35) Carvalho, J.A.M., 170 (Tu-W25:4), 419 Celik, A., 106 (Mo-P4:274), 218 (Tu-P7:151), 264 Caparevic, Z., 386 (We-P11:182) (We-P13:332) (Tu-P9:362, Tu-P9:364) Caporaso, A., 431 (We-P14:385) Carvalho, M.D.T., 521 (Th-P15:131), 539 Celinska-Lowehoff, M., 391 (We-P11:204) Caporaso, R., 431 (We-P14:385) (Th-P15:210) Celinska-Lowenhoff, M., 560 (Th-P16:302) Cappello, C., 526 (Th-P15:151) Casagrande, C., 392 (We-P11:208) Cellai, A.P., 441 (We-P14:431)

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

223 Cemerlic-Adjic, N., 262 (Tu-P9:352) 321 (We-W38:3), 467 (Th-W50:5), 476 Chernogubova, E., 492 (Th-P15:2) Cenarro, A., 133 (Mo-P6:396), 233 (Tu-P7:220), (Th-W54:6), 507 (Th-P15:65), 509 Cherubini, A., 108 (Mo-P4:284) 262 (Tu-P9:354), 406 (We-P11:275), 495 (Th-P15:74), 534 (Th-P15:187) Chester, A., 306 (We-W30:4) (Th-P15:16), 546 (Th-P15:244), 547 Chapman, R.H., 51 (Mo-P1:29) Cheta, D., 445 (We-P14:445) A (Th-P15:247) Charf, A.M., 512 (Th-P15:90), 527 (Th-P15:154, Chiang, M.-T., 95 (Mo-P3:221) Çene, N., 64 (Mo-P1:85) Th-P15:155) Chiariello, G., 261 (Tu-P9:348) Centenaro, C., 398 (We-P11:238) Charland, S.L., 53 (Mo-P1:36), 161 (Tu-W20:5), Chiba, T., 13 (Mo-W2:1), 185 (Tu-P7:3), 187 U Cepeda, J.M., 129 (Mo-P6:382) 324 (We-W39:7), 568 (Th-P16:339) (Tu-P7:11), 227 (Tu-P7:191), 253 (Tu-P8:311) Cermanová, M., 562 (Th-P16:315), 563 Charlton-Menys, V., 37 (Mo-W14:4) Chiba, Y., 564 (Th-P16:320) T (Th-P16:316) Chater, R., 123 (Mo-P5:355) Chicu, M., 91 (Mo-P2:205), 446 (We-P14:449) Cermanova, M., 562 (Th-P16:314), 563 Chaturvedi, N., 80 (Mo-P1:155, Mo-P1:156), 104 Chien, K.L., 48 (Mo-P1:15), 369 (We-P11:106) H (Th-P16:317) (Mo-P4:262) Chien, Y.L., 436 (We-P14:408) Cernohorsky, D., 359 (We-P11:60) Chaturvedi, S., 80 (Mo-P1:154), 107 (Mo-P4:278) Chiesa, G., 167 (Tu-W23:7), 453 (We-P14:483), O Cerutti, C., 355 (We-P11:44) Chau, L.-Y., 95 (Mo-P3:221) 454 (We-P14:484), 477 (Th-W55:3), 478 Cesari, F., 85 (Mo-P2:177), 441 (We-P14:431) Chaves, F.J., 130 (Mo-P6:384), 135 (Mo-P6:407), (Th-W55:6), 536 (Th-P15:198), 537 140 371 136 226 389 Ceska, R., (Mo-P6:429, Mo-P6:430), (Mo-P6:412), (Tu-P7:187), (Th-P15:199), 570 (Th-P16:347) R 407 (We-P11:117), (We-P12:278) (We-P11:197) Chimonas, T.E., 505 (Th-P15:60), 510 213 186 191 577 Cetin, I., (Tu-P7:129) Chayama, K., (Tu-P7:5), (Tu-P7:31), (Th-P15:81) 569 Ceylan-Isik, A., (Th-P16:345) (Th-P16:380) Chin, C., 587 (Th-P17:425) 349 207 Chaaba, R., (We-P11:18) Chazov, E., (Tu-P7:103) Chin, H.-C., 425 (We-P13:357) 556 324 I Chaava, H., (Th-P16:288) Cheema, F.A., (We-W39:5) Chin, R., 187 (Tu-P7:13), 362 (We-P11:76) 454 275 370 Chaava, K.H., (We-P14:487) Chelstowski, K., (Tu-P10:414), Chin-Dusting, J., 539 (Th-P15:208) 538 387 533 Chabert, M., (Th-P15:206) (We-P11:110), (We-P11:187), Chin-Dusting, J.P., 355 (We-P11:42) N 385 Chachanidze, N., (We-P11:180) (Th-P15:181) Chinellato, A., 47 (Mo-P1:8), 66 (Mo-P1:91), 121 113 516 Chacra, A.P.M., (Mo-P5:304) Chen, A.-P., (Th-P15:107) (Mo-P5:345) D 583 186 Chaduneli, E., (Th-P16:410) Chen, B., (Tu-P7:6) Chio, K., 193 (Tu-P7:37) 389 583 498 Chagunava, K., (We-P11:198), Chen, B.-S., (Th-P15:26) Chiodini, P., 54 (Mo-P1:40) (Th-P16:410) Chen, B.S., 190 (Tu-P7:27) E Chirkova, L., 356 (We-P11:45) Chait, A., 13 (Mo-W2:1), 227 (Tu-P7:191) Chen, C.-W., 265 (Tu-P9:369) Chiti, I., 446 (We-P14:453) Chajek - Shaul, T., 463 (Th-W48:2) Chen, C.H., 296 (Tu-P10:508) X Chiu, T.-Y., 265 (Tu-P9:369) Chalasani, N.P., 410 (We-P12:290) Chen, H., 193 (Tu-P7:37) Chkhaidze, Z., 65 (Mo-P1:87) Chaldakov, G.N., 86 (Mo-P2:181), 188 (Tu-P7:16) Chen, J., 381 (We-P11:160) Chlebowski, R., 485 (Th-W59:1) Chalikias, G.K., 87 (Mo-P2:184), 533 Chen, J.H., 99 (Mo-P4:240), 383 (We-P11:170), Chlebus, K., 129 (Mo-P6:380), 424 (We-P13:352) (Th-P15:184) 397 (We-P11:231) Chlubek, D., 433 (We-P14:391, We-P14:392) Chambaz, C., 220 (Tu-P7:158) Chen, J.W., 235 (Tu-P7:230), 238 (Tu-P7:242), Chlupac, J., 159 (Tu-W19:6) Chambaz, J., 538 (Th-P15:206) 242 (Tu-P7:260), 251 (Tu-P8:304), 253 Chmiela, M., 98 (Mo-P4:235), 143 (Mo-P6:443) Chambers, J., 80 (Mo-P1:155, Mo-P1:156) (Tu-P8:312), 293 (Tu-P10:493) Cho, H., 503 (Th-P15:48) Chambers, M., 240 (Tu-P7:253) Chen, J.Y., 99 (Mo-P4:240) Cho, K.H., 517 (Th-P15:112) Chambers, S.T., 274 (Tu-P10:409) Chen, K., 372 (We-P11:121) Choe, H.M., 98 (Mo-P4:239) Chamorro, C.I., 89 (Mo-P2:194) Chen, L., 256 (Tu-P8:325) Choe, K.H., 98 (Mo-P4:238, Mo-P4:239) Chan, D.C., 329 (We-W42:5), 370 (We-P11:111), Chen, M.F., 48 (Mo-P1:15), 369 (We-P11:106), 267 519 (Th-P15:118), 534 (Th-P15:185), 535 434 (We-P14:399) Choe, Y.H., (Tu-P9:376) 364 (Th-P15:193), 556 (Th-P16:285), 577 Chen, P.C., 48 (Mo-P1:15) Chogle, A.R., (We-P11:83) 234 (Th-P16:379) Chen, P.R., 437 (We-P14:409) Choi, H.J., (Tu-P7:227) 98 Chan, K.W., 186 (Tu-P7:6) Chen, Q., 94 (Mo-P3:220), 515 (Th-P15:103) Choi, H.M., (Mo-P4:238) 566 Chan, L., 244 (Tu-P7:273) Chen, R., 202 (Tu-P7:79), 203 (Tu-P7:84) Choi, J., (Th-P16:331) 423 455 Chan, L.B., 94 (Mo-P3:219) Chen, X., 516 (Th-P15:108), 544 (Th-P15:231) Choi, J.H., (We-P13:349), (We-P14:489) 234 279 Chan, P., 253 (Tu-P8:309) Chen, X.Y., 93 (Mo-P2:213) Choi, J.Y., (Tu-P7:227), (Tu-P10:429) 503 519 Chan, Q., 56 (Mo-P1:47), 390 (We-P11:201), 430 Chen, Y., 87 (Mo-P2:185), 535 (Th-P15:194) Choi, S.H., (Th-P15:48), (Th-P15:122) 247 (We-P14:381), 437 (We-P14:410, Chen, Y.C., 409 (We-P12:287) Choi, Y., (Tu-P7:285) 423 We-P14:411) Chen, Y.H., 95 (Mo-P3:221), 235 (Tu-P7:230), Choi, Y.H., (We-P13:349) 265 Chancharme, L., 393 (We-P11:215) 238 (Tu-P7:242), 242 (Tu-P7:260), 251 Chou, H.-Y., (Tu-P9:369) Chandalia, M., 79 (Mo-P1:149) (Tu-P8:304), 253 (Tu-P8:312) Chou, M., 73 (Mo-P1:122), 377 (We-P11:144) Chandra, R., 508 (Th-P15:72), 587 (Th-P17:428) Chen, Y.L., 235 (Tu-P7:230), 253 (Tu-P8:312) Chou, M.Y., 459 (Th-W46:1) Chang, D.S., 232 (Tu-P7:215), 540 (Th-P15:214) Chen, Y.W., 413 (We-P12:304) Choudhury, S., 64 (Mo-P1:83) Chang, G., 391 (We-P11:207), 392 (We-P11:209) Chen, Y.Y., 515 (Th-P15:103) Chow, M.S.S., 147 (Mo-P6:459) Chang, M.K., 459 (Th-W46:1) Cheng, J.C., 409 (We-P12:287) Chow, W.S., 294 (Tu-P10:495) Chang, N.C., 549 (Th-P16:255) Cheng, J.T., 253 (Tu-P8:309) Christen, A., 65 (Mo-P1:90) Chang, P.-F., 95 (Mo-P3:221) Cheng, S., 332 (We-W44:1) Christensen, J.H., 208 (Tu-P7:106), 269 Chang, Q., 147 (Mo-P6:459) Cheng, T.H., 296 (Tu-P10:508) (Tu-P9:388), 382 (We-P11:163), 474 Chantepie, S., 509 (Th-P15:74), 534 (Th-P15:187) Cheng, Y.L., 233 (Tu-P7:219) (Th-W53:6), 531 (Th-P15:175), 584 Chantepre, S., 507 (Th-P15:65) Chenni, A., 446 (We-P14:450) (Th-P16:414) Chanussot, F., 69 (Mo-P1:105) Chenot, F., 553 (Th-P16:274) Christidis, D., 560 (Th-P16:303) Chao, H.H., 296 (Tu-P10:508) Cheon, B.W., 266 (Tu-P9:373), 314 (We-W34:7) Christophersen, B., 126 (Mo-P5:364) Chao, T.H., 99 (Mo-P4:240), 397 (We-P11:231) Cherki, M., 189 (Tu-P7:20), 443 (We-P14:437), Chrysanthopoulou, A., 109 (Mo-P4:285) Chaoyong, Z., 242 (Tu-P7:262) 452 (We-P14:476), 473 (Th-W53:3), 521 Chu, N.-F., 425 (We-P13:357) Chapman, J., 190 (Tu-P7:24), 328 (We-W41:6) (Th-P15:130) Chu, P., 121 (Mo-P5:344) Chapman, M.J., 12 (Mo-W1:5), 180 (Tu-S8:1), Chern, C.-I., 265 (Tu-P9:369) Chu, S., 271 (Tu-P10:394)

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

224 Chu, T.T.W., 379 (We-P11:151) Clementi, F., 372 (We-P11:122) Constantinescu, E., 193 (Tu-P7:40) Chuang, E., 466 (Th-W49:5, Th-W49:6), 549 Clerin, V., 256 (Tu-P8:325) Conte, M., 205 (Tu-P7:92), 277 (Tu-P10:422), 349 (Th-P16:258), 552 (Th-P16:268) Clissa, C., 355 (We-P11:43) (We-P11:16), 381 (We-P11:159) Chudakova, D.A., 131 (Mo-P6:387), 146 Clogenson, S., 516 (Th-P15:106) Contorno, F., 404 (We-P11:264) (Mo-P6:455) Cloutier, M., 189 (Tu-P7:20), 539 (Th-P15:212) Contreras, C., 79 (Mo-P1:152) A Chudoba, P., 104 (Mo-P4:265) Coady, E., 80 (Mo-P1:155, Mo-P1:156), 104 Contreras, D., 484 (Th-W58:7) Chugunova, L.A., 108 (Mo-P4:281), 209 (Mo-P4:262) Cook, J., 556 (Th-P16:284), 557 (Th-P16:289) (Tu-P7:111), 289 (Tu-P10:474) Cobo Sanz, J.M., 453 (We-P14:479) Cook, J.R., 116 (Mo-P5:317), 117 (Mo-P5:325) U Chumakova, O.S., 146 (Mo-P6:455) Cobzariu, F., 110 (Mo-P4:291), 111 (Mo-P4:294) Cooke, A., 254 (Tu-P8:316) Chumburidze, Sh.D., 385 (We-P11:181), 388 Coca Pérez, M.A., 117 (Mo-P5:323) Cooney, J., 484 (Th-W58:5) T (We-P11:191), 578 (Th-P16:385) Cocciolillo, G.C., 450 (We-P14:468) Cooper, J., 24 (Mo-W7:6), 131 (Mo-P6:389), 312 Chun, J., 535 (Th-P15:192) Cocoana, A., 110 (Mo-P4:291), 111 (Mo-P4:294) (We-W33:6), 315 (We-W35:3), 368 H Chung, Y.-L., 589 (Th-P17:436) Codony, R., 451 (We-P14:474) (We-P11:103) Chung, Y.-S., 503 (Th-P15:48), 519 (Th-P15:122) Coen, E., 281 (Tu-P10:440) Cooper, J.A., 301 (We-PL3:3) O Chuo, B.W., 437 (We-P14:409) Coen, M., 430 (We-P14:381) Cooper, M.E., 355 (We-P11:42), 556 173 353 261 495 Ciabattoni, G., (Tu-W26:7), (We-P11:35), Cofán, M., (Tu-P9:349), (Th-P15:16) (Th-P16:286, Th-P16:287) 355 363 469 146 R (We-P11:43), (We-P11:78), Cofan, M., (Mo-P6:456) Cooper-Dehoff, R.M., 334 (We-W44:7) 524 493 (Th-W51:4), (Th-P15:144) Cogny, A., (Th-P15:8) Cope, A.P., 86 (Mo-P2:182) 86 163 Cianﬂone, D., (Mo-P2:182) Cohen, A., (Tu-W21:4) Copin, C., 234 (Tu-P7:228) 380 38 554 Cianﬂone, K., (We-P11:157) Cohen, H., (Mo-W15:1), (Th-P16:276) Coral, R., 138 (Mo-P6:418) 147 333 150 305 Ciani, F., (Mo-P6:460), (We-W44:3) Cohen, J.C., (Tu-PL2:4), (We-W30:1) Coratelli, P., 563 (Th-P16:318) I 31 453 Ciano, O., (Mo-W11:5) Cohen, L., (We-P14:479) Corbalan, R., 65 (Mo-P1:89) 54 186 Ciardullo, A.V., (Mo-P1:40) Cohn, J.S., (Tu-P7:8) Corbella, E., 261 (Tu-P9:350) 273 589 113 505 N Ciari, I., (Tu-P10:404), (Th-P17:435) Cokkinos, D.V., (Mo-P5:306), Cordova, A., 252 (Tu-P8:306) 298 590 509 510 Cibulka, R., (Tu-P10:515), (Th-P17:442) (Th-P15:60), (Th-P15:77), Corella, D., 47 (Mo-P1:9), 133 (Mo-P6:398), 175 240 360 D Ciccarelli, L., (Tu-P7:254, Tu-P7:255), (Th-P15:81) (Tu-W28:1), 333 (We-W44:4) 402 447 (We-P11:65) Colacicco, A.M., (We-P11:255), Corlianò, F., 49 (Mo-P1:18) Ciccarone, E., 380 (We-P11:156) (We-P14:458), 530 (Th-P15:172) Cornelli, L., 477 (Th-W55:3), 478 (Th-W55:6) E Cicero, A., 240 (Tu-P7:255) Colafrancesco, V., 277 (Tu-P10:422), 349 Correia, A.M., 198 (Tu-P7:62) Cicero, A.F.G., 50 (Mo-P1:22), 61 (Mo-P1:69), 68 (We-P11:16) Corsi, A.M., 471 (Th-W52:4), 480 (Th-W56:6), X (Mo-P1:102), 240 (Tu-P7:254), 366 Colak, E., 379 (We-P11:150), 421 (We-P13:341) 530 (Th-P15:171), 534 (Th-P15:188) (We-P11:93), 424 (We-P13:351), 453 Colangeli, I., 554 (Th-P16:277), 558 (Th-P16:296) Corsi, M.M., 209 (Tu-P7:112) (We-P14:482), 532 (Th-P15:179), 564 Colantuono, G., 454 (We-P14:486) Corsini, A., 157 (Tu-W18:6), 201 (Tu-P7:76), 250 (Th-P16:321) Coleman, R., 205 (Tu-P7:93) (Tu-P8:299), 251 (Tu-P8:300), 338 Cicha, I., 218 (Tu-P7:152) Colhoun, H., 37 (Mo-W14:4) (We-S13:1), 566 (Th-P16:332) Ciecko, T., 463 (Th-W48:3) Colina, I., 206 (Tu-P7:97), 415 (We-P13:315) Cortella, I., 133 (Mo-P6:400) Ciecwierz, D., 424 (We-P13:352), 442 Coll, B., 163 (Tu-W21:5), 202 (Tu-P7:81), 400 Cortellaro, M., 285 (Tu-P10:457) (We-P14:432), 449 (We-P14:465) (We-P11:247), 416 (We-P13:318), 513 Cortés, B., 439 (We-P14:418), 585 (Th-P17:419) Cifkova, R., 48 (Mo-P1:13), 124 (Mo-P5:356) (Th-P15:95) Cortes, B., 146 (Mo-P6:456), 447 (We-P14:457) Cighetti, G., 294 (Tu-P10:498) Collen, D., 94 (Mo-P3:218), 490 (Th-W61:8) Cortese, C., 43 (Mo-S7:1), 146 (Mo-P6:453), 259 Cignarella, A., 27 (Mo-W9:4), 445 (We-P14:448) Collet, X., 31 (Mo-W11:6), 153 (Tu-W16:7) 268 353 Cigolini, M., 75 (Mo-P1:133), 411 (We-P12:293) Colli, S., 92 (Mo-P2:210), 212 (Tu-P7:127), 391 (Tu-P9:338), (Tu-P9:382), 374 423 Ciloglu, F., 528 (Th-P15:160) (We-P11:206), 392 (We-P11:208), 474 (We-P11:33), (We-P11:131), Cimpanelli, M., 549 (Th-P16:257) (Th-W53:7) (We-P13:346) 147 Cinti, S., 320 (We-W37:7) Collini, M.D., 256 (Tu-P8:324) Cortese, G., (Mo-P6:457) 90 222 Ciocoiu, M., 91 (Mo-P2:205), 446 (We-P14:449) Coll Ins, A., 446 (We-P14:452) Corti, R., (Mo-P2:200), (Tu-P7:169) 112 Ciorica, G., 46 (Mo-P1:3), 362 (We-P11:73), 365 Collins, D., 561 (Th-P16:307) Coscia, F., (Mo-P5:300) 353 (We-P11:86) Collins, H., 149 (Tu-PL2:2) Cosciug, I., (We-P11:34) 390 Cipollone, F., 8 (Mo-PL1:4), 17 (Mo-W4:3), 156 Collins, J., 31 (Mo-W11:3) Cosemans, J., (We-P11:202) 325 (Tu-W18:2), 246 (Tu-P7:280), 247 Collot-Teixeira, S., 516 (Th-P15:106), 517 Cosemans, J.M.E.M., (We-W40:4) 549 (Tu-P7:282), 248 (Tu-P7:287), 537 (Th-P15:110) Cosentino, M., (Th-P16:257) 397 (Th-P15:199), 588 (Th-P17:431) Colnago, D., 212 (Tu-P7:123) Cosin, J., (We-P11:235) Ciric- Zdravkovc, S., 288 (Tu-P10:470) Colombo, F., 422 (We-P13:343) Cossalter, R., 62 (Mo-P1:75) Ciric- Zdravkovic, S., 393 (We-P11:214) Colombo, G., 157 (Tu-W18:6) Costa, R.P., 435 (We-P14:403) Ciric-Zdravkovic, S., 421 (We-P13:337) Colquhoun, D., 330 (We-W42:7), 442 Costacou, T., 50 (Mo-P1:21) Cisek, M., 119 (Mo-P5:335) (We-P14:435), 538 (Th-P15:204) Costaiola, L., 31 (Mo-W11:5) Ciucci, A., 252 (Tu-P8:305) Combe, N., 198 (Tu-P7:60), 449 (We-P14:466) Costales, P., 331 (We-W43:5) Ciuti, G., 325 (We-W40:3), 396 (We-P11:227) Comegna, C., 580 (Th-P16:393) Costet, P., 306 (We-W30:7) Civeira, F., 133 (Mo-P6:396), 233 (Tu-P7:220), Coméra, C., 31 (Mo-W11:6) Costet, P.H., 331 (We-W43:4) 262 (Tu-P9:354), 406 (We-P11:275), 495 Comijn, E.M., 95 (Mo-P3:223) Costo, A., 103 (Mo-P4:259) (Th-P15:16), 546 (Th-P15:244), 547 Conceicao, R., 170 (Tu-W25:4) Côté, C., 415 (We-P13:313) (Th-P15:247) Cong, Z., 325 (We-W40:5) Côté, M., 165 (Tu-W22:5), 421 (We-P13:340) Clandinin, M., 512 (Th-P15:89) Connelly, P.W., 476 (Th-W55:1) Cottin, Y., 370 (We-P11:113), 427 (We-P13:365) Clara, A., 62 (Mo-P1:74), 79 (Mo-P1:152), 105 Consensi, A., 414 (We-P12:309) Couillard, C., 445 (We-P14:446) (Mo-P4:270), 268 (Tu-P9:381) Consoli, A., 14 (Mo-W2:5), 216 (Tu-P7:144), 352 Couremenou, C., 58 (Mo-P1:56), 84 (Mo-P2:171) Clarke, M.C., 21 (Mo-W6:2) (We-P11:29), 353 (We-P11:35), 355 Coutinho, M., 63 (Mo-P1:79) Clarke, M.W., 546 (Th-P15:241) (We-P11:43), 380 (We-P11:156) Couture, P., 443 (We-P14:438), 445 (We-P14:446) Clement, N., 168 (Tu-W24:5) Consoli, C., 165 (Tu-W22:6) Covetti, G., 261 (Tu-P9:348)

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

225 Cowan, P.A., 381 (We-P11:158) D’Addato, S., 50 (Mo-P1:24), 425 (We-P13:358) David, S., 419 (We-P13:330) Cowley, D., 469 (Th-W51:5) D’Alessandris, C., 169 (Tu-W24:6) David-Duﬁlho, M., 214 (Tu-P7:134) Cox, C., 316 (We-W35:6) D’Amico, F., 411 (We-P12:297) Davidson, B.L., 74 (Mo-P1:127) Cramer, C., 543 (Th-P15:230) D’Amico, R., 46 (Mo-P1:4) Davidson, M.H., 1 (Su-S1:3), 555 (Th-P16:280, A Crea, F., 205 (Tu-P7:92), 277 (Tu-P10:422), 309 D’Angelo, A., 240 (Tu-P7:254, Tu-P7:255), 360 Th-P16:281, Th-P16:283), 566 (Th-P16:331) (We-W32:1), 349 (We-P11:16), 381 (We-P11:65) Davidson-Smith, H., 254 (Tu-P8:316) U (We-P11:159), 480 (Th-W56:8) D’Archivio, M., 186 (Tu-P7:7) Davies, A.H., 92 (Mo-P2:211), 587 (Th-P17:426) Crepaldi, G., 303 (We-ML7:1), 424 (We-P13:354) D’Atri, L.P., 231 (Tu-P7:212) Davies, G., 116 (Mo-P5:317) 288 91 Crescenzio, N., (Tu-P10:472) D’Atri, P., (Mo-P2:203) Davies, G.M., 117 (Mo-P5:325), 556 549 402 447 T Crespi, C., (Th-P16:257) D’Introno, A., (We-P11:255), (Th-P16:284), 557 (Th-P16:289) 159 530 Crespo, J., (Tu-W19:5) (We-P14:458), (Th-P15:172) Davies, M., 71 (Mo-P1:113, Mo-P1:114), 174 367 527 H Crespo, M., (We-P11:99) D’Souza, C.J.M., (Th-P15:158) (Tu-W27:3) 168 253 200 Crestani, M., (Tu-W24:3), (Tu-P8:313), D’Souza, S.E., (Tu-P7:70) Davies, M.J., 541 (Th-P15:218) 256 257 372 198 O (Tu-P8:323), (Tu-P8:330), Dabadie, H., (Tu-P7:60) Daviglus, M., 56 (Mo-P1:47) (We-P11:119), 439 (We-P14:422), 465 Dabela, M.L.G., 263 (Tu-P9:360) Davignon, J., 136 (Mo-P6:409), 186 (Tu-P7:8) (Th-W49:4), 472 (Th-W52:7) Daculsi, R., 159 (Tu-W19:6) Davis, A., 208 (Tu-P7:107) R Cribas, P.A., 52 (Mo-P1:30) Dadan, J., 271 (Tu-P10:393) Dawood, N., 82 (Mo-P1:167) Crippa, G., 376 (We-P11:139) Dadashova, G.M., 409 (We-P12:286) Day, N.E., 70 (Mo-P1:109) Crisafulli, A., 24 (Mo-W7:7) Daga, M.K., 70 (Mo-P1:110) Deakin, S., 332 (We-W44:2) Crnjakovic, J.C., 204 (Tu-P7:89) Dahlbäck, B., 314 (We-W35:1) Deambrosis, P., 47 (Mo-P1:8), 66 (Mo-P1:91), Croft, K.D., 546 (Th-P15:241) Dai, L., 310 (We-W32:7) I 121 (Mo-P5:345) Cromley, D.A., 540 (Th-P15:214) Dai, X.Y., 254 (Tu-P8:317), 492 (Th-P15:3), 543 343 Crook, M., 424 (We-P13:353) (Th-P15:227, Th-P15:229) De Backer, G.G., (We-S16:1) N 289 Crooke, R.M., 466 (Th-W49:5), 532 (Th-P15:180) Daiber, A., 470 (Th-W51:7) De Barros-Mazon, S., (Tu-P10:476) 438 Cruickshank, J.K., 170 (Tu-W25:2) Daida, H., 417 (We-P13:321), 559 (Th-P16:301) Debbou, S., (We-P14:415) 537 D Cruz, M., 116 (Mo-P5:322) Daito, M., 411 (We-P12:296) De Beer, F.C., (Th-P15:200) 537 Cruz, M.C., 273 (Tu-P10:403) Dalén, J., 264 (Tu-P9:366) De Beer, M.C., (Th-P15:200) 276 E Cruz, M.L.Y., 289 (Tu-P10:476) Dallal, G.E., 580 (Th-P16:395) De Biase, A., (Tu-P10:420) Császár, A., 156 (Tu-W17:7) Dalla Nora, E., 311 (We-W33:3), 320 (We-W37:7) Debreova, M., 57 (Mo-P1:54) X Csaszar, A., 140 (Mo-P6:427) Dallinga-Thie, G.M., 38 (Mo-W15:3), 315 De Bruin, T.W., 130 (Mo-P6:383) Csiba, L., 296 (Tu-P10:504) (We-W35:4), 489 (Th-W61:5), 538 De Castro, I., 146 (Mo-P6:456) Csípö, I., 296 (Tu-P10:504) (Th-P15:207), 551 (Th-P16:263), 560 De Caterina, R., 181 (Tu-S9:2), 231 (Tu-P7:213), Cubells, M., 374 (We-P11:130) (Th-P16:306) 248 (Tu-P7:290) Cubillo, P., 395 (We-P11:224), 531 (Th-P15:176) Dalpino, F., 55 (Mo-P1:42) De Cesare, D., 246 (Tu-P7:280), 247 (Tu-P7:282), Cubrilo, K., 126 (Mo-P5:367), 287 (Tu-P10:468), Damacus, C., 62 (Mo-P1:76) 248 (Tu-P7:287) 361 (We-P11:68, We-P11:70), 362 Damaskos, D.S., 113 (Mo-P5:306), 505 De Chiara, B., 276 (Tu-P10:420) (We-P11:74, We-P11:75), 378 (We-P11:149) (Th-P15:60), 510 (Th-P15:81) De Craen, A.J.M., 37 (Mo-W14:5) Cubrilo-Turek, M., 205 (Tu-P7:91) Damjanovic, S., 126 (Mo-P5:365), 361 Dede, D.S., 264 (Tu-P9:365) Cuccurullo, C., 246 (Tu-P7:280), 247 (We-P11:71), 426 (We-P13:363), 522 Deedwania, P., 161 (Tu-W20:6), 552 (Th-P16:267) (Tu-P7:282), 248 (Tu-P7:287) (Th-P15:134) Deepa, R., 79 (Mo-P1:149) Cuccurullo, F., 246 (Tu-P7:280), 247 (Tu-P7:282), Damm, P., 14 (Mo-W2:4) Deev, A., 116 (Mo-P5:321) 127 518 248 (Tu-P7:287) Dan, A., (Mo-P5:371), (Th-P15:115) De Fabiani, E., 168 (Tu-W24:3), 253 (Tu-P8:313), 419 Cuchel, M., 149 (Tu-PL2:2), 167 (Tu-W23:5), 564 Dandamudi, R., (We-P13:330) 257 (Tu-P8:330), 439 (We-P14:422), 465 218 (Th-P16:322) Daniel, W.G., (Tu-P7:152) (Th-W49:4) 62 131 Cucuruz, M., (Mo-P1:76) Dankovtseva, E.N., (Mo-P6:387) De Faria, E., 55 (Mo-P1:42), 540 (Th-P15:213) 409 514 Cuda, C., (We-P12:285) Dannenberg, H., (Th-P15:98) De Faria, E.C., 289 (Tu-P10:476), 526 208 31 Cudnoch-Jedrzejewska, A., (Tu-P7:108) Daogang, Y., (Mo-W11:6) (Th-P15:150) 523 Darkovska, T., 272 (Tu-P10:402) Cuéllar, C., (Th-P15:136) De Feo, F., 414 (We-P12:309) 244 Dart, A.M., 146 (Mo-P6:454), 162 (Tu-W21:2) Culacciati, D., (Tu-P7:272) Defesche, J.C., 19 (Mo-W5:1), 138 (Mo-P6:421) 27 467 Das, B., 70 (Mo-P1:110) Cullen, P., (Mo-W9:4), (Th-W50:3) De Filippis, E.A., 353 (We-P11:35) Culler, C.E., 219 (Tu-P7:156) Dashti, G., 395 (We-P11:223) De Franco, V., 405 (We-P11:270) Cuniberti, L., 195 (Tu-P7:48), 504 (Th-P15:54) Daskalaki, M., 77 (Mo-P1:142), 204 (Tu-P7:90), Degasperi, G.R., 526 (Th-P15:150) Cunningham, D., 419 (We-P13:330) 210 (Tu-P7:118), 395 (We-P11:225) De Geest, B., 94 (Mo-P3:218), 153 (Tu-W16:6), Curb, D., 64 (Mo-P1:83) Daskalakis, P., 347 (We-P11:9), 348 (We-P11:10) 490 (Th-W61:8) Currie, M.G., 558 (Th-P16:297) Daskalopoulou, E., 361 (We-P11:69) Degenhardt, R., 565 (Th-P16:328) Curyllo, B., 129 (Mo-P6:380) Dasopoulou, C., 67 (Mo-P1:99), 104 (Mo-P4:266) Deger, F., 525 (Th-P15:146) Cutt, H., 386 (We-P11:185) Dasselaar, M., 452 (We-P14:477) 258 259 Cvijovic, G., 126 (Mo-P5:367), 287 (Tu-P10:468), Date, H., 93 (Mo-P2:215) De Giosa, G., (Tu-P9:336), (Tu-P9:337, 260 324 361 (We-P11:68, We-P11:70), 362 Datelova, M., 57 (Mo-P1:54) Tu-P9:340), (Tu-P9:343), (We-P11:74, We-P11:75), 378 (We-P11:149) Dautin, G., 535 (Th-P15:190) (We-W39:6) 269 Cvirn, G., 93 (Mo-P2:212) Davdison, M., 308 (We-W31:3) Degli Esposti, M., (Tu-P9:388) 260 545 Czarnocka, B., 271 (Tu-P10:393) DavÌ, G., 353 (We-P11:35) De Graaf, J., (Tu-P9:345), (Th-P15:240) 306 Cziraky, M.J., 568 (Th-P16:339) Davì, G., 172 (Tu-W26:3), 355 (We-P11:43), 363 de Graaf, J., (We-W30:6) 444 Czlonkowska, A., 282 (Tu-P10:443) (We-P11:78), 469 (Th-W51:4), 524 De Graaf, Y., (We-P14:444) Czopf, L., 356 (We-P11:47) (Th-P15:144) De Groot, E., 124 (Mo-P5:357), 260 (Tu-P9:342), Davì, V., 524 (Th-P15:144) 265 (Tu-P9:367), 444 (We-P14:444), 585 D’Adamo, M., 165 (Tu-W22:6), 425 Davi’, G., 88 (Mo-P2:192), 173 (Tu-W26:7) (Th-P16:415) (We-P13:355) David, L., 46 (Mo-P1:3), 365 (We-P11:86) de Groot, E., 309 (We-W32:3)

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

226 De Haan, W., 489 (Th-W61:5), 551 (Th-P16:263), De Moner, A., 79 (Mo-P1:152) Diamant, M., 525 (Th-P15:145) 560 (Th-P16:306) Demonty, I., 380 (We-P11:157) Diament, J., 280 (Tu-P10:437), 542 (Th-P15:224) Deiana, L., 273 (Tu-P10:405), 336 (We-W45:7) Demosky, S., 320 (We-W38:1) Diani, E., 477 (Th-W55:3), 478 (Th-W55:6) Deinite, G., 106 (Mo-P4:273) Dempsey, R.J., 18 (Mo-W4:5) Dias, V., 117 (Mo-P5:326) De Jager, S.C.A., 247 (Tu-P7:284) Denardin Victor Porto, O., 513 (Th-P15:92) Díaz, J.L., 129 (Mo-P6:382) A De Jager, W.J., 98 (Mo-P4:236) Denarie, N., 269 (Tu-P9:387) Díaz-Peromingo, J.A., 124 (Mo-P5:359) Dejanov, P., 128 (Mo-P5:374) Denchev, S., 354 (We-P11:38) Di Bonito, P., 51 (Mo-P1:25) Dejanova, B., 128 (Mo-P5:374), 297 Deneuville, M., 81 (Mo-P1:161), 123 Dickson, G., 95 (Mo-P3:224) U (Tu-P10:512), 407 (We-P12:279), 418 (Mo-P5:354) Diczfalusy, U., 562 (Th-P16:312) (We-P13:326) Deng, D., 588 (Th-P17:429, Th-P17:430, Dietz, R., 568 (Th-P16:340) T De Jong, A., 258 (Tu-P9:336) Th-P17:432) Díez, J., 206 (Tu-P7:97), 245 (Tu-P7:274), 415 De Jong, P.E., 16 (Mo-W3:6) Deng, D.X., 230 (Tu-P7:206) (We-P13:315) H De Keyzer, D., 464 (Th-W48:7) Dengler, T.J., 407 (We-P11:276) Di Febbo, C., 29 (Mo-W10:4) Dekker, J.M., 23 (Mo-W7:4), 502 (Th-P15:44), Denisova, D.V., 68 (Mo-P1:103) Di Felice, A., 125 (Mo-P5:360) O 525 (Th-P15:145) Deniz, A., 269 (Tu-P9:385), 524 (Th-P15:143) Diffenderfer, M.R., 11 (Mo-W1:1) 386 487 Dekleva, M., (We-P11:182) De Nooijer, R., (Th-W60:4) Di Fulvio, P., 14 (Mo-W2:5), 352 (We-P11:29), 498 370 R De La Cruz, F., (Th-P15:28) Dentan, G., (We-P11:113) 353 (We-P11:35) 62 107 259 De La Fuente, N., (Mo-P1:74) Denti, L., (Mo-P4:276), (Tu-P9:341) Di Garbo, V., 90 (Mo-P2:199), 420 (We-P13:336), 116 364 De La Iglesia, R., (Mo-P5:322) Deo, S., (We-P11:83) 437 (We-P14:412) 364 163 399 de la Iglesia, R., (We-P11:85) De Oliveira Lima, E., (Tu-W21:3), Digenio, A.G., 11 (Mo-W1:1) 167 De La Llera-Moya, M., (Tu-W23:5) (We-P11:241) Di Gennaro, A., 392 (We-P11:208) I 399 473 Del Arco, A., (We-P11:240) De Pascale, C., (Th-W53:5) Di Giannuario, G., 205 (Tu-P7:92) 452 507 591 De La Torre, J., (We-P14:475) Dergunov, A.D., (Th-P15:66), Dijkhuizen, P., 19 (Mo-W5:2) 286 N De La Vega, J., (Tu-P10:462) (Th-P17:443) Dika, Z., 376 (We-P11:136) 116 137 220 De La Vega Jr., J.M., (Mo-P5:322) Derkacz, A., (Mo-P6:415), (Tu-P7:160), Di Leo, E., 19 (Mo-W5:3) 249 252 281 297 D Deleris, P., (Tu-P8:295), (Tu-P8:307) (Tu-P10:438), (Tu-P10:511) Dilic, M., 106 (Mo-P4:275) 405 95 Delgado Alves, J., (We-P11:271) Derks, S., (Mo-P3:223) Di Lullo, L., 580 (Th-P16:393) Delgado Lista, J., 439 (We-P14:418) De Roos, A., 267 (Tu-P9:375) Di Marino, L., 165 (Tu-W22:4) E Dell’Agli, M., 439 (We-P14:422), 481 (Th-W57:3) Derosa, G., 240 (Tu-P7:254, Tu-P7:255), 360 Di Marzo, V., 41 (Mo-S4:3) Dell’Aquila, F., 268 (Tu-P9:382), 353 (We-P11:65), 366 (We-P11:93), 453 Di Minno, G., 207 (Tu-P7:104), 315 (We-W35:2) X (We-P11:33) (We-P14:482) Dimitrijevic, E., 288 (Tu-P10:470) Dell’Omo, G., 386 (We-P11:184), 387 Derouiche, A., 280 (Tu-P10:436), 518 Dimitrijevic-Sreckovic, V., 379 (We-P11:150), (We-P11:186) (Th-P15:114, Th-P15:116) 421 (We-P13:341) Della Bella, A., 229 (Tu-P7:202) Derouiche, A.F., 443 (We-P14:437), 473 Dimitrov, D., 370 (We-P11:112) Dellanoce, C., 276 (Tu-P10:420) (Th-W53:3) Dimitrov, G.L., 273 (Tu-P10:406) Del Mese, P., 298 (Tu-P10:516), 329 (We-W42:4) Deruiter, M.C., 205 (Tu-P7:94) Dimitrov, S., 354 (We-P11:38) de Lorgeril, M., 180 (Tu-S9:1), 316 (We-W36:1) De Sain-Van Der Velden, M.G.M., 134 Dimitrova, R., 310 (We-W32:5) De Los Santos, A.R., 62 (Mo-P1:75) (Mo-P6:403) Dimmeler, S., 302 (We-PL3:4) Del Pezzo, M., 56 (Mo-P1:46) De Salve, A., 329 (We-W42:4) Dimopoulos, K., 84 (Mo-P2:171) Delplanque, B., 443 (We-P14:436), 449 Descamps, O.S., 553 (Th-P16:274) Dina, C.H., 347 (We-P11:8) (We-P14:466), 589 (Th-P17:433) Desco-Menéndez, M.M., 276 (Tu-P10:417) 169 Del Prato, S., 3 (Su-S2:2), 350 (We-P11:23), 369 De Silvestris, M., 229 (Tu-P7:202) Dinarrelo, C.A., (Tu-W24:7) 215 (We-P11:108), 386 (We-P11:184), 387 De Simone, R., 420 (We-P13:336), 437 Ding, H., (Tu-P7:137) 521 (We-P11:186), 528 (Th-P15:159) (We-P14:412) Ding, L., (Th-P15:129) 160 Del Puppo, M., 256 (Tu-P8:323), 472 (Th-W52:7) De Souza, H.P., 539 (Th-P15:210) Ding, R., (Tu-W20:3) 271 Del Santo, K., 409 (We-P12:285), 558 De Souza, J.A., 534 (Th-P15:187) Ding, W., (Tu-P10:394) 105 (Th-P16:295) De Souza, R., 442 (We-P14:433), 476 Dinya, E., (Mo-P4:267) 14 216 Del Turco, S., 248 (Tu-P7:290) (Th-W55:1), 478 (Th-W55:7) Di Pietro, N., (Mo-W2:5), (Tu-P7:144), 352 de Man-van Ginkel, J.M., 357 (We-P11:51) Després, J.P., 24 (Mo-W8:1), 41 (Mo-S4:4), 165 (We-P11:29) 86 405 De Maria, R., 276 (Tu-P10:420) (Tu-W22:5), 329 (We-W42:3), 340 Di Renzo, M., (Mo-P2:180), (We-P11:270) 173 439 Dembinksa-Kiec, A., 290 (Tu-P10:479) (We-S14:3), 415 (We-P13:313), 421 Di Santo, S., (Tu-W26:5), (We-P14:420) 454 Dembinska-Kiec, A., 35 (Mo-W13:7), 76 (We-P13:340), 475 (Th-W54:4, Th-W54:5) Disconzi, E., (We-P14:484) (Mo-P1:136), 137 (Mo-P6:416), 141 Despres, J.P., 306 (We-W30:5), 484 (Th-W58:6) Di Silvestre, S., 14 (Mo-W2:5), 216 (Tu-P7:144), (Mo-P6:433), 192 (Tu-P7:34), 199 (Tu-P7:64, Desroches, S., 443 (We-P14:438) 352 (We-P11:29) Tu-P7:66), 208 (Tu-P7:105), 288 De Teresa, E., 572 (Th-P16:356), 584 Disoteo, O., 114 (Mo-P5:309) (Tu-P10:469), 295 (Tu-P10:501), 416 (Th-P16:413) Ditiatkovski, M., 33 (Mo-W12:3) (We-P13:319), 417 (We-P13:324) Dethlefsen, C., 213 (Tu-P7:128), 448 Di Todaro, F., 108 (Mo-P4:284) Dembinska-Kiec, A.M., 192 (Tu-P7:36) (We-P14:462) Di Tomo, P., 14 (Mo-W2:5), 216 (Tu-P7:144), 352 De Meester, A., 553 (Th-P16:274) Deutsch, E., 220 (Tu-P7:161) (We-P11:29) De Meo, D., 369 (We-P11:107) Devangelio, E., 355 (We-P11:43) Djarmati, D., 75 (Mo-P1:131, Mo-P1:132) De Metrio, M., 297 (Tu-P10:510) Devaraj, S., 359 (We-P11:61), 452 (We-P14:478) Djeric, M., 82 (Mo-P1:164), 566 (Th-P16:333) Demir, O., 74 (Mo-P1:130), 112 (Mo-P5:301), De Vos, P., 33 (Mo-W12:4) Djokic, B., 261 (Tu-P9:347) 164 (Tu-W21:7), 289 (Tu-P10:473) Devriese, A., 293 (Tu-P10:494) Djordjevic, P., 421 (We-P13:341) Demir, S., 106 (Mo-P4:274) De Winther, M.P.J., 225 (Tu-P7:181) Djordjevic, P.B., 379 (We-P11:150) Demirpence, E., 269 (Tu-P9:385), 524 Deyneli, O., 215 (Tu-P7:136) Djordjevic-Denic, G., 75 (Mo-P1:131, (Th-P15:143) Dhingra, S., 196 (Tu-P7:54) Mo-P1:132) Demirtas, K., 92 (Mo-P2:208), 398 (We-P11:237) Dhutia, H., 80 (Mo-P1:155, Mo-P1:156) Djukanovic, B., 211 (Tu-P7:119) Demirtas, S., 284 (Tu-P10:455), 289 (Tu-P10:473) Diab, I., 266 (Tu-P9:371) Djuric, D., 53 (Mo-P1:37)

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

227 Djuricic, I., 450 (We-P14:469) Dritsas, A., 113 (Mo-P5:306) Dziegiel, P., 104 (Mo-P4:265), 270 (Tu-P10:392) Dluzniewski, M., 175 (Tu-W27:7), 208 Drobniak-Heldak, D., 76 (Mo-P1:136), 208 Dzupinkova, Z., 189 (Tu-P7:19) (Tu-P7:108), 533 (Th-P15:181) (Tu-P7:105), 288 (Tu-P10:469) Dobiasova, M., 371 (We-P11:117), 504 Drogari, E., 134 (Mo-P6:404), 251 (Tu-P8:303), 158 (Th-P15:53) 333 (We-W44:6) Eaton, J.W., (Tu-W18:7) A 430 Dobosz, T., 137 (Mo-P6:415) Dropinski, J., 391 (We-P11:204), 560 Ebbels, T., (We-P14:381) Dobreva, D., 438 (We-P14:417) (Th-P16:302) Ebenbichler, C., 155 (Tu-W17:4), 410 U Dobric, S., 570 (Th-P16:348) Drozdz, W., 295 (Tu-P10:501) (We-P12:292) Dobrin, A., 228 (Tu-P7:195) Drueding, R., 161 (Tu-W20:5) Ebensperger, R., 216 (Tu-P7:141) T Doetschman, T., 486 (Th-W59:5) Drummond, M., 121 (Mo-P5:344) Eber, B., 283 (Tu-P10:449), 413 (We-P12:306) Dogliotti, G., 209 (Tu-P7:112) Dubska, L., 553 (Th-P16:273) Eberini, I., 154 (Tu-W16:8), 201 (Tu-P7:76) H Dogramatzi, F., 558 (Th-P16:293) Dubuc, G., 136 (Mo-P6:409) Ebisuno, M., 417 (We-P13:320), 498 (Th-P15:29) Dogru, T., 206 (Tu-P7:96), 395 (We-P11:226), 417 Duchateau, G., 296 (Tu-P10:505), 453 Ebrahimian, T.G., 190 (Tu-P7:26) O (We-P13:323) (We-P14:480) Echbili, A., 438 (We-P14:415) Doko, A., 64 (Mo-P1:85), 272 (Tu-P10:399), 274 Duchateau, G.S.M.J., 450 (We-P14:471) Eckhardt, E.R., 28 (Mo-W9:7) (Tu-P10:407, Tu-P10:408), 283 (Tu-P10:448) Ducobu, J., 524 (Th-P15:141), 525 (Th-P15:146), Eckhart, A., 243 (Tu-P7:265) R Dolecki, M., 295 (Tu-P10:501) 554 (Th-P16:278) Edelstein, C., 18 (Mo-W4:7) Domae, N., 411 (We-P12:296) Duda-Seiman, D.M., 46 (Mo-P1:3), 110 Eden, E.R., 197 (Tu-P7:59) Domagala, T.B., 391 (We-P11:204), 560 (Mo-P4:291), 111 (Mo-P4:294), 362 Edfeldt, K., 407 (We-P11:277) (Th-P16:302) (We-P11:73), 365 (We-P11:86, We-P11:87) Edirimanne, E.R.V., 274 (Tu-P10:410) I Dombrowicz, D., 487 (Th-W60:3) Dudziak, J., 83 (Mo-P2:168, Mo-P2:169) Edvinsson, L., 382 (We-P11:167) Dominguez-Rodriguez, A., 122 (Mo-P5:349), 244 Dufﬁeld, E., 552 (Th-P16:270), 580 (Th-P16:394) Edwards, J.Y., 482 (Th-W57:6) N (Tu-P7:270) Duffy, S.J., 146 (Mo-P6:454) Efthimiadis, A., 557 (Th-P16:292), 558 Domke, I., 586 (Th-P17:422) Dugas, S., 115 (Mo-P5:315) (Th-P16:293), 576 (Th-P16:377) Donadel, G., 165 (Tu-W22:6), 221 (Tu-P7:166), Duhem, C., 487 (Th-W60:3) Efthimiadis, I., 557 (Th-P16:292), 558 D 450 (We-P14:468) Duivenvoorden, I., 32 (Mo-W11:7) (Th-P16:293), 576 (Th-P16:377) Donald, A., 265 (Tu-P9:367) Duivenvoorden, R., 265 (Tu-P9:367), 444 Efthymiou, H., 568 (Th-P16:341) E Doncheva, N.I., 275 (Tu-P10:415), 438 (We-P14:444) Egashira, K., 249 (Tu-P8:294), 482 (Th-W57:4) 276 (We-P14:417) Dulin-Iñiguez, E., (Tu-P10:417) Egashira, T., 73 (Mo-P1:125) 161 324 357 X Doneen, A.L., (Tu-W20:5), (We-W39:7) Dumicic, J., (We-P11:53) Eggerman, T., 310 (We-W32:8) 190 234 365 Dong, B.H., (Tu-P7:25), (Tu-P7:224), Dumitrasciuc, M., (We-P11:87) Eghbal, M.A., 445 (We-P14:447) 251 494 539 568 574 (Tu-P8:301), (Th-P15:10), Dumler, I., (Th-P16:340), (Th-P16:365) Egido, J., 228 (Tu-P7:197), 239 (Tu-P7:246), 447 57 (Th-P15:209) Duncea, C., (Mo-P1:51) (We-P14:454), 572 (Th-P16:356), 584 31 51 521 Donnarumma, G., (Mo-W11:5), (Mo-P1:25) Dunér, P., (Th-P15:128) (Th-P16:413), 590 (Th-P17:441) 267 117 Doornbos, J., (Tu-P9:375) Dunlap, R., (Mo-P5:324) Ehnholm, C., 39 (Mo-W15:5), 320 (We-W37:6), 288 205 Dordjevic, J., (Tu-P10:470) Durakovic, Z., (Tu-P7:91) 500 (Th-P15:37), 540 (Th-P15:216), 576 250 566 464 Dorent, R., (Tu-P8:299), (Th-P16:332) Durand, H., (Th-W48:7) (Th-P16:378) Dorfmeister, B., 38 (Mo-W15:4), 138 Durand, J.B., 91 (Mo-P2:207) Ehrman, W.E., 530 (Th-P15:168) (Mo-P6:420) Durant, S., 163 (Tu-W21:4) Ehrman, W.L., 440 (We-P14:423) Dorighello, G.G., 365 (We-P11:91) Durgam, G.G., 392 (We-P11:210) Eid, H.M.A., 357 (We-P11:52) Dorignac, E., 296 (Tu-P10:505) Durham, K., 550 (Th-P16:259, Th-P16:260, Eidenmüller, B., 408 (We-P12:282) Döring, A., 71 (Mo-P1:115) Th-P16:262) Eisler, B., 394 (We-P11:220) Dormi, A., 50 (Mo-P1:22, Mo-P1:24), 68 Duriez, P., 215 (Tu-P7:140) Ekstrand, J., 248 (Tu-P7:289) (Mo-P1:102), 425 (We-P13:358) Durigutto, P., 278 (Tu-P10:427) Ekström, K., 226 (Tu-P7:188), 227 (Tu-P7:190) Dorn, J., 412 (We-P12:301) Durrington, P.N., 12 (Mo-W1:5), 37 (Mo-W14:4) El-Saed, A., 265 (Tu-P9:368) Doronzo, G., 298 (Tu-P10:516), 329 (We-W42:4) Durst, R., 514 (Th-P15:98) El-Shanti, N., 210 (Tu-P7:116) Dos Santos, L., 197 (Tu-P7:56) Dusinská, M., 188 (Tu-P7:17) El-Tobgy, S., 102 (Mo-P4:254) Dougalis, A., 361 (We-P11:69) Dusinska, M., 189 (Tu-P7:19), 292 (Tu-P10:488), 92 110 Douglas, S., 489 (Th-W61:1) 446 (We-P14:452) Eldem, O., (Mo-P2:208), (Mo-P4:293) 18 Douillon, M., 249 (Tu-P8:295) Dutkiewicz, M., 276 (Tu-P10:416) Eldrup, N., (Mo-W4:6) 70 318 Doumas, M., 530 (Th-P15:170) Dutta, A.K., 546 (Th-P15:245) Elharchaoui, K., (Mo-P1:109), 544 Dourtsiou, S., 353 (We-P11:36) Duvillard, L., 311 (We-W33:4), 535 (Th-P15:190) (We-W36:6), (Th-P15:235) 435 Dovlatova, N.L., 283 (Tu-P10:447) Duzguncinar, O., 269 (Tu-P9:385), 524 Elias, M.C., (We-P14:403) 532 Draeger, N.M., 178 (Tu-W29:3) (Th-P15:143) Eliassen, K., (Th-P15:180) 92 152 212 Dragan, S., 110 (Mo-P4:291), 111 (Mo-P4:294), Dvir, D., 213 (Tu-P7:130) Eligini, S., (Mo-P2:210), (Tu-W16:3), 391 474 445 (We-P14:445) Dvorakova, J., 128 (Mo-P5:376), 553 (Tu-P7:127), (We-P11:206), Dragani, A., 88 (Mo-P2:192), 173 (Tu-W26:7) (Th-P16:273) (Th-W53:7) Dragasevic, M., 502 (Th-P15:46), 503 Dvorscak, D., 357 (We-P11:53) Elikir, G., 65 (Mo-P1:90), 504 (Th-P15:54) (Th-P15:47) Dworakowski, R., 424 (We-P13:352) Elisaf, M., 63 (Mo-P1:78), 368 (We-P11:104), 369 Dragomir, E., 355 (We-P11:41) Dwyer, T., 483 (Th-W58:3) (We-P11:105), 499 (Th-P15:32, Th-P15:33), Dragulescu, St.I., 46 (Mo-P1:3) Dyduch, G., 199 (Tu-P7:64, Tu-P7:66), 200 501 (Th-P15:42), 503 (Th-P15:49), 517 Draijer, R., 265 (Tu-P9:367), 444 (We-P14:444) (Tu-P7:68) (Th-P15:113), 530 (Th-P15:170), 560 Draskovic, D., 502 (Th-P15:46), 503 (Th-P15:47) Dyer, A.R., 56 (Mo-P1:47), 437 (We-P14:410, (Th-P16:303), 561 (Th-P16:308), 577 Drazetin, M., 564 (Th-P16:324) We-P14:411) (Th-P16:381), 582 (Th-P16:404) Drennon, K.D., 243 (Tu-P7:266) Dzenkeviciute, V., 66 (Mo-P1:92), 214 Elisaf, M.S., 553 (Th-P16:271) Drenos, F., 24 (Mo-W7:6) (Tu-P7:132) Ellingsen, O., 100 (Mo-P4:244), 111 (Mo-P5:298) Drissi, A., 443 (We-P14:437), 452 (We-P14:476), Dzhekova-Stojkova, S., 73 (Mo-P1:123), 272 Ellingsen, Ø., 215 (Tu-P7:139) 473 (Th-W53:3) (Tu-P10:402) Elliott, P., 56 (Mo-P1:47), 390 (We-P11:201), 430

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

228 (We-P14:381), 437 (We-P14:410, Eto, M., 217 (Tu-P7:147), 405 (We-P11:269), 439 Federici, G., 146 (Mo-P6:453), 147 (Mo-P6:457), We-P14:411) (We-P14:421), 545 (Th-P15:239), 585 353 (We-P11:33) Ellis, P.R., 177 (Tu-W28:6) (Th-P16:417) Federici, M., 165 (Tu-W22:6), 221 (Tu-P7:166), El Messal, M., 123 (Mo-P5:355), 473 (Th-W53:3) Eto, T., 93 (Mo-P2:215) 312 (We-W33:7), 372 (We-P11:122), 425 Elmgren, A., 254 (Tu-P8:315) Evangelisti, L., 396 (We-P11:230), 398 (We-P13:355), 450 (We-P14:468) A Elosua, R., 383 (We-P11:171) (We-P11:239) Federico, L., 25 (Mo-W8:6) Elsen, B., 260 (Tu-P9:342) Evans, V., 95 (Mo-P3:224) Fedi, S., 85 (Mo-P2:177) Elsen, B.M., 265 (Tu-P9:367) Evstifeeva, S., 98 (Mo-P4:237) Fedotova, I., 348 (We-P11:11) U Elte, J.W., 31 (Mo-W11:3) Ewerlin, L., 38 (Mo-W15:2) Feeman, W.E., 70 (Mo-P1:112), 114 (Mo-P5:310) Eltobgi, S., 266 (Tu-P9:371) Ewert, R., 214 (Tu-P7:135) Feher, G., 82 (Mo-P1:165), 356 (We-P11:47), 398 T Emam, A., 476 (Th-W55:1), 478 (Th-W55:7) Exner, M., 525 (Th-P15:149) (We-P11:236) Emanuele, E., 73 (Mo-P1:121), 281 (Tu-P10:440), Eychmueller, A., 493 (Th-P15:6) Feigin, V.L., 57 (Mo-P1:53) H 404 (We-P11:266) Ezhov, M., 569 (Th-P16:346) Feinberg, M.S., 213 (Tu-P7:130) Emanueli, C., 191 (Tu-P7:29) Ezhov, M.V., 404 (We-P11:263), 581 Feinstein, M., 308 (We-W31:3) O Emeis, J.J., 32 (Mo-W11:7), 393 (We-P11:215) (Th-P16:400) Feinstein, S., 69 (Mo-P1:104), 308 (We-W31:3) 208 Emmett, N., (Tu-P7:107) Feitosa-Filho, G., 537 (Th-P15:202), 542 227 561 R Emukhvari, M., (Tu-P7:193) Faas, F., (Th-P16:307) (Th-P15:224) 498 508 Endo, K., (Th-P15:29) Fabbi, P., (Th-P15:73) Feldman, J., 256 (Tu-P8:325) 575 116 273 Endo, T., (Th-P16:370) Fabiani, F., (Mo-P5:322), (Tu-P10:403), Feldmann, M., 92 (Mo-P2:211) 417 286 364 Endoh, K., (We-P13:320) (Tu-P10:462), (We-P11:85) Feldstein, C.A., 62 (Mo-P1:75), 376 (We-P11:137) 27 278 Engel, T., (Mo-W9:4) Fabris, B., (Tu-P10:427) Felici, C., 273 (Tu-P10:404), 589 (Th-P17:435) I 131 231 282 Engert, J.C., (Mo-P6:391) Faccenda, F., (Tu-P7:211), (Tu-P10:445) Felix, S.B., 214 (Tu-P7:135), 571 (Th-P16:352) 60 Faergeman, O., 466 (Th-W50:1), 580 Enomoto, M., (Mo-P1:65, Mo-P1:66, Fellin, R., 108 (Mo-P4:284), 311 (We-W33:3), 76 519 (Th-P16:394) N Mo-P1:67), (Mo-P1:139), 317 (We-W36:5), 424 (We-P13:351), 471 Fagerberg, B., 22 (Mo-W6:6), 52 (Mo-P1:32), 349 (Th-P15:120) (Th-W52:4), 530 (Th-P15:171), 534 248 (We-P11:17), 382 (We-P11:165) D Epistolato, M.C., (Tu-P7:290) (Th-P15:188) 518 Fagnani, R., 439 (We-P14:422) Er-Rachdi, L., (Th-P15:114) Fellström, B., 9 (Mo-ML1:1), 578 (Th-P16:387) Erakovic, V., 393 (We-P11:214) Fahlisch, F., 30 (Mo-W10:7) Feng, D.M., 224 (Tu-P7:177) E Erbel, R., 535 (Th-P15:192) Fairwell, T., 320 (We-W38:1) Feng, J.-T., 494 (Th-P15:11), 516 (Th-P15:107), Erdem, G., 417 (We-P13:323) Fait, T., 407 (We-P12:278) 536 (Th-P15:196), 574 (Th-P16:367) X Erglis, A., 142 (Mo-P6:438) Faith, J., 131 (Mo-P6:391) Feng, X. R., 97 (Mo-P3:231) Erhardt, L.R., 118 (Mo-P5:332), 119 Falciani, M., 391 (We-P11:205) Feng, Y., 94 (Mo-P3:218) (Mo-P5:333), 179 (Tu-W29:6), 462 Falco, A., 88 (Mo-P2:192), 172 (Tu-W26:3), 173 Feng, Y.M., 490 (Th-W61:8) (Th-W47:4) (Tu-W26:7), 469 (Th-W51:4) Fenster, A., 308 (We-W31:4) Ericsson, P., 242 (Tu-P7:262) Falcó, C., 531 (Th-P15:176) Ferdinand, K., 551 (Th-P16:265), 552 Erikci, S., 417 (We-P13:323) Falcone, C., 404 (We-P11:266) (Th-P16:267) Eriksson, A.C., 90 (Mo-P2:201) Faleiro, L.L., 429 (We-P13:374) Ferezou, J., 433 (We-P14:393) Eriksson, P., 145 (Mo-P6:449), 158 (Tu-W19:1), Faleri, M.L., 212 (Tu-P7:127) Ferguson, M., 267 (Tu-P9:379) 316 (We-W35:6), 406 (We-P11:272) Falezza, G., 411 (We-P12:293) Ferlosio, A., 252 (Tu-P8:305) Erlich, H.A., 332 (We-W44:1) Falk, E., 490 (Th-W61:6) Fernandez, J., 565 (Th-P16:325) Erne, P., 191 (Tu-P7:30) Falkner, K.L., 412 (We-P12:301) 565 Ernerudh, J., 170 (Tu-W25:3) Falletta, A., 62 (Mo-P1:73) Fernandez, L., (Th-P16:325) 159 420 Ernst, J., 194 (Tu-P7:46) Fan, J., 238 (Tu-P7:241) Fernandez, P., (Tu-W19:6), (We-P13:336) 513 Errigo, A., 137 (Mo-P6:414), 139 (Mo-P6:422) Fan, L.M., 94 (Mo-P3:220) Fernàndez-Ballart, J.D., (Th-P15:95) 54 Ertan, C., 74 (Mo-P1:129), 112 (Mo-P5:301), 164 Fan, Q., 59 (Mo-P1:61) Fernandez- Britto, J.E., (Mo-P1:39) 50 61 (Tu-W21:7) Fang, Y.J., 379 (We-P11:151) Fernandez-Britto, J.E., (Mo-P1:23), 484 Ertl, G., 313 (We-W34:5), 353 (We-P11:32), 471 Farad, C., 387 (We-P11:189) (Mo-P1:70), (Th-W58:7) 384 (Th-W52:5) Faria, E.C., 508 (Th-P15:71), 509 (Th-P15:74) Fernández-Fernández, J.M., (We-P11:172) 383 Erzen, B., 76 (Mo-P1:135), 212 (Tu-P7:126) Farndale, R., 326 (We-W40:7) Fernandez-Fernandez, M., (We-P11:171) 123 Esakia, N., 416 (We-P13:317) Farnier, M., 174 (Tu-W27:3), 370 (We-P11:113), Fernández-Miranda, C., (Mo-P5:353) 273 Escalona, F., 347 (We-P11:5) 427 (We-P13:365), 554 (Th-P16:278) Fernández-Riejos, P., (Tu-P10:403) 116 364 Escalona-Pérez, F., 132 (Mo-P6:395) Faro, R., 268 (Tu-P9:381) Fernandez-Riejos, P., (Mo-P5:322), Eschen, O., 208 (Tu-P7:106) Farsang, C., 572 (Th-P16:356), 584 (Th-P16:413) (We-P11:85) Eschert, H., 238 (Tu-P7:243) Faruqi, A.H., 540 (Th-P15:214) Fernández Britto, J., 117 (Mo-P5:323) Escobales, N., 367 (We-P11:99) Fasano, T., 19 (Mo-W5:3), 136 (Mo-P6:413) Fernandez De La Puebla, R.A., 135 (Mo-P6:408) Esfahani, A., 455 (We-P14:488) Fatini, C., 85 (Mo-P2:177) Fernández De Los Rios, A., 531 (Th-P15:173) España, F., 89 (Mo-P2:194), 395 (We-P11:224), Fauler, G., 583 (Th-P16:409) Fernández de los Ríos, A., 365 (We-P11:88) 531 (Th-P15:176) Faulkner, D., 478 (Th-W55:7) Fernández Meseguer, A., 60 (Mo-P1:68), 366 Espinosa, O., 389 (We-P11:197) Faulkner, D.A., 476 (Th-W55:1) (We-P11:95) Espinosa, P., 308 (We-W31:3) Favari, E., 12 (Mo-W1:6), 166 (Tu-W23:3), 524 Ferns, G., 289 (Tu-P10:475) Esposito, G.P., 86 (Mo-P2:183), 88 (Mo-P2:190) (Th-P15:142) Ferramosca, E., 125 (Mo-P5:360) Esposito, K., 328 (We-W42:1) Fayer, F., 133 (Mo-P6:400) Ferrandi, C., 157 (Tu-W18:6) Esposito, M.-J., 119 (Mo-P5:336) Fazia, M., 537 (Th-P15:199) Ferrando, M., 571 (Th-P16:351) Esposito, P., 207 (Tu-P7:104) Fazia, M.L., 8 (Mo-PL1:4), 246 (Tu-P7:280), 247 Ferrannini, E., 14 (Mo-W2:7), 479 (Th-W56:4), Esteban-Salan, M., 553 (Th-P16:275) (Tu-P7:282), 248 (Tu-P7:287) 526 (Th-P15:152) Estellés, A., 89 (Mo-P2:194), 395 (We-P11:224), Febbraio, M., 490 (Th-W61:7) Ferrante, F., 275 (Tu-P10:411) 531 (Th-P15:176) Fedele, D., 350 (We-P11:21, We-P11:22) Ferrara, F., 18 (Mo-W4:7) Ethirajan, P., 246 (Tu-P7:281) Federici, A., 454 (We-P14:486) Ferrari, I., 240 (Tu-P7:255), 360 (We-P11:65)

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

229 Ferrari, M., 549 (Th-P16:257) Fletcher, J.P., 34 (Mo-W12:7), 96 (Mo-P3:229) Franzini, L., 224 (Tu-P7:178) Ferrari, R., 217 (Tu-P7:148), 218 (Tu-P7:149) Flicker, L., 512 (Th-P15:88) Frascerra, S., 526 (Th-P15:152) Ferraro, M., 71 (Mo-P1:116), 389 (We-P11:196, Flierl, U., 201 (Tu-P7:75) Frasheri, A., 404 (We-P11:264) We-P11:199) Florentin, E., 535 (Th-P15:190) Frayn, K., 31 (Mo-W11:3) A Ferre, N., 202 (Tu-P7:81) Florkowski, C.M., 99 (Mo-P4:242) Fredericks, S., 87 (Mo-P2:184), 533 (Th-P15:184) Ferré, R., 400 (We-P11:247), 513 (Th-P15:95) Fogari, R., 240 (Tu-P7:254) Fredrikson, G.N., 231 (Tu-P7:213), 327 Ferreira, A., 101 (Mo-P4:250, Mo-P4:251) Fogelstrand, L., 503 (Th-P15:50) (We-W41:3) U Ferreira, R., 84 (Mo-P2:172) Foka, P., 237 (Tu-P7:238) Freedman, B.I., 14 (Mo-W2:6), 89 (Mo-P2:196), Ferreira-Jardim, A., 442 (We-P14:435) Folco, G., 392 (We-P11:208) 335 (We-W45:5) T Ferrelli, F., 221 (Tu-P7:166) Folco, G.C., 213 (Tu-P7:129) Freeman, L., 482 (Th-W57:5) Ferri, N., 157 (Tu-W18:6), 244 (Tu-P7:271), 250 Foncea, R., 216 (Tu-P7:141) Frei, B., 472 (Th-W52:6) H (Tu-P8:299) Fonda, M., 278 (Tu-P10:427) Freiberger, T., 132 (Mo-P6:392) Ferrières, J., 553 (Th-P16:272) Fonseca, A.E., 429 (We-P13:374) Freimark, D., 213 (Tu-P7:130) O Ferrini, S., 396 (We-P11:227), 530 (Th-P15:169) Fonseca, F., 349 (We-P11:15) Freisinger, F., 53 (Mo-P1:35), 576 (Th-P16:374) Ferroni, P., 355 (We-P11:43), 469 (Th-W51:4) Fonseca, F.A.H., 263 (Tu-P9:360), 348 Freitas, J., 120 (Mo-P5:337) 471 480 435 Ferrucci, L., (Th-W52:4), (Th-W56:6), (We-P11:13), (We-P14:403) Freitas, S., 63 (Mo-P1:79) R 530 534 349 (Th-P15:171), (Th-P15:188) Fonseca, M., (We-P11:15) French, M., 512 (Th-P15:89) 93 486 Ferstl, U., (Mo-P2:212) Fontaine, V., (Th-W59:5) French, P.M., 587 (Th-P17:426) 355 291 292 Feugier, P., (We-P11:44) Fontana, V., (Tu-P10:485), (Tu-P10:486) Fresa, R., 554 (Th-P16:277) 293 556 Feuters, S., (Tu-P10:491) Forbes, J.M., (Th-P16:287) Fretzen, A., 558 (Th-P16:297) 515 557 I Feyaerts, N., (Th-P15:102) Forder, P., (Th-P16:290) Fricke, C., 450 (We-P14:470) 126 130 Fey Froslie, K., (Mo-P5:364) Forga, L., (Mo-P6:385) Fridfeldt, J., 84 (Mo-P2:173) 277 229 571 577 Fialova, L., (Tu-P10:421) Fóris, G., (Tu-P7:203), (Th-P16:355), Friedlander, Y., 133 (Mo-P6:399), 335 N 543 Fici, G., (Th-P15:230) (Th-P16:382) (We-W45:3), 514 (Th-P15:98) 113 14 352 Ficker, E.S., (Mo-P5:304) Formoso, G., (Mo-W2:5), (We-P11:29), Friedrich, I., 581 (Th-P16:397) D 71 353 355 380 Fiedler, G.M., (Mo-P1:115) (We-P11:35), (We-P11:43), Friedrichs, S., 18 (Mo-W4:4) 319 542 Fievet, C., (We-W37:4), (Th-P15:223) (We-P11:156) Frigerio, B., 258 (Tu-P9:336), 259 (Tu-P9:337, Figg, N., 21 (Mo-W6:2) Fornage, M., 138 (Mo-P6:419) E Tu-P9:340), 260 (Tu-P9:343), 324 Figueiredo Neto, A.M., 586 (Th-P17:423) Fornari, M., 504 (Th-P15:54) (We-W39:6), 474 (Th-W53:7) Figueras, R., 130 (Mo-P6:386) Forrest, M.J., 463 (Th-W48:3) X Frigerio, M., 309 (We-W32:2), 326 (We-W40:6) Figueroa, Y., 367 (We-P11:99) Förstermann, U., 295 (Tu-P10:502) Frikke-Schmidt, R., 35 (Mo-W13:6) Filatov, D., 582 (Th-P16:402) Forstermann, U., 216 (Tu-P7:142), 470 Friões, F., 101 (Mo-P4:250) Filip, C., 203 (Tu-P7:83) (Th-W51:7) Fritsche-Danielson, R., 236 (Tu-P7:236), 264 Filipe, C., 486 (Th-W59:5) Fort, J.M., 374 (We-P11:130) (Tu-P9:366), 314 (We-W34:6), 394 Filipiak, K., 282 (Tu-P10:443) Fortmann, S.P., 138 (Mo-P6:419) (We-P11:218) Filipovic, D., 193 (Tu-P7:42) Fortuño, A., 245 (Tu-P7:274) Frizzell, N., 226 (Tu-P7:186) Filippatos, T., 368 (We-P11:104), 499 Foschi, E., 399 (We-P11:243, We-P11:244) Frøbert, O., 208 (Tu-P7:106), 213 (Tu-P7:128), (Th-P15:33), 503 (Th-P15:49), 577 Fossati, C., 114 (Mo-P5:309) 448 (We-P14:462) (Th-P16:381), 582 (Th-P16:404) Foster, H., 95 (Mo-P3:224) Froese, S., 471 (Th-W52:5) Filippatos, T.D., 431 (We-P14:382), 553 Foster, K., 95 (Mo-P3:224) Froguel, P., 310 (We-W33:1) (Th-P16:271) Fotiadis, D., 265 (Tu-P9:370), 298 (Tu-P10:517) 504 Filippov, S., 228 (Tu-P7:196), 240 (Tu-P7:253) Fotino, C., 350 (We-P11:23), 386 (We-P11:184), Frohlich, J., (Th-P15:53) 299 Filova, E., 159 (Tu-W19:6), 250 (Tu-P8:298), 252 387 (We-P11:186), 528 (Th-P15:159) Frostegård, J., (Tu-P10:518) 29 (Tu-P8:308), 404 (We-P11:265) Fouchier, S.W., 138 (Mo-P6:421), 585 Frostegard, J., (Mo-W10:3) 7 Finch, J., 288 (Tu-P10:471) (Th-P17:418) Fruchart, J.-C., (Mo-PL1:2) 215 234 Fink, H.S., 318 (We-W36:7) Foudi, N., 355 (We-P11:44) Fruchart, J.C., (Tu-P7:140), (Tu-P7:228), 487 492 Finocchi, A., 298 (Tu-P10:514), 525 (Th-P15:147) Fougerat, A., 249 (Tu-P8:295) (Th-W60:3), (Th-P15:1) 542 Fioravanti, C., 558 (Th-P16:296) Fourchaud, L., 538 (Th-P15:206) Fu, Y., (Th-P15:222) 130 135 Fioravanti, M., 369 (We-P11:107) Fournier, N., 538 (Th-P15:206) Fuentes, F., (Mo-P6:386), (Mo-P6:408) 253 460 Fiore, C., 411 (We-P12:297) Foxwell, B., 288 (Tu-P10:471) Fuhrman, B., (Tu-P8:310), (Th-W46:5) 33 Fiore, M., 188 (Tu-P7:16) Foz, M., 46 (Mo-P1:2) Fuikuda, N., (Mo-W12:6) 177 Fiorentino, R., 259 (Tu-P9:338) Fraccarollo, D., 218 (Tu-P7:153), 313 Fujii, A., (Tu-W28:7) Fiorito, A., 68 (Mo-P1:102) (We-W34:5), 353 (We-P11:32) Fujii, M., 280 (Tu-P10:435) Fioritoni, F., 88 (Mo-P2:192) Fragidis, S., 81 (Mo-P1:162), 122 (Mo-P5:348) Fujimura, M., 101 (Mo-P4:252), 106 Fioritoni, G., 88 (Mo-P2:192) Frances, F., 47 (Mo-P1:9), 133 (Mo-P6:398), 333 (Mo-P4:271), 362 (We-P11:77), 569 Firmann, M., 363 (We-P11:81), 364 (We-P11:82) (We-W44:4) (Th-P16:344), 572 (Th-P16:359) Firth, J.C., 585 (Th-P16:415) Franceschi, C., 273 (Tu-P10:405) Fujino, A., 290 (Tu-P10:478) Fischer, J.W., 245 (Tu-P7:276), 247 (Tu-P7:283) Franceschini, G., 136 (Mo-P6:413), 152 Fujino, M., 571 (Th-P16:354) Fischer, S., 349 (We-P11:15) (Tu-W16:3), 166 (Tu-W23:3), 301 Fujioka, Y., 249 (Tu-P8:293), 369 (We-P11:109) Fischetti, F., 278 (Tu-P10:427) (We-PL3:2), 305 (We-W30:2) Fujita, M., 509 (Th-P15:76) Fiser, I., 12 (Mo-W1:4) Franci, B., 558 (Th-P16:295) Fujita, R., 510 (Th-P15:83) Fisher, R.M., 231 (Tu-P7:213) Franco, J., 538 (Th-P15:204) Fujita, T., 231 (Tu-P7:210) Fishman, I., 554 (Th-P16:279) Franco, M., 129 (Mo-P6:382) Fujiu, K., 164 (Tu-W22:3) Fitzgerald, D.J., 171 (Tu-W26:1) Francois, A., 220 (Tu-P7:161) Fujiura, Y., 520 (Th-P15:124) FitzGerald, G.A., 151 (Tu-ML5:1) Francolini, G., 217 (Tu-P7:148), 218 (Tu-P7:149) Fujiwara, Y., 454 (We-P14:485) Flammer, A.J., 90 (Mo-P2:200), 358 (We-P11:54) Frank, E., 527 (Th-P15:158) Fukae, H., 520 (Th-P15:124) Flegar-Mestric, Z., 282 (Tu-P10:446) Frants, R.R., 138 (Mo-P6:421), 506 (Th-P15:62), Fuki, I., 149 (Tu-PL2:2) Fleischer-Brielmaier, E., 141 (Mo-P6:432) 518 (Th-P15:117), 585 (Th-P17:418) Fuki, I.V., 540 (Th-P15:214)

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

230 Fukuda, A., 249 (Tu-P8:293), 369 (We-P11:109) Galli, C., 443 (We-P14:440), 472 (Th-W53:1) Gasque, P., 157 (Tu-W18:5) Fukuda, D., 448 (We-P14:460) Galli, G.V., 439 (We-P14:422), 481 (Th-W57:3) Gaston, A.-T., 195 (Tu-P7:50) Fukuda, N., 96 (Mo-P3:225), 185 (Tu-P7:2), 187 Galli, S., 308 (We-W31:6) Gaston, A.T., 278 (Tu-P10:426) (Tu-P7:12) Gallistl, S., 93 (Mo-P2:212) Gaudet, D., 131 (Mo-P6:391), 175 (Tu-W27:6), Fukuhara, Y., 235 (Tu-P7:231) Gälman, C., 39 (Mo-W15:7), 188 (Tu-P7:18) 306 (We-W30:5), 475 (Th-W54:4), 484 A Fuller, J., 37 (Mo-W14:4) Galuppo, P., 353 (We-P11:32) (Th-W58:6), 586 (Th-P17:420) Fülöp, P., 571 (Th-P16:355) Galvani, M., 471 (Th-W52:4) Gaudio, C., 266 (Tu-P9:374), 268 (Tu-P9:380) Furie, B., 28 (Mo-W10:1) Gálvez Moraleda, A., 366 (We-P11:95) Gaunt, M.E., 267 (Tu-P9:378) U Furie, B.C., 28 (Mo-W10:1) Galvez Moraleda, A., 60 (Mo-P1:68) Gaus, K., 167 (Tu-W23:6) Furkranz, A., 160 (Tu-W19:7) Galyavich, A.S., 67 (Mo-P1:96) Gautier, E., 190 (Tu-P7:24), 328 (We-W41:6) T Furman, C., 234 (Tu-P7:228), 492 (Th-P15:1), 526 Gamberger, D., 47 (Mo-P1:5) Gavarró, A., 69 (Mo-P1:107) (Th-P15:151) Gambert, P., 311 (We-W33:4), 535 (Th-P15:190) Gavish, D., 102 (Mo-P4:255), 115 (Mo-P5:314), H Fürnsinn, C., 38 (Mo-W15:4) Gambillara, V., 220 (Tu-P7:158) 554 (Th-P16:276) Furtado, A., 545 (Th-P15:237) Gamez, R., 565 (Th-P16:325) Gavrancic, C., 564 (Th-P16:324) O Furubayashi, K., 243 (Tu-P7:267) Gamliel-Lazarovich, A., 388 (We-P11:193) Gavrilova, Ye.A., 189 (Tu-P7:23) 469 494 Furuki, K., 60 (Mo-P1:65, Mo-P1:66, Mo-P1:67), Gan, L., (Th-W51:3), (Th-P15:10) Gavrisheva, N.A., 242 (Tu-P7:262) 163 236 R 76 (Mo-P1:139), 519 (Th-P15:120) Gan, L.-M., (Tu-W21:6), (Tu-P7:236), Gaw, A., 572 (Th-P16:356), 576 (Th-P16:376), 59 264 Furusyo, N., (Mo-P1:60) (Tu-P9:366) 584 (Th-P16:413) 255 559 207 314 Furuyama, S., (Tu-P8:319), (Th-P16:298) Gan, L.M., (Tu-P7:101), (We-W34:6) Gayral, S., 249 (Tu-P8:295), 252 (Tu-P8:307) 583 46 Fusegawa, Y., (Th-P16:407) Ganazzi, D., (Mo-P1:4) Gazes, P., 51 (Mo-P1:26) 397 524 Fuset, M.P., (We-P11:235) Ganci, A., (Th-P15:144) Gazi, I., 368 (We-P11:104), 369 (We-P11:105), I 140 67 84 Fust, G.Y., (Mo-P6:427) Gandarias, J.M., (Mo-P1:97), (Mo-P2:174) 499 (Th-P15:32, Th-P15:33), 501 (Th-P15:42), 77 52 Fytili-Kavakiotou, C.A., (Mo-P1:142) Gandelman, G., (Mo-P1:33) 503 (Th-P15:49), 553 (Th-P16:271) 567 N Ganji, S., (Th-P16:335) Gaziano, J.M., 17 (Mo-W4:1), 66 (Mo-P1:93) Gabbasov, Z., 207 (Tu-P7:103) 63 383 Ganotakis, E.S., (Mo-P1:78), Gazzara, R.A., 555 (Th-P16:280, Th-P16:281, Gabbi, C., 256 (Tu-P8:323), 257 (Tu-P8:328), 472 414 423 D (We-P11:168), (We-P12:307), Th-P16:282, Th-P16:283) (Th-W52:7) (We-P13:350) Gazzaruso, C., 141 (Mo-P6:434), 404 Gable, D., 312 (We-W33:6), 368 (We-P11:103) Ganotopoulou, A., 429 (We-P13:373) (We-P11:266) E Gabrielli, B., 171 (Tu-W25:5) Gao, F., 360 (We-P11:67), 368 (We-P11:101), 533 Gazzerro, P., 33 (Mo-W12:5) Gabrielsen, A., 248 (Tu-P7:289) (Th-P15:182) Ge, D., 144 (Mo-P6:446) X Gac, P., 220 (Tu-P7:160) Gao, R.L., 65 (Mo-P1:88) Geary, R., 549 (Th-P16:258), 552 (Th-P16:268) Gachechiladze, D., 97 (Mo-P4:234), 572 Gao, W.G., 154 (Tu-W17:1) Gecheva, S., 397 (We-P11:232) (Th-P16:357) Garcia, A., 105 (Mo-P4:270) Geis, S., 558 (Th-P16:297) Gachet, C., 28 (Mo-W10:2) Garcia, A.B., 130 (Mo-P6:384), 135 (Mo-P6:407), Geldnere, K., 263 (Tu-P9:358) Gaciong, Z., 289 (Tu-P10:477) 136 (Mo-P6:412) Gelissen, I., 541 (Th-P15:219) Gadau, S., 191 (Tu-P7:29) Garcia, J.A.D., 197 (Tu-P7:56) Gelonesi, N., 141 (Mo-P6:434) Gaddi, A., 420 (We-P13:334), 424 (We-P13:351), Garcia, M., 399 (We-P11:240) Gelosa, P., 463 (Th-W48:6) 564 (Th-P16:321) García-Barreno, P., 276 (Tu-P10:417) Gemelli, F., 102 (Mo-P4:257), 112 (Mo-P5:300), Gaddi, A.V., 50 (Mo-P1:22), 61 (Mo-P1:69), 68 García-Díaz, J.D., 105 (Mo-P4:268, Mo-P4:269) 469 (Th-W51:6) (Mo-P1:102), 366 (We-P11:93), 425 Garcia-Gonzalez, M.J., 122 (Mo-P5:349), 244 Genc, H., 206 (Tu-P7:96), 395 (We-P11:226), 417 (We-P13:358), 453 (We-P14:482), 532 (Tu-P7:270) (Th-P15:179) García-Iglesias, T., 378 (We-P11:148) (We-P13:323) 412 Gaddoni, M., 61 (Mo-P1:69), 420 (We-P13:334) García-Otín, A.L., 133 (Mo-P6:396), 262 Genco, R.J., (We-P12:301) 520 Gadyani, L., 118 (Mo-P5:328) (Tu-P9:354), 495 (Th-P15:16), 546 Generoso Jr, J.R., (Th-P15:123) 333 Gafencu, A., 228 (Tu-P7:195) (Th-P15:244) Genest, J., (We-W44:5) 419 Gaffney, J., 246 (Tu-P7:281) Garcia-Otin, A.L., 233 (Tu-P7:220), 406 Genovese, A., (We-P13:331) 85 207 Gagné, C., 136 (Mo-P6:409) (We-P11:275), 547 (Th-P15:247) Gensini, G.F., (Mo-P2:177), (Tu-P7:102), 325 391 396 Gainza, D., 65 (Mo-P1:89), 80 (Mo-P1:157), 125 García-Salas, M., 585 (Th-P17:419) (We-W40:3), (We-P11:205), 398 (Mo-P5:361) García-Suárez, F., 124 (Mo-P5:359) (We-P11:227, We-P11:230), 441 480 Gaion, R.M., 445 (We-P14:448) Garcia De Jalon, A., 511 (Th-P15:84), 567 (We-P11:239), (We-P14:431), 530 572 Gajdos, M., 118 (Mo-P5:329, Mo-P5:330) (Th-P16:334) (Th-W56:6), (Th-P15:169), 584 Gajin, P., 75 (Mo-P1:131) García García, A., 60 (Mo-P1:68), 366 (Th-P16:356), (Th-P16:413) Galán, E., 448 (We-P14:459) (We-P11:95) Gentil, J., 364 (We-P11:85) Galar, B., 270 (Tu-P10:391), 291 (Tu-P10:483) Gardete-Correia, L., 380 (We-P11:154) Gentile, M., 54 (Mo-P1:40), 56 (Mo-P1:46), 231 Galard, R., 374 (We-P11:130) Gargalovic, P., 518 (Th-P15:117) (Tu-P7:211), 282 (Tu-P10:445) Galasso, R., 31 (Mo-W11:5), 51 (Mo-P1:25), 54 Gargalovic, P.S., 219 (Tu-P7:156) Gentileschi, P., 165 (Tu-W22:6) (Mo-P1:40), 56 (Mo-P1:46) Garibaldi, S., 508 (Th-P15:73) Georgakopoulos, K.R., 395 (We-P11:225) Galderisi, C., 580 (Th-P16:393) Garlaschelli, K., 141 (Mo-P6:431) George, J., 463 (Th-W48:2) Galea, V., 64 (Mo-P1:82) Garlichs, C.D., 218 (Tu-P7:152) George, P.M., 99 (Mo-P4:242), 135 (Mo-P6:406), Galeas, T., 64 (Mo-P1:82) Garmy-Susini, B., 486 (Th-W59:5) 274 (Tu-P10:409) Galiana, J., 129 (Mo-P6:382) Garofano, T., 330 (We-W43:2) George, S., 244 (Tu-P7:273) Galiotto, M., 75 (Mo-P1:133) Garrett, B., 476 (Th-W54:7), 567 (Th-P16:337) George, S.J., 248 (Tu-P7:288) Galitsina, N.A., 108 (Mo-P4:281), 209 Garrido, D., 62 (Mo-P1:75), 376 (We-P11:137) Georgiev, M., 126 (Mo-P5:367), 287 (Tu-P7:111), 289 (Tu-P10:474) Garzaniti, A., 404 (We-P11:266) (Tu-P10:468), 361 (We-P11:68, We-P11:70), Galjak, M., 352 (We-P11:31) Gasior, Z., 263 (Tu-P9:361) 362 (We-P11:74, We-P11:75), 378 Gallagher, P.J., 160 (Tu-W20:3) Gasol, A., 62 (Mo-P1:74), 79 (Mo-P1:152) (We-P11:149) Gallego, A., 585 (Th-P17:419) Gasparetto, C., 244 (Tu-P7:272) Georgiou, N., 145 (Mo-P6:452) Gallego, R., 447 (We-P14:454) Gasparovic, J., 446 (We-P14:452) Georgoula, M., 553 (Th-P16:271)

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

231 Gerasimova, B., 297 (Tu-P10:512) Gimpelewicz, C., 123 (Mo-P5:352) Gojkovic-Bukarica, L.J., 211 (Tu-P7:119) Gerdes, N., 168 (Tu-W24:4), 327 (We-W41:5) Gimpelewicz, C.R., 251 (Tu-P8:300) Gojkovic Bukarica, L.J., 198 (Tu-P7:63), 206 Gerdsen, R., 562 (Th-P16:312) Ginghina, C., 93 (Mo-P2:214) (Tu-P7:98) Gerli, R., 277 (Tu-P10:423) Ginsberg, H.N., 15 (Mo-W3:3) Gok, M., 206 (Tu-P7:96), 395 (We-P11:226), 417 A Germani, M.A., 369 (We-P11:107) Ginzinger, D., 171 (Tu-W25:5) (We-P13:323) Geroldi, D., 404 (We-P11:266) Giordano Sciacca, P., 381 (We-P11:159) Goke, B., 141 (Mo-P6:432) Gerritsen, H., 26 (Mo-W9:1) Giovannini, C., 186 (Tu-P7:7) Golalipoor, M.J., 209 (Tu-P7:113), 247 U Gerrity, R.G., 354 (We-P11:40) Giovannini, M., 275 (Tu-P10:411), 441 (Tu-P7:286) Gerry, A.B., 256 (Tu-P8:327), 523 (Th-P15:138) (We-P14:430), 564 (Th-P16:321) Gold, A., 161 (Tu-W20:6) T Gers, E., 253 (Tu-P8:313), 465 (Th-W49:4) Giovannitti, M.G., 369 (We-P11:108) Goldberg, A.C., 3 (Su-S2:3) Gesteiro, E., 365 (We-P11:88), 531 (Th-P15:173) Giral, P., 467 (Th-W50:5) Goldberg, J., 324 (We-W39:5) H Ghaderi, M., 280 (Tu-P10:434) Girard, P.M., 163 (Tu-W21:4) Goldin, M., 308 (We-W31:3) Ghalim, N., 518 (Th-P15:114, Th-P15:116) Giribaldi, M.G., 229 (Tu-P7:202), 591 Goldschmid, D., 117 (Mo-P5:324) O Ghanbari, H., 419 (We-P13:330) (Th-P17:444) Golikova, I., 211 (Tu-P7:122), 282 (Tu-P10:444) Ghannadi, A., 438 (We-P14:416) Giribela, A.H., 501 (Th-P15:41) Goliszek, L., 263 (Tu-P9:361) 280 117 Gharizadeh, B., (Tu-P10:434) Girolami, M., (Mo-P5:324) Gomaraschi, M., 152 (Tu-W16:3) R 240 360 139 188 414 Ghelﬁ, M., (Tu-P7:255), (We-P11:65) Girona, J., (Mo-P6:425), (Tu-P7:15), Gomes, A.M., 500 (Th-P15:35) 188 443 452 Ghenev, P.I., (Tu-P7:16) (We-P12:310), (We-P14:439), Gomes, A.R., 520 (Th-P15:123) 203 522 Gheorghita, N., (Tu-P7:83) (We-P14:476), (Th-P15:133) Gomes, W.J., 263 (Tu-P9:360) 508 205 Ghigliotti, G., (Th-P15:73) Gittenberger-De Groot, A.C., (Tu-P7:94) Gómez, L., 504 (Th-P15:54) 74 277 349 I Ghilarduzzi, A., (Mo-P1:127) Giubilato, S., (Tu-P10:422), (We-P11:16) Gómez, P., 123 (Mo-P5:353) 277 349 328 Ghirlanda, G., (Tu-P10:422), Giugliano, D., (We-W42:1) Gomez, P., 447 (We-P14:457) 63 163 399 (We-P11:16) Giuliano, I., (Mo-P1:79), (Tu-W21:3), Gomez, R., 91 (Mo-P2:203) N 133 400 Ghisoni, F., (Mo-P6:396) (We-P11:241), (We-P11:245) Gomez, R.M., 231 (Tu-P7:212) 127 414 Gholizade, L., (Mo-P5:372) Giuliano, T., (We-P12:309) Gómez, S.L., 229 (Tu-P7:201), 586 (Th-P17:423) D 203 296 65 Ghorbanihaghjo, A., (Tu-P7:86), Giunta, G., (Mo-P1:90) Gomez-Enterria, P., 130 (Mo-P6:385) 525 532 556 (Tu-P10:506), (Th-P15:148), Giunti, S., (Th-P16:286, Th-P16:287) Gomez-Guerrero, C., 228 (Tu-P7:197) (Th-P15:177) Giusti, B., 207 (Tu-P7:102), 480 (Th-W56:6) E GomezDeLaCamara,A.,58 (Mo-P1:59) Giacco, R., 165 (Tu-W22:4) Giusti, C., 76 (Mo-P1:138) Gómez Luna, M.J., 439 (We-P14:418) Giachelli, C.M., 323 (We-W39:4) Giusti, P., 47 (Mo-P1:8), 66 (Mo-P1:91), 121 X Gómez Luna, P., 439 (We-P14:418), 448 Giachino, P., 288 (Tu-P10:472) (Mo-P5:345) (We-P14:459) Giacomelli, C., 414 (We-P12:309) Gizlis, B., 348 (We-P11:10) Gómez Martínez, P., 60 (Mo-P1:68) Giaid, A., 489 (Th-W61:1) Gkogkos, K., 81 (Mo-P1:162), 122 (Mo-P5:348) Gomulka, S., 263 (Tu-P9:361) Gialafos, E., 204 (Tu-P7:90), 210 (Tu-P7:118), Glaesmer, H., 53 (Mo-P1:35) Gonen, A., 169 (Tu-W24:7) 395 (We-P11:225) Glandorff, C., 247 (Tu-P7:283) Gong, Y.J., 97 (Mo-P3:231) Giampietro, O., 76 (Mo-P1:138), 430 Glaser, N., 359 (We-P11:61) Gonnelli, S., 409 (We-P12:285), 558 (Th-P16:295) (We-P14:379), 446 (We-P14:453) Glavce, C., 69 (Mo-P1:106) Gonzalez, J.I., 133 (Mo-P6:398) Gianazza, E., 154 (Tu-W16:8) Glibetic, M., 430 (We-P14:378), 449 González, R.M., 363 (We-P11:80) Gianella, A., 463 (Th-W48:6) (We-P14:464) Gonzalez, V., 130 (Mo-P6:384), 135 (Mo-P6:407), Giannakopoulou, V.N., 505 (Th-P15:60), 510 Gliemann, J., 514 (Th-P15:96) 136 (Mo-P6:412), 389 (We-P11:197) (Th-P15:81) Glineur, C., 487 (Th-W60:3) 132 Giannessi, D., 310 (We-W32:6) Glorian, M., 168 (Tu-W24:5) González-Alegre, M.T., (Mo-P6:395) 347 375 Gianni, M., 422 (We-P13:343) Glorioso, N., 35 (Mo-W13:4) Gonzalez-Alegre, M.T., (We-P11:5), Giannico, I.M., 46 (Mo-P1:4) Glowinska, B., 211 (Tu-P7:121), 377 (We-P11:132) 537 Giannini, L., 391 (We-P11:205) (We-P11:141) González-Díez, M., (Th-P15:201) 378 Giannini, S., 115 (Mo-P5:316) Gmeiner, B., 525 (Th-P15:149) González-Hita, M., (We-P11:148) 378 Giannoulis, G.R., 572 (Th-P16:358) Gnass, M., 391 (We-P11:204), 560 (Th-P16:302) Gonzalez-Hita, M., (We-P11:145) 132 Giardina, E., 425 (We-P13:355) Gnasso, A., 146 (Mo-P6:453), 147 (Mo-P6:457), González-Santos, P., (Mo-P6:395) 347 375 Giardinelli, A., 14 (Mo-W2:5), 216 (Tu-P7:144), 259 (Tu-P9:338), 268 (Tu-P9:382), 353 Gonzalez-Santos, P., (We-P11:5), 352 (We-P11:29) (We-P11:33), 374 (We-P11:131), 423 (We-P11:132) 60 366 Gidlund, M., 229 (Tu-P7:201), 400 (We-P11:246), (We-P13:346) González Quintela, A., (Mo-P1:68), 521 (Th-P15:131), 586 (Th-P17:423) Go, A.S., 138 (Mo-P6:419) (We-P11:95) Gijbels, M.J.J., 225 (Tu-P7:181) Go, Y., 348 (We-P11:14) Gonzalo-Marin, M., 137 (Mo-P6:417) Gika, H., 574 (Th-P16:368) Goda, A., 64 (Mo-P1:85), 272 (Tu-P10:399), 274 Goppelt-Struebe, M., 218 (Tu-P7:152) Gil, B., 46 (Mo-P1:2) (Tu-P10:407, Tu-P10:408), 283 (Tu-P10:448) Goracy, I., 275 (Tu-P10:414), 370 (We-P11:110), Gil-Extremera, B., 174 (Tu-W27:3) Godala, M., 62 (Mo-P1:77), 425 (We-P13:356) 387 (We-P11:187) Gilabert, R., 261 (Tu-P9:349, Tu-P9:350) Godàs, G., 443 (We-P14:439) Goracy, J., 84 (Mo-P2:175), 569 (Th-P16:343) Gilardi, F., 168 (Tu-W24:3), 257 (Tu-P8:330) Godfrey, D., 327 (We-W41:4) Goralska, J., 295 (Tu-P10:501) Gilbert, D., 219 (Tu-P7:155) Godio, C., 253 (Tu-P8:313), 372 (We-P11:119), Gorchakova, T.V., 230 (Tu-P7:209) Gilbert, G., 51 (Mo-P1:26) 465 (Th-W49:4) Gordillo-Moscoso, A., 249 (Tu-P8:292), 371 Gilio, D., 167 (Tu-W23:7), 453 (We-P14:483), Godoy, E., 47 (Mo-P1:9) (We-P11:118) 477 (Th-W55:3), 570 (Th-P16:347) Goebel, F.D., 400 (We-P11:248) Gordon, P., 501 (Th-P15:40) Gill, J.A.S., 424 (We-P13:353) Goessens, B.M.B., 357 (We-P11:51) Gordon, S., 514 (Th-P15:97) Gill, J.M.R., 504 (Th-P15:55) Goetz, B., 228 (Tu-P7:196) Gordts, P., 515 (Th-P15:102) Gill, K.S., 350 (We-P11:19) Gogoladze, K., 385 (We-P11:180) Gorgone, G., 141 (Mo-P6:434) Gillard, J.H., 267 (Tu-P9:378) Goh, Y., 512 (Th-P15:89) Gori, A.M., 85 (Mo-P2:177), 325 (We-W40:3), Gilman, S., 213 (Tu-P7:130) Goi, G., 209 (Tu-P7:112) 391 (We-P11:205), 398 (We-P11:239), 441 Gimenez, F., 133 (Mo-P6:398) Gois, J.M., 280 (Tu-P10:437) (We-P14:431), 480 (Th-W56:6)

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

232 Gorovoy, M., 487 (Th-W60:1) Gronholdt, M.L., 18 (Mo-W4:6) Gurtskaia, Z., 97 (Mo-P3:233) Gorter, P.M., 335 (We-W45:4) Grönroos, P., 68 (Mo-P1:101) Gusev, D., 287 (Tu-P10:466) Gostiljac, D., 127 (Mo-P5:373), 358 (We-P11:57), Grönros, J., 314 (We-W34:6) Gutteck, U., 582 (Th-P16:403) 379 (We-P11:150), 421 (We-P13:341) Gronros, J., 207 (Tu-P7:101) Guy, E., 490 (Th-W61:7) Goto, H., 400 (We-P11:246) Groothoff, J.W., 260 (Tu-P9:342) Guyton, J.R., 1 (Su-S1:2) A Gotsis, A., 353 (We-P11:36) Grosse, J., 320 (We-W37:7) Gottardi, G., 589 (Th-P17:433) Grossi, S.G., 412 (We-P12:301) Gotto Jr, A., 7 (Mo-PL1:1) Grosskopf, I., 38 (Mo-W15:1) Habti, N., 77 (Mo-P1:143) U Gotto Jr., A.M., 331 (We-W43:3) Grossman, E., 169 (Tu-W24:7) Haddeman, E., 444 (We-P14:444) Goudevenos, J., 577 (Th-P16:381) Grosso, D.M., 197 (Tu-P7:58) Haemmerle, G., 15 (Mo-W3:1) T Goudriaan, N., 235 (Tu-P7:229) Groux-Degroote, S., 26 (Mo-W9:1) Haffner, D., 218 (Tu-P7:150) Goumas, G.S., 52 (Mo-P1:30) Groyer, E., 195 (Tu-P7:50), 278 (Tu-P10:426) Haffner, I., 200 (Tu-P7:71), 226 (Tu-P7:189) H Gounari, E., 77 (Mo-P1:142) Gruber, H.-J., 570 (Th-P16:349) Haﬁdi, A., 123 (Mo-P5:355) Gouni-Berthold, I., 565 (Th-P16:328) Gruchala, M., 129 (Mo-P6:380) Hagen, T., 472 (Th-W52:6) O Gourdy, P., 486 (Th-W59:5) Grudzinska, M., 289 (Tu-P10:477) Hagerty, B., 38 (Mo-W15:4) Gouridou, E., 361 (We-P11:69) Grundt, H., 449 (We-P14:463) Hagg, D., 22 (Mo-W6:6) Goutkidou, S., 128 (Mo-P5:377) Grundy, S.M., 79 (Mo-P1:149), 121 (Mo-P5:344), Hägg, D.A., 234 (Tu-P7:225) R Goyal, P., 222 (Tu-P7:170), 392 (We-P11:210), 340 (We-S14:2), 466 (Th-W50:2) Hägg, S., 357 (We-P11:50) 546 (Th-P15:245) Gryglas, P., 276 (Tu-P10:416) Hägg, U., 163 (Tu-W21:6), 264 (Tu-P9:366) Gozdecka, H., 560 (Th-P16:302) Grzybowska, J., 192 (Tu-P7:34) Hagg, U., 207 (Tu-P7:101) Graessler, J., 522 (Th-P15:132) Gschwend, J., 30 (Mo-W10:7) Hagiwara, N., 486 (Th-W59:4) I Graf, S., 65 (Mo-P1:90) Guagnano, M.T., 363 (We-P11:78), 380 Hagstrup Christensen, J., 181 (Tu-S9:3) Graff, J., 121 (Mo-P5:344) (We-P11:156), 469 (Th-W51:4) Hague, W., 330 (We-W42:7) N Graham, I., 95 (Mo-P3:224) Guardamagna, O., 147 (Mo-P6:457), 288 Hagymási, K., 105 (Mo-P4:267) Graham, M.J., 466 (Th-W49:5), 532 (Th-P15:180) (Tu-P10:472) Hahalis, G., 109 (Mo-P4:285) Gram, J., 159 (Tu-W19:4) Guardiola, M., 139 (Mo-P6:425), 400 Hahn, J.Y., 573 (Th-P16:361) D Granata, A., 250 (Tu-P8:299), 566 (Th-P16:332) (We-P11:247), 513 (Th-P15:95) Haidari, M., 309 (We-W32:4) Grandi, A.M., 422 (We-P13:343) Guasti, L., 549 (Th-P16:257) Hajek, T., 111 (Mo-P4:295) E 26 204 Grandl, M., (Mo-W9:2) Gudel, J.G., (Tu-P7:89) Hajer, G.R., 479 (Th-W56:3), 569 (Th-P16:342) 51 160 Grandy, S., (Mo-P1:29) Gudmundsen, O., (Tu-W20:3) Hajjar, D.P., 331 (We-W43:3) X 99 407 Gratsiansky, N.A., (Mo-P4:243) Gudmundsson, G.H., (We-P11:277) Hakala, J.K., 232 (Tu-P7:216), 244 (Tu-P7:269) 419 468 Grattagliano, I., (We-P13:331) Gudnason, V., (Th-W50:7) Hakem, D., 102 (Mo-P4:256), 387 (We-P11:189) 267 133 Graves, M.J., (Tu-P9:378) Gueli, M.C., (Mo-P6:400) Halil, M., 264 (Tu-P9:365) 240 360 12 321 Gravina, A., (Tu-P7:254), (We-P11:65) Guerin, M., (Mo-W1:5), (We-W38:3) Halka, A., 106 (Mo-P4:272) 320 154 Gray, S.L., (We-W37:7) Guerini Rocco, A., (Tu-W16:8) Hallberg, C., 15 (Mo-W3:2) 381 108 401 Graziani, F., (We-P11:159) Guerra, G., (Mo-P4:284), (We-P11:253) Hallén, K., 357 (We-P11:50) 98 143 589 Grebowska, A., (Mo-P4:235), (Mo-P6:443) Guerranti, R., (Th-P17:435) Halpern, A.R., 256 (Tu-P8:324) Green, F., 289 (Tu-P10:475) Guetta, J., 230 (Tu-P7:207) Halter, D., 26 (Mo-W9:1) Gregan, S., 92 (Mo-P2:211), 288 (Tu-P10:471) Guglielmi, M., 29 (Mo-W10:4) Hamaguchi, M., 564 (Th-P16:323) Gregg, R.E., 564 (Th-P16:322) Guglielmi, V., 165 (Tu-W22:6) Hamasaki, Y., 233 (Tu-P7:223) Greisler, H.P., 241 (Tu-P7:258) Gugliemini, G., 583 (Th-P16:408) Hambly, B.D., 250 (Tu-P8:297) Grembiale, R.D., 206 (Tu-P7:100), 313 Guidoin, R., 402 (We-P11:258), 403 Hamed, M., 523 (Th-P15:138) (We-W34:4) (We-P11:260, We-P11:261) Hamidi Alamdari, D., 295 (Tu-P10:500) Gremy, G., 190 (Tu-P7:24) Guiffre, A., 96 (Mo-P3:229) Hamilton-Craig, I., 330 (We-W42:7) Grenegård, M., 91 (Mo-P2:206), 173 (Tu-W26:6), Guiffre, A.K., 34 (Mo-W12:7) Hamlat, N., 194 (Tu-P7:45) 287 (Tu-P10:467), 413 (We-P12:305) Guillaume, M., 119 (Mo-P5:336) Hamlin, C., 174 (Tu-W27:3) Gresele, P., 583 (Th-P16:408) Guillen, M., 133 (Mo-P6:398) Hammami, M., 69 (Mo-P1:105), 131 Grewal, J., 107 (Mo-P4:279) Güimil-Carbajal, D., 124 (Mo-P5:359) 349 438 Grga, A., 282 (Tu-P10:446) Guimon-Bardesi, A., 553 (Th-P16:275) (Mo-P6:388), (We-P11:18), Griffen, S., 359 (We-P11:61) Guisasola-Zulueta, M.C., 276 (Tu-P10:417) (We-P14:415) 69 131 Grifﬁn, M., 145 (Mo-P6:452) Guize, L., 553 (Th-P16:272) Hammami, S., (Mo-P1:105), (Mo-P6:388), 349 Grigorashvili, G., 454 (We-P14:487) Gulmez, O., 74 (Mo-P1:129), 100 (Mo-P4:246), (We-P11:18) 203 Grigore, L., 141 (Mo-P6:431), 475 (Th-W54:3) 112 (Mo-P5:301), 164 (Tu-W21:7) Hammarström, S., (Tu-P7:85) 500 Grimaldi, C., 33 (Mo-W12:5) Gun, C., 412 (We-P12:300) Hammel, M., (Th-P15:36) 574 Grimaldi, M., 400 (We-P11:245) Gundry, S.R., 440 (We-P14:423), 530 Hamodraka, E., (Th-P16:368) 145 149 Grimble, R.F., 160 (Tu-W20:3) (Th-P15:168) Hamsten, A., (Mo-P6:449), (Tu-PL2:3), Gripois, D., 433 (We-P14:393), 443 Gunnarsson, P., 91 (Mo-P2:206), 171 (Tu-W25:7), 200 (Tu-P7:72), 231 (Tu-P7:213), 315 (We-P14:436), 589 (Th-P17:433) 287 (Tu-P10:467) (We-W35:2), 316 (We-W35:6), 357 Grizenkova, J., 315 (We-W35:3) Guo, D.P., 94 (Mo-P3:220) (We-P11:50), 492 (Th-P15:2), 505 Grobbe, D.E., 290 (Tu-P10:480) Guo, F., 223 (Tu-P7:175), 224 (Tu-P7:177), 293 (Th-P15:56) Grobbee, D.E., 79 (Mo-P1:153), 291 (Tu-P10:482) (Tu-P10:490), 521 (Th-P15:129) Han, C.Y., 13 (Mo-W2:1), 227 (Tu-P7:191) Groen, A., 495 (Th-P15:15) Guo, L., 27 (Mo-W9:5) Han, J., 331 (We-W43:3) Groen, A.K., 31 (Mo-W11:6), 319 (We-W37:5), Gupta, H., 310 (We-W32:7) Hancu, N., 155 (Tu-W17:6), 402 (We-P11:256) 335 (We-W45:6), 544 (Th-P15:235) Gupta, M., 161 (Tu-W20:6) Hane, K., 240 (Tu-P7:252) Groene, H.-J., 407 (We-P11:276) Gupta, S.K., 70 (Mo-P1:110) Hanefeld, M., 581 (Th-P16:397) Gromadzka, G., 282 (Tu-P10:443) Gurakuqi, G.C., 583 (Th-P16:409) Hanisova, I., 111 (Mo-P4:295) Grombirikova, H., 132 (Mo-P6:392) Guralnik, J.M., 530 (Th-P15:171) Hansel, B., 467 (Th-W50:5) Gromov, A.A., 294 (Tu-P10:497) Gursoy, Y.C., 74 (Mo-P1:130), 284 (Tu-P10:455) Hanselaar, W., 265 (Tu-P9:367)

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

233 Hansen, J.B., 497 (Th-P15:25), 506 (Th-P15:63), Hattori, H., 38 (Mo-W15:3), 506 (Th-P15:62), 538 Heller, R., 325 (We-W40:4) 511 (Th-P15:87) (Th-P15:207) Helliwell, T., 81 (Mo-P1:159) Hansen, L., 459 (Th-W46:1) Hatzigeorgiou, G.C., 505 (Th-P15:60), 510 Hellsten, A., 158 (Tu-W18:7) Hansen, U., 144 (Mo-P6:447) (Th-P15:81) Helou, J., 420 (We-P13:333) A Hansson, E., 237 (Tu-P7:240) Hatzikallinikidou, E., 77 (Mo-P1:142) Helske, S., 100 (Mo-P4:245), 110 (Mo-P4:292), Hansson, G.K., 167 (Tu-W24:1), 237 (Tu-P7:240), Hatzitolios, A., 108 (Mo-P4:282), 272 157 (Tu-W18:5), 242 (Tu-P7:264) 242 (Tu-P7:262), 248 (Tu-P7:289), 327 (Tu-P10:401) Hendrix, S., 485 (Th-W59:1) U (We-W41:5), 406 (We-P11:272), 407 Hauer, A., 90 (Mo-P2:198) Henneman, P., 506 (Th-P15:62) (We-P11:276, We-P11:277), 460 (Th-W46:4) Hauer, A.D., 33 (Mo-W12:4) Hennig, B., 444 (We-P14:443) T Hanyu, O., 361 (We-P11:72), 575 (Th-P16:373) Hauner, H., 164 (Tu-W22:2) Henriksen, T., 126 (Mo-P5:364) Hao, H., 246 (Tu-P7:279) Havekes, L., 318 (We-W37:1) Henriquez, R.R., 587 (Th-P17:428) H Hao, X.R., 254 (Tu-P8:317), 492 (Th-P15:3), 543 Havekes, L.M., 32 (Mo-W11:7), 37 (Mo-W14:5), Henttonen, A.T., 251 (Tu-P8:302) (Th-P15:227, Th-P15:229) 205 (Tu-P7:94), 227 (Tu-P7:194), 331 Heras, M., 139 (Mo-P6:425) O Harada, L.M., 520 (Th-P15:123) (We-W43:6), 489 (Th-W61:5), 506 Herbertsson, H., 203 (Tu-P7:85) Harada-Shiba, M., 319 (We-W37:3), 505 (Th-P15:62), 518 (Th-P15:117), 551 Hergenc, G., 55 (Mo-P1:43), 371 (We-P11:114) 560 (Th-P15:58), 564 (Th-P16:320) (Th-P16:263), (Th-P16:306) Herget, J., 243 (Tu-P7:265) R 562 Haraguchi, K., 73 (Mo-P1:122), 377 Havel, E., (Th-P16:314) Herman, Z.S., 559 (Th-P16:299), 573 491 (We-P11:144) Havel, R.J., (Th-S17:2) (Th-P16:363) 226 227 Haram, P.M., 100 (Mo-P4:244), 202 (Tu-P7:77), Håversen, L., (Tu-P7:188), (Tu-P7:190) Hermann, B., 18 (Mo-W4:5) 255 450 428 (We-P13:369) Havinga, R., (Tu-P8:318), (We-P14:471) Hermann, F., 222 (Tu-P7:169), 358 (We-P11:54) 48 55 56 I Harangi, M., 292 (Tu-P10:489), 296 (Tu-P10:504) Hayakawa, T., (Mo-P1:14), (Mo-P1:45), Hermann, M., 222 (Tu-P7:169), 525 (Th-P15:149) 59 76 Harari, A., 169 (Tu-W24:7) (Mo-P1:48), (Mo-P1:63), (Mo-P1:137), Hermansson, A., 237 (Tu-P7:240) 348 Harats, D., 38 (Mo-W15:1), 44 (Mo-S7:4), 169 (We-P11:12) Hermens, W.T., 19 (Mo-W5:2) N 520 (Tu-W24:7), 554 (Th-P16:276) Hayashi, E., (Th-P15:124) Hernandez, A., 138 (Mo-P6:418) 58 59 574 D Hare, D., 217 (Tu-P7:146) Hayashi, J., (Mo-P1:57), (Mo-P1:60), Hernandez, J., 367 (We-P11:99) Harilogis, K., 322 (We-W38:6) (Th-P16:369) Hernandez, R., 268 (Tu-P9:381) 85 460 Harnish, D.C., 256 (Tu-P8:326), 257 (Tu-P8:329) Hayashida, K., (Mo-P2:179), (Th-W46:7) Hernandez-Nazara, A., 378 (We-P11:145) Hayden, M., 25 (Mo-W8:4) E Harris, A.K., 250 (Tu-P8:297) Hernandez-Ono, A., 15 (Mo-W3:3) Hayden, M.R., 19 (Mo-W5:2), 166 (Tu-W23:4), Harris, H., 587 (Th-P17:425) Hernandez-Vargas, P., 228 (Tu-P7:197) 319 (We-W37:4), 542 (Th-P15:223) X Harris, M., 541 (Th-P15:219) Hernberg, Å., 264 (Tu-P9:363) Hayek, T., 205 (Tu-P7:93), 529 (Th-P15:163) Harris, T., 317 (We-W36:5) Herrera-Gonzalez, A., 51 (Mo-P1:28), 545 Haykal, W.J., 126 (Mo-P5:366) Harris, W.S., 449 (We-P14:463), 472 (Th-W53:2) (Th-P15:238) Hazen, S.L., 24 (Mo-W7:5) Harris-Hooker, S., 208 (Tu-P7:107) Herrington, D., 89 (Mo-P2:196) Hazirolan, T., 269 (Tu-P9:385) Hartman, D., 309 (We-W32:3), 364 (We-P11:84) Herrmann, J., 535 (Th-P15:192) He, G., 87 (Mo-P2:185) Hartmann, M., 42 (Mo-S6:3) Herz, J., 331 (We-W43:6) He, H., 224 (Tu-P7:177), 521 (Th-P15:129) Hartvigsen, K., 459 (Th-W46:1) Hess, Z., 363 (We-P11:79) He, W., 331 (We-W43:3) Hartwich, J., 295 (Tu-P10:501) Heta, N., 283 (Tu-P10:448) Headlam, H.A., 546 (Th-P15:241) Harvey, E.J., 237 (Tu-P7:238) Heta Alliu, N., 272 (Tu-P10:399), 274 Heather, A.K., 221 (Tu-P7:164), 232 (Tu-P7:218) Hasagawa, M., 430 (We-P14:377) (Tu-P10:407, Tu-P10:408) Heayn, M., 256 (Tu-P8:326) Hase, T., 511 (Th-P15:85) Heusch, G., 535 (Th-P15:192) Hebrang, A., 282 (Tu-P10:446) 239 241 582 Hasegawa, M., (Tu-P7:247), (Tu-P7:257), Hedin, U., 248 (Tu-P7:289), 406 (We-P11:272), Heverin, M., (Th-P16:403) 433 434 124 (We-P14:394), (We-P14:395, 489 (Th-W61:4) Hezemans, R., (Mo-P5:357) 435 436 55 64 We-P14:396), (We-P14:402), Hedman, M., 576 (Th-P16:378) Higashiyama, A., (Mo-P1:45), (Mo-P1:83) 509 510 562 (We-P14:407), (Th-P15:78), Hedrick, C.C., 335 (We-W45:5) Higuchi, M., (Th-P16:311) 280 291 (Th-P15:80) Heemskerk, J., 390 (We-P11:202) Higuchi, M.L., (Tu-P10:437), 394 575 406 Hashimoto, A., (We-P11:219), Heemskerk, J.W.M., 325 (We-W40:4), 390 (Tu-P10:484), (We-P11:274) 243 (Th-P16:373) (We-P11:203) Higuchi, T., (Tu-P7:268) 377 385 280 Hashimoto, H., (We-P11:140), Heeneman, S., 390 (We-P11:202) Higuchi-Dos-Santos, M.H., (Tu-P10:437) 586 (We-P11:178) Heeren, J., 30 (Mo-W11:1), 38 (Mo-W15:2), 185 Hihi, A., (Th-P17:421) 210 254 116 273 Hashimoto, K., (Tu-P7:115), (Tu-P8:314), (Tu-P7:4), 446 (We-P14:451), 493 (Th-P15:6), Hijano, S., (Mo-P5:322), (Tu-P10:403), 294 354 364 (Tu-P10:499), (We-P11:37) 508 (Th-P15:70), 520 (Th-P15:125) (We-P11:85) Hashimoto, M., 104 (Mo-P4:264), 133 Hegazy, A.M., 387 (We-P11:188) Hildebrand, R.B., 152 (Tu-W16:2), 319 (Mo-P6:397), 405 (We-P11:269), 444 Hegele, R.A., 308 (We-W31:4) (We-W37:5), 320 (We-W37:6) (We-P14:441) Hegyi, L., 587 (Th-P17:426) Hilden, H., 359 (We-P11:62) Hashizume, S., 101 (Mo-P4:252), 106 Heidland, A., 573 (Th-P16:362) Hill, M., 538 (Th-P15:205) (Mo-P4:271), 362 (We-P11:77), 569 Heikkilä, H.M., 244 (Tu-P7:269) Hingorani, A., 483 (Th-W58:1) (Th-P16:344), 572 (Th-P16:359) Heine, R.J., 23 (Mo-W7:4), 502 (Th-P15:44), 525 Hino, A., 60 (Mo-P1:65, Mo-P1:66, Mo-P1:67), Haskard, D., 288 (Tu-P10:471) (Th-P15:145) 76 (Mo-P1:139), 519 (Th-P15:120) Haskard, D.O., 157 (Tu-W18:4) Heinecke, J., 227 (Tu-P7:191) Hirai, Y., 60 (Mo-P1:65, Mo-P1:66, Mo-P1:67), Hassunizadeh, B., 419 (We-P13:330) Heinecke, J.W., 13 (Mo-W2:1) 76 (Mo-P1:139), 519 (Th-P15:120) Hata, Y., 417 (We-P13:322) Heinle, H., 198 (Tu-P7:63), 211 (Tu-P7:119) Hiramatsu, S., 427 (We-P13:366) Hatakeyama, K., 93 (Mo-P2:215), 246 Hekimi, S., 586 (Th-P17:421) Hirano, K., 28 (Mo-W9:6), 237 (Tu-P7:237), 510 (Tu-P7:279) Helbig, F., 214 (Tu-P7:135) (Th-P15:82), 511 (Th-P15:86), 575 Hatano, B., 33 (Mo-W12:6) Held, C., 308 (We-W31:5) (Th-P16:372) Hatch, N., 489 (Th-W61:3) Helfenstein, T., 263 (Tu-P9:360), 348 Hiraoka, A., 367 (We-P11:100) Hatori, K., 193 (Tu-P7:41) (We-P11:13), 349 (We-P11:15) Hiraoka, E., 133 (Mo-P6:397) Hatseras, D.I., 87 (Mo-P2:184), 533 (Th-P15:184) Hellenius, M.L., 231 (Tu-P7:213) Hirata, K., 133 (Mo-P6:397), 498 (Th-P15:27)

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

234 Hirata, Y., 187 (Tu-P7:13), 362 (We-P11:76), 587 Horke, S., 295 (Tu-P10:502) Hübner, K., 547 (Th-P15:248) (Th-P17:424) Hörkkö, S., 459 (Th-W46:1) Huby, T., 190 (Tu-P7:24), 328 (We-W41:6), 476 Hiratsuka, A., 519 (Th-P15:120) Horký, K., 385 (We-P11:179) (Th-W54:6) Hiratuka, T., 520 (Th-P15:124) Horncastle, D., 157 (Tu-W18:4) Huczek, Z., 358 (We-P11:56) Hirawa, N., 575 (Th-P16:370) Hornick, P., 288 (Tu-P10:471) Hudecová, Z., 188 (Tu-P7:17) A Hirono, A., 49 (Mo-P1:17) Hornos, A., 375 (We-P11:132) Hudecova, Z., 292 (Tu-P10:488) Hirose, Y., 394 (We-P11:219) Horská, A., 188 (Tu-P7:17) Hudson, T.J., 131 (Mo-P6:391) Hirota, A., 376 (We-P11:138) Horska, A., 446 (We-P14:452) Hueb, W., 347 (We-P11:8) U Hirowatari, Y., 428 (We-P13:370) Horstman, L.L., 291 (Tu-P10:485), 292 Huertas, A., 138 (Mo-P6:418) Hitman, G., 37 (Mo-W14:4) (Tu-P10:486) Huertas-Vazquez, A., 397 (We-P11:234) T Hiukka, A., 359 (We-P11:62), 500 (Th-P15:37) Horswell, S.D., 21 (Mo-W6:3) Huesca-Gomez, C., 534 (Th-P15:186) Hjalmarsson, P., 169 (Tu-W25:1), 170 (Tu-W25:3) Horszczaruk, G., 358 (We-P11:56) Huff, M.W., 482 (Th-W57:6) H 460 216 470 Hjerpe, C., (Th-W46:4) Hortmann, M., (Tu-P7:142), (Th-W51:7) Hufnagel, B., 352 (We-P11:30) 421 580 Hjortnaes, J., (We-P13:338) Horvath, K.V., (Th-P16:395) Hughes, A., 80 (Mo-P1:155, Mo-P1:156) 138 495 O Hlatky, M.A., (Mo-P6:419) Horvath, P., (Th-P15:14) Hughes, A.D., 104 (Mo-P4:262) 57 587 Hlubik, P., (Mo-P1:52) Hosken, B., (Th-P17:428) Huhtaniemi, I., 221 (Tu-P7:163) 385 129 R Hlubocká, Z., (We-P11:179) Hosoi, T., (Mo-P6:379) Huijkman, N.C.A., 450 (We-P14:471) 117 187 Hoag, G., (Mo-P5:326) Hosokawa, T., (Tu-P7:11) Huisman, M., 421 (We-P13:338) 118 119 127 Hobbs, F.D.R., (Mo-P5:332), Hossini, N., (Mo-P5:372) Huisman, M.V., 125 (Mo-P5:363), 331 179 567 (Mo-P5:333), (Tu-W29:6) Hostalek, U., (Th-P16:336) (We-W43:6) Hobbs, H.H., 150 (Tu-PL2:4), 305 (We-W30:1) Hostmark, A.T., 390 (We-P11:200) Hulthe, J., 52 (Mo-P1:32), 349 (We-P11:17), 382 I Hochleitner, M., 65 (Mo-P1:86) Hotoleanu, C., 57 (Mo-P1:51), 378 (We-P11:147) (We-P11:165) Hodroj, W., 355 (We-P11:44) Hou, H.J., 195 (Tu-P7:49), 228 (Tu-P7:199), 565 Humphries, S., 24 (Mo-W7:6), 129 (Mo-P6:381), N Hoeber, S., 471 (Th-W52:5) (Th-P16:327) 312 (We-W33:6), 368 (We-P11:103) Hoefer, I.E., 569 (Th-P16:342) Hou, M., 541 (Th-P15:221) Humphries, S.E., 131 (Mo-P6:389), 138 Hoffmanm, U., 216 (Tu-P7:143) Houard, X., 239 (Tu-P7:246) D (Mo-P6:420), 145 (Mo-P6:451, Mo-P6:452), Hoffmann, M., 143 (Mo-P6:442), 507 Houde, A., 586 (Th-P17:420) 301 (We-PL3:3), 312 (We-W33:5), 315 (Th-P15:69), 581 (Th-P16:397) Hoursalas, I.S., 113 (Mo-P5:306), 509 E (We-W35:2, We-W35:3), 335 (We-W45:6) Hoffmeier, A., 238 (Tu-P7:243) (Th-P15:77) Hung, G., 466 (Th-W49:5) Hofker, M.H., 225 (Tu-P7:181), 518 (Th-P15:117) House, A.A., 308 (We-W31:4) Huo, Y., 97 (Mo-P3:231), 494 (Th-P15:12) X Höﬂer, G., 15 (Mo-W3:1) Houska, M., 250 (Tu-P8:298) 573 Hofman, A., 35 (Mo-W13:5) Hovingh, G.K., 544 (Th-P15:235) Hur, J., (Th-P16:361) 135 Hofnagel, O., 494 (Th-P15:9) Howard, A.N., 440 (We-P14:426) Hurndell, N., (Mo-P6:406) 15 24 Hoisington, W., 413 (We-P12:303) Howard, B.V., 176 (Tu-W28:3), 485 (Th-W59:1) Hurt-Camejo, E., (Mo-W3:2), (Mo-W7:6), 414 497 Hojjat, H., 395 (We-P11:223) Howarth, S.P.S., 267 (Tu-P9:378) (We-P12:310), (Th-P15:23) 236 Holaj, R., 389 (We-P11:195) Hoy, J., 162 (Tu-W21:2) Huseby, S., (Tu-P7:234) 460 Holdaas, H., 578 (Th-P16:387) Hoydal, M., 100 (Mo-P4:244), 111 (Mo-P5:298) Husegawa, Y., (Th-W46:6) 175 Holdt, L.M., 316 (We-W35:5) Høydal, M., 215 (Tu-P7:139) Huskin, A.L., (Tu-W27:5) 507 Holewijn, S., 260 (Tu-P9:345) Hrafnkelsdottir, T., 159 (Tu-W19:3) Hussein, H., (Th-P15:65) 526 Holgado, C., 286 (Tu-P10:462) Hribal, M., 312 (We-W33:7) Huth, K.C., (Th-P15:151) Holgado, T., 116 (Mo-P5:322), 286 (Tu-P10:462) Hribal, M.L., 21 (Mo-W6:4), 367 (We-P11:98), Hutri-Kähönen, N., 68 (Mo-P1:101) Hollman, G., 422 (We-P13:342), 427 371 (We-P11:116) Hutten, B.A., 16 (Mo-W3:6), 335 (We-W45:6), (We-P13:367) Hruba, F., 57 (Mo-P1:54) 484 (Th-W58:6) Holm, M.V., 178 (Tu-W29:3) Hsia, J., 176 (Tu-W28:3), 485 (Th-W59:1) Huupponen, R., 279 (Tu-P10:430) Holmberg, C., 124 (Mo-P5:358), 576 Hsu, C., 193 (Tu-P7:37) Huwait, E., 237 (Tu-P7:238) (Th-P16:378) Hsu, C.H., 99 (Mo-P4:240) Huzarska, M., 573 (Th-P16:363) Holme, I., 161 (Tu-W20:4), 179 (Tu-W29:7), 478 Hsu, F.C., 14 (Mo-W2:6) Hwang, P.H., 79 (Mo-P1:151) (Th-W55:5) Hsu, H.C., 48 (Mo-P1:15), 369 (We-P11:106) Hyanek, J., 128 (Mo-P5:376), 553 (Th-P16:273) Holmes, E., 390 (We-P11:201), 430 (We-P14:381) Hu, B.L., 96 (Mo-P3:230), 222 (Tu-P7:167) Hyspler, R., 359 (We-P11:60), 562 (Th-P16:314) Holt, D.W., 87 (Mo-P2:184), 533 (Th-P15:184) Hu, D.Y., 81 (Mo-P1:160) Hyvönen, M.T., 245 (Tu-P7:275) Holvoet, P., 464 (Th-W48:7), 470 (Th-W52:1) Hu, F.U., 489 (Th-W61:1) Holzhütter, H.G., 547 (Th-P15:248) Hu, L., 331 (We-W43:6) 75 Homan, R., 228 (Tu-P7:196), 240 (Tu-P7:253), Hu, W., 196 (Tu-P7:51), 202 (Tu-P7:79), 203 Iagulli, M.P., (Mo-P1:133) 580 543 (Th-P15:230) (Tu-P7:84), 539 (Th-P15:211) Iannacci, G.R., (Th-P16:393) 255 Hombach, V., 30 (Mo-W10:7), 394 (We-P11:220) Hu, Y., 462 (Th-W48:1) Iannelli, P., (Tu-P8:322) 261 Homer, V.M., 135 (Mo-P6:406) Hua, X., 299 (Tu-P10:518) Iannuzzi, A., (Tu-P9:348) Homma, K., 425 (We-P13:359), 460 (Th-W46:6), Huang, C.I., 110 (Mo-P4:290) Iannuzzo, G., 231 (Tu-P7:211), 282 (Tu-P10:445) 501 (Th-P15:39), 583 (Th-P16:407) Huang, C.Y., 270 (Tu-P10:389, Tu-P10:390) Iantorno, M., 450 (We-P14:468) Homma, S., 258 (Tu-P9:335) Huang, L., 322 (We-W38:7) Iborra, R.T., 527 (Th-P15:154, Th-P15:155), 540 Homma, Y., 425 (We-P13:359), 460 (Th-W46:6), Huang, M., 193 (Tu-P7:37) (Th-P15:215) 583 (Th-P16:407) Huang, T.S., 79 (Mo-P1:151) Ibrahim, M., 266 (Tu-P9:371) Hommes, D.W., 124 (Mo-P5:357) Huang, Y., 413 (We-P12:304) Ibrahim, R., 418 (We-P13:328) Honavar, J., 310 (We-W32:7) Huang, Z., 331 (We-W43:3) Ibrir, M., 102 (Mo-P4:256), 387 (We-P11:189) Hong, T., 97 (Mo-P3:231) Hubacek, J., 139 (Mo-P6:423), 141 (Mo-P6:435), Ide, N., 216 (Tu-P7:143), 275 (Tu-P10:412) Hoo, R.L.C., 186 (Tu-P7:6) 486 (Th-W59:6) IDEALE Study Group, , 123 (Mo-P5:354) Hooper, A.J., 546 (Th-P15:241) Hubacek, J.A., 138 (Mo-P6:420), 139 IDEAL Steering Committee, , 178 (Tu-W29:5) Horejsi, R., 310 (We-W32:5) (Mo-P6:424) Idris, A., 436 (We-P14:406) Hori, M., 237 (Tu-P7:237), 511 (Th-P15:86) Hubbart, C.S., 145 (Mo-P6:451) Iemma, G., 313 (We-W34:4)

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

235 Iezzi, A., 8 (Mo-PL1:4), 246 (Tu-P7:280), 247 Ireland, H., 315 (We-W35:3) Iwase, T., 101 (Mo-P4:252), 362 (We-P11:77), (Tu-P7:282), 248 (Tu-P7:287) Iriarte, J.A., 67 (Mo-P1:97), 84 (Mo-P2:174) 569 (Th-P16:344), 572 (Th-P16:359) Igarashi, M., 425 (We-P13:359) Iribarren, C., 138 (Mo-P6:419) Iwata, A., 192 (Tu-P7:33), 268 (Tu-P9:383), 578 Igarashi, O., 430 (We-P14:380) Irjala, K., 221 (Tu-P7:163) (Th-P16:386) A Igdoura, S.A., 488 (Th-W60:6) Irvine, S.A., 237 (Tu-P7:238) Izar, M., 349 (We-P11:15) Iglesias-Gallego, M., 124 (Mo-P5:359) Isaacs, A., 35 (Mo-W13:5), 306 (We-W30:6) Izar, M.C.O., 263 (Tu-P9:360), 348 (We-P11:13), Iglseder, B., 155 (Tu-W17:4) Isaacsohn, J., 123 (Mo-P5:352) 435 (We-P14:403) U Ignatov, N., 134 (Mo-P6:402) Isabelle, M., 189 (Tu-P7:20), 539 (Th-P15:212) Izquierdo, M.T., 286 (Tu-P10:461) Ihara, S., 349 (We-P11:15) Isailovic, T., 126 (Mo-P5:365), 361 (We-P11:71), Izquierdo, R.M., 77 (Mo-P1:141) T Ihara, S.S.M., 348 (We-P11:13), 435 426 (We-P13:363), 522 (Th-P15:134) Izraeljan, A., 31 (Mo-W11:3) (We-P14:403) Isawa, Y., 235 (Tu-P7:231) Izumi, Y., 388 (We-P11:194) H Ihibashi, S., 582 (Th-P16:405) Ishibashi, S., 319 (We-W37:3) 229 215 498 Ii, H., (Tu-P7:200) Ishida, T., (Tu-P7:138), (Th-P15:27) J, Z.S., 393 (We-P11:217) 405 585 507 O Iijima, K., (We-P11:269), (Th-P16:417) Ishida, Y., (Th-P15:67) Jaakkola, O., 241 (Tu-P7:256) Iiyama, M., 348 (We-P11:14) Ishigai, Y., 564 (Th-P16:323) Jabauri, A.T., 132 (Mo-P6:393), 583 (Th-P16:406) Ijäs, P., 93 (Mo-P2:216), 246 (Tu-P7:278) Ishigami, H., 539 (Th-P15:211) Jacevic, V., 570 (Th-P16:348) R Ijiri, Y., 434 (We-P14:397), 436 (We-P14:405) Ishigami, M., 510 (Th-P15:79) Jáchymová, M., 144 (Mo-P6:448), 365 Ikarugi, H., 436 (We-P14:405) Ishihara, N., 499 (Th-P15:30) (We-P11:90), 385 (We-P11:179), 496 Ikeda, K., 185 (Tu-P7:2) Ishihara, T., 520 (Th-P15:124) (Th-P15:18) Ikeda, M., 436 (We-P14:404) Ishii, E., 233 (Tu-P7:223) Jackson, C., 244 (Tu-P7:273) Ikeda, T., 564 (Th-P16:320) Ishikawa, I., 413 (We-P12:304) I Jackson, C.L., 210 (Tu-P7:116), 394 Ikeda, Y., 16 (Mo-W3:7), 101 (Mo-P4:252), 106 Ishikawa, K., 87 (Mo-P2:186), 296 (Tu-P10:507), (We-P11:218) (Mo-P4:271), 210 (Tu-P7:115), 254 297 (Tu-P10:509), 388 (We-P11:192), 460 N Jackson, G., 405 (We-P11:268) (Tu-P8:314), 294 (Tu-P10:499), 354 (Th-W46:6), 572 (Th-P16:359) Jackson, R., 485 (Th-W59:1) (We-P11:37), 362 (We-P11:77), 497 Ishikawa, P., 432 (We-P14:389) Jackson, S.P., 325 (We-W40:4) D (Th-P15:22), 507 (Th-P15:67), 569 Ishikawa, T., 161 (Tu-W20:7), 428 (We-P13:370) Jacobs, F., 490 (Th-W61:8) (Th-P16:344), 572 (Th-P16:359) Ishikawa, Y., 249 (Tu-P8:293), 369 (We-P11:109) Jacobs, H., 421 (We-P13:338) E Ikegami, C., 28 (Mo-W9:6), 237 (Tu-P7:237), 510 Ishiwata, K., 425 (We-P13:359), 583 (Th-P16:407) Jacobson, T.A., 2 (Su-S1:4) (Th-P15:82), 575 (Th-P16:372) Ishizaki, J., 520 (Th-P15:124) Jacquet, J., 153 (Tu-W16:7) Ikemoto, S., 454 (We-P14:485) Ishizaki, M., 290 (Tu-P10:481) X Jagielski, P., 119 (Mo-P5:335) Ikenoya, M., 547 (Th-P16:249) Islam, A., 523 (Th-P15:138) 537 Ikewaki, K., 496 (Th-P15:17), 564 (Th-P16:322), Ismail, T., 423 (We-P13:347) Jahangiri, A., (Th-P15:200) 527 579 (Th-P16:392) Iso, K., 279 (Tu-P10:431) Jaichander, P., (Th-P15:158) 119 Ikushima, I., 520 (Th-P15:124) Isoda, K., 168 (Tu-W24:4) Jalalinia, S.F., (Mo-P5:334) 201 Ilic, M., 418 (We-P13:325) Isoir, M., 220 (Tu-P7:161) Jamborova, G., (Tu-P7:74) 512 Ilic, S., 386 (We-P11:182) Isosaki, M., 546 (Th-P15:242) James, A.P., (Th-P15:88) 332 Illnait, J., 565 (Th-P16:325) Isoviita, P.M., 93 (Mo-P2:216) James, R.W., (We-W44:2) 295 Ilyinskaya, O.P., 96 (Mo-P3:226) Issaoui, M., 438 (We-P14:415) James Kang, Y., (Tu-P10:503) 229 Imachi, H., 215 (Tu-P7:138) Itabe, H., 501 (Th-P15:39) Jancar, S., (Tu-P7:201) 104 Imadu, Y., 520 (Th-P15:124) Itai, K., 63 (Mo-P1:81) Janczak, D., (Mo-P4:265) 556 Imaizumi, S., 192 (Tu-P7:33), 536 (Th-P15:197), Ito, H., 394 (We-P11:219) Jandeleit-Dahm, K., (Th-P16:286) 355 556 561 (Th-P16:310), 562 (Th-P16:313), 578 Ito, K., 104 (Mo-P4:264), 444 (We-P14:441) Jandeleit-Dahm, K.A., (We-P11:42), (Th-P16:386) Ito, T., 339 (We-S13:3), 549 (Th-P16:256) (Th-P16:287) 390 Imaizumi, T., 60 (Mo-P1:65, Mo-P1:66, Itoh, T., 505 (Th-P15:58) Jandrot-Perrus, M., (We-P11:202) 210 287 Mo-P1:67), 76 (Mo-P1:139), 394 Itsiopoulos, C., 177 (Tu-W28:4) Jangavadze, M., (Tu-P7:114), (We-P11:219), 519 (Th-P15:120) Iurciuc, M., 362 (We-P11:73) (Tu-P10:465) 144 365 Imamura, T., 93 (Mo-P2:215), 246 (Tu-P7:279) Iurciuc, S., 362 (We-P11:73), 365 (We-P11:86) Janíková, L., (Mo-P6:448), (We-P11:90), 496 Imanishi, N., 548 (Th-P16:251) Iuzzolino, L., 589 (Th-P17:434) (Th-P15:18) Inaba, S., 464 (Th-W49:1) Ivanov, D., 191 (Tu-P7:30) Janikova, L., 552 (Th-P16:269) Inada, S., 210 (Tu-P7:115), 354 (We-P11:37) Ivanov, P., 397 (We-P11:232) Janin-Maniﬁcat, L., 427 (We-P13:365) Inazu, A., 255 (Tu-P8:321), 579 (Th-P16:388) Ivanova, M.V., 78 (Mo-P1:147) Janiszewski, M., 208 (Tu-P7:108) Indigeno, P., 147 (Mo-P6:457) Ivanova, R., 354 (We-P11:38) Jankowski, K., 212 (Tu-P7:125) Indovina, A., 90 (Mo-P2:199), 437 (We-P14:412) Ivanusa, M., 118 (Mo-P5:327) Jansen, H., 16 (Mo-W3:4) Ingemansson, A., 239 (Tu-P7:249) Ivert, T., 357 (We-P11:50) Janssen, J.W., 235 (Tu-P7:229) Innocente, S., 102 (Mo-P4:257) Ivetic, V., 193 (Tu-P7:42), 564 (Th-P16:324) Jantzen, F., 571 (Th-P16:352) Inoue, M., 210 (Tu-P7:115), 254 (Tu-P8:314), 294 Ivey, M.E., 242 (Tu-P7:263) Janushevskaya, E.V., 96 (Mo-P3:226) (Tu-P10:499), 354 (We-P11:37) Ivkovic-Lazar, T., 377 (We-P11:142) Jarauta, E., 262 (Tu-P9:354), 406 (We-P11:275), Inoue, N., 191 (Tu-P7:28) Iwai, C., 104 (Mo-P4:264), 133 (Mo-P6:397), 444 495 (Th-P15:16), 546 (Th-P15:244), 547 Inoue, Y., 413 (We-P12:304), 579 (Th-P16:392) (We-P14:441) (Th-P15:247) Ionita, M., 346 (We-P11:1) Iwai, N., 16 (Mo-W3:7) Jardine, A., 578 (Th-P16:387) Ioriya, K., 548 (Th-P16:250, Th-P16:251, Iwai, T., 413 (We-P12:304) Jares, M., 416 (We-P13:316) Th-P16:252, Th-P16:253) Iwakura, Y., 169 (Tu-W24:7) Jary, E., 538 (Th-P15:205) Iotti, M., 74 (Mo-P1:127) Iwama, M., 259 (Tu-P9:339) Jassó, I., 105 (Mo-P4:267) Iovine, C., 31 (Mo-W11:5) Iwamoto, N., 493 (Th-P15:7), 539 (Th-P15:211) Jastrzebska, M., 84 (Mo-P2:175), 370 Irace, C., 146 (Mo-P6:453), 259 (Tu-P9:338), 268 Iwamoto, Y., 350 (We-P11:20) (We-P11:110), 569 (Th-P16:343) (Tu-P9:382), 353 (We-P11:33), 374 Iwamura, M., 454 (We-P14:485) Jatta, K., 280 (Tu-P10:434) (We-P11:131), 423 (We-P13:346) Iwanaga, T., 497 (Th-P15:22) Jauhiainen, M., 39 (Mo-W15:5), 85 (Mo-P2:176), Iraklianou, S., 509 (Th-P15:77) Iwaniec, T., 391 (We-P11:204) 320 (We-W37:6), 463 (Th-W48:4), 500

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

236 (Th-P15:37), 540 (Th-P15:216), 576 (Th-P15:185), 535 (Th-P15:193), 577 Kaczmarek, P., 271 (Tu-P10:397) (Th-P16:378) (Th-P16:379) Kadl, A., 160 (Tu-W19:7) Jauhianen, M., 152 (Tu-W16:2) Johnson, J., 244 (Tu-P7:273) Kadota, A., 59 (Mo-P1:63) Javadzadeh, A., 525 (Th-P15:148) Johnson, J.A., 334 (We-W44:7) Kadowaki, S., 348 (We-P11:12) Javashvili, L.V., 416 (We-P13:317) Johnson, J.L., 319 (We-W37:2) Kadowaki, T., 48 (Mo-P1:14), 52 (Mo-P1:31), 55 A Javorsky, M., 560 (Th-P16:305) Johnson, K., 317 (We-W36:5) (Mo-P1:45), 56 (Mo-P1:48), 58 (Mo-P1:58), Jaye, M., 492 (Th-P15:1), 540 (Th-P15:214) Johnson, S.K., 453 (We-P14:483), 477 59 (Mo-P1:63), 76 (Mo-P1:137), 164 Jebashvili, M., 410 (We-P12:291) (Th-W55:3), 478 (Th-W55:6) (Tu-W22:1, Tu-W22:3), 196 (Tu-P7:53), 260 U Jeberean, R.A., 346 (We-P11:1), 427 Johnston, J., 558 (Th-P16:297) (Tu-P9:344), 265 (Tu-P9:368), 348 (We-P13:364) Johs, A., 500 (Th-P15:36) (We-P11:12) T Jee, S.H., 132 (Mo-P6:394) Jokinen, E., 55 (Mo-P1:44), 576 (Th-P16:378) Kahan, N., 115 (Mo-P5:314) Jelakovic, B., 376 (We-P11:136), 384 Jonasson, L., 169 (Tu-W25:1), 170 (Tu-W25:3), Kähönen, M., 68 (Mo-P1:101) H (We-P11:175) 271 (Tu-P10:396), 278 (Tu-P10:428), 323 Kaiafa, G., 108 (Mo-P4:282), 272 (Tu-P10:401) Jelic-Ivanovic, Z., 60 (Mo-P1:64), 139 (We-W39:3), 328 (We-W41:7) Kajinami, K., 283 (Tu-P10:450), 411 O (Mo-P6:426), 279 (Tu-P10:432) Jones, A., 360 (We-P11:67), 368 (We-P11:101), (We-P12:295) 281 Jemaa, R., 69 (Mo-P1:105) 533 (Th-P15:182) Kajiwara, I., (Tu-P10:439) 63 109 R Jembrek-Gostovic, M., 47 (Mo-P1:5) Jones, B., 21 (Mo-W6:3) Kakaﬁka, A., (Mo-P1:78), (Mo-P4:286), 355 560 Jeng, J.S., 434 (We-P14:399) Jones, E.E., (We-P11:42) (Th-P16:303) 21 171 Jenkins, D.J., 432 (We-P14:388), 478 (Th-W55:7) Jones, E.L., (Mo-W6:3) Kakar, S., (Tu-W25:5) 324 65 410 Jenkins, D.J.A., 177 (Tu-W28:6), 442 Jones, L., (We-W39:5) Kakauridze, N., (Mo-P1:87), (We-P12:291) 515 442 (We-P14:433), 455 (We-P14:488), 476 Jones, N., (Th-P15:100) Kakauridze, N.G., (We-P14:434) I 174 343 577 39 (Th-W55:1) Jones, P.H., (Tu-W27:4), (We-S15:4), Käkelä, R., (Mo-W15:5) 408 Jennings, G., 488 (Th-W60:5) (Th-P16:383) Kakucs, R., (We-P12:283) 337 243 N Jennings, G.L., 146 (Mo-P6:454) Jones, P.J., (We-S12:1) Kakudo, K., (Tu-P7:268) 380 447 507 Jentsch, A., 318 (We-W36:7) Jones, P.J.H., (We-P11:157), Kakuta, Y., (Th-P15:67) 429 D Jeren, B.J., 204 (Tu-P7:89) (We-P14:456) Kalaivani Sailaja, J., (We-P13:376) 207 402 Jeric, M., 357 (We-P11:53) Jonsdottir, I.H., (Tu-P7:101) Kalani, Z., (We-P11:257) 178 Kalev, M., 375 (We-P11:133) Jerkovic, R., 204 (Tu-P7:88) Jonsson, B., (Tu-W29:5) E 286 390 Kalimanovska, V., 351 (We-P11:26), 502 Jern, S., 87 (Mo-P2:187), 90 (Mo-P2:202), 159 Jonsson, G., (Tu-P10:460), (We-P11:200) 15 (Th-P15:46), 503 (Th-P15:47) (Tu-W19:3) Jönsson-Rylander, A.-C., (Mo-W3:2) X 199 Kalimanovska-Ostric, D., 60 (Mo-P1:64), 139 Jernås, M., 234 (Tu-P7:225) Joost, H.G., (Tu-P7:64) Jørgensen, K.A., 474 (Th-W53:6) (Mo-P6:426) Jeromin, F., 464 (Th-W48:8) Jossa, F., 231 (Tu-P7:211), 282 (Tu-P10:445) Kalina, A., 140 (Mo-P6:427) Jessup, W., 27 (Mo-W9:5), 167 (Tu-W23:6), 492 Josse, A., 432 (We-P14:388) Kalinov, K., 438 (We-P14:417) (Th-P15:4), 493 (Th-P15:8), 538 Josse, A.R., 177 (Tu-W28:6) Kaliszczak, R., 286 (Tu-P10:463), 287 (Th-P15:205), 541 (Th-P15:219) Josse, R.G., 476 (Th-W55:1) (Tu-P10:464) Jez, W., 78 (Mo-P1:144) Jotic, A., 351 (We-P11:25, We-P11:26, Kallio, K., 55 (Mo-P1:44) Jhanke, S., 325 (We-W40:5) We-P11:27), 352 (We-P11:28) Kallio, T., 124 (Mo-P5:358) Ji, J., 203 (Tu-P7:84), 370 (We-P11:111), 534 Jovanova, S., 70 (Mo-P1:108) Kalmár, T., 229 (Tu-P7:203), 577 (Th-P16:382) (Th-P15:185), 535 (Th-P15:193), 577 Jovanovic, T., 202 (Tu-P7:78) Kalme, V., 281 (Tu-P10:442) (Th-P16:379) Joven, J., 202 (Tu-P7:81), 416 (We-P13:318) Kalmykov, M., 189 (Tu-P7:21) Jialal, I., 359 (We-P11:61), 452 (We-P14:478) Jover, E., 46 (Mo-P1:2) Kalofoutis, A., 67 (Mo-P1:99) Jian, L., 512 (Th-P15:88) Juarez-Rojas, J., 422 (We-P13:344) Kalogeropoulos, A., 109 (Mo-P4:285) Jiang, J.-D., 464 (Th-W49:1) Juergens, G., 93 (Mo-P2:212) Kalogirou, M., 561 (Th-P16:308) Jiang, M., 245 (Tu-P7:277), 482 (Th-W57:7) Juhan-Vague, I., 158 (Tu-W19:2), 315 Kalokerinos, G., 58 (Mo-P1:55), 109 Jiang, M.J., 409 (We-P12:287), 573 (Th-P16:364) (We-W35:2) (Mo-P4:288), 272 (Tu-P10:400) 96 222 Jiang, Z.S., (Mo-P3:230), (Tu-P7:167), Jukema, J.W., 37 (Mo-W14:7), 98 (Mo-P4:236), Kalompokis, B., 109 (Mo-P4:288) 232 254 492 (Tu-P7:217), (Tu-P8:317), 393 (We-P11:215), 487 (Th-W60:4), 489 Kalopissis, A.D., 538 (Th-P15:206) 543 (Th-P15:3), (Th-P15:229) (Th-W61:2, Th-W61:5), 551 (Th-P16:263), Kälvegren, H., 84 (Mo-P2:173), 413 291 292 Jimenez, J.J., (Tu-P10:485), (Tu-P10:486) 560 (Th-P16:306) (We-P12:305) 447 Jimenez, Y., (We-P14:457) Julius, U.A., 507 (Th-P15:68) Kalvelis, A., 59 (Mo-P1:62), 281 (Tu-P10:442) 448 Jiménez-Gómez, Y., (We-P14:459) Jungner, I., 468 (Th-W50:6) Kamanna, V., 567 (Th-P16:335) 447 Jimenez-Gomez, Y., (We-P14:454) Junyent, M., 261 (Tu-P9:349, Tu-P9:350), 495 Kamaratos, A., 347 (We-P11:9), 348 (We-P11:10) 243 465 Jin, D., (Tu-P7:267), (Th-W49:2) (Th-P15:16) Kamari, Y., 169 (Tu-W24:7) 190 251 494 Jin, H.Y., (Tu-P7:25), (Tu-P8:301), Jurado, M.C., 229 (Tu-P7:201), 586 (Th-P17:423) Kambouromiti, G., 127 (Mo-P5:370) (Th-P15:10) Jurcut, C., 93 (Mo-P2:214), 236 (Tu-P7:233), 414 Kamei, N., 164 (Tu-W22:1) 197 Jindrichova, E., (Tu-P7:57) (We-P12:308) Kamenova, A., 397 (We-P11:232) 588 Jing, D., (Th-P17:429, Th-P17:430, Jurcut, R., 93 (Mo-P2:214), 236 (Tu-P7:233), 414 Kamilova, F.H., 83 (Mo-P1:462) Th-P17:432) (We-P12:308) Kaminniy, I., 585 (Th-P16:416) 505 Jinno, K., (Th-P15:58) Juric, K.J., 204 (Tu-P7:89) Kamiyama, Y., 296 (Tu-P10:507), 297 Jitaru, D., 91 (Mo-P2:205) Juricskay, I., 82 (Mo-P1:165) (Tu-P10:509), 388 (We-P11:192) Joguet, V., 269 (Tu-P9:387) Jurisic-Erzen, D., 204 (Tu-P7:88) Kanaki, T., 482 (Th-W57:7) Johansen, B., 236 (Tu-P7:234) Jurka, A., 263 (Tu-P9:358) Kanaya, A., 317 (We-W36:5) Johansson, B.R., 196 (Tu-P7:52) Jy, W., 291 (Tu-P10:485), 292 (Tu-P10:486) Kanazawa, K., 104 (Mo-P4:264), 133 Johansson, D., 460 (Th-W46:4) (Mo-P6:397), 444 (We-P14:441) Johansson, M.E., 207 (Tu-P7:101), 469 Kaakinen, R., 497 (Th-P15:23) Kanda, A., 564 (Th-P16:323) (Th-W51:3) Kabakci, G., 264 (Tu-P9:365) Kanda, M., 94 (Mo-P3:217) Johnson, A.G., 370 (We-P11:111), 534 Kacimi, G., 194 (Tu-P7:45) Kandikijan, P., 418 (We-P13:326)

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

237 Kandikjan, P., 407 (We-P12:279) Kassis, A.N., 447 (We-P14:456) Keith, J., 256 (Tu-P8:325) Kandoussi, A., 215 (Tu-P7:140) Kassner, U., 567 (Th-P16:336) Kékes, E., 156 (Tu-W17:7) Kane, J.P., 566 (Th-P16:331) Kaste, M., 93 (Mo-P2:216), 246 (Tu-P7:278) Kelishadi, R., 61 (Mo-P1:71), 426 (We-P13:361) Kaneko, E., 185 (Tu-P7:3), 253 (Tu-P8:311) Kastelein, J., 138 (Mo-P6:420), 309 (We-W32:3), Kell, P., 404 (We-P11:267) A Kaneko, M., 417 (We-P13:322) 364 (We-P11:84), 533 (Th-P15:183) Keller, C., 216 (Tu-P7:143), 275 (Tu-P10:412) Kanellakis, P., 488 (Th-W60:5) Kastelein, J.J.P., 16 (Mo-W3:6), 19 (Mo-W5:2), Kellishadi, R., 427 (We-P13:368) Kaneshi, T., 48 (Mo-P1:12) 24 (Mo-W7:5), 37 (Mo-W14:7), 41 Kellner-Weibel, G., 541 (Th-P15:217) U Kaneski, C., 237 (Tu-P7:239) (Mo-S6:1), 70 (Mo-P1:109), 95 (Mo-P3:223), Kemi, O., 100 (Mo-P4:244), 111 (Mo-P5:298) Kang, C.-S., 265 (Tu-P9:369) 124 (Mo-P5:357), 134 (Mo-P6:403), 153 Kemi, O.J., 202 (Tu-P7:77) T Kang, H.J., 573 (Th-P16:361) (Tu-W16:5), 265 (Tu-P9:367), 318 Kemp, T., 476 (Th-W55:1), 478 (Th-W55:7) Kang, M.G., 132 (Mo-P6:394) (We-W36:6), 401 (We-P11:250), 457 Kendall, C.W., 432 (We-P14:388), 478 H Kang, M.K., 423 (We-P13:349) (Th-PL4:1), 466 (Th-W49:6), 484 (Th-W55:7) Kangawa, K., 94 (Mo-P3:217) (Th-W58:6), 544 (Th-P15:235), 552 Kendall, C.W.C., 177 (Tu-W28:6), 442 O Kanjuh, S., 351 (We-P11:27) (Th-P16:268) (We-P14:433), 455 (We-P14:488), 476 Kanjuh, V., 198 (Tu-P7:63), 206 (Tu-P7:98), 211 Kastellanos, S., 58 (Mo-P1:55) (Th-W55:1) 351 379 283 (Tu-P7:119), (We-P11:27), Kasuga, T., (Tu-P10:450) Kendereski, A., 126 (Mo-P5:367), 287 R 195 (We-P11:150) Katagiri, H., (Tu-P7:47) (Tu-P10:468), 361 (We-P11:68, We-P11:70), 355 73 377 Kantharidis, P., (We-P11:42) Kataoka, R., (Mo-P1:122), (We-P11:144) 362 (We-P11:74, We-P11:75), 378 579 526 Kapanadze, K., (Th-P16:390, Th-P16:391) Kato, L.S., (Th-P15:150) (We-P11:149) 454 556 73 Kapetivadze, V., (We-P14:487), Kato, R., (Mo-P1:125) Kennedy-Walton, E., 254 (Tu-P8:316) 528 I (Th-P16:288) Kato, T., (Th-P15:161) Kenyeres, P., 82 (Mo-P1:165), 398 (We-P11:236) 525 558 Kapiotis, S., (Th-P15:149) Katona, K.N., (Th-P16:294) Kerkhofs, M., 119 (Mo-P5:336) 529 259 Kaplan, M., (Th-P15:163) Katou, T., (Tu-P9:339) Kerleau, J.M., 261 (Tu-P9:351) N 350 347 348 Kapoor, A., (We-P11:19) Katsanaki, A., (We-P11:9), (We-P11:10) Kersten, S., 257 (Tu-P8:331), 344 (We-S16:3) 350 251 Kapoor, R., (We-P11:19) Katsichti, P., (Tu-P8:303) Kesmarky, G., 82 (Mo-P1:165), 356 (We-P11:47), D 160 109 272 Karabeg, E., (Tu-W19:7) Katsigianni, G., (Mo-P4:288), 398 (We-P11:236) 67 Karabinos, I., (Mo-P1:99) (Tu-P10:400) Kesteloot, H., 390 (We-P11:201), 437 Karachentsev, Y., 383 (We-P11:169), 418 Katsikas, G., 414 (We-P12:307), 423 E (We-P14:410) (We-P13:327) (We-P13:350) Keszthelyi, Z., 356 (We-P11:47), 398 Karadi, I., 140 (Mo-P6:427) Katsouras, C., 265 (Tu-P9:370) X (We-P11:236) Karagiannis, A., 109 (Mo-P4:286) Katsuda, S., 255 (Tu-P8:321) Ketelhuth, D.F.J., 237 (Tu-P7:240), 521 Karakozoglou, A., 81 (Mo-P1:162), 122 Katsumoto, M., 191 (Tu-P7:31), 577 (Th-P16:380) (Th-P15:131), 586 (Th-P17:423) (Mo-P5:348) Katus, H.A., 407 (We-P11:276) Kettani, A., 123 (Mo-P5:355) Karamouzis, M., 431 (We-P14:382) Kaufman, S., 566 (Th-P16:329) Keul, P., 535 (Th-P15:192) Karanam, S., 394 (We-P11:218) Kaul, M.G., 493 (Th-P15:6) Kevorkova, Yu.G., 67 (Mo-P1:98) Karatzis, E.N., 84 (Mo-P2:171) Kaveri, S., 278 (Tu-P10:426) Khakhutaishvili, I., 210 (Tu-P7:114), 287 Kardassis, D., 228 (Tu-P7:195) Kaveri, S.K., 195 (Tu-P7:50) (Tu-P10:465) Kardos, L., 292 (Tu-P10:489) Kawaguchi, A., 122 (Mo-P5:350), 281 Khakpour, F., 529 (Th-P15:165) Kargiannis, A., 63 (Mo-P1:78) (Tu-P10:439) Khalil, A., 189 (Tu-P7:20), 473 (Th-W53:3), 521 Karhunen, P., 18 (Mo-W4:4) Ka Wah, L.I., 368 (We-P11:103) (Th-P15:130), 539 (Th-P15:212), 543 Karimian, J., 111 (Mo-P5:296, Mo-P5:297), 118 Kawahara, M., 238 (Tu-P7:244) (Mo-P5:331) Kawai, Y., 428 (We-P13:372) (Th-P15:228) 195 278 Kärkkäinen, S., 241 (Tu-P7:256) Kawakami, A., 234 (Tu-P7:226) Khallou-Laschet, J., (Tu-P7:50), Karlsson, H., 171 (Tu-W25:7) Kawamoto, T., 511 (Th-P15:86) (Tu-P10:426) 475 Karlsson, L., 87 (Mo-P2:187), 90 (Mo-P2:202), Kawamura, A., 517 (Th-P15:111), 571 Khaw, K.-T., (Th-W54:5) 37 70 159 (Tu-W19:3) (Th-P16:354) Khaw, K.T., (Mo-W14:7), (Mo-P1:109), 318 335 Karpenko, O.M., 189 (Tu-P7:23) Kawamura, H., 388 (We-P11:194) (We-W36:6), (We-W45:6) 192 Karras, S., 353 (We-P11:36) Kawamura, M., 187 (Tu-P7:13), 362 (We-P11:76), Khazaei, M., (Tu-P7:35) 132 Karry, R., 529 (Th-P15:163) 587 (Th-P17:424) Khelaia, M.B., (Mo-P6:393) 410 Karvounaris, S.T., 414 (We-P12:307) Kawano, M., 582 (Th-P16:405) Khelashvili, M., (We-P12:291) 127 Kas, J., 203 (Tu-P7:82) Kawashiri, M., 255 (Tu-P8:321), 579 Khodavandi, A., (Mo-P5:372) 194 Kasai, M., 430 (We-P14:380) (Th-P16:388) Kholová, I., (Tu-P7:44) Kasalova, Z., 371 (We-P11:117) Kawecka, M., 281 (Tu-P10:438) Khosravi, A., 53 (Mo-P1:38), 61 (Mo-P1:71), 426 Kasanuki, H., 486 (Th-W59:4) Kaynar, G., 92 (Mo-P2:208), 100 (Mo-P4:246), (We-P13:361) Kasem, I., 452 (We-P14:475) 289 (Tu-P10:473), 398 (We-P11:237) Khoury, J., 126 (Mo-P5:364) Kasemi, N., 64 (Mo-P1:85) Kazdova, L., 197 (Tu-P7:57), 371 (We-P11:115), Khusnutdinova, E.K., 396 (We-P11:228) Kaser, S., 410 (We-P12:292) 373 (We-P11:123), 463 (Th-W48:5) Khwaja, H., 289 (Tu-P10:475) Kashiiwagi, A., 58 (Mo-P1:58) Kazi, M., 406 (We-P11:272) Kido, T., 239 (Tu-P7:247), 241 (Tu-P7:257), 290 Kashirina, N.M., 96 (Mo-P3:227) Kazimirova, A., 446 (We-P14:452) (Tu-P10:481), 433 (We-P14:394), 434 Kashiwagi, A., 265 (Tu-P9:368) Keber, I., 75 (Mo-P1:134), 76 (Mo-P1:135), 212 (We-P14:395, We-P14:396), 436 Kashyap, M., 567 (Th-P16:335) (Tu-P7:126) (We-P14:407), 509 (Th-P15:78), 510 Kashyap, M.L., 174 (Tu-W27:4) Kebrdlova, V., 140 (Mo-P6:429) (Th-P15:80) Kasikcioglu, H., 528 (Th-P15:160) Kee, P., 322 (We-W38:5) Kiec-Wilk, B., 76 (Mo-P1:136), 192 (Tu-P7:36), Kasinski, N., 348 (We-P11:13) Keech, A., 330 (We-W42:7), 342 (We-S15:2), 359 208 (Tu-P7:105), 288 (Tu-P10:469), 290 Kaski, J.C., 87 (Mo-P2:184), 122 (Mo-P5:349), (We-P11:62), 557 (Th-P16:290) (Tu-P10:479) 244 (Tu-P7:270), 533 (Th-P15:184) Keech, A.C., 174 (Tu-W27:1) Kiersnowska-Rogowska, B., 270 (Tu-P10:391), Kassai, A., 229 (Tu-P7:203), 577 (Th-P16:382) Keidar, S., 205 (Tu-P7:93), 388 (We-P11:193), 291 (Tu-P10:483) Kassem, M., 185 (Tu-P7:4) 484 (Th-W58:4), 554 (Th-P16:279) Kihara, T., 559 (Th-P16:300)

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

238 Kihlström, E., 84 (Mo-P2:173) Kita, T., 49 (Mo-P1:20), 85 (Mo-P2:179), 195 Koivuniemi, A., 245 (Tu-P7:275) Kikuchi, K., 377 (We-P11:144), 574 (Th-P16:369) (Tu-P7:47), 332 (We-W43:7), 460 Koizumi, J., 255 (Tu-P8:321) Kilic, S., 206 (Tu-P7:96), 395 (We-P11:226) (Th-W46:7), 516 (Th-P15:105) Kojic-Damjanov, S., 82 (Mo-P1:164), 566 Kilit, C., 106 (Mo-P4:274), 218 (Tu-P7:151), 264 Kita, Y., 48 (Mo-P1:14), 52 (Mo-P1:31), 55 (Th-P16:333) (Tu-P9:362, Tu-P9:364) (Mo-P1:45), 56 (Mo-P1:48, Mo-P1:50), 58 Kojima, S., 162 (Tu-W20:8) A Kim, C., 391 (We-P11:207), 392 (We-P11:209) (Mo-P1:58), 59 (Mo-P1:63), 64 (Mo-P1:83), Kojima, T., 259 (Tu-P9:339) Kim, D.J., 503 (Th-P15:48), 519 (Th-P15:122) 76 (Mo-P1:137), 260 (Tu-P9:344) Kojima, Y., 498 (Th-P15:27) Kim, D.K., 267 (Tu-P9:376) Kitagawa, T., 106 (Mo-P4:271), 235 (Tu-P7:231) Kokame, K., 185 (Tu-P7:3), 193 (Tu-P7:41) U Kim, H.H., 266 (Tu-P9:373), 314 (We-W34:7) Kitaguchi, C., 255 (Tu-P8:319) Kokkoris, S., 572 (Th-P16:358) Kim, H.J., 132 (Mo-P6:394), 503 (Th-P15:48), Kitajima, K., 16 (Mo-W3:5) Kokubo, Y., 16 (Mo-W3:7) T 519 (Th-P15:122) Kitajima, S., 238 (Tu-P7:241), 519 (Th-P15:121) Kolansky, D.M., 564 (Th-P16:322) Kim, H.S., 573 (Th-P16:361) Kitamura, Y., 417 (We-P13:321) Kolasinska-Kloch, W., 76 (Mo-P1:136), 208 H Kim, H.W., 266 (Tu-P9:373), 314 (We-W34:7) Kitaoka, C., 283 (Tu-P10:450) (Tu-P7:105), 288 (Tu-P10:469), 290 Kim, J., 391 (We-P11:207), 392 (We-P11:209) Kitaoka, H., 348 (We-P11:14) (Tu-P10:479) O Kim, J.W., 217 (Tu-P7:145), 266 (Tu-P9:372, Kitayama, M., 283 (Tu-P10:450) Koliakos, G., 295 (Tu-P10:500) 314 227 Tu-P9:373), (We-W34:7) Kitchens, R.L., (Tu-P7:194) Kolosov, E., 240 (Tu-P7:251) 98 66 121 R Kim, J.Y., (Mo-P4:238, Mo-P4:239) Kiwanuka, E., (Mo-P1:91), (Mo-P5:345) Kolovou, G.D., 113 (Mo-P5:306), 505 132 234 536 561 Kim, K.M., (Mo-P6:394), (Tu-P7:227), Kiya, Y., (Th-P15:197), (Th-P16:310), (Th-P15:60), 509 (Th-P15:77), 510 247 279 562 571 (Tu-P7:285), (Tu-P10:429) (Th-P16:313), (Th-P16:354) (Th-P15:81) 358 366 568 Kim, M.A., (We-P11:58), (We-P11:94) Kiyan, J., (Th-P16:340) Koltai, K., 82 (Mo-P1:165), 356 (We-P11:47), 398 544 566 417 559 Kim, P.M., (Th-P15:232, Th-P15:236), Kiyanagi, T., (We-P13:321), (We-P11:236) I (Th-P16:330) (Th-P16:301) Komiyama, C., 564 (Th-P16:323) 366 430 Kim, S., (We-P11:94) Kiyose, C., (We-P14:377) Komori, H., 332 (We-W43:7), 516 (Th-P15:105) 358 573 286 357 N Kim, S.H., (We-P11:58), (Th-P16:361) Kjeldsen, S.E., (Tu-P10:460), Komsa, R., 134 (Mo-P6:402) 517 390 Kim, S.S., (Th-P15:112) (We-P11:52), (We-P11:200) Komsa-Penkova, R., 397 (We-P11:232) 132 296 D Kim, S.W., (Mo-P6:394) Klaffke, W., (Tu-P10:505) Konas, D., 112 (Mo-P5:301), 164 (Tu-W21:7) 234 356 Kim, S.Y., (Tu-P7:227) Klefortova, I., (We-P11:48) Kond, K., 239 (Tu-P7:247) Kim, Y.K., 517 (Th-P15:112) Kleiner, D., 237 (Tu-P7:239) Kondo, K., 234 (Tu-P7:226), 241 (Tu-P7:257), E Kim, Y.S., 573 (Th-P16:361) Klementova, M., 371 (We-P11:115) 430 (We-P14:377, We-P14:380), 433 Kim, Y.W., 247 (Tu-P7:285) Klima, H., 586 (Th-P17:422) (We-P14:394), 434 (We-P14:395, X Kimura, G., 528 (Th-P15:161) Klimek, K., 370 (We-P11:110) We-P14:396), 435 (We-P14:402), 436 Kimura, S., 296 (Tu-P10:507), 297 (Tu-P10:509), Klingenberg, R., 407 (We-P11:276) (We-P14:407), 509 (Th-P15:78), 510 388 (We-P11:192) Klinik, I., 471 (Th-W52:5) (Th-P15:80) King, V.L., 489 (Th-W61:3) Kloch, M., 76 (Mo-P1:136), 208 (Tu-P7:105), 288 Kondo, T., 191 (Tu-P7:28), 367 (We-P11:97) King III, S., 476 (Th-W54:7) (Tu-P10:469), 290 (Tu-P10:479) Kondoh, H., 73 (Mo-P1:122), 377 (We-P11:144) King Im, J.U., 267 (Tu-P9:378) Klosiewicz-Latoszek, L., 477 (Th-W55:4) Kondratova, N., 368 (We-P11:102) Kingwell, B.A., 146 (Mo-P6:454), 162 Klug, E., 551 (Th-P16:264) Kong, W., 464 (Th-W49:1) (Tu-W21:2) Klumpp, S., 352 (We-P11:30) Koniari, E., 134 (Mo-P6:404) Kinjo, S., 378 (We-P11:146) Knight, B.L., 515 (Th-P15:101) Kono, S., 280 (Tu-P10:435) Kino, K., 548 (Th-P16:250, Th-P16:251, Knobler, H., 52 (Mo-P1:33) Konodo, K., 187 (Tu-P7:11) Th-P16:252, Th-P16:253) Knopp, R.H., 174 (Tu-W27:4) 347 Kinoshita, F., 428 (We-P13:372) Ko, C., 482 (Th-W57:5) Konstantinou, E., (We-P11:9) 315 Kinoshita, K., 510 (Th-P15:83) Ko, Y.H., 247 (Tu-P7:285) Konstantoulas, C.J., (We-W35:3) 203 Kinoshita, M., 503 (Th-P15:51), 509 (Th-P15:76) Kobayashi, A., 296 (Tu-P10:507), 297 Kontrova, K., (Tu-P7:82) 321 467 Kinoshita, S., 113 (Mo-P5:307), 434 (Tu-P10:509), 388 (We-P11:192) Kontush, A., (We-W38:3), (Th-W50:5), 507 509 534 (We-P14:398) Kobayashi, C., 436 (We-P14:404) (Th-P15:65), (Th-P15:74), Kinsella, M.G., 489 (Th-W61:4) Kobayashi, H., 547 (Th-P16:249) (Th-P15:187) 489 Kiortsis, D.N., 431 (We-P14:382), 553 Kobayashi, J., 255 (Tu-P8:321), 579 (Th-P16:388) Koolwijk, P., (Th-W61:2) 80 104 (Th-P16:271) Kobayashi, K., 528 (Th-P15:161) Kooner, J., (Mo-P1:155, Mo-P1:156), Kipshidze, N., 65 (Mo-P1:87) Kobayashi, T., 195 (Tu-P7:47) (Mo-P4:262) 194 Kipshidze, N.N., 132 (Mo-P6:393), 410 Kobzev, V.F., 78 (Mo-P1:147), 81 (Mo-P1:158) Koota, S., (Tu-P7:44) 132 (We-P12:291), 442 (We-P14:434), 578 Koc, B., 417 (We-P13:323) Kopalkova, L., (Mo-P6:392) (Th-P16:385), 579 (Th-P16:389, Th-P16:390), Koch, L.G., 202 (Tu-P7:77) Kopecky Jr., J., 371 (We-P11:115) 583 (Th-P16:406) Kochman, J., 358 (We-P11:56) Kopff, A., 440 (We-P14:424, We-P14:425) Kirby, A., 330 (We-W42:7) Kocic, M., 261 (Tu-P9:347) Kopff, M., 440 (We-P14:424, We-P14:425) Kirchgessner, T.G., 219 (Tu-P7:156) Kockx, M., 27 (Mo-W9:5), 493 (Th-P15:8), 538 Kopprasch, S., 522 (Th-P15:132) Kireev, R.A., 250 (Tu-P8:296) (Th-P15:205), 541 (Th-P15:219) Korczak, D., 212 (Tu-P7:125) Kirkpatrick, P., 267 (Tu-P9:378) Kodua, T., 410 (We-P12:291) Korennaya, V.V., 444 (We-P14:442) Kirmizis, D., 89 (Mo-P2:193) Koeijvoets, K.C.M.C., 315 (We-W35:4) Korita, I., 272 (Tu-P10:399), 274 (Tu-P10:407, Kishimoto, Y., 239 (Tu-P7:247), 241 (Tu-P7:257), Koelle, P., 400 (We-P11:248) Tu-P10:408), 283 (Tu-P10:448) 430 (We-P14:377), 433 (We-P14:394), 434 Koenig, W., 478 (Th-W56:1) Korkushko, O., 189 (Tu-P7:21) (We-P14:395, We-P14:396), 435 Koestenberger, M., 93 (Mo-P2:212) Kornacewicz-Jach, Z., 84 (Mo-P2:175), 286 (We-P14:402), 436 (We-P14:407), 509 Koh, H., 373 (We-P11:125) (Tu-P10:463), 287 (Tu-P10:464), 569 (Th-P15:78), 510 (Th-P15:80) Köhler, M., 200 (Tu-P7:72) (Th-P16:343) Kisilevsky, R., 495 (Th-P15:13), 544 Kohlmann, O., 376 (We-P11:138) Korneti, P., 547 (Th-P15:246) (Th-P15:232, Th-P15:236), 566 (Th-P16:330) Kohno, H., 378 (We-P11:146) Koroleva, O.S., 131 (Mo-P6:387) Kisliak, O., 379 (We-P11:153) Koide, N., 417 (We-P13:320), 498 (Th-P15:29) Korotaeva, A.A., 581 (Th-P16:400) Kiso, Y., 454 (We-P14:485) Koike, T., 238 (Tu-P7:241) Korpela, R., 431 (We-P14:383)

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

239 Korporaal, S.J., 90 (Mo-P2:198) Kowalewski, M., 211 (Tu-P7:121), 377 Krzeminska - Pakula, M., 98 (Mo-P4:235), 143 Kortelainen, M-L., 251 (Tu-P8:302) (We-P11:141) (Mo-P6:443) Korth, R.-M., 506 (Th-P15:64) Kowalska, M., 269 (Tu-P9:388) Kubies, D., 404 (We-P11:265) Kortsaris, A.X., 87 (Mo-P2:184), 533 Kowalski, J., 62 (Mo-P1:77), 412 (We-P12:299), Kuboki, K., 279 (Tu-P10:431) A (Th-P15:184) 425 (We-P13:356) Kubota, N., 164 (Tu-W22:1) Korvenranta, H., 124 (Mo-P5:358) Kowalski, M., 412 (We-P12:299) Kucharchuk, V.V., 557 (Th-P16:291) Korzh, I., 348 (We-P11:11), 571 (Th-P16:353) Kozak, L., 132 (Mo-P6:392) Kuchibhotla, S., 490 (Th-W61:7) U Korzh, O., 239 (Tu-P7:248), 281 (Tu-P10:441) Kozaki, K., 217 (Tu-P7:147), 585 (Th-P16:417) Kucuk, M.A., 74 (Mo-P1:130), 289 (Tu-P10:473) Kosaka, K., 496 (Th-P15:17) Kozàkovà, M., 474 (Th-W53:7) Kuczynska, K., 276 (Tu-P10:416) T Koscak, K., 357 (We-P11:53) Kozarova, M., 560 (Th-P16:305) Kufaishi, H.F., 488 (Th-W60:6) Koseki, M., 28 (Mo-W9:6), 237 (Tu-P7:237), 510 Kozlowska-Wojciechowska, M., 78 (Mo-P1:144), Kuhl, P., 194 (Tu-P7:43) H (Th-P15:82), 575 (Th-P16:372) 435 (We-P14:401), 451 (We-P14:472) Kuhn, H., 528 (Th-P15:162) Kosmider, A., 223 (Tu-P7:173, Tu-P7:174), 432 Kozminski, P., 188 (Tu-P7:14) Kuijpers, M., 390 (We-P11:202) O (We-P14:390) Kraaijeveld, A.O., 98 (Mo-P4:236), 487 Kuijpers, M.J.E., 390 (We-P11:203) Kosmidou, I., 277 (Tu-P10:424) (Th-W60:4) Kuiper, J., 33 (Mo-W12:4), 90 (Mo-P2:198) 177 255 Kostapanos, M., 369 (We-P11:105), 499 Krag, T., 382 (We-P11:167) Kuipers, F., (Tu-W28:5), (Tu-P8:318), R 318 450 495 (Th-P15:33), 561 (Th-P16:308), 577 Krajewska, B., 270 (Tu-P10:392) (We-W37:1), (We-P14:471), (Th-P16:381), 582 (Th-P16:404) Kraml, P.J., 277 (Tu-P10:421) (Th-P15:15) 19 24 Kostara, C., 368 (We-P11:104), 582 (Th-P16:404) Kranidis, A., 104 (Mo-P4:266) Kuivenhoven, J.A., (Mo-W5:2), 70 95 Kostarska-Srokosz, E., 533 (Th-P15:181) Kranjcevic, S., 83 (Mo-P2:170) (Mo-W7:5), (Mo-P1:109), (Mo-P3:223), 134 138 335 I Kostic, N., 386 (We-P11:182) Krapivner, S., 492 (Th-P15:2), 505 (Th-P15:56) (Mo-P6:403), (Mo-P6:420), 544 589 Kostic, V.S., 352 (We-P11:28) Krasnokutskiy, S., 239 (Tu-P7:248) (We-W45:6), (Th-P15:235), Kostic, Z., 441 (We-P14:428) Krassas, G.E., 568 (Th-P16:341) (Th-P17:437) N 116 585 Kostidou, H., 295 (Tu-P10:500) Kratzmeier, M., 588 (Th-P17:429, Th-P17:430, Kukharchuk, V., (Mo-P5:321), Kostner, K., 442 (We-P14:435), 469 (Th-W51:5), Th-P17:432) (Th-P16:416) D 357 538 (Th-P15:204) Krause, B., 543 (Th-P15:230) Kukolja, K., (We-P11:53) 559 Kostov, D., 382 (We-P11:164) Krautkrämer, M., 526 (Th-P15:151) Kulach, A., (Th-P16:299) Kuliczkowski, W., 281 (Tu-P10:438) E Kostovska, S., 272 (Tu-P10:402) Krauze, J., 72 (Mo-P1:117) Kulikov, I.V., 78 (Mo-P1:147), 81 (Mo-P1:158) Kosuge, K., 361 (We-P11:72), 575 (Th-P16:373) Kravchun, N., 383 (We-P11:169), 418 Kuller, L.H., 52 (Mo-P1:31) X Kosztáczky, B., 229 (Tu-P7:203), 571 (We-P13:327) Kumagai, K., 99 (Mo-P4:241), 268 (Tu-P9:383) (Th-P16:355), 577 (Th-P16:382) Krdzalic, N., 106 (Mo-P4:275) Kumar, P., 246 (Tu-P7:281) Kotake, H., 225 (Tu-P7:185), 366 (We-P11:96) Kremastinos, D., 574 (Th-P16:368) Kume, A., 417 (We-P13:321), 559 (Th-P16:301) Kotani, K., 520 (Th-P15:127) Krempf, M., 306 (We-W30:7), 331 (We-W43:4) Kume, N., 85 (Mo-P2:179), 460 (Th-W46:7) Kotchuev, G., 239 (Tu-P7:248) Krennmair, G., 283 (Tu-P10:449), 413 Kumon, Y., 210 (Tu-P7:115), 254 (Tu-P8:314), Kotowski, I., 150 (Tu-PL2:4) (We-P12:306) 294 (Tu-P10:499), 539 (Th-P15:211) Kotsia, A., 298 (Tu-P10:517) Krettek, A., 22 (Mo-W6:6) Kumor, P., 263 (Tu-P9:361) Kotur-Stevuljevic, J., 381 (We-P11:161) Krieger, M., 330 (We-W43:1) Kunii, H., 87 (Mo-P2:186) Koubaa, N., 131 (Mo-P6:388), 349 (We-P11:18), Krieger, M.H., 197 (Tu-P7:56, Tu-P7:58) Kunimatsu, M., 528 (Th-P15:161) 438 (We-P14:415) Krieglstein, J., 352 (We-P11:30) Kunnas, T., 241 (Tu-P7:256) Koukoulidou, Z., 277 (Tu-P10:424), 361 Krinos, X., 58 (Mo-P1:56), 84 (Mo-P2:171) Kunnas, T.A., 251 (Tu-P8:302) 233 (We-P11:69) Krispin, A., (Tu-P7:222) Kunne, C., 495 (Th-P15:15) 67 104 169 170 Koulouris, S., (Mo-P1:99), (Mo-P4:266) Kristenson, M., (Tu-W25:1), (Tu-W25:3), Kunstmann, S., 65 (Mo-P1:89), 80 (Mo-P1:157), 109 422 427 Kountana, E., (Mo-P4:286) (We-P13:342), (We-P13:367) 125 (Mo-P5:361), 201 (Tu-P7:73) 30 317 Kountidis, M., (Mo-W10:7) Kritchevsky, S., (We-W36:5) Kuo, S., 193 (Tu-P7:37) 81 122 27 167 Kountouras, J., (Mo-P1:162), (Mo-P5:348) Kritharides, L., (Mo-W9:5), (Tu-W23:6), Kuo, W.W., 270 (Tu-P10:389, Tu-P10:390) 89 492 493 Koutoupa, E., (Mo-P2:193) (Th-P15:4), (Th-P15:5, Th-P15:8), Kupari, M., 100 (Mo-P4:245), 110 (Mo-P4:292), 64 538 541 Koutrakis, K., (Mo-P1:82) (Th-P15:205), (Th-P15:219) 242 (Tu-P7:264) 262 414 Kovac, M., (Tu-P9:352) Kritikos, H.D., (We-P12:307) Kurata, H., 239 (Tu-P7:247), 241 (Tu-P7:257) 397 118 Kovacheva, K., (We-P11:232) Krivosikova, Z., (Mo-P5:329, Mo-P5:330) Kurbanov, R.D., 67 (Mo-P1:98), 83 (Mo-P1:462) 200 53 Kovacs, A., (Tu-P7:72) Krneta, M., (Mo-P1:34) Kurihara, N., 377 (We-P11:140), 385 383 418 103 Koval, S., (We-P11:169), (We-P13:327) Kroese, A., (Mo-P4:258) (We-P11:178) Kovalyova, I.S., 548 (Th-P16:254) Kronenberg, M., 80 (Mo-P1:154) Kuriyama, H., 547 (Th-P16:249) Kovalyova, O., 240 (Tu-P7:251) Kroner, C., 444 (We-P14:444) Kurkowska-Jastrzebska, I., 282 (Tu-P10:443) Kovanen, P., 242 (Tu-P7:264), 497 (Th-P15:23), Kroschinsky, F., 412 (We-P12:298) Kurkutyte, S., 66 (Mo-P1:92) 540 (Th-P15:216) Krotin, M., 127 (Mo-P5:373), 358 (We-P11:57) Kurobe, H., 106 (Mo-P4:271), 235 (Tu-P7:231) Kovanen, P.T., 8 (Mo-PL1:3), 93 (Mo-P2:216), Krstacic, A., 47 (Mo-P1:5) Kurosawa, S., 22 (Mo-W6:5) 100 (Mo-P4:245), 110 (Mo-P4:292), 157 Krstacic, G., 47 (Mo-P1:5) Kurpesa, M., 98 (Mo-P4:235), 143 (Mo-P6:443) (Tu-W18:5), 166 (Tu-W23:3), 232 Krstevska, M., 73 (Mo-P1:123), 272 Kurtanidze, T., 389 (We-P11:198) (Tu-P7:216), 244 (Tu-P7:269), 245 (Tu-P10:402), 373 (We-P11:126) Kurtanidze, T.I., 385 (We-P11:181) (Tu-P7:275), 246 (Tu-P7:278), 249 Krstevska, Z., 356 (We-P11:46) Kurth, T., 66 (Mo-P1:93) (Tu-P8:291), 460 (Th-W46:3), 463 Krug, A.W., 522 (Th-P15:132) Kurtsdotter, I., 200 (Tu-P7:72) (Th-W48:4), 490 (Th-W61:6), 496 Krüger, M., 295 (Tu-P10:502) Kurtz, T.W., 373 (We-P11:123), 463 (Th-W48:5) (Th-P15:19), 497 (Th-P15:24) Kruijt, J.K., 152 (Tu-W16:2) Kuryata, D.V., 580 (Th-P16:396) Kovar, J., 139 (Mo-P6:424), 197 (Tu-P7:57), 407 Kruit, J.K., 255 (Tu-P8:318), 450 (We-P14:471) Kuryata, O.V., 126 (Mo-P5:366) (We-P12:278) Krusinova, E., 371 (We-P11:115) Kusakabe, T., 575 (Th-P16:371) Kow, L., 381 (We-P11:162) Kruth, H., 515 (Th-P15:100) Kusano, J., 503 (Th-P15:51), 509 (Th-P15:76) Kowalczyk, E., 440 (We-P14:424, We-P14:425) Krysiak, R., 559 (Th-P16:299) Kusch, A., 568 (Th-P16:340)

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

240 Kush, D., 174 (Tu-W27:3) Laloux, B., 163 (Tu-W21:4) Lätti, S., 244 (Tu-P7:269) Kusuhara, M., 581 (Th-P16:398) Lam, H., 193 (Tu-P7:37) Laucevicius, A., 214 (Tu-P7:132) Kuswardhani, T., 346 (We-P11:2) Lam, K.S.L., 186 (Tu-P7:6), 187 (Tu-P7:10) Laudani, R., 106 (Mo-P4:273) Kutschera, J., 93 (Mo-P2:212) Lam, M.C.W., 186 (Tu-P7:6) Laulagnier, K., 252 (Tu-P8:307) Kuvshinova, E., 250 (Tu-P8:296) Lam, W.M.W., 93 (Mo-P2:213) Laurent, E., 271 (Tu-P10:395) A Kuwahara, H., 505 (Th-P15:58) Lamarche, B., 175 (Tu-W27:6), 443 Laurent, S., 163 (Tu-W21:4) Kuwasako, T., 510 (Th-P15:82) (We-P14:438), 445 (We-P14:446), 474 Laurent, Y., 370 (We-P11:113), 427 (We-P13:365) Kuwashima, R., 186 (Tu-P7:5), 191 (Tu-P7:31), (Th-W54:1), 475 (Th-W54:4) Lauretani, F., 471 (Th-W52:4), 480 (Th-W56:6), U 577 (Th-P16:380) Lamb, H.J., 267 (Tu-P9:375) 530 (Th-P15:171), 534 (Th-P15:188) Kuzmanic, D., 376 (We-P11:136), 384 Lambert, D., 507 (Th-P15:66) Laurie, A.D., 135 (Mo-P6:406) T (We-P11:175) Lambert, G., 306 (We-W30:7) Laurita, E., 422 (We-P13:343) Kuznetsov, V., 109 (Mo-P4:287) Lambropoulos, S., 63 (Mo-P1:78) Lauro, D., 165 (Tu-W22:6), 221 (Tu-P7:166), 312 H Kuznetsova, S., 109 (Mo-P4:287) Lamm, G., 283 (Tu-P10:449), 413 (We-P12:306) (We-W33:7), 371 (We-P11:116), 372 Kuznetsova, S.M., 107 (Mo-P4:280) Lancellotti, S., 19 (Mo-W5:3) (We-P11:122), 425 (We-P13:355), 450 O Kuznetsova, T.V., 283 (Tu-P10:447) Landa, V., 463 (Th-W48:5) (We-P14:468) 286 Kvas, E., 12 (Mo-W1:4) Landaas, S., (Tu-P10:460) Lauro, R., 165 (Tu-W22:6), 169 (Tu-W24:6), 173 105 R Kwasniak, M., 141 (Mo-P6:433) Landi, A., (Mo-P4:267) (Tu-W26:5), 221 (Tu-P7:166), 298 366 70 Kyoko, T., (We-P11:96) Landi, P., (Mo-P1:111) (Tu-P10:514), 312 (We-W33:7), 372 420 507 157 Kyotani, S., (We-P13:335), (Th-P15:67) Landis, R.C., (Tu-W18:4) (We-P11:122), 425 (We-P13:355), 450 39 570 Kypreos, K.E., (Mo-W15:8) Landl, E.-M., (Th-P16:349) (We-P14:468) 214 571 Landsberger, M., (Tu-P7:135), Lauwers, A., 515 (Th-P15:102) I 370 L’Huillier, I., (We-P11:113) (Th-P16:352) Lavecchia, A., 372 (We-P11:119) Laakso, M., 194 (Tu-P7:44) 493 Lane, A.E., (Th-P15:8) Laverda, B., 350 (We-P11:21, We-P11:22) Laaksonen, R., 18 (Mo-W4:4), 236 (Tu-P7:235) 236 N Langaas, M., (Tu-P7:234) Lavitrano, M.L., 207 (Tu-P7:102) Laane, P., 375 (We-P11:133) 142 334 Langaee, T.Y., (Mo-P6:439), (We-W44:7) Lawlor, D.A., 34 (Mo-W13:3) Laatsch, A., 30 (Mo-W11:1), 493 (Th-P15:6), 508 401 D Lange, J.M., (We-P11:250) Lawn, R.M., 166 (Tu-W23:2) (Th-P15:70) 14 89 Langefeld, C.D., (Mo-W2:6), (Mo-P2:196), Lawrence, J.M., 330 (We-W42:6), 358 La Barba, G., 88 (Mo-P2:192), 173 (Tu-W26:7) 335 (We-W45:5) (We-P11:55) E Lablanche, J.-M., 578 (Th-P16:384) Langer, A., 572 (Th-P16:356), 584 (Th-P16:413) Lay, P., 587 (Th-P17:425) Labrou, A., 353 (We-P11:36) Langlois, M., 293 (Tu-P10:494) Lazarev, P.A., 548 (Th-P16:254) X Labudovic, D., 140 (Mo-P6:428), 502 Langmann, T., 26 (Mo-W9:2), 192 (Tu-P7:36) Lazaro, I., 188 (Tu-P7:15), 522 (Th-P15:133) (Th-P15:43), 531 (Th-P15:174) Langslet, G., 551 (Th-P16:266) Lazovic, M., 393 (We-P11:214) Labudovic, D.D., 70 (Mo-P1:108), 547 Laniewska, I., 175 (Tu-W27:7) Le, S.J., 325 (We-W40:5) (Th-P15:246) Lankin, Z., 354 (We-P11:39), 585 (Th-P16:416) Le, V.H., 441 (We-P14:429) Labuzek, K., 573 (Th-P16:363) Lánská, V., 385 (We-P11:179) Leake, D.S., 256 (Tu-P8:327), 523 (Th-P15:138) La Carrubba, S., 71 (Mo-P1:116) Lanska, V., 48 (Mo-P1:13), 124 (Mo-P5:356), 139 Leanderson, P., 84 (Mo-P2:173) Lackland, D., 51 (Mo-P1:26) (Mo-P6:423), 486 (Th-W59:6) Leandersson, P., 158 (Tu-W18:7) Laclaustra, M., 130 (Mo-P6:385) Lanza, M., 414 (We-P12:309) Lebioda, A., 137 (Mo-P6:415) Lacombe, K., 163 (Tu-W21:4) Lapcikova, M., 252 (Tu-P8:308) Lebrazi, H., 280 (Tu-P10:436), 518 (Th-P15:114, Lægreid, A., 236 (Tu-P7:234) Lapice, E., 31 (Mo-W11:5), 51 (Mo-P1:25) Th-P15:116) Laezza, C., 33 (Mo-W12:5) Lapini, I., 207 (Tu-P7:102), 391 (We-P11:205), 194 Laffargue, M., 249 (Tu-P8:295), 252 (Tu-P8:307) 530 (Th-P15:169) Lebrun, S., (Tu-P7:43) 549 Lafontan, M., 40 (Mo-S4:1) Lapinleimu, J., 313 (We-W34:3) Lecchini, S., (Th-P16:257) 443 Laganovic, M., 376 (We-P11:136), 384 Lapinski, M., 276 (Tu-P10:416) Lecef, J.M., (We-P14:437) 473 (We-P11:175) Lapolla, A., 350 (We-P11:22) Lecerf, J.M., (Th-W53:3) 239 Lagercrantz, J., 145 (Mo-P6:449) Lappalainen, J., 242 (Tu-P7:264), 460 (Th-W46:3) Leclercq, A., (Tu-P7:246) 493 Laggner, H., 525 (Th-P15:149) Lapsley, K.G., 434 (We-P14:396), 476 Le Couteur, D.G., (Th-P15:5) 374 Laggner, P., 500 (Th-P15:36) (Th-W55:1) Lecube, A., (We-P11:130) 99 383 Laghi, L., 50 (Mo-P1:24), 68 (Mo-P1:102), 425 Lapsys, N., 442 (We-P14:435) Lee, C.H., (Mo-P4:240), (We-P11:170) 437 (We-P13:358), 453 (We-P14:482), 532 Laratta, E., 21 (Mo-W6:4), 367 (We-P11:98), 371 Lee, C.M., (We-P14:409) 171 (Th-P15:179) (We-P11:116) Lee, G., (Tu-W25:5) 573 Lago, A., 397 (We-P11:235) Larigauderie, G., 234 (Tu-P7:228), 492 (Th-P15:1) Lee, H.Y., (Th-P16:361) Lagunas, R., 216 (Tu-P7:141) Larmann, J., 535 (Th-P15:192) Lee, J.L., 333 (We-W44:5) Lähdesmäki, K., 496 (Th-P15:19) Larosa, J.C., 121 (Mo-P5:344) Lee, K.W., 503 (Th-P15:48), 519 (Th-P15:122) Lahrach, H., 280 (Tu-P10:436), 518 (Th-P15:114, Larsson, D.A., 529 (Th-P15:166) Lee, L., 78 (Mo-P1:146) Th-P15:116) Larsson, P., 159 (Tu-W19:3) Lee, M., 166 (Tu-W23:3) Lai, B., 587 (Th-P17:425) Lartigue, A., 219 (Tu-P7:155) Lee, M.K., 423 (We-P13:349) Lai, K., 257 (Tu-P8:329) Lascasas, A.A., 435 (We-P14:403) Lee, M.N., 455 (We-P14:489) Laine, P., 157 (Tu-W18:5) La Sorda, R., 14 (Mo-W2:5) Lee, M.R., 455 (We-P14:489) Laios, E., 134 (Mo-P6:404), 333 (We-W44:6) Lass, A., 15 (Mo-W3:1) Lee, S.D., 270 (Tu-P10:389, Tu-P10:390) Lalanne, L., 453 (We-P14:479) Lassila, M., 556 (Th-P16:287) Lee, S.H., 98 (Mo-P4:238, Mo-P4:239), 267 Lalayanc, M.R., 89 (Mo-P2:195) Lasunción, M.A., 186 (Tu-P7:9) (Tu-P9:376), 588 (Th-P17:431) Lalic, K., 351 (We-P11:25, We-P11:26, Latkovskis, G., 142 (Mo-P6:438) Lee, S.J., 202 (Tu-P7:77) We-P11:27), 502 (Th-P15:46), 503 Latorre, G., 383 (We-P11:171) Lee, T.M., 549 (Th-P16:255) (Th-P15:47) Latrilha, M.C., 501 (Th-P15:41), 535 Lee, W.J., 423 (We-P13:349) Lalic, N.M., 351 (We-P11:25, We-P11:26, (Th-P15:191) Lee, W.L., 242 (Tu-P7:260) We-P11:27), 352 (We-P11:28) Latrilha, M.C.M., 347 (We-P11:8) Lee, Y., 587 (Th-P17:425) Lally, S., 39 (Mo-W15:6) Lattanzio, S., 524 (Th-P15:144) Lee, Y.M., 455 (We-P14:489)

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

241 Lee, Y.T., 48 (Mo-P1:15), 369 (We-P11:106) Levkau, B., 157 (Tu-W18:6), 535 (Th-P15:192) Lievens, J., 94 (Mo-P3:218), 153 (Tu-W16:6), 490 Lee-Rueckert, M., 540 (Th-P15:216) Levy, A.P., 230 (Tu-P7:207) (Th-W61:8) Legedz, L., 355 (We-P11:44) Levy, N., 230 (Tu-P7:207) Likitjaroen, Y., 109 (Mo-P4:289) Le Goff, W., 321 (We-W38:3), 541 (Th-P15:220) Lewandowski, J., 276 (Tu-P10:416) Lima, E., 400 (We-P11:245) A Legssyer, I., 524 (Th-P15:141) Lewandowski, M., 84 (Mo-P2:175), 286 Limon, I., 168 (Tu-W24:5) Le Hello, C., 57 (Mo-P1:51) (Tu-P10:463), 287 (Tu-P10:464), 569 Limon, J., 129 (Mo-P6:380) Lehmann, R., 358 (We-P11:54) (Th-P16:343) Lin, C.-P., 265 (Tu-P9:369) U Lehrke, M., 141 (Mo-P6:432) Lewandowski, Z., 212 (Tu-P7:125) Lin, C.C., 383 (We-P11:170) Lehtimäki, T., 18 (Mo-W4:4), 68 (Mo-P1:101), Lewczuk, P., 512 (Th-P15:88) Lin, C.P., 293 (Tu-P10:493) T 124 (Mo-P5:358) Lewinski, A., 412 (We-P12:299), 425 Lin, F.Y., 235 (Tu-P7:230), 242 (Tu-P7:260), 251 Lehtinen, A.B., 89 (Mo-P2:196) (We-P13:356) (Tu-P8:304) H Lehtiniemi, J., 235 (Tu-P7:232) Lewis, P., 77 (Mo-P1:140), 317 (We-W36:3) Lin, H.-H., 95 (Mo-P3:221) Lehto, M., 39 (Mo-W15:5) Li, C., 464 (Th-W49:1), 588 (Th-P17:429, Lin, L.J., 99 (Mo-P4:240), 397 (We-P11:231) O Leibovitz, E., 102 (Mo-P4:255), 115 (Mo-P5:314), Th-P17:430, Th-P17:432) Lin, M., 464 (Th-W49:1) 554 (Th-P16:276) Li, D.Y., 59 (Mo-P1:61) Lin, M.S., 549 (Th-P16:255) 71 235 238 242 Leichtle, A., (Mo-P1:115) Li, G.H., 96 (Mo-P3:230), 232 (Tu-P7:217), 393 Lin, S.J., (Tu-P7:230), (Tu-P7:242), R 359 500 251 253 Leinonen, E., (We-P11:62), (Th-P15:37) (We-P11:217), 529 (Th-P15:167) (Tu-P7:260), (Tu-P8:304), 85 293 Leinonen, M., (Mo-P2:176) Li, H., 216 (Tu-P7:142), 470 (Th-W51:7) (Tu-P8:312), (Tu-P10:493) 476 572 59 Leiter, L.A., (Th-W55:1), (Th-P16:356), Li, H.B., 144 (Mo-P6:445) Lin, S.P., (Mo-P1:61) 584 450 (Th-P16:413) Li, H.G., 212 (Tu-P7:124), 565 (Th-P16:327) Lin, Y., (We-P14:471) 133 233 61 532 I Leitersdorf, E., (Mo-P6:399), Li, J., 215 (Tu-P7:138), 223 (Tu-P7:175), 293 Linarello, S., (Mo-P1:69), (Th-P15:179), 514 564 (Tu-P7:222), (Th-P15:98) (Tu-P10:490) (Th-P16:321) 160 103 Leitinger, N., (Tu-W19:7) Li, J.J., 195 (Tu-P7:49) Lindahl, A.K., (Mo-P4:258) N 124 171 Lejskova, M., (Mo-P5:356) Li, J.Y., 81 (Mo-P1:160) Lindahl, M., (Tu-W25:7) 511 196 Lekhal, S., (Th-P15:87) Li, K., 494 (Th-P15:12) Lindahl, P., (Tu-P7:52) D 254 413 Lelliott, C., (Tu-P8:315) Li, L., 202 (Tu-P7:79), 203 (Tu-P7:84) Lindahl, T., (We-P12:305) 580 566 Lemaulf, F., (Th-P16:395) Li, M., 94 (Mo-P3:219) Lindberg, R., (Th-P16:329) Lembcke, A., 218 (Tu-P7:150) Lindegaard, M.L.S., 14 (Mo-W2:4), 497 E Li, N., 237 (Tu-P7:238) Lembcke, J., 71 (Mo-P1:115) (Th-P15:21) Li, Q.K., 195 (Tu-P7:49), 212 (Tu-P7:124), 228 Leme Da Rocha Martinez, T., 54 (Mo-P1:41), 79 Lindén, D., 254 (Tu-P8:315) X (Tu-P7:199), 322 (We-W38:7), 565 (Mo-P1:150) Lindgren, P., 178 (Tu-W29:5) (Th-P16:327) Lemieux, I., 165 (Tu-W22:5), 421 (We-P13:340), Lindman, A.S., 467 (Th-W50:4) Li, W., 158 (Tu-W18:7), 271 (Tu-P10:396), 328 475 (Th-W54:4, Th-W54:5) Lindsberg, P.J., 93 (Mo-P2:216), 246 (Tu-P7:278) (We-W41:7), 529 (Th-P15:166) Lemieux, S., 445 (We-P14:446), 586 (Th-P17:420) Lindstedt, K.A., 100 (Mo-P4:245), 110 Li, W.T., 383 (We-P11:170) Lemire, M., 131 (Mo-P6:391) (Mo-P4:292), 232 (Tu-P7:216), 242 Li, X.Y., 94 (Mo-P3:220) Lemonidis, K.M., 466 (Th-W49:5) (Tu-P7:264), 244 (Tu-P7:269), 249 Li, Y., 65 (Mo-P1:88), 515 (Th-P15:100) Lenihan, D.J., 91 (Mo-P2:207) (Tu-P8:291), 460 (Th-W46:3) Li, Y.H., 199 (Tu-P7:67), 397 (We-P11:231), 573 Lensing, A.W.A., 74 (Mo-P1:127) Lindström, E., 91 (Mo-P2:206), 173 (Tu-W26:6), (Th-P16:364) Lenti, L., 173 (Tu-W26:5), 298 (Tu-P10:514), 525 203 (Tu-P7:85) Li, Y.Q., 144 (Mo-P6:445) (Th-P15:147) Ling, L., 165 (Tu-W22:7) Li, Z., 464 (Th-W49:1) Lenti, M., 207 (Tu-P7:102), 396 (We-P11:230) Ling, W., 541 (Th-P15:221) 369 Lentzas, I., 347 (We-P11:9), 348 (We-P11:10) Liamis, G., (We-P11:105) Linhartova, K., 111 (Mo-P4:295) 193 Leonchik, L., 14 (Mo-W2:6) Liang, H., (Tu-P7:37) Linseisen, J., 177 (Tu-W28:5) 195 322 Leone, A., 106 (Mo-P4:273) Liao, D.F., (Tu-P7:49), (We-W38:7) Lionetti, M., 431 (We-P14:385) 434 Leonetti, S., 266 (Tu-P9:374), 268 (Tu-P9:380) Liau, C.S., (We-P14:399) Lipinska, A., 212 (Tu-P7:125) 277 Leontari, R., 64 (Mo-P1:82) Liavas, C., (Tu-P10:424) Lira, M.T., 65 (Mo-P1:89), 80 (Mo-P1:157) 361 Leppänen, P., 194 (Tu-P7:44) Liavas, C.H., (We-P11:69) Lishnevskaya, V., 189 (Tu-P7:21) 168 480 Leren, T.P., 36 (Mo-W14:3) Libby, P., (Tu-W24:2, Tu-W24:4), Lisitzyn, D.M., 505 (Th-P15:59) Le Roy, B., 449 (We-P14:466) (Th-W56:5) Lissner, L., 421 (We-P13:339) 146 147 Lesczynska-Golabek, I., 416 (We-P13:319) Liberatoscioli, L., (Mo-P6:453), Liszewska-Pfejfer, D., 212 (Tu-P7:125) 353 Leskinen, M.J., 244 (Tu-P7:269) (Mo-P6:457), (We-P11:33) Litovsky, S., 309 (We-W32:4) 499 501 Lesnik, P., 190 (Tu-P7:24), 328 (We-W41:6) Liberopoulos, E., (Th-P15:32), Little, P.J., 242 (Tu-P7:263) Lessiani, G., 88 (Mo-P2:192) (Th-P15:42), 517 (Th-P15:113), 560 Littlewood, T.D., 21 (Mo-W6:2) Leszczynska-Golabek, I., 35 (Mo-W13:7), 417 (Th-P16:303) Liu, C.H., 144 (Mo-P6:445) (We-P13:324) Liberopoulos, E.N., 63 (Mo-P1:78), 553 Liu, G., 95 (Mo-P3:222) Letocha, O., 132 (Mo-P6:392) (Th-P16:271) Liu, G.-Q., 498 (Th-P15:26) Leu, H.B., 238 (Tu-P7:242), 293 (Tu-P10:493) Librelotto, J., 523 (Th-P15:136) Liu, H.-R., 498 (Th-P15:26) Leutke, M., 218 (Tu-P7:153), 313 (We-W34:5) Licastro, F., 209 (Tu-P7:112) Liu, J., 464 (Th-W49:1) Levander, L., 287 (Tu-P10:467) Licata, G., 420 (We-P13:336), 437 (We-P14:412) Liu, J.C., 296 (Tu-P10:508) Levels, H.A.N., 533 (Th-P15:183) Licenziati, M.R., 261 (Tu-P9:348) Liu, L.S., 210 (Tu-P7:117), 232 (Tu-P7:217), 233 Levels, J.H., 124 (Mo-P5:357) Lichtenstein, A.H., 380 (We-P11:157) (Tu-P7:219), 234 (Tu-P7:224), 254 Levels, J.H.M., 153 (Tu-W16:5), 589 Lichtman, J., 82 (Mo-P1:167) (Tu-P8:317), 403 (We-P11:262), 516 (Th-P17:437) Licis, N., 142 (Mo-P6:438) (Th-P15:108), 539 (Th-P15:209), 543 Levenson, J., 269 (Tu-P9:387) Licitra, R., 266 (Tu-P9:374), 268 (Tu-P9:380) (Th-P15:227), 544 (Th-P15:231) Lever, M., 274 (Tu-P10:409) Liebermann, H., 214 (Tu-P7:135) Liu, N., 372 (We-P11:120) Lever, M.J., 587 (Th-P17:426) Liebisch, G., 26 (Mo-W9:2) Liu, P.Y., 99 (Mo-P4:240), 199 (Tu-P7:67) Levesque, H., 219 (Tu-P7:155), 261 (Tu-P9:351) Liedberg, B., 158 (Tu-W18:7) Liu, Q., 256 (Tu-P8:325) Levi, M., 533 (Th-P15:183) Liens, D., 121 (Mo-P5:346), 178 (Tu-W29:4) Liu, S.L., 199 (Tu-P7:67), 573 (Th-P16:364)

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

242 Liu, T.L., 437 (We-P14:409) Lorenzova, A., 141 (Mo-P6:435), 285 (Tu-P7:217), 233 (Tu-P7:219), 393 Liu, X.J., 59 (Mo-P1:61) (Tu-P10:458) (We-P11:217), 529 (Th-P15:167) Liu, Y., 195 (Tu-P7:49), 212 (Tu-P7:124), 228 Loria, P., 46 (Mo-P1:4), 256 (Tu-P8:323), 257 Lyberg, T., 357 (We-P11:52) (Tu-P7:199), 322 (We-W38:7), 335 (Tu-P8:328), 410 (We-P12:289), 411 469 565 472 (We-W45:5), (Th-W51:5), (We-P12:294), (Th-W52:7) Ma, J., 541 (Th-P15:221) 127 A (Th-P16:327) Lorincz, I., (Mo-P5:371) Ma, R., 202 (Tu-P7:79) 572 81 Liu, Y.X., (Th-P16:360) Losy, F., (Mo-P1:161) Mabuchi, H., 255 (Tu-P8:321), 579 (Th-P16:388) 351 51 U Liuba, P., (We-P11:24) Lotan, C., (Mo-P1:27) Macchioni, D., 472 (Th-W52:7) 407 514 Liubimova, L., (We-P12:280) Lotan, H., (Th-P15:98) Macdonell, G., 174 (Tu-W27:3) 205 512 Liuzzi, G., (Tu-P7:92) Lottenberg, A.M., (Th-P15:90) Macedo, A., 546 (Th-P15:242) T 277 349 31 540 Liuzzo, G., (Tu-P10:422), (We-P11:16) Lottenberg, A.M.P., (Mo-W11:4), Macedo, M.E., 120 (Mo-P5:337) 37 Livingstone, S., (Mo-W14:4) (Th-P15:215) Macesic, M., 352 (We-P11:28) H 241 527 Liwanag, M., (Tu-P7:258) Lottenberg, S.A., (Th-P15:154, Th-P15:155) Macfarlane, L.A., 168 (Tu-W24:4) 360 101 Ljubic, S., (We-P11:64) Lourenço, P., (Mo-P4:250, Mo-P4:251) Macfarlane, R., 508 (Th-P15:72) O Ljung, T., 421 (We-P13:339) Lourida, E., 503 (Th-P15:49) Macfarlane, R.D., 587 (Th-P17:428) Ljungberg, A., 254 (Tu-P8:315) Loutﬁ, M., 123 (Mo-P5:355) Machado, C., 419 (We-P13:330) Llamas, R., 374 (We-P11:130) Loutsidis, K.E., 84 (Mo-P2:171) R Machida, M., 430 (We-P14:377) Llobera, M., 498 (Th-P15:28) Louvel, J.P., 261 (Tu-P9:351) Machida, N., 239 (Tu-P7:247), 241 (Tu-P7:257), Llorente Cortes, V., 331 (We-W43:5) Lovati, M.R., 343 (We-S16:2), 454 (We-P14:484) 433 (We-P14:394), 434 (We-P14:395, Lloret, R., 552 (Th-P16:267) Lovcanska, J., 532 (Th-P15:178) We-P14:396), 435 (We-P14:402), 436 Lloyd-Jones, D., 483 (Th-W58:2) Love, W., 588 (Th-P17:429, Th-P17:432) (We-P14:407), 509 (Th-P15:78), 510 I Locsey, L., 127 (Mo-P5:371), 292 (Tu-P10:489), Low, P.S., 590 (Th-P17:438) (Th-P15:80) 518 (Th-P15:115) Lowe, G.D., 312 (We-W33:5) Machova, L., 404 (We-P11:265) N Loeher, A., 238 (Tu-P7:243) Löwel, H., 71 (Mo-P1:115) Macut, D., 126 (Mo-P5:365), 426 (We-P13:363), Loennechen, J.P., 428 (We-P13:369) Lowry, D., 393 (We-P11:212) 522 (Th-P15:134) Loffredo, L., 298 (Tu-P10:514) Lozano, A., 447 (We-P14:457) D Macut, D.J., 361 (We-P11:71) Loﬁng, J., 566 (Th-P16:329) Lüblinghoff, N., 143 (Mo-P6:442) Madani, M., 581 (Th-P16:399) Lohman, K., 14 (Mo-W2:6) Luca’, F., 24 (Mo-W7:7) E Madaric, J., 103 (Mo-P4:260) Lohse, P., 141 (Mo-P6:432) Lucarini, L., 396 (We-P11:230), 398 Madec, S., 14 (Mo-W2:7) Loiodice, F., 372 (We-P11:119) (We-P11:239) Madeddu, P., 191 (Tu-P7:29) X Lomakovsky, O., 282 (Tu-P10:444) Lucchesi, D., 350 (We-P11:23), 386 559 Lombardi, S., 75 (Mo-P1:133) (We-P11:184), 387 (We-P11:186), 528 Madej, A., (Th-P16:299) 46 Lombardini, R., 221 (Tu-P7:165) (Th-P15:159) Madeo, B., (Mo-P1:4) 107 Lombardini, S., 411 (We-P12:294) Lucicesare, A., 61 (Mo-P1:69), 68 (Mo-P1:102), Madhavan, R., (Mo-P4:278) 309 Lombardo, M., 221 (Tu-P7:166) 366 (We-P11:93), 532 (Th-P15:179) Madjid, M., (We-W32:4) 503 Lommi, J., 100 (Mo-P4:245), 110 (Mo-P4:292), Lucock, M., 77 (Mo-P1:140), 317 (We-W36:3) Maeba, R., (Th-P15:51) 59 574 242 (Tu-P7:264) Luell, S., 463 (Th-W48:3) Maeda, N., (Mo-P1:60), (Th-P16:369) 505 Lomtatidze, G., 389 (We-P11:198) Luescher, T., 222 (Tu-P7:169) Maeda, R., (Th-P15:58) 58 59 Lomtatidze, G.V., 385 (We-P11:181) Luescher, T.F., 358 (We-P11:54) Maeda, S., (Mo-P1:57), (Mo-P1:60) 503 509 Lonardo, A., 410 (We-P12:289), 411 Luetjohann, D., 18 (Mo-W4:4) Maeda, T., (Th-P15:51), (Th-P15:76) 53 570 576 (We-P12:294) Lukic, L.J., 351 (We-P11:25, We-P11:27), 352 Maerz, W., (Mo-P1:35), (Th-P16:349), Loncar, S., 53 (Mo-P1:34) (We-P11:28) (Th-P16:374) 286 Long, C., 16 (Mo-W3:5) Lukman, S.T., 232 (Tu-P7:215) Maestre, M., (Tu-P10:462) 86 Long, C.J., 210 (Tu-P7:116) Lulla, C.P., 364 (We-P11:83) Maffei, S., (Mo-P2:180) 276 Long, C.L., 372 (We-P11:121) Lumb, P., 405 (We-P11:268), 424 (We-P13:353) Mafrici, A., (Tu-P10:420) 193 Longcore, A., 550 (Th-P16:259) Luna, P., 62 (Mo-P1:75) Maggi, A., (Tu-P7:39) 475 Longo, V., 528 (Th-P15:159) Lund, S., 159 (Tu-W19:4) Maggi, F., (Th-W54:3) 424 Lonn, E., 107 (Mo-P4:279), 308 (We-W31:5) Lund-Katz, S., 167 (Tu-W23:5) Maggi, S., (We-P13:354) Loo, R.L., 430 (We-P14:381) Lundström, J., 200 (Tu-P7:72), 357 (We-P11:50) Magnussen, C.G., 483 (Th-W58:3) Lookene, A., 514 (Th-P15:96) Lungu, V., 427 (We-P13:364) Magyar, M.T., 296 (Tu-P10:504) Lopes, N.H., 347 (We-P11:8) Luo, D., 581 (Th-P16:401) Mahadik, S.R., 364 (We-P11:83) Lopez, A., 125 (Mo-P5:360) Luo, L.L., 402 (We-P11:258), 403 (We-P11:260, Maher, A., 390 (We-P11:201) Lopez, I., 448 (We-P14:461) We-P11:261) Maher, J.J., 171 (Tu-W25:5) Lopez, J.C., 367 (We-P11:99) Luo, S.S., 403 (We-P11:259, We-P11:262) Mahera, K., 128 (Mo-P5:377) Lopez-Cabañas, J.A., 406 (We-P11:275) Lupanov, V., 98 (Mo-P4:237) Mahieu, E., 293 (Tu-P10:494) Lopez-Campos, P., 364 (We-P11:85) Lupattelli, G., 17 (Mo-W4:3), 221 (Tu-P7:165), Mahyuddin, M.M., 423 (We-P13:347) Lopez-Franco, O., 228 (Tu-P7:197) 277 (Tu-P10:423), 420 (We-P13:333) Maibaum, E., 390 (We-P11:201), 430 López-Miranda, J., 439 (We-P14:418), 448 Luscher, T.F., 90 (Mo-P2:200) (We-P14:381) (We-P14:459), 585 (Th-P17:419) Lusis, A.J., 34 (Mo-W13:1), 130 (Mo-P6:383), Maio, R., 313 (We-W34:4) Lopez-Miranda, J., 135 (Mo-P6:408), 447 219 (Tu-P7:156), 375 (We-P11:135), 518 Maio, R.C., 549 (Th-P16:257) (We-P14:454, We-P14:457) (Th-P15:117) . Maioli, M., 137 (Mo-P6:414) Lopez-Parra, V., 228 (Tu-P7:197) Lusso, S., 70 (Mo-P1:111) Maioli, M., 139 (Mo-P6:422) López-Picazo Ferrer, J.J., 61 (Mo-P1:72) Lusta, K.A., 208 (Tu-P7:109) Maisano, C., 324 (We-W39:5) Lopez-Segura, F., 447 (We-P14:454) Lutay, M., 211 (Tu-P7:122), 282 (Tu-P10:444) Maisch, B., 352 (We-P11:30) López-Tejero, D., 498 (Th-P15:28) Lütjohann, D., 318 (We-W36:6), 450 Maiz, A., 216 (Tu-P7:141) Lo Prete, A.C., 537 (Th-P15:202), 542 (We-P14:470), 562 (Th-P16:312), 582 Maiza, D., 57 (Mo-P1:51) (Th-P15:224) (Th-P16:403) Majer, L.M., 204 (Tu-P7:89) Lorenz, R., 514 (Th-P15:99) Lv, Y.C., 212 (Tu-P7:124), 222 (Tu-P7:167), 232 Majima, M., 195 (Tu-P7:47)

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

243 Majkova, Z., 444 (We-P14:443) Mangiafico, M., 411 (We-P12:297) Marcondes, J.A., 535 (Th-P15:191) Majstorov, V., 101 (Mo-P4:253) Mangiafico, R., 411 (We-P12:297) Marcovina, S.M., 13 (Mo-W2:3), 480 (Th-W56:8) Makarevich, P.I., 89 (Mo-P2:195) Mangione, P., 536 (Th-P15:198) Marcovitch, O., 553 (Th-P16:274) Makarewicz-Wujec, M., 435 (We-P14:401) Manglano, X., 62 (Mo-P1:75) Marcucci, R., 85 (Mo-P2:177), 325 (We-W40:3), A Makarova, N., 255 (Tu-P8:320), 487 (Th-W60:2) Manigrasso, M.R., 363 (We-P11:78), 469 396 (We-P11:227), 398 (We-P11:239), 530 Mäkinen, J., 221 (Tu-P7:163) (Th-W51:4) (Th-P15:169) Mäkinen, J.I., 221 (Tu-P7:163) Manila, L., 78 (Mo-P1:146), 117 (Mo-P5:324) Marcus, D., 248 (Tu-P7:289) U Makino, H., 564 (Th-P16:320) Mankovsky, B.N., 366 (We-P11:92) Mareev, V., 582 (Th-P16:402) Makino, I., 73 (Mo-P1:122) Mannarino, E., 17 (Mo-W4:3), 23 (Mo-W7:3), Mareev, Yu., 354 (We-P11:39) T Makki, H., 427 (We-P13:365) 102 (Mo-P4:257), 112 (Mo-P5:300), 221 Marenzi, G., 297 (Tu-P10:510), 298 (Tu-P10:513) Makrevska, S., 356 (We-P11:46) (Tu-P7:165), 269 (Tu-P9:386), 277 Maresca, A.M., 422 (We-P13:343) H Maksimov, V.N., 78 (Mo-P1:147) (Tu-P10:423), 420 (We-P13:333), 469 Margaglione, M., 315 (We-W35:2) Maksimovic, J., 101 (Mo-P4:253) (Th-W51:6) Mari, E., 311 (We-W33:3) O Malatsidze, V., 556 (Th-P16:288) Mannarino, M., 269 (Tu-P9:386), 277 Marimon, F., 163 (Tu-W21:5) Malaval, C., 153 (Tu-W16:7) (Tu-P10:423) Marin, C., 447 (We-P14:457) 209 23 102 Malavazos, A.E., (Tu-P7:112) Mannarino, M.R., (Mo-W7:3), Marin, R., 350 (We-P11:22) R 91 231 420 469 Malaver, E., (Mo-P2:203), (Tu-P7:212) (Mo-P4:257), (We-P13:333), Marinello, E., 273 (Tu-P10:404) 137 141 Malczewska-Malec, M., (Mo-P6:416), (Th-W51:6) Marín Hinojosa, C., 439 (We-P14:418), 448 416 417 86 (Mo-P6:433), (We-P13:319), Manni, L., (Mo-P2:181) (We-P14:459) 396 398 (We-P13:324) Mannini, L., (We-P11:227), Marini, M.A., 367 (We-P11:98), 371 35 I Malczewska-Malec, M.M., (Mo-W13:7) (We-P11:239) (We-P11:116) 112 146 147 Malekzadeh, G., (Mo-P5:302) Mannucci, L., (Mo-P6:453), Marino, F., 549 (Th-P16:257) 297 353 Maleska Ivanovska, V., (Tu-P10:512) (Mo-P6:457), (We-P11:33) Marinov, A., 104 (Mo-P4:263) N 249 67 104 Malet, N., (Tu-P8:295) Manolis, A.S., (Mo-P1:99), (Mo-P4:266) Marinova, I., 423 (We-P13:348) 262 127 557 Maletin, M., (Tu-P9:352) Manolopoulos, V.G., (Mo-P5:370), Marinovich, M., 168 (Tu-W24:3) D 33 Malfitano, A.M., (Mo-W12:5) (Th-P16:292) Mariolis, A., 348 (We-P11:10) 80 505 Malik, I., (Mo-P1:155, Mo-P1:156) Manolopoulou, D., (Th-P15:60) Mariotti, M., 430 (We-P14:379), 446 Malikovska, S., 532 (Th-P15:178) Manoni, M., 391 (We-P11:205) E (We-P14:453) Malinin, A., 392 (We-P11:211), 393 (We-P11:212) Mansego, M.L., 130 (Mo-P6:384), 136 Markou, G., 56 (Mo-P1:49) Malinova, V., 404 (We-P11:265) (Mo-P6:412), 389 (We-P11:197) X Markovic-Lipkovski, J., 211 (Tu-P7:119) Malinverno, A., 244 (Tu-P7:272) Manshaus, T.E., 36 (Mo-W14:3) Marnelos, P.G., 58 (Mo-P1:56) Maliouri, A., 81 (Mo-P1:162), 122 (Mo-P5:348) Manson, J.E., 176 (Tu-W28:3), 485 (Th-W59:1) Marniemi, J., 68 (Mo-P1:101) Mallat, Z., 326 (We-W41:2) Mansor, N.M., 423 (We-P13:347) Marogna, M., 422 (We-P13:343) Mallik, S., 82 (Mo-P1:167) Mansour, J., 386 (We-P11:185) Marongiu, P., 137 (Mo-P6:414) Mallinson, D., 210 (Tu-P7:116), 254 (Tu-P8:316) Mantero, F., 263 (Tu-P9:359) Maroni, L., 549 (Th-P16:257) Malloggi, L., 369 (We-P11:108) Mantilla, T., 46 (Mo-P1:2), 58 (Mo-P1:59) Marotta, G., 231 (Tu-P7:211), 282 (Tu-P10:445) Maltby, D., 171 (Tu-W25:5) Mantovani, A., 537 (Th-P15:199) Marotta, P., 207 (Tu-P7:104) Maltinti, M.S., 310 (We-W32:6) Mantovani, L.G., 178 (Tu-W29:1) Marrugat, J., 79 (Mo-P1:152), 383 (We-P11:171), Malý, J., 562 (Th-P16:315), 563 (Th-P16:316) Manyam, H., 419 (We-P13:330) 384 (We-P11:172) Maly, J., 563 (Th-P16:317) Manzanares, J.M., 139 (Mo-P6:425) Marschang, P., 12 (Mo-W1:4) Malyshev, P.P., 89 (Mo-P2:195) Manzano, L., 105 (Mo-P4:268, Mo-P4:269) 202 Malyszko, J., 188 (Tu-P7:14) Manzato, E., 350 (We-P11:22) Marsillach, J., (Tu-P7:81) 262 263 Malyutina, S.K., 57 (Mo-P1:53), 78 (Mo-P1:147) Manzini, S., 446 (We-P14:453) Marte, A.P., (Tu-P9:353), (Tu-P9:357), 546 Mamcarz, A., 208 (Tu-P7:108) Manzoni, C., 343 (We-S16:2) (Th-P15:242, Th-P15:243) 146 Mammi, C., 221 (Tu-P7:166) Mao, Y.J., 494 (Th-P15:12) Martin, B., (Mo-P6:456) 516 Mamo, J.C., 512 (Th-P15:88) Maoddi, I., 336 (We-W45:7) Martin, J., (Th-P15:106) 433 443 Manabe, I., 164 (Tu-W22:3), 196 (Tu-P7:53) Mapplebeck, S., 145 (Mo-P6:451) Martin, J.C., (We-P14:393), 589 Manaf, A., 224 (Tu-P7:176) Marais, A.D., 585 (Th-P16:415) (We-P14:436), (Th-P17:433) 312 Manasievska, E., 356 (We-P11:46) Maraldi, C., 317 (We-W36:5) Martin, J.F., (We-W34:1) 133 262 Manca, E., 278 (Tu-P10:427) Marangoni, F., 472 (Th-W53:1) Martín-Fuentes, P., (Mo-P6:396), 495 546 Manca, M., 61 (Mo-P1:69), 269 (Tu-P9:388), 420 Maranhão, R.C., 113 (Mo-P5:304, Mo-P5:305), (Tu-P9:354), (Th-P15:16), (We-P13:334), 424 (We-P13:351), 564 347 (We-P11:8), 466 (Th-W49:7), 501 (Th-P15:244) (Th-P16:321) (Th-P15:41), 509 (Th-P15:75), 535 Martin-Fuentes, P., 233 (Tu-P7:220), 406 Mancas, S., 46 (Mo-P1:3), 110 (Mo-P4:291), 111 (Th-P15:191) (We-P11:275), 547 (Th-P15:247) (Mo-P4:294), 362 (We-P11:73), 365 Maranhao, R.C., 537 (Th-P15:202), 542 Martin-Nizard, F., 215 (Tu-P7:140) (We-P11:86, We-P11:87), 445 (We-P14:445) (Th-P15:224) Martin-Ventura, J.L., 228 (Tu-P7:197), 239 Mancilha-Carvalho, J., 390 (We-P11:201) Marasciulo, F.L., 454 (We-P14:486) (Tu-P7:246), 572 (Th-P16:356), 584 Mancini, E., 125 (Mo-P5:360) Marbaghi, A., 112 (Mo-P5:299) (Th-P16:413), 590 (Th-P17:441) Mancini, F.P., 255 (Tu-P8:322), 431 (We-P14:385) Marc, M., 62 (Mo-P1:76) Martineau, P., 572 (Th-P16:356), 584 Mancini, M., 18 (Mo-W4:7), 431 (We-P14:385) Marcello, C., 311 (We-W33:3) (Th-P16:413) Mancuso, J.P., 11 (Mo-W1:1) Marchesi, C., 422 (We-P13:343) Martines, G., 86 (Mo-P2:183), 88 (Mo-P2:190) Mancuso, M.R., 367 (We-P11:98) Marchesi, M., 453 (We-P14:483), 477 Martinez, B., 67 (Mo-P1:97), 84 (Mo-P2:174) Mandal, K., 407 (We-P11:277) (Th-W55:3), 478 (Th-W55:6), 536 Martínez, E., 364 (We-P11:85) Mandreoli, M., 125 (Mo-P5:360) (Th-P15:198), 570 (Th-P16:347) Martinez, E., 116 (Mo-P5:322) Manduteanu, I., 355 (We-P11:41) Marchesi, P., 537 (Th-P15:199) Martínez, J., 123 (Mo-P5:353) Mang, C., 470 (Th-W51:7) Marchesi, S., 221 (Tu-P7:165), 277 (Tu-P10:423) Martinez, L., 262 (Tu-P9:353), 263 (Tu-P9:357), Mangeri, E., 268 (Tu-P9:380) Marchie, A., 476 (Th-W55:1), 478 (Th-W55:7) 546 (Th-P15:243) Mangge, H., 72 (Mo-P1:119), 310 (We-W32:5) Marchiori, M., 475 (Th-W54:3), 502 (Th-P15:45) Martinez, L.O., 153 (Tu-W16:7)

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

244 Martinez, S., 130 (Mo-P6:384), 135 (Mo-P6:407), Masum, R., 388 (We-P11:194) Mayor, V., 363 (We-P11:81), 364 (We-P11:82) 136 (Mo-P6:412) Mata, N., 130 (Mo-P6:385, Mo-P6:386) Mayr, M., 589 (Th-P17:436) Martinez, T., 50 (Mo-P1:23) Mata, P., 129 (Mo-P6:382), 130 (Mo-P6:385, Mayr, U., 462 (Th-W48:1) Martinez, T.L.R., 66 (Mo-P1:94) Mo-P6:386) Mäyränpää, M., 110 (Mo-P4:292), 246 Martinez-Alvarado, R., 422 (We-P13:344) Matasconi, M., 39 (Mo-W15:7), 188 (Tu-P7:18) (Tu-P7:278), 490 (Th-W61:6) A Martinez-Cercos, R., 62 (Mo-P1:74) Mateo De Acosta, O., 363 (We-P11:80) Mäyränpää, M.I., 157 (Tu-W18:5) Martínez-Dolz, L., 85 (Mo-P2:178), 286 Mateos, E., 62 (Mo-P1:74) Mazurek, W., 281 (Tu-P10:438), 297 (Tu-P10:461) Matheny, M.K., 185 (Tu-P7:1) (Tu-P10:511) U 159 488 497 Martínez-González, J., (Tu-W19:5), Mathiesen, E.B., (Th-P15:25) Mazza, F., 372 (We-P11:119) 537 14 (Th-W60:7), (Th-P15:201) Mathiesen, E.R., (Mo-W2:4) Mazzocca, C., 391 (We-P11:205) T 226 415 Martinez-Hervas, S., (Tu-P7:187) Mathieu, P., (We-P13:313) Mazzone, A., 310 (We-W32:6), 414 (We-P12:309) 142 397 Martìnez-Lòpez, E., (Mo-P6:437) Matkov, O., (We-P11:232) McAinch, A., 375 (We-P11:134) H 378 128 Martinez-Lopez, E., (We-P11:145) Matoska, V., (Mo-P5:376) McCallum, J., 335 (We-W45:3) 571 408 Martínez-Sales, V., (Th-P16:351) Mátrai, M., (We-P12:283) McCormick, J., 566 (Th-P16:329) O Martinez Leme Da Rocha, T., 120 (Mo-P5:338), Matsuda, H., 96 (Mo-P3:225) McCue, I.S., 523 (Th-P15:138) 512 (Th-P15:91), 513 (Th-P15:92) Matsuda, M., 425 (We-P13:359) McDermott-Roe, C., 516 (Th-P15:106) Martini, R., 106 (Mo-P4:273) Matsuda, Y., 104 (Mo-P4:264), 133 (Mo-P6:397), R McDonald, R.A., 210 (Tu-P7:116) Martini, S., 133 (Mo-P6:400) 444 (We-P14:441) McEneny, J., 226 (Tu-P7:186), 522 (Th-P15:135) Martino, E., 426 (We-P13:362) Matsui, H., 231 (Tu-P7:210) McFarlane, C., 226 (Tu-P7:186) Martino, F., 426 (We-P13:362) Matsui, J., 506 (Th-P15:61), 542 (Th-P15:225), McGovern, M., 567 (Th-P16:337) Martino, M., 147 (Mo-P6:460) 543 (Th-P15:226) 174 I Martino, S., 207 (Tu-P7:104), 288 (Tu-P10:472) Matsuki, K., 506 (Th-P15:61), 542 (Th-P15:225), McGovern, M.E., (Tu-W27:4) 221 232 Martinotti, S., 380 (We-P11:156) 543 (Th-P15:226) McGrath, K.C-Y., (Tu-P7:164), N Martinovic, S., 120 (Mo-P5:342), 377 Matsumoto, H., 388 (We-P11:192) (Tu-P7:218) 516 517 (We-P11:143), 386 (We-P11:183) Matsumoto, K., 96 (Mo-P3:225), 185 (Tu-P7:2), McGregor, J.L., (Th-P15:106), Martins, M.C., 429 (We-P13:374) 187 (Tu-P7:12), 511 (Th-P15:86) (Th-P15:110) D 178 Martorell, E., 129 (Mo-P6:382) Matsumoto, M., 448 (We-P14:460) McGuire, A., (Tu-W29:2) Martorell, L.L., 159 (Tu-W19:5) Matsumoto, T., 33 (Mo-W12:6), 49 (Mo-P1:17), Mchetti, N., 355 (We-P11:43) E Martorell, M.P., 268 (Tu-P9:381) 96 (Mo-P3:225), 101 (Mo-P4:252), 106 McHowat, J., 223 (Tu-P7:172) Marusic, E., 125 (Mo-P5:361), 201 (Tu-P7:73) (Mo-P4:271), 187 (Tu-P7:12), 235 McInerey, M.F., 202 (Tu-P7:77) X Marutsuka, K., 319 (We-W37:3) (Tu-P7:231), 362 (We-P11:77), 569 McKenney, J.M., 1 (Su-S1:1), 174 (Tu-W27:4) Maruyama, C., 420 (We-P13:335) (Th-P16:344), 572 (Th-P16:359) McKibben, B., 226 (Tu-P7:186) Maruyama, T., 420 (We-P13:335) Matsunaga, A., 268 (Tu-P9:383), 396 McKinnon, H.J., 210 (Tu-P7:116), 254 Maruyama, Y., 87 (Mo-P2:186), 290 (We-P11:229), 570 (Th-P16:350) (Tu-P8:316) (Tu-P10:478), 296 (Tu-P10:507), 297 Matsuo, K., 496 (Th-P15:17) McLeod, E., 222 (Tu-P7:171) (Tu-P10:509), 388 (We-P11:192) Matsuo, Y., 192 (Tu-P7:33), 536 (Th-P15:197), McMahon, R., 106 (Mo-P4:272) Marwick, T., 538 (Th-P15:204) 561 (Th-P16:310), 571 (Th-P16:354) McMurray, J.J.V., 551 (Th-P16:264) März, W., 72 (Mo-P1:118, Mo-P1:119), 143 Matsuoka, H., 60 (Mo-P1:66) McNulty, M., 588 (Th-P17:432) (Mo-P6:442), 310 (We-W32:5), 581 Matsushima, T., 510 (Th-P15:83) McPheat, W.L., 236 (Tu-P7:236) (Th-P16:397), 583 (Th-P16:409) Matsushita, K., 367 (We-P11:97) McPherson, P.A.C., 522 (Th-P15:135) Marzoll, A., 245 (Tu-P7:276), 247 (Tu-P7:283) Matsuura, F., 166 (Tu-W23:1), 575 (Th-P16:372) McQueen, M., 308 (We-W31:5) 565 4 301 Mas, R., (Th-P16:325) Matsuzawa, Y., (Su-S2:4), (We-PL3:1) McTaggart, F., 12 (Mo-W1:5), 577 (Th-P16:383), 123 139 76 430 Masana, L., (Mo-P5:355), (Mo-P6:425), Matteucci, E., (Mo-P1:138), 580 (Th-P16:395) 163 188 400 446 (Tu-W21:5), (Tu-P7:15), (We-P14:379), (We-P14:453) Medbury, H., 96 (Mo-P3:229) 414 416 54 56 (We-P11:247), (We-P12:310), Mattiello, A., (Mo-P1:40), (Mo-P1:46) Medbury, H.J., 34 (Mo-W12:7) 443 513 298 329 (We-P13:318), (We-P14:439), Mattiello, L., (Tu-P10:516), (We-W42:4) Medeiros, A.M., 131 (Mo-P6:390) 522 22 (Th-P15:95), (Th-P15:133) Mattson Hultén, L., (Mo-W6:6) Medeiros, A.M.B., 278 (Tu-P10:425) Maschi, O., 168 (Tu-W24:3) Mattsson-Hultén, L., 15 (Mo-W3:2) Medina, P., 395 (We-P11:224) Masella, R., 165 (Tu-W22:4), 186 (Tu-P7:7) Matuo, H., 259 (Tu-P9:339) Medina, W.L., 520 (Th-P15:123) Masenko, V., 569 (Th-P16:346) Mauger, J.F., 474 (Th-W54:1) Medina-Urrutia, A.X., 534 (Th-P15:186) Masenko, V.P., 283 (Tu-P10:447), 404 Maumus, S., 155 (Tu-W17:5) Megnien, J.-L., 269 (Tu-P9:387) (We-P11:263) Maurantonio, M., 46 (Mo-P1:4) Mehdizadeh, M., 385 (We-P11:177) Maseri, A., 86 (Mo-P2:182) Mauri, M., 103 (Mo-P4:259) Mehrabian, M., 375 (We-P11:135) Masini, E., 391 (We-P11:205) Mauriège, P., 165 (Tu-W22:5), 421 (We-P13:340) 533 Masmoudi, A.S., 349 (We-P11:18) Mauro, G., 71 (Mo-P1:116) Meijers, J., (Th-P15:183) 589 Masnatta, L., 195 (Tu-P7:48) Mauro, G.F., 389 (We-P11:196, We-P11:199) Meijers, J.C., (Th-P17:437) 153 291 Masoudi, A.H., 438 (We-P14:414) Mauss, S., 401 (We-P11:251) Meijers, J.C.M., (Tu-W16:5), Massa, E., 108 (Mo-P4:282), 272 (Tu-P10:401) Maussang, D., 296 (Tu-P10:505) (Tu-P10:482) 239 590 Massana, L., 453 (We-P14:479) Mavlyanova, M.B., 67 (Mo-P1:98) Meilhac, O., (Tu-P7:246), (Th-P17:441) 393 Massironi, P.G., 116 (Mo-P5:318), 204 Mavrogeni, E., 383 (We-P11:168) Meilman, H., (We-P11:212) (Tu-P7:87), 309 (We-W32:2) Maxim, I., 521 (Th-P15:130), 543 (Th-P15:228) Meiner, V., 133 (Mo-P6:399), 514 (Th-P15:98) Mastuo, K., 578 (Th-P16:386) Maxova, H., 243 (Tu-P7:265) Meini, S., 405 (We-P11:270) Masturzo, P., 554 (Th-P16:277), 558 (Th-P16:296) May, P., 331 (We-W43:6) Melão, A., 84 (Mo-P2:172) Masuda, D., 28 (Mo-W9:6), 237 (Tu-P7:237), 510 May, R.P., 500 (Th-P15:36) Melek, M., 106 (Mo-P4:274), 218 (Tu-P7:151), (Th-P15:82), 575 (Th-P16:372, Th-P16:373) Mayer, C.M., 570 (Th-P16:349) 264 (Tu-P9:362, Tu-P9:364) Masuda, Y., 435 (We-P14:402), 510 (Th-P15:80), Mayer Jr., O., 363 (We-P11:79) Melidonis, A., 347 (We-P11:9) 511 (Th-P15:86) Mayet, J., 80 (Mo-P1:155, Mo-P1:156), 104 Mello, N.R., 501 (Th-P15:41) Masulli, M., 51 (Mo-P1:25) (Mo-P4:262) Melloni, M., 191 (Tu-P7:29)

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

245 Melnichenko, A.A., 499 (Th-P15:34), 500 Migale, M., 146 (Mo-P6:453), 259 (Tu-P9:338) Mitrovic, A., 202 (Tu-P7:78) (Th-P15:38) Migliaresi, P., 207 (Tu-P7:104), 315 (We-W35:2) Mitsios, J.V., 173 (Tu-W26:4) Melody, T., 368 (We-P11:101) Miglietta, D., 219 (Tu-P7:157) Mitsubayashi, H., 388 (We-P11:194) Memi, E., 568 (Th-P16:341) Migliori, M., 564 (Th-P16:321) Mitsudo, K., 122 (Mo-P5:350) A Memon, L., 60 (Mo-P1:64), 279 (Tu-P10:432) Miguelino, E., 359 (We-P11:61) Mitsumata, M., 33 (Mo-W12:6), 185 (Tu-P7:2) Mendez, A.J., 381 (We-P11:158) Mihalas, G., 46 (Mo-P1:3) Mitsunami, K., 52 (Mo-P1:31) Mendez, G.F., 174 (Tu-W27:3) Mihara, M., 362 (We-P11:77) Mitsuoka, H., 85 (Mo-P2:179), 460 (Th-W46:7) U Mendez, M., 62 (Mo-P1:75) Miida, T., 361 (We-P11:72), 575 (Th-P16:373) Mitsutake, R., 268 (Tu-P9:383) Mendoza, S., 565 (Th-P16:325) Mijailovic, M., 352 (We-P11:28) Miura, I.M., 520 (Th-P15:123) T Mendy, F., 198 (Tu-P7:60) Mikhailidis, D., 577 (Th-P16:381) Miura, K., 290 (Tu-P10:481) Menecali, C., 23 (Mo-W7:3) Mikhailidis, D.P., 63 (Mo-P1:78), 509 (Th-P15:77) Miura, S., 13 (Mo-W1:7), 99 (Mo-P4:241), 192 H Meneghelo, R., 170 (Tu-W25:4), 419 Mikhailova, I., 227 (Tu-P7:192) (Tu-P7:33), 255 (Tu-P8:319), 268 (We-P13:332) Miki, T., 428 (We-P13:371) (Tu-P9:383), 293 (Tu-P10:492), 536 O Menes, I., 127 (Mo-P5:371) Mikov, M., 566 (Th-P16:333) (Th-P15:197), 559 (Th-P16:298), 561 Menghini, R., 312 (We-W33:7) Mikros, S., 572 (Th-P16:358) (Th-P16:310), 562 (Th-P16:311, Th-P16:313), 138 504 Menjivar, M., (Mo-P6:418) Miksztowicz, V., (Th-P15:52) 571 (Th-P16:354), 578 (Th-P16:386) R 55 203 Menna-Barreto, L., (Mo-P1:42) Mikulik, K., (Tu-P7:82) Miwa, K., 255 (Tu-P8:321) 21 501 Mensenkamp, A.R., (Mo-W6:3) Miles, M., (Th-P15:40) Miyahara, Y., 97 (Mo-P3:232) 452 127 358 Mensink, R.P., (We-P14:477) Milic, N., (Mo-P5:373), (We-P11:57) Miyakoda, G., 394 (We-P11:219), 513 255 351 352 Meoli, A., (Tu-P8:322) Milicic, T., (We-P11:25, We-P11:27), (Th-P15:93) 410 I Meparidze, M., (We-P12:291) (We-P11:28) Miyakoshi, H., 519 (Th-P15:121) 6 53 Mercalli, F., (Su-S3:4) Milincic, Z., (Mo-P1:37) Miyamatsu, N., 58 (Mo-P1:58), 260 (Tu-P9:344), 408 127 358 Mericli, M., (We-P12:283) Milinic, N., (Mo-P5:373), (We-P11:57) 265 (Tu-P9:368) N 105 499 577 Merino, J., (Mo-P4:270) Milionis, H., (Th-P15:33), (Th-P16:381), Miyamoto, Y., 104 (Mo-P4:264), 133 51 545 582 Merino-Ibarra, E., (Mo-P1:28), (Th-P16:404) (Mo-P6:397), 444 (We-P14:441), 564 D 406 (Th-P15:238) Milioti, N., (We-P11:273) (Th-P16:320) 38 46 116 Merkel, M., (Mo-W15:2) Millan, J., (Mo-P1:2), (Mo-P5:320) Miyashita, Y., 384 (We-P11:176), 417 Mermer, S., 74 (Mo-P1:130) Millanvoye-Van Brussel, E., 214 (Tu-P7:134) E (We-P13:320), 498 (Th-P15:29), 499 Mersmann, J., 535 (Th-P15:192) Millar, J.S., 11 (Mo-W1:1), 564 (Th-P16:322) (Th-P15:30) Mervaala, E., 431 (We-P14:383) Miller, D.D., 392 (We-P11:210) X Miyata, T., 185 (Tu-P7:3), 193 (Tu-P7:41) Mesa, M., 565 (Th-P16:325) Miller, G., 312 (We-W33:6) Miyauchi, K., 510 (Th-P15:79), 559 (Th-P16:301) Meshkov, A.N., 89 (Mo-P2:195) Miller, G.J., 301 (We-PL3:3), 315 (We-W35:3) Miyazaki, A., 520 (Th-P15:127) Mestrovic, T., 83 (Mo-P2:170) Miller, S.R., 267 (Tu-P9:378) Miyazaki, M., 243 (Tu-P7:267), 465 (Th-W49:2) Meszaros, P., 262 (Tu-P9:352) Miller, Y.I., 459 (Th-W46:1) Miyazaki, O., 575 (Th-P16:373) Metelko, Z., 360 (We-P11:64) Millhouse, F., 78 (Mo-P1:146), 117 (Mo-P5:324) Miyazaki, S., 187 (Tu-P7:13), 362 (We-P11:76), Metso, J., 320 (We-W37:6), 540 (Th-P15:216) Milliat, F., 220 (Tu-P7:161) 587 (Th-P17:424) Metzger, S., 463 (Th-W48:2) Millo, B., 286 (Tu-P10:463), 287 (Tu-P10:464), Miyazaki, T., 417 (We-P13:321), 559 Meulenberg, J.M., 19 (Mo-W5:2) 387 (We-P11:187) (Th-P16:301) Meurs, I., 90 (Mo-P2:198) Milo, B., 175 (Tu-W27:7) Mizia, M., 263 (Tu-P9:361) Meuwese, M.C., 24 (Mo-W7:5) Milo, H., 133 (Mo-P6:399) Mizia-Stec, K., 263 (Tu-P9:361) Mevorach, D., 233 (Tu-P7:222) Milosevic, D., 78 (Mo-P1:148) 417 Meyer, B.J., 493 (Th-P15:8) Milovanovic, Z., 570 (Th-P16:348) Mizukawa, S., (We-P13:322) 528 Meyer, M.C., 223 (Tu-P7:172) Miltiadous, G., 517 (Th-P15:113), 530 Mizuno, H., (Th-P15:161) 373 Meyer-Kirchrath, J., 247 (Tu-P7:283) (Th-P15:170) Mlejnek, P., (We-P11:123) 401 Mezzetti, A., 8 (Mo-PL1:4), 17 (Mo-W4:3), 246 Miname, M., 262 (Tu-P9:353), 263 (Tu-P9:357), Mmiro, F., (We-P11:250) 516 544 (Tu-P7:280), 247 (Tu-P7:282), 248 546 (Th-P15:242, Th-P15:243) Mo, Z.C., (Th-P15:108), (Th-P15:231) 192 (Tu-P7:287), 537 (Th-P15:199) Minamino, N., 505 (Th-P15:58) Mobarake, J.I., (Tu-P7:35) 579 Micari, A., 24 (Mo-W7:7) Minichilli, F., 70 (Mo-P1:111), 225 (Tu-P7:183) Mochizuki, S., (Th-P16:392) 91 Miccoli, R., 350 (We-P11:23), 369 (We-P11:108), Minici, C., 445 (We-P14:448) Mocikova, H., (Mo-P2:204) 427 386 (We-P11:184), 387 (We-P11:186), 528 Minoretti, P., 73 (Mo-P1:121), 281 (Tu-P10:440) Mock, L., (We-P13:365) 80 (Th-P15:159) Minushkina, L.O., 146 (Mo-P6:455) Modi, S., (Mo-P1:154) 310 Michaelides, I., 67 (Mo-P1:99), 104 (Mo-P4:266) Mion Jr, D., 512 (Th-P15:90) Moeller, R., (We-W32:5) Michalis, L., 265 (Tu-P9:370), 298 (Tu-P10:517) Mirabelli, F., 266 (Tu-P9:374), 268 (Tu-P9:380) Moen, C.J.A., 138 (Mo-P6:421), 518 Michea, L., 125 (Mo-P5:361), 201 (Tu-P7:73) Miranda, A., 65 (Mo-P1:90) (Th-P15:117), 585 (Th-P17:418) Michel, J.B., 239 (Tu-P7:246), 590 (Th-P17:441) Mirdamadi, H.Z., 229 (Tu-P7:203), 292 Moguilevsky, N., 524 (Th-P15:141) Michetti, N., 88 (Mo-P2:192), 353 (We-P11:35), (Tu-P10:489) Mogylnytska, L., 366 (We-P11:92) 469 (Th-W51:4) Miret, S., 296 (Tu-P10:505) Mohamadi, B., 438 (We-P14:414) Micholt, I., 413 (We-P12:303) Miroslava, A., 214 (Tu-P7:133), 262 (Tu-P9:356) Mohammad Hossini, S., 127 (Mo-P5:372) Micic, D., 126 (Mo-P5:367), 287 (Tu-P10:468), Mislanová, C., 188 (Tu-P7:17) Mohammadi, A., 63 (Mo-P1:80) 361 (We-P11:68, We-P11:70), 362 Mislanova, C.S., 292 (Tu-P10:488) Mohammadifard, N., 427 (We-P13:368) (We-P11:74, We-P11:75), 378 (We-P11:149) Misra, A., 125 (Mo-P5:363) Mohammd Hossini, S., 125 (Mo-P5:362) Miclea, S., 402 (We-P11:256) Mistrik, A., 103 (Mo-P4:260) Mohan, V., 79 (Mo-P1:149) Miconi, V., 75 (Mo-P1:133) Mitauba, N., 367 (We-P11:100) Mohebbi Nobandegani, Z., 63 (Mo-P1:80) Midei, M., 393 (We-P11:212) Mitchel, Y., 174 (Tu-W27:3) Mohebi Nobandegani, Z., 112 (Mo-P5:299, Mielcarz, G., 440 (We-P14:426) Mitro, N., 253 (Tu-P8:313), 256 (Tu-P8:323), 257 Mo-P5:302) Miele, C., 21 (Mo-W6:4) (Tu-P8:330), 372 (We-P11:119), 465 Mohira, O., 428 (We-P13:372) Mierzecki, A., 275 (Tu-P10:414), 370 (Th-W49:4), 472 (Th-W52:7) Moia, R., 244 (Tu-P7:272) (We-P11:110) Mitrogianni, Z.O.I., 530 (Th-P15:170) Moir, S., 538 (Th-P15:204)

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

246 Mokuno, H., 417 (We-P13:321), 559 (Th-P16:301) Moridani, M.Y., 445 (We-P14:447) Muntoni, S.E., 536 (Th-P15:195) Molcanyiova, A., 560 (Th-P16:305) Moriguchi, E., 432 (We-P14:389), 556 Munzel, T., 470 (Th-W51:7) Moleri, E., 136 (Mo-P6:413) (Th-P16:284), 557 (Th-P16:289) Mura, A., 273 (Tu-P10:405) Molina, J.C., 65 (Mo-P1:89), 80 (Mo-P1:157) Moriguchi, E.H., 500 (Th-P15:35) Murakami, E., 279 (Tu-P10:431), 285 Molinero, E., 67 (Mo-P1:97), 84 (Mo-P2:174) Moriguchi, S., 319 (We-W37:3) (Tu-P10:456) A Mollica, L., 154 (Tu-W16:8) Moriguchi, Y., 432 (We-P14:389) Murakami, H., 506 (Th-P15:61), 542 Molyneux, S.L., 99 (Mo-P4:242) Morihira, M., 73 (Mo-P1:122), 377 (We-P11:144) (Th-P15:225), 543 (Th-P15:226) Momeni, E., 125 (Mo-P5:362) Morikawa, A.T., 509 (Th-P15:75) Murakami, Y., 48 (Mo-P1:14), 55 (Mo-P1:45), 56 U Momi, S., 583 (Th-P16:408) Morikawa, Y., 290 (Tu-P10:481) (Mo-P1:50), 59 (Mo-P1:63), 348 (We-P11:12) Momiyama, Y., 73 (Mo-P1:125), 281 Morimoto, M., 238 (Tu-P7:241) Muramatsu, M., 129 (Mo-P6:379) T (Tu-P10:439), 559 (Th-P16:300), 581 Morita, T., 198 (Tu-P7:61), 220 (Tu-P7:162), 284 Murano, T., 417 (We-P13:320), 498 (Th-P15:29), (Th-P16:398) (Tu-P10:454) 499 (Th-P15:30) H Monaco, C., 86 (Mo-P2:182), 92 (Mo-P2:211), Morita, Y., 425 (We-P13:359) Murao, K., 215 (Tu-P7:138) 288 (Tu-P10:471), 587 (Th-P17:426) Moriyama, K., 519 (Th-P15:121) Murasaki, K., 486 (Th-W59:4) O Monereo, S., 46 (Mo-P1:2) Moriyama, S., 564 (Th-P16:323) Murata, K., 52 (Mo-P1:31), 58 (Mo-P1:58), 265 Monjamed, Z., 119 (Mo-P5:334), 382 Morken, B., 103 (Mo-P4:258) (Tu-P9:368) (We-P11:166) Mormile, C., 231 (Tu-P7:211) Mureddu, G., 336 (We-W45:7) R Monopoli, A., 191 (Tu-P7:29), 219 (Tu-P7:157), Morrone, F., 426 (We-P13:362) Murohara, T., 191 (Tu-P7:28), 367 (We-P11:97) 583 (Th-P16:408) Morrow, M.P., 544 (Th-P15:233) Murphy, A., 539 (Th-P15:208) Monos, E., 408 (We-P12:283) Mortensen, A., 450 (We-P14:470) Murphy, M., 106 (Mo-P4:272) 409 558 397 Montagnani, A., (We-P12:285), Moscardo, A., (We-P11:235) Murrah, N.V., 324 (We-W39:5) I 410 (Th-P16:295) Moschen, A., (We-P12:292) Murray, E., 484 (Th-W58:5) 167 454 410 Montagnani, M., (Tu-W23:7), Mosistrapishvili, M., (We-P12:291) Murugappan, A., 107 (Mo-P4:278) 150 N (We-P14:486) Mosley, T.H., (Tu-PL2:4) Muruve, D.A., 94 (Mo-P3:219) 141 103 Montalcini, T., (Mo-P6:434) Mostaza, J., (Mo-P4:259) Musil, F., 359 (We-P11:60) 17 35 584 283 D Montali, A., (Mo-W4:3), (Mo-W13:4), Motoyama, A., (Tu-P10:450) Musino, L., 336 (We-W45:7) 198 (Th-P16:412) Motta, C., (Tu-P7:60) Musseri, M., 514 (Th-P15:98) 553 155 Montant, P., (Th-P16:274) Moulin, P., (Tu-W17:3) Mussoni, L., 88 (Mo-P2:191), 92 (Mo-P2:209, E 263 51 Monteiro, C.M.R., (Tu-P9:360) Mountford, W., (Mo-P1:26) Mo-P2:210), 212 (Tu-P7:123), 241 515 574 Montero, E., (Th-P15:104) Moustogiannis, G., (Th-P16:368) (Tu-P7:259), 463 (Th-W48:6), 474 X 480 77 Montero, I., (Th-W56:5) Moutiqui, T., (Mo-P1:143) (Th-W53:7), 591 (Th-P17:445) 103 438 Montes, J., (Mo-P4:259) Movahedian, A., (We-P14:416) Mustaﬁna, O.E., 387 (We-P11:190), 396 409 558 550 Montomoli, M., (We-P12:285), Moya, M.D., (Th-P16:262) (We-P11:228) 501 (Th-P16:295) Moyna, N., (Th-P15:40) Muthumala, A., 131 (Mo-P6:389) 404 204 210 Montorsi, F., (We-P11:267) Moyssakis, I., (Tu-P7:90), (Tu-P7:118), Muzzio, M.L., 504 (Th-P15:52) 298 308 395 Montorsi, P., (Tu-P10:513), (We-W31:6), (We-P11:225) Myasoedova, V.A., 230 (Tu-P7:209) 404 146 (We-P11:267) Mozas, P., (Mo-P6:456) Myers, R., 138 (Mo-P6:419) Montorzi, G., 220 (Tu-P7:158) Muderrisoglu, H., 74 (Mo-P1:129, Mo-P1:130), Mylonas, S., 64 (Mo-P1:82) Mooijaart, S.P., 37 (Mo-W14:5) 92 (Mo-P2:208), 100 (Mo-P4:246), 110 Mylonopoulou, M., 572 (Th-P16:358) Moon, B., 15 (Mo-W3:3) (Mo-P4:293), 112 (Mo-P5:301), 164 Myloslavsky, D., 383 (We-P11:169), 418 Moon, S.K., 266 (Tu-P9:373), 314 (We-W34:7) (Tu-W21:7), 284 (Tu-P10:455), 289 (We-P13:327) Mooser, V., 363 (We-P11:81), 364 (We-P11:82) (Tu-P10:473), 398 (We-P11:237) Mysliwiec, M., 108 (Mo-P4:283), 188 (Tu-P7:14), Moraes Alberto Almeida, C., 120 (Mo-P5:338) Muehlich, S., 218 (Tu-P7:152) 238 (Tu-P7:245), 284 (Tu-P10:451) Morange, P., 315 (We-W35:2) Mueller, M.A., 464 (Th-W48:8) Mysoedova, V.A., 444 (We-P14:442) Morazzoni, P., 10 (Mo-ML3:2) Mueller, O., 588 (Th-P17:429, Th-P17:430, Morcillo, S., 137 (Mo-P6:417) Th-P17:432) 201 Morderid, L., 126 (Mo-P5:364) Mugishima, H., 33 (Mo-W12:6) Nachtigal, P., (Tu-P7:74) 125 127 Moreau, M., 476 (Th-W54:6) Muid, S., 224 (Tu-P7:176), 423 (We-P13:347) Nadaﬁ, M., (Mo-P5:362), (Mo-P5:372) Moreau, P., 524 (Th-P15:141) Mujawar, Z., 544 (Th-P15:233) Nadaraia, K.A., 583 (Th-P16:406) Morehouse, L.A., 322 (We-W38:5) Mukai, S., 528 (Th-P15:161) Nádasy, G.L., 408 (We-P12:283) Moreno, B., 46 (Mo-P1:2) Mukaida, Y., 240 (Tu-P7:252) Naderi, G.H., 394 (We-P11:222), 395 Moreno, J.A., 135 (Mo-P6:408), 585 (Th-P17:419) Mukhamedova, N., 542 (Th-P15:222) (We-P11:223), 526 (Th-P15:153) Moreno, J.J., 435 (We-P14:400) Mukherjee, S., 146 (Mo-P6:454) Nadler, J.L., 354 (We-P11:40) Moreno, M.U., 245 (Tu-P7:274) Müller, A., 318 (We-W36:7) Naemura, A., 434 (We-P14:397), 436 Moreno Gutierrez, J.A., 439 (We-P14:418) Müller, C., 286 (Tu-P10:460) (We-P14:405) Moreno Luna, R., 448 (We-P14:459) Müller, F., 30 (Mo-W10:7) Nagai, M., 234 (Tu-P7:226) Morgan, A., 316 (We-W35:6) Muller, M., 79 (Mo-P1:153), 290 (Tu-P10:480) Nagai, R., 164 (Tu-W22:3), 196 (Tu-P7:53), 448 Morgan, R.E., 25 (Mo-W8:5) Mullhi, D., 360 (We-P11:67), 368 (We-P11:101), (We-P14:460) Mori, H., 94 (Mo-P3:217), 97 (Mo-P3:232), 317 533 (Th-P15:182) Nagamine, T., 575 (Th-P16:371) (We-W36:4), 432 (We-P14:389), 441 Munari, M.R., 401 (We-P11:253) Nagano, M., 68 (Mo-P1:100), 72 (Mo-P1:120), 73 (We-P14:427) Mundo, H., 367 (We-P11:99) (Mo-P1:125) Mori, I., 243 (Tu-P7:268) Munnix, I., 390 (We-P11:202) Nagano, Y., 411 (We-P12:296) Mori, K., 436 (We-P14:404), 578 (Th-P16:386) Munnix, I.C.A., 325 (We-W40:4), 390 Nagasaka, S., 582 (Th-P16:405) Mori, M., 317 (We-W36:4), 432 (We-P14:389), (We-P11:203) Nagata, M., 559 (Th-P16:300) 441 (We-P14:427), 501 (Th-P15:39) Muñoz-Garcia, B., 228 (Tu-P7:197), 590 Nagaya, N., 94 (Mo-P3:217), 97 (Mo-P3:232) Mori, T., 386 (We-P11:185), 394 (We-P11:219), (Th-P17:441) Nagel, J.M., 141 (Mo-P6:432) 513 (Th-P15:93) Muntean, W., 93 (Mo-P2:212) Nagorni, S., 288 (Tu-P10:470), 393 (We-P11:214), Moriarty, P.M., 563 (Th-P16:319) Muntoni, S.A., 536 (Th-P15:195) 421 (We-P13:337)

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

247 Nagumo, A., 564 (Th-P16:320) Naretto, V.G., 288 (Tu-P10:472) Newman, A., 317 (We-W36:5) Nahari, E., 233 (Tu-P7:222) Nartsupha, C., 11 (Mo-W1:1) Newman, C., 37 (Mo-W14:4) Naim, A., 412 (We-P12:302), 415 (We-P12:311) Narumiya, S., 195 (Tu-P7:47) Newton, R.S., 11 (Mo-W1:2) Naito, K., 280 (Tu-P10:435) Naruse, Y., 290 (Tu-P10:481) Neyen, C., 514 (Th-P15:97) A Najaﬁ Doulatabad, S., 63 (Mo-P1:80), 112 Naruszewicz, M., 175 (Tu-W27:7), 223 Neykova, A., 134 (Mo-P6:402) (Mo-P5:299, Mo-P5:302) (Tu-P7:173, Tu-P7:174), 275 (Tu-P10:414), Nezic, D., 206 (Tu-P7:98) Naka, K., 298 (Tu-P10:517) 286 (Tu-P10:463), 287 (Tu-P10:464), 370 Nezic, L., 570 (Th-P16:348) U Nakada, Y., 579 (Th-P16:392) (We-P11:110), 387 (We-P11:187), 432 Ng, H.K., 93 (Mo-P2:213) Nakagami, T., 350 (We-P11:20) (We-P14:390), 477 (Th-W55:4), 533 Nguyen, M.N., 329 (We-W42:5), 519 T Nakagawa, H., 290 (Tu-P10:481) (Th-P15:181), 569 (Th-P16:343) (Th-P15:118), 556 (Th-P16:285) Nakagawa-Toyama, Y., 28 (Mo-W9:6), 237 Narvaez, I., 67 (Mo-P1:97), 84 (Mo-P2:174) Nguyen, T., 476 (Th-W55:1) H (Tu-P7:237), 510 (Th-P15:82), 575 Nascetti, S., 420 (We-P13:334) Nguyen, T.T., 550 (Th-P16:260, Th-P16:262) (Th-P16:372) Nascimento Maria Do, H., 120 (Mo-P5:338), 513 Nicholls, S.J., 152 (Tu-W16:1), 153 (Tu-W16:4) O Nakai, K., 411 (We-P12:296) (Th-P15:92) Nicholson, A.C., 331 (We-W43:3) Nakai, Y., 377 (We-P11:140), 385 (We-P11:178) Nasibullin, T.R., 387 (We-P11:190), 396 Nicholson, J.K., 390 (We-P11:201) 417 512 Nakajima, K., (We-P13:322), (We-P11:228) Nicin, S., 100 (Mo-P4:248) R 558 575 51 545 (Th-P15:90), (Th-P16:294), Nasiff-Hadad, A., (Mo-P1:28), Nickenig, G., 486 (Th-W59:5) (Th-P16:371) (Th-P15:238) Nicolaides, A.N., 145 (Mo-P6:452) 225 238 170 419 Nakajima, Y., (Tu-P7:185), (Tu-P7:244), Nasir, K., (Tu-W25:4), (We-P13:332) Nicolaou, V.N., 58 (Mo-P1:56), 84 (Mo-P2:171) 366 206 415 (We-P11:96) Natal, C., (Tu-P7:97), (We-P13:315) Nicolas, V., 239 (Tu-P7:246) 420 526 I Nakamori, T., (We-P13:335) Natali, A., (Th-P15:152) Nicoletti, A., 195 (Tu-P7:50), 237 (Tu-P7:240), 73 161 442 Nakamura, H., (Mo-P1:125), (Tu-W20:7), Natoli, S., (We-P14:435) 278 (Tu-P10:426), 327 (We-W41:5) 559 581 98 569 (Th-P16:300), (Th-P16:398) Naumov, V., (Mo-P4:237), (Th-P16:346) Nicolini, E., 422 (We-P13:343) N 59 76 404 581 Nakamura, K., (Mo-P1:63), (Mo-P1:137), Naumov, V.G., (We-P11:263), Nicolle, C., 453 (We-P14:479) 348 (We-P11:12) (Th-P16:400) Nicoloff, G., 347 (We-P11:6, We-P11:7) D 63 68 267 Nakamura, M., (Mo-P1:81), (Mo-P1:100), Naumova, A., (Tu-P9:379) Niederfellner, G., 520 (Th-P15:125) 72 243 193 (Mo-P1:120), (Tu-P7:268) Naumovic, N., (Tu-P7:42) Niedojadlo, A., 263 (Tu-P9:361) Nakamura, Y., 52 (Mo-P1:31), 56 (Mo-P1:48, Naumovski, N., 77 (Mo-P1:140), 317 E Nielsen, J.E., 497 (Th-P15:21) Mo-P1:50), 58 (Mo-P1:58), 59 (Mo-P1:63), 64 (We-W36:3), 441 (We-P14:429) Nielsen, L.B., 14 (Mo-W2:4), 490 (Th-W61:6), (Mo-P1:83), 243 (Tu-P7:268), 260 Nauze, M., 31 (Mo-W11:6) X 497 (Th-P15:21) (Tu-P9:344), 265 (Tu-P9:368), 348 Navarro, M.A., 511 (Th-P15:84), 567 Nielsen, P., 446 (We-P14:451) (We-P11:12), 520 (Th-P15:127) (Th-P16:334) Niemeier, A., 185 (Tu-P7:4) Nakandakare, E., 263 (Tu-P9:357) Navarro, S., 395 (We-P11:224) Niemiec, P., 143 (Mo-P6:444) Nakandakare, E.R., 31 (Mo-W11:4), 512 Navin, T., 92 (Mo-P2:211) Nieminen, M.S., 85 (Mo-P2:176), 171 (Tu-W25:6) (Th-P15:90), 527 (Th-P15:154, Th-P15:155), Nawawi, H., 224 (Tu-P7:176), 418 (We-P13:328), Nierman, M., 138 (Mo-P6:420) 540 (Th-P15:215), 558 (Th-P16:294) 423 (We-P13:347) Nierman, M.C., 16 (Mo-W3:6), 19 (Mo-W5:2), Nakano, A., 523 (Th-P15:139) Naylor, A.S., 207 (Tu-P7:101) 134 (Mo-P6:403), 585 (Th-P16:415) Nakano, H., 258 (Tu-P9:334) Nazli, N., 264 (Tu-P9:365) Nieuwenhuizen, W.F., 32 (Mo-W11:7) Nakano, K., 249 (Tu-P8:294), 482 (Th-W57:4) Neal, R., 551 (Th-P16:265) Niglio, T., 426 (We-P13:362) Nakano, S., 420 (We-P13:335) Nechifor, M., 203 (Tu-P7:83) Niimura, H., 268 (Tu-P9:383), 396 (We-P11:229), Nakano, T., 512 (Th-P15:90), 558 (Th-P16:294), Nedeljkovic, S., 53 (Mo-P1:37) 570 585 (Th-P16:417) Nedyalkov, A., 104 (Mo-P4:263) (Th-P16:350) 169 278 Nakano, Y., 420 (We-P13:335) Neems, R., 308 (We-W31:3) Nijm, J., (Tu-W25:1), (Tu-P10:428) 23 502 525 Nakata, A., 186 (Tu-P7:5), 191 (Tu-P7:31), 577 Neggazi, S., 194 (Tu-P7:45) Nijpels, G., (Mo-W7:4), (Th-P15:44), (Th-P16:380) Negishi, S., 430 (We-P14:380) (Th-P15:145) 131 Nakazato, K., 575 (Th-P16:371) Negrão, C.E., 113 (Mo-P5:304), 509 (Th-P15:75) Nikitin, A.G., (Mo-P6:387) 57 Nakazawa, T., 253 (Tu-P8:311) Negrao, C.E., 527 (Th-P15:154, Th-P15:155) Nikitin, Y.P., (Mo-P1:53) 444 Nakbi, A., 69 (Mo-P1:105), 131 (Mo-P6:388), 349 Negre-Salvayre, A., 534 (Th-P15:187) Nikitina, N.A., (We-P14:442) 109 272 (We-P11:18), 438 (We-P14:415) Negrotto, S., 91 (Mo-P2:203), 231 (Tu-P7:212) Nikitopoulou, P., (Mo-P4:288), Nakhai Pour, H.R., 79 (Mo-P1:153), 290 Neil, H.A.W., 37 (Mo-W14:4) (Tu-P10:400) 235 (Tu-P10:480) Nelson, J.J., 484 (Th-W58:5) Nikkari, S., (Tu-P7:232) 235 241 Nalini, N., 199 (Tu-P7:65), 429 (We-P13:376) Nematbakhsh, M., 192 (Tu-P7:35) Nikkari, S.T., (Tu-P7:232), (Tu-P7:256), Nalivaiko, E., 375 (We-P11:134) Nemchyna, O., 211 (Tu-P7:122), 282 251 (Tu-P8:302) Nam, K.H., 455 (We-P14:489) (Tu-P10:444) Nikolic, A., 115 (Mo-P5:313) Nambi, P., 256 (Tu-P8:324, Tu-P8:325) Nemtsova, V., 348 (We-P11:11), 571 (Th-P16:353) Nikolic, D., 53 (Mo-P1:37) Namgaladze, D., 513 (Th-P15:94) Nenova, K., 382 (We-P11:164) Nikolic, M., 441 (We-P14:428) Nampoothiri, V.K., 426 (We-P13:360) Nestel, P., 177 (Tu-W28:7) Nikolic, M.S., 493 (Th-P15:6) Nannipieri, M., 14 (Mo-W2:7), 479 (Th-W56:4) Neufeld, E.B., 320 (We-W38:1) Nikolov, A., 347 (We-P11:6, We-P11:7) Nantel, G., 439 (We-P14:419) Neumark, Y., 514 (Th-P15:98) Nikolova, V., 86 (Mo-P2:181) Naoumova, R.P., 21 (Mo-W6:3), 128 Neumeier, D., 526 (Th-P15:151) Nilsen, D.W.T., 449 (We-P14:463) (Mo-P6:378), 130 (Mo-P6:383), 545 Neuvonen, P.J., 562 (Th-P16:312) Nilsen, O., 215 (Tu-P7:139) (Th-P15:237) Neuwirth, C., 128 (Mo-P6:378) Nilsson, J., 231 (Tu-P7:213), 233 (Tu-P7:221), Naples, M., 25 (Mo-W8:6) Neve, J., 524 (Th-P15:141), 525 (Th-P15:146) 327 (We-W41:3), 406 (We-P11:273), 481 Napoleão, P., 84 (Mo-P2:172) Neves, M.Q.T.S., 527 (Th-P15:154, Th-P15:155), (Th-W57:1), 521 (Th-P15:128) Napolitano, M., 225 (Tu-P7:184), 448 558 (Th-P16:294) Nilsson, L.C., 169 (Tu-W25:1), 170 (Tu-W25:3) (We-P14:461), 519 (Th-P15:119) Neves, V.C., 113 (Mo-P5:304) Nilsson, R., 200 (Tu-P7:72), 357 (We-P11:50) Napper, F.L., 160 (Tu-W20:3) Newby, A., 244 (Tu-P7:273) Nilsson, S.K., 514 (Th-P15:96) Narducci, M., 277 (Tu-P10:422), 349 (We-P11:16) Newby, A.C., 481 (Th-W57:2) Nilsson, U.K., 90 (Mo-P2:201)

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

248 Ninio, E., 173 (Tu-W26:4), 464 (Th-W48:7) (Mo-P6:400), 334 (We-W45:1), 404 Oh, B.H., 573 (Th-P16:361) Ninkovic, M., 82 (Mo-P1:164) (We-P11:264) Oh, D.J., 217 (Tu-P7:145), 266 (Tu-P9:372, Ninomiya, K., 249 (Tu-P8:293), 369 Notø, A.T.W., 497 (Th-P15:25) Tu-P9:373), 314 (We-W34:7) (We-P11:109) Noto, D., 62 (Mo-P1:73), 133 (Mo-P6:400), 426 Oh, G.T., 455 (We-P14:489) Nishida, K.-I., 564 (Th-P16:323) (We-P13:362), 524 (Th-P15:144) Ohike, Y., 405 (We-P11:269) A Nishida, M., 28 (Mo-W9:6) Nounopoulos, C., 67 (Mo-P1:99) Ohira, M., 417 (We-P13:320), 498 (Th-P15:29), Nishihira, K., 93 (Mo-P2:215), 246 (Tu-P7:279) Novakovic, A., 206 (Tu-P7:98) 505 (Th-P15:58) Nishikawa, H., 192 (Tu-P7:33), 268 (Tu-P9:383), Novakovic, T., 379 (We-P11:150), 421 Ohkaru, Y., 497 (Th-P15:22) U 578 (Th-P16:386) (We-P13:341) Ohlstein, E.H, 489 (Th-W61:1) Nishimoto, T., 339 (We-S13:2, We-S13:3), 549 Noveanu, L., 46 (Mo-P1:3) Ohmori, R., 73 (Mo-P1:125), 281 (Tu-P10:439), T (Th-P16:256) Novelli, G., 425 (We-P13:355) 559 (Th-P16:300), 581 (Th-P16:398) Nishimura, K., 104 (Mo-P4:264), 444 Novellino, E., 372 (We-P11:119) Ohmori, Y., 436 (We-P14:404) H (We-P14:441) Novkovic, M., 422 (We-P13:345) Ohmura, H., 417 (We-P13:321), 559 (Th-P16:301) Nishimura, M., 497 (Th-P15:22) Novotna, J., 243 (Tu-P7:265) Ohni, M., 417 (We-P13:322) O Nishtar, S., 424 (We-P13:353) Nowacki, P., 107 (Mo-P4:277) Ohnishi, H., 58 (Mo-P1:57) 220 Nisic, T., 421 (We-P13:341) Nowicka, G., 142 (Mo-P6:436), 432 Ohno, M., (Tu-P7:162) 237 R Nissel, R., 218 (Tu-P7:150) (We-P14:390), 477 (Th-W55:4) Ohno-Iwashita, Y., (Tu-P7:237) 297 417 Nissen, S.E., 183 (Tu-S11:3) Nowicki, P., (Tu-P10:511) Ohnuki, H., (We-P13:322) 107 73 281 Nissen-Meyer, L.S., 532 (Th-P15:180) Nowik, M., (Mo-P4:277) Ohsuzu, F., (Mo-P1:125), (Tu-P10:439), 289 559 581 Nistor, E., 365 (We-P11:86) Nozynski, J., (Tu-P10:477) (Th-P16:300), (Th-P16:398) 108 272 48 367 Nita, C., 155 (Tu-W17:6) Ntaios, G., (Mo-P4:282), (Tu-P10:401) Ohta, T., (Mo-P1:12), (We-P11:100) I 412 366 Nitschke, Y., 144 (Mo-P6:447) Nucci Da Silva, L.P., (We-P12:300) Ohtani, S., (We-P11:96) 191 245 Nitsotolis, T., 572 (Th-P16:358) Numaguchi, Y., (Tu-P7:28) Ohwaki, K., (Tu-P7:277) 31 512 195 N Nitzan, O., 253 (Tu-P8:310) Nunes, V.S., (Mo-W11:4), (Th-P15:90), Oida, H., (Tu-P7:47) 527 540 558 225 238 Nizankowski, R., 192 (Tu-P7:34) (Th-P15:154), (Th-P15:215), Oikawa, S., (Tu-P7:185), (Tu-P7:244), 366 D Niznick, J., 115 (Mo-P5:315) (Th-P16:294) (We-P11:96) 261 164 196 Njo, T., 235 (Tu-P7:229) Núñez, I., (Tu-P9:349, Tu-P9:350) Oishi, Y., (Tu-W22:3), (Tu-P7:53) 123 Oka, K., 244 (Tu-P7:273) Njølstad, I., 467 (Th-W50:4) Núñez, V., (Mo-P5:353) E 380 Oka, M., 229 (Tu-P7:200), 240 (Tu-P7:252) Noale, M., 424 (We-P13:354) Nuño-González, P., (We-P11:155) 313 Okabayashi, M., 411 (We-P12:295) Nobecourt, E., 71 (Mo-P1:113, Mo-P1:114), 152 Nuotio, I.O., (We-W34:3) X 93 246 Okada, K., 59 (Mo-P1:60), 574 (Th-P16:369) (Tu-W16:1), 153 (Tu-W16:4), 541 Nuotio, K., (Mo-P2:216), (Tu-P7:278) Nürnberg, P., 144 (Mo-P6:447) Okada, M., 575 (Th-P16:373) (Th-P15:218) Nus, M., 333 (We-W44:4), 523 (Th-P15:136) Okada, T., 498 (Th-P15:27) Nobili, E., 463 (Th-W48:6) Nuti, R., 409 (We-P12:285), 558 (Th-P16:295) Okajima, F., 225 (Tu-P7:185), 238 (Tu-P7:244), Nobuyoshi, M., 122 (Mo-P5:350) Nyhalah, J.D., 529 (Th-P15:166) 366 (We-P11:96) Noera, G., 61 (Mo-P1:69), 420 (We-P13:334), 424 Nylænde, M., 103 (Mo-P4:258) Okamura, K., 99 (Mo-P4:241), 293 (Tu-P10:492) (We-P13:351) Nylander, M., 413 (We-P12:305) Okamura, T., 48 (Mo-P1:14), 52 (Mo-P1:31), 55 Nofer, J.-R., 517 (Th-P15:111) (Mo-P1:45), 56 (Mo-P1:48), 58 (Mo-P1:58), Noguchi, N., 548 (Th-P16:250) O, K., 274 (Tu-P10:410), 276 (Tu-P10:418) 59 (Mo-P1:63), 64 (Mo-P1:83), 76 Noguchi, T., 548 (Th-P16:251, Th-P16:252, O’Dea, K., 177 (Tu-W28:4) (Mo-P1:137), 265 (Tu-P9:368), 348 Th-P16:253) O’Dell, S.D., 144 (Mo-P6:446) (We-P11:12) 512 Nogueira Filho, J., (Th-P15:91) O’Leary, D.H., 307 (We-W31:1) Okamura, Y., 454 (We-P14:485) 255 579 Nohara, A., (Tu-P8:321), (Th-P16:388) O’Rahilly, S., 13 (Mo-W2:2), 320 (We-W37:7) Okamura T, T., 260 (Tu-P9:344) 90 222 358 Noll, G., (Mo-P2:200), (Tu-P7:169), Oba, K., 258 (Tu-P9:334) Okayama, A., 48 (Mo-P1:14), 55 (Mo-P1:45), 56 (We-P11:54) Obayashi, K., 361 (We-P11:72) (Mo-P1:48), 59 (Mo-P1:63), 63 (Mo-P1:81), 186 191 577 Nomura, S., (Tu-P7:5), (Tu-P7:31), Obici, L., 536 (Th-P15:198) 64 (Mo-P1:83), 72 (Mo-P1:120), 76 (Th-P16:380) Obrenovic, R., 379 (We-P11:150), 421 (Mo-P1:137), 348 (We-P11:12) 280 Nonaka, R., (Tu-P10:435) (We-P13:341) Okazaki, M., 430 (We-P14:380), 539 155 Nony, P., (Tu-W17:3) Obrenovitsh, R., 408 (We-P12:284) (Th-P15:211), 575 (Th-P16:373) 357 Noori, P., (We-P11:50) Obrien, P.J., 445 (We-P14:447) Okmen, E., 528 (Th-P15:160) 141 Norata, G., (Mo-P6:431) Ochman, K., 129 (Mo-P6:380) Okong, P., 401 (We-P11:250) 30 193 Norata, G.D., (Mo-W11:2), (Tu-P7:39), Oda, K., 129 (Mo-P6:379) Okopien, B., 559 (Th-P16:299), 573 (Th-P16:363) 211 (Tu-P7:120), 475 (Th-W54:3), 537 Odak, D., 282 (Tu-P10:446) Oksala, N., 235 (Tu-P7:232) (Th-P15:199) Ødegård, R., 379 (We-P11:152) Oksjoki, R., 157 (Tu-W18:5), 460 (Th-W46:3) Norbury, G., 129 (Mo-P6:381) Odermarsky, M., 351 (We-P11:24) Okuda, N., 64 (Mo-P1:83) Nordestgaard, B.G., 18 (Mo-W4:6), 35 Odoardi, M.R., 410 (We-P12:289) Okuno, T., 511 (Th-P15:86), 519 (Th-P15:121) (Mo-W13:6), 37 (Mo-W14:6), 74 Oelze, M., 470 (Th-W51:7) Okutsu, R., 394 (We-P11:219), 513 (Th-P15:93) (Mo-P1:128), 145 (Mo-P6:450) Oestvang, J., 236 (Tu-P7:234) Oldani, E., 258 (Tu-P9:336), 308 (We-W31:6) Nordin Fredrikson, G., 406 (We-P11:273) Ogami, N., 354 (We-P11:37) Oldani, E.C., 204 (Tu-P7:87), 258 (Tu-P9:333) Nordoy, A., 511 (Th-P15:87) Ogarkov, M.Y., 81 (Mo-P1:158) Oleksyk, O., 373 (We-P11:124), 450 Norman, B., 397 (We-P11:233) Ogawa, H., 162 (Tu-W20:8), 246 (Tu-P7:279) (We-P14:467) Norman, D., 515 (Th-P15:101) Ogawa, K., 434 (We-P14:397) Olgun, A., 206 (Tu-P7:96) Norman, G., 278 (Tu-P10:425) Ogawa, Y., 506 (Th-P15:61) Olijhoek, J., 421 (We-P13:338) Noshpal, M., 532 (Th-P15:178) Ognjanovic, S., 126 (Mo-P5:365), 361 Olijhoek, J.K., 479 (Th-W56:3), 569 (Th-P16:342) N o s ikov, V. V. , 131 (Mo-P6:387), 146 (Mo-P6:455) (We-P11:71), 426 (We-P13:363), 522 Olin, M., 582 (Th-P16:403) Noskova, L., 252 (Tu-P8:308) (Th-P15:134) Olivecrona, G., 514 (Th-P15:96) Nospal, M., 584 (Th-P16:411) Ogura, M., 559 (Th-P16:300), 581 (Th-P16:398) Oliveira, A.S., 280 (Tu-P10:437) Notarbartolo, A., 62 (Mo-P1:73), 133 Ogura, S., 231 (Tu-P7:210) Oliveira, H., 55 (Mo-P1:42), 540 (Th-P15:213)

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

249 Oliveira, H.C.F., 365 (We-P11:91), 505 Osaki, F., 210 (Tu-P7:115), 254 (Tu-P8:314), 354 Pagnan, A., 74 (Mo-P1:127), 263 (Tu-P9:359), (Th-P15:57), 526 (Th-P15:150) (We-P11:37) 502 (Th-P15:45) Oliveira, T.V., 466 (Th-W49:7) Oscarsson, J., 254 (Tu-P8:315) Pagoni, S., 58 (Mo-P1:55), 109 (Mo-P4:288), 272 Oliver, M.F., 491 (Th-S17:3) Ose, L., 36 (Mo-W14:3), 337 (We-S12:3), 551 (Tu-P10:400) A Oliviera, S., 291 (Tu-P10:484) (Th-P16:266) Pahlman, R., 576 (Th-P16:378) Olivieri, R., 219 (Tu-P7:157) Oshida, K., 417 (We-P13:321) Påhlsson, P., 287 (Tu-P10:467) Olivieri, V., 73 (Mo-P1:121), 281 (Tu-P10:440) Oshima, S., 574 (Th-P16:366) Pahor, M., 317 (We-W36:5) U Olkkonen, V.M., 39 (Mo-W15:5) Osipov, S.V., 557 (Th-P16:291) Pai, C.Y., 163 (Tu-W21:3), 399 (We-P11:241) Olofsson, K.E., 233 (Tu-P7:221) Oskolkova, O., 160 (Tu-W19:7) Paigen, B., 535 (Th-P15:194) T Olofsson, P.S., 393 (We-P11:216) Osman, A., 51 (Mo-P1:27) Pailer, S., 570 (Th-P16:349) Olsen, B., 280 (Tu-P10:434) Osmancik, P., 91 (Mo-P2:204), 416 (We-P13:316) Paim, B.A., 508 (Th-P15:71) H Olsson, A., 161 (Tu-W20:4), 406 (We-P11:272), Osokina, N.YE., 189 (Tu-P7:22) Paizis, I., 210 (Tu-P7:118) 581 (Th-P16:401) Ostblom, M., 158 (Tu-W18:7) Paju, S., 171 (Tu-W25:6), 463 (Th-W48:4) O Olsson, A.G., 169 (Tu-W25:1), 278 (Tu-P10:428), Östergren-Lundén, G., 239 (Tu-P7:249) Pajukanta, P., 130 (Mo-P6:383), 305 (We-W30:3), 491 (Th-S17:1) Ostojic, M., 53 (Mo-P1:34), 351 (We-P11:25, 333 (We-W44:5), 397 (We-P11:234) 145 Olsson, P.G., (Mo-P6:449) We-P11:26, We-P11:27), 379 (We-P11:150) Pakker, N., 401 (We-P11:250) R 55 371 Onat, A., (Mo-P1:43), (We-P11:114) Ostric-Kalimanovska, D., 279 (Tu-P10:432) Palasciano, G., 419 (We-P13:331) 141 Ongari, M., (Mo-P6:431) Ota, A., 28 (Mo-W9:6) Palasti, I., 140 (Mo-P6:427) 191 583 Ongini, E., (Tu-P7:29), (Th-P16:408) Otani, K., 482 (Th-W57:4) Palazzuoli, A., 147 (Mo-P6:460), 333 (We-W44:3) 259 Ono, K., (Tu-P9:339) Otiman, G., 293 (Tu-P10:491), 445 (We-P14:445) Paldanius, M., 85 (Mo-P2:176) 454 I Ono, Y., (We-P14:485) Otljanska, M., 532 (Th-P15:178) Palencia, M., 85 (Mo-P2:178), 89 (Mo-P2:194), 63 72 Onoda, T., (Mo-P1:81), (Mo-P1:120) Ottestad, I., 551 (Th-P16:266) 286 (Tu-P10:461), 395 (We-P11:224), 531 49 Onolfo, S., (Mo-P1:16, Mo-P1:18) Otvos, J., 501 (Th-P15:40) (Th-P15:176) N 106 218 264 Onrat, E., (Mo-P4:274), (Tu-P7:151), Otvos, J.D., 70 (Mo-P1:109), 113 (Mo-P5:303) Paletas, K., 295 (Tu-P10:500) (Tu-P9:362, Tu-P9:364) Ou, X., 254 (Tu-P8:317), 492 (Th-P15:3), 543 Palmer, A.J., 121 (Mo-P5:346), 178 (Tu-W29:4) D 534 535 Ooi, E.M.M., (Th-P15:185), (Th-P15:227, Th-P15:229) Palmer, M.K., 12 (Mo-W1:5) 577 (Th-P15:193), (Th-P16:379) Ouadahi, N., 102 (Mo-P4:256), 387 (We-P11:189) Palmieri, V., 207 (Tu-P7:104), 315 (We-W35:2), Oonishi, H., 59 (Mo-P1:60) E Ouchi, Y., 217 (Tu-P7:147), 405 (We-P11:269), 419 (We-P13:331) Öörni, K., 242 (Tu-P7:264), 496 (Th-P15:19), 497 585 (Th-P16:417) Palomino, S.A.P., 406 (We-P11:274) (Th-P15:23, Th-P15:24) X Oude Egbrink, M., 390 (We-P11:202) Paltseva, E., 287 (Tu-P10:466) Opgen-Rhein, B., 218 (Tu-P7:150) Oude Egbrink, M.G.A., 390 (We-P11:203) Pan, H., 464 (Th-W49:1) Opolski, G., 358 (We-P11:56) Oudghiri, A.I., 443 (We-P14:437) Pan, M., 27 (Mo-W9:3) Orakzai, R., 419 (We-P13:332) Ouyang, G., 144 (Mo-P6:445) Panagiotakos, D.B., 58 (Mo-P1:56), 84 Orakzai, S., 419 (We-P13:332) Ouzilleau, B., 190 (Tu-P7:24), 328 (We-W41:6) (Mo-P2:171) Oram, J.F., 13 (Mo-W2:1), 227 (Tu-P7:191) Ovanesov, M.V., 29 (Mo-W10:5) Panagiotidou, A., 353 (We-P11:36) Orbe, J., 143 (Mo-P6:441), 245 (Tu-P7:274), 480 Ovchinnikova, O.A., 242 (Tu-P7:262) Panasenko, O.M., 499 (Th-P15:34), 500 (Th-W56:5), 590 (Th-P17:441) Ovental, A., 484 (Th-W58:4) (Th-P15:38) Orchard, T.J., 50 (Mo-P1:21) Oviedo-Orta, E., 406 (We-P11:273) Panayiotou, A., 145 (Mo-P6:452) Ordovas, J.M., 135 (Mo-P6:408), 175 (Tu-W28:1) Owen, J.S., 95 (Mo-P3:224) Pandey, D., 30 (Mo-W10:6), 222 (Tu-P7:170) Orekhov, A.N., 208 (Tu-P7:109), 209 (Tu-P7:110), Owens, D., 39 (Mo-W15:6) Pandolﬁ, A., 14 (Mo-W2:5), 216 (Tu-P7:144), 352 230 (Tu-P7:209), 232 (Tu-P7:214), 250 Oyama, T., 417 (We-P13:320), 498 (Th-P15:29) 353 380 (Tu-P8:296), 444 (We-P14:442), 499 (We-P11:29), (We-P11:35), Ozaki, T., 243 (Tu-P7:268) (Th-P15:34), 500 (Th-P15:38) (We-P11:156) Ozansoy, G., 569 (Th-P16:345) 18 Orekohov, A., 227 (Tu-P7:192) Pandolfo, M., (Mo-W4:4) Ozawa, H., 460 (Th-W46:6), 583 (Th-P16:407) 142 378 Orenstein, J.M., 544 (Th-P15:233) Panduro, A., (Mo-P6:437), Ozawa, Y., 388 (We-P11:194) 380 Oresic, M., 236 (Tu-P7:235) (We-P11:145), (We-P11:155) Ozer, C., 114 (Mo-P5:312) 121 Orhan, G., 528 (Th-P15:160) Pandya, A., (Mo-P5:344) Ozgul, A., 110 (Mo-P4:293) 89 Orian, Sh., 196 (Tu-P7:55) Pangalou, M., (Mo-P2:193) Ozin, B., 74 (Mo-P1:129), 92 (Mo-P2:208), 100 135 Oribe, A., 116 (Mo-P5:322) Paniagua, J.A., (Mo-P6:408) (Mo-P4:246), 110 (Mo-P4:293), 112 325 398 Orive, A.I., 273 (Tu-P10:403) Paniccia, R., (We-W40:3), (We-P11:239) (Mo-P5:301), 164 (Tu-W21:7), 398 54 56 261 Orlandi, A., 252 (Tu-P8:305) Panico, S., (Mo-P1:40), (Mo-P1:46), (We-P11:237) Orloff, D.G., 42 (Mo-S6:4) (Tu-P9:348) Ozturk, E., 507 (Th-P15:65) Orolin, J., 560 (Th-P16:304) Panidis, D., 522 (Th-P15:134) Ozturk, S., 114 (Mo-P5:312) Oroojy, H., 394 (We-P11:222) Panza, F., 402 (We-P11:255), 447 (We-P14:458), Orrasch, M., 47 (Mo-P1:8) 530 (Th-P15:172) Orsini, L., 554 (Th-P16:277), 558 (Th-P16:296) Paccaud, F., 363 (We-P11:81), 364 (We-P11:82) Paoletti, R., 251 (Tu-P8:300) Orso, E., 26 (Mo-W9:2) Pachulia, L.S., 388 (We-P11:191) Paoletti, V., 469 (Th-W51:4) Ortega, C., 47 (Mo-P1:9), 133 (Mo-P6:398) Pacienza, N., 91 (Mo-P2:203), 231 (Tu-P7:212) Paolisso, G., 534 (Th-P15:188) Ortega, K., 512 (Th-P15:90) Pacini, G., 363 (We-P11:78) Papa, R., 426 (We-P13:362) Ortega, L., 228 (Tu-P7:197) Packard, C.J., 12 (Mo-W1:5), 36 (Mo-W14:1), Papac-Milicevic, N., 488 (Th-W60:8) Ortiz, E., 62 (Mo-P1:74) 484 (Th-W58:5) Papadakis, I.E., 58 (Mo-P1:56), 84 (Mo-P2:171) Ortiz, G., 138 (Mo-P6:418) Packianathan, M., 541 (Th-P15:219) Papadakis, J.A., 383 (We-P11:168), 414 Ortiz-Muñoz, G., 228 (Tu-P7:197) Padín-Paz, E., 124 (Mo-P5:359) (We-P12:307), 423 (We-P13:350) Oruc, S., 264 (Tu-P9:362, Tu-P9:364) Padovani, R., 411 (We-P12:293) Papadopoulos, C., 277 (Tu-P10:424) Os, I., 286 (Tu-P10:460), 390 (We-P11:200) Padoveze, A.F., 466 (Th-W49:7) Papadopoulos, D., 204 (Tu-P7:90), 395 Osa, A., 85 (Mo-P2:178), 286 (Tu-P10:461), 531 Pagador, A., 78 (Mo-P1:146) (We-P11:225) (Th-P15:176) Pagani, R., 589 (Th-P17:435) Papadopoulou, C., 224 (Tu-P7:180) Osada, J., 511 (Th-P15:84), 567 (Th-P16:334) Pagano, G., 62 (Mo-P1:73) Papadopoulou, L., 353 (We-P11:36)

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

250 Papafaklis, M., 265 (Tu-P9:370), 298 Pasqui, A.L., 86 (Mo-P2:180), 147 (Mo-P6:460), Pejkovic, D., 361 (We-P11:68, We-P11:70), 362 (Tu-P10:517) 333 (We-W44:3), 405 (We-P11:270) (We-P11:74) Papamichael, C., 251 (Tu-P8:303) Passaniti, M., 24 (Mo-W7:7) Peklo, M.M., 96 (Mo-P3:226, Mo-P3:227) Papapanagiotou, A., 67 (Mo-P1:99) Passarelli, M., 527 (Th-P15:154, Th-P15:155), Peknicova, J., 203 (Tu-P7:82) Papathanasiou, M., 347 (We-P11:9), 348 540 (Th-P15:215) Pekova, S., 128 (Mo-P5:376) A (We-P11:10) Passaro, A., 311 (We-W33:3) Pelikanova, T., 371 (We-P11:115) Pape, T.D., 25 (Mo-W8:4) Passeri, C., 173 (Tu-W26:7) Pellegrini, E., 46 (Mo-P1:4) Papp, E., 398 (We-P11:236) Pasterkamp, G., 517 (Th-P15:110) Pelosi, G.C., 384 (We-P11:174) U Paragh, G., 229 (Tu-P7:203), 292 (Tu-P10:489), Pastier, D., 538 (Th-P15:206) Pelosi, V., 445 (We-P14:448) 296 (Tu-P10:504), 518 (Th-P15:115), 571 Pastorelli, M., 86 (Mo-P2:180), 147 (Mo-P6:460), Peña, J.L., 61 (Mo-P1:70) T (Th-P16:355), 577 (Th-P16:382) 333 (We-W44:3) Peña Quián, Y., 117 (Mo-P5:323) Páramo, J.A., 143 (Mo-P6:441), 245 (Tu-P7:274), Patel, D.D., 515 (Th-P15:101) Penas, J.L., 54 (Mo-P1:39) H 480 (Th-W56:5) Paternò, R., 18 (Mo-W4:7) Pencic, B., 386 (We-P11:182) Paramo, J.A., 590 (Th-P17:441) Patricio, P.R., 365 (We-P11:91) Peng, K., 251 (Tu-P8:301) O Pare, G., 131 (Mo-P6:391) Patrignani, P., 29 (Mo-W10:4) Pengo, V., 74 (Mo-P1:127) Paredes, S., 414 (We-P12:310) Patrono, C., 173 (Tu-W26:7), 363 (We-P11:78), Pennefather, P.S., 445 (We-P14:447) R Parente, R., 244 (Tu-P7:271), 439 (We-P14:422), 469 (Th-W51:4), 588 (Th-P17:431) Pennings, M., 319 (We-W37:5) 481 (Th-W57:3) Patrzalek, D., 104 (Mo-P4:265) Pennisi, P., 411 (We-P12:297) Parhofer, K.G., 141 (Mo-P6:432) Patsch, J., 410 (We-P12:292) Penno, G., 350 (We-P11:23), 369 (We-P11:108), Parini, P., 39 (Mo-W15:7), 188 (Tu-P7:18) Patsch, J.R., 12 (Mo-W1:4), 155 (Tu-W17:4) 386 (We-P11:184), 387 (We-P11:186), 528 Paris, A., 589 (Th-P17:433) Patsch, W., 38 (Mo-W15:4) (Th-P15:159) I Parisi, N., 411 (We-P12:297) Patten, R.D., 485 (Th-W59:3) Pentikäinen, M.O., 157 (Tu-W18:5), 232 Park, C.G., 217 (Tu-P7:145), 266 (Tu-P9:372, Patterson, A.P., 517 (Th-P15:109) (Tu-P7:216) N Tu-P9:373), 314 (We-W34:7) Patti, L., 165 (Tu-W22:4) Penz, S., 30 (Mo-W10:6), 326 (We-W40:7) Park, E., 247 (Tu-P7:285) Pauciullo, P., 231 (Tu-P7:211), 282 (Tu-P10:445) Peovska, I., 101 (Mo-P4:253) D Park, E.J., 234 (Tu-P7:227) Paul, J.L., 538 (Th-P15:206) Pepe, G., 396 (We-P11:230) Park, H.J., 98 (Mo-P4:238) Paulsson-Berne, G., 237 (Tu-P7:240), 248 Pépin, A., 415 (We-P13:313) Park, H.K., 247 (Tu-P7:285) (Tu-P7:289), 327 (We-W41:5), 406 Pepine, C.J., 334 (We-W44:7) E Park, J.E., 132 (Mo-P6:394), 234 (Tu-P7:227), (We-P11:272) Peracino, A.P., 480 (Th-W56:8) 247 (Tu-P7:285), 267 (Tu-P9:376), 279 Paulsson Berne, G., 489 (Th-W61:4) Perdikari, E., 56 (Mo-P1:49) X (Tu-P10:429), 423 (We-P13:349), 517 Paulweber, B., 155 (Tu-W17:4) Pereira, A., 50 (Mo-P1:23), 54 (Mo-P1:41), 66 (Th-P15:112) Paumelle, R., 487 (Th-W60:3) (Mo-P1:94), 79 (Mo-P1:150) Park, J.G., 455 (We-P14:489) Pavlidis, A.N., 113 (Mo-P5:306), 509 Pereira, G., 363 (We-P11:80) Park, K.C., 234 (Tu-P7:227) (Th-P15:77), 510 (Th-P15:81) Peretz, H., 142 (Mo-P6:440) Park, K.W., 573 (Th-P16:361) Pavlidis, G., 81 (Mo-P1:162), 122 (Mo-P5:348) Perevozskaya, I., 174 (Tu-W27:3) Park, M.Y., 234 (Tu-P7:227), 247 (Tu-P7:285), Pavlova, O., 281 (Tu-P10:441) Perez, I., 447 (We-P14:457) 279 (Tu-P10:429) Pavlovic, K., 262 (Tu-P9:352) Pérez-Camino, M.C., 452 (We-P14:475) Park, S.H., 517 (Th-P15:112) Pavlovic, S.U., 127 (Mo-P5:373), 358 Perez-Faustinelli, S., 381 (We-P11:158) Park, Y.B., 573 (Th-P16:361) (We-P11:57) Pérez-Jiménez, F., 439 (We-P14:418), 448 Parker, A., 254 (Tu-P8:316) Pawlak, D., 238 (Tu-P7:245), 284 (Tu-P10:451) (We-P14:459), 585 (Th-P17:419) Parks, J.S., 166 (Tu-W23:4) Pawlak, K., 238 (Tu-P7:245), 284 (Tu-P10:451) Perez-Jimenez, F., 135 (Mo-P6:408), 447 Parodi, O., 276 (Tu-P10:420) Pawlicki, L., 62 (Mo-P1:77), 412 (We-P12:299), (We-P14:454, We-P14:457) Parolari, A., 92 (Mo-P2:209), 116 (Mo-P5:318), 425 (We-P13:356) Pérez-Martínez, P., 585 (Th-P17:419) 212 (Tu-P7:123), 398 (We-P11:238) Paximadas, S., 58 (Mo-P1:55), 109 (Mo-P4:288), Perez-Martinez, P., 135 (Mo-P6:408), 447 Parolini, C., 167 (Tu-W23:7), 454 (We-P14:484), 272 (Tu-P10:400) (We-P14:454) 477 (Th-W55:3), 478 (Th-W55:6), 536 Payne, S., 160 (Tu-W20:3) Pérez-Méndez, O., 537 (Th-P15:203) (Th-P15:198), 570 (Th-P16:347) Pazzucconi, F., 251 (Tu-P8:300) Perez-Mendez, O.A., 534 (Th-P15:186) Parquet, M., 433 (We-P14:393) Pearce, E., 316 (We-W35:6) Pérez-Pérez, L.M., 363 (We-P11:80) Parra, S., 163 (Tu-W21:5), 416 (We-P13:318) Pecin, I., 376 (We-P11:136), 384 (We-P11:175) Perez De Oteyza, C., 58 (Mo-P1:59) Parra-Rojas, I., 142 (Mo-P6:437) Pecka, M., 563 (Th-P16:317) Perheentupa, A., 221 (Tu-P7:163) Parramon, N., 498 (Th-P15:28) Peczynska, J., 211 (Tu-P7:121) Peric, M., 206 (Tu-P7:98), 211 (Tu-P7:119) Parri, M.S., 310 (We-W32:6) Pederiva, C., 275 (Tu-P10:411), 441 (We-P14:430) Perkov, S., 282 (Tu-P10:446) Parrill, A., 487 (Th-W60:2) Pedersen, J.I., 467 (Th-W50:4) Pernice, V., 404 (We-P11:264) Partenza, A., 336 (We-W45:7) Pedersen, O., 159 (Tu-W19:4) Perona, J.S., 399 (We-P11:240), 515 (Th-P15:104) Parthasarathy, S., 271 (Tu-P10:395), 473 Pedersen, T., 161 (Tu-W20:4), 179 (Tu-W29:7) Perret, B., 31 (Mo-W11:6) (Th-W53:4), 527 (Th-P15:157, Th-P15:158), Pedersen, T.R., 44 (Mo-S7:5), 160 (Tu-W20:1) Perron, P., 306 (We-W30:5), 475 (Th-W54:4), 484 561 (Th-P16:309) Pedrazzoli, R., 49 (Mo-P1:16, Mo-P1:18) (Th-W58:6) Partoush, A., 460 (Th-W46:5) Pedrinelli, R., 386 (We-P11:184), 387 Perségol, L., 311 (We-W33:4) Partyka, L., 35 (Mo-W13:7), 137 (Mo-P6:416), (We-P11:186) Persson, L., 92 (Mo-P2:211) 192 (Tu-P7:34), 290 (Tu-P10:479), 416 Pedro, E., 420 (We-P13:334), 424 (We-P13:351), Perticone, F., 21 (Mo-W6:4), 141 (Mo-P6:434), (We-P13:319), 417 (We-P13:324) 564 (Th-P16:321) 206 (Tu-P7:100), 313 (We-W34:4), 371 Parving, H.-H., 159 (Tu-W19:4) Pedro, T., 226 (Tu-P7:187) (We-P11:116) Paschalidou, H., 557 (Th-P16:292), 558 Pegiou, T.H., 295 (Tu-P10:500) Perticone, M., 21 (Mo-W6:4), 367 (We-P11:98), (Th-P16:293), 576 (Th-P16:377) Peighambari, M.M., 581 (Th-P16:399) 371 (We-P11:116) Pascual, V., 47 (Mo-P1:9) Peilot, H., 15 (Mo-W3:2) Pertsemlidis, A., 150 (Tu-PL2:4), 305 Pasqualini, L., 102 (Mo-P4:257), 112 Peinado-Onsurbe, J., 374 (We-P11:130), 498 (We-W30:1) (Mo-P5:300), 269 (Tu-P9:386) (Th-P15:28) Perttunen-Nio, H., 359 (We-P11:62)

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

251 Perunicic-Pekovic, G., 418 (We-P13:325), 450 Pinto, L., 348 (We-P11:13), 349 (We-P11:15), 435 Ponthieux, A., 507 (Th-P15:66) (We-P14:469) (We-P14:403) Poole-Wilson, P.A., 471 (Th-W52:5) Perusse, L., 586 (Th-P17:420) Pinto, X., 146 (Mo-P6:456) Poon, E., 147 (Mo-P6:459) Pes, G., 273 (Tu-P10:405) Piorecka, B., 119 (Mo-P5:335) Popescu, A., 346 (We-P11:1), 427 (We-P13:364) A Pes, G.M., 137 (Mo-P6:414), 139 (Mo-P6:422) Pirags, V., 263 (Tu-P9:358) Pop Gorceva, D., 101 (Mo-P4:253) Pesavento, R., 74 (Mo-P1:127) Pires, M., 63 (Mo-P1:79) Popov, B., 275 (Tu-P10:415) Pescara, L., 363 (We-P11:78) Pirillo, A., 528 (Th-P15:162) Popova, S., 374 (We-P11:128, We-P11:129) U Pescatello, L., 501 (Th-P15:40) Pirkova, A.A., 581 (Th-P16:400) Popovic, B., 126 (Mo-P5:365), 361 (We-P11:71), Pesenti, S., 73 (Mo-P1:121) Pirola, C., 250 (Tu-P8:299) 426 (We-P13:363), 522 (Th-P15:134) T Pesic, L., 393 (We-P11:214) Pirro, M., 23 (Mo-W7:3), 112 (Mo-P5:300), 269 Popovic, D., 202 (Tu-P7:78) Pesiney, C., 195 (Tu-P7:48) (Tu-P9:386), 277 (Tu-P10:423), 420 Popovic, L.J., 502 (Th-P15:46), 503 (Th-P15:47) H Peston, D., 587 (Th-P17:426) (We-P13:333), 469 (Th-W51:6) Popovic, M., 564 (Th-P16:324) Petakov, M., 126 (Mo-P5:365), 361 (We-P11:71), Pisanti, S., 33 (Mo-W12:5) Popovic, S., 421 (We-P13:341) O 426 (We-P13:363), 522 (Th-P15:134) Pisciotta, L., 136 (Mo-P6:411), 147 (Mo-P6:457), Popovska, S., 273 (Tu-P10:406) Petcov, B., 362 (We-P11:73), 365 (We-P11:87) 554 (Th-P16:277), 558 (Th-P16:296) Popovski, A., 66 (Mo-P1:95) 119 273 589 Petrak, O., 389 (We-P11:195) Piskorz, A., (Mo-P5:335) Porcelli, B., (Tu-P10:404), (Th-P17:435) R 171 137 220 Petraki, M., 322 (We-W38:6) Pitas, R.E., (Tu-W25:5) Poreba, R., (Mo-P6:415), (Tu-P7:160), 124 281 297 Petrault, O., 215 (Tu-P7:140) Pitha, J., (Mo-P5:356) (Tu-P10:438), (Tu-P10:511) 93 76 212 Petriashvili, I., 579 (Th-P16:390) Pitkäniemi, J., (Mo-P2:216) Poredos, P., (Mo-P1:135), (Tu-P7:126) 277 349 29 Petriczek, T., 192 (Tu-P7:34) Pitocco, D., (Tu-P10:422), (We-P11:16) Porreca, E., (Mo-W10:4) 256 285 I Petrioli, R., 409 (We-P12:285) Pittman, D., (Tu-P8:325) Porta, B., (Tu-P10:457) 53 500 Petrobelli, F., 263 (Tu-P9:359) Pittrow, D., (Mo-P1:35) Portal, V.L., (Th-P15:35) 114 105 Petrovska, S., 128 (Mo-P5:374), 297 Pizzi, G.L., (Mo-P5:309) Portas, R., (Mo-P4:270) N 130 419 (Tu-P10:512), 407 (We-P12:279) Plaisier, C.L., (Mo-P6:383) Portincasa, P., (We-P13:331) 62 79 105 47 Petrulioniene, Z., 66 (Mo-P1:92), 214 (Tu-P7:132) Planas, A., (Mo-P1:74), (Mo-P1:152), Portoles, O., (Mo-P1:9) D 268 372 Pettersen, A., 284 (Tu-P10:453) (Mo-P4:270), (Tu-P9:381) Porzio, O., (We-P11:122) 51 463 82 422 Pettersson, C., 503 (Th-P15:50) Planer, D., (Mo-P1:27), (Th-W48:2) Posadas-Romero, C., (Mo-P1:163), Plat, J., 452 (We-P14:477), 562 (Th-P16:312) (We-P13:344), 534 (Th-P15:186), 537 E Pettinella, C., 588 (Th-P17:431) Plata, C., 383 (We-P11:171) (Th-P15:203) Peuchant, E., 198 (Tu-P7:60) Pleteneva, O.P., 189 (Tu-P7:22) Posadas-Romero, R., 422 (We-P13:344) X Pezzullo, S., 207 (Tu-P7:104), 315 (We-W35:2) Pliam, M., 78 (Mo-P1:146), 117 (Mo-P5:324) Posadas-Sanchez, R., 82 (Mo-P1:163) Pfeffer, M.A., 551 (Th-P16:264) Pljesa, S., 418 (We-P13:325), 450 (We-P14:469) Pospechova, K., 201 (Tu-P7:74) Pﬁster, P., 566 (Th-P16:332) Plonska, E., 286 (Tu-P10:463), 287 (Tu-P10:464) Pospisilova, H., 285 (Tu-P10:458) Pﬁster, P.J., 250 (Tu-P8:299) Plösch, T., 450 (We-P14:471) Pospisilova, N., 201 (Tu-P7:74) Phanthumchinda, K., 109 (Mo-P4:289) Plüddemann, A., 514 (Th-P15:97) Post, S.R., 28 (Mo-W9:7) Phenekos, C., 127 (Mo-P5:370) Pochetti, G., 372 (We-P11:119) Posthouwer, D., 291 (Tu-P10:482) Phiippidis, P., 157 (Tu-W18:4) Pocoví, M., 129 (Mo-P6:382), 495 (Th-P15:16) Postic, M., 430 (We-P14:378), 449 (We-P14:464) Philippova, M., 160 (Tu-W19:7), 191 (Tu-P7:30) Pocovi, M., 146 (Mo-P6:456) Postiglione, A., 18 (Mo-W4:7) Phillips, M., 381 (We-P11:162) Pocsai, Z., 292 (Tu-P10:489) Poston, R.N., 224 (Tu-P7:180) Phillips, M.C., 167 (Tu-W23:5) Podhorska, M., 104 (Mo-P4:265) Potenza, M.A., 454 (We-P14:486) Pi-Sunyer, F.X., 329 (We-W42:3) Podhorska-Okolow, M., 270 (Tu-P10:392) Potì, F., 12 (Mo-W1:6) 375 Piantadosi, C., (We-P11:134) Pogorelova, T.E., 394 (We-P11:221) Potockova, J., 277 (Tu-P10:421) 14 Piantelli, M., (Mo-W2:5) Poirier, P., 165 (Tu-W22:5) Potocnakova, L., 423 (We-P13:348) 350 Piarulli, F., (We-P11:21, We-P11:22) Pojskic, B., 106 (Mo-P4:275) Potsis, T., 64 (Mo-P1:82) 229 Piazza, G., (Tu-P7:202) Pokoca, L., 271 (Tu-P10:397) Pou, J.M., 79 (Mo-P1:152) 415 Pibarot, P., (We-P13:313) Polack, A., 514 (Th-P15:98) Poulopoulou, C., 572 (Th-P16:358) 407 Picard, F., (We-P11:276) Polak, W., 104 (Mo-P4:265) Poulsen, G., 159 (Tu-W19:4) 384 Picca, M., (We-P11:174) Poledne, R., 48 (Mo-P1:13), 124 (Mo-P5:356), Poulsen, I.M., 531 (Th-P15:175) 240 Piccinni, M., (Tu-P7:255) 141 (Mo-P6:435), 285 (Tu-P10:458), 407 Pourmoghadas, M., 114 (Mo-P5:311) 240 360 Piccinni, M.N., (Tu-P7:254), (We-P11:65) (We-P12:278) Poussier, B., 252 (Tu-P8:306) 252 Pichiorri, F., (Tu-P8:305) Poletti, A., 211 (Tu-P7:120) Povoa, R.M.S., 348 (We-P11:13) 405 Pieragalli, D., (We-P11:270) Poli, D., 325 (We-W40:3), 396 (We-P11:227) Powell, C., 550 (Th-P16:259) Pieri, P.L., 480 (Th-W56:8) Poli, S., 325 (We-W40:3), 396 (We-P11:227) Pownall, H.J., 193 (Tu-P7:37) Pierre, S., 202 (Tu-P7:77) Poliakova, E.O., 283 (Tu-P10:447) Pozner, R., 91 (Mo-P2:203) Pietzsch, J., 507 (Th-P15:68), 522 (Th-P15:132) Polisecki, E., 576 (Th-P16:376) Pozner, R.G., 231 (Tu-P7:212) Pigna, G., 584 (Th-P16:412) Polito, F., 147 (Mo-P6:458) Pozo, A., 375 (We-P11:132) Pignatelli, P., 173 (Tu-W26:5), 298 (Tu-P10:514), Polito, P., 580 (Th-P16:393) Prada, J.L., 399 (We-P11:240), 452 (We-P14:475) 439 (We-P14:420), 525 (Th-P15:147) Pollak, A., 51 (Mo-P1:27) Prakken, B.J., 98 (Mo-P4:236) Pilegaard, K., 450 (We-P14:470) Pöllänen, P., 221 (Tu-P7:163) Prandoni, P., 74 (Mo-P1:127), 502 (Th-P15:45) Pille, J., 47 (Mo-P1:6), 439 (We-P14:419) Polonskaya, Ya.V., 523 (Th-P15:137) Pranteda, C., 519 (Th-P15:119) Pilvi, T.K., 431 (We-P14:383) Polus, A., 192 (Tu-P7:34, Tu-P7:36), 199 Prassl, R., 500 (Th-P15:36) Pilz, S., 72 (Mo-P1:118, Mo-P1:119), 310 (Tu-P7:64, Tu-P7:66), 200 (Tu-P7:68) Pratesi, C., 207 (Tu-P7:102) (We-W32:5) Polvani, G., 591 (Th-P17:445) Pravenec, M., 203 (Tu-P7:82), 373 (We-P11:123), Pimentel, I., 170 (Tu-W25:4) Polydera, A., 523 (Th-P15:140) 463 (Th-W48:5) Pineau, T., 306 (We-W30:7), 331 (We-W43:4) Pombo Gregoire, I., 198 (Tu-P7:62) Prawitt, J., 185 (Tu-P7:4) Pinedo, S., 318 (We-W36:6) Pomerleau, S., 445 (We-P14:446) Preden-Kerekovic, V., 282 (Tu-P10:446) Pinelli, M., 76 (Mo-P1:138) Pomilio, G., 488 (Th-W60:5) Premuzic, I., 83 (Mo-P2:170) Pinheiro, T., 84 (Mo-P2:172) Pônitz, V., 449 (We-P14:463) Prentice, R.L., 176 (Tu-W28:3)

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

252 Presotto, C., 219 (Tu-P7:157) Quinn, C.M., 492 (Th-P15:4), 541 (Th-P15:219) Raptopoulou-Gigi, M., 557 (Th-P16:292), 576 Preusch, M., 407 (We-P11:276) Quintão, E.C.R., 31 (Mo-W11:4) (Th-P16:377) Pricolo, F., 240 (Tu-P7:254, Tu-P7:255), 360 Quintao, E.C.R., 512 (Th-P15:90), 527 Raselli, S., 141 (Mo-P6:431), 475 (Th-W54:3) (We-P11:65) (Th-P15:154, Th-P15:155), 539 (Th-P15:210), Rashtchizadeh, N., 203 (Tu-P7:86), 296 Primard, E., 261 (Tu-P9:351) 558 (Th-P16:294) (Tu-P10:506), 525 (Th-P15:148), 532 A Prince, C., 50 (Mo-P1:21) Quon, M.J., 454 (We-P14:486) (Th-P15:177) Princen, H.M.G., 393 (We-P11:215), 489 Quyyumi, A.Q., 324 (We-W39:5) Rasic, Z., 450 (We-P14:469) (Th-W61:2), 551 (Th-P16:263) Rasic-Milutinovic, Z., 418 (We-P13:325) U 74 446 Prins, M.H., (Mo-P1:127) Rabiei, K., 427 (We-P13:368) Raslova, K., (We-P14:452) 134 213 382 Prinsen, B.H., (Mo-P6:403) Racek, J., 298 (Tu-P10:515), 590 (Th-P17:442) Rasmussen, J.G., (Tu-P7:128), T 325 398 448 Prisco, D., (We-W40:3), (We-P11:239), Rada, M., 110 (Mo-P4:291), 111 (Mo-P4:294), (We-P11:163), (We-P14:462) 530 587 (Th-P15:169) 365 (We-P11:86), 445 (We-P14:445) Rassoul, F., (Th-P17:427) H 449 545 Pritchard, D., (We-P14:463) Radaelli, T., 213 (Tu-P7:129) Rato, Q., (Th-P15:237) 426 297 298 Priya, K., (We-P13:360) Radak, D.J., 75 (Mo-P1:131, Mo-P1:132), 115 Ravagnani, P., (Tu-P10:510), O 83 (Tu-P10:513) Prkacin, I., (Mo-P2:170) (Mo-P5:313) 54 79 Ravani, A., 258 (Tu-P9:333, Tu-P9:336), 308 Proença Vieira, L., (Mo-P1:41), Radallah, D., 77 (Mo-P1:143) (We-W31:6) R (Mo-P1:150) Rader, D., 180 (Tu-S8:3) Progia, E., 77 (Mo-P1:142) Ravani, A.L., 204 (Tu-P7:87) Rader, D.J., 11 (Mo-W1:1), 16 (Mo-W3:5), 149 Prohaszka, Z., 140 (Mo-P6:427) Ravani, M., 310 (We-W32:6) (Tu-PL2:2), 167 (Tu-W23:5), 496 Proks, V., 404 (We-P11:265) Ray, A., 125 (Mo-P5:363) (Th-P15:20), 540 (Th-P15:214), 564 Prost, J., 446 (We-P14:450) Raygoza-Perez, M., 422 (We-P13:344) (Th-P16:322) I Protasiewicz, M., 220 (Tu-P7:160), 281 Rayner, B., 587 (Th-P17:425) Radhika, A., 242 (Tu-P7:261) (Tu-P10:438), 297 (Tu-P10:511) Raz, A., 388 (We-P11:193) Radosavljevic, T., 75 (Mo-P1:132) N Protich, M., 438 (We-P14:417) Razali, R., 423 (We-P13:347) Radovanovic, N., 100 (Mo-P4:248) Protopappa, M., 89 (Mo-P2:193) Razmadze, M., 97 (Mo-P4:234) Radukhina, N.V., 96 (Mo-P3:226) Puccetti, L., 86 (Mo-P2:180), 147 (Mo-P6:460), Razny, U., 199 (Tu-P7:64, Tu-P7:66), 200 D Radulescu, L., 590 (Th-P17:438) 333 (We-W44:3) (Tu-P7:68) Rafecas, M., 451 (We-P14:473, We-P14:474) Pucci, G., 112 (Mo-P5:300), 269 (Tu-P9:386), 420 Real, J., 130 (Mo-P6:384) E Raffa, S., 24 (Mo-W7:7) (We-P13:333), 469 (Th-W51:6) Real, J.T., 135 (Mo-P6:407), 136 (Mo-P6:412), Raﬁei, M., 82 (Mo-P1:461) Pucci, L., 350 (We-P11:23), 386 (We-P11:184), 226 (Tu-P7:187) Ragino, Y.I., 294 (Tu-P10:497) X 387 (We-P11:186), 528 (Th-P15:159) Rebelo, I., 120 (Mo-P5:337) Ragino, Yu.I., 523 (Th-P15:137) Pucci, S., 252 (Tu-P8:305) Rebuzzi, A., 381 (We-P11:159) Ragonesi, P.D., 360 (We-P11:65) Puchta, M., 212 (Tu-P7:125) Recalde, D., 133 (Mo-P6:396), 233 (Tu-P7:220), Raimbekova, I.R., 404 (We-P11:263) Pucillo, L.P., 399 (We-P11:243, We-P11:244) 262 (Tu-P9:354), 406 (We-P11:275), 495 Raitakari, O., 279 (Tu-P10:430), 313 (We-W34:3) Puglisi, L., 445 (We-P14:448) (Th-P15:16), 546 (Th-P15:244), 547 Raitakari, O.T., 68 (Mo-P1:101), 221 (Tu-P7:163), Puisac, B., 406 (We-P11:275) (Th-P15:247) 483 (Th-W58:3) Pujia, A., 141 (Mo-P6:434), 404 (We-P11:266) Recchiuti, A., 88 (Mo-P2:192) 488 Puk, C.G., 113 (Mo-P5:304), 509 (Th-P15:75), Raj, T., (Th-W60:5) Rechcinski, T., 98 (Mo-P4:235), 143 (Mo-P6:443) 556 537 (Th-P15:202), 542 (Th-P15:224) Rajaram, Y., (Th-P16:286) Reckless, J.P.D., 330 (We-W42:6), 358 298 590 Puntoni, M., 70 (Mo-P1:111), 225 (Tu-P7:183) Rajdl, D., (Tu-P10:515), (Th-P17:442) (We-P11:55) 107 Puranik, R., 152 (Tu-W16:1), 153 (Tu-W16:4), Raje, N., (Mo-P4:278) Record, M., 252 (Tu-P8:307) 351 502 232 (Tu-P7:218) Rajkovic, N., (We-P11:25, We-P11:26), Redaelli, L., 141 (Mo-P6:431), 229 (Tu-P7:202), 503 Puranik, R.A.J., 71 (Mo-P1:114) (Th-P15:46), (Th-P15:47) 499 (Th-P15:31), 589 (Th-P17:434) 76 208 288 Puscariu, T., 93 (Mo-P2:214) Rajtar, R., (Mo-P1:136), (Tu-P7:105), Reddy, U., 324 (We-W39:5) 290 Pussinen, P.J., 171 (Tu-W25:6), 463 (Th-W48:4) (Tu-P10:469), (Tu-P10:479) Redon, J., 389 (We-P11:197) 574 Putnina, A.V., 281 (Tu-P10:442) Rallidis, L., (Th-P16:368) Redondo, S., 249 (Tu-P8:292), 371 (We-P11:118) 25 Putter, H., 267 (Tu-P9:375) Ramachandran, A., (Mo-W8:2) Reekmans, S., 515 (Th-P15:102) 453 Putz-Bankuti, C., 583 (Th-P16:409) Ramcharan, J., (We-P14:480) Refatllari, E., 272 (Tu-P10:399), 274 (Tu-P10:407, 518 Pyörälä, K., 154 (Tu-W17:1) Ramdani, B., (Th-P15:114, Th-P15:116) Tu-P10:408), 283 (Tu-P10:448) 537 Pyszel, A., 220 (Tu-P7:160) Ramires, J.A., (Th-P15:202) Reganon, E., 571 (Th-P16:351) Ramires, J.A.F., 280 (Tu-P10:437), 406 Register, T.C., 14 (Mo-W2:6) Qiao, Q., 154 (Tu-W17:1) (We-P11:274) Rehácek, V., 562 (Th-P16:315) Qin, P., 257 (Tu-P8:329) Ramires, J.L., 291 (Tu-P10:484) Rehacek, V., 563 (Th-P16:316) Qin, S., 567 (Th-P16:335) Ramirez, A., 65 (Mo-P1:90) Reich, J.G., 547 (Th-P15:248) Qu, S.L., 223 (Tu-P7:175), 224 (Tu-P7:177), 293 Ramji, D.P., 237 (Tu-P7:238) Reid, J., 330 (We-W42:6), 358 (We-P11:55) (Tu-P10:490), 521 (Th-P15:129) Ramón, L., 89 (Mo-P2:194), 531 (Th-P15:176) Reid, K.J., 82 (Mo-P1:167) Quagliarini, F., 35 (Mo-W13:4) Ramos, R.F., 521 (Th-P15:131) Reims, H., 357 (We-P11:52) Quan, Z.H., 144 (Mo-P6:445) Ramponi, G., 273 (Tu-P10:404) Reiner, Z., 205 (Tu-P7:91), 384 (We-P11:175), Quax, P.H.A., 33 (Mo-W12:4) Ramunni, A., 563 (Th-P16:318) 461 (Th-W47:2) Querfeld, U., 218 (Tu-P7:150) Ranalletta, M., 166 (Tu-W23:1) Reininger, A.J., 326 (We-W40:7) Quertermous, T., 5 (Su-S3:1, Su-S3:3), 138 Randon, J., 355 (We-P11:44) Reis, M.M., 280 (Tu-P10:437), 291 (Tu-P10:484), (Mo-P6:419), 224 (Tu-P7:178), 230 Raneli, G., 420 (We-P13:336), 437 (We-P14:412) 406 (We-P11:274) (Tu-P7:206) Ranganath, L.R., 81 (Mo-P1:159), 134 Reisfeld, R.A., 33 (Mo-W12:4) Quignard-Boulange, A., 433 (We-P14:393) (Mo-P6:401) Reiss, P., 401 (We-P11:250) Quílez, J., 451 (We-P14:473) Ranieri, G., 563 (Th-P16:318) Reitano, R., 350 (We-P11:22) Quimbo, R., 568 (Th-P16:339) Ranzini, M., 401 (We-P11:253) Reiter, R.J., 122 (Mo-P5:349) Quinet, E., 256 (Tu-P8:325) Raposo, B., 488 (Th-W60:7) Religa, P., 289 (Tu-P10:477) Quinet, E.M., 256 (Tu-P8:324) Rapp, H., 82 (Mo-P1:165), 398 (We-P11:236) Relvas, W., 349 (We-P11:15)

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

253 Relvas, W.G.M., 263 (Tu-P9:360), 348 Rimm, E.B., 303 (We-ML6:1) Rolfo, E., 288 (Tu-P10:472) (We-P11:13), 435 (We-P14:403) Rini, G.B., 425 (We-P13:355) Rolland, C., 31 (Mo-W11:6), 153 (Tu-W16:7) Remaley, A.T., 320 (We-W38:1) Rinninger, F., 166 (Tu-W23:4) Rollins, J., 535 (Th-P15:194) Remy-Zolghadri, M., 159 (Tu-W19:6) Rioja, J., 132 (Mo-P6:395), 347 (We-P11:5), 375 Roman, G., 155 (Tu-W17:6) A Ren, S., 87 (Mo-P2:188) (We-P11:132) Roman, P., 103 (Mo-P4:259) Ren, Z., 233 (Tu-P7:219), 494 (Th-P15:11), 516 Rip, J., 19 (Mo-W5:2), 134 (Mo-P6:403) Román García, J., 60 (Mo-P1:68), 366 (Th-P15:108), 536 (Th-P15:196), 544 Risch, N., 138 (Mo-P6:419) (We-P11:95) U (Th-P15:231) Risè, P., 472 (Th-W53:1) Romano, E., 396 (We-P11:230) Renaudin, C., 121 (Mo-P5:346), 178 (Tu-W29:4) Ristic, M., 127 (Mo-P5:373), 358 (We-P11:57) Romano, G., 31 (Mo-W11:5) T Renauld, A., 376 (We-P11:137) Ristic-Medic, D., 430 (We-P14:378), 449 Romanov, Yu., 207 (Tu-P7:103) Rendina, V., 431 (We-P14:385) (We-P14:464) Romashchenko, A.G., 78 (Mo-P1:147), 81 H Rendu, F., 214 (Tu-P7:134) Rita Roscini, A., 277 (Tu-P10:423) (Mo-P1:158) Renier, G., 165 (Tu-W22:7) Ritsch, A., 12 (Mo-W1:4) Romeo, R., 588 (Th-P17:429, Th-P17:430, O Rensen, P., 318 (We-W37:1) Riva, A., 10 (Mo-ML3:2) Th-P17:432) Rensen, P.C.N., 32 (Mo-W11:7), 37 (Mo-W14:5), Riva, E., 275 (Tu-P10:411), 441 (We-P14:430) Romeo, S., 481 (Th-W57:3) 227 489 506 399 (Tu-P7:194), (Th-W61:5), Rivas-Garcia, F., (We-P11:240) Romero, C., 87 (Mo-P2:184), 533 (Th-P15:184) R 518 551 31 165 (Th-P15:62), (Th-P15:117), Rivellese, A.A., (Mo-W11:5), (Tu-W22:4) Romero García, I., 448 (We-P14:459) 560 102 (Th-P16:263), (Th-P16:306) Rizk, H., (Mo-P4:254) Romic, Z.R., 204 (Tu-P7:89) 582 171 Rentsch, K.M., (Th-P16:403) Rizki, G., (Tu-W25:5) Romijn, J.A., 32 (Mo-W11:7), 318 (We-W37:1) 383 577 Repa, A., (We-P11:168) Rizos, E., (Th-P16:381) Roncal, C., 143 (Mo-P6:441) 191 372 450 I Resink, T., (Tu-P7:30) Rizza, S., (We-P11:122), (We-P14:468) Ronchini, K., 400 (We-P11:246) 160 481 Resink, T.J., (Tu-W19:7) Rizzi, L., (Th-W57:3) Rönnau, C., 214 (Tu-P7:135) 275 441 404 Restelli, R., (Tu-P10:411), (We-P14:430) Rizzo, M., (We-P11:264) Roohafza, H., 120 (Mo-P5:340), 374 N 551 77 317 Retterstøl, K., (Th-P16:266) Roach, P.D., (Mo-P1:140), (We-W36:3), (We-P11:127), 384 (We-P11:173) 390 441 Reutelingsperger, C.P.M., (We-P11:203) (We-P14:429) Ros, E., 130 (Mo-P6:386), 146 (Mo-P6:456), 261 D 550 228 Revkin, J.H., (Th-P16:260, Th-P16:261, Robciuc, M., (Tu-P7:195) (Tu-P9:349, Tu-P9:350), 495 (Th-P15:16) 494 Th-P16:262) Robenek, H., (Th-P15:9) Rosada, J., 76 (Mo-P1:138) Reyes, F., 216 (Tu-P7:141) Robenek, M.J., 494 (Th-P15:9) E Roscini, A.R., 221 (Tu-P7:165) Rezzani, R., 205 (Tu-P7:93) Robertson, A.K.L., 242 (Tu-P7:262) Rose, H., 162 (Tu-W21:2), 578 (Th-P16:387) Rha, S.W., 217 (Tu-P7:145), 266 (Tu-P9:372, Robertson, C.E., 437 (We-P14:411) X Rosenblat, M., 459 (Th-W46:2) Tu-P9:373), 314 (We-W34:7) Robertson, M., 484 (Th-W58:5) Rosenfeld, M., 267 (Tu-P9:379) Rhee, I.L., 267 (Tu-P9:376) Robins, S., 561 (Th-P16:307) Rosengren, A., 22 (Mo-W6:6), 421 (We-P13:339) Rhees, B.K., 332 (We-W44:1) Robitaille, J., 586 (Th-P17:420) Rosengren, B., 15 (Mo-W3:2) Ria, M., 145 (Mo-P6:449) Rocca, B., 325 (We-W40:2) Rosenson, R.S., 175 (Tu-W27:5) Ria, R., 563 (Th-P16:318) Rocha, M.P., 535 (Th-P15:191) Rosipal, S., 57 (Mo-P1:54) Riahi, S., 531 (Th-P15:175), 584 (Th-P16:414) Rocha Gonçalves, F., 101 (Mo-P4:250, Rosolová, H., 363 (We-P11:79) Ribalta, J., 139 (Mo-P6:425), 400 (We-P11:247), Mo-P4:251) Ross, C.J.D., 19 (Mo-W5:2) 443 (We-P14:439), 513 (Th-P15:95) Rochette, L., 370 (We-P11:113) Rossi, A., 256 (Tu-P8:323) Ribeiro, A.B., 376 (We-P11:138) Rochite, C.E., 262 (Tu-P9:353) Rossi, L., 207 (Tu-P7:102), 396 (We-P11:230), Ribeiro, I.C.D., 527 (Th-P15:154, Th-P15:155) Rochitte, C.E., 263 (Tu-P9:357) 401 (We-P11:253) Ribeiro, R., 63 (Mo-P1:79) Rock, E., 443 (We-P14:439), 513 (Th-P15:95) 298 525 Riboldi, S., 107 (Mo-P4:276), 259 (Tu-P9:341) Rode, S., 514 (Th-P15:99) Rossi, P., (Tu-P10:514), (Th-P15:147) 336 Riccardi, G., 31 (Mo-W11:5), 51 (Mo-P1:25), 165 Rodella, S., 411 (We-P12:293) Rossi, R., (We-W45:7) 275 441 (Tu-W22:4) Rodero, M., 523 (Th-P15:136) Rossi, S., (Tu-P10:411), (We-P14:430) 229 Ricchi, M., 257 (Tu-P8:328), 410 (We-P12:289), Roditakis, G., 383 (We-P11:168) Rossignoli, A., (Tu-P7:202) 270 411 (We-P12:294) Rodrigues, D.G., 466 (Th-W49:7) Rossini, K., (Tu-P10:392) 392 Ricciardi, E., 273 (Tu-P10:405) Rodrigues, M.R., 347 (We-P11:8) Rossoni, G., (We-P11:208) 485 Riccobene, S., 411 (We-P12:297) Rodriguez, A., 511 (Th-P15:84), 567 Rossouw, J., (Th-W59:1) 481 Rice, G.E., 146 (Mo-P6:454) (Th-P16:334) Rota, F., (Th-W57:3) 115 Ricevuti, G., 244 (Tu-P7:272) Rodriguez, B., 64 (Mo-P1:83) Rotella, C.M., (Mo-P5:316) 174 Rich, S.S., 14 (Mo-W2:6), 89 (Mo-P2:196), 335 Rodríguez, C., 537 (Th-P15:201) Roth, E., (Tu-W27:3) 149 (We-W45:5) Rodriguez, C., 488 (Th-W60:7) Rothblat, G., (Tu-PL2:2) Richard, V., 219 (Tu-P7:155), 261 (Tu-P9:351) Rodriguez, J.A., 143 (Mo-P6:441), 480 Rothblat, G.H., 167 (Tu-W23:5), 540 Richards, A.M, 99 (Mo-P4:242) (Th-W56:5) (Th-P15:214), 541 (Th-P15:217), 550 Richter, A., 84 (Mo-P2:173) Rodriguez, M., 138 (Mo-P6:418) (Th-P16:262) Richter, D.J., 52 (Mo-P1:30) Rodriguez-Lee, M., 15 (Mo-W3:2) Rottenberg, M.E., 407 (We-P11:277) Richter, V., 587 (Th-P17:427) Rodríguez Martínez, A., 380 (We-P11:155) Roubalova, K., 277 (Tu-P10:421) Richter, W.O., 399 (We-P11:242), 401 Roebroek, A., 515 (Th-P15:102) Rouis, M., 234 (Tu-P7:228), 492 (Th-P15:1), 526 (We-P11:251) Roganovic, D., 53 (Mo-P1:34) (Th-P15:151) Rico, M.A., 116 (Mo-P5:322), 286 (Tu-P10:462) Rogers, S.A., 237 (Tu-P7:238) Rousodimos, K., 58 (Mo-P1:55), 272 Ridderstråle, W., 159 (Tu-W19:3) Rognmo, O., 428 (We-P13:369) (Tu-P10:400) Riecansky, I., 103 (Mo-P4:260), 423 Rogolino, A., 85 (Mo-P2:177) Rousset, X., 538 (Th-P15:206) (We-P13:348) Rohbaninoubar, M., 203 (Tu-P7:86), 296 Rovati, G., 392 (We-P11:208) Riedel, T., 159 (Tu-W19:6), 250 (Tu-P8:298) (Tu-P10:506), 532 (Th-P15:177) Rowley, K., 177 (Tu-W28:4) Riesen, W., 222 (Tu-P7:169), 358 (We-P11:54) Roig, L., 105 (Mo-P4:270) Roy, S., 220 (Tu-P7:158) Rigamonti, E., 454 (We-P14:484), 477 Roik, M., 358 (We-P11:56) Roytberg, G., 368 (We-P11:102) (Th-W55:3), 478 (Th-W55:6) Rokusujew, A., 238 (Tu-P7:243) Roytberg, G.E., 214 (Tu-P7:133), 262 (Tu-P9:356) Righini, P., 248 (Tu-P7:290) Rolandi, G., 173 (Tu-W26:7) Roze, S., 121 (Mo-P5:346), 178 (Tu-W29:4)

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

254 Rozhkova, Z., 109 (Mo-P4:287) (We-P13:352), 442 (We-P14:432), 449 (We-P11:229), 536 (Th-P15:197), 559 Rozi, P., 89 (Mo-P2:193) (We-P14:465) (Th-P16:298), 561 (Th-P16:310), 562 Rozkova, T., 116 (Mo-P5:321) Rypacek, F., 252 (Tu-P8:308), 404 (We-P11:265) (Th-P16:311, Th-P16:313), 570 (Th-P16:350), Ruan, C.G., 402 (We-P11:258), 403 (We-P11:260, Ryu, H.Y., 98 (Mo-P4:238, Mo-P4:239) 571 (Th-P16:354), 578 (Th-P16:386), 590 We-P11:261) Rywik, S., 135 (Mo-P6:405) (Th-P17:440) A Ruan, K.-H., 230 (Tu-P7:205) Sakuma, N., 528 (Th-P15:161) Ruano, J., 585 (Th-P17:419) Saava, M., 375 (We-P11:133) Sakuma, T., 432 (We-P14:389) Rubba, F., 54 (Mo-P1:40), 56 (Mo-P1:46) Sabaretnam, T., 493 (Th-P15:5) Sala, A., 213 (Tu-P7:129), 392 (We-P11:208) U 124 Rubba, P., 54 (Mo-P1:40), 56 (Mo-P1:46), 231 Saborido-Froján, J., (Mo-P5:359) Sala, M., 275 (Tu-P10:411) 220 (Tu-P7:211), 261 (Tu-P9:348), 282 Sabourin, J.C., (Tu-P7:161) Sala-Newby, G.B., 248 (Tu-P7:288) T 76 212 (Tu-P10:445), 323 (We-W39:2) Sabovic, M., (Mo-P1:135), (Tu-P7:126) Salageanu, A., 236 (Tu-P7:233) 207 Ruberu, K., 167 (Tu-W23:6) Saburova, O., (Tu-P7:103) Salakhova, L.R., 67 (Mo-P1:96) H 454 Rubin, E.M., 167 (Tu-W23:7) Sacco, M.G., (We-P14:484) Salas-Salvado, J., 146 (Mo-P6:456) 476 Rubio, L., 216 (Tu-P7:141) Sacks, F.M., (Th-W55:2) Salazar, J., 400 (We-P11:247), 513 (Th-P15:95) 284 O Rubio, L.A., 453 (We-P14:483) Sade, E., (Tu-P10:455) Salen, P., 180 (Tu-S9:1), 316 (We-W36:1) 110 262 263 Rubio, M.M., 47 (Mo-P1:9) Sade, L.E., (Mo-P4:293) Salgado, W., (Tu-P9:353), (Tu-P9:357) 120 374 513 R Rudling, M., 39 (Mo-W15:7), 188 (Tu-P7:18) Sadeghi, M., (Mo-P5:340), Salgado Filho, W., (Th-P15:92) 384 563 Rudnicka, W., 98 (Mo-P4:235), 143 (Mo-P6:443) (We-P11:127), (We-P11:173) Saliani, M.T., (Th-P16:318) 77 574 Rueda, J., 85 (Mo-P2:178), 89 (Mo-P2:194), 286 Sadiq, F., (Mo-P1:143) Salichou, C., (Th-P16:368) 523 423 (Tu-P10:461), 395 (We-P11:224), 531 Sadovski, E.V., (Th-P15:137) Saligova, J., (We-P13:348) 53 124 (Th-P15:176) Saeidi, M., (Mo-P1:38) Salo, M.K., (Mo-P5:358) I 528 43 Rueda Vicente, J., 366 (We-P11:95) Saeki, T., (Th-P15:161) Salonen, J.T., (Mo-S6:5) Saenko, E.L., 29 (Mo-W10:5) 500 Ruel, G., 445 (We-P14:446) Salonen, R., (Th-P15:37) Saenz, P., 130 (Mo-P6:385, Mo-P6:386) 113 505 N Ruelland, A., 449 (We-P14:466) Salpea, K.D., (Mo-P5:306), (Th-P15:60), Saez, G., 389 (We-P11:197) 509 510 Ruf, G., 53 (Mo-P1:35) (Th-P15:77), (Th-P15:81) Saez, Y., 67 (Mo-P1:97), 84 (Mo-P2:174) 382 D Ruf, N., 144 (Mo-P6:447) Salsali, M., (We-P11:166) Sagara, M., 317 (We-W36:4) 240 Ruggeri, Z.M., 172 (Tu-W26:2) Salvadeo, S., (Tu-P7:254, Tu-P7:255) Saglam, H., 106 (Mo-P4:274) Salvadeo, S.A.T., 360 (We-P11:65) Ruggiero, C., 108 (Mo-P4:284) E Sahin, F., 65 (Mo-P1:86) Salvador, A., 85 (Mo-P2:178), 89 (Mo-P2:194), Rugina, M., 236 (Tu-P7:233) Sahinarslan, A., 114 (Mo-P5:312) 286 (Tu-P10:461), 395 (We-P11:224), 531 Ruiz, E., 249 (Tu-P8:292), 371 (We-P11:118) X Sahpaz, S., 215 (Tu-P7:140) (Th-P15:176) Ruiz-Gutiérrez, V., 452 (We-P14:475) Saiki, A., 417 (We-P13:320), 498 (Th-P15:29) Salvanos, L., 346 (We-P11:3, We-P11:4), 347 Ruiz-Gutierrez, V., 399 (We-P11:240), 515 Saikku, P., 85 (Mo-P2:176) (We-P11:9), 348 (We-P11:10) (Th-P15:104) Saile, R., 280 (Tu-P10:436), 443 (We-P14:437), Salvatore, S., 177 (Tu-W28:6), 432 (We-P14:388) Ruíz-Madrigal, B., 378 (We-P11:148) 518 (Th-P15:114, Th-P15:116) Salvayre, R., 534 (Th-P15:187) Ruìz-Madrigal, B., 142 (Mo-P6:437) Sainaghi, P.P., 49 (Mo-P1:16, Mo-P1:18) Salviti, E., 49 (Mo-P1:16, Mo-P1:18) Ruiz-Madrigal, B., 378 (We-P11:145), 380 Sainz Gutiérrez, J.C., 60 (Mo-P1:68), 366 Salvucci, F., 404 (We-P11:266) (We-P11:155) (We-P11:95) Samaha, F.F., 328 (We-W42:2) Rull, A., 202 (Tu-P7:81) Saito, H., 430 (We-P14:377) Samarel, A.M., 241 (Tu-P7:258) Rumana, N., 56 (Mo-P1:50) Saito, I., 384 (We-P11:176) Sambiase, N.V., 291 (Tu-P10:484), 406 Ruocco, A., 18 (Mo-W4:7) Saito, M., 439 (We-P14:421), 545 (Th-P15:239) (We-P11:274) 174 Ruoff, G.E., (Tu-W27:4) Saito, S., 348 (We-P11:12) Samco, A., 98 (Mo-P4:237) 189 Rusak, L.V., (Tu-P7:23) Saito, Y., 25 (Mo-W8:3), 245 (Tu-P7:277), 482 Samko, A.N., 404 (We-P11:263) 90 222 Ruschitzka, F., (Mo-P2:200), (Tu-P7:169), (Th-W57:7), 520 (Th-P15:127), 576 Samnergard, A., 316 (We-W35:6) 358 (We-P11:54) (Th-P16:375) Samohodskaya, L.M., 89 (Mo-P2:195) 207 Russo, C., (Tu-P7:104) Saitta, A., 147 (Mo-P6:458) Samoila, C., 293 (Tu-P10:491) 411 Russo, E., (We-P12:297) Saitta, C., 147 (Mo-P6:458) Samoilenco, E.Y., 581 (Th-P16:400) 298 329 Russo, I., (Tu-P10:516), (We-W42:4) Saiz, C., 133 (Mo-P6:398) Samoilenko, E., 569 (Th-P16:346) 536 Rust, S., (Th-P15:195) Saja, K., 242 (Tu-P7:261) Samoilova, E.V., 581 (Th-P16:400) 96 Rutkevich, P.N., (Mo-P3:226, Mo-P3:227) Sajdok, J., 203 (Tu-P7:82) Samouilidis, J., 128 (Mo-P5:377), 277 144 Rutsch, F., (Mo-P6:447) Saji, B., 198 (Tu-P7:61), 284 (Tu-P10:454) (Tu-P10:424) 78 117 Ryan, C., (Mo-P1:146), (Mo-P5:324) Sajic, Z., 198 (Tu-P7:63) Sampietro, T., 70 (Mo-P1:111), 225 (Tu-P7:183) Ryan, E., 512 (Th-P15:89) Saka, S., 575 (Th-P16:370) Samsam Shariat, S.Z., 529 (Th-P15:165) Ryan, R.O., 514 (Th-P15:96) Sakac, D., 262 (Tu-P9:352) Samuelsson, H., 234 (Tu-P7:225) Rybakova, L.P., 272 (Tu-P10:398) Sakai, N., 134 (Mo-P6:403), 510 (Th-P15:79), 511 Sancak, S., 215 (Tu-P7:136) Rybalkin, I.N., 96 (Mo-P3:226) (Th-P15:86), 519 (Th-P15:121) Sánchez, E., 448 (We-P14:459) Ryban, L., 488 (Th-W60:8) Sakai, T., 425 (We-P13:359) Sanchez, M., 186 (Tu-P7:7) Rye, K., 232 (Tu-P7:218) Sakai, Y., 519 (Th-P15:121) Sánchez, R., 85 (Mo-P2:178) Rye, K.-A., 71 (Mo-P1:113, Mo-P1:114), 152 Sakamoto, T., 162 (Tu-W20:8) Sanchez, R., 65 (Mo-P1:90) (Tu-W16:1), 541 (Th-P15:218) Sakarellos, C., 322 (We-W38:6) Sánchez-Enriquez, S., 378 (We-P11:148) Rye, K.A., 153 (Tu-W16:4), 167 (Tu-W23:6), 322 Sakarellos-Daitsiotis, M., 322 (We-W38:6) Sánchez-Fernández, M.J., 276 (Tu-P10:417) (We-W38:5), 370 (We-P11:111), 534 Sakashita, N., 409 (We-P12:288) Sánchez-Leira, J., 124 (Mo-P5:359) (Th-P15:185), 535 (Th-P15:193), 536 Sakata, K., 63 (Mo-P1:81) Sánchez-Montero, J.M., 333 (We-W44:4), 523 (Th-P15:197), 541 (Th-P15:219), 561 Sakata, S., 528 (Th-P15:161) (Th-P15:136) (Th-P16:310), 562 (Th-P16:311, Th-P16:313), Saksi, J., 93 (Mo-P2:216), 246 (Tu-P7:278) Sánchez-Muniz, F.J., 333 (We-W44:4), 365 577 (Th-P16:379) Saku, K., 13 (Mo-W1:7), 99 (Mo-P4:241), 192 (We-P11:88), 523 (Th-P15:136), 531 Ryliskyte, L., 214 (Tu-P7:132) (Tu-P7:33), 255 (Tu-P8:319), 268 (Th-P15:173) Rynkiewicz, A., 129 (Mo-P6:380), 424 (Tu-P9:383), 293 (Tu-P10:492), 396 Sánchez-Wandelmer, J., 186 (Tu-P7:9)

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

255 Sánchez Chaparro, M.A., 60 (Mo-P1:68), 366 Sarzynska-Dlugosz, I., 282 (Tu-P10:443) 570 (Th-P16:349), 576 (Th-P16:374), 583 (We-P11:95) Sasaki, J., 280 (Tu-P10:435), 576 (Th-P16:375) (Th-P16:409) Sanchez Fdez De La Vega, C., 114 (Mo-P5:308) Sasaki, S., 290 (Tu-P10:481) Schattner, A., 52 (Mo-P1:33) Sánchez Mora, C., 273 (Tu-P10:403) Sasse, B., 90 (Mo-P2:200) Schattner, M., 91 (Mo-P2:203), 231 (Tu-P7:212) A Sanchis, E.M., 47 (Mo-P1:9) Sata, M., 448 (We-P14:460) Schaub, R., 24 (Mo-W7:5) Sandbæk, G., 103 (Mo-P4:258) Satara, S.S., 570 (Th-P16:348) Scheen, A., 329 (We-W42:3) Sanders, J., 312 (We-W33:5) Satchell, L., 523 (Th-P15:138) Scheffer, P.G., 502 (Th-P15:44), 525 (Th-P15:145) U Sanders, T.A.B., 344 (We-S16:4) Sato, A., 350 (We-P11:20) Scheja, L., 520 (Th-P15:125) Sandhofer, A., 12 (Mo-W1:4), 155 (Tu-W17:4), Sato, F., 547 (Th-P16:249) Scheld, H.H., 238 (Tu-P7:243) T 410 (We-P12:292) Sato, H., 409 (We-P12:288) Schemeit, F., 446 (We-P14:451) Sandhu, M.S., 335 (We-W45:6) Sato, K., 63 (Mo-P1:81), 68 (Mo-P1:100), 72 Schiffmann, R., 237 (Tu-P7:239) H Sandison, A., 587 (Th-P17:426) (Mo-P1:120), 486 (Th-W59:4) Schilder, J.C., 265 (Tu-P9:367) Sangiorgi, G.M., 248 (Tu-P7:290) Sato, N., 259 (Tu-P9:339), 428 (We-P13:370) Schillaci, G., 23 (Mo-W7:3), 102 (Mo-P4:257), O Sangiorgio, R., 73 (Mo-P1:121), 281 (Tu-P10:440) Sato, R., 283 (Tu-P10:450), 411 (We-P12:295), 112 (Mo-P5:300), 269 (Tu-P9:386), 277 Sangle, G., 87 (Mo-P2:188) 493 (Th-P15:7) (Tu-P10:423), 420 (We-P13:333), 457 173 298 469 Sanguigni, V., (Tu-W26:5), (Tu-P10:514), Sato, T., 229 (Tu-P7:200), 240 (Tu-P7:252) (Th-PL4:3), (Th-W51:6) R 439 525 527 587 (We-P14:420), (Th-P15:147) Sato, Y., 191 (Tu-P7:32) Schiller, J., (Th-P15:156), (Th-P17:427) 244 327 Sani, M., (Tu-P7:271) Satoh, A., 60 (Mo-P1:65, Mo-P1:66), 73 Schiopu, A., (We-W41:3) 395 227 Sanidas, E.A., (We-P11:225) (Mo-P1:122), 377 (We-P11:144), 519 Schippers, E.F., (Tu-P7:194) 245 194 San José, G., (Tu-P7:274) (Th-P15:120) Schleef, R., (Tu-P7:43) 401 119 I Sankatsing, R.R., (We-P11:250) Sauerwein, H., 364 (We-P11:84) Schlegel-Zawadzka, M., (Mo-P5:335) 243 573 Sanke, T., (Tu-P7:268) Saugel, B., 526 (Th-P15:151) Schmid, U., (Th-P16:362) 154 208 213 Sansoy, V., (Tu-W17:2) Savarese, G., 112 (Mo-P5:300), 269 (Tu-P9:386), Schmidt, E.B., (Tu-P7:106), (Tu-P7:128), N 482 382 448 474 Santamarina-Fojo, S., (Th-W57:5) 420 (We-P13:333) (We-P11:163), (We-P14:462), 473 527 531 584 Santanam, N., (Th-W53:4), Savasci, S., 395 (We-P11:226) (Th-W53:6), (Th-P15:175), D 561 (Th-P15:157), (Th-P16:309) Savo, A., 372 (We-P11:122) (Th-P16:414) 165 578 Santangelo, C., (Tu-W22:4) Savopoulos, C., 108 (Mo-P4:282), 272 Schmieder, R., (Th-P16:387) Santilli, F., 172 (Tu-W26:3), 355 (We-P11:43), Schmitz, G., 26 (Mo-W9:2), 192 (Tu-P7:36) E (Tu-P10:401) 363 (We-P11:78), 524 (Th-P15:144) Schnabel, D., 144 (Mo-P6:447) Savoski, Z., 432 (We-P14:387) Santini, E., 14 (Mo-W2:7), 479 (Th-W56:4) Schnaitmann, E., 399 (We-P11:242) X Savvopoulou, A., 353 (We-P11:36) Santoro, A., 33 (Mo-W12:5), 125 (Mo-P5:360) Schneider, A., 507 (Th-P15:69) Sawabe, M., 129 (Mo-P6:379) Santos, A., 349 (We-P11:15) Schneider, B., 562 (Th-P16:312) Sawada, S., 559 (Th-P16:300), 581 (Th-P16:398) Santos, A.O., 263 (Tu-P9:360), 348 (We-P11:13), Schneider, M.D., 32 (Mo-W12:2) Sawamura, T., 96 (Mo-P3:225), 231 (Tu-P7:210), 435 (We-P14:403) Schneider, W., 482 (Th-W57:7) 523 (Th-P15:139) Santos, F.C., 512 (Th-P15:90) Schnohr, P., 35 (Mo-W13:6) Sawanobori, K., 547 (Th-P16:249) Santos, M.C., 84 (Mo-P2:172) Schoﬁeld, R.S., 142 (Mo-P6:439) Sawayama, Y., 58 (Mo-P1:57), 59 (Mo-P1:60), Santos, M.T., 397 (We-P11:235) Scholten, H.J., 265 (Tu-P9:367) 574 (Th-P16:369) Santos, R.D., 170 (Tu-W25:4), 262 (Tu-P9:353), Schönbeck, U., 168 (Tu-W24:4) Saxena, M., 229 (Tu-P7:204) 263 (Tu-P9:357), 419 (We-P13:332), 546 Schreiber, D., 588 (Th-P17:430) Sayed-Tabatabaei, F.A., 35 (Mo-W13:5) (Th-P15:242, Th-P15:243) Schreiber, R., 540 (Th-P15:213) Sbraccia, P., 165 (Tu-W22:6), 221 (Tu-P7:166), Santos, R.M., 120 (Mo-P5:337) Schreier, L., 195 (Tu-P7:48), 504 (Th-P15:52, 312 425 450 Santosa, S., 380 (We-P11:157) (We-W33:7), (We-P13:355), Th-P15:54) Santucci De Magistris, M., 56 (Mo-P1:46) (We-P14:468) Schreier, S., 525 (Th-P15:149) 225 Santure, M., 175 (Tu-W27:6), 306 (We-W30:5) Sbrana, F., (Tu-P7:183) Schrøder, M., 450 (We-P14:470) 420 Sanz-Paris, A., 511 (Th-P15:84), 567 Scaglione, R., (We-P13:336) Schroeder, T.V., 497 (Th-P15:21) 411 (Th-P16:334) Scaglioni, F., (We-P12:294) Schrör, K., 247 (Tu-P7:283) 47 66 121 Saougkos, V., 530 (Th-P15:170) Scaldaferri, L., (Mo-P1:8), (Mo-P1:91), Schulte, H., 467 (Th-W50:3) Saougos, V., 503 (Th-P15:49), 561 (Th-P16:308) (Mo-P5:345) Schultheiss, M., 353 (We-P11:32) 18 Sapienza, M., 62 (Mo-P1:73) Scanu, A.M., (Mo-W4:7) Schulz, C., 313 (We-W34:5) 266 268 Saporito, F., 24 (Mo-W7:7) Scappaticci, M., (Tu-P9:374), Schupp, N., 573 (Th-P16:362) Saracco, P., 288 (Tu-P10:472) (Tu-P9:380) Schuster, H., 183 (Tu-S11:1) 591 Saracini, C., 480 (Th-W56:6) Scarabollolo, L., (Th-P17:444) Schusterova, I., 423 (We-P13:348) Saramin, C., 47 (Mo-P1:8), 66 (Mo-P1:91), 121 Scarabottolo, L., 229 (Tu-P7:202) Schwager, T., 547 (Th-P15:248) (Mo-P5:345) Scaroni, C., 263 (Tu-P9:359) Schwartz, S.M., 133 (Mo-P6:399) Sarau, C.A., 46 (Mo-P1:3), 362 (We-P11:73), 365 Scarpace, P.J., 185 (Tu-P7:1) Schwarz, G., 581 (Th-P16:401) (We-P11:87) Scarpelli, D., 371 (We-P11:116) Schwarz, P.M., 470 (Th-W51:7) Sardella, A., 24 (Mo-W7:7) Scazzocchio, B., 186 (Tu-P7:7) Schwegler, B., 358 (We-P11:54) Sardo, M.A., 147 (Mo-P6:458) Schaap, F., 138 (Mo-P6:420) Schwenkglenks, M.M., 178 (Tu-W29:3) Sarecka, B., 72 (Mo-P1:117) Schaap, F.G., 38 (Mo-W15:4), 335 (We-W45:6), Sciacqua, A., 21 (Mo-W6:4), 206 (Tu-P7:100), Sargsyan, K., 310 (We-W32:5) 506 (Th-P15:62) 313 (We-W34:4), 367 (We-P11:98) Sari, I., 55 (Mo-P1:43), 371 (We-P11:114) Schaefer, E.J., 10 (Mo-ML3:1), 11 (Mo-W1:1), Scoditti, U., 107 (Mo-P4:276) Sarigianni, M., 295 (Tu-P10:500) 458 (Th-PL4:4), 576 (Th-P16:376), 580 Scorsin, M., 86 (Mo-P2:183), 88 (Mo-P2:190) Sarkiss, M.G., 91 (Mo-P2:207) (Th-P16:395) Scott, R., 392 (We-P11:211), 551 (Th-P16:264), Sarnataro, D., 33 (Mo-W12:5) Schaefer, J.R., 352 (We-P11:30) 566 (Th-P16:331) Sarraf-Zadegan, N., 120 (Mo-P5:340) Schäfer, A., 201 (Tu-P7:75), 218 (Tu-P7:153), 313 Scott, R.S., 135 (Mo-P6:406) Sarrafzadegan, N., 46 (Mo-P1:1), 53 (Mo-P1:38), (We-W34:5) Scotti, E., 253 (Tu-P8:313), 465 (Th-W49:4) 427 (We-P13:368) Schalkwijk, C., 159 (Tu-W19:4) Scozzafava, A., 206 (Tu-P7:100) Sartore, G., 350 (We-P11:21, We-P11:22) Scharnagl, H., 53 (Mo-P1:35), 72 (Mo-P1:118), Sebastiao, K.I., 546 (Th-P15:242)

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

256 Sebestjen, M., 75 (Mo-P1:134), 76 (Mo-P1:135), Shahmohammadi Mousavi, A., 581 (Th-P16:399) Shimosawa, T., 231 (Tu-P7:210) 212 (Tu-P7:126) Shaish, A., 38 (Mo-W15:1), 169 (Tu-W24:7) Shin, H.M., 279 (Tu-P10:429) Secchi, G., 137 (Mo-P6:414), 139 (Mo-P6:422) Shakhtshneider, E.V., 78 (Mo-P1:147), 81 Shingu, T., 186 (Tu-P7:5), 191 (Tu-P7:31), 577 Seccomandi, P.M., 211 (Tu-P7:120) (Mo-P1:158) (Th-P16:380) Sedda, V., 276 (Tu-P10:420) Shamkhalova, M., 356 (We-P11:48) Shinozaki, S., 187 (Tu-P7:11), 193 (Tu-P7:41) A Sedlmayr, P., 93 (Mo-P2:212) Shankar, S.S., 400 (We-P11:249), 410 Shiomi, M., 238 (Tu-P7:241), 339 (We-S13:3), Seedorf, K., 520 (Th-P15:125) (We-P12:290) 501 (Th-P15:39), 549 (Th-P16:256) Segawa, T., 68 (Mo-P1:100), 72 (Mo-P1:120), 259 Shao, J., 196 (Tu-P7:51) Shiota, N., 244 (Tu-P7:269) U (Tu-P9:339) Shapira, C., 554 (Th-P16:279) Shiozaki, S., 185 (Tu-P7:3) Seip, R.L., 113 (Mo-P5:303), 501 (Th-P15:40) Shapira, I., 142 (Mo-P6:440), 285 (Tu-P10:459) Shirai, K., 268 (Tu-P9:383), 417 (We-P13:320), T Sekikawa, A., 52 (Mo-P1:31), 58 (Mo-P1:58), 260 Shariﬁ, B., 156 (Tu-W18:1) 498 (Th-P15:29), 499 (Th-P15:30), 576 (Tu-P9:344), 265 (Tu-P9:368) Sharma, J., 229 (Tu-P7:204) (Th-P16:375), 578 (Th-P16:386) H Selas, M., 84 (Mo-P2:172) Sharman, J., 538 (Th-P15:204) Shirai, M., 246 (Tu-P7:279) Seljeﬂot, I., 103 (Mo-P4:258), 126 (Mo-P5:364), Sharp, J., 523 (Th-P15:138) Shirasawa, T., 129 (Mo-P6:379) O 284 (Tu-P10:453), 357 (We-P11:52), 390 Shavit, O., 116 (Mo-P5:317), 117 (Mo-P5:325) Shishido, S.M., 197 (Tu-P7:56) 146 (We-P11:200) Shaw, J.A., (Mo-P6:454) Shiu, S.W.M., 294 (Tu-P10:495) 467 459 R Selmer, R., (Th-W50:4) Shaw, P.X., (Th-W46:1) Shivalkar, B., 413 (We-P12:303) 201 550 Semecky, V., (Tu-P7:74) Shear, C.L., (Th-P16:259, Th-P16:260, Shlyakhto, E.V., 242 (Tu-P7:262) 109 Semertzidis, P., (Mo-P4:286) Th-P16:261, Th-P16:262) Shmeleva, V.M., 272 (Tu-P10:398) 585 160 Senda, Y., (Th-P16:417) Shearman, C.P., (Tu-W20:3) Shojaie, M., 64 (Mo-P1:84), 114 (Mo-P5:311) 384 213 Sentí, M., (We-P11:172) Shechter, M., (Tu-P7:130) Shoji, K., 511 (Th-P15:85) I 383 280 Senti, M., (We-P11:171) Sheikine, Y., (Tu-P10:434) Shooshtarizadeh, S.H., 120 (Mo-P5:341) 217 266 438 Seo, H.S., (Tu-P7:145), (Tu-P9:372, Sheinkova, G., (We-P14:417) Shore, A.C., 104 (Mo-P4:262) 314 83 N Tu-P9:373), (We-W34:7) Shek, A.B., (Mo-P1:462) Shoulders, C.C., 21 (Mo-W6:3), 130 (Mo-P6:383) 455 111 121 Seo, Y.J., (We-P14:489) Shekarchizadeh, P., (Mo-P5:297), Shpitzen, S., 133 (Mo-P6:399) 236 D Seppänen-Laakso, T., (Tu-P7:235) (Mo-P5:343) Shubevska, S., 373 (We-P11:126) 125 275 Sepulveda, D., (Mo-P5:361) Shekerdjiski, R., (Tu-P10:415) Shulzhenko, D.V., 107 (Mo-P4:280) Serban, M., 62 (Mo-P1:76) Shelia, G.D., 385 (We-P11:181), 578 Shushakova, N., 574 (Th-P16:365) E Serbanescu, F., 236 (Tu-P7:233) (Th-P16:385) Si, S., 464 (Th-W49:1) Serebruany, V., 392 (We-P11:211), 393 Shen, G., 87 (Mo-P2:188), 88 (Mo-P2:189) Siablis, D., 109 (Mo-P4:285) X (We-P11:212) Shen, J., 250 (Tu-P8:297) Siamopoulos, K.C., 517 (Th-P15:113) Seres, I., 229 (Tu-P7:203), 292 (Tu-P10:489), 296 Shen, L., 190 (Tu-P7:27) Sianni, A., 429 (We-P13:373) (Tu-P10:504), 518 (Th-P15:115), 571 Shen, Y., 403 (We-P11:259) Sica, A., 381 (We-P11:159) (Th-P16:355), 577 (Th-P16:382) Sheng, L., 572 (Th-P16:360) Sicard, P., 427 (We-P13:365) Sergienko, I., 569 (Th-P16:346) Shengelia, R., 65 (Mo-P1:87) Sidiropoulos, P.I., 414 (We-P12:307), 423 Serhiyenko, A., 373 (We-P11:124), 450 Shenhar-Tsarfaty, S., 142 (Mo-P6:440) (We-P13:350) (We-P14:467), 568 (Th-P16:338) Shepherd, J., 121 (Mo-P5:344), 183 (Tu-S11:2), Sidorenko, B.A., 131 (Mo-P6:387), 146 Serhiyenko, L., 568 (Th-P16:338) 576 (Th-P16:376) (Mo-P6:455) Serhiyenko, V., 373 (We-P11:124), 450 Sheridan, P., 308 (We-W31:5) Sidovska, B., 532 (Th-P15:178) (We-P14:467), 568 (Th-P16:338) Shestakova, M., 356 (We-P11:45, We-P11:48) Sidovska-Ivanovska, B., 373 (We-P11:126) Serino, M., 312 (We-W33:7), 372 (We-P11:122) Shestakova, M.V., 108 (Mo-P4:281), 209 424 Serone, A.P., 370 (We-P11:111), 534 (Tu-P7:111), 289 (Tu-P10:474) Siebert, J., (We-P13:352) 136 (Th-P15:185) Shetty, R., 415 (We-P13:313) Siedah, N.G., (Mo-P6:409) 295 417 Serracino-Inglott, F., 106 (Mo-P4:272) Shetty, S., 28 (Mo-W9:7) Siedlecka, D., (Tu-P10:501), Serrano, V., 216 (Tu-P7:141) Shevelev, A.Y., 96 (Mo-P3:227) (We-P13:324) 564 Sertic, J., 384 (We-P11:175) Shi, G.Y., 199 (Tu-P7:67), 397 (We-P11:231), 573 Siegelman, E.S., (Th-P16:322) 412 Serusclat, A., 155 (Tu-W17:3) (Th-P16:364) Siegert, G., (We-P12:298) 387 Servini, Z., 432 (We-P14:387) Shi, L.B., 494 (Th-P15:12) Siennicka, A., (We-P11:187) 17 221 Sesso, H.D., 66 (Mo-P1:93) Shi, W.Y., 144 (Mo-P6:445) Siepi, D., (Mo-W4:3), (Tu-P7:165) 225 Sesti, G., 21 (Mo-W6:4), 141 (Mo-P6:434), 169 Shi, X.B., 81 (Mo-P1:160) Sierakowska-Fijalek, A., (Tu-P7:182) 271 (Tu-W24:6), 206 (Tu-P7:100), 313 Shibuya, K., 547 (Th-P16:249) Sierakowska Fijalek, A., (Tu-P10:397) 30 222 326 (We-W34:4), 367 (We-P11:98), 371 Shibuya, M., 191 (Tu-P7:28) Siess, W., (Mo-W10:6), (Tu-P7:170), (We-P11:116) Shibuya, T., 191 (Tu-P7:32) (We-W40:7), 392 (We-P11:210) Sestini, I., 207 (Tu-P7:102), 480 (Th-W56:6) Shigematsu, M., 59 (Mo-P1:60) Siest, G., 507 (Th-P15:66) Setacci, C., 589 (Th-P17:435) Shih, Y.Y., 409 (We-P12:287) Sigurdsson, G., 468 (Th-W50:7) Sethi, A.A., 145 (Mo-P6:450) Shiina, Y., 460 (Th-W46:6), 583 (Th-P16:407) Siirtola, A., 124 (Mo-P5:358) Setina, M., 285 (Tu-P10:458) Shimabukuro, T., 48 (Mo-P1:12) Sijbrands, E.J.G., 38 (Mo-W15:3), 315 Seuc, A., 363 (We-P11:80) Shimada, K., 417 (We-P13:321), 559 (We-W35:4), 538 (Th-P15:207) Severina, A., 356 (We-P11:45) (Th-P16:301) Silacci, P., 220 (Tu-P7:158) Severs, N.J., 494 (Th-P15:9) Shimada, Y., 434 (We-P14:397) Sileli, M., 109 (Mo-P4:286) Sevo, G., 78 (Mo-P1:148) Shimizu, K., 191 (Tu-P7:32) Sillesen, H., 18 (Mo-W4:6) Seyama, Y., 454 (We-P14:485) Shimizu, M., 104 (Mo-P4:264), 133 (Mo-P6:397), Silva, F., 201 (Tu-P7:76) Seydell, T., 537 (Th-P15:202), 542 (Th-P15:224) 444 (We-P14:441) Silva, J.L., 113 (Mo-P5:305), 509 (Th-P15:75) Sha, S., 428 (We-P13:371) Shimokado, K., 185 (Tu-P7:3), 187 (Tu-P7:11), Silva, J.M., 545 (Th-P15:237) Shaban, M., 118 (Mo-P5:328) 193 (Tu-P7:41), 234 (Tu-P7:226), 253 Silva, M., 400 (We-P11:245) Shah, F., 308 (We-W31:3) (Tu-P8:311), 430 (We-P14:377) Silva, P.M., 545 (Th-P15:237) Shah, P.K., 156 (Tu-W18:1), 327 (We-W41:3) Shimomitsu, T., 428 (We-P13:372) Silva, S., 131 (Mo-P6:390) Shaham, M., 133 (Mo-P6:399) Shimomura, I., 237 (Tu-P7:237), 510 (Th-P15:82) Silva, V.M., 113 (Mo-P5:305)

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

257 Silva-Nunes, J., 380 (We-P11:154) Skoglund, C., 284 (Tu-P10:452), 413 Sodré, F.L., 508 (Th-P15:71), 509 (Th-P15:74) Silveira, A., 505 (Th-P15:56) (We-P12:305) Soﬁ, F., 85 (Mo-P2:177), 441 (We-P14:431), 530 Silvennoinen-Kassinen, S., 85 (Mo-P2:176) Skogsberg, J., 200 (Tu-P7:72), 357 (We-P11:50) (Th-P15:169) Silverstein, R., 490 (Th-W61:7) Skottova, N., 560 (Th-P16:304) Soininen, P., 496 (Th-P15:19) A Silvestre, J.S., 190 (Tu-P7:26) Skoufas, P.D., 58 (Mo-P1:56), 84 (Mo-P2:171) Soininen, R., 489 (Th-W61:4) Sim, R., 514 (Th-P15:97) Skouma, A., 251 (Tu-P8:303) Sokolova Djokic, L., 120 (Mo-P5:342), 377 Sima, A., 69 (Mo-P1:106), 193 (Tu-P7:40), 415 Skrbic, R., 570 (Th-P16:348) (We-P11:143), 386 (We-P11:183) U (We-P13:314) Skvortsov, A., 582 (Th-P16:402) Sol, B.G.M., 357 (We-P11:51) Simaku, L., 283 (Tu-P10:448) Slavin, D.E., 480 (Th-W56:7) Solà, R., 443 (We-P14:439) T Simanek, V., 560 (Th-P16:304) Slavotinek, J., 381 (We-P11:162) Sola, R., 452 (We-P14:476) Simell, O., 55 (Mo-P1:44) Slevin, M., 246 (Tu-P7:281) Solakivi, T., 241 (Tu-P7:256) H Simes, J., 330 (We-W42:7), 557 (Th-P16:290) Slinkin, M.A., 96 (Mo-P3:227) Solbiati, F., 422 (We-P13:343) Simes, R.J., 174 (Tu-W27:1) Sloane, T., 167 (Tu-W23:6) Soldani, F., 399 (We-P11:243, We-P11:244) O Simeunovic, D., 53 (Mo-P1:37) Slobodskiy, V., 211 (Tu-P7:122) Soldati, S., 454 (We-P14:484) Simeunovic, S., 53 (Mo-P1:37) Slooff, V., 260 (Tu-P9:342) Solerte, B., 404 (We-P11:266) 220 228 258 Simionescu, M., (Tu-P7:159), Sloop, G., (Tu-P9:335) Solfrizzi, V., 402 (We-P11:255), 447 R 355 590 428 (Tu-P7:195), (We-P11:41), Slordahl, S., (We-P13:369) (We-P14:458), 530 (Th-P15:172) 563 (Th-P17:438) Slovacek, L., (Th-P16:317) Solheim, S., 284 (Tu-P10:453) 502 274 Simioni, P., (Th-P15:45) Slow, S., (Tu-P10:409) Solichová, D., 563 (Th-P16:316) 490 357 Simolin, M., (Th-W61:6) Slunjski, D., (We-P11:53) Solichova, D., 201 (Tu-P7:74), 359 (We-P11:60), 269 359 I Simon, A., (Tu-P9:387) Smahelova, A., (We-P11:60) 562 (Th-P16:314) 163 566 Simon, T., (Tu-W21:4) Small, R., (Th-P16:331) Solini, A., 14 (Mo-W2:7), 479 (Th-W56:4) 112 551 Simonetti, S., (Mo-P5:300) Small, R.D., (Th-P16:264) Solomon, H., 405 (We-P11:268) N 272 274 131 349 Simoni, L., (Tu-P10:399), (Tu-P10:407, Smaoui, M., (Mo-P6:388), (We-P11:18) Solovieva, E., 116 (Mo-P5:321) 444 Tu-P10:408) Smart, E., (We-P14:443) Soma, M., 448 (We-P14:460) D 57 506 Simonova, G.I., (Mo-P1:53) Smelt, A.H.M., (Th-P15:62) Son, B.K., 585 (Th-P16:417) 335 99 Simons, J., (We-W45:3) Smetanina, I.N., (Mo-P4:243) Song, K., 363 (We-P11:81) Simons, J.P., 95 (Mo-P3:224) Smidt, U., 159 (Tu-W19:4) E Song, K.J., 517 (Th-P15:112) Simons, L.A., 335 (We-W45:3) Smirnov, V., 207 (Tu-P7:103) Song, Y., 215 (Tu-P7:137) Simopoulos, A.P., 316 (We-W36:2) Smirnova, N., 356 (We-P11:48) X Sonmez, A., 206 (Tu-P7:96), 395 (We-P11:226), Simurka, P., 57 (Mo-P1:54) Smith, A., 472 (Th-W52:6) 417 (We-P13:323) Sindermann, J.R., 238 (Tu-P7:243) Smith, D.H.G., 551 (Th-P16:264) Sonoji, S.L., 364 (We-P11:83) Singaraja, R.R., 166 (Tu-W23:4), 319 Smith, G., 568 (Th-P16:340) Sorge, R., 173 (Tu-W26:5) (We-W37:4), 542 (Th-P15:223) Smith, J., 566 (Th-P16:331) Sørhaug, S., 215 (Tu-P7:139) Singer, W., 476 (Th-W55:1) Smith, J.A., 551 (Th-P16:264) Sorice, M., 330 (We-W43:2) Singh, N.N., 237 (Tu-P7:238) Smith, J.D., 541 (Th-P15:220) Sorli, J.V., 47 (Mo-P1:9), 133 (Mo-P6:398) Singh, R., 229 (Tu-P7:204), 546 (Th-P15:245) Smith, L.M., 390 (We-P11:201) Sornsakrin, M., 508 (Th-P15:70) Sinisalo, J., 85 (Mo-P2:176), 171 (Tu-W25:6) Smith, S., 308 (We-W31:5) Soro-Paavonen, A., 500 (Th-P15:37) Sinkiewicz, W., 83 (Mo-P2:168, Mo-P2:169) Smith, T.F., 324 (We-W39:7) Sorondila, K., 509 (Th-P15:77) Sinone, J.L., 412 (We-P12:300) Smith, W., 561 (Th-P16:307) Sorour, K., 266 (Tu-P9:371) Siow, Y.L., 274 (Tu-P10:410), 276 (Tu-P10:418) Smolej, L., 562 (Th-P16:315) 552 580 Sipka, S., 296 (Tu-P10:504) Smolkova, B., 446 (We-P14:452) Sosef, F., (Th-P16:270), (Th-P16:394) 279 Sirinian, I., 35 (Mo-W13:4), 330 (We-W43:2) Snapper, J., 95 (Mo-P3:223) Soska, V., (Tu-P10:433) 273 Siroka, R., 298 (Tu-P10:515), 590 (Th-P17:442) Sneck, M., 497 (Th-P15:24) Sotgia, S., (Tu-P10:405) 280 518 Siroký, O., 563 (Th-P16:316) Sneddon, A.A., 222 (Tu-P7:171) Souhaili, H., (Tu-P10:436), (Th-P15:114, Sirolli, V., 216 (Tu-P7:144) Snegurskaya, I., 383 (We-P11:169), 418 Th-P15:116) 25 Sironi, L., 463 (Th-W48:6) (We-P13:327) Soukhatcheva, G., (Mo-W8:4) 128 131 Sirsjö, A., 393 (We-P11:216) Snehalatha, C., 25 (Mo-W8:2) Soutar, A.K., (Mo-P6:378), (Mo-P6:390), 136 197 306 Sirtori, C.R., 152 (Tu-W16:3), 154 (Tu-W16:8), Sniderman, A.D., 36 (Mo-W14:2), 545 (Mo-P6:410), (Tu-P7:59), 515 166 (Tu-W23:3), 167 (Tu-W23:7), 251 (Th-P15:240) (We-W30:4), (Th-P15:101) 138 (Tu-P8:300), 258 (Tu-P9:336), 259 Snieder, H., 144 (Mo-P6:446) Southwick, A., (Mo-P6:419) 577 (Tu-P9:337, Tu-P9:340), 260 (Tu-P9:343), 324 Snively, B.M., 13 (Mo-W2:3) Southworth, H., (Th-P16:383) (We-W39:6), 453 (We-P14:483), 454 Snoeys, J., 94 (Mo-P3:218), 490 (Th-W61:8) Souza, J.M., 280 (Tu-P10:437) (We-P14:484), 474 (Th-W53:7), 477 Soares, M.P., 198 (Tu-P7:62) Soyama, Y., 290 (Tu-P10:481) (Th-W55:3, Th-W55:4), 478 (Th-W55:6), 570 Sobajic, S., 450 (We-P14:469) Sozen, M., 129 (Mo-P6:381) (Th-P16:347) Sobenin, I.A., 209 (Tu-P7:110), 230 (Tu-P7:209), Spagnoli, L.G., 252 (Tu-P8:305) Siscovick, D.S., 133 (Mo-P6:399) 250 (Tu-P8:296), 444 (We-P14:442), 499 Spagnuolo, V., 71 (Mo-P1:116), 389 Sjoberg, S., 22 (Mo-W6:6) (Th-P15:34), 500 (Th-P15:38) (We-P11:196, We-P11:199) Sjögren, P., 231 (Tu-P7:213) Sobiczewski, W., 129 (Mo-P6:380), 424 Spallarossa, P., 508 (Th-P15:73) Sjöwall, C., 284 (Tu-P10:452) (We-P13:352), 442 (We-P14:432), 449 Spanakis, E.K., 414 (We-P12:307), 423 Skalik, R., 297 (Tu-P10:511) (We-P14:465) (We-P13:350) Skilton, M., 155 (Tu-W17:3) Soboleva, E., 207 (Tu-P7:103) Spanos, N., 522 (Th-P15:134) Skjærpe, P.A., 506 (Th-P15:63) Sobotova, D., 279 (Tu-P10:433) Spasic, S., 60 (Mo-P1:64), 139 (Mo-P6:426), 279 Skoczynska, A., 137 (Mo-P6:415), 297 Soccio, R.S., 27 (Mo-W9:3) (Tu-P10:432), 381 (We-P11:161) (Tu-P10:511) Soderberg, S., 330 (We-W42:7) Spasojevic-Kalimanovska, V., 60 (Mo-P1:64), 139 Skodova, Z., 48 (Mo-P1:13), 139 (Mo-P6:423), Soderberg-Naucler, C., 289 (Tu-P10:477) (Mo-P6:426), 279 (Tu-P10:432) 486 (Th-W59:6) Söderlund, S., 500 (Th-P15:37) Spector, T.D., 144 (Mo-P6:446) Skogh, T., 284 (Tu-P10:452) Söderström, M., 173 (Tu-W26:6), 203 (Tu-P7:85) Spek, C., 309 (We-W32:3)

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

258 Spence, J.D., 269 (Tu-P9:384), 308 (We-W31:4) Stein, E.A., 37 (Mo-W14:7) Stroes, E.S., 19 (Mo-W5:2), 124 (Mo-P5:357), Spencer-Jones, N.J., 144 (Mo-P6:446) Stein, M., 161 (Tu-W20:6), 551 (Th-P16:265), 153 (Tu-W16:5), 265 (Tu-P9:367) Spertus, J.A., 82 (Mo-P1:167) 552 (Th-P16:267) Stroes, E.S.G., 16 (Mo-W3:6), 24 (Mo-W7:5), 37 Spieker, L., 222 (Tu-P7:169) Steinberg, H.O., 400 (We-P11:249), 410 (Mo-W14:7), 70 (Mo-P1:109), 134 Spieker, L.E., 90 (Mo-P2:200) (We-P12:290) (Mo-P6:403), 401 (We-P11:250), 544 A Spigonardo, F., 246 (Tu-P7:280), 247 Steiner, G., 342 (We-S15:1) (Th-P15:235) (Tu-P7:282), 248 (Tu-P7:287) Steinhagen-Thiessen, E., 567 (Th-P16:336) Strong, J.P., 258 (Tu-P9:335) Spillmann, F., 153 (Tu-W16:6) Steinshamn, S., 215 (Tu-P7:139) Strony, J., 356 (We-P11:49) U Spin, J.M., 230 (Tu-P7:206) Stellin, L., 86 (Mo-P2:183), 88 (Mo-P2:190) Stros, P., 91 (Mo-P2:204), 416 (We-P13:316) Spite, M., 520 (Th-P15:126) Stengel, D., 173 (Tu-W26:4), 464 (Th-W48:7) Strunz, C.M., 501 (Th-P15:41) T Spollen, L., 237 (Tu-P7:239) Stenuit, P., 119 (Mo-P5:336) Strydom, A.J.C., 276 (Tu-P10:419) Sposito, A., 476 (Th-W54:6) Stephens, D.J., 21 (Mo-W6:3) Stuber, M., 267 (Tu-P9:375) H Sprong, H., 26 (Mo-W9:1) Stephens, J., 24 (Mo-W7:6), 312 (We-W33:6) Stulc, T., 371 (We-P11:117) Spyrou, A., 499 (Th-P15:32) Stephens, J.W., 312 (We-W33:5) Stuppia, L., 29 (Mo-W10:4) O Squadrito, F., 24 (Mo-W7:7), 147 (Mo-P6:458) Sterbakova, G., 111 (Mo-P4:295) Sturm, J., 77 (Mo-P1:140), 317 (We-W36:3) 297 402 382 Squellerio, I., (Tu-P10:510), Sterev, I.V., (We-P11:164) Stutzbach, P., 504 (Th-P15:54) 220 R (We-P11:254) Stergiopulos, N., (Tu-P7:158) Su, J., 299 (Tu-P10:518), 466 (Th-W49:6), 552 190 340 Squiban, C., (Tu-P7:26) Stern, M., (We-S14:1) (Th-P16:268) 377 352 Srdic, B., (We-P11:142) Sternic, N., (We-P11:28) Su, T.C., 48 (Mo-P1:15), 79 (Mo-P1:151), 369 421 408 Sreckovic, B., (We-P13:341) Stevitsh Gajitsh, V., (We-P12:284) (We-P11:106), 434 (We-P14:399), 437 200 520 120 386 Srivastava, S., (Tu-P7:70), (Th-P15:126) Stic, M., (Mo-P5:342), (We-P11:183) (We-P14:409) I 433 85 530 Stachowska, E., (We-P14:392) Sticchi, E., (Mo-P2:177), (Th-P15:169) Suastika, K., 346 (We-P11:2) 433 471 Stachowska, E.W.A., (We-P14:391) Stichtenoth, D.O., (Th-W52:5) Subasigüller, A., 153 (Tu-W16:6) 199 200 325 N Stachura, J., (Tu-P7:64, Tu-P7:66), Stickler, P., (We-W40:5) Subbaiah, P.V., 495 (Th-P15:14) 263 (Tu-P7:68) Stifts, A., (Tu-P9:358) Subeska Stratova, S., 128 (Mo-P5:374) 573 239 D Stachura-Kulach, A., (Th-P16:363) Stillemark-Billton, P., (Tu-P7:249) Subeska Stratrova, S., 418 (We-P13:326), 584 20 331 487 194 Staels, B., (Mo-W6:1), (We-W43:4), Stinn, W., (Tu-P7:43) (Th-P16:411) (Th-W60:3) Stirling, C.A., 330 (We-W42:6), 358 (We-P11:55) Subirana, I., 383 (We-P11:171) E Stahmer, B., 166 (Tu-W23:4) Stockinger, H., 195 (Tu-P7:50) Subramanian, S., 13 (Mo-W2:1) Stainer, W., 283 (Tu-P10:449) Stockton, J., 375 (We-P11:135) Succurro, E., 367 (We-P11:98) X Staines, H., 449 (We-P14:463) Stojakovic, N., 570 (Th-P16:348) Suchanek, P., 141 (Mo-P6:435) Stakos, D., 127 (Mo-P5:370) Stojakovic, T., 53 (Mo-P1:35), 576 (Th-P16:374), Suciu, O., 57 (Mo-P1:51), 378 (We-P11:147) Stalenhoef, A.F.H., 260 (Tu-P9:345), 306 583 (Th-P16:409) Suda, T., 506 (Th-P15:61), 542 (Th-P15:225), 543 (We-W30:6), 545 (Th-P15:240) Stojanovic, J., 502 (Th-P15:46), 503 (Th-P15:47) (Th-P15:226) Stamatelopoulos, K., 251 (Tu-P8:303) Stojanovic, V., 393 (We-P11:214) Sudano, I., 90 (Mo-P2:200), 358 (We-P11:54) Stamatis, H., 523 (Th-P15:140) Stojnic, N., 211 (Tu-P7:119) Sudhakaran, P.R., 242 (Tu-P7:261), 453 Stamenkovic-Pejkovic, D., 126 (Mo-P5:367), 287 Stojsic, D., 422 (We-P13:345) (We-P14:481) (Tu-P10:468), 362 (We-P11:75), 378 Stojsic, J., 422 (We-P13:345) Suehiro, T., 210 (Tu-P7:115), 254 (Tu-P8:314), (We-P11:149) Stokic, E., 115 (Mo-P5:313), 377 (We-P11:142) 294 (Tu-P10:499), 354 (We-P11:37) Stamler, J., 56 (Mo-P1:47), 390 (We-P11:201), Stolen, T., 428 (We-P13:369) Suemitsu, Y., 417 (We-P13:322) 430 (We-P14:381), 437 (We-P14:410, Stølen, T., 215 (Tu-P7:139), 379 (We-P11:152) 523 We-P14:411) Stolf, N., 291 (Tu-P10:484), 406 (We-P11:274) Sugawara, F., (Th-P15:139) 225 366 Stamp, G.W., 587 (Th-P17:426) Stoll, M., 467 (Th-W50:3) Sugihara, H., (Tu-P7:185), (We-P11:96) 496 511 Stancu, C., 193 (Tu-P7:40), 415 (We-P13:314) Stolyhwo, A., 442 (We-P14:432), 449 Sugimoto, T., (Th-P15:17), (Th-P15:86) 294 Standing, C., 234 (Tu-P7:225) (We-P14:465) Sugiura, T., (Tu-P10:499) 104 444 Stanek, E.J., 53 (Mo-P1:36), 174 (Tu-W27:4), 568 Stolyhwo Gofron, M., 442 (We-P14:432), 449 Sugiyama, D., (Mo-P4:264), (Th-P16:339) (We-P14:465) (We-P14:441) 96 Stangl, H., 38 (Mo-W15:4) Stone, N.J., 4 (Su-S2:5) Sugiyama, H., (Mo-P3:225) 375 Stanislaus, S., 566 (Th-P16:329) Stoneman, V.E.A.S., 21 (Mo-W6:2) Suh, M., (We-P11:135) 217 266 Stanková, B., 144 (Mo-P6:448), 365 (We-P11:90), Stonik, J., 320 (We-W38:1) Suh, S.Y., (Tu-P7:145), (Tu-P9:372, 314 496 (Th-P15:18) Stopczynska, I., 129 (Mo-P6:380) Tu-P9:373), (We-W34:7) 209 289 Stankovic, S., 418 (We-P13:325) Stopka, P., 292 (Tu-P10:487) Sukhareva, O.Y., (Tu-P7:111), Stankulov, I.S., 188 (Tu-P7:16) Stopper, H., 573 (Th-P16:362) (Tu-P10:474) Starodubova, A., 379 (We-P11:153) Storozhakov, G., 379 (We-P11:153) Sullivan, D., 557 (Th-P16:290) Staruchova, M., 292 (Tu-P10:488) Stowasser, M., 469 (Th-W51:5) Sumarac-Dumanovic, M., 126 (Mo-P5:367), 287 Stasiak-Barmtua, A., 271 (Tu-P10:393) Strand, D., 295 (Tu-P10:502) (Tu-P10:468), 361 (We-P11:68, We-P11:70), States, J.C., 200 (Tu-P7:70) Strand, J., 550 (Th-P16:259) 362 (We-P11:74, We-P11:75), 378 Stavek, P., 48 (Mo-P1:13), 124 (Mo-P5:356), 285 Stranden, E., 103 (Mo-P4:258) (We-P11:149) (Tu-P10:458) Straub, J., 561 (Th-P16:307) Sumarokov, A.B., 283 (Tu-P10:447), 394 Stearns-Kurosawa, D.J., 22 (Mo-W6:5) Strauch, B., 389 (We-P11:195) (We-P11:221), 404 (We-P11:263) Stefanick, M.L., 176 (Tu-W28:3), 485 (Th-W59:1) Strelkova, A., 126 (Mo-P5:368), 360 (We-P11:66), Sumner, G., 308 (We-W31:5) Stefanidou, S., 128 (Mo-P5:377) 419 (We-P13:329) Sumpio, B., 252 (Tu-P8:306) Stefanovic, A., 381 (We-P11:161) Strelkova, A.V., 415 (We-P13:312) Sun, G.-T., 498 (Th-P15:26) Stefanutti, C., 448 (We-P14:461) Stritecka, H., 57 (Mo-P1:52) Sun, L., 494 (Th-P15:11), 516 (Th-P15:107), 536 Steffensen, R., 35 (Mo-W13:6) Strizevsky, A., 388 (We-P11:193) (Th-P15:196), 574 (Th-P16:367) Steg, P.G., 370 (We-P11:113), 427 (We-P13:365) Strobl, W., 38 (Mo-W15:4) Sun, W.Q., 190 (Tu-P7:25), 223 (Tu-P7:175), 224 Stehouwer, C., 159 (Tu-W19:4) Stroes, E., 309 (We-W32:3), 364 (We-P11:84), (Tu-P7:177), 234 (Tu-P7:224), 251 Stehouwer, C.D.A., 23 (Mo-W7:4) 533 (Th-P15:183) (Tu-P8:301), 521 (Th-P15:129)

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

259 Sun, X.M., 197 (Tu-P7:59), 306 (We-W30:4) Tabata, Y., 94 (Mo-P3:217) Tamsma, J.T., 125 (Mo-P5:363), 267 (Tu-P9:375), Sun, Y.H., 190 (Tu-P7:25), 251 (Tu-P8:301) Taborsky, L., 128 (Mo-P5:376), 553 (Th-P16:273) 331 (We-W43:6) Sunagawa, K., 249 (Tu-P8:294), 482 (Th-W57:4) Tabrah, S., 129 (Mo-P6:381) Tamura, K., 49 (Mo-P1:17) Sundram, K., 436 (We-P14:406) Tabukashvili, R., 454 (We-P14:487), 556 Tan, K.C.B., 294 (Tu-P10:495) A Sundvall, J., 576 (Th-P16:378) (Th-P16:288) Tan, L.G., 232 (Tu-P7:215) Sung, F.C., 48 (Mo-P1:15), 369 (We-P11:106) Tacconelli, S., 29 (Mo-W10:4) Tan, R., 544 (Th-P15:232, Th-P15:236), 566 Sung, J., 423 (We-P13:349) Tada, N., 428 (We-P13:370), 511 (Th-P15:85) (Th-P16:330) U Sun Hwang, L., 436 (We-P14:408) Taddei, S., 151 (Tu-ML4:1) Tan, S.A., 232 (Tu-P7:215) Superko, A., 567 (Th-P16:337) Tagliaﬁco, E., 257 (Tu-P8:328) Tan, Y.-L., 516 (Th-P15:107), 536 (Th-P15:196), T Superko, R., 476 (Th-W54:7), 567 (Th-P16:337), Taher, M., 529 (Th-P15:165) 574 (Th-P16:367) 588 (Th-P17:429) Tahira, K., 33 (Mo-W12:6), 96 (Mo-P3:225), 185 Tan, Y.L., 494 (Th-P15:11) H Superko, S., 476 (Th-W54:7) (Tu-P7:2), 187 (Tu-P7:12) Tanabe, J., 506 (Th-P15:61), 542 (Th-P15:225), Suresh, R., 356 (We-P11:49) Tai, M.H., 193 (Tu-P7:37) 543 (Th-P15:226) O Surrenti, C., 441 (We-P14:431) Taibi, N., 209 (Tu-P7:113), 247 (Tu-P7:286) Tanaka, F., 63 (Mo-P1:81), 68 (Mo-P1:100), 72 Susak, S., 100 (Mo-P4:248) Tailford, K., 325 (We-W40:5) (Mo-P1:120) 290 498 Sussekov, A., 116 (Mo-P5:321) Taira, K., (Tu-P10:478), (Th-P15:27) Tanaka, H., 498 (Th-P15:27) R 239 Sussman, H., 588 (Th-P17:430) Tajima, N., (Tu-P7:247) Tanaka, K., 448 (We-P14:460) 482 575 Sutherland, B.G., (Th-W57:6) Takada, H., (Th-P16:371) Tanaka, M., 85 (Mo-P2:179), 434 (We-P14:398), 260 48 Sutton-Tyrell, K., (Tu-P9:344) Takada, K., (Mo-P1:12) 460 (Th-W46:7) 427 16 319 497 Suwa, J., (We-P13:366) Takagi, A., (Mo-W3:7), (We-W37:3), Tanaka, N., 73 (Mo-P1:125), 129 (Mo-P6:379), 109 I Suwanwela, N.C., (Mo-P4:289) (Th-P15:22) 581 (Th-P16:398) 575 185 Suzuki, K., (Th-P16:371) Takagi, H., (Tu-P7:2) Tanaka, R., 259 (Tu-P9:339) 96 187 249 361 Suzuki, R., (Mo-P3:225), (Tu-P7:12) Takahashi, A., (Tu-P8:293), (We-P11:72), Tanaka, S., 428 (We-P13:371) N 434 575 Suzuki, T., (We-P14:397) (Th-P16:373) Tanasescu, C., 414 (We-P12:308) 14 367 Svarrer, E.M.M., (Mo-W2:4) Takahashi, I., (We-P11:100) Taner, A., 264 (Tu-P9:362, Tu-P9:364) D 506 434 Svartberg, J., (Th-P15:63) Takahashi, M., (We-P14:398) Taneva, B., 101 (Mo-P4:253) 478 243 465 Svendsen, M., (Th-W55:5) Takai, S., (Tu-P7:267), (Th-W49:2) Tang, C., 271 (Tu-P10:394) 171 173 Takamiya, T., 52 (Mo-P1:31), 58 (Mo-P1:58), 260 E Svensson, A.-C., (Tu-W25:7), Tang, C.J., 210 (Tu-P7:117), 403 (We-P11:262) 203 (Tu-P9:344), 265 (Tu-P9:368) (Tu-W26:6), (Tu-P7:85) Tang, C.K., 144 (Mo-P6:445), 233 (Tu-P7:219), 227 Takamori, N., 49 (Mo-P1:17) X Svensson, L., (Tu-P7:190) 254 (Tu-P8:317), 322 (We-W38:7), 492 474 Takanami, Y., 428 (We-P13:372) Svensson, M., (Th-W53:6) (Th-P15:3), 494 (Th-P15:10), 516 Svensson, P.-A., 22 (Mo-W6:6), 234 (Tu-P7:225) Takano, T., 501 (Th-P15:39) (Th-P15:108), 529 (Th-P15:167), 543 Svensson, P.A., 207 (Tu-P7:101) Takao, K., 503 (Th-P15:51), 509 (Th-P15:76) (Th-P15:227, Th-P15:229), 544 (Th-P15:231) Svenungsson, E., 299 (Tu-P10:518) Takase, H., 394 (We-P11:219), 511 (Th-P15:85), Tang, C.S., 494 (Th-P15:12) Svindland, A., 532 (Th-P15:180) 513 (Th-P15:93) Tang, T., 267 (Tu-P9:378) Svinolupova, S.I., 189 (Tu-P7:23) Takata, H., 210 (Tu-P7:115), 254 (Tu-P8:314), Tang, X.Y., 521 (Th-P15:129) Sviridov, D., 162 (Tu-W21:2), 539 (Th-P15:208), 354 (We-P11:37) Tang, Y.L., 190 (Tu-P7:25), 251 (Tu-P8:301), 494 542 (Th-P15:222), 544 (Th-P15:233) Takata, K., 367 (We-P11:100) (Th-P15:10) Swedenborg, J., 248 (Tu-P7:289), 406 Takata, M., 255 (Tu-P8:321) Tanganelli, P., 248 (Tu-P7:290) (We-P11:272) Takayasu, S., 542 (Th-P15:225) Tani, M., 234 (Tu-P7:226), 241 (Tu-P7:257), 433 Syed, F., 106 (Mo-P4:272) Takechi, N., 377 (We-P11:140), 385 (We-P11:178) (We-P14:394), 434 (We-P14:395, Symeonides, P., 67 (Mo-P1:99), 104 (Mo-P4:266) Takeda, M., 575 (Th-P16:373) We-P14:396), 435 (We-P14:402), 436 Symonides, B., 276 (Tu-P10:416) Takenaka, H., 503 (Th-P15:51), 509 (Th-P15:76) (We-P14:407), 509 (Th-P15:78) Syrigos, D., 58 (Mo-P1:55) Takenaka, M., 377 (We-P11:140), 385 Tanigawa, H., 149 (Tu-PL2:2), 293 (Tu-P10:492), Syvänne, M., 576 (Th-P16:378) (We-P11:178) 571 (Th-P16:354) Syväranta, S., 110 (Mo-P4:292), 242 (Tu-P7:264) Takeuchi, A., 435 (We-P14:402) 73 Szabo, L., 127 (Mo-P5:371) Takeuchi, H., 294 (Tu-P10:499) Taniguchi, H., (Mo-P1:125) 574 Szapary, L., 82 (Mo-P1:165) Takeuchi, T., 519 (Th-P15:120) Taniguchi, K., (Th-P16:366) 559 Szapary, P., 496 (Th-P15:20) Takeuchi, Y., 413 (We-P12:304) Tanimoto, K., (Th-P16:301) 225 238 Szapary, P.O., 564 (Th-P16:322) Takeya, M., 409 (We-P12:288) Tanimura, K., (Tu-P7:185), (Tu-P7:244) 243 Szarek, M., 37 (Mo-W14:4), 179 (Tu-W29:7), 581 Taki, H., 280 (Tu-P10:436), 518 (Th-P15:114, Tannock, L.R., (Tu-P7:266) 482 (Th-P16:401) Th-P15:116) Tansey, T., (Th-W57:5) 266 268 Szczeklik, A., 391 (We-P11:204), 560 Taki, M., 509 (Th-P15:76) Tanzilli, G., (Tu-P9:374), (Tu-P9:380) 380 (Th-P16:302) Talaei, M., 120 (Mo-P5:340) Taraborrelli, M., (We-P11:156) 96 Székács, B., 408 (We-P12:283) Talbot, C., 587 (Th-P17:426) Tararak, E.M., (Mo-P3:226) 108 Szekeres, M., 408 (We-P12:283) Tall, A.R., 166 (Tu-W23:1) Tarasov, E.V., (Mo-P4:281) 215 Szentagotai, L., 155 (Tu-W17:6) Talmud, P., 24 (Mo-W7:6) Tarcin, O., (Tu-P7:136) 12 578 Szkolka, T., 108 (Mo-P4:283) Talmud, P.H., 306 (We-W30:6) Tardif, J.-C., (Mo-W1:3), (Th-P16:384) 551 Szlanka, B., 127 (Mo-P5:371) Talmud, P.J., 20 (Mo-W5:4), 30 (Mo-W11:1), 138 Tardif, J.C., (Th-P16:264) 75 411 Szollár, L., 429 (We-P13:375) (Mo-P6:420), 301 (We-PL3:3), 335 Targher, G., (Mo-P1:133), (We-P12:293) Szopa, M., 416 (We-P13:319) (We-W45:6) Tarlet, G., 220 (Tu-P7:161) Szotek, E.S., 241 (Tu-P7:258) Tam, S.P., 495 (Th-P15:13), 544 (Th-P15:232, Tarnow, L., 159 (Tu-W19:4) Szuba, A., 104 (Mo-P4:265), 220 (Tu-P7:160), Th-P15:236), 566 (Th-P16:330) Tarquinio, M., 454 (We-P14:486) 270 (Tu-P10:392), 281 (Tu-P10:438) Tamaki, T., 235 (Tu-P7:231) Tartan, Z., 528 (Th-P15:160) Szucs, T.D., 178 (Tu-W29:3) Tamakoshi, K., 367 (We-P11:97) Tartaro, A., 380 (We-P11:156) Szuesz, G., 413 (We-P12:306) Tamarat, R., 190 (Tu-P7:26), 220 (Tu-P7:161) Tarugi, P., 19 (Mo-W5:3) Tamasawa, N., 506 (Th-P15:61), 542 Tasci, I., 206 (Tu-P7:96), 395 (We-P11:226), 417 T, Z.Y., 393 (We-P11:217) (Th-P15:225), 543 (Th-P15:226) (We-P13:323)

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

260 Tashiro, J., 520 (Th-P15:127) Teupser, D., 194 (Tu-P7:46), 200 (Tu-P7:71), 226 Tobe, K., 164 (Tu-W22:1, Tu-W22:3), 196 Tashiro, K., 233 (Tu-P7:223) (Tu-P7:189), 316 (We-W35:5), 464 (Tu-P7:53) Tasic, D., 75 (Mo-P1:131, Mo-P1:132) (Th-W48:8) Toborek, M., 444 (We-P14:443) Tasic, N., 75 (Mo-P1:131, Mo-P1:132) Thaminy, A., 443 (We-P14:436), 449 Tocci, E., 426 (We-P13:362) Taskinen, M.-R., 130 (Mo-P6:383), 500 (We-P14:466), 589 (Th-P17:433) Tochino, Y., 510 (Th-P15:82) A (Th-P15:37) Thaunat, O., 195 (Tu-P7:50) Todiere, G., 333 (We-W44:3) Taskinen, M.R., 333 (We-W44:5), 359 Thaw, K.T., 24 (Mo-W7:5) Todorov, I., 531 (Th-P15:174) (We-P11:62), 397 (We-P11:234) Theilmeier, G., 535 (Th-P15:192) Todorova, B., 140 (Mo-P6:428), 502 (Th-P15:43), U Tassopoulos, D., 56 (Mo-P1:49) Thelen, K.M., 582 (Th-P16:403) 531 (Th-P15:174) Tatsukawa, M., 574 (Th-P16:369) Thelle, D., 234 (Tu-P7:225), 421 (We-P13:339) Todorova, B.B., 70 (Mo-P1:108), 547 T Tavares, E.R., 466 (Th-W49:7) Theodorakis, P., 265 (Tu-P9:370) (Th-P15:246) Tavassoli, A., 46 (Mo-P1:1), 53 (Mo-P1:38) Theodoridis, D., 353 (We-P11:36) Todorovic, L., 393 (We-P11:214) H Tavridou, A., 127 (Mo-P5:370), 557 Theodosiou, E., 128 (Mo-P5:377) Tödter, K., 520 (Th-P15:125) (Th-P16:292), 558 (Th-P16:293) The Procardis Consortium, , 145 (Mo-P6:449) Todua, F., 97 (Mo-P4:234) O Taylor, A., 129 (Mo-P6:381) Thiery, J., 71 (Mo-P1:115), 194 (Tu-P7:46), 200 Todua, I., 267 (Tu-P9:377) 25 413 Taylor, D., (Mo-W8:6) (Tu-P7:71), 226 (Tu-P7:189), 316 Toelken, M., (We-P12:303) 121 278 R Taylor, D.C.A., (Mo-P5:344) (We-W35:5), 464 (Th-W48:8) Toffoli, B., (Tu-P10:427) 330 358 382 531 Taylor, G.J., (We-W42:6), (We-P11:55) Tholens, A.P., 518 (Th-P15:117) Toft, E., (We-P11:163), (Th-P15:175), 167 584 Taylor, J., (Tu-W23:6) Thom, S.A.M.C.G., 104 (Mo-P4:262) (Th-P16:414) 224 280 Taylor, P.R., (Tu-P7:180) Thomas, B., 514 (Th-P15:97) Togashi, R., (Tu-P10:435) 134 120 Taylor, W., (Mo-P6:401) Thomas, F., 482 (Th-W57:5) Toghianifar, N., (Mo-P5:340) I 443 33 327 Tchernof, A., (We-P14:438) Thomas, G.N., 379 (We-P11:151) Toh, B.H., (Mo-W12:3), (We-W41:4) 461 587 Tedeschi-Reiner, E., (Th-W47:2) Thomas, M., 145 (Mo-P6:451) Tohda, H., (Th-P17:424) 278 149 N Tedesco, F., (Tu-P10:427) Thomas, M.C., 556 (Th-P16:287) Tohyama, J., (Tu-PL2:2) 488 507 Tedesco, V., (Th-W60:6) Thompson, C., 381 (We-P11:162) Tokgözoglu, L., (Th-P15:65) 517 264 269 D Tedgui, A., (Th-P15:110) Thompson, D., 121 (Mo-P5:344) Tokgozoglu, L., (Tu-P9:365), 23 502 525 524 Teerlink, T., (Mo-W7:4), (Th-P15:44), Thompson, J.C., 243 (Tu-P7:266) (Tu-P9:385), (Th-P15:143) (Th-P15:145) Tokimitsu, I., 511 (Th-P15:85) Thompson, P.D., 113 (Mo-P5:303) E Teferici, D., 64 (Mo-P1:85) Toledo-Leiva, P., 128 (Mo-P6:378) Thompson, S., 24 (Mo-W7:6) Tegnér, J., 200 (Tu-P7:72), 357 (We-P11:50) Tolwinska, J., 377 (We-P11:141) Thompson, S.R., 312 (We-W33:5) X Teivainen-Lædre, P.A., 532 (Th-P15:180) Tomás, M., 384 (We-P11:172) Thorsson, B., 468 (Th-W50:7) Tejedor, D., 130 (Mo-P6:385) Tomas, M., 383 (We-P11:171) Thuillez, C., 219 (Tu-P7:155), 261 (Tu-P9:351) Tejerina, T., 249 (Tu-P8:292), 371 (We-P11:118) Tomassetti, D., 422 (We-P13:343) Thum, T., 353 (We-P11:32), 471 (Th-W52:5) Telford, D.E., 482 (Th-W57:6) Tomic, D., 377 (We-P11:142) Thuren, T., 550 (Th-P16:259) Temali, I., 272 (Tu-P10:399), 274 (Tu-P10:407, Tomilina, N., 78 (Mo-P1:145) Tian, X., 588 (Th-P17:429, Th-P17:430, Tu-P10:408), 283 (Tu-P10:448) Tomita, S., 235 (Tu-P7:231) Th-P17:432) Tembl, J., 397 (We-P11:235) Tomita, T., 436 (We-P14:404) Tian, Y.F., 529 (Th-P15:167) Temiz, A., 284 (Tu-P10:455), 289 (Tu-P10:473) Tomkin, G., 39 (Mo-W15:6) Tibolla, G., 193 (Tu-P7:39), 211 (Tu-P7:120) Tenedini, E., 257 (Tu-P8:328) Tomlinson, B., 147 (Mo-P6:459), 379 Ticha, A., 359 (We-P11:60) Teng, Y., 95 (Mo-P3:222) (We-P11:151) Tietz, A.B., 141 (Mo-P6:432) Tengvall, P., 284 (Tu-P10:452) Tomoike, H., 16 (Mo-W3:7), 505 (Th-P15:58) 255 392 Tentes, I.K., 87 (Mo-P2:184), 533 (Th-P15:184) Tigyi, G., (Tu-P8:320), (We-P11:210), Tonchev, A.B., 188 (Tu-P7:16) 487 Tentolouris, N., 210 (Tu-P7:118) (Th-W60:2) Tonelli, C., 107 (Mo-P4:276) 85 Tepsic, J., 449 (We-P14:464) Tiirola, T., (Mo-P2:176) Tong, Q.G., 81 (Mo-P1:160) 354 585 Terada, E., 198 (Tu-P7:61), 220 (Tu-P7:162), 284 Tikhaze, K., (We-P11:39), (Th-P16:416) Tong, Z.Y., 96 (Mo-P3:230) 410 (Tu-P10:454) Tilg, H., (We-P12:292) Tonini, G.C., 521 (Th-P15:131), 586 (Th-P17:423) 318 Teramoto, T., 123 (Mo-P5:351), 187 (Tu-P7:13), Till, U., (We-W36:7) Tonkin, A., 330 (We-W42:7) 80 362 (We-P11:76), 503 (Th-P15:51), 509 Tillin, T., (Mo-P1:155, Mo-P1:156) Tonolo, G., 139 (Mo-P6:422) 387 (Th-P15:76), 510 (Th-P15:83), 587 Timasheva, Y.R., (We-P11:190) Tonstad, S., 126 (Mo-P5:364), 478 (Th-W55:5) 137 (Th-P17:424) Tinahones, F.J., (Mo-P6:417) Toouli, J., 381 (We-P11:162) 240 Terasaki, M., 409 (We-P12:288) Tinelli, C., (Tu-P7:254, Tu-P7:255) Topic, A., 139 (Mo-P6:426), 351 (We-P11:26), 242 Terasaki, Y., 409 (We-P12:288) Ting, C.T., (Tu-P7:260) 502 (Th-P15:46), 503 (Th-P15:47) Ter Avest, E., 260 (Tu-P9:345), 545 (Th-P15:240) Tiran, B., 72 (Mo-P1:118, Mo-P1:119) Topolcan, O., 363 (We-P11:79) Terayama, K., 564 (Th-P16:323) Tiravanti, E., 454 (We-P14:486) Toprak, A., 215 (Tu-P7:136) Tercé, F., 31 (Mo-W11:6), 153 (Tu-W16:7) Tircol, M., 355 (We-P11:41) Toptsi, D., 128 (Mo-P5:377) Terencio, J., 498 (Th-P15:28) Tisheva, S., 134 (Mo-P6:402) Tormene, D., 74 (Mo-P1:127), 502 (Th-P15:45) Tereshina, H.V., 189 (Tu-P7:22) Tissent, A., 77 (Mo-P1:143) Tormos, M.C., 389 (We-P11:197) Terkeltaub, R., 144 (Mo-P6:447) Titov, V.N., 505 (Th-P15:59), 557 (Th-P16:291) Törnberg, I., 237 (Tu-P7:240) Terrazzani, G., 47 (Mo-P1:8), 66 (Mo-P1:91), 121 Tjønna, A., 215 (Tu-P7:139) Torng, P.L., 434 (We-P14:399) (Mo-P5:345) Tjonna, A.E., 428 (We-P13:369) Tornqvist, M., 223 (Tu-P7:173) Tershakovec, A., 555 (Th-P16:280, Th-P16:281, Tjønna, A.E., 379 (We-P11:152) Tornvall, P., 280 (Tu-P10:434) Th-P16:282, Th-P16:283) Tkac, I., 560 (Th-P16:305) Torra, M., 69 (Mo-P1:107) Terzieva, D., 262 (Tu-P9:355) Tkachuk, N., 574 (Th-P16:365) Torres-Tamayo, M., 537 (Th-P15:203) Terzieva, L., 354 (We-P11:38) Tkachuk, S., 568 (Th-P16:340) Torri, A., 168 (Tu-W24:3), 257 (Tu-P8:330) Terzis, G., 109 (Mo-P4:285) Tkachuk, V.A., 89 (Mo-P2:195) Torrisi, M.R., 330 (We-W43:2) Terzuoli, L., 273 (Tu-P10:404), 589 (Th-P17:435) To, F., 521 (Th-P15:128) Tortorella, V., 372 (We-P11:119) Tesauro, M., 221 (Tu-P7:166), 298 (Tu-P10:514), To, K.Y.Y., 327 (We-W41:4) Toseska Trajkovska, K.N., 70 (Mo-P1:108) 425 (We-P13:355), 450 (We-P14:468) Toba, K., 417 (We-P13:322) Tosheska, K., 502 (Th-P15:43), 531 (Th-P15:174)

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

261 Tosheskatrajkovska, K., 140 (Mo-P6:428) Tsai, L.M., 99 (Mo-P4:240), 397 (We-P11:231) Tusie, T., 138 (Mo-P6:418), 397 (We-P11:234) Tosi, I., 128 (Mo-P6:378) Tsai, W.C., 99 (Mo-P4:240), 383 (We-P11:170), Tutunaru, D., 446 (We-P14:449) Toth, K., 82 (Mo-P1:165), 356 (We-P11:47), 398 397 (We-P11:231) Tuzcu, E.M., 457 (Th-PL4:2), 468 (Th-W51:1) (We-P11:236) Tsai, Y.-C., 219 (Tu-P7:154) Tverdal, A., 467 (Th-W50:4) A Tous, M., 202 (Tu-P7:81) Tsakiris, A.K., 58 (Mo-P1:56) Tvrzická, E., 144 (Mo-P6:448), 365 (We-P11:90), Toutouzas, P.K., 52 (Mo-P1:30) Tsalenko, A., 230 (Tu-P7:206) 496 (Th-P15:18) Towney, A.K., 21 (Mo-W6:3) Tsao, C.R., 242 (Tu-P7:260) Twisk, J., 19 (Mo-W5:2), 95 (Mo-P3:223) U Toyoshima, H., 367 (We-P11:97) Tsao, P., 230 (Tu-P7:206) Tyaneva, J., 382 (We-P11:164) Toyota, Y., 367 (We-P11:100) Tsao, P.S., 5 (Su-S3:1) TybjæRg-Hansen, A., 35 (Mo-W13:6), 37 T Tozawa, R., 339 (We-S13:2) Tsapas, A., 295 (Tu-P10:500) (Mo-W14:6) Tracchi, I., 508 (Th-P15:73) Tsatralis, T., 232 (Tu-P7:218) Tybjaerg-Hansen, A., 145 (Mo-P6:450) H Trahtemberg, U., 233 (Tu-P7:222) Tschöpe, C., 153 (Tu-W16:6) Tybjærg-Hansen, A., 74 (Mo-P1:128) Trajkovska, S., 373 (We-P11:126) Tselepis, A., 368 (We-P11:104), 369 Tylavsky, F., 381 (We-P11:158) O Tramontano, D., 255 (Tu-P8:322) (We-P11:105), 431 (We-P14:382), 499 Tyllis, T., 145 (Mo-P6:452) Tran, P.K., 489 (Th-W61:4) (Th-P15:32, Th-P15:33), 501 (Th-P15:42), Tynngård, N., 413 (We-P12:305) Tran Lundmark, K., 489 (Th-W61:4) 503 (Th-P15:49), 561 (Th-P16:308) Tzeis, S., 52 (Mo-P1:30) R Trauner, M., 583 (Th-P16:409) Tselepis, A.D., 173 (Tu-W26:4), 322 (We-W38:6), Tziakas, D.N., 87 (Mo-P2:184), 533 (Th-P15:184) Trautwein, E.A., 337 (We-S12:2), 476 (Th-W55:1) 523 (Th-P15:140), 553 (Th-P16:271) Tzimas, T., 298 (Tu-P10:517) Travers, C., 77 (Mo-P1:140), 317 (We-W36:3) Tseng, G.H., 199 (Tu-P7:67) Tziomalos, K., 63 (Mo-P1:78), 109 (Mo-P4:286) Traversa, M., 329 (We-W42:4) Tsiandoulas, A., 89 (Mo-P2:193) Tzotzas, T., 431 (We-P14:382), 568 (Th-P16:341) 590 501 I Treﬁl, L., (Th-P17:442) Tsianos, E., (Th-P15:42) Tzovaras, A., 58 (Mo-P1:55) 316 127 Tregouet, D., (We-W35:6) Tsigalou, C., (Mo-P5:370) Tzovaras, V., 499 (Th-P15:32) 476 471 N Tréguier, M., (Th-W54:6) Tsikas, D., (Th-W52:5) Tzvetkova, T., 262 (Tu-P9:355) Trein, A., 399 (We-P11:242) Tsimihodimos, V., 369 (We-P11:105), 503 Tremblay, A., 165 (Tu-W22:5), 421 (We-P13:340) (Th-P15:49) Ubaldi, S., 231 (Tu-P7:211), 282 (Tu-P10:445) D Tremblay, G., 131 (Mo-P6:391), 175 (Tu-W27:6), Tsiple, I., 353 (We-P11:34) Uboldi, P., 193 (Tu-P7:39), 528 (Th-P15:162) 475 (Th-W54:4), 484 (Th-W58:6) Tsironis, L.D., 523 (Th-P15:140) Ucchino, S., 246 (Tu-P7:280), 247 (Tu-P7:282), E Tremoli, E., 42 (Mo-S6:2), 88 (Mo-P2:191), 92 Tsiskarishvili, D., 389 (We-P11:198), 583 248 (Tu-P7:287) (Mo-P2:209, Mo-P2:210), 101 (Mo-P4:249), (Th-P16:410) Uchida, Y., 511 (Th-P15:86) 116 (Mo-P5:318), 204 (Tu-P7:87), 212 Tsizh, O., 211 (Tu-P7:122) X Uchitel, I.A., 283 (Tu-P10:447), 394 (Tu-P7:123, Tu-P7:127), 241 (Tu-P7:259), 258 Tsouli, S., 499 (Th-P15:32), 501 (Th-P15:42) (Tu-P9:333), 259 (Tu-P9:337, Tu-P9:340), 260 Tsuboi, N., 168 (Tu-W24:4) (We-P11:221) 539 (Tu-P9:343), 285 (Tu-P10:457), 294 Tsuboi, Y., 562 (Th-P16:311) Ueda, K., (Th-P15:211) 332 516 (Tu-P10:498), 297 (Tu-P10:510), 298 Tsuchida, M., 255 (Tu-P8:321) Ueda, Y., (We-W43:7), (Th-P15:105), 575 (Tu-P10:513), 308 (We-W31:6), 309 Tsuji, E., 113 (Mo-P5:307), 434 (We-P14:398) (Th-P16:372) 425 (We-W32:2), 315 (We-W35:2), 324 Tsuji, K., 434 (We-P14:398) Uehara, G., (We-P13:359) 13 255 293 (We-W39:6), 326 (We-W40:6), 391 Tsujii, K., 575 (Th-P16:372) Uehara, Y., (Mo-W1:7), (Tu-P8:319), 396 536 (We-P11:206), 398 (We-P11:238), 402 Tsukahara, R., 487 (Th-W60:2) (Tu-P10:492), (We-P11:229), 559 561 (We-P11:254), 463 (Th-W48:6), 474 Tsukahara, T., 487 (Th-W60:2) (Th-P15:197), (Th-P16:298), 562 (Th-W53:7), 591 (Th-P17:445) Tsukamoto, K., 28 (Mo-W9:6) (Th-P16:310), (Th-P16:311, Th-P16:313), 570 Tretjakovs, P., 263 (Tu-P9:358) Tsunemi, A., 33 (Mo-W12:6), 96 (Mo-P3:225), (Th-P16:350) 283 Trevisan, D., 263 (Tu-P9:359) 185 (Tu-P7:2), 187 (Tu-P7:12) Uenishi, H., (Tu-P10:450) 33 96 185 Trevisan, M., 412 (We-P12:301) Tsushima, M., 281 (Tu-P10:439), 507 Ueno, T., (Mo-W12:6), (Mo-P3:225), 187 Triantafyllou, K.A., 67 (Mo-P1:99), 104 (Th-P15:67), 564 (Th-P16:320) (Tu-P7:2), (Tu-P7:12) 260 (Mo-P4:266) Tsusima, M., 420 (We-P13:335) Ueno, Y., (Tu-P9:344) 48 52 55 Triantos, A., 431 (We-P14:382) Tsutsumi, K., 322 (We-W38:7), 565 (Th-P16:327) Ueshima, H., (Mo-P1:14), (Mo-P1:31), 56 Triassi, M., 54 (Mo-P1:40) Tu, Y.L., 222 (Tu-P7:167), 393 (We-P11:217), 529 (Mo-P1:45), (Mo-P1:47, Mo-P1:48, 58 59 64 Trifunovic-Zamaklar, D., 127 (Mo-P5:373), 358 (Th-P15:167) Mo-P1:50), (Mo-P1:58), (Mo-P1:63), (We-P11:57) Tudor, C., 346 (We-P11:1), 427 (We-P13:364) (Mo-P1:83), 76 (Mo-P1:137), 260 Trigatti, B.L., 488 (Th-W60:6) Tugeeva, E., 356 (We-P11:48) (Tu-P9:344), 265 (Tu-P9:368), 348 Trigui, A., 438 (We-P14:415) Tukhtamuradova, G.U., 67 (Mo-P1:98) (We-P11:12), 430 (We-P14:381), 437 Trindade, K., 16 (Mo-W3:5), 496 (Th-P15:20) Tulyakova, G.H., 396 (We-P11:228) (We-P14:410) Triscornia, S., 350 (We-P11:23), 386 Tumer, N., 185 (Tu-P7:1) Uhrin, P., 488 (Th-W60:8) (We-P11:184), 387 (We-P11:186), 528 Tummala, S., 543 (Th-P15:230) Uitto, V.-J., 171 (Tu-W25:6) (Th-P15:159) Tung, S.P., 110 (Mo-P4:290) Ulfhammer, E., 87 (Mo-P2:187), 159 (Tu-W19:3) Trivedi, R., 267 (Tu-P9:378) Tuomainen, A.M., 463 (Th-W48:4) Ulus, T., 74 (Mo-P1:130), 284 (Tu-P10:455), 289 Tron, F., 219 (Tu-P7:155) Tuomainen, T.-P., 500 (Th-P15:37) (Tu-P10:473) Trosien, J.A., 249 (Tu-P8:291) Tuomilehto, J., 154 (Tu-W17:1), 180 (Tu-S8:2), Ulusoylar, S., 569 (Th-P16:345) Trovati, M., 298 (Tu-P10:516), 329 (We-W42:4) 471 (Th-W52:3) Ulzurrun, E., 132 (Mo-P6:395), 347 (We-P11:5), Troyer, D., 494 (Th-P15:9) Tupin, E., 327 (We-W41:5), 406 (We-P11:272) 375 (We-P11:132) Trpkovski, Z., 432 (We-P14:387) Turczyn, B., 137 (Mo-P6:415) Umaerus, M., 15 (Mo-W3:2) Trsinski, D., 357 (We-P11:53) Turek, S., 205 (Tu-P7:91) Umeda, M., 413 (We-P12:304) Trusz-Gluza, M., 73 (Mo-P1:124), 143 Turin, T.C., 56 (Mo-P1:50) Umeda, Y., 186 (Tu-P7:5) (Mo-P6:444) Turkmen, S., 55 (Mo-P1:43), 371 (We-P11:114) Umemura, S., 575 (Th-P16:370) Tryggvason, K., 489 (Th-W61:4) Turner, N., 106 (Mo-P4:272) Umezawa, K., 187 (Tu-P7:11) Trzos, M., 417 (We-P13:324) Turriziani, M., 450 (We-P14:468) Unal, S., 528 (Th-P15:160) Tsagou, V., 104 (Mo-P4:266) Turto, H., 100 (Mo-P4:245), 110 (Mo-P4:292), Ungureanu, D., 91 (Mo-P2:205) Tsai, C.E., 437 (We-P14:409) 242 (Tu-P7:264) Unverdorben, S., 565 (Th-P16:328)

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

262 Ural, A.U., 206 (Tu-P7:96), 395 (We-P11:226) (Mo-P4:236), 152 (Tu-W16:2), 230 Varcoe, R.L., 96 (Mo-P3:229) Urata, H., 255 (Tu-P8:319), 562 (Th-P16:311) (Tu-P7:208), 247 (Tu-P7:284), 319 Vareka, T., 552 (Th-P16:269) Urban, A., 508 (Th-P15:71), 540 (Th-P15:213) (We-W37:5), 320 (We-W37:6), 487 Varela, C., 125 (Mo-P5:361) Urban, M., 211 (Tu-P7:121), 271 (Tu-P10:393), (Th-W60:4) Varga, E., 292 (Tu-P10:489), 296 (Tu-P10:504) 377 (We-P11:141) van den Heuvel, D., 26 (Mo-W9:1) Varì, R., 186 (Tu-P7:7) A Urdinez, P., 91 (Mo-P2:203), 231 (Tu-P7:212) Van Den Hoogen, C.M., 551 (Th-P16:263) Varo, N., 206 (Tu-P7:97), 415 (We-P13:315), 480 Urseanu, S., 365 (We-P11:87) Van Der Bom, J.G., 291 (Tu-P10:482) (Th-W56:5) Urzua, A., 201 (Tu-P7:73) Van Der Graaf, A., 585 (Th-P16:415) Varthaman, A., 278 (Tu-P10:426) U Uscatescu, V., 93 (Mo-P2:214) van der Graaf, Y., 103 (Mo-P4:261), 335 Vashirnia, M., 438 (We-P14:416) Ushakova, T., 368 (We-P11:102) (We-W45:4), 357 (We-P11:51), 421 Vasiliadis, I.K., 113 (Mo-P5:306) T Ushakova, T.I., 214 (Tu-P7:133), 262 (Tu-P9:356) (We-P13:338), 479 (Th-W56:3) Vasilje, L., 352 (We-P11:31) Usher, J.L., 134 (Mo-P6:401) Van Der Hoogt, C.C., 227 (Tu-P7:194), 489 Vasovic, O.D., 78 (Mo-P1:148) H Usher, S., 142 (Mo-P6:440) (Th-W61:5), 551 (Th-P16:263), 560 Vataman, E., 565 (Th-P16:326) Usmanov, V., 213 (Tu-P7:130) (Th-P16:306) Vatankhah, A., 296 (Tu-P10:506), 532 O Ustinov, S.N., 78 (Mo-P1:147), 81 (Mo-P1:158) Van Der Hoorn, J.W.A., 393 (We-P11:215), 489 (Th-P15:177) Ustrell, R., 69 (Mo-P1:107) (Th-W61:2) Vatrano, M., 206 (Tu-P7:100), 313 (We-W34:4) 291 R Usuda, M., 510 (Th-P15:80) Van Der Krabben, M.D., (Tu-P10:482) Vaudo, G., 102 (Mo-P4:257), 221 (Tu-P7:165), 279 225 Usui, S., (Tu-P10:431) Van Der Made, I., (Tu-P7:181) 269 (Tu-P9:386), 277 (Tu-P10:423), 469 187 239 241 390 Uto, H., (Tu-P7:11), (Tu-P7:247), Van Der Meijden, P., (We-P11:202) (Th-W51:6) 430 495 (Tu-P7:257), (We-P14:377, We-P14:380), Van Der Oever, K., (Th-P15:15) Vaughan, A., 227 (Tu-P7:191) 433 434 26 (We-P14:394), (We-P14:395, van der Poel, S., (Mo-W9:1) Vaulin, N.A., 99 (Mo-P4:243) I 435 436 533 We-P14:396), (We-P14:402), Van Der Pol, T., (Th-P15:183) Vavil Caragie, F., 565 (Th-P16:326) 509 510 79 290 (We-P14:407), (Th-P15:78), Van Der Schouw, Y.T., (Mo-P1:153), Vavlukis, M., 101 (Mo-P4:253) N (Th-P15:80) (Tu-P10:480) Vázquez, C., 129 (Mo-P6:382) 239 37 70 Utsunomiya, K., (Tu-P7:247) Van Der Steeg, W.A., (Mo-W14:7), Vazquez, E., 383 (We-P11:171) 528 D Uyarel, H., (Th-P15:160) (Mo-P1:109) Vecchio, F., 426 (We-P13:362) 590 495 Uyy, E., (Th-P17:438) Van Der Velde, A., (Th-P15:15) Vecera, R., 560 (Th-P16:304) 201 van der Vleuten, G.M., 306 (We-W30:6) Uzzo, M., (Tu-P7:76) Vecka, M., 144 (Mo-P6:448), 292 (Tu-P10:487), E Van Der Wall, E.E., 98 (Mo-P4:236), 487 365 (We-P11:90), 496 (Th-P15:18), 552 Vaag, A., 159 (Tu-W19:4) (Th-W60:4) (Th-P16:269) X Vacas, M., 67 (Mo-P1:97), 84 (Mo-P2:174) Van Der Westhuyzen, D., 514 (Th-P15:97) Vegeto, E., 193 (Tu-P7:39) Vaccarino, V., 82 (Mo-P1:167), 324 (We-W39:5), Van Der Westhuyzen, D.R., 28 (Mo-W9:7), 537 Veglia, F., 116 (Mo-P5:318), 204 (Tu-P7:87), 241 401 (We-P11:252) (Th-P15:200) (Tu-P7:259), 294 (Tu-P10:498), 297 Vaccaro, O., 31 (Mo-W11:5), 51 (Mo-P1:25) Van Der Zwan, L.P., 502 (Th-P15:44), 525 (Tu-P10:510), 298 (Tu-P10:513), 309 Vaes, M., 525 (Th-P15:146) (Th-P15:145) (We-W32:2), 402 (We-P11:254) Vaessen, S.F.C., 95 (Mo-P3:223), 335 (We-W45:6) Van Deursen, D., 16 (Mo-W3:4) Vehmaan-Kreula, P., 157 (Tu-W18:5) Vagena, M., 272 (Tu-P10:400) Van Dissel, J.T., 227 (Tu-P7:194) Veierod, M.B., 467 (Th-W50:4) Vailaya, A., 230 (Tu-P7:206) Van Duijn, C.M., 35 (Mo-W13:5) Veiga, L., 84 (Mo-P2:172) Vakalis, K., 298 (Tu-P10:517) van Duijn, C.M., 306 (We-W30:6) Vejnovic, M., 422 (We-P13:345) Vakhtangadze, T., 97 (Mo-P4:234), 227 Van Duynhoven, J., 453 (We-P14:480) Vekic, J., 351 (We-P11:26) (Tu-P7:193) Van Duyvenvoorde, W., 32 (Mo-W11:7) 309 Valcavi, R., 107 (Mo-P4:276), 259 (Tu-P9:341) Van Eck, M., 90 (Mo-P2:198), 152 (Tu-W16:2), Vela, D., (We-W32:4) 381 Valderrama, J., 133 (Mo-P6:398) 319 (We-W37:5), 320 (We-W37:6), 542 Velasquez-Mieyer, P.A., (We-P11:158) 95 Valdes Belmar, J.L., 61 (Mo-P1:72) (Th-P15:223) Veldman, R.J., (Mo-P3:223) 110 111 Valdivielso, P., 132 (Mo-P6:395), 347 (We-P11:5) Van Es, T., 33 (Mo-W12:4) Velimirovici, D., (Mo-P4:291), 365 445 Valduga, C.J., 466 (Th-W49:7) Van Gaal, L., 329 (We-W42:3) (Mo-P4:294), (We-P11:87), Valeille, K., 433 (We-P14:393) Van Gilst, W.H., 16 (Mo-W3:6) (We-P14:445) 574 Valente, E., 399 (We-P11:243, We-P11:244) Vanhaeverbeek, M., 119 (Mo-P5:336), 524 Velissaridou, A., (Th-P16:368) 356 Valenti, C., 363 (We-P11:80) (Th-P15:141), 525 (Th-P15:146) Veltri, E., (We-P11:49) 383 418 Valenti, G., 259 (Tu-P9:341) Van Heemst, D., 37 (Mo-W14:5) Velykykh, N., (We-P11:169), Valenti, V., 133 (Mo-P6:400) Van Heyningen, C., 122 (Mo-P5:347) (We-P13:327) 18 Valentine, W., 121 (Mo-P5:346), 178 (Tu-W29:4), Van Horn, L., 176 (Tu-W28:3) Vemuganti, R., (Mo-W4:5) 487 (Th-W60:2) Van Leeuwen, M., 16 (Mo-W3:4) Venco, A., 549 (Th-P16:257) Valetti, C., 536 (Th-P15:198) Van Leuven, S., 533 (Th-P15:183) Venegas, P., 201 (Tu-P7:73) Valles, J., 397 (We-P11:235) Van Leuven, S.I., 124 (Mo-P5:357), 153 Veniant, M., 566 (Th-P16:329) Vallvé, J.C., 414 (We-P12:310), 443 (We-P14:439) (Tu-W16:5) Venn, A., 483 (Th-W58:3) Valtueña, S., 224 (Tu-P7:178) Van Linthout, S., 153 (Tu-W16:6) Venturi, C., 376 (We-P11:139) Valverde, M.A., 383 (We-P11:171), 384 Van Mechelen, R., 235 (Tu-P7:229) Verbovenko, J., 281 (Tu-P10:442) (We-P11:172) van Meer, G., 26 (Mo-W9:1) Verbovetski, I., 233 (Tu-P7:222) Van’T Hooft, F., 492 (Th-P15:2) Vanmunsteren, J.C., 205 (Tu-P7:94) Vercesi, A.E., 505 (Th-P15:57), 508 (Th-P15:71), Van’T Hooft, F.M., 505 (Th-P15:56) Van Oostrom, A., 31 (Mo-W11:3) 526 (Th-P15:150) Van ’T Veer, C., 533 (Th-P15:183) Van Oostrom, O., 569 (Th-P16:342) Verchere, B., 25 (Mo-W8:4) van ’t Veer, C., 309 (We-W32:3) Van Tol, A., 38 (Mo-W15:3), 506 (Th-P15:62), Vered, S., 52 (Mo-P1:33) Van Ahlen, H., 404 (We-P11:267) 538 (Th-P15:207) Vergès, B., 311 (We-W33:4) Van Antwerpen, P., 524 (Th-P15:141), 525 Vanvliet, A., 549 (Th-P16:258) Verges, B., 427 (We-P13:365), 535 (Th-P15:190) (Th-P15:146) Van Vlijmen, B.J.M., 331 (We-W43:6) Verhaar, M.C., 479 (Th-W56:3), 569 (Th-P16:342) Van Berkel, T.J., 90 (Mo-P2:198) Vapaatalo, H., 431 (We-P14:383) Verhoeven, A., 16 (Mo-W3:4) Van Berkel, T.J.C., 33 (Mo-W12:4), 98 Várbíró, S., 408 (We-P12:283) Vermue, H.P.A., 525 (Th-P15:145)

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

263 Verna, R., 17 (Mo-W4:3) Viviani, B., 168 (Tu-W24:3) Vyankandondera, J., 401 (We-P11:250) Veronesi, M., 50 (Mo-P1:24) Vlachogiannis, E., 128 (Mo-P5:377), 277 Vyroubal, P., 562 (Th-P16:314) Verran, J., 246 (Tu-P7:281) (Tu-P10:424), 361 (We-P11:69) Vytasek, R., 243 (Tu-P7:265) Verrone, A.M., 411 (We-P12:294) Vladica, M., 69 (Mo-P1:106), 415 (We-P13:314) 77 317 258 262 Veysey, M., (Mo-P1:140), (We-W36:3) Vladimirova-Kitova, L., (Tu-P9:332), W, D.H., 393 (We-P11:217) A 350 Viaggi, S., (We-P11:21) (Tu-P9:355) W, Z., 393 (We-P11:217) 475 502 139 Vianello, D., (Th-W54:3), (Th-P15:45) Vlasakova, Z., (Mo-P6:423) Waddington, S.N., 197 (Tu-P7:59) U 34 96 96 Vicaretti, M., (Mo-W12:7), (Mo-P3:229) Vlasik, T.N., (Mo-P3:226, Mo-P3:227) Waeber, G., 363 (We-P11:81), 364 (We-P11:82) 210 463 Vichos, S., (Tu-P7:118) Vlodavsky, I., (Th-W48:2) Wågberg, M., 236 (Tu-P7:236) 62 79 78 81 T Vidal-Barraquer, F., (Mo-P1:74), Vo evo d a, M . I . , (Mo-P1:147), (Mo-P1:158) Wagenknecht, L.E., 14 (Mo-W2:6), 89 105 268 576 (Mo-P1:152), (Mo-P4:270), Vogel, M., (Th-P16:374) (Mo-P2:196) 567 H (Tu-P9:381) Vogt, A., (Th-P16:336) Wagner, E., 15 (Mo-W3:1) 320 218 Vidal Puig, A., (We-W37:7) Vogt, C., (Tu-P7:153) Wagner, J.A., 480 (Th-W56:7) 537 587 O Vidaure Garcés, V., (Th-P15:203) Vogt, S., (Th-P17:425) Wågsäter, D., 393 (We-P11:216) Videcnik, V., 75 (Mo-P1:134) Vohl, M.-C., 586 (Th-P17:420) Wahlroos, S., 381 (We-P11:162) Vidgen, E., 476 (Th-W55:1), 478 (Th-W55:7) Vohl, M.C., 131 (Mo-P6:391), 484 (Th-W58:6) Währborg, P., 421 (We-P13:339) R Vidjak, V., 282 (Tu-P10:446) Voidonikola, P., 251 (Tu-P8:303) Wait, R., 88 (Mo-P2:191), 591 (Th-P17:445) Viegas-Crespo, A.M., 84 (Mo-P2:172) Voinea, M., 355 (We-P11:41) Waitman, D., 115 (Mo-P5:314) Vieira, C., 63 (Mo-P1:79), 546 (Th-P15:243) Vo is ar d , R . , 30 (Mo-W10:7), 394 (We-P11:220) Wajngarten, M., 542 (Th-P15:224) Vieira, J.L., 500 (Th-P15:35), 556 (Th-P16:284), Voisin, P., 190 (Tu-P7:26) Wakabayashi, K., 33 (Mo-W12:6) 557 (Th-P16:289) Vo lf , P. , 140 (Mo-P6:427) I Wakasa, M., 283 (Tu-P10:450) Vieira, L.P., 66 (Mo-P1:94) Volfson, V., 484 (Th-W58:4) Wakayama, A., 56 (Mo-P1:50) Viejo, L.F., 105 (Mo-P4:268, Mo-P4:269) Völker, W., 144 (Mo-P6:447) N Wakikawa, T., 579 (Th-P16:392) Vigil Chacon, A.B., 253 (Tu-P8:313), 465 Volkmann, R., 163 (Tu-W21:6) Walczak, A., 142 (Mo-P6:436) (Th-W49:4) Volkova, N., 253 (Tu-P8:310), 460 (Th-W46:5) Waldner, I., 500 (Th-P15:36) D Vigna, G.B., 530 (Th-P15:171) Volkovova, K., 292 (Tu-P10:488), 446 Waldo, S., 515 (Th-P15:100) Viikari, J., 68 (Mo-P1:101), 279 (Tu-P10:430) (We-P14:452) Waldum, H., 202 (Tu-P7:77), 215 (Tu-P7:139) E Viikari, J.S.A., 313 (We-W34:3) Vollandt, R., 318 (We-W36:7) Walker, M.G., 106 (Mo-P4:272) Viikari, L., 279 (Tu-P10:430) Vollenweider, P., 363 (We-P11:81), 364 Walldius, G., 468 (Th-W50:6) Viiri, L., 18 (Mo-W4:4) (We-P11:82) X Wallerath, T., 194 (Tu-P7:43) Vik, H., 160 (Tu-W20:3) Vo lp ato , S . , 317 (We-W36:5), 530 (Th-P15:171), 413 Vikeli, D., 572 (Th-P16:358) 534 (Th-P15:188) Wallin, L., (We-P12:305) 90 Vikman, P., 382 (We-P11:167) Vo lp e, R . , 47 (Mo-P1:6), 439 (We-P14:419) Wallmark, K., (Mo-P2:202) 192 Vikstedt, R., 320 (We-W37:6), 540 (Th-P15:216) Von Bergmann, K., 562 (Th-P16:312) Walter, Z., (Tu-P7:34) 146 Vila, V., 571 (Th-P16:351) von Bergmann, K., 318 (We-W36:6) Walton, A.S., (Mo-P6:454) 200 Villaescusa Pedemonte, M., 61 (Mo-P1:72) von Birgelen, C., 42 (Mo-S6:3) Wan, Y.U., (Tu-P7:68) 163 264 Villagran, A., 201 (Tu-P7:73) Vo n B r em en , D . , 446 (We-P14:451) Wandt, B., (Tu-W21:6), (Tu-P9:366) 96 210 Villar, J., 130 (Mo-P6:386) Von Eckardstein, A., 27 (Mo-W9:4) Wang, G.X., (Mo-P3:230), (Tu-P7:117), 222 232 233 Villarreal, T., 138 (Mo-P6:418) von Eckardstein, A., 582 (Th-P16:403) (Tu-P7:167), (Tu-P7:217), 402 403 Villegas-Barreto, C., 381 (We-P11:158) Von Holt, K., 194 (Tu-P7:43) (Tu-P7:219), (We-P11:258), Viña, J., 226 (Tu-P7:187) Von Landenberg, P., 29 (Mo-W10:3) (We-P11:259, We-P11:260, We-P11:261, 529 Vinagre, C.G., 113 (Mo-P5:304, Mo-P5:305), 509 Von Mulhen, C.A., 278 (Tu-P10:425) We-P11:262), (Th-P15:167) 196 202 494 (Th-P15:75) Von Müller, L., 30 (Mo-W10:7) Wang, J., (Tu-P7:51), (Tu-P7:79), 516 536 Vincent, M., 495 (Th-P15:13) Voorbij, H.A.M., 291 (Tu-P10:482) (Th-P15:11), (Th-P15:107), 574 Vincent-Martin, M., 370 (We-P11:113) Voron’Ko, O.E., 146 (Mo-P6:455) (Th-P15:196), (Th-P16:367) 156 219 521 Vindis, C., 534 (Th-P15:187) Voshol, P., 318 (We-W37:1) Wang, L., (Tu-W18:1), (Tu-P7:154), Vini, M.P., 173 (Tu-W26:4) Voshol, P.J., 32 (Mo-W11:7), 320 (We-W37:7), (Th-P15:129) 110 Vinogradova, T.V., 57 (Mo-P1:53) 518 (Th-P15:117) Wang, L.M., (Mo-P4:290) Violi, F., 173 (Tu-W26:5), 298 (Tu-P10:514), 391 Votteas, V., 204 (Tu-P7:90), 210 (Tu-P7:118), 395 Wang, N., 166 (Tu-W23:1) (We-P11:206), 439 (We-P14:420), 525 (We-P11:225) Wang, S., 190 (Tu-P7:25), 223 (Tu-P7:175), 234 (Th-P15:147) Voyno-Yasenetskaya, T., 487 (Th-W60:1) (Tu-P7:224), 293 (Tu-P10:490), 464 Virsaladze, D.K., 416 (We-P13:317) Vrablik, M., 138 (Mo-P6:420), 140 (Mo-P6:430), (Th-W49:1), 494 (Th-P15:10), 539 Visev, K., 128 (Mo-P5:375) 371 (We-P11:117), 407 (We-P12:278) (Th-P15:209) Vishnyakova, T.G., 517 (Th-P15:109) Vranckx, R., 239 (Tu-P7:246) Wang, S.-C., 425 (We-P13:357) Visioli, F., 443 (We-P14:440), 472 (Th-W52:6, Vrentzos, G.E., 383 (We-P11:168), 414 Wang, W.Z., 565 (Th-P16:327) Th-W53:1) (We-P12:307), 423 (We-P13:350) Wang, X., 149 (Tu-PL2:2), 518 (Th-P15:117), 535 Visseren, F.L., 569 (Th-P16:342) Vrhovski-Hebrang, D., 282 (Tu-P10:446) (Th-P15:194), 540 (Th-P15:214) Visseren, F.L.J., 103 (Mo-P4:261), 335 Vrins, C., 495 (Th-P15:15) Wang, X.H., 515 (Th-P15:103) (We-W45:4), 357 (We-P11:51), 421 Vrints, C., 413 (We-P12:303) Wang, Y., 186 (Tu-P7:6), 464 (Th-W49:1) (We-P13:338), 479 (Th-W56:3) Vryonidou, A., 127 (Mo-P5:370) Wang, Y.H., 79 (Mo-P1:151) Vissers, M.N., 318 (We-W36:6), 484 (Th-W58:6) Vrzalová, J., 363 (We-P11:79) Wang, Z., 96 (Mo-P3:230), 212 (Tu-P7:124), 222 Vissich, P.S., 501 (Th-P15:40) Vucic Lovrencic, M., 360 (We-P11:64) (Tu-P7:167), 232 (Tu-P7:217), 233 Visvikis, S., 507 (Th-P15:66) Vukotic, M., 53 (Mo-P1:37) (Tu-P7:219), 234 (Tu-P7:224), 254 Visvikis-Siest, S., 155 (Tu-W17:5) Vukusic, A., 125 (Mo-P5:361) (Tu-P8:317), 464 (Th-W49:1), 492 Vita, J.A., 313 (We-W34:2) Vulev, I., 103 (Mo-P4:260) (Th-P15:3), 494 (Th-P15:10), 516 Vitório, T.S., 113 (Mo-P5:305) Vulic, D., 53 (Mo-P1:34) (Th-P15:108), 529 (Th-P15:167), 539 Viuda-Unceta, J.M., 553 (Th-P16:275) Vuorela, P., 236 (Tu-P7:235) (Th-P15:209), 543 (Th-P15:227, Th-P15:229), Vivancos, M., 435 (We-P14:400) Vyagova, D., 86 (Mo-P2:181) 544 (Th-P15:231)

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

264 Wang, Z.B., 195 (Tu-P7:49), 212 (Tu-P7:124), 322 Wesolowska, T., 275 (Tu-P10:414) Winkler, K., 123 (Mo-P5:352), 143 (Mo-P6:442), (We-W38:7) Wessel, T.R., 142 (Mo-P6:439) 507 (Th-P15:69), 547 (Th-P15:248), 581 Wang, Z.Q., 212 (Tu-P7:124), 492 (Th-P15:3), Westendorp, R.G.J., 37 (Mo-W14:5) (Th-P16:397) 543 (Th-P15:229) Westerterp, M., 489 (Th-W61:5), 560 Winklhofer-Roob, B., 443 (We-P14:439) Wang, Z.W., 65 (Mo-P1:88) (Th-P16:306) Winklhoffer-Roob, B., 513 (Th-P15:95) A Wanschel, A.C.B.A., 197 (Tu-P7:56) Westerweel, P.E., 569 (Th-P16:342) Wirajaya, P.K., 346 (We-P11:2) Wareham, N.J., 24 (Mo-W7:5), 37 (Mo-W14:7), Westheim, A., 286 (Tu-P10:460), 390 Wisloff, U., 100 (Mo-P4:244), 111 (Mo-P5:298), 318 (We-W36:6), 475 (Th-W54:5) (We-P11:200) 428 (We-P13:369) U Warita, S., 259 (Tu-P9:339) Wetterö, J., 284 (Tu-P10:452) Wisløff, U., 162 (Tu-W21:1), 215 (Tu-P7:139), Warneke, C., 91 (Mo-P2:207) Wetzker, R., 325 (We-W40:4) 379 (We-P11:152) T Wasag, B., 129 (Mo-P6:380) Wheaton, A., 561 (Th-P16:309) Wit, F.W., 401 (We-P11:250) Wassertheil-Smoller, S., 176 (Tu-W28:3), 485 Wheeler-Jones, C.D.P., 473 (Th-W53:5) Witkosky, J., 566 (Th-P16:329) H (Th-W59:1) Whipple, C., 466 (Th-W49:5) Witta, J., 537 (Th-P15:200) Wasteson, P., 196 (Tu-P7:52) Whiss, P.A., 90 (Mo-P2:201) Wittchen, H.U., 53 (Mo-P1:35) O Watanabe, F., 498 (Th-P15:29) Whitall, R., 368 (We-P11:103) Witteman, J.C.M., 35 (Mo-W13:5) 33 417 146 Watanabe, H., (Mo-W12:6), White, A.J., (Mo-P6:454) Wittert, G.A., 375 (We-P11:134) 500 310 R (We-P13:320), (Th-P15:37) White, C.R., (We-W32:7) Witting, P., 587 (Th-P17:425) 191 258 557 Watanabe, K., (Tu-P7:32), (Tu-P9:334) Whiting, M., (Th-P16:290) Witztum, J.L., 459 (Th-W46:1) 259 228 Watanabe, S., (Tu-P9:339) Whitinger, C., (Tu-P7:196) Wj Wahle, K., 222 (Tu-P7:171) 290 326 Watanabe, T., (Tu-P10:478) Whitman, S.C., (We-W41:1) Wocial, B., 276 (Tu-P10:416) 182 129 145 Waters, D.D., (Tu-S10:2) Whittall, R., (Mo-P6:381), (Mo-P6:451) Woelkers, D.A., 459 (Th-W46:1) I 463 71 Waters, M.G., (Th-W48:3) Wichmann, E., (Mo-P1:115) Woerly, G., 487 (Th-W60:3) 363 217 Waterworth, D., (We-P11:81) Widdop, R., (Tu-P7:146) Wohl, P., 371 (We-P11:115) 199 200 387 N Wator, L., (Tu-P7:64, Tu-P7:66), Widecka, K., (We-P11:187) Wojtkielewicz, K., 211 (Tu-P7:121) 344 (Tu-P7:68) Widhalm, K., (We-S16:5) Wolfe, M.L., 11 (Mo-W1:1), 564 (Th-P16:322) 390 389 D Watson, S., (We-P11:202) Widimsky, J., (We-P11:195) Wolff, B., 214 (Tu-P7:135) 329 370 91 416 Watts, G.F., (We-W42:5), (We-P11:111), Widimsky, P., (Mo-P2:204), (We-P13:316) Wolff, D.A., 175 (Tu-W27:5) 519 (Th-P15:118), 534 (Th-P15:185), 535 Wiegand, J., 507 (Th-P15:69) Wolmarans, K.H., 585 (Th-P16:415) E (Th-P15:193), 556 (Th-P16:285), 577 Wieland, H., 507 (Th-P15:69), 581 (Th-P16:397) Wolmer, N., 289 (Tu-P10:477) (Th-P16:379) Wierzbicki, A., 405 (We-P11:268), 424 Wolthoorn, J., 26 (Mo-W9:1) X Webb, M.B.T., 129 (Mo-P6:381) (We-P13:353) Wong, J., 478 (Th-W55:7) Weber, T., 283 (Tu-P10:449), 413 (We-P12:306) Wierzbicki, A.S., 465 (Th-W49:3) Wong, J.M.W., 442 (We-P14:433), 455 Webster, C.J., 480 (Th-W56:7) Wiesli, P., 358 (We-P11:54) (We-P14:488), 476 (Th-W55:1) Wedel, M., 549 (Th-P16:258) Wiesner, S., 218 (Tu-P7:150) Wong, K.S., 93 (Mo-P2:213) Wedel, M.K., 466 (Th-W49:6) Wight, T.N., 13 (Mo-W2:1), 489 (Th-W61:4) Wong, N.C., 94 (Mo-P3:219) Wedel, M.W., 552 (Th-P16:268) Wikinski, R., 504 (Th-P15:52, Th-P15:54) Wong, R.L.C., 186 (Tu-P7:6) Weghube, D., 344 (We-S16:5) Wiklund, O., 22 (Mo-W6:6), 24 (Mo-W7:6), 226 Woo, C.W., 274 (Tu-P10:410), 276 (Tu-P10:418) Wehr, H., 135 (Mo-P6:405) (Tu-P7:188), 227 (Tu-P7:190), 503 Wood, D.A., 44 (Mo-S7:2), 462 (Th-W47:3) Wei, D.H., 210 (Tu-P7:117), 222 (Tu-P7:167), 232 (Th-P15:50) Woods, J.W., 463 (Th-W48:3) (Tu-P7:217), 234 (Tu-P7:224), 539 Wikstrand, J., 52 (Mo-P1:32), 349 (We-P11:17), Woollard, K., 539 (Th-P15:208) (Th-P15:209) 382 (We-P11:165) 24 Wei, J., 464 (Th-W49:1) Wikström, J., 314 (We-W34:6) Wootton, P., (Mo-W7:6) 375 Wei, W., 464 (Th-W48:7) Wilde, J., 200 (Tu-P7:71) Worthley, M., (We-P11:134) 375 Weihrauch, G., 310 (We-W32:5) Wilfert, W., 200 (Tu-P7:71) Worthley, S.G., (We-P11:134) 271 Weiler, H., 194 (Tu-P7:43) Wilgenbus, P., 295 (Tu-P10:502) Wosik Erenbek, M., (Tu-P10:397) 80 Weinberg, P.D., 200 (Tu-P7:69) Wilke, M., 512 (Th-P15:89) Wright, A., (Mo-P1:155, Mo-P1:156) 104 Weise, C., 464 (Th-W48:8) Wilke, N., 392 (We-P11:210) Wright, A.R., (Mo-P4:262) 256 Weiss, N., 216 (Tu-P7:143), 275 (Tu-P10:412), Will, J., 218 (Tu-P7:150) Wrobel, J., (Tu-P8:324, Tu-P8:325) 188 400 (We-P11:248) Willems Van Dijk, K., 138 (Mo-P6:421), 205 Wsólová, L., (Tu-P7:17) 189 292 Weissberg, P.L., 156 (Tu-W18:3) (Tu-P7:94), 506 (Th-P15:62), 585 Wsolova, L., (Tu-P7:19), (Tu-P10:488), 446 Weissen-Plenz, G., 144 (Mo-P6:447), 238 (Th-P17:418) (We-P14:452) 425 (Tu-P7:243) Willems van Dijk, K., 318 (We-W37:1) Wu, D.-M., (We-P13:357) Weissglas, D., 397 (We-P11:234) Willers, S., 351 (We-P11:24) Wu, F.L., 270 (Tu-P10:390) Weitz, J.I., 324 (We-W40:1) William-Olsson, L., 254 (Tu-P8:315) Wu, G., 190 (Tu-P7:27) Weksler, B.B., 213 (Tu-P7:131) Williams, A., 386 (We-P11:185) Wu, H.L., 199 (Tu-P7:67), 397 (We-P11:231), 573 Welch, K.M.A., 182 (Tu-S10:3) Williams, J., 160 (Tu-W20:3) (Th-P16:364) Weller, H., 493 (Th-P15:6) Williams, M.W.Y., 34 (Mo-W12:7) Wu, J., 368 (We-P11:101), 464 (Th-W49:1) Welty, F.K., 11 (Mo-W1:1) Williams, P.A., 21 (Mo-W6:3) Wu, J.H.Y., 546 (Th-P15:241) Wenger, N., 82 (Mo-P1:167) Williams, S.A., 480 (Th-W56:7) Wu, T., 221 (Tu-P7:164) Wenger, N.K., 121 (Mo-P5:344) Wilpshaar, W., 578 (Th-P16:387) Wu, T.C., 238 (Tu-P7:242), 251 (Tu-P8:304), 293 Werba, J.P., 116 (Mo-P5:318), 195 (Tu-P7:48), Wilson, P.G., 243 (Tu-P7:266) (Tu-P10:493) 204 (Tu-P7:87), 258 (Tu-P9:333), 309 Wilson, P.W.F., 461 (Th-W47:1) Wu, Y., 381 (We-P11:160) (We-W32:2) Wiltfgang, J., 512 (Th-P15:88) Wu, Y.F., 65 (Mo-P1:88) Werkkala, K., 100 (Mo-P4:245), 110 Windler, E., 49 (Mo-P1:19), 177 (Tu-W28:5), 338 Wunderlich, T., 581 (Th-P16:397) (Mo-P4:292), 242 (Tu-P7:264) (We-S12:4), 408 (We-P12:282) Wybranska, I., 137 (Mo-P6:416), 141 Werman-Venkert, R., 169 (Tu-W24:7) Wing, L.Y.C., 409 (We-P12:287) (Mo-P6:433) Wernecke, K., 218 (Tu-P7:150) Winkelmann, B., 143 (Mo-P6:442) Wybranska, I.I., 35 (Mo-W13:7) Werner, N., 486 (Th-W59:5) Winkelmann, B.R., 72 (Mo-P1:119) Wyde, P., 309 (We-W32:4)

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

265 Xanthoulea, S., 225 (Tu-P7:181) Yamazaki, K., 520 (Th-P15:127) Yildirir, A., 74 (Mo-P1:129, Mo-P1:130), 92 Xavier, H., 50 (Mo-P1:23) Yamazaki, Y., 187 (Tu-P7:13), 362 (We-P11:76) (Mo-P2:208), 100 (Mo-P4:246), 110 Xia, J.-H., 494 (Th-P15:11), 516 (Th-P15:107), Yamori, Y., 185 (Tu-P7:2), 317 (We-W36:4), 432 (Mo-P4:293), 112 (Mo-P5:301), 164 536 (Th-P15:196), 574 (Th-P16:367) (We-P14:389), 441 (We-P14:427) (Tu-W21:7), 284 (Tu-P10:455), 289 A Xia, M., 541 (Th-P15:221) Yan, D., 39 (Mo-W15:5) (Tu-P10:473), 398 (We-P11:237) Xiao, C., 521 (Th-P15:129) Yan, J., 171 (Tu-W25:5) Yilmaz, A., 218 (Tu-P7:152) U Xiao, J.X., 195 (Tu-P7:49), 228 (Tu-P7:199), 565 Yan, Z.-q., 167 (Tu-W24:1) Yilmaz, M.I., 395 (We-P11:226), 417 (Th-P16:327) Yan, Z.Q., 407 (We-P11:277) (We-P13:323) 222 239 241 Xie, L.Y., (Tu-P7:167) Yanagisawa, C., (Tu-P7:247), Yin, D., 116 (Mo-P5:317), 117 (Mo-P5:325), 556 233 430 433 T Xie, M., (Tu-P7:219) (Tu-P7:257), (We-P14:377), (Th-P16:284), 557 (Th-P16:289) 64 434 Xifoli, A., (Mo-P1:82) (We-P14:394), (We-P14:395, Yin, O.Q.P., 147 (Mo-P6:459) 97 494 435 436 H Xiong, Z.W., (Mo-P3:231), (Th-P15:12) We-P14:396), (We-P14:402), Yin, T.Y., 402 (We-P11:258), 403 (We-P11:260, 186 187 509 510 Xu, A., (Tu-P7:6), (Tu-P7:10) (We-P14:407), (Th-P15:78), We-P11:261) 382 O Xu, C.-B., (We-P11:167) (Th-P15:80) Yin, W.D., 195 (Tu-P7:49), 212 (Tu-P7:124), 228 Xu, F., 202 (Tu-P7:79), 203 (Tu-P7:84) Yanagisawa, N., 417 (We-P13:321) (Tu-P7:199), 322 (We-W38:7), 565 Xu, H., 216 (Tu-P7:142) Yanai, H., 428 (We-P13:370), 511 (Th-P15:85) (Th-P16:327) R Xu, J., 14 (Mo-W2:6) Yang, A.E., 488 (Th-W60:6) Yin, X.-B., 494 (Th-P15:11), 516 (Th-P15:107), Xu, L.-H., 158 (Tu-W18:7) Yang, C.Y., 193 (Tu-P7:37) 536 (Th-P15:196), 574 (Th-P16:367) Xu, Q., 32 (Mo-W12:1), 462 (Th-W48:1), 589 Yang, J.H., 254 (Tu-P8:317), 492 (Th-P15:3), 543 Yip Cheng, K., 187 (Tu-P7:10) (Th-P17:436) (Th-P15:227, Th-P15:229) YlÄ-Herttuala, S., 194 (Tu-P7:44) Xu, Q.B., 407 (We-P11:277) Yang, N.-C., 95 (Mo-P3:221) I Ylä-Herttuala, S., 39 (Mo-W15:5) Xu, Y.L., 94 (Mo-P3:220) Yang, X., 144 (Mo-P6:445) 195 Xu, Z.X., 190 (Tu-P7:25) Yang, X.D., 223 (Tu-P7:175), 224 (Tu-P7:177), Yokode, M., (Tu-P7:47) N 122 Xue, H., 190 (Tu-P7:27) 293 (Tu-P10:490), 521 (Th-P15:129) Yokoi, H., (Mo-P5:350) 509 Xue, L., 494 (Th-P15:12) Yang, Y.L., 436 (We-P14:408) Yokota, K., (Th-P15:78) 25 D Yang, Y.Z., 96 (Mo-P3:230), 144 (Mo-P6:445), Yokote, K., (Mo-W8:3) 133 181 Y, F. , 393 (We-P11:217) 190 (Tu-P7:25), 210 (Tu-P7:117), 233 Yokoyama, M., (Mo-P6:397), (Tu-S9:4), E Y, G . H . , 393 (We-P11:217) (Tu-P7:219), 234 (Tu-P7:224), 251 249 (Tu-P8:293), 369 (We-P11:109), 498 Y, Y. Z . , 393 (We-P11:217) (Tu-P8:301), 494 (Th-P15:10), 516 (Th-P15:27) X Yaghmai, P., 196 (Tu-P7:55) (Th-P15:108), 539 (Th-P15:209), 543 Yokoyama, S., 319 (We-W37:3), 493 (Th-P15:7), Yagi, S., 101 (Mo-P4:252), 106 (Mo-P4:271), 362 (Th-P15:227), 544 (Th-P15:231) 539 (Th-P15:211), 564 (Th-P16:320) (We-P11:77), 569 (Th-P16:344), 572 Yannarelli, G., 195 (Tu-P7:48) Yokoyama, T., 547 (Th-P16:249) (Th-P16:359) Yano, E., 187 (Tu-P7:13), 362 (We-P11:76) Yonemura, A., 559 (Th-P16:300), 581 Yagyu, H., 319 (We-W37:3), 582 (Th-P16:405) Yanushevskaya, E.V., 96 (Mo-P3:227) (Th-P16:398) Yakhini, Z., 5 (Su-S3:2), 230 (Tu-P7:206) Yao, F., 96 (Mo-P3:230), 222 (Tu-P7:167), 232 Yoneyama, S., 290 (Tu-P10:481) Yakunina, N.YU., 131 (Mo-P6:387) (Tu-P7:217) Yoo, B.S., 98 (Mo-P4:238, Mo-P4:239) Yamada, N., 164 (Tu-W22:3), 576 (Th-P16:375) Yap, A., 78 (Mo-P1:146) Yoo, S.E., 132 (Mo-P6:394), 234 (Tu-P7:227), Yamada, S., 339 (We-S13:3), 549 (Th-P16:256) Yaremenko, E.M., 548 (Th-P16:254) 279 (Tu-P10:429) Yamada, T., 255 (Tu-P8:319), 559 (Th-P16:298), Yarmohamadian, M.H., 120 (Mo-P5:341) Yoon, J., 98 (Mo-P4:238, Mo-P4:239), 247 562 (Th-P16:311) Yarnykh, V., 267 (Tu-P9:379) (Tu-P7:285) 49 425 Yamaguchi, H., (Mo-P1:17), Yaroslavov, A.A., 500 (Th-P15:38) York-Defalco, C., 466 (Th-W49:5) 460 583 575 (We-P13:359), (Th-W46:6), Yasuda, G., (Th-P16:370) Yoshida, H., 428 (We-P13:370), 433 487 (Th-P16:407) Yasuda, S., (Th-W60:2) (We-P14:394), 511 (Th-P15:85) 280 498 Yamaguchi, M., (Tu-P10:435) Yasuda, T., (Th-P15:27) Yoshida, M., 185 (Tu-P7:3), 234 (Tu-P7:226) 501 256 Yamaguchi, S., (Th-P15:39) Yates, D.W., (Tu-P8:324) Yoshida, T., 48 (Mo-P1:12) 87 367 Yamaguchi, T., (Mo-P2:186) Yatsuya, H., (We-P11:97) Yoshie, H., 73 (Mo-P1:122), 377 (We-P11:144) Yamamoto, A., 122 (Mo-P5:350), 564 264 269 524 Yavuz, B., (Tu-P9:365), (Tu-P9:385), Yoshikawa, T., 428 (We-P13:372) (Th-P16:320) (Th-P15:143) Yoshimasa, Y., 564 (Th-P16:320) Yamamoto, J., 185 (Tu-P7:2), 434 (We-P14:397), Yavuz, B.B., 264 (Tu-P9:365) Yoshimura, N., 503 (Th-P15:51), 509 (Th-P15:76) 436 (We-P14:405) Yavuz, D., 215 (Tu-P7:136) Yoshinaka, Y., 547 (Th-P16:249) Yamamoto, K., 280 (Tu-P10:435), 519 Yazici, D., 215 (Tu-P7:136) Yoshino, G., 198 (Tu-P7:61), 220 (Tu-P7:162), (Th-P15:121) Yazici, M., 55 (Mo-P1:43), 371 (We-P11:114) 279 (Tu-P10:431), 284 (Tu-P10:454), 285 Yamamoto, N., 220 (Tu-P7:162) Ycas, J., 161 (Tu-W20:6), 551 (Th-P16:265), 552 (Tu-P10:456) Yamamoto, T., 56 (Mo-P1:48) (Th-P16:267) 241 430 Yamamoto, Y., 575 (Th-P16:370) Ye, D., 152 (Tu-W16:2), 320 (We-W37:6) Yoshioka, E., (Tu-P7:257), (We-P14:377), 433 434 Yamamoto-Kimura, L., 82 (Mo-P1:163) Ye, P., 59 (Mo-P1:61), 372 (We-P11:121), 572 (We-P14:394), (We-P14:395, 435 436 Yamamura, T., 510 (Th-P15:79) (Th-P16:360) We-P14:396), (We-P14:402), 509 510 Yaman, M., 264 (Tu-P9:362, Tu-P9:364) Ye, S., 160 (Tu-W20:3), 316 (We-W35:6) (We-P14:407), (Th-P15:78), Yamanaka, S., 294 (Tu-P10:499) Ye, X., 190 (Tu-P7:25), 251 (Tu-P8:301) (Th-P15:80) 290 Yamashita, A., 93 (Mo-P2:215) Yebra, M., 123 (Mo-P5:353) Yoshita, K., (Tu-P10:481) Yamashita, H., 191 (Tu-P7:32) Yegorova, Y.V., 222 (Tu-P7:168), 580 Yoshizumi, M., 235 (Tu-P7:231), 501 (Th-P15:39) Yamashita, S., 28 (Mo-W9:6), 237 (Tu-P7:237), (Th-P16:396) You, S.E., 517 (Th-P15:112) 510 (Th-P15:79), 511 (Th-P15:86), 519 Yehya, H., 102 (Mo-P4:254) Young, I.S., 226 (Tu-P7:186), 522 (Th-P15:135) (Th-P15:121), 575 (Th-P16:372) Yi, G.-H., 494 (Th-P15:11), 516 (Th-P15:107), Young, J.L., 168 (Tu-W24:4) Yamashita, T., 436 (We-P14:405) 536 (Th-P15:196), 574 (Th-P16:367) Youseﬁ, A.R., 120 (Mo-P5:341) Yamasita, S., 510 (Th-P15:82) Yi, G.H., 233 (Tu-P7:219), 254 (Tu-P8:317), 492 Yu, B., 561 (Th-P16:309) Yamauchi, T., 164 (Tu-W22:1, Tu-W22:3) (Th-P15:3), 516 (Th-P15:108), 543 Yu, J., 217 (Tu-P7:147) Yamazaki, H., 245 (Tu-P7:277), 482 (Th-W57:7) (Th-P15:227, Th-P15:229), 544 (Th-P15:231) Yu, P., 400 (We-P11:245)

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

266 Yu, Q.S., 210 (Tu-P7:117), 403 (We-P11:259, Tu-P7:174), 387 (We-P11:187), 432 Zhao, X., 87 (Mo-P2:185) We-P11:262) (We-P14:390) Zhao, Z.Z., 234 (Tu-P7:224), 539 (Th-P15:209) Yu, R., 549 (Th-P16:258), 552 (Th-P16:268) Zarrilli, V., 255 (Tu-P8:322) Zheng, P., 541 (Th-P15:220) Yu, X., 215 (Tu-P7:138) Zateyshchikov, D.A., 131 (Mo-P6:387), 146 Zheng, Q., 22 (Mo-W6:5) Yu, Y., 238 (Tu-P7:241) (Mo-P6:455) Zhou, B., 56 (Mo-P1:47), 430 (We-P14:381), 437 A Yuan, C., 267 (Tu-P9:379) Zateyshchikova, A.A., 146 (Mo-P6:455) (We-P14:410), 498 (Th-P15:26) Yuan, H., 487 (Th-W60:2) Zaujec, J., 488 (Th-W60:8) Zhou, B.F., 65 (Mo-P1:88) Yuan, X., 95 (Mo-P3:222), 372 (We-P11:120) Zavaroni, I., 5 (Su-S3:3), 224 (Tu-P7:178) Zhou, G., 295 (Tu-P10:503) U Yuan, X.-M., 158 (Tu-W18:7), 271 (Tu-P10:396), Zavjalova, L.G., 68 (Mo-P1:103) Zhou, X., 167 (Tu-W24:1), 331 (We-W43:3), 460 529 (Th-P15:166) Zcharia, E., 463 (Th-W48:2) (Th-W46:4) T Yuan, X.M., 328 (We-W41:7) Zdansky, P., 201 (Tu-P7:74) Zhou, X.F., 529 (Th-P15:167) Yuan, Z., 555 (Th-P16:282) Zdravkovic, D., 127 (Mo-P5:373), 358 Zhou, Z., 375 (We-P11:135) H Yucel, M., 74 (Mo-P1:129), 100 (Mo-P4:246) (We-P11:57) Zhu, F., 87 (Mo-P2:188) Yudin, N.S., 81 (Mo-P1:158) Zdravkovic, M., 127 (Mo-P5:373), 358 Zhu, H., 541 (Th-P15:221) O Yui, K., 373 (We-P11:125) (We-P11:57) Zidek, V., 203 (Tu-P7:82), 373 (We-P11:123), 463 Yuksel, S., 106 (Mo-P4:274), 218 (Tu-P7:151) Zdzienicka, A., 76 (Mo-P1:136), 137 (Th-W48:5) Yurugi-Kobayashi, T., 195 (Tu-P7:47) (Mo-P6:416), 141 (Mo-P6:433), 208 Zidkova, J., 203 (Tu-P7:82) R Yusoff, K., 224 (Tu-P7:176), 418 (We-P13:328), (Tu-P7:105), 288 (Tu-P10:469), 416 Zidkova, K., 140 (Mo-P6:429, Mo-P6:430) 423 (We-P13:347) (We-P13:319) Ziegler, J.T., 89 (Mo-P2:196) Yusuf, S., 308 (We-W31:5) Zdziennicka, A., 290 (Tu-P10:479) Zielinski, M., 559 (Th-P16:299) Zechner, R., 15 (Mo-W3:1) Zielonka, J., 84 (Mo-P2:175), 286 (Tu-P10:463), I Zecova, S., 124 (Mo-P5:356) 287 (Tu-P10:464), 569 (Th-P16:343) Zabala, S., 130 (Mo-P6:385) Zegura, B., 75 (Mo-P1:134), 76 (Mo-P1:135) Zieske, A., 258 (Tu-P9:335) Zabel, M., 104 (Mo-P4:265), 270 (Tu-P10:392) N Zeiher, A.M., 322 (We-W39:1) Zikic, L.J., 78 (Mo-P1:148) Zabunova, M., 142 (Mo-P6:438) Zekanowska, E., 83 (Mo-P2:168, Mo-P2:169) Zilica, M., 281 (Tu-P10:442) Zadak, Z., 359 (We-P11:60), 562 (Th-P16:314) Zelinka, T., 389 (We-P11:195) Zilidis, A., 204 (Tu-P7:90) D Zafaranloo, N., 581 (Th-P16:399) Zeljkovic, A., 139 (Mo-P6:426), 502 (Th-P15:46), Zilli Vieira, C.L., 163 (Tu-W21:3), 399 Zaﬁrovska, K., 297 (Tu-P10:512) 503 (Th-P15:47) (We-P11:241) E Zaggelidou, E., 64 (Mo-P1:82) Zeljkovic Vrkic, T., 376 (We-P11:136) Zimetti, F., 166 (Tu-W23:3), 524 (Th-P15:142), Zago, V., 504 (Th-P15:52) Zeller, M., 370 (We-P11:113), 427 (We-P13:365) 541 (Th-P15:217) Zaguri, R., 233 (Tu-P7:222) X Zellmann, S., 30 (Mo-W10:7) Zimlichman, R., 102 (Mo-P4:255) 581 Zahedi, L., (Th-P16:399) Zeman, M., 292 (Tu-P10:487), 552 (Th-P16:269) Zimmer, D.P., 558 (Th-P16:297) 529 Zainuddin, M., (Th-P15:164) Zembala, M., 289 (Tu-P10:477) Zimmermann, R., 15 (Mo-W3:1) 94 Zaiss, A.K., (Mo-P3:219) Zemmour, D., 102 (Mo-P4:256), 387 Zineh, I., 142 (Mo-P6:439), 334 (We-W44:7) 562 563 Zajíc, J., (Th-P16:315), (Th-P16:316) (We-P11:189) Zinellu, A., 273 (Tu-P10:405) 562 Zajic, J., (Th-P16:314) Zenari, L., 411 (We-P12:293) Zingaro, L., 294 (Tu-P10:498), 298 (Tu-P10:513) 144 496 Zák, A., (Mo-P6:448), (Th-P15:18) Zeng, D.-X., 494 (Th-P15:11), 516 (Th-P15:107), Zirlik, A., 168 (Tu-W24:4) 292 365 Zak, A., (Tu-P10:487), (We-P11:90) 536 (Th-P15:196), 574 (Th-P16:367) Zisi, F., 77 (Mo-P1:142) 72 73 143 Zak, I., (Mo-P1:117), (Mo-P1:124), Zeng, J., 71 (Mo-P1:113) Zivic, D., 377 (We-P11:143) (Mo-P6:444) Zeng, W., 306 (We-W30:6) Zivkovic, M., 288 (Tu-P10:470), 393 118 382 Zakerimoghadam, M., (Mo-P5:328), Zeng, W-W., 138 (Mo-P6:420) (We-P11:214) (We-P11:166) Zeng, W.-W., 498 (Th-P15:26) Zivkovic, R., 127 (Mo-P5:373), 358 (We-P11:57) 387 396 Zakirova, A.N., (We-P11:190), Zeng, W.W., 190 (Tu-P7:27) Ziyaeva, A.V., 67 (Mo-P1:98) (We-P11:228) Zeng, Y., 494 (Th-P15:11), 516 (Th-P15:107), 536 Zlatohlavek, L., 140 (Mo-P6:429, Mo-P6:430), 289 Zakliczynski, M., (Tu-P10:477) (Th-P15:196), 574 (Th-P16:367) 407 (We-P12:278) 245 Zalba, G., (Tu-P7:274) Zepeda-Carrillo, E., 380 (We-P11:155) Zo, J.H., 358 (We-P11:58), 366 (We-P11:94) 9 Zalewski, A., (Mo-ML2:1) Zhang, B., 13 (Mo-W1:7), 99 (Mo-P4:241), 268 Zoeller, R.F., 501 (Th-P15:40) 78 351 Zamaklar, M., (Mo-P1:148), (We-P11:25, (Tu-P9:383), 293 (Tu-P10:492), 396 Zoja, C., 463 (Th-W48:6) We-P11:26), 502 (Th-P15:46), 503 (We-P11:229), 559 (Th-P16:298), 561 Zokirov, N.U., 67 (Mo-P1:98) (Th-P15:47) (Th-P16:310), 562 (Th-P16:311, Th-P16:313), Zoric, S., 126 (Mo-P5:367), 287 (Tu-P10:468), Zamble, A., 215 (Tu-P7:140) 570 (Th-P16:350), 578 (Th-P16:386), 590 361 (We-P11:68, We-P11:70), 362 Zambon, A., 342 (We-S15:3), 475 (Th-W54:3), (Th-P17:440) (We-P11:74, We-P11:75), 378 (We-P11:149) 502 (Th-P15:45) Zhang, C., 195 (Tu-P7:49), 228 (Tu-P7:199), 255 Zorin, A.V., 283 (Tu-P10:447) Zambón, D., 261 (Tu-P9:349, Tu-P9:350) (Tu-P8:320), 322 (We-W38:7), 565 Zorio, E., 85 (Mo-P2:178), 89 (Mo-P2:194), 286 Zamboulis, C., 109 (Mo-P4:286) (Th-P16:327), 572 (Th-P16:360) (Tu-P10:461), 395 (We-P11:224), 531 Zamora- González, J., 537 (Th-P15:203) Zhang, J., 186 (Tu-P7:6) (Th-P15:176) Zamora-Gonzalez, J., 82 (Mo-P1:163), 422 Zhang, L., 177 (Tu-W28:7), 196 (Tu-P7:51), 230 Zornitzki, T., 52 (Mo-P1:33) (We-P13:344), 534 (Th-P15:186) (Tu-P7:205), 567 (Th-P16:335) Zouaoui Boudjeltia, K., 119 (Mo-P5:336), 524 Zanda, M., 244 (Tu-P7:271) Zhang, X., 196 (Tu-P7:51) (Th-P15:141), 525 (Th-P15:146) Zanella, M.T., 376 (We-P11:138) Zhang, Y.-L., 15 (Mo-W3:3) Zschörnig, O., 527 (Th-P15:156), 587 Zannad, F., 578 (Th-P16:387) Zhang, Z., 28 (Mo-W9:6), 237 (Tu-P7:237), 310 (Th-P17:427) Zanni, D., 114 (Mo-P5:309) (We-W32:7), 490 (Th-W61:8), 510 Zu, X.-H., 574 (Th-P16:367) Zannis, V., 228 (Tu-P7:195) (Th-P15:82), 575 (Th-P16:372) Zu, X.H., 212 (Tu-P7:124) Zannis, V.I., 39 (Mo-W15:8) Zhao, B., 515 (Th-P15:100) Zubareva, M., 116 (Mo-P5:321) Zanotti, I., 12 (Mo-W1:6), 166 (Tu-W23:3), 524 Zhao, C.Y., 494 (Th-P15:12) Zuch, C., 86 (Mo-P2:183), 88 (Mo-P2:190) (Th-P15:142) Zhao, H.L., 93 (Mo-P2:213) Zuliani, G., 108 (Mo-P4:284), 401 (We-P11:253), Zapletalova, P., 132 (Mo-P6:392) Zhao, L.C., 65 (Mo-P1:88) 471 (Th-W52:4), 530 (Th-P15:171), 534 Zapolska-Downar, D., 223 (Tu-P7:173, Zhao, R., 88 (Mo-P2:189) (Th-P15:188)

XIV International Symposium on Atherosclerosis, Rome, Italy, June 18–22, 2006

267 Zulli, A., 217 (Tu-P7:146) Zunino, J., 63 (Mo-P1:79) Zurlo, A., 401 (We-P11:253) Zuurman, M., 16 (Mo-W3:6) A Zweier, J.L., 87 (Mo-P2:185) Zwergal, A., 526 (Th-P15:151) Zwinderman, A., 364 (We-P11:84) U Zwinderman, A.H., 37 (Mo-W14:7) Zycband, E.I., 463 (Th-W48:3) T Zykova, T., 126 (Mo-P5:368), 360 (We-P11:66), 419 (We-P13:329) H Zykova, T.A., 415 (We-P13:312) Zyriax, B., 408 (We-P12:282) O Zyriax, B.-CHR., 177 (Tu-W28:5) R

I N D E X

268 Lorenzini Foundation Symposium: 304

ISA 2006 FONDAZIONE GIOVANNI LORENZINI MEDICAL SCIENCE FOUNDATION Via A. Appiani 7 - 20121 Milan (Italy) Phone: (+39) 02 29006267 - Fax: (+39) 02 29007018 E-mail: [email protected]

http://www.isa2006.org http://www.athero.org

http://www.lorenzinifoundation.org